<SEC-DOCUMENT>0001193125-24-125209.txt : 20240430
<SEC-HEADER>0001193125-24-125209.hdr.sgml : 20240430
<ACCEPTANCE-DATETIME>20240430163006
ACCESSION NUMBER:		0001193125-24-125209
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		81
FILED AS OF DATE:		20240430
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Atlantic Coastal Acquisition Corp. II
		CENTRAL INDEX KEY:			0001893219
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				871013956
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276618
		FILM NUMBER:		24897739

	BUSINESS ADDRESS:	
		STREET 1:		6 ST JOHNS LANE, FLOOR 5
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		248-890-7200

	MAIL ADDRESS:	
		STREET 1:		6 ST JOHNS LANE, FLOOR 5
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d509388ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:acab="http://www.atlanticcoastalacquisition.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-4/A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden113139180" contextRef="P01_01_2023To12_31_2023">S-4/A</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To12_31_2023" id="ixv-46169">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To12_31_2023" id="ixv-46170">0001893219</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden113139203" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">NY</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden113139209" contextRef="P01_01_2023To12_31_2023">NY</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acab-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_07_2022To01_07_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-07</xbrli:startDate> <xbrli:endDate>2022-01-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_19_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-19</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_19_2022To01_19_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-19</xbrli:startDate> <xbrli:endDate>2022-01-19</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_16_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_16_2022To08_16_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-16</xbrli:startDate> <xbrli:endDate>2022-08-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_15_2023To12_15_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-15</xbrli:startDate> <xbrli:endDate>2023-12-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_15_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_11_2024To01_11_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-11</xbrli:startDate> <xbrli:endDate>2024-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:BasisAxis">acab:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:WorkingCapitalLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">acab:FederalAndStateAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acab:AssetsHeldInTrustMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acab:AssetsHeldInTrustMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">acab:FederalAndStateAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:WorkingCapitalLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acab:ClassAAndClassBCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:RedeemableCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfInitialPublicOfferMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfInitialPublicOfferMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdjustedExercisePriceOneMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:AdjustedExercisePriceOfWarrantsAxis">acab:AdjustedExercisePriceOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdjustedExercisePriceTwoMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:AdjustedExercisePriceOfWarrantsAxis">acab:AdjustedExercisePriceTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:BasisAxis">acab:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:RedeemableCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acab:ClassAAndClassBCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-13</xbrli:startDate> <xbrli:endDate>2022-01-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2022_MinimumMembersrtRangeAxis_PostBusinessCombinationMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">acab:PostBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-18</xbrli:startDate> <xbrli:endDate>2023-04-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_18_2023To04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-18</xbrli:startDate> <xbrli:endDate>2023-04-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-18</xbrli:startDate> <xbrli:endDate>2023-04-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_14_2023To11_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetHeldInTrustMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-14</xbrli:startDate> <xbrli:endDate>2023-11-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-25</xbrli:startDate> <xbrli:endDate>2021-10-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-25</xbrli:startDate> <xbrli:endDate>2021-10-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_25_2021To10_25_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-25</xbrli:startDate> <xbrli:endDate>2021-10-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_DirectorMembersrtTitleOfIndividualAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-25</xbrli:startDate> <xbrli:endDate>2021-10-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-25</xbrli:startDate> <xbrli:endDate>2021-10-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_25_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-10-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_01_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acab:NonRedemptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-04</xbrli:startDate> <xbrli:endDate>2023-04-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acab:NonRedemptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_14_2023To10_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetHeldInTrustMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-14</xbrli:startDate> <xbrli:endDate>2023-10-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_08_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_AbproBioCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:AbproBioCoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_AbproMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:AbproMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_12_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:UnderwriterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-21</xbrli:startDate> <xbrli:endDate>2024-01-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2024_AdvisorMemberACABInvesteeAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="acab:InvesteeAxis">acab:AdvisorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><div style="display:inline;">As filed with the Securities and Exchange Commission on April&#160;30, 2024.</div> </div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">Registration </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-276618</div> </div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div> </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">Amendment No. 2</div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">to </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden113139180;display:inline;">S-4</div></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 2pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To12_31_2023" id="ixv-47229">Atlantic Coastal Acquisition Corp. II</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 32%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 32%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:stateprovnameen" id="ixv-47230">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-47231">6770</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-47232">87-1013956</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023" id="ixv-47233">6 St Johns Lane, Floor 5</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023" id="ixv-47234">New York</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden113139209;display:inline;">NY</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023" id="ixv-47235">10013</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023" id="ixv-47236">248</ix:nonNumeric>)-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-47237">890-7200</ix:nonNumeric></div></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47238">Shahraab Ahmad</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Chairman and Chief Executive Officer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Atlantic Coastal Acquisition Corp. II </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47239">6 St Johns Lane, Floor 5</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47240">New York</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden113139203;display:inline;">NY</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47241">10013</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47242">248</ix:nonNumeric>)-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47243">890-7200</ix:nonNumeric></div></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stephen C. Ashley</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Pillsbury Winthrop Shaw Pittman LLP</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">31 W. 52nd Street</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">New York, NY 10019</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(212) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">858-1000</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Jonathan H. Talcott</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">E. Peter Strand</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Michael K. Bradshaw, Jr.</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Nelson Mullins Riley&#160;&amp;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Scarborough LLP</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">101 Constitution Avenue</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">NW, Suite 900</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, DC 20001</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(202) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">689-2800</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Approximate date of commencement of proposed sale of the securities to the public: </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">As soon as practicable after this registration statement becomes effective and upon completion of the business combination. </div></div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box:&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12b-2</div> of the Exchange Act.: </div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 15%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 61%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 19%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:entityfilercategoryen" id="ixv-47244">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-47245">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/>
<td colspan="2" style="height: 6pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-47246">&#9746;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:boolballotbox" id="ixv-47247">&#9744;</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">13e-4(i)</div> (Cross-Border Issuer Tender Offer)&#8194;&#9744; </div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">14d-1(d)</div> (Cross-Border Third-Party Tender Offer)&#8194;&#9744; </div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary proxy statement/prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">PRELIMINARY PROXY STATEMENT/PROSPECTUS </span></span></p> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">DATED APRIL&#160;30, 2024, SUBJECT TO COMPLETION </span></span></p> </div> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g03k03.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, Atlantic Coastal Acquisition Corp. II (&#8220;ACAB&#8221;) and Abpro Merger Sub Corp. (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of ACAB, entered into a Business Combination Agreement (as it may be amended and/or restated from time to time, the &#8220;Business Combination Agreement&#8221;) with Abpro Corporation (&#8220;Abpro&#8221;). If the Business Combination Agreement is adopted by Abpro&#8217;s stockholders, the Business Combination Agreement and the transactions contemplated thereby, including the issuance of Series A common stock (as defined herein) to be issued as the merger consideration (the &#8220;ACAB New Common Shares&#8221;), are approved by ACAB&#8217;s stockholders, and the business combination is subsequently completed, Merger Sub will merge with and into Abpro with Abpro surviving the merger as a wholly owned subsidiary of ACAB (the &#8220;Business Combination&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the effective time of the Business Combination (the &#8220;Effective Time&#8221;), Abpro will cause Abpro preferred shares that are issued and outstanding immediately prior to the Effective Time to be converted into shares of Abpro common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the Business Combination and without any action on the part of ACAB, Merger Sub, Abpro or holders of any of Abpro&#8217;s securities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All shares of Abpro common stock issued and outstanding immediately prior to the Effective Time will be canceled and converted into the right to receive the number of ACAB New Common Shares based on the Exchange Ratio (as defined in the Business Combination Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All shares of Abpro common stock and Abpro preferred shares held in the treasury of Abpro will be canceled without any conversion thereof and no payment or distribution will be made with respect thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and exchanged for one validly issued, fully paid and nonassessable share of ACAB New Common Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each Abpro option that is outstanding immediately prior to the Effective Time, whether vested or unvested, will be converted into an option to purchase a number of ACAB New Common Shares (such option, an &#8220;Exchanged Option&#8221;) equal to the product (rounded down to the nearest whole number) of (i)&#160;the number of shares of Abpro common stock subject to such Abpro option immediately prior to the Effective Time and (ii)&#160;the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of such Abpro option immediately prior to the Effective Time divided by (B)&#160;Exchange Ratio. Except as specifically provided in the Business Combination Agreement, following the Effective Time, each Exchanged Option will continue to be governed by the same terms and conditions (including vesting and exercisability terms) as were applicable to the corresponding former Abpro option immediately prior to the Effective Time; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(v)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each unvested Abpro restricted stock unit that is either held by an Abpro employee or held by a member of the Post-Closing Board (as defined below), shall be converted into a restricted stock unit representing the right to receive on settlement, a number of ACAB New Common Shares equal to the Exchange Ratio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Abpro common stock outstanding, the number of shares of Abpro preferred stock outstanding, the number of outstanding stock options, restricted stock awards and restricted stock unit awards of Abpro, in each case as of February&#160;29, 2024, (i) the estimated exchange ratio of shares of ACAB&#8217;s Series A common stock for each share of Abpro common stock is 2.04, (ii) the total number of shares of ACAB&#8217;s </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series A common stock expected to be issued in connection with the Business Combination is approximately 50&#160;million, and it is anticipated that following Closing, ACAB&#8217;s public stockholders will retain an ownership interest of approximately 1.3% of the outstanding capital stock of the combined company, the Sponsor (as defined below) will retain an ownership interest of approximately 7.1% of the outstanding capital stock of the combined company and the holders of shares of Abpro capital stock will own approximately 78.1% of the outstanding capital stock of the combined company. The foregoing ownership percentages with respect to the combined company following the Business Combination exclude any outstanding warrants and assume that (i) there are no redemptions of any stock by ACAB&#8217;s public stockholders in connection with the Business Combination, and (ii) no awards are issued under the Incentive Plan (as defined herein). All shares currently held by ACAB public stockholders and all of the stock issued in the Business Combination to existing Abpro securityholders will be freely tradable without registration under the Securities Act, and without restriction by persons other than the combined company&#8217;s &#8220;affiliates&#8221; (as defined under Rule 144 under the Securities Act), including the combined company&#8217;s directors, executive officers and other affiliates, subject to lock-up restrictions. <span style="font-weight:bold">Because</span> <span style="font-weight:bold">the level of stockholder redemptions will not be known until the ACAB Special Meeting,</span> <span style="font-weight:bold">holders of ACAB&#8217;s Series A common stock will not know at the time of the vote the percentage of the </span><span style="font-weight:bold">combined company</span><span style="font-weight:bold">&#8217;s outstanding capital stock that they will hold.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s units, Series A common stock and public warrants are publicly traded on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbols &#8220;ACABU&#8221;, &#8220;ACAB&#8221;, and &#8220;ACABW&#8221;, respectively. We intend to apply to list ACAB&#8217;s Series A common stock and public warrants on Nasdaq under the symbols &#8220;ABP&#8221; and &#8220;ABPW&#8221;, respectively, upon the Closing. ACAB will not have units traded following Closing. Following the Closing, ACAB intends to change its name to &#8220;Abpro Holdings, Inc.&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB will hold a special meeting of stockholders (the &#8220;Special Meeting&#8221;) to consider matters relating to the proposed Business Combination. ACAB and Abpro cannot complete the Business Combination unless ACAB&#8217;s stockholders consent to the approval of the Business Combination Agreement and the transactions contemplated thereby, including the issuance of ACAB&#8217;s Series A common stock to be issued as the merger consideration, and Abpro&#8217;s stockholders consent to adoption and approval of the Business Combination Agreement and the transactions contemplated thereby. ACAB and Abpro are sending you this proxy statement/prospectus to ask you to vote in favor of these and the other matters described in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting will be held at 9:00 a.m. eastern time, on,&#8195;&#8195;&#8195;&#8195;2024, in virtual format. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">YOUR VOTE IS VERY IMPORTANT, REGARDLESS OF THE NUMBER OF SHARES OF COMMON STOCK YOU OWN. To ensure your representation at the Special Meeting, please complete and return the enclosed proxy card or submit your proxy by following the instructions contained in this proxy statement/prospectus and on your proxy card. Please submit your proxy promptly whether or not you expect to attend the meeting. Submitting a proxy now will NOT prevent you from being able to vote in person (which would include presence at a virtual meeting) at the meeting. If you hold your shares in &#8220;street name&#8221;, you should instruct your broker, bank or other nominee how to vote in accordance with the voting instruction form you receive from your broker, bank or other nominee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACAB board of directors has unanimously approved the Business Combination Agreement and the transactions contemplated thereby and recommends that ACAB stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Business Combination Agreement, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the issuance of Series A common stock to be issued as the merger consideration and &#8220;<span style="font-weight:bold">FOR</span>&#8221; the other matters to be considered at the Special Meeting. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">This proxy statement/prospectus provides you with detailed information about the proposed Business Combination. It also contains or references information about ACAB and Abpro and certain related matters. You are encouraged to read this proxy statement/prospectus carefully. In particular, you should read the &#8220;</span><span style="font-weight:bold"><span style="font-style:italic"><a href="#tx509388_8">Risk Factors</a></span></span><span style="font-weight:bold">&#8221; section beginning on page&#160;45 for a discussion of the risks you should consider in evaluating the proposed Business Combination and how it will affect you. </span></p></div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB files reports, proxy statements and other information with the SEC as required by the Exchange Act. You can read ACAB&#8217;s SEC filings, including this proxy statement/prospectus, over the Internet at the SEC&#8217;s website at<span style="font-style:italic">&#160;<span style="text-decoration:underline">http://www.sec.gov</span>.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy statement/prospectus or you have any questions regarding the accompanying proxy statement/prospectus, you may contact Morrow Sodali LLC, ACAB&#8217;s proxy solicitor, at ACAB.info@investor.morrowsodali.com or (800) <span style="white-space:nowrap">662-5200</span> (toll free). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ SHAHRAAB AHMAD </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman and Chief Executive Officer </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Business Combination, the issuance of shares of Series A common stock in connection with the Business Combination or the other transactions described in this proxy statement/prospectus, or passed upon the adequacy or accuracy of the disclosure in this proxy statement/prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus is dated,&#8195;&#8195;&#8195;&#8195;2024, and is first being mailed to stockholders of ACAB on or about,&#8195;&#8195;&#8195;&#8195;2024. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Atlantic Coastal Acquisition Corp. II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">6 St Johns Lane, Floor 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">New York, NY 10013 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICE OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SPECIAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TO BE HELD ON&#8195;&#8195;&#8195;&#8195;, 2024 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE STOCKHOLDERS OF ATLANTIC COASTAL ACQUISITION CORP. II: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that a special meeting of stockholders of Atlantic Coastal Acquisition Corp. II (&#8220;ACAB&#8221;), a Delaware corporation, will be held at 9:00 a.m. eastern time, on&#8195;&#8195;&#8195;&#8195;, 2024, in virtual format (the &#8220;Special Meeting&#8221;). You are cordially invited to attend the Special Meeting, which will be held for the following purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Business Combination Proposal &#8212;</span> To consider and vote upon a proposal to approve the Business Combination Agreement, dated as of December&#160;11, 2023 (as it may be amended and/or restated from time to time, the &#8220;Business Combination Agreement&#8221;), by and among ACAB, Abpro Merger Sub Corp. (&#8220;Merger Sub&#8221;) and Abpro Corporation (&#8220;Abpro&#8221;) and the transactions contemplated thereby, pursuant to which Merger Sub will merge with and into Abpro with Abpro surviving the merger as a wholly owned subsidiary of ACAB (the &#8220;Business Combination&#8221;). A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex A</span> (Proposal No.&#160;1); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Charter Approval Proposal &#8212;</span> To consider and vote upon a proposal to adopt the Second Amended and Restated Certificate of Incorporation (the &#8220;Proposed Charter&#8221;) in the form attached hereto as <span style="font-style:italic">Annex B</span> (Proposal No.&#160;2); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Governance Proposal</span> &#8212; To consider and act upon, on a <span style="white-space:nowrap">non-binding</span> advisory basis, a separate proposal with respect to certain governance provisions in the Proposed Charter in order to give holders of ACAB&#8217;s common stock the opportunity to present their separate views on important corporate governance procedures (Proposal No.&#160;3); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Director Election Proposal</span> &#8212; To consider and vote upon a proposal to elect five directors to serve on the Board of Directors of the Post-Combination Company (the &#8220;Board&#8221;) until the 2025 annual meeting of stockholders, in the case of Class&#160;I directors, the 2026 annual meeting of stockholders, in the case of Class&#160;II directors, and the 2027 annual meeting of stockholders, in the case of Class&#160;III directors, and, in each case, until their respective successors are duly elected and qualified (Proposal No.&#160;4); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Merger Issuance Proposal &#8212;</span> To consider and vote upon a proposal to approve, for purposes of complying with applicable listing rules of The Nasdaq Global Market (&#8220;Nasdaq&#8221;), the issuance of shares of Series A common stock pursuant to the Business Combination (Proposal No.&#160;5); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Incentive Plan Proposal &#8212;</span> To consider and vote upon a proposal to approve and adopt the Incentive Plan (as defined herein) (Proposal No.&#160;6); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Adjournment Proposal &#8212;</span> To consider and vote upon a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal, or we determine that one or more of the closing conditions to Business Combination Agreement is not satisfied or waived (Proposal No.&#160;7). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These items of business are described in the attached proxy statement/prospectus, which we encourage you to read in its entirety before voting. Only holders of record of ACAB common stock at the close of business on&#8195;&#8195;&#8195;, 2024 (the &#8220;ACAB Record Date&#8221;) are entitled to notice of the Special Meeting and to vote and have their votes counted at the Special Meeting and any adjournments or postponements of the Special Meeting. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to ACAB&#8217;s Existing Charter, ACAB will provide holders of its Public Shares (as defined herein) with the opportunity to redeem their Public Shares for cash equal to their pro rata share of the aggregate amount on deposit in ACAB&#8217;s trust account, which holds the proceeds of the ACAB IPO (as defined herein), as of two business days prior to the consummation of the transactions contemplated by the Business Combination Proposal (including interest earned on the funds held in the trust account and not previously released to ACAB to pay its taxes). For illustrative purposes, based on funds in the trust account of approximately $7.2&#160;million on February&#160;29, 2024, the estimated redemption price as defined in ACAB&#8217;s amended and restated charter, which is projected to be approximately $10.20 (the &#8220;Redemption Price&#8221;), would have been approximately $&#8195;&#8195;&#8195;&#8195;, excluding additional interest earned on the funds held in the trust account and not previously released to ACAB to pay taxes. Public stockholders (as defined herein) may elect to redeem their shares even if they vote for the Business Combination Proposal. A holder of Public Shares, together with any affiliate of such holder or any other person with whom such holder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3) of the Exchange Act), will be restricted from seeking redemption rights with respect to more than 15% of the Public Shares without the consent of ACAB. Accordingly, all Public Shares in excess of 15% held by a public stockholder, together with any affiliate of such holder or any other person with whom such holder is acting in concert or as a &#8220;group,&#8221; will not be redeemed for cash without the consent of ACAB. Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;Sponsor&#8221;), and ACAB&#8217;s directors and officers have agreed to waive their redemption rights in connection with the consummation of the Business Combination with respect to any shares of common stock they may hold. Currently, the Initial Stockholders (as defined herein) own approximately 91.8% of ACAB common stock, consisting of the Founder Shares (as defined herein). Founder Shares will be excluded from the pro rata calculation used to determine the Redemption Price. The Sponsor and ACAB&#8217;s directors and officers have agreed to vote any shares of common stock owned by them in favor of each of the proposals presented at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Sponsor, ACAB&#8217;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#8220;Series B Holders&#8221;) voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company (the &#8220;Conversion&#8221;) in accordance with the charter amendment. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board (as defined below)). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74 per share redeemed. As a result of the Conversion and the results of the stockholder meetings described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After careful consideration, ACAB&#8217;s board of directors (the &#8220;ACAB Board&#8221;) has determined that the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal are fair to and in the best interests of ACAB and its stockholders and unanimously recommends that you vote or give instruction to vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Business Combination Proposal, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Charter Approval Proposal, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Governance Proposal, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Director Election Proposal, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Merger Issuance Proposal, &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Incentive Plan Proposal and &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Adjournment Proposal, if presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consummation of the Business Combination is conditional on approval of each of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal. If any of these proposals is not approved, the other proposals, except the Adjournment Proposal, will not be presented to stockholders for a vote. The proxy statement/prospectus accompanying this notice explains the Business Combination Agreement and the transactions contemplated thereby, as well as the proposals to be considered at the Special Meeting. Please review the proxy statement/prospectus carefully. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All ACAB stockholders are cordially invited to attend the Special Meeting in virtual format. ACAB stockholders may attend, vote and examine the list of ACAB stockholders entitled to vote at the Special Meeting by visiting and entering the control number found on their proxy card, voting instruction form or notice included in their proxy materials. The Special Meeting will be held in virtual meeting format only. You will not be able to attend the Special Meeting physically. To ensure your representation at the Special Meeting, you are urged to complete, sign, date and return the enclosed proxy card as soon as possible. If your shares are held in an account at a brokerage firm or bank, you must instruct your broker or bank on how to vote your shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your vote is important regardless of the number of shares you own. Whether you plan to attend the Special Meeting or not, please sign, date and return the enclosed proxy card as soon as possible in the envelope provided. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your participation. We look forward to your continued support. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:46%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">By Order of the Board of Directors</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&#160;</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> &#160;<p style=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&#160;</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ SHAHRAAB AHMAD</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad <span style="font-style:italic"></span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chairman and Chief Executive Officer</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED IN FAVOR OF EACH OF THE PROPOSALS. TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST ELECT TO HAVE ACAB REDEEM YOUR SHARES FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO ACAB&#8217;S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE SPECIAL MEETING. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#8217;S DWAC (DEPOSIT AND WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL NOT BE REDEEMED FOR CASH. IF YOU HOLD THE SHARES IN STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. SEE &#8220;</span><span style="font-weight:bold"><span style="font-style:italic">ACAB&#8217;S SPECIAL MEETING OF STOCKHOLDERS &#8212; REDEMPTION RIGHTS</span></span><span style="font-style:italic">&#8221; FOR MORE SPECIFIC INSTRUCTIONS. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="text-decoration:underline">Page</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_1a">ADDITIONAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_1">BASIS OF PRESENTATION AND GLOSSARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_2">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_3">QUESTIONS AND ANSWERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_4">SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_6">MARKET PRICE AND DIVIDEND INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_7">FORWARD-LOOKING STATEMENTS; SUMMARY RISK FACTORS; MARKET, RANKING AND OTHER INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_8">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc509388_5">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc509388_8a">ACAB&#8217;S SPECIAL MEETING OF STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_9">PROPOSAL NO. 1 &#8212; THE BUSINESS COMBINATION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_10">PROPOSAL NO. 2 &#8212; THE CHARTER APPROVAL PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_11">PROPOSAL NO. 3 &#8212; THE GOVERNANCE PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_12">PROPOSAL NO. 4 &#8212; THE DIRECTOR ELECTION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_13">PROPOSAL NO. 5 &#8212; THE MERGER ISSUANCE PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_14">PROPOSAL NO. 6 &#8212; THE INCENTIVE PLAN PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_15">PROPOSAL NO. 7 &#8212; THE ADJOURNMENT PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_16">INFORMATION ABOUT ACAB</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_17">MANAGEMENT OF ACAB</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_18">ACAB MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_19">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF ACAB AND THE POST-COMBINATION COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_20">INFORMATION ABOUT ABPRO</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_21">ABPRO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_22">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF ABPRO</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_23">MANAGEMENT AND BOARD OF THE POST-COMBINATION COMPANY FOLLOWING THE BUSINESS COMBINATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc509388_23a">ABPRO EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_24">THE BUSINESS COMBINATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_25">PUBLIC TRADING MARKETS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_26">THE BUSINESS COMBINATION AGREEMENT AND RELATED AGREEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_27">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_28">COMPARISON OF STOCKHOLDERS&#8217; RIGHTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_29">DESCRIPTION OF CAPITAL STOCK OF THE POST-COMBINATION COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_30">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_31">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_32">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_33">OTHER MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_34">APPRAISAL RIGHTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_35">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc509388_36">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ANNEXES</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_36">ANNEX A - BUSINESS COMBINATION AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">A-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_37">ANNEX B - FORM OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">B-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx509388_38">ANNEX C - FORM OF AMENDED AND RESTATED BYLAWS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">C-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_1a">ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB files reports, proxy statements and other information with the SEC as required by the Exchange Act. You can read ACAB&#8217;s SEC filings, including this proxy statement/prospectus, over the Internet at the SEC&#8217;s website at http://www.sec.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination or the Proposals to be presented at the special meeting, you should contact ACAB&#8217;s proxy solicitation agent at the following address and telephone number: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Morrow Sodali LLC </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">333 Ludlow Street, 5th Floor, South Tower </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Stamford, CT 06902 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Individuals call toll-free (800) 662-5200 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Banks and brokers call (203) 658-9400 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Email: ACAB.info@investor.morrowsodali.com </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an ACAB stockholder and would like to request documents, please do so by &#8195;&#8195;&#8195;&#8195;, 2024, in order to receive them before the special meeting. If you request any documents from ACAB, ACAB will mail them to you by first class mail, or another equally prompt means. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_1">BASIS OF PRESENTATION AND GLOSSARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this proxy statement/prospectus, unless otherwise noted or the context otherwise requires, references to: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">ACAB</span>&#8221; are to Atlantic Coastal Acquisition Corp. II, a Delaware corporation; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">ACAB IPO</span>&#8221; are to the initial public offering by ACAB which closed on January&#160;19, 2022; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">ACAB warrants</span>&#8221; are to the warrants exercisable to purchase Series A common stock of ACAB; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Abpro</span>&#8221; are to Abpro Corporation, a Delaware corporation; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Available Cash</span>&#8221; are to, as of the Closing (a)&#160;the amount of funds contained in the trust account (after reduction for the aggregate amount of payments made or required to be made in connection with the redemptions of Public Shares), plus (b)&#160;the amount of funds available to consummate the Business Combination pursuant to a PIPE financing, forward purchase agreements, an equity line of credit, convertible note financing, and other sources of financing minus (c)&#160;unpaid SPAC expenses; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Business Combination Agreement</span>&#8221; are to the Business Combination Agreement, dated as of December&#160;11, 2023, by and among ACAB, Merger Sub and Abpro, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Code</span>&#8221; are to the Internal Revenue Code of 1986, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">common stock</span>&#8221; are to Series A common stock and Series B common stock of ACAB; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Company Owners</span>&#8221; are to the stockholders of Abpro prior to the Closing; </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Completion Window</span>&#8221; are to the period following the completion of the ACAB IPO at the end of which, if ACAB has not completed its initial business combination, it will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to ACAB to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of ACAB&#8217;s remaining stockholders and the ACAB Board, dissolve and liquidate, subject to ACAB&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. On December&#160;15, 2023, the stockholders of ACAB approved the proposal to extend the Completion Window to March&#160;19, 2024 and further provide that the ACAB Board may, without another stockholder vote, further extend the Completion Window on a monthly basis up to six times by an additional one month each time thereafter by resolution of the ACAB Board, if requested by the Sponsor, until September&#160;19, 2024, subject in each case to certain advance notice requirements. On April 15, 2024, the ACAB Board adopted a resolution to extend the Completion Window to May 19, 2024; </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">DGCL</span>&#8221; are to the Delaware General Corporation Law, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; are to the Securities Exchange Act of 1934, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Existing Charter</span>&#8221; are to the Amended and Restated Certificate of Incorporation of ACAB, dated January&#160;18, 2022, as amended by Amendment No.&#160;1 dated April&#160;18, 2023 and Amendment No. 2 dated December&#160;15, 2023; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Founder Shares</span>&#8221; are to (i)&#160;the one (1)&#160;share of ACAB&#8217;s Series B common stock held by the Sponsor; (ii)&#160;the 7,499,999 shares of ACAB&#8217;s Series B common stock that were converted by the Initial Stockholders into ACAB&#8217;s Series A common stock on April&#160;18, 2023; and (iii)&#160;ACAB&#8217;s Series A common stock issued upon the automatic conversion of the one (1)&#160;share of ACAB&#8217;s Series B common stock at the time of ACAB&#8217;s initial business combination as provided herein. The 7,500,000 Founder Shares are held of record by the Initial Stockholders as of the ACAB Record Date; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">GAAP</span>&#8221; are to generally accepted accounting principles in the United States, as applied on a consistent basis; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Initial Stockholders</span>&#8221; are to the Sponsor, Apeiron Investment Group and certain directors of ACAB who hold Founder Shares as of the date of this proxy statement/prospectus; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Investment Company Act</span>&#8221; are to the Investment Company Act of 1940, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Maximum Redemption Scenario</span>&#8221; are to the redemption scenario assuming that holders of 667,391, or approximately 1.4% of ACAB&#8217;s outstanding Series A common stock, exercise redemption rights; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Merger Sub</span>&#8221; are to Abpro Merger Sub Corp., a Delaware corporation; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Post-Combination Company</span>&#8221; are to ACAB following the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">private placement warrants</span>&#8221; are to ACAB&#8217;s warrants issued to the Sponsor in a private placement simultaneously with the closing of the ACAB IPO; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Public Shares</span>&#8221; are to shares of ACAB&#8217;s Series A common stock sold as part of the units in the ACAB IPO (whether they were purchased in the ACAB IPO or thereafter in the open market); </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">public stockholders</span>&#8221; are to the holders of ACAB&#8217;s Public Shares, including the Sponsor and ACAB&#8217;s directors and officers to the extent the Sponsor and ACAB&#8217;s directors or officers purchase Public Shares; provided, that each of their status as a &#8220;public stockholder&#8221; shall only exist with respect to such Public Shares; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">public warrants</span>&#8221; are to ACAB&#8217;s warrants sold as part of the units in the ACAB IPO (whether they were purchased in the ACAB IPO or thereafter in the open market); </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">SEC</span>&#8221; are to the Securities and Exchange Commission; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; are to the Securities Act of 1933, as amended; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Series A common stock</span>&#8221; are to the Series A common stock, par value $0.0001 per share, of ACAB; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Series B common stock</span>&#8221; are to the Series B common stock, par value $0.0001 per share, of ACAB; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Sponsor</span>&#8221; are to Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Sponsor Letter Agreement</span>&#8221; are to the Amended Sponsor Letter Agreement, dated January&#160;18, 2024, among Abpro, ACAB, the Sponsor and Abpro Bio International, Inc.; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">VWAP</span>&#8221; are to volume weighted average price; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">warrants</span>&#8221; are to the public warrants and the private placement warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless specified otherwise, amounts in this proxy statement/prospectus are presented in United States (&#8220;U.S.&#8221;) dollars. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Defined terms in the financial statements contained in this proxy statement/prospectus have the meanings ascribed to them in the financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_2">TRADEMARKS, TRADE NAMES AND SERVICE MARKS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB, Abpro and Abpro&#8217;s subsidiary own or have rights to trademarks, trade names and service marks that they use in connection with the operation of their business. In addition, their names, logos and website names and addresses are their trademarks or service marks. Other trademarks, trade names and service marks appearing in this proxy statement/prospectus are the property of their respective owners. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to in this proxy statement/prospectus are listed without the applicable <sup style="font-size:75%; vertical-align:top">&#174;</sup>, <sup style="font-size:75%; vertical-align:top">&#8482;</sup> and <sup style="font-size:75%; vertical-align:top">SM</sup> symbols, but they will assert, to the fullest extent under applicable law, their rights to these trademarks, trade names and service marks. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_3">QUESTIONS AND ANSWERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The questions and answers below highlight only selected information from this proxy statement/prospectus and only briefly address some commonly asked questions about the Business Combination, the Special Meeting and the proposals to be presented at the Special Meeting, including with respect to the proposed Business Combination. The following questions and answers do not include all the information that is important to ACAB and Abpro stockholders. You are urged to read carefully this entire proxy statement/prospectus, including the Annexes and the other documents referred to herein, to fully understand the Business Combination and the voting procedures for the Special Meeting. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT IS THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">ACAB, Merger Sub, a wholly owned subsidiary of ACAB, and Abpro have entered into the Business Combination Agreement, pursuant to which Merger Sub will merge with and into Abpro with Abpro surviving the merger as a wholly owned subsidiary of ACAB. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ACAB will hold the Special Meeting to, among other things, obtain the approvals required for the Business Combination and the other transactions contemplated by the Business Combination Agreement and you are receiving this proxy statement/prospectus in connection with such meeting. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements</span>&#8221; beginning on page&#160;250. In addition, a copy of the Business Combination Agreement is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex A</span>. We urge you to read carefully this proxy statement/prospectus, including the Annexes and the other documents referred to herein, in their entirety. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHY AM I RECEIVING THIS DOCUMENT? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">ACAB is sending this proxy statement/prospectus to its stockholders to help them decide how to vote their shares of ACAB common stock with respect to the matters to be considered at the Special Meeting. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination cannot be completed unless ACAB&#8217;s stockholders approve the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal set forth in this proxy statement/prospectus for their approval. Information about the Special Meeting, the Business Combination and the other business to be considered by stockholders at the Special Meeting is contained in this proxy statement/prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This document constitutes a proxy statement and a prospectus of ACAB. It is a proxy statement because the board of directors of ACAB is soliciting proxies using this proxy statement/prospectus from its stockholders. It is a prospectus because ACAB, in connection with the Business Combination, is offering shares of ACAB&#8217;s Series A common stock in exchange for the outstanding shares of Abpro common stock and preferred stock. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Merger Consideration</span>&#8221;. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">FOLLOWING THE BUSINESS COMBINATION, WHAT WILL BE THE COMBINED COMPANY&#8217;S LIQUIDITY POSITION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Following the closing of the Business Combination, assuming no ACAB Public Shares are redeemed, and no additional funding is obtained, the combined company is expected to have cash of $&#8195;&#8195;&#8195; million and working capital of $&#8195;&#8195;&#8195; million on its balance sheet. Assuming 50% of ACAB Public Shares are redeemed, and no additional funding is obtained, the combined company is expected to have cash of $&#8195;&#8195;&#8195; million and a working capital deficit of $&#8195;&#8195;&#8195; million on its balance sheet. Assuming the maximum ACAB Public Shares are redeemed, and no additional funding is obtained, the combined company is expected to have cash of $&#8195;&#8195;&#8195; million and a working capital deficit of $&#8195;&#8195;&#8195; million on its balance sheet to fund operations. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The management teams of ACAB and Abpro are continuing to analyze the available financing options based on cost, amount available as the result of the proposed PIPE Financing and future effects that any financing would have on the capitalization of the combined company. The Post-Combination Company intends to use any funds raised in connection with the Business Combination to repay any debt obligations of Abpro and ACAB outstanding as of the Closing Date and to pay transaction expenses. Any remaining proceeds will be used to fund the Post-Combination Company&#8217;s clinical trials and operations. As of December 31, 2023, Abpro had approximately $1.4&#160;million of principal outstanding under the promissory note dated October 18, 2023 issued to Abpro Bio International Inc. (with the option to draw approximately an additional $4.6&#160;million prior to the Closing Date) and $0.3&#160;million of principal outstanding under promissory notes issued by it to related parties and ACAB had approximately $1.7&#160;million of outstanding advances from related parties and $0.2&#160;million of principal outstanding under promissory notes issued by it to related parties. As of the date of this proxy statement/prospectus, the estimated transaction expenses for merger and acquisition fees, proxy solicitor fees, market maker fees, legal fees, PIPE Financing fees, independent registered public accounting firms fees and other fees payable by ACAB and Abpro are approximately $1.8&#160;million and $1.4&#160;million (exclusive of the deferred underwriters&#8217; fees settled in Series A common stock shares), respectively. The aggregate fees due at closing are anticipated to be approximately $3.2&#160;million. The management of ACAB and Abpro do not currently anticipate repayment of any other material payables in connection with the consummation of the Business Combination, including any potential settlement payments related to ongoing legal proceedings. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accordingly, assuming no ACAB shares are redeemed, and no additional funding is obtained, the Post-Combination Company is expected to have cash of $&#8195;&#8195;&#8195; million and working capital of $&#8195;&#8195;&#8195; million on its balance sheet, after deducting repayment of Abpro&#8217;s and ACAB&#8217;s outstanding debt obligations and approximately $&#8195;&#8195;&#8195; in liabilities related to transaction expenses not paid on or prior to the Closing Date. Assuming 50% of ACAB Public Shares are redeemed, and no additional funding is obtained, the Post-Combination Company is expected to have cash of $&#8195;&#8195;&#8195; million and a working capital deficit of $&#8195;&#8195;&#8195;&#160;million on its balance sheet, after deducting repayment of Abpro&#8217;s and ACAB&#8217;s outstanding debt obligations and approximately $&#8195;&#8195;&#8195; in liabilities related to transaction expenses not paid on or prior to the Closing Date. Assuming the maximum ACAB Public Shares are redeemed, and no additional funding is obtained, the Post-Combination Company is expected to have cash of $&#8195;&#8195;&#8195; million and a working capital deficit of $&#8195;&#8195;&#8195; million on its balance sheet to fund operations after deducting repayment of Abpro&#8217;s and ACAB&#8217;s outstanding debt obligations, and approximately $&#8195;&#8195;&#8195; in liabilities related to transaction expenses not paid on or prior to the Closing Date. The fees will be a liability of the Post-Combination Company after the Closing Date. The Abpro management team is expected to complete a PIPE and/or other financing arrangement to pay these fees at closing. There is no firm commitment for a PIPE financing or other financing arrangement. The Post-Combination Company is not expected to have any outstanding debt obligations as of the Closing Date. </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Abpro does not currently have sufficient funds to support its operations through a potential closing of the Business Combination prior to the current Termination Date, which is September&#160;19, 2024, and it will need to raise additional capital immediately to continue operations. In the absence of additional sources of financing, Abpro expects that its existing cash and cash equivalents will only allow it to continue its planned operations until the end of September 2024. There can be no assurance that Abpro will be able to timely secure such additional funding on acceptable terms and conditions, or at all. If Abpro cannot obtain sufficient capital immediately, it will not have sufficient cash and liquidity to finance its business operations as currently contemplated and may need to substantially alter, or possibly even discontinue, its operations, and as a result, would not be able to consummate the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that the number of Public Shares redeemed in connection with the Business Combination exceeds the number of Public Shares redeemed in the Maximum Redemption Scenario and the Available Closing Cash condition is otherwise not satisfied, pursuant to the Business Combination Agreement, Abpro may waive compliance with such condition. However, ACAB cannot guarantee that Abpro will grant any such waiver. In such event the Available Closing Cash condition is waived under the Maximum Redemption </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Scenario, Abpro expects that its existing cash and cash equivalents will only allow it to continue its planned operations until the end of September 2024. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, Abpro has concluded that there is substantial doubt over its ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable Abpro will be unable to meet its obligations as they become due within one year after the date that the financial statements included in this proxy statement/prospectus are issued. Even if Abpro is able to raise additional financing immediately and is able to consummate the Business Combination, the proceeds from the Business Combination may not be sufficient to alleviate its current going concern. Assuming that the condition that, at Closing, the Available Closing Cash is at least $8.7&#160;million, is satisfied and not waived, upon consummation of the Business Combination, Abpro expects to raise sufficient cash to fund its clinical trials and operations into 2025 based on its current business plan, and expectations and assumptions considering current macroeconomic conditions. However, these plans have not been finalized, no definitive agreement regarding a PIPE financing in connection with the Business Combination Agreement has been executed and there can be no assurance that Abpro will be successful in raising any cash in connection with the Business Combination and the Available Closing Cash condition may be waived and the Business Combination could be consummated with cash proceeds less than the Minimum Cash Condition. Abpro&#8217;s future capital requirements and the adequacy of available funds will depend on many factors, please see &#8220;<span style="font-style:italic">Abpro </span><span style="font-style:italic">Management&#8217;s</span><span style="font-style:italic"> </span><span style="font-style:italic">Discussion</span><span style="font-style:italic"> </span><span style="font-style:italic">and Analysis of</span><span style="font-style:italic"> </span><span style="font-style:italic">Financial</span><span style="font-style:italic"> </span><span style="font-style:italic">Condition</span><span style="font-style:italic"> </span><span style="font-style:italic">and</span><span style="font-style:italic"> </span><span style="font-style:italic">Results</span><span style="font-style:italic"> </span><span style="font-style:italic">of</span><span style="font-style:italic"> </span><span style="font-style:italic">Operations &#8212; Liquidity, Capital Resources and Going Concern</span>.&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">ARE THERE ANY CONDITIONS THAT RAISE SUBSTANTIAL DOUBT ABOUT ABPRO&#8217;S ABILITY TO CONTINUE AS A&#160;GOING&#160;CONCERN? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As December 31, 2023, Abpro had $<span style="font-weight:bold"></span>723 thousand<span style="font-weight:bold"> </span>in cash and working capital (deficit) of $(10,539) thousand. Abpro has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. Abpro may need to raise additional capital through loans or additional investments from the Sponsor, shareholders, officers, directors, or third parties. Abpro&#8217;s officers, directors and the Sponsor may, but are not obligated to, loan Abpro funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet Abpro&#8217;s working capital needs. Accordingly, Abpro may not be able to obtain additional financing. If Abpro is unable to raise additional capital, it may be required to take additional measures to conserve&#160;liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. Abpro cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about Abpro&#8217;s ability to continue as a&#160;going&#160;concern. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT WILL ABPRO STOCKHOLDERS RECEIVE IN THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If the Business Combination is completed, prior to the consummation of the Business Combination, each share of each series of Abpro preferred stock issued and outstanding immediately prior to the effective time of the Business Combination (the &#8220;Effective Time&#8221;) (other than shares owned by Abpro as treasury stock or dissenting shares) will be converted into the right to receive a share of Abpro common stock. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each share of Abpro common stock issued and outstanding immediately prior to the Effective Time (other than shares owned by Abpro as treasury stock or dissenting shares) will be converted into the right to receive a number of shares of Series A common stock (deemed to have a value of $10.00 per share) with an aggregate implied pre-money value equal to $500,000,000 (such valuation excluding the Abpro Incentive Shares (as defined herein)) divided by the number of shares of Abpro common stock outstanding on a fully diluted basis immediately prior to the Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the Business Combination Agreement provides existing holders of Abpro common stock with a contingent right to receive a pro rata portion of up to 14,500,000 additional shares of Post-Combination Company Series A common stock (the &#8220;Earn-out Shares&#8221;), subject to the following contingencies: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">33% of the Earn-out Shares if, at any time during the 5 years following the Closing (the &#8220;Earnout Period&#8221;), the volume-weighted average trading sale price of one share of Post-Combination Company Series A common stock is greater than or equal to $13.00 per share for any twenty trading days within any thirty trading day period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">33% of the Earn-out Shares if, at any time during the Earnout Period, the volume-weighted average trading sale price of one share of Post-Combination Company Series A common stock is greater than or equal to $15.00 per share for any twenty trading days within any thirty trading day period; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">33% of the Earn-out Shares if, at any time during the Earnout Period, the volume-weighted average trading sale price of one share of Post-Combination Company Series A common stock is greater than or equal to $18.00 per share for any twenty trading days within any thirty trading day period. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of Abpro common stock outstanding, the number of shares of Abpro preferred stock outstanding, the number of outstanding stock options, restricted stock awards and restricted stock unit awards as of&#8195;&#8195;&#8195;&#8195;, 2024, the total number of shares of ACAB&#8217;s Series A common stock expected to be issued to holders of shares of Abpro capital stock in connection with the closing of the Business Combination (the &#8220;Closing&#8221;) is approximately&#8195;&#8195;&#8195;&#8195;million. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">HOW WILL THE COMBINED COMPANY BE MANAGED FOLLOWING THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Following the Closing, it is expected that the current management of Abpro will become the management of the Post-Combination Company, and the Post-Combination Company&#8217;s board of directors will consist of five (5) directors, which shall be divided into three (3) classes, designated Class I, II and III, with Class I directors, consisting of &#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195;, serving until the first annual meeting of the Post-Combination Company (but any subsequent Class I directors serving a three-year&#160;term), Class II directors, consisting of &#8195;&#8195;&#8195;&#8195;and &#8195;&#8195;&#8195;&#8195;, serving until the second annual meeting of the Post-Combination Company (but any subsequent Class II directors serving a three-year&#160;term), and Class III directors, consisting of &#8195;&#8195;&#8195;&#8195;, serving until the third annual meeting of the Post-Combination Company, with the number of directors assigned to each class to be mutually agreed by ACAB and Abpro prior to the effectiveness of the registration statement. Pursuant to the Business Combination Agreement, (i) ACAB will designate &#8195;&#8195;&#8195;&#8195; as a Class I director, who is expected to qualify as an independent director under Nasdaq rules; and (ii) Abpro shall designate four (4) persons for election to the initial Post-Combination Company Board, of whom shall be a Class I director, of whom shall be a Class II director and of whom shall a Class III director, at least two (2) of whom shall be required to qualify as an independent director under Nasdaq rules. Please see the section entitled &#8220;<span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management of ACAB and the Post-Combination Company</span>&#8221; for further information. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHEN DO YOU EXPECT THE BUSINESS COMBINATION TO BE COMPLETED? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">It is currently anticipated that the Business Combination will be consummated promptly following the Special Meeting, which is set for&#8195;&#8195;&#8195;&#8195;, 2024; however, such meeting could be adjourned, as described herein. However, neither ACAB nor Abpro can assure you of when or if the Business Combination will be completed and it is possible that factors outside of the control of both companies could result in the Business Combination being completed at a different time or not at all. ACAB must first obtain the approval of its stockholders for certain of the proposals set forth in this proxy statement/prospectus for their approval, Abpro must first obtain the written consent of its stockholders for the Business Combination and ACAB and Abpro must also first obtain certain necessary regulatory approvals and satisfy other closing conditions. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Conditions to Closing of the Business Combination</span>&#8221; beginning on page&#160;251. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT HAPPENS IF THE BUSINESS COMBINATION IS NOT COMPLETED? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If the Business Combination is not completed, Abpro stockholders will not receive any consideration for their shares of Abpro capital stock. Instead, Abpro will remain an independent company. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">QUESTIONS AND ANSWERS ABOUT ACAB&#8217;S SPECIAL STOCKHOLDER MEETING </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHEN AND WHERE IS THE SPECIAL MEETING? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Special Meeting will be held at 9:00 a.m. eastern time, on&#8195;&#8195;&#8195;&#8195;, 2024, in virtual format. ACAB stockholders may attend, vote and examine the list of ACAB stockholders entitled to vote at the Special Meeting by visiting &#8195;&#8195;and entering the control number found on their proxy card, voting instruction form or notice included in their proxy materials. The Special Meeting will be held in virtual meeting format only. You will not be able to attend the Special Meeting physically. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT AM I BEING ASKED TO VOTE ON AND WHY IS THIS APPROVAL NECESSARY? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The stockholders of ACAB are being asked to vote on the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to adopt the Business Combination Agreement and the transactions contemplated thereby. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 1 &#8212; The Business Combination Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to adopt the Second Amended and Restated Certificate of Incorporation (the &#8220;Proposed Charter&#8221;) in the form attached hereto as <span style="font-style:italic">Annex B</span>. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A separate proposal with respect to certain governance provisions in the Proposed Charter, which are being separately presented in order to give holders of ACAB&#8217;s common stock the opportunity to present their separate views on important corporate governance procedures and which will be voted upon on a <span style="white-space:nowrap">non-binding</span> advisory basis. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 3 &#8212; The Governance Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to elect five directors to serve on the Board until the 2025 annual meeting of stockholders, in the case of Class&#160;I directors, the 2026 annual meeting of stockholders, in the case of Class&#160;II directors, and the 2027 annual meeting of stockholders, in the case of Class&#160;III directors, and, in each case, until their respective successors are duly elected and qualified. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 4 &#8212; The Director Election Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to approve, for purposes of complying with applicable listing rules of Nasdaq, the issuance of shares of Series A common stock pursuant to the Business Combination. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 5 &#8212; The Merger Issuance Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">6.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to approve and adopt the Incentive Plan. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 6 &#8212; The Incentive Plan Proposal</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">7.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal, or we determine that one or more of the closing conditions to Business Combination Agreement is not satisfied or waived. See the section entitled &#8220;<span style="font-style:italic">Proposal No. 7 &#8212; The Adjournment Proposal</span>.&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ACAB will hold the Special Meeting to consider and vote upon these proposals. This proxy statement/prospectus contains important information about the proposed Business Combination and the other matters to be acted upon at the Special Meeting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stockholders should read this proxy statement/prospectus carefully, including the Annexes and the other documents referred to herein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Consummation of the Business Combination is conditional on approval of each of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal, subject to the terms of the Business Combination Agreement. If any of these proposals is not approved, the other proposals, except the Adjournment Proposal, will not be presented to stockholders for a vote. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">The vote of stockholders is important. Stockholders are encouraged to vote as soon as possible after carefully reviewing this proxy statement/prospectus. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">I AM AN ACAB WARRANT HOLDER. WHY AM I RECEIVING THIS PROXY STATEMENT/PROSPECTUS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Upon consummation of the Business Combination, the ACAB warrants shall, by their terms, entitle the holders to purchase Series A common stock at a purchase price of $11.50 per share. This proxy statement/prospectus includes important information about Abpro and the business of Abpro and its subsidiary following consummation of the Business Combination. As holders of ACAB warrants will be entitled to purchase Series A common stock of ACAB upon consummation of the Business Combination, ACAB urges you to read the information contained in this proxy statement/prospectus carefully. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHY IS ACAB PROPOSING THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">ACAB was organized to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2022, ACAB completed its initial public offering of 30,000,000 units, with each unit consisting of one Public Share and <span style="white-space:nowrap">one-half</span> of one public warrant, each whole public warrant to purchase one share of common stock at a price of $11.50, raising total gross proceeds of $300,000,000, which included the partial exercise by the underwriters in the ACAB IPO (the &#8220;Underwriters&#8221;) of their over- allotment option. Since the ACAB IPO, ACAB&#8217;s activity has been limited to the evaluation of business combination candidates. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Abpro is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. Abpro is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune<sup style="font-size:75%; vertical-align:top">&#174;</sup> and MultiMab<sup style="font-size:75%; vertical-align:top">TM</sup> antibody discovery and engineering platforms, Abpro is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Based on its due diligence investigations of Abpro and the industry in which it operates, including the financial and other information provided by Abpro in the course of their negotiations in connection with the Business Combination Agreement, ACAB believes that the Business Combination with Abpro is advisable and in the best interests of ACAB and its stockholders. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Recommendation of the ACAB Board and Reasons for the Business Combination.</span>&#8221; </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DID THE ACAB BOARD OBTAIN A THIRD-PARTY VALUATION OR FAIRNESS OPINION IN DETERMINING WHETHER OR NOT TO PROCEED WITH THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The ACAB Board did not obtain a third-party valuation or fairness opinion in connection with their determination to approve the Business Combination with Abpro. The directors and officers of ACAB and ACAB&#8217;s advisors have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and backgrounds, together with the experience and sector expertise of ACAB&#8217;s financial advisors and consultants, enabled them to make the necessary analyses and determinations regarding the Business Combination with Abpro. In addition, ACAB&#8217;s directors and officers and ACAB&#8217;s advisors have substantial experience with mergers and acquisitions. Accordingly, investors will be relying solely on the judgment of the ACAB Board and ACAB&#8217;s advisors in valuing Abpro&#8217;s business. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DO I HAVE REDEMPTION RIGHTS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you are a holder of Public Shares, you have the right to demand that ACAB redeem such shares for a pro rata portion of the cash held in ACAB&#8217;s trust account. ACAB sometimes refers to these rights to demand redemption of the Public Shares as &#8220;redemption rights.&#8221; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of Public Shares, together with any affiliate of such holder or any other person with whom such holder is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3) of the Exchange Act) will be restricted from seeking redemption with respect to more than 15% of the Public Shares without the consent of ACAB. Accordingly, all Public Shares in excess of 15% held by a public stockholder, together with any affiliate of such stockholder or any other person with whom such holder is acting in concert or as a &#8220;group,&#8221; will not be redeemed without the consent of ACAB. Abpro is not required to consummate the Business Combination if there is not at least $8,700,000 of Available Cash. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WILL HOW I VOTE AFFECT MY ABILITY TO EXERCISE REDEMPTION RIGHTS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">No. You may exercise your redemption rights whether you vote your Public Shares for or against, or whether you abstain from voting on, the Business Combination Proposal or any other proposal described in this proxy statement/prospectus. As a result, the Business Combination Proposal can be approved by stockholders who will redeem their Public Shares and no longer remain stockholders and the Business Combination may be consummated even though the funds available from ACAB&#8217;s trust account and the number of public stockholders are substantially reduced as a result of redemptions by public stockholders. However, Abpro is not required to consummate the Business Combination if there is not at least $8,700,000 of Available Cash. Also, with fewer Public Shares and public stockholders, the trading market for ACAB&#8217;s Series A common stock may be less liquid than the market for Public Shares prior to the Business Combination and ACAB may not be able to meet the listing standards of a national securities exchange. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">HOW DO I EXERCISE MY REDEMPTION RIGHTS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you are a holder of Public Shares and wish to exercise your redemption rights, you must (i)&#160;demand that ACAB redeem your shares for cash no later than the second business day preceding the vote on the Business Combination Proposal by delivering your stock to ACAB&#8217;s transfer agent physically or electronically using Depository Trust Company&#8217;s DWAC (Deposit and Withdrawal at Custodian) system. Any holder of Public Shares will be entitled to demand that such holder&#8217;s shares be redeemed for a pro rata portion of the amount then in the trust account (which, for illustrative purposes, was approximately $&#8195;&#8195;&#8195;&#8195;, or $&#8195;&#8195;&#8195;&#8195;per share, as of&#8195;&#8195; , 2024, the ACAB Record Date). Such amount, including interest earned on the funds held in the trust account and not previously released to ACAB to pay its taxes, will be paid promptly upon consummation of the Business Combination. However, under Delaware law, the proceeds held in the trust account could be subject to claims which could take priority over those of ACAB&#8217;s public stockholders exercising redemption rights, regardless of whether such holders vote for or against the Business Combination Proposal. Therefore, the <span style="white-space:nowrap">per-share</span> distribution from the trust account in such a situation may be less than originally anticipated due to such claims. Your vote on any proposal will have no impact on the amount you will receive upon exercise of your redemption rights. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Any request for redemption, once made by a holder of Public Shares, may be withdrawn at any time up to the time the vote is taken with respect to the Business Combination Proposal at the Special Meeting. If you deliver your shares for redemption to ACAB&#8217;s transfer agent and later decide prior to the Special Meeting not to elect redemption, you may request that ACAB&#8217;s transfer agent return the shares (physically or electronically). You may make such request by contacting ACAB&#8217;s transfer agent at the address listed at the end of this section. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a holder of Public Shares properly makes a request for redemption and the Public Shares are delivered as described to ACAB&#8217;s transfer agent as described herein, then, if the Business Combination is consummated, ACAB will redeem these shares for a pro rata portion of funds deposited in the trust account. If you exercise </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
your redemption rights, then you will be exchanging your shares of ACAB common stock for cash and you will cease to have any rights as an ACAB stockholder (other than the right to receive the redemption amount) upon consummation of the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the material U.S. federal income tax considerations for holders of Public Shares with respect to the exercise of these redemption rights, see &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Considerations &#8212; Material U.S. Federal Income Tax Consequences of the Redemption of ACAB Public Stockholders</span>&#8221; beginning on page&#160;267. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a holder of Public Shares and you exercise your redemption rights, it will not result in the loss of any public warrants that you may hold. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DO I HAVE APPRAISAL RIGHTS IF I OBJECT TO THE PROPOSED BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">No. Neither ACAB stockholders nor its unit or warrant holders have appraisal rights in connection with the Business Combination under the DGCL. See the section entitled &#8220;<span style="font-style:italic">ACAB&#8217;s Special Meeting of Stockholders &#8212; Appraisal Rights.</span>&#8221; </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT HAPPENS TO THE FUNDS DEPOSITED IN THE TRUST ACCOUNT AFTER CONSUMMATION OF THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A total of $306,000,000 in net proceeds of the ACAB IPO and the amount raised from the private sale of warrants simultaneously with the consummation of the ACAB IPO was placed in the trust account following the ACAB IPO. On April&#160;18, 2023, in connection with approval of the charter amendment proposal to extend the date by which ACAB must consummate a business combination to December&#160;19, 2023, holders of an aggregate of 26,564,308 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares and as a result, such holders received a payment of approximately $10.41 per share that they redeemed. On December&#160;15, 2023, in connection with approval of the charter amendment proposed to further extend the date by which ACAB must consummate a business transaction to September&#160;19, 2024 (subject to additional approval by the ACAB Board), holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares and as a result, such holders received a payment of approximately $10.74 per share redeemed. After such redemptions, and as of December&#160;31, 2023, there was approximately $7.4&#160;million in the trust account. The funds held in the trust account have been on deposit in a demand deposit bank account, owned and controlled by the trustee since December&#160;29, 2023. After consummation of the Business Combination, the funds in the trust account will be used to pay holders of the Public Shares who exercise redemption rights, to pay fees and expenses incurred in connection with the Business Combination and for the Post-Combination Company&#8217;s working capital and general corporate purposes. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">HOW IS THE PAYMENT OF THE DEFERRED UNDERWRITING COMMISSIONS GOING TO AFFECT THE AMOUNT LEFT IN THE TRUST ACCOUNT UPON THE COMPLETION OF THE BUSINESS COMBINATION? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The deferred underwriting commissions in connection with the ACAB IPO will be released to the underwriters only on completion of the Business Combination. The deferred underwriting commission is payable if a business combination is consummated without regard to the number of public shares redeemed by holders in connection with such Business Combination. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2024, ACAB and Cantor Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;) entered into the Fee Reduction Agreement, pursuant to which Cantor agreed to settle $10,290,000 of deferred underwriting fees payable in connection with the ACAB IPO, resulting in a remainder of $6,000,000 of deferred underwriting fees payable by ACAB to Cantor upon the closing of the Business Combination (the &#8220;Reduced Deferred Fee&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
The Reduced Deferred Fee shall be payable to Cantor in the form of 600,000 shares of Post-Combination Company common stock. As a result of the Reduced Deferred Fee not being payable in cash under any circumstances, payment of the deferred underwriting commissions will not affect the amount left in the Trust Account upon the completion of the Business Combination. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cantor agreed to the Reduced Deferred Fee after discussions with ACAB as a result of the anticipated transaction costs and redemptions in connection with the Closing of the Business Combination, which, without additional financing, would result in Available Closing Cash of less than $8.7 million and permit Abpro to terminate the Business Combination Agreement, and the Business Combination would not be consummated. The Reduced Deferred Fee would reduce the amount of transaction costs that would otherwise be paid from funds in the trust account at Closing, providing additional liquidity to ACAB in order to meet the Available Closing Cash condition. Although Cantor has not resigned as an underwriter pursuant to Section 11(b)(1) of the Securities Act, Cantor has not had any role in the identification or evaluation of Abpro as a business combination target for ACAB. ACAB did not expect Cantor to provide a service in connection with the closing of the Business Combination; therefore, the Reduced Deferred Fee agreement has not created any role in connection with the closing of the Business Combination that ACAB is seeking to fill. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You should read the section of this proxy statement/prospectus entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; for disclosure regarding the Reduced Deferred Fee on a percentage basis for shares at each redemption level. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT HAPPENS IF THE BUSINESS COMBINATION IS NOT CONSUMMATED? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If ACAB does not complete the Business Combination with Abpro for whatever reason, ACAB would search for another target business with which to complete a business combination. If ACAB does not complete the Business Combination with Abpro or another target business within the Completion Window, ACAB must redeem 100% of the outstanding Public Shares, at a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the amount then held in the trust account including interest earned on the funds held in the trust account and not previously released to ACAB to pay taxes (less up to $100,000 of interest to pay dissolution expenses) divided by the number of outstanding Public Shares. The Sponsor has no redemption rights in the event a business combination is not effected in the Completion Window, and, accordingly, their Founder Shares will be worthless. Additionally, in the event of such liquidation, there will be no distribution with respect to ACAB&#8217;s outstanding warrants. Accordingly, the warrants will expire worthless. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">HOW DO THE INITIAL STOCKHOLDERS INTEND TO VOTE ON THE PROPOSALS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Initial Stockholders of record are entitled to vote an aggregate of one (1)&#160;share of Series B common stock (held by the Sponsor) prior to consummation of the business combination. The Sponsor has agreed to vote any Founder Shares and any Public Shares held by them as of the ACAB Record Date in favor of each of the proposals presented at the Special Meeting. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Sponsor, ACAB&#8217;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#8220;Series B Holders&#8221;) voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company (the &#8220;Conversion&#8221;) in accordance with the charter amendment to extend the date by which a business combination must be consummated to December&#160;19, 2023. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74 per share redeemed. As a result of the Conversion and the results of the stockholder meeting described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT HAPPENS IF A SUBSTANTIAL NUMBER OF THE PUBLIC STOCKHOLDERS VOTE IN FAVOR OF THE BUSINESS COMBINATION PROPOSAL AND EXERCISE THEIR REDEMPTION RIGHTS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Our public Stockholders are not required to vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Business Combination in order to exercise their redemption rights. Accordingly, the Business Combination may be consummated even though the funds available from our trust account and the number of public stockholders are reduced as a result of redemptions by public stockholders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a public stockholder exercises its redemption rights, such exercise will not result in the loss of any warrants that it may hold. Regardless of the number of shares of common stock redeemed, the public warrant holders will retain the 15,000,000 ACAB public warrants (including the ACAB public warrants retained by ACAB public stockholders who exercised their respective redemption rights in connection with the extension meetings). Each of the retained outstanding public warrants would each have a value of approximately $&#8195;&#8195;&#8195; per warrant based on the closing price of the ACAB public warrants on the Nasdaq Capital Market on &#8195;&#8195;&#8195;, 2024. If a substantial number of, but not all, public stockholders exercise their redemption rights, but choose to exercise their retained warrants, any non-redeeming Stockholders would experience dilution to the extent such warrants are exercised and additional Post-Combination Company common stock is issued. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement provides that Abpro&#8217;s obligation to consummate the Business Combination is conditioned on, among other things, the minimum cash condition. The minimum cash condition requires that ACAB shall have Available Cash of at least $8,700,000 equal to the sum of (without duplication) (a) the amount of cash available to be released from the trust account as of immediately prior to the Closing (after reduction for the aggregate amount of payments made or required to be made in connection with the SPAC stockholder redemption), plus the amount of funds available to consummate the Business Combination pursuant to a PIPE Financing, minus unpaid SPAC expenses (the &#8220;Minimum Cash Condition&#8221;). If the Minimum Cash Condition is not met, and such condition is not waived by Abpro, then the Business Combination Agreement may be terminated, and the proposed Business Combination may not be consummated. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally, as a result of redemptions, the trading market for Post-Combination Company common stock may be less liquid than the market for the ACAB Series A common stock was prior to consummation of the Business Combination and we may not be able to meet the listing standards of Nasdaq. In addition, with less funds available from the trust account, the working capital infusion from the trust account into Abpro&#8217;s business will be reduced. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is anticipated that, upon completion of the Business Combination, and assuming no holders of Public Shares exercise their redemption rights and excluding the impacts of the &#8220;<span style="font-style:italic">Additional Dilution Sources</span>&#8221; in the sensitivity table below: (i) public stockholders will retain an ownership interest of approximately 1.3% of the outstanding Post-Combination Company Series A common stock; (ii) the ACAB initial stockholders will own approximately 7.1% of the outstanding Post-Combination Company Series A common stock; (iii)&#160;the PIPE Investors will own approximately 7.6% of the outstanding Post-Combination Company Series A common stock; and (iv) the Abpro stockholders will own approximately 78.1% of the outstanding Post-Combination Company Series A common stock. Assuming 100% of the holders of Public Shares exercise their redemption rights and excluding the impacts of the &#8220;<span style="font-style:italic">Additional Dilution Sources</span>&#8221; in the sensitivity table below: (i) public stockholders will retain no ownership interest of the outstanding Post-Combination Company Series A common stock; (ii) the ACAB initial stockholders will own approximately 7.2% of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
outstanding Post-Combination Company Series A common stock; (iii) the PIPE Investors will own approximately 7.7% of the outstanding Post-Combination Company Series A common stock; and (iv) the Abpro stockholders will own approximately 79.1% of the outstanding Post-Combination Company Series&#160;A common stock. </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The below sensitivity table shows the potential impact of redemptions on the share ownership by non-redeeming stockholders in a no redemption scenario, 25% redemption scenario, 75% redemption scenario, and 100% redemption scenario. The service provider row in the below sensitivity table includes the 600,000 shares of Post-Combination Company Series A common stock to be paid in satisfaction of the deferred underwriting commissions incurred in connection with the ACAB IPO in each redemption scenario because. The information in the below sensitivity table has been rounded to the nearest whole number or the nearest decimal, and does not give effect to any outstanding warrants or earn-out shares. Therefore, the sum of the numbers in a column may not conform exactly to the total figure given for that column in the below sensitivity table. In addition, certain percentages presented in the below sensitivity table reflect calculations based upon the underlying information prior to rounding and, accordingly, may not conform exactly to the percentages that would be derived if the relevant calculations were based upon the rounded numbers or may not sum due to rounding. Additionally, the below sensitivity table assumes the following will occur immediately prior to the Effective Time (as defined herein): (1) the exercise of all Public Warrants and Private Placement Warrants outstanding; (2) the exercise of all outstanding Abpro options outstanding; and (3) the exercise of all outstanding Abpro restricted stock units. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:96%;border:0;margin-left:auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemption </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming 25%<br/>Redemption </span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;75%<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;100%<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership<br/>in Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity%</span><span style="font-style:italic"></span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership<br/>in Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity%</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership<br/>in Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity%</span><span style="font-style:italic"></span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Ownership<br/>in Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">ACAB public stockholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">667,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,543<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>0.5<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%<span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>166,848</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>0.0</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">ACAB public warrants</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">Total ACAB public<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,667,391</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">15.0</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,500,543</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">14.9</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,166,848</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">14.7</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">15,000,000</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">14.5</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">ACAB Initial Stockholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">ACAB Private Placement Warrants</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">Sponsor Total<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,391,667</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">16.7</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,391,667</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">16.7</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,391,667</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">16.7</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">17,391,667</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">16.8</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Service Providers</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1.1<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%<span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1.1</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other Investors</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1.7<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%<span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span>1.7</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman;font-weight:bold">Total ACAB non-public<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,350,225</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">19.5</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,350,225</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">19.5</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,350,225</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">19.5</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">20,350,225</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">19.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold">%</span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Abpro Securityholders</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Shares Issuable Upon Exercise of Abpro Stock Options and Restricted Stock Units</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,115,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,115,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,115,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,115,489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Earnout Shares<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">PIPE Investors<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total Shares Outstanding<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,281,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,114,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,780,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,613,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table></div> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Fully-diluted total Public Shares is based on sum of Public Shares and Public Warrants. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Fully-diluted number of shares held by the Sponsor is based on sum of Private Placement Shares plus Private Placement Warrants plus Founder Shares held by the Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Fully-diluted total ACAB non-public shares include the shares held by the Sponsor, the shares transferred to service providers and to other investors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Fully-diluted Post-Combination Company total shares is based on ACAB total public and non-public shares, the shares issued to Abpro stockholders plus Abpro options and Abpro restricted stock units, the earnout shares and shares issued to PIPE investors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">For all scenarios, reflects the potential issuance of up to 14,500,000 of Earnout Shares if, within five calendar years after the Closing Date, the volume weighted average price of shares of Series A common stock on Nasdaq, or any other national securities exchange on which the shares of Series A common stock are then traded meets or exceeds three-tier target prices defined in the Business Combination Agreement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">For all scenarios, reflects the issuance of 3,763,400 shares to the investors in the proposed PIPE Financing, at the purchase price of $10.00 per share, net of related estimated placement agent fees of 7%. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share ownership presented in the table above is only presented for illustrative purposes and is based on a number of assumptions. ACAB cannot predict how many of its Public Stockholders will exercise their right to have their </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Shares redeemed for cash. As a result, the redemption amount and the number of Public Shares redeemed in connection with the Business Combination may differ from the amounts presented above. As such, the ownership percentages and voting power of current ACAB stockholders and Abpro stockholders may also differ from the presentation above if the actual redemptions are different from these assumptions. Public Stockholders that do not elect to redeem their Public Shares will experience dilution as a result of the Business Combination. The Public Stockholders currently own approximately 8.2% of ACAB&#8217;s capital stock, assuming that no warrants have been exercised, and approximately 42.3% on a fully diluted basis. As noted in the above table, if no Public Stockholders redeem their Public Shares in connection with the Business Combination, the Public Stockholders will go from owning approximately 42.3% of the ACAB&#8217;s capital stock prior to the Business Combination to owning approximately 15% of the total shares outstanding of the Post-Combination Company, on a fully diluted basis. The Public Stockholders will own approximately 1.3%, 1%, 0.3% and 0% (assuming no warrants have been exercised) and 15%, 14.9%, 14.7% and 14.5% (on a fully diluted basis and including the issuance of the Earnout Shares) of the total shares outstanding of the Post-Combination Company immediately after the Effective Time, assuming redemptions scenarios of 0%, 25%, 75% and 100% as shown above, respectively. </p> </div> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT CONSTITUTES A QUORUM AT THE SPECIAL MEETING? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">A majority of the voting power of the issued and outstanding common stock of ACAB entitled to vote at the Special Meeting must be present, in person (which would include presence at a virtual meeting) or represented by proxy, at the Special Meeting to constitute a quorum and in order to conduct business at the Special Meeting. Abstentions and broker <span style="white-space:nowrap">non-votes</span> will be counted as present for the purpose of determining a quorum. In the absence of a quorum, the chairman of the Special Meeting has power to adjourn the Special Meeting. As of the ACAB Record Date for the Special Meeting,&#8195;&#8195;&#8195;&#8195;shares of common stock would be required to achieve a quorum. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT VOTE IS REQUIRED TO APPROVE EACH PROPOSAL AT THE SPECIAL MEETING? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">The Business Combination Proposal:</span> The majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting is required to approve the Business Combination Proposal. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Business Combination Proposal, will have no effect on the Business Combination Proposal. ACAB stockholders must approve the Business Combination Proposal in order for the Business Combination to occur. If ACAB stockholders fail to approve the Business Combination Proposal, the Business Combination will not occur. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Charter Approval Proposal:</span> The affirmative vote of (i)&#160;the holders of a majority of the Founder Shares then outstanding, voting separately as a single class, (ii)&#160;the holders of a majority of the outstanding shares of common stock, voting together as a single class, is required to approve the Charter Approval Proposal. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Charter Approval Proposal, will have the same effect as a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; such Charter Approval Proposal. The Business Combination is conditioned upon the approval of the Charter Approval Proposal, subject to the terms of the Business Combination Agreement. Notwithstanding the approval of the Charter Approval Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Charter Approval Proposal will not be effected. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Governance Proposal:</span> The majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting is required to approve the Governance Proposal, which is a <span style="white-space:nowrap">non-binding</span> advisory vote. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Governance Proposal, will have no effect on the Governance Proposal. The Business Combination is not conditioned on the approval of the Governance Proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Director Election Proposal:</span> Directors are elected by a plurality of all of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. This means that the five director nominees who receive the most affirmative votes will be elected. Stockholders may not cumulate their votes with respect to the election of directors. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Director Election Proposal, will have no effect on the Director Election Proposal. The Business Combination is not conditioned on the approval of the Director Election Proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Merger Issuance Proposal:</span> The majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting is required to approve the Merger Issuance Proposal. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Merger Issuance Proposal, will have no effect on the Merger Issuance Proposal. The Business Combination is conditioned upon the approval of the Merger Issuance Proposal, subject to the terms of the Business Combination Agreement. Notwithstanding the approval of the Merger Issuance Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Merger Issuance Proposal will not be effected. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Incentive Plan Proposal:</span> The majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting is required to approve the Incentive Plan Proposal. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Incentive Plan Proposal, will have no effect on the Incentive Plan Proposal. The Business Combination is conditioned upon the approval of the Incentive Plan Proposal, subject to the terms of the Business Combination Agreement. Notwithstanding the approval of the Incentive Plan Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Incentive Plan Proposal will not be effected. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Adjournment Proposal:</span> The majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting is required to approve the Adjournment Proposal. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Adjournment Proposal, will have no effect on the Adjournment Proposal. The Business Combination is not conditioned on the approval of the Adjournment Proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As further discussed in the section entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; beginning on page 264 of this proxy statement/prospectus, Abpro, the Sponsor and ACAB&#8217;s directors and officers have entered into the Sponsor Letter Agreement with ACAB pursuant to which the Sponsor and such directors and officers have agreed to vote the Sponsor&#8217;s one (1)&#160;share of Series B common stock in favor of the each of the proposals presented at the Special Meeting, regardless of how public stockholders vote. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">DO ANY OF ACAB&#8217;S DIRECTORS OR OFFICERS HAVE INTERESTS IN THE BUSINESS COMBINATION THAT MAY DIFFER FROM OR BE IN ADDITION TO THE INTERESTS OF ACAB STOCKHOLDERS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Initial Stockholders, certain members of the ACAB Board and our officers may have interests in the Business Combination that are different from or in addition to your interests. You should take these interests into account in deciding whether to approve the Business Combination. These interests include, among other things, the interests listed below: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that unless ACAB consummates an initial business combination, ACAB&#8217;s officers, directors and the Sponsor will not receive reimbursement for any out-of-pocket&#160;expenses incurred by them to the </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
extent that such expenses exceed the amount of available proceeds not deposited in the Trust Account. As of February&#160;29, 2024, the Sponsor has incurred out-of-pocket expenses in the amount of $1.47&#160;million, consisting of fees and expenses related to the Business Combination and other public company expenses. $1.44 million of such expenses include repayment obligations due to Shahraab Ahmad, who is our Chief Executive Officer. Additional expenses may be incurred prior to consummation of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Initial Stockholders have agreed not to redeem any Series A common stock held by them in connection with a shareholder vote to approve a proposed initial business combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor paid an aggregate of $25,000 for 7,500,000 Founder Shares, of which 7,200,000 are currently owned by the Sponsor. Following the extension meeting held on April 18, 2023, the Initial Stockholders, as the sole holders of shares of Series B common stock, agreed to convert all of their shares of Series B common stock to shares of Series A common stock, on a one-for-one basis, in accordance with the charter amendment approved at the special meeting. The 3,241,667&#160;shares of Post-Combination Company Series A common Stock that the Initial Stockholders will hold following the Business Combination, if unrestricted and freely tradable, and in the case of the shares held by the Sponsor, following expiration of the lock-up, would have had an aggregate market value of $&#8195;&#8195;&#8195; based upon the closing price of $&#8195;&#8195;&#8195; per share on Nasdaq on &#8195;&#8195;&#8195;, 2024, the most recent closing price. This represents a &#8195;&#8195;% gain on the Sponsor&#8217;s investment. If we do not consummate an initial business combination by September 19, 2024, then the Founder Shares will be worthless; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, given the differential in the purchase price that the Sponsor paid for the Founder Shares as compared to the price of the Series A common stock sold as part of the Units in the Initial Public Offering, the Sponsor may earn a positive rate of return on their investment even if the Post-Combination Company common stock trades below $&#8195;&#8195;&#8195; per share and the public stockholders experience a negative rate of return following the Closing. Accordingly, the economic interests of the Sponsor diverge from the economic interests of public stockholders because the Sponsor will realize a gain on its investment from the completion of any business combination while public stockholders will realize a gain only if the post-closing trading price exceeds $&#8195;&#8195;&#8195; per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, at the time of the Initial Public Offering, the Initial Stockholders and certain of ACAB&#8217;s current officers and directors agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Series A common stock (other than Public Shares) held by them if ACAB fails to complete an initial business combination by September 19, 2024. The Initial Stockholders and our officers and directors did not receive separate consideration for such waivers. Due to such waivers, the value of the Founder Shares and Private Placement Warrants are dependent on the consummation of a business combination. This may incentivize such persons to complete a business combination on terms or conditions that are not in the best interest of the public stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Sponsor paid $13,850,000 for 13,850,000 Private Placement Warrants, which, if unrestricted and freely tradable, would have had an aggregate market value of $&#8195;&#8195;&#8195; based upon the closing price of $&#8195;&#8195;&#8195; per Public Warrants (although holders of the Private Placement Warrants have certain rights that differ from the rights of holders of the Public Warrants) on Nasdaq on &#8195;&#8195;&#8195;, 2024, the most recent closing price, and the fact that the Private Placement Warrants will expire worthless if a business combination is not consummated by September 19, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Registration Rights Agreement was entered into by the Sponsor and certain other affiliates of ACAB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, pursuant to the Business Combination Agreement, for a period of six (6) years following the consummation of the Business Combination, we are required to (i) maintain provisions in the Proposed Charter providing for continued indemnification of ACAB&#8217;s directors and officers and (ii)&#160;continue ACAB&#8217;s directors&#8217; and officers&#8217; liability insurance after the Business Combination (i.e., a &#8220;tail policy&#8221;); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and ACAB&#8217;s officers and directors will lose their entire investment in ACAB and will not be reimbursed for any out-of-pocket expenses if an initial business combination is not consummated by September 19, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that if the trust account is liquidated, including in the event ACAB is unable to complete an initial business combination by September 19, 2024, the Sponsor has agreed to indemnify ACAB to ensure that the proceeds in the Trust Account are not reduced below $10.20 per Public Share, or such lesser per Public Share amount as is in the Trust Account on the liquidation date, by the claims of prospective target businesses with which ACAB has entered into an acquisition agreement or claims of any third party for services rendered or products sold to ACAB, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that ACAB may be entitled to distribute or pay over funds held by ACAB outside the Trust Account to the Sponsor or any of its affiliates prior to the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, pursuant to the subscription agreement (the &#8220;Polar Subscription Agreement&#8221;) among ACAB, the Sponsor and Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;), the Sponsor is the primary obligor for an amount up to $360,000 to be loaned to ACAB by Sponsor in one or more subsequent transactions between the Sponsor and ACAB. If the Business Combination is not consummated, the Sponsor would be liable to repay such indebtedness to Polar and ACAB may be unable to repay its obligations owing to the Sponsor; and </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that it is currently contemplated that a designee of ACAB will serve as a director of the <span style="white-space:nowrap">Post-Combination</span> Company following the Closing. As such, in the future, such person may receive any cash fees or equity awards that the Post-Combination Company Board determines to pay its directors. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As a result of the foregoing interests, the Sponsor and our directors and officers will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to public stockholders rather than liquidate. Based on the closing price per share of the Public Shares on &#8195;&#8195;&#8195;, 2024 as reported on Nasdaq of $&#8195;&#8195;&#8195; , in the aggregate, the Sponsor and its affiliates have approximately $&#8195;&#8195;&#8195; million at risk that depends upon the completion of a business combination. Such amount consists of 3,241,667&#160;shares of Series A common stock held by the Sponsor and 13,850,000 Private Placement Warrants. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT DO I NEED TO DO NOW? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">ACAB urges you to read carefully and consider the information contained in this proxy statement/prospectus, including the Annexes and the other documents referred to herein, and to consider how the Business Combination will affect you as a stockholder and/or warrant holder of ACAB. Stockholders should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus and on the enclosed proxy card. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">HOW DO I VOTE? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you are a holder of record of ACAB common stock on the ACAB Record Date, you may vote in person (which would include presence at a virtual meeting) at the Special Meeting or by submitting a proxy for the Special Meeting. You may submit your proxy by completing, signing, dating and returning the enclosed proxy card in the accompanying <span style="white-space:nowrap">pre-addressed</span> postage paid envelope. If you hold your shares in &#8220;street name,&#8221; which means your shares are held of record by a broker, bank or nominee, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. In this regard, you must provide the broker, bank or nominee with instructions on how to vote your shares or, if you wish to attend the meeting and vote in person (which would include presence at a virtual meeting), obtain a proxy from your broker, bank or nominee. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">IF MY SHARES ARE HELD IN &#8220;STREET NAME&#8221; BY A BROKER, BANK OR OTHER NOMINEE, WILL MY BROKER, BANK OR OTHER NOMINEE VOTE MY SHARES FOR ME? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If your shares are held in &#8220;street name&#8221; in a stock brokerage account or by a broker, bank or other nominee, you must provide the record holder of your shares with instructions on how to vote your shares. Please follow the voting instructions provided by your broker, bank or other nominee. Please note that you may not vote shares held in &#8220;street name&#8221; by returning a proxy card directly to ACAB or by voting in person (which would include presence at a virtual meeting) at the Special Meeting unless you provide a &#8220;legal proxy&#8221;, which you must obtain from your broker, bank or other nominee. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under the rules of Nasdaq, brokers who hold shares in &#8220;street name&#8221; for a beneficial owner of those shares typically have the authority to vote in their discretion on &#8220;routine&#8221; proposals when they have not received instructions from beneficial owners. However, brokers are not permitted to exercise their voting discretion with respect to the approval of matters that Nasdaq determines to be <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> without specific instructions from the beneficial owner. It is expected that all proposals to be voted on at the Special Meeting are <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> matters. Broker <span style="white-space:nowrap">non-votes</span> occur when a broker or nominee is not instructed by the beneficial owner of shares to vote on a particular proposal for which the broker does not have discretionary voting power. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are an ACAB stockholder holding your shares in &#8220;street name&#8221; and you do not instruct your broker, bank or other nominee on how to vote your shares, your broker, bank or other nominee will not vote your shares on the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal or the Adjournment Proposal. Such broker <span style="white-space:nowrap">non-votes</span> will be the equivalent of a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; the Charter Approval Proposal, but will have no effect on the vote count for such other proposals. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT IF I ATTEND THE SPECIAL MEETING AND ABSTAIN OR DO NOT VOTE? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For purposes of the Special Meeting, an abstention occurs when a stockholder attends the meeting in person (which would include presence at a virtual meeting) and does not vote or returns a proxy with an &#8220;abstain&#8221; vote. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are an ACAB stockholder that attends the Special Meeting in person (which would include presence at a virtual meeting) and fails to vote on the Charter Approval Proposal, or if you respond to such proposal with an &#8220;abstain&#8221; vote, your failure to vote or &#8220;abstain&#8221; vote in each case will have the same effect as a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; such proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are an ACAB stockholder that attends the Special Meeting in person (which would include presence at a virtual meeting) and fails to vote on the Business Combination Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal or the Adjournment Proposal, or if you respond to such proposals with an &#8220;abstain&#8221; vote, your failure to vote or &#8220;abstain&#8221; vote in each case will have no effect on the vote count for such proposals. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT WILL HAPPEN IF I RETURN MY PROXY CARD WITHOUT INDICATING HOW TO VOTE? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you sign and return your proxy card without indicating how to vote on any particular proposal, the common stock represented by your proxy will be voted as recommended by the ACAB Board with respect to that proposal. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">MAY I CHANGE MY VOTE AFTER I HAVE MAILED MY SIGNED PROXY CARD? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Yes. Stockholders may send a later-dated, signed proxy card to ACAB&#8217;s transfer agent at the address set forth at the end of this section so that it is received prior to the vote at the Special Meeting or attend the </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Special Meeting in person (which would include presence at a virtual meeting) and vote. Stockholders also may revoke their proxy by sending a notice of revocation to ACAB&#8217;s transfer agent, which must be received prior to the vote at the Special Meeting. </td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT HAPPENS IF I FAIL TO TAKE ANY ACTION WITH RESPECT TO THE SPECIAL MEETING? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you fail to take any action with respect to the Special Meeting and the Business Combination is approved by stockholders and consummated, you will become a stockholder of the Post-Combination Company. Failure to take any action with respect to the Special Meeting will not affect your ability to exercise your redemption rights. If you fail to take any action with respect to the Special Meeting and the Business Combination is not approved, you will continue to be a stockholder and/or warrant holder of ACAB. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT SHOULD I DO IF I RECEIVE MORE THAN ONE SET OF VOTING MATERIALS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stockholders may receive more than one set of voting materials, including multiple copies of this proxy statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your ACAB shares. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHO CAN HELP ANSWER MY QUESTIONS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If you have questions about the Business Combination or if you need additional copies of the proxy statement/prospectus or the enclosed proxy card you should contact: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Morrow Sodali LLC </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">333 Ludlow Street, 5<sup style="font-size:75%; vertical-align:top">th</sup> Floor, South Tower </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stamford, CT 06902 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: <span style="text-decoration:underline">ACAB.info@investor.morrowsodali.com</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stockholders may call toll free: (800) <span style="white-space:nowrap">662-5200</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Banks and Brokers may call collect: (203) <span style="white-space:nowrap">658-9400</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may also obtain additional information about ACAB from documents filed with the SEC by following the instructions in the section entitled &#8220;<span style="font-style:italic">Where You Can Find Additional Information.</span>&#8221; If you are a holder of Public Shares and you intend to seek redemption of your Public Shares, you will need to deliver your stock (either physically or electronically) to ACAB&#8217;s transfer agent at the address below prior to the vote at the Special Meeting. If you have questions regarding the certification of your position or delivery of your stock, please contact: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Continental Stock Transfer&#160;&amp; Trust Company </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1 State Street, 30th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10004 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(212) <span style="white-space:nowrap">509-4000</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">Q:</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">WHAT ARE THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF EXERCISING MY REDEMPTION RIGHTS? </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A:</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The U.S. federal income tax consequences of exercising redemption rights that may be relevant to holders of Public Shares are discussed in more detail in the section entitled &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Considerations &#8211; Material U.S. Federal Income Tax Consequences of the</span> <span style="font-style:italic">Redemption of ACAB Public</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
<span style="font-style:italic">Stockholders.</span>&#8221; The discussion of the U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and is not a complete analysis or description of all of the U.S. federal income tax considerations that are applicable to holders of Public Shares in respect of the exercise of their redemption rights, nor does it address any tax considerations arising under U.S. state or local or <span style="white-space:nowrap">non-U.S.</span> tax laws. </td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">TAX MATTERS ARE COMPLICATED, AND THE TAX CONSEQUENCES TO HOLDERS OF PUBLIC SHARES OF EXERCISING THEIR REDEMPTION RIGHTS WILL DEPEND ON THE FACTS OF THEIR OWN SITUATION. EACH HOLDER OF PUBLIC SHARES SHOULD CONSULT THEIR OWN TAX ADVISOR AS TO THE SPECIFIC TAX CONSEQUENCES OF THE EXERCISE OF REDEMPTION RIGHTS TO SUCH HOLDER IN THEIR PARTICULAR CIRCUMSTANCES. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_4">SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information included in this proxy statement/prospectus and does not contain all of the information that may be important to you. You should read this entire document and its annexes and the other documents to which we refer before you decide how to vote. Each item in this summary includes a page reference directing you to a more complete description of that item</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Business Combination and the Business Combination Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, ACAB entered into the Business Combination Agreement with Merger Sub and Abpro. Pursuant to the Business Combination Agreement, the parties thereto will enter into a Business Combination transaction by which Merger Sub will merge with and into Abpro, with Abpro surviving such merger as a wholly owned subsidiary of ACAB. In connection with the closing of the Business Combination: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Effective Time, by virtue of the merger and without any action on the part of ACAB, Merger Sub, Abpro or the holders of any of Abpro securities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each share of Merger Sub common stock issued and outstanding as of immediately prior to the Effective Time will be converted into one share of common stock, par value $0.0001, of Abpro; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each share of Abpro common stock (other than shares owned by Abpro as treasury stock) issued and outstanding as of immediately prior to the Effective Time shall be canceled and extinguished and converted into the right to receive a number of shares of Series A common stock (deemed to have a value of $10.00 per share) with an aggregate implied value equal to $500,000,000 divided by the number of shares of Abpro common stock outstanding on a fully diluted basis immediately prior to the Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each share of Abpro common stock held immediately prior to the Effective time by Abpro as treasury stock shall be canceled and extinguished, and no consideration shall be paid with respect thereto. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to the terms of our certificate of incorporation, each outstanding share of Series B common stock will be converted into one share of Series A common stock in connection with the Closing and will no longer be outstanding and will cease to exist. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Business Combination Agreement and the Business Combination and other transactions contemplated thereby, see the section entitled &#8220;<span style="font-style:italic">The Business Combination</span>&#8221; and &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Merger Consideration </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, at the Effective Time: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding share of Abpro common stock will be cancelled and converted into (i)&#160;the right to receive a pro rata share of 72.5&#160;million shares of Series A Common Stock (22.5&#160;million of which shares will be set aside and equally divided among the Sponsor, Abpro and Abpro Bio Co., Ltd. for each such party to use in the PIPE Financing or to obtain capital for ACAB or the Surviving Company (such shares, the &#8220;Abpro Incentive Shares&#8221;). Any of the Abpro Incentive Shares that are not used or allocated by the Sponsor, Abpro or Abpro Bio Co., Ltd. by the Closing shall be deemed forfeited and shall not be issued to any other party)&#160;(ii) the right to receive a pro rata portion of up to 14,500,000 additional shares of Series A Common Stock (the <span style="white-space:nowrap">&#8220;Earn-out</span> Shares&#8221;), to be earned 1/3 if the volume weighted average price (&#8220;VWAP&#8221;) of the Post-Combination Company&#8217;s stock is above $13.00 for any 20 trading days within any consecutive 30 trading day period; 1/3 if such VWAP is above $15.00; and 1/3 if such VWAP is above $18.00, at any point prior to the fifth anniversary of the Closing Date. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro option will be converted into an option to purchase a number of shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such option immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio (rounded up to the nearest whole cent). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro RSU (whether vested or unvested) will be converted into restricted shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such RSU immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to closing, each outstanding share of Abpro preferred stock will be converted into shares of Abpro common stock in accordance with its terms, equal to the number of shares of Abpro common stock obtained by dividing the liquidation preference of such share of Abpro preferred stock by the Exchange Ratio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, see the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; The Business Combination Agreement &#8212; Consideration to Abpro&#8217;s Stockholders</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ownership of the Post-Combination Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, there are 8,167,391 shares of ACAB common stock issued and outstanding, including one share of Series B common stock, each of which will be converted into one share of Series A common stock at the Closing. As of the date of this proxy statement/prospectus, there are an aggregate of 28,850,000 warrants outstanding. Each whole warrant entitles the holder thereof to purchase one share of Series A common stock. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination and assuming no redemptions), assuming that (i)&#160;one share of Series B common stock is converted into one share of Series A common stock and (ii)&#160;each outstanding warrant is exercised and one share of Series A common stock is issued as a result of such exercise, the ACAB fully-diluted stock capital would be 37,017,391 shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, in connection with approval of the charter amendment proposal to extend the date by which ACAB must consummate a business combination to December&#160;19, 2023, holders of an aggregate of 26,564,308 Series A common stock exercised, and did not reverse, their right to redeem their shares and as a result, such holders received a payment of approximately $10.41 per share that they redeemed. The funds held in the trust account have been on deposit in a demand deposit bank account, owned and controlled by the trustee since December&#160;29, 2023. In connection with such charter amendment, the Sponsor entered into <span style="white-space:nowrap">Non-Redemption</span> Agreements with several unaffiliated third parties and agreed to transfer, after consummation of a business combination, an aggregate of 825,225 shares of Series A common stock to such parties in exchange for them agreeing not to redeem their Series A common stock. On December&#160;15, 2023, in connection with approval of the charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board), holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares and as a result, such holders received a payment of approximately $10.74&#160;per share redeemed. After such redemptions, and as of December&#160;31, 2023, there was approximately $7.4&#160;million in the trust account. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. As a result of the Conversion and the results of the stockholder meetings described above, </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination (assuming no Public Shares have been redeemed and no public warrants have been exercised), we will have a total of 49,815,527 shares of Series A common stock outstanding, consisting of (i)&#160;38,884,511 shares issued to holders of shares of common stock of Abpro, (ii)&#160;667,391 shares held by ACAB&#8217;s public stockholders and (iii) 3,541,667 shares held by the Initial Stockholders, (iv) 1,808,558 shares transferred to investors (v)&#160;1,150,000 shares issued to service providers and (vi)&#160;3,763,400 issued to PIPE Investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination (assuming that holders of 667,391 Public Shares exercise their redemption rights (representing the maximum redemptions consistent with satisfying the Minimum Cash Condition at an assumed Redemption Price of $10.93 per share) and no public warrants have been exercised), we will have a total of 49,148,136 shares of Series A common stock outstanding, consisting of (i)&#160;38,884,511 shares issued to holders of shares of common stock of Abpro, (ii) 3,541,667 shares held by the Initial Stockholders, (iii) 1,808,558 shares transferred to investors (iv)&#160;1,150,000 shares issued to service providers and (v) 3,763,400 issued to PIPE Investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The numbers of shares and percentage interests set forth above are based on a number of assumptions, including that ACAB and Abpro do not issue any additional equity securities prior to the Business Combination. If the actual facts differ from our assumptions, the numbers of shares and percentage interests set forth above will be different. See the sections entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Consolidated Combined Financial Information</span>&#8221; and &#8220;<span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management of ACAB and the Post-Combination Company</span>&#8221; in this proxy statement/prospectus for further information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACAB board of directors believes that each of the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal is in the best interests of ACAB and our stockholders and recommends that our stockholders vote &#8220;FOR&#8221; each Proposal (or in the case of the Director Election Proposal, &#8220;FOR ALL NOMINEES&#8221;) being submitted to a vote of the stockholders at the special meeting. For more information, see the sections entitled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;1 &#8212; The Business Combination Proposal</span>,&#8221; &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;2 &#8212; The Charter Approval Proposal</span>,&#8221; &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;3 &#8212; The Governance Proposal</span>,&#8221; &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4 &#8212; The Director Election Proposal</span>,&#8221; &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;5 &#8212;</span> <span style="font-style:italic">The Merger Issuance Proposal</span>,&#8221; &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;6 &#8212; The Incentive Plan Proposal</span>&#8221; and &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;7 &#8212; The Adjournment Proposal</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the ACAB Board in favor of approval of these Proposals, you should keep in mind that, aside from their interests as stockholders, our Sponsor and certain of our directors and officers have interests in the Business Combination that are different from, or in addition to, your interests as a stockholder. Please see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of ACAB&#8217;s Directors and Officers in the Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACAB&#8217;s Special Meeting of Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting of stockholders will be held on&#8195;&#8195;&#8195;&#8195;, 2024 at 9:00 a.m., eastern time, in virtual format. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of ACAB&#8217;s Directors and Executive Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of ACAB Board in favor of approval of the proposals, you should keep in mind that the directors and executive officers of ACAB have interests in the Business Combination and other </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposals that may be different from, or in addition to, those of ACAB stockholders generally. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor holds an aggregate of 13,850,000 private placement warrants that would expire worthless if a business combination is not consummated, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our public warrants of $&#8195;&#8195;&#8195;&#8195;per warrant on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor may convert any working capital loans that it has and may make to us into shares of our Series A common stock, at the price of $10.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed not to redeem any of the shares of our common stock held by it in connection with a stockholder vote to approve the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Initial Stockholders paid an aggregate of $25,000 for the Founder Shares and that such securities will have a significantly higher value at the time of the business combination, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that Shahraab Ahmad, who is ACAB&#8217;s Chief Executive Officer and serves on the ACAB Board and owns a material interest in the Sponsor, is the manager and owns 22.3% of the equity interest of the Sponsor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated appointment of&#8195;&#8195;&#8195;&#8195;, as director on the board of the combined company in connection with the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the trust account is liquidated, including in the event we are unable to complete an Initial Business Combination within the required time period, the Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.20 per Public Share, or such lesser amount per Public Share as is in the Trust Account on the liquidation date, by the claims of (a)&#160;any third party for services rendered or products sold to us or (b)&#160;a prospective target business with which we have entered into an acquisition agreement, but only if such a third party or target business has not executed a waiver of all rights to seek access to the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our independent directors own an aggregate of 250,000 Founder Shares, which if unrestricted and freely tradeable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other ACAB stockholders experience a negative rate of return in the post-business combination company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor, officers and directors will be reimbursed for <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and ACAB&#8217;s officers and directors will lose their entire investment in us if an initial business combination is not completed; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Sponsor, officers and directors will lose their entire investment in us if an initial business combination is not completed. At the closing of the Business Combination, we anticipate the </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Sponsor will own a combined 13,850,000 private placement warrants and 3,241,667&#160;shares of the combined company&#8217;s common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the sections entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of ACAB&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; of this proxy statement/prospectus for a further discussion of these and other risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Abpro Directors and Executive Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of ACAB Board in favor of approval of the proposals, you should keep in mind that the directors and executive officers of Abpro have interests in the Business Combination and other proposals that may be different from, or in addition to, those of ACAB stockholders generally. These interests include, among other things, the fact that certain of Abpro&#8217;s directors and officers will become directors and officers of the Post-Combination Company, upon the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the sections entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of Abpro&#8217;s Directors and Executive Officers in the Business Combination</span>&#8221; of this proxy statement/prospectus for a further discussion of this and other risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Approvals </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the HSR Act and the rules&#160;that have been promulgated thereunder by the Federal Trade Commission (&#8220;FTC&#8221;), certain transactions may not be consummated unless an HSR Notification and Report Form&#160;has been furnished to the Antitrust Division of the Department of Justice (&#8220;Antitrust Division&#8221;) and the FTC by each party and certain waiting period requirements have been satisfied. The Business Combination is subject to these requirements and may not be completed until the expiration of a <span style="white-space:nowrap">30-day</span> waiting period following the two filings of the required Notification and Report Forms with the Antitrust Division and the FTC or until early termination is granted. In April 2024, ACAB and Abpro filed the required forms under the HSR Act with respect to the Business Combination with the Antitrust Division and the FTC and requested early termination. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time before or after consummation of the Business Combination, notwithstanding expiration or termination of the waiting period under the HSR Act, the Antitrust Division or the FTC, or any state, foreign or other governmental authority could take such action under applicable antitrust laws as such authority deems necessary or desirable in the public interest, including seeking to enjoin the consummation of the Business Combination, conditionally approving the Business Combination upon divestiture of assets or other remedies, and/or subjecting the completion of the Business Combination to regulatory conditions or seeking other remedies. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. ACAB cannot assure you that the Antitrust Division, the FTC, any state attorney general, or any other government authority will not attempt to challenge the Business Combination on antitrust grounds, and, if such a challenge is made, ACAB cannot assure you as to its result. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of ACAB common stock are not entitled to appraisal rights in connection with the Business Combination under Delaware law. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conditions to the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of ACAB, Abpro and Merger Sub to consummate the Business Combination are subject to the satisfaction or waiver (where permissible) at or prior to the Effective Time of the following conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the written consent of the requisite stockholders of Abpro in favor of the approval and adoption of the Business Combination Agreement and the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal having each been approved and adopted by the requisite affirmative vote of the ACAB stockholders in accordance with the Delaware General Corporation Law, ACAB&#8217;s organizational documents and the rules and regulations of Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no order or law issued by any court of competent jurisdiction or other governmental entity or other legal restraint or prohibition preventing the consummation of the transactions contemplated by Business Combination being in effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the applicable waiting period or consent under the HSR Act relating to the Business Combination, and any commitments by the parties not to consummate the Business Combination before a certain date under a timing agreement entered into with a governmental entity, shall have expired or been terminated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the registration statement/proxy statement becoming effective in accordance with the provisions of the Securities Act, no stop order being issued by the SEC and remaining in effect with respect to the registration statement/proxy statement, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after giving effect to the transactions contemplated by the Business Combination Agreement (including any Transaction Financing), ACAB having at least $5,000,001 of net tangible assets immediately after the effective time of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB&#8217;s newly issued Series A common stock in connection with the transactions contemplated by the Business Combination Agreement being approved for listing on Nasdaq. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of ACAB and Merger Sub to consummate the Business Combination are subject to the satisfaction or waiver (where permissible) at or prior to the Effective Time of the following additional conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain representations and warranties of Abpro, as detailed in the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Representations and Warranties &#8212; Representations and Warranties of Abpro</span>&#8221; being true and correct as of the closing date, subject to certain exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro having performed and complied in all material respects with the covenants and agreements required to be performed or complied with by it under the Business Combination Agreement prior to the closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">since the date of the Business Combination Agreement, no Abpro Material Adverse Effect having occurred and continuing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Abpro Preferred Stock conversion having been duly authorized; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB having received the Ancillary Documents to which Abpro is a party, duly executed by Abpro and in full force and effect; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB having received a certificate executed by an authorized officer of Abpro confirming that the conditions of certain of the above bullet points in this section have been satisfied, as detailed in the </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Representations and Warranties &#8212; Representations and Warranties of Abpro.&#8221;</span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Abpro to consummate the Business Combination are subject to the satisfaction or waiver (where permissible) at or prior to Effective Time of the following additional conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain representations and warranties of ACAB and Merger Sub (the &#8220;ACAB Parties&#8221;), as detailed in the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Representations and Warranties &#8212; Representations and Warranties of the SPAC Parties,</span>&#8221; being true and correct as of the closing date, subject to certain exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ACAB Parties having performed and complied in all material respects with the covenants and agreements required to be performed or complied with by them under the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there being at least $8,700,000 in Available Cash; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">since the date of the Business Combination Agreement, no ACAB Material Adverse Effect having occurred and continuing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Employment Agreements shall have been signed by the respective executives party thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro having received the Ancillary Documents to which ACAB or the Sponsor is a party, duly executed by SPAC or Sponsor and in full force and effect; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro having received a certificate executed by an authorized officer of ACAB confirming that the conditions certain of the above bullet points in this section have been satisfied, as detailed in the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Representations and Warranties &#8212; Representations and Warranties of the SPAC Parties.</span>&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the conditions to closing the Business Combination, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Representations and Warranties &#8212;Representations and Warranties of Abpro.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be terminated under certain circumstances prior to the Closing, including, but not limited to, (i)&#160;by mutual written consent of ACAB and Abpro, (ii)&#160;by Abpro if ACAB breaches its representations, warranties or covenants such that the conditions set forth in the Business Combination Agreement would not be satisfied, and such party fails to cure such breach (other than for certain limited exceptions), (iii) by ACAB if Abpro breaches its representations, warranties or covenants such that the conditions set forth in the Business Combination Agreement would not be satisfied, and such party fails to cure such breach (other than for certain limited exceptions), (iv) by either ACAB or Abpro if the Business Combination is not consummated by June&#160;1, 2024, (v) by either ACAB or Abpro if any governmental entity issues an order or taken any other action permanently enjoining, restraining or otherwise prohibiting the Business Combination and such order or other action has become final <span style="white-space:nowrap">and&#160;non-appealable,&#160;(vi)</span> by either ACAB or Abpro if certain required approvals are not obtained from the ACAB stockholders after the conclusion of a special meeting of ACAB&#8217;s stockholders held for such purpose at which such stockholders voted on such approvals and (vii)&#160;by ACAB, if Abpro does not deliver to ACAB the required Company Stockholder Written Consent (as defined in the Business Combination Agreement) prior to the Company Stockholder Written Consent Deadline (as defined in the Business Combination Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement, other than customary confidentiality obligations, except in the case of willful breach or fraud. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proxy Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies may be solicited by mail, telephone or in person. ACAB has engaged Morrow Sodali LLC to assist in the solicitation of proxies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a stockholder grants a proxy, it may still vote its shares in person if it revokes its proxy before the extraordinary general meeting. A stockholder also may change its vote by submitting a later-dated proxy as described in the section entitled &#8220;<span style="font-style:italic">ACAB&#8217;s Special Meeting of Stockholders &#8212; Revoking Your Proxy</span>.&#8221;<span style="font-style:italic">&#160;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the signing of the Business Combination Agreement, Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;Sponsor&#8221;) entered into an agreement with ACAB, the Company and Abpro Bio International, Inc. (the &#8220;Sponsor Letter Agreement&#8221;), whereby Sponsor agrees to (i)&#160;retain 2.95&#160;million shares of ACAB Series A Common Stock held by it, (ii)&#160;divide 2,458,333 shares of ACAB Series A Common Stock held by it among the Sponsor, who will be entitled to 491,667 of the shares, Abpro, who will be entitled to 983,333 of the shares, and Abpro Bio International, Inc. who will be entitled to 983,333 of the shares, for such party to use to obtain <span style="white-space:nowrap">non-redemption</span> commitments from ACAB stockholders or other capital for ACAB or the Surviving Company (with any shares unused for such purpose to be retained by such party) and (ii)&#160;forfeit the remainder of any ACAB Series A Common Stock and ACAB Series B Common Stock held by it. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Sponsor Letter Agreement, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Support Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, ACAB, Abpro and the Sponsor entered into the Sponsor Support Agreement pursuant to which the Sponsor agreed to, among other things, vote all of its shares of ACAB Series A Common Shares and ACAB Series B Common Shares held by it, whether now owned or hereafter acquired, (i)&#160;in favor of the approval and adoption of the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (ii)&#160;against any proposal, action or agreement that would impede, interfere with, delay, postpone or discourage any provision of the Sponsor Support Agreement, the Business Combination Agreement or the transactions contemplated thereby (including the Business Combination). In addition, in the Sponsor Support Agreement, the Sponsor agrees to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of ACAB Series B Common Stock held by the Sponsor convert into shares of ACAB Series A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Sponsor Support Agreement, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Support Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro Support Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, certain Abpro stockholders (the &#8220;Abpro Supporting Stockholders&#8221;) entered into support agreements with Abpro (the &#8220;Abpro Support Agreements&#8221;). Under the Abpro Support Agreements, each Abpro Supporting Stockholder agreed, within 48 hours after the date that the Proxy/Information Statement is disseminated by Abpro to its stockholders following </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the effectiveness of the Registration Statement, to execute and deliver a written consent with respect to all outstanding shares of Abpro common stock and Abpro preferred stock held by such Abpro Supporting Stockholder (the &#8220;Subject Abpro Shares&#8221;) approving the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination). In addition to the foregoing, each Abpro Supporting Stockholder agreed that, at any meeting of the holders of Abpro capital stock, each such Abpro Supporting Stockholder will appear at the meeting, in person or by proxy, and cause its Subject Abpro Shares to be counted as present thereat for purposes of calculating a quorum and voted (i)&#160;to approve and adopt the Business Combination Agreement, the transactions contemplated thereby (including the Business Combination), and any other matters necessary or reasonably requested by Abpro for consummation of the Business Combination, and (ii)&#160;against any proposal that conflicts or materially impedes or interferes with, or would adversely affect or delay, the consummation of the transactions contemplated by the Business Combination Agreement (including the Business Combination). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Abpro Support Agreements also prohibits the Abpro Supporting Stockholders from, prior to the Effective Time, among other things, (i)&#160;selling, assigning, transferring (including by operation of law), placing a lien on, pledging, disposing of or otherwise encumbering any of the Subject Abpro Shares, except if such transaction is in compliance with applicable securities laws, the governing documents of Abpro and the Business Combination Agreement, and the transferee agrees to be bound by the terms of the Abpro Support Agreement (ii)&#160;pledging, encumbering or creating a Lien on any Subject Abpro Shares or entering into any contract, option, commitment or other arrangement or understanding with respect to the foregoing, (iii)&#160;granting any proxies or powers of attorney or entering into a voting agreement or other arrangement with respect to any Subject Abpro Shares, or (iv)&#160;taking any action in furtherance of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Abpro Support Agreements, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Abpro Support Agreements.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to Closing, certain Abpro stockholders will enter into <span style="white-space:nowrap">lock-up</span> agreements (the &#8220;Abpro <span style="white-space:nowrap">Lock-up</span> Agreements&#8221;), pursuant to which Abpro stockholders will agree not to transfer, following the Closing, such Abpro stockholder&#8217;s shares of ACAB New Common Shares constituting such Abpro stockholder&#8217;s Merger Consideration until the earlier of (x)&#160;the twelve month anniversary of the date of the Closing, (y)&#160;if the reported last sale price of the shares of ACAB New Common Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, right issuances, reorganizations, recapitalizations and the like) for any twenty (20)&#160;trading days within any thirty (30)&#160;trading day period commencing at least <span style="white-space:nowrap">one-hundred</span> and fifty (150)&#160;days after the Closing, and (z)&#160;the date after the Closing on which the Surviving Company consummates a liquidation, merger, capital stock exchange, reorganization or other similar transaction with an unaffiliated third party that results in all of the Surviving Company&#8217;s stockholders having the right to exchange their common stock of the Surviving Company for cash, securities or other property. Approximately 32,065,593 ACAB New Common Shares held by such Abpro stockholders will be subject to the Abpro Lock-up Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founders Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the ACAB IPO, on January&#160;13, 2022, certain of ACAB&#8217;s directors and executive officers and ACAB entered into a letter agreement (the &#8220;Founders Letter Agreement&#8221;), pursuant to which, among other things, these holders have agreed not to transfer, assign or sell any of their founder shares until one year after the date of the consummation of a business combination, subject to certain limited exceptions. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Founders Letter Agreement, see the subsection entitled &#8220;<span style="font-style:italic">Other Agreements &#8212; Founders Letter Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the ACAB IPO, on January&#160;13, 2022, ACAB entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Sponsor and each member of the ACAB Board. Pursuant to the Registration Rights Agreement, these holders, and the holders of warrants issued upon conversion of working capital loans, if any, are entitled to make up to three demands to register certain of the ACAB securities held by them under the Securities Act and to have the securities covered thereby registered for resale pursuant to Rule 415 under the Securities Act. In addition, the holders have certain &#8220;piggyback&#8221; registration rights applicable to registration statements filed after the consummation of the Business Combination. Approximately 3,491,667 ACAB New Common Shares will be subject to the Registration Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Registration Rights Agreement, see the subsection entitled &#8220;<span style="font-style:italic">Other Agreements &#8212; Registration Rights Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pipe Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Abpro and ACAB management teams are in the process of discussing with potential investors a PIPE financing up to gross proceeds of $37.6&#160;million to support the Post-Combination Company at Closing. At this time, there is no firm commitment for a PIPE or other financing arrangement as of the date of this filing. The terms of any such private placement, including whether any of the Sponsor or ACAB&#8217;s directors or officers or their affiliates will participate in such private placement, have not yet been determined. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Organizational Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate in simplified terms the current structure of ACAB and Abpro and the expected structure of the Post-Combination Company upon the consummation of the Business Combination on a fully diluted basis: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pre-Business Combination ACAB Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram illustrates the pre-Business Combination organizational structure of ACAB and its subsidiaries: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g09g09.jpg" alt="LOGO"/>
 </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pre-Business Combination Abpro Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram illustrates the pre-Business Combination organizational structure of Abpro and its subsidiaries: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g15x15.jpg" alt="LOGO"/>
 </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Business Combination ACAB Structure - No Redemption Scenario </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram illustrates the post-Business Combination organizational structure of the Post-Combination Company and its subsidiaries in the No Redemption Scenario: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g10g10.jpg" alt="LOGO"/>
 </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Business Combination ACAB Structure - Maximum Redemption Scenario </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following diagram illustrates the post-Business Combination organizational structure of the Post-Combination Company and its subsidiaries in the Maximum Redemption Scenario: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g11g11.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACAB Nasdaq Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s Series A common stock is listed on Nasdaq under the symbol &#8220;ACAB&#8221;. ACAB&#8217;s public warrants are listed on Nasdaq under the symbol &#8220;ACABW&#8221;. ACAB&#8217;s units are listed on Nasdaq under the symbol &#8220;ACABU&#8221;. Following the Business Combination, the Post-Combination Company&#8217;s Series A common stock (including common stock issuable in the Business Combination) will be listed on Nasdaq under the symbol &#8220;ABP&#8221;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of Stockholders&#8217; Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Business Combination, the rights of ACAB stockholders who remain stockholders of the Post-Combination Company in the Business Combination will no longer be governed by the ACAB Charter and ACAB&#8217;s bylaws and instead will be governed by the Proposed Charter and the Proposed Bylaws. See the section entitled &#8220;<span style="font-style:italic">Comparison of Stockholders&#8217; Rights</span>&#8221; in this proxy statement/prospectus. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information about ACAB </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2022, ACAB completed its initial public offering of 30,000,000 units, with each unit consisting of one Public Share and <span style="white-space:nowrap">one-half</span> of one public warrant, each whole public warrant to purchase one share of common stock at a price of $11.50, raising total gross proceeds of $300,000,000, which included the partial exercise by the Underwriters in the ACAB IPO of their over-allotment option. Since the ACAB IPO, ACAB&#8217;s activity has been limited to the evaluation of business combination candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information about Abpro </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. Abpro is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary <span style="font-style:italic">DiversImmune</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> and <span style="font-style:italic">MultiMab</span><sup style="font-size:75%; vertical-align:top">TM</sup> antibody discovery and engineering platforms, Abpro is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro was incorporated in Delaware in August 2004 under the name IE LAB, Inc., commenced operations in May 2007, and changed its name to Abpro Corporation in September 2007. Abpro&#8217;s headquarters are located at 68 Cummings Park Drive, Woburn, MA 01801 and its main telephone number is (617) <span style="white-space:nowrap">225-0808.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Selected Historical Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is providing the following selected historical financial information to assist you in your analysis of the financial aspects of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s balance sheet data as of December&#160;31, 2023 and 2022 and statement of operations data for the years ended December&#160;31, 2023 and 2022 are derived from ACAB&#8217;s audited financial statements, included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro&#8217;s balance sheet data as of December&#160;31, 2023 and 2022 and statement of operations data for the fiscal years ended December&#160;31, 2023 and 2022 are derived from Abpro&#8217;s audited financial statements, included elsewhere in this proxy statement/prospectus. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This information is only a summary and should be read in conjunction with each of ACAB&#8217;s and Abpro&#8217;s financial statements and related notes and the sections entitled titled &#8220;<span style="font-style:italic">ACAB Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; and &#8220;<span style="font-style:italic">Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; included elsewhere in this proxy statement/prospectus. The historical results included below and elsewhere in this proxy statement/prospectus are not indicative of the future performance of ACAB or Abpro. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Selected Historical Financial Information: ACAB</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Years<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Statement of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operation and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 1,666,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 2,050,410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,666,056</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,050,410</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on cash and marketable securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,754,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,121,971</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Penalties and interest on taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(142,041 </td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on marketable securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(362,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,664,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,761,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,998,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,710,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,177,463</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(823,991</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net Income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold"> 2,821,459</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold"> 886,918</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding , Redeemable Series&#160;A common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,257,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,438,356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per common share, Redeemable Series&#160;A common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, <span style="white-space:nowrap">Non-redeemable</span> Series&#160;A and Series&#160;B common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, <span style="white-space:nowrap">Non-redeemable</span> Series&#160;A and Series&#160;B common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Balance Sheet Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">As of<br/>December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">As of<br/>December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 37,365,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">310,560,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,888,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,642,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redemption value of Series A Common Stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,292,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309,097,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,815,118</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,179,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Selected Historical Financial Information: Abpro</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="font-style:italic">(In thousands)</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Years<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Statement of Operations and Comprehensive Loss Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 1,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(11,746</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(16,685</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(248</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(11,706</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(16,885</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11,706</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(17,215</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#8211; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,356,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,311,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share &#8211; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:77%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">(In thousands)</span></span><span style="font-weight:bold"></span></p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Balance Sheet Data</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,<br/>2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 3,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 11,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(85,135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(75,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Selected Unaudited Pro Forma Condensed Combined Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined financial information gives effect to the Business Combination, the other events contemplated by the Business Combination Agreement and the financing transaction described in the section entitled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>.&#8221; The Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, ACAB will be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of Post-Combination Company will represent a continuation of the financial statements of Abpro with the Business Combination treated as the equivalent of Abpro issuing stock for the net assets of ACAB, accompanied by a recapitalization. The net assets of ACAB will be stated at historical cost, with no goodwill or other intangible assets are recorded. Operations prior to the Business Combination will be those of Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined balance sheet data as of December&#160;31, 2023 gives pro&#160;forma effect to the Business Combination and the other events contemplated by the Business Combination Agreement as if they had occurred on December&#160;31, 2023. The selected unaudited pro forma condensed </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combined statement of operations for the year ended December&#160;31, 2023, combines the historical statements of operations of ACAB for the year ended December&#160;31, 2023, and the historical statements of operations of Abpro for the year ended December&#160;31, 2023 on a pro forma basis as if the Business Combination, the other events contemplated by the Business Combination Agreement and the financing transaction had been consummated on January&#160;1, 2023, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined financial information has been derived from, and should be read in conjunction with, the more detailed unaudited pro forma condensed combined financial information of the Post-Combination Company appearing elsewhere in this proxy statement/prospectus and the accompanying notes in the section titled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>.&#8221; The unaudited pro forma condensed combined financial information is derived from, and should be read in conjunction with, the historical financial statements and related notes of ACAB and Abpro for the applicable periods included elsewhere in this proxy statement/prospectus. The selected unaudited pro forma condensed combined financial information has been presented for informational purposes only and is not necessarily indicative of what the Post-Combination Company&#8217;s financial position or results of operations actually would have been had the Business Combination, the other events contemplated by the Business Combination Agreement and the financing transaction been completed as of the dates indicated. The selected unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the Post-Combination Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is providing the following selected unaudited pro forma condensed combined financial information to assist you in your analysis of the financial aspects of the Business Combination. The unaudited pro forma condensed combined financial information has been prepared using the assumptions below with respect to the potential redemption by ACAB&#8217;s Public Stockholders of shares of ACAB Series A Common Stock for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming No Redemption &#8212; this scenario assumes that no Public Stockholders of ACAB exercise redemption rights with respect to their Public Shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming Maximum Redemptions: This scenario assumes that all 667,391 Public Shares of ACAB are redeemed upon consummation of the Business Combination for an aggregate redemption payment of $7.4&#160;million, assuming a redemption price of $10.93 per share upon consummation of the Business Combination. ACAB&#8217;s Current Charter provides that ACAB may not consummate any business combination unless it has net tangible assets of at least $5,000,001 upon consummation. In addition, the &#8220;Maximum Redemption&#8221; scenario also considers that the consummation of the transaction is subject to the requirement that there should be at least $8.7&#160;million in Available Cash at the closing pursuant to the Business Combination Agreement. The Available Cash is defined as at the closing the amount of funds contained in the Trust Account (after reduction for the aggregate amount of payments made or required to be made in connection with the SPAC stockholder redemption), plus the amount of funds available to consummate the Business Combination pursuant to a PIPE Financing, minus unpaid SPAC expenses. This maximum level of redemptions would allow to satisfy all obligations of the combined entity at closing of the transaction, including the minimum net tangible asset, minimum available closing cash and payment of transaction costs, without which anticipated transaction would not close. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The two redemption scenarios assumed in the unaudited pro forma condensed combined balance sheet and statement of operations do not include adjustments for the 28,850,000 outstanding Public Warrants and Private Warrants issued in connection with ACAB&#8217;s Initial Public Offering as such securities are not exercisable until 30 days after the Closing. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the actual facts are different than these assumptions, then the amounts and shares outstanding in the unaudited pro forma condensed combined financial information will be different and those changes could be material. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(In thousands)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined<br/>(Assuming No<br/>Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined<br/>(Assuming<br/>Maximum<br/>Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Unaudited Pro Forma Combined Balance Sheet Data as of December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 38,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 31,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 14,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 14,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 23,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 16,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(In thousands, except share and per share data)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined<br/>(Assuming No<br/>Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma<br/>Combined<br/>(Assuming<br/>Maximum<br/>Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Selected Unaudited Pro Forma Combined Statement of Operations &#8211; Year Ended December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 21,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 21,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,081</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,081</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding - basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_6">MARKET PRICE AND DIVIDEND INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ACAB </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s Series A common stock, units and public warrants and are traded on Nasdaq under the symbols ACAB, ACABU and ACABW, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing price of the Series A common stock, units and public warrants on December&#160;8, 2023, the last trading day before announcement of the execution of the Business Combination Agreement, was $10.65, $10.53 and $0.027, respectively. As of&#8195;&#8195;&#8195; , 2024, the ACAB Record Date, the most recent closing price for each Series A common stock, unit and public warrant was $&#8195;&#8195;&#8195;, $&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the Series A common stock, units and public warrants should obtain current market quotations for their securities. The market price of ACAB&#8217;s securities could vary at any time before the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of&#8195;&#8195;&#8195;&#8195;, 2024, there were&#8195;&#8195;&#8195;&#8195;holders of record of ACAB&#8217;s units,&#8195;&#8195;&#8195;&#8195;holders of record of ACAB&#8217;s Series A common stock, one holder of record of ACAB&#8217;s Series B common stock and&#8195;&#8195;&#8195;&#8195;holders of record of ACAB&#8217;s public warrants. The number of holders of record does not include a substantially greater number of &#8220;street name&#8221; holders or beneficial holders whose units, Public Shares and public warrants are held of record by banks, brokers and other financial institutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB has not paid any cash dividends on its common stock to date and does not intend to pay cash dividends prior to the completion of the Business Combination. The payment of cash dividends in the future will be dependent upon the Post-Combination Company&#8217;s revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment of any cash dividends subsequent to the Business Combination will be within the discretion of the Post-Combination Company&#8217;s board of directors at such time. The Post-Combination Company&#8217;s ability to declare dividends may also be limited by restrictive covenants pursuant to any debt financing agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Abpro </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical market price information for Abpro&#8217;s capital stock is not provided because there is no public market for Abpro&#8217;s capital stock. See &#8220;<span style="font-style:italic">Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_7">FORWARD-LOOKING STATEMENTS; SUMMARY RISK FACTORS; MARKET, RANKING AND OTHER INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. All statements, other than statements of present or historical fact included in this proxy statement/prospectus, regarding the proposed Business Combination, ACAB&#8217;s ability to consummate the Business Combination, the benefits of the transaction, the Post-Combination Company&#8217;s future financial performance following the Business Combination and the Post-Combination Company&#8217;s strategy, expansion plans, future operations, future operating results, estimated revenues, losses, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe&#8221;, &#8220;project&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;strategy&#8221;, &#8220;future&#8221;, &#8220;opportunity&#8221;, &#8220;plan&#8221;, &#8220;may&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, &#8220;will be&#8221;, &#8220;will continue&#8221;, &#8220;will likely result&#8221; or the negative of such terms or similar expressions. However, the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Except as otherwise required by applicable law, ACAB disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this proxy statement/prospectus. ACAB cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements contained in this proxy statement/prospectus include, but are not limited to, statements about the ability of ACAB and Abpro prior to the Business Combination, and the Post-Combination Company following the Business Combination, to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">meet the closing conditions to the Business Combination, including approval by stockholders of ACAB and Abpro on the expected terms and schedule; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfy the minimum trust account or Minimum Cash Condition following redemptions by ACAB&#8217;s public stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">realize the benefits expected from the proposed Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract, train and retain an effective sales force and other key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implement business plans, forecasts, and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enhance future operating and financial results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receive certain governmental and regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">comply with laws and regulations applicable to its business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully defend litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upgrade and maintain information technology systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquire and protect intellectual property, including copyrights, patents, trademarks and trade secrets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain the listing of ACAB&#8217;s or the Post-Combination Company&#8217;s securities on Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">meet future liquidity requirements and comply with restrictive covenants related to any long-term indebtedness; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully deploy the proceeds from the Business Combination. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements which speak only as of the date hereof. You should understand that the following important factors, in addition to those discussed under the heading &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and elsewhere in this proxy statement/prospectus, could affect the future results of ACAB and Abpro prior to the Business Combination, and the Post-Combination Company following the Business Combination, and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements in this proxy statement/prospectus: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Business Combination may not be completed in a timely manner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Business Combination may not be completed by ACAB&#8217;s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by ACAB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against ACAB, Abpro or others following announcement of the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to disruption of management&#8217;s time from ongoing business operations and potential difficulties in employee retention due to the proposed transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of the announcement or pendency of the Business Combination on Abpro&#8217;s business relationships, performance, and business generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to Abpro&#8217;s ability to achieve and maintain profitability and generate cash; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to the potential infringement on the intellectual property rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the price of ACAB&#8217;s securities may be volatile due to a variety of factors, including changes in the competitive and regulated industries in which Abpro plans to operate, variations in performance across competitors, changes in laws and regulations affecting Abpro&#8217;s business and changes in the combined capital structure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against Abpro or against ACAB related to the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dependence on senior management and other key employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">factors relating to the business, operations and financial performance of Abpro, including, but not limited to: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to achieve successful clinical results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro currently has no products approved for commercial sale; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to obtain regulatory approval for its products, and any related restrictions or limitations of any approved products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to obtain licensing of third-party intellectual property rights for future discovery and development of Abpro&#8217;s antibody therapeutics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to commercialize product candidates and achieve market acceptance of such product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s success is dependent on drug candidates which it licenses from third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to respond to general economic conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro has incurred significant losses since inception, and it expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, it may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s ability to develop and maintain effective internal controls. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of a third-party valuation in determining whether or not to pursue the Business Combination; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other factors that could cause actual results to differ from those implied by the forward-looking statements in this proxy statement/prospectus are more fully described under the heading &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and elsewhere in this proxy statement/prospectus. The risks described under the heading &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; are not exhaustive. Other sections of this proxy statement/prospectus describe additional factors that could adversely affect the business, financial condition or results of operations of ACAB and Abpro prior to the Business Combination, and the Post-Combination Company following the Business Combination. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can ACAB or Abpro assess the impact of all such risk factors on the business of ACAB and Abpro prior to the Business Combination, and the Post-Combination Company following the Business Combination, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to ACAB or Abpro or persons acting on their behalf are expressly qualified in their entirety by the foregoing cautionary statements. ACAB and Abpro prior to the Business Combination, and the Post-Combination Company following the Business Combination, undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements of belief and similar statements reflect the beliefs and opinions of ACAB or Abpro, as applicable, on the relevant subject. These statements are based upon information available to ACAB or Abpro, as applicable, as of the date of this proxy statement/prospectus, and while such party believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that ACAB or Abpro, as applicable, has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market and industry data used throughout this proxy statement/prospectus, including statements regarding market size and growth, and the incidence of certain medical conditions, is based on the good faith estimates of Abpro&#8217;s management, which in turn are based upon Abpro&#8217;s management&#8217;s review of internal surveys, independent industry surveys and publications, and other third-party research and publicly available information. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While Abpro is not aware of any misstatements regarding the industry data presented herein, its estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and &#8220;<span style="font-style:italic">Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; in this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_8">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following risk factors will apply to our business and operations following the completion of the Business Combination. These risk factors are not exhaustive and investors are encouraged to perform their own investigation with respect to the business, financial condition and prospects of Abpro and our business, financial condition and prospects following the completion of the Business Combination. You should carefully consider the following risk factors in addition to the other information included in this proxy statement/prospectus, including matters addressed in the section entitled &#8220;Forward-Looking Statements; Summary Risk Factors; Market, Ranking and Other Industry Data&#8221;. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial, which may also impair our business or financial condition. The following discussion should be read in conjunction with the &#8220;Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the financial statements of Abpro and notes to the financial statements included herein. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In this section &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Abpro prior to the Business Combination and to the Post-Combination Company following the Business Combination. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on the business, financial condition, results of operations, cash flows and future prospects of the Post-Combination Company, in which event the market price of the Post-Combination Company&#8217;s common stock could decline, and you could lose part or all of your investment. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Relating to Abpro&#8217;s Business and Industry </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are a preclinical stage biopharmaceutical company with a history of losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical and biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical stage biopharmaceutical company with a history of losses. Since our inception, we have devoted our resources to the development of antibody product candidates, our technologies and our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms. We are not profitable and have had significant operating losses since our inception. As of December&#160;31, 2022 and 2023, we had an accumulated deficit of $93.9&#160;million and $105.6 million, respectively. For the years ended December&#160;31, 2022 and 2023, our net loss was $17.2&#160;million and $11.7 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our collaboration agreements, research and development programs and from general and administrative costs associated with our operations. We continue to incur significant research and development, or R&amp;D, and other expenses related to ongoing operations and expect to incur losses for the foreseeable future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical studies and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. It may take several years and require significant expenditures to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure are inherently unpredictable and can occur at any stage. We may also be required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional unplanned costs or result in delays in clinical development. In addition, we may be required to redesign or otherwise modify our plans with respect to an ongoing or planned clinical trial, and changing the design of a clinical trial can be expensive and time consuming. An unfavorable outcome in one or more trials would be a major setback for our product candidates and for us. An unfavorable outcome in one or more trials may require us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse effect on our business, financial position, results of operations and future growth prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of product candidates based on novel technologies. We believe that we are at a sufficiently mature development stage with both lead candidates that given adequate funding and, in the case of ABP-102, continued successful collaboration with Celltrion, these programs would be able to enter clinical trials in 2025 (in the case of ABP-102) and in 2026 (in the case of ABP-201). However, there can be no guarantee that both or either will do so, and to date, we have not yet had any discussions with the U.S. Food and Drug Administration, or the FDA, regarding the clinical trial design for our lead product candidates. We have never generated any revenue from product sales, and have not obtained regulatory approval for any of our product candidates. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays, and difficulties frequently encountered by preclinical stage biopharmaceutical companies such as ours. We currently do not expect to generate any near-term revenue other than from certain milestone payments under the collaboration agreements relating to our two lead antibodies. We do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials, and the regulatory approval process for our product candidates. We expect our net losses to increase substantially as we enter into clinical development of our lead programs. However, the amount of our future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, our, and our existing or future partners, successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, achieving contractual milestones under our collaboration agreements, manufacturing any approved products on commercially reasonable terms, realizing royalties on any approved products under our collaboration agreements, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, and our existing or future partners, are unable to develop our technologies and commercialize one or more of our product candidates or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve profitability, which will have a material and adverse effect on our business, financial condition, results of operations and prospects. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates are in early stages of development and have never been tested in a human subject. Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products on the market and all of our product candidates, <span style="white-space:nowrap">including&#160;ABP-102,&#160;for</span> the potential treatment of breast and gastric cancers,&#160;and <span style="white-space:nowrap">ABP-201,&#160;for</span> the potential treatment of wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD) and diabetic macular edema (DME), have not yet entered clinical trials. In particular, none of our product candidates has ever been tested in a human subject. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future partner must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutic antibodies similar to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in submitting investigational new drug applications, or INDs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions imposed by the FDA, or comparable foreign authorities regarding the scope or design of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in enrolling research subjects in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">high <span style="white-space:nowrap">drop-out</span> rates of research subjects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater than anticipated clinical trial costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">poor effectiveness of our product candidates during clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">varying interpretations of data by the FDA and similar foreign regulatory agencies. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our approach to the discovery and development of our antibodies using our DiversImmune<sup style="font-size:75%; vertical-align:top">&#174;</sup> and MultiMab<sup style="font-size:75%; vertical-align:top">TM</sup> may not result in a marketable therapeutic antibody product. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scientific research that forms the basis of our efforts to discover product candidates based on our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms is ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic antibodies based on our platforms is both preliminary and limited. We may not be correct in our assumptions about the superiority of our platforms to competing technologies. If our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms are not able to develop next-generation approved antibody constructs that are effective against clinically validated targets at the necessary speed or scale, it could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our next-generation bispecific antibodies may not demonstrate the therapeutic effects of, or benefits at least comparable to, monospecific antibodies that we anticipate once tested in humans. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our product candidates have been tested in humans. We may ultimately discover that our product candidates do not possess certain properties that we believe are helpful for therapeutic effectiveness, including strong binding for increased efficacy and increased binding sites for increased potency, and safety, including reduced immunogenicity and optimized binding domain position, or dosing, including a longer circulating half-life resulting in reduced dosing required. For example, when administered in a human, we may find that our product candidates perform differently than in preclinical studies. We currently have only limited preclinical data, and no conclusive evidence, to suggest that we can introduce these favorable properties into any of our product candidates. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, certain of our product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Although certain of our product candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our common stock will decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we are aware of only nine bispecific antibodies that have been approved by the FDA. As such, we believe the FDA has limited early experience with bispecific antibody-based therapeutics, which may increase </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the complexity, uncertainty and length of the regulatory approval process for our product candidates. For example, the FDA may require us to provide additional data to support our regulatory applications. We and our existing or future partners may never receive approval to market and commercialize any product candidate. Even if we or an existing or future partner obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or an existing or future partner may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our product candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could require us to change our focus, approach to antibody development and reengineer the antibody. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any revenue from the sale or licensing of product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The antibodies we are developing use relatively new technologies. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a product or treatment based on our platforms and technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future partners. Market acceptance of our product candidates will depend on, among other factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of our receipt of any marketing and commercialization approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms of any approvals and the countries in which approvals are obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety and efficacy of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any adverse side effects associated with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">relative convenience and ease of administration of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to accept any new methods of administration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our physician education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of adequate government and third-party payor reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the pricing of our products, particularly as compared to alternative treatments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need substantial additional funds to advance development of our product candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant additional funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, that are approved for commercial sale. In addition, upon the Closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and progress of preclinical and clinical development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and scope of preclinical and clinical programs we decide to pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaboration and research and development agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of milestone or royalty payments we may receive under collaboration agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain our current licenses and research and development programs and to establish new collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of regulatory approvals; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of debt and equity securities and payments received under our collaboration agreements. We will be required to seek additional funding in the future and currently intend to do so through additional collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on specific product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Through our AbMed subsidiary, we have <span style="white-space:nowrap">in-licensed</span> certain intellectual property rights relating to <span style="white-space:nowrap">ABP-201</span> from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of the terms of our license agreement with MedImmune/AstraZeneca. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The license agreement with MedImmune/AstraZeneca provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022), These target dates were not met, which gives MedImmune/AstraZeneca a termination right. We communicated with Medimmune/AstraZeneca in September 2021 regarding the development timeline, but no further discussion has been held. We continue to provide annual development reports to MedImmune/AstraZeneca, most recently in January 2024. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect a material impact on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development of ABP-200, which we are no longer developing. We believe that we do not need the intellectual property licensed under that agreement for the development and eventual commercialization of ABP-201 or any of our other programs. The risks described elsewhere pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license from third parties, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates. If such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> is being developed and commercialized through a worldwide strategic partnership with Celltrion Inc. (&#8220;Celltrion&#8221;) (KRX:068270), a leading Korean biopharmaceutical company headquartered in Incheon, South Korea. <span style="white-space:nowrap">ABP-201</span> is being developed and commercialized through a territorial partnership with Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;), a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company headquartered in Daegu, South Korea. <span style="white-space:nowrap">ABP-150</span> is being developed under a collaboration agreement with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (&#8220;NJCTTQ&#8221;), headquartered in Nanjing, China. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to explore strategic and geographic-oriented partnerships that provide us with near-term economic benefits where we retain product rights to key strategic markets. More generally, we may also seek out third-party partners, such as biotech companies, pharmaceutical companies and distributors, for marketing, distribution, development, licensing or broader arrangements to complement our own capabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenues from our existing collaborations for licensing and <span style="white-space:nowrap">co-development</span> of our product candidates and any future similar arrangements, will depend on our ability to successfully develop the product candidates and receive necessary product approvals for commercialization in the agreed territories. We have limited ability to control the actions of our joint development and any other third-party partners, and successful product development will depend to some extent on such third parties to perform the functions assigned to them in our contracts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties have significant discretion in determining the efforts and resources that they will apply to these collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical study or clinical trial results, changes in strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties could independently develop, or develop with other third parties, products that compete directly or indirectly with our product candidate if the partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation or other legal proceedings that could jeopardize, invalidate or render unenforceable our intellectual property or proprietary information or expose us to litigation, other legal proceedings or potential liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties may infringe, misappropriate or violate the intellectual property rights of others, which may expose us to litigation, other legal proceedings and potential liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third parties may engage in misconduct, including <span style="white-space:nowrap">non-compliance</span> with regulatory requirements, that may result in governmental investigations or other actions or lawsuits against us or the third party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes may arise between our third-party collaborators and our company that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a partner of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure of our existing and any future collaborations would negatively affect our business plans and strategy for our product candidate pipeline, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our partners cease development efforts under our existing or future collaborations, or if any of those agreements is terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A portion of our future revenue and cash resources is expected to be derived from our license and collaboration agreements. Revenue from these collaborations depends upon continuation of the collaborations, reimbursement of development costs, the achievement of milestones and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the extent that any of our existing or future partners were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining, enforcing and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense, and present significant distractions to our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, joint ventures and <span style="white-space:nowrap">out-</span> or <span style="white-space:nowrap">in-licensing</span> of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies or hospitals. The competition for partners is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the partner terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur <span style="white-space:nowrap">non-recurring</span> or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exposure to unknown liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to retain key employees of any acquired business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are unable to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If third parties on which we intend to rely on to conduct certain preclinical studies, or any future clinical trials, do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to rely on third-party clinical investigators, contract research organizations, or CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies of our product candidates and will do the same for any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with good laboratory practices, or GLPs, and clinical trials to be conducted in accordance with good clinical practices, or GCPs, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we may rely on third-party manufacturing and supply partners for preclinical and clinical development materials, our supply may become limited or interrupted or may not be of satisfactory quantity or quality. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We produce only small-scale quantities of our antibodies and reagents for characterization, in vivo and in vitro assessment. We may rely on third-party contract manufacturers to manufacture our preclinical and clinical trial product supplies. We do not currently own manufacturing facilities for producing such supplies. There can be no assurance that our preclinical or clinical development product supplies will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices, or cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to initiate or continue clinical trials of product candidates under development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of the cooperation of an existing or future partner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to cease distribution or to recall batches of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our third-party manufacturers may be unable to successfully scale manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials, we will need to manufacture large quantities of our product candidates. We may use third parties for our manufacturing needs. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <span style="white-space:nowrap">scale-up</span> activities. If our manufacturing partners are unable to successfully scale the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the market opportunities for our product candidates are smaller than we believe they are, our future product revenues may be adversely affected and our business may suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our understanding of both the number of people who suffer from HER2+ breast and gastric cancers or other tumors that can be treated with VEGF inhibitors, are based on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases. The number of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients in the United States, Europe, or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, there are several factors that could contribute to making the actual number of patients who receive our potential product candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face competition from entities that have developed or may develop product candidates for the treatment of the diseases that we are initially targeting, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors are often larger and better funded. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody and immunoregulatory therapeutics fields. We believe that while our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms, their associated intellectual property, the characteristics of our antibody product candidates in development, and our scientific and technical <span style="white-space:nowrap">know-how</span> give us a competitive advantage in this space, competition from many sources remains. Given the number of competitors, we strive to differentiate ourselves from them and contrast the perceived advantages of our technologies and product candidates. There is a risk that some of our competitors will take issue with our positioning and make allegations regarding our company or our business practices. Any such allegations could divert management&#8217;s attention, which could have an adverse effect on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of several companies that are developing antibodies for the treatment of cancer and autoimmune diseases. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future partners. In addition, these companies compete with us in recruiting scientific and managerial talent. Our success will partially depend on our ability to develop and protect antibodies that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the antibodies we develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to compete with antibody developers, such as Adimab Inc., AnaptysBio, Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Inc., Jounce Therapeutics, Inc., MorphoSys AG, Precigen, Inc., and Regeneron Pharmaceuticals, Inc. If our lead product candidates are approved, they will compete with a range of treatments that are either in development or currently marketed. For example, some of our product candidates will compete against traditional cancer therapies, such as chemotherapy, as well as immune-based treatments for cancer, such as CAR T and TCR therapies, developed or currently marketed by Bellicum Pharmaceuticals, Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Cellectis S.A., Gilead Sciences, Inc., Novartis AG, Precigen, Inc., AstraZeneca and Genentech, Inc. (a member of the Roche Group, or Genentech/Roche). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Ian Chan, our chief executive officer and <span style="white-space:nowrap">co-founder,</span> and Robert Markelewicz, our chief medical officer. We have one written employment agreement with Ian Chan and have offer letters with Robert Markelewicz and Christian Zapf. The loss of one or more members of our executive team, management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;2024, we had 20 full-time employees and one part-time employee. Our focus on the development of our product candidates will require adequate staffing. We may need to hire and retain new employees to execute our future clinical development and manufacturing plans. We cannot provide assurance that we will be able to hire and/or retain adequate staffing levels to develop our product candidates or run our operations and/ or to accomplish all of our objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may experience difficulties in managing our growth and expanding our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited experience in product development and have not begun clinical trials for any of our product candidates. As our product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. We may also experience difficulties in the discovery and development of new antibody product candidates using our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms if we are unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If any of our product candidates is approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such future products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into partnerships with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to <span style="white-space:nowrap">co-promote</span> products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on partnership with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Price controls imposed in foreign markets may adversely affect our future profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between <span style="white-space:nowrap">low-priced</span> and high-priced member states, can further reduce prices. In some countries, we or future partners may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our antibody product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, our ability to market and derive revenue from the product candidates could be compromised. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While we have not yet initiated clinical trials for any of our product candidates, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw their approval of the product or seize the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to recall the product or change the way the product is administered to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for harm caused to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product may become less competitive; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Litigation and legal proceedings may substantially increase our costs and harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been, are, and may in the future become, party to lawsuits and legal proceedings including, without limitation, actions and proceedings in the ordinary course of business relating to our collaboration partners, directors, officers, stockholders, intellectual property rights, employment matters and the safety or efficacy of our products, which will cause us to incur legal fees and other costs related thereto, including potential expenses for the reimbursement of legal fees of officers and directors under indemnification obligations. See &#8220;<span style="font-style:italic">Information About Abpro &#8212; Legal Proceedings</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expense of defending against such litigation and legal proceedings may be significant and there can be no assurance that we will be successful in any defense. Further, the amount of time that may be required to resolve such lawsuits or legal proceedings is unpredictable, and these actions may divert management&#8217;s attention from the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of our business, which could adversely affect our business, results of operations, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash flows. Our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated operations, cash flows and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. Litigation and legal proceedings are subject to inherent uncertainties, and an adverse result in such matters that may arise from time to time could have a material adverse effect on our business, results of operations, and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we move into conducting clinical trials of our product candidates, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of antibody treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently do not have product liability insurance and will need to obtain such insurance prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, waste, abuse or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other wasteful or abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant criminal, civil, and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm, and the curtailment or restructuring of our operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those of CROs or other contractors or consultants we currently use or may use in the future, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal computer systems and those of CROs and other contractors and consultants we use or may use in the future, may be vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical data or data from any future clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our information technology systems could face serious disruptions that could adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research, development and manufacturing involves the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our facilities comply with the relevant guidelines of the Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our current operations are concentrated across two locations in close proximity, and we or the third parties upon whom we depend may be adversely affected by natural disasters and we may not be adequately protected from a serious disaster. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current operations are concentrated across two locations in close proximity outside of Boston, Massachusetts. Any unplanned event, such as flood, fire, explosion, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Natural disasters such as snowstorms or hurricanes could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. We do not currently have disaster recovery and business continuity plans in place and this may have adverse consequences in the event of a serious disaster or similar event. As a result, we may incur substantial expenses, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain protection with respect to our owned and <span style="white-space:nowrap">in-licensed</span> intellectual property and proprietary technology. We rely on patents and other forms of intellectual property rights, including <span style="white-space:nowrap">in-licenses</span> of intellectual property rights of others, to protect our current or future platforms, product candidates, methods used to manufacture our current or future product candidates and methods for treating patients using our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict whether any future patent applications will result in the issuance of patents that effectively protect any of our product candidates or will effectively prevent others from commercializing competitive products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also rely on our ability to preserve our trade secrets, to prevent third parties from infringing, misappropriating or violating our proprietary rights and to operate without infringing, misappropriating or violating the proprietary rights of others. The patent prosecution process is expensive, complex and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance. There is no assurance that all of the potentially relevant prior art relating to our owned or <span style="white-space:nowrap">in-licensed</span> patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending application. Even if patents do successfully issue and even if such patents cover our current or any future technologies or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any current or future technologies or product candidates that we may develop. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If patent applications we own or have <span style="white-space:nowrap">in-licensed</span> with respect to our development programs and current or future technologies or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could dissuade companies from collaborating with us to develop current or future technologies or product candidates, and threaten our ability to commercialize current or future products. Any such outcome could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of biopharmaceutical companies are generally uncertain because they involve complex legal and factual considerations and have, in recent years, been the subject of much legislation and litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights is highly uncertain. The standards applied by the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or <span style="white-space:nowrap">in-licensed</span> patents or narrow the scope of our patent protection. Publications of discoveries in scientific literature often lag behind the actual discoveries and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or <span style="white-space:nowrap">in-licensed</span> patents or pending applications, or that we or our licensors were the first to file for patent protection of such inventions. There is no assurance that all potentially relevant prior art relating to our owned or <span style="white-space:nowrap">in-licensed</span> patents and patent applications has been found. We may be unaware of prior art that could be used to invalidate an issued patent or prevent our owned or <span style="white-space:nowrap">in-licensed</span> pending patent applications from issuing as patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity, or enforceability, and patents and patent applications may be challenged in the courts in the patent office in the Unites States and abroad. For example, we or our licensors may be subject to a third-party <span style="white-space:nowrap">pre-issuance</span> submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or interference proceedings, declaratory judgment actions or counterclaims challenging our owned or <span style="white-space:nowrap">in-licensed</span> patent rights or the rights of others. An adverse determination in any such submission, proceeding, or litigation could prevent the issuance of, reduce the scope of, invalidate, or render unenforceable our owned or <span style="white-space:nowrap">in-licensed</span> patent rights, limit our ability to stop others from using or commercializing similar or identical platforms and products, allow third parties to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or <span style="white-space:nowrap">in-licensed</span> patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future platforms or product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure to obtain or any loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, some of our owned and <span style="white-space:nowrap">in-licensed</span> patents and patent applications may in the future be <span style="white-space:nowrap">co-owned</span> with third parties. If we are unable to obtain an exclusive license to any such third-party <span style="white-space:nowrap">co-owners&#8217;</span> interest in such patents or patent application, such <span style="white-space:nowrap">co-owners</span> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <span style="white-space:nowrap">co-owners</span> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our owned and <span style="white-space:nowrap">in-licensed</span> patents may be subject to a reservation of rights by one or more third parties. For example, we <span style="white-space:nowrap">in-license</span> certain patent rights covering ABP-110 from the National Cancer Institute, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
NCI, a division of the National Institutes of Health, or NIH. As a result, the U.S. government may have certain rights, including <span style="white-space:nowrap">so-called</span> <span style="white-space:nowrap">march-in</span> rights, to such patent rights and any products or technology developed from such patent rights. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a <span style="white-space:nowrap">non-exclusive</span> license authorizing the U.S. government to use the invention for <span style="white-space:nowrap">non-commercial</span> purposes. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise <span style="white-space:nowrap">march-in</span> rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its <span style="white-space:nowrap">march-in</span> rights if it determines that action is necessary because we fail to achieve the practical application of government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations under any license, collaboration or other intellectual property related agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing, commercializing and protecting our current or future technologies or product candidates or we could lose certain rights to grant sublicenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technologies and product candidates. Our current license agreements impose, and any future license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. We previously were party to an Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;), which was terminated by MSK in September 2023 for our failure to fulfil our payment obligations to MSK. MSK has demanded payments totaling approximately $1.2&#160;million. We have contacted MSK about possible settlement and are evaluating a counterproposal received from MSK in February 2024. We are in breach of our obligations under our license agreement with MedImmune/AstraZeneca. See &#8220; &#8212;<span style="font-style:italic"> Through our AbMed subsidiary, we have <span style="white-space:nowrap">in-licensed</span> certain intellectual property rights relating to <span style="white-space:nowrap">ABP-201</span> from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of the terms of our license agreement with MedImmune/AstraZeneca</span>.&#8221; Our breach of this license agreement or breach of any other license agreement, or the use of intellectual property licensed to us in an unauthorized manner, may require us to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications that we license from third parties. For example, pursuant to each of our intellectual property licenses with MedImmune, and NCI, our licensors retain control of preparation, filing, prosecution, and maintenance, and, in certain circumstances, enforcement and defense of the patents and patent applications. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products or product candidates that are subject of such licensed rights could be materially adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect our competitive position on our current or future technologies or product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, the standard expiration of a patent is generally 20 years after it is filed. Various extensions may be available. However, the life of a patent and the protection it affords is limited. As a result, our owned and <span style="white-space:nowrap">in-licensed</span> patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). Additionally, a patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. An extension may not be granted or may be limited because of, for example a failure to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States has recently enacted and implemented wide-ranging patent reform legislation. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, which could increase the uncertainties and costs surrounding the prosecution of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications and the enforcement or defense of our owned or <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-invent&#8221;</span></span> system to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. These provisions also allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to challenge the validity of a patent by the USPTO administered post grant proceedings, including derivation, reexamination, inter partes review, post-grant review, and interference proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications and the enforcement or defense of our issued owned or <span style="white-space:nowrap">in-licensed</span> patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. The recent decision by the Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc. precludes claims directed to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and that is unmodified. This decision has yet to be clearly interpreted by other courts and by the USPTO. We cannot assure you that the interpretations of this decision or that subsequent rulings will not adversely impact our owned or <span style="white-space:nowrap">in-licensed</span> patents or patent applications. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing owned or <span style="white-space:nowrap">in-licensed</span> patents and patents that we might obtain or <span style="white-space:nowrap">in-license</span> in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may have a material adverse effect on our and our licensors&#8217; ability to obtain new patents or to protect and enforce our owned or <span style="white-space:nowrap">in-licensed</span> patents or that we may obtain or <span style="white-space:nowrap">in-license</span> in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our current or future products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bispecific antibodies are a relatively new scientific field. As the field of antibody and immunoregulatory therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our or our licensors&#8217; intellectual property rights. Even if such rights are not directly challenged, disputes could lead to the weakening of our or our licensors&#8217; intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are many issued and pending patents that claim aspects of our current or future product candidates and modifications that we may need to apply to our current or future product candidates. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant for products we wish to develop. Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If those third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be able to market such technology or product candidates or perform research and development or other activities covered by these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on current or future technologies or product candidates in all countries throughout the world would be prohibitively expensive. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our owned and <span style="white-space:nowrap">in-licensed</span> patents or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our owned or <span style="white-space:nowrap">in-licensed</span> intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our owned or <span style="white-space:nowrap">in-licensed</span> patents at risk of being invalidated or interpreted narrowly, could put our owned or <span style="white-space:nowrap">in-licensed</span> patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our and our licensors&#8217; efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or <span style="white-space:nowrap">in-license.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business, financial condition, results of operations and prospects may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current or any future product candidates and use our proprietary technologies without infringing, misappropriating or violating the proprietary and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our licensors, or any future strategic partners may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any future product candidates and technologies, including derivation, reexamination, inter partes review, post-grant review, or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United States </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as opposition proceedings. In some instances, we may be required to indemnify our licensors for the costs associated with any such adversarial proceedings or litigation. For example, our majority-owned subsidiary, AbMed Corporation, is obligated under the Collaboration and License Agreement with MedImmune to indemnify and hold harmless Medimmune for damages arising from intellectual property infringement by us resulting from exercise of the license from MedImmune. Third parties may assert infringement claims against us, our licensors or our strategic partners based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us, our licensors or our strategic partners to enforce or to otherwise assert their patent rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a material adverse impact on our ability to commercialize our current or any future platforms or product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors, or any future strategic partners are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, we could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed. In addition, we or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be <span style="white-space:nowrap">non-exclusive,</span> which could give our competitors access to the same technology or intellectual property rights licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing platforms or product candidates. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we or our licensors may find it necessary to pursue claims or initiate lawsuits to protect or enforce our owned or <span style="white-space:nowrap">in-licensed</span> patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to our owned or <span style="white-space:nowrap">in-licensed</span> patent or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would divert our management&#8217;s attention. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, indefiniteness, lack of written description, obviousness or <span style="white-space:nowrap">non-enablement.</span> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensors and the patent examiner were unaware during </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or certain aspects of our platform technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our product candidates and technologies if competitors or third parties design around such product candidates and technologies without legally infringing, misappropriating or violating our owned or <span style="white-space:nowrap">in-licensed</span> patents or other intellectual property rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop or market our current or future technologies or product candidates, which may not be available on commercially reasonable terms or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the antibody landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing, misappropriating or violating third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally or covering antibodies directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or product candidates. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our current or future technologies or product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platforms, our product candidates or the use of our technologies. Third-party intellectual property right holders may also actively bring infringement, misappropriation or violation claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or product candidates that are held to be infringing, misappropriating or violating. We might, if possible, also be forced to redesign current or future technologies or product candidates so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for certain aspects of our current or future technologies and product candidates, we also consider trade secrets, including confidential and unpatented <span style="white-space:nowrap">know-how,</span> important to the maintenance of our competitive position. However, trade secrets and <span style="white-space:nowrap">know-how</span> can be difficult to protect. We protect trade secrets and confidential and unpatented <span style="white-space:nowrap">know-how,</span> in part, by entering into <span style="white-space:nowrap">non-disclosure</span> and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We may also become involved in inventorship disputes relating to inventions and patents developed by our employees or consultants under such agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret, or securing title to an employee-or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217; or consultants&#8217; former employers or their clients. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property, and would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or product candidates, which could materially harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and <span style="white-space:nowrap">in-licensed</span> patents and/or applications and any patent rights we may own or <span style="white-space:nowrap">in-license</span> in the future. The USPTO and various <span style="white-space:nowrap">non-U.S.</span> government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our <span style="white-space:nowrap">in-licensed</span> intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <span style="white-space:nowrap">non-compliance</span> can </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>others may be able to make compounds or formulations that are similar to our product candidates, but that are not covered by the claims of any patents, should they issue, that we own, license or control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own, license or control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>we or our licensors might not have been the first to file patent applications covering certain of our owned and <span style="white-space:nowrap">in-licensed</span> inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or violating our owned or <span style="white-space:nowrap">in-licensed</span> intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>it is possible that our owned or <span style="white-space:nowrap">in-licensed</span> pending patent applications will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>issued patents that we own, <span style="white-space:nowrap">in-license</span> or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>we may not develop additional proprietary platforms that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>we may choose not to file a patent in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent covering such trade secrets or <span style="white-space:nowrap">know-how;</span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>the patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our product candidates are in preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to commence clinical trials of our two lead product candidates, <span style="white-space:nowrap">ABP-102</span> for the treatment of breast and gastric cancers, and <span style="white-space:nowrap">ABP-201</span> for the treatment of wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD) and diabetic macular edema (DME) in 2025 and 2026, respectively. Commencing these clinical trials is subject to finalizing the trial design and filing an IND or similar filing with the FDA or similar foreign regulatory authority. Even after we file our IND or comparable submissions in other jurisdictions, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in completing our preclinical studies and initiating or completing clinical trials of our product candidates. We do not know whether planned preclinical studies and clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed for a variety of reasons, including delays related to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory approval to commence a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining institutional review board, or IRB, approval at each clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recruiting suitable patients to participate in a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">having patients complete a clinical trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adding new clinical trial sites; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing sufficient quantities of our product candidates for use in clinical trials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the severity of the disease under investigation, our payments for conducting clinical trials, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications we are investigating. Especially because our product candidates may initially target indications that may be characterized as orphan markets, the clinical trial timeline for the regulatory process could be prolonged if sufficient patients cannot be enrolled in a timely manner. Furthermore, we expect to rely on our partners, CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our product candidates, resulting in substantial harm to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our existing or future partners to begin selling them. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the FDA has limited early experience with bispecific antibody-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. For example, the FDA may require us to provide additional data to support our regulatory applications, including Biologics License Applications, or BLAs. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future conduct clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct one or more clinical trials outside the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&#160;the data may be considered valid without the need for an <span style="white-space:nowrap">on-site</span> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <span style="white-space:nowrap">on-site</span> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP and the FDA is able to validate the data from the study through an onsite inspection, if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we or our existing or future partners obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#8220;Phase 4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may fail to obtain and maintain orphan drug designation from the FDA for our current and future product candidates, as applicable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy may include filing for orphan drug designation if and where available for our product candidates. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and <span style="white-space:nowrap">user-fee</span> exemptions. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may pursue orphan designations for our lead product candidates <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201.</span> However, while we may seek orphan drug designations for our product candidates, we may never receive such designations. In addition, orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. Even if we obtain such designations, we may not be the first to obtain regulatory approval of a product candidate for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. We may also fail to meet requirements to maintain orphan drug designation while developing <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201.</span> In addition, exclusive marketing rights in the United States may be limited if we decide to seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the orphan-designated disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may attempt to secure approval from the FDA through the use of accelerated approval pathways. If unable to obtain approval under an accelerated pathway, we may be required to conduct additional preclinical studies or clinical trials which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek an accelerated approval development pathway for our product candidates, including <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201.</span> Under the accelerated approval provisions of the Federal Food, Drug, and Cosmetic Act, or the FDCA, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval development pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical profile or risks and benefits for accelerated approval. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug&#8217;s clinical profile or risks and benefits, the FDA may withdraw its approval of the drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we choose to pursue accelerated approval, we intend to seek feedback from the FDA or will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that, after our evaluation of the feedback from the FDA or other factors, we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. A failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate would result in a longer time period to commercialize such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-marketing requirements, including the completion of confirmatory post-market clinical trial(s) to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post-market study with due diligence, a post-market study does not confirm the predicted clinical benefit, other evidence shows that the product is not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA, was enacted, which, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January&#160;1, 2019) <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act, or the ACA, was enacted. The Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions that resulted in aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. The IRA includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delaying the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. In August 2023, the government selected the first 10 drugs to be put through the Medicare drug price negotiation program, which is currently subject to several constitutional challenges. The outcomes of these challenges on the IRA, and the effect of the IRA on our business and the healthcare industry in general, are not yet known. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to product pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, reduce the cost of products under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. The HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. It is unclear what effect such legislative and enforcement interest may have on prescription devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any marketed product, which could have an adverse effect on patients for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from products that we may successfully develop and for which we may obtain regulatory marketing authorization and may affect our overall financial condition and ability to develop product candidates. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory marketing authorization that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, or the ACA, was enacted, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjected therapeutic biologics to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, and added a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part D. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, some provisions of the ACA have yet to be fully implemented and certain provisions have been subject to judicial and Congressional challenges, as well as efforts by the Trump Administration to repeal or replace certain aspects of the ACA. For example, since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. On December&#160;20, 2017, Congress passed The Tax Cuts and Jobs Act, which includes a provision repealing the individual mandate under the ACA, effective January&#160;1, 2019. We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2024 unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. Additionally, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future customers and accordingly, our financial operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, on December&#160;13, 2016, President Obama signed the 21st Century Cures Act, or Cures Act, into law. Among other provisions, the Cures Act reauthorized the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2020; created a new priority review voucher program for drug applications determined to be material national security threat medical countermeasure applications; revised the FDCA to streamline review of combination product applications; required FDA to evaluate the potential use of &#8220;real world evidence&#8221; to help support approval of new indications for approved drugs; provided a new &#8220;limited population&#8221; approval pathway for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorized FDA to designate a drug as a &#8220;regenerative advanced therapy,&#8221; thereby making it eligible for certain expedited review and approval designations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or existing or future partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors, among others, will play a primary role in the prescription and recommendation of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violation of the federal Anti-Kickback Statue carries criminal penalties and fines as well as administrative sanctions under the Civil Money Penalties Law. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalties laws that impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouse as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicare or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services reimbursed by third-party payors, including private insurers; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other health care providers and health care entities, or marketing expenditures; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we receive marketing and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategy, or a REMS, after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We intend to rely on third-party manufacturers and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future partners, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers, and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and <span style="white-space:nowrap">non-compliance</span> with such laws can subject us to criminal and/or civil liability and harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of<span style="font-weight:bold"> </span>government agencies and government-affiliated hospitals, universities, and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will adopt a Code of Business Conduct and Ethics, which will be effective upon the Closing of the Business Combination, and expect to prepare and implement policies and procedures to ensure compliance with such code. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comprehensive tax reform bills could adversely affect our business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. government is in the process of enacting comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include, among others, (i)&#160;a permanent reduction to the corporate income tax rate, (ii)&#160;a partial limitation on the deductibility of business interest expense, (iii)&#160;a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) and (iv)&#160;a <span style="white-space:nowrap">one-time</span> tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate. Notwithstanding the reduction in the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business and financial condition could be adversely affected. This proxy statement/prospectus does not discuss any such tax legislation or the manner in which it might affect purchasers of our common stock. We urge our stockholders to consult with their legal and tax advisors with respect to any such legislation and the potential tax consequences of investing in our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage points change (by value) in the ownership of its equity over a rolling three-year period), the corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards and certain other <span style="white-space:nowrap">pre-change</span> tax attributes to offset its post-change income and taxes may be limited. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may have experienced such ownership changes in the past, and we may experience ownership changes in the future, some of which are outside of our control. As of December&#160;31, 2022, we had federal net operating loss carryforwards of approximately $66.4&#160;million, and our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to our company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Becoming a Public Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limited and coverage or incur substantially higher costs to obtain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for shares of Post-Combination Company common stock will depend in part on the research and reports that third-party securities analysts publish about us and the industries in which we operate. We may be unable or slow to attract research coverage and if one or more analysts cease coverage of us, the price and trading volume of our securities would likely be negatively impacted. If any of the analysts that may cover us change their recommendation regarding our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst that may cover us ceases covering us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price or trading volume of our securities to decline. Moreover, if one or more of the analysts who cover us downgrades the Post-Combination Company common stock, or if our reporting results do not meet their expectations, the market price of shares of Post-Combination Company common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, we will become a public reporting company subject to the rules and regulations established from time to time by the SEC and Nasdaq. These rules and regulations will require, among other things that we establish and periodically evaluate procedures with respect to our internal control over financial reporting. Reporting obligations as a public company are likely to place a considerable strain on our financial and management systems, processes and controls, as well as on our personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a public company, we will be required to document and test our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act so that our management can certify as to the effectiveness of our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act could impair our ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have concluded that our disclosure controls and procedures were not effective as of December&#160;31, 2022. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We concluded that our internal control over financial reporting was ineffective as of December&#160;31, 2022 because a material weakness existed in our internal control over financial reporting. Management identified errors related to the completeness and accuracy of financial data, relating to unrecorded liabilities as of December&#160;31, 2022. These errors were corrected prior to the issuance of the consolidated financial statements for the year ended December&#160;31, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to improve our internal control over financial reporting. These remediation measures may be time consuming and costly, and there is no assurance that these initiatives will ultimately have the intended effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material weakness in internal control over financial reporting is a deficiency, or a combination of deficiencies, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis. If we identify any material weaknesses in internal control over financial reporting, any such material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To address this material weakness, management has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal controls over financial reporting, including the addition of qualified accounting personnel in charge of period-end close procedures, accrued liability estimates, and improvement of internal communications within the Company as it relates to the impact of new and outstanding contractual arrangements. We can offer no assurance that these initiatives will ultimately have the intended effects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting methods and policies for public companies are subject to review, interpretation and guidance from our independent registered accounting firm and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise change or revise our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Relating to ACAB </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In this subsection &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ACAB prior to the Business Combination and to the Post-Combination Company following the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Past performance by our management team or Atlantic Coastal Acquisition Corp. may not be indicative of business and operating results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding performance by, or businesses associated with, our management team and their affiliates is presented for informational purposes only. Past performance by our management team or Atlantic Coastal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Acquisition Corp. (&#8220;ACA I&#8221;) is not a guarantee of success with respect to any business combination we may consummate. You should not rely on the historical record of our management team&#8217;s or their affiliates&#8217; performance as indicative of our future performance of an investment in our company or the returns our company will, or is likely to, generate going forward. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain of our executive officers and directors previously served as executive officers and directors of ACA I, which went public in March 2021. In December 2021, ACA I announced a definitive agreement for a business combination with Essentium, Inc., a leading innovator of industrial additive manufacturing solutions. Such definitive agreement was subsequently terminated on February&#160;9, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete the initial business combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including restrictions on the nature of our investments and restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination and instead be required to liquidate. In addition, we may have imposed upon us burdensome requirements, including registration as an investment company with the SEC, adoption of a specific form of corporate structure and reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that our anticipated principal activities will subject us to the Investment Company Act. The proceeds held in the trust account may be invested by the trustee only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule <span style="white-space:nowrap">2a-7</span> under the Investment Company Act. Because the investment of the proceeds will be restricted to these instruments, we believe we will meet the requirements for the exemption provided in <span style="white-space:nowrap">Rule3a-1</span> promulgated under the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to consummate our initial business combination within the required time period, our public stockholders may receive only approximately $10.93&#160;per share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section&#160;3(a)(1)(A) of the Investment Company Act), on December&#160;29, 2023, we instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of the consummation of our business combination or liquidation. As a result, following the liquidation of securities in the Trust Account we will receive minimal interest on the funds held in the Trust Account, which would reduce the dollar amount our public stockholders would receive upon any redemption or liquidation of ACAB. Because the funds in the Trust Account were previously held in such U.S. government securities or money market funds for a period of almost 24 months, there is a greater risk that ACAB will be deemed to be an unregistered investment company under the Investment Company Act. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including restrictions on the nature of our investments and restrictions on the issuance of securities, and we might be forced to abandon our efforts to complete a business combination and instead be required to liquidate. If we are required to liquidate, our stockholders would not be able to realize the benefits of owning shares in a successor operating business, including the potential appreciation in the value of our shares and warrants following such a transaction, and our warrants would expire worthless. In addition, we would be subject to additional burdensome regulatory requirements, which may include registration as an investment company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the SEC, adoption of a specific form of corporate structure and reporting, record keeping, voting, proxy and disclosure requirements and expenses for which we have not allotted funds. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that our anticipated principal activities will subject us to the Investment Company Act. The proceeds held in the trust account may be invested by the trustee only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule <span style="white-space:nowrap">2a-7</span> under the Investment Company Act. Because the investment of the proceeds will be restricted to these instruments, we believe we will meet the requirements for the exemption provided in <span style="white-space:nowrap">Rule3a-1</span> promulgated under the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to consummate our initial business combination within the required time period, our public stockholders may receive only approximately $10.93&#160;per share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. As an early-stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business and lead to financial loss. Due to the political uncertainty involving Russia and Ukraine and the Middle East, there is an increased likelihood that escalation of tensions could result in cyber attacks that could either directly or indirectly impact our business and lead to financial loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect the business, investments and results of our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to laws and regulations enacted by national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on the business, investments and results of our operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The SEC has recently issued final rules relating to certain activities of SPACs. Certain of the procedures that we, a potential business combination target or others may determine to undertake in connection with such proposals may increase our costs and the time needed to complete our initial business combination and may constrain the circumstances under which we could complete an initial business combination. The need for compliance with the SPAC Final Rules (defined below) may cause us to liquidate the funds in the Trust Account or liquidate the Company at an earlier time than we might otherwise choose. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;30, 2022, the SEC issued proposed rules (the &#8220;SPAC Proposed Rules&#8221;) relating to, among other items, enhancing disclosures in business combination transactions involving SPACs and private operating companies; amending the financial statement requirements applicable to transactions involving shell companies; effectively eliminating the safe harbor relating to the use of projections in SEC filings in connection with proposed business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination transactions; increasing the potential liability of certain participants in proposed business combination transactions; and the extent to which SPACs could become subject to regulation under the Investment Company Act, including a proposed rule that would provide SPACs a safe harbor from treatment as an investment company if they satisfy certain conditions that limit a SPAC&#8217;s duration, asset composition, business purpose, and activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;24, 2024, the SEC announced final rules substantially similar to the SPAC Proposed Rules (the &#8220;SPAC Final Rules&#8221;), which will become effective on July&#160;1, 2024. These rules may materially increase the costs and time needed to complete the business combination or impair our ability to complete the business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There has been and may in the future be diversity in the capital structure, financial accounting policies, and resultant financial reporting by SPACs, which may have a material effect on our financial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2021, the staff of the SEC issued a statement related to warrants issued by special purpose acquisition companies, which resulted in the warrants issued by many special purpose acquisition companies being classified as liabilities rather than equity as previously reported. While we are accounting for our warrants as equity, further statements by the SEC relating to accepted accounting of special purpose acquisition companies could result in the correction of accounting errors in previously issued financial statements, restatements of previously issued audited financial statements, the filing of notices that previously issued financial statements may not be relied upon and findings of material weaknesses and significant deficiencies in internal controls over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have identified a material weakness in our disclosure controls and procedures that, if unsuccessfully remediated, could adversely affect our ability to report our financial results on a timely and accurate basis and to consummate an initial business combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures contained a material weakness as of September&#160;30, 2023 and December&#160;31, 2023, respectively, which remains unremedied as of the date of filing due to the Company not filing timely tax returns, utilizing cash withdrawn from the trust account for tax obligations for operating purposes and over-accrual of expenses. Our management is currently evaluating remedial actions in response to the foregoing material weakness, but no such actions have been taken as of the date of filing. Failure to achieve and maintain effective disclosure controls and procedures could adversely affect our ability to report our financial results on a timely and accurate basis and to consummate an initial business combination. If we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses, as described in our Annual Report on Form 10-K/A filed April&#160;1, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Relating to the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In this subsection &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ACAB prior to the Business Combination and to the Post-Combination Company following the Business Combination. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subsequent to the consummation of the Business Combination, the post-combination company may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we have conducted due diligence on Abpro, we cannot assure you that this diligence revealed all material issues that may be present in Abpro, that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of our control will not later arise. As a result, we may be forced to later write-down <span style="white-space:nowrap">or&#160;write-off&#160;assets,</span> restructure our operations or incur impairment or other charges that could result in losses. Even if our due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even though these charges may <span style="white-space:nowrap">be&#160;non-cash&#160;items</span> and may not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us following the completion of the Business Combination or our securities. In addition, charges of this nature may cause us to be unable to obtain future financing on favorable terms or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Sponsor and other Initial Stockholders of ACAB have interests in the Business Combination that are different from or are in addition to other stockholders in recommending that stockholders vote in favor of approval of the Business Combination Proposal. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering the ACAB Board&#8217;s recommendation that our stockholders vote in favor of the approval of the Business Combination Proposal, ACAB&#8217;s stockholders should be aware that our directors and officers and the Sponsor have interests in the Business Combination that may be different from, or in addition to, the interests of ACAB&#8217;s stockholders. These interests include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor holds an aggregate of 13,850,000 private placement warrants that would expire worthless if a business combination is not consummated, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our public warrants of $&#8195;&#8195;&#8195;&#8195;per warrant on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor, officers and directors have agreed not to redeem any of the shares of our common stock held by them in connection with a stockholder vote to approve the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Initial Stockholders paid an aggregate of $25,000 for the Founder Shares and that such securities will have a significantly higher value at the time of the business combination, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that certain of ACAB&#8217;s officers and directors collectively own, directly or indirectly, a material interest in the Sponsor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated appointment of&#8195;&#8195;&#8195;&#8195;, a member of&#8195;&#8195;&#8195;&#8195;, as a director on the board of the combined company in connection with the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the trust account is liquidated, including in the event we are unable to complete an Initial Business Combination within the required time period, the Sponsor has agreed to indemnify us to ensure that the proceeds in the trust account are not reduced below $10.20 per Public Share, or such lesser amount per Public Share as is in the trust account on the liquidation date, by the claims of (a)&#160;any third party for services rendered or products sold to us or (b)&#160;a prospective target business with which we have entered into an acquisition agreement, but only if such a third party or target business has not executed a waiver of all rights to seek access to the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our independent directors own an aggregate of 250,000 Founder Shares, which if unrestricted and freely tradeable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other ACAB stockholders experience a negative rate of return in the post-business combination company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor, officers and directors will be reimbursed for <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and ACAB&#8217;s officers and directors will lose their entire investment in us if an Initial Business Combination is not completed. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, as of the date of this proxy statement/prospectus, there has been no reimbursement to the Sponsor, officers or directors for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf, and no such amounts have been incurred as of the date of this proxy statement/prospectus. However, on October&#160;14, 2023 and November&#160;14, 2023, ACAB issued unsecured promissory notes (the &#8220;2023 Notes&#8221;) to the Sponsor in the aggregate principal amounts of $80,000 and $80,000, respectively, in connection with monthly extensions of the deadline to consummate an initial business combination. In the event that ACAB does not consummate an initial business combination, all amounts loaned to ACAB under the 2023 Notes will be forgiven except to the extent that ACAB has funds available to it outside of its trust account established in connection with the ACAB IPO. The balance will be paid by ACAB at the Closing. In addition, on December&#160;8, 2023, December&#160;11, 2023 and December&#160;12, 2023, the Sponsor advanced us $10,000, $1,630,000 and $15,000, respectively, to fund the account for the funds used in operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The founders, executive officers and directors of ACAB have agreed to vote in favor of the business combination, regardless of how other public stockholders vote, however, there is only one (1)&#160;founder share entitled to vote in connection with an initial business combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike many other blank check companies in which the founders, executive officers and directors agree to vote their founder shares and any public shares purchased during or after an initial public offering in accordance with the majority of the votes cast by the public stockholders in connection with an initial business combination, our founders, executive officers and directors have agreed (and their permitted transferees will agree), pursuant to the terms of a letter agreement entered into with ACAB, to vote any common stock held by them in favor of our initial business combination. As a result, in addition to the one (1)&#160;founder share held by ACAB&#8217;s founders, executive officers and directors that are entitled to vote, we would need 333,696 or approximately 50.0%, of the 667,391 public shares remaining after the April 2023 and December 2023 stockholder redemptions to be voted in favor of a transaction (assuming all issued and outstanding shares are voted) in order to have such initial business combination approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACAB&#8217;s Initial Stockholders hold a significant number of shares of our common stock and the Sponsor holds a significant number of our warrants. They will lose their entire investment in us if we do not complete an Initial Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and our independent directors hold 7,450,000 Founder Shares, representing approximately 20% of the total outstanding shares upon completion of the ACAB IPO and approximately 91.2% of the total outstanding shares after the December 2023 charter amendment. The Founder Shares will be worthless if we do not complete an initial business combination by September&#160;19, 2024. In addition, the Sponsor holds 13,850,000 private placement warrants that will also be worthless if we do not complete an initial business combination by September&#160;19, 2024. On December&#160;15, 2023, the stockholders of ACAB approved the proposal to extend the Completion Window to March&#160;19, 2024 and further provide that the ACAB Board may, without another stockholder vote, further extend the Completion Window on a monthly basis up to six times by an additional one </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
month each time thereafter by resolution of the ACAB Board, if requested by the Sponsor, until September&#160;19, 2024, subject in each case to certain advance notice requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Founder Shares are identical to the shares of Series A common stock included in the units, except that (a)&#160;the Founder Shares are subject to certain transfer restrictions and (b)&#160;the Sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed (i)&#160;to waive their redemption rights with respect to their Founder Shares and Public Shares owned in connection with the completion of an initial business combination, (ii)&#160;to waive their rights to liquidating distributions from the trust account with respect to their Founder Shares if we fail to complete an Initial Business Combination by September&#160;19, 2024 (although they will be entitled to liquidating distributions from the trust account with respect to any Public Shares they hold if we fail to complete an initial business combination by September&#160;19, 2024). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74&#160;per share redeemed. As a result of the Conversion and the results of the stockholder meeting described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The personal and financial interests of the Sponsor, officers and directors may have influenced their motivation in identifying and selecting the business combination, completing the business combination and influencing our operation following the business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Initial Stockholders have limited or no influence in voting in favor of each of the proposals presented at the Special Meeting. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders of record are entitled to vote an aggregate of one (1)&#160;share of Series B common stock (held by the Sponsor) prior to consummation of the business combination. The Sponsor has agreed to vote any Founder Shares and any Public Shares held by them as of the ACAB Record Date in favor of each of the proposals presented at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment to extend the date by which a business combination must be consummated to September&#160;19, 2024. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74&#160;per share redeemed.<span style="font-weight:bold"><span style="font-style:italic"> </span></span>As a result of the Conversion and the results of the stockholder meeting described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Sponsor, directors, officers, advisors or any of their respective affiliates may elect to purchase Public Shares from public stockholders, which may influence the vote on the Business Combination Proposal and reduce the public &#8220;float&#8221; of our Series A common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor, directors, officers, advisors or any of their respective affiliates may purchase Public Shares in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination, although they are under no obligation to do so. There is no limit on the number of Public Shares the Sponsor, directors, officers, advisors or any of their respective affiliates may purchase in such transactions, subject to compliance with applicable law and Nasdaq rules. Any such privately negotiated purchases may be effected at purchase prices that are in excess of the per share pro rata portion of the trust account. None of the funds in the trust account will be used to purchase Public Shares in such transactions. None of the Sponsor, directors, officers, advisors or any of their respective affiliates will make any such purchases when they are in possession of any material <span style="white-space:nowrap">non-public</span> information not disclosed to the seller of such Public Shares or during a restricted period under Regulation M under the Exchange Act. Such a purchase could include a contractual acknowledgement that such stockholder, although still the record holder of such Public Shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights, and could include a contractual provision that directs such stockholder to vote such shares in a manner directed by the purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Sponsor, directors, officers, advisors or any of their respective affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of any such purchases of Public Shares could be to vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining stockholder approval of the Business Combination or to satisfy a closing condition in the Business Combination Agreement, where it appears that such requirement would otherwise not be met. Any such purchases of our Public Shares may result in the completion of the Business Combination that may not otherwise have been possible. Any such purchases will be reported pursuant to Section&#160;13 and Section&#160;16 of the Exchange Act to the extent the purchasers are subject to such reporting requirements. In addition, if such purchases are made, the public &#8220;float&#8221; of our Series A common stock may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange. See the section entitled &#8220;<span style="font-style:italic">The Business Combination &#8212; Potential Purchases of Public Shares</span>&#8221; for a description of how the Sponsor, directors, officers, advisors or any of their respective affiliates will select which stockholders or warrantholders to purchase securities from in any private transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACAB has not obtained a third-party valuation or fairness opinion, and consequently, there is no assurance from an independent source that the merger consideration is fair to its stockholders from a financial point of view. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is not required to, and has not, obtained an opinion from an independent investment banking firm that the merger consideration it is paying for Abpro is fair to ACAB&#8217;s stockholders from a financial point of view. The fair market value of Abpro has been determined by the ACAB Board based upon standards generally accepted by the financial community, such as potential sales and the price for which comparable businesses or assets have been valued. Accordingly, ACAB&#8217;s stockholders will be relying on the judgment of its board of directors with respect to such matters and assuming the risk that its board of directors may not have properly valued the business. The lack of a third-party valuation or fairness opinion may also lead an increased number of stockholders to vote against the proposed Business Combination or demand redemption of their shares for cash, which could potentially impact ACAB&#8217;s ability to consummate the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We cannot assure you that our diligence review has identified all material risks associated with the Business Combination, and you may be less protected as an investor from any material issues with respect to Abpro&#8217;s business, including any material omissions or misstatements contained in the registration statement or proxy statement/prospectus relating to the Business Combination than an investor in an initial public offering. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before entering into the Business Combination Agreement, we performed a due diligence review of Abpro and its business and operations; however, we cannot assure you that our due diligence review identified all material issues, and certain unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Additionally, the scope of due diligence we have conducted in conjunction with the Business Combination may be different than would typically be conducted in the event Abpro pursued an underwritten initial public offering. In a typical initial public offering, the underwriters of the offering conduct due diligence on the company to be taken public, and following the offering, the underwriters are subject to liability to private investors for any material misstatements or omissions in the registration statement. While potential investors in an initial public offering typically have a private right of action against the underwriters of the offering for any of these material misstatements or omissions, there are no underwriters of the Series A common stock that will be issued pursuant to the registration statement of which this proxy statement/prospectus forms a part and thus no corresponding right of action is available to investors in the Business Combination, for any material misstatements or omissions in the registration statement or this proxy statement/prospectus. Therefore, as an investor in the Business Combination, you may be exposed to future losses, impairment charges, write-downs, write-offs or other charges that could have a significant negative effect on Abpro&#8217;s financial condition, results of operations and the price of its securities, which could cause you to lose some or all of your investment without recourse against an underwriter that may have been available had Abpro been taken public through an underwritten public offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACAB and Abpro will incur significant transaction costs in connection with the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of ACAB and Abpro has incurred and expects that it will incur significant, <span style="white-space:nowrap">non-recurring</span> costs in connection with consummating the Business Combination. ACAB and Abpro may also incur additional costs to retain key employees. ACAB and Abpro will also incur significant legal, financial advisor, accounting, banking and consulting fees, fees relating to regulatory filings and notices, SEC filing fees, printing and mailing fees and other costs associated with the Business Combination. ACAB and Abpro estimate that they will incur $3.2&#160;million (exclusive of the deferred underwriters&#8217; fees) aggregate transaction costs. Some of these costs are payable regardless of whether the Business Combination is completed. See &#8220;<span style="font-style:italic">The Business Combination &#8212; Terms of the Business Combination</span>&#8221; beginning on page&#160;234. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The unaudited pro forma condensed combined financial information included in this proxy statement/prospectus is preliminary and the actual financial condition and results of operations after the Business Combination may differ materially. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information included in this proxy statement/prospectus is presented for illustrative purposes only and is not necessarily indicative of what our actual financial position or results of operations would have been had the Business Combination been completed on the date(s) indicated. The preparation of the pro forma financial information is based upon available information and certain assumptions and estimates that ACAB and Abpro currently believe are reasonable. The unaudited pro forma financial information reflects adjustments, which are based upon preliminary estimates, among other things, to allocate the purchase price to Abpro&#8217;s net assets. The purchase price allocation reflected in this proxy statement/prospectus is preliminary, and the final allocation of the purchase price will be based upon the actual purchase price and the fair value of the assets and liabilities of Abpro as of the date of the completion of the Business Combination. In addition, following the completion of the Business Combination, there may be further refinements of the purchase price allocation as additional information becomes available. Accordingly, the final purchase accounting adjustments may differ materially from the pro forma adjustments reflected in this proxy statement/prospectus. See &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;111. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our stockholders may be held liable for claims by third parties against us to the extent of distributions received by them. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are forced to file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a &#8220;preferential transfer&#8221; or a &#8220;fraudulent conveyance.&#8221; As a result, a bankruptcy court could seek to recover all amounts received by our stockholders. Furthermore, because we intend to distribute the proceeds held in the trust account to our public stockholders promptly after expiration of the time we have to complete an initial business combination, this may be viewed or interpreted as giving preference to our public stockholders over any potential creditors with respect to access to or distributions from our assets. Furthermore, our board may be viewed as having breached their fiduciary duties to our creditors and/or may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy or <span style="white-space:nowrap">winding-up</span> petition or an involuntary bankruptcy or <span style="white-space:nowrap">winding-up</span> petition is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover such proceeds, and the members of the ACAB board of directors may be viewed as having breached their fiduciary duties to our creditors, thereby exposing the members of ACAB board of directors to claims of punitive damages. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy or <span style="white-space:nowrap">winding-up</span> petition or an involuntary bankruptcy or <span style="white-space:nowrap">winding-up</span> petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a &#8220;preferential transfer&#8221; or a &#8220;fraudulent conveyance.&#8221; As a result, a bankruptcy or insolvency court could seek to recover all amounts received by our stockholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing it and us to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy or <span style="white-space:nowrap">winding-up</span> petition or an involuntary bankruptcy or <span style="white-space:nowrap">winding-up</span> petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our stockholders and the per share amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy or <span style="white-space:nowrap">winding-up</span> petition or an involuntary bankruptcy or <span style="white-space:nowrap">winding-up</span> petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, the per share amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulatory approvals may not be received, may take longer than expected or may impose conditions that are not presently anticipated or cannot be met. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the transactions contemplated by the Business Combination Agreement can be completed, approval must be obtained under the HSR Act through the termination or expiration of the waiting period under the HSR Act. In deciding whether to terminate the HSR waiting period or allow it to expire, the relevant United States governmental authorities will consider a variety of factors, including the effect of the Business Combination on competition within the United States or any portion thereof. The terms and conditions of the approval that is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted may impose requirements, limitations or costs, or place restrictions on the conduct of the Post-Combination Company&#8217;s business. The requirements, limitations or costs imposed by the relevant governmental authorities could delay the Closing or diminish the anticipated benefits of the Business Combination. Additionally, the completion of the Business Combination is conditioned on the absence of certain orders, injunctions, decrees or laws by any court or other governmental authority that would enjoin or prohibit the completion of the Business Combination. ACAB and Abpro believe that the Business Combination should not raise significant regulatory concerns and that ACAB and Abpro will be able to obtain all requisite regulatory approvals in a timely manner. However, ACAB and Abpro cannot be certain when or if regulatory approvals will be obtained or, if obtained, the conditions that may imposed. In addition, neither ACAB nor Abpro can provide assurance that any such conditions, terms, obligations or restrictions will not result in delay. See &#8220;<span style="font-style:italic">The Business Combination</span> &#8212; <span style="font-style:italic">Regulatory Matters</span>&#8221; beginning on page&#160;248. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro&#8217;s past and potential future transactions with foreign-based commercial partners and investors may be subject to review by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;). CFIUS actions, including potentially imposing restrictions or conditions on these transactions, or forcing Abpro to terminate these transactions, could adversely impact our business and operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CFIUS has authority to review certain direct or indirect foreign investments in U.S. businesses for national security considerations. Among other things, CFIUS is authorized to require mandatory filings for certain foreign investments in the United States and to self-initiate national security reviews of certain foreign direct and indirect investments in U.S. businesses if the parties to such investments choose not to file voluntarily. With respect to transactions that CFIUS determines present unresolved national security concerns, CFIUS has the power to suspend transactions, impose mitigation measures or recommend that the president of the United States block pending transactions or order divestitures of completed transactions when national security concerns cannot be mitigated. Whether CFIUS has jurisdiction to review an acquisition or investment transaction depends on, among other factors: the nature and structure of the transaction; whether the target entity or assets constitute a U.S. business; the level of beneficial ownership and voting interests acquired by foreign persons; and the nature of any information, control, access or governance rights that the transaction affords foreign persons. For example, any transaction that could result in foreign &#8220;control&#8221; (as such term is defined in the CFIUS regulations) of a U.S. business is within CFIUS&#8217;s jurisdiction, including such a transaction carried out through a joint venture. In addition, CFIUS has jurisdiction over certain investments that do not result in control of a U.S. business by a foreign person but that afford a foreign person certain access, involvement or governance rights in a &#8220;TID U.S. business,&#8221; that is, a U.S. business that: (1)&#160;produces, designs, tests, manufactures, fabricates, or develops one or more &#8220;critical technologies;&#8221; (2) owns, operates, manufactures, supplies or services certain &#8220;covered investment critical infrastructure;&#8221; or (3)&#160;maintains or collects, directly or indirectly, &#8220;sensitive personal data&#8221; of U.S. citizens. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have in the past entered into, and may in the future enter into, commercial arrangements with foreign persons including, for example, our collaboration agreement with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a Chinese company, for <span style="white-space:nowrap">ABP-150.</span> In addition, foreign investors have invested in us in the past and may invest in us in the future, and we may continue to pursue partnerships and operations outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CFIUS has broad discretion to interpret its regulations, and CFIUS policies and practices are evolving rapidly. As a result, we cannot predict whether CFIUS may seek to review our past or potential future transactions involving a foreign person, even if such transactions did not or will not require a mandatory CFIUS filing at the time of the transaction. Any review by CFIUS of one or more of Abpro&#8217;s past or potential future transactions involving a foreign person may have outsized impacts on, among other things, the certainty, timing, feasibility and cost of the transaction in question, and there can be no assurance that we and the foreign person will be able to maintain (if the transaction has already been completed), or proceed with (if the transaction is pending), the transaction on acceptable terms or at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The consummation of the Business Combination is subject to a number of conditions and if those conditions are not satisfied or waived, the Business Combination Agreement may be terminated in accordance with its terms and the Business Combination may not be completed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement is subject to a number of conditions which must be fulfilled in order to complete the Business Combination. Those conditions include: approval of the Business Combination Agreement by Abpro stockholders, approval of the proposals required to effect the Business Combination by ACAB stockholders, as well as receipt of certain requisite regulatory approvals, absence of orders prohibiting completion of the Business Combination, effectiveness of the registration statement of which this proxy statement/prospectus is a part, approval of the shares of Series A common stock to be issued to Abpro stockholders for listing on Nasdaq, the requirement that ACAB have $8,700,000 in Available Cash, the accuracy of the representations and warranties by both parties (subject to the materiality standards set forth in the Business Combination Agreement) and the performance by both parties of their covenants and agreements. These conditions to the Closing may not be fulfilled in a timely manner or at all, and, accordingly, the Business Combination may not be completed. In addition, the parties can mutually decide to terminate the Business Combination Agreement at any time, before or after stockholder approval, or ACAB or Abpro may elect to terminate the Business Combination Agreement in certain other circumstances. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; The Business Combination Agreement &#8212; Termination.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may waive one or more of the conditions to the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may agree to waive, in whole or in part, one or more of the conditions to our obligations to complete the Business Combination, to the extent permitted by our Charter, bylaws and applicable laws. For example, it is a condition to our obligation to close the Business Combination that certain of Abpro&#8217;s representations and warranties be true and correct in all material respects as of the date of the Business Combination Agreement and the Effective Time. However, if our Board determines that it is in our best interests to proceed with the Business Combination, then our Board may elect to waive that condition and close the Business Combination. For additional information please see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; The Business Combination Agreement &#8212;</span> <span style="font-style:italic">Conditions to Closing of the Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The exercise of discretion by our directors and officers in agreeing to changes to the terms of or waivers of closing conditions in the Business Combination Agreement may result in a conflict of interest when determining whether such changes to the terms of the Business Combination Agreement or waivers of conditions are appropriate and in the best interests of our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the period leading up to the consummation of the Business Combination, other events may occur that, pursuant to the Business Combination Agreement, would require us to agree to amend the Business Combination Agreement, to consent to certain actions or to waive rights that it is entitled to under the Business Combination Agreement. Such events could arise because of changes in the course of the business of Abpro, a request by Abpro and its management to undertake actions that would otherwise be prohibited by the terms of the Business Combination Agreement or the occurrence of other events that would have a material adverse effect on the business of Abpro and could entitle us to terminate the Business Combination Agreement. In any such circumstance, it would be in our discretion, acting through our Board, to grant its consent or waive its rights. The existence of the financial and personal interests of our directors described elsewhere in this proxy statement/prospectus may result in a conflict of interest on the part of one or more of our directors between what he or she may believe is best for us and our stockholders and what he or she may believe is best for himself or herself or his or her affiliates in determining whether or not to take the requested action. As of the date of this proxy statement/prospectus, we do not believe there will be any changes or waivers that our directors and officers would be likely to make after our stockholder approval of the Business Combination has been obtained. While certain changes could be made without further stockholder approval, if there is a change to the terms of the Business Combination that would have a material impact on the stockholders, we will be required to circulate a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
new or amended proxy statement/prospectus or supplement thereto and resolicit the vote of our stockholders with respect to the Business Combination Proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of the Business Combination Agreement could negatively impact Abpro and ACAB. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is not completed for any reason, including as a result of Abpro stockholders declining to adopt the Business Combination Agreement or ACAB stockholders declining to approve the proposals required to effect the Business Combination, the ongoing businesses of Abpro and ACAB may be adversely impacted and, without realizing any of the anticipated benefits of completing the Business Combination, Abpro and ACAB would be subject to a number of risks, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro or ACAB may experience negative reactions from the financial markets, including negative impacts on its stock price (including to the extent that the current market price reflects a market assumption that the Business Combination will be completed); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro may experience negative reactions from its customers, vendors and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro and ACAB will have incurred substantial expenses and will be required to pay certain costs relating to the Business Combination, whether or not the Business Combination is completed; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">since the Business Combination Agreement restricts the conduct of Abpro&#8217;s and ACAB&#8217;s businesses prior to completion of the Business Combination, each of Abpro and ACAB may not have been able to take certain actions during the pendency of the Business Combination that would have benefitted it as an independent company, and the opportunity to take such actions may no longer be available (see the section entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; The Business Combination Agreement &#8212; Covenants of the Parties</span>&#8221; beginning on page 256 of this proxy statement/prospectus for a description of the restrictive covenants applicable to Abpro and ACAB). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is terminated and Abpro&#8217;s board of directors seeks another merger or business combination, Abpro stockholders cannot be certain that Abpro will be able to find a party willing to offer equivalent or more attractive consideration than the consideration ACAB has agreed to provide in the Business Combination or that such other merger or business combination is completed. If the Business Combination Agreement is terminated and the ACAB Board seeks another merger or business combination, ACAB stockholders cannot be certain that ACAB will be able to find another acquisition target that would constitute a business combination or that such other merger or business combination will be completed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to complete an initial business combination on or prior to April&#160;19, 2024 (or September&#160;19, 2024, subject to approval by the ACAB Board), our public stockholders may receive only approximately $10.20 per share on the liquidation of our trust account (or less than $10.20 per share in certain circumstances where a third party brings a claim against us that the Sponsor is unable to indemnify), and our warrants will expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to complete an initial business combination on or prior to April&#160;19, 2024 (or September&#160;19, 2024, subject to approval by the ACAB Board), our public stockholders may receive only approximately $10.20 per share on the liquidation of our trust account (or less than $10.20 per share in certain circumstances where a third party brings a claim against us that the Sponsor is unable to indemnify (as described below)), and our warrants will expire worthless. On December&#160;15, 2023, the stockholders of ACAB approved the proposal to extend the Completion Window to March&#160;19, 2024 and further provide that the ACAB Board may, without another stockholder vote, further extend the Completion Window on a monthly basis up to six times by an additional one month each time thereafter by resolution of the ACAB Board, if requested by the Sponsor, until September&#160;19, 2024, subject in each case to certain advance notice requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If third parties bring claims against us, the proceeds held in our trust account could be reduced and the per share redemption amount received by stockholders may be less than $10.20 per share. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our placing of funds in the trust account may not protect those funds from third-party claims against us. Although we will seek to have all vendors, service providers (other than our independent registered public accounting firm), prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders, such parties may not execute such agreements, or even if they execute such agreements, they may not be prevented from bringing claims against the trust account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust account. Although no third parties have refused to execute an agreement waiving such claims to the monies held in the trust account to date, if any third party refuses to execute such an agreement in the future, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#8217;s engagement would be significantly more beneficial to us than any alternative. Making such a request of potential target businesses may make our acquisition proposal less attractive to them and, to the extent prospective target businesses refuse to execute such a waiver, it may limit the field of potential target businesses that we might pursue if the Business Combination is not consummated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our Public Shares, if we are unable to complete our Business Combination within the prescribed timeframe, or upon the exercise of a redemption right in connection with our Business Combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the ten years following redemption. Accordingly, <span style="white-space:nowrap">the&#160;per-share&#160;redemption</span> amount received by public stockholders could be less than the $10.20 per Public Share initially held in the trust account, due to claims of such creditors. The Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party (other than our independent registered public accounting firm) for services rendered or products sold to us, or a prospective target business with which we have entered into a letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the trust account to below the lesser of (a) $10.20 per Public Share and (b)&#160;the actual amount per Public Share held in the trust account, if less than $10.20 per share due to reductions in the value of the trust assets as of the date of the liquidation of the trust account, in each case including interest earned on the funds held in the trust account and not previously released to us to pay our taxes, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the Underwriters against certain liabilities, including liabilities under the Securities Act. However, we have not asked the Sponsor to reserve for such indemnification obligations, nor have we independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and we believe that the Sponsor&#8217;s only assets are securities of our company. Therefore, we cannot assure you that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for an initial business combination and redemptions could be reduced to less than $10.20 per Public Share. In such event, we may not be able to complete an initial business combination, and you would receive such lesser amount per share in connection with any redemption of your Public Shares. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We cannot be certain as to the number of Public Shares that will be redeemed and the potential impact to public stockholders who do not elect to redeem their Public Shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no guarantee that a stockholder&#8217;s decision whether to redeem its shares of Series A common stock for a pro rata portion of the trust account will put the stockholder in a better future economic position. We can give no assurance as to the price at which a stockholder may be able to sell its Public Shares in the future following the Closing or any alternative business combination. Certain events following the consummation of any initial business combination, including the Business Combination, and including redemptions of Public Shares may cause an increase or decrease in our stock price, and may result in a lower value realized now than a stockholder of ACAB might realize in the future had the stockholder not redeemed its shares. Similarly, if a stockholder does not redeem its shares, the stockholder will bear the risk of ownership of the Public Shares after the consummation of any initial business combination, and there can be no assurance that a stockholder can sell its shares in the future for a greater amount than the Redemption Price. A stockholder should consult the stockholder&#8217;s own tax and/or financial advisor for assistance on how this may affect his, her or its individual situation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;18, 2024, the most recent practicable date prior to the date of this proxy statement/prospectus, the closing price per share of Series A common stock was $10.56. Public stockholders should be aware that, while we are unable to predict the price per share of Series A common stock following the consummation of the Business Combination&#8212;and accordingly we are unable to predict the potential impact of redemptions on the per share value of Public Shares owned by <span style="white-space:nowrap">non-redeeming</span> stockholders&#8212;increased levels of redemptions by public stockholders may be a result of the price per share of Series A common stock falling below the Redemption Price. We expect that more public stockholders may elect to redeem their Public Shares if the share price of the Series A common stock is below the projected Redemption Price of $10.20 per share, and we expect that more public stockholders may elect not to redeem their Public Shares if the share price per share of the Series A common stock is above the projected Redemption Price of $10.20 per share. Each Public Share that is redeemed will represent both (i)&#160;a reduction, equal to the amount of the Redemption Price, of the cash that will be available to ACAB from the trust account and (ii)&#160;a corresponding increase in each public stockholder&#8217;s pro rata ownership interest in ACAB following the consummation of the Business Combination. Based on the amount of funds left in the Trust Account as of December&#160;31, 2023, the Minimum Cash Condition in favor of Abpro as set forth in the Business Combination Agreement will not be satisfied by funds in the Trust Account alone and, so, a capital raise or related financing may be needed if the Minimum Cash Condition is not revised or waived. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, if a public stockholder exercises its redemption rights, such exercise will not result in the loss of any warrants that it may hold. If a substantial number of, but not all, public stockholders exercise their redemption rights, any <span style="white-space:nowrap">non-redeeming</span> stockholders would experience dilution to the extent such warrants are exercised and additional Series A common stock is issued. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete the Business Combination even if a substantial majority of our stockholders do not agree. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter does not provide a specified maximum redemption threshold, except that in no event will we redeem Public Shares in an amount that would cause our net tangible assets to be less than $5,000,001 (such that we are not subject to the SEC&#8217;s &#8220;penny stock&#8221; rules). The Closing is subject to the satisfaction or waiver (where permissible) of certain conditions, including the requirement that ACAB having at least $8,700,000 in available cash (after taking into account payments required to satisfy redemptions of Public Shares by ACAB&#8217;s public stockholders). Based on the amount of funds left in the Trust Account as of December&#160;31, 2023, the Minimum Cash Condition in favor of Abpro as set forth in the Business Combination Agreement will not be satisfied by funds in the Trust Account alone and, so, a capital raise or related financing may be needed if the minimum cash condition is not revised or waived. As a result, assuming we have external financing, we may be able to complete the Business Combination even though a majority of our public stockholders do not agree with the transaction and have redeemed their shares or have entered into privately negotiated agreements to sell their shares to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sponsor, officers, directors, advisors or any of their respective affiliates. In the event the aggregate cash consideration we would be required to pay for all shares of Series A common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed Business Combination exceed the aggregate amount of cash available to us, we will not complete the Business Combination or redeem any shares, all shares of Series A common stock submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACAB stockholders will have a reduced ownership and voting interest after the Business Combination and will exercise less influence over management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the issuance of the shares to Abpro stockholders, current ACAB stockholders&#8217; percentage ownership will be diluted. Assuming no public stockholders exercise their redemption rights and excluding any shares issuable pursuant to ACAB&#8217;s outstanding warrants, current ACAB stockholders&#8217; percentage ownership in the Post-Combination Company following the issuance of shares to Abpro stockholders would be 8%. Additionally, of the expected members of the Post-Combination Company&#8217;s board of directors after the completion of the Business Combination, only one will be a current director of ACAB and the rest will be current directors of Abpro or appointed by current stockholders of Abpro. The percentage of the Post-Combination Company&#8217;s common stock that will be owned by current ACAB stockholders as a group will vary based on the number of Public Shares for which the holders thereof request redemption in connection with the Business Combination. To illustrate the potential ownership percentages of current ACAB stockholders under different redemption levels, based on the number of issued and outstanding shares of ACAB common stock and Abpro capital stock on December&#160;31, 2023, and based on the merger consideration, current ACAB stockholders, as a group, will own (1)&#160;if there are no redemptions of Public Shares, 8% of the Post-Combination Company&#8217;s common stock expected to be outstanding immediately after the Business Combination or (2)&#160;if there are redemptions of 100% of the outstanding Public Shares, 7% of the Post-Combination Company&#8217;s common stock expected to be outstanding immediately after the Business Combination. Because of this, current ACAB stockholders, as a group, will have less influence on the board of directors, management and policies of the Post-Combination Company than they now have on the board of directors, management and policies of ACAB. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal proceedings in connection with the Business Combination, the outcomes of which are uncertain, could delay or prevent the completion of the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawsuits may be filed against ACAB or its directors and officers in connection with the Business Combination, or the equity holders of Abpro may make an application for relief under Delaware law. Defending such additional lawsuits could require ACAB to incur significant costs and draw the attention of ACAB&#8217;s management team away from the Business Combination. Further, the defense or settlement of any lawsuit or claim that remains unresolved at the time the Business Combination is consummated may adversely affect ACAB&#8217;s business, financial condition, results of operations and cash flows. Such legal proceedings could also delay or prevent the Business Combination from becoming effective within the completed timeframe. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our directors may decide not to enforce the indemnification obligations of the Sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the trust account are reduced below the lesser of (a) $10.20 per Public Share and (b)&#160;the actual amount per Public Share held in the trust account as of the date of the liquidation of the trust account, if less than $10.20 per share due to reductions in the value of the trust assets, in each case including interest earned on the funds held in the trust account and not previously released to us to pay our taxes, less taxes payable, and the Sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against the Sponsor to enforce its indemnification obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we currently expect that our independent directors would take legal action on our behalf against the Sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their business judgment and subject to their fiduciary duties may choose not to do so in any particular instance. If our independent directors choose not to enforce these indemnification obligations, the amount of funds in the trust account available for distribution to our public stockholders may be reduced below $10.20 per share. As of December&#160;29, 2023, the funds held in the trust account have been on deposit in a demand deposit bank account, owned and controlled by the trustee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not have sufficient funds to satisfy indemnification claims of our directors and officers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify our officers and directors to the fullest extent permitted by law. However, our officers and directors have agreed, and any persons who may become officers or directors prior to an initial business combination will agree, to waive any right, title, interest or claim of any kind in or to any monies in the trust account and to not seek recourse against the trust account for any reason whatsoever. Accordingly, any indemnification provided will be able to be satisfied by us only if (a)&#160;we have sufficient funds outside of the trust account or (b)&#160;we consummate an Initial Business Combination. Our obligation to indemnify our officers and directors may discourage stockholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we consummate the Business Combination, there is no guarantee that the public warrants will be in the money at the time they become exercisable, and they may expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price for our warrants is $11.50 per share of Series A common stock. There is no guarantee that the public warrants will be in the money following the time they become exercisable and prior to their expiration, and as such, the warrants may expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least 50% of the then-outstanding public warrants. As a result, the exercise price of the warrants could be increased, the exercise period could be shortened and the number of shares of our Series A common stock purchasable upon exercise of a warrant could be decreased, all without a holder&#8217;s approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our warrants were issued in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then-outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then-outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash or stock (at a ratio different than initially provided), shorten the exercise period or decrease the number of shares of our Series A common stock purchasable upon exercise of a warrant. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have received written notice from Nasdaq that we are not in compliance with Nasdaq&#8217;s market value of publicly held shares and publicly held shares requirements and if we are unable to regain compliance with Nasdaq continued listing standards, Nasdaq may delist our securities from trading on its exchange, which could limit investors&#8217; ability to make transactions in our securities, subject us to additional trading restrictions and adversely affect our ability to consummate the Business Combination. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5450(b)(1)(B) (the &#8220;Publicly Held Shares Requirement&#8221;) requires a minimum of 1,100,000 publicly held shares of our common stock and Nasdaq Listing Rule 5450(b)(2)(C) (the &#8220;Market Value of </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Publicly Held Shares Requirement&#8221;) requires us to maintain a minimum market value of publicly held shares of $15,000,000. On April&#160;18, 2024, we received letters (the &#8220;Notices&#8221;) from Nasdaq notifying us that, we have not, as of the fiscal year ended December&#160;31, 2023, maintained a minimum of 1,100,000 publicly held shares, as required under the Publicly Held Shares Requirement and (ii)&#160;we have failed to maintain a minimum market value of publicly held shares of $15,000,000 for the 30 consecutive business day period preceding the Notices, as required under the Market Value of Publicly Held Shares Requirement. There is no assurance that we will be able to regain compliance with the Publicly Held Shares Requirement or the Market Value of Publicly Held Shares Requirement. The Notices had no immediate effect on the listing of our common stock on The Nasdaq Global Market. We have been provided initial compliance periods of 45 calendar days and 180 calendar days to regain compliance with the Publicly Held Shares Requirement and the Market Value of Publicly Held Shares Requirement, respectively. We have submitted a plan to Nasdaq to obtain an extension of up to 180 calendar days to regain compliance with the Publicly Held Shares Requirement. During the compliance periods, our shares of common stock will continue to be listed and traded on The Nasdaq Global Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we cannot assure you that our securities will be listed on Nasdaq after the Business Combination. In connection with the Business Combination, we will be required to demonstrate compliance with Nasdaq&#8217;s initial listing requirements, which are more rigorous than Nasdaq&#8217;s continued listing requirements. For instance, our stock price would generally be required to be at least $4.00 per share, and we will be required to have a minimum of 400 unrestricted round lot holders (with at least 50% of such holders holding unrestricted securities). We cannot assure you that we will be able to meet those initial listing requirements at that time. Our continued eligibility for listing may depend on, among other things, the number of our shares that are redeemed. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Nasdaq delists our securities from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on <span style="white-space:nowrap"><span style="white-space:nowrap">an&#160;over-the-counter&#160;market.</span></span> If this were to occur, we could face significant material adverse consequences, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a limited availability of market quotations for our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced liquidity for our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination that our Series A common stock is a &#8220;penny stock&#8221; which will require brokers trading in our Series A common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a limited amount of news and analyst coverage; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a decreased ability to issue additional securities or obtain additional financing in the future. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents <span style="white-space:nowrap">or&#160;pre-empts&#160;the</span> states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because our units, Series A common stock and public warrants are listed on Nasdaq, our units, Series A common stock and public warrants qualify as covered securities. Although the states <span style="white-space:nowrap">are&#160;pre-empted&#160;from</span> regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. While we are not aware of a state having used these powers to prohibit or restrict the sale of securities issued by blank check companies, other than the state of Idaho, certain state securities regulators view blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank check companies in their states. Further, if we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulation in each state in which we offer our securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The ability to successfully effect the Business Combination and the Post-Combination Company&#8217;s ability to successfully operate the business thereafter will be largely dependent upon the efforts of certain key personnel of Abpro. The loss of such key personnel could negatively impact the operations and financial results of the combined business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to successfully effect the Business Combination and the Post-Combination Company&#8217;s ability to successfully operate the business following the Closing is dependent upon the efforts of certain key personnel of Abpro. Although we expect key personnel to remain with the Post-Combination Company following the Business Combination, there can be no assurance that they will do so. It is possible that Abpro will lose some key personnel, the loss of which could negatively impact the operations and profitability of the Post-Combination Company. Furthermore, following the Closing, certain of the key personnel of Abpro may be unfamiliar with the requirements of operating a company regulated by the SEC, which could cause Post-Combination Company to have to expend time and resources helping them become familiar with such requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Business Combination&#8217;s benefits do not meet the expectations of investors or securities analysts, the market price of ACAB&#8217;s securities or, following the consummation of the Business Combination, the combined company&#8217;s securities, may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of ACAB&#8217;s securities may decline as a result of the Business Combination if we do not achieve the perceived benefits of the Business Combination as rapidly, or to the extent anticipated by, financial analysts or the effect of the Business Combination on our financial results is not consistent with the expectations of financial analysts. Accordingly, holders of ACAB&#8217;s securities following the consummation of the Business Combination may experience a loss as a result of a decline in the market price of such common stock. In addition, a decline in the market price of ACAB&#8217;s securities following the consummation of the Business Combination could adversely affect our ability to issue additional securities and to obtain additional financing in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Activities taken by existing ACAB stockholders to increase the likelihood of approval of the Business Combination Proposal and the other proposals described in this proxy statement/prospectus could have a depressive effect on ACAB&#8217;s securities. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material nonpublic&#160;information regarding ACAB or its securities, the Sponsor, directors, officers, advisors and/or any of their respective affiliates may purchase shares from institutional and other investors who vote, or indicate an intention to vote, against the Business Combination Proposal, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire shares of ACAB common stock or to not vote their shares against the business combination proposal. Business Combination Proposal. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options and, with Abpro&#8217;s consent, the transfer to such investors or holders of shares owned by the Sponsors for nominal value. In such transactions, the purchase price for the ACAB common stock will not exceed the per-share redemption amount available to redeeming stockholders. In addition, the purchasers described above will waive redemption rights, if any, with respect to the ACAB common stock they acquire in such transactions. The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements to consummate the Business Combination where it appears that such requirements would otherwise not be met, however, such purchased shares would not be voted in favor of approving the Business Combination. Entering into any such arrangements may have a depressive effect on ACAB&#8217;s securities. For example, as a result of these arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than the market price and may therefore be more likely to sell the shares they own, either prior to or immediately after the special meeting. The details of such purchases would be&#160;disclosed by ACAB in a Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> prior to the Special Meeting, and would be made in </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compliance with Rule&#160;14e-5&#160;under the&#160;Securities Exchange Act of 1934, relying on the Tender Offer Compliance and Disclosure Interpretation&#160;166.01 (March&#160;22, 2022). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Relating to Redemption </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no guarantee that an ACAB public stockholder&#8217;s decision whether to redeem their Public Shares for a pro rata portion of the trust account will put such stockholder in a better future economic position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No assurance can be given as to the price at which a public stockholder may be able to sell the shares of our Series A common stock in the future following the completion of the Business Combination. Certain events following the consummation of any business combination, including the Business Combination, may cause an increase in our stock price, and may result in a lower value realized now than an ACAB stockholder might realize in the future had the stockholder not elected to redeem such stockholder&#8217;s Public Shares. Similarly, if an ACAB public stockholder does not redeem his, her or its shares, such stockholder will bear the risk of ownership of our Series A common stock after the consummation of the Business Combination, and there can be no assurance that a stockholder can sell his, her or its shares of our Series A common stock in the future for a greater amount than the Redemption Price set forth in this proxy statement/prospectus. An ACAB public stockholder should consult his, her or its own tax and/or financial advisor for assistance on how this may affect its individual situation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If ACAB public stockholders fail to comply with the redemption requirements specified in this proxy statement/prospectus, they will not be entitled to redeem their Public Shares for a pro rata portion of the funds held in the trust account. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exercise their redemption rights, holders are required to deliver their stock, either physically or electronically using Depository Trust Company&#8217;s DWAC System, to ACAB&#8217;s transfer agent two business days prior to the vote at the Special Meeting. If a holder properly seeks redemption as described in this proxy statement/prospectus and the Business Combination with Abpro is consummated, ACAB will redeem these shares for a pro rata portion of funds deposited in the trust account and the holder will no longer own such shares following the Business Combination. See the section entitled &#8220;<span style="font-style:italic">ACAB&#8217;s Special Meeting of Stockholders</span> &#8212;<span style="font-style:italic"> Redemption Rights</span>&#8221; for additional information on how to exercise your redemption rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If a public stockholder fails to receive notice of ACAB&#8217;s offer to redeem its Public Shares in connection with the Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB will comply with the proxy rules when conducting redemptions in connection with the Business Combination. Despite ACAB&#8217;s compliance with these rules, if a public stockholder fails to receive ACAB&#8217;s proxy materials, such stockholder may not become aware of the opportunity to redeem its shares. In addition, the proxy materials that ACAB will furnish to holders of its Public Shares in connection with the Business Combination will describe the various procedures that must be complied with in order to validly redeem Public Shares. In the event that a stockholder fails to comply with these or any other procedures, its shares may not be redeemed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The ability of ACAB stockholders to exercise redemption rights with respect to a large number of shares could increase the probability that the Business Combination would be unsuccessful and that stockholders would have to wait for liquidation in order to redeem their stock, despite certain financing arrangements intended to provide ACAB additional cash and to preserve the funds held in the trust account. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time ACAB entered into the Business Combination Agreement, ACAB did not know how many stockholders would exercise their redemption rights, and therefore ACAB structured the Business Combination and the related transactions based on its expectations as to the number of shares that will be submitted for redemption. The Business Combination Agreement requires ACAB to have at least $8,700,000 of Available Cash. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a larger number of shares are submitted for redemption than initially expected, we may need to restructure the transaction to reserve a greater portion of the cash in the trust account. The above considerations may limit our ability to complete the Business Combination or optimize our capital structure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If you or a &#8220;group&#8221; of stockholders of which you are a part are deemed to hold an aggregate of more than 15% of the Public Shares, you (or, if a member of such a group, all of the members of such group in the aggregate) will lose the ability to redeem all such shares in excess of 15% of the Public Shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A public stockholder, together with any of his, her or its affiliates or any other person with whom it is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3) of the Exchange Act), will be restricted from redeeming in the aggregate his, her or its Public Shares or, if part of such a group, the group&#8217;s Public Shares, in excess of 15% of the Public Shares without the consent of ACAB. Your inability to redeem any such excess Public Shares could result in you suffering a material loss on your investment in ACAB if you sell such excess Public Shares in open market transactions. ACAB cannot assure you that the value of such excess Public Shares will appreciate over time following the Business Combination or that the market price of the Public Shares will exceed the <span style="white-space:nowrap">per-share</span> Redemption Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, ACAB&#8217;s stockholders&#8217; ability to vote all of their Public Shares (including such excess shares) for or against the Business Combination Proposal is not restricted by this limitation on redemption. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The U.S. federal income tax treatment of the redemption of our Series A common stock as a sale of such Series A common stock depends on a stockholder&#8217;s specific facts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax treatment of a redemption of our Series A common stock will depend on whether the redemption qualifies as a sale of such Series A common stock under Section&#160;302 of the Code, which will depend largely on the total number of shares of our stock treated as held by the stockholder electing to redeem its Series A common stock (including any stock constructively owned by the holder, including as a result of owning public warrants) relative to all of our shares of stock outstanding before and after the redemption. If such redemption is not treated as a sale of Series A common stock for U.S. federal income tax purposes, the redemption will instead be treated as a corporate distribution. See &#8220;<span style="font-style:italic">Material U.S. Federal Income Tax Considerations &#8212; Material U.S. Federal Income Tax Consequences of the Redemption of ACAB Public Stockholders</span>&#8221; for a more detailed discussion of the U.S. federal income tax treatment of a redemption of Series A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A new 1% U.S. federal excise tax could be imposed on us in connection with redemptions by us of our shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into federal law. The IRA provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the excise tax. The IRS and the Treasury have issued a notice of an intention to issue proposed regulations (the &#8220;Notice&#8221;); the Notice also provides interim guidance on which taxpayers can rely until issuance of the proposed regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IRA excise tax applies only to repurchases that occur after December&#160;31, 2022. It is uncertain whether, and/or to what extent, the excise tax could apply to any redemptions of our public shares after December&#160;31, 2022, including any redemptions in connection with initial business combination or extension requests, or exchanges of stock pursuant to an acquisitive reorganization (i.e., pursuant to the initial business combination or otherwise). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Under the Notice, distributions pursuant to a complete liquidation of the Company (e.g., in the event we do not consummate an initial business combination) generally are not subject to this 1% excise tax, and other redemptions or repurchases of stock made during the same taxable year as the taxable year the Company completely liquidates and dissolves also would be exempt. Any redemption or other repurchase that occurs after December&#160;31, 2022, in connection with a business combination, extension request or otherwise may be subject to the excise tax. Whether and to what extent we would be subject to the excise tax in connection with a business combination or otherwise would depend on a number of factors, including (i)&#160;the fair market value of the stock subject to redemptions and repurchases or exchanged in an acquisitive reorganization in connection with the business combination, (ii)&#160;the structure of the business combination, (iii)&#160;the nature and amount of any private investment in public equity or other equity issuances in connection with the business combination (or otherwise issued not in connection with the business combination but issued within the same taxable year of the business combination) and (iv)&#160;the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by us, and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a business combination and in our ability to complete a business combination, and might affect the structure chosen for a business combination and any potential financing in connection with the business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to warrantholders, thereby making their warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last sales price of the Series A common stock has been at least $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within the 30 <span style="white-space:nowrap">trading-day</span> period ending on the third business day prior to the date on which we give notice of such redemption and provided certain other conditions are met. Redemption of the outstanding warrants could force warrantholders (i)&#160;to exercise their warrants and pay the exercise price therefor at a time when it may be disadvantageous for them to do so, (ii)&#160;to sell their warrants at the then-current market price when they might otherwise wish to hold their warrants or (iii)&#160;to accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of their warrants. None of the private placement warrants will be redeemable by ACAB so long as they are held by the Sponsor or its permitted transferees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Further, even if the Business Combination is completed, there can be no assurance that ACAB&#8217;s warrants will be in the money during their exercise period, and they may expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price for the ACAB warrants is $11.50 per share of common stock. There can be no assurance that the warrants will be in the money following the time they become exercisable and prior to their expiration, and as such, the warrants may expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Relating to Ownership of the Post-Combination Company&#8217;s Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of shares of the Post-Combination Company&#8217;s Series A common stock and warrants after the Business Combination will be affected by factors different from those currently affecting the prices of shares of ACAB&#8217;s Series A common stock, may be volatile and may decline, resulting in a loss of some or all of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, holders of shares of Abpro common stock (including shares of Abpro common stock resulting from the Preferred Stock Conversion) will become holders of shares of the Post-Combination Company&#8217;s Series A common stock. Prior to the Business Combination, ACAB has had limited operations. Upon completion of the Business Combination, the Post-Combination Company&#8217;s results of operations will depend upon the performance of Abpro&#8217;s businesses, which are affected by factors that are different from those currently affecting the results of operations of ACAB. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our Series A common stock following the Business Combination is likely to be volatile. The stock market recently has experienced extreme volatility. This volatility often has been unrelated or disproportionate to the operating performance of particular companies. You may not be able to resell your shares at an attractive price due to a number of factors such as those listed in &#8220;&#8212;<span style="font-style:italic">Risks Relating to Abpro&#8217;s Business and Industry</span>&#8221; and the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic on our financial condition and the results of operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our operating and financial performance and prospects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our quarterly or annual earnings or those of other companies in our industry compared to market expectations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions that impact demand for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future announcements concerning our business, our clients&#8217; businesses or our competitors&#8217; businesses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the public&#8217;s reaction to our press releases, other public announcements and filings with the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market&#8217;s reaction to our reduced disclosure and other requirements as a result of being an &#8220;emerging growth company&#8221; under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of our public float; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">coverage by or changes in financial estimates by securities analysts or failure to meet their expectations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market and industry perception of our success, or lack thereof, in pursuing our growth strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strategic actions by us or our competitors, such as acquisitions or restructurings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations which adversely affect our industry or us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in accounting standards, policies, guidance, interpretations or principles; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in senior management or key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances, exchanges or sales, or expected issuances, exchanges or sales of our capital stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in our dividend policy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse resolution of new or pending litigation against us; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in general market, economic and political conditions in the United States and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war and responses to such events. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These broad market and industry factors may materially reduce the market price of our Series A common stock, regardless of our operating performance. In addition, price volatility may be greater if the public float and trading volume of our Series A common stock is low. As a result, you may suffer a loss on your investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of market volatility, stockholders have instituted securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such litigation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Concentration of ownership among existing executive officers, directors and their affiliates, including the investment funds they represent, may prevent new investors from influencing significant corporate decisions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Post-Combination Company&#8217;s executive officers, directors and their affiliates, including the investment funds they represent, as a group will beneficially own approximately&#8195;&#8195;&#8195;&#8195;% of the Post-Combination Company&#8217;s common stock. As a result, these stockholders </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors, amendment of the Proposed Charter and approval of significant corporate transactions. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our issuance of additional shares of Series A common stock or convertible securities could make it difficult for another company to acquire us, may dilute your ownership of us and could adversely affect our stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed Business Combination, we intend to file a registration statement with the SEC on Form <span style="white-space:nowrap">S-8</span> providing for the registration of shares of our Series A common stock issued or reserved for issuance under the Incentive Plan. Subject to the satisfaction of vesting conditions and the expiration of <span style="white-space:nowrap">lock-up</span> agreements, shares registered under the registration statement on Form <span style="white-space:nowrap">S-8</span> will be available for resale immediately in the public market without restriction. From time to time in the future, we may also issue additional shares of our Series A common stock or securities convertible into Series A common stock pursuant to a variety of transactions, including acquisitions. The issuance by us of additional shares of our Series A common stock or securities convertible into our Series A common stock would dilute your ownership of us and the sale of a significant amount of such shares in the public market could adversely affect prevailing market prices of our Series A common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, we expect to obtain financing or to further increase our capital resources by issuing additional shares of our capital stock or offering debt or other equity securities, including senior or subordinated notes, debt securities convertible into equity, or shares of preferred stock. Issuing additional shares of our capital stock, other equity securities, or securities convertible into equity may dilute the economic and voting rights of our existing stockholders, reduce the market price of our Series A common stock, or both. Debt securities convertible into equity could be subject to adjustments in the conversion ratio pursuant to which certain events may increase the number of equity securities issuable upon conversion. Preferred stock, if issued, could have a preference with respect to liquidating distributions or a preference with respect to dividend payments that could limit our ability to pay dividends to the holders of our common stock. Our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, which may adversely affect the amount, timing or nature of our future offerings. As a result, holders of our Series A common stock bear the risk that our future offerings may reduce the market price of our Series A common stock and dilute their percentage ownership. See &#8220;<span style="font-style:italic">Description of Capital Stock of the Post-Combination Company</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales, or the perception of future sales, of our common stock by us, our existing stockholders or other third parties in the public market following the Closing could cause the market price for our common stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of substantial amounts of shares of our Series A common stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, we will have a total of 49,815,527 shares of Series A common stock outstanding, consisting of (i)&#160;38,884,511 shares issued to holders of shares of common stock of Abpro, (ii)&#160;667,391 shares held by ACAB&#8217;s public stockholders (assuming no redemptions by such public stockholders) and (iii)&#160;3,541,667 shares held by the Initial Stockholders (all of which will be subject to transfer restrictions pursuant to the Founders Letter Agreement). After the applicable <span style="white-space:nowrap">lock-up</span> periods and subject to registration, all shares issued in the Business Combination will be freely tradable under the Securities Act and without restriction by persons other than our &#8220;affiliates&#8221; (as defined under Rule 144 of the Securities Act, referred to herein as &#8220;Rule 144&#8221;), including our directors, executive officers and other affiliates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, pursuant to the Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements, certain Abpro stockholders will agree that they will not, during the period beginning at the Effective Time and continuing to and including the date that is one (1)&#160;year after the date of the Effective Time, subject to earlier release conditions, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Series A common stock, or any options or warrants to purchase any shares of Series A common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Series A common stock, or any interest in any of the foregoing (in each case, subject to certain exceptions set forth in the Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements). See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221; for a description of the Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the expiration or waiver of the <span style="white-space:nowrap">lock-ups</span> described above, shares held by certain of our stockholders will be eligible for resale, subject to, in the case of certain stockholders, volume, manner of sale and other limitations under Rule 144. In addition, pursuant to the Registration Rights Agreement, certain stockholders will have the right, subject to certain conditions, to require us to register the sale of their shares of our Series A common stock under the Securities Act. By exercising their registration rights and selling a large number of shares, these stockholders could cause the prevailing market price of our Series A common stock to decline. Following completion of the Business Combination, the shares covered by registration rights would represent approximately&#8195;&#8195;&#8195;&#8195;% of our outstanding common stock. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Registration Rights Agreement</span>&#8221; for a description of these registration rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As restrictions on resale end or if these stockholders exercise their registration rights, the market price of shares of our Series A common stock could drop significantly if the holders of these shares sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our shares of Series A common stock or other securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the shares of our Series A common stock reserved for future issuance under the Incentive Plan will become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements, <span style="white-space:nowrap">lock-up</span> agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. The number of shares to be reserved for future issuance under the Incentive Plan is expected to equal the sum of (i) 10% of the total outstanding shares of Series A common stock on a fully diluted basis immediately after the Closing, (ii)&#160;the number of shares available for future grants under our equity plans in effect prior to the Business Combination and (iii)&#160;any shares which are subject to awards under our equity plans in effect prior to the Business Combination that become available for grant under the share recycling provisions of the Incentive Plan. In addition, the Incentive Plan is expected to include an evergreen feature that will allow our board of directors, in its sole discretion, to reserve additional shares of Series A common stock for future issuance under the Incentive Plan each calendar year, beginning&#8195;&#8195;&#8195;&#8195;, 20&#8195;&#8195;&#8195;&#8195;and ending on and including&#8195;&#8195;&#8195;&#8195;, 20&#8195;, equal to the lesser of&#8195;% of the shares of Series A common stock outstanding on the final day of the immediately preceding calendar year and a smaller number of shares determined by the board of directors. We expect to file one or more registration statements on Form <span style="white-space:nowrap">S-8</span> under the Securities Act to register shares of our Series A common stock or securities convertible into or exchangeable for shares of our Series A common stock issued pursuant to our equity incentive plans. Any such Form <span style="white-space:nowrap">S-8</span> registration statements will automatically become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open market. The initial registration statement on Form <span style="white-space:nowrap">S-8</span> is expected to cover approximately&#8195;&#8195;&#8195;&#8195;million shares of our Series A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from our business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination, we will become subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires that we file annual, quarterly and current reports </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to our business and financial condition. The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal control over financial reporting and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. As a result, we will incur significant legal, accounting and other expenses that we did not previously incur. Our entire management team and many of our other employees will need to devote substantial time to compliance and may not effectively or efficiently manage our transition into a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the need to establish the corporate infrastructure demanded of a public company may also divert management&#8217;s attention from implementing our business strategy, which could prevent us from improving our business, results of operations and financial condition. We have made, and will continue to make, changes to our internal control over financial reporting, including IT controls, and procedures for financial reporting and accounting systems to meet our reporting obligations as a public company. However, the measures we take may not be sufficient to satisfy our obligations as a public company. If we do not continue to develop and implement the right processes and tools to manage our changing enterprise and maintain our culture, our ability to compete successfully and achieve our business objectives could be impaired, which could negatively impact our business, financial condition and results of operations. In addition, we cannot predict or estimate the amount of additional costs we may incur to comply with these requirements. We anticipate that these costs will materially increase our general and administrative expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These rules and regulations result in our incurring legal and financial compliance costs and will make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As a public reporting company, we will be subject to rules and regulations established from time to time by the SEC regarding our internal control over financial reporting. If we fail to establish and maintain effective internal control over financial reporting and disclosure controls and procedures, we may not be able to accurately report our financial results or report them in a timely manner. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, we will become a public reporting company subject to the rules and regulations established from time to time by the SEC and Nasdaq. These rules and regulations will require, among other things that we establish and periodically evaluate procedures with respect to our internal control over financial reporting. Reporting obligations as a public company are likely to place a considerable strain on our financial and management systems, processes and controls, as well as on our personnel. Abpro has concluded that its disclosure controls and procedures were not effective as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a public company, we will be required to document and test our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act so that our management can certify as to the effectiveness of our internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act could impair our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities analysts do not publish research or reports about the Post-Combination Company&#8217;s business or if they downgrade the Post-Combination Company&#8217;s stock or the Post-Combination Company&#8217;s sector, the Post-Combination Company&#8217;s stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for the Post-Combination Company common stock will rely in part on the research and reports that industry or financial analysts publish about the Post-Combination Company or its business. We may be unable or slow to attract research coverage and if one or more analysts cease coverage of us, the price and trading volume of our securities would likely be negatively impacted. If any of the analysts that may cover us change their recommendation regarding our securities adversely, or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst that may cover us ceases covering us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price or trading volume of our securities to decline. Moreover, if one or more of the analysts who cover us downgrades our Series A common stock, or if our reporting results do not meet their expectations, the market price of our Series A common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in our governing documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter, the Post-Combination Company&#8217;s bylaws and Delaware law contain or will contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our board of directors. Among other things, the Proposed Charter and/or the Post-Combination Company&#8217;s bylaws will include the following provisions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a staggered board, which means that our board of directors is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations on convening special stockholder meetings, which could make it difficult for our stockholders to adopt desired governance changes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prohibition on stockholder action by written consent, which means that our stockholders will only be able to take action at a meeting of stockholders and will not be able to take action by written consent for any matter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a forum selection clause, which means certain litigation against us can only be brought in Delaware; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without further action by our stockholders; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance notice procedures, which apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the DGCL, which prevents interested stockholders, such as certain stockholders holding more than 15% of our outstanding common stock, from engaging in certain business combinations unless (i)&#160;prior to the time such stockholder became an interested stockholder, the board of directors approved the transaction that resulted in such stockholder becoming an interested stockholder, (ii)&#160;upon consummation of the transaction that resulted in such stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the common stock, or (iii)&#160;following board approval, such business combination receives the approval of the holders of at least <span style="white-space:nowrap">two-thirds</span> of our outstanding common stock not held by such interested stockholder at an annual or special meeting of stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any provision of the Proposed Charter, the Post-Combination Company&#8217;s bylaws or Delaware law that has the effect of delaying, preventing or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Proposed Charter and the Post-Combination Company&#8217;s bylaws will provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter and the Post-Combination Company&#8217;s bylaws, each of which will become effective prior to the completion of the Business Combination, will provide that, unless we consent in writing to the selection of an alternative forum, the (a)&#160;Court of Chancery (the &#8220;Chancery Court&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (i)&#160;any derivative action, suit or proceeding brought on our behalf; (ii)&#160;any action, suit or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or stockholders to us or to our stockholders; (iii)&#160;any action, suit or proceeding asserting a claim arising pursuant to the DGCL, the Proposed Charter or the Post-Combination Company&#8217;s bylaws; or (iv)&#160;any action, suit or proceeding asserting a claim governed by the internal affairs doctrine; and (b)&#160;subject to the foregoing, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Notwithstanding the foregoing, such forum selection provisions shall not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts of the United States have exclusive jurisdiction. The exclusive forum provision may increase the costs for a stockholder to bring a claim or limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Proposed Charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As noted above, the Proposed Charter and the Post-Combination Company&#8217;s bylaws will provide that the federal district courts of the United States of America shall have jurisdiction over any action arising under the Securities Act. Accordingly, there is uncertainty as to whether a court would enforce such provision. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not intend to pay dividends on our Series A common stock for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, we do not anticipate declaring or paying any cash dividends on our Series A common stock in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our business prospects, results of operations, financial condition, cash requirements and availability, certain restrictions related to our indebtedness, industry trends and other factors that our board of directors may deem relevant. Any such decision will also be subject to compliance with contractual restrictions and covenants in the agreements governing our current and future indebtedness. In addition, we may incur additional indebtedness, the terms of which may further restrict or prevent us from paying dividends on our common stock. As a result, you may have to sell some or all of your Series A common stock after price appreciation in order to generate cash flow from your investment, which you may not be able to do. Our inability or decision not to pay dividends, particularly when </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
others in our industry have elected to do so, could also adversely affect the market price of our Series A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Post-Combination Company qualifies as an &#8220;emerging growth company&#8221; within the meaning of the Securities Act and if it takes advantage of certain exemptions from disclosure requirements available to emerging growth companies, it could make its securities less attractive to investors and may make it more difficult to compare its performance to the performance of other public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro is currently an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act, and the Post-Combination Company will be able to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis), reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the Post-Combination Company&#8217;s stockholders may not have access to certain information they may deem important. Abpro cannot predict whether investors will find the Post-Combination Company&#8217;s securities less attractive because it will rely on these exemptions. If some investors find the Post-Combination company&#8217;s securities less attractive as a result of its reliance on these exemptions, the trading prices of its securities may be lower than they otherwise would be, there may be a less active trading market for the Post-Combination Company&#8217;s securities and the trading prices of its securities may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.235&#160;billion or more; (b)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of the initial public offering of ACAB; (c)&#160;the date on which it has issued more than $1&#160;billion in nonconvertible debt during the previous three years; or (d)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior second fiscal quarter end. For so long as the Post-Combination Company remains an emerging growth company, it is permitted and intends to rely on exemptions from certain disclosure. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply <span style="white-space:nowrap">to&#160;non-emerging&#160;growth</span> companies but any such election to opt out is irrevocable. Abpro has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Post-Combination Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Post-Combination Company&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our Series A common stock less attractive because we will rely on these exemptions. If some investors find our Series A common stock less attractive as a result, there may be a less active trading market for our Series A common stock and our stock price may be more volatile. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A market for the Post-Combination Company&#8217;s securities may not develop, which would adversely affect the liquidity and price of such securities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Business Combination, the price of the Post-Combination Company&#8217;s securities may fluctuate significantly due to the market&#8217;s reaction to the Business Combination and general market and economic conditions. An active trading market for the Post-Combination Company&#8217;s securities following the Business Combination may never develop or, if developed, it may not be sustained. In addition, the price of the Post-Combination Company&#8217;s securities after the Business Combination can vary due to general economic conditions and forecasts, ACAB&#8217;s general business condition and the release of ACAB&#8217;s financial reports. Additionally, if the Post-Combination Company&#8217;s securities become delisted from Nasdaq and are quoted on the OTC Bulletin Board (an inter-dealer automated quotation system for equity securities that is not a national securities exchange) or the Post-Combination Company&#8217;s securities are not listed on Nasdaq and are quoted on the OTC Bulletin Board, the liquidity and price of Post-Combination Company&#8217;s securities may be more limited than if Post-Combination Company was quoted or listed on the NYSE, Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc509388_5">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Defined terms included below have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X</span> and presents the combination of the historical financial information of ACAB and Abpro, adjusted to give effect to the Business Combination and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the &#8220;Combined Company&#8221; refer to the Post-Combination Company and its consolidated subsidiaries after giving effect to the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of December&#160;31, 2023, combines the historical balance sheet of ACAB as of December&#160;31, 2023, and the historical balance sheet of Abpro as of December&#160;31, 2023, on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on December&#160;31, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December&#160;31, 2023, combines the historical statements of operations of ACAB for the year ended December&#160;31, 2023, and the historical statements of operations of Abpro for the year ended December&#160;31, 2023 on a pro forma basis as if the Business Combination, the other events contemplated by the Business Combination Agreement and the financing transaction had been consummated on January&#160;1, 2023, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information and accompanying notes have been derived from and should be read in conjunction with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited financial statements of ACAB as of and for the year ended December 31, 2023, and the related notes, which are included elsewhere in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited consolidated financial statements of Abpro as of and for the year ended December 31, 2023, and the related notes, which are included elsewhere in this proxy statement/ prospectus; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other information relating to ACAB and Abpro contained in this proxy statement/prospectus, including the Business Combination Agreement and the description of certain terms thereof set forth in the section entitled &#8220;<span style="font-style:italic">Proposal No.&#160;1 &#8212; The Business Combination Proposal.</span>&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information should also be read together with the sections titled &#8220;<span style="font-style:italic">ACAB Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span style="font-style:italic">Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; as well as other financial information included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Description of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 11, 2023, ACAB, Merger Sub (a wholly owned subsidiary of ACAB) and Abpro entered into the Business Combination Agreement by and among Abpro, ACAB, and the Merger Sub, pursuant to which the Merger Sub will merge with and into Abpro (the &#8220;Business Combination&#8221;), with Abpro as the surviving corporation in the Business Combination, and becoming a wholly owned subsidiary of ACAB. In connection with the Business Combination, ACAB will change its name to &#8220;Abpro Holdings, Inc.&#8221; (also referred to as the &#8220;Post-Combination Company&#8221;). Upon the consummation of the Business Combination, the Business Combination Consideration will be distributed as follows (in each case, rounded down to the nearest whole share): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each outstanding share of Abpro common stock will be cancelled and converted into the right to receive a number of shares of Post-Combination Company common stock equal to the Exchange Ratio (rounded down to the nearest whole share); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each outstanding share of Abpro preferred stock will be cancelled and converted into the right to receive a number of shares of Post-Combination Company common stock equal to (A)&#160;the aggregate number of shares of Abpro common stock that would be issued upon conversion of the shares of Abpro preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio (rounded down to the nearest whole share); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each outstanding Abpro stock option will be converted into an option, as applicable, to purchase a number of shares of Post-Combination Company common stock equal to (A)&#160;the number of shares of Abpro common stock subject to such option multiplied by (B)&#160;the Exchange Ratio at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio (rounded down to the nearest whole share). Each option to purchase shares of Post-Combination Company common stock will otherwise be subject to the same terms as the Abpro stock options, as applicable, prior to such conversion. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each outstanding share of Abpro unvested restricted stock unit will be cancelled and converted into the right to receive a number of restricted stock units of Post-Combination Company common stock determined based on the Exchange Ratio (rounded down to the nearest whole share); </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing, Abpro&#8217;s stockholders shall be issued up to 14,500,000 additional shares of the Post- Combination Company common stock (&#8220;Earnout Shares&#8221;) if, within five calendar years after the closing of the Business Combination, the volume weighted average price of shares of Series A Common Stock on Nasdaq, or any other national securities exchange on which the shares of Series A Common Stock are then traded (&#8220;VWAP&#8221;) meets or exceeds three-tier target prices defined in the agreement, as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, the VWAP is greater than or equal to $13.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;First Share Target&#8221;) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, the VWAP is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;Second Share Target&#8221;) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, the VWAP is greater than or equal to $18.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;Third Share Target&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These shares are contingently issuable upon the achievement of the set market performance targets. Considering the underlying contingent consideration to be transferred are common stocks, and as such is indexed to the Post-Combination Company&#8217;s own stock and classified in stockholders&#8217; equity in the statement of financial position, we deemed the contingent payments under the earnout provisions to qualify for the scope exception in ASC <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">815-10-15-74(a).</span></span></span> As a result, the contingent consideration obligation will be recognized when the contingency is resolved, and the consideration is paid or becomes payable and has no impact on the pro forma condensed financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on their contractual terms, Abpro&#8217;s outstanding warrants will expire upon the consummation of the Business Combination unless exercised prior to the closing date. It was assumed, for purposes of the unaudited pro forma condensed combined financial information below, that 61,009 common stock warrants outstanding at December 31, 2023 will expire at the closing of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, Abpro and Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;), an Abpro stockholder, entered into an agreement (the &#8220;Sponsor Share Letter&#8221;), pursuant to which Sponsor agreed to, at the closing date, (i)&#160;retain 2,950,000 shares of Series A Common Stock of ACAB, (ii)&#160;retain 291,667 shares, and transfer 983,333 shares to Abpro and 983,333 of the shares Abpro Bio (&#8220;Promote Shares&#8221;), for such parties to use to obtain <span style="white-space:nowrap">non-redemption</span> commitments from SPAC stockholders or other capital for SPAC or the Surviving Corporation (with any shares unused for such purpose to be retained by such party), and (iii)&#160;forfeit the remainder of any Series A Common Stock and Series B Common Stock held by Sponsor (or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
966,441 Series A shares and 1 Series B shares). It was also agreed in the Sponsor Share Letter that the Sponsor will transfer 200,000 shares to one of ACAB&#8217;s financial advisors for the services provided prior to the merger date. The transfer of 983,333 shares of ACAB Series A Common Stock to Abpro Bio was reflected in the pro forma condensed financial statements as a part of the recapitalization in conjunction with the Business Combination and this transfer has no financial impact. As it relates to 983,333 shares transferred to Abpro, the corresponding issuance costs will be recorded at the date these shares are transferred to third-party investors against <span style="white-space:nowrap">non-redemption</span> or capital commitments. As there were no transfers of shares to the third-party investors made through the date of this proxy statement/prospectus, the pro forma condensed financial statements will reflect impact of such transfers of the shares upon their execution. If 983,333 shares of Series A common stock held by Abpro and 291,667 shares held by the Sponsor are transferred to third-party investors in conjunction with their capital commitments, the maximum related costs would be approximately $13.5&#160;million based on the estimated fair value at December 31, 2023 ($10.58 per share at December 31, 2023) with the corresponding decrease in the <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital.</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Minimum Cash Condition and Proposed PIPE Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Closing is conditioned upon ACAB satisfying the Minimum Cash Condition. The Business Combination Agreement provides that the parties will use commercially reasonable efforts in connection with facilitating any necessary financing transactions required to meet the Minimum Cash Condition. These efforts are expected to include the pursuit of subscription agreements with certain investors (the &#8220;PIPE Investors&#8221;) for the purchase of ACAB securities for an aggregate purchase price of at least $37.6 million (the &#8220;Proposed PIPE Investments&#8221;), which has been included in both the no redemption and maximum redemption scenarios because management considers the Proposed PIPE Investments as probable, as it is anticipated that ACAB will enter into subscription agreements for the Proposed PIPE Investments prior to mailing the prospectus/proxy statement in an amount sufficient to meet the Minimum Cash Condition at any level of redemption. There is no assurance that ACAB will enter into subscriptions for the Proposed PIPE Investments on these terms or at all and ACAB will update this prospectus/proxy statement with additional information following the entry into any subscription agreements for the Proposed PIPE Investments. Without giving effect to the receipt of proceeds from the Proposed PIPE Investments, the Minimum Cash Condition is not expected to be met. The aggregate proceeds from, and the consummation of, the Proposed PIPE Investments are not anticipated to be contingent upon the amount of actual redemptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Minimum Cash Condition, the obligation of the parties to consummate the Business Combination pursuant to the Business Combination Agreement is also subject to a condition that the net tangible assets of the Post Combination Company, upon Closing and after giving effect to the redemption and the Proposed PIPE Investments, shall be at least $5,000,001. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Accounting for the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination will be accounted for as a reverse recapitalization in accordance with US&#160;GAAP. Under this method of accounting, ACAB will be treated as the acquired company and Abpro will be treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of the Post-Combination Company will represent a continuation of the financial statements of Abpro, with the Business Combination treated as the equivalent of Abpro issuing stock for the net assets of ACAB, accompanied by a recapitalization. The net assets of ACAB will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of Abpro. Abpro has been determined to be the accounting acquirer based on an evaluation of the following facts and circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is expected that the Post-Combination Company Board will consist of five directors, four of whom shall be designated by Abpro and one of whom shall be designated by ACAB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s existing senior management team will comprise the senior management of the Combined Company; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro&#8217;s operations prior to the Business Combination will comprise the ongoing operations of the Post-Combination Company as ACAB had minimal operations <span style="white-space:nowrap">pre-combination.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Basis of Pro Forma Presentation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X.</span> The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of the Post-Combination Company upon consummation of the Business Combination in accordance with GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial information are described in the accompanying notes. The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies, tax savings or cost savings. Any cash proceeds remaining after the consummation of the Business Combination and the other events contemplated by the Business Combination Agreement are expected to be used for general corporate purposes. Further, the unaudited pro forma condensed combined financial information does not purport to project the future operating results or financial position of the Post-Combination Company following the consummation of the Business Combination. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. ACAB and Abpro have not had any historical relationship prior to the transactions discussed in this proxy statement/prospectus. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information contained herein assumes that the ACAB stockholders approve the Business Combination. Pursuant to ACAB&#8217;s current Charter, the Public Stockholders may elect to redeem their Public Shares upon the closing of the Business Combination for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account. ACAB cannot predict how many of its Public Stockholders will exercise their right to redeem their Public Shares for cash. Therefore, the unaudited pro forma condensed combined financial information present two redemption scenarios as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming No Redemption: this scenario assumes that no Public Stockholders of ACAB exercise redemption rights with respect to their Public Shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Assuming Maximum Redemptions: This scenario assumes that all 667,391 Public Shares of ACAB are redeemed upon consummation of the Business Combination for an aggregate redemption payment of $7.4&#160;million, assuming a redemption price of $10.93 per share upon consummation of the Business Combination. ACAB&#8217;s Current Charter provides that ACAB may not consummate any business combination unless it has net tangible assets of at least $5,000,001 upon consummation. In addition, the &#8220;Maximum Redemption&#8221; scenario also considers that the consummation of the transaction is subject to the requirement that there should be at least $8.7&#160;million in Available Cash at the closing pursuant to the Business Combination Agreement. The Available Cash is defined as at the closing the amount of funds contained in the Trust Account (after reduction for the aggregate amount of payments made or required to be made in connection with the SPAC stockholder redemption), plus the amount of funds available to consummate the Business Combination pursuant to a PIPE Financing, minus unpaid SPAC expenses. This maximum level of redemptions would allow to satisfy all obligations of the combined entity at closing of the transaction, including the minimum net tangible asset, minimum available closing cash and payment of transaction costs, without which anticipated transaction would not close.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The two redemption scenarios assumed in the unaudited pro forma condensed combined balance sheet and statement of operations do not include adjustments for the 28,850,000 outstanding Public Warrants and Private Warrants issued in connection with ACAB&#8217;s Initial Public Offering as such securities are not exercisable until 30 days after the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma Post-Combination Company common stock issued and outstanding immediately after the Business Combination, presented under the two redemption scenarios: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span><br/><span style="font-weight:bold">(Assuming&#160;No&#160;Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span><br/><span style="font-weight:bold">(Assuming&#160;Maximum&#160;Redemption)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company Series&#160;A shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">667,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founder Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Shares transferred to investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.68</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares&#160;issued to service providers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.31</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued to PIPE Investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.66</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued in merger to Abpro shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Founder Shares included 7,200,000 shares held by ACAB&#8217;s sponsor and 300,000 shares which have been transferred to ACAB&#8217;s directors and Apeiron. The Founder Shares held by ACAB&#8217;s sponsor of 7,200,000 were reduced by 966,442 forfeited shares, 983,333 shares transferred to ABI, 983,333 shares transferred to Abpro and 200,000 shares transferred to one of ACAB&#8217;s financial advisors under the terms of the Sponsor Share Letter. As it relates to 983,333 shares transferred to Abpro, the corresponding shares were excluded from the shares outstanding since these shares are held by the Combined Company. The shares held by Abpro will be included in the shares outstanding on the date these shares are transferred to third-party investors against <span style="white-space:nowrap">non-redemption</span> or capital commitments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on April&#160;4, 2023, ACAB and the Sponsor entered into agreements with several unaffiliated third parties in exchange for them agreeing not to redeem certain public shares of ACAB at the special meeting called by the Company (the &#8220;Meeting&#8221;) to approve an extension of time for the Company to consummate an initial business combination (the &#8220;Charter Amendment Proposal&#8221;). In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of 825,225 shares of ACAB held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such <span style="white-space:nowrap">Non-Redeemed</span> Shares through the Meeting. As such, the Founder Shares were reduced and the corresponding Series A shares transferred to investors were increased by 825,225 shares. </p> <div> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma table above excludes Post-Combination Company shares reserved for the future issuance of Abpro outstanding options and restricted stock units. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the total Post-Combination Company shares issuable to the Abpro shareholders in both the no redemption and maximum redemption scenarios as of December 31, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#8195;&#8195;%&#8195;&#8195;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,083,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,919,295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,275,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,082,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,667,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,725,385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F Preferred Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,130,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserved for stock option exercises</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,022,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserved for restricted stock units vesting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">50,000,000</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom"><span style="font-weight:bold">100.0%</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing, the Abpro stockholders will have the right to receive the Contingent Consideration upon the occurrence of certain triggering events. Because the Contingent Consideration is contingently issuable based upon the price of Post- Combination Company common stock reaching certain thresholds that have not yet been achieved, the pro forma Post-Combination Company common stock issued and outstanding immediately after the Business Combination excludes the Contingent Consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the total Post-Combination Company shares issuable to Abpro in connection with the Business Combination. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:81%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued in merger to Abpro</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Post-Combination Company shares reserved for the future exercise of Abpro vested options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,022,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Post-Combination Company shares reserved for Abpro unvested restricted stock units</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Combination Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shares potentially issued to Abpro</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total merger consideration to be received by current equityholders of Abpro on the Closing Date will be the issuance of (or grant of options to purchase) Post-Combination Company equity with an aggregate value equal to approximately $500 million, comprised of (i) 38,884,511 shares of Post-Combination Company Series A common stock, (ii) options to purchase 11,022,188 shares of Post-Combination Company Series A common stock (iii) and 93,301 shares of Post-Combination Company Series A common stock issuable upon the exercise of restricted stock units, each multiplied by the deemed value of $10.00 per share. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the actual facts are different than these assumptions, then the amounts and shares outstanding in the unaudited pro forma condensed combined financial information will be different and those changes could be material. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF DECEMBER 31, 2023 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No&#160;Redemption<br/>Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;Maximum&#160;Redemption<br/>Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">ACAB</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additional<br/>Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">ASSETS</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(12)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(4)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,367</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(6)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(210</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(7)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,557</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(11)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred offering costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(878</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(6)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and marketable securities held in trust account, current</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,729</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,897</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,522</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and marketable securities held in trust account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap"><span style="white-space:nowrap">Right-of-use</span></span> asset -operating lease</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Security deposits</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Patents</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Total assets</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">37,366</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">3,355</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(1,741</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">38,980</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(7,372</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">31,608</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top" colspan="28"><span style="font-weight:bold">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9pt; font-family:Times New Roman;font-weight:bold">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued offering costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Excise tax payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Advance from related parties</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(11)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Income taxes payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock to be redeemed</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,729</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liability, current</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Finance lease liability, current</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, current&#8212;related parties</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,902</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(11)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33,286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred underwriting fees payable</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(10,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">(7)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liability, noncurrent</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(43,786</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No&#160;Redemption<br/>Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;Maximum&#160;Redemption<br/>Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">ACAB</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro&#160;Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additional<br/>Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Convertible Preferred stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series F Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,991</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series E Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,841</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,841</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series D Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,622</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,949</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,949</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A Redeemable, Convertible Preferred Stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,795</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(75,599</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; (deficit) equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(4)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(8)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(8)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital</span></span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,911</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(12)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(4)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(5)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,395</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(6)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(7)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(8)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(9)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(10)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated (deficit) equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(6)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(7)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(9)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,819</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right"><span style="font-weight:bold">(10)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-controlling</span> interest</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(85,135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,937</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,372</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Total liabilities, convertible preferred stock and stockholders&#8217; (deficit) equity</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">37,366</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">3,355</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1,741)</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">38,980</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(7,372)</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">31,608</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of December&#160;31, 2023 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the payment of $29.7&#160;million from Trust Account for the redemption of 2,768,301 shares of ACAB Series A Common Stock. In connection with the special meeting of stockholders of ACAB on December&#160;15, 2023, stockholders holding 2,768,301 shares of ACAB Series A Common Stock issued in the Initial Public Offering of ACAB exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. As a result, approximately $29.7&#160;million (approximately $10.74 per share after removal of interest available to pay taxes) was removed from the Trust Account to pay such holders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the liquidation and reclassification of cash and marketable securities held in the Trust Account that becomes available for general use by the Post-Combination Company following the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the transfer of ACAB&#8217;s Series&#160;A Common Stock subject to possible redemptions as of December&#160;31, 2023 to permanent equity. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the net proceeds of $35&#160;million from the PIPE financing (gross proceeds of $37.6&#160;million by issuance of 3,763,400 shares of Series&#160;A Common Stock at the purchase price of $10.00 per share, net of related estimated agent placement fees of $2.6 million). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the exchange of all Abpro preferred stock (Series A preferred, Series&#160;B preferred, and Series&#160;C preferred, Series&#160;D preferred, Series&#160;E preferred, Series&#160;F preferred) into Post-Combination Company Series A common stock pursuant to the conversion rate for such shares of Abpro preferred stock effective immediately prior to the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the preliminary estimated payment of direct and incremental transaction costs incurred prior to or concurrent with the Business Combination of approximately $3.2&#160;million (exclusive of the deferred underwriters&#8217; discount discussed below) which are to be cash settled upon the Closing in accordance with the Business Combination Agreement. Transaction costs include legal, accounting, financial advisory and other professional fees related to the Business Combination. Of the total cash transaction costs of approximately $3.2&#160;million, approximately $1.4&#160;million are expected to be incurred by Abpro and charged to additional <span style="white-space:nowrap">paid-in</span> capital and approximately $1.8&#160;million are to be incurred by ACAB and charged to expenses through accumulated deficit. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the settlement of $10.5&#160;million deferred payable settled through issuance of 600,000 shares to Cantor, cash payment of $210,000 and forgiveness of the remaining balance. The fair value of the shares was $6,348,000 (based on the market value of $10.58 per share as of December&#160;31, 2023) and the excess of $3,942,000 is accounted for as the recovery of accumulated deficit (since the initial accretion to the mezzanine reduced the accumulated deficit). For more information regarding the Cantor deferred underwriting fees, see &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions&#8212;ACAB &#8212; Deferred Underwriting Fee.</span>&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the recapitalization of Abpro equity as a result of the exchange of Abpro common stock for Series A Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of ACAB&#8217;s accumulated deficit to additional <span style="white-space:nowrap">paid-in&#160;capital.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents approximately $5.8&#160;million of <span style="white-space:nowrap">non-cash</span> transaction costs attributable to the payments in 350,000 shares of Series&#160;A common stock shares for legal services and 200,000 shares of Series&#160;A common stock shares for financial advisor services rendered to ACAB in connection with the Merger and payable upon the consummation of the Merger (based on the market value of $10.58 per share as of December&#160;31, 2023). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects repayment of $3.6&#160;million in liabilities upon closing, including $1.7&#160;million of advances from related parties and $1.9&#160;million in notes payable consisting of $1,442,000 to Abpro Bio, $300,000 to Abpro&#8217;s executives and $160,000 to ACAB&#8217;s Sponsor. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the same facts as described in the No redemption scenario, except that all 667,391 outstanding public shares of ACAB are redeemed for cash in connection with the Business Combination, resulting in a distribution to public shareholders of $7.4&#160;million, paid out in cash, and a reduction to permanent equity of equivalent amount. ACAB&#8217;s Current Charter provides that ACAB may not consummate any business combination unless it has net tangible assets of at least $5,000,001 upon consummation. In addition, the &#8220;Maximum Redemption&#8221; scenario also considers that the consummation of the transaction is subject to the requirement that there should be at least $8.7&#160;million in Available Closing Cash at the closing pursuant to the Business Combination Agreement. The Available Closing Cash is defined as at the closing the amount of funds contained in the Trust Account (after reduction for the aggregate amount of payments made or required to be made in connection with the SPAC Stockholder Redemption), plus the amount of funds available to consummate the Merger pursuant to a PIPE Financing, minus unpaid SPAC expenses. This maximum level of redemptions would allow to satisfy all obligations of the combined entity at closing of the transaction, including the minimum net tangible asset, minimum available closing cash and payment of transaction costs, without which anticipated transaction would not close.</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computations of the pro forma net tangible assets under the no redemption and maximum redemption scenarios are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">(in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proforma net tangible assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOR THE YEAR ENDED DECEMBER 31, 2023 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share data) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No Redemption<br/>Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;Maximum<br/>Redemption&#160;Scenario</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">ACAB</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additional<br/>Transaction<br/>Accounting</span><br/><span style="font-weight:bold">Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma</span><br/><span style="font-weight:bold">Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Collaboration revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Royalty</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Operating expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Transaction costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,850<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(2</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,819<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(3</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,669</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,666</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,669</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,081</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,081</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Other income (expense)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,755</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest and penalties on tax obligations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(142</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(142</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(142</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,755</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(50</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(50</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Income (Loss) before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,706</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,177</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,177<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(1</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Net income (loss)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">2,822</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(11,706</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)</span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(12,247</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(21,131</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">&#8212;&#8194;</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold">(21,131</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">)</span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Weighted average shares outstanding of Abpro common stock&#8212;basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,356,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Basic and diluted net loss per share&#8212;Abpro common stock&#8212;basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.25)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, <span style="white-space:nowrap">Non-redeemable</span> common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, <span style="white-space:nowrap">non-redeemable</span> common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding , Common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,257,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Basic and diluted net income (loss) per common share, Common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended December 31, 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction accounting adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects an adjustment to eliminate interest income related to the Trust Account, including elimination of the related income tax expenses. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the transaction costs expected to be incurred by ACAB. Since the Business Combination is expected to be accounted for as a reverse merger and recapitalization of Abpro into ACAB, the costs to be incurred by ACAB to consummate the merger are expensed as incurred. This adjustment is <span style="white-space:nowrap">non-recurring</span> in nature and is not expected to have a continuing effect on future period statements of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents approximately $5.8&#160;million of <span style="white-space:nowrap">non-cash</span> transaction costs attributable to the payments in 350,000 Series A common stock shares for legal services and 200,000 of Series A common stock shares for financial advisor services rendered to ACAB in connection with the Merger and payable upon the consummation of the merger (based on the market value of $10.58 per share as of December&#160;31, 2023). This adjustment is <span style="white-space:nowrap">non-recurring</span> in nature and is not expected to have a continuing effect on future period statements of operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Notes to Unaudited Pro Forma Condensed Combined Financial Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. Basis of Presentation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, ACAB will be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of the Post-Combination Company will represent a continuation of the financial statements of Abpro, and the Business Combination will be treated as the equivalent of Abpro issuing stock for the net assets of ACAB, accompanied by a recapitalization. The net assets of ACAB will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of December 31, 2023, combines the historical balance sheet of ACAB as of December 31, 2023, and the historical balance sheet of Abpro as of December 31, 2023, on a pro forma basis as if the Business Combination, the other events contemplated by the Business Combination Agreement and financing transaction had been consummated on December 31, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023, combines the historical statements of operations of ACAB for the year ended December 31, 2023, and the historical statements of operations of Abpro for the year ended December 31, 2023 on a pro forma basis as if the Business Combination, the other events contemplated by the Business Combination Agreement and financing transaction had been consummated on January 1, 2023, the beginning of the earliest period presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information and accompanying notes have been derived from and should be read in conjunction with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited financial statements of ACAB as of and for the year ended December 31, 2023, and the related notes, which are included elsewhere in this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited consolidated financial statements of Abpro as of and for the year ended December&#160;31, 2023, and the related notes, which are included elsewhere in this proxy statement/ prospectus; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other information relating to ACAB and Abpro contained in this proxy statement/prospectus, including the Business Combination Agreement and the description of certain terms thereof set forth in the section entitled &#8220;<span style="font-style:italic">Proposal No.&#160;1 &#8212; The Business Combination Proposal.</span>&#8221; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information should also be read together with the sections titled &#8220;<span style="font-style:italic">ACAB Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span style="font-style:italic">Abpro Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; as well as other financial information included elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma adjustments reflecting the consummation of the Business Combination are based on information available as of the date of this proxy statement/prospectus and certain assumptions and methodologies that management believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in these notes, may be revised as additional information becomes available and is evaluated. Therefore, the actual adjustments may materially differ from the pro forma adjustments that appear in this proxy statement/prospectus. Management considers this basis of presentation to be reasonable under the circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">One-time</span> direct and incremental transaction costs anticipated to be incurred by Abpro prior to, or concurrent with, the Closing are reflected in the unaudited pro forma condensed combined balance sheet as a direct reduction to the Post-Combination Company&#8217;s additional <span style="white-space:nowrap">paid-in</span> capital and are assumed to be cash settled. Since the Business Combination is expected to be accounted for as a reverse merger and recapitalization of Abpro into ACAB, the costs incurred by ACAB to consummate the merger are expensed as incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Financial Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X.</span> The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of Abpro upon consummation of the Business Combination in accordance with GAAP. Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial information are described in the accompanying notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies, tax savings or cost savings. Any cash proceeds remaining after the consummation of the Business Combination and the other related events contemplated by the Merger Agreement are expected to be used for general corporate purposes. The unaudited pro forma condensed combined financial information does not purport to project the future operating results or financial position of Abpro following the completion of the Business Combination. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. ACAB and Abpro have not had any historical relationship prior to the transactions. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information contained herein assumes that the ACAB stockholders approve the Business Combination. Pursuant to its existing charter, ACAB will provide stockholders the opportunity to redeem the outstanding shares of common stock for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account, which holds the proceeds of the IPO, as of two business days prior to the consummation of the transactions contemplated by the Merger Agreement (including interest earned on the funds held in the Trust Account, net of taxes) upon the closing of the transactions contemplated by the Merger Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The level of redemptions assumed in the unaudited pro forma condensed combined balance sheet and statements of operations are based on the assumption that there are no adjustments for the outstanding Public Warrants and Private Warrants issued in connection with the IPO as such securities are not exercisable until 30 days after the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the actual facts are different than these assumptions, then the amounts and shares outstanding in the unaudited pro forma condensed combined financial information will be different and those changes could be material. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma basic and diluted income per share amounts presented in the unaudited pro forma condensed combined statements of operations are based upon the number of the Combined Company&#8217;s shares outstanding, assuming the Business Combination occurred on January 1, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Loss per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Represents the net loss per share calculated using the historical shares of ACAB Common Stock outstanding, and the issuance of additional shares in connection with the Business Combination and other related events, assuming all shares were outstanding since January 1, 2023. As the Business Combination and other related events are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable in connection with the Business Combination have been outstanding for the entire period presented. Under the maximum redemption scenario, the shares assumed to be redeemed by the Public Stockholders are eliminated as of January 1, 2023. The stock options, restricted stock units and warrants were excluded in the earnings per share calculation as they would be anti-dilutive. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended</span><br/><span style="font-weight:bold">December&#160;31, 2023</span><br/><span style="font-weight:bold">Pro Forma Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(in thousands, except share and <span style="white-space:nowrap">per-share</span> data)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding-basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share-basic and diluted <sup style="font-size:75%; vertical-align:top">(1) </sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company Series A shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">667,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founder Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,541,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Shares transferred to investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,808,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued to service providers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued to PIPE Investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,763,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-Combination Company shares issued in merger to Abpro</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,884,511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The outstanding warrants, stock options and restricted stock units of the Post-Combination Company are anti-dilutive and are not included in the calculation of basic or diluted net loss per share. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following outstanding shares of common stock equivalents are excluded from the computation of pro forma diluted net loss per share for all the periods and scenarios presented as they have an anti-dilutive effect: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Year Ended<br/>December&#160;31, 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Pro Forma Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No</span><br/><span style="font-weight:bold">Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming</span><br/><span style="font-weight:bold">Maximum</span><br/><span style="font-weight:bold">Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACAB Public Warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACAB Private Warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,850,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abpro Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,022,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,022,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abpro Restricted Stock Units</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">39,965,489</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom" align="right"><span style="font-weight:bold">39,965,489</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA COMBINED PER SHARE FINANCIAL INFORMATION </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables set forth: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">historical per share information of ACAB for the year ended December 31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">historical per share information of Abpro for the year ended December 31, 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unaudited pro forma per share information of the combined company for the year ended December 31, 2023, after giving effect to the Business Combination, as follows: </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Assuming No Redemption: </span>This presentation assumes that no public stockholders of ACAB exercise redemption rights with respect to their Public Shares for a pro rata share of the funds in the Trust Account. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Assuming Maximum Redemption: </span>This scenario assumes that all 667,391 Public Shares of ACAB are redeemed upon consummation of the Business Combination for an aggregate redemption payment of $7.4&#160;million, assuming a redemption price of $10.93 per share upon consummation of the Business Combination. ACAB&#8217;s Current Charter provides that ACAB may not consummate any business combination unless it has net tangible assets of at least $5,000,001 upon consummation. In addition, the &#8220;Maximum Redemption&#8221; scenario also considers that the consummation of the transaction is subject to the requirement that there should be at least $8.7&#160;million in Available Cash at the closing pursuant to the Business Combination Agreement. The Available Cash is defined as at the closing the amount of funds contained in the Trust Account (after reduction for the aggregate amount of payments made or required to be made in connection with the SPAC stockholder redemption), plus the amount of funds available to consummate the Business Combination pursuant to a PIPE Financing, minus unpaid SPAC expenses. This maximum level of redemptions would allow to satisfy all obligations of the combined entity at closing of the transaction, including the minimum net tangible asset, minimum available closing cash and payment of transaction costs, without which anticipated transaction would not close.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables should be read in conjunction with the summary historical financial information included elsewhere in this proxy statement/prospectus, and the historical financial statements of ACAB and Abpro and the related notes thereto that are included elsewhere in this proxy statement/prospectus. The unaudited ACAB and Abpro pro forma combined per share information is derived from, and should be read in conjunction with, the unaudited pro forma condensed combined financial statements and the related notes thereto included elsewhere in this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined net income per share information below does not purport to represent the actual results of operations that would have occurred had the companies been combined during the periods presented, nor does it purport to represent the actual results of operations for any future date or period. The unaudited pro forma combined book value per share information below does not purport to represent what the value of ACAB and Abpro would have been had the companies been combined during the periods presented. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Combined Pro Forma</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro&#160;Equivalent<br/>Per Share Pro Forma <sup style="font-size:75%; vertical-align:top">(b) </sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">ACAB<br/>(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro</span><br/><span style="font-weight:bold">(Historical)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming&#160;No<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Assuming<br/>Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">As of and for the year ended December&#160;31, 2023</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;31, 2023 book value per share <sup style="font-size:75%; vertical-align:top">(a) </sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2.11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Weighted average shares:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding <span style="white-space:nowrap">Non-redeemable</span> common stock&#8212;basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,815,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,148,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding , Common stock subject to possible redemption&#8212;basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,257,894</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of Abpro common stock&#8212;basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,356,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Income (loss) per share:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, <span style="white-space:nowrap">Non-redeemable</span> common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, Common stock subject to possible redemption</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 0.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share&#8212;Abpro common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">(a)</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Book value per share is calculated using the formula: total permanent equity divided by the total number of shares of common stock outstanding classified in permanent equity. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">(b)</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Abpro equivalent pro forma basic and diluted per share data and book value is calculated by multiplying the combined pro forma per share data by the ratio of the ACAB shares to be issued to Abpro&#8217;s shareholders upon closing. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc509388_8a">ACAB&#8217;S SPECIAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is furnishing this proxy statement/prospectus to ACAB&#8217;s stockholders as part of the solicitation of proxies by the ACAB Board for use at the Special Meeting of ACAB stockholders to be held on&#8195;&#8195;&#8195;&#8195;&#8195;, 2024, and at any adjournment or postponement thereof. This proxy statement/prospectus provides ACAB&#8217;s stockholders with information they need to know to be able to vote or instruct their vote to be cast at the Special Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Date, Time and Place of Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting of stockholders will be held on&#8195;&#8195;&#8195;&#8195;&#8195;, 2024, at 9:00 a.m., eastern time, in virtual format. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Power; Record Date </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be entitled to vote or direct votes to be cast at the Special Meeting if you owned shares of common stock at the close of business on &#8195;&#8195;&#8195;&#8195;&#8195; , 2024, which is the record date for the Special Meeting. You are entitled to one vote for each share of common stock that you owned as of the close of business on the ACAB Record Date. If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker, bank or other nominee to ensure that votes related to the shares you beneficially own are properly counted. On the ACAB Record Date, there were&#8195;&#8195;&#8195;&#8195;shares of common stock outstanding, of which&#8195;&#8195;&#8195;&#8195;are Public Shares entitled to vote at the Special Meeting, and 7,500,000 are Founder Shares (of which only one (1)&#160;share of Series B common stock is entitled to vote at the Special Meeting). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purpose of the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Special Meeting, ACAB is asking holders of ACAB common stock to vote on the following proposals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Business Combination Proposal</span>&#8212;To consider and vote upon a proposal to approve the Business Combination Agreement and the transactions contemplated thereby (Proposal No.&#160;1); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Charter Approval Proposal</span>&#8212;To consider and vote upon a proposal to adopt the Proposed Charter in the form attached hereto as <span style="font-style:italic">Annex B</span> (Proposal No.&#160;2); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Governance Proposal</span>&#8212;To consider and act upon, on a <span style="white-space:nowrap">non-binding</span> advisory basis, a separate proposal with respect to certain governance provisions in the Proposed Charter in order to give holders of ACAB&#8217;s common stock the opportunity to present their separate views on important corporate governance procedures (Proposal No.&#160;3); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Director Election Proposal</span>&#8212;To consider and vote upon a proposal to elect five directors to serve on the Board until the 2025 annual meeting of stockholders, in the case of Class&#160;I directors, the 2026 annual meeting of stockholders, in the case of Class&#160;II directors, and the 2027 annual meeting of stockholders, in the case of Class&#160;III directors, and, in each case, until their respective successors are duly elected and qualified (Proposal No.&#160;4); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Merger Issuance Proposal</span>&#8212;To consider and vote upon a proposal to approve, for purposes of complying with applicable listing rules of Nasdaq, the issuance of shares of Series A common stock pursuant to the Business Combination (Proposal No.&#160;5); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Incentive Plan Proposal&#8212;</span>To consider and vote upon a proposal to approve and adopt the Incentive Plan (Proposal No.&#160;6); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">The Adjournment Proposal&#8212;</span>To consider and vote upon a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal or we determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived (Proposal No.&#160;7). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote of ACAB&#8217;s Sponsor, Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB has entered an agreement with the Sponsor and ACAB&#8217;s directors and officers, pursuant to which each agreed to vote any shares of common stock owned by them in favor of each of the proposals presented at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have waived any redemption rights, including with respect to any Public Shares purchased in the ACAB IPO or in the aftermarket, in connection an initial business combination. The Founder Shares held by the Initial Stockholders have no redemption rights upon our liquidation and will be worthless if no business combination is effected by us within the Completion Window. However, the Sponsor and ACAB&#8217;s directors and officers are entitled to redemption rights upon our liquidation with respect to any Public Shares they may own. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quorum and Required Vote for Proposals for the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of ACAB stockholders is necessary to hold a valid meeting. A quorum will be present at the Special Meeting if a majority of the issued and outstanding common stock entitled to vote as of the ACAB Record Date is represented in person (which would include presence at a virtual meeting) or by proxy. Abstentions and broker <span style="white-space:nowrap">non-votes</span> will be counted as present for the purpose of determining a quorum. As of the ACAB Record Date,&#8195;&#8195;&#8195;&#8195;shares of common stock would be required to achieve a quorum. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of each of the Business Combination Proposal, Governance Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal, if presented, will require the affirmative vote of the majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to each of the Business Combination Proposal, the Governance Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal or the Adjournment Proposal, if presented, will have no effect on the Business Combination Proposal, the Governance Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal or the Adjournment Proposal. ACAB&#8217;s Sponsor and its directors and officers have agreed to vote their shares of common stock in favor of each of the proposals presented at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of the Charter Approval Proposal will require the affirmative vote of (i)&#160;the holders of a majority of the Founder Shares then outstanding, voting separately as a single class, (ii)&#160;the holders of a majority of the Series A common stock then outstanding, voting separately as a single Series and (iii)&#160;the holders of a majority of the outstanding shares of common stock on the ACAB Record Date, voting together as a single class. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to the Charter Approval Proposal, will have the same effect as a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; such proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors are elected by a plurality of all of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. This means that the five (5)&#160;director nominees who receive the most affirmative votes will be elected. Stockholders may not cumulate their votes with respect to the election of directors. Accordingly, a stockholder&#8217;s failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, as well as an abstention from voting and a broker <span style="white-space:nowrap">non-vote</span> with regard to election of directors, will have no effect on the election of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned on the approval of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal at the Special Meeting, subject to the terms of the Business Combination Agreement. The Business Combination is not conditioned on the Governance Proposal, the Director Election Proposal or the Adjournment Proposal. If the Business Combination Proposal is not approved, the other proposals (except the Adjournment Proposal) will not be presented to the stockholders for a vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important for you to note that in the event that the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal do not receive the requisite vote for approval, ACAB will not consummate the Business Combination. If ACAB does not consummate the Business Combination and fails to complete an initial business combination within the Completion Window, it will be required to dissolve and liquidate the trust account by returning the then remaining funds in such account to its public stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The ACAB Board unanimously determined that the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination, were advisable, fair to, and in the best interests of, ACAB and its stockholders. Accordingly, the ACAB Board unanimously recommends that its stockholders &#8220;FOR&#8221; each of the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the ACAB Board to vote in favor of approval of the proposals, stockholders should keep in mind that the Sponsor and ACAB&#8217;s directors and officers have interests in such proposals that are different from or in addition to (and which may conflict with) those of ACAB stockholders. Stockholders should take these interests into account in deciding whether to approve the proposals presented at the Special Meeting, including the Business Combination Proposal. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Business Combination with Abpro or another business combination is not consummated within the Completion Window, ACAB will cease all operations except for the purpose of winding up, redeeming 100% of the outstanding Public Shares for cash and, subject to the approval of its remaining stockholders and the ACAB Board, dissolving and liquidating. In such event, the Founder Shares held by ACAB&#8217;s Initial Stockholders which were acquired for an aggregate purchase price of $25,000 prior to the ACAB IPO, would be worthless because ACAB&#8217;s Initial Stockholders are not entitled to participate in any redemption or distribution with respect to such shares. Such shares had an aggregate market value of $&#8195;&#8195;&#8195;&#8195;based upon the closing price of $&#8195;&#8195;&#8195;&#8195;per share of Series A common stock on Nasdaq on&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date. Certain Founder Shares are subject to certain <span style="white-space:nowrap">time-and</span> performance-based vesting provisions as described under &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement.</span>&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor purchased an aggregate of 13,850,000 private placement warrants from ACAB for an aggregate purchase price of $13,850,000 (or $1.00 per warrant). These purchases took place on a private placement basis simultaneously with the consummation of the ACAB IPO and the subsequent partial exercise of their over-allotment option by the Underwriters. A portion of the proceeds ACAB received from these purchases were placed in the trust account. Such warrants had an aggregate market value of&#8195;&#8195;&#8195;&#8195;$ based upon the closing price of $&#8195;&#8195;&#8195;&#8195;per public warrant on Nasdaq on&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date. The private placement warrants will become worthless if ACAB does not consummate a business combination within the Completion Window. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If ACAB is unable to complete a business combination within the Completion Window, its executive officers will be personally liable under certain circumstances described herein to ensure that the proceeds in the trust account are not reduced by the claims of target businesses or claims of vendors or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
other entities that are owed money by ACAB for services rendered or contracted for or products sold to ACAB. If ACAB consummates a business combination, on the other hand, ACAB will be liable for all such claims. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB&#8217;s directors and officers, and their affiliates are entitled to reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by them in connection with certain activities on ACAB&#8217;s behalf, such as identifying and investigating possible business targets and business combinations. However, if ACAB fails to consummate a business combination within the Completion Window, they will not have any claim against the trust account for reimbursement. Accordingly, ACAB may not be able to reimburse these expenses if the Business Combination or another business combination is not consummated within the Completion Window. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The continued indemnification of current directors and officers and the continuation of directors&#8217; and officers&#8217; liability insurance. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Abstentions and Broker <span style="white-space:nowrap">Non-Votes</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstentions are considered present for the purposes of establishing a quorum and will have the same effect as a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; the Charter Approval Proposal. Broker <span style="white-space:nowrap">non-votes</span> are considered present for the purposes of establishing a quorum and will have the effect of a vote &#8220;<span style="font-weight:bold">AGAINST</span>&#8221; the Charter Approval Proposal. Abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Business Combination Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, if your shares are held in &#8220;street&#8221; name and you do not instruct your broker, bank or other nominee on a timely basis on how to vote your shares, your broker, bank or other nominee, in its sole discretion, may either leave your shares unvoted or vote your shares on routine matters, but not on any <span style="white-space:nowrap">non-routine</span> matters. <span style="font-weight:bold">None of the proposals at the Special Meeting are routine matters. As such, without your voting instructions, your brokerage firm cannot vote your shares on any proposal to be voted on at the Special Meeting.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Your Shares&#8212;Stockholders of Record </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB stockholders may vote electronically at the Special Meeting by visiting&#8195;&#8195;&#8195;&#8195;&#8195;or by proxy. ACAB recommends that you submit your proxy even if you plan to attend the Special Meeting. If you vote by proxy, you may change your vote by submitting a later dated proxy before the deadline or by voting electronically at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are owned directly in your name with our transfer agent, Continental, you are considered, with respect to those shares, the &#8220;stockholder of record.&#8221; If your shares are held in a stock brokerage account or by a bank or other nominee or intermediary, you are considered the beneficial owner of shares held in &#8220;street name&#8221; and are considered a <span style="white-space:nowrap">&#8220;non-record</span> (beneficial) stockholder.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are an ACAB stockholder of record you may use the enclosed proxy card to tell the persons named as proxies how to vote your shares. If you properly complete, sign and date your proxy card, your shares will be voted in accordance with your instructions. The named proxies will vote all shares at the Special Meeting for which proxies have been properly submitted and not revoked. If you sign and return your proxy card but do not mark your card to tell the proxies how to vote, your shares will be voted &#8220;<span style="font-weight:bold">FOR</span>&#8221; each of the proposals presented at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your shares will be counted for purposes of determining a quorum if you vote: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">via the Internet; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by telephone; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by submitting a properly executed proxy card or voting instruction form by mail; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">electronically at the Special Meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstentions will be counted for determining whether a quorum is present for the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting instructions are printed on the proxy card or voting information form you received. Either method of submitting a proxy will enable your shares to be represented and voted at the Special Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Your Shares&#8212;Beneficial Owners </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in an account at a brokerage firm, bank or other nominee, then you are the beneficial owner of shares held in &#8220;street name&#8221; and this proxy statement/prospectus is being sent to you by that broker, bank or other nominee. The broker, bank or other nominee holding your account is considered to be the stockholder of record for purposes of voting at the Special Meeting. As a beneficial owner, you have the right to direct your broker, bank or other nominee regarding how to vote the shares in your account by following the instructions that the broker, bank or other nominee provides you along with this proxy statement/prospectus. Your broker, bank or other nominee may have an earlier deadline by which you must provide instructions to it as to how to vote your shares. As a beneficial owner, if you wish to vote at the Special Meeting, you will need to bring to the Special Meeting a legal proxy from your broker, bank or other nominee authorizing you to vote those shares. That is the only way we can be sure that the broker, bank or nominee has not already voted your shares of common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revoking Your Proxy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder and you give a proxy, you may revoke it at any time before it is exercised by doing any one of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may send another proxy card with a later date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may notify ACAB&#8217;s Secretary in writing before the Special Meeting that you have revoked your proxy; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">you may attend the Special Meeting and vote electronically by visiting &#8195;&#8195;&#8195;&#8195; and entering the control number found on your proxy card, instruction form or notice you previously received. Attendance at the Special Meeting will not, in and of itself, revoke a proxy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker for information on how to change or revoke your voting instructions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Additional Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Special Meeting has been called only to consider the approval of the Business Combination Proposal, the Charter Approval Proposal, the Governance Proposal, the Director Election Proposal, the Merger Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal. Under ACAB&#8217;s bylaws, other than procedural matters incident to the conduct of the Special Meeting, no other matters may be considered at the Special Meeting if they are not included in this proxy statement/prospectus, which serves as the notice of the Special Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who Can Answer Your Questions About Voting Your Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder and have any questions about how to vote or direct a vote in respect of your shares of ACAB common stock, you may call Morrow Sodali LLC, ACAB&#8217;s proxy solicitor, at (800) <span style="white-space:nowrap">662-5200</span> or ACAB at (248) <span style="white-space:nowrap">890-7200.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Public Shares may seek to redeem their shares for cash, regardless of whether they vote for or against, or abstain from voting on, the Business Combination Proposal. Any stockholder holding Public Shares may demand that ACAB redeem such shares for a pro rata portion of the trust account (which, for illustrative purposes, was $&#8195; per share as of&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date), calculated as of two business days prior to the anticipated consummation of the Business Combination. If a holder properly seeks redemption as described in this section and the Business Combination with Abpro is consummated, ACAB will redeem these shares for a pro rata portion of funds deposited in the trust account and the holder will no longer own these shares following the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of Public Shares, together with any affiliate of his or any other person with whom he is acting in concert or as a &#8220;group&#8221; (as defined in Section&#160;13(d)(3) of the Exchange Act), will be restricted from seeking redemption rights with respect to more than 15% of the Public Shares without the consent of ACAB. Accordingly, all Public Shares in excess of 15% held by a public stockholder, together with any affiliate of such holder or any other person with whom such holder is acting in concert or as a &#8220;group,&#8221; will not be redeemed for cash without the consent of ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers will not have redemption rights with respect to any shares of common stock owned by them, directly or indirectly in connection with the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB public stockholders may seek to redeem their shares for cash, regardless of whether they vote for or against, or abstain from voting on, the Business Combination Proposal. Holders may demand redemption by delivering their stock, either physically or electronically using Depository Trust Company&#8217;s DWAC System, to ACAB&#8217;s transfer agent no later than the second business day preceding the vote on the Business Combination Proposal. If you hold the shares in street name, you will have to coordinate with your broker to have your shares certificated or delivered electronically. Certificates that have not been tendered (either physically or electronically) in accordance with these procedures will not be redeemed for cash. There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through the DWAC system. The transfer agent will typically charge the tendering broker $80.00 and it would be up to the broker whether or not to pass this cost on to the redeeming stockholder. In the event the proposed Business Combination is not consummated this may result in an additional cost to stockholders for the return of their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any request to redeem such shares, once made, may be withdrawn at any time up to the vote on the Business Combination Proposal. Furthermore, if a holder of a Public Share delivered its certificate in connection with an election of its redemption and subsequently decides prior to the applicable date not to elect to exercise such rights, it may simply request that the transfer agent return the certificate (physically or electronically). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination is not approved or completed for any reason, then ACAB&#8217;s public stockholders who elected to exercise their redemption rights will not be entitled to redeem their shares for a pro rata portion of the trust account, as applicable. In such case, ACAB will promptly return any shares delivered by public stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing price of Series A common stock on&#8195;&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date, was $&#8195;&#8195;&#8195;&#8195;. The cash held in the trust account on such date was approximately $&#8195;&#8195;&#8195;&#8195; ($&#8195;&#8195;&#8195;&#8195;per Public Share). Prior to exercising redemption rights, stockholders should verify the market price of ACAB common stock as they may receive higher proceeds from the sale of their common stock in the public market than from exercising their redemption rights if the market price per share is higher than the Redemption Price. ACAB cannot assure its stockholders that they will be able to sell their shares of ACAB common stock in the open market, even if the market price per share is higher than the Redemption Price stated above, as there may not be sufficient liquidity in its securities when its stockholders wish to sell their shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a holder of Public Shares exercises its redemption rights, then it will be exchanging its shares of ACAB common stock for cash and will no longer own those shares. You will be entitled to receive cash for these shares only if you properly demand redemption no later than the second business day preceding the vote on the Business Combination Proposal by delivering your stock certificate (either physically or electronically) to ACAB&#8217;s transfer agent prior to the vote at the Special Meeting, and the Business Combination is consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither stockholders, unit holders nor warrant holders of ACAB have appraisal rights in connection the Business Combination under the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proxy Solicitation Costs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is soliciting proxies on behalf of the ACAB Board. This solicitation is being made by mail but also may be made by telephone or in person. ACAB and its directors, officers and employees may also solicit proxies in person, by telephone or by other electronic means. ACAB will bear the cost of the solicitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB has hired Morrow Sodali LLC to assist in the proxy solicitation process. ACAB will pay that firm a fee of $30,000 plus disbursements. Such payment will be made from <span style="white-space:nowrap">non-trust</span> account funds. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB will ask banks, brokers and other institutions, nominees and fiduciaries to forward the proxy materials to their principals and to obtain their authority to execute proxies and voting instructions. ACAB will reimburse them for their reasonable expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Initial Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of&#8195;&#8195;&#8195;&#8195;&#8195; , 2024, the ACAB Record Date, and prior to consummation of a business combination. the Initial Stockholders of record were entitled to vote an aggregate of one (1)&#160;Founder Share, represented by one (1)&#160;share of Series B common stock held by the Sponsor, that was issued prior to the ACAB IPO. The Sponsor has agreed to vote the Founder Share, as well as any shares of common stock acquired in the aftermarket, in favor of each of the proposals presented at the Special Meeting. The Founder Shares have no right to participate in any redemption distribution and will be worthless if no business combination is effected by ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, under the Sponsor Letter Agreement, certain Founder Shares (or shares of common stock issuable upon conversion thereof) will be subject to (i)&#160;certain <span style="white-space:nowrap">lock-up</span> restrictions and (ii)&#160;certain time and performance-based vesting provisions. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purchases of ACAB Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material nonpublic information regarding ACAB or its securities, the Sponsor, Abpro, the Company Owners and/or their respective affiliates may purchase shares from institutional and other investors who vote, or indicate an intention to vote, against the Business Combination Proposal, or execute agreements to purchase shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire shares of ACAB&#8217;s common stock or vote their shares in favor of the Business Combination Proposal. The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements to consummate the Business Combination where it appears that such requirements would otherwise not be met. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options and, with Abpro&#8217;s consent, the transfer to such investors or holders of shares or warrants owned by the Sponsor for nominal value. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entering into any such arrangements may have a depressive effect on ACAB common stock. For example, as a result of these arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he owns, either prior to or immediately after the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If such transactions are effected, it could be to cause the Business Combination to be approved in circumstances where such approval could not otherwise be obtained. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the Business Combination Proposal and other proposals and would likely increase the chances that such proposals would be approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No agreements dealing with the above arrangements or purchases have been entered into as of the date of this proxy statement/prospectus by the Sponsor, Abpro, the Company Owners or any of their respective affiliates. ACAB will file a Current Report on Form <span style="white-space:nowrap">8-K</span> to disclose arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the Business Combination Proposal or the satisfaction of any closing conditions. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_9">PROPOSAL NO. 1 &#8212; THE BUSINESS COMBINATION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of ACAB common stock are being asked to approve the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination. ACAB stockholders should read carefully this proxy statement/prospectus in its entirety for more detailed information concerning the Business Combination Agreement, which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus. Please see the sections entitled &#8220;<span style="font-style:italic">The Business Combination</span>&#8221; and &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements</span>&#8221; in this proxy statement/prospectus for additional information regarding the Business Combination and a summary of certain terms of the Business Combination Agreement. You are urged to read carefully the Business Combination Agreement in its entirety before voting on this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Business Combination Proposal (and consequently, the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination) will be adopted and approved only if at least a majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Business Combination Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Business Combination Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned upon the approval of the Business Combination Proposal, subject to the terms of the Business Combination Agreement. If the Business Combination Proposal is not approved, the other proposals (except the Adjournment Proposal, as described below) will not be presented to the stockholders for a vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Business Combination Proposal. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of ACAB&#8217;s Directors and Officers in the Business Combination Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the ACAB Board in favor of approval of the Business Combination, you should keep in mind that certain of ACAB&#8217;s directors and executive officers have interests in the Incentive Plan that are different from, or in addition to, your interests as a stockholder. For more information about the interests of ACAB&#8217;s directors and executive officers in the Business Combination, see &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of ACAB&#8217;s Directors and Officers in the Business Combination</span>&#8221; beginning on page&#160;242 of this proxy statement/prospectus.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE BUSINESS COMBINATION PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_10">PROPOSAL NO. 2 &#8212; THE CHARTER APPROVAL PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stockholders are being asked to adopt the Proposed Charter in the form attached hereto as <span style="font-style:italic">Annex B</span>, which, in the judgment of the ACAB Board, is necessary to adequately address the needs of the Post-Combination Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the key changes effected by the Proposed Charter, but this summary is qualified in its entirety by reference to the full text of the Proposed Charter, a copy of which is included as <span style="font-style:italic">Annex B</span>: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Changes to Authorized Capital Stock </span></span><span style="font-style:italic">&#8212; </span>the Existing Charter authorized the issuance of 111,000,000 total shares, consisting of (a) 110,000,000 shares of common stock, of which (i) 100,000,000 shares were Series A common stock, and (ii) 10,000,000 shares were Series B common stock, and (b) 1,000,000 shares of preferred stock. The Proposed Charter authorizes the issuance of &#8195;&#8195;&#8195;&#8195; total shares, consisting of (a) &#8195;&#8195;&#8195;&#8195; shares of common stock, and (b) &#8195;&#8195;&#8195;&#8195; shares of preferred stock, and an elimination of Series B common stock and any rights of holders thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Required Vote to Amend the Charter </span></span><span style="font-style:italic">&#8212; </span>require an affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Post-Combination Company, voting together as a single class, to amend, alter, repeal or rescind, in whole or in part, certain provisions of the Proposed Charter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Required Vote to Amend the Bylaws </span></span><span style="font-style:italic">&#8212; </span>require an affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Post-Combination Company entitled to vote generally in an election of directors to adopt, amend, alter, repeal or rescind the Post-Combination Company&#8217;s bylaws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Director Removal </span></span><span style="font-style:italic">&#8212; </span>provide for the removal of directors with cause only by stockholders voting at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock of the Post-Combination Company entitled to vote at an election of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Removal of Blank Check Company Provisions </span></span><span style="font-style:italic">&#8212; </span>eliminate various provisions applicable only to blank check companies, including business combination requirements. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons for the Amendments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of these amendments was negotiated as part of the Business Combination. The ACAB Board&#8217;s reasons for proposing each of these amendments to the Existing Charter is set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Existing Charter authorizes 111,000,000 shares, consisting of (a) 110,000,000 shares of common stock, including (i) 100,000,000 shares of Series A common stock, and (ii) 10,000,000 shares of Series B common stock, and (b) 1,000,000 shares of preferred stock. The Proposed Charter provides that ACAB will be authorized to issue &#8195;&#8195;&#8195;&#8195; shares, consisting of &#8195;&#8195;&#8195;&#8195; shares of common stock and &#8195;&#8195;&#8195;&#8195; shares of preferred stock. Upon the conversion of the Series B common stock to Series A common stock and the elimination of the blank check provisions in our Existing Charter, the ACAB Board has determined that there will no longer be a need to continue with two series of common stock and, therefore, this amendment eliminates the Series B common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This amendment also increases the authorized number of shares because the ACAB Board believes that it is important for us to have available for issuance a number of authorized shares of common stock and preferred stock sufficient to support our growth and to provide flexibility for future corporate needs (including, if needed, as part of financing for future growth acquisitions). The shares would be issuable as consideration for the merger and the other transactions contemplated by in this proxy statement/prospectus, and for any proper corporate purpose, including future acquisitions, capital raising transactions consisting of equity or convertible debt, stock dividends or issuances under current and any future stock incentive plans. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACAB Board believes that these additional shares will provide us with needed flexibility to issue shares in the future in a timely manner and under circumstances we consider favorable without incurring the risk, delay and potential expense incident to obtaining stockholder approval for a particular issuance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Required Vote to Amend the Charter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At present, our Existing Charter may only be amended with the approval of a majority of the ACAB Board and the holders of a majority of our outstanding shares. This amendment requires an affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all the then-outstanding shares of voting stock of the Post-Combination Company, voting together as a single class, to amend, alter, repeal or rescind certain provisions of the Proposed Charter. We believe that supermajority voting requirements are appropriate at this time to protect all stockholders against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, the ACAB Board was cognizant of the potential for certain stockholders to hold a substantial beneficial ownership of our common stock following the Business Combination. We further believe that going forward, a supermajority voting requirement encourages the person seeking control of the Post-Combination Company to negotiate with the board of directors to reach terms that are appropriate for all stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Required Vote to Amend the Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At present, our Existing Charter provides that our bylaws may be amended by the affirmative vote of the holders of a majority of the voting power of all then outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. This amendment requires an affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Post-Combination Company entitled to vote generally in an election of directors to adopt, amend, alter, repeal or rescind the Post-Combination Company&#8217;s bylaws. The ability of the majority of the Board to amend the bylaws remains unchanged. We believe that supermajority voting requirements are appropriate at this time to protect all stockholders against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, the ACAB Board was cognizant of the potential for certain stockholders to hold a substantial beneficial ownership of our common stock following the Business Combination. We further believe that going forward, a supermajority voting requirement encourages the person seeking control of the Post-Combination Company to negotiate with the board of directors to reach terms that are appropriate for all stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Removal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At present, our Existing Charter provides that, directors may be removed from office at any time, but only for cause and only by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. This amendment provides for the removal of directors with cause only by stockholders voting at least <span style="white-space:nowrap">two-thirds</span> (66 and 2/3%) of the voting power of all of the then outstanding shares of voting stock of the Post-Combination Corporation entitled to vote at an election of directors. We believe that supermajority voting requirements are appropriate at this time to protect all stockholders against the potential self-interested actions by one or a few large stockholders. In reaching this conclusion, the ACAB Board was cognizant of the potential for certain stockholders to hold a substantial beneficial ownership of our common stock following the Business Combination. We further believe that going forward, a supermajority voting requirement encourages the person seeking control of the Post-Combination Company to negotiate with the board of directors to reach terms that are appropriate for all stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Blank Check Company Provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Existing Charter contains various provisions applicable only to blank check companies. This amendment eliminates certain provisions related to our status as a blank check company, which is desirable because these provisions will serve no purpose following the Business Combination. For example, these proposed amendments </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remove the requirement to dissolve the Post-Combination Company and allow it to continue as a corporate entity with perpetual existence following consummation of the Business Combination. Perpetual existence is the usual period of existence for corporations and we believe it is the most appropriate period for the Post-Combination Company following the Business Combination. In connection with the Business Combination, all shares of Series B common stock will automatically be converted into shares of Series A common stock, pursuant to the terms of the Existing Charter. Upon the conversion of the Series B common stock to Series A common stock, the ACAB Board has determined that there will no longer be a need to continue with two series of common stock and, therefore, this amendment eliminates the Series B common stock. In addition, certain other provisions in our Existing Charter require that proceeds from the ACAB IPO be held in the trust account until a business combination or liquidation of merger has occurred. These provisions cease to apply once the Business Combination is consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE CHARTER APPROVAL PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_11">PROPOSAL NO. 3 &#8212; THE GOVERNANCE PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stockholders are also being asked to vote on a separate proposal with respect to certain governance provisions in the Proposed Charter, which are separately being presented in order to give holders of ACAB&#8217;s common stock the opportunity to present their separate views on important corporate governance procedures and which will be voted upon on a <span style="white-space:nowrap">non-binding</span> advisory basis. In the judgment of the ACAB Board, these provisions are necessary to adequately address the needs of the Post-Combination Company. Accordingly, regardless of the outcome of the <span style="white-space:nowrap">non-binding</span> advisory vote on these proposals, Abpro and ACAB intend that the Proposed Charter in the form set forth in <span style="font-style:italic">Annex B</span> will take effect at consummation of the Business Combination, assuming adoption of Proposal No.&#160;2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal 3A: Changes to Authorized Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal &#8212; Reasons for the Amendments &#8212; Changes to Authorized Capital Stock</span>&#8221; for a description and reasons for the amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal 3B: Required Vote to Amend the Charter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal &#8212; Reasons for the Amendments &#8212; Required Vote to Amend the Charter</span>&#8221; for a description and reasons for the amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal 3C: Required Vote to Amend the Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal &#8212; Reasons for the Amendments &#8212; Required Vote to Amend the Bylaws</span>&#8221; for a description and reasons for the amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal 3D: Director Removal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal &#8212; Reasons for the Amendments &#8212; Director Removal</span>&#8221; for a description and reasons for the amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposal 3E: Removal of Blank Check Company Provisions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Proposal No. 2 &#8212; The Charter Approval Proposal &#8212; Reasons for the Amendments &#8212; Removal of Blank Check Company Provisions</span>&#8221; for a description and reasons for the amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If each of the Business Combination Proposal and the Charter Approval Proposal is not approved, the Governance Proposal will not be presented at the Special Meeting. The approval of the Governance Proposal requires the majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Governance Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is not conditioned upon the approval of the Governance Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, a vote to approve the Governance Proposal is an advisory vote, and therefore, is not binding on ACAB, Abpro or their respective boards of directors. Accordingly, regardless of the outcome of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">non-binding</span> advisory vote, ACAB and Abpro intend that the Proposed Charter, in the form set forth in<span style="font-style:italic">&#160;Annex</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;B</span>&#160;and containing the provisions noted above, will take effect at consummation of the Business Combination, assuming adoption of Proposal No.&#160;2. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Governance Proposal. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement&#8221;</span> for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE GOVERNANCE PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_12">PROPOSAL NO. 4 &#8212; THE DIRECTOR ELECTION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal are approved at the Special Meeting, stockholders are being asked to elect five (5)&#160;directors to the Board, effective upon the Closing, with each Class&#160;I director having a term that expires at the Post-Combination Company&#8217;s annual meeting of stockholders in 2025, each Class&#160;II director having a term that expires at the Post-Combination Company&#8217;s annual meeting of stockholders in 2026 and each Class&#160;III director having a term that expires at the Post-Combination Company&#8217;s annual meeting of stockholders in 2027, or, in each case, until their respective successors are duly elected and qualified, or until their earlier resignation, removal or death. The election of these directors is contingent upon approval of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal and the Incentive Plan Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACAB Board has nominated&#8195;&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;to serve as the Class&#160;I directors, &#8195;&#8195;&#8195;&#8195; and&#8195;&#8195;&#8195;&#8195; to serve as the Class&#160;II directors, and&#8195;&#8195;&#8195;&#8195;to serve as the Class&#160;III director. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information for each nominee is set forth in the section entitled &#8220;<span style="font-style:italic">Management and Board of Directors of the Post-Combination Company Following the Business Combination</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a quorum is present, directors are elected by a plurality of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. This means that the five (5)&#160;director nominees who receive the most affirmative votes will be elected. Votes marked &#8220;FOR&#8221; a nominee will be counted in favor of that nominee. Proxies will have full discretion to cast votes for other persons in the event any nominee is unable to serve. Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is not conditioned upon the approval of the Director Election Proposal. Notwithstanding the approval of each of the five (5)&#160;director nominees to the Board in the Director Election Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Director Election Proposal will not be affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Director Election Proposal. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement&#8221;</span> for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of ACAB&#8217;s Directors and Officers in the Director Election Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the ACAB Board in favor of approval of the Director Election Proposal, you should keep in mind that certain of ACAB&#8217;s directors and executive officers have interests in the Director Election Proposal that are different from, or in addition to, your interests as a stockholder. For more information about the interests of ACAB&#8217;s directors and executive officers in the Business Combination, see &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of ACAB&#8217;s Directors and Officers in the Business Combination</span>&#8221; beginning on page 242 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ELECTION OF EACH OF THE FIVE DIRECTOR NOMINEES TO THE BOARD OF DIRECTORS IN THE DIRECTOR ELECTION PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_13">PROPOSAL NO. 5 &#8212; THE MERGER ISSUANCE PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, we intend to effect the issuance of shares of Series A common stock to the holders of Abpro&#8217;s capital stock pursuant to the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Business Combination Agreement are complex and only briefly summarized above. For further information, please see the full text of the Business Combination Agreement, which is attached as <span style="font-style:italic">Annex A</span> hereto. The discussion herein is qualified in its entirety by reference to the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Why ACAB Needs Stockholder Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are seeking stockholder approval in order to comply with Nasdaq Listing Rule 5635(a), (b), (c) and (d). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a), stockholder approval is required prior to the issuance of securities in connection with the acquisition of another company if such securities are not issued in a public offering for cash and (i)&#160;have, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such securities (or securities convertible into or exercisable for common stock); or (ii)&#160;the number of shares of common stock to be issued is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the stock or securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum aggregate number of shares of common stock issuable pursuant to the Business Combination Agreement represents greater than 20% of the number of shares of common stock before such issuance. As a result, stockholder approval of the issuance of shares of Series A common stock issuable pursuant to the Business Combination Agreement is required under Nasdaq regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholder approval of the Merger Issuance Proposal is also a condition to the Closing under the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effect of Proposal on Current Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Merger Issuance Proposal is adopted, we will issue 38,884,511 of Series A common stock to the Abpro stockholders upon the Closing. The issuance of the shares of Series A common stock described above would result in significant dilution to Series A common stock and result in Series A common stock having a smaller percentage interest in the voting power, liquidation value and aggregate book value of ACAB. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Proposal is not approved, the Merger Issuance Proposal will not be presented at the Special Meeting. The approval of the Merger Issuance Proposal requires the majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Merger Issuance Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned upon the approval of the Merger Issuance Proposal, subject to the terms of the Business Combination Agreement. Notwithstanding the approval of the Merger Issuance Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Merger Issuance Proposal will not be effected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Merger Issuance Proposal. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE MERGER ISSUANCE PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_14">PROPOSAL NO. 6 &#8212; THE INCENTIVE PLAN PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Special Meeting, holders of ACAB common stock will be asked to approve the Abpro Holdings, Inc. 2024 Incentive Award Plan (the &#8220;Incentive Plan&#8221;). The Incentive Plan will become effective, if at all, upon the Closing, subject to consummation of the Business Combination and subject to stockholder approval. If the Incentive Plan is not approved by ACAB&#8217;s stockholders, or if the Business Combination Agreement is terminated prior to the consummation of the Business Combination, the Incentive Plan will not become effective. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purpose of the Incentive Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Incentive Plan is to enhance the Post-Combination Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Equity awards and equity-linked compensatory opportunities are intended to motivate high levels of performance and align the interests of directors, employees and consultants with those of stockholders by giving directors, employees and consultants the perspective of an owner with an equity or equity-linked stake in our company and providing a means of recognizing their contributions to the Post-Combination Company&#8217;s success. Our board of directors believes that equity ownership opportunities and/or equity-linked compensatory opportunities are necessary to remain competitive in its industry and are essential to recruiting and retaining the highly qualified employees who help us meet our goals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the Incentive Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the material terms of the Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Type of Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan provides for the issuance of stock options (including <span style="white-space:nowrap">non-statutory</span> stock options and incentive stock options), stock appreciation rights (referred to as &#8220;SARs&#8221;), restricted stock, restricted stock&#160;units (referred to as &#8220;RSUs&#8221;), stock bonuses, and performance compensation awards, to directors, officers, employees, consultants, and advisors of the Post-Combination Company or its affiliates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shares of Post-Combination Company Common Stock Available for Issuance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan provides for an aggregate number of shares of Post-Combination Company common stock to be reserved for future issuance, which will be equal to 10% of the number of shares of ACAB common stock on a fully diluted basis as of immediately following the Effective Time (the &#8220;Initial Share Limit&#8221;) plus shares subject to outstanding equity awards granted under Abpro&#8217;s existing incentive plan that will be converted into equity awards denominated in shares of Post-Combination Company common stock under the Incentive Plan immediately prior to, and contingent, upon, the consummation of the transactions contemplated in the Business Combination Agreement, plus an annual increase on the first day of each fiscal year beginning in&#8195;&#8195;&#8195;&#8195;and ending in&#8195;&#8195;&#8195;&#8195;, equal to the lesser of (A)&#8195;&#8195;&#8195;&#8195;(&#8195;&#8195;&#8195;&#8195;%) percent of the shares outstanding on the last day of the immediately preceding fiscal year and (B)&#160;such smaller number of shares as determined by the Post-Combination Company board of directors or the Committee (as defined below). Shares subject to an award under the Incentive Plan that are forfeited, cancelled, expired, unexercised or are settled in cash under the Incentive Plan will again become available for awards under the Incentive Plan. Shares of Post-Combination Company common stock that are tendered or exchanged by a participant or withheld by the Post-Combination Company as payment in connection with any award under the Incentive Plan, as well as any shares exchanged by a participant or withheld by the Post-Combination Company or any subsidiary thereof to satisfy tax withholding obligations related to any full value award, will become available for subsequent awards under the Incentive Plan. Shares, if </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any, that are tendered or exchanged by a participant or withheld by the Post-Combination Company as full or partial payment in connection with the exercise of any option or SAR under the Incentive Plan or the payment of any tax withholding obligation related thereto or not issued by the Post-Combination Company in connection with the stock settlement of any SAR will be added to the aggregate number of shares available for awards under the Incentive Plan. Shares, if any, underlying awards that are granted in assumption of, or in substitution for, outstanding awards previously granted by an entity acquired by the Post-Combination Company or with which the Post-Combination Company combines will not be counted against the aggregate number of shares available for awards under the Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Director Limits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">non-employee</span> director of the Post-Combination Company may not be granted awards in respect of such service as a <span style="white-space:nowrap">non-employee</span> director under the Incentive Plan during any calendar year that, when aggregated with such <span style="white-space:nowrap">non-employee</span> director&#8217;s cash fees received with respect to such calendar year, exceed $750,000 in total value; provided, however, that the <span style="white-space:nowrap">non-employee</span> directors who are considered independent (under the rules of the Nasdaq or other securities exchange on which the Post-Combination Company common stock is traded) may make exceptions to this limit for a <span style="white-space:nowrap">non-executive</span> chair of the Post-Combination Company board of directors, if any, in which case the <span style="white-space:nowrap">non-employee</span> director receiving such additional compensation may not participate in the decision to award such compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan will be administered by a committee of at least two people as the Post-Combination Company board of directors may appoint, or if no such committee has been appointed by the Post-Combination Company board of directors, the Post-Combination Company board of directors (the &#8220;Committee&#8221;). The Committee may interpret the Incentive Plan and may prescribe, amend and rescind rules and make all other determinations necessary or desirable for the administration of the Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan permits the Committee to select the eligible recipients who will receive awards, to determine the terms and conditions of those awards, including but not limited to the exercise price or other purchase price of an award, the number of shares of Post-Combination Company common stock or cash or other property subject to an award, the term of an award and the vesting schedule applicable to an award, and to amend the terms and conditions of outstanding awards. All decisions made by the Committee pursuant to the provisions of the Incentive Plan will be final, conclusive and binding on all persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligible Participants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the directors, officers, employees, consultants, and advisors (or prospective directors, officers, employees, consultants and advisors) of the Post-Combination Company or any of its affiliates are eligible to participate in the Incentive Plan, provided that they have been selected by the Committee to receive awards under the Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">RSUs and Restricted Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs and restricted stock in respect of Post-Combination Company common stock may be granted under the Incentive Plan. The Committee will determine the purchase price, vesting schedule and performance objectives, if any, applicable to the grant of RSUs and restricted stock. If the restrictions, performance objectives or other conditions determined by the Committee are not satisfied, the RSUs and restricted stock will be forfeited. Subject to the provisions of the Incentive Plan and the applicable individual award agreement, the Committee may provide for the lapse of restrictions in installments or the acceleration or waiver of restrictions (in whole or part) under certain circumstances as set forth in the applicable individual award agreement, including the attainment of certain performance goals, a participant&#8217;s termination of employment or service under certain circumstances or a participant&#8217;s death or disability. The rights of holders of RSUs and restricted stock upon a termination of employment or service will be set forth in individual award agreements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the applicable award agreement provides otherwise, participants with restricted stock will generally have all of the rights of a stockholder during the restricted period, including the right to vote and receive dividends declared with respect to such restricted stock, provided, that any dividends declared during the restricted period with respect to such restricted stock will only become payable if the underlying restricted stock vests. During the restricted period, participants with RSUs will generally not have any rights of a stockholder, but, if the applicable individual award agreement so provides, may be credited with dividend equivalent rights that will be paid at the time that shares in respect of the related RSUs are delivered to the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options to acquire Post-Combination Company common stock may be granted under the Incentive Plan. Options may be in the form of <span style="white-space:nowrap">non-qualified</span> options or &#8220;incentive stock options&#8221; within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended, as set forth in the applicable individual option award agreement. The maximum number of shares that may be granted pursuant to options intended to be incentive stock options under the Incentive Plan is equal to the Initial Share Limit (subject to adjustment in accordance with the terms of the Incentive Plan). The exercise price of all options granted under the Incentive Plan will be determined by the Committee, but in no event may the exercise price be less than 100% of the fair market value of the underlying shares of Post-Combination Company common stock on the date of grant (other than options granted in substitution or previously granted awards, as defined in the Incentive Plan). The maximum term of all options granted under the Incentive Plan will be determined by the Committee, but may not exceed 10&#160;years. Each option will vest and become exercisable (including in the event of the optionee&#8217;s termination of employment or service) at such time and subject to such terms and conditions as determined by the Committee and set forth in the applicable individual option agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SARs may be granted under the Incentive Plan either alone or in conjunction with all or part of any option granted under the Incentive Plan. A SAR granted under the Incentive Plan entitles its holder to receive, at the time of exercise, an amount per share equal to the excess of the fair market value (at the date of exercise) of a share of Post-Combination Company common stock over the base price of the SAR. A SAR granted in conjunction with all or part of an option under the Incentive Plan entitles its holder to receive, at the time of exercise of the SAR and surrender of the related option, an amount per share equal to the excess of the fair market value (at the date of exercise) of a share of Post-Combination Company common stock over the exercise price of the related option. Each SAR will be granted with a base price that is not less than 100% of the fair market value of the related shares of Post-Combination Company common stock on the date of grant (other than SARs granted in substitution of previously granted awards). The maximum term of all SARs granted under the Incentive Plan will be determined by the Committee, but may not exceed 10&#160;years. The Committee may determine to settle the exercise of a SAR in Post-Combination Company common stock, cash, or any combination thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each SAR will vest and become exercisable (including in the event of the SAR holder&#8217;s termination of employment or service under certain circumstances) at such time and subject to such terms and conditions as determined by the Committee and set forth in in the applicable individual SAR agreement. SARs granted in conjunction with all or part of an option will be exercisable at such times and subject to all of the terms and conditions applicable to the related option. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Bonuses and Cash Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may issue unrestricted shares of Post-Combination Company common stock or other awards denominated in Post-Combination Company common stock, either alone or in tandem with other awards, in such amounts as the Committee may determine in its sole discretion from time to time. Each stock bonus award will be evidenced by an award agreement setting forth the terms and conditions of such awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Performance Goals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may grant equity-based awards and incentives under the Incentive Plan that are subject to the achievement of performance objectives selected by the Committee in its sole discretion, including, without limitation, one or more of the following business criteria: (i)&#160;net earnings or net income (before or after taxes); (ii)&#160;basic or diluted earnings per share (before or after taxes); (iii)&#160;revenue or revenue growth (measured on a net or gross basis); (iv)&#160;gross profit or gross profit growth; (v)&#160;operating profit (before or after taxes); (vi)&#160;return measures (including, but not limited to, return on assets, capital, invested capital, equity, or sales); (vii)&#160;cash flow (including, but not limited to, operating cash flow, free cash flow, net cash provided by operations and cash flow return on capital); (viii)&#160;financing and other capital raising transactions (including, but not limited to, sales of the Post-Combination Company&#8217;s equity or debt securities); (ix)&#160;earnings before or after taxes, interest, depreciation and/or amortization; (x)&#160;gross or operating margins; (xi)&#160;productivity ratios; (xii)&#160;share price (including, but not limited to, growth measures and total stockholder return); (xiii)&#160;expense targets; (xiv)&#160;margins; (xv)&#160;productivity and operating efficiencies; (xvi)&#160;customer satisfaction; (xvii)&#160;customer growth; (xviii)&#160;working capital targets; (xix)&#160;measures of economic value added; (xx)&#160;inventory control; (xxi)&#160;enterprise value; (xxii)&#160;sales; (xxiii)&#160;debt levels and net debt; (xxiv)&#160;combined ratio; (xxv)&#160;timely launch of new facilities; (xxvi)&#160;client retention; (xxvii)&#160;employee retention; (xxviii)&#160;timely completion of new product rollouts; (xxix)&#160;cost targets; (xxx)&#160;reductions and savings; (xxxi)&#160;productivity and efficiencies; (xxxii)&#160;strategic partnerships or transactions; and (xxxiii)&#160;personal targets, goals or completion of projects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any one (1)&#160;or more of the performance criteria may be used on an absolute or relative basis to measure the performance of the Post-Combination Company and/or one or more affiliates as a whole or any business unit(s) of the Post-Combination Company and/or one or more affiliates or any combination thereof, as the Committee may deem appropriate, or any of the above performance criteria may be compared to the performance of a selected group of comparison or peer companies, or a published or special index that the board of directors of the Post-Combination Company, in its sole discretion, deems appropriate, or as compared to various stock market indices. The Committee also has the authority to provide for accelerated vesting of any award based on the achievement of performance goals pursuant to the performance criteria. Any performance criteria that are financial metrics, may be determined in accordance with GAAP or may be adjusted when established to include or exclude any items otherwise includable or excludable under GAAP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equitable Adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of (i)&#160;any dividend (other than ordinary cash dividends) or other distribution (whether in the form of cash, Post-Combination Company common stock, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, <span style="white-space:nowrap">spin-off,</span> <span style="white-space:nowrap">split-up,</span> <span style="white-space:nowrap">split-off,</span> combination, repurchase or exchange of shares of Post-Combination Company common stock or other securities of the Post-Combination Company, issuance of warrants or other rights to acquire Post-Combination Company common stock or other securities of the Post-Combination Company, or other similar corporate transaction or event (including, without limitation, a change in control (as defined below)) that affects the Post-Combination Company common stock, or (ii)&#160;unusual or infrequently occurring events (including, without limitation, a change in control) affecting the Post-Combination Company, any affiliate, or the financial statements of the Post-Combination Company or any affiliate, or changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange or inter-dealer quotation system, accounting principles or law, such that in either case an adjustment is determined by the Committee in its sole discretion to be necessary or appropriate to prevent the dilution or enlargement of the benefits intended to be made available under the Incentive Plan, then the Committee shall make any such adjustments in such manner as it may deem equitable, including without limitation any or all of the following: (a)&#160;adjusting any or all of (A)&#160;the number of shares of Post-Combination Company common stock or other securities of the Post-Combination Company (or number and kind of other securities or other property) that may be delivered in respect of awards or with respect to which awards may be granted under the Incentive Plan, and (B)&#160;the terms of any outstanding award, including, without limitation, (1)&#160;the number of shares of Post-Combination Company common stock or other securities of the Post-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination Company (or number and kind of other securities or other property) subject to outstanding awards or to which outstanding awards relate, (2)&#160;the exercise price with respect to any award or (3)&#160;any applicable performance measures (including, without limitation, performance criteria and performance goals); (b)&#160;providing for a substitution or assumption of awards in a manner that substantially preserves the applicable terms of such awards; (c)&#160;accelerating the exercisability or vesting of, lapse of restrictions on, or termination of, awards or providing for a period of time for exercise prior to the occurrence of such event; (d)&#160;modifying the terms of awards to add events, conditions or circumstances (including termination of employment within a specified period after a change in control) upon which the exercisability or vesting of or lapse of restrictions thereon will accelerate; (e)&#160;deeming any performance measures (including, without limitation, performance criteria and performance goals) satisfied at target, maximum or actual performance through closing or such other level determined by the Committee in its sole discretion, or providing for the performance measures to continue (as is or as adjusted by the Committee) after closing; (f)&#160;providing that for a period prior to the change in control determined by the Committee in its sole discretion, any options or SARs that would not otherwise become exercisable prior to the change in control will be exercisable as to all shares of Post-Combination Company common stock subject thereto (but any such exercise will be contingent upon and subject to the occurrence of the change in control and if the change in control does not take place after giving such notice for any reason whatsoever, the exercise will be null and void) and that any options or SARs not exercised prior to the consummation of the change in control will terminate and be of no further force and effect as of the consummation of the change in control; and (g)&#160;canceling any one or more outstanding awards and causing to be paid to the holders thereof, in cash, Post-Combination Company common stock, other securities or other property, or any combination thereof, the value of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Incentive Plan, a &#8220;change in control&#8221; means, in summary, the first to occur of any of the following events: (i)&#160;one person or group of persons becomes the beneficial owner, directly or indirectly, of more than 50% of the combined voting power of the then issued and outstanding securities of the Post-Combination Company, whether&#160;pursuant to a sale of securities, merger or otherwise, (ii)&#160;during any period of not more than two&#160;(2) consecutive years, individuals who constitute the board of directors of the Post-Combination Company as of the beginning of the period cease for any reason to constitute at least a majority of the board of directors of the Post-Combination Company or (iii)&#160;the consummation of a sale, transfer or other disposition of all or substantially all of the business and assets of the Post-Combination Company, whether by sale of assets, merger or otherwise (determined on a consolidated basis), to one person or group of persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each participant will be required to make arrangements satisfactory to the Committee regarding payment of an amount up to the maximum statutory rates in the participant&#8217;s applicable jurisdictions with respect to any award granted under the Incentive Plan, as determined by the Post-Combination Company. The Post-Combination Company has the right, to the extent permitted by law, to deduct any such taxes from any payment of any kind otherwise due to the participant. With the approval of the Committee, the participant may satisfy the foregoing requirement by either electing to have the Post-Combination Company withhold from delivery of shares of Post-Combination Company common stock, cash or other property, as applicable, or by delivering already owned unrestricted shares of Post-Combination Company common stock, in each case, having a value not exceeding the applicable taxes to be withheld and applied to the tax obligations. The Post-Combination Company may also use any other method of obtaining the necessary payment or proceeds, as permitted by law, to satisfy its withholding obligation with respect to any award. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment and Termination of the Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan provides the Post-Combination Company&#8217;s board of directors with authority to amend, alter or terminate the Incentive Plan, but no such action may impair the rights of any participant with respect to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding awards without the participant&#8217;s consent. The Committee may amend an award, prospectively or retroactively, but no such amendment may materially impair the rights of any participant without the participant&#8217;s consent. Stockholder approval of any such action will be obtained if required to comply with applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan&#160;Term </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Incentive Plan will terminate on the 10th anniversary of the date on which ACAB&#8217;s stockholders approve the Incentive Plan, although awards granted before that time will remain outstanding in accordance with their terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, the Post-Combination Company intends to file with the SEC a registration statement on Form <span style="white-space:nowrap">S-8</span> covering the shares of Post-Combination Company common stock issuable under the Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material U.S. Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a general summary under current law of the principal United States federal income tax consequences related to awards under the Incentive Plan. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes, and federal employment taxes, are not discussed. This summary is not intended as tax advice to participants, who should consult their own tax advisors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Non-Qualified Stock Options</span>. If an optionee is granted an NSO under the Incentive Plan, the optionee should not have taxable income on the grant of the option. Generally, the optionee should recognize ordinary income at the time of exercise in an amount equal to the fair market value of the shares acquired on the date of exercise, less the exercise price paid for the shares. The optionee&#8217;s basis in our common stock for purposes of determining gain or loss on a subsequent sale or disposition of such shares generally will be the fair market value of our common stock on the date the optionee exercises such option. Any subsequent gain or loss will be taxable as a long-term or short-term capital gain or loss. We or our subsidiaries or affiliates generally should be entitled to a federal income tax deduction at the time and for the same amount as the optionee recognizes ordinary income. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Incentive Stock Options</span>. A participant receiving ISOs should not recognize taxable income upon grant or at the time of exercise. However, the excess of the fair market value of the shares of our common stock received over the option exercise price is an item of tax preference income potentially subject to the alternative minimum tax. If stock acquired upon exercise of an ISO is held for a minimum of two years from the date of grant and one year from the date of exercise and otherwise satisfies the ISO requirements, the gain or loss (in an amount equal to the difference between the fair market value on the date of disposition and the exercise price) upon disposition of the stock will be treated as a long-term capital gain or loss, and we will not be entitled to any deduction. If the holding period requirements are not met, the ISO will be treated as one that does not meet the requirements of the Code for ISOs and the participant will recognize ordinary income at the time of the disposition equal to the excess of the amount realized over the exercise price, but not more than the excess of the fair market value of the shares on the date the ISO is exercised over the exercise price, with any remaining gain or loss being treated as capital gain or capital loss. We and our subsidiaries or affiliates generally are not entitled to a federal income tax deduction upon either the exercise of an ISO or upon disposition of the shares acquired pursuant to such exercise, except to the extent that the participant recognizes ordinary income on disposition of the shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Awards</span>. The current federal income tax consequences of other awards authorized under the Incentive Plan generally follow certain basic patterns: SARs are taxed and deductible in substantially the same manner as NSOs; nontransferable restricted stock subject to a substantial risk of forfeiture results in income recognition equal to the excess of the fair market value over the price paid, if any, only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant through a Section&#160;83(b) election under the Code); RSUs, dividend equivalents and other stock or cash based awards are generally subject to tax at the time of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(unless the recipient elects to accelerate recognition as of the date of grant through a Section&#160;83(b) election under the Code); RSUs, dividend equivalents and other stock or cash based awards are generally subject to tax at the time of payment. We and our subsidiaries or affiliates generally should be entitled to a federal income tax deduction at the time and for the same amount as the optionee recognizes ordinary income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;409A of the Code </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain types of awards under the Incentive Plan may constitute, or provide for, a deferral of compensation subject to Section&#160;409A of the Code. Unless certain requirements set forth in Section&#160;409A of the Code are complied with, holders of such awards may be taxed earlier than would otherwise be the case (e.g., at the time of vesting instead of the time of payment) and may be subject to an additional 20% penalty tax (and, potentially, certain interest, penalties and additional state taxes). To the extent applicable, the Incentive Plan and awards granted under the Incentive Plan are intended to be structured and interpreted in a manner intended to either comply with or be exempt from Section&#160;409A of the Code and the Department of Treasury regulations and other interpretive guidance that may be issued under Section&#160;409A of the Code. To the extent determined necessary or appropriate by the plan administrator, the Incentive Plan and applicable award agreements may be amended to further comply with Section&#160;409A of the Code or to exempt the applicable awards from Section&#160;409A of the Code. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The benefits or amounts that may be received or allocated to participants under the Incentive Plan will be determined at the discretion of the plan administrator and are not currently determinable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of ACAB&#8217;s Directors and Officers in the Incentive Plan Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the ACAB Board in favor of approval of the Incentive Plan, you should keep in mind that certain of ACAB&#8217;s directors and executive officers have interests in the Incentive Plan that are different from, or in addition to, your interests as a stockholder. For more information about the interests of ACAB&#8217;s directors and executive officers in the Business Combination, see &#8220;<span style="font-style:italic">The Business Combination &#8212; Interests of </span><span style="font-style:italic">ACAB&#8217;s Directors and Officers in the Business Combination</span>&#8221; beginning on page&#160;242 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Proposal is not approved, the Incentive Plan Proposal will not be presented at the Special Meeting. The approval of the Incentive Plan Proposal requires the majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Incentive Plan Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is conditioned upon the approval of the Incentive Plan Proposal, subject to the terms of the Business Combination Agreement. Notwithstanding the approval of the Incentive Plan Proposal, if the Business Combination is not consummated for any reason, the actions contemplated by the Incentive Plan Proposal will not be effected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Incentive Plan Proposal. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE INCENTIVE PLAN PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_15">PROPOSAL NO. 7 &#8212; THE ADJOURNMENT PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal, if adopted, will allow the ACAB Board to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal, or we determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived. In no event will the ACAB Board adjourn the Special Meeting or consummate the Business Combination beyond the date by which it may properly do so under the Existing Charter and Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Consequences if the Adjournment Proposal is not Approved </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved by stockholders, the ACAB Board may not be able to adjourn the Special Meeting to a later date in the event that there are insufficient votes for the approval of the Business Combination Proposal, the Charter Approval Proposal, the Merger Issuance Proposal or the Incentive Plan Proposal, or we determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived. If ACAB does not consummate the Business Combination and fails to complete an initial business combination within the Completion Window (subject to the requirements of law), ACAB will be required to dissolve and liquidate its trust account by returning the then remaining funds in such account to its public stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required for Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approval of the Adjournment Proposal requires the majority of the votes cast by the stockholders present in person (which would include presence at a virtual meeting) or represented by proxy at the Special Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to vote by proxy or to vote in person (which would include presence at a virtual meeting) at the Special Meeting, abstentions and broker <span style="white-space:nowrap">non-votes</span> will have no effect on the Adjournment Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination is not conditioned upon the approval of the Adjournment Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and ACAB&#8217;s directors and officers have agreed to vote the Founder Shares and any Public Shares owned by them in favor of the Adjournment Proposal, if presented. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE ACAB BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE ACAB STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ADJOURNMENT PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_16">INFORMATION ABOUT ACAB </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In this section &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ACAB prior to the Business Combination and to the Post-Combination Company following the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introduction </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a blank check company incorporated in May 2021 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses, which is referred to as an &#8220;initial business combination&#8221;. Our efforts to identify a prospective target business were not limited to any particular industry, sector or geographic region. Prior to executing the Business Combination Agreement, our efforts were limited to organizational activities, completion of our initial public offering and the evaluation of possible business combination targets. We have neither engaged in any operations nor generated any revenue to date. Based on our business activities, we are a &#8220;shell company&#8221; as defined under the Exchange Act because we have no operations and nominal assets consisting almost entirely of cash. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company History </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Sponsor purchased 7,187,500 shares of Founder Shares for an aggregate purchase price of $25,000, or approximately $0.003 per share. Due to the underwriters&#8217; election to partially exercise their overallotment option (discussed below), 3,750 shares were forfeited. In October 2021, the Sponsor transferred 50,000 Founder Shares to each of Ms.&#160;Lord, Mr.&#160;Kahlon, Mr.&#160;Stanwood, Mr.&#160;Dove and Mr.&#160;Schiano in compensation for their services as independent directors of ours. In January 2022, the Company effectuated a <span style="white-space:nowrap"><span style="white-space:nowrap">1.044-for-1</span></span> stock split, resulting in an aggregate of 7,503,750 Founder Shares outstanding. The number of Founder Shares issued was determined based on the expectation that the Founder Shares would represent approximately 20% of the outstanding shares of common stock upon completion of the ACAB IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2022, we consummated the ACAB IPO of 30,000,000 units (inclusive of the over-allotment units described below), with each unit consisting of one share of Series A common stock and <span style="white-space:nowrap">one-half</span> of one public warrant. Each whole public warrant entitles the holder thereof to purchase one share of Series A common stock at a price of $11.50 per share, subject to certain adjustments. The units were sold at a price of $10.00 per unit, generating gross proceeds to us of $300,000,000. On the date of the ACAB IPO, the Underwriters purchased 3,900,000 units (the &#8220;over-allotment units&#8221;) pursuant to their partial exercise of the over-allotment option, generating gross proceeds of $39,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneous with the consummation of the ACAB IPO, we consummated the private placement of an aggregate of 13,850,000 private placement warrants to the Sponsor at a price of $1.00 per private placement warrant, generating total proceeds of $13,850,000. Each whole private placement warrant entitles the holder thereof to purchase one share of Series A common stock at a price of $11.50 per share, subject to certain adjustments. Of the gross proceeds received from the ACAB IPO and the private placement warrants, $306,000,000 was placed in the trust account (the &#8220;trust account&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;4, 2022, we announced that, commencing March&#160;7, 2022, holders of the units may elect to separately trade the shares of Series A common stock and the warrants included in the units. Those units not separated continued to trade on Nasdaq under the symbol &#8220;ACABU&#8221; and the shares of Series A common stock and warrants that were separated trade under the symbols &#8220;ACAB&#8221; and &#8220;ACABW,&#8221; respectively. No fractional warrants were issued upon separation of the units and only whole warrants trade. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, in connection with approval of the charter amendment proposal to extend the date by which ACAB must consummate a business combination to December&#160;19, 2023, holders of an aggregate of 26,564,308 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares and as a result, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such holders received a payment of approximately $10.41 per share that they redeemed. The funds held in the trust account have been on deposit in a demand deposit bank account, owned and controlled by the trustee since December&#160;29, 2023. In connection with such charter amendment, the Sponsor entered into <span style="white-space:nowrap">Non-Redemption</span> Agreements with several unaffiliated third parties and agreed to transfer, after consummation of a business combination, an aggregate of 825,225 shares of Series A common stock to such parties in exchange for them agreeing not to redeem their Series A common stock. On December&#160;15, 2023, in connection with the approval of the charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board), holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74 per share redeemed. After such redemptions, and as of December&#160;31, 2023, there was approximately $7.2&#160;million in the trust account. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. As a result of the Conversion and the results of the stockholder meetings described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Redemption of Public Shares and Liquidation if no Initial Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;15, 2023, the stockholders of ACAB approved the proposal to extend the Completion Window to March&#160;19, 2024 and further provide that the ACAB Board may, without another stockholder vote, further extend the Completion Window on a monthly basis up to six times by an additional one month each time thereafter by resolution of the ACAB Board, if requested by the Sponsor, until September&#160;19, 2024, subject in each case to certain advance notice requirements. If we are unable to complete our initial business combination within such period, we will: (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <span style="white-space:nowrap">per-share</span> price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we fail to complete our initial business combination within aforementioned time period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Restrictions in Connection with the Special Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders of record are entitled to vote an aggregate of one (1)&#160;share of Series B common stock (held by the Sponsor) prior to consummation of the business combination. The Sponsor has agreed to vote any Founder Shares and any Public Shares held by them as of the ACAB Record Date in favor of each of the proposals presented at the Special Meeting. See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement</span>&#8221; for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment to extend the date by which a business combination must be consummated to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&#160;19, 2023. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74 per share redeemed. As a result of the Conversion and the results of the stockholder meetings described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently maintain our executive offices at 6 St Johns Lane, Floor 5, New York, New York, 10013, and our telephone number is (248) <span style="white-space:nowrap">890-7200.</span> Our executive offices are provided to us by the Sponsor. The cost for this space is included in the $10,000 per month fee that we pay to the Sponsor for office space, administrative and support services. We consider our current office space adequate for our current operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, the principal executive offices of ACAB will be those of Abpro, at which time nothing more will be paid to the Sponsor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have four officers. These individuals are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the initial business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_17">MANAGEMENT OF ACAB </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In this section &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ACAB prior to the Business Combination and to the Post-Combination Company following the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s current directors and executive officers are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:26%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:64%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Chairman of the Board of Directors</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony D. Eisenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Strategy Officer and Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Chryssicas</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer and Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Burt Jordan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joanna Lord</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Dove</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curtis Collar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darren Stanwood</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dominick J. Schiano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Shahraab Ahmad </span>has been our Chief Executive Officer and Chairman of the Board of Directors since October 2021. Mr.&#160;Ahmad also served as Chief Executive Officer of ACA I from December 2020 until October 2023 and Chairman of the Board of Directors of ACA since December 2020. Prior to this, he most recently served as the Chief Investment Officer for Decca Capital Ltd, a fund founded by Mr.&#160;Ahmad that invested across capital structures in the U.S. and Europe from April 2015 until December 2018. Prior to his tenure at Decca Capital Ltd, Mr.&#160;Ahmad served as a portfolio manager for Hutchin Hill Capital, LP from 2008 to 2013 and Sailfish Capital Partners, LLC from 2005 to 2008 and J.P. Morgan from 1999 to 2004, where he last <span style="white-space:nowrap">co-headed</span> the High Yield Credit trading group. At J.P. Morgan, Mr.&#160;Ahmad managed credit portfolios across the U.S. and Europe. Mr.&#160;Ahmad holds a B.A. in Mathematics and Economics from Wesleyan University and studied corporate finance at the London School of Economics. We believe Mr.&#160;Ahmad&#8217;s eight years of experience investing in private technology companies and 20 years of investment experience as an investor across capital structures and hedge fund manager make him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Anthony D. Eisenberg</span> serves as our Chief Strategy Officer and has served as a director since January 2022. Mr.&#160;Eisenberg also served as Chief Strategy Officer and a director of ACA I from February 2021 to October 2023. Since 2013, Mr.&#160;Eisenberg has managed Tappan Street, a multi-strategy family office with expertise in environmental, social and corporate governance principles and private market investments. Since March 2020, Mr.&#160;Eisenberg has also served on the board of advisors of Komma, a mobility company targeting the urban mobility vehicle market. From 2013 to 2019, Mr.&#160;Eisenberg served on the board of advisors of Michigan Income Principal-Protected Growth Fund, an impact investing fund in partnership with the State of Michigan and the US Department of Treasury and led the firm&#8217;s development activities. Mr.&#160;Eisenberg began his career in politics working in the Office of U.S. Senator Debbie Stabenow, Patton Boggs and the D.C. based research group Marwood Group, prior to his principal investing career, which began at the hedge fund Christofferson Robb&#160;&amp; Company. Mr.&#160;Eisenberg holds an M.B.A. in Finance from Georgetown <span style="white-space:nowrap">University-The</span> McDonough School of Business, a J.D. from the University of Michigan Law School and a B.B.A. in Finance and Political Science from the University of Miami. We believe Mr.&#160;Eisenberg&#8217;s experience in public policy and expertise in private market investments makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jason Chryssicas </span>has been our Chief Financial Officer and has served as a director since January 2022. Mr.&#160;Chryssicas also served as Chief Financial Officer of ACA I from April 2022 to October 2023. Over the course of his career, Mr.&#160;Chryssicas has served in a variety of leadership positions within financial services and capital markets, including Investor Relations, Investment Banking, Corporate Development and Strategy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&#160;Chryssicas has served in various roles at Cantor Fitzgerald and BGC Partners Inc. since 2013 including his current role as Head of Investor Relations at both firms. Prior to this, Mr.&#160;Chryssicas held positions at Goldman Sachs and Ernst&#160;&amp; Young. Mr.&#160;Chryssicas holds a B.A. in Accounting from Western Washington University. We believe Mr.&#160;Chryssicas&#8217; experience in financial services, capital markets and investor relations makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Burt Jordan </span>has been our president since November 2021 and has served as a director since January 2022. Mr.&#160;Jordan also served as president and a director of ACA I from December 2020 to October 2023. Mr.&#160;Jordan was an executive at Ford Motor Company (NYSE: F) (&#8220;Ford&#8221;) from July 1999 until July 2020, where he most recently served as vice president of Global Purchasing Operations and Supply Chain Sustainability. At Ford, Mr.&#160;Jordan was responsible for Ford&#8217;s commodity-related and Indirect Purchasing and Supplier Sourcing program around the world for the past 10 years. In June 2020, Mr.&#160;Jordan was named the 2020 CPO of the Year by the National Minority Supplier Development Council, which recognized his impactful leadership within Ford and the larger supplier-diversity community. Mr.&#160;Jordan holds a B.B.A. in Business Administration from Alma College. We believe Mr.&#160;Jordan&#8217;s extensive experience as a senior executive of a major automobile corporation and his demonstrated leadership skills make him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Joanna Lord </span>has served as a director since January 2022. Ms.&#160;Lord also served as a director of ACA I from December 2020 to October 2023. Since June 2021, Ms.&#160;Lord has served as the Chief Marketing Officer of Reforge Inc. Prior to joining Reforge, Ms.&#160;Lord served as the Chief Marketing Officer of Skyscanner LTD from January 2019 until December 2020 and ClassPass from 2016 to 2019 and the Vice President of Marketing at Porch from 2014 to 2016. Ms.&#160;Lord received her M.A. in Communications from Pepperdine University and B.A. in Journalism/Communications from St. Michaels College. We believe Ms.&#160;Lord&#8217;s 15 years of marketing leadership experience in technology companies makes her well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Bryan Dove </span>has served as a director since January 2022. Mr.&#160;Dove also served as a director of ACA I from February 2021 to October 2023. Since April 2021, Mr.&#160;Dove has served as the Chief Executive Officer of CommerceHub. Additionally, since September 2020, Mr.&#160;Dove has served as the Chairperson of Travalyst. Prior to this, Mr.&#160;Dove was an executive at Skyscanner LTD from June 2015 until June 2020, where he served as Chief Executive Officer. Mr.&#160;Dove was also a director at Skyscanner LTD from 2018 to 2020. Prior to joining Skyscanner, Mr.&#160;Dove held several senior leadership positions within the technology industry at Amazon (2014 to 2015), Microsoft (2009 to 2014), and Eclipsys Corporation (2004 to 2009). Bryan also served as a board director at a privately held artificial intelligence company specializing in the real estate and financial sectors (July 2020 to April 2021). We believe Mr.&#160;Dove&#8217;s experience as a CEO and senior executive leading and scaling high-growth companies makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Curtis Collar</span> has served as a director since November 2023. Mr.&#160;Collar has served as Chief Sales&#160;&amp; Marketing Officer at Nanotech Energy since April 2022. Before joining Nanotech Energy, Mr.&#160;Collar served as DuPont&#8217;s Global Technology Manager &#8211; Electric Vehicles from January 2020 to April 2022. He and his global teams identified, developed, and commercialized new technologies that created competitive advantages, aiming to improve the range, efficiency, and safety of EVs, and developed collaborations with some of the sector&#8217;s biggest names. Previous roles had seen him responsible for building, developing, and leading the inaugural technical roadmap and technical teams for electric vehicles at SABIC from 2015 to 2020. Prior to those roles he spent time at several smaller companies building and executing business plans, delivering robust business pipelines from the ground up in various material technologies including plastics, coatings, adhesives and textiles, and subsequent applications. Mr.&#160;Collar received his B.S. in Chemical Engineering from Rutgers University. We believe Mr.&#160;Collar&#8217;s experience as a senior executive and his technical expertise makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Darren Stanwood </span>has served as a director since January 2022. Since October 2015, Mr.&#160;Stanwood has served as the managing member of Fields Texas Ltd. Holdings LLC, a private investment and retail advisory firm focused on the global consumer and retail sectors. Mr.&#160;Stanwood received his B.S.B.A. in Marketing/Economics from the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Suffolk University&#8211;-Sawyer School of Management. We believe Mr.&#160;Stanwood&#8217;s experience in investing in the global consumer and retail industries makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Dominick J. Schiano </span>has served as a director since January 2022. Since July 2007, Mr.&#160;Schiano has served as the President and <span style="white-space:nowrap">Co-Founding</span> Partner of Evergreen. Evergreen supports private equity sponsors by sourcing investment opportunities, and providing strategic, operational, and financial guidance with respect to portfolio company investments in the industrial sector. Mr.&#160;Schiano is a Senior Advisor to The Gores Group LLC and past President of Gores Holdings II, Inc. (NASDAQ: GSHTU) that successfully merged with Verra Mobility Corp. (NASDQ: VRRM) in 2017. Evergreen has also previously been engaged by TowerBrook Capital Partners where Mr.&#160;Schiano was a member of the Management Advisory Board and by DLJ Merchant Banking Partners, the private equity arm of Credit Suisse where he served as Vice Chairman-Global Industrial Partners. Mr.&#160;Schiano has also served on numerous local government, private company, joint venture and public company boards, including STR Holdings Inc. (NYSE: STRI) where he served on the Audit and Special Transaction Committees and Material Sciences Corporation (Nasdaq: MASC) where he served on the Audit, Compensation and Governance Committees and led the Special Committee responsible for its sale in 2013. Prior to forming Evergreen, Mr.&#160;Schiano served as a Managing Director and member of the Investment Committee of Questor Partners Funds. Previously, Mr.&#160;Schiano served in various senior executive roles at Textron Inc. (NYSE: TXT), TRW Inc, Wickes Companies Inc., and its predecessor, Gulf+Western Industries Inc. Mr.&#160;Schiano attended Long Island University, majoring in Finance, and has completed the University of Pennsylvania-Wharton School Management Development Program and the Northwestern University-Kellogg School Mergers and Acquisitions Program. We believe Mr.&#160;Schiano&#8217;s experience in providing investment advisory services and <span style="white-space:nowrap">co-investing</span> with private equity sponsors makes him well-qualified to serve on our Board of Directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Advisor </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our management team, we are supported by the following special advisor: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apeiron Investment Group is the family office and merchant banking business of Christian Angermayer. Apeiron Investment Group provides strategic and operational support for a variety of investment initiatives and entrepreneurial pursuits. The firm invests across all phases of a company&#8217;s life cycle with an emphasis on early-stage opportunities. Apeiron has investment expertise in financial services, deep technology, life sciences, media&#160;&amp; entertainment and real estate technology. Apeiron has several significant portfolio investments, including: ATAI Life Sciences AG, CRYPTOLOGY Asset Group PLC, Rejuveron Life Sciences AG, Presight Capital, Elevate Capital and Apeiron Advisory LTD, which serve specific mandates as part of Apeiron Investment Group&#8217;s broader strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Number and Terms of Office of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have 9 directors. Our board of directors is divided into three classes with only one class of directors being elected in each year and each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one full year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors, consisting of Mr.&#160;Ahmad, Mr.&#160;Jordan and Ms.&#160;Lord, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Mr.&#160;Eisenberg, Mr.&#160;Dove and Mr.&#160;Collar, will expire at the second annual meeting of stockholders. The term of office of the third class of directors, consisting of Mr.&#160;Chryssicas, Mr.&#160;Stanwood and Mr.&#160;Schiano, will expire at the third annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our officers may consist of a Chief Executive Officer, Chief Financial Officer, President, Corporate Secretary and such other offices as may be determined by the board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq rules require that a majority of our board of directors be independent. An &#8220;independent director&#8221; is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company&#8217;s board of directors, would interfere with the director&#8217;s exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that Ms.&#160;Lord, Mr.&#160;Collar, Mr.&#160;Stanwood, Mr.&#160;Dove and Mr.&#160;Schiano are &#8220;independent directors&#8221; as defined under Nasdaq and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary Compensation Table </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our executive officers or directors have received any cash compensation for services rendered to us. In connection with potentially providing financing or other investments in connection with our initial business combination, in no event will the Sponsor or any of our existing officers or directors, or any entity with which the Sponsor or officers are affiliated, be paid any finder&#8217;s fee, reimbursement, consulting fee, monies in respect of any payment of a loan or other compensation by the company prior to, or in connection with any services rendered in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is) other than the repayment of any loans from our Sponsor, officers and directors for working capital purposes and reimbursement of any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor, officers and directors will be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. We do not have a policy that prohibits the Sponsor, executive officers or directors, or any of their respective affiliates, from negotiating for the reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses by a target business. Our audit committee reviews on a quarterly basis all payments that were made to the Sponsor, officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with identifying and consummating an initial business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB did not make any equity awards to any of its executive officers or directors during the fiscal year ended December&#160;31, 2023. No executive officers or directors of ACAB hold any outstanding equity awards in us as of December&#160;31, 2023. In October 2021, the Sponsor transferred 50,000 Founder Shares to each of Ms.&#160;Lord, Mr.&#160;Kahlon, Mr.&#160;Stanwood, Mr.&#160;Dove and Mr.&#160;Schiano in compensation for their services as independent directors of ACAB. In November 2023, Mr.&#160;Kahlon resigned from the ACAB Board, triggering a forfeiture of 50,000 Founder Shares then-held by Mr.&#160;Kahlon to the Sponsor. The Sponsor subsequently assigned 50,000 Founder Shares to Mr.&#160;Collar in connection with Mr.&#160;Collar&#8217;s appointment to the ACAB Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form <span style="white-space:nowrap">8-K,</span> as required by the SEC. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management&#8217;s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities Authorized for Issuance Under Equity Compensation Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had no equity compensation plans or outstanding equity awards. The following table is presented as of December&#160;31, 2023 in accordance with SEC requirements: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Plan Category</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities <br/>to&#160;be&#160;Issued&#160;Upon<br/>Exercise of <br/>Outstanding<br/>Options, <br/>Warrants and<br/>Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Weighted<br/>Average <br/>Exercise<br/>Price of <br/>Outstanding<br/>Options,<br/>Warrants <br/>and Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities <br/>Remaining<br/>Available <br/>for&#160;Future&#160;Issuance<br/>Under Equity <br/>Compensation<br/>Plans</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation on Liability and Indemnification of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Existing Charter provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. In addition, our Existing Charter provides that our directors will not be personally liable for monetary damages to us or stockholders for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our Existing Charter. Our bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. Except with respect to any Public Shares they may have acquired in the ACAB IPO or thereafter (in the event we do not consummate an initial business combination), our officers and directors have agreed to waive (and any other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for any reason whatsoever, including with respect to such indemnification. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_18">ACAB MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion should be read in conjunction with &#8220;Summary Historical Financial Data for ACAB,&#8221; &#8220;Unaudited Pro Forma Condensed Combined Financial Statements,&#8221; and ACAB&#8217;s consolidated financial statements, including the notes thereto, included elsewhere in this proxy statement/prospectus. Certain statements in this &#8220;ACAB Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements that involve risks and uncertainties, such as statements regarding ACAB&#8217;s plans, objectives, expectations and intentions. ACAB&#8217;s future results and financial condition may differ materially from those currently anticipated as a result of the factors described under sections titled &#8220;Forward-Looking Statements; Summary Risk Factors; Market, Ranking and Other Industry Data&#8221; and &#8220;Risk Factors.&#8221; In this section &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ACAB prior to the Business Combination and to the Post-Combination Company following the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a blank check company formed under the laws of the State of Delaware on May&#160;20, 2021 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. We intend to effectuate our initial business combination using cash from the proceeds of the ACAB IPO and the sale of the private placement warrants, our capital stock, debt or a combination of cash, stock and debt. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of additional shares or the creation of one or more classes of preferred stock in connection with an initial business combination: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution provisions in the Founder Shares resulted in the issuance of Series A common stock on a greater than <span style="white-space:nowrap"><span style="white-space:nowrap">one-to-one</span></span> basis upon conversion of the Founder Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may subordinate the rights of holders of our common stock if the rights, preferences, designations and limitations attaching to the preferred shares are senior to those afforded our shares of Series A common stock and/or our other securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">could cause a change in control if a substantial number of shares of our Series A common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may adversely affect prevailing market prices for our Series A common stock and/or warrants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, if we issue debt securities or otherwise incur significant incur significant indebtedness, it could result in: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to obtain necessary additional financing if any document governing such debt contains covenants restricting our ability to obtain such financing while the debt security is outstanding; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to pay dividends on our shares of Series A common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Series A common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an initial business combination will be successful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Proposed Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">The Business Combination</span>&#8221; elsewhere in this proxy statement/prospectus, which disclosure is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements</span>&#8221; elsewhere in this proxy statement/prospectus, which disclosure is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have neither engaged in any operations nor generated any revenues to date. Our only activities from May&#160;20, 2021 (inception) through December&#160;31, 2023 were organizational activities, those necessary to consummate the Initial Public Offering, described below, and identifying a target company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on cash and marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, we had a net income of $2,821,459 which consists of interest income from bank of $52,304 and interest earned on cash and marketable securities held in the Trust Account of $5,754,715, partially offset by operating and formation costs of $1,666,056, interest and penalties on tax obligations of $142,041 and provision for income taxes of $1,177,463. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, we had a net income of $886,918 which consists of interest income from bank of $1,848 and interest earned marketable securities held in the Trust Account of $4,121,971, offset by operating and formation costs of $2,050,410, compensation expense of $362,500 and provision for income taxes of $823,991. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2022, we consummated our Initial Public Offering of 30,000,000 Units, which includes the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000. Simultaneously with the closing of our Initial Public Offering, we consummated the sale of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor, generating gross proceeds of $13,850,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs amounted to $17,204,107, consisting of $5,760,000 of underwriting discount (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs. We have agreed to pay a deferred underwriting fee to the underwriters upon the consummation of our Initial Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the Initial Public Offering or an aggregate of $10,500,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The promissory note issued in connection with unsecured loans from our Sponsor to finance our liquidity needs through the consummation of our Initial Public Offering was <span style="white-space:nowrap">non-interest</span> bearing and the aggregate amount of $149,539 outstanding under the promissory note as of January&#160;19, 2022 was fully repaid on February&#160;22, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Initial Public Offering, the partial exercise of the over-allotment option, and the sale of Private Placement Warrants, a total of $306,000,000 was placed in the Trust Account. We incurred $17,204,107 in Initial Public Offering related costs, including $5,760,000 of underwriting fees and $944,107 of other costs. On April&#160;18, 2023, we held a special meeting of stockholders to approve the charter amendment proposal to extend the date by which ACAB must consummate a business combination to December&#160;19, 2023, and as a result 26,564,308 shares of our Series A common stock were redeemed at approximately $10.41 per share. On December&#160;13, 2023, stockholders holding a total of 2,768,301 public shares of Series A common stock exercised and did not reverse, their right to redeem their public shares in connection with the vote upon the Charter Amendment Proposal. As a result of the foregoing, those holders will receive a payment of approximately $10.68 per share redeemed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had cash and marketable securities held in the Trust Account of $37,101,441 ($29,728,990 was redeemed and withdrawn in January 2024) consisting of money market funds invested primarily in United States Treasuries. Interest income on the balance in the Trust Account may be used by us to pay taxes. Through December&#160;31, 2023, we have withdrawn an amount of $278,935,245 which consists of $276,471,460 attributable to redemptions within 2023 and $2,463,785 attributable to withdrawals to pay tax obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December&#160;29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income and excise taxes payable), to complete our Business Combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had cash of $264,538. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor has committed to provide us $1,750,000 to fund our expenses relating to investigating and selecting a target business and other working capital requirements. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023 and November&#160;14, 2023, the Company issued non-interest bearing, unsecured promissory notes in the aggregate principal amount of $80,000, respectively, (the &#8220;Extension Promissory Notes&#8221;) to the Sponsor. The $80,000 was deposited into the Company&#8217;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to $10.20 per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. As of December&#160;31, 2023, the Company owed $160,000 due under the Extension Promissory Notes with no further borrowings available. On December&#160;18, 2023, the Company amended the Extension Promissory Notes to remove the Sponsor&#8217;s right to convert the note into Series A common stock at a price equal to $10.20 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, December&#160;11, 2023 and December&#160;12, 2023, the Sponsor advanced ACAB $10,000, $1,630,000, and $15,000, respectively, to fund the account for the funds used in operations. As of December&#160;31, 2023, the Sponsor advanced the Company $1,655,000 as is reflected in the consolidated balance sheets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, cash used in operating activities was $3,845,177. Net income of $2,821,459 was affected by interest earned on cash and marketable securities held in the Trust Account of $5,754,715. Changes in operating assets and liabilities used $911,921 of cash for operating activities. For the year ended December 31, 2022, cash used in operating activities was $1,184,963. Net income of $886,918 was affected by interest earned on marketable securities held in the Trust Account of $4,121,971 and compensation expenses of $362,500. Changes in operating assets and liabilities provided $1,687,590 of cash for operating activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, <span style="white-space:nowrap">undertaking&#160;in-depth&#160;due</span> diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. If we are unable to complete our Initial Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Going Concern </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2023, the Company had $264,538 in its operating bank accounts and a working capital deficit of $5,394,929. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#8217;s assessment of going concern considerations in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40 &#8220;Presentation of Financial Statements &#8212; Going Concern,&#8221; the Company has until September 19, 2024 (subject to additional approval by the ACAB Board), to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before September 19, 2024, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s plan is to complete a business combination on or prior to September 19, 2024, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after September&#160;19, 2024. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no obligations, assets or liabilities, which would be considered <span style="white-space:nowrap">off-balance</span> sheet arrangements as of December&#160;31, 2023. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating <span style="white-space:nowrap">off-balance</span> sheet arrangements. We have not entered into any <span style="white-space:nowrap">off-balance</span> sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any <span style="white-space:nowrap">non-financial</span> assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of condensed financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Common Stock Subject to Possible Redemption </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for our common stock subject to possible conversion in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#8217; equity. Our common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity outside of the stockholders&#8217; equity section of our condensed balance sheets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#8217; deficit. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Income (Loss) Per Common Share </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recent Accounting Standards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures (&#8220;ASU&#160;2024-09&#8221;), which will require us to disclose specified additional information in our income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU&#160;2023-09 will also require us to disaggregate our income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU&#160;2023-09 will become effective for annual periods beginning after December&#160;15, 2024. We are still reviewing the impact of <span style="white-space:nowrap">ASU&#160;2023-09.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued <span style="white-space:nowrap">ASU&#160;No.&#160;2020-06,</span> &#8220;Debt&#8212;Debt with Conversion and Other Options <span style="white-space:nowrap">(Subtopic&#160;470-20)</span> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity <span style="white-space:nowrap">(Subtopic&#160;815-40):</span> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; <span style="white-space:nowrap">(&#8220;ASU&#160;2020-06&#8221;),</span> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. <span style="white-space:nowrap">ASU&#160;2020-06</span> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. <span style="white-space:nowrap">ASU&#160;2020-06</span> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that <span style="white-space:nowrap">ASU&#160;2020-06</span> would have on our financial position, results of operations or cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued Accounting Standards Update <span style="white-space:nowrap">(&#8220;ASU&#8221;)&#160;2016-13&#160;&#8211;</span> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments <span style="white-space:nowrap">(&#8220;ASU&#160;2016-13&#8221;).&#160;This&#160;update</span> requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted <span style="white-space:nowrap">ASU&#160;2016-13&#160;on</span> January&#160;1, 2023. The adoption of <span style="white-space:nowrap">ASU&#160;2016-13&#160;did</span> not have a material impact on its financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_19">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF ACAB AND THE POST-COMBINATION COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding (i)&#160;the actual beneficial ownership of ACAB common stock as of February&#160;29, 2024 and (ii)&#160;expected beneficial ownership of the Post-Combination Company common stock immediately following the Closing, assuming that no Public Shares are redeemed, and alternatively that the maximum number of Public Shares are redeemed, by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is, or is expected to be, the beneficial owner of more than 5% of issued and outstanding shares of ACAB common stock or of the Post-Combination Company common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our current executive officers and directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who will become an executive officer or director of the Post-Combination Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all executive officers and directors of ACAB as a group <span style="white-space:nowrap">pre-Business</span> Combination and all executive officers and directors of the Post-Combination Company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In addition, the rules include shares of ACAB or the Post-Combination Company common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable within 60 days of February&#160;29, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The beneficial ownership of shares of ACAB common stock <span style="white-space:nowrap">pre-Business</span> Combination is based on 8,167,391 shares of ACAB common stock (including 8,167,390 Series A shares and 1 Series B share) issued and outstanding as of February&#160;29, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of shares of the Post-Combination Company common stock assuming no Public Shares are redeemed has been determined based upon the following: (i)&#160;that no shares of Series A common stock are redeemed, (ii)&#160;that other than as reflected, none of the investors set forth in the table below has purchased or purchases shares of ACAB common stock <span style="white-space:nowrap">(pre-Business</span> Combination) or Post-Combination Company common stock, (iii)&#160;that 38,884,511 shares of the Post-Combination Company common stock are issued to the Abpro stockholders, and (iv)&#160;there will be an aggregate of 49,815,527 shares of the Post-Combination Company common stock issued and outstanding immediately following the Closing, which excludes the earnout shares and assumes there will be no other newly issued shares of ACAB common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected beneficial ownership of shares of the Post-Combination Company assuming the maximum number of Public Shares have been redeemed has been determined based on the following: (i)&#160;that 667,391 shares of Series A common stock are redeemed (maximum redemptions scenario), (ii) that other than as reflected, none of the investors set forth in the table below has purchased or purchases shares of ACAB common stock <span style="white-space:nowrap">(pre-Business</span> Combination) or Post-Combination Company stock, (iii)&#160;that 38,884,511 shares of the Post-Combination Company common stock are issued to the Abpro stockholders, and (iv)&#160;there will be an aggregate of 49,148,136 shares of the Post-Combination Company common stock issued and outstanding immediately following the Closing, which excludes the earnout shares and assumes there will be no other newly issued shares of ACAB common stock. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">After the Business Combination</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="18" align="center"><span style="font-weight:bold">Before the Business Combination</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">No Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">With Maximum<br/>Redemption</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">Series&#160;A&#160;Common</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock Beneficially<br/>Owned</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Series B Common<br/>Stock&#160;Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Series A Common<br/>Stock&#160;Beneficially<br/>Owner</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Series A Common<br/>Stock&#160;Beneficially<br/>Owner</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Address of Beneficial<br/>Owner(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number&#160;of<br/>Shares(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">%&#160;of&#160;Total<br/>Voting&#160;Power</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number&#160;of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Five Percent Holders <span style="white-space:nowrap">Pre-Business</span> Combination</span></span><span style="font-weight:bold">:</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-style:italic">Atlantic Coastal Acquisition Management II</span> LLC(3)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,199,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Directors and Executive Officers <span style="white-space:nowrap">Pre-Business</span> Combination</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shahraab Ahmad(3)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,199,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Anthony D. Eisenberg(5)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jason Chryssicas(5)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Burt Jordan(5)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Joanna Lord(5)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Bryan Dove(5)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Curtis Collar(5)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Darren Stanwood(5)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dominick J. Schiano(5)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">All executive officers and directors as a group (9 persons)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,449,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,491,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,491,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Directors and Executive Officers of Post-Business Combination Company</span></span>(7)<span style="font-weight:bold"><span style="font-style:italic">:</span></span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">All executive officers and directors as a group persons)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Five Percent Holders Post-Business Combination</span></span><span style="font-weight:bold"> </span>(7)<span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Abpro Bio International, Inc.(9)(10)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,606,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,606,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,747,813</td>
<td style="white-space:nowrap;vertical-align:bottom">(8)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,747,813</td>
<td style="white-space:nowrap;vertical-align:bottom">(8)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Atlantic Coastal Acquisition Management II LL(3)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,199,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shahraab Ahmad(3)(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,199,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,241,667</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Unless otherwise noted, the business address of each of the following entities or individuals is c/o Atlantic Coastal Acquisition Corp. II, 6 St Johns Lane, Floor 5, New York, NY 10013. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Such Series B common stock will automatically convert into Series A common stock concurrently with or immediately following the consummation of our initial business combination on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis, subject to adjustment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Atlantic Coastal Acquisition Management II LLC, our Sponsor, is the record holder of the shares reported herein. Shahraab Ahmad is the manager and the majority owner of our Sponsor. Accordingly, Mr.&#160;Ahmad may be deemed to beneficially own all of the shares held by our Sponsor. Mr.&#160;Ahmad disclaims beneficial ownership of any securities held by our Sponsor except to the extent of his pecuniary interest therein. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Excludes (i) an aggregate of 2,933,108&#160;shares that our Sponsor has agreed to forfeit upon the consummation of the Business Combination pursuant to the Sponsor Letter Agreement, (ii) 825,225 shares to be transferred to investors in connection with the Non-Redemption Agreements and (iii) 13,850,000 private warrants held by our Sponsor exercisable for 13,850,000 shares of Series A common stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Does not include any shares held by our Sponsor. This individual is a member of our Sponsor but does not have voting or dispositive control over the shares held by our Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Shares of Series A common stock held by such holder are converted Founder Shares which the holder agreed not to vote in connection with the Special Meeting. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Assumes an Exchange Ratio of 2.04 for Abpro stockholders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Reflects 1,095,945 shares of Series A common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">The business address for Abpro Bio International, Inc. is 139, Techno jungang-daero, Yuga-myeon, <span style="white-space:nowrap">Dalseong-gun,</span> Daegu, Republic of Korea. Abpro Bio International, Inc. is a subsidiary of Abpro Bio Co. Ltd, a publicly traded company listed on the KOSDAQ market of the Korea Exchange (KOSDAQ: 195990). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Includes 983,333&#160;shares transferred from the Sponsor upon the consummation of the Business Combination pursuant to the Sponsor Letter Agreement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_20">INFORMATION ABOUT ABPRO </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this section, the terms &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;future,&#8221; &#8220;strategy,&#8221; &#8220;likely,&#8221; or the negative of these terms, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these or any other forward-looking statements. These risks and uncertainties include, but are not limited to, those risks set forth under &#8220;Risk Factors.&#8221; Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on current expectations and reflect management&#8217;s opinions only as of the date hereof. These forward-looking statements speak only as of the date of hereof. Abpro expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Abpro,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Abpro Corporation prior to the Business Combination and to the Post-Combination Company and its consolidated subsidiaries after giving effect to the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. We are focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging our proprietary<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top"> </sup></span>and<span style="font-style:italic">&#160;MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span><span style="font-style:italic"> </span>antibody discovery and engineering platforms, we are developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Our two lead product candidates, <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201,</span> feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target. <span style="white-space:nowrap">ABP-102</span> is designed to redirect a patient&#8217;s immune system to fight cancer by engaging T cells through <span style="white-space:nowrap">co-targeting</span> human epidermal growth factor receptor 2, or HER2, and cluster of differentiation 3, or CD3, <span style="white-space:nowrap">T-cell</span> <span style="white-space:nowrap">co-receptor.</span> We plan initially to develop <span style="white-space:nowrap">ABP-102</span> for difficult to treat HER2+ solid tumors, focusing on orphan indications. <span style="white-space:nowrap">ABP-201</span> is designed to block blood vessel formation and normalize damaged vessels through <span style="white-space:nowrap">co-targeting</span> vascular endothelial growth factor, or VEGF, and <span style="white-space:nowrap">angiopoietin-2,</span> or <span style="white-space:nowrap">ANG-2.</span> We plan to develop <span style="white-space:nowrap">ABP-201</span> to treat vascular disease of the eye, focusing on wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD). We intend to follow these two lead product candidates with a broad pipeline of <span style="white-space:nowrap">CD3-targeting</span> <span style="white-space:nowrap">T-cell</span> engagers based on the differentiated format of <span style="white-space:nowrap">ABP-102.</span> We expect to initiate clinical trials for <span style="white-space:nowrap">ABP-102</span> in the second half of 2025 and in the first half of 2026 for ABP-201. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> is being developed and commercialized through a worldwide strategic partnership with Celltrion Inc. (&#8220;Celltrion&#8221;) (KRX:068270), a leading Korean biopharmaceutical company headquartered in Incheon, South Korea, under a Collaboration Agreement entered into in September 2022. We received an initial milestone payment of $2.0 million from Celltrion in connection with this agreement. In addition, we are eligible for net sales milestone payments of up to $1.75&#160;billion and development milestone payments of up to $8.0&#160;million under that agreement. In 2022, we also received an equity investment in our Series F preferred stock of $2.0&#160;million from Celltrion. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-201</span> is being developed and commercialized through a territorial partnership with Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;), a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company formerly named Ugint Co Ltd with diversified holdings in precision machine tools, equipment and biotechnology headquartered in Daegu, South Korea, under a collaboration and license agreement entered into in January 2020 that granted Abpro Bio exclusive </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development and commercialization rights in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia, Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan). We received a $30&#160;million equity investment from Abpro Bio in connection with that agreement, and we are potentially eligible for net sales milestones of up to $485&#160;million and development milestones of up to $56.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;is our antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both clinically validated and novel targets that have been traditionally difficult to access. This provides us with high affinity and high specificity<span style="font-weight:bold"></span>&#160;antibody building blocks with drug-like properties that we then use to engineer novel therapeutics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span>&#160;is our engineering platform that provides us with the flexibility to combine these antibody building blocks in different combinations and orientations to rapidly create &#8220;fit for purpose&#8221; novel full-length multi-specific antibody constructs. Our antibody constructs, including our TetraBi antibody format, can potentially benefit patients with the goal of improved efficacy, better safety profiles, and more convenient dosing regimens relative to current <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> therapies. Furthermore, in contrast to single-format bispecific antibody platforms that are only able to provide a single solution to different biological problems, our platform enables us to design a diverse suite of full-length multi-specific antibody formats to address new problems in medicine. Our approach is designed to result in therapeutic candidates with differentiated characteristics, including potentially stronger binding affinity, improved safety, more convenient dosing regimens and streamlined manufacturing processes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-102:</span> Next generation <span style="white-space:nowrap">T-cell</span> engager targeting HER2 and CD3 for HER2+ solid tumors </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:70%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-style:italic"><span style="white-space:nowrap">ABP-102</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Key Characteristics of <span style="white-space:nowrap">ABP-102</span></span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" rowspan="5">


<img src="g509388g01j05.jpg" alt="LOGO"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">&#8226;&#8195;&#8202;Dual-arm</span> affinity-tuned construct for selective killing and cytokine release on HER2-high target cells, with reduced killing and cytokine release on HER2-low target cells to reduce &#8220;on-target, off-tumor&#8221; toxicity</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Bivalent HER2 binding to promote more selective HER2-high target cell engagement</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;TetraBiTM IgG-[L]-scFv format with functionally monovalent CD3 binding at the hinge region to prevent T cell activation in the absence of tumor cells</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Cross-reactivity to human and cynomolgus CD3 for toxicity assessment</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Engineered for reduced Fc receptor engagement</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Symmetrical structure with natural antibody features for efficient manufacturing and a potentially improved dosing profile</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">ABP-102,</span> is a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 being developed for the treatment of HER2+ solid tumors, including breast and gastric cancers. <span style="white-space:nowrap">ABP-102</span> features bivalent HER2 binding sites and is engineered through affinity tuning to selectively target tumor cells expressing high and intermediate levels of HER2, with reduced activity on cells expressing <span style="white-space:nowrap"><span style="white-space:nowrap">low-to-negative</span></span> levels of HER2. <span style="white-space:nowrap">ABP-102</span> also features an affinity-tuned CD3 binding domain to provide enhanced potential for safety. <span style="white-space:nowrap">ABP-102</span> harnesses the power of the immune system by redirecting and activating cytotoxic T cells to attack tumor tissue. <span style="white-space:nowrap">ABP-102</span> may provide an improved therapeutic window to attack tumor </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cells while reducing systemic toxicity by promoting <span style="white-space:nowrap">&#8220;on-target,</span> <span style="white-space:nowrap">on-tumor&#8221;</span> effects, with reduced potential for <span style="white-space:nowrap">&#8220;on-target,</span> <span style="white-space:nowrap">off-tumor&#8221;</span> toxicity toward endogenous tissues. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical in vitro studies, <span style="white-space:nowrap">ABP-102</span> has demonstrated selectivity in both cytokine secretion and cytotoxicity with HER2-high and intermediate breast, ovarian, and gastric cancer cell lines, including those that are resistant to Herceptin (trastuzumab), with reduced activity on <span style="white-space:nowrap">HER2-low</span> and negligible activity on HER2-negative cell lines. We plan to initiate a Phase 1/2 clinical trial of <span style="white-space:nowrap">ABP-102</span> with our partner Celltrion in the second half of 2025, focusing on HER2+ breast and gastric cancers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe <span style="white-space:nowrap">ABP-102</span> is an improvement over currently approved HER2-targeting agents such as Herceptin, Perjeta (pertuzumab), and Kadcyla <span style="white-space:nowrap">(T-DM1),</span> as well as other HER2-targeting agents currently in development, because it relies on the redirection of cytotoxic T cells to selectively target and eliminate tumor cells, while sparing endogenous HER2-expressing cells. Current HER2-directed therapies, which are designed either to block HER2 function or deliver toxic payloads to the tumor, are only effective in a subset of HER2+ patients, cause undesirable side effects, and are limited by the onset of drug resistance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is management&#8217;s belief that <span style="white-space:nowrap">ABP-102</span> has the potential to provide longer lasting or even curative results in a broader set of patients than are currently addressed by HER2-directed therapies. The Global HER2+ market is forecast to grow to $12.1&#160;billion by 2030, at a CAGR of 1.5%, according to Research and Markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the TetraBi antibody format of <span style="white-space:nowrap">ABP-102</span> provides a potentially transformative approach to immuno-oncology. The TetraBi antibody format features two affinity-tuned binding sites, and thus bivalent binding for the tumor antigen, creating a stronger connection to the tumor cell compared to monovalent binding. In addition, the placement of the CD3 binding domain in the middle, or hinge region, of the TetraBi antibody format results in a therapeutic candidate that, in preclinical studies, selectively activates T cells only in the presence of tumor cells. We have designed <span style="white-space:nowrap">ABP-102</span> with the goal of a favorable safety profile and potential for an enhanced therapeutic window. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are leveraging the TetraBi antibody format of <span style="white-space:nowrap">ABP-102</span> to pursue a broad pipeline of immuno-oncology agents that target highly expressed antigens on a diverse range of tumor types, as depicted in the following chart. Our platform of T cell engagers has the potential to translate into an industry-leading pipeline of therapeutic agents with the goal of improving the treatment of patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">TetraBi series of <span style="white-space:nowrap">CD3-targeting</span> <span style="white-space:nowrap">T-cell</span> engagers </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g24m01.jpg" alt="LOGO"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-201:</span> Ligand trap targeting VEGF and <span style="white-space:nowrap">ANG-2</span> for vascular diseases of the eye </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:70%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">ABP-201</span></span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Key&#160;characteristics&#160;of&#160;ABP-201</span></span></span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<img src="g509388g16p07.jpg" alt="LOGO"/>
</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Dual inhibition of VEGF and <span style="white-space:nowrap">ANG-2</span> to block angiogenesis</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Four high-affinity binding sites for increased potential potency</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Dual targeting in single molecule</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Natural antibody structure for potentially improved dosing</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Symmetrical structure for efficient manufacturing</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-201</span> is a different TetraBi antibody format, designed to simultaneously inhibit VEGF and <span style="white-space:nowrap">ANG-2</span> for the potential treatment of vascular diseases of the eye, including diabetic macular edema, or DME, and wet <span style="white-space:nowrap">age-related</span> macular degeneration, or Wet AMD. In both DME and Wet AMD, blood vessels form abnormally and leak fluid, resulting in vision loss. Whereas VEGF drives new blood vessel formation, <span style="white-space:nowrap">ANG-2</span> acts to destabilize blood vessels and contributes to vessel leakage. The current standard of care for DME and Wet AMD includes intravitreal injections of VEGF-targeted agents, including Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab, used <span style="white-space:nowrap">off-label).</span> However, these drugs require eye injections every one to two months and are only effective in a subset of patients, many of whom eventually develop resistance. Because <span style="white-space:nowrap">ABP-201</span> has a high binding capacity, with a total of four binding sites per molecule, we believe <span style="white-space:nowrap">ABP-201</span> could be administered less frequently than current agents. Recently, the VEGF and <span style="white-space:nowrap">ANG-2</span> <span style="white-space:nowrap">co-targeting</span> agent Vabysmo (faricimab), was approved by the FDA, and clinical trial results showed a dose-dependent improvement in best-corrected visual acuity relative to Lucentis, providing strong support for this approach. In 2022, the combined worldwide sales of Eylea and Lucentis exceeded $10.5&#160;billion according to company filings. Through our AbMed subsidiary, we have in-licensed certain intellectual property rights relating to ABP-201 from MedImmune (now AstraZeneca), and are in breach of the terms of our license agreement with MedImmune/AstraZeneca. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Development Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to conduct a Phase 1, multiple-ascending dose evaluation of the safety and initial efficacy of <span style="white-space:nowrap">ABP-201</span> in patients with wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD). Following the identification of the maximum tolerated dose (MTD) or the safety and tolerability of the maximum administered dose (MAD), a larger randomized phase 2 study is planned. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an experienced leadership team with significant industry <span style="white-space:nowrap">know-how</span> and deep experience in antibody discovery and development, biomarker discovery and validation, clinical development and regulatory approval, partnerships, operations, and corporate finance. Our leadership team has broad industry experience from working at pharmaceutical and Biotech companies, including Celgene, NantWorks, Frequency Therapeutics, the Bill and Melinda Gates Medical Research Institute and Moderna. We also have a group of scientific advisors comprised of leaders in our industry across various disciplines, including Robert Langer, PhD, David H. Koch, Professor at MIT and a <span style="white-space:nowrap">co-founder</span> of Moderna; Laurie Glimcher, MD, President and CEO of Dana-Farber Cancer Institute; Ron Levy, MD, Professor and Chief, Division of Oncology, Stanford School of Medicine; George Tsokos, MD, Professor of Medicine, Beth Israel Deaconess Medical Center; Dr.&#160;Shiv Pillai, PhD, Professor of Medicine, Harvard Medical School and Massachusetts General Hospital and Steven Schnittman, MD, PhD, who previously served as Medical Branch Chief of the AIDS division at the National Institutes of Health and Vice President, Global Clinical Research at Bristol Myers Squibb. Dr.&#160;Langer is a member of our board of directors, and the other advisors serve on our Scientific Advisory Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Pipeline </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-style:italic"> </span>and<span style="font-style:italic">&#160;MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span>&#160;platforms and licensing strategy have generated a pipeline of next-generation antibody product candidates, as reflected in the following table: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g00n37.jpg" alt="LOGO"/>
 </p> <div> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-201</span> is held through our majority-owned subsidiary AbMed Corporation, or AbMed. AstraZeneca (formerly MedImmune) owns a minority stake in AbMed and, with respect to Asia, the Middle East and certain other countries, <span style="white-space:nowrap">ABP-201</span> is being developed and commercialized through a territorial partnership with Abpro Bio, with our company retaining rights in the rest of the world. <span style="white-space:nowrap">ABP-102</span> is being developed and commercialized through our world-wide strategic partnership with Celltrion. We hold world-wide exclusive rights to <span style="white-space:nowrap">ABP-110</span> under a patent license granted by the National Cancer Institute, or NCI, a division of the NIH. <span style="white-space:nowrap">ABP-150</span> is being developed under a collaboration agreement with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (&#8220;NJCTTQ&#8221;), pursuant to which NJCTTQ has exclusive commercialization rights in China and Thailand and we retain commercialization rights in the rest of the world. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. Traditionally, creating antibodies against targets and validating them as potential therapies has been time consuming and labor-intensive. We believe that our proprietary antibody platforms and approach overcome these limitations, however, we have yet to (i)&#160;produce antibodies on a scale needed for clinical trials or commercialization or (ii)&#160;evaluate any of our product candidates in a patient. By leveraging the speed, quality, and target-access of our<span style="font-style:italic"> DiversImmune</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> platform, we have generated a proprietary collection of antibody building blocks that enable us to establish our own pipeline of next-generation antibody product candidates. We believe our ability to leverage our<span style="font-style:italic"> MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platform to design novel <span style="white-space:nowrap">bi-and</span> multi-specific antibody constructs with natural, antibody-like structures presents a significant opportunity to unleash the immune system&#8217;s natural ability to fight disease and to elicit responses from broader patient populations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our key strategies to achieve this mission are: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Aggressively advance our lead product candidates, <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201,</span> into the clinic</span>. We plan to initiate a Phase 1/2 clinical trial of <span style="white-space:nowrap">ABP-102</span> in the second half of 2025, focusing on HER2+ breast and gastric cancers. Additionally, we are planning to advance <span style="white-space:nowrap">ABP-201</span> into Phase 1 clinical trials also in the first half of 2026 for the treatment of Wet AMD. We believe that the development of our lead antibody product candidates, if successful, will generate substantial value and provide us with differentiated products to pursue in large markets with significant unmet medical needs. <span style="white-space:nowrap">IND-enabling</span> studies are underway for both lead product candidates in preparation for final GLP toxicity studies and GMP manufacturing for filing the IND and we will request Pre-IND meetings beforehand with the FDA when appropriate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Rapidly follow <span style="white-space:nowrap">ABP-102</span> with a broad pipeline of <span style="white-space:nowrap">CD3-targeting</span> <span style="white-space:nowrap">T-cell</span> engagers and leverage this approach to other immune cell targets</span>. We are building on the optimized format of <span style="white-space:nowrap">ABP-102</span> to </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
aggressively develop a suite of immuno-oncology agents that redirect T cells to a diverse range of liquid and solid tumors. <span style="white-space:nowrap">ABP-110,</span> targeting GPC3 on hepatocellular carcinoma, and <span style="white-space:nowrap">ABP-150,</span> targeting Claudin 18.2 on gastric cancer, are currently in preclinical development. We may also use this &#8220;pipeline in a format&#8221; strategy with other immune cell targets, including CD137 and CD47. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage our </span><span style="font-weight:bold"><span style="font-style:italic">DiversImmune</span></span><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span><span style="font-weight:bold"> and </span><span style="font-weight:bold"><span style="font-style:italic">MultiMab</span></span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span><span style="font-weight:bold"> platforms to grow our pipeline of antibody product candidates</span>. We plan to continue investing in our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms to maintain our competitive advantage. We will continue to expand our collection of high affinity and high specificity antibody building blocks against both clinically validated and novel therapeutic targets, and apply our &#8220;fit for purpose&#8221; antibody engineering approach to construct novel multi-valent, multi-specific therapeutic product candidates. We will continue to build on the success of existing immuno-oncology or cell therapies that use the power of T cells to fight cancer, such as chimeric antigen receptor <span style="white-space:nowrap">T-cell,</span> or CAR T, therapy, but will focus on simpler, more accessible, and less expensive approaches that provide a universal solution for large populations of cancer patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Continue to explore and execute strategic collaborations</span>. In addition to the development and commercialization collaborations we have entered into with Celltrion and Abpro Bio, we entered into a collaboration agreement in January 2019 with NJCTTQ, a pharmaceutical company specializing in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing, China, for the development of novel bispecific antibody therapies for immuno-oncology, including potentially best in class <span style="white-space:nowrap">T-cell</span> engagers. Under that agreement, we are jointly developing <span style="white-space:nowrap">ABP-150,</span> a <span style="white-space:nowrap">T-cell</span> engager designed to fight cancer through <span style="white-space:nowrap">co-targeting</span> CD3 and Claudin 18.2. NJCTTQ has exclusive commercialization rights in China and Thailand and we retain commercialization rights in the rest of the world. We will continue to explore strategic and geographic-oriented partnerships that provide us with near-term economic benefits where we retain product rights to key strategic markets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Build a leading fully integrated <span style="white-space:nowrap"><span style="white-space:nowrap">discovery-to-commercial</span></span> antibody therapeutics company</span>. We have assembled an experienced scientific and business team, and have built robust discovery and antibody engineering platforms that allow us to create a broad pipeline of novel product candidates. As we advance our product candidates into clinical development, we intend to complement our discovery and development strengths with clinical expertise and commercial capabilities to build a fully integrated company. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Introduction to Monoclonal and Dual-Targeting Antibodies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Antibodies are large and diversified proteins produced by B cell immune responses to counter threats including infectious entities such as viruses, bacteria, and fungi. Antibodies can be raised against antigens seen by the immune system as <span style="white-space:nowrap">&#8220;non-self,&#8221;</span> and therefore antibodies against human proteins are often raised using a variety of immunization strategies in mice or other animals. The resulting antibodies can then be used as building blocks to develop therapeutics for molecular targets, including proteins overexpressed on the surface of cancer cells. Because they recognize their target antigens with high affinity and high specificity, and because they are natural elements of the immune system, antibodies have been used effectively as drugs for over 30 years. Monoclonal antibodies are the largest and most rapidly growing class of therapeutic proteins and have become a mainstay of therapeutic options for patients with cancer, autoimmune disorders, and other diseases. As of June&#160;30, 2022, 162 antibody therapies have been approved by at least one regulatory agency in the world, including 122 approvals in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An immunoglobulin G, or IgG, is the most common type of antibody and comprises two identical heavy chains and two identical light chains, which assemble to form a <span style="white-space:nowrap">Y-shaped</span> molecule, as depicted in the following graphic. The bottom tail of the &#8220;Y&#8221; is called the fragment crystallizable, or Fc, region, and is structurally constant across entire classes of antibodies. The Fc region of an antibody interacts with a variety of receptors on immune cells and is also responsible for the long circulating half-life of an antibody. The tips of the &#8220;Y&#8221; are called the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fragment variable, or Fv, regions, and contain the antigen-binding sites. A natural antibody recognizes a single target antigen and is therefore &#8220;monospecific.&#8221; Because it features two identical binding sites, however, it is &#8220;bivalent&#8221; for that target. Bivalency is a critical feature of natural antibodies. Just as it is much easier to hang from a bar with two arms rather than one, bivalent binding has been shown in preclinical studies to provide a much stronger connection to the target antigen than would be possible with monovalent binding. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g17p00.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although natural antibodies recognize a single target, they can be engineered in different ways to bind two or more targets, resulting in a bispecific or multispecific antibody. While there are many different types of dual-targeting antibodies, several mechanisms of action can be implemented for a bispecific construct, including dual binding, cross-linking, and cell-cell bridging, as depicted in the following graphics. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:68%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Two antibodies in one</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g509388g17p01.jpg" alt="LOGO"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Replaces a combination of two monospecific antibodies</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Simplifies the regulatory process, decreases manufacturing costs, and provides more favorable reimbursement conditions</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Ensures both targets are engaged in the same place at the same <br/>time</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:68%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Cross-linking</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g509388g17p03.jpg" alt="LOGO"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Cross-links two targets on the same cell</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Physically connects two proteins and can be used to activate pathways that are otherwise inactive or more potently inhibit pathways that are already active</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Can produce a synergistic effect, where the dual-targeting antibody <span style="white-space:nowrap">out-performs</span> the corresponding combination of two single-targeting antibodies</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:65%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Cell-bridging</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g509388g40n10.jpg" alt="LOGO"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Bridges two cells, physically bringing them into close proximity</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Promote immune cell activation to kill the tumor cells to which they are attached</p></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Platforms </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach consists of two technology platforms: our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;platform, which we use to generate therapeutic &#8220;building blocks,&#8221; which are high affinity and high specificity antibodies with functional activity against therapeutic targets; and our<span style="font-style:italic">&#160;MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span>&#160;platform, which we use to construct therapeutic product candidates by assembling the building blocks into different combinations of <span style="white-space:nowrap">bi-</span> and multi-specific antibodies. Together, these platforms support our strategy of building a broad pipeline of next generation antibody therapeutics that are designed to address a wide range of human diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">DiversImmune</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span></span><span style="font-weight:bold">: Our antibody discovery platform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;platform was built to address a key bottleneck in the antibody therapeutics industry: the ability to rapidly generate high affinity and high specificity antibodies against virtually any target of interest. Although<span style="font-style:italic">&#160;in vitro</span>&#160;methods, such as phage and yeast display, have been developed to mimic the immune system, these methods typically rely on collections of antibodies from unimmunized donors and as a result generally yield relatively low affinity antibodies. Improving these antibodies through affinity maturation (<span style="font-style:italic">i.e.</span>, mutation and selection) is often a lengthy process and is not always successful. In contrast, the adaptive immune system of a mouse has a <span style="white-space:nowrap">built-in</span> mechanism called somatic hypermutation that improves the affinity of antibodies up to one thousand times, yielding high affinity and high specificity antibodies suitable for therapeutic development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The greatest challenge with mouse-based methods, however, lies in generating a strong and diverse immune response to the target of interest. The mammalian immune system has a mechanism called tolerance that prevents it from making antibodies against proteins that are perceived as &#8220;self.&#8221; Thus, to generate a strong immune response against a target that is difficult to access, either because the target is not particularly immunogenic, or capable of producing an immune response, or because the target, a human protein, is very similar to the corresponding mouse protein, it is necessary to &#8220;break tolerance.&#8221; A key component of our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> platform is our genetically engineered hyperimmune mouse which seeks to solve this problem in two ways. First, the mouse has been genetically engineered so that more of its antibody-generating B cells survive and proliferate than in a <span style="white-space:nowrap">non-engineered</span> mouse. This results in a larger and more diverse collection of high affinity antibodies. Second, the mouse has a hyperactive immune system in which its tolerance to self-antigens has been &#8220;broken.&#8221; This enables us to generate a diverse array of antibodies against a wide range of targets, including targets that are very similar between mouse and human. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;platform comprises three key steps, all focused on generating a diverse collection of high quality antibodies: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Immunization</span>. We have developed an integrated collection of immunization methods, termed Raptor, which includes purified proteins, engineered cells, viral-like particles, and DNA. These methods all work in concert with the goal to elicit a strong and diverse immune response. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Diversification</span>. We have developed hyperimmune mouse, along with a variety of <span style="white-space:nowrap">co-stimulation</span> methods, to optimize the immune response to each target and yield a diverse collection of antibodies that recognize different epitopes, or binding regions, on the same target protein. This is a critical component of our discovery process as we believe it greatly increases the probability of identifying antibodies with the desired functional properties necessary for therapeutic development. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Optimization</span>. We have streamlined the processes of humanization and optimization so that we can rapidly advance antibodies with the desired functional properties to fully developed building blocks. These building blocks can then be assembled into novel therapeutic product candidates using our <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platform. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g24m02.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;platform has been used to generate antibodies for pharmaceutical and biotechnology companies. We are now using this platform internally to create what management believe to be an industry-leading collection of building blocks to support a growing pipeline of therapeutic product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">MultiMab</span></span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span><span style="font-weight:bold">: Our antibody engineering platform</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our<span style="font-style:italic">&#160;MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span>&#160;platform enables us to build a diverse array of <span style="white-space:nowrap">bi-and</span> multi-specific antibody formats, allowing us to optimize the format of our product candidates. Because biology is diverse and complex, there is no &#8220;one size fits all&#8221; solution to engineering multi-specific antibodies. Instead, different problems call for different solutions. We draw from a suite of different antibody formats to choose the one that we believe best suits the disease and mechanism we are targeting. Despite having multiple formats from which to choose, our formats typically contain two key features: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Bivalent binding</span>. Bivalent binding, or binding with two points of contact, takes advantage of the concept of avidity, specifically that multipoint connections are much stronger than single point connections. In order to maximize efficacy, we build bivalent binding into our therapeutic product candidates where increased strength of binding is desirable. For example, <span style="white-space:nowrap">ABP-102</span> features two identical binding sites for HER2, rather than one. This enables the molecule to bind tightly to HER2+ tumor cells, forming a strong immunological synapse, or <span style="white-space:nowrap"><span style="white-space:nowrap">cell-to-cell</span></span> interaction, between the tumor cell and the cytotoxic T cell. We believe this is critical to generating a strong and sustained immune response and differentiates <span style="white-space:nowrap">ABP-102</span> from other <span style="white-space:nowrap">T-cell</span> engaging bispecific antibodies that only feature a single binding site for the tumor-specific antigen. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Fc region</span>. The Fc region of an antibody interacts with various receptors on immune cells to control both the immune response to antibody binding and the circulating half-life of an antibody. To take advantage of these natural functions, we build Fc regions into all our therapeutic product candidates. For example, ABP-102 features a human IgG1 Fc region that promotes a long circulating half-life, and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td align="left" style="vertical-align:top">
has been further engineered to reduce or eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to reduce potentially harmful side-effects associated with inflammation and cytokine release. Similarly, <span style="white-space:nowrap">ABP-201</span> features an Fc region that results in greater stability and, due to its size, a longer ocular half-life, potentially enabling more convenient dosing for patients. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both of our lead product candidates, <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201,</span> are TetraBi antibodies that feature two high affinity binding sites for each of their targets and Fc regions for longer half-lives. In addition, both product candidates are symmetrical, with two identical heavy chains and two identical light chains. Many bispecific antibody formats are asymmetrical, featuring two different heavy chains. This creates the possibility of chain mispairing, which complicates the manufacturing process as it is necessary to rigorously characterize each batch and minimize the presence of mispaired species. With our TetraBi antibody format, this allows for straightforward manufacturing, as there is no possibility of chain mispairing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">MultiMab</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span></span><span style="font-weight:bold">&#160;antibody engineering platform </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g24m04.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key advantages of our antibody technology platforms </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our<span style="font-style:italic">&#160;DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span>&#160;and<span style="font-style:italic">&#160;MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span>&#160;platforms overcome several significant limitations associated with competing antibody technologies and have the following key competitive advantages: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Superior target access</span>. By breaking immune tolerance, our <span style="font-style:italic">DiversImmune</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> platform enables us to generate high quality antibodies against traditionally <span style="white-space:nowrap"><span style="white-space:nowrap">difficult-to-target</span></span> proteins, providing access to new therapeutic targets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Superior speed of antibody discovery</span>. By generating a wide diversity of high quality antibodies against a single target, our <span style="font-style:italic">DiversImmune</span><sup style="font-size:75%; vertical-align:top">&#174;</sup> platform accelerates the discovery phase by increasing the probability of identifying high quality antibodies with the appropriate function. This speed allows us to rapidly scale and build a broad portfolio of functional building blocks to address disease-specific challenges that are not currently met by existing therapeutics or products. However, any product candidate developed with our platforms will still be subject to clinical trial requirements prior to approval, and we cannot accelerate clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Superior flexibility in engineering novel therapeutics</span>. By providing access to a diverse array of <span style="white-space:nowrap">bi-</span> and multi-specific antibody formats, our <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platform enables us to rapidly test a broad range of solutions, shortening the timeline for lead selection and increasing the chance of finding an optimal format that meets key performance specifications. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">B cell cloning platform </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platform we have developed a B cell cloning platform that enables us to isolate potently neutralizing antibodies to <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2,</span></span> RSV, and other viruses recognizing conserved viral epitopes resistant to mutational escape. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Immuno-Oncology Strategy For T Cell Engagement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the most promising strategies in cancer therapy is to direct cytotoxic T cells to kill tumor cells. This can be achieved using dual-targeting antibodies, which bind simultaneously to a tumor-specific antigen on a tumor cell and to CD3 on a T cell, bringing these cells into close proximity and causing the T cell to kill the tumor cell. First-generation bispecific antibodies were called Bispecific <span style="white-space:nowrap">T-cell</span> Engagers, or BiTEs, and contained two Fv regions, one for the tumor antigen and one for CD3. Because they do not contain an Fc region, BiTEs have very short circulating half-lives, requiring patients to wear an infusion pump for continuous intravenous administration. Second-generation bispecific antibodies contain an Fc region, but typically have only one binding site for the tumor antigen. This results in weaker binding to the tumor cell than could be achieved with the corresponding bivalent antibody. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key features of the TetraBi antibody format for <span style="white-space:nowrap">T-cell</span> engagement </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g24m06.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro&#8217;s TetraBi antibody format improves upon both first-and second-generation bispecific <span style="white-space:nowrap">T-cell</span> engaging antibodies, as summarized in the following table. First,<span style="font-weight:bold"></span>&#160;unlike first-generation bispecific antibodies, our TetraBi antibodies contain an Fc region, which provides enhanced stability and a longer circulating half-life for potentially more convenient dosing. Second, unlike second-generation antibodies, our TetraBi antibodies have two binding sites for the tumor antigen, rather than one. Bivalent binding promotes maximal efficacy via an avidity-based binding effect for the tumor associated antigen, allowing for the establishment of strong </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connections between the T cell and the tumor cell, leading to sustained activation through clustering of the T cell receptor complex in the presence of high antigen densities. By placing the <span style="white-space:nowrap">CD3-binding</span> domain in the hinge region of the molecule, the TetraBi antibody format has been shown in preclinical studies to exhibit monovalent-like interaction with CD3. This is important in preventing TetraBi antibodies from activating T cells in the absence of tumor cells, which could lead to undesirable toxicities such as cytokine release syndrome, or CRS, a potentially life-threatening toxicity associated with T cell targeted therapies. Finally, unlike second-generation antibodies, our TetraBi antibodies contain two identical heavy chains and two identical light chains. This allows for easy manufacturing, as there is no possibility of mispairing between two different heavy chains. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key advantages of our TetraBi antibody format </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g24m05.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">ABP-102,</span> illustrates the key advantages of this format. <span style="white-space:nowrap">ABP-102</span> is bivalent for HER2, providing stronger binding to tumor cells than could be achieved with first- and second-generation formats that are monovalent for HER2. <span style="white-space:nowrap">ABP-102</span> has been shown in preclinical mouse studies not to activate T cells in the absence of tumor cells, but induce T cells to kill tumor cells in a HER2-dependent manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the TetraBi antibody format of our <span style="white-space:nowrap">ABP-102</span> product candidate offers several significant competitive advantages over other bispecific antibody formats and other approaches to <span style="white-space:nowrap">T-cell-based</span> therapy: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Bivalent binding</span>. By including two binding sites for the tumor antigen, our antibodies are designed to form a much stronger connection to tumor cells than competitor molecules that feature only a single binding site. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Potentially better dosing through inclusion of an Fc region</span>. By including an Fc region, our TetraBi antibodies are designed to have long circulating half-lives, enabling potentially more convenient dosing for patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Controlled immune effector function through Fc engineering</span>. By introducing defined mutations into the Fc region, we are potentially able to diminish or eliminate <span style="white-space:nowrap">Fc-mediated</span> interactions that can contribute to unwanted side effects such as CRS. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Lower immunogenicity</span>. By closely resembling human antibodies with natural amino acid sequences, our TetraBi antibodies may have a reduced risk of being immunogenic, or capable of producing an undesirable immune response, which could otherwise lead to decreased efficacy. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Streamlined manufacturing</span>. By building symmetrical molecules with two identical heavy chains and two identical light chains, our molecules are designed to eliminate complications arising from potential chain mispairing. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Advantages of TetraBi antibodies over CAR T therapy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T cells can also be directed to kill tumor cells by genetically modifying them to express a chimeric antigen receptor, or CAR. A CAR is a synthetic receptor in which an Fv domain of an antibody that recognizes a tumor-specific antigen is linked to a portion of the <span style="white-space:nowrap">T-cell</span> receptor, typically <span style="white-space:nowrap">CD3-zeta,</span> as well as one or more costimulatory domains. T cells expressing a CAR, or CAR T cells, bind to and subsequently kill tumor cells expressing the appropriate antigen. CAR T therapy has demonstrated efficacy in liquid tumors and as of 2023, six CAR T therapeutics have garnered FDA approval, including agents targeting hematological malignancies such as lymphomas, leukemias, and multiple myeloma. However, there are currently no approvals in solid tumor indications. Unlike antibody therapy, CAR T therapy is a complex, multi-step process. After a patient&#8217;s white blood cells are collected, T cells are isolated and activated. They are then genetically engineered to express the CAR. The CAR T cells then need to be grown for several weeks before being infused back into the patient. Prior to infusion, however, patients have to undergo chemotherapy to deplete immune cells, providing an opportunity for the CAR T cells to engraft in the patient. Despite the effectiveness of this approach, there are several challenges to the widespread adoption of CAR T therapy. The process of engineering CAR T cells is technically challenging, time-consuming, and expensive. In addition, there are significant toxicities associated with CAR T therapy, including CRS. Although patients receiving CAR T therapy are often treated for CRS while undergoing therapy, treatments for CRS, namely administration of immuno-suppressive agents, can also reduce the efficacy of the therapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have yet to observe any advantages of TetraBi antibodies in a clinical trial, and TetraBi antibodies have not yest received marketing approval, we believe our next-generation <span style="white-space:nowrap">CD3-targeted</span> <span style="white-space:nowrap">T-cell</span> engagers have several advantages over CAR T therapies. Like CAR T therapy, we are redirecting cytotoxic T cells to fight cancer. Unlike CAR T therapy, however, potential treatment with our TetraBi antibodies should be straightforward and convenient for patients. They will not be required to travel large distances to <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">state-of-the-art</span></span></span> cancer centers, but may instead be treated by simple intravenous infusion in local clinics. They will not be required to wait weeks for their T cells to undergo a lengthy and complex modification process, and they will not need to undergo chemotherapy to deplete their immune cells. It will also be potentially much easier to manage toxicities by altering the dose of the antibody. Finally, our TetraBi antibody therapy is expected to be less expensive, reducing obstacles associated with payment and reimbursement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Target Markets </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidates are currently targeting the therapeutic areas of cancer and ophthalmology. The global breast cancer monoclonal antibodies market size is estimated to grow by USD 15&#160;billion at a CAGR of 12.5% between 2022 and 2027, according to Technavio. North America is estimated to contribute 42% to the growth of the global market during the forecast period, according to the same source. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Immuno-oncology / oncology </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oncology therapeutics accounted for $143&#160;billion in branded pharmaceutical sales in 2019&#8212;approximately 20% of global pharmaceutical sales. Analyst consensus figures indicate a 12% CAGR, and global oncology therapeutics sales are forecasted to hit $250&#160;billion by 2024, according to McKinsey&#160;&amp; Co. In 2022, global sales of Rituxan/MabThera (rituximab), Avastin, and Herceptin combined for $11.55&#160;billion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Ophthalmology </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global ophthalmology market is expected to experience growth in the forecast period of 2023 to 2030. Data from Bridge Market Research analyzes that the market is growing with a CAGR of 6.4% in the forecast period of 2023 to 2030 and is expected to reach $84&#160;billion by 2030, from $51&#160;billion in 2022. The global wet <span style="white-space:nowrap">age-related</span> macular degeneration (AMD) market, estimated at $6.9&#160;billion in 2018, is projected to reach $10.4&#160;billion by 2024, registering a CAGR of 7.1% during the forecast period. The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&amp;S intelligence (Prescient&#160;&amp; Strategic Intelligence). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-102</span> for HER2+ breast and gastric cancers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">ABP-102,</span> is a TetraBi antibody targeting HER2 and CD3. It is an affinity-tuned, Fc engineered dual-targeting antibody with a human IgG1-like structure. <span style="white-space:nowrap">ABP-102</span> features two binding sites for bivalent binding to cells expressing HER2, and two binding sites for CD3 in a format that promotes functional monovalency during cell binding. We believe this structure provides greater potential for clinical applications compared with other HER2-directed <span style="white-space:nowrap">T-cell-engaging</span> bispecific antibodies that have only one binding site for the tumor-specific antigen (<span style="font-style:italic">i.e.</span>, HER2), allowing for an avidity-enhanced effect. <span style="white-space:nowrap">ABP-102</span> is designed to redirect T cells to tumor cells that are overexpressing HER2 at high or intermediate levels. In preclinical studies, we have shown that <span style="white-space:nowrap">ABP-102</span> selectivity promotes T cell activation, cytokine release and cytotoxicity in the presence of HER2-high and intermediate expressing cells, including HER2+ breast, ovarian, and gastric cancer cell lines. We have also observed reduced or no cytotoxic activity against cell lines expressing low/endogenous levels of HER2. This feature provides the opportunity for an improved therapeutic window to attack tumor cells while reducing systemic toxicity by promoting <span style="white-space:nowrap">&#8220;on-target,</span> <span style="white-space:nowrap">on-tumor&#8221;</span> effects, with reduced potential for <span style="white-space:nowrap">&#8220;on-target,</span> <span style="white-space:nowrap">off-tumor&#8221;</span> toxicity toward endogenous tissues. We plan to initiate clinical trials of <span style="white-space:nowrap">ABP-102</span> in the second half of 2025 with our partner Celltrion, focusing on HER2+ breast and gastric cancers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background and market opportunity for HER2+ breast and gastric cancers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Breast cancer is the most common cancer in women in the United States, except for skin cancers. It is about 30% (or 1 in 3) of all new female cancers each year. The American Cancer Society&#8217;s estimates for breast cancer in the United States for 2023 are: About 297,790 new cases of invasive breast cancer will be diagnosed in women. About 55,720 new cases of ductal carcinoma in situ (DCIS) will be diagnosed. About 43,700 women will die from breast cancer. Breast cancer is the second leading cause of cancer death in women (only lung cancer kills more women each year). The chance that a woman will die from breast cancer is about 1 in 39 (about 2.5%). The American Cancer Society&#8217;s estimates for stomach cancer (also known as gastric cancer) in the United States for 2023 are approximately26,500 new cases (15,930 in men and 10,570 in women) and approximately 11,130 deaths (6,690 men and 4,440 women). Stomach cancer accounts for about 1.5% of all new cancers diagnosed in the United States each year, according to the American Cancer Society. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, HER2 directed therapies generated approximately $10.3 billion in full year sales. The four drugs that made up this number include PERJETA (approximately $4.6 billion), KADCYLAZ (approximately $2.3 billion), HERCEPTIN (approximately $2.2 billion), and ENHERTU (approximately $1.2 billion), according to public disclosures made by Genentech/Roche and Daiichi Sankyo/AstraZeneca. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:55%"/>

<td style="vertical-align:bottom;width:41%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Cancer type</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incidence&#160;of&#160;high&#160;HER2&#160;expression</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breast</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">~20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Endometrial</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">8-35</span></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gastroesophageal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">4-22</span></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pancreatic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">2-29</span></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cervical</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">1-21</span></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bladder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">5-15</span></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Cancer Treatment Reviews </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential competitive advantages of <span style="white-space:nowrap">ABP-102</span> versus approved anti-HER2 therapies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current HER2-directed therapies have demonstrated increased chemical off target toxicity (e.g., TKIs and ADCs) and/or reduced efficacy from drug resistance or limited potency requiring combination with chemotherapy (i.e., mAbs), especially in the relapsed and refractory disease population. <span style="white-space:nowrap">ABP-102</span> seeks to overcome these challenges as a single-agent therapy that potently engages the patient&#8217;s natural immune system without toxic chemicals to directly target and destroy the tumor. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential benefits of <span style="white-space:nowrap">ABP-102</span> in immuno-oncology </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> is a TetraBi antibody that is designed to bind simultaneously to HER2 overexpressed on a tumor cell and CD3 on a T cell, thereby bringing the two cells into close proximity and promoting <span style="white-space:nowrap">T-cell</span> activation that leads to killing of the tumor cell. <span style="white-space:nowrap">ABP-102</span> is a differentiated therapeutic in that it is able to selectively target HER2-high and intermediate expressing cells, with reduced activity on <span style="white-space:nowrap">HER2-low</span> or negative cells, an engineered design feature to promote safety for endogenous HER2-expressing tissues. The TetraBi antibody format of <span style="white-space:nowrap">ABP-102</span> is intended to improve on the clinical efficacy of HER2 targeted therapy by inducing infiltration of T cells into HER2+ tumors. In addition to HER2+ breast cancer, <span style="white-space:nowrap">ABP-102</span> can potentially target any solid tumor in which HER2 is overexpressed, including HER2+ gastric, esophageal, endometrial, ovarian, colorectal, lung, pancreatic, cervical, gallbladder, and bladder cancers, as well as HER2+ pediatric indications including osteosarcoma. By targeting both HER2 and CD3, <span style="white-space:nowrap">ABP-102</span> may overcome many of the limitations of single-targeting agents. For instance, agents targeting HER2 alone, such as Herceptin, face problems with drug resistance, often caused by alterations in the HER2 signaling pathway or other related <span style="white-space:nowrap">pro-proliferative</span> pathways. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> works by a different mechanism, engaging cytotoxic T cells to kill the tumor cells rather than blocking the function of HER2. As such, we believe that <span style="white-space:nowrap">ABP-102</span> could lead to more durable responses in patients, with reduced risk of drug resistance. Furthermore, <span style="white-space:nowrap">ABP-102</span> possesses an advanced TetraBi antibody format, unlike that of competing agents that only feature a single binding site for HER2. Having two binding sites for HER2 enables higher binding potential and selectivity for tumor cells, which may result in greater potency and an improved therapeutic index. In addition, this dual binding may provide access to a broader patient population, including patients that express intermediate levels of HER2. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">ABP-102</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">immune-mediated </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">HER2+ tumor cell death </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g24m08.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preclinical data </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For <span style="white-space:nowrap">ABP-102</span> to be both safe and effective, it must only activate T cells when HER2+ tumor cells are present. The key safety risk for <span style="white-space:nowrap">T-cell</span> engaging therapies is CRS, in which T cells and other white blood cells become activated, leading to the over-production of <span style="white-space:nowrap">pro-inflammatory</span> cytokines. This can cause high fever, swelling, redness, extreme fatigue, nausea, and, in rare cases, death. The <span style="white-space:nowrap">ABP-102</span> Fc region is engineered to have reduced binding to Fc receptors and C1q, thereby making T cell engagement the definitive mechanism of action. By positioning the <span style="white-space:nowrap">CD3-binding</span> domain near the hinge region of the molecule, it selectively activates T cells only in the presence of HER2+ tumor cells. Thus, when <span style="white-space:nowrap">ABP-102</span> is added to T cells or PBMCs alone, the T cells do not release <span style="white-space:nowrap">pro-inflammatory</span> cytokines like TNFa, <span style="white-space:nowrap">IL-6,</span> <span style="white-space:nowrap">IL-2and</span> IFNg. When HER2+ tumor cells are introduced, however, <span style="white-space:nowrap">ABP-102</span> causes potent activation of the T cells, along with cytokine release reflecting T cell activation. This strong dependency on HER2 for T cell engagement may result in a beneficial therapeutic index for <span style="white-space:nowrap">ABP-102,</span> enabling a dose to be found that is both safe and effective. In addition, HER2 is expressed at lower levels in some tissues of the human body, including heart and lung tissues. Therefore, we have engineered <span style="white-space:nowrap">ABP-102</span> to promote selectivity for T cell activation and killing of HER2-high and intermediate target cells, which is a key differentiating feature. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical in vitro studies, <span style="white-space:nowrap">ABP-102</span> has shown strong antitumor activity that is dependent on the presence of <span style="white-space:nowrap">CD3-positive</span> T cells, a key component of cellular immunity within human peripheral blood mononuclear cells, or PBMCs. PBMCs consist of monocytes and lymphocytes, which are white blood cells made up of T cells, B cells, and natural killer, or NK cells. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have tested <span style="white-space:nowrap">ABP-102</span> for cytotoxicity on a wide variety of cell lines with a broad range of HER2 surface expression levels, from high to intermediate to low, as determined by flow cytometry with trastuzumab biosimilar antibody (Figure 1). These cell lines include HER2-high expressing cell lines such as <span style="white-space:nowrap">SKBR-3,</span> <span style="white-space:nowrap">BT-474,</span> and <span style="white-space:nowrap">NCI-N87,</span> and also HCC1954 breast cancer cells, which are HER2+, but resistant to Herceptin. <span style="white-space:nowrap">ABP-102a,</span> b, and c lead candidate affinity-tuned constructs were all able to kill all cell lines expressing <span style="white-space:nowrap"><span style="white-space:nowrap">high-to-intermediate</span></span> HER2 levels at a similar dose range for maximum cytotoxicity to the parental HER2 x CD3 TetraBi construct with unmodified HER2 and CD3 affinity. <span style="white-space:nowrap"><span style="white-space:nowrap">MDA-MB-453</span></span> cells are reported to be HER2 intermediate in the literature, and this was similar in our flow cytometry assessment; <span style="white-space:nowrap">ABP-102</span> similarly shows killing of that cell line as well. However, in contrast to the HER2 x CD3 parental TetraBi antibody, <span style="white-space:nowrap">ABP-102a,</span> b, and c have reduced activity on HER2 <span style="white-space:nowrap"><span style="white-space:nowrap">low-to-negative</span></span> cells, including the <span style="white-space:nowrap"><span style="white-space:nowrap">ZR-75-1,</span></span> <span style="white-space:nowrap">MCF-7,</span> HT55, <span style="white-space:nowrap">JIMT-1</span> cell lines, in which erbb2/HER2 gene expression is not amplified. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In these studies, <span style="white-space:nowrap">ABP-102a,</span> b and c exhibited selective cytotoxicity in the presence of human PBMCs that was dependent on HER2 expression level, with preferential killing of HER2-high expressing cell lines and reduced activity on <span style="white-space:nowrap">HER2-low</span> cell lines. This selectivity for targeting of HER2-high expressing cells may help to widen the therapeutic window of a T cell engager with less potential for toxicity toward tissues expressing endogenous levels of HER2. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 1. <span style="white-space:nowrap">ABP-102</span> is effective in vitro against a range of cancer cell lines expressing high and intermediate HER2 levels, but shows reduced activity on HER2 low to negative cell lines. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g89s10.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Figure 1 legend</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cell lines were harvested with Accutase followed by staining with 1 ug/mL trastuzumab biosimilar antibody, followed by staining with anti-human <span style="white-space:nowrap">IgG-PE</span> secondary antibody. Flow cytometry data were collected using a BD FACSCelesta and analyzed in FlowJo software as quantified by median fluorescence intensity (MFI). For cytotoxicity analysis, PBMCs were added at a 10:1 E:T ratio (100,000 PBMCs: 10,000 seeded target cells) and incubated with antibodies for 42 hours, at which time cytotoxicity was quantified using the CellTiterGlo2.0 protocol for each cell line. Lead clones <span style="white-space:nowrap">ABP-102a,</span> b, and c are shown as compared to a positive control <span style="white-space:nowrap">(non-affinity</span> tuned CD3 x HER2 parental TetraBi), as well as a comparator molecule (HER2 x CD3 monovalent heterodimer). An isotype control bispecific antibody with an intact CD3 binding arm was used as a negative control. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine whether T cell activation differences account for the observed differential activity on HER2-high and intermediate cells, we assessed culture supernatants for cytokine release (Figure 2). Similar cytotoxicity is observed with <span style="white-space:nowrap">ABP-102a,</span> b, and c on the HER2-high <span style="white-space:nowrap">(SKBR-3)</span> cell line, with a modest reduction in cytokine release compared to the HER2 x CD3 parental control TetraBi molecule. However, when using cell lines with <span style="white-space:nowrap">HER2-low</span> expression <span style="white-space:nowrap">(MCF-7)</span> as target cells, we observe less cytotoxicity with <span style="white-space:nowrap">ABP-102a,</span> b, and c as compared to the HER2 x CD3 parental control TetraBi molecule. On <span style="white-space:nowrap">HER2-low</span> expressing cells, we also observe a markedly reduced cytokine release profile, reflecting reduced activation of T cells as compared to the HER2 x CD3 parental control TetraBi molecule. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This data demonstrates the selectivity of our <span style="white-space:nowrap">ABP-102</span> candidate lead molecules, a feature which should help to promote cytotoxicity for HER2 overexpressing cells while potentiating an environment for durable T cell responses, while also mitigating risks to endogenous HER2-expressing tissues including the heart and lungs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Figure 2. <span style="white-space:nowrap">ABP-102</span> exhibits selectivity for HER2 overexpressing cells through differential activation of T cell cytotoxicity and cytokine release against HER2-high <span style="white-space:nowrap">(SKBR-3)</span> and <span style="white-space:nowrap">HER2-low</span> <span style="white-space:nowrap">(MCF-7)</span> cell lines. </span></p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g98s89.jpg" alt="LOGO"/>
 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g97s30.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 2 legend: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PBMCs were added at a 10:1 E:T ratio and incubated for 42 hours, at which time cytotoxicity was quantified using the CellTiterGlo2.0 protocol. Cytokine release was detected in supernatants diluted 1:5 in assay buffer before addition to a sensitive multiplexed bead-based assay for quantification of <span style="white-space:nowrap">IL-2,</span> IFNg, TNFa, and <span style="white-space:nowrap">IL-6</span> (R&amp;D Systems/Biotechne), with detection and quantification on a MagPix system (Luminex). </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> lead candidates are currently under evaluation with HER2-high and <span style="white-space:nowrap">HER2-low</span> expressing cell line xenograft tumor models in mice, with human PBMCs as effector cells. Final selection of a lead molecule will be based on cumulative in vitro data and anti-tumor efficacy in the HER2 tumor in vivo models. Expression cell lines are currently in development for production of <span style="white-space:nowrap">ABP-102a,</span> b, and c, with plans in place for CMC activities ahead of GLP toxicology studies and clinical trials.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clinical development of <span style="white-space:nowrap">ABP-102</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In collaboration with Celltrion, we plan to initiate <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> Phase 1/2 clinical trials with <span style="white-space:nowrap">ABP-102</span> in the second half of 2025 in HER2+ solid tumors, including breast and gastric cancer as well as orphan drug indications. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-201</span> for DME and Wet AMD </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second lead product candidate, <span style="white-space:nowrap">ABP-201,</span> is a different TetraBi antibody that simultaneously targets VEGF and <span style="white-space:nowrap">ANG-2.</span> <span style="white-space:nowrap">ABP-201</span> binds with very high, or subnanomolar, affinity to <span style="white-space:nowrap">ANG-2</span> and most of the major isoforms of VEGF, including VEGF165, VEGF189, and VEGF121. Due to its TetraBi antibody format, <span style="white-space:nowrap">ABP-201</span> features two binding sites for each of VEGF and <span style="white-space:nowrap">ANG-2,</span> which distinguishes it from bispecific antibodies that feature only a single binding site for each target. <span style="white-space:nowrap">ABP-201</span> is formulated for intravitreal injection and is designed to function as a &#8220;ligand trap,&#8221; removing both VEGF and <span style="white-space:nowrap">ANG-2</span> from the eye. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our majority-owned subsidiary, AbMed Corporation, we are developing <span style="white-space:nowrap">ABP-201</span> for potential indications in ophthalmology, including DME and Wet AMD. DME is an eye condition brought on by diabetes in which blood vessels form abnormally and leak fluid into the macula of the eye, resulting in blurred vision and, in extreme cases, blindness. Wet AMD is similarly a severe eye condition caused by the growth and leakage of abnormal blood vessels under the retina and macula of the eye, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. VEGF is a clinically validated target in both DME and Wet AMD, where Eylea and Lucentis are approved and in widespread use. As depicted in the following chart, VEGF and <span style="white-space:nowrap">ANG-2</span> act in concert to promote angiogenesis. In normal blood vessel development, <span style="white-space:nowrap">ANG-2</span> plays a role in destabilizing mature blood vessels, creating an environment in which vessel branching can occur. VEGF then promotes the sprouting of new blood vessels. In DME and Wet AMD, however, excessive destabilization of blood vessels by <span style="white-space:nowrap">ANG-2</span> contributes to vessel leakage, or edema. In addition, upregulation of <span style="white-space:nowrap">ANG-2</span> is the primary mechanism of resistance to VEGF inhibition. We believe that effective control of angiogenesis and inhibition of vessel leakage requires simultaneous inhibition of both pathways. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g56s02.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current treatment options for DME </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the underlying molecular cause of DME and Wet AMD is not completely understood, both VEGF and <span style="white-space:nowrap">ANG-2</span> play central roles in new blood vessel growth&#8212;a hallmark common to both ocular diseases. Several biological therapies have been developed to inhibit VEGF by binding to and sequestering the protein. The current <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> includes Lucentis, a recombinant humanized monoclonal antibody fragment that binds VEGF, and Eylea, a recombinant fusion protein containing portions of the human VEGF receptor. Another VEGF antibody is Avastin, a recombinant human monoclonal antibody which is approved for the treatment of several cancer indications and is used <span style="white-space:nowrap">off-label</span> for the treatment of DME and wet AMD. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the approval of Lucentis for the treatment of DME in 2012, the use of intravitreal injections was less common in North America and laser photocoagulation, or the use of light to coagulate tissue, was the primary treatment. Prior to the Lucentis DME approval, several treatments including Avastin and Macugen (pegaptanib sodium injection) were used <span style="white-space:nowrap">off-label.</span> Macugen received <span style="white-space:nowrap">FDA-approval</span> for the treatment of Wet AMD in 2004. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional products were approved and launched in 2014, namely Eylea, Ozurdex (dexamethasone intravitreal implant), and Iluvien (fluocinolone acetonide intravitreal implant), as well as the approval in 2022 of Vabysmo. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
According to estimates by Future Market Insights, intravitreal injections control a large market share of the treatment used in DME patients. In 2021, over 94% of DME patients were utilizing anti-VEGF intravitreal injections and implants, according to the same source. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current treatment options for Wet AMD </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucentis, Eylea, and Vabysmo were initially <span style="white-space:nowrap">FDA-approved</span> for the treatment of Wet AMD and DME. Avastin is used <span style="white-space:nowrap">off-label</span> for the treatment of Wet AMD. Because anti-VEGF treatments do not appear to cause regression of new blood vessels, current therapies require regular intraocular injections, typically as often as seven times per year, and real-world studies indicate that less than 20% of patients treated with anti-VEGF biologics improve their visual acuity by 15 or more letters. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to frequent injections, anti-VEGF treatments have been associated with subretinal fibrosis, or the formation of excess connective tissue under the retina, as well as retinal scarring in some patients. We believe a more effective therapy that requires less frequent dosing would address the deficiencies of current therapy and be rapidly adopted as the new standard of care for the treatment of the disease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background and market opportunity for DME and Wet AMD </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DME is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and studies show that DME patients utilize significantly higher healthcare resources than <span style="white-space:nowrap">non-DME</span> diabetic patients. The growing incidences of diabetes across the globe should further increase the burden of DME. As of 2022, nearly 422&#160;million people worldwide have diabetes, and the number is expected to grow to 592 million within the next 20 years, according to Future Market Insights. North America is projected to be the largest market in terms of value and accounted for over 60% of total market revenue in 2021, according to the same source. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMD is a progressive disease that results in a gradual loss of vision as people age. Approximately up to 10% of total cases of AMD represent an advanced form of the disease called Wet AMD, which is a severe eye condition that results in blurred vision and can lead to significant vision loss or blindness due to abnormal blood vessel formation in the eye. Although Wet AMD represents only 10% of AMD, it is responsible for 90% of <span style="white-space:nowrap">AMD-related</span> severe vision loss. Wet AMD is a leading cause of vision loss, with approximately 200,000&#160;cases of Wet AMD diagnosed per year in North America, according to ResearchAndMarkets.com. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, Eylea and Lucentis, the leading approved biologics for the treatment of DME and Wet AMD accounted for over $10.4&#160;billion in worldwide sales according to company filings. It is important to note that the first biosimilar for Lucentis was approved in the third quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential <span style="white-space:nowrap">ABP-201</span> Competitive Advantages </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike Eylea and Lucentis, <span style="white-space:nowrap">ABP-201</span> seeks to inhibit both VEGF and <span style="white-space:nowrap">ANG-2.</span> Unlike Vabysmo, <span style="white-space:nowrap">ABP-201</span> has two binding sites for VEGF and <span style="white-space:nowrap">ANG-2,</span> designed to more effectively trap each ligand. <span style="white-space:nowrap">ABP-201</span> also has a longer half-life in the eye than Eylea, which contributes to pharmacological durability. </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clinical Development Plan for Wet AMD </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to conduct a Phase 1, multiple-ascending dose evaluation of the safety and initial efficacy of <span style="white-space:nowrap">ABP-201</span> in patients with wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD). Following the identification of the maximum tolerated dose (MTD) or the safety and tolerability of the maximum administered dose (MAD), a larger randomized phase 2 study is planned. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential benefits of <span style="white-space:nowrap">ABP-201</span> in ophthalmology </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One way to <span style="white-space:nowrap">co-inhibit</span> VEGF and <span style="white-space:nowrap">ANG-2</span> is to add an <span style="white-space:nowrap">ANG-2</span> inhibitor to an approved VEGF inhibitor. The shortcoming of this approach is that the two agents are not physically linked and as a result will accumulate differently and be cleared from the eye at different rates. It is therefore difficult to ensure that both targets are inhibited in the same place at the same time. In contrast to this dual agent approach, other investigational agents, including <span style="white-space:nowrap">ABP-201,</span> use a single-agent dual-targeting antibody to ensure that both targets are engaged at the same time. Clinical trial results with Vabysmo, a bispecific antibody <span style="white-space:nowrap">co-targeting</span> VEGF and <span style="white-space:nowrap">ANG-2,</span> showed a dose-dependent improvement in best-corrected visual acuity relative to Lucentis, providing strong support for this approach. Importantly, our single agent approach may have regulatory advantages over the dual agent approach given that the necessary efficacy endpoints for approval could include <span style="white-space:nowrap">non-inferiority</span> in contrast with superiority to current <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care.</span></span> The dosing regimens of current DME and AMD drugs, specifically Lucentis and Eylea, are characterized by relatively frequent injections, initially every month followed by every other month. The frequency of injection is determined by a combination of the potency of the drug and its clearance rate from the eye. Large molecules generally clear slower than smaller molecules, and <span style="white-space:nowrap">ABP-201</span> is approximately twice the size of Eylea and approximately four times the size of Lucentis. <span style="white-space:nowrap">ABP-201</span> also has a higher binding capacity than either Eylea or Lucentis, with two binding sites for VEGF and two binding sites for <span style="white-space:nowrap">ANG-2.</span> As such, we believe that <span style="white-space:nowrap">ABP-201</span> will require less frequent dosing, providing a significant advantage in the commercial setting. In addition, as increased signaling by <span style="white-space:nowrap">ANG-2</span> in response to anti-VEGF therapy is one of the primary mechanisms of resistance to VEGF inhibitors, we anticipate that <span style="white-space:nowrap">ABP-201</span> will not suffer from drug resistance to the same extent as drugs that target VEGF alone. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a rat laser-induced choroidal neovascularization model, <span style="white-space:nowrap">ABP-201</span> administered intravitreally resulted in comparable reductions in vascular leakage and vascular lesion volume as Eylea. In this model, a laser is used to ablate blood vessels in the choroid (the vascular layer underlying the retina). The area ablated then heals (becomes revascularized) spontaneously by the formation of neovascular &#8220;lesions.&#8221; Anti-angiogenic agents can then be assessed by how much they can delay this healing, as measured by how well they can reduce vascular leakage and neovascular lesion size. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g02p02.jpg" alt="LOGO"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Source: Ora, Inc., CNV Study with Intravitreally-injected Abpro Test Article ABP201 in Brown Norway Rats, December&#160;20, 2023.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmacological durability is desired in agents administered intravitreally injection given the risk of injection-associated inflammation and the uncomfortable nature of the injection. A major contributing factor to pharmacological durability is half-life. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Administration of <span style="white-space:nowrap">ABP-201</span> resulted in significantly reduced vascular leakage and neovascular lesion volume compared to a vehicle control and comparable to Eylea. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A major concern for all intravitreally-administered agents is the potential for inflammation, either caused by the agent or the injection procedure. Given that intravitreal injection itself is associated with the potential for ocular inflammation among other toxicities, increasing the pharmacological durability of such agents is critical in minimizing the potential for such toxicities. As such, <span style="white-space:nowrap">ABP-201</span> is engineered to both maximize half-life in the eye and to reduce any Fc receptor-mediated inflammatory responses. In preclinical PK models, <span style="white-space:nowrap">ABP-201</span> displays a favorable ocular half-life compared to Faricimab (RG7716/Vabysmo) or Eylea (aflibercept). In addition, <span style="white-space:nowrap">ABP-201</span> is well tolerated in rabbit toxicity studies. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g03p03.jpg" alt="LOGO"/>
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g509388g04p03.jpg" alt="LOGO"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Source: PoweredResearch, Safety, Tolerability, and Pharmacokineti C Study Following Intravitreal (IVT) Delivery of a Novel Compound in Rabbit, April&#160;27, 2021.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Administration of <span style="white-space:nowrap">ABP-201</span> results in intraocular pressure (IOP) increases comparable to vehicle control (left panel above). Additionally, ocular examinations (OE) to evaluate ocular surface morphology, anterior segment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and posterior segment inflammation, cataract formation, and retinal changes were performed. The OE scores can range from 0, indicating no abnormalities, to 48, indicating a maximum number of maximally severe abnormalities. Other than a mild increase in OE score of 5 at day 1 post-injection, which returned to 0 for the duration of the study, the OE scores were identical to that of the vehicle control. Taken together, the lack of increases in IOP and OE scores suggests that <span style="white-space:nowrap">ABP-201</span> is well-tolerated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vitreous humor in the human eye is approximately 4 ml. Given the small volume of the vitreous humor, agents injected intravitreally must be able to be sufficiently concentrated so as to be injected in small enough volumes to not produce significant increases in IOP. Excessive increases in IOP resulting in ocular hypertension is associated with a variety of adverse events such as ocular inflammation, glaucoma, and retinal detachment. As such, <span style="white-space:nowrap">ABP-201</span> formulation efforts have achieved a 100 mg/ml concentration with acceptable biophysical characteristics, especially viscosity. We believe that this concentration will allow us to administer efficacious dose levels of <span style="white-space:nowrap">ABP-201</span> in small enough volumes to avoid toxic increases in IOP. Even so, preliminary evidence suggests that higher concentrations are achievable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other programs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional TetraBi antibody <span style="white-space:nowrap">T-cell</span> engagers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building on the <span style="white-space:nowrap">CD3-directed</span> TetraBi antibody format of <span style="white-space:nowrap">ABP-102,</span> we are using our <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms to develop a broad pipeline of immuno-oncology agents that target highly expressed antigens on a diverse range of tumor types. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-110</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-110</span> is a TetraBi antibody targeting GPC3 and CD3 for the potential treatment of hepatocellular carcinoma, or HCC, the major form of liver cancer. <span style="white-space:nowrap">ABP-110</span> is designed to bind bivalently to GPC3 on HCC cells and CD3 on cytotoxic T cells, bringing these two cell types into close proximity and triggering sustained <span style="white-space:nowrap">T-cell</span> activation and tumor cell killing. GPC3 is an onco-fetal antigen that is only expressed during fetal development and on HCC cells, making it an ideal tumor antigen target.&#8195;GPC3 expression is also prognostic of poor overall survival in HCC, suggesting that <span style="white-space:nowrap">ABP-110</span> may be most effective in the patients at highest risk and most in need of novel therapeutic interventions. Targeting this patient population may provide for a relatively rapid path to approval given the unmet medical need in HCC. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g05p04.jpg" alt="LOGO"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Source: Abpro internal data. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated three lead candidates that have displayed potent T cell-mediated killing of GPC3-positive tumor cells. The next steps are to assess the pharmacokinetics and in vivo efficacy in preclinical GPC3-positive tumor models. We expect to initiate clinical trials for <span style="white-space:nowrap">ABP-110</span> in the first half of 2027. According to SNS Insider, the global liver cancer therapeutics market is projected to reach $12.9&#160;billion by 2030. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">ABP-150</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-150</span> is a TetraBi antibody targeting claudin 18.2 and CD3 for the potential treatment of gastric cancers. Like our other T cell engagers, <span style="white-space:nowrap">ABP-150</span> is designed to bind bivalently to claudin 18.2 on gastric cancer cells and to CD3 on cytotoxic T cells, leading to T cell-mediated killing of gastric tumor cells. Claudin 18.2 is exclusively expressed on gastric tissue, a tissue with a high physiological turnover rate, making it tolerant of even moderate acute toxicity without unacceptable or chronic toxic effects. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g30k30.jpg" alt="LOGO"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Source: Abpro internal data.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g509388g31k31.jpg" alt="LOGO"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Source: Abpro internal data.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinically, <span style="white-space:nowrap">ABP-150</span> shows potent killing in in vitro T cell-mediated killing assays. In both mouse syngeneic tumor models using human <span style="white-space:nowrap">CD3-transgenic</span> mice and human tumor xenograft models using human peripheral blood mononuclear cells as a source of T cells, <span style="white-space:nowrap">ABP-150</span> shows potent efficacy. As <span style="white-space:nowrap">ABP-150</span> cross-reacts with mouse claudin 18.2, but not mouse CD3, we demonstrated in a human <span style="white-space:nowrap">CD3-transgenic</span> mouse toxicity model that <span style="white-space:nowrap">ABP-150</span> is well tolerated, with little impact on body weight, appetite (food consumption) or body temperature. <span style="white-space:nowrap">IL-6,</span> a key cytokine for the initiation of cytokine release syndrome, saw little increase over vehicle (placebo) control. The next steps are to evaluate toxicity in a <span style="white-space:nowrap">non-human</span> primate model. We expect to initiate clinical trials for <span style="white-space:nowrap">ABP-150</span> in the first half of 2027. According to Data Bridge Market Research, the global gastric cancer market is projected to reach $13.1&#160;billion by 2029. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> neutralizing antibody program </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October 2023, according to data published by the Word Health Organization, the COVID pandemic has resulted in over 771&#160;million confirmed cases and over 6&#160;million deaths have been reported globally. While vaccination efforts have made tremendous strides in bringing the pandemic under control, vaccination is contraindicated in some individuals, such as the immunocompromised. For these patients, there are no currently available prophylactic therapies. The only therapies available are Nirmatrelvir/ritonavir, molnupiravir, and remdesivir. While these are effective therapies, their toxicities preclude them from being used as prophylactics. Monoclonal antibodies are ideal molecules to serve as prophylactic therapies as they can effectively neutralize the <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> virus and have a proven safety profile and can be engineered to extend their half-lives. However, all antibody therapies and prophylactics to date have become ineffective due to <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> viral mutation. In response to the global pandemic, Abpro sought to develop COVID antibodies targeting highly conserved (resistant to mutation) areas of the virus with highly potent neutralizing antibodies engineered to have extended half-lives to allow for dosing intervals of greater than six months, through collaborations with third parties in the form of in-license agreements. Several candidate molecules were evaluated through different stages of development. The most advanced molecule was developed through GMP manufacturing and evaluated in a clinical trial. However, the clinical trial was not successful. Since the health threats from the COVID pandemic have now decreased, Abpro is not planning to focus on this area at this time. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Collaborations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing next generation antibodies both independently and in collaboration with leading global biopharmaceutical companies and <span style="white-space:nowrap">non-profit</span> and government research institutions. We <span style="white-space:nowrap">in-license</span> some of the technology that we use in the <span style="white-space:nowrap">ABP-110</span> and <span style="white-space:nowrap">ABP-201</span> molecules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">In-licensing</span> agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We <span style="white-space:nowrap">in-license</span> rights to intellectual property relevant or potentially relevant to our development and commercialization plans in the ordinary course of business. We have <span style="white-space:nowrap">in-licensed</span> rights to certain intellectual property from the National Institutes of Health, or NIH, and from AstraZeneca (formerly Medimmune). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">National Institutes of <span style="white-space:nowrap">Health&#8212;ABP-110</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017 we entered into a patent license agreement effective as of August&#160;1, 2017 with the National Cancer Institute, or NCI, a division of the NIH, pursuant to which we received an exclusive, worldwide license, with the right to sublicense (subject to certain conditions), under certain patent rights to make, have made, use, have used, sell, have sold, offer to sell and import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies for the treatment of liver cancer. The license was amended in May 2020 and October 2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of <span style="white-space:nowrap">GPC-3</span> expressing liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. We agreed to pay NCI a $25,000 issuance fee in connection with the October 2023 amendment to the patent license agreement. Under the amended patent license agreement, we will be obligated to pay a $25,000 minimum annual royalty, creditable against any earned royalties, and to pay royalties of a single digit percentage based on net sales of licensed products. We also agreed to pay up to an aggregate of approximately $16.0&#160;million of benchmark royalties, which are payable upon achieving certain clinical, regulatory and commercial milestones. We also agreed to pay sublicense royalties ranging from a <span style="white-space:nowrap">mid-single</span> digit percentage to a <span style="white-space:nowrap">low-double</span> digit percentage based on the fair value of the consideration we receive from any sublicensees. The royalty term expires on a licensed <span style="white-space:nowrap"><span style="white-space:nowrap">patent-to-licensed</span></span> patent and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis upon the earlier of (i)&#160;the date an application in the licensed patents has been abandoned, (ii)&#160;the date a licensed patent expires or (iii)&#160;the date a licensed patent has been held invalid or unenforceable by a court of competent jurisdiction or administrative agency. Unless earlier terminated, our agreement with NCI will expire upon expiration of all licensed patent rights. NCI may terminate our agreement upon the occurrence of specified bankruptcy events for us or if we are in material default or breach of the agreement and do not cure within a specified notice and cure period. NCI may terminate the agreement if necessary to meet the public use requirement specified by federal regulations and we are not reasonably satisfying such requirements. We may also terminate the agreement as to any licenses in any country or territory upon 60 days written notice. Upon expiration or termination of the agreement, we are required to return to NCI or destroy all licensed products and other materials in the licensed patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our license is subject to the reserved rights of NCI and the U.S. government. Additionally, all licensed products used or sold in the United States are required to be manufactured substantially within the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">AstraZeneca </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2016, we entered into a collaboration and license agreement through our majority-owned subsidiary, AbMed Corporation, or AbMed, and MedImmune (now AstraZeneca), pursuant to which MedImmune granted AbMed an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license under specified patent rights and <span style="white-space:nowrap">know-how</span> to make, use, sell certain of its proprietary <span style="white-space:nowrap">ANG-2/VEGF-H1RK</span> bispecific antibodies. We hold 82% of the capital stock of AbMed, and MedImmune (now AstraZeneca) holds the remainder. We are responsible for the operational activities of AbMed, and bear all costs necessary to operate AbMed. Our chief executive officer, Ian Chan, is also the chief executive officer of AbMed and oversees the business strategy and operations of AbMed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, AbMed agreed to pay milestone and royalty payments, including up to $244.0&#160;million in milestone payments, which are comprised of $14.0&#160;million upon meeting certain clinical development milestones, $80.0&#160;million upon achieving certain regulatory events and $150.0&#160;million upon meeting certain worldwide commercial sales thresholds; and tiered high-single digit to low teens percentage royalties based on annualized net sales of each product commercialized from our collaboration on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless earlier terminated in accordance with its terms, the agreement with AbMed and AstraZeneca remains in effect on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first commercial sale of a licensed product in a country, and (iii)&#160;the expiration of regulatory exclusivity for a licensed product in a country. AbMed could be required to redeem AstraZeneca&#8217;s equity stake in certain circumstances. We are in breach of the terms of our license agreement with AstraZeneca. See &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Relating to Abpro&#8217;s Business and Industry &#8212; Through our AbMed subsidiary, we have <span style="white-space:nowrap">in-licensed</span> certain intellectual property rights relating to <span style="white-space:nowrap">ABP-201</span> from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of the terms of our license agreement with MedImmune/AstraZeneca</span>.&#8221; AstraZeneca may terminate our agreement on the basis of this breach, or upon the occurrence of specified bankruptcy events for us or if we are in material default or breach of the agreement and do not cure within a specified notice and cure period. We may also terminate the agreement upon 90 days written notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, we entered into an amendment to this agreement pursuant to which Medimmune granted us a <span style="white-space:nowrap">non-exclusive</span> sublicense to certain additional intellectual property rights held by Medimmune under an agreement with EMD Millipore Corporation and the <span style="white-space:nowrap">know-how</span> included under the agreement was amended. In August 2017, we entered into a side letter with MedImmune to clarify our agreement regarding the timing of our required contribution to AbMed and the issuance of MedImmune&#8217;s equity stake. The agreement was further amended in November 2017, March 2018 and December 2019 to modify the dates for the achievement of certain development and commercialization milestones and AbMed agreed to use commercially reasonable efforts to reach these development and commercialization milestones within specified timeframes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Partnerships </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Celltrion </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-102</span> is being developed and commercialized through a worldwide strategic partnership with Celltrion Inc. (&#8220;Celltrion&#8221;) (KRX:068270), a leading Korean biopharmaceutical company headquartered in Incheon, South Korea, under a Collaboration Agreement entered into in September 2022. We received an initial milestone payment of $2.0 million from Celltrion in connection with this agreement. We also received an equity investment in our Series F preferred stock of $2.0&#160;million from Celltrion. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to form a joint steering committee to oversee the collaboration that includes representatives from both our company and Celltrion. Celltrion agreed to use commercially reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones by certain dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Collaboration Agreement, our company is responsible for certain in vitro <span style="white-space:nowrap">pre-clinical</span> work, and Celltrion is responsible for in vivo preclinical work, CMC, clinical development and commercialization on a worldwide basis. All costs and expenses for future development and commercialization of the molecule are required to be paid initially by Celltrion. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject to a 50/50 split. Following commercial approval of <span style="white-space:nowrap">ABP-102,</span> we have agreed to reimburse Celltrion 87.5% of its direct and certain indirect costs and expenses incurred through first commercial sale. Celltrion is entitled to offset amounts otherwise due to us under the agreement until our share of these costs has been paid back; provided that we are entitled to a minimum 25% of profit from commercial sales and from third party collaborators regardless of the amount of unreimbursed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development costs outstanding (and then 50% once the reimbursement has been made in full). In addition, we are entitled to up to over $1.75&#160;billion in development and sales milestones. We are responsible for world-wide patent prosecution, with Celltrion reimbursing 50% of our <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, our agreement with Celltrion will remain in effect so long as <span style="white-space:nowrap">ABP-102</span> is being developed or commercialized anywhere in the world.&#8195;Either party may terminate our agreement upon the occurrence of specified bankruptcy events relating to the other party.&#8195;We may terminate the agreement if Celltrion is in material default or breach of the agreement and does not cure within a specified notice and cure period. Celltrion may also terminate the agreement upon 180 days written notice. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Abpro Bio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">ABP-201</span> is being developed and commercialized through a territorial partnership with Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;), a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company formerly named Ugint Co Ltd. with diversified holdings in precision machine tools, equipment and biotechnology headquartered in Daegu, South Korea granting Abpro Bio exclusive development and commercialization rights under a Collaboration and License agreement entered into in January 2020, in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia, Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our company, through our majority owned subsidiary, AbMed Corporation received an equity investment of $30&#160;million from Abpro Bio in connection with this agreement. Under the Collaboration and License Agreement, we granted Abpro Bio an exclusive, royalty-bearing sublicenseable (subject to certain restrictions) license under specified patent rights and <span style="white-space:nowrap">know-how</span> to make, use, sell certain proprietary <span style="white-space:nowrap">ANG-2/VEGF-H1RK</span> bispecific antibodies in China, Japan, South Korea and certain other countries in South East Asia, the Middle East and the Commonwealth of Independent States (CIS). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to form a joint steering committee to oversee the collaboration that includes representatives from both AbMed Corporation and Abpro Bio. Abpro Bio agreed to use commercially reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones by certain dates. Under the agreement, Abpro Bio agreed to pay us a double-digit percentage royalty in the low teens, tiered based on cumulative net sales by Abpro Bio, its affiliates or sublicensees beginning with the first commercial sale of a licensed product in its territory. We are also entitled to payments totaling approximately $540&#160;million subject to the satisfaction of certain development and sales milestones. We are responsible for patent prosecution and Abpro Bio has agreed to reimburse us for patent costs in its licensed territory. Unless earlier terminated in accordance with its terms, the agreement with Abpro Bio remains in effect on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first commercial sale of a licensed product in a country, and (iii)&#160;the expiration of regulatory exclusivity for a licensed product in a country. We may terminate the agreement upon the occurrence of specified bankruptcy events relating to Abpro Bio or if Abpro Bio is in material default or breach of the agreement and does not cure within a specified notice and cure period. Abpro Bio may also terminate the agreement upon 90 days written notice. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">NJCTTQ </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a collaboration agreement in January 2019 with NJCTTQ, a pharmaceutical company specializing in research and development, production and commercialization of drugs for cardiovascular </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing, China. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to form a joint steering committee to oversee the collaboration that includes representatives from both our company and NJCTTQ. NJCTTQ paid a technology access fee to us and agreed to reimburse our preclinical research and development costs for the selected program up to CMC stage. Under the agreement, CMC development costs and GLP toxicology costs are shared equally, with each party thereafter being responsible for its own development and commercialization costs in its territory, with the NJCTTQ territory being China and Thailand and our company retaining rights to the rest of the world. The parties agreed to pay reciprocal royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory. In addition, NJCTTQ agreed to pay us milestones based on commercial approval and sales in its territory of up to $405&#160;million and we agreed to pay NJCTTQ a milestone based on commercial approval in our territory of $5&#160;million. ABP-150 is being developed under this agreement. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless earlier terminated in accordance with its terms, the initial term of this agreement is five years from its effective date, with automatic renewals for an additional five years unless objected to in writing by a party at least six months prior to expiration of the initial term. If no joint development program gets to clinical stage within the first five years of the collaboration, then the agreement by its terms will not be renewed after expiration. Either party has the right to terminate in the case of material default or breach of the agreement by the other party not cured within a specified period, in which case the parties&#8217; rights and obligations under the agreement are terminated, except for rights accrued prior to termination and customary survival clauses. If the agreement is terminated other than for cause, the territorial rights and payment obligations of each party relating to the development and commercialization of a licensed product in its territory survive such termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement remains unrenewed at this time after the expiration of its initial term. However, notwithstanding the agreement&#8217;s expiration, the low single-digit royalties and the $5 million milestone payable to NJCTTQ based on commercial approval in our territory, as described above, will continue to apply. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We produce small-scale quantities of our antibodies and reagents for characterization,<span style="font-style:italic">&#160;in vitro</span> and<span style="font-style:italic"> in vivo</span> preclinical assessment of product candidates at our Woburn, Massachusetts research and development facilities. We do not have, and we do not currently plan to acquire or develop, the infrastructure, facilities or capabilities to manufacture current Good Manufacturing Practices, or cGMP, bulk drug substance or filled drug product for use in human clinical trials. We intend to utilize third-party manufacturers such as contract manufacturing organizations, or CMOs, to produce, test and release cGMP bulk drug substance and drug product for our planned clinical trials. We expect to continue to rely on such third parties to manufacture clinical trial material for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and biopharmaceutical industries, and the immuno-oncology and ophthalmology subsectors, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary <span style="font-style:italic">DiversImmune</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">&#174;</sup></span> and <span style="font-style:italic">MultiMab</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span> platforms, along with our scientific expertise in the field of biologics and immuno-oncology, provide us with competitive advantages, a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions, are actively developing potentially competitive products and technologies. Our competitors generally fall within the following categories: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Antibody developers</span>. Such as Adimab Inc., AnaptysBio, Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Inc., Jounce Therapeutics, Inc., MorphoSys AG, Precigen, Inc. and Regeneron Pharmaceuticals, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Immune-based treatments for cancer, such as CAR T and TCR therapies</span>. Such as Bellicum Pharmaceuticals, Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Cellectis S.A., Gilead </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Sciences, Inc., Novartis AG, Precigen, Inc., AstraZeneca and Genentech, Inc. (a member of the Roche Group, or Genentech/Roche). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Treatments for Ophthalmology related indications</span>. Such as Allergan plc, Genentech/Roche, Novartis International AG, and Regeneron Pharmaceuticals, Inc. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or <span style="white-space:nowrap">non-competitive.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accelerated merger and acquisition activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. Competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products&#8217; entry, if any. We believe the factors determining the success of our product pipeline will be the efficacy, safety and convenience of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success will depend significantly on our and our licensors&#8217; ability to obtain and maintain patent and other proprietary protection for our product candidates and the other technology, inventions and improvements we consider important to our business, defend any patents we obtain or <span style="white-space:nowrap">in-license,</span> preserve the confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third parties. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing and <span style="white-space:nowrap">in-licensing</span> U.S., international (under Patent Cooperation Treaty, or PCT) and foreign patent applications related to our product candidates and other proprietary technology, inventions and improvements that we consider are important to the development and implementation of our business. We also rely on trade secrets, <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain our proprietary and intellectual property position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ABP-102</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we own two patent families that cover compositions of matter, methods of use, and methods of manufacture for our <span style="white-space:nowrap">ABP-102</span> product candidate, a bispecific HER2 and CD3 binding antibody. The first and second families each consist of one pending international Patent Cooperation Treaty (&#8220;PCT&#8221;) patent application. Any patents resulting from these applications would be expected to expire in 2042, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ABP-110</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have licensed one patent family from the US Department of Health and Human Services that covers compositions of matter, methods of use, and methods of manufacture related to our <span style="white-space:nowrap">ABP-110</span> product candidate, a tetravalent bispecific <span style="white-space:nowrap">glypican-3</span> (GPC3) and CD3 binding antibody. This family includes one issued patent in the United States and issued patents in China, Japan, South Korea, and Singapore. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The patents in this family are expected to expire in 2033, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ABP-150</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we own one patent family that covers compositions of matter, methods of use, and methods of manufacture for our <span style="white-space:nowrap">ABP-150</span> product candidate, a bispecific Claudin18.2 and CD3 binding antibody. This family includes applications that are currently pending in the United States, China, Europe, Japan, South Korea, and Thailand. The patents in this family are expected to expire in 2041, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ABP-201</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we own one patent family that covers compositions of matter, methods of use, and methods of manufacture for our <span style="white-space:nowrap">ABP-201</span> product candidate, which binds to both <span style="white-space:nowrap">angiopoietin-2,</span> or <span style="white-space:nowrap">ANG-2,</span> and vascular endothelial growth factor, or VEGF. This family includes a pending international PCT application and pending applications in the United States, China, Europe, Japan, and South Korea. Any patents resulting from that application would be expected to expire in 2042, excluding any patent term adjustments and/or extensions. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our majority-owned subsidiary AbMed Corporation, we have also exclusively licensed from MedImmune/AstraZeneca certain intellectual property originally entered in connection with ABP-200, which we are no longer developing. As of December&#160;31, 2023, we have licensed three patent families from MedImmune/AstraZeneca comprised of pending and/or issued U.S. and foreign patents and applications. The patents in these families are not expected to cover ABP-201 and/or are expected to expire before commercialization of ABP-201, excluding any patent term adjustments and/or extensions. We believe that we do not need the intellectual property licensed under this agreement for the development and eventual commercialization of ABP-201 or any of our other programs. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, one of these licensed patent families includes three issued U.S. patents, and issued patents in Australia, Brazil, China, Hong Kong, Japan, Mexico, Russia, South Korea, as well as pending applications in Europe and India. The patents in this family are expected to expire in 2025, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the second family of these licensed patent families includes two issued patents in the United States and issued patents in Australia, China, Japan, and South Korea, as well as pending applications in Canada, Europe, Hong Kong, and Israel. Any patents resulting from that application would be expected to expire in 2037, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the third family of these licensed patents includes two issued patents in the United States, and issued patents in Australia, China, Europe, Hong Kong, Japan, and South Korea, as well as pending applications in Australia, Canada, Europe, Hong Kong, and Israel. Any patents resulting from that application would be expected to expire in 2037, excluding any patent term adjustments and/or extensions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory framework </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20&#160;years from the earliest filing date of a <span style="white-space:nowrap">non-provisional</span> patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed <span style="white-space:nowrap">co-owned</span> patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. However, as to the FDA component, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following the FDA approval. Additionally, only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any of our patents. The FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. An extension may also not be granted because of, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to the expiration of relevant patents, or otherwise failing to satisfy applicable requirements. The actual protection afforded by a patent varies on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, from <span style="white-space:nowrap"><span style="white-space:nowrap">country-to-country,</span></span> and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. In addition to patents, we rely upon unpatented trade secrets and <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> confidentiality and invention assignment agreements with our employees and consultants. We also have or intend to implement executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. These confidentiality agreements are designed to protect our proprietary information and, in the case of invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. However, these agreements may be breached, and we may not have adequate remedies for any breach, with a third party. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for use, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. To the extent that our employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. For more information regarding the risks related to our intellectual property, proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to Intellectual Property.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government regulation and product approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Governmental authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing, and export and import of products such as those we are developing. Our therapeutic product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Government regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and, in the case of therapeutic biologics, the Public Health Service Act, or PHSA, and implementing regulations of each. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to approve pending applications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of an approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning or untitled letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seizures or administrative detention of product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">total or partial suspension of production or distribution; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions, fines, disgorgement, or civil or criminal penalties. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">BLA approval process </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a therapeutic biologic may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLPs, and other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND, which must become effective before human clinical trials may begin, and applicable institutional review boards (IRBs)/ ethics committee approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCPs, to establish the safety and efficacy of the product candidate for its intended use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of a BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with cGMPs to assure that the facilities, methods, and controls are adequate to preserve the product candidate&#8217;s identity, strength, quality, and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection at selected clinical research sites, the contract research organization if the monitoring of the study was outsourced, and/or inspection of the Sponsor organization to assess GCP compliance may also be required and; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the BLA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity, and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <span style="white-space:nowrap">30-day</span> time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria, and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected suspected adverse reactions in a timely manner, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigation brochure or any findings from other studies or animal or<span style="font-style:italic">&#160;in vitro</span>&#160;testing that suggest a significant risk in humans exposed to the product candidate. An IRB at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the informed consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the study until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 1</span></span>&#8212;The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 2</span></span>&#8212;Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 3</span></span>&#8212;Clinical trials are undertaken to further evaluate dosage, clinical efficacy, and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A pivotal study is a clinical study that adequately meets regulatory agency requirements for the evaluation of a product candidate&#8217;s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal studies are also Phase 3 studies but may be Phase 2 studies if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. Human clinical trials are inherently uncertain, and Phase 1, Phase 2, and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a new product candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before a BLA or New Drug Application, or NDA, is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of such &#8220;Phase 4&#8221; clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate, and finalize a process for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer must develop methods for testing the quality, purity, and potency of the product candidate. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its proposed shelf-life. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of product development, nonclinical studies, and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, proposed labeling, and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for products and an annual establishment fee on facilities used to manufacture prescription biological or drug products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, plan is necessary to assure the safe use of the product. If the FDA concludes a REMS plan is needed, the sponsor of the BLA must submit a proposed REMS plan. The FDA will not approve a BLA without a REMS plan, if required. The FDA has authority to require a REMS plan to ensure that the benefits of a drug or therapeutic biologic outweigh the risks. Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control. Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Post-approval requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product candidate reaches the market. Later discovery of previously unknown problems with a product candidate may result in restrictions on the product candidate or even complete withdrawal of the product candidate from the market. After approval, some types of changes to the approved product candidate, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved therapeutic candidates that have been commercialized, and the FDA under some circumstances has the power to prevent or limit further marketing of a product candidate based on the results of these post-marketing programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any therapeutic candidates manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">record-keeping requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reporting of adverse experiences with the product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing the FDA with updated safety and efficacy information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product sampling and distribution requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complying with FDA promotion and advertising requirements, which include, among other things, standards for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record-keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations would also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use if our product candidates are approved. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Orphan Drug Act </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition &#8212; generally a disease or condition that affects fewer than 200,000 individuals in the United </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the BLA application user fee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New legislation and regulations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance documents, and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further new legislation will be enacted or FDA regulations, guidance documents, policies, or interpretations changed or what the effect of such changes, if any, may be. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Review and approval of drug products outside the United States </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any drug product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales, and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pharmaceutical coverage, pricing and reimbursement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product candidate could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs also has become a priority of federal, state and foreign governments and other third-party payors, and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring adequate coverage and payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require a clinical trial that compares the cost effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Healthcare law and regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians, patient privacy laws and regulations, and other healthcare laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, arrange for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violation of the federal Anti-Kickback Statue carries criminal penalties and fines as well as administrative sanctions under the Civil Money Penalties Law. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit an individual or entity from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
knowingly and willingly falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing, or covering up a material fact, or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created by the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous local, state, and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services that are reimbursed by third-party payors, including private insurers; local, state, and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other health care providers and health care entities, or marketing expenditures; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the locale and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines or relevant compliance guidance promulgated by the federal government; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any such requirements, we may be subject to sanctions, including criminal fines, significant civil monetary penalties, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Healthcare reform </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% as of January&#160;1, 2019 and further revised, effective January&#160;1, 2025 under the IRA), <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Effective January&#160;1, 2025, certain provisions of the Inflation Reduction Act of 2022 will reduce Medicare Part D beneficiaries&#8217; annual <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> maximum from $7,050 to $2,000, thereby effectively eliminating the coverage gap. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In August 2011, the Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress, including a reduction of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, this will remain in effect through 2030 unless additional Congressional action is taken. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The U.S. American Taxpayer Relief Act of 2012 was signed into law in 2013, which among other things, further reduced Medicare payments to several types of providers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On May&#160;30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Further Consolidated Appropriations Act, signed into law in 2019, repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instituted in the future. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to product pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of therapies under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. It is unclear what effect such legislative and enforcement interest may have on our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, on December&#160;13, 2016, President Obama signed the 21st Century Cures Act, or Cures Act, into law. Among other provisions, the Cures Act reauthorized the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2020; created a new priority review voucher program for drug applications determined to be material national security threat medical countermeasure applications; revised the FDCA to streamline review of combination product applications; required FDA to evaluate the potential use of &#8220;real world evidence&#8221; to help support approval of new indications for approved drugs; provided a new &#8220;limited population&#8221; approval pathway for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorized FDA to designate a drug as a &#8220;regenerative advanced therapy,&#8221; thereby making it eligible for certain expedited review and approval designations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we received for any approved product, which could have an adverse effect on customers for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop products. If we, or any third parties we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 2024, we have 20 full-time employees and one part-time employee; 13 of whom are primarily engaged in research and development activities and 6 of whom have an M.D. or Ph.D. degree. None of our employees are represented by a labor union or covered by a collective bargaining agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We occupy approximately 13,974 square feet of office and laboratory space in Woburn, Massachusetts, under a lease that expires on September&#160;30, 2025, which we use for our corporate headquarters as well as certain of our research and development activities. We occupy approximately 2,800 square feet of office and laboratory space in Burlington, Massachusetts, under a lease that expires on April&#160;30, 2025, which we use primarily for research and development activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2023, we entered into a settlement agreement with Parexel International (IRL) Limited relating to payment obligations arising out of a clinical trial performed by Parexel, which was <span style="white-space:nowrap">co-financed</span> by our company and Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062), a biopharmaceutical company headquartered in Shanghai, China (&#8220;Mabwell&#8221;). Our company made some but not all installment payments due under the settlement agreement and Parexel filed a complaint in Superior Court in Middlesex County, Massachusetts in April 2023. Parexel subsequently amended the complaint twice and filed a motion for default judgment in September 2023 seeking contractual damages of approximately $640,000 plus additional damages under Massachusetts Chapter&#160;93A for deceptive business practices. A hearing on the motion was held on January&#160;9, 2024. The court asked for additional submissions by January&#160;16, 2024 and indicated that a ruling would follow thereafter. On January&#160;26, 2024, the court entered a judgment in the case awarding Parexel a total of approximately $700,000 and rejecting Parexel&#8217;s claim under Chapter 93A. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2022, we received an invoice from Mabwell in connection with the manufacturing of certain clinical material for approximately $3.5&#160;million. We dispute the amount and its contractual basis but have engaged in discussion with Mabwell to resolve this matter amicably. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into an Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;), which was subsequently amended by Amendment No.&#160;1 to Exclusive License Agreement dated March&#160;31, 2017, Amendment No.&#160;2 to Exclusive License Agreement dated March&#160;31, 2018, and Amendment No.&#160;3 to Exclusive License Agreement dated December&#160;31, 2019 (collectively, the &#8220;Exclusive MSK License Agreement&#8221;). In June 2023, we received a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling at least $1,060,404.91 in principal and $169,173.45 in interest. We do not dispute the payment obligations under the Exclusive MSK License Agreement and have not made the payment to preserve cash. We have contacted MSK about possible settlement and are evaluating a counterproposal received from MSK in February 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are unable to predict the ultimate outcome of these matters, the timing of any final decisions of various agencies or courts, or the impact on our results of operations, financial condition or cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_21">ABPRO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, and cash flows of our company as of and for the periods presented below. The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes and other financial information included elsewhere in this proxy statement/prospectus. The discussion and analysis should also be read together with the section of this proxy statement/prospectus entitled &#8220;Information About Abpro&#8221; and the unaudited pro forma condensed combined financial information in the section of this proxy statement/prospectus entitled &#8220;Unaudited Pro Forma Condensed Combined Financial Information.&#8221; The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Actual results and timing of selected events could differ materially from those discussed or implied by the forward-looking statements as a result of various factors, including those discussed below and detailed elsewhere in this proxy statement/prospectus, particularly in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements; Summary Risk Factors; Market, Ranking and Other Industry Data.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Abpro,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and other similar terms refer to Abpro Corporation and its subsidiaries prior to the Business Combination and to the Company and its consolidated subsidiaries after giving effect to the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. We are focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging our proprietary DiversImmune<sup style="font-size:75%; vertical-align:top">&#174;</sup> and MultiMab<sup style="font-size:75%; vertical-align:top">TM</sup> antibody discovery and engineering platforms, we are developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our two lead product candidates, <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201,</span> feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target. <span style="white-space:nowrap">ABP-102</span> is designed to redirect a patient&#8217;s immune system to fight cancer by engaging T cells through <span style="white-space:nowrap">co-targeting</span> human epidermal growth factor receptor 2, or HER2, and cluster of differentiation 3, or CD3, <span style="white-space:nowrap">T-cell</span> <span style="white-space:nowrap">co-receptor.</span> We plan initially to develop <span style="white-space:nowrap">ABP-102</span> for difficult to treat HER2+ solid tumors, focusing on orphan indications. <span style="white-space:nowrap">ABP-201</span> is designed to block blood vessel formation and normalize damaged vessels through <span style="white-space:nowrap">co-targeting</span> vascular endothelial growth factor, or VEGF, and <span style="white-space:nowrap">angiopoietin-2,</span> or <span style="white-space:nowrap">ANG-2.</span> We plan to develop <span style="white-space:nowrap">ABP-201</span> to treat vascular disease of the eye, focusing on wet <span style="white-space:nowrap">age-related</span> macular degeneration (Wet AMD). We intend to follow these two lead product candidates with a broad pipeline of <span style="white-space:nowrap">CD3-targeting</span> <span style="white-space:nowrap">T-cell</span> engagers based on the differentiated format of <span style="white-space:nowrap">ABP-102.</span> We expect to initiate clinical trials for <span style="white-space:nowrap">ABP-102</span> in the second half of 2025 and for ABP-201 in the first half of 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Impact of Macroeconomic Events </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Economic uncertainty in various global markets caused by political instability and conflicts, such as the ongoing conflicts in the Ukraine, and Israel, and economic challenges have led to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions, which have caused record inflation globally. Our business, financial condition, and results of operations could be materially and adversely affected by further negative impacts on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen. Although, to date, our results of operations has not been materially impacted by these global economic and geopolitical conditions, it is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impossible to predict the extent to which our operations may be impacted in the short and long term. The extent and duration of these market disruptions, whether as a result of the military conflict between Russia and Ukraine, the effects of the Russian sanctions, the conflict between Israel and Hamas, geopolitical tensions, record inflation, or otherwise, are impossible to predict. Any such disruptions may also magnify the impact of other risks described or incorporated by reference in this proxy filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Results of Operations for the Years Ended December 31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a comparative discussion of our results of operations for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:73%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For the Years Ended<br/>December 31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">2023</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">2022</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom" align="center"><span style="font-size:8pt"><span style="font-weight:bold">Change</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-size:8pt"><span style="font-weight:bold">%</span></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,900</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,907</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-94</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,754</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,488</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-56</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,358</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,846</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from Operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,685</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-30</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(200</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-120</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,706</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,215</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-32</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Collaboration revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration revenue decreased during the year ended December&#160;31, 2023 compared to the prior period by </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$1.9&#160;million. This decrease was primarily driven by the revenue of $1.9&#160;million recognized under the collaboration agreement with Celltrion related to <span style="white-space:nowrap">ABP-102</span> in 2022. We did not generate any material revenue during the year ended December&#160;31, 2023. Our ability to generate product revenues in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate, or enter into collaborations that provide for payments to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies and clinical materials. The following tables summarize our research and development expenses by product candidate and program for the years ended December&#160;31, 2023 and 2022: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ABP-110</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ABP-102</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ABP-150</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ABP-201</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ABP-100</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SARS-CoV-2 neutralizing antibody program</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Unallocated research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">4,266</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">$</span><span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="font-weight:bold"></span><span style="font-weight:bold">9,754</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses include engineering platform-related expenses that are not allocable to a specific product candidate or program, as well as stock-based compensation, other employee-related expenses that are not related to a specific product candidate or program, and facilities and depreciation expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased by $5.5&#160;million for the year ended December&#160;31, 2023 as compared to the year ended December&#160;31, 2022 primarily due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A decrease of $4.5&#160;million in expenses associated with the research programs for the development of <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> neutralizing antibodies responsible for COVID </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A decrease of $0.8&#160;million in milestone payments. In 2022 the Company made payments under the exclusive license agreement with Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;) for the research and development of <span style="white-space:nowrap">ABP-100.</span> The MSK License Agreement was terminated in September 2023. </p></td></tr></table> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In response to the global pandemic, Abpro prioritized the development of therapeutic COVID-neutralizing antibodies through an internal discovery program and through collaborations with third parties in the form of in-license agreements. Several candidate molecules were evaluated through different stages of development. The most advanced molecule was developed through GMP manufacturing and evaluated in a clinical trial, which represented a significant portion of the Research and development expenses above. However, the clinical trial was not successful. Since the health threats from the COVID pandemic have now decreased, Abpro is not planning to focus on this area at this time. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of compensation and benefits to our personnel, including the costs related to our management services agreements, directors, and senior advisors; professional service fees, including accounting and legal services and other consulting services. General and administrative expenses decreased by $1.4&#160;million for the year ended December&#160;31, 2023 as compared to the year ended December&#160;31, 2022 primarily due to the decrease in stock-based compensation in connection with the issuance of options for consulting services in 2022 with the fair value of $1.7&#160;million that were fully vested at the issuance date. The decrease was offset by an increase of $0.4&#160;million in accounting and audit fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income (Expenses), Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expenses), net increased by $240&#160;thousand, to $40&#160;thousand in income for the year ended December&#160;31, 2023 from ($200) thousand in expenses for the year ended December&#160;31, 2022. This change is primarily due to $225&#160;thousand in interest expenses attributable to interest accrued on unpaid vendor invoices incurred during the year ended December&#160;31, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidity, Capital Resources and Going Concern </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has financed its operations primarily through the sale of equity securities and issuance of promissory notes and, to a lesser extent, through the revenue from collaboration arrangements. Since its inception, the Company has incurred significant recurring losses, including a net loss of $11.7&#160;million and $17.2&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023, the Company had an accumulated deficit of $105.6&#160;million. The Company expects to incur operating losses for the foreseeable future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without giving effect to the anticipated net proceeds from the Business Combination and the PIPE Investment, the Company expects that its existing cash and cash equivalents will be insufficient to fund our operations, including clinical trial expenses and capital expenditure requirements, for at least the next 12 months from the original issuance date of our consolidated financial statements as of December&#160;31, 2023. To finance our operations beyond that point, we would need to raise additional capital, which cannot be assured. We have concluded that these circumstances raise substantial doubt about our ability to continue as a going concern within one year after the original issuance date of our annual financial statements. We believe that the estimated net proceeds, assuming the maximum redemption scenario, of $29&#160;million from the Business Combination and the PIPE Investment, together with our existing cash and cash equivalents, will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could exhaust its available capital resources sooner than it expects. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2023, the Company entered into a promissory note agreement with Abpro Bio International, Inc. (&#8220;ABI&#8221;) to fund up to $6&#160;million. The Company received $4.2&#160;million through the date of filing of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Future Funding Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects its expenses to increase in connection with its ongoing activities, particularly as it advances the preclinical activities and clinical trials of its product candidates. In addition, upon the Closing of the merger, the Company expects to incur additional costs associated with operating as a public company. The timing and amount of the Company&#8217;s operating expenditures will depend largely on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for the Company&#8217;s current or future product candidates, particularly the planned Phase 1/2 clinical trial for <span style="white-space:nowrap">ABP-102</span> in the second half of 2025, focusing on HER2+ breast and gastric cancers, as well as Phase 1 clinical trials for <span style="white-space:nowrap">ABP-201</span> in the first half of 2026 for the treatment of Wet AMD; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical development plans The Company establishes for its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and characteristics of product candidates and programs that The Company develops or may <span style="white-space:nowrap">in-license;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that the Company perform more studies for its product candidates than those that the Company currently expects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Company&#8217;s ability to obtain marketing approval for its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of filing, prosecuting, defending and enforcing the Company&#8217;s patent claims and other intellectual property rights covering its product candidates, including any such patent claims and intellectual property rights that The Company has licensed pursuant to the terms of its license agreement; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company&#8217;s ability to maintain, expand and defend the scope of its intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against the Company or its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to the Company&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Company&#8217;s ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent the Company retains development or commercialization responsibilities under any new licensing, collaboration or similar arrangement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which the Company may receive regulatory approval in regions where The Company chooses to commercialize its products on its own; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of any other business, product or technology that the Company acquires or in which The Company invests; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Company&#8217;s need and ability to hire additional management and scientific and medical personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs to operate as a public company in the United States, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for The Company&#8217;s business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market acceptance of the Company&#8217;s product candidates, to the extent any are approved for commercial sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as the Company can generate substantial product revenue, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of the Company may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of the Company&#8217;s stockholders and the rights of the stockholders of the combined organization following the Closing of the merger. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit the Company&#8217;s ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds through equity or debt financings or other arrangements when needed, the Company may be required to delay, scale back or discontinue the development and commercialization of one or more of its product candidates or delay its pursuit of potential <span style="white-space:nowrap">in-licenses</span> or acquisitions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the years ended December&#160;31, 2023, and 2022: </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">For&#160;the&#160;Years&#160;Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,402</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,952</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-17</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(48</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-26</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-91</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&#160;31, 2023 decreased by $1.5&#160;million as compared to the year ended December&#160;31, 2022. The decrease was primarily driven by the decrease in the research and development expenses of approximately $5.5&#160;million, offset by the decrease in share-based compensation of $1.7&#160;million and $2.2&#160;million net changes in operating assets and liabilities mainly attributed to a decrease in accounts payable due to repayment with limited spending and an increase in accounts receivables due to receipt of outstanding AR from a collaboration agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities decreased by $17&#160;thousand for the year ended December&#160;31, 2023 as compared to the year of 2022. The Company purchased the lab equipment for $48&#160;thousand during year ended December&#160;31, 2023 and capitalized $65&#160;thousand in patent costs during the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities decreased by $8.9&#160;million for the year ended December&#160;31, 2023 as compared to the year ended December&#160;31, 2022. During the year ended December&#160;31, 2023 the Company received proceeds of $1.4&#160;million from a promissory note with ABI as compared to proceeds of $10&#160;million received from the issuance of Series F Preferred Stock in 2022. In addition, the Company paid $0.4&#160;million in offering costs in connection with the Business Combination during the year ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Critical Accounting Policies and Estimates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with US&#160;GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described below. We believe that the accounting policies are critical for fully understanding and evaluating our financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Share-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for share-based payments in accordance with Accounting Standard Codification Topic 718, Compensation&#8212;Stock Compensation (&#8220;ASC 718&#8221;). Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and <span style="white-space:nowrap">non-employees)</span> based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to stock compensation expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the exercise prices of options granted, the Company&#8217;s Board has considered the fair value of the common stock as of the measurement date. The fair value of the common stock has been determined by the Board at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s proposed products, an evaluation or benchmark of the Company&#8217;s competition, the current business climate in the marketplace, the illiquid nature of the common stock, arm&#8217;s length sales of the Company&#8217;s capital stock, including convertible preferred stock, the effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the awards is estimated based on the simplified method for grants to employees and is based on the contractual term for <span style="white-space:nowrap">non-employee</span> awards. The risk- free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on history and expectation of paying no dividends. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Convertible Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Emerging Growth Company Status </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply <span style="white-space:nowrap">to&#160;non-emerging&#160;growth</span> companies but any such election to opt out is irrevocable. Abpro has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Post-Combination Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Post-Combination Company&#8217;s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.235&#160;billion or more; (b)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of the initial public offering of ACAB; (c)&#160;the date on which it has issued more than $1&#160;billion in nonconvertible debt during the previous three years; or (d)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior second fiscal quarter end. For so long as the Post-Combination Company remains an emerging growth company, it is permitted and intends to rely on exemptions from certain disclosure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Recent Accounting Pronouncements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 2<span style="font-style:italic">, Summary of Significant Accounting Policies</span><span style="font-style:italic"></span>&#160;of the Notes to the Financial Statements for a discussion of recent accounting pronouncements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_22">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF ABPRO </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of shares of Abpro capital stock as of February&#160;29, 2024 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is known to be the beneficial owner of more than 5% of the outstanding shares of Abpro capital stock as of such date; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Abpro&#8217;s current executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all executive officers and directors of Abpro as a group prior to the consummation of the Business Combination. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable, exercisable within 60 days, or exercisable as a result of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The beneficial ownership of shares of Abpro capital stock prior to the consummation of the Business Combination is based on (i)&#160;9,381,408 shares of Abpro common stock issued and outstanding and (ii) 9,725,520 shares of Abpro common stock issuable upon conversion of Abpro preferred stock issued and outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, Abpro believes that all persons named in the table below have sole voting and investment power with respect to the voting securities beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:57%"/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Shares&#160;of<br/>Common Stock<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;of&#160;Shares&#160;of<br/>Common&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">5% Holders of Abpro</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abpro Bio International, Inc.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,677,925</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orion Investment Holdings Limited<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">987,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and Executive Officers of Abpro</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,288,144</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,420,973</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Mitrano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Zapf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158,750</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Markelewicz</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">358,355</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(9)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Wook (Miles) Suk</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">336,041</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(10)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">364,455</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(11)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C. Mark Tang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,708</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(12)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Abpro directors and executive officers as a group (8 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,969,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise noted, the business address of each of the following entities or individuals is c/o Abpro Corporation, 68 Cummings Park Drive, Woburn, MA 01801. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Interests shown consist of Abpro common stock and preferred stock of Abpro on an <span style="white-space:nowrap">as-converted</span> basis to common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address for Abpro Bio International, Inc. is 139, Techno jungang-daero, Yuga-myeon, <span style="white-space:nowrap">Dalseong-gun,</span> Daegu, Republic of Korea. Abpro Bio International, Inc. is a subsidiary of Abpro Bio Co. Ltd, a publicly traded company listed on the KOSDAQ market of the Korea Exchange (KOSDAQ: 195990). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address for Orion Investment Holdings Limited is Unit 2302, 23/F, New World Tower 1, 18 Queen&#8217;s Road, Central, Hong Kong. Ms. Mui Fan Juliet Chui is the sole owner and director of Orion. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 2,929,515 shares of common stock, 3,303,966 shares of common stock issuable upon conversion of 3,303,966 shares of Series E Preferred Stock, and 444,444 shares of common stock issuable upon conversion of 444,444 shares of Series F Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 3,192,199 shares of common stock and 1,095,945&#160;shares of common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 1,420,973&#160;shares of common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 158,750&#160;shares of common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 358,355&#160;shares of common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 36,041&#160;shares of common stock held directly and 300,000 shares of common stock underlying options that are currently exercisable or exercisable within 60 days after February&#160;29, 2024 held by Biocelsus International Co. Ltd., an entity controlled by Mr. Suk. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 199,973&#160;shares of common stock and 164,482 shares of common stock underlying options that are currently exercisable or exercisable within 60&#160;days after February&#160;29, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 17,708&#160;shares of common stock and 25,000&#160;shares of common stock underlying options that are currently exercisable or exercisable within 60&#160;days after February&#160;29, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_23">MANAGEMENT AND BOARD OF THE POST-COMBINATION COMPANY FOLLOWING THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Directors After the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following persons are expected to serve as executive officers and directors of the Post-Combination Company upon consummation of the Business Combination: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">Ian Chan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">51</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Robert J. Markelewicz, Jr., M.D., M.M.Sc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">Richard J. Mitrano</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">SVP of Finance</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Christian Zapf</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">55</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">SVP of Corporate Development and General Counsel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">Jin Wook (Miles) Suk</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Ian Chan</span> has served as Abpro&#8217;s Chief Executive Officer since January 2020 and has served on its board of directors since <span style="white-space:nowrap">co-founding</span> Abpro in 2004. Mr.&#160;Chan previously served as Abpro&#8217;s Chief Executive Officer from 2004 to 2018 and Chairman of its board of directors from 2004 to January 2020. Mr.&#160;Chan served as <span style="white-space:nowrap">co-Chief</span> Executive Officer and as a director of Abpro Bio. Co. Ltd. (KOSDAQ: 195990) from August 2019 to November 2023. Mr.&#160;Chan earned an A.B. in Biology and Economics from Brown University and an M.B.A. from the Harvard Business School. We believe Mr.&#160;Chan&#8217;s experience on Abpro&#8217;s board of directors and as Abpro&#8217;s chief executive officer, as well as his experience in the industry, qualifies him to serve on the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Robert J. Markelewicz, Jr., M.D., M.M.Sc.</span>, has served as our Chief Medical Officer since June 2018. Prior to that, he was Senior Medical Director at Celgene Corporation, a cancer and immunology pharmaceutical company, from December 2014 to July 2018, and Medical Director at Parexel International Corporation, a provider of biopharmaceutical services, from December 2012 to December 2014. Dr.&#160;Markelewicz is a Diplomate of the American Board of Nuclear Medicine and an Allopathic Physician in the State of Rhode Island and the Commonwealth of Massachusetts. Dr.&#160;Markelewicz received an Sc.B. in Biology, an M.M.Sc. in Medical Science and an M.D. from Brown University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Richard J. Mitrano</span> has served as our Senior Vice President of Finance since November 2023. Previously, he served as Vice President of Finance and Operations for Frequency Therapeutics, Inc. from July 2015 to November 2023. From 2012 to 2015, Mr.&#160;Mitrano served as the Corporate Controller of Semprus Biosciences, where he oversaw all accounting and finance operations and provided strategic direction and oversight. Mr.&#160;Mitrano was a contract Accounting Manager for Predictive Biosciences, Inc., a diagnostics company, from 2010 to 2012. From 2008 to 2010, Mr.&#160;Mitrano served as Corporate Controller of Pioneer Behavioral Health, a company providing behavioral health services. Mr.&#160;Mitrano holds a B.A. in Accounting from Bentley University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Christian Zapf</span> has served as our Senior Vice President of Corporate Development and General Counsel since November 2020. From 2018 to 2020, he was General Counsel of CLEARink Displays, a company developing reflective displays with color and video capability. From 2010 to 2017, he served as Vice President and Counsel, Corporate Development of NantWorks, a healthcare and technology investment company, from 2006 to 2010, he served as Vice President and Counsel, Corporate Development of Abraxis BioScience, an oncology-focused proprietary drug development company, and from 2004 to 2006, he served as Counsel, Corporate Development at American Pharmaceutical Partners, Inc., the predecessor of Abraxis. Mr.&#160;Zapf received a B.A. in Philosophy from Cambridge University, a J.D. from Columbia University and an M.B.A. from INSEAD. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jin Wook (Miles) Suk</span> has served as a member of Abpro&#8217;s board of directors since January 2020. From September 2011 to September 2019, Mr.&#160;Suk served on the board of directors, and as a senior director and advisor, of Gan&#160;&amp; Lee Pharmaceuticals Co., Ltd., a public pharmaceutical company specializing in the development, production, and commercialization of insulin analogs and medical devices. Mr.&#160;Suk <span style="white-space:nowrap">co-founded</span> Bio CND Inc., a pharmaceutical company, which was later acquired. Mr.&#160;Suk also has extensive experience in licensing, strategic alliance, and <span style="white-space:nowrap">co-development</span> deals at LG Life Sciences, Ltd., a company engaged in manufacturing, supply, and distribution of pharmaceutical products, animal health products and specialty chemicals. Mr.&#160;Suk earned a B.S. in Microbiology from Michigan State University. We believe that Mr.&#160;Suk&#8217;s business experience, and his previous service on the board of directors of a public company in the industry, qualify him to serve as a member of the board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Composition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company&#8217;s board will be reconstituted and initially be comprised of five members who will be voted upon by the stockholders at the special meeting. Pursuant to the Proposed Charter, the Post-Combination Company&#8217;s board will be divided into three classes, with members of each class serving staggered three-year terms. If Proposal No.&#160;4 is approved at the special meeting, each Class&#160;I director, consisting of&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;will have a term that expires at the Post-Combination Company&#8217;s next annual meeting of stockholders in 2025, each Class&#160;II director, consisting of&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, will have a term that expires at the Post-Combination Company&#8217;s annual meeting of stockholders in 2026 and each Class&#160;III director, consisting of&#8195;&#8195;&#8195;&#8195;, will have a term that expires at Post-Combination Company&#8217;s annual meeting of stockholders in 2027, or in each case until their respective successors are duly elected and qualified, or until their earlier resignation, removal or death. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified. This classification of the Post-Combination Company&#8217;s board may have the effect of delaying or preventing changes in control or management of the Post-Combination Company. Subject to the terms of any series of preferred stock that the Post-Combination Company may issue in the future, any or all of the Post-Combination Company&#8217;s directors may be removed from office at any time, but only for cause and only by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock of the Post-Combination Company entitled to vote generally in the election of directors, voting together as a single class, at a meeting called for that purpose. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Independence </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nasdaq rules require that a majority of the Post-Combination Company&#8217;s board be independent. An &#8220;independent director&#8221; is defined generally as a person other than an executive officer or employee of the listed company or any other individual having a relationship, which, in the opinion of the board would interfere with the director&#8217;s exercise of independent judgment in carrying out the responsibilities of a director. It is anticipated that each individual expected to serve on the Post-Combination Company&#8217;s board upon consummation of the Business Combination, other than &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195; will qualify as an independent director under Nasdaq listing standards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Oversight of Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the key functions of the board of the Post-Combination Company will be informed oversight of the Post-Combination Company&#8217;s risk management process. The board of the Post-Combination Company does not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anticipate having a standing risk management committee, but rather anticipates administering this oversight function directly through the board of the Post-Combination Company as a whole, as well as through various standing committees of the board of the Post-Combination Company that address risks inherent in their respective areas of oversight. In particular, the board of the Post-Combination Company will be responsible for monitoring and assessing strategic risk exposure and the Post-Combination Company&#8217;s audit committee will have the responsibility to consider and discuss the Post-Combination Company&#8217;s major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. The compensation committee will also assess and monitor whether the Post-Combination Company&#8217;s compensation plans, policies and programs comply with applicable legal and regulatory requirements. The nominating and corporate governance committee will monitor the effectiveness of the Post-Combination Company&#8217;s governance guidelines and provide oversight with respect to corporate governance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of the Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, it is anticipated that the Post-Combination Company&#8217;s board will have three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members will serve on these committees until their resignation or until otherwise determined by the board of directors. The board of directors may establish other committees as it deems necessary or appropriate from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company will establish an audit committee of the board of directors to be in place upon the Closing. The audit committee will consist of &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195;, with &#8195;&#8195;&#8195;&#8195; serving as chair. The Post-Combination Company&#8217;s board of directors will affirmatively determine that each director to be appointed to the audit committee will qualify as independent under Nasdaq listing rules applicable to board members generally and under the Nasdaq listing rules and Exchange Act Rule <span style="white-space:nowrap">10A-3</span> with respect to audit committee members. All members of Post-Combination Company&#8217;s audit committee will meet the requirements for financial literacy under the applicable Nasdaq listing rules. In addition, &#8195;&#8195;&#8195;&#8195; qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The audit committee&#8217;s responsibilities will include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting the Post-Combination Company&#8217;s board in the oversight of (i)&#160;accounting and financial reporting processes of the Post-Combination Company and the audits of the financial statements of Post-Combination Company, (ii)&#160;preparation and integrity of the financial statements of the Post-Combination Company, (iii)&#160;compliance by the Post-Combination Company with financial statement and regulatory requirements, (iv)&#160;performance of the Post-Combination Company&#8217;s internal finance and accounting personnel and its independent registered public accounting firms, and (v)&#160;qualifications and independence of the Post-Combination Company&#8217;s independent registered public accounting firms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with each of the internal and independent registered public accounting firms the overall scope and plans for audits, including authority and organizational reporting lines and adequacy of staffing and compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>reviewing and discussing with management and internal auditors the Post-Combination Company&#8217;s system of internal control and discuss with the independent registered public accounting firm any significant matters regarding internal controls over financial reporting that have come to its attention during the conduct of its audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>reviewing and discussing with management, internal auditors and independent registered public accounting firm the Post-Combination Company&#8217;s financial and critical accounting practices, and policies relating to risk assessment and management; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"></span><span style="font-weight:bold"></span>receiving and reviewing reports of the independent registered public accounting firm discussing (i)&#160;all critical accounting matters in the firm&#8217;s audit of the Post-Combination Company&#8217;s financial statements, (ii)&#160;all alternative treatments of financial information within U.S. GAAP that have been discussed with management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent registered public accounting firm, and (iii)&#160;other material written communications between the independent registered public accounting firm and management, such as any management letter or schedule of unadjusted differences; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the independent registered public accounting firm the annual and quarterly financial statements and section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Post-Combination Company prior to the filing of the Post-Combination Company&#8217;s Annual Reports on Form <span style="white-space:nowrap">10-K</span> and Quarterly Reports on <span style="white-space:nowrap">Form&#160;10-Q;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, or establishing, standards for the type of information and the type of presentation of such information to be included in, earnings press releases and earnings guidance provided to analysts and rating agencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing with management and the independent registered public accounting firm any changes in Post-Combination Company&#8217;s critical accounting principles and the effects of alternative U.S. GAAP&#160;methods, <span style="white-space:nowrap">off-balance</span> sheet&#160;structures and regulatory and accounting initiatives; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing material pending legal proceedings involving the Post-Combination Company and other contingent liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">meeting periodically with the Chief Executive Officer, Chief Financial Officer, the senior internal auditing executive and the independent registered public accounting firm in separate executive sessions to discuss results of examinations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving all transactions between the Post-Combination Company and related parties or affiliates of the officers of the Post-Combination Company requiring disclosure under Item 404 of Regulation <span style="white-space:nowrap">S-K</span> prior to the Post-Combination Company entering into such; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for the receipt, retention and treatment of complaints received by the Post-Combination Company regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submissions by employees or contractors of concerns regarding questionable accounting or accounting matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing periodically with the Post-Combination Company&#8217;s management, the independent registered public accounting firm and outside legal counsel (i)&#160;legal and regulatory matters which may have a material effect on the financial statements, and (ii)&#160;corporate compliance policies or codes of conduct, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding the Post-Combination Company&#8217;s financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing policies for the hiring of employees and former employees of the independent registered public accounting firm. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, we anticipate our nominating and governance committee will consist of &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195;, each of whom qualifies as an independent director according to the rules and regulations of the SEC and Nasdaq with respect to nominating and governance committee membership. We anticipate that &#8195;&#8195;&#8195;&#8195; will serve as chairman of the nominating and governance committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Post-Combination Company&#8217;s board will adopt a written charter for the nominating and governance committee, which will be available on the Corporate Governance section of the Post-Combination Company&#8217;s website upon the consummation of the Business Combination. Reference to the Post-Combination Company&#8217;s website in this proxy statement/prospectus does not include or incorporate the information on the Post-Combination Company&#8217;s website into this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee responsibilities will include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the Post-Combination Company&#8217;s board the criteria for appointment as a director; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, considering, recruiting and recommending candidates to fill new positions on the Post-Combination Company&#8217;s board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing candidates recommended by stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducting the appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending director nominees for approval by the Post-Combination Company&#8217;s board and election by the stockholders at the next annual meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee will recommend to the board of directors candidates for nomination for election at the annual meeting of the stockholders. In identifying and evaluating potential candidates, the nominating and corporate governance committee will consider several factors, including, without limitation, high personal and professional integrity, strong ethics and values, the ability to make mature business judgments, experience in corporate management such as serving as an officer or former officer of a publicly held company, experience as a board member of another publicly held company, professional and academic experience relevant to our business, leadership skills, experience in finance and accounting, or executive compensation practices, whether candidate has the time required for preparation, participation and attendance at board of directors meetings and committee meetings, if applicable, independence, and the ability to represent the best interests of the Post-Combination Company&#8217;s stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, we anticipate our compensation committee will consist of &#8195;&#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;&#8195;, and &#8195;&#8195;&#8195;&#8195;, each of whom qualifies as an independent director according to the rules and regulations of Nasdaq with respect to compensation committee membership. We anticipate that &#8195;&#8195;&#8195;&#8195; will serve as chairman of the compensation committee. The Post-Combination Company&#8217;s board will adopt a written charter for the compensation committee, which will be available on the Corporate Governance section of the Post-Combination Company&#8217;s website upon the consummation of the Business Combination. Reference to the Post-Combination Company&#8217;s website in this proxy statement/prospectus does not include or incorporate the information on the Post-Combination Company&#8217;s website into this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee will be responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the performance of the Chief Executive Officer and executive management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting the Post-Combination Company&#8217;s board in developing and evaluating potential candidates for executive positions (including Chief Executive Officer); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving goals and objectives relevant to the Chief Executive Officer and other executive officer compensation, evaluating the Chief Executive Officer&#8217;s and other executive officers&#8217; performance in light of these corporate goals and objectives, and setting Chief Executive Officer and other executive officer compensation levels consistent with its evaluation and the Post-Combination Company&#8217;s philosophy; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving the salaries, bonus and other compensation for all executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving compensation packages for new corporate officers and termination packages for corporate officers as requested by management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with the Post-Combination Company&#8217;s board and senior officers plans for officer development and corporate succession plans for the Chief Executive Officer and other senior officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations concerning executive compensation policies and plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to the Post-Combination Company&#8217;s board the adoption of or changes to the compensation of the Post-Combination Company&#8217;s directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the awards made under any executive officer bonus plan, and providing an appropriate report to the Post-Combination Company&#8217;s board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations concerning long-term incentive compensation plans, including the use of stock options and other equity-based plans, and, except as otherwise delegated by the Post-Combination Company&#8217;s board, acting as the &#8220;Plan Administrator&#8221; for equity-based and employee benefit plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for the Post-Combination Company&#8217;s executive officers and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing periodic reports from management on matters relating to the Post-Combination Company&#8217;s personnel appointments and practices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting management in complying with the Company&#8217;s proxy statement and annual report disclosure requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuing an annual Report of the Compensation Committee on Executive Compensation for the Post-Combination Company&#8217;s annual proxy statement in compliance with applicable SEC rules and regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">annually evaluating the committee&#8217;s performance and the committee&#8217;s charter and recommending to the Post-Combination Company&#8217;s board any proposed changes to the charter or the committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">undertaking all further actions and discharging all further responsibilities imposed upon the committee from time to time by the Post-Combination Company&#8217;s board, the federal securities laws or the rules and regulations of the SEC. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company&#8217;s board will adopt a code of business conduct and ethics (&#8220;Code of Ethics&#8221;) that will apply to all of the Post-Combination Company&#8217;s directors, officers and employees in accordance with applicable federal securities laws. Upon the consummation of the Business Combination, the Code of Ethics will be available on the Post-Combination Company&#8217;s website. In addition, the Post-Combination Company intends to post on its website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the Code of Ethics rather than by filing a Current Report on Form <span style="white-space:nowrap">8-K.</span> The reference to the Post-Combination Company&#8217;s website in this proxy statement/prospectus does not include or incorporate by reference the information on the Post-Combination Company&#8217;s website into this statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clawback Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective October 2023 ACAB adopted a Clawback Policy (the &#8220;Clawback Policy&#8221;). Under the policy, in the event ACAB is required to prepare an accounting restatement due to material noncompliance of ACAB with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any financial reporting requirement under the U.S. federal securities laws, the Board will take, in its discretion, such action it deems necessary to recover from its executive officers who received incentive-based compensation, based on performance in a year for which ACAB is required to prepare restated financial statements, the excess of what would have been paid to the executive officer under the accounting restatement. This applies during a lookback period of three years, and the amounts to be reclaimed are as determined by the Board in its sole discretion. For purposes of the&#160;Clawback&#160;Policy, an executive officer is any of ACAB&#8217;s officers who are required, or who have been required during the immediately preceding three calendar years, to file reports pursuant to Section&#160;16 of the Exchange Act as well as ACAB&#8217;s Chief Legal Officer, if not included. This policy may, in certain circumstances, be applied to other current or former employees whose actions or omissions contributed to the circumstances requiring the restatement and also involved willful misconduct or a willful violation of any of ACAB&#8217;s rules. Additionally, if the Board determines that detrimental conduct has occurred that results in a material adverse impact, any incentive compensation paid during the prior year may be subject to clawback. Incentive compensation excludes base salary and other compensation but includes equity compensation and bonuses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the SEC adopted new <span style="white-space:nowrap">Rule&#160;10D-1&#160;under</span> the&#160;Exchange Act, which requires national securities exchanges, including Nasdaq, to establish listing standards relating to executive officer incentive compensation clawback and disclosure rules. In February 2023, Nasdaq released its final version of the proposed listing standards, which require listed companies to adopt, no later than December&#160;1, 2023, clawback policies providing for the recovery of erroneously awarded incentive-based compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company board of directors expects to review director compensation periodically to ensure that director compensation remains competitive such that the Post-Combination Company is able to recruit and retain qualified directors. Upon the consummation of the Business Combination, the Post-Combination Company will adopt a director compensation program that is designed to align compensation with its business objectives and the creation of stockholder value, while enabling the Post-Combination Company to attract, retain, incentivize, and reward directors who contribute to the long-term success of the Post-Combination Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity that has one or more executive officers serving on our board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation on Liability and Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter, which, if approved by the ACAB stockholders, will become effective upon consummation of the Business Combination, will limit a directors&#8217; liability to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any transaction from which the director derives an improper personal benefit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any unlawful payment of dividends or redemption of shares; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for any breach of a director&#8217;s duty of loyalty to the corporation or its stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delaware law and the amended and restated bylaws of the Post-Combination Company (the &#8220;Proposed Bylaws&#8221;) provide that the Post-Combination Company will, in certain situations, indemnify its directors and officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct payment, or reimbursement of reasonable expenses (including attorneys&#8217; fees and disbursements) in advance of the final disposition of the proceeding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Post-Combination Company will enter into separate indemnification agreements with its directors and officers. These agreements, among other things, require the Post-Combination Company to indemnify its directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by a director or officer in any action or proceeding arising out of their services as one of its directors or officers or any other company or enterprise to which the person provides services at its request. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company plans to maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which its directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe these provisions in the Proposed Charter and the Proposed Bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc509388_23a">ABPRO EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for Abpro&#8217;s executive officers who are named in the &#8220;Summary Compensation Table&#8221; below. As an emerging growth company, Abpro complies with the executive compensation disclosure rules applicable to &#8220;smaller reporting companies,&#8221; as such term is defined in the rules promulgated under the Securities Act, which require compensation disclosure for Abpro&#8217;s principal executive officer, Abpro&#8217;s two most highly compensated executive officers other than its principal executive officers and up to two additional individuals for whom disclosure would have been provided but for the fact such individuals were not serving as Abpro executive officers as of the last completed fiscal year end. These officers are referred to as Abpro&#8217;s named executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2023, Abpro&#8217;s &#8220;named executive officers&#8221;, or NEOs,&#160;and their positions were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Ian Chan, our Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Robert Markelewicz, our Chief Medical Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Christian Zapf, our Senior Vice President Corporate Development and General Counsel. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on Abpro&#8217;s current plans, considerations, expectations and determinations regarding future compensation programs. The actual compensation programs that Abpro adopts following the completion of the Business Combination may differ materially from the currently planned programs summarized in this discussion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of Abpro&#8217;s named executive officers for the years ended December&#160;31, 2023 and December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:59%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus<br/>($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>awards<br/>($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">502,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">502,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,875,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,645,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Markelewicz</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">466,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Medical Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">80,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">565,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Zapf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">338,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">338,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SVP Corporate Development and General Counsel</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">334,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">576,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column represent the amount of base salary earned for service during 2022 and 2023. The following base salary amounts for 2022 were accrued but unpaid as of December&#160;31, 2022: $8,219 for Mr.&#160;Chan, $7,618 for Dr.&#160;Markelewicz and $5,529 for Mr.&#160;Zapf. The following base salary amounts for 2023 were accrued but unpaid as of December&#160;31, 2023: $9,925 for Mr.&#160;Chan, $9,198 for Dr.&#160;Markelewicz and $6,677 for Mr.&#160;Zapf. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column represent the amount of bonus earned for service during 2022 and 2023. The bonus amounts for 2022 were accrued at December&#160;31, 2022 but unpaid in 2023. No bonus was declared yet in 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts shown in this column represent the aggregate grant date fair value of the stock options awarded to the named executive officers in fiscal years 2022 and 2023. These values have been determined in accordance with FASB ASC Topic 718 using a Black-Scholes model. For a discussion of the assumptions and methodologies used to calculate the amounts referred to above, please see the discussion of option awards contained in Note 2 Summary of Significant Accounting Policies, to Abpro&#8217;s financial statements included elsewhere in this proxy statement/prospectus. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by the named executive officers upon exercise of the stock options. No stock option was awarded to the named executive officers in 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">Narrative Disclosure to the Summary Compensation Table </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Elements of Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation of our NEOs generally consists of base salary, annual cash bonus opportunities, long term incentive compensation in the form of equity awards and other benefits, as described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, responsibilities, and contributions. Each NEO&#8217;s initial base compensation was specified in their employment agreement, as described below, and is reviewed (and, if applicable, adjusted) from time to time by Abpro&#8217;s board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Bonus </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The NEOs are eligible for a performance-based cash bonus opportunity. Each executive&#8217;s target bonus is set annually by Abpro&#8217;s compensation committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Long Term Equity Incentives </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro&#8217;s equity-based incentive awards are designed to align their interests and the interests of their stockholders with those of their employees and consultants, including the NEOs. The Abpro board of directors or compensation committee approves equity grants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro has entered into an employment agreement with Mr.&#160;Chain and employment offer letters with each of Dr.&#160;Markelewicz and Mr.&#160;Zapf, the material terms of which are summarized below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ian Chan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;15, 2020, Ian Chan entered into an Employment Agreement with Abpro setting forth the terms and conditions of his employment as Chief Executive Officer and President (the &#8220;Chan Employment Agreement&#8221;). During the term of the agreement, Mr.&#160;Chan will be nominated to serve as a member of the board of directors of Abpro. The initial term of the agreement was three years commencing on January&#160;15, 2020 (the &#8220;Effective Date&#8221;), and the agreement automatically extends in <span style="white-space:nowrap">one-year</span> increments on each anniversary of the Effective Date (the &#8220;Anniversary&#8221;), unless written notice of an intent not to extend is given by either party 180 days prior to the next Anniversary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chan Employment Agreement provides for a base salary of $500,000 (&#8220;Base Salary&#8221;), subject to annual review by Abpro&#8217;s compensation committee, and may be increased from time to time during Mr.&#160;Chan&#8217;s term of service, in the board of directors&#8217; sole discretion. Mr.&#160;Chan is also eligible to receive a discretionary bonus with a specified annual target amount of 50% of his annual Base Salary, as well as incentive compensation, including without limitation, options to acquire shares of Abpro. Mr.&#160;Chan may also receive fringe benefits, is eligible to participate in any executive benefit plans from time to time in effect for executive officers of Abpro, and is entitled to reimbursement for reasonable travel and other business expenses incurred by him in the performance of his duties and responsibilities to Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Chan&#8217;s employment may be terminated for death, disability, by Mr.&#160;Chan without Cause (as defined in the Chan Employment Agreement), by Abpro without Cause; by Mr.&#160;Chan for Good Reason (as defined in the Chan Employment Agreement), or by Abpro for Cause. In the event Mr.&#160;Chan is terminated without Cause, Abpro will continue to pay Mr.&#160;Chan his annual Base Salary in effect immediately prior to such termination for a period </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to the greater of the remaining term of the Chan Employment Agreement, and 24 months (the &#8220;Termination Payment Period&#8221;), plus an amount equal to 1/12<sup style="font-size:75%; vertical-align:top">th</sup> of any bonus compensation paid to Mr.&#160;Chan for the fiscal year immediately preceding the year of termination. Additionally, all awards granted under Abpro&#8217;s long-term incentive plan shall fully vest. Abpro shall be required to maintain in effect for Mr.&#160;Chan for the Termination Payment Period, all group health insurance, unless Mr.&#160;Chan&#8217;s continued participation would result in income tax liability for other executives of Abpro. In the event that Mr.&#160;Chan terminates his employment for Good Reason, he shall be entitled to the same termination benefits as if he was terminated without Cause. In the event that Mr.&#160;Chan is terminated for Cause, Abpro shall have no further obligation to Mr.&#160;Chan except as provided pursuant to the terms of any executive benefit plan of Abpro in which Mr.&#160;Chan is then a participant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that during the term of the Chan Employment Agreement there occurs a &#8220;Change in Control&#8221; (as defined in the Chan Employment Agreement) and, within 24 months after the Change in Control, Mr.&#160;Chan&#8217;s employment is terminated by Abpro without Cause, or Mr.&#160;Chan terminates his employment for Good Reason, Abpro shall pay to Mr.&#160;Chan within 30 days following such termination, in lieu of any benefit outlined in the preceding paragraph, an amount, based on Mr.&#160;Chan&#8217;s then current annual Base Salary rate, equal to the greater of (A)&#160;the Base Salary Mr.&#160;Chan would receive during the remainder of the term of the Chan Employment Agreement absent such termination, and (B)&#160;two years of Base Salary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chan Employment Agreement contains customary confidentiality provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Robert Markelewicz Jr. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;11, 2018, Abpro provided Robert Markelewicz Jr. with an offer letter setting forth the terms and conditions of his employment as Senior Vice President, Head of Clinical Research and Development, which provides for a base salary of $420,000, a discretionary bonus with a specified annual target amount of 40% of his annual base salary, a $35,000 signing bonus, and eligibility to participate in employee benefit programs established by Abpro. Pursuant to the offer letter, Dr.&#160;Markelewicz was also granted 233,500 stock options that vest in full upon a change in control. The offer letter also provides that in the event Dr.&#160;Markelewicz is terminated without cause (as defined below), that he is eligible to receive severance consisting of six months of continued base compensation, provided that he signed a separation agreement and release prepared by Abpro, and provided that he sign a confidentiality, <span style="white-space:nowrap">non-compete</span> and <span style="white-space:nowrap">non-solicitation</span> agreement, which contains (i)&#160;customary confidentiality provisions, (ii)&#160;a <span style="white-space:nowrap">non-compete</span> covenant for one year post-termination of employment, and (iii)&#160;and <span style="white-space:nowrap">non-solicit</span> covenants relating to employees and customers for 24 months and 18 months post-termination of employment, respectively. The offer letter defines &#8220;cause&#8221; as (i)&#160;poor work performance, as determined by Abpro, (ii) misconduct, as determined by Abpro, or (iii)&#160;any conduct that Abpro deems materially harmful to its business, interests, or reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Christian Zapf </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;5, 2020, Abpro provided Christian Zapf with an offer letter setting forth the terms and conditions of his employment as Senior Vice President of Corporate Development and General Counsel, which provides for a base salary of $325,000, a discretionary bonus with a specified annual target amount of 35% of his annual base salary, and eligibility to participate in employee benefit programs established by Abpro. Mr.&#160;Zapf was granted 180,000 stock options as consideration for entering into Abpro&#8217;s Employee <span style="white-space:nowrap">Non-Solicitation,</span> <span style="white-space:nowrap">Non-Competition,</span> Confidentiality and Assignment Agreement, which contains (i)&#160;customary invention assignment and confidentiality provisions and <span style="white-space:nowrap">(ii)&#160;non-compete</span> and <span style="white-space:nowrap">non-solicit</span> covenants for one year post-termination of employment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the number of shares of common stock underlying outstanding option awards for each named executive officer as of December&#160;31, 2023. All awards were granted pursuant to 2014 Stock Incentive Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:49%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Exercise<br/>Price<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/3/2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253,439</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/3/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/21/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">282,404</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/21/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/19/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332,500</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,500</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/19/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/14/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256,666</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128,334</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/14/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208,542</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Markelewicz</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/28/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">263,500</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,398</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/19/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,611</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,389</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/19/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/14/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,333</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,667</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/14/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,291</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,709</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Zapf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/4/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138,750</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,250</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/4/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,458</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,542</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/18/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option became fully vested and exercisable on January&#160;1, 2018. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option became fully vested and exercisable on April&#160;6, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests as follows: 25% vested on June&#160;19, 2021 and the remaining 75% becomes vested in 36&#160;equal monthly installments thereafter, subject to continued service through each vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests as follows: 25% vested on April&#160;14, 2022 and the remaining 75% becomes vested in 36&#160;equal monthly installments thereafter, subject to continued service through each vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests as follows: 25% vested on February&#160;18, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service through each vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option became fully vested and exercisable on August&#160;27, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option became fully vested and exercisable on December&#160;12, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests as follows: 25% vested on November&#160;18, 2021 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee&#160;Director</span> Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual compensation for Abpro&#8217;s <span style="white-space:nowrap">non-employee</span> directors is composed of cash and stock-based equity compensation. Cash compensation paid to our <span style="white-space:nowrap">non-employee</span> directors consists of an annual retainer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes the compensation of each person serving as a <span style="white-space:nowrap">non-employee</span> director for the year ended December&#160;31, 2023. Ian Chan, Abpro&#8217;s CEO, did not receive any additional compensation for his service as a director in 2023. The compensation of Mr.&#160;Ian Chan as a named executive officer is set forth above under &#8220; &#8212;Summary Compensation Table.&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:57%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Director&#160;Fees&#160;Earned<br/>or Paid in Cash<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Tang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miles Suk</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column represent the amount of board director fees or consulting fees paid in cash during 2023. Only Mr.&#160;Robert Langer and Mr.&#160;Eugene Chan received director compensation in 2023. The rest of the board members did not receive any compensation for their board service during 2023. The director fees of $250,000 paid to Mr.&#160;Eugene Chan included both director fees and consulting fees. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">No stock option was awarded to the directors in 2023. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table lists all outstanding equity awards held by <span style="white-space:nowrap">non-employee</span> directors as of December&#160;31, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Aggregate<br/>Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Aggregate<br/>Number&#160;of<br/>Unvested<br/>Restricted<br/>Stock&#160;Units</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,191,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Langer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Tang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miles Suk</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_24">THE BUSINESS COMBINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following is a discussion of the Business Combination and the material terms of the Business Combination Agreement among ACAB, Merger Sub and Abpro. You are urged to read carefully the Business Combination Agreement in its entirety, a copy of which is attached as Annex A to this proxy statement/prospectus. This summary does not purport to be complete and may not contain all of the information about the Business Combination Agreement that is important to you. We encourage you to read the Business Combination Agreement carefully and in its entirety. This section is not intended to provide you with any factual information about ACAB or Abpro. Such information can be found elsewhere in this proxy statement/prospectus. Capitalized terms used in this section but not defined shall have their respective meanings as set forth in the Business Combination Agreement. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Terms of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transaction Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s and Abpro&#8217;s boards of directors have approved the Business Combination Agreement. The Business Combination Agreement provides for the merger of Merger Sub with and into Abpro, with Abpro surviving as a wholly-owned subsidiary of ACAB. In connection with the consummation of the Business Combination, ACAB will change its corporate name to &#8220;Abpro Holdings, Inc.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Merger Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, at the Effective Time: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding share of Abpro common stock will be cancelled and converted into (i)&#160;the right to receive a pro rata share of 72.5&#160;million shares of Series A Common Stock (22.5&#160;million of which shares will be set aside and equally divided among the Sponsor, Abpro and Abpro Bio Co., Ltd. for each such party to use in the PIPE Financing or to obtain capital for ACAB or the Surviving Company (such shares, the &#8220;Abpro Incentive Shares&#8221;). Any of the Abpro Incentive Shares that are not used or allocated by the Sponsor, Abpro or Abpro Bio Co., Ltd. by the Closing shall be deemed forfeited and shall not be issued to any other party)&#160;(ii) the right to receive a pro rata portion of up to 14,500,000 additional shares of Series A Common Stock (the <span style="white-space:nowrap">&#8220;Earn-out</span> Shares&#8221;), to be earned 1/3 if the volume weighted average price (&#8220;VWAP&#8221;) of the Post-Combination Company&#8217;s stock is above $13.00 for any 20 trading days within any consecutive 30 trading day period; 1/3 if such VWAP is above $15.00; and 1/3 if such VWAP is above $18.00, at any point prior to the fifth anniversary of the Closing Date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro option will be converted into an option to purchase a number of shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such option immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio (rounded up to the nearest whole cent). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro RSU (whether vested or unvested) will be converted into restricted shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such RSU immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to closing, each outstanding share of Abpro preferred stock will be converted into shares of Abpro common stock in accordance with its terms, equal to the number of shares of Abpro common stock obtained by dividing the liquidation preference of such share of Abpro preferred stock by the Exchange Ratio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8211; The Business Combination Agreement &#8211; Consideration to Abpro&#8217;s Stockholders</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conversion of Shares; Exchange Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion of Abpro common stock issued or issuable upon the Abpro preferred stock conversion will occur automatically immediately prior to the Effective Time of the merger. As soon as reasonably practicable after the Effective Time of the merger, the Post-Combination Company will exchange shares of Abpro common stock (after taking effect of the Abpro preferred stock conversion) for merger consideration to be received in the merger pursuant to the terms of the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB is a blank check company incorporated as a corporation in Delaware on May&#160;20, 2021 and formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Business Combination is the result of an extensive search for a transaction, whereby ACAB evaluated over 50 potential counterparties utilizing ACAB&#8217;s network and the investing, operating and transaction experience of ACAB&#8217;s management team and the ACAB Board. The terms of the transactions contemplated by the Business Combination Agreement were the result of negotiations between representatives of ACAB and representatives of Abpro over the course of approximately 20&#160;weeks. The following is a discussion of the background of the contemplated Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;19, 2022, ACAB completed its initial public offering of 30,000,000 units, including 3,900,000 units sold upon partial exercise of the Underwriters&#8217; over-allotment option. Each unit consisted of one share of Series A common stock and <span style="white-space:nowrap">one-half</span> of one redeemable warrant to purchase one share of Series A common stock. The units were sold at an offering price of $10.00 per unit, generating gross proceeds of $300&#160;million (before underwriting discounts and commissions and offering expenses). Simultaneously with the consummation of ACAB&#8217;s IPO and the sale of the units, ACAB sold 13,850,000 warrants at a price of $1.00 per warrant in a private placement to the Sponsor, generating gross proceeds of $13.85&#160;million, with each warrant being exercisable to purchase one share of Series A common stock at a price of $11.50 per share. The net proceeds from ACAB&#8217;s IPO and the private placement with the Sponsor (other than limited funds held outside the trust for the purposes detailed in ACAB&#8217;s filings with the SEC) were deposited in a trust account established for the benefit of ACAB&#8217;s public stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the consummation of ACAB&#8217;s IPO, neither ACAB nor any authorized person on its behalf held any substantive discussions, formal or otherwise, with respect to a Business Combination involving ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After its initial public offering, ACAB commenced an active search for businesses and assets to pursue a Business Combination. Representatives of ACAB contacted, and were contacted by, over 50 companies, advisors and other persons, in the aggregate, with respect to potential transactions. Some of the potential transaction counterparties (i)&#160;were positioned, operationally and financially, to be successful as a public company and would benefit from the increased ability to access capital that a public listing would provide, (ii)&#160;had a significant TAM and growth expansion opportunities, (iii)&#160;were profitable or had significant potential to become profitable, (iv)&#160;had a strong and experienced management team, and (v)&#160;had a business model in place designed to address risks and uncertainties associated with a changing economic environment and changes in the industries in which such companies operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB entered into <span style="white-space:nowrap">non-disclosure</span> agreements with over 20 potential transaction counterparties in addition to Abpro, and engaged in varying levels of discussions, negotiations and due diligence with respect to those companies based on, among other factors, interest from, and due diligence access granted by, such companies and the terms on which such companies were willing to consider a potential transaction with ACAB (including with respect to valuation). ACAB&#8217;s due diligence efforts with potential transaction counterparties (which included, in many instances, meetings with the senior management of the companies and their respective advisors) included, among other things, investigation and review of (depending on the company): business plan and financial projections (including assumptions, opportunities and risks underlying such plan and projections); </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
historical and expected financial performance; macroeconomic trends impacting the business and the industry in which the company operates; competitive positioning versus comparable companies in the applicable industry; growth opportunities; the company&#8217;s technology and potential impact from trends in the overall economy and industry in which the company operates; regulatory environment; and benefits/challenges related to such company engaging in a potential transaction with ACAB and becoming a public company. In the case of certain of these potential transaction counterparties, representatives of ACAB, in consultation with the ACAB Board, engaged in discussions regarding potential terms of a Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB ultimately determined not to proceed with any of its other potential Business Combination opportunities for a variety of reasons, including because (i)&#160;the potential counterparty pursued an alternative transaction or strategy, (ii)&#160;valuation expectations did not align between the potential counterparty and ACAB or (iii)&#160;ACAB concluded that the opportunity was not as attractive as the Abpro Business Combination opportunity, as a result of factors that included, but were not limited to, the valuation, the maturity of the counterparty, the business plan, the senior management team, the prevailing financing conditions, and the growth opportunities of the potential counterparty and the industry in which the potential counterparty operates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Tony Eisenberg, Chief Strategy Officer of ACAB, met Patrick Sturgeon, Managing Director at Brookline Capital Markets (&#8220;Brookline&#8221;), at an industry conference. Mr.&#160;Sturgeon mentioned to Mr.&#160;Eisenberg that Mr.&#160;Sturgeon had a compelling potential target, Abpro, for ACAB&#8217;s consideration and provided a brief overview of such target. Mr.&#160;Eisenberg agreed that this sounded interesting and further agreed to set up a call between Brookline and Shahraab Ahmad, Chief Executive Officer of ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;11, 2023, ACAB entered into an engagement letter with J.V.B. Financial Group, LLC, acting through its Cohen &amp; Company Capital Markets division (&#8220;Cohen&#8221;), pursuant to which ACAB engaged Cohen to act as its capital markets advisor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the several weeks following June&#160;27, 2023, multiple calls were held between ACAB&#8217;s management team and Brookline to discuss Abpro as a potential target. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;19, 2023, a group call was held between Mr.&#160;Eisenberg, Ian Chang (Chief Executive Officer of Abpro), Christian Zapf (General Counsel of Abpro), and Mengsha Wang (Abpro Director of Corporate Development). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;20, 2023, ACAB and Abpro executed a <span style="white-space:nowrap">non-disclosure</span> agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on July&#160;21, 2023, Abpro began providing ACAB&#8217;s management access to a virtual data room in connection with ACAB&#8217;s evaluation of a potential Business Combination with Abpro. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on July&#160;21, 2023, Abpro began providing business and financial due diligence materials to ACAB&#8217;s management in connection with ACAB&#8217;s evaluation of a potential Business Combination. On August&#160;28, 2023, Abpro granted virtual data room access to the full ACAB team, including ACAB&#8217;s advisors. From July&#160;21, 2023, through December&#160;11, 2023 (the date on which the Business Combination Agreement was signed), various representatives of ACAB, including Pillsbury, Brookline and other advisors conducted legal, financial, accounting, business and tax due diligence of Abpro through a site visit, meetings, document review and numerous telephonic conferences with representatives of Abpro. Calabrese assisted with certain aspects of ACAB&#8217;s financial due diligence of Abpro, but did not otherwise play any role in the negotiation of the Business Combination. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2023, Mr.&#160;Chang, Mr.&#160;Zapf, Ms.&#160;Wang, Mr.&#160;Ahmad, Mr.&#160;Eisenberg, and the Brookline team held a second group call to further discuss a potential Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between August&#160;5, 2023, and August&#160;14, 2023, a series of calls were held between representatives of ACAB and Brookline to discuss potential deal terms and a draft term sheet. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;14, 2023, ACAB sent a draft term sheet to Brookline, which Brookline subsequently shared with Abpro. In the weeks following August&#160;14, 2023, the parties discussed the terms of the draft term sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;28, 2023, a group call was held between Abpro&#8217;s management and the ACAB Board, during which Abpro&#8217;s management provided an overview of Abpro and directly addressed the ACAB Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;1, 2023, ACAB shared the draft term sheet with Pillsbury Winthrop Shaw Pittman LLP (&#8220;Pillsbury&#8221;), counsel for ACAB, for Pillsbury&#8217;s review. Also on September&#160;1, 2023, the ACAB Board held a meeting to discuss the potential Business Combination with Abpro and terms thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;1, 2023, the ACAB Board authorized ACAB&#8217;s management to pursue and finalize a binding term sheet with Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;5, 2023, an <span style="white-space:nowrap">all-hands</span> call was held between Abpro&#8217;s management, ACAB&#8217;s management, Brookline, Pillsbury, and Loeb &amp; Loeb LLP (&#8220;Loeb&#8221;), counsel for Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;15, 2023, ACAB and Abpro entered into a term sheet effective as of September&#160;18, 2023. Also on September&#160;15, 2023, a <span style="white-space:nowrap">kick-off</span> call was held between Abpro&#8217;s management, ACAB&#8217;s management, and Brookline to discuss next steps in connection with the potential Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;18, 2023, ACAB representatives including Mr.&#160;Eisenberg, Jason Chryssicas (CFO), and Darren Stanwood (Director) conducted an onsite visit to Abpro, during which the ACAB representatives met members of Abpro&#8217;s management and scientific teams. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on September&#160;18, 2023, a legal <span style="white-space:nowrap">kick-off</span> call was held between ACAB&#8217;s management, Abpro&#8217;s management, Pillsbury, Loeb, and Brookline to set out various timelines and responsibilities in connection with the potential Business Combination. Following this call, both ACAB and Abpro began working intensively on a potential Business Combination. ACAB&#8217;s management team was particularly focused on conducting further due diligence with respect to Abpro and began regularly updating the ACAB Board regarding a potential deal with Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Abpro and ACAB publicly announced the potential transaction and the term sheet that was executed between the parties on September&#160;18, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;23, 2023, Abpro informed ACAB that Abpro had changed its law firm from Loeb to Nelson Mullins Riley&#160;&amp; Scarborough LLP (&#8220;Nelson Mullins&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2023, Nelson Mullins, on behalf of Abpro, shared an initial draft of the Business Combination Agreement with ACAB and Pillsbury. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on November&#160;2, 2023, ACAB&#8217;s management and Abpro&#8217;s management worked to amend the term sheet to, among other things, reduce the number of shares to be received by Abpro&#8217;s original stockholders in connection with the potential Business Combination from 72,500,000 shares to 50,000,000 shares, with the remaining shares to be received by incoming investors. The change in structure was driven by investor and market feedback. The number of shares allocated to the Sponsor pursuant to the term sheet were also reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;2, 2023, Abpro received a report from Health Advances laying out the valuation of its two lead programs. Specifically, the report set forth a risk-adjusted present value of future revenue from both programs of approximately $1.2&#160;billion. The report was shared with the ACAB Board, and the ACAB Board considered this report in connection with its determination of a pre-combination equity valuation of Abpro. Additionally, in considering the $500 million pre-money valuation of Abpro (which was down from the valuation for Abpro of $725 million at the time the potential transaction was first announced), the ACAB board considered, among other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
things, Abpro&#8217;s existing partnership agreements, including its strategic development and commercialization agreements with Celltrion&#160;Inc., a leading Korean biopharmaceutical company. Given such agreements and the ACAB Board&#8217;s view that Abpro had a promising path forward in achieving FDA for its drug candidates, the ACAB Board did not believe financial comparisons to otherwise similarly situated companies would provide the best means of ascertaining the valuation of Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, the ACAB Board held a meeting during which ACAB&#8217;s management and the ACAB Board discussed, among other things, certain prospective terms and conditions of the Business Combination Agreement. During such meeting, the ACAB Board unanimously agreed that ACAB should proceed with the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;22, 2023, Pillsbury provided ACAB&#8217;s management team with a Red Flags Due Diligence Report, highlighting the key issues that they identified over the course of their diligence. Pillsbury also expressed their intention to furnish updates specifically regarding the litigation section of the report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;22, 2023, Pillsbury provided ACAB&#8217;s management team with a revised Red Flags Due Diligence Report, emphasizing issues in conjunction with ACAB&#8217;s advisor, Gary Sommerville&#8217;s (&#8220;Sommerville&#8221;) intellectual property report. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;24, 2023, the ACAB Board approved the Business Combination Agreement contingent on completion of satisfactory diligence with respect to Abpro&#8217;s outstanding litigation and the ACAB Board&#8217;s satisfactory review of Abpro&#8217;s projected cash flow for the following 12 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;28, 2023, Pillsbury provided ACAB&#8217;s management team with an addendum to the Red Flags Due Diligence Report. This addendum encompassed updates to the litigation section and highlighted issues arising from the most recent revised Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;30, 2023, Pillsbury provided ACAB&#8217;s management team with a compiled version of the Red Flags Due Diligence Report, and explicitly directed its dissemination to the ACAB Board. This compiled report included updates to the litigation section and also incorporated additional insights from Sommerville, particularly focusing on recent observations related to the Company&#8217;s intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, ACAB and Abpro executed the Business Combination Agreement and related transaction documentation. Prior to the commencement of trading of the shares of ACAB common stock on Nasdaq on December&#160;12, 2023, ACAB filed a Current Report on Form <span style="white-space:nowrap">8-K</span> announcing, among other things, the execution of the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 11, 2024, ACAB entered into an amended engagement letter with Cohen, pursuant to which ACAB engaged Cohen to act as its capital markets advisor in connection with the initial business combination, in exchange for the right to receive (i)&#160;200,000 Founder Shares, such shares to be delivered following the closing of&#160;an initial business combination and (ii)&#160;a transaction fee in connection with any such offering involving Cohen equal to 4% of the gross proceeds raised in connection with such offering, subject to the terms of the amended engagement letter. The amended engagement letter with Cohen supersedes and replaces the prior engagement letter entered into on April&#160;11, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information relating to the ownership of ACAB following the Closing, see &#8220;<span style="font-style:italic">Beneficial Ownership of Securities</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Abpro and ACAB management teams are in the process of discussing with potential investors a PIPE financing up to gross proceeds of $35 million to support the Post-Combination Company at Closing. At this time, there is no firm commitment for a PIPE or other financing arrangement as of the date of this filing. The terms of any such private placement, including whether any of the Sponsor or ACAB&#8217;s directors or officers or their affiliates will participate in such private placement, have not yet been determined. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the ACAB Board and Reasons for the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s board of directors, in evaluating the Business Combination, consulted with ACAB&#8217;s management and legal and financial advisors. In reaching its unanimous resolution (i)&#160;that the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination and the issuance of shares of common stock in connection therewith, are advisable and in the best interests of ACAB and its stockholders and (ii)&#160;to recommend that the ACAB stockholders adopt the Business Combination Agreement and approve the Business Combination and the other transactions contemplated by the Business Combination Agreement, ACAB&#8217;s board of directors considered a range of factors, including, but not limited to, the factors discussed below. In light of the number and wide variety of factors considered in connection with its evaluation of the Business Combination, ACAB&#8217;s board of directors did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. ACAB&#8217;s board of directors viewed its decision as being based on all of the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This explanation of ACAB&#8217;s reasons for the Business Combination and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under &#8220;<span style="font-style:italic">Forward-Looking Statements; Summary Risk Factors; Market, Ranking and Other Industry Data</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In approving the Business Combination, ACAB&#8217;s board of directors determined not to obtain a fairness opinion. The officers and directors of ACAB have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and background, together with experience and sector expertise of ACAB&#8217;s financial advisors, enabled them to make the necessary analyses and determinations regarding the Business Combination. In addition, ACAB&#8217;s officers and directors and ACAB&#8217;s financial advisors have substantial experience performing valuations of companies in connection with mergers and acquisitions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s board of directors considered a number of factors pertaining to the Business Combination as generally supporting its decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including, but not limited to, the following material factors:<span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top"> </sup></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Proprietary Antibody Platform and Robust Therapeutic Pipeline of Candidates: </span>By leveraging its proprietary DiversImmune<sup style="font-size:75%; vertical-align:top">&#174;</sup> and MultiMab<sup style="font-size:75%; vertical-align:top">TM</sup> antibody discovery and engineering platforms, Abpro is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Abpro&#8217;s two lead product candidates, <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201,</span> feature its next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target and has potential applications for a number of different diseases, including cancer; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Established Development and Commercialization Partnerships:</span> Abpro has strategic development and commercialization partnerships with Celltrion Inc., a leading Korean biopharmaceutical company headquartered in Incheon, South Korea (KRX:068270), and Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;), a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company formerly named Ugint Co Ltd with diversified holdings in precision machine tools, equipment and biotechnology headquartered in Daegu, South Korea; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Size and Future Growth of Target Markets: </span>Abpro&#8217;s target markets include the breast cancer monoclonal antibodies market, estimated to grow by $15&#160;billion at a CAGR of 12.5% between 2022 and 2027 and the global oncology therapeutics market, estimated to grow to $250&#160;billion by 2024 at a CAGR of 12%; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Advantages over Approved Therapies: </span>Abpro&#8217;s <span style="white-space:nowrap">ABP-102</span> and <span style="white-space:nowrap">ABP-201</span> seek to address current negative effects and/or reduced efficacy of approved therapies through unique approaches using its DiversImmune<sup style="font-size:75%; vertical-align:top">&#174;</sup> and MultiMab<sup style="font-size:75%; vertical-align:top">TM </sup>platforms. If either of these therapies were approved, the existing market could be significantly disrupted; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Due Diligence.</span> Due diligence examinations of Abpro by ACAB and its representatives and advisors, including Pillsbury, Calabrese, and Cantor, through meetings, document review and numerous telephonic conferences with representatives of Abpro covering various areas, including, but not limited to, legal, financial, accounting, business and tax. Scientific due diligence was performed by an independent consultant of ACAB to validate the underlying scientific data of Abpro&#8217;s portfolio; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholder Liquidity.</span> The obligation in the Business Combination Agreement to have ACAB Series A common stock issued as merger consideration listed on Nasdaq, a major U.S. stock exchange, which ACAB&#8217;s board of directors believes has the potential to offer stockholders enhanced liquidity; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financial Condition.</span> ACAB&#8217;s board of directors also considered factors such as Abpro&#8217;s historical financial results, outlook, financial plan, debt structure and unit economics. In considering these factors, ACAB&#8217;s board of directors reviewed Abpro&#8217;s historical growth and its current prospects for growth if Abpro achieves its business plan and various historical and current balance sheet items of Abpro. In reviewing these factors, ACAB&#8217;s board of directors noted that Abpro is well-positioned for strong future growth; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Experienced and Proven Management Team.</span> Abpro has an experienced leadership team with significant industry <span style="white-space:nowrap">know-how</span> and deep experience in antibody discovery and development, biomarker discovery and validation, clinical development and regulatory approval, partnerships, operations, and corporate finance. The leadership team has broad industry experience from working at pharmaceutical and Biotech companies, including Celgene, NantWorks, Frequency Therapeutics, the Bill and Melinda Gates Medical Research Institute and Moderna. Abpro also has a group of scientific advisors comprised of leaders in its industry across various disciplines; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Lock</span>-<span style="font-style:italic">Up</span>. Certain stockholders of Abpro will agree to be subject to a <span style="white-space:nowrap">12-month</span> lockup in respect of their ACAB Series A common stock subject to certain customary exceptions, which will provide important stability to the trading in the common stock of ACAB in the period immediately following completion of the Business Combination; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Alternatives.</span> ACAB&#8217;s board of directors believes, after a thorough review of other business combination opportunities reasonably available to ACAB, that the proposed Business Combination represents the best potential business combination for ACAB and the most attractive opportunity for ACAB&#8217;s management to accelerate its business plan based upon the process utilized to evaluate and assess other potential acquisition targets, and ACAB&#8217;s board of directors&#8217; belief that such process has not presented a better alternative; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Negotiated Transaction.</span> The financial and other terms of the Business Combination Agreement and the fact that such terms and conditions were the product of arm&#8217;s length negotiations between ACAB and Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s board of directors also considered a variety of uncertainties and risks and other potentially negative factors concerning the Business Combination including, but not limited to, the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Macroeconomic Risks.</span> Macroeconomic uncertainty, including the potential impact of the conflicts in Ukraine and the Middle East, and the effects it could have on the Post-Combination Company&#8217;s revenues; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Business Plan and Projections May Not Be Achieved.</span> The risk that Abpro may not be able to execute on the business plan, and realize the financial performance as set forth in the financial projections, in each case, presented to management of ACAB; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulatory Approvals May Not be Obtained. </span>The risk that none of Abpro&#8217;s therapies are approved by regulatory authorities in each target market, or that material changes must be made to such therapies in order to gain regulatory approval; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Early-Stage Company and Limited Operating History.</span> The fact that Abpro is an early-stage company with a history of losses and a limited operating history; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Technology Risk. </span>The risks associated with operating in an industry that is characterized by rapid technological change; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Risk.</span> The potential that a significant number of ACAB stockholders elect to redeem their shares prior to the consummation of the Business Combination and pursuant to ACAB&#8217;s Existing Charter, which would potentially make the Business Combination more difficult or impossible to complete; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholder Vote.</span> The risk that ACAB&#8217;s stockholders may fail to provide the respective votes necessary to effect the Business Combination; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Closing Conditions.</span> The fact that the completion of the Business Combination is conditioned on the satisfaction of certain closing conditions that are not within ACAB&#8217;s control; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Litigation.</span> The possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Listing Risks.</span> The challenges associated with preparing Abpro, a private entity, for the applicable disclosure and listing requirements to which Abpro will be subject as a publicly traded company on Nasdaq; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Benefits May Not Be Achieved.</span> The risks that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation of ACAB.</span> The risks and costs to ACAB if the Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in ACAB being unable to effect a business combination by September&#160;19, 2024; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Growth Initiatives May Not be Achieved.</span> The risk that Abpro&#8217;s growth initiatives may not be fully achieved or may not be achieved within the expected timeframe; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Third</span>-<span style="font-style:italic">Party Valuation</span>. The risk that ACAB did not obtain a third-party valuation or fairness opinion in connection with the Business Combination; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ACAB Stockholders Receiving a Minority Position in Abpro.</span> The risk that ACAB stockholders will hold a minority position in Abpro; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fees and Expenses.</span> The fees and expenses associated with completing the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to considering the factors described above, ACAB&#8217;s board of directors also considered other factors including, without limitation: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interests of Certain Persons.</span> Some officers and directors of ACAB may have interests in the Business Combination (see &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Interests of ACAB&#8217;s Directors and Officers in the Business Combination</span>&#8221;); and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Risks Factors.</span> Various other risk factors associated with the business of Abpro, as described in the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; appearing elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s board also considered the respective interests and conflicts of the various investment banks, consultants, and other advisors involved in the transaction, including the fact that (i)&#160;Cantor will be entitled to 600,000 shares of ACAB Series A common stock in deferred underwriting compensation for its acting as an underwriter in the IPO, (ii)&#160;Calabrese will be entitled to a fee of $&#8195;&#8195;&#8195;&#8195;for its role as financial consultant to ACAB; and (iii)&#160;Brookline Capital Markets will be entitled to a fee equal to $&#8195;&#8195;&#8195;&#8195;for its role as financial advisor to Abpro. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s board of directors concluded that the potential benefits that it expected ACAB and its stockholders to achieve as a result of the Business Combination outweighed the potentially negative and other factors associated with the Business Combination. ACAB&#8217;s board of directors also noted that the ACAB stockholders would have an economic interest in the Post-Combination Company (the size of which would depend on the level of ACAB stockholders that sought redemption of their public shares into cash). Accordingly, ACAB&#8217;s board of directors unanimously determined that the Business Combination and the transactions contemplated by the Business Combination Agreement, were advisable and in the best interests of ACAB and its stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Satisfaction of 80% Test </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is a requirement under Nasdaq that the business or assets acquired in an initial business combination have a fair market value of at least 80% of the assets held in the trust account (excluding taxes payable on interest earned) at the time of the execution of a definitive agreement for an initial business combination. In connection with its evaluation and approval of the Business Combination, the ACAB Board determined that the fair market value of Abpro exceeded at least 80% of the assets held in the trust account (excluding taxes payable on interest earned) at the time of the execution of a definitive agreement for an initial business combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of the Sponsor and ACAB&#8217;s Directors and Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interests of Sponsor and ACAB Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the ACAB Board to vote in favor of the Business Combination, stockholders should be aware that, aside from their interests as stockholders, our Sponsor and certain of our directors and officers have interests in the Business Combination that are different from, or in addition to, those of other stockholders generally. Our directors were aware of and considered these interests, among other matters, in evaluating the Business Combination, and in recommending to stockholders that they approve the Business Combination. In certain instances, the ACAB Board had the conflicted transactions approved by the audit committee of the board in accordance with ACAB&#8217;s related party transaction policy. These interests may have influenced the members of the ACAB Board in making their recommendation that you vote in favor of the approval of the Business Combination. Stockholders should take these interests into account in deciding whether to approve the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor holds an aggregate of 13,850,000 private placement warrants that would expire worthless if a business combination is not consummated, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our public warrants of $&#8195;&#8195;&#8195;&#8195;per warrant on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, pursuant to the subscription agreement (the &#8220;Polar Subscription Agreement&#8221;) among ACAB, the Sponsor and Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;), the Sponsor is the primary obligor for an amount up to $360,000 to be loaned to ACAB by Sponsor in one or more subsequent transactions between the Sponsor and ACAB. If the Business Combination is not consummated, the Sponsor would be liable to repay such indebtedness to Polar and ACAB may be unable to repay its obligations owing to the Sponsor; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor may convert any working capital loans that it has and may make to us into shares of our Series A common stock, at the price of $10.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor has agreed not to redeem any of the shares of our common stock held by it in connection with a stockholder vote to approve the Business Combination; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Initial Stockholders paid an aggregate of $25,000 for the Founder Shares and that such securities will have a significantly higher value at the time of the business combination, which if unrestricted and freely tradable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting, resulting in a theoretical gain of $&#8195;&#8195;&#8195;&#8195;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that certain of ACAB&#8217;s officers and directors collectively own, directly or indirectly, a material interest in the Sponsor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated appointment of&#8195;&#8195;&#8195;&#8195;, a member of&#8195;&#8195;&#8195;&#8195;, as director on the board of the combined company in connection with the Closing; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the trust account is liquidated, including in the event we are unable to complete an Initial Business Combination within the required time period, the Sponsor has agreed to indemnify us to ensure that the proceeds in the Trust Account are not reduced below $10.20 per Public Share, or such lesser amount per Public Share as is in the Trust Account on the liquidation date, by the claims of (a)&#160;any third party for services rendered or products sold to us or (b)&#160;a prospective target business with which we have entered into an acquisition agreement, but only if such a third party or target business has not executed a waiver of all rights to seek access to the trust account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our independent directors own an aggregate of 250,000 Founder Shares, which if unrestricted and freely tradeable would be valued at approximately $&#8195;&#8195;&#8195;&#8195;, based on the closing price of our Series A common stock of $&#8195;&#8195;&#8195;&#8195;per share on&#8195;&#8195;&#8195;&#8195;, 2024, the record date for the special meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to stockholders rather than liquidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and its affiliates can earn a positive rate of return on their investment, even if other ACAB stockholders experience a negative rate of return in the post-business combination company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor, officers and directors will be reimbursed for <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf, such as identifying potential target businesses and performing due diligence on suitable business combinations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the Sponsor and ACAB&#8217;s officers and directors will lose their entire investment in us if an Initial Business Combination is not completed; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that our Sponsor, officers and directors will lose their entire investment in us if an Initial Business Combination is not completed. At the closing of the Business Combination, we anticipate our Sponsor will own a combined 13,850,000 private placement warrants and 3,241,667 shares of the combined company&#8217;s common stock. Our ability to repay the loan (either in cash or, at our Sponsor&#8217;s election, through the conversion of the loan into common stock as described above) is dependent upon the completion of an Initial Business Combination. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table set forth below sets out the total investment made by our Sponsor for the private placement warrants and the Founder Shares and the value of such securities, based on the closing price of our public warrants and our Series A common stock as of&#8195;&#8195;&#8195;&#8195;, 2024: </p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Security</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total Capital<br/>Contribution</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value&#160;as<br/>of&#8195;&#8195;,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private placement warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founder Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the members of our Sponsor include our officers and directors, all of whom made a direct or indirect capital contribution in our Sponsor in exchange for their respective membership interests therein. These membership interests in our Sponsor provide our officers and directors with an indirect economic interest in the total number of private placement warrants and shares of Founder Shares anticipated to be held by our Sponsor as of the completion of the Business Combination. The table set forth below summarizes the direct or indirect interest that our officers and directors (or trusts, retirement accounts or entities related to such persons) hold in the private placement warrants and Founder Shares along with the total capital contributions made by our officers and directors (or trusts, retirement accounts or entities related to such persons) for their direct or indirect interests in the Founder Shares and the value of such interests based on the closing price of the public warrants and Series A common stock as of&#8195;&#8195;&#8195;&#8195;, 2024, all of which would be lost if an initial business combination is not completed by us within the required time period: </p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:37%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total Capital<br/>Contribution</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value&#160;as<br/>of&#8195;&#8195;,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Chairman&#160;and&#160;Chief&#160;Executive&#160;Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony D. Eisenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Chief Strategy Officer and Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">375,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Chryssicas</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Chief Financial Officer and Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Burt Jordan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">President and Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joanna Lord</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194; </td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Dove</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curtis Collar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darren Stanwood</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8211;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dominick J. Schiano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise described above, we do not believe that there are any material ACAB securities held by ACAB&#8217;s officers and directors, loans extended or fees due from ACAB to ACAB&#8217;s officers and directors, or <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses for which ACAB&#8217;s officers and directors are awaiting reimbursement from ACAB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Calabrese served as a financial consultant to ACAB in connection with the Business Combination. In addition, part of the IPO underwriting fee was deferred and conditioned on the completion of a business combination. Cantor will be entitled to 600,000 shares of the Combined Company contingent on the completion of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Purchases of Public Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the stockholder vote to approve the Business Combination, our Sponsor, directors, officers, advisors or any of their respective affiliates may privately negotiate transactions to purchase public shares from stockholders who would have otherwise elected to have their shares redeemed in conjunction with the Business Combination for a per share pro rata portion of the Trust Account. There is no limit on the number of public shares our Sponsor, directors, officers, advisors or any of their respective affiliates may purchase in such transactions, subject to compliance with applicable law and the rules of Nasdaq or any other exchange on which our securities may be listed. Any such privately negotiated purchases may be effected at purchase prices that are in excess of the per share pro rata portion of the Trust Account. However, our Sponsor, directors, officers, advisors and their respective affiliates have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the Trust Account will be used to purchase public shares in such transactions. None of our Sponsor, directors, officers, advisors or any of their respective affiliates will make any such purchases when they are in possession of any material <span style="white-space:nowrap">non-public</span> information not disclosed to the seller of such public shares or during a restricted period under Regulation M under the Exchange Act. Such a purchase could include a contractual acknowledgement that such stockholder, although still the record holder of such public shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights, and could include a contractual provision that directs such stockholder to vote such shares in a manner directed by the purchaser. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that our Sponsor, directors, officers, advisors or any of their respective affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of any such purchases of public shares could be to (a)&#160;vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining stockholder approval of the Business Combination or (b)&#160;to satisfy a closing condition in the Business Combination Agreement, where it appears that such requirement would otherwise not be met. Any such purchases of our public shares may result in the completion of the Business Combination that may not otherwise have been possible. Any such purchases will be reported pursuant to Section&#160;13 and Section&#160;16 of the Exchange Act to the extent the purchasers are subject to such reporting requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if such purchases are made, the public &#8220;float&#8221; of our Series A Common Stock may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material nonpublic information regarding ACAB or its securities, the Sponsor, directors, officers, advisors and/or any of their respective affiliates may purchase shares from institutional and other investors who vote, or indicate an intention to vote, against the Business Combination Proposal, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire shares of ACAB common stock or to not vote their shares against the Business Combination Proposal. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options and, with Abpro&#8217;s consent, the transfer to such investors or holders of shares owned by the Sponsors for nominal value. In such transactions, the purchase price for the ACAB common stock will not exceed the per-share redemption amount available to redeeming stockholders. In addition, the purchasers described above will waive redemption rights, if any, with respect to the ACAB common stock they acquire in such transactions. The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements to consummate the Business Combination where it appears that such requirements would otherwise not be met, however, such purchased shares would not be voted in favor of approving the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any purchases by our Sponsor, officers, directors, advisors or any of their respective affiliates who are affiliated purchasers under Rule <span style="white-space:nowrap">10b-18</span> under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule <span style="white-space:nowrap">10b-18,</span> which is a safe harbor from liability for manipulation under Section&#160;9(a)(2) of and Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. Rule <span style="white-space:nowrap">10b-18</span> has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. Our Sponsor, officers, directors, advisors and any of their respective affiliates will not make purchases of Series A Common Stock if the purchases would violate Section&#160;9(a)(2) of or Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. The details of such purchases would be disclosed by ACAB in a Current Report on Form 8-K prior to the Special Meeting, and would be made in compliance with Rule&#160;14e-5 under the Securities Exchange Act of 1934, relying on the Tender Offer Compliance and Disclosure Interpretation 166.01 (March&#160;22, 2022). </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of the Sponsor and ACAB&#8217;s Directors and Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the ACAB Board to vote in favor of approval of the proposals, stockholders should keep in mind that the Sponsor and ACAB&#8217;s directors and officers have interests in such proposals that are different from or in addition to (and which may conflict with) those of ACAB stockholders. ACAB&#8217;s directors were aware of and considered these interests, among other matters, in evaluating the Business Combination, and in recommending to stockholders that they approve the Business Combination. In certain instances, the ACAB Board had the conflicted transactions approved by the audit committee of the ACAB Board in accordance with ACAB&#8217;s related party transaction policy. These interests may have influenced the members of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ACAB Board in making their recommendation that you vote in favor of the approval of the Business Combination. Stockholders should take these interests into account in deciding whether to approve the proposals presented at the Special Meeting, including the Business Combination Proposal. These interests include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the Business Combination with Abpro or another business combination is not consummated within the Completion Window, ACAB will cease all operations except for the purpose of winding up, redeeming 100% of the outstanding Public Shares for cash and, subject to the approval of its remaining stockholders and the ACAB Board, dissolving and liquidating. In such event, the 7,200,000 Founder Shares held by the Sponsor which were acquired for an aggregate purchase price of $25,000 prior to the ACAB IPO, along with 250,000 Founder Shares held by certain of ACAB&#8217;s directors, would be worthless because those holders are not entitled to participate in any redemption or distribution with respect to such shares. Such shares had an aggregate market value of $&#8195;&#8195;&#8195;&#8195;based upon the closing price of $&#8195;&#8195;&#8195;&#8195;per share of Series A common stock on Nasdaq on&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor purchased an aggregate of 13,850,000 private placement warrants from ACAB for an aggregate purchase price of $13,850,000 (or $1.00 per warrant). These purchases took place on a private placement basis simultaneously with the consummation of the ACAB IPO and the subsequent exercise of their over-allotment option by the Underwriters. A portion of the proceeds ACAB received from these purchases were placed in the trust account. Such warrants had an aggregate market value of $&#8195;&#8195;&#8195;&#8195;based upon the closing price of $ per public warrant on Nasdaq on&#8195;&#8195;&#8195;&#8195;, 2024, the ACAB Record Date. The private placement warrants will become worthless if ACAB does not consummate a Business Combination within the Completion Window. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each of ACAB&#8217;s officers and certain of ACAB&#8217;s directors hold a direct or indirect interest in the Sponsor, which interest will become worthless if ACAB does not consummate a business combination within the Completion Window. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor has agreed not to redeem any of the Founder Shares held by it in connection with a stockholder vote to approve the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor and its affiliates can earn a positive rate of return on their investment, even if other ACAB stockholders experience a negative rate of return in the Post-Business Combination company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8195;&#8195;&#8195;&#8195;will become a director of the Post-Combination Company after the Closing. As such, in the future they will receive any cash fees, stock options or stock awards that the Board determines to pay to its directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If ACAB is unable to complete a business combination within the Completion Window, its executive officers will be personally liable under certain circumstances described herein to ensure that the proceeds in the trust account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by ACAB for services rendered or contracted for or products sold to ACAB. If ACAB consummates a business combination, on the other hand, ACAB will be liable for all such claims. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB&#8217;s directors and officers, and their affiliates are entitled to reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by them in connection with certain activities on ACAB&#8217;s behalf, such as identifying and investigating possible business targets and business combinations. However, if ACAB fails to consummate a business combination within the Completion Window, they will not have any claim against the trust account for reimbursement. Accordingly, ACAB may not be able to reimburse these expenses if the Business Combination or another business combination is not consummated within the Completion Window. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On October&#160;14, 2023 and November&#160;14, 2023, ACAB issued unsecured promissory notes (the &#8220;2023 Notes&#8221;) to the Sponsor in the aggregate principal amounts of $80,000 and $80,000, respectively, in connection with monthly extensions of the deadline to consummate an initial business combination. In </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the event that ACAB does not consummate an initial business combination, all amounts loaned to ACAB under the 2023 Notes will be forgiven except to the extent that ACAB has funds available to it outside of its trust account established in connection with the ACAB IPO. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On December&#160;8, 2023, December&#160;11, 2023 and December&#160;12, 2023, the Sponsor advanced ACAB $10,000, $1,630,000 and $15,000, respectively, to fund the account for the funds used in operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The continued indemnification of current directors and officers and the continuation of directors&#8217; and officers&#8217; liability insurance for six years after the Closing Date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Part of the IPO underwriting fee was deferred and conditioned on the completion of a Business Combination. Pursuant to a fee letter with Cantor, no fees are payable to Cantor are contingent on the completion of the Business Combination, except 600,000 shares of the Post-Combination Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Sponsor is the primary obligor for an amount up to $360,000 due under the Polar Subscription Agreement, to be loaned to ACAB by Sponsor in one or more subsequent transactions between the Sponsor and ACAB. If the Business Combination is not consummated, the Sponsor would be liable to repay such indebtedness to Polar and ACAB may be unable to repay its obligations owing to the Sponsor. </p></td></tr></table> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Abpro Directors and Executive Officers in the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the ACAB Board to vote in favor of approval of the proposals, ACAB stockholders should keep in mind that Abpro&#8217;s directors and officers have interests in such proposals that are different from or in addition to (and which may conflict with) those of ACAB stockholders. These interests include, among other things, the interests listed below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of Abpro&#8217;s directors and executive officers will serve as officers and directors of the Post-Combination Company following the consummation of the Business Combination. Specifically, the following individuals who are currently executive officers of Abpro are expected to become executive officers of the Post-Combination Company upon the Closing, serving in the offices set forth opposite their names below: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Markelewicz, Jr., M.D., M.M.Sc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Mitrano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP of Finance</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Zapf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP of Corporate Development and General Counsel</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In addition, the following individuals who are currently members of the Abpro board of directors are expected to become members of the Post-Combination Company board of directors upon the Closing: Ian Chan, Jin Wook (Miles) Suk, &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Under the terms of the Business Combination Agreement, from and after the consummation of the Business Combination, the Post-Combination Company will indemnify certain persons, including Abpro&#8217;s directors and executive officers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As of the date of the Business Combination Agreement, certain of Abpro&#8217;s executive officers and directors held Abpro options. The treatment of such options in connection with the Business Combination is described in &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements&#8212;Merger</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<span style="font-style:italic">Consideration</span>.&#8221; The holding of such awards by such executive officers and directors as of September&#160;30, 2023 is set forth in the table below. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Abpro Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Vested</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Unvested</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,229,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">456,251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert J. Markelewicz, Jr., M.D., M.M.Sc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,099</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Mitrano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Zapf</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Y. Chan, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,314,202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">877,701</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jin Wook (Miles) Suk</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Langer, Sc.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Tang</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Abpro Board were aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination and the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Purchases of Public Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the stockholder vote to approve the Business Combination, our Sponsor, directors, officers, advisors or any of their respective affiliates may privately negotiate transactions to purchase Public Shares from stockholders who would have otherwise elected to have their shares redeemed in conjunction with the Business Combination for a per share pro rata portion of the trust account. There is no limit on the number of Public Shares our Sponsor, directors, officers, advisors or any of their respective affiliates may purchase in such transactions, subject to compliance with applicable law and the rules of Nasdaq or any other exchange on which our securities may be listed. Any such privately negotiated purchases may be affected at purchase prices that are in excess of the per share pro rata portion of the trust account. However, our Sponsor, directors, officers, advisors and their respective affiliates have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase Public Shares in such transactions. None of our Sponsor, directors, officers, advisors or any of their respective affiliates will make any such purchases when they are in possession of any material <span style="white-space:nowrap">non-public</span> information not disclosed to the seller of such Public Shares or during a restricted period under Regulation M under the Exchange Act. Such a purchase could include a contractual acknowledgement that such stockholder, although still the record holder of such Public Shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights, and could include a contractual provision that directs such stockholder to vote such shares in a manner directed by the purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that our Sponsor, directors, officers, advisors or any of their respective affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of any such purchases of Public Shares could be to (a)&#160;vote such shares in favor of the Business Combination and thereby increase the likelihood of obtaining stockholder approval of the Business Combination or (b)&#160;to satisfy a closing condition in the Business Combination Agreement, where it appears that such requirement would otherwise not be met. Any such purchases of our Public Shares may result in the completion of the Business Combination that may not otherwise have been possible. Any such purchases will be reported pursuant to Section&#160;13 and Section&#160;16 of the Exchange Act to the extent the purchasers are subject to such reporting requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if such purchases are made, the public &#8220;float&#8221; of our Series A common stock may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Sponsor, officers, directors, advisors or any of their respective affiliates anticipate that they may identify the stockholders with whom our Sponsor, officers, directors, advisors or any of their respective affiliates may pursue privately negotiated purchases by either the stockholders contacting us directly or by our receipt of redemption requests submitted by stockholders following our mailing of proxy materials in connection with the Business Combination. To the extent that our Sponsor, officers, directors, advisors or any of their respective affiliates enter into a privately negotiated purchase, they would identify and contact only potential selling stockholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against the Business Combination, whether or not such stockholder has already submitted a proxy with respect to the Business Combination but only if such shares have not already been voted at the stockholder meeting related to the Business Combination. Our Sponsor, officers, directors, advisors or any of their respective affiliates will select which stockholders to purchase shares from based on the negotiated price and number of shares and any other factors that they may deem relevant, and will only purchase Public Shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any purchases by our Sponsor, officers, directors, advisors or any of their respective affiliates who are affiliated purchasers under Rule <span style="white-space:nowrap">10b-18</span> under the Exchange Act will only be made to the extent such purchases are able to be made in compliance with Rule <span style="white-space:nowrap">10b-18,</span> which is a safe harbor from liability for manipulation under Section&#160;9(a)(2) of and Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. Rule <span style="white-space:nowrap">10b-18</span> has certain technical requirements that must be complied with in order for the safe harbor to be available to the purchaser. Our Sponsor, officers, directors, advisors and any of their respective affiliates will not make purchases of Series A common stock if the purchases would violate Section&#160;9(a)(2) of or Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Matters </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the HSR Act and the rules&#160;that have been promulgated thereunder by the Federal Trade Commission (&#8220;FTC&#8221;), certain transactions may not be consummated unless an HSR Notification and Report Form&#160;has been furnished to the Antitrust Division of the Department of Justice (&#8220;Antitrust Division&#8221;) and the FTC by each party and certain waiting period requirements have been satisfied. The Business Combination is subject to these requirements and may not be completed until the expiration of a <span style="white-space:nowrap">30-day</span> waiting period following the two filings of the required Notification and Report Forms with the Antitrust Division and the FTC or until early termination is granted. In April 2024, ACAB and Abpro filed the required forms under the HSR Act with respect to the Business Combination with the Antitrust Division and the FTC and requested early termination. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time before or after consummation of the Business Combination, notwithstanding expiration or termination of the waiting period under the HSR Act, the Antitrust Division or the FTC, or any state, foreign or other governmental authority could take such action under applicable antitrust laws as such authority deems necessary or desirable in the public interest, including seeking to enjoin the consummation of the Business Combination, conditionally approving the Business Combination upon divestiture of assets or other remedies, and/or subjecting the completion of the Business Combination to regulatory conditions or seeking other remedies. Private parties may also seek to take legal action under the antitrust laws under certain circumstances. ACAB cannot assure you that the Antitrust Division, the FTC, any state attorney general, or any other government authority will not attempt to challenge the Business Combination on antitrust grounds, and, if such a challenge is made, ACAB cannot assure you as to its result. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_25">PUBLIC TRADING MARKETS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s Series A common stock is listed on Nasdaq under the symbol &#8220;ACAB&#8221;. ACAB&#8217;s public warrants are listed on Nasdaq under the symbol &#8220;ACABW&#8221;. ACAB&#8217;s units are listed on Nasdaq under the symbol &#8220;ACABU&#8221;. Following the Business Combination, the Post-Combination Company&#8217;s Series A common stock (including common stock issuable in the Business Combination) will be listed on Nasdaq under the symbol &#8220;ABP&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_26">THE BUSINESS COMBINATION AGREEMENT AND RELATED AGREEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This section describes the material terms of the Business Combination Agreement. The description in this section and elsewhere in this proxy statement/prospectus is qualified in its entirety by reference to the complete text of the Business Combination Agreement, a copy of which is attached as Annex&#160;A to this proxy statement/prospectus. This summary does not purport to be complete and may not contain all of the information about the Business Combination Agreement that is important to you. You are encouraged to read the Business Combination Agreement carefully and in its entirety. This section is not intended to provide you with any factual information about ACAB or Abpro. Such information can be found elsewhere in this proxy statement/prospectus. Unless the context otherwise requires, all references in this subsection to &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to ACAB prior to the consummation of the Business Combination. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of the Business Combination Agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement are also modified in part by the underlying disclosure schedules delivered by each of ACAB and Abpro to each other (the &#8220;disclosure schedules&#8221;), which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders, and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an investment decision. Additionally, the representations and warranties of the parties to the Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this proxy statement/prospectus. Accordingly, no person should rely on the representations and warranties in the Business Combination Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of the actual state of facts about ACAB, Merger Sub, the Sponsor, Abpro or any other matter. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Business Combination Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Structure of the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, ACAB entered into a Business Combination Agreement with Abpro and Merger Sub, pursuant to which Merger Sub will merge with and into Abpro, with Abpro surviving as a wholly-owned&#160;subsidiary of ACAB.&#160;In connection with the consummation of the Business Combination, ACAB will change its corporate name to &#8220;Abpro Holdings, Inc.&#8221; The respective boards of directors of ACAB and Abpro have duly approved the Business Combination Agreement and the transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consideration to Abpro&#8217;s Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, at the Effective Time: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding share of Abpro common stock will be cancelled and converted into (i)&#160;the right to receive a pro rata share of 72.5&#160;million shares of Series&#160;A Common Stock (22.5&#160;million of which shares will be set aside and equally divided among the Sponsor, Abpro and Abpro Bio Co., Ltd. for each such party to use in the PIPE Financing or to obtain capital for ACAB or the Surviving Company (such shares, the &#8220;Abpro Incentive Shares&#8221;). Any of the Abpro Incentive Shares that are not used or allocated by the Sponsor, Abpro or Abpro Bio Co., Ltd. by the Closing shall be deemed forfeited and shall not be issued to any other party) (ii)&#160;the right to receive a pro rata portion of up to 14,500,000 additional shares of Series&#160;A Common Stock (the <span style="white-space:nowrap">&#8220;Earn-out</span> Shares&#8221;), to be earned 1/3 if the volume weighted average price (&#8220;VWAP&#8221;) of the Post-Combination Company&#8217;s stock is above $13.00 for any 20 trading days within any consecutive 30 trading day period; 1/3 if such VWAP is above $15.00; and 1/3 if such VWAP is above $18.00, at any point prior to the fifth anniversary of the Closing Date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro option will be converted into an option to purchase a number of shares of Series&#160;A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such option immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio, at an exercise price per share equal to the current exercise price per share for such option divided by the Exchange Ratio (rounded up to the nearest whole cent). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding Abpro RSU (whether vested or unvested) will be converted into restricted shares of Series&#160;A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Abpro common stock subject to such RSU immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to closing, each outstanding share of Abpro preferred stock will be converted into shares of Abpro common stock in accordance with its terms, equal to the number of shares of Abpro common stock obtained by dividing the liquidation preference of such share of Abpro preferred stock by the Exchange Ratio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Merger, it is contemplated that the Post-Combination Company will have a single class of common stock. The consideration described in the foregoing bullets and as set forth in the table below is collectively referred to as the &#8220;Business Combination Consideration.&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:43%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Type of Security</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number<br/>Issuable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Recipients</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Common Stock (issued at Closing)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Holders of Abpro Common Stock</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Common Stock (issued at Closing)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Holders of Abpro Preferred Stock</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Common Stock (upon attainment of First Share Target)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Holders of Abpro Common Stock</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Common Stock (upon attainment of Second Share Target)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Holders of Abpro Common Stock</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Common Stock (upon attainment of Third Share Target)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Holders of Abpro Common Stock</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase shares of Series&#160;A Common Stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Holders of Abpro options</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Holders of Abpro RSUs</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain related agreements have been, or will be entered into on or prior to the completion of the Business Combination, including the Sponsor Letter Agreement, the Sponsor Support Agreement, the Abpro Support Agreements and the Lockup Letter. See &#8220;<span style="font-style:italic"> &#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Related Agreements</span>&#8221; for more information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conditions to the Closing of the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conditions to Each Party&#8217;s Obligations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The respective obligations of each party to the Business Combination Agreement to consummate the transactions contemplated by the Business Combination are subject to the satisfaction (or, if permitted by applicable law, waiver by the party for whose benefit such condition exists) of the following conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each applicable waiting period (and any extensions thereof, or any timing agreements, understandings or commitments obtained by request or other action of the United&#160;States Federal Trade Commission or the Antitrust Division of the United&#160;States Department of Justice, as applicable) or consent under the HSR Act shall have expired, been terminated or obtained (or deemed, by applicable law, to have been obtained), as applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no order or law issued by any court of competent jurisdiction or other governmental entity or other legal restraint or prohibition preventing the consummation of the transactions contemplated by the Business Combination Agreement (including the Closing) being in effect; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">this proxy statement/prospectus becoming effective in accordance with the provisions of the Securities Act, no stop order being issued by the SEC and remaining in effect with respect to this proxy statement/prospectus, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the stockholders of Abpro shall have approved the Business Combination Agreement and related transactions via written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adoption and approval of the Business Combination Agreement, the ancillary documents, and the transactions and proposals contemplated thereby, in each case by the requisite vote of ACAB&#8217;s stockholders in accordance with the DGCL and ACAB&#8217;s governing documents (the &#8220;ACAB Stockholder Approval&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB&#8217;s initial listing application with Nasdaq in connection with the transactions contemplated by the Business Combination Agreement being approved and, immediately following the Effective Time, ACAB satisfying any applicable initial and continuing listing requirements of Nasdaq, and ACAB not having received any notice of <span style="white-space:nowrap">non-compliance&#160;in</span> connection therewith that has not been cured or would not be cured at or immediately following the Effective Time, and the Series&#160;A Common Stock (including the shares of Series A Common Stock to be issued in connection with the Business Combination) having been approved for listing on Nasdaq; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after giving effect to the transactions contemplated by the Business Combination Agreement (including any ACAB stockholder redemption), the Post-Combination Company having at least $5,000,001 of net tangible assets (as determined in accordance with <span style="white-space:nowrap">Rule&#160;3a51-1(g)(1)&#160;of</span> the Exchange&#160;Act) immediately after the Effective Time. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Conditions to the Obligations of the SPAC Parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of ACAB and Merger Sub (together, the &#8220;SPAC Parties&#8221;) to consummate the transactions contemplated by the Business Combination Agreement (including the Closing) are subject to the satisfaction (or, if permitted by applicable law, waiver by ACAB on behalf of itself and Merger Sub) of the following further conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">(i) the Company Fundamental Representations (as defined in the Business Combination Agreement) shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all material respects as of such earlier date) and (ii)&#160;the other representations and warranties shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of such earlier date), except, in the case of this clause (ii), where the failure of such representations and warranties to be true and correct, taken as a whole, does not, and would not reasonably be expected to, cause a Company Material Adverse Effect (as defined in the Business Combination Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro having performed and complied in all material respects with the covenants and agreements required to be performed or complied with by it under the Business Combination Agreement at or prior to the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Abpro Preferred Stock conversion having been duly authorized; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">since the date of the Business Combination Agreement, no Company Material Adverse Effect having occurred that is continuing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at or prior to the Closing, ACAB having received a certificate duly executed by an authorized officer of Abpro, dated as of the Closing Date, to the effect that the conditions specified in Section&#160;6.2(a), Section&#160;6.2(b)&#160;and Section&#160;6.2(c)&#160;of the Business Combination Agreement are satisfied; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each Ancillary Document to which Abpro is or is to be a party having been executed and delivered by Abpro and is in full force and effect; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of the agreements set forth on Section&#160;6.2(g) of the Company Disclosure Schedule having been terminated as of immediately prior to Closing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Conditions to the Obligations of Abpro </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Abpro to consummate the transactions contemplated by the Business Combination Agreement (including the Closing) are subject to the satisfaction (or, if permitted by applicable law, waiver by Abpro) of the following further conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">(i)&#160;the SPAC Fundamental Representations (as defined in the Business Combination Agreement) shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or&#160;&#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) (except for<span style="font-style:italic">&#160;de minimis</span><span style="font-style:italic"></span>&#160;inaccuracies) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) as of such earlier date) and (ii)&#160;the representations and warranties of the SPAC Parties (as defined in the Business Combination Agreement) contained in Article&#160;4 of this Agreement shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) as of such earlier date), except, in the case of this clause (ii), where the failure of such representations and warranties to be true and correct, taken as a whole, does not, and would not reasonably be expected to, cause a SPAC Material Adverse Effect (as defined in the Business Combination Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the SPAC Parties having performed and complied in all material respects with the covenants and agreements required to be performed or complied with by them under the Business Combination Agreement at or prior to the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there being at least $8,700,000&#160;in Available Cash. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Employment Agreements of certain executives of Abpro having been signed and delivered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">since the date of the Business Combination Agreement, no SPAC Material Adverse Effect having occurred that is continuing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at or prior to the Closing, ACAB shall have delivered, or caused to be delivered, to the Company a certificate duly executed by an authorized officer of ACAB, dated as of the Closing Date, to the effect that the conditions specified in Section&#160;6.3(a), Section&#160;6.3(b)&#160;and Section&#160;6.3(d)&#160;of the Business Combination Agreement are satisfied; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each Ancillary Document to which ACAB or Sponsor is or is to be a party having been executed and delivered by ACAB or Sponsor and is in full force and effect. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Representations and Warranties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Representations and Warranties of Abpro </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, Abpro made various representations and warranties to ACAB that are subject, in some cases, to specified exceptions and qualifications contained in the Business Combination Agreement or in the disclosure schedule that Abpro delivered to ACAB in connection with the Business Combination Agreement. These representations and warranties relate to, among other things: organization and qualification; capitalization; authority; Abpro&#8217;s subsidiaries; financial statements; the absence of undisclosed liabilities; consents requisite government approvals; permits; material contracts; absence of material changes; litigation; compliance with applicable law; employee benefit plans; environmental matters; intellectual property; labor matters; insurance; tax matters; brokers; real and personal property; transactions with affiliates; data privacy and security; compliance with international trade and anti-corruption&#160;laws; information supplied; health and drug regulatory compliance; investigation; and the Investment Company Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Representations and Warranties of the SPAC Parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, the SPAC Parties made various representations and warranties to Abpro that are subject, in some cases, to specified exceptions and qualifications contained in the Business Combination Agreement or in the disclosure schedule that Abpro delivered to ACAB in connection with the Business Combination Agreement. These representations and warranties relate to, among other things: organization and qualification; authority; consents and requisite government approvals; brokers; information supplied; capitalization; SEC filings; the Trust Account; transactions with affiliates; litigation; compliance with applicable law; activities by Merger Sub; internal controls over financial reporting and other financial disclosure compliance requirements; compliance with Nasdaq listing requirements; financial statements; the absence of undisclosed liabilities; employee matters; tax matters; investigation; business activities; the Investment Company Act; and the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material Adverse Effect </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, certain representations and warranties of Abpro and the SPAC Parties are qualified in whole or in part by materiality thresholds. In addition, certain representations and warranties of Abpro and the SPAC Parties are qualified in whole or in part by certain &#8220;material adverse effect&#8221; standards for purposes of determining whether a breach of such representations and warranties have occurred (and for purposes of determining whether certain conditions to Closing have been satisfied, as discussed above in &#8220;<span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Conditions to Closing of the Business Combination</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, a &#8220;Company Material Adverse Effect&#8221; means any state of facts, event, change, effect, occurrence, circumstance or development that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a)&#160;the business, assets, results of operations or condition (financial, regulatory, clinical or otherwise) of Abpro, or (b)&#160;the ability of Abpro to consummate the Merger; provided, however, in the case of clause (a), none of the following will be taken into account in determining whether a Company Material Adverse Effect has occurred or would be reasonably expected to occur: any adverse state of facts, event, change, effect, occurrence, circumstance or development arising from or related to (i)&#160;general business or economic conditions in or affecting the United&#160;States, European Union or Australia, or changes therein, or the global economy generally, (ii)&#160;any national or international political or social conditions in the United&#160;States, European Union or any other country, including the engagement by the United&#160;States, European Union or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&#160;changes in conditions of the financial, banking, capital or securities markets generally in the United&#160;States, European Union or any other country or region in the world, or changes therein, including changes in interest rates in the United&#160;States, European Union or any other country and changes in exchange rates for the currencies of any countries, (iv)&#160;changes or proposed changes in any applicable laws or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GAAP after the date of the Business Combination Agreement, (v)&#160;any state of facts, event, change, effect, occurrence, circumstance or development that is generally applicable to the industries or markets in which Abpro or its subsidiaries operates, (vi)&#160;subject to certain exceptions, the execution or public announcement of the Business Combination Agreement or the pendency or consummation of the transactions contemplated by the Business Combination Agreement, including the impact thereof on the relationships, contractual or otherwise, of Abpro with employees, contingent workers, customers, investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, or other third parties related thereto, (vii)&#160;any failure by Abpro or its subsidiaries to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (i)&#160;through (vi)&#160;or (viii)), or (viii)&#160;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics or pandemics or the worsening of any pandemics (including <span style="white-space:nowrap">COVID-19),</span> acts of God or other natural disasters or comparable events in the United&#160;States, European Union or any other country or region in the world, or any escalation of the foregoing; provided, however, that any state of facts, event, change, effect, occurrence, circumstance or development resulting from a matter described in any of the foregoing clauses (i)&#160;through (v)&#160;or (viii)&#160;may be taken into account in determining whether a Company Material Adverse Effect has occurred or would be reasonably expected to occur to the extent, and solely to the extent, the same has a material and disproportionate adverse effect on Abpro relative to other participants operating in the industries or markets in which Abpro and its subsidiaries operates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, a &#8220;SPAC Material Adverse Effect&#8221; means any state of facts, event, change, effect, occurrence, circumstance or development that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a)&#160;the business, assets, results of operations or condition (financial, regulatory or otherwise) of the SPAC Parties, taken as a whole, or (b)&#160;the ability of ACAB or Merger Sub to consummate the Merger; provided, however, in the case of clause (a), none of the following will be taken into account in determining whether a SPAC Material Adverse Effect has occurred or would be reasonably expected to occur: any adverse state of facts, event, change, effect, occurrence, circumstance or development (regardless of materiality) arising from or related to (i)&#160;general business or economic conditions in or affecting the United&#160;States, or changes therein, or the global economy generally, (ii)&#160;any national or international political or social conditions in the United&#160;States or any other country, including the engagement by the United&#160;States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&#160;changes in conditions of the financial, banking, capital or securities markets generally in the United&#160;States or any other country or region in the world, or changes therein, including changes in interest rates in the United&#160;States or any other country and changes in exchange rates for the currencies of any countries,&#160;(iv)&#160;changes or proposed changes in any applicable laws or GAAP after the date of the Business Combination Agreement, (v)&#160;any event, change, effect, occurrence, circumstance or development that is generally applicable to the industries or markets in which any SPAC Party operates, (vi)&#160;subject to certain exceptions, the execution or public announcement of the Business Combination Agreement or the pendency or consummation of the transactions contemplated by the Business Combination Agreement, including the impact thereof on the relationships, contractual or otherwise, of any SPAC Party with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees or other third parties related thereto, (vii)&#160;any failure by any SPAC Party to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (i)&#160;through (vi)&#160;or (viii)), or (viii)&#160;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics or pandemics or the worsening of any pandemic (including <span style="white-space:nowrap">COVID-19),</span> acts of God or other natural disasters or comparable events in the United&#160;States or any other country or region in the world, or any escalation of the foregoing, (ix)&#160;any state of facts, event, change, effect, occurrence, circumstance or development relating to Abpro or the Abpro&#160;stockholders, or (x)&#160;any ACAB Stockholder Redemption, in and of itself, or (xi)&#160;subject to certain exceptions, any breach of any covenants, agreements or obligations of a PIPE investor under a subscription agreement (including any breach of any PIPE investor&#8217;s obligations to fund its commitment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereunder when required); provided, however, that any state of facts, event, change, effect, occurrence, circumstance or development resulting from a matter described in any of the foregoing clauses (i)&#160;through (v)&#160;or (viii)&#160;may be taken into account in determining whether a SPAC Material Adverse Effect has occurred or would be reasonably expected to occur to the extent, and solely to the extent, the same has a material and disproportionate adverse effect on the SPAC Parties, taken as a whole, relative to other SPACs operating in the industries in which the SPAC Parties operate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Covenants of the Parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Covenants of Abpro </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro made certain covenants under the Business Combination Agreement, including, among others, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Subject to certain exceptions, prior to the Closing, Abpro shall, operate its business in the ordinary course in all material respects and use commercially reasonable efforts to maintain and preserve intact its business organization, assets, properties and material business relations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Subject to certain exceptions, prior to the Closing, Abpro shall not do any of the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">declare, set a record date for, set aside, make or pay any <span style="white-space:nowrap">non-cash&#160;distribution</span> in respect of, or repurchase, any equity securities of Abpro; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">merge, consolidate, combine or amalgamate with any person or purchase or otherwise acquire any corporation, partnership, limited liability company, joint venture, association, or other business entity or organization or division thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adjust, split, combine, subdivide, recapitalize, reclassify or otherwise effect any change in respect of any equity securities of Abpro or issue any other security in respect of, in lieu of or in substitution for Abpro&#8217;s equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt or propose any amendments, supplements, restatements or modifications to Abpro&#8217;s governing documents (except as required to effect the conversion of the Abpro Preferred Stock); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">(a) sell, assign, transfer, convey, abandon, lease, license, allow to lapse or expire or otherwise dispose of any material assets or properties (including the leased real property but excluding intellectual property rights), other than obsolete assets or properties or in the ordinary course of business; or (b)&#160;create, subject to or incur any lien (other than certain permitted liens) in respect of any material assets or properties (including the leased real property but excluding intellectual property rights); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">transfer, issue, deliver, sell, pledge, grant or otherwise directly or indirectly dispose of, or subject to a lien, (a)&#160;any equity securities of Abpro, or (b)&#160;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating Abpro to transfer, issue, deliver, sell, pledge, grant or otherwise directly or indirectly dispose of, or subject to a lien, any equity securities of Abpro (provided that Abpro may grant equity securities to current and new employees pursuant to the existing Abpro equity incentive plan, subject to Abpro providing ACAB and its legal counsel with prior notice and an opportunity to review the proposed grants at least five (5)&#160;business days prior to any proposed approval); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incur, create, assume or otherwise become liable for (whether directly, contingently or otherwise), or guarantee for the benefit of another person, any indebtedness in excess of $500,000 (other than equipment financing and trade payables incurred in the ordinary course of business), individually or in the aggregate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into, amend, modify, waive any material benefit or right under, novate, assign, assume or terminate or rescind any material contract (excluding any expiration or automatic extension or renewal of any such material contract pursuant to its terms or entering into additional work orders pursuant to, and in accordance with the terms of, any material contract); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any loans, advances or capital contributions of money or other property to, or guarantees for the benefit of, or any investments in, any person, in excess of $250,000, individually or in the aggregate, other than (a)&#160;the reimbursement of expenses of employees in the ordinary course of business, and (b)&#160;prepayments and deposits to suppliers of Abpro in the ordinary course of business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except pursuant to the Business Combination Agreement and as required under the terms of any employee benefit plan, (i)&#160;amend or modify in any material respect, adopt, enter into, terminate or rescind any material employee benefit plan or any benefit or compensation plan, policy, program of contract that would be an employee benefit plan if in effect as of the date of the Business Combination Agreement, (ii)&#160;increase or agree to increase the compensation or bonus payable, or pay or agree to pay any bonus to, to any current or former key employee or contingent worker, other than, in each case, individual annual and merit-based&#160;raises of up to 10% in the salary or wages of any such key employee or contingent worker and bonus payments made in the ordinary course of business and consistent with past practice, as applicable, (iii)&#160;take any action to accelerate any payment, right to payment or benefit, or the vesting or funding of any payment, right to payment or benefit, payable or to become payable to any current or former key employee or contingent worker, (iv)&#160;waive or release any noncompetition, <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">no-hire,</span> nondisclosure or other restrictive covenant obligation of any current or former key employee, (v)&#160;increase the severance or change in control pay or benefits of, any current or former executive director, manager, officer or employee, or (vi)&#160;hire or terminate (other than for cause) or furlough the employment of key employee (or person who would be a key employee, were they hired by Abpro), or terminate any group of employees if such group termination would trigger the U.S. Worker Adjustment and Retraining Notification Act of 1988; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into, assume, assign, amend any material term of or terminate (excluding any expiration in accordance with its terms) any collective bargaining or similar agreement (including agreements with works councils and trade unions and side letters) to which it is a party or by which it is bound, other than in the ordinary course of business consistent with past practice; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make, change or revoke any material tax election or material tax accounting method, file any material tax return in a manner materially inconsistent with past practice, amend any material tax return, enter into any agreement with a governmental entity with respect to a material amount of taxes, settle or compromise any claim or assessment by a governmental entity in respect of any material amount of taxes, surrender any right to claim a refund of a material amount of taxes, consent to any extension or waiver of the statutory period of limitation applicable to any material tax claim or assessment (other than an extension or waiver that arises pursuant to an extension to file a Tax Return obtained in the ordinary course of business) or enter into any tax sharing or similar agreement (other than any agreement entered into in the ordinary course of business, the primary purpose of which does not relate to taxes); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">waive, release, compromise, settle or satisfy any pending or threatened claim or compromise or settle any liability, whether by contract or otherwise, the performance of which would, at any time, (a)&#160;involve the payment of more than $250,000 in the aggregate, (b)&#160;impose any material, <span style="white-space:nowrap">non-monetary</span> obligations on it (or ACAB or any of its affiliates after the Closing), (c)&#160;require it to accept or concede material injunctive relief or (d)&#160;involve a governmental entity or alleged criminal wrongdoing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">change Abpro&#8217;s accounting principles, policies, procedures, practices or methods in any material respect, or make any change which would materially affect the reported consolidated assets, liabilities or results of operations of Abpro, other than changes that are made in accordance with GAAP or Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract with any broker, finder, investment banker or other person under which such person is or will be entitled to any broker fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract or other arrangement that materially restricts Abpro or its affiliates&#8217; ability to engage or compete in any material line of business or enter into a new material line of business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any capital expenditure that in the aggregate exceeds $1,000,000, other than any capital expenditure (or series of related capital expenditures) consistent with the capital expenditures budget set forth in Abpro&#8217;s disclosure schedules to the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voluntarily fail to maintain in full force and effect material insurance policies covering Abpro and its affiliates and their respective properties, assets and businesses in a form and amount consistent with past practice; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any transaction or amend in any material respect any existing contract with any Company Related Party, as defined in the Business Combination Agreement, excluding, to the extent permitted under the Business Combination Agreement, ordinary course payments of annual compensation, provision of benefits or reimbursement of expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, assign, transfer, convey, abandon, lease, license, or otherwise dispose of, or create or incur any lien (other than certain permitted liens) on, any intellectual property rights, except granting <span style="white-space:nowrap">non-exclusive&#160;licenses</span> pursuant to material transfer agreement, contract research agreements, clinical trial agreements or services or supply agreements in which research, development, clinical trials or supply services are being performed for Abpro or other Contracts <span style="white-space:nowrap">containing&#160;non-exclusive</span> licenses, in each case, that are entered into by Abpro in the ordinary course of business and where the grant of rights to use any such intellectual property are incidental, and not material to, any performance under each such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow to lapse or expire or fail to take any action necessary to maintain any intellectual property rights, except with respect to intellectual property rights that in the reasonable judgment of management of Abpro are immaterial to the business of Abpro; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract to take, or cause to be taken, or otherwise become obligated to take, any of the actions set forth in the foregoing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to the Closing, Abpro shall not, and shall direct its respective representatives not to, directly or indirectly: (i)&#160;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition Proposal; (ii)&#160;furnish or disclose any <span style="white-space:nowrap">non-public&#160;information</span> to any person in connection with, or that could reasonably be expected to lead&#160;to, a Company Acquisition Proposal; (iii)&#160;enter into any contract or other arrangement or understanding regarding a Company Acquisition Proposal; (iv)&#160;prepare or take any steps in connection with a public offering of any equity securities of Abpro (or any affiliate or successor of Abpro); or (v)&#160;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any person to do or seek to do any of the foregoing. Abpro agrees to (A)&#160;notify ACAB promptly upon any SPAC Party obtaining any SPAC Acquisition Proposal, and to describe the terms and conditions of any such SPAC Acquisition Proposal in reasonable detail (including the identity of any Person making such SPAC Acquisition Proposal), and (B)&#160;keep ACAB reasonably informed on a reasonably current basis of any modifications to such offer or information. A &#8220;Company Acquisition Proposal&#8221; means any transaction or series of related transactions under which any person(s), directly or indirectly, acquires or otherwise purchases Abpro or all or substantially all of the assets or business of Abpro (whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise), or any material equity or similar investment in Abpro, excluding (i)&#160;the Business Combination Agreement, the ancillary documents and the transactions contemplated thereby, (ii)&#160;the issuance of options in the ordinary course of business, and (iii)&#160;a capital raise. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As promptly as reasonably practicable (and in any event within 48&#160;hours) following the time at which the registration statement of which this proxy statement/prospectus forms a part is declared effective under the Securities Act, Abpro is required to obtain and deliver to ACAB a true and correct copy of the Abpro Stockholder Approval, and through its board of directors, will recommend to the Abpro stockholders, the approval and adoption of the Business Combination Agreement, the ancillary documents to which Abpro is or will be a party, the amendment to Abpro&#8217;s charter to permit the conversion of the Abpro Preferred Stock, and the transactions contemplated thereby. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Subject to certain exceptions, at or prior to the Closing, Abpro will purchase and maintain in effect for a period of six&#160;years after the Effective Time, without lapses in coverage, a &#8220;tail&#8221; policy or policies providing liability insurance coverage for Abpro&#8217;s directors and officers with respect to any acts, errors or omissions occurring on or prior to the Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Abpro will use commercially reasonable efforts to obtain from all Abpro stockholders who have not previously entered into an Abpro Support Agreement, Abpro Support Agreements prior to the Closing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Covenants of ACAB </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB made certain covenants under the Business Combination Agreement, including, among others, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As promptly as practicable after the registration statement of which this proxy statement/prospectus forms a part is declared effective under the Securities Act, ACAB will (i)&#160;duly give notice of, convene and hold, the Special Meeting for the purposes of obtaining the ACAB Stockholder Approval; and&#160;(ii)&#160;through the Board, recommend to its stockholders the adoption and approval of the Business Combination Agreement, the ancillary documents, and the transactions and proposals contemplated thereby. The Board will not (and no committee thereof will) withdraw or modify such recommendation, except that, if the Board, after consultation with its legal counsel, determines in good faith that failure to withdraw or modify the Board Recommendation would be inconsistent with the Board&#8217;s fiduciary duties to its stockholders under applicable law, then the Board may make a ACAB Change in Recommendation so long as ACAB provides Abpro with at least 48&#160;hours&#8217; advance written notice of such withdrawal or modification. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As promptly as reasonably practicable (and in any event within one business&#160;day) following the date of the Business Combination Agreement, ACAB, as the sole stockholder of Merger Sub, will approve and adopt the Business Combination Agreement, the ancillary documents to which Merger Sub is or will be a party and the transactions contemplated thereby. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Subject to certain exceptions, prior to the Closing, ACAB will not, and will cause its subsidiaries not to, do any of the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek an approval from the <span style="white-space:nowrap">pre-Closing&#160;ACAB</span> stockholders, or otherwise adopt any amendments, supplements, restatements or modifications to its trust agreement or the governing documents of any SPAC Party or any of their subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">declare, set aside, make or pay any dividends on or make any other distribution or payment in respect of, any equity securities of ACAB or any of its subsidiaries, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any issued and outstanding equity securities of ACAB or any of its subsidiaries, as applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">split, combine or reclassify any of its capital stock or other equity securities or issue any other security in respect of, in lieu of or in substitution for shares of its capital stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incur, create, guarantee or assume (whether directly, contingently or otherwise) any indebtedness except for indebtedness for borrowed money in an amount not to exceed $1,000,000 in the aggregate; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any loans or advances to, or capital contributions in, any other person, other than to, or in, ACAB or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issue any equity securities of ACAB or any of its subsidiaries or grant any options, warrants or stock appreciation rights with respect to equity securities of ACAB or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into, renew, modify or revise any ACAB related party transaction (or any contract or agreement that if entered into prior to the execution and delivery of the Business Combination Agreement would be a ACAB related party transaction), other than the entry into any contract with a ACAB related party with respect to the incurrence of indebtedness permitted by the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">engage in any activities or business, or incur any material liabilities, other than with respect to any activities, businesses or liabilities that are (i)&#160;permitted or contemplated by, (ii)&#160;liabilities incurred in connection with, the Business Combination Agreement or any ancillary document, or in connection with or incidental or related to ACAB&#8217;s continuing corporate (or similar) existence or it being (or continuing to be) a public company listed on Nasdaq, or (iii)&#160;administrative or ministerial in nature and not material; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction involving ACAB or its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract with any broker, finder, investment banker or other person under which such person is or will be entitled to any brokerage fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by the Business Combination Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make, change or revoke any material tax election or material tax accounting method, file any material tax return in a manner materially inconsistent with past practice, amend any material tax return, enter into any agreement with a governmental entity with respect to a material amount of taxes, settle or compromise any claim or assessment by a governmental entity in respect of any material amount of taxes, surrender any right to claim a refund a material amount of taxes, consent to any extension or waiver of the statutory period of limitation applicable to any tax claim or assessment (other than an extension or waiver that arises pursuant to an extension to file a Tax Return obtained in the ordinary course of business), or enter into any tax sharing or similar agreement (other than any agreement entered into in the ordinary course of business, the primary purpose of which does not relate to taxes); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">waive, release, compromise, settle or satisfy any pending or threatened material claim (which shall include, but not limited to, any pending or threatened proceeding); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any change in any method of financial accounting or financial accounting principles, policies, procedures or practices except changes that are made (i)&#160;in accordance with PCAOB standards, or (ii)&#160;as required by any securities law or any order, directive, guideline, recommendation, statement, comment or guidance issued, passed, approved, published, promulgated or released by, the SEC, following reasonable prior consultation with Abpro; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make or permit to be made any distribution of amounts held in Trust Account (other than interest income earned on the funds held therein as permitted by ACAB&#8217;s trust agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create any new subsidiary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">(a) merge, consolidate, combine or amalgamate with any person, or (b)&#160;purchase or otherwise acquire (whether by merging or consolidating with, purchasing any equity securities in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, limited liability company, joint venture, association or other business entity or organization or division thereof; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any contract to take, or cause to be taken, any of the actions set forth in the foregoing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB shall use its reasonable best efforts to: (i)&#160;cause the Series A Common Stock issuable in accordance with the Business Combination Agreement to be approved for listing on Nasdaq; (ii)&#160;satisfy all applicable initial and continuing listing requirements of Nasdaq; (iii)&#160;cause the name of ACAB to be changed to &#8220;Abpro Holdings, Inc.&#8221; with effect from the Closing; and (iv)&#160;cause the trading symbol under which the Series A Common Stock is listed for trading on Nasdaq to be changed to &#8220;ABP&#8221; and have the Series A Common Stock listed for trading with such trading symbol. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">At the Closing, ACAB shall (i)&#160;cause the documents, certificates and notices required to be delivered to the trustee pursuant to the trust agreement pertaining to Trust Account to be so delivered and (ii)&#160;make all appropriate arrangements to cause such trustee to (A)&#160;pay as and when due all amounts payable to any Public Stockholders who elect to redeem their Public Shares, (B)&#160;pay any amounts due to the underwriters of the Initial Public Offering for their deferred underwriting commissions as set forth in such trust agreement and (C)&#160;immediately thereafter, pay all remaining amounts then available in the Trust Account to ACAB in accordance with such trust agreement. After compliance with the foregoing, Trust Account shall terminate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Subject to certain exceptions, at or prior to the Closing, ACAB will purchase and maintain in effect for a period of six&#160;years after the Effective Time, without lapses in coverage, a &#8220;tail&#8221; policy providing&#160;liability insurance coverage for ACAB&#8217;s directors and officers with respect to any acts, errors or omissions occurring on or prior to the Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to the Closing or termination of the Business Combination Agreement in accordance with its terms, the SPAC Parties shall not, and each of them shall direct their representatives not to, directly or indirectly: (i)&#160;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a SPAC Acquisition Proposal; (ii)&#160;furnish or disclose <span style="white-space:nowrap">any&#160;non-public</span> information to any person in connection with, or that would reasonably be expected to lead to, a SPAC Acquisition Proposal; (iii)&#160;enter into any contract or other arrangement or understanding regarding a SPAC Acquisition Proposal; (iv)&#160;other than in connection with the Business Combination Agreement, the ancillary documents or the transactions contemplated hereby or thereby, prepare or take any steps in connection with an offering of any securities of any SPAC Party (or any affiliate or successor of any SPAC Party); or (v)&#160;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or encourage any effort or attempt by any person to do or seek to do any of the foregoing. ACAB agrees to (A)&#160;notify Abpro promptly upon any SPAC Party obtaining any SPAC Acquisition Proposal, and to describe the terms and conditions of any such SPAC Acquisition Proposal in reasonable detail (including the identity of any Person making such SPAC Acquisition Proposal), and (B)&#160;keep Abpro reasonably informed on a reasonably current basis of any modifications to such offer or information. A &#8220;SPAC Acquisition Proposal&#8221; means any transaction or series of related transactions under which ACAB or any of its controlled affiliates, directly or indirectly, acquires or otherwise purchases any other person(s), engages in a business combination with any other person(s), or acquires or otherwise purchases at least a majority of the voting securities of such person or all or substantially all of the assets or businesses of any other person(s), in each case excluding the Business Combination Agreement, the ancillary documents and the transactions contemplated thereby. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Prior to the Closing and subject to ACAB stockholder approval, the Board will (i)&#160;approve and adopt the Incentive Plan and (ii)&#160;on or as soon as practicable following the filing of an effective registration statement on <span style="white-space:nowrap">Form&#160;S-8&#160;(or</span> other applicable form) with respect to the Post-Combination Company common stock issuable under the Incentive Plan, the Board will approve the Closing RSU Awards. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mutual Covenants of the Parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties made certain mutual covenants under the Business Combination Agreement, including, among others, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">using reasonable best efforts to consummate the Business Combination, including to obtain all consents of governmental entities as may be required to consummate the Business Combination, and making appropriate filings pursuant to the HSR Act and take other actions to cause the expiration or termination of any applicable waiting periods under the HSR Act (as of the date of this proxy statement/prospectus, ACAB is in breach of its HSR filing covenant under the Business Combination Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">keeping certain information confidential in accordance with the existing <span style="white-space:nowrap">non-disclosure&#160;agreements</span> between ACAB and Abpro, and providing each other with reasonable access to each other&#8217;s directors, officers, books and records (subject to certain customary restrictions); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining each other&#8217;s consent prior to making relevant public announcements regarding the Business Combination, subject to certain exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">using reasonable best efforts to cause the Business Combination to constitute a transaction treated as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to execute subscription agreements with potential sources of PIPE Financing and to use commercially reasonable efforts to cooperate in connection with any PIPE Financing, provided that Abpro has the right to review and approve (which approval shall not be unreasonably conditioned, withheld or delayed) any such materials relating to the PIPE Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">taking all actions as may be necessary or appropriate such that the Board will be comprised of the individuals appointed in accordance with the Business Combination Agreement and as described in the section entitled &#8220;<span style="font-style:italic">Management and Board of the Post-Combination Company Following the Business Combination</span>&#8221;; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delivering to each other a written statement setting forth a complete and accurate schedule of its good faith estimate of certain unpaid expenses as of the Closing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board of Directors and Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing, it is expected that the Post-Combination Company Board, which will be divided into three classes, will consist of five directors, four of whom shall be designated by Abpro and one of whom, who shall be independent, will be designated by the Sponsor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing, it is expected that the current executive officers of Abpro will become the executive officers of the Post-Combination Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Survival of Representations, Warranties and Covenants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations, warranties, agreements and covenants in the Business Combination Agreement terminate at the Effective Time, except for the covenants and agreements which, by their terms, contemplate performance after the Effective Time and those representations and warranties set forth in Section&#160;3.25, Section&#160;3.27, Section&#160;4.17 and Section&#160;4.20 of the Business Combination Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including, among others, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by the mutual written consent of ACAB and Abpro; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by ACAB, if any of the representations or warranties made by Abpro in the Business Combination Agreement are not true and correct or if Abpro fails to perform any of its covenants or agreements </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
under the Business Combination Agreement (including an obligation to consummate the Closing) such that certain conditions to the obligations of ACAB, as described above in the section entitled &#8220;<span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Conditions to Closing of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Other Conditions to the Obligations of the SPAC Parties</span>&#8221; could not be satisfied and the breach (or breaches) of such representations or warranties or failure (or failures) to perform such covenants or agreements is (or are) not cured or cannot be cured within the earlier of (i)&#160;30&#160;days after written notice thereof, and (ii)&#160;June&#160;1, 2024 (the &#8220;Termination Date&#8221;). This termination right is not available to the SPAC Parties if the SPAC Party is then in breach of the Business Combination Agreement so as to prevent certain conditions to the obligations of Abpro, as described above in the section entitled &#8220;<span style="font-style:italic">&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Conditions to Closing of the Business Combination</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">Other Conditions to the Obligations of Abpro</span>,&#8221; from being satisfied; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by Abpro, if any of the representations or warranties made by the SPAC Parties in the Business Combination Agreement are not true and correct or if any SPAC Party fails to perform any of its covenants or agreements under the Business Combination Agreement (including an obligation to consummate the Closing) such that certain conditions to the obligations of Abpro, as described above in the section entitled &#8220;&#8212;<span style="font-style:italic"></span><span style="font-style:italic">&#160;Conditions to Closing of the Business Combination</span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Other Conditions to the Obligations of Abpro</span>&#8221; could not be satisfied and the breach (or breaches) of such representations or warranties or failure (or failures) to perform such covenants or agreements is (or are) not cured or&#160;cannot be cured within the earlier of (i)&#160;30&#160;days after written notice thereof, and (ii)&#160;the Termination Date. This termination right is not available to Abpro if Abpro is then in breach of the Business Combination Agreement so as to prevent certain conditions to the obligations of the SPAC Parties, as described above in the section entitled &#8220;&#8212;<span style="font-style:italic"></span><span style="font-style:italic">&#160;Conditions to Closing of the Business Combination</span><span style="font-style:italic">&#160;&#8212;</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Other Conditions to the Obligations of the SPAC Parties</span>,&#8221; from being satisfied; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either ACAB or Abpro, if the transactions contemplated by the Business Combination Agreement (including the Closing) are not consummated on or prior to the Termination Date; unless the breach of any covenants or obligations under the Business Combination Agreement by the party seeking to terminate proximately caused the failure to consummate the transactions contemplated by the Business Combination Agreement, subject to a customary extension right; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either ACAB or Abpro, if any governmental entity issues an order or takes any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by the Business Combination Agreement and such order or other action becomes final and <span style="white-space:nowrap">non-appealable;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by either ACAB or Abpro, if the Special Meeting has been held (including any adjournment or postponement thereof), has concluded, ACAB&#8217;s stockholders have duly voted and the ACAB Stockholder Approval was not obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by ACAB, if Abpro does not deliver the Abpro Stockholder Approval when required under the Business Combination Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than customary confidentiality obligations, except in the case of a &#8220;Willful Breach&#8221; (as defined in the Business Combination Agreement) of any covenant or agreement under the Business Combination Agreement or &#8220;Fraud&#8221; (as defined in the Business Combination Agreement). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fees and Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set out below, the fees and expenses incurred in connection with the Business Combination Agreement, the ancillary documents thereto, and the transactions contemplated thereby, including the fees and disbursements of counsel, financial advisors and accountants, will be paid by the party incurring such fees or expenses;<span style="font-style:italic">&#160;provided</span><span style="font-style:italic"></span>&#160;that, in the event the Closing occurs, ACAB shall pay all unpaid Abpro expenses and unpaid ACAB expenses from the Trust Account. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governing Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement is governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of Delaware. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be amended or modified only by a written agreement executed and delivered by (i)&#160;if prior to Closing, ACAB and Abpro, and (ii)&#160;if after the Closing, ACAB and the Sponsor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, Sponsor entered into an agreement with ACAB, the Company and Abpro Bio International, Inc. (the &#8220;Sponsor Letter Agreement&#8221;), whereby Sponsor agrees to (i)&#160;retain 2.95&#160;million shares of ACAB Series A Common Stock held by it, (ii)&#160;divide 2,458,333 shares of ACAB Series A Common Stock held by it among the Sponsor, who will be entitled to 491,667 of the shares, Abpro, who will be entitled to 983,333 of the shares, and Abpro Bio International, Inc. who will be entitled to 983,333 of the shares, for such party to use to obtain <span style="white-space:nowrap">non-redemption</span> commitments from ACAB stockholders or other capital for ACAB or the Surviving Company (with any shares unused for such purpose to be retained by such party) and (iii)&#160;forfeit the remainder of any ACAB Series A Common Stock and ACAB Series B Common Stock held by it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Support Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, the Sponsor entered into the Sponsor Support Agreement with ACAB and Abpro. Under the Sponsor Support Agreement, the Sponsor agreed to vote, at any meeting of the stockholders of ACAB and in any action by written consent of the stockholders of ACAB, all of its shares of Series&#160;B Common Stock (together with any other equity securities of ACAB that it holds of record or beneficially, as of the date of the Sponsor Support Agreement, or of which it acquires record or beneficial ownership after the date thereof, the &#8220;Subject ACAB Equity Securities&#8221;) (i)&#160;in favor of (a)&#160;the Business Combination Agreement and the transactions contemplated thereby and (b)&#160;the other proposals that ACAB and Abpro agreed in the Business Combination Agreement shall be submitted at such meeting for approval by ACAB&#8217;s stockholders (together with the proposal to obtain the ACAB stockholders&#8217; approval for the Business Combination, the &#8220;Required Transaction Proposals&#8221;) and (ii)&#160;against any proposal that conflicts or materially impedes or interferes with any Required Transaction Proposals or that would adversely affect or delay the Business Combination. The Sponsor Support Agreement also prohibits the Sponsor from, among other things and subject to certain exceptions, transferring any Subject ACAB Equity Securities held by the Sponsor or taking any action that would have the effect of preventing or materially delaying the Sponsor from performing its obligations under the Sponsor Support Agreement, until the earlier of the Closing or the termination of the Sponsor Support Agreement according to its terms. In addition, in the Sponsor Support Agreement, the Sponsor agrees to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution&#160;protections with respect to the rate at which the shares of Series&#160;B Common Stock held by the Sponsor convert into shares of Series A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. An aggregate of 6,374,774&#160;shares of Series A Common Stock and 1&#160;share of Series&#160;B Common Stock are subject to the Sponsor Support Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sponsor Support Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Sponsor Support Agreement, a form of which is attached as an exhibit to the Business Combination Agreement, the terms of which are incorporated herein by reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro Support Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, certain Abpro stockholders (the &#8220;Abpro Supporting Stockholders&#8221;) entered into support agreements with the Company (the &#8220;Abpro Support Agreements&#8221;). Under the Abpro Support Agreements, each Abpro Supporting Stockholder agreed, within 48&#160;hours after the date that the proxy statement/prospectus is disseminated by Abpro to its stockholders following the effectiveness of the registration statement of which this proxy statement/prospectus forms a part, to execute and deliver a written consent with respect to all outstanding shares of Abpro common stock and Abpro preferred stock held by such Abpro Supporting Stockholder (the &#8220;Subject Abpro Shares&#8221;) approving the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination). In addition to the foregoing, each Abpro Supporting Stockholder agreed that, at any meeting of the holders of Abpro capital stock, each such Abpro Supporting Stockholder will appear at the meeting, in person or by proxy, and cause its Subject Abpro Shares to be counted as present thereat for purposes of calculating a quorum and voted (i)&#160;to approve and adopt the Business Combination Agreement, the transactions contemplated thereby (including the Business Combination), and any other matters necessary or reasonably requested by Abpro for consummation of the Business Combination, and (ii)&#160;against any proposal that conflicts or materially impedes or interferes with, or would adversely affect or delay, the consummation of the transactions contemplated by the Business Combination Agreement (including the Business Combination). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Abpro Support Agreements also prohibit the Abpro Supporting Stockholders from, prior to the Effective Time, among other things, (i)&#160;selling, assigning, transferring (including by operation of law), placing a lien on, pledging, disposing of or otherwise encumbering any of the Subject Abpro Shares, except if such transaction is in compliance with applicable securities laws, the governing documents of Abpro and the Business Combination Agreement, and the transferee agrees to be bound by the terms of the Abpro Support Agreement (ii)&#160;pledging, encumbering or creating a Lien on any Subject Abpro Shares or entering into any contract, option, commitment or other arrangement or understanding with respect to the foregoing, (iii)&#160;granting any proxies or powers of attorney or entering into a voting agreement or other arrangement with respect to any Subject Abpro Shares, or (iv)&#160;taking any action in furtherance of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Abpro Support Agreements does not purport to be complete and is qualified in its entirety by the terms and conditions of the Abpro Support Agreements, a form of which is attached as an exhibit to the Business Combination Agreement, the terms of which are incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro <span style="white-space:nowrap">Lock-Up</span> Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to Closing, certain Abpro stockholders will enter into <span style="white-space:nowrap">lock-up</span> agreements (the &#8220;Abpro <span style="white-space:nowrap">Lock-up</span> Agreements&#8221;), pursuant to which Abpro stockholders will agree not to transfer, following the Closing, such Abpro stockholder&#8217;s shares of Series A Common Stock constituting such Abpro stockholder&#8217;s Merger Consideration until the earlier of (x)&#160;the twelve month anniversary of the date of the Closing, (y)&#160;if the reported last sale price of the shares of Series A Common Stock equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, right issuances, reorganizations, recapitalizations and the like) for any twenty (20)&#160;trading days within any thirty (30)&#160;trading day period commencing at least <span style="white-space:nowrap">one-hundred</span> and fifty (150)&#160;days after the Closing, and (z)&#160;the date after the Closing on which the Post-Combination Company consummates a liquidation, merger, capital stock exchange, reorganization or other similar transaction with an unaffiliated third party that results in all of the Post-Combination Company&#8217;s stockholders having the right to exchange their common stock of the Post-Combination Company for cash, securities or other property. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founders Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the ACAB IPO, on January&#160;13, 2022, certain of ACAB&#8217;s directors and executive officers and ACAB entered into a letter agreement (the &#8220;Founders Letter Agreement&#8221;), pursuant to which, among other things, these holders have agreed not to transfer, assign or sell any of their Founder Shares until one year after the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of the consummation of a business combination, subject to certain limited exceptions. Notwithstanding the foregoing, (1)&#160;if the last reported sale price of the common stock of the surviving entity following a business combination equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any <span style="white-space:nowrap">30-trading</span> day period commencing at least 150&#160;days after the consummation of a business combination, or (2)&#160;if a liquidation, merger, stock exchange or other similar transaction is consummated after a business combination which results in all stockholders having the right to exchange their shares of common stock for cash, securities or other property, then the Founder Shares will be released. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the ACAB IPO, on January&#160;13, 2022, ACAB entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Sponsor and each member of the ACAB Board, pursuant to which these holders, and the holders of warrants issued upon conversion of working capital loans, if any, are entitled to make up to three demands to register certain of the ACAB securities held by them under the Securities Act and to have the securities covered thereby registered for resale pursuant to Rule 415 under the Securities Act. In addition, the holders have certain &#8220;piggyback&#8221; registration rights applicable to registration statements filed after the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registration Rights Agreement provides that any registration statement filed under the Securities Act will not be permitted to become effective until the securities covered thereby are released from the lockup restrictions under the Founders Letter Agreement described above. If the Business Combination is consummated, the Post-Combination Company will bear the costs and expenses of filing any such registration statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_27">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion does not purport to be a complete analysis or discussion of all potential tax effects relevant to the Business Combination. Stockholders are advised to consult with their own personal tax advisors concerning the specific U.S. federal, state, local, and <span style="white-space:nowrap">non-U.S.</span> income and other tax consequences of the Business Combination and related transactions applicable to them. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material U.S. Federal Income Tax Consequences of the Redemption of ACAB Public Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax consequences for holders of shares of Series A common stock that elect to have their Series A common stock redeemed for cash in connection with the Business Combination. This discussion applies only to Series A common stock that is held as a capital asset for U.S. federal income tax purposes. This discussion is a summary only and does not describe all of the tax consequences that may be relevant to holders of shares of Series A common stock in light of each holder&#8217;s particular circumstances, including but not limited to the alternative minimum tax, the Medicare tax on certain net investment income and the different consequences that may apply if such a holder is subject to special rules that apply to certain types of investors, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial institutions or financial services entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governments or agencies or instrumentalities thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">individual retirement or other <span style="white-space:nowrap">tax-deferred</span> accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons owning (actually or constructively) 5% or more of ACAB&#8217;s voting shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders subject to a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting with respect to their Series A common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Series A common stock as part of a &#8220;straddle,&#8221; constructive sale, hedge, conversion or other integrated transaction or similar transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons owning (actually or constructively) any Abpro securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. holders (as defined below) whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships or other pass-through entities or arrangements for U.S. federal income tax purposes and any beneficial owners of such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">passive foreign investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a person required to accelerate the recognition of any item of gross income as a result of such income being recognized on an applicable financial statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Sponsor and persons related to the Sponsor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Founder Shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> entities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Series A common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Series A common stock and partners in such partnerships should consult their own tax advisors about the consequences of the matters discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this proxy statement/prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or <span style="white-space:nowrap">non-U.S.</span> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB has not sought, and will not seek, a ruling from the IRS as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. Holders of shares of Series A common stock are urged to consult their tax advisor with respect to the application of U.S. federal tax laws to their particular situation, as well as any tax consequences arising under the laws of any state, local or foreign jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, the term &#8220;U.S. holder&#8221; means a beneficial owner of Series A common stock who or that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is included in gross income for U.S. federal income tax purposes regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust, if (i)&#160;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more &#8220;United States persons&#8221; (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&#160;it has a valid election in effect under the Treasury regulations to be treated as a United States person. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that a U.S. holder&#8217;s Series A common stock is redeemed pursuant to the redemption provisions described in this proxy statement/prospectus under the section entitled &#8220;<span style="font-style:italic">ACAB&#8217;S Special Meeting of Stockholders &#8212; Redemption Rights</span>,&#8221; the treatment of the redemption for U.S. federal income tax purposes will depend on whether the redemption qualifies as a sale of such holder&#8217;s Series A common stock under Section&#160;302 of the Code. If the redemption qualifies as a sale of Series A common stock, the U.S. holder will be treated as described under &#8220;<span style="font-style:italic">U.S. Holders &#8212; Taxation of Redemption Treated as a Sale of Series A Common Stock</span>&#8221; below. If the redemption does not qualify as a sale of Series A common stock, the U.S. holder will be treated as receiving a corporate distribution with the tax consequences described below under &#8220;<span style="font-style:italic">U.S. Holders &#8212; Taxation of Redemption Treated as a Distribution</span>.&#8221; Whether a redemption qualifies for sale treatment will depend largely on the total number of shares of ACAB&#8217;s stock treated as held by the U.S. holder relative to all of ACAB&#8217;s shares outstanding both before and after the redemption. The redemption of Series A common stock generally will be treated as a sale of Series A common stock (rather than as a corporate distribution) if the redemption (i)&#160;is &#8220;substantially disproportionate&#8221; with respect to the U.S. holder, (ii)&#160;results in a &#8220;complete termination&#8221; of the U.S. holder&#8217;s interest in ACAB or (iii)&#160;is &#8220;not essentially equivalent to a dividend&#8221; with respect to the U.S. holder. These tests are explained more fully below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining whether any of the foregoing tests are satisfied, a U.S. holder takes into account not only stock actually owned by the U.S. holder, but also shares of ACAB&#8217;s stock that are constructively owned by it. A U.S. holder may constructively own, in addition to stock owned directly, stock owned by certain related individuals and entities in which the U.S. holder has an interest or that have an interest in such U.S. holder, as well as any stock the U.S. holder has a right to acquire by exercise of an option, which would generally include shares of Series A common stock which could be acquired pursuant to the exercise of a public warrant. In order to meet the substantially disproportionate test, the percentage of ACAB&#8217;s outstanding voting stock actually and constructively owned by the U.S. holder immediately following the redemption of its Series A common stock must, among other requirements, be less than 80% of the percentage of our outstanding voting stock actually and constructively owned by the U.S. holder immediately before the redemption. There will be a complete termination of a U.S. holder&#8217;s interest if either (i)&#160;all of the shares of ACAB&#8217;s stock actually and constructively owned by the U.S. holder are redeemed or (ii)&#160;all of the shares of ACAB&#8217;s stock actually owned by the U.S. holder are redeemed and the U.S. holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of stock owned by certain family members and the U.S. holder does not constructively own any other shares of ACAB&#8217;s stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The redemption of Series A common stock will not be essentially equivalent to a dividend if the redemption results in a &#8220;meaningful reduction&#8221; of the U.S. holder&#8217;s proportionate interest in ACAB. Whether the redemption will result in a meaningful reduction in a U.S. holder&#8217;s proportionate interest in ACAB will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority stockholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a &#8220;meaningful reduction.&#8221; The application of these tests generally also takes into account related transactions that occur contemporaneously with the redemption, including any contemporaneous purchases of common stock by the relevant holder (or persons whose ownership is attributed to such holder) and issuances of common stock. A U.S. holder should consult with its own tax advisors as to the tax consequences of a redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If none of the foregoing tests is satisfied, then the redemption will be treated as a corporate distribution and the tax effects will be as described under &#8220;<span style="font-style:italic">U.S. Holders&#8212;Taxation of Redemption Treated as a Distribution</span>&#8221; below. After the application of those rules, any remaining tax basis of the U.S. holder in the redeemed Series A common stock will be added to the U.S. holder&#8217;s adjusted tax basis in its remaining stock, or, if it has none, possibly to the U.S. holder&#8217;s adjusted tax basis in other stock constructively owned by it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">U.S. Holders-Taxation of Redemption Treated as a Sale of Series A Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the redemption of a U.S. holder&#8217;s shares of Series A common stock is treated as a sale, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. holder&#8217;s adjusted tax basis in the Series A common stock treated as sold. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder&#8217;s holding period for the Series A common stock so disposed of exceeds one year. It is unclear, however, whether the redemption rights with respect to the Series A common stock described in this proxy statement/prospectus may suspend the running of the applicable holding period for this purpose. If the running of the holding period for the Series A common stock is suspended, then <span style="white-space:nowrap">non-corporate</span> U.S. holders may not be able to satisfy the <span style="white-space:nowrap">one-year</span> holding period requirement for long-term capital gain treatment, in which case any gain on a redemption of the shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. holders may be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the amount of gain or loss recognized by a U.S. holder is an amount equal to the difference between (i)&#160;the amount of cash received in the redemption and (ii)&#160;the U.S. holder&#8217;s adjusted tax basis in its Series A common stock so redeemed. A U.S. holder&#8217;s adjusted tax basis in its Series A common stock generally will equal the U.S. holder&#8217;s acquisition cost. Gain or loss is calculated separately with respect to each block of stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">272 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
A&#160;block of stock is stock of the same Series Acquired for the same price on the same day. U.S. holders who hold different blocks of Series A common stock should consult their tax advisors to determine how the above rules apply to them. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">U.S. Holders-Taxation of Redemption Treated as a Distribution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the redemption of a U.S. holder&#8217;s shares of Series A common stock is treated as a distribution, such distribution generally will constitute a dividend for U.S. federal income tax purposes to the extent paid from ACAB&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. holder&#8217;s adjusted tax basis in its Series A common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of Series A common stock and will be treated as described under &#8220;<span style="font-style:italic">U.S. Holders&#8212;Taxation of Redemption Treated as a Sale of</span> <span style="font-style:italic">Series A Common Stock</span>&#8221; above. Dividends received by a U.S. holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends received by a <span style="white-space:nowrap">non-corporate</span> U.S. holder may constitute &#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. It is unclear whether the redemption rights with respect to the Series A common stock described in this proxy statement/prospectus may prevent a U.S. holder from satisfying the applicable holding period requirements with respect to the dividends received deduction or the preferential tax rate on qualified dividend income, as the case may be. If the holding period requirements are not satisfied, then a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> U.S. holders may be subject to tax on such dividend at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, information reporting requirements may apply to the proceeds of the redemption of the Series A common stock, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number or a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section applies to you if you are a <span style="white-space:nowrap">&#8220;Non-U.S.</span> holder&#8221; with respect to Series A common stock. As used herein, the term <span style="white-space:nowrap">&#8220;Non-U.S.</span> holder&#8221; means a beneficial owner of Series A common stock who or that is for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a <span style="white-space:nowrap">non-resident</span> alien individual (other than certain former citizens and residents of the United States subject to U.S. tax as expatriates); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity taxable as a corporation) that is not organized in or under the laws of the United States, any state thereof or the District of Columbia; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate or trust that is not a U.S. holder; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition of the Series A common stock. If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of redeeming your Series A common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">273 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The characterization for U.S. federal income tax purposes of the redemption of a <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s Series A common stock pursuant to the redemption provisions described in this proxy statement/prospectus under the section entitled &#8220;<span style="font-style:italic">ACAB&#8217;S Special Meeting of Stockholders &#8212; Redemption Rights</span>&#8221; generally will correspond to the U.S. federal income tax characterization of such a redemption of a U.S. holder&#8217;s Series A common stock, as described under &#8220;<span style="font-style:italic">U.S. Holders</span>&#8221; above, and the consequences of the redemption to the <span style="white-space:nowrap">Non-U.S.</span> holder will be as described below under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span></span> <span style="font-style:italic">Holders &#8212; Taxation of Redemption Treated as a Sale of Series A Common Stock</span>&#8221; and &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders &#8212; Taxation of Redemption Treated as a</span> <span style="font-style:italic">Distribution</span>,&#8221; as applicable. It is possible that because the applicable withholding agent may not be able to determine the proper characterization of a redemption of a <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s Series A common stock, the withholding agent might treat the redemption as a distribution subject to withholding tax, as discussed further below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Taxation of Redemption Treated as a Sale of Series A Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If ACAB&#8217;s redemption of a <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s shares of Series A common stock is treated as a sale, a <span style="white-space:nowrap">Non-U.S.</span> holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized in connection with such redemption, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> holder); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ACAB is or has been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five year period ending on the date of disposition or the period that the <span style="white-space:nowrap">Non-U.S.</span> holder held the Series A common stock, and, in the case where shares of Series A common stock are regularly traded on an established securities market, the <span style="white-space:nowrap">Non-U.S.</span> holder has owned, directly or constructively, more than 5% of the Series A common stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s holding period for the shares of Series A common stock. There can be no assurance that the Series A common stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless an applicable treaty provides otherwise, gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">Non-U.S.</span> holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">Non-U.S.</span> holder that is a corporation for U.S. federal income tax purposes may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a 30% rate (or lower applicable treaty rate). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the second bullet point above applies to a <span style="white-space:nowrap">Non-U.S.</span> holder, gain recognized by such holder in connection with a redemption treated as a sale of Series A common stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, ACAB may be required to withhold U.S. federal income tax at a rate of 15% of the amount realized upon such redemption. ACAB does not believe it currently is or has been at any time since its formation a U.S. real property holding corporation, and ACAB does not expect to be a U.S. real property holding corporation immediately after the Business Combination is completed. However, such determination is factual in nature, and no assurance can be provided that ACAB will not be treated as a U.S. real property holding corporation in a future period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Taxation of Redemption Treated as a Distribution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the redemption of a <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s shares of Series A common stock is treated as a distribution, such a distribution, to the extent paid out of ACAB&#8217;s current or accumulated earnings and profits (as determined under U.S. federal income tax principles), generally will constitute a dividend for U.S. federal income tax purposes and, provided such dividend is not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s conduct of a trade or business within the United States, the gross amount of the dividend will be subject to withholding tax at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> holder is eligible for a reduced rate of withholding tax under an applicable income tax </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">274 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E).</span></span> Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s adjusted tax basis in its shares of Series A common stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of Series A common stock, which will be treated as described under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders</span>&#8212;<span style="font-style:italic">Taxation of Redemption Treated as a Sale of Series A Common Stock</span>&#8221; above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding tax generally does not apply to dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> holder who provides an IRS Form <span style="white-space:nowrap">W-8ECI,</span> certifying that the dividends are effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to regular U.S. federal income tax as if the <span style="white-space:nowrap">Non-U.S.</span> holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A <span style="white-space:nowrap">Non-U.S.</span> holder that is a corporation for U.S. federal income tax purposes receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a rate of 30% (or a lower applicable treaty rate). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because it may not be certain at the time a <span style="white-space:nowrap">Non-U.S.</span> holder is redeemed whether such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s redemption will be treated as a sale or a corporate distribution, and because such determination will depend in part on a <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s particular circumstances, the applicable withholding agent may not be able to determine whether (or to what extent) a <span style="white-space:nowrap">Non-U.S.</span> holder is treated as receiving a dividend for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Therefore, the applicable withholding agent may withhold tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the gross amount of any consideration paid to a <span style="white-space:nowrap">Non-U.S.</span> holder in redemption of such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s Series A common stock, unless (i)&#160;the applicable withholding agent has established special procedures allowing <span style="white-space:nowrap">Non-U.S.</span> holders to certify that they are exempt from such withholding tax and (ii)&#160;such <span style="white-space:nowrap">Non-U.S.</span> holders are able to certify that they meet the requirements of such exemption (e.g., because such <span style="white-space:nowrap">Non-U.S.</span> holders are not treated as receiving a dividend under the Section&#160;302 tests described above). However, there can be no assurance that any applicable withholding agent will establish such special certification procedures. If an applicable withholding agent withholds excess amounts from the amount payable to a <span style="white-space:nowrap">Non-U.S.</span> holder, such <span style="white-space:nowrap">Non-U.S.</span> holder generally may obtain a refund of any such excess amounts by timely filing an appropriate claim for refund with the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-U.S.</span> holders should consult their own tax advisors regarding the application of the foregoing rules in light of their particular facts and circumstances and any applicable procedures or certification requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with the proceeds from a redemption of Series A common stock. A <span style="white-space:nowrap">Non-U.S.</span> holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">Non-U.S.</span> holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Foreign Account Tax Compliance Act Withholding Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;), impose withholding of 30% on payments of dividends on the Series A common stock to &#8220;foreign financial institutions&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">275 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(which is broadly defined for this purpose and in general includes investment vehicles) and certain other <span style="white-space:nowrap">non-U.S.</span> entities unless various U.S. information reporting and due diligence requirements (generally relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied by, or an exemption applies to, the payee (typically certified by the delivery of a properly completed IRS Form <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E).</span></span> The IRS has issued proposed regulations (on which taxpayers may rely until final regulations are issued) that would generally not apply these withholding requirements to gross proceeds from sales or other disposition proceeds from the Series A common stock. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Under certain circumstances, a <span style="white-space:nowrap">Non-U.S.</span> holder might be eligible for refunds or credits of such withholding taxes, and a <span style="white-space:nowrap">Non-U.S.</span> holder might be required to file a U.S. federal income tax return to claim such refunds or credits. Holders of shares of Series A common stock should consult their tax advisors regarding the effects of FATCA on the redemption of their Series A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A new 1% U.S. federal excise tax is expected to be imposed on ACAB in connection with redemptions of Series A common stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022 the Inflation Reduction Act of 2022 (the &#8220;<span style="text-decoration:underline">IR Act</span>&#8221;) became law, which, among other things, imposes a 1% excise tax on the fair market value of certain repurchases (including certain redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign (i.e., <span style="white-space:nowrap">non-U.S.)</span> corporations. The excise tax will apply to stock repurchases occurring in 2023 and beyond. The amount of the excise tax is generally 1% of the fair market value of the shares of stock repurchased at the time of the repurchase. The U.S. Department of Treasury has been given authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the excise tax; however, no guidance has been issued to date. While not free from doubt, absent such guidance, we currently expect that ACAB (whose securities are currently traded on the Nasdaq Global Market) will be subject to the excise tax with respect to any redemptions of its Series A common stock in connection with the Business Combination that are treated as repurchases for this purpose. The extent of the excise tax that may be incurred would depend on a number of factors, including the fair market value of the Series A common stock redeemed, the extent such redemptions could be treated as dividends and not repurchases, and the content of any regulations and other guidance from the U.S. Department of the Treasury that may be issued and applicable to the redemptions. In addition, issuances of stock by a repurchasing corporation in a year in which such corporation repurchases stock may reduce the amount of excise tax imposed with respect to such repurchase. The excise tax is imposed on the repurchasing corporation itself, not the stockholders from which shares are repurchased and ultimately may cause the remaining stockholders to bear the economic impact of the excise tax. That said, the imposition of the excise tax could reduce the amount of cash available to ACAB for effecting the redemptions of Series A common stock such that the <span style="white-space:nowrap">per-share</span> redemption amount received by redeeming holders of Series A common stock may be less than $10.20 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consummation of the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consummation of the Business Combination will not result in a sale, exchange or other disposition of Series A common stock by a U.S. Holder or a <span style="white-space:nowrap">Non-U.S.</span> Holder. Accordingly, no gain or loss will be recognized by a U.S. Holder or a <span style="white-space:nowrap">Non-U.S.</span> Holder that does not elect to have their Series A common stock redeemed for cash and remains an ACAB stockholder at the time of the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE INFORMATION PROVIDED ABOVE IS NOT TAX ADVICE. YOU ARE URGED TO CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE APPLICATION OF U.S. FEDERAL INCOME TAX LAWS TO YOUR PARTICULAR SITUATION, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR THE LAWS OF ANY STATE, LOCAL OR FOREIGN JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">276 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_28">COMPARISON OF STOCKHOLDERS&#8217; RIGHTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is a summary comparison of material differences between the rights of ACAB stockholders under ACAB&#8217;s existing charter and bylaws (left column), and the rights of Post-Combination Company stockholders under the forms of the Proposed Charter and the Post-Combination Company&#8217;s bylaws (right column). The summary set forth below is not intended to be complete or to provide a comprehensive discussion of each company&#8217;s governing documents. This summary is qualified in its entirety by reference to the full text of ACAB&#8217;s existing charter and bylaws, and the forms of the Proposed Charter, which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex B</span>, and the Post-Combination Company&#8217;s bylaws, which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex C</span>, as well as the relevant provisions of the DGCL. </p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Authorized Capital Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">ACAB Common Stock</span>. ACAB is currently authorized to issue 110,000,000 shares of common stock (the &#8220;Common Stock&#8221;), including (i) 100,000,000 shares of Series A common stock and (ii) 10,000,000 shares of Series B common stock. As of January&#160;1, 2024, there were 8,167,390 shares of Series A common stock outstanding and 1 share of Series B common stock outstanding.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-style:italic">Post-Combination Company Common Stock</span>. The Post-Combination Company is authorized to issue 110,000,000 shares of common stock (the &#8220;Common Stock&#8221;).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">ACAB Preferred Stock</span>. ACAB is currently authorized to issue 1,000,000 shares of preferred stock (the &#8220;Preferred Stock&#8221;). As of January&#160;1, 2024, there were no shares of Preferred Stock outstanding.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-style:italic">Post-Combination Company Preferred Stock</span>. The Post-Combination Company is authorized to issue 1,000,000 shares of preferred stock (the &#8220;Preferred Stock&#8221;).</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Conversion Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Shares of Series B common stock are convertible into shares of Series A common stock on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis (the &#8220;Initial Conversion Ratio&#8221;) at any time at the election of a holder of such shares of Series B common stock.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Notwithstanding the Initial Conversion Ratio, in the case that additional shares of Series A common stock, or equity linked securities, are issued or deemed issued in excess of the amounts sold in ACAB&#8217;s IPO and related to the closing of the initial business combination, the ratio for which the shares of Series B common stock shall convert into shares of Series A common stock will be adjusted so that the number of shares of Series A common stock issuable upon conversion of all shares of Series B common stock will equal, in the aggregate, 25% of the sum of (a)&#160;the total number of all shares of Series A common stock issued in the Offering (including any shares of Series A common stock issued pursuant to the Underwriters&#8217; over-allotment option) plus (b)&#160;the sum of (x)&#160;all shares of Series A common stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued in connection with or in</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">277 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">relation to the consummation of a Business Combination (including any shares of Series A common stock issued pursuant to a forward purchase agreement), excluding any shares of Series A common stock or equity-linked securities or rights issued, or to be issued, to any seller in a Business Combination and any private placement warrants issued to the Sponsor, or ACAB&#8217;s officers and directors upon the conversion of working capital loans made to ACAB, minus (y)&#160;the number of shares of Series A common stock redeemed in connection with a Business Combination, provided that such conversion of shares of Series B common stock shall never be less than the Initial Conversion Ratio.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The conversion ratio is to be adjusted to account for any subdivision (by stock split, subdivision, exchange, stock dividend, reclassification, recapitalization or otherwise) or combination (by reverse stock split, exchange, reclassification, recapitalization or otherwise) or similar reclassification or recapitalization of the outstanding shares of Series A common stock into a greater or lesser number of shares occurring after the original filing of the Amended and Restated Certificate without a proportionate and corresponding subdivision, combination or similar reclassification or recapitalization of the outstanding shares of Series B common stock.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Each share of Series B common stock shall convert into its pro rata number of shares of Series A common stock. The pro rata share for each holder of Series B common stock will be determined as follows: each share of Series B common stock shall convert into such number of shares of Series A common stock as is equal to the product of one (1)&#160;multiplied by a fraction, the numerator of which shall be the total number of shares of Series A common stock into which all of the issued and outstanding shares of Series B common stock shall be converted and the denominator of which shall be the total number of issued and outstanding shares of Series B common stock at the time of conversion</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Number and Qualification of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The number of directors of ACAB, other than those who may be elected by the holders of one or more series of the Preferred Stock, shall be fixed from time to time exclusively by the Board pursuant to a resolution adopted by a majority of the Board. No reduction of the authorized number of directors will have the effect of removing any director before that director&#8217;s term of office expires. No director need be a stockholder of ACAB or a resident of the State of Delaware.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the Proposed Charter, the total number of directors constituting the whole Post-Combination Company Board of Directors (the &#8220;Post-Combination Company Board&#8221;) shall be determined from time to time by resolution of the Post-Combination Company Board. Except as otherwise expressly delegated by resolution of the Board of Directors, the Board of Directors shall have the exclusive power and authority to appoint and remove officers of the Post-Combination Company. Directors need not be stockholders.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">278 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Structure of Board; Election of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board is divided into three classes, as nearly equal in number as possible and designated Class&#160;I, Class&#160;II and Class&#160;III. The term of the initial Class&#160;I expires at the first annual meeting of the stockholders ACAB; the term of the initial Class&#160;II Directors expires at the second annual meeting of the stockholders of ACAB; and the term of the initial Class&#160;III Directors expires at the third annual meeting of the stockholders of ACAB.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each succeeding annual meeting of the stockholders of ACAB, beginning with the first annual meeting of the stockholders of ACAB, each of the successors elected to the class of directors whose term expires at that annual meeting shall be elected for a three-year term or until the election and qualification of their respective successors in office, subject to their earlier death, resignation or removal.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of one or more series of Preferred Stock, voting separately by class or series, to elect directors pursuant to the terms of one or more series of Preferred Stock, the election of directors shall be determined by a plurality of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote thereon. Notwithstanding any of the foregoing, and except as otherwise required by law, whenever the holders of one or more series of the Preferred Stock shall have the right, voting separately by class or series, to elect one or more directors, the term of office, the filling of vacancies, the removal from office and other features of such directorships shall be governed by the terms of such series of the Preferred Stock as set forth in the ACAB Charter (including any Preferred Stock Designation) and such directors shall not be included in any of the classes created pursuant to of the foregoing unless expressly provided by such terms.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the initial business combination, the holders of Series B common stock, voting together as a single class, shall have the exclusive right to elect and remove any director, and the holders of Series A common stock shall have no right to vote on the election or removal of any director.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At all meetings of stockholders for the election of directors at which a quorum is present, a plurality of the votes cast shall be sufficient to elect directors.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the special rights of the holders of any class or series of Preferred Stock to elect directors, the Board of Directors (other than those directors elected by the holders of any class or series of Preferred Stock) shall be classified three classes: Class&#160;I, Class&#160;II, and Class&#160;III. Each class shall consist of <span style="white-space:nowrap">one-third</span> of the total number of directors constituting the entire Board of Directors. The initial Class&#160;I Directors shall serve for a term expiring at the first annual meeting of stockholders of the Post-Combination Company following the filing of the Proposed Charter; the initial Class&#160;II Directors shall serve for a term expiring at the second annual meeting of stockholders following the filing of the Proposed Charter; and the initial Class&#160;III Directors shall serve for a term expiring at the third annual meeting of stockholders following the filing of the Proposed Charter. At each annual meeting of stockholders beginning with the first annual meeting of stockholders, the successors of the class of directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in the third year following the year of their election. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">279 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Removal of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">In accordance with the DGCL, any or all of the directors may be removed from office at any time, but only for cause and only by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock of ACAB entitled to vote generally in the election of directors, voting together as a single class. Prior to the closing of the initial business combination, the holders of Series B common stock, voting together as a single class, shall have the exclusive right to elect and remove any director, and the holders of Series A common stock shall have no right to vote on the election or removal of any director.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to any limitation imposed by applicable law or the Proposed Charter, the Board of Directors or any individual director or directors may be removed with cause by the affirmative vote of the holders of 66 2/3% of the voting power of all then-outstanding shares of capital stock of the Post-Combination Company entitled to vote generally at an election of directors.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Voting</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of each share of ACAB Common Stock:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Except as otherwise required by law or the ACAB Charter (including any Preferred Stock Designation), exclusively possess all voting power with respect to ACAB.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Except as otherwise required by law or the ACAB Charter (including any Preferred Stock Designation), are entitled to one vote for each such share on each matter properly submitted to the stockholders on which the holders of the Common Stock are entitled to vote.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Except as otherwise required by law or the ACAB Charter (including any Preferred Stock Designation), at any annual or special meeting of the stockholders of ACAB, holders of the Series A common stock and holders of the Series B common stock, voting together as a single class, shall have the exclusive right to vote for the election of directors and on all other matters properly submitted to a vote of the stockholders. Notwithstanding the foregoing, except as otherwise required by law or the ACAB Charter (including any Preferred Stock Designation), holders of shares of any series of Common Stock shall not be entitled to vote on any amendment to the ACAB Charter (including any amendment to any Preferred Stock Designation) that relates solely to the terms of one or more outstanding series of Preferred Stock or other series of Common Stock if the holders of such affected series of Preferred Stock or Common Stock, as applicable, are entitled exclusively, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the ACAB Charter (including any Preferred Stock Designation) or the DGCL.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or the Proposed</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charter (or any Certificate of Designation made thereunder), the holders of Common Stock shall exclusively possess all voting power with respect to the Post-Combination Company. The holders of shares of Common Stock shall be entitled to one vote for the election of directors and on all matters submitted to a vote of stockholders of the Post-Combination Company.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Proposed Charter (including any preferred stock designation) that relates solely to the rights, powers, preferences (or the qualifications, limitations or restrictions thereof) or other terms of one or more outstanding series of preferred stock if the holders of such affected series of preferred stock are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Proposed Charter (including any preferred stock designation) or pursuant to the DGCL.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">280 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise required by law or the ACAB Charter (including any Preferred Stock Designation), for so long as any shares of Series B common stock shall remain outstanding, ACAB shall not, without the prior vote or written consent of the holders of a majority of the shares of Series B common stock then outstanding, voting separately as a single class, amend, alter or repeal any provision of the ACAB Charter, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or special rights of the Series B common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Supermajority Voting Provisions</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">See &#8220;<span style="font-style:italic">Voting</span>.&#8221;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">See &#8220;<span style="font-style:italic">Voting</span>.&#8221;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Cumulative Voting</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Delaware law allows for cumulative voting only if provided for in the ACAB Charter; however, the ACAB Charter does not authorize cumulative voting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Proposed Charter does not authorize cumulative voting.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Vacancies on the Board of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise provided by law or in the ACAB Charter, any vacancy occurring in the Board (whether caused by resignation, death, or otherwise) may be filled solely and exclusively by a majority vote of the remaining directors then in office, even if less than a quorum, or by a sole remaining director (and not by stockholders). A director elected to fill any vacancy will hold office for the remainder of the full term of the class of directors to which the new directorship was added or in which the vacancy occurred or until his or her successor shall have been elected and qualified.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unless otherwise provided in the Proposed Charter, and subject to the rights of the holders of any series of Preferred Stock or as otherwise provided by applicable law, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders and except as otherwise provided by applicable law, shall be filled solely by a majority vote of the directors then in office, although less than a quorum, or by a sole remaining director. Directors chosen pursuant to any of the foregoing provisions shall hold office until the expiration of the term of the class for which elected and until their successors are duly elected and qualified or until their earlier resignation, removal from office, death or incapacity.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Amendments to Certificate of Incorporation</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, an amendment to the ACAB Charter generally requires the approval of the Board and a majority of the combined voting power of the then outstanding shares of voting stock, voting together as a single class.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, see &#8220;<span style="font-style:italic">Voting</span>.&#8221;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Under Delaware law, an amendment to the Proposed Charter generally requires the approval of the Post-Combination Company Board of Directors and a majority of the combined voting power of the then outstanding shares of voting stock, voting together as a single class. The affirmative vote of a majority of Post-Combination Company&#8217;s Board of Directors</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">281 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and at least 66 2/3% in voting power of the outstanding shares entitled to vote thereon is required to amend certain provisions of the Proposed Charter.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, see &#8220;<span style="font-style:italic">Voting</span>.&#8221;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Amendment of Bylaws</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Board shall have the power and is expressly authorized to adopt, amend, alter or repeal the Bylaws. The Bylaws also may be adopted, amended, altered or repealed by the stockholders; provided, however, that in addition to any vote of the holders of any class or series of capital stock of ACAB required by applicable law or the ACAB Charter, the affirmative vote of the holders of at least a majority of the voting power of all outstanding shares of capital stock of ACAB entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend, alter or repeal the Bylaws.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Except as provided in the Proposed Bylaws or the provisions of the Proposed Charter, the Board of Directors is expressly empowered to adopt, alter, change, amend or repeal the Bylaws of the Post- Combination Company by the vote of at least a majority of the directors of the Post-Combination Company then in office. In addition, to any vote of the holders of any class or series of stock of the Post-Combination Company required by applicable law or the Proposed Charter, the Proposed Bylaws may also be adopted, amended, or repealed by affirmative vote of the holders of at least 66 2/3% of the voting power of all then- outstanding shares of the capital stock of the Post- Combination Company entitled to vote generally in the election of directors, voting together as a single class.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Quorum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Board of Directors. </span>A majority of the Board shall constitute a quorum for the transaction of business at any meeting of the Board. <span style="font-style:italic"></span></p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholders. </span>The presence, in person or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock of ACAB representing a majority of the voting power of all outstanding shares of capital stock of ACAB entitled to vote at such meeting shall constitute a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series shall constitute a quorum of such class or series for the transaction of such business.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Board of Directors</span>. Except as may be otherwise specifically provided by law, the Proposed Charter or the Proposed Bylaws, a quorum of the Board of Directors shall consist of a majority of the whole Board of Directors. <span style="font-style:italic"></span></p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholders</span>. Except as may be otherwise specifically provided by law, the Proposed Charter or the Proposed Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the voting power of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Stockholder Action by Written Consent</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as may be otherwise provided for in the ACAB Charter (including any Preferred Stock Designation) relating to the rights of the holders of any outstanding series of Preferred Stock, subsequent to the consummation of the Offering, any action required or permitted to be taken by the stockholders of ACAB must be effected by a duly called annual or special meeting of such stockholders and may not be effected</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Proposed Charter provides that the taking of any action by the stockholders in lieu of a meeting of the stockholders is specifically denied.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">282 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">by written consent of the stockholders other than with respect to the Series B Common Stock with respect to which action may be taken by written consent.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Special Stockholder Meetings</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to the rights, if any, of the holders of any outstanding series of the Preferred Stock, and to the requirements of applicable law, special meetings of stockholders of ACAB may be called only by the Chairman of the Board, Chief Executive Officer, or the Board pursuant to a resolution adopted by a majority of the Board. The ability of the stockholders to call a special meeting is specifically denied by the ACAB Charter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the special rights of the holders of one or more classes or series of Preferred Stock, special meetings of the stockholders of the Post-Combination Company may be called, for any purpose or purposes as is a proper matter for stockholder action under the DGCL, by (i)&#160;the Chairman of the Board of Directors, (ii)&#160;the Chief Executive Officer, or (iii)&#160;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors. Such special meetings may not be called by stockholders or any other person or persons.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Notice of Stockholder Meetings</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">ACAB must give, in any manner permitted by law, not less than 10 nor more than 60 days before the date of any meeting of stockholders, written notice stating the place, if any, date, and time of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting and the record date for determining stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, to each stockholder of record entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. Notice of the time, place, if any, and purpose of any meeting of stockholders (to the extent required) may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Stockholder Proposals (Other than Nomination of Persons for Election as Directors)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">No business may be transacted at an annual meeting of stockholders, other than business that is either (i)&#160;specified in ACAB&#8217;s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii)&#160;otherwise properly brought before the annual meeting by or at the direction of the Board or (iii)&#160;otherwise properly brought before the annual</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The annual meeting of the stockholders of the Post-Combination Company, for the purpose of election of directors and for such other business as may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the Post-</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">283 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">meeting by any stockholder of ACAB (x)&#160;who is a stockholder of record entitled to vote at such annual meeting on the date of the giving of the notice provided for in the ACAB Charter and on the record date for the determination of stockholders entitled to vote at such annual meeting and (y)&#160;who complies with the notice procedures set forth in the ACAB Charter. To be timely, a stockholder&#8217;s notice must be delivered to or mailed and received by the Corporate Secretary not fewer than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding annual meeting. However, if ACAB did not hold an annual meeting the previous year, or if the date of the subject annual meeting date is more than 30 days before or more than 60 days after such anniversary date of the previous year&#8217;s annual meeting, then the deadline is the 120th day before the meeting and not later than the later of (x)&#160;the close of business on the 90th day before the meeting or (y)&#160;the close of business on the 10th day following the day on which public announcement of the date of the annual meeting is first made by ACAB.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For a stockholder to cause a proposal to be properly brought before an annual meeting of the stockholders, the stockholder&#8217;s notice must set forth as to each such matter the stockholder proposes to bring before the annual meeting: (A)&#160;a brief description of the business desired to be brought before the annual meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event such business includes a proposal to amend these Bylaws, the language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (B)&#160;the name and record address of such stockholder and the name and address of the beneficial owner, if any, on whose behalf the proposal is made, (C)&#160;the class or series and number of shares of capital stock of ACAB that are owned beneficially and of record by such stockholder and by the beneficial owner, if any, on whose behalf the proposal is made, (D)&#160;a description of all arrangements or understandings between such stockholder and the beneficial owner, if any, on whose behalf the proposal is made and any other person or persons (including their names) in connection with the proposal of such business by such stockholder, (E)&#160;any material interest of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made in such business and (F)&#160;a representation that such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the annual meeting to bring such business before the meeting.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Combination Company and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&#160;pursuant to the Post-Combination Company&#8217;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or at the direction of the Board of Directors; or (iii)&#160;by any stockholder of the Post-Combination Company who was a stockholder of record at the time of giving the stockholder&#8217;s notice, who is entitled to vote at the meeting and who complied with the notice procedures set forth below.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For business to be properly brought before an annual meeting by a stockholder, the stockholder must (i)&#160;provide Timely Notice (as defined below) thereof in writing and in proper written form to the Secretary of the Post-Combination Company, and (ii)&#160;provide any updates or supplements to such notice at the times and in the forms required by the Proposed Bylaws. To be timely, a stockholder&#8217;s notice must be delivered to, or mailed and received at, the principal executive offices of the Post-Combination Company not less than ninety (90)&#160;nor more than <span style="white-space:nowrap">one-hundred</span> twenty (120)&#160;days prior to the <span style="white-space:nowrap">one-year</span> anniversary of the preceding year&#8217;s annual meeting; provided, however, that, if no annual meeting was held in the preceding year, to be timely, a stockholder&#8217;s notice must be so delivered, or mailed and received, not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or, if later, the tenth (10th) day following the day on which public disclosure of the date of such annual meeting was first made by the Post-Combination Company; provided, further, that, if the date of the annual meeting is more than thirty (30)&#160;days before or after such anniversary date, to be timely, a stockholder&#8217;s notice must be so delivered, or mailed and received, not later than the ninetieth (90th) day prior to such annual meeting or, if later, the tenth (10th) day following the day on which public disclosure of the date of such annual meeting was first made by the Post-Combination Company (such notice within such time periods, &#8220;Timely Notice&#8221;).</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">284 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At any stockholders meeting, only such business as is specified in the notice of such stockholders meeting given by or at the direction of the person or persons calling such meeting may come before such meeting.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Stockholder Nominations of Persons for Election as Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nominations of persons for election to the Board at any annual meeting of stockholders, or at any special meeting of stockholders called for the purpose of electing directors as set forth in ACAB&#8217;s notice of such special meeting, may be made (i)&#160;by or at the direction of the Board or (ii)&#160;by any stockholder of ACAB (x)&#160;who is a stockholder of record entitled to vote in the election of directors on the date of the giving of the notice provided in the ACAB Charter and on the record date for the determination of stockholders entitled to vote at such special meeting and (y)&#160;who complies with the notice procedures set forth in the ACAB Charter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Nominations of any individual for election to the Post- Combination Board at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i)&#160;by or at the direction of the Post-Combination Board, including by any committee or persons authorized to do so by the Post-Combination Board or the Proposed Bylaws, or (ii)&#160;by a stockholder present in person (A)&#160;who was a record owner of shares of the Post-Combination Company at the time of giving the notice provided for in the Proposed Bylaws, (B)&#160;is entitled to vote at the meeting and (C)&#160;has complied with the requirements of the Proposed Bylaws as to such notice and nomination.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Limitation of Liability of Directors and Officers</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">To the fullest extent permitted by the DGCL, as it existed on the date of the ACAB Charter or as it is thereafter amended, a director of ACAB will not be personally liable to ACAB or its stockholders for monetary damages for breach of fiduciary duty as a director unless a director violated his or her duty of loyalty to ACAB or its stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived improper personal benefit from his or her actions as a director. Any amendment, modification or repeal of such provision will not adversely affect a director of ACAB with respect to any conduct of such director occurring prior to such amendment, modification or repeal.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of the Post-Combination Company shall not be personally liable to the Post-Combination Company or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Post-Combination Company shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended, automatically and without further action, upon the date of such amendment.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Indemnification of Directors, Officers, Employees and Agents</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">To the fullest extent permitted by applicable law, ACAB shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she is or was a director or officer of ACAB or, while a director or officer of ACAB, is or was serving at the request of ACAB as a director,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Post-Combination Company shall indemnify its directors and its executive officers to the fullest extent not prohibited by the DGCL or any other applicable law; provided, however, that the Post-Combination Company may modify the extent of such indemnification by individual contracts with its directors and executive officers.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">285 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (an &#8220;Indemnitee&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys&#8217; fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection with such proceeding; provided, however, that, except as provided in the ACAB Charter with respect to proceedings to enforce rights to indemnification, ACAB shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by such Indemnitee only if such proceeding (or part thereof) was authorized by the Board.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company shall have the power to indemnify (including the power to advance expenses) its other officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person except executive officers to such officers or other persons as the Board of Directors shall determine.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Dividends, Distributions and Stock Repurchases</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The holders of ACAB Common Stock, are entitled to receive, when and as declared by the Board, out of any assets of ACAB legally available therefor, such dividends as may be declared from time to time by the Board and hare equally on a per share basis in such dividends and distributions.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to applicable law and the rights and preferences of the holders of any outstanding series of Post- Combination Company preferred stock, the holders of the shares of Post-Combination Company common stock shall be entitled to receive, when, as and if declared by the Board of Directors, out of the assets of the Post- Combination Company which are by law available therefor, dividends payable either in cash, in property or in shares of capital stock.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Liquidation</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Upon any Liquidation, whether voluntary or involuntary, subject to applicable law, the rights, if any, of the holders of any outstanding series of the Preferred Stock, the holders of shares of Common Stock shall be entitled to receive all the remaining assets of ACAB available for distribution to its stockholders, ratably in proportion to the number of shares of Series A common stock (on an as converted basis with respect to the Series B common stock) held by them.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to applicable law and the rights, if any, of the holders of any outstanding class or series of the Preferred Stock, in the event of any voluntary or involuntary liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Post-Combination Company, after payment or provision for payment of the debts and other liabilities of the Post- Combination Company, the holders of the shares of the Common Stock shall be entitled to receive all the remaining assets of the Post-Combination Company available for distribution to its stockholders, ratably in proportion to the number of shares of the Common Stock held by them.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Stockholder Rights Plan</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">While Delaware law does not include a statutory provision expressly validating stockholder rights plans,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">286 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such plans have generally been upheld by court decisions applying Delaware law.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">ACAB does not have a stockholder rights plan currently in effect, but under the DGCL, the Board could adopt such a plan without stockholder approval.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Preemptive Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The ACAB Charter and the ACAB Bylaws do not provide holders of ACAB capital stock with preemptive rights. Thus, as a general matter, if additional shares of ACAB capital stock are issued, the current holders of ACAB capital stock will own a proportionately smaller interest in a larger number of outstanding shares of ACAB capital stock to the extent that they do not participate in the additional issuance.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">None.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Duties of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, the standards of conduct for directors have developed through Delaware court case law. Generally, directors of Delaware corporations are subject to a duty of loyalty and a duty of care. The duty of loyalty requires directors to refrain from self-dealing, and the duty of care requires directors in managing ACAB&#8217;s affairs to use that level of care which ordinarily careful and prudent persons would use in similar circumstances. When directors act consistently with their duties of loyalty and care, their decisions generally are presumed to be valid under the business judgment rule.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Board may exercise all such powers and authority of ACAB and do all such lawful acts and things as are not by statute or the ACAB Charter or the ACAB Bylaws directed or required to be exercised or done solely by the stockholders.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Under statutory and decisional law, directors of Delaware corporations owe fiduciary duties to the corporation, including duty of care and duty of loyalty.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Inspection of Books and Records; Stockholder Lists</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Inspection</span>. Under Section&#160;220 of the DGCL, any stockholder, in person or by attorney or other agent, has, upon written demand under oath stating the purpose thereof, the right during the usual hours for business to inspect for any proper purpose and to make copies and extracts from ACAB&#8217;s stock ledger, a list of its stockholders and its other books and records. <span style="font-style:italic"></span></p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting List</span>. ACAB will cause to be prepared an alphabetical list of the names of all of its stockholders who are entitled to vote at a stockholders meeting or any adjournment thereof; provided, however, if the record</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The books and records of the Post-Combination Company may be kept within or outside the State of Delaware at such place or places as may from time to time be designated by the Board of Directors. Such books and records may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">287 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">date for determining stockholders entitled to vote is less than 10 days before the meeting date, the list will reflect the stockholders entitled to vote as of the 10th day before the meeting date. The list will be arranged in alphabetical order and showing the address and the number and class of shares registered in the name of each stockholder. The stockholders&#8217; list must be available for inspection by any stockholder, beginning at least 10 days prior to the meeting, and continuing through the meeting, during ordinary business hours at the principal place of business of ACAB. Such list will be produced and kept open at the time and place of the meeting. During such period, and during the whole time of the meeting, the stockholders&#8217; list will be subject to the inspection of any stockholder, or the stockholder&#8217;s agent or attorney, for any purpose germane to the meeting. In cases where the record date for determining stockholders entitled to vote is fewer than 10 days prior to the meeting, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">records so kept comply with Section&#160;224 of the DGCL.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Secretary shall prepare and make, at least ten (10)&#160;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&#160;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&#160;during ordinary business hours, at the principal place of business of the Post- Combination Company. In the event that the Post- Combination Company determines to make the list available on an electronic network, the Post- Combination Company may take reasonable steps to ensure that such information is available only to stockholders of the Post-Combination Company. The list shall be open to examination of any stockholder during the time of the meeting as provided by law.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3" align="center"><span style="font-weight:bold">Choice of Forum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The ACAB Charter provides that unless ACAB consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for (i)&#160;any derivative action brought by on behalf of ACAB, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of ACAB&#8217;s directors, officers or other employees, agents or stockholders to ACAB or ACAB&#8217;s stockholders, (iii)&#160;any action arising under the ACAB Charter, ACAB Bylaws or the DGCL or (iv)&#160;any action asserting a claim against ACAB governed by the internal affairs doctrine. In addition, the ACAB Charter designates the federal district courts of the United States of America as the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of ACAB&#8217;s capital stock will be deemed to have notice of and consented to the exclusive forum provisions in the ACAB Charter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Proposed Charter and Proposed Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on behalf of the Post-Combination Company; (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of the Post-Combination Company&#8217;s current or former directors, officers, or other employees to the Post-Combination Company or its stockholders; (iii)&#160;any action or proceeding asserting a claim against the Post-Combination Company or any of its current or former directors, officers, or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, the Proposed Charter or the Proposed Bylaws; (iv)&#160;any action or proceeding to interpret, apply, enforce, or determine the validity of the Proposed Charter or the Proposed Bylaws; (v)&#160;any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&#160;any action asserting a claim against the Post-Combination Company or any of its directors, officers, or other employees governed by</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">288 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Proposed Charter and Proposed Bylaws will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Post-Combination Company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying this offering.</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">289 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_29">DESCRIPTION OF CAPITAL STOCK OF THE POST-COMBINATION COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of the Post-Combination Company&#8217;s capital stock, as expected to be in effect upon the consummation of the Business Combination. We expect to adopt the Proposed Charter and the Proposed Bylaws in connection with the Closing, and this description summarizes the provisions that are expected to be included in such documents. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description of the matters set forth in this section titled &#8220;<span style="font-style:italic">Description of Capital Stock of the Post-Combination Company</span>,&#8221; you should refer to the Proposed Charter, the Proposed Bylaws, the forms of which are attached as <span style="font-style:italic">Annex B</span> and <span style="font-style:italic">Annex C</span> to this proxy statement/prospectus, respectively, and to the applicable provisions of Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized Capitalization </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, the Post-Combination Company&#8217;s authorized capital stock will consist of 110,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. No shares of preferred stock will be issued or outstanding immediately after the Business Combination. Unless the Post-Combination Company&#8217;s board of directors determines otherwise, the Post-Combination Company will issue all shares of its capital stock in uncertificated form. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Combination Company Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Voting rights. </span></span>Holders of shares of Post-Combination Company common stock will be entitled to one (1)&#160;vote for each share of common stock held as of the record date on all matters submitted to a vote of stockholders, provided, however, that, except as otherwise required in the Proposed Charter or by applicable law, the holders of Post-Combination Company common stock will not be entitled to vote on any amendment to our Proposed Charter that relates solely to the terms of one or more outstanding series of Post-Combination Company preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to our Proposed Charter (including any certificate of designation relating to any series of Post-Combination Company preferred stock) or pursuant to the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dividend rights. </span></span>Subject to applicable law and the rights and preferences of the holders of any outstanding series of the Post-Combination Company preferred stock, and to the other provisions of the Proposed Charter, the holders of common stock shall be entitled to the payment of dividends on the common stock in cash, in property or in shares of the Post-Combination when, as and if declared thereon by the Post-Combination Company board of directors from time to time out of assets or funds of the Post-Combination Company legally available therefor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Rights upon liquidation. </span></span>Subject to the rights of holders of Post-Combination Company preferred stock, upon the Post-Combination Company&#8217;s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to any future holders of preferred stock having liquidation preferences, if any, the holders of common stock will be entitled to receive pro rata the Post-Combination Company&#8217;s remaining assets available for distribution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Combination Company Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Proposed Charter, the Post-Combination Company&#8217;s board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. The board of directors has the discretion to determine the rights, powers, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">290 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of authorizing the Post-Combination Company&#8217;s board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of the outstanding voting stock. Additionally, the issuance of preferred stock may adversely affect the holders of common stock by restricting dividends on the common stock, diluting the voting power of the common stock or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of the common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently outstanding an aggregate of 15,000,000 public warrants, which, following the consummation of the Business Combination, will entitle the holder to acquire Post-Combination Company common stock. Each whole warrant will entitle the registered holder to purchase one share of Post-Combination Company common stock at an exercise price of $11.50 per share, subject to adjustment as discussed below, beginning the later of 30 days after the Closing and twelve months from the closing of our Initial Public Offering, which occurred on January&#160;19, 2022. A holder may exercise its warrants only for a whole number of shares of Post-Combination Company common stock. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Accordingly, unless holder has at least two Units, such holder will not be able to receive or trade a whole warrant. The warrants will expire at 5:00 p.m., New York City time, on the earlier to occur of five years after the completion of the Business Combination or redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company will not be obligated to deliver any shares of Post-Combination Company common stock pursuant to the exercise of a public warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Post-Combination Company common stock issuable upon exercise of the public warrants is then effective and a current prospectus relating thereto is available, subject to the Post-Combination Company satisfying its obligations described below with respect to registration, or a valid exemption from registration is available, including in connection with a cashless exercise. No public warrant will be exercisable for cash or on a cashless basis, and the Post-Combination Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a public warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In the event that a registration statement is not effective for the exercised public warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Post-Combination Company common stock underlying such unit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable, but in no event later than 20 business days after the Closing, the Post-Combination Company will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the shares of Post-Combination Company common stock issuable upon exercise of the public warrants, and will use commercially reasonable efforts to cause the same to become effective within 60 business days after the Closing and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the public warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if shares of Post-Combination Company common stock are, at the time of any exercise of a public warrant, not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the <span style="white-space:nowrap">Post-Combination</span> Company may, at its option, require holders of public warrants who exercise their warrants to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">291 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Post-Combination Company so elects, it will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the public warrants for that number of shares of Post-Combination Company common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Post-Combination Company common stock underlying the public warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the public warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; means the volume weighted average price of the shares of Post-Combination Company common stock for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Post-Combination Company may redeem the outstanding warrants (except as described herein with respect to the private placement warrants): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption (the <span style="white-space:nowrap">&#8220;30-day</span> redemption period&#8221;) to each warrant holder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the last reported sale price of the Series A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending three business days before the Post-Combination Company sends the notice of redemption to the warrant holders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Post-Combination Company will not redeem the public warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of Post-Combination Company common stock issuable upon exercise of the public warrants is then effective and a current prospectus relating to those shares of Post-Combination Company common stock is available throughout the <span style="white-space:nowrap">30-day</span> redemption period. If and when the public warrants become redeemable, the Post-Combination Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The redemption criterion discussed above was established to prevent a redemption call unless there is at the time of the call a significant premium to the public warrant exercise price. If the foregoing conditions are satisfied and the Post-Combination Company issues a notice of redemption of the public warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of shares of the Post-Combination Company common stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 public warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Post-Combination Company calls the public warrants for redemption as described above, its management will have the option to require any holder that wishes to exercise its public warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their warrants on a &#8220;cashless basis,&#8221; the Post-Combination Company&#8217;s management will consider, among other factors, the Post-Combination Company&#8217;s cash position, the number of warrants that are outstanding and the dilutive effect on the Post-Combination Company&#8217;s stockholders of issuing the maximum number of shares of Post-Combination Company common stock issuable upon the exercise of its public warrants. If the Post-Combination Company&#8217;s management takes advantage of this option, all holders of public warrants would pay the exercise price by surrendering their warrants for that number of shares of Post-Combination Company common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Post-Combination Company common stock underlying the public warrants, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">292 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
multiplied by the excess of the &#8220;fair market value&#8221; of the Post-Combination Company common stock over the exercise price of the public warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; will mean the average last reported sale price of shares of Post-Combination Company common stock for the ten trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If the Post-Combination Company&#8217;s management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Post-Combination Company common stock to be received upon exercise of the public warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. If the Post-Combination Company calls the public warrants for redemption and management does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their private placement warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis, as described in more detail below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of a warrant may notify the Post-Combination Company in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the Post-Combination Company common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Dilution Adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Post-Combination Company common stock is increased by a share capitalization payable in shares of Post-Combination Company common stock, or by a <span style="white-space:nowrap">split-up</span> of common stock or other similar event, then, on the effective date of such share capitalization, <span style="white-space:nowrap">split-up</span> or similar event, the number of shares of Post-Combination Company common stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares of common stock. A rights offering to holders of common stock entitling holders to purchase Post-Combination Company common stock at a price less than the fair market value will be deemed a share capitalization of a number of shares of Post-Combination Company common stock equal to the product of&#8201; (i)&#160;the number of shares of Post-Combination Company common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Post-Combination Company common stock) and (ii)&#160;the quotient of&#8201; (x)&#160;the price per share of Post-Combination Company common stock paid in such rights offering and (y)&#160;the fair market value. For these purposes (i)&#160;if the rights offering is for securities convertible into or exercisable for shares of Post-Combination Company common stock, in determining the price payable for Post-Combination Company common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;fair market value means the VWAP of shares of Post-Combination Company common stock as reported during the ten (10)&#160;trading day period ending on the trading day prior to the first date on which the Post-Combination Company common stock trades on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the Post-Combination Company, at any time while the warrants are outstanding and unexpired, pays a dividend or make a distribution in cash, securities or other assets to the holders of Post-Combination Company common stock on account of such Post-Combination Company common stock (or other securities into which the warrants are convertible), other than (a)&#160;as described above, or (b)&#160;certain ordinary cash dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Post-Combination Company common stock is decreased by a consolidation, combination, reverse share split or reclassification of Post-Combination Company common stock or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of shares of Post-Combination Company common stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding share of Post-Combination Company common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">293 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of Post-Combination Company common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Post-Combination Company common stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Post-Combination Company common stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding Post-Combination Company common stock (other than those described above or that solely affects the par value of such Post-Combination Company common stock), or in the case of any merger or consolidation of the Post-Combination Company with or into another corporation (other than a consolidation or merger in which the Post-Combination Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding Post-Combination Company common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Post-Combination Company as an entirety or substantially as an entirety in connection with which the Post-Combination Company is dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the Post-Combination Company common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of Post-Combination Company common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Post-Combination Company common stock in such a transaction is payable in the form of Post-Combination Company common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants in order to determine and realize the option value component of the warrant. This formula is to compensate the warrant holder for the loss of the option value portion of the warrant due to the requirement that the warrant holder exercise the warrant within 30&#160;days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and the Post-Combination Company. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, and that all other modifications or amendments will require the vote or written consent of the holders of at least 50% of the then outstanding Public Warrants, and, solely with respect to any amendment to the terms of the private placement warrants, a majority of the then outstanding private placement warrants. You should review a copy of the warrant agreement, which is filed as an exhibit to the registration statement pertaining to our initial public offering, for a complete description of the terms and conditions applicable to the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their warrants and receive Post-Combination Company common stock. After the issuance of Post-Combination Company common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Post-Combination Company will, upon exercise, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">294 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
round down to the nearest whole number the number of shares of Post-Combination Company common stock to be issued to the warrant holder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently 13,850,000 private placement warrants outstanding. The private placement warrants (including the shares of Post-Combination Company common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the Closing (except in limited circumstances) and they will not be redeemable by the Post-Combination Company so long as they are held by the Sponsor or its permitted transferees. The founders, or their permitted transferees, have the option to exercise the private placement warrants for cash or on a cashless basis. Otherwise, the private placement warrants have terms and provisions that are identical to the public warrants. If the private placement warrants are held by holders other than the Sponsor or its permitted transferees, the private placement warrants will be redeemable by the Post-Combination Company in all redemption scenarios and exercisable by the holders on the same basis as the public warrants included in the Units sold in the ACAB IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that number of shares of Post-Combination Company common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Post-Combination Company common stock underlying the private placement warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the private placement warrants by (y)&#160;the fair market value. For these purposes, the &#8220;fair market value&#8221; shall mean the average last reported sale price of the shares of Post-Combination Company common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. Even during such periods of time when insiders will be permitted to sell Post-Combination Company securities, an insider cannot trade in Post-Combination Company securities if he or she is in possession of material <span style="white-space:nowrap">non-public</span> information. Accordingly, unlike public stockholders who could exercise their public warrants and sell the shares of Post-Combination Company common stock received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions of the Proposed Charter and the Proposed Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter and the Proposed Bylaws, as they will be in effect at the consummation of the Business Combination, will contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with the Post-Combination Company&#8217;s board of directors, which may result in an improvement of the terms of any such acquisition in favor of the stockholders. However, they also give the Post-Combination Company&#8217;s board of directors the power to discourage acquisitions that some stockholders may favor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized but Unissued Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of Post-Combination Company common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter provides that the Post-Combination Company&#8217;s board of directors will be divided into three classes of directors, with the classes to be as nearly equal in number as possible, and with each director </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">295 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
serving a three-year term. As a result, approximately <span style="white-space:nowrap">one-half</span> of the Post-Combination Company&#8217;s board of directors will be elected each year. The classification of directors will have the effect of making it more difficult for stockholders to change the composition of the Post-Combination Company&#8217;s board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Action; Special Meetings of Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter will provide that stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. As a result, a holder controlling a majority of Post-Combination Company capital stock would not be able to amend the Post-Combination Company&#8217;s bylaws or remove directors without holding a meeting of stockholders called in accordance with the Post-Combination Company&#8217;s bylaws. Further, the Proposed Bylaws will provide that only the chairperson of Post-Combination Company&#8217;s board of directors, a majority of the board of directors or the Chief Executive Officer of the Post-Combination Company may call special meetings of stockholders, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of stockholders to force consideration of a proposal or for stockholders controlling a majority of Post-Combination Company capital stock to take any action, including the removal of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advance Notice Requirements for Stockholder Proposals and Director Nominations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Proposed Bylaws will establish an advance notice procedure for stockholder proposals to be brought before an annual meeting or special meeting of stockholders. Generally, in order for any matter to be &#8220;properly brought&#8221; before a meeting, the matter must be (a)&#160;specified in a notice of meeting given by or at the direction of the Post-Combination Company&#8217;s board of directors, (b)&#160;if not specified in a notice of meeting, otherwise brought before the meeting by the board of directors or the chairperson of the meeting, or (c)&#160;otherwise properly brought before the meeting by a stockholder present in person who (1)&#160;was a stockholder at the time of giving the notice, (2)&#160;is entitled to vote at the meeting, and (3)&#160;has complied with the advance notice procedures specified in the Post-Combination Company&#8217;s bylaws or properly made such proposal in accordance with Rule <span style="white-space:nowrap">14a-8</span> under the Exchange Act and the rules and regulations thereunder, which proposal has been included in the proxy statement for the annual meeting. Further, for business to be properly brought before an annual meeting by a stockholder, the stockholder must (a)&#160;provide Timely Notice (as defined below) thereof in writing and in proper form to the secretary and (b)&#160;provide any updates or supplements to such notice at the times and in the forms required by the Proposed Bylaws. To be timely, a stockholder&#8217;s notice must be delivered to, or mailed and received at, the Post-Combination Company&#8217;s principal executive offices not less than 90 days nor more than 120&#160;days prior to the <span style="white-space:nowrap">one-year</span> anniversary of the preceding year&#8217;s annual meeting; <span style="font-style:italic">provided, however</span>, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered, or mailed and received, not later than the 90th day prior to such annual meeting or, if later, the 10th day following the day on which public disclosure of the date of such annual meeting was first made (such notice within such time periods, &#8220;Timely Notice&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders at an annual meeting or special meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Post-Combination Company&#8217;s board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to the Post-Combination Company&#8217;s secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by the holders of a majority of the outstanding voting securities until the next stockholder meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, there is no right to vote cumulatively (which allows stockholders to cast all of the votes such stockholder is entitled to for a single nominee for a board of directors rather than only being able to vote the number of shares such stockholder holds for or against each nominee) unless expressly authorized in the certificate of incorporation. The Proposed Charter does not authorize cumulative voting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">296 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Charter or Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the Business Combination, the Post-Combination Company&#8217;s bylaws may be amended or repealed by a majority vote of the Post-Combination Company&#8217;s board of directors or by the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares entitled to vote generally in the election of directors, voting together as a single class. The affirmative vote of a majority of Post-Combination Company&#8217;s board of directors and at least 66 2/3% in voting power of the outstanding shares entitled to vote thereon would be required to amend certain provisions of the Proposed Charter. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations on Liability and Indemnification of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter and Post-Combination Company&#8217;s bylaws will provide indemnification and advancement of expenses for the Post-Combination Company&#8217;s directors and officers to the fullest extent permitted by the DGCL, subject to certain limited exceptions. The Post-Combination Company has entered into, or will enter into, indemnification agreements with each of its directors and officers. In some cases, the provisions of those indemnification agreements may be broader than the specific indemnification provisions contained under Delaware law. In addition, as permitted by Delaware law, the Proposed Charter and the Post-Combination Company&#8217;s bylaws will include provisions that eliminate the personal liability of directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict the Post-Combination Company&#8217;s rights and the rights of the Post-Combination Company&#8217;s stockholders in derivative suits to recover monetary damages against a director for breach of fiduciary duties as a director. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions may be held not to be enforceable for violations of the federal securities laws of the United&#160;States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dissenters&#8217; Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, the Post-Combination Company&#8217;s stockholders will have appraisal rights in connection with a merger or consolidation of the Post-Combination Company. Pursuant to Section&#160;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of the Post-Combination Company&#8217;s stockholders may bring an action in the company&#8217;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of the Post-Combination Company&#8217;s shares at the time of the transaction to which the action relates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forum Selection </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Charter and Proposed Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on behalf of the Post-Combination Company; (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of the Post-Combination Company&#8217;s current or former directors, officers, or other employees to the Post-Combination Company or its stockholders; (iii)&#160;any action or proceeding asserting a claim against the Post-Combination Company or any of its current or former directors, officers, or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, the Proposed Charter or the Proposed Bylaws; (iv)&#160;any action or proceeding to interpret, apply, enforce, or determine the validity of the Proposed Charter or the Proposed Bylaws; (v)&#160;any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">297 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&#160;any action asserting a claim against the Post-Combination Company or any of its directors, officers, or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Proposed Charter and Proposed Bylaws will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Post-Combination Company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying this offering. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, the Post-Combination Company would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of the Proposed Charter and the Proposed Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Post-Combination Company or its directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for the Post-Combination Company&#8217;s common stock will be Continental Stock Transfer&#160;&amp; Trust Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Trading Symbol and Market </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application will be made for the shares of the Post-Combination Company&#8217;s common stock and Public Warrants to be approved for listing on Nasdaq under the symbols &#8220;ABP&#8221; and &#8220;ABPW,&#8221; respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">298 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_30">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Relationships and Related Person Transactions&#8212;Post-Combination Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Transactions Policy Following the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the consummation of the Business Combination, the Post-Combination Company Board expects to adopt a written policy on transactions with related persons that is in conformity with the requirements for issuers having publicly held Common Stock that is listed on Nasdaq. Under the policy, the Post-Combination Company will develop and implement processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. If it is determined that a transaction or relationship is a related person transaction requiring compliance with the policy, the Post-Combination Company&#8217;s audit committee will be required to review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm&#8217;s length dealings with an unrelated third party and the extent of the related person&#8217;s interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of the Post-Combination Company&#8217;s code of business conduct and ethics (which will also be put in place in connection with the Business Combination), and either approve or disapprove the related person transaction. In particular, the Post-Combination Company&#8217;s policy will require the Post-Combination Company&#8217;s audit committee to consider, among other factors it deems appropriate: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the related person&#8217;s relationship to the Post-Combination Company and interest in the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the material facts of the proposed transaction, including the proposed aggregate value of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s or a director nominee&#8217;s independence in the event the related person is a director or director nominee or an immediate family member of the director or director nominee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the benefits to the Post-Combination Company of the proposed transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if applicable, the availability of other sources of comparable products or services; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an assessment of whether the proposed transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If advance audit committee approval of a related person transaction requiring the audit committee&#8217;s approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the audit committee, subject to ratification of the transaction by the audit committee at the audit committee&#8217;s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then, upon such recognition, the transaction will be presented to the audit committee for ratification at the audit committee&#8217;s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. The Post-Combination Company&#8217;s management will update the audit committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director will be permitted to participate in the approval of a related person transaction for which he or she is a related person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under our code of business conduct and ethics, which will be adopted effective upon the consummation of the Business Combination, the Post-Combination Company&#8217;s employees, directors and director nominees will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">299 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Relationships and Related Person Transactions&#8212;Abpro </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director and Executive Officer Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro has granted stock options to its directors and executive officers, as more fully described in the section &#8220;<span style="font-style:italic">Abpro Executive and Director Compensation.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Abpro Bio International, Inc. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro Bio International, Inc. (&#8220;Abpro Bio&#8221;) owns approximately 35% of Abpro. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Abpro Bio Collaboration Agreement</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro entered into a Collaboration and License Agreement (the &#8220;Abpro Bio Collaboration Agreement&#8221;) in January 2020 with AbMed Corporation and Abpro Bio to develop and commercialize <span style="white-space:nowrap">ABP-201</span> through a territorial partnership that granted Abpro Bio exclusive development and commercialization rights in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia, Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro agreed to form a joint steering committee to oversee the collaboration that includes representatives from both Abpro and Abpro Bio. Abpro Bio agreed to use commercially reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones by certain dates. Under the Collaboration Agreement, Abpro Bio agreed to pay Abpro a double-digit percentage royalty in the low teens, tiered based on cumulative net sales by Abpro Bio, its affiliates or sublicensees beginning with the first commercial sale of a licensed product in its territory. Abpro is also entitled to payments totaling approximately $540&#160;million, subject to the satisfaction of certain development and sales milestones. Abpro is responsible for patent prosecution and Abpro Bio has agreed to reimburse Abpro for patent costs in its licensed territory. Unless earlier terminated in accordance with its terms, the agreement with Abpro Bio remains in effect on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first commercial sale of a licensed product in a country, and (iii)&#160;the expiration of regulatory exclusivity for a licensed product in a country. Abpro may terminate the agreement upon the occurrence of specified bankruptcy events relating to Abpro Bio or if Abpro Bio is in material default or breach of the agreement and does not cure within a specified notice and cure period. Abpro Bio may also terminate the agreement upon 90 days written notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with entering the Abpro Bio Collaboration Agreement, Abpro Bio made a $30&#160;million equity investment in Abpro. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Series E and Series F Preferred Stock Offerings</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, Abpro issued and sold to Abpro Bio in a private placement an aggregate of 3,303,966, or 100%, of Abpro&#8217;s Series E Redeemable Convertible Preferred Stock at a purchase price of $9.08 per share for an aggregate purchase price of approximately $30.0&#160;million. Each share of Series E Redeemable Convertible Preferred Stock will automatically convert into one share of Post-Combination Company common stock upon closing of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2022, Abpro issued and sold to Abpro Bio in a private placement an aggregate of 444,444, or 80%, of Abpro&#8217;s Series F Redeemable Convertible Preferred Stock at a purchase price of $18.00 per share for an aggregate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">300 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price of approximately $8.0&#160;million. Each share of Series F Redeemable Convertible Preferred Stock will automatically convert into one share of Post-Combination Company common stock upon closing of the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">2023 Promissory Note</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2023, Abpro issued a Promissory Note for the benefit of Abpro Bio in the principal amount of up to $6&#160;million for expenses incurred in connection with the Business Combination and for Abpro operating expenses. Amounts borrowed under the Promissory Note plus accrued interest are due and payable on the earlier of (i)&#160;the closing of the Business Combination and (ii)&#160;April&#160;18, 2025. The Promissory Note accrues interest at 5% per annum until the maturity date and 7% thereafter. Abpro intends to repay the Promissory Note in full with the proceeds from the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Promissory Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, Abpro issued a Promissory Note for the benefit of Ian Chan in the principal amount of $176,625. Amounts borrowed under the Promissory Note plus accrued interest are due and payable on the earlier of (i) the closing of the Business Combination and (ii) June&#160;29, 2025. The Promissory Note accrues interest at 5% per annum until the maturity date and 7% thereafter. Abpro intends to repay the Promissory Note in full with the proceeds from the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, Abpro issued a Promissory Note for the benefit of Eugene Chan in the principal amount of $123,638. Amounts borrowed under the Promissory Note plus accrued interest are due and payable on the earlier of (i) the closing of the Business Combination and (ii) June&#160;29, 2025. The Promissory Note accrues interest at 5% per annum until the maturity date and 7% thereafter. Abpro intends to repay the Promissory Note in full with the proceeds from the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consulting Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;1, 2023, Abpro entered into a consulting agreement with NEM LLC, whose sole member is Eugene Chan, Abpro&#8217;s Chairman. The Consulting Agreement provides for annual payment of $250,000 paid monthly, and a possible performance bonus of up to 50%. The Consulting Agreement has a term of 12 months, and automatically renews for additional <span style="white-space:nowrap">12-month</span> terms thereafter unless cancelled by either party. Either party may terminate the agreement with 60 days&#8217; notice to the other party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director and Officer Indemnification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abpro&#8217;s charter and bylaws provide for indemnification and advancement of expenses for its directors and officers to the fullest extent permitted by the DGCL, subject to certain limited exceptions. Abpro has entered into indemnification agreements with certain of the members of its board directors. Following the Business Combination, Abpro expects that these agreements will be replaced with new indemnification agreements for each director and officer of the Post-Combination Company. For additional information, see &#8220;<span style="font-style:italic">Comparison of Stockholders&#8217; Rights &#8212; Indemnification of Directors, Officers, Employees and Agents</span>&#8221; and &#8220;<span style="font-style:italic">Description of Capital Stock of the Post-Combination Company &#8212; Limitations on Liability and Indemnification of Officers and Directors</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Relationships and Related Person Transactions&#8212;ACAB </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founder Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Sponsor purchased 7,187,500 Founder Shares for an aggregate purchase price of $25,000, or approximately $0.0035 per share. Due to the underwriters&#8217; election to partially exercise their overallotment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">301 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option, 3,750 shares were forfeited. In October 2021, the Sponsor transferred 50,000 Founder Shares to each of Ms.&#160;Lord, Mr.&#160;Kahlon, Mr.&#160;Stanwood, Mr.&#160;Dove and Mr.&#160;Schiano, ACAB&#8217;s independent directors. The number of Founder Shares issued was determined based on the expectation that such Founder Shares would represent approximately 20% of the outstanding shares upon completion of the ACAB IPO. On January&#160;13, 2022, ACAB effectuated a <span style="white-space:nowrap"><span style="white-space:nowrap">1.044-for-1</span></span> stock split, resulting in an aggregate of 7,503,750 founder shares outstanding and held by the Initial Stockholders. The Founder Shares will be worthless if ACAB does not complete an initial business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, there are 8,167,391 shares of ACAB common stock issued and outstanding, including one share of Series B common stock, each of which will be converted into one share of Series A common stock at the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the Series B Holders voluntarily converted 7,499,999 shares of Series B common stock of ACAB they held as of such date into 7,499,999 shares of Series A common stock of the Company in accordance with the charter amendment. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from ACAB&#8217;s trust account. On December&#160;15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal to further extend the date by which ACAB must consummate a business combination to September&#160;19, 2024 (subject to additional approval by the ACAB Board). In connection with the December&#160;15, 2023 stockholder meeting, holders of an aggregate of 2,768,301 shares of Series A common stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately $10.74 per share redeemed. As a result of the Conversion and the results of the stockholder meeting described above, ACAB has an aggregate of 8,167,390 shares of Series A common stock outstanding and one (1)&#160;share of Series B common stock (held by the Sponsor) outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor purchased an aggregate of 13,850,000 private placement warrants at a price of $1.00 per warrant ($13,850,000 in the aggregate) in a private placement that occurred simultaneously with the closing of the ACAB IPO. Each private placement warrant entitles the holder thereof to purchase one share of ACAB&#8217;s Series A common stock at a price of $11.50 per share. The private placement warrants (including the Series A common stock issuable upon exercise thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registration Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Founder Shares, private placement warrants and any&#160;units the Sponsor or our officers, directors or their affiliates may be issued in payment of working capital loans made to us (and all underlying securities), are entitled to registration rights pursuant to a Registration Rights Agreement dated January&#160;13, 2022, by and among ACAB, the Sponsor and certain other securityholders of ACAB. The holders of a majority of these securities are entitled to make up to three demands that we register such securities. The holders of a majority of the units issued in payment of working capital loans made to us (or underlying securities) can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to our consummation of a business combination. We will bear the expenses incurred in connection with the filing of any such registration statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Opportunities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of ACAB&#8217;s officers or directors becomes aware of an initial business combination opportunity that falls within the line of business of any entity to which he or she has then-current fiduciary or contractual obligations, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">302 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity. ACAB&#8217;s officers and directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director and Officer Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by ACAB to the Sponsor, officers and directors, or any their respective affiliates, prior to, or in connection with any services rendered in order to effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is), other than the repayment of any loans from the Sponsor, officers and directors for working capital purposes and reimbursement of any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on ACAB&#8217;s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. ACAB does not have a policy that prohibits the Sponsor, executive officers or directors, or any of their respective affiliates, from negotiating for the reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses by a target business. ACAB&#8217;s audit committee reviews on a quarterly basis all payments that were made to the Sponsor, officers, directors or ACAB or their respective affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by such persons in connection with activities on ACAB&#8217;s behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the Sponsor agreed to loan ACAB an aggregate of up to $250,000 to cover expenses related to the ACAB IPO pursuant to a promissory note (the &#8220;2021 Note&#8221;). The 2021 Note was <span style="white-space:nowrap">non-interest</span> bearing and payable upon the completion of the ACAB IPO. The outstanding borrowings under the 2021 Note in the amount of $149,539 were repaid on February&#160;22, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023 and November&#160;14, 2023, ACAB issued unsecured promissory notes (the &#8220;2023 Notes&#8221;) to the Sponsor in the aggregate principal amounts of $80,000 and $80,000, respectively, in connection with monthly extensions of the deadline to consummate an initial business combination. In the event that ACAB does not consummate an initial business combination, all amounts loaned to ACAB under the 2023 Notes will be forgiven except to the extent that ACAB has funds available to it outside of its trust account established in connection with the ACAB IPO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Loans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to meet our working capital needs following the consummation of ACAB IPO, the Sponsor has committed to advance ACAB up to $1,750,000 to fund expenses relating to investigating and selecting a target business and other working capital requirements after the ACAB IPO and prior to the Business Combination. In addition, the Sponsor or an affiliate of the Sponsor or certain of ACAB&#8217;s directors and officers may, but are not obligated to, loan ACAB funds as may be required. Each loan would be evidenced by a promissory note. Up to $1,500,000 of such loan may be convertible into additional warrants of the post-business combination entity at a price of $1.00 per warrant at the option of the lender. The&#160;warrants would be identical to the private placement warrants. The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB does not expect to seek loans from parties other than the Sponsor or an affiliate of the Sponsor as it does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the trust account. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, December&#160;11, 2023 and December 12, 2023, the Sponsor advanced ACAB $10,000, $1,630,000, and $15,000, respectively, to fund the account for the funds used in operations. The advances from the Sponsor do not accrue interest and are payable upon the closing of the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">303 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about the Sponsor Letter Agreement, see the subsection entitled &#8220;<span style="font-style:italic">The Business Combination Agreement and Related Agreements &#8212; Related Agreements &#8212; Sponsor Letter Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Deferred Underwriting Fee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2024, ACAB and Cantor entered into the Fee Reduction Agreement, pursuant to which Cantor has agreed to settle $10,290,000 of the deferred underwriting fees payable, resulting in a remainder of $6,000,000 of deferred underwriting fees payable (the &#8220;Reduced Deferred Fee&#8221;) by the Company to Cantor upon the closing of the contemplated Transaction with Abpro. The Reduced Deferred Fee shall be payable to Cantor in the form of 600,000 shares of Post-Combination Company common stock. The Fee Reduction Agreement only applies to the consummation of the Business Combination with Abpro and no other potential business combinations that may be contemplated or consummated by ACAB. In the event that ACAB does not consummate the Business Combination with Abpro, the original deferred fee shall become due and payable by ACAB to Cantor as originally set forth in the Underwriting Agreement, upon the consummation of a business combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor agreed to the Reduced Deferred Fee after discussions with ACAB as a result of the anticipated transaction costs and redemptions in connection with the Closing of the Business Combination, which, without additional financing, would result in Available Closing Cash of less than $8.7 million and permit Abpro to terminate the Business Combination Agreement, and the Business Combination would not be consummated. The Reduced Deferred Fee would reduce the amount of transaction costs that would otherwise be paid from funds in the trust account at Closing, providing additional liquidity to ACAB in order to meet the Available Closing Cash condition. Although Cantor has not resigned as an underwriter pursuant to Section&#160;11(b)(1) of the Securities Act, Cantor has not had any role in the identification or evaluation of Abpro as a business combination target for ACAB. ACAB did not expect Cantor to provide a service in connection with the closing of the Business Combination; therefore, the Reduced Deferred Fee agreement has not created any role in connection with the closing of the Business Combination that ACAB is seeking to fill. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Polar Subscription Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 10, 2024, ACAB, Polar Multi-Strategy Master Fund (&#8220;Polar&#8221;), and the Sponsor entered into a subscription agreement (the &#8220;Polar Subscription Agreement&#8221;) pursuant to which Polar agreed to provide a capital contribution to the Sponsor in an aggregate amount of up to $360,000 (the &#8220;Capital Contribution&#8221;) in exchange for 1 share of ACAB&#8217;s Series A common stock held by the Sponsor for each $1 invested by Polar as of the closing of ACAB&#8217;s initial business combination, provided that the obligation to make capital contributions will terminate on September 19, 2024 (the date by which ACAB must consummate its initial business combination). Funds invested by Polar pursuant to the Polar Subscription Agreement will in turn will be loaned by the Sponsor to ACAB on an interest-free basis (the &#8220;SPAC Loan&#8221;) in order to fund ACAB&#8217;s working capital needs and other expenses in connection with the Business Combination. On April 18, 2024, Polar funded $270,000 of the Capital Contribution to the Sponsor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, ACAB will pay to the Sponsor the principal amount outstanding under the SPAC Loan. In addition, Polar will be entitled to receive from the Sponsor an amount equal to the Capital Contribution in cash or shares of ACAB&#8217;s Series A common stock held by Sponsor, at Polar&#8217;s election. If Polar elects to receive repayment in shares, then the Sponsor will transfer, or ACAB (or the Post-Combination Company, following the Closing Date) will issue to Polar, shares of ACAB Series A common stock at a rate of 1 share for each $10 invested by Polar as of the&#160;Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that ACAB or the Sponsor defaults on certain of its obligations under the Polar Subscription Agreement, and such default continues uncured for a period of five business days following written notice by Polar to ACAB and the Sponsor (the &#8220;Default Date&#8221;), ACAB (or the Post-Combination Company following the </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">304 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Closing Date) will immediately issue to Polar 36,000 shares of ACAB Series A common stock on the Default Date and will subsequently issue an additional 36,000 shares of ACAB Series A common stock on each monthly anniversary of the Default Date thereafter, until such default is cured. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ACAB&#8217;s Management Participation in the Post-Combination Company </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After our initial business combination, members of ACAB&#8217;s management team who remain with ACAB may be paid consulting, management or other fees from the Post-Combination Company with any and all amounts being fully disclosed to stockholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to stockholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a stockholder meeting held to consider an initial business combination, as applicable, as it will be up to the directors of the Post-Combination Company to determine executive and director compensation. In such event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form <span style="white-space:nowrap">8-K,</span> as required by the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Material Interests Relating to the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s directors and officers will be eligible for continued indemnification and continued coverage under ACAB&#8217;s directors&#8217; and officers&#8217; liability insurance for six years after the Closing Date pursuant to the Business Combination Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s officers and directors, and their affiliates are entitled to reimbursement <span style="white-space:nowrap"><span style="white-space:nowrap">of&#160;out-of-pocket&#160;expenses</span></span> incurred by them in connection with certain activities on ACAB&#8217;s behalf, such as identifying and investigating possible business targets and business combinations. However, if ACAB fails to consummate a business combination by September&#160;19, 2024, they will not have any claim against the trust account for reimbursement. There have not been any material <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses subject to reimbursement and ACAB does not anticipate any such expenses prior to Closing. ACAB&#8217;s officers and directors, and their affiliates, expect to incur (or guaranty) approximately $&#8195;&#8195;&#8195;&#8195;million of transaction expenses (excluding the deferred underwriting commissions being held in the trust account). Accordingly, ACAB may not be able to reimburse these expenses if the Business Combination or another business combination, is not completed by such date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Procedures with Respect to Review and Approval of Related Person Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Code of Business Conduct and Ethics requires us to avoid, wherever possible, all related party transactions that could result in actual or potential conflicts of interests, except under guidelines approved by the Board of Directors (or the audit committee). Related-party transactions are defined as transactions in which (1)&#160;the aggregate amount involved will or may be expected to exceed $120,000 in any calendar year, (2)&#160;we or any of our subsidiaries is a participant, and (3)&#160;any (a)&#160;executive officer, director or nominee for election as a director, (b)&#160;greater than 5% beneficial owner of our shares of common stock, or (c)&#160;immediate family member, of the persons referred to in clauses (a)&#160;and (b), has or will have a direct or indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity). A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper personal benefits as a result of his or her position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee, pursuant to its written charter, is responsible for reviewing and approving related-party transactions to the extent we enter into such transactions. The audit committee will consider all relevant factors when determining whether to approve a related party transaction, including whether the related party transaction is on terms no less favorable to us than terms generally available from an unaffiliated third-party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction. No director may participate in the approval of any transaction in which he is a related party, but that director is required to provide </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">305 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the audit committee with all material information concerning the transaction. We also require each of our directors and executive officers to complete a directors&#8217; and officers&#8217; questionnaire that elicits information about related party transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director, employee or officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To further minimize conflicts of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated with any of the Sponsor or our officers or directors including (i)&#160;an entity that is either a portfolio company of, or has otherwise received a material financial investment from, any private equity fund or investment company (or an affiliate thereof) that is affiliated with any of the foregoing, (ii)&#160;an entity in which any of the foregoing or their affiliates are currently passive investors, (iii)&#160;an entity in which any of the foregoing or their affiliates are currently officers or directors, or (iv)&#160;an entity in which any of the foregoing or their affiliates are currently invested through an investment vehicle controlled by them, unless we have obtained an opinion from an independent investment banking firm, or another independent entity that commonly renders valuation opinions on the type of target business we are seeking to acquire, and the approval of a majority of our disinterested independent directors that the business combination is fair to our unaffiliated stockholders from a financial point of view. Furthermore, no finder&#8217;s fees, reimbursements, consulting fee, monies in respect of any payment of a loan or other compensation will be paid by us to the Sponsor, our officers or directors, or any of their respective affiliates, for services rendered to us prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is), other than the repayment of any loans from the Sponsor, officers and directors for working capital purposes and reimbursement of any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">306 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_31">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Atlantic Coastal Acquisition Corp. II. as of December&#160;31, 2023 and 2022 and for the years ended December&#160;31, 2022 and 2023 have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere in this proxy statement/prospectus, and are included in reliance on such report given on the authority of such firm as an expert in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Abpro Corporation as of December&#160;31, 2023 and 2022, and for each of the two years in the period ended December&#160;31, 2023, included in the Proxy Statement of Atlantic Coastal Acquisition Corp. II, which is referred to and made part of this proxy statement/prospectus and Registration Statement, have been audited by Wolf&#160;&amp; Company, P.C., independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">307 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_32">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legality of shares of ACAB&#8217;s Series A common stock offered by this proxy statement/prospectus will be passed upon for ACAB by Pillsbury Winthrop Shaw Pittman LLP, New York, NY. Certain attorneys of Pillsbury Winthrop Shaw Pittman LLP have an economic interest in the Sponsor representing less than 0.1% of its capitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters will be passed upon for Abpro by Nelson Mullins Riley&#160;&amp; Scarborough LLP, Washington, D.C. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">308 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_33">OTHER MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, the ACAB Board does not know of any matters that will be presented for consideration at the Special Meeting other than as described in this proxy statement/prospectus. If any other matters properly come before the Special Meeting, or any adjournment or postponement thereof, and are voted upon, the enclosed proxy will be deemed to confer discretionary authority on the individuals that it names as proxies to vote the shares represented by the proxy as to any of these matters. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">309 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_34">APPRAISAL RIGHTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of ACAB common stock are not entitled to appraisal rights in connection with the Business Combination under Delaware Law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">310 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_35">WHERE YOU CAN FIND ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB files reports, proxy statements and other information with the SEC as required by the Exchange Act. You can read ACAB&#8217;s SEC filings, including this proxy statement/prospectus, over the Internet at the SEC&#8217;s website at<span style="font-style:italic">&#160;http://www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination or the Proposals to be presented at the special meeting, you should contact ACAB&#8217;s proxy solicitation agent at the following address and telephone number: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Morrow Sodali LLC </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">333 Ludlow Street, 5th Floor, South Tower </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Stamford, CT 06902 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Individuals call toll-free (800) <span style="white-space:nowrap">662-5200</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Banks and brokers call (203) <span style="white-space:nowrap">658-9400</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Email: ACAB.info@investor.morrowsodali.com </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">If you are an ACAB stockholder and would like to request documents, please do so by</span><span style="font-weight:bold">&#8195;</span><span style="font-weight:bold">&#8195;</span><span style="font-weight:bold">&#8195;</span><span style="font-weight:bold">&#8195;</span><span style="font-weight:bold">, 2024, in order to receive them before the special meeting</span>. If you request any documents from ACAB, ACAB will mail them to you by first class mail, or another equally prompt means. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information included in this proxy statement/prospectus relating to ACAB has been supplied by ACAB, and all such information relating to Abpro has been supplied by Abpro. Information provided by either ACAB or Abpro does not constitute any representation, estimate or projection of any other party. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither ACAB nor Abpro has authorized anyone to give any information or make any representation about the Business Combination or the parties that is different from, or in addition to, the information that included in this proxy statement/prospectus or in any of the materials that have been incorporated in this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or purchase, the securities offered by this proxy statement/prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this proxy statement/prospectus does not extend to you. The information included in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">311 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="acab:NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" id="hidden113139487" contextRef="P01_01_2023To12_31_2023">P10D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acab-20231231.xsd"/></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc509388_36" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 95%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;text-align:center;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Page</div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Financial Statements of Atlantic Coastal Acquisition Corp. II as of and for the years ended December&#160;31, 2023 and 2022</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_1" style="display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID No. 688) </a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_2" style="display:inline;">CONSOLIDATED BALANCE SHEETS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_3" style="display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_4" style="display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT) FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_5" style="display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_6" style="display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Consolidated Financial Statements of Abpro Corporation as of and for the years ended December&#160;31, 2023 and 2022</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_101" style="display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_102" style="display:inline;">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER&#160;31, 2023 AND 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_103" style="display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_104" style="display:inline;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_105" style="display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_106" style="display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-35</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin509388_1">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors of </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlantic Coastal Acquisition Corp. II </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Opinion on the Financial Statements </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Atlantic Coastal Acquisition Corp. II (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related statements of operations, stockholders&#8217; deficit and cash flows for each of the two years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2023, in conformity with accounting principles generally accepted in the United States of America. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Explanatory Paragraph &#8211; Going Concern </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming tha<div style="display:inline;">t t</div>he Company will continue as a going concern. As described in Note 1 to the financial statements, the Company is a Special Purpose Acquisition Corporation that was formed for the purpose of completing a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses on or before April&#160;19, 2024, subject to deposits into the trust account maintained for the benefit of the Company&#8217;s public stockholders the lesser of (a) $30,000 or (b) $0.045 for each Public Share that is not redeemed in connection with the Meeting, or the Company may, without another stockholder vote, elect to extend the business combination deadline on a monthly basis by an additional six months through September&#160;19, 2024. The Company entered into a business combination agreement with a business combination target on December&#160;11, 2023 however, the completion of this transaction is subject to the conditions noted above. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans with regard to these matters are also described in Note 1. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Basis for Opinion </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum LLP </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum LLP </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">East Hanover, NJ </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;28, 2024 </div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin509388_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ATLANTIC COASTAL ACQUISITION CORP. II </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 75%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">ASSETS</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Current assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47253">264,538</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47254">392,446</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47255">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47256">377,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Cash and marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47257">29,728,990</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47258">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total Current Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47259">29,993,528</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47260">770,226</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Cash and marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47261">7,372,451</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47262">309,790,455</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">TOTAL ASSETS</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47263">37,365,979</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47264">310,560,681</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47265">469,268</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47266">1,243,172</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Excise tax payable</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:ExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47267">3,062,004</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:ExciseTaxPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47268">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued offering costs</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:AccruedOfferingCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47269">5,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:AccruedOfferingCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47270">75,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47271">308,194</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47272">823,991</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Common stock to be redeemed (</div><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47273"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47274">2,768,301</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares of Series A common stock)</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47275">29,728,990</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47276">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Extension promissory note - related party</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47277">160,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47278">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Advance from related parties</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47279">1,655,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47280">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total Current Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47281">35,388,456</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47282">2,142,163</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47283">10,500,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47284">10,500,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Liabilities</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47285">45,888,457</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47286">12,642,163</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Commitments (Note 6)</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-47287"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true" id="ixv-47288"/></td>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Series&#160;A common stock subject to possible redemption; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47289"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47290">667,391</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47291"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47292">30,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued and outstanding at December&#160;31, 2023 and 2022&#160;at redemption value of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47293">10.93</ix:nonFraction></div><div style="display:inline;"> and $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47294">10.30</ix:nonFraction></div><div style="display:inline;">&#160;per share, respectively</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47295">7,292,641</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47296">309,097,930</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Stockholders&#8217; Deficit</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Preferred stock, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47297"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47298">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47299"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47300">1,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized, </div><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47301"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47302"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47303"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47304">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> issued and outstanding</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47305">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47306">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Series&#160;A common stock, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47307"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47308">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47309"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47310">100,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47311"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47312">7,499,999</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47313"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47314">none</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> issued outstanding (excluding </div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47315">667,391</ix:nonFraction></div><div style="display:inline;"> and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47316">30,000,000</ix:nonFraction></div><div style="display:inline;">&#160;shares subject to possible redemption) as of December&#160;31, 2023 and 2022, respectively</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47317">749</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47318">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Series&#160;B common stock, $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47319"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47320">0.0001</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> par value; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47321"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47322">10,000,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares authorized; </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47323"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47324">1</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> and </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47325"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47326">7,500,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> shares issued&#160;and outstanding as of December&#160;31, 2023 and 2022, respectively</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47327">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47328">750</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47329">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47330">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47331">15,815,868</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47332">11,180,162</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Total Stockholders&#8217; Deficit</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47333">15,815,118</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47334">11,179,412</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47335">37,365,979</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47336">310,560,681</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin509388_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ATLANTIC COASTAL ACQUISITION CORP. II </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 76%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Operation and formation costs</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:OperationAndFormationCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47337">1,666,056</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:OperationAndFormationCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47338">2,050,410</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47339">1,666,056</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47340">2,050,410</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Other income (expense):</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Interest income &#8211; bank</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47341">52,304</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47342">1,848</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Interest earned on Cash and marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:InvestmentIncomeExpenseNonoperating" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47343">5,754,715</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:InvestmentIncomeExpenseNonoperating" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47344">4,121,971</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Penalties and interest on taxes</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="acab:PenaltiesAndInterestOnTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47345">142,041</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:PenaltiesAndInterestOnTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47346">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Unrealized loss on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47347">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47348">362,500</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Total other income, net</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47349">5,664,978</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47350">3,761,319</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income before provision for income taxes</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47351">3,998,922</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47352">1,710,909</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Provision for income taxes</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47353">1,177,463</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47354">823,991</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net income</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47355">2,821,459</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47356">886,918</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Weighted average shares outstanding, Redeemable common stock</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47357"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47358">11,257,894</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47359"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47360">28,438,356</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Basic and diluted net income per share, Series A common stock</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47361"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47362">0.15</ix:nonFraction></ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47363"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47364">0.02</ix:nonFraction></ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Weighted average shares outstanding, Nonredeemable Series A and Series B common stock</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47365"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47366">7,500,000</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47367"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47368">7,500,000</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Basic and diluted net income per share, Series B common stock</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47369"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47370">0.15</ix:nonFraction></ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47371"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47372">0.02</ix:nonFraction></ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin509388_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ATLANTIC COASTAL ACQUISITION CORP. II </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">FOR THE YEAR ENDED DECEMBER&#160;31, 2023 AND 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 40%;"><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td>
<td><div style="display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series A</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series B</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Stockholders&#8217;<br/>Deficit</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8212; December&#160;31, 2021</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47373">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47374">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47375">7,503,750</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47376">750</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47377">24,250</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47378">1,793</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47379">23,207</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sale of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47380">13,850,000</ix:nonFraction> Private Placement Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47381">13,850,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47382">13,850,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Founder Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47383">3,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation Expense &#8211; Fair value of assigned Founder Shares to Apeiron</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47384">362,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47385">362,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of Public Warrants at issuance</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 1pt; margin-top: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right; line-height: normal;">&#8212;&#8194;</div> </td>
<td style="white-space:nowrap;vertical-align:bottom"> <div style="margin-bottom: 1pt; margin-top: 0px; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47386">8,100,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47387">8,100,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Allocated value of transaction costs to Series A common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47388">505,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47389">505,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of Series A common stock to redemption amount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47390">21,831,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47391">12,065,287</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47392">33,896,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47393">886,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47394">886,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8212; December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47395">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47396">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47397">7,500,000</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47398">750</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47399">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47400">11,180,162</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47401">11,179,412</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of Series A common stock to redemption amount</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47402">4,395,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47403">4,395,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholder <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-redemption</div> agreement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:StockholderNonRedemptionAgreementAdjustment" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47404">1,378,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:StockholderNonRedemptionAgreementAdjustment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47405">1,378,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholder <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-redemption</div> agreement</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:StockholderNonRedemptionAgreementAdjustmentReduction" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47406">1,378,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:StockholderNonRedemptionAgreementAdjustmentReduction" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47407">1,378,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Excise tax</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:AdjustmentsToAdditionalPaidInCapitalExciseTax" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47408">3,062,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:AdjustmentsToAdditionalPaidInCapitalExciseTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47409">3,062,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Series Class&#160;B shares to Series Class&#160;A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-redeemable</div> shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47410">7,499,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47411">749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47412">7,499,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47413">749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47414">2,821,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47415">2,821,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance &#8212; December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47416">7,499,999</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47417">749</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47418">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47419">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47420">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47421">15,815,868</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47422">15,815,118</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin509388_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ATLANTIC COASTAL ACQUISITION CORP. II </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 72%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 4%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Cash Flows from Operating <div style="letter-spacing: 0px; top: 0px;display:inline;">Activities</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Net income</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47423">2,821,459</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47424">886,918</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Adjustments to reconcile net income to net cash used in operating activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Interest earned on Cash and <div style="display:inline;">marketable </div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">securities </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;">held </div>in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47425">5,754,715</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47426">4,121,971</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Compensation expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47427">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47428">362,500</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Changes in operating assets and <div style="letter-spacing: 0px; top: 0px;display:inline;">liabilities</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47429">377,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47430">377,780</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47431">773,904</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47432">1,241,379</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47433">515,797</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47434">823,991</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47435">3,845,177</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47436">1,184,963</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Cash Flows from Investing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Investment of cash in Trust Account</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47437">160,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47438">306,000,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash withdrawn from Trust Account to pay franchise and income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47439">2,132,269</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47440">331,516</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash withdrawn from Trust Account in connection with redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:ProceedsFromTrustAccountInConnectionWithRedemption" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47441">276,471,460</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:ProceedsFromTrustAccountInConnectionWithRedemption" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47442">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash provided by (used in) investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47443">278,443,729</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47444">305,668,484</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Cash Flows from Financing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from sale of Units, net of underwriting discounts paid</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47445">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47446">294,240,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from sale of Private Placement Warrants</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47447">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47448">13,850,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from extension promissory note &#8211; related party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47449">160,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47450">49,262</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Proceeds from convertible promissory note - <div style="display:inline;">related </div>party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47451">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47452">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Repayment of promissory note &#8211; related party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47453">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47454">149,539</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Advances from related party</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47455">1,655,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47456">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Payment of offering costs</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47457">70,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47458">743,830</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Redemption of common stock</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47459">276,471,460</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47460">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net cash (used in) provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47461">274,726,460</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47462">307,245,893</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Net Change in Cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47463">127,908</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47464">392,446</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Cash &#8211; Beginning</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47465">392,446</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47466">&#8212;</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Cash &#8211; Ending</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47467">264,538</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47468">392,446</ix:nonFraction></div></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Supplementary cashflow information:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Income taxes paid</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47469">1,799,627</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47470">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred offering costs included in accrued offering costs</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47471">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47472">717,219</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Initial classification of Series A common stock subject to possible redemption</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47473">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47474">309,097,930</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Deferred underwriting fee payable</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47475">&#8212;</ix:nonFraction></div>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47476">10,500,000</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139489" id="ixv-26883"><div id="fin509388_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTE&#160;1&#160;&#8212;&#160;ORGANIZATION AND PLAN OF BUSINESS OPERATIONS </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Atlantic Coastal Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in Delaware on May&#160;20, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). On November 30, 2023 the Company formed Abpro Merger Sub Corp. (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of the Company. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had not yet commenced any operations. All activity for the period May&#160;20, 2021 (inception) through December&#160;31, 2023 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;13, 2022. On January&#160;19, 2022, the Company consummated the Initial Public Offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47477">30,000,000</ix:nonFraction> units (the &#8220;Units&#8221; and, with respect to the shares of Series A common stock included in the Units being offered, the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of its over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47478">3,900,000</ix:nonFraction> Units at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47479">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="acab:GrossProceedsFromInitialPublicOffer" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47480">300,000,000</ix:nonFraction>, which is described in Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="acab:ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" contextRef="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47481">13,850,000</ix:nonFraction> warrants (each, a &#8220;Private Placement Warrant&#8221; and, collectively, the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction name="acab:ClassOfWarrantsOrRightsIssuePricePerUnit" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47482">1.00</ix:nonFraction> per Private Placement Warrant in a private placement to Atlantic Coastal Acquisition Management II LLC (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47483">13,850,000</ix:nonFraction>, which is described in Note 4. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs amounted to $<ix:nonFraction name="acab:TransactionCostsOfIssuance" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47484">17,204,107</ix:nonFraction>, consisting of $<ix:nonFraction name="acab:UnderwritingFeesNetOfReimbursementByUnderwriters" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47485">5,760,000</ix:nonFraction> of underwriting fees (net of $<ix:nonFraction name="acab:ReimbursementByUnderwriters" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47486">240,000</ix:nonFraction> reimbursed by the underwriters), $<ix:nonFraction name="acab:DeferredUnderwritingCommissionNonCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47487">10,500,000</ix:nonFraction> of deferred underwriting fees, and $<ix:nonFraction name="acab:OtherOfferingCosts" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47488">944,107</ix:nonFraction> of other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the Initial Public Offering on January&#160;19, 2022, an amount of $<ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P01_13_2022To01_13_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47489">306,000,000</ix:nonFraction> ($<ix:nonFraction name="acab:PerSharePaymentMadeToAcquireRestrictedInvestments" contextRef="PAsOn01_13_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47490">10.20</ix:nonFraction> per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), to be invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of <ix:nonNumeric name="acab:TermOfRestrictedInvestments" contextRef="P01_13_2022To01_13_2022" format="ixt-sec:durday" id="ixv-47491">185</ix:nonNumeric> days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earlier of: (i)&#160;the consummation of a Business Combination or (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s stockholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">While the Company&#8217;s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Placement Warrants, which are placed in the Trust Account are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-7</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139489" continuedAt="TextSelectionAppend_113139489_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_1" continuedAt="TextSelectionAppend_113139489_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_2" continuedAt="TextSelectionAppend_113139489_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least </div></div><ix:nonFraction name="acab:PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" contextRef="PAsOn01_13_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47493">80</ix:nonFraction>% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn01_13_2022_MinimumMembersrtRangeAxis_PostBusinessCombinationMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47494">50</ix:nonFraction>% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. <br/></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn01_13_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47495">10.20</ix:nonFraction> per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="acab:MinimumNetWorthNeededToConsummateBusinessCombination" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47496">5,000,001</ix:nonFraction> either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Company&#8217;s shares prior to the Initial Public Offering (the &#8220;Initial Stockholders&#8221;) have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction name="acab:PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47497">15</ix:nonFraction>% or more of the Public Shares, without the prior consent of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">The Initial Stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination prior to September 19, 2024 and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s Initial Business Combination or to redeem</div> <div style="display:inline;"><ix:nonFraction name="acab:PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47498">100</ix:nonFraction></div><div style="display:inline;">% of its Public Shares if the Company does not complete a Business Combination or (ii)&#160;with respect to any other provision relating to stockholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">pre-initial</div> business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-8</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_3" continuedAt="TextSelectionAppend_113139489_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139489_4" continuedAt="TextSelectionAppend_113139489_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_5" continuedAt="TextSelectionAppend_113139489_6"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_6" continuedAt="TextSelectionAppend_113139489_7"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company had <ix:nonNumeric name="acab:TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durmonth" id="ixv-47500">15</ix:nonNumeric> months from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than<div style="letter-spacing: 0px; top: 0px;display:inline;"> <div style="-sec-ix-hidden:hidden113139487;display:inline;">ten</div></div> business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $<ix:nonFraction name="us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47501">100,000</ix:nonFraction> of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining stockholders and the Company&#8217;s board of directors, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from April&#160;19, 2023 to October&#160;19, 2023, subject to additional Extension(s) up to December&#160;19, 2023 upon election by the Sponsor. The extension was approved and a result <ix:nonFraction name="acab:TemporaryEquityStockRedeemedDuringThePeriodShares" contextRef="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47502">26,564,308</ix:nonFraction> shares of the Company&#8217;s Series A common stock were redeemed at approximately $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47503">10.41</ix:nonFraction> per share. <br/></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_7" continuedAt="TextSelectionAppend_113139489_8"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">On April&#160;18, 2023, the Sponsor, the Company&#8217;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#8220;Series B Holders&#8221;) voluntarily converted <ix:nonFraction name="acab:ConversionOfPermanentEquityIntoTemporaryEquityShares" contextRef="P04_18_2023To04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47504">7,499,999</ix:nonFraction> shares of Series B Common Stock of the Company they held as of such date into <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47505">7,499,999</ix:nonFraction> shares of Series A common stock of the Company (the &#8220;Conversion&#8221;) in accordance with the amended and restated certificate of incorporation, as amended. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from the Company&#8217;s trust account. As a result of the Conversion and the results of the Meeting described above, the Company has an aggregate of <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47506">10,935,691</ix:nonFraction> shares of Series A common stock outstanding and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47507">1</ix:nonFraction> share of Series B Common Stock (held by the Sponsor) outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="display:inline;">On October&#160;14, 2023 and November&#160;14, 2023, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing, unsecured promissory notes in the aggregate principal amount of $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47508"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47509">80,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;">, respectively, (the &#8220;Notes&#8221;) to the Sponsor. The $</div><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P10_14_2023To10_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47510"><ix:nonFraction name="us-gaap:PaymentsToAcquireRestrictedInvestments" contextRef="P11_14_2023To11_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47511">80,000</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"> was deposited into the Company&#8217;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>$</div><div style="display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn11_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47512"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47513">10.20</ix:nonFraction></ix:nonFraction></div><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">p</div></div>er share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October&#160;19, 2023 to November&#160;19, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November&#160;19, 2023 to December&#160;19, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro Corporation, a Delaware corporation, entered into a business combination agreement (the &#8220;Business Combination Agreement&#8221;). Please see the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> filed on December&#160;12, 2023 for more information on the terms of the Business Combination Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Merger.</div></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_8" continuedAt="TextSelectionAppend_113139489_9"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-9 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_9" continuedAt="TextSelectionAppend_113139489_10"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139489_10" continuedAt="TextSelectionAppend_113139489_11"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_11" continuedAt="TextSelectionAppend_113139489_12"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_12" continuedAt="TextSelectionAppend_113139489_13"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;15, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from December&#160;19, 2023 to March&#160;19, 2024, subject to deposits into the trust account maintained for the benefit of the Company&#8217;s public stockholders the lesser of (a) $<ix:nonFraction name="acab:AmountToBeDepositedInTrustAccount" contextRef="P12_15_2023To12_15_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47514">30,000</ix:nonFraction> or (b) $<ix:nonFraction name="acab:PerShareValueOfTheAmountToBeDepositedInTrustAccount" contextRef="P12_15_2023To12_15_2023" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-47515">0.045</ix:nonFraction> for each Public Share that is not redeemed in connection with the Meeting. If the Company has not consummated a Business Combination by the Extended Date, the Company may, without another stockholder vote, elect to extend the Extended Date on a monthly basis up to six times by an additional one month each time thereafter, until September&#160;19, 2024. The extension was approved and a result <ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" contextRef="PAsOn12_15_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47516">2,768,301</ix:nonFraction> public shares of Series A common stock exercised and did not reverse, their right to redeem their public shares in connection with the vote upon the Charter Amendment Proposal. As a result of the foregoing, those holders will receive a payment of approximately $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_15_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47517">10.68</ix:nonFraction> per share redeemed. This resulted in $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfTrustAssetsToPayExpenses" contextRef="P12_15_2023To12_15_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47518">29,728,990</ix:nonFraction> being withdrawn from the trust account and paid to redeeming stockholders. The payment to the redeeming stockholders was processed in January 2024, as such $<ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47519">29,728,990</ix:nonFraction> has been removed form Series A common stock subject to redemption and recorded as common stock to be redeemed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($<ix:nonFraction name="acab:PerShareAmountAvailableForDistribution" contextRef="PAsOn01_13_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47520">10.00</ix:nonFraction>). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $</div><div style="display:inline;"><ix:nonFraction name="acab:PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47521">10.20</ix:nonFraction></div><div style="display:inline;"> per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;display:inline;">indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2023, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47522">264,538</ix:nonFraction> in its operating bank accounts and a working capital deficit of $<ix:nonFraction name="acab:WorkingCapitalLoan" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47523">5,394,929</ix:nonFraction>. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_13" continuedAt="TextSelectionAppend_113139489_14"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-10 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_14" continuedAt="TextSelectionAppend_113139489_15"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139489_15" continuedAt="TextSelectionAppend_113139489_16"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_16" continuedAt="TextSelectionAppend_113139489_17"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_17" continuedAt="TextSelectionAppend_113139489_18"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. The Company will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40</div> &#8220;Presentation of Financial Statements&#8212;Going Concern,&#8221; the Company has until April 19, 2024, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before April 19, 2024, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s plan is to complete a business combination on or prior to April 19, 2024, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after April 19, 2024. </div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, close of the Initial Public Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of current conflicts around the globe, including Russia&#8217;s invasion of Ukraine and the Israel-Hamas war, and related sanctions, on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. <br/></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_18" continuedAt="TextSelectionAppend_113139489_19"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Inflation Reduction Act of 2022 </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal <ix:nonFraction name="acab:PercentageOfFederalExciseTaxOnStockBuyBack" contextRef="PAsOn08_16_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47524">1</ix:nonFraction>% excise tax on certain repurchases of stock by publicly traded&#160;U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after <ix:nonNumeric name="acab:EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" contextRef="P08_16_2022To08_16_2022" format="ixt:date-monthname-day-year-en" id="ixv-47525">January 1, 2023</ix:nonNumeric>. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-11</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_19" continuedAt="TextSelectionAppend_113139489_20"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139489_20" continuedAt="TextSelectionAppend_113139489_21"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139489_21" continuedAt="TextSelectionAppend_113139489_22"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139489_22"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">Any redemption or other repurchase that occurs after December&#160;31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i)&#160;the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii)&#160;the structure of a Business Combination, (iii)&#160;the nature and amount of any &#8220;PIPE&#8221; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv)&#160;the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and impact the Company&#8217;s ability to complete a Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023 and December&#160;13, 2023, the Company&#8217;s stockholders redeemed&#160;<ix:nonFraction name="acab:CommonStockSharesRedeemable" contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47527">26,564,308</ix:nonFraction>&#160;Series&#160;Class A shares for a total of $<ix:nonFraction name="acab:CommonStockValueRedeemable" contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47528">276,471,460</ix:nonFraction> and redeemed&#160;<ix:nonFraction name="acab:CommonStockSharesRedeemable" contextRef="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47529">2,768,301</ix:nonFraction>&#160;Series&#160;Class A shares for a total of $<ix:nonFraction name="acab:CommonStockValueRedeemable" contextRef="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47530">29,728,990</ix:nonFraction>, respectively. The Company evaluated the classification and accounting of the stock redemption under ASC 450, &#8220;Contingencies&#8221;. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of December&#160;31, 2023 and determined that a contingent liability should be calculated and recorded. As of December&#160;31, 2023, the Company recorded $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47531">3,062,004</ix:nonFraction>&#160;of excise tax liability calculated as <ix:nonFraction name="acab:PercentageOfSharesRedeemable" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47532">1</ix:nonFraction>% of shares redeemed. </div></ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139701" id="ixv-27084"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 2&#8201;&#8212;&#8201;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27087"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the SEC. </div></ix:nonNumeric><ix:nonNumeric name="acab:EmergingGrowthCompanyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27093"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-1<div style="letter-spacing: 0px; top: 0px;display:inline;">2</div></ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139701" continuedAt="TextSelectionAppend_113139701_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_1" continuedAt="TextSelectionAppend_113139701_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_2" continuedAt="TextSelectionAppend_113139701_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139701_3" continuedAt="TextSelectionAppend_113139701_4"><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27118"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27127"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27133"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47533"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47534">no</ix:nonFraction></ix:nonFraction>t have any cash equivalents as of December&#160;31, 2023 and 2022. The Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47535">264,538</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47536">392,446</ix:nonFraction> in cash at December&#160;31, 2023 and 2022, respectively. </div></ix:nonNumeric><ix:nonNumeric name="acab:AssetsHeldInTrustAccountPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27139"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Cash and Marketable Securities Held in Trust Account </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At December&#160;31, 2023 and 2022, all of the Company&#8217;s investments held in the Trust Account are invested in cash and money market funds invested primarily in United States Treasuries and are classified as trading securities, respectively. Trading securities are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </div></div></div></ix:nonNumeric><ix:nonNumeric name="acab:TemporaryEquityPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139527" id="ixv-27151"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Common Stock Subject to Possible Redemption </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#8217; equity. The Company&#8217;s Series A common stock feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2023 and 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheet. <br/></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-1<div style="letter-spacing: 0px; top: 0px;display:inline;">3</div></ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_113139527" continuedAt="TextSelectionAppend_113139527_1"><ix:continuation id="TextSelectionAppend_113139701_4" continuedAt="TextSelectionAppend_113139701_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_5" continuedAt="TextSelectionAppend_113139701_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_6" continuedAt="TextSelectionAppend_113139701_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_113139701_7" continuedAt="TextSelectionAppend_113139701_8"><ix:continuation id="TextSelectionAppend_113139527_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and accumulated deficit. </div></div> <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27182"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 76%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr>
<td style="width:82%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;<ix:nonFraction name="acab:GrossProceeds" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47537">300,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds allocated to Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:ProceedsAllocatedToPublicWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47538">8,100,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A common stock issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:CommonStockIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47539">16,699,058</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47540">33,896,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47541">309,097,930</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="acab:TemporaryEquityRedemptionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47542">276,471,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemptions (redeemed in December 2023, paid in January 2024)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47543">29,728,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47544">4,395,161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47545">7,292,641</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27331"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A&#8212;&#8220;Expenses of Offering&#8221;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder&#8217;s equity. As of January&#160;19, 2022, offering costs in the aggregate of $<ix:nonFraction name="acab:OfferingCosts" contextRef="PAsOn01_19_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47546">17,204,107</ix:nonFraction>, of which an aggregate of $<ix:nonFraction name="acab:OfferingCostsAllocatedInTemporaryEquity" contextRef="P01_19_2022To01_19_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47547">16,699,058</ix:nonFraction> have been charged to temporary equity and an aggregate of $<ix:nonFraction name="acab:OfferingCostsAllocatedInShareholdersEquity" contextRef="P01_19_2022To01_19_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47548">505,049</ix:nonFraction> have been charged to stockholders&#8217; equity. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47549"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47550">no</ix:nonFraction></ix:nonFraction> deferred offering costs recorded in the accompanying consolidated balance sheets respectively. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27341"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47551">250,000</ix:nonFraction>. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139796" id="ixv-27347"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes.&#8221; ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-14</ix:exclude> </div></div></div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_113139796" continuedAt="TextSelectionAppend_113139796_1"><ix:continuation id="TextSelectionAppend_113139701_8" continuedAt="TextSelectionAppend_113139701_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_113139796_1" continuedAt="TextSelectionAppend_113139796_2"><ix:continuation id="TextSelectionAppend_113139701_9" continuedAt="TextSelectionAppend_113139701_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_10" continuedAt="TextSelectionAppend_113139701_11"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_113139701_11" continuedAt="TextSelectionAppend_113139701_12"><ix:continuation id="TextSelectionAppend_113139796_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of December&#160;31, 2023 and 2022, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it<div style="letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized <div style="letter-spacing: 0px; top: 0px;display:inline;">tax</div> benefits will materially change over the next twelve months. </div> </ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139479" id="ixv-27386"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Income per Common Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47553">28,850,000</ix:nonFraction> Series A common stock in the aggregate. As of December&#160;31, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income per common stock for the periods presented.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-15</ix:exclude> </div></div></div> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_113139479" continuedAt="TextSelectionAppend_113139479_1"><ix:continuation id="TextSelectionAppend_113139701_12" continuedAt="TextSelectionAppend_113139701_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_113139479_1" continuedAt="TextSelectionAppend_113139479_2"><ix:continuation id="TextSelectionAppend_113139701_13" continuedAt="TextSelectionAppend_113139701_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_14" continuedAt="TextSelectionAppend_113139701_15"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_113139701_15" continuedAt="TextSelectionAppend_113139701_16"><ix:continuation id="TextSelectionAppend_113139479_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): </div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27416"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 36%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Redeemable</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nonredeemable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;and&#160;Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Basic and diluted net income per common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Allocation of net income, as adjusted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47555">1,693,350</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47556">1,128,109</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47557">701,826</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47558">185,092</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="display:inline;">Basic and diluted weighted average shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47559"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47560">11,257,894</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47561"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47562">7,500,000</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47563"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47564">28,438,356</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47565"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47566">7,500,000</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Basic and diluted net income per common stock</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47567"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47568">0.15</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47569"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47570">0.15</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47571"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47572">0.02</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47573"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47574">0.02</ix:nonFraction></ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27646"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheet, primarily due to their short-term nature. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27652"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div> settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815. </div> </ix:nonNumeric><ix:nonNumeric name="acab:WarrantsDisclosurePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139700" id="ixv-47575"></ix:nonNumeric></ix:continuation></div> </div> </div> </div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139701_16" continuedAt="TextSelectionAppend_113139701_17"><ix:continuation id="TextSelection_113139700"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#8217; equity. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139667" id="ixv-27675"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company adopted ASC Topic 718, &#8220;Compensation<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div></div></div>Stock Compensation,&#8221; guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or </div></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_113139667" continuedAt="TextSelectionAppend_113139667_1"><ix:continuation id="TextSelectionAppend_113139701_17" continuedAt="TextSelectionAppend_113139701_18"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-16 </div></div></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_18" continuedAt="TextSelectionAppend_113139701_19"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139667_1" continuedAt="TextSelectionAppend_113139667_2"><ix:continuation id="TextSelectionAppend_113139701_19" continuedAt="TextSelectionAppend_113139701_20"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139701_20" continuedAt="TextSelectionAppend_113139701_21"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139701_21"><ix:continuation id="TextSelectionAppend_113139667_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the statements of operations. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27713"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU 2023-09 will become effective for Annual periods beginning after December 15, 2024. The Company is still reviewing the impact of ASU 2023-09.</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued Accounting Standards Updated (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(Subtopic470-20)and</div> Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity(Subtopic&#160;815-40):Accounting</div> for Convertible Instruments and Contracts in an Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity&#8221;(&#8220;ASU&#160;2020-06&#8221;),which</div> simplifies accounting for convertible instruments by removing major separation models required under current GAAP. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> would have on our financial position, results of operations or cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8211;Financial</div> Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8221;).&#160;This</div> update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> on January&#160;1, 2023. The adoption of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU2016-13</div> did not have a material impact on its financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="acab:DisclosureOfInitialPublicOffering" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27737"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;3&#8201;&#8212;&#8201;INITIAL PUBLIC OFFERING </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Initial Public Offering, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47576">30,000,000</ix:nonFraction> Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47577">3,900,000</ix:nonFraction> units, at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47578">10.00</ix:nonFraction> per Unit. <ix:nonNumeric name="us-gaap:CommonStockConversionBasis" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis" id="ixv-27745">Each Unit consists of one share of the Company&#8217;s Series A common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;).</ix:nonNumeric> Each Public Warrant entitles the holder to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47579">one</ix:nonFraction> share of Series A common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47580">11.50</ix:nonFraction> per whole share (see Note 7). </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1<div style="letter-spacing: 0px; top: 0px;display:inline;">7</div> </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="acab:DisclosureOfPrivatePlacement" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-27756"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;4&#8201;&#8212;&#8201;PRIVATE PLACEMENT </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <ix:nonFraction name="acab:ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47581">13,850,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="acab:ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." contextRef="PAsOn12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47582">1.00</ix:nonFraction> per Private Placement Warrant, for an aggregate purchase price of $<ix:nonFraction name="acab:ProceedsFromTheIssuanceOfWarrants" contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47583">13,850,000</ix:nonFraction>, in a private placement. Each Private Placement Warrant is exercisable to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47584">one</ix:nonFraction> Series A common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47585">11.50</ix:nonFraction> per share, subject to adjustments (see Note 7). A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139372" id="ixv-27764"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;5&#8201;&#8212;&#8201;RELATED PARTY TRANSACTIONS </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor paid $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47586">25,000</ix:nonFraction> to cover certain offering costs of the Company in consideration for <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47587">7,187,500</ix:nonFraction> shares of Series B common stock (the &#8220;Founder Shares&#8221;). On January&#160;13, 2022, the Company effectuated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;<ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P10_25_2021To10_25_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-47588">1.044</ix:nonFraction>-for-1&#160;stock</div></div> split, resulting in an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47589">7,503,750</ix:nonFraction> Founder Shares outstanding (see Note 7). Due to the underwriters&#8217; election to partially exercise their overallotment option, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47590">3,750</ix:nonFraction> shares were forfeited. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor, founders, executive officers and directors have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until <ix:nonNumeric name="acab:LockInPeriodOfShares" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen" id="ixv-47591">one year</ix:nonNumeric> after the completion of a Business Combination that results in all of the Company&#8217;s stockholders having the right to exchange their Series A common stock for cash, securities, or other property&#160;(except with respect to permitted transferees). Notwithstanding the foregoing, (x)&#160;if the last reported sale price of the Series A common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47592">12.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="acab:NumberOfTradingDaysForDeterminingSharePrice" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday" id="ixv-47593">20</ix:nonNumeric> trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">any&#160;<ix:nonNumeric name="acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday" id="ixv-47594">30</ix:nonNumeric>-trading&#160;day</div> period commencing at least <ix:nonNumeric name="acab:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday" id="ixv-47595">150</ix:nonNumeric> days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of common stock for cash, securities or other property, then such securities will be released from these restrictions. Any permitted transferees would be subject to the same restrictions and other agreements of the founders with respect to any Founder Shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor transferred <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47596">250,000</ix:nonFraction> Founder Shares to five director nominees (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_DirectorMembersrtTitleOfIndividualAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47597">50,000</ix:nonFraction> shares to each director nominee) for no consideration, to serve in his or her capacity as an independent director of the Company. The Company assigned the number of shares of Series B common stock of the Company, par value $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47598">0.0001</ix:nonFraction> per share. The transfer of the Founders Shares to five director nominees is&#160;within the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and expensed when earned. Shares granted to these directors are forfeited if their status as director is terminated for any reason prior to the date of the initial Business Combination&#160;and, as such, there has been no stock-based compensation expense recognized in the accompanying financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2021, the Company and Apeiron Investment Group Ltd. (&#8220;Apeiron&#8221;) entered into an Agreement to which Apeiron will serve as an advisor to the Company in connection with identifying one or more businesses with which the Company may effectuate its Initial Business Combination. As consideration for Apeiron&#8217;s willingness to provide the service set forth in the Agreement, the Sponsor shall pay or transfer to Apeiron (or its designee) on behalf of the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;non-refundable</div> fee in the form of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47599">50,000</ix:nonFraction> shares of the Company&#8217;s Series B common stock (&#8220;Fee Shares&#8221;). The transfer of the Founder Shares to Apeiron is not directly related to or in connection with the Initial Public Offering and not within the scope of offering costs as defined in Note 2. The transfer of the Fee Shares is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47600">50,000</ix:nonFraction> Fee Shares granted to Apeiron was $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47601">362,500</ix:nonFraction> or $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_01_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47602">7.25</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. The Founders Shares were granted subject to a performance condition (i.e., the closing date of the Initial </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-18</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139372" continuedAt="TextSelectionAppend_113139372_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139372_1" continuedAt="TextSelectionAppend_113139372_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139372_2" continuedAt="TextSelectionAppend_113139372_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Public Offering). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2022, the Company recognized $</div></div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47604">362,500</ix:nonFraction>&#160;in the operations as stock-based compensation expense as the Company determined that the performance condition has been met at the date of issuance/closing of the Initial Public Offering. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#8220;Promissory Note&#8221;), pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_25_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47605">250,000</ix:nonFraction>. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing and is payable on the earlier of April&#160;30, 2022, or the consummation of the Initial Public Offering. As of December&#160;31, 2023 and 2022, the Company has <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2023_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47606"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47607">no</ix:nonFraction></ix:nonFraction> outstanding balance under the Promissory Note, respectively. <br/></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139372_3"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Sponsor has committed to advance the Company up to $<ix:nonFraction name="us-gaap:OtherCommitment" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47608">1,750,000</ix:nonFraction> to fund the expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Initial Business Combination. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If the Company consummated an Initial Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The final terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $<ix:nonFraction name="acab:WorkingCapitalLoansConvertibleIntoEquityWarrants" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47609">1,500,000</ix:nonFraction> of such Working Capital Loans may be convertible into additional warrants of the post-Business Combination entity at a price of $<ix:nonFraction name="acab:DebtInstrumentConversionPricePerShare" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47610">1.00</ix:nonFraction> per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Prior to the completion of the Initial Business Combination, the Company does not expect to seek loans from parties other than the Sponsor or its affiliates as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. There are <ix:nonFraction name="acab:WorkingCapitalLoansOutstanding" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47611"><ix:nonFraction name="acab:WorkingCapitalLoansOutstanding" contextRef="PAsOn12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47612">no</ix:nonFraction></ix:nonFraction> Working Capital Loans outstanding as of December&#160;31, 2023 and 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Extension Promissory Notes &#8212; Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023 and November&#160;14, 2023, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing, unsecured promissory notes in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn11_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47613"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47614">80,000</ix:nonFraction></ix:nonFraction>, respectively, (the &#8220;Extension Promissory Notes&#8221;) to the Sponsor. The $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47615">80,000</ix:nonFraction> was deposited into the Company&#8217;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47616">10.20</ix:nonFraction> per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. As of December&#160;31, 2023, the Company owed $<ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47617">160,000</ix:nonFraction> due under the Extension Promissory Notes with no further borrowings available. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;18, 2023, the Company amended the Extension Promissory Notes to remove the Sponsor&#8217;s right to convert the note into Series A common stock at a price equal to </div></div></div><div style="display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$</div><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn12_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47618">10.20</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> per share.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advance from Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, December&#160;11, 2023, and December&#160;12, 2023, the Sponsor advanced the Company $<ix:nonFraction name="us-gaap:OtherLoansPayable" contextRef="PAsOn12_08_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47619">10,000</ix:nonFraction>, $<ix:nonFraction name="us-gaap:OtherLoansPayable" contextRef="PAsOn12_11_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47620">1,630,000</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:OtherLoansPayable" contextRef="PAsOn12_12_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47621">15,000</ix:nonFraction>, respectively, to fund tax obligations. As of December&#160;31, 2023, the Sponsor advanced the Company $<ix:nonFraction name="us-gaap:OtherLoansPayable" contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47622">1,655,000</ix:nonFraction> and is reflected in the consolidated balance sheets.</div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-19 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139478" id="ixv-27853"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">&#160;</div></div></div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a registration rights agreement entered into on January&#160;13, 2022, the holders of the Founder Shares, Private Placement Warrants, and any Private Placement Warrants that may be issued upon conversion of the Working Capital Loans (and any Series A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and conversion of Founder Shares) will be entitled to registration rights. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lock-up</div> period. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to a cash underwriting discount of $<ix:nonFraction name="acab:UnderwritingDiscountPerShare" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47623">0.20</ix:nonFraction> per Unit, or $<ix:nonFraction name="acab:PaymentOfUnderwritingDiscount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47624">6,000,000</ix:nonFraction> in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $<ix:nonFraction name="acab:DeferredUnderwritingDiscountPerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47625">0.35</ix:nonFraction> per Unit, or $<ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47626">10,500,000</ix:nonFraction> in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. <br/></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advisors </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2022, the Company and Farvahar Capital (&#8220;Farvahar&#8221;) entered into an agreement under which Farvahar served as an advisor to the Company in connection with the Initial Public Offering. Farvahar was engaged to represent the Company&#8217;s interests only and is independent of the underwriters. The underwriters reimbursed the Company for the fees payable to Farvahar in respect of the provision of such advisory services. The Company agreed to pay Farvahar a fee of <ix:nonFraction name="acab:PercentageOfAdvisoryServiceFee" contextRef="P01_07_2022To01_07_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47627">0.08</ix:nonFraction>% of the gross proceeds of the Initial Public Offering, including any exercise of the underwriters&#8217; over-allotment option with respect to the Initial Public Offering or $<ix:nonFraction name="acab:AdvisoryServiceFee" contextRef="P01_07_2022To01_07_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47628">240,000</ix:nonFraction> in the aggregate. Farvahar did not act as an underwriter in connection with the Initial Public Offering; it did not identify or solicit potential investors in the Initial Public Offering. As of December&#160;31, 2022, the Company received the reimbursement from the underwriters and paid Farvahar.<br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Capital Market Advisor </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On April&#160;11, 2023, the Company entered into a services agreement with an advisor. The Advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will be paid a fee for their services. All consideration is to be paid simultaneously with the closing of the business combination. </div></div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Redemption</div> Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about April&#160;4, 2023, the Company and Atlantic Coastal Acquisition Management II LLC (the &#8220;Sponsor&#8221;), entered into agreements <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;Non-Redemption</div> Agreements&#8221;) with several unaffiliated third parties in exchange for them agreeing not to redeem an aggregate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="acab:NumberOfSharesNotAvailableForRedemption" contextRef="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47629">3,300,900</ix:nonFraction>shares(&#8220;Non-Redeemed</div> Shares&#8221;) of the Company&#8217;s Series A common stock sold in its initial public offering (the &#8220;Public Shares&#8221;) at the special meeting called by the Company (the &#8220;Meeting&#8221;) to approve an extension of time for the Company to consummate an initial business<div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-20</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139478" continuedAt="TextSelectionAppend_113139478_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139478_1" continuedAt="TextSelectionAppend_113139478_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139478_2" continuedAt="TextSelectionAppend_113139478_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">combination (the &#8220;Charter Amendment Proposal&#8221;) from <ix:nonNumeric name="acab:ThresholdDateForConsummationOfBusinessCombinationOne" contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-47632">April 19, 2023</ix:nonNumeric> to <ix:nonNumeric name="acab:ThresholdDateForConsummationOfBusinessCombinationTwo" contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-47633">October 19, 2023</ix:nonNumeric> (an &#8220;Extension&#8221;), subject to additional Extension(s) up to <ix:nonNumeric name="acab:ThresholdDateForConsummationOfBusinessCombinationThree" contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-47634">December 19, 2023</ix:nonNumeric> upon election by the Sponsor. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of <ix:nonFraction name="acab:InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" contextRef="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47635">825,225</ix:nonFraction> shares of the Company held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Redeemed</div> Shares through the Meeting.</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;), and Abpro Corporation, a Delaware corporation &#8220;Abpro&#8221;), entered into a business combination agreement (the &#8220;Business Combination Agreement&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Pursuant to the Business Combination Agreement, on the Closing Date (as defined in the Business Combination Agreement), Merger Sub, a newly formed, wholly-owned direct subsidiary of the Company, will be merged with and into the Abpro (the &#8220;Business Combination,&#8221; together with the other transactions related thereto, the &#8220;Proposed Transactions&#8221;), with the Abpro surviving the Business Combination as a wholly-owned direct subsidiary of the Company (the &#8220;Surviving Company&#8221;). In connection with the consummation of the Business Combination, the Company will change its corporate name to &#8220;Abpro Holdings, Inc.&#8221; The respective boards of directors of the Company and Abpro have duly approved the Business Combination Agreement and the transactions contemplated thereby. </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Business Combination (the &#8220;Effective Time&#8221;), Abpro will cause (i)&#160;all outstanding Abpro convertible notes to be converted into shares of Company Common Stock, (ii)&#160;all outstanding Abpro warrants to acquire equity securities of the Company to be converted into a number of shares of shares of Company Common Stock and (iii)&#160;the Abpro Preferred Shares (including those shares resulting from the convertible notes conversion and warrant conversion) that are issued and outstanding immediately prior to the Effective Time to be converted into shares of Abpro Common Stock. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conditions to closing </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="display:inline;">The obligations of the Company and Abpro to consummate the Business Combination are subject to certain closing conditions, including, but not limited to, (i)&#160;the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;the absence of any law or governmental order or other legal restraint or prohibition preventing the consummation of the Business Combination, (iii)&#160;the Registration Statement being declared effective under the Securities Act, (iv)&#160;the ACAB New Common Shares to be issued in connection with the Business Combination having been approved for listing on Nasdaq, (v)&#160;the approval of certain of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>the Company Proposals by the Company&#8217;s stockholders, (vi)&#160;obtaining the Abpro written consent approving the Business Combination; (vii)&#160;the Company having at least $</div><div style="display:inline;"><ix:nonFraction name="acab:MinimumNetWorthNeededToConsummateBusinessCombination" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47636">5,000,001</ix:nonFraction></div><div style="display:inline;"> of net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Securities Exchange Act of 1934, as amended) remaining after the Closing; and (viii)&#160;the Company arranging for binding commitments of at least $</div><div style="display:inline;"><ix:nonFraction name="acab:MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47637">8.7</ix:nonFraction></div><div style="display:inline;">&#160;million in available closing cash consisting of funds in the Trust Account (after reduction for payments made in connection with redemptions by the Company stockholders) plus any funds available pursuant to a PIPE&#160;Financing, forward purchase agreement, equity line of credit, convertible note financing and other sources of financing, less any Unpaid SPAC Expenses, as described in the Business Combination Agreement, subject to the Abpro&#8217;s waiver of such amount.</div><br/></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139478_3" continuedAt="TextSelectionAppend_113139478_4"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Letter Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;Sponsor&#8221;) entered into an agreement with the Company, the Abpro and Abpro Bio Co., Ltd (the &#8220;Sponsor Letter Agreement&#8221;), whereby Sponsor agrees to (i)&#160;retain <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47638">2.95</ix:nonFraction>&#160;million shares of the Company&#8217;s Series A Common Stock held by it, (ii)&#160;divide <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47639">2,458,333</ix:nonFraction> shares of the Company&#8217;s Series A Common Stock held by it <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-21</ix:exclude> </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_113139478_4" continuedAt="TextSelectionAppend_113139478_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139478_5" continuedAt="TextSelectionAppend_113139478_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139478_6" continuedAt="TextSelectionAppend_113139478_7"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139478_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">among the Sponsor, who will be entitled to <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47642">491,667</ix:nonFraction> of the shares, Abpro, who will be entitled to <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_11_2023_AbproBioCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47643">983,333</ix:nonFraction> of the shares, and Abpro Bio Co., Ltd, who will be entitled to <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_11_2023_AbproMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47644">983,333</ix:nonFraction> of the shares, for such party to use to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">obtain&#160;non-redemption&#160;commitments</div> from the Company&#8217;s stockholders or other capital for ACAB or the Surviving Company (with any shares unused for such purpose to be retained by such party) and (ii)&#160;forfeit the remainder of any the Company&#8217;s Series A Common Stock and the Company&#8217;s Series B Common Stock held by it.<br/></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro and the Sponsor entered into the Sponsor Support Agreement pursuant to which the Sponsor agreed to, among other things, vote all of its shares of the Company&#8217;s Series A Common Shares and the Company&#8217;s Series B Common Shares held by it, whether now owned or hereafter acquired, (i)&#160;in favor of the approval and adoption of the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (ii)&#160;against any proposal, action or agreement that would impede, interfere with, delay, postpone or discourage any provision of the Sponsor Support Agreement, the Business Combination Agreement or the transactions contemplated thereby (including the Business Combination). In addition, in the Sponsor Support Agreement, the Sponsor agrees to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of the Company&#8217;s Series B Common Stock held by the Sponsor convert into shares of the Company&#8217;s Series A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139271" id="ixv-27980"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;7&#8201;&#8212;&#8201;STOCKHOLDERS&#8217; DEFICIT </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock &#8212;</div></div></div></div>The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47645"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47646">1,000,000</ix:nonFraction></ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47647"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47648">0.0001</ix:nonFraction></ix:nonFraction> par value preferred stock. At December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47649"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47650"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47651"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47652">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued or outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Common Stock &#8212;</div></div></div></div>The Company is authorized to issue up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47653"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47654">100,000,000</ix:nonFraction></ix:nonFraction> shares of Series A, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47655"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47656">0.0001</ix:nonFraction></ix:nonFraction> par value common stock. Holders of the Company&#8217;s common stock are entitled to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" id="ixv-47657">one vote</ix:nonNumeric> for each share. At December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47658"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47659">7,499,999</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47660"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47661">no</ix:nonFraction></ix:nonFraction> shares of Series A common stock issued and outstanding, excluding <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47662">667,391</ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47663">30,000,000</ix:nonFraction> shares subject to possible redemption, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B Common Stock &#8212;</div></div></div></div>The Company is authorized to issue up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47664"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47665">10,000,000</ix:nonFraction></ix:nonFraction> shares of Series B, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47666"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47667">0.0001</ix:nonFraction></ix:nonFraction> par value common stock. Holders of the Company&#8217;s common stock are entitled to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" id="ixv-47668">one vote</ix:nonNumeric> for each share. At December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47669"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47670">7,500,000</ix:nonFraction></ix:nonFraction> shares of Series B common stock issued and outstanding, of which an aggregate of up to <ix:nonFraction name="acab:SharesAreSubjectToForfeiture" contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47671">978,500</ix:nonFraction> shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part so that the Initial Stockholders will own <ix:nonFraction name="acab:PercentageOfCommonStockIssuedAndOutstanding" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47672">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding common stock after the Initial Public Offering (assuming Initial Stockholders do not purchase any Public Shares in the Initial Public Offering). On January&#160;13, 2022, the Company effectuated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;<ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P01_13_2022To01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-47673">1.044</ix:nonFraction>-for-1&#160;stock</div></div> split, resulting in an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47674">7,503,750</ix:nonFraction> Founder Shares outstanding. Due to the underwriters&#8217; election to partially exercise their overallotment option, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47675">3,750</ix:nonFraction> shares were forfeited, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47676"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47677">1</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47678"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47679">7,500,000</ix:nonFraction></ix:nonFraction> Series B common stock are issued and outstanding at December&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A common stock and Series B common stock will vote together as a single class on all other matters submitted to a vote of stockholders, except as required by law. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Series B common stock will automatically convert into shares of Series A common stock concurrently or immediately following the consummation of an Initial Business Combination, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-for-one</div></div> basis, subject to adjustment as provided herein. In the case that additional shares of Series A common stock, or equity-linked securities, are issued or deemed issued in connection with the Initial Business Combination, the number of shares of Series A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, <ix:nonFraction name="acab:PercentageOfCommonStockIssuedAndOutstanding" contextRef="PAsOn12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47680">20</ix:nonFraction>% of the total number of shares of Series A common stock outstanding after such conversion (after <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-22</ix:exclude> </div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139271" continuedAt="TextSelectionAppend_113139271_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139271_1" continuedAt="TextSelectionAppend_113139271_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139271_2" continuedAt="TextSelectionAppend_113139271_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">giving effect to any redemption of shares of Series A common stock by Public Stockholders), including the total number of shares of Series A common stock, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the Initial Business Combination, excluding any shares of Series A common stock or equity-linked securities exercisable for or convertible into shares of Series A common stock issued, or to be issued, to any seller in the Initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers, or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:CommonStockConversionBasis" contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis" id="ixv-47683">one-for-one</ix:nonNumeric></div></div> basis. <br/></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139271_3" continuedAt="TextSelectionAppend_113139271_4"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139271_4" continuedAt="TextSelectionAppend_113139271_5"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants &#8212;</div></div></div></div> As of December&#160;31, 2023 and 2022, there are <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47684"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47685">15,000,000</ix:nonFraction></ix:nonFraction> outstanding Public Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) <ix:nonNumeric name="acab:PeriodAfterWhichTheWarrantsAreExercisable" contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47686">30</ix:nonNumeric> days after the consummation of a Business Combination or (b) <ix:nonNumeric name="acab:PeriodAfterWhichTheWarrantsAreExercisable" contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durmonth" id="ixv-47687">12</ix:nonNumeric> months from the closing of the Initial Public Offering, provided in each case that there is an effective registration statement under the Securities Act covering the Series A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the public warrant agreement) and such shares are registered, qualified, or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not be obligated to deliver any Series A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Series A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Series A common stock upon exercise of a warrant unless Series A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric name="acab:NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durday" id="ixv-47688">20</ix:nonNumeric> business days after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Series A common stock issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within <ix:nonNumeric name="acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durday" id="ixv-47689">60</ix:nonNumeric> business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If any such registration statement has not been declared effective by the <ix:nonNumeric name="acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis" format="ixt-sec:durday" id="ixv-47690">60</ix:nonNumeric>th business day following the closing of a Business Combination, holders of the warrants will have the right, during the period beginning on the <ix:nonNumeric name="acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis" format="ixt-sec:durday" id="ixv-47691">61</ix:nonNumeric>st business day after the closing of a Business Combination and ending upon such registration statement being declared effective by the SEC, and during any other period when the Company fails to have maintained an effective registration statement covering the issuance of the shares of Series A common stock issuable upon exercise of the warrants, to exercise such warrants on a &#8220;cashless basis.&#8221; Notwithstanding the above, if the shares of Series A common stock are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the Public Warrants: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $<ix:nonFraction name="acab:ClassOfWarrantsOrRightsRedemptionPricePerUnit" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47692">0.01</ix:nonFraction> per warrant; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-23</ix:exclude></div></div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_113139271_5" continuedAt="TextSelectionAppend_113139271_6"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139271_6" continuedAt="TextSelectionAppend_113139271_7"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139271_7" continuedAt="TextSelectionAppend_113139271_8"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139271_8" continuedAt="TextSelectionAppend_113139271_9">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon not less than <ix:nonNumeric name="acab:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47694">30</ix:nonNumeric>&#160;days&#8217; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the reported last sale price of the Series&#160;A common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47695">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="acab:NumberOfTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47696">20</ix:nonNumeric> trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;<ix:nonNumeric name="acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47697">30</ix:nonNumeric>-trading&#160;day</div> period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. </div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><br/></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of Series A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Series A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. <br/></div></ix:continuation></div></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_113139271_9"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">In addition, if (x)&#160;the Company issues additional shares of Series A common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47698">9.20</ix:nonFraction> per share of Series A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction name="acab:ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47699">60</ix:nonFraction>% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#8217;s Series A common stock during the <ix:nonNumeric name="acab:NumberOfTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47700">20</ix:nonNumeric> trading day period starting on the trading day after the day on which the Company completes a Business Combination (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction name="acab:VolumeWeightedAveragePriceOfShares" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47701">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" contextRef="P01_01_2023To12_31_2023_AdjustedExercisePriceOneMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47702">115</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price, and the $<ix:nonFraction name="acab:PerShareRedemptionTriggerPrice" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47703">18.00</ix:nonFraction> per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" contextRef="P01_01_2023To12_31_2023_AdjustedExercisePriceTwoMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47704">180</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there are <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47705"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47706">13,850,000</ix:nonFraction></ix:nonFraction> Private Placement Warrants, The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants (including the Series A common stock issuable upon the exercise of the Private Placement Warrants) are not transferable, assignable or salable until <ix:nonNumeric name="acab:ClassOfWarrantsOrRightsLockInPeriod" contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday" id="ixv-47707">30</ix:nonNumeric> days after the completion of an Initial Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-redeemable</div> so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-24 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139597" id="ixv-28125"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;8&#8201;&#8212;&#8201;INCOME TAXES&#160;</div></div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-28131"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 8%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47708">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47709">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Startup/Organization Expenses</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47710">686,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47711">388,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47712">686,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47713">388,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47714">686,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47715">388,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47716">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47717">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-28277"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2023 and 2022 consists of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"/>
<td style="vertical-align: bottom; width: 7%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 7%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47718">1,177,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47719">823,991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47720">298,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47721">388,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47722">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47723">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47724">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-47725">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47726">298,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47727">388,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47728">1,177,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47729">823,991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company did <ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47730"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47731">no</ix:nonFraction></ix:nonFraction>t have any U.S. federal and state net operating loss carryovers available to offset future taxable income. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December&#160;31, 2023 and 2022, the change in the valuation allowance was $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47732">298,330</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47733">388,575</ix:nonFraction>, respectively. </div> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-28437"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 65%;"/>
<td style="vertical-align: bottom; width: 13%;"/>
<td/>
<td/>
<td/>
<td style="vertical-align: bottom; width: 12%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47734">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47735">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meals&#160;&amp; entertainment</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47736">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47737">4.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business combination expenses</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47738">0.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47739">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fines and penalties</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47740">0.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47741">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47742">7.46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47743">22.71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"/>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47744">29.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47745">48.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"/>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-25</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_113139597" continuedAt="TextSelectionAppend_113139597_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139597_1" continuedAt="TextSelectionAppend_113139597_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_113139597_2">The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.</ix:continuation> </div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-28588"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTE&#160;9&#8201;&#8212;&#8201;FAIR VALUE MEASUREMENTS </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the guidance in ASC 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 91%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-28642"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 71%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47748">1</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47749">309,790,455</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric> <div style="clear:both;max-height:0pt;text-indent: 0px;"></div> </div></div></div></div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_113139663" id="ixv-28731"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTE 10&#8201;&#8212;&#8201;SUBSEQUENT EVENTS </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="display:inline;">On January&#160;11, 2024, the Company entered into an amended services agreement with and advisor, that <div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">was origin</div>ally entered into on<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">April 11 2023</div>. The advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will receive </div><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn01_11_2024_AdvisorMemberACABInvesteeAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47750">200,000</ix:nonFraction></div><div style="display:inline;"> shares of Series a common stock in the post-closing Company and </div><div style="display:inline;"><ix:nonFraction name="acab:PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" contextRef="P01_11_2024To01_11_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47751">4</ix:nonFraction></div><div style="display:inline;">% of the gross proceeds raised from investors and received by the Company or the target prior to the business combination or simultaneously. All consideration is to be paid simultaneously with the closing of the business combination.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;18, 2024, the Sponsor, the Company, Abpro and Abpro Bio entered into an amendment to the Sponsor Letter Agreement (the &#8220;Amended Sponsor Letter Agreement&#8221;), which amended the amount of shares </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-26</ix:exclude> </div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_113139663" continuedAt="TextSelectionAppend_113139663_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_113139663_1" continuedAt="TextSelectionAppend_113139663_2"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_113139663_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">each party thereunder is entitled to, consistent with the description previously disclosed on December&#160;11, 2023 and as contemplated in the Business Combination Agreement, dated as of December&#160;11, 2023, by and among the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro. For the avoidance of doubt, the Amended Sponsor Letter Agreement supersedes and replaces the Sponsor Letter Agreement in its entirety. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;21, 2024, the Company received a partial waiver from an underwriter from the initial public offering that was entitled to a portion of the deferred underwriter fee. Subject to the closing of the businesses combination between the Company and Abpro, the underwriter waived $<ix:nonFraction name="acab:UnderwriterFeeWaivedOff" contextRef="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47753">4,290,000</ix:nonFraction> of the underwriter fee in exchange for <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47754">600,000</ix:nonFraction> of common stock in the post-merger Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;22, 2024, the Company issued a press release announcing that it filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-4</div> with the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&#160;19, 2024 in connection with the previously announced proposed business combination with Abpro (the &#8220;Business Combination&#8221;). </div> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-27 </div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2023 AND 2022 </div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="index2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 90%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Consolidated Financial Statements:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_101" style="display:inline;">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">F-30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_102" style="display:inline;">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">F-31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_103" style="display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">F-32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_104" style="display:inline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">F-33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_105" style="display:inline;">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">F-34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin509388_106" style="display:inline;">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">F-35-F-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin509388_101">Report of Independent Registered Public Accounting Firm </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the Stockholders and the Board of Directors of Abpro Corporation: </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">We have audited the accompanying consolidated balance sheets of Abpro Corporation and Subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; deficit and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Emphasis of a Matter Regarding Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred net losses since its inception, and has negative cash flows from operations and will need additional funding to complete planned development efforts. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ Wolf &amp; Company, P.C. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Boston, MA </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">March 1, 2024 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-30 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin509388_102" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(Amounts in thousands, except share and per share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 85%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Assets</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Current assets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 723</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 7,325</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accounts receivable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,030</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred offering costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">878</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Prepaid expenses and other current assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">208</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">292</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total current assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,897</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,647</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">137</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Property and equipment, net</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">323</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div><div style="display:inline;"> asset - operating lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">966</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,479</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Security deposits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">66</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">66</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Patents, net</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">186</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">196</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Note receivable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total assets</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;"> 3,355</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;"> 11,852</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Liabilities, convertible preferred stock and stockholders&#8217; deficit</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accounts payable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 7,916</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 8,152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,897</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating lease liability, current</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">567</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">500</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Finance lease liability, current</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">130</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">255</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Notes payable, current &#8211; related parties</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,742</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total current liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">12,436</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">10,868</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating lease liability, noncurrent</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">455</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,022</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Finance lease liability, noncurrent</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">97</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total liabilities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">12,891</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">11,987</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Commitments and Contingencies (Note 8)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series F Convertible Preferred Stock, $0.001 par value; authorized shares &#8211; 4,444,444; issued and outstanding shares &#8211; 555,555; liquidation preference of $10,000 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series E Convertible Preferred Stock, $0.001 par value; authorized shares &#8211; 4,405,286; issued and outstanding shares &#8211; 3,303,966; liquidation preference of $30,000 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">29,841</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">29,841</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series D Convertible Preferred Stock, $0.001 par value; authorized, issued and outstanding shares &#8211; 1,220,261; liquidation preference of $18,194 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,622</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,622</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series C Convertible Preferred Stock, $0.001 par value; authorized, issued and outstanding shares &#8211; 2,005,688; liquidation preference of $15,725 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14,949</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14,949</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series B Convertible Preferred Stock, $0.001 par value; authorized, issued and outstanding shares &#8211; 626,636; liquidation preference of $1,798 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,401</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,401</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Series A Redeemable, Convertible Preferred Stock, $0.001 par value; authorized, issued and outstanding shares &#8211; 19,258 shares; liquidation preference of $1,795 at December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Stockholders&#8217; deficit:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Common stock, $0.001 par value; authorized shares &#8211; 40,000,000; issued and outstanding shares &#8211; 9,375,158 and 9,337,658 at December&#160;31, 2023 and 2022, respectively</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Treasury stock, 102,776 shares at cost</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Additional </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div><div style="display:inline;"> capital</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">19,911</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,606</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accumulated deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(105,571</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(93,865</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total Abpro Corporation&#8217;s stockholders&#8217; deficit</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(85,684</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(76,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-controlling</div><div style="display:inline;"> interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total stockholders&#8217; deficit</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(85,135</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(75,734</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;"> 3,355</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;"> 11,852</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-31 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin509388_103" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(Amounts in thousands, except share and per share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Revenue:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Collaboration revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 99</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 1,999</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Royalty</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total revenues</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">122</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,029</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating expenses:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Research and development</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4,266</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,754</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">General and administrative</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">7,602</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">8,960</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total operating expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">11,868</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">18,714</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Loss from operations</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,746</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(16,685</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Other income (expense):</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Interest income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">63</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Interest expense</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(248</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total other income (expense), net</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">40</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(200</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Loss before income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(16,885</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Income tax expense (Note 13)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> (11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> (17,215</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss per share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Basic and diluted</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> (1.25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> (1.85</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Weighted average shares outstanding - basic and diluted</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,356,648</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,311,698</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 250pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The accompanying notes are an integral part of these consolidated financial statements </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-32 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin509388_104" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">For the Years Ended December 31, 2023 and 2022 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(Amounts in thousands, except share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 6pt; border-collapse: collapse;">
<tr>
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series&#160;A<br/>Redeemable,<br/>Convertible<br/>Preferred<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series B</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series C</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series D</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series E</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Series F</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Treasury Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Additional</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-In</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div><br/><div style="display:inline;">Abpro&#8217;s</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Stockholders&#8217;</div></div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">controlling</div></div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Stockholders&#8217;</div></div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Accumulated</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px; white-space: nowrap;display:inline;"><div style="display:inline;">Balances, as of <br/>December&#160;31, <br/>2021</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">19,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">626,636</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,401</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,005,688</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14,949</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,220,261</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,622</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,303,966</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">29,841</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,381,269</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(102,776</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">13,588</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(76,650</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(63,086</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(62,537</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Issuance of preferred stock, net of financing costs of $9</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">555,555</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Vesting of restricted stock units</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="display:inline;">59,165</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="display:inline;">4,018</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="display:inline;">4,018</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="display:inline;">4,018</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(17,215</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(17,215</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(17,215</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Balances, as of December&#160;31, 2022</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">19,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">626,636</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,401</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,005,688</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14,949</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,220,261</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,622</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,303,966</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">29,841</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">555,555</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,440,434</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(102,776</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,606</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(93,865</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(76,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(75,734</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Vesting of restricted stock units</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="display:inline;">37,500</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,305</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,305</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,305</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Balances, as of December&#160;31, 2023</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">19,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">626,636</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,401</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,005,688</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14,949</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,220,261</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,622</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,303,966</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">29,841</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">555,555</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,477,934</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(102,776</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">19,911</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(105,571</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(85,684</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">549</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(85,135</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 195pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-33 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin509388_105" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(Amounts in thousands) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash Flows from Operating Activities:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(17,215</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Depreciation and amortization expense</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">279</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">372</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Share-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,305</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4,018</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Amortization of operating lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div><div style="display:inline;"> assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">513</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">484</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Changes in operating assets and liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accounts receivable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,942</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(1,990</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Prepaid expenses and other current assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(35</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Note receivable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accounts payable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(743</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6,244</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">484</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(454</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating lease liability</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(500</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(440</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net cash used in operating activities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(7,402</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(8,952</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash Flows from Investing Activities:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Patent costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Purchase of property and equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net cash used in investing activities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash Flows from Financing Activities:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Proceeds from notes payable - related parties</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,442</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Proceeds from issuance of preferred stock, net of financing costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,991</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Repayment of finance lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(222</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(207</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Payment of offering costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(371</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net cash provided by financing activities</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">849</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,784</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net change in cash and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(6,601</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">767</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash and restricted cash - beginning of year</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">7,462</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6,695</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash and restricted cash - end of year</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 861</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 7,462</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="4" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">Supplemental disclosure of cash flow information and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div><div style="display:inline;"> transactions:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Interest paid</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Operating </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div><div style="display:inline;"> asset recognized upon adoption of ASC 842</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 1,963</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Reclassification of capital lease liability to finance lease liability upon adoption of ASC&#160;842</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 558</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred offering costs included in accounts payable</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 507</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Settlement of bonus accrual in notes payable - related parties</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 300</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 70pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-34 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin509388_106" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">ABPRO CORPORATION AND SUBSIDIARY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">(Amounts in thousands, except share and per share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Organization and Description of the Business </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Nature of Operations </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Abpro Corporation (the &#8220;Company&#8221;) founded in 2004, was incorporated under the laws of the State of Delaware. The Company is headquartered in Woburn, Massachusetts. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of more advanced or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;11, 2023, the Company entered into a business combination agreement (the &#8220;Business Combination Agreement&#8221;) with Atlantic Coastal Acquisition Corp. II, a Delaware corporation (&#8220;ACAB&#8221;) and Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;). Pursuant to the Business Combination Agreement, on the Closing of the Business Combination, the Company will merge with and into Merger Sub, a newly formed, wholly-owned direct subsidiary of ACAB, (the &#8220;Business Combination&#8221;), with the Company surviving the Business Combination as a wholly-owned direct subsidiary&#160;of ACAB (the &#8220;Surviving Company&#8221;). In connection with the consummation of the Business Combination, ACAB will change its corporate name to &#8220;Abpro Holdings, Inc.&#8221; </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Immediately prior to the effective time of the Business Combination, the Company&#8217;s Preferred Shares that are issued and outstanding will be converted into shares of the Company&#8217;s common stock. As a result of the Business Combination, among other things, each share of the Company&#8217;s common stock, par value $0.001 per share, will be converted into the right to receive the number of shares of newly issued ACAB Series A Common Stock (the &#8220;ACAB New Common Shares&#8221;), par value $0.0001 per share, calculated based on the Exchange Ratio as set forth in the Business Combination Agreement. &#8220;Exchange Ratio&#8221; is defined in the Business Combination Agreement as the Equity Value Per Share of each respective share of the Company, divided by (b) $10.00, where &#8220;Equity Value Per Share&#8221; means (a)&#160;the Equity Value of $725,000, divided by (b)&#160;the Fully Diluted Company Capitalization. Pursuant to the Business Combination Agreement, 22.5&#160;million of the ACAB New Common Shares to be issued to the Company&#8217;s shareholders will be reduced from 72.5&#160;million shares of the Merger Consideration and equally divided among the Sponsor, the Company and Abpro Bio Co., Ltd. for each such party to use in the PIPE Financing or to obtain capital for ACAB or the Surviving Company. Consummation of the transactions contemplated by the Business Combination Agreement are subject to satisfaction or waiver of customary conditions of the respective parties, including receipt of required regulatory approvals, receipt of approval from shareholders of ACAB and the Company for consummation of the Business Combination and certain other actions related thereto by our shareholders. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-35 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Business Combination Agreement may be terminated under certain circumstances prior to the Closing, including, but not limited to, (i)&#160;by mutual written consent of ACAB and the Company, (ii)&#160;by the Company if ACAB breaches its representations, warranties or covenants such that the conditions set forth in the Business Combination Agreement would not be satisfied, and such party fails to cure such breach (other than for certain limited exceptions), (iii) by ACAB if the Company breaches its representations, warranties or covenants such that the conditions set forth in the Business Combination Agreement would not be satisfied, and such party fails to cure such breach (other than for certain limited exceptions), (iv) by either ACAB or the Company if the Business Combination is not consummated by June&#160;1, 2024, (v) by either ACAB or the Company if any governmental entity issues an order or taken any other action permanently enjoining, restraining or otherwise prohibiting the Business Combination and such order or other action has become final and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-appealable,</div><div style="display:inline;"> (vi)&#160;by either ACAB or the Company if certain required approvals are not obtained from the ACAB stockholders after the conclusion of a special meeting of ACAB&#8217;s stockholders held for such purpose at which such shareholders voted on such approvals and (vii)&#160;by ACAB, if the Company does not deliver to ACAB the required Company Stockholder Written Consent prior to the Company Stockholder Written Consent Deadline as defined in the Business Combination Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement, other than customary confidentiality obligations, except in the case of Willful Breach or fraud. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt abouts its ability to continue as a going concern within one year after the date that the consolidated financial statements are available to be issued. Through December&#160;31, 2023, the Company has funded its operations mainly through equity and debt financing and to a lesser extent, payments received in connection with collaboration and license agreements. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Since inception, the Company has incurred recurring losses, including a net loss of $11,706 and $17,215 for the years ended December&#160;31, 2023 and 2022, respectively. The Company had an accumulated deficit of $105,571 as of December&#160;31, 2023. The Company expects to incur operating losses for the foreseeable future. On October&#160;18, 2023, the Company entered into a promissory note agreement with Abpro Bio International, Inc. (&#8220;ABI&#8221;), a significant investor in the Company&#8217;s Series E and F convertible preferred stock (See Note 9), to receive up to $6,000. The Company received $3,315 through the date of issuance of these consolidated financial statements under this promissory note, including $1,442 during the year ended December&#160;31, 2023 (see Note 9 for terms and conditions). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. The Company plans to continue to fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company may require initiating steps to slow cash burn, extending the cash runway until financing can be secured. The consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-36 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Summary of Significant Accounting Policies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying consolidated financial statements include all of the accounts of the Company and its subsidiary, AbMed Corporation (&#8220;AbMed&#8221;). All intercompany balances and transactions have been eliminated in consolidation. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant estimates in these consolidated financial statements include stock-based compensation expense, fair value of common stock, revenue allocated to various performance obligations under license and collaboration agreements, </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div><div style="display:inline;"> and clinical accrued expenses, discount rates in relation to lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div><div style="display:inline;"> assets and liabilities, valuation and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Cash </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. As of December&#160;31, 2023 and 2022, the Company has not experienced a loss on its accounts for which it exceeds federally insured deposit limits. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Restricted Cash </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The restricted cash balance is related to a balance provided as a collateral associated with the letter of credit for one of the Company&#8217;s facility leases (Note 7&#8201;&#8212; Leases) and is reported as a long-term asset in the consolidated balance sheets. The following tables reconcile cash and restricted cash to amounts shown in the consolidated statements of cash flows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 80%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">723</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">7,325</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Restricted Cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">137</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total cash and restricted cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">861</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">7,462</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Accounts receivable </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Accounts receivable are stated at the amount management expects to collect from outstanding balances under its license and collaboration arrangements. Prior to January&#160;1, 2023, the Company assessed the need for an allowance for potentially uncollectible accounts receivable considering historical </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">write-off</div><div style="display:inline;"> experience and any specific risks identified in customer collection matters. Based on the assessment, the Company determined that no amount for allowance for doubtful accounts was required as of December&#160;31, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Effective January&#160;1, 2023, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 326 Financial Instruments&#8211;Credit Losses (&#8220;ASC 326&#8221;), which requires measurement and recognition of </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-37 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">expected credit losses for financial assets. The Company records receivables net of any allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be collected. As of December&#160;31, 2023, the Company determined that no amount for allowance for doubtful accounts was required. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred offering costs consist of legal, accounting, underwriting fees and other costs that are directly related to the Business Combination. These costs will be accounted for as a reduction of proceeds received upon completion of the closing of the Business Combination. As of December&#160;31, 2023 and 2022, the Company had deferred offering costs of $878 and $0. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Property and equipment are stated at cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operations as incurred. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Classification</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Estimated Useful Life (in years)</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Computer&#160;hardware&#160;and&#160;software</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">3&#8194;-&#8194;5</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Lab equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">3 - 5</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Furniture and fixtures</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">5 - 7</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:center;"><div style="display:inline;">Shorter&#160;of&#160;useful&#160;life&#160;or&#160;lease&#160;term</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Leases </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company accounts for leases in accordance with ASC Topic 842, </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Leases </div></div><div style="display:inline;">(&#8220;ASC 842&#8221;). Under ASC 842, the Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. As a lessee, the Company records a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div><div style="display:inline;"> asset and a lease liability in its consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated statement of operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company recognizes operating lease </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div><div style="display:inline;"> (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets represent the Company&#8217;s right to use an underlying asset during the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company&#8217;s lease term includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also include any advance lease payments made and are net of any lease incentives. As most of the Company&#8217;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar economic environment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company enters into lease agreements for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included in </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div><div style="display:inline;"> asset &#8211; </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-38 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">operating lease, and Operating lease liability &#8211; current and Operating lease liability &#8211; noncurrent in the consolidated balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability &#8211; current and Finance lease liability &#8211; noncurrent in the consolidated balance sheets. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Patents </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company incurs costs related to patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the date of the patent application on a straight-line basis over the estimated useful life of 20 years, which is the legal life of the patent. All costs associated with abandoned patents applications are expensed. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Impairment of Long-lived Assets </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company periodically evaluates its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December&#160;31, 2023 and 2022. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company recognizes revenue in accordance with the guidance of</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">&#160;Revenue From Contracts With Customers</div></div><div style="display:inline;">, Accounting Standards Codification Topic 606 (&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">License and collaboration revenues </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company&#8217;s license and collaboration revenues have been generated primarily through collaborative research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of intellectual property and associated </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div><div style="display:inline;"> and the provision of other goods and services. Payments to the Company under these arrangements typically include one or more of the following: </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div><div style="display:inline;"> license fees; milestone payments; and royalties on future product sales. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">License of Intellectual Property</div></div><div style="display:inline;">. If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-39 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">revenue allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue associated with the bundled performance obligation. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Milestone Payments.</div></div><div style="display:inline;">&#160;At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur, the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the Company </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluates</div><div style="display:inline;"> the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">catch-up</div><div style="display:inline;"> basis, which would affect the reported amount of license and collaboration revenues in the period of adjustment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Royalties.</div></div><div style="display:inline;">&#160;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s research and development expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Income taxes are accounted for under the asset and liability method, as required by FASB ASC Topic 740, </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Income Taxes </div></div><div style="display:inline;">(&#8220;ASC 740&#8221;). The Company provides for federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December&#160;31, 2023 and 2022. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-40 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company accounts for share-based payments in accordance with Accounting Standard Codification Topic 718, </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Compensation&#8212;Stock Compensation </div></div><div style="display:inline;">(&#8220;ASC 718&#8221;). Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees)</div><div style="display:inline;"> based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected term, risk-free interest rate and expected dividends. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In determining the exercise prices of options granted, the Company&#8217;s Board has considered the fair value of the common stock as of the measurement date. The fair value of the common stock has been determined by the Board at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s proposed products, an evaluation or benchmark of the Company&#8217;s competition, the current business climate in the marketplace, the illiquid nature of the common stock, arm&#8217;s length sales of the Company&#8217;s capital stock, including convertible preferred stock, the effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company does not have a history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the awards is estimated based on the simplified method for grants to employees and is based on the contractual term for </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div><div style="display:inline;"> awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on history and expectation of paying no dividends. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Convertible Preferred Stock </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity (see Note 10). </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-controlling</div> Interest </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company holds an 82% ownership interest in its consolidated subsidiary, AbMed. </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-controlling</div><div style="display:inline;"> interest represents the portion of net book value in AbMed that is not owned by the Company and is reported as a component in stockholders&#8217; equity in the consolidated balance sheets. The Company bears all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-controlling</div><div style="display:inline;"> interest holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00 per share for each preferred share of AbMed stock held by the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-controlling</div><div style="display:inline;"> interest holder plus all accrued and unpaid dividends thereon. The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-controlling</div><div style="display:inline;"> interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed for the years ended December&#160;31, 2023 and 2022. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-41 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Net Loss Per Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company follows the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div><div style="display:inline;"> method to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities. The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div><div style="display:inline;"> method determines net loss per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div><div style="display:inline;"> method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods of loss, there is no allocation required under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div><div style="display:inline;"> method due to there being no distributed earnings for the period coupled with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F (see Note 10) do not contain a contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common stock. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December&#160;31, 2023 and 2022, basic and diluted net loss per share is the same for each period. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders, because their effect was anti-dilutive: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 66%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Convertible preferred stock</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,725,520</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">9,725,520</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Common stock warrants</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">61,009</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">61,009</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Options for common stock</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">5,414,848</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">5,464,521</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Unvested restricted common stock units</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">45,835</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">83,335</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">15,247,212</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">15,334,385</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Segment Reporting </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company conducts its business activities and reports financial results as one operating segment and one reportable segment, which is consistent with the Company structure and the way the Company operates its business. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In June 2016, the FASB issued Accounting Standards Update </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2016-13,</div><div style="display:inline;"> Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div><div style="display:inline;"> requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div><div style="display:inline;"> within ASU </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2019-04,</div><div style="display:inline;"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASC 326 is effective for fiscal years beginning after December&#160;15, 2022. The Company adopted this standard on January&#160;1, 2023, which had no material impact on the Company&#8217;s consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-42 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Property and Equipment </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s property and equipment include the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Furniture and fixtures</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 53</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 53</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Lab equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,049</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Computer hardware and software</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">788</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">788</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Equipment under finance leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">740</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">740</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Property and Equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,693</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,645</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Less: Accumulated Depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(2,591</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(2,322</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 323</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Depreciation expense was $269 and $372 for the years ended December&#160;31, 2023 and 2022. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued Expenses </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued expenses consisted of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued salaries and wages</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,398</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;"> 766</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued professional fees</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">93</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">651</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Other accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">590</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">480</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,081</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,897</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">License and Collaboration Agreements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">NJCTTQ Collaboration Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In January 2019, the Company entered into a collaboration agreement with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (&#8220;NJCTTQ&#8221;) to research, develop and commercialize two anti-Claudin 18.2 lead antibodies (the &#8220;NJCTTQ agreement&#8221;). Under the NJCTTQ agreement, the Company granted a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-sublicensable</div><div style="display:inline;"> research license and an exclusive, sublicensable license to NJCTTQ within the People&#8217;s Republic of China and Thailand (the &#8220;NJCTTQ Territory&#8221;).</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">&#160;</div></div><div style="display:inline;">The initial term of this agreement was 5 years, which could be automatically renewed for another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement, then this agreement would not be renewed. The agreement expired in January 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company is eligible to receive up to an aggregate of $405,000 of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div><div style="display:inline;"> milestone payments from NJCTTQ upon achieving certain development, regulatory approval, and commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay NJCTTQ up to an aggregate of $5,000 in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#8217;s territory, which includes all other countries other than the NJCTTQ Territory. No </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-43 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">milestones have been reached through December&#160;31, 2023, no products were sold by NJCTTQ, and no related revenue amounts have been recorded in the accompanying consolidated financial statements. No regulatory milestones were achieved by the Company in the Company&#8217;s territory through December&#160;31, 2023. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company and NJCTTQ agreed to pay reciprocal royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory. Through December&#160;31, 2023, no products were sold by NJCTTQ or the Company under the NJCTTQ agreement. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div> Collaboration and License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In December 2019, the Company entered into an exclusive collaboration and license agreement with a related party, ABI (the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;ABP-100</div><div style="display:inline;"> agreement&#8221;). Under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> agreement, the Company granted ABI the license to develop and commercialize products and services based on the Company&#8217;s </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Her2-hu-OKT3</div></div><div style="display:inline;"> bispecific antibody </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;ABP-100&#8221;)</div><div style="display:inline;"> within the territories of People&#8217;s Republic of China, Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States, as defined in the agreement. Unless earlier terminated, the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> agreement, will expire upon the satisfaction of all obligations under the agreement following the expiration of the last royalty payment obligation. Either party may terminate the agreement in the event of any uncured material breach by the other party. The license granted under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> agreement was a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">sub-license</div><div style="display:inline;"> from Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;) pursuant to MSK License Agreement (see Note 6). This agreement was terminated due to the termination of the MSK License Agreement in September 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> agreement, ABI agreed to use commercially reasonable efforts to reach certain development and commercial milestones for at least one licensed product or licensed service within specified timeframes. ABI is committed to pay the Company running royalties on net sales of any licensed products or services from the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div><div style="display:inline;"> digit percentages to the low double-digit percentage, and the guaranteed annual minimum royalties of $30 starting on the first anniversary of the effective date of the agreement (which annual minimum royalties may be credited against the running royalties on net sales of any licensed products or services). Through the termination of this agreement in September 2023, no products were sold by ABI under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> agreement. During the years ended December&#160;31, 2023 and 2022, the Company earned $23 and $30, respectively, in minimum royalty payments, included in royalty revenue. As of December&#160;31, 2023 and 2022, the accounts receivable were $53 and $30, respectively, associated with the minimum royalties under this agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In addition to the royalty payments, the Company may receive up to $498,000 in milestone payments per licensed product or licensed service upon the achievement of specified research and development and sales milestone events. No milestones have been reached through the termination of this agreement in September 2023. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is also entitled to research funding fees for costs incurred by the Company for certain sponsored research activities and the reimbursement of 60% of the costs of certain product development directed activities, as outlined in the agreement. During the years ended December&#160;31, 2023 and 2022, the Company did not earn any research funding fees. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Further, the Company is to be reimbursed for patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights in the license territory. During the years ended December&#160;31, 2023 and 2022, the Company received $0 and $15, respectively, in reimbursements of patent costs included in collaboration revenue. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-201</div> Collaboration and License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In January 2020, the Company&#8217;s consolidated subsidiary, Abmed, entered into a collaboration and license agreement with ABI (the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;ABP-201</div><div style="display:inline;"> Agreement&#8221;), pursuant to which the Company granted to ABI an </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-44 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain of its proprietary </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ANG-2/VEGF-HIRK</div><div style="display:inline;"> bispecific antibodies within the licensed territory comprising People&#8217;s Republic of China, Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with its terms, the agreement remains in effect on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">country-by-country</div></div><div style="display:inline;"> basis until the expiration of the last royalty term in such country. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Under the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-201</div><div style="display:inline;"> agreement, ABI agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified territories and timeframes. ABI is committed to pay the Company up to $56,500 in milestone payments upon achieving certain research and development events, up to $485,000 in milestone payments based on annual net sales per each licensed product, and a double-digit percentage royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first commercial sale of a licensed product in its territory. No milestones have been reached through December&#160;31, 2023, no products were sold by ABI, and no related revenue amounts have been recorded in the accompanying consolidated financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is also to be reimbursed for patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights in the license territory. During the years ended December&#160;31, 2023 and 2022, the Company earned $32 and $48, respectively, in reimbursements of patent costs included in collaboration revenue. As of December&#160;31, 2023 and 2022, the accounts receivable were $32 and $0, respectively, associated with the patent cost reimbursement under this agreement. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Celltrion Collaboration and License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In September 2022, the Company entered into an exclusive collaboration and license agreement with Celltrion, Inc. (the &#8220;Celltrion Agreement&#8221;), a company organized and existing under the laws of South Korea (&#8220;Celltrion&#8221;). Under this agreement, the Company granted to Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have used, sell and have sold certain of its proprietary </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-102</div><div style="display:inline;"> bispecific antibodies. The License Agreement also provides that the Company is to perform certain preclinical in vitro studies. The License Agreement will remain in effect for so long as </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-102</div><div style="display:inline;"> is being developed or commercialized anywhere in the world. Celltrion may terminate the license agreement at any time by providing&#160;six months prior written notice to the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Celltrion is committed to pay the Company up to $10,000 in milestone payments upon granting the license and achieving certain research and development events, up to $1,750,000 in milestone payments based on annual net sales per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third-party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject to a 50/50 split. Following commercial approval of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-102,</div><div style="display:inline;"> the Company has agreed to reimburse Celltrion 87.5% of its direct and certain indirect costs and expenses incurred through first commercial sale. Celltrion is entitled to offset amounts otherwise due to us under the agreement until our share of these costs has been paid back; provided that the Company is entitled to a minimum 25% of profit from commercial sales and from third-party collaborators regardless of the amount of unreimbursed development costs outstanding (and then 50% once the reimbursement has been made in full). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The first milestone of $2,000 was achieved upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement, in December 2022 and was received in January 2023. The Company allocated $64 to the initial obligation to perform in vitro testing for the research and development services and the remaining $1,936 to the license of the Company&#8217;s intellectual property, bundled with the associated </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how,</div><div style="display:inline;"> which was recognized in revenue during the year ended December&#160;31, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s initial obligation to perform in vitro testing for the research and development services represents a distinct performance obligation. The revenue for this performance obligation will be recognized on a straight-line based over the term of the studies. The related deferred revenue was $0 and $64 as of </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-45 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">December&#160;31, 2023 and 2022, respectively. During the years ended December&#160;31, 2023 and 2022, the Company recognized $64 and $0, respectively, in connection with this performance obligation, included in collaboration revenue. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company is also to be reimbursed for 50% of all documented out of pocket patent costs associated with the preparation, filing, prosecution and maintenance of patent rights in the license territory. During the years ended December&#160;31, 2023 and 2022, the Company earned $3 and $0, respectively, in reimbursements of patent costs included in collaboration revenue. As of December&#160;31, 2023 and 2022, the accounts receivable were $3 and $0, respectively, associated with the patent cost reimbursement under this agreement. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Milestone Payments.</div></div><div style="display:inline;">&#160;The Company is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments which are paid upon receipt of regulatory approvals.&#160;Except for the first milestone of $2,000 achieved in 2022, no&#160;other milestone payments were earned through December&#160;31, 2023. The Company evaluated whether the remaining milestones are considered probable of being reached and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluate</div><div style="display:inline;"> the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">catch-up</div><div style="display:inline;"> basis, which would affect the reported amount of collaboration revenues in the period of adjustment. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Profit Splits.</div></div><div style="display:inline;">&#160;As the license is deemed to be the predominant item to which profit splits relate, the Company will recognize revenue when the related sales or third-party collaborator income occur.&#160;No&#160;profit split revenue was recognized through December&#160;31, 2023. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Commitments under Research and Collaboration Agreements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">MedImmune License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In August 2016, the Company entered into a collaboration and license agreement with MedImmune Limited (&#8220;MedImmune&#8221;), pursuant to which the Company received from MedImmune an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property rights relating to the Company&#8217;s </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-200</div><div style="display:inline;"> product candidates (the &#8220;MedImmune License Agreement&#8221;). The Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in effect on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">country-by-country</div></div><div style="display:inline;"> basis until the expiration of the last royalty term in such country as to be determined by the launch of products based on the </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-200</div><div style="display:inline;"> product candidates. The Company is no longer developing </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-200.</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Under the MedImmune License Agreement, the Company agreed to pay milestone and royalty payments, including up to $244,000 in milestone payments, which are comprised of $14,000 upon meeting certain clinical development milestones, $80,000 upon achieving certain regulatory events and $150,000 upon meeting certain worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales of each product commercialized from our collaboration on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">country-by-country</div></div><div style="display:inline;"> basis. No milestones have been reached and no products were sold by the Company through December&#160;31, 2023. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">NCI License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In August 2017, the Company entered into a patent license agreement with the National Cancer Institute (the &#8220;NCI&#8221;), a division of the National Institutes of Health (the &#8220;NIH&#8221;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies for the </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-46 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">treatment of liver cancer (the &#8220;NCI License Agreement&#8221;). The license agreement was amended in May 2020 and October 2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">GPC-3</div><div style="display:inline;"> expressing liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless earlier terminated, the Company&#8217;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may also terminate the agreement as to any licenses in any country or territory upon 60 days written notice. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Pursuant to the NCI agreement and amendments, the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $3,995 due upon achievement of clinical and regulatory milestones, and up to $12,000 milestone payments due upon achievement of commercial milestones. No milestones have been reached and no products were sold by the Company through December&#160;31, 2023. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company also has to pay the guaranteed annual minimum royalties of $25 starting on the effective date of the agreement (which annual minimum royalties may be credited against the running royalties on net sales of any licensed products or services). During each of the years ended December&#160;31, 2023 and 2022, the Company incurred $25, in minimum royalty payments, included in research and development expenses. Under the amendment entered into in March 2020, the Company is also liable for the extension royalties of $225 payable under this agreement were rescheduled to become due in several installments starting in March 2022. As of both December&#160;31, 2023 and 2022, the accrued extension royalties were $200, included in accrued expenses and accounts payable in the consolidated balance sheets. Additionally, in connection with the October 2023 amendment to the license agreement, the Company paid a $25 amendment fee to NCI, included in &#8220;General and administrative&#8221; expenses. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company also agreed to reimburse patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights. During the years ended December&#160;31, 2023 and 2022, the Company expensed $2 and $0, respectively, related to the patent costs reimbursements, included in &#8220;General and administrative&#8221; expenses. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Mabwell License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In October 2020, the Company entered into an exclusive collaboration and license agreement with Mabwell (Shanghai) BioScience Co., Ltd. (&#8220;Mabwell&#8221;) (the &#8220;Mabwell License Agreement&#8221;). The agreement was amended in November 2020. Under the Mabwell license agreement, the Company received a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div><div style="display:inline;"> royalty-free research purpose license as well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#8217;s series of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">anti-SARS-CoV-2</div></div><div style="display:inline;"> monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical, clinical and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance of marketing authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#8217;s request, to supply the Licensed Antibodies to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed to undertake certain joint clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier terminated, the Mabwell License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a) the expiration of the last to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed Product, and determined on </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">jurisdiction-by-jurisdiction</div></div><div style="display:inline;"> basis. Either party may terminate the agreement in the event of any uncured material breach by the other party. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The agreement provides for development milestones of up to $32,500 and annual sales milestone payments of up to $50,000 payable by the Company to Mabwell. The agreement also provides for a profit sharing, with Mabwell sharing 50% of the net profits from the licensed product sales in certain territories as defined in the agreement. The Company will also make tiered royalty payments in the mid to high single-digits on net sales of commercial products in the licensed territory. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-47 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">During 2023 and 2022, development activities under the Mabwell collaboration agreement were immaterial to the consolidated financial statements. No milestones in the Mabwell License Agreement have been reached through December&#160;31, 2023. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">MSK License Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In March 2017, the Company entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#8220;MSK License Agreement&#8221;), pursuant to which the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use and sell certain of MSK&#8217;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March&#160;31, 2017, on March&#160;31, 2018, and January&#160;1, 2020. Unless earlier terminated in accordance with its terms, the agreement remains in effect on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">country-by-country</div></div><div style="display:inline;"> basis until the expiration of the last royalty term in such country as to be determined by the launch of products based on MSK antibodies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Under the MSK License Agreement license agreement, as amended, the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified territories and timeframes. The Company is committed to pay MSK up to $10,500 in milestone payments upon achieving certain research and development and commercialization events or within a certain number of months of the effective date, up to $30,000 in milestone payments based on net sales, and tiered </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single-digit</div><div style="display:inline;"> percentage royalties based on annualized net sales of each product commercialized from the collaboration with guaranteed annual minimum royalties between $20 and $30 depending on certain development events. During each of the years ended December&#160;31, 2023 and 2022, the Company incurred $20 in minimum royalty, included in research and development expenses. During the years ended December&#160;31, 2023 and 2022, the Company incurred $0 and $750, respectively, in milestone payments, included in research and development expenses. As of December&#160;31, 2023 and 2022, the accrued minimum royalty and milestone payments were $790 and $770, respectively, included in accounts payable in the consolidated financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company also agreed to reimburse patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights in the license territory. During the years ended December&#160;31, 2023 and 2022, the Company expensed $49 and $244, respectively, related to the patent costs reimbursements, included in &#8220;General and administrative&#8221; expenses. As of December&#160;31, 2023 and 2022, the accrued liabilities for the patent costs reimbursements were $273 and $244, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On September&#160;19, 2023, MSK License Agreement was terminated by MSK due to the Company&#8217;s failure to make the payments. During the years ended December&#160;31, 2023 and 2022, the Company incurred $4 and $165 in interest expenses for the unpaid amounts due to MSK. As of December&#160;31, 2023 and 2022, the accrued liabilities for the unpaid interest were $169 and $165, respectively, included in accrued expenses. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">VAZYME License agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In April 2021, the Company entered into a License Agreement with VAZYME Biotech Co., Ltd (&#8220;VAZYME&#8221;) (the VAZYME License Agreement&#8221;), pursuant to which the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop and commercialize VAZYME proprietary </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">anti-SARS-CoV-2</div></div><div style="display:inline;"> monoclonal antibodies. Unless earlier terminated in accordance with its terms, the agreement remains in effect on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">country-by-country</div></div><div style="display:inline;"> basis until the expiration of the last royalty term in such country. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Under the VAZYME License Agreement, the Company agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones for such antibodies. The Company also agreed to pay $200 payment to VAZYME at the effective date of the agreement. The Company is committed to pay VAZYME up to $11,100 in milestone payments upon achieving certain research and development events, up to $70,000 in milestone payments based on annual net sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized from the collaboration. No milestones in the VAZYME License Agreement have been reached through December&#160;31, 2023. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-48 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">In December 2021, the Company entered into a Cooperation Agreement with Chengdu </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Bio-Innovate</div><div style="display:inline;"> Pharmaceutical Technology Co., Ltd </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;Bio-Innovate&#8221;)</div><div style="display:inline;"> and a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">three-way</div><div style="display:inline;"> sharing agreement with VAZYME and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Bio-Innovate</div><div style="display:inline;"> (&#8220;the Company&#8221;, &#8220;VAZYME&#8221; and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Bio-Innovate&#8221;,</div><div style="display:inline;"> collectively &#8220;all parties&#8221;), pursuant to which the Company entrust </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Bio-Innovate</div><div style="display:inline;"> to perform certain preclinical testing and all parties agreed that VAZYME will ship the agreed antibodies to </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Bio-Innovate</div><div style="display:inline;"> rather than the Company to fulfill the requirements under the VAZYME License Agreement. During the year ended December&#160;31, 2022, the Company recorded $200 in &#8220;Research and development&#8217; expenses after VAZYME fulfilled the shipment. These amounts were included in &#8220;Accounts payable&#8221; in the consolidated financial statements as of both December&#160;31, 2023 and 2022. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Leases </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s leases are for office and laboratory spaces, classified as operating leases, and laboratory equipment, classified as finance leases. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On November&#160;19, 2021, in connection with its laboratory and office space in Woburn, MA, the Company provided to the landlord a standby letter of credit in the amount of $131 (the &#8220;LOC&#8221;), which serves as security for the Company&#8217;s performance of its obligations under the lease. The letter of credit is automatically extended without a written amendment for a period of one year, for each and every future expiration date, unless the Company elects not to extend this letter of credit through November&#160;30, 2025. The letter of credit allows for borrowings in the aggregate of up to $131 and bears interest at a per annum rate of the U.S. prime rate plus 1%, with the minimum interest rate no less than 4.25%. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The components of lease expense were as follows as of and for the years ended December&#160;31, 2023 and 2022: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years&#160;ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating lease costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">594</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">594</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Finance lease costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Amortization of ROU assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">240</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">247</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Interest on lease liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total lease costs</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">850</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">871</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The total cash paid for amounts included in the measurement of lease liabilities for the years ended December&#160;31, 2023 and 2022 included the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating cash flows from operating leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">500</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">440</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Financing cash flows from finance leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">222</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">207</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Lease term and discount rate were as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 65%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Weighted-average remaining lease term </div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">(in years)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1.73&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2.72&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Finance leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">0.25 years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1.17 years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Weighted-average discount rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.66</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.66</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Finance leases</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-49 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company had the following future minimum payments due under its operating and finance lease agreements as of December&#160;31, 2023: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 67%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Finance</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Operating</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">2024</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">131</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">613</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">744</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">2025</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">465</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">465</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total future minimum lease payments</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">131</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,078</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,209</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Less: amount representing interest</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Present value of future minimum lease payments</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">130</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,022</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,152</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Less: current maturities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(130</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(567</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(697</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Obligations under lease liability, noncurrent</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">455</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">455</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Litigation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company, from time to time, is subject to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material adverse effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on known facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment, the Company then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company records a provision for a contingent liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On September&#160;12, 2023, a CRO vendor filed a lawsuit against the Company based on the Company&#8217;s failure to make certain installments pursuant to a settlement agreement entered into with this vendor on January&#160;23, 2023. Under the settlement agreement, the Company agreed to pay a total of $1,644 to the vendor, with $600 due 5 business days after the settlement effective date and ten monthly installments, approximately $104 of each, starting in February 2023. This settlement amount was included in the accounts payable in the consolidated financial statements as of December&#160;31, 2022. The Company made the upfront payment and the first four monthly installments for a total of $1,016 but failed to make the monthly installment payments due after May 2023. On January&#160;24, 2024, the Company received the endorsement on motion for default judgment which requested the Company to pay approximately $700 to the CRO vendor. This amount was included in the accounts payable in the consolidated financial statements as of December&#160;31, 2023. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In addition to the lawsuit from CRO vendor above, the Company accrued $379 and $348 as of December&#160;31, 2023 and 2022, respectively, for disputed invoices with vendors. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In June 2023, the Company received a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $1,230 for the services performed under the MSK License Agreement (see Note 6) and is included in accounts payable and accrued expenses in the consolidated financial statements as of December&#160;31, 2023. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The MedImmune License Agreement (see Note 6) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company continues to provide annual development reports to MedImmune/AstraZeneca, most recently in January 2024. The Company does not expect a material impact on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-200,</div><div style="display:inline;"> which the Company is no longer developing. The Company believes that it is not using and does not expect to use the intellectual property rights licensed thereunder in connection with the development and eventual commercialization of </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-201</div><div style="display:inline;"> if such development efforts are successful. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-50 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Notes Payable &#8211; Related Parties </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Promissory Note with ABI </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On October&#160;18, 2023, the Company entered into a promissory note agreement with ABI, a significant investor in the Company&#8217;s Series E and F convertible preferred stock, to receive up to $6,000. The promissory note accrues interest at a rate of 5% per annum on the principal amount of each installment from the installment funding date until the maturity date and at a rate of 7% per annum after the maturity date if any amounts then remain outstanding. The &#8220;Maturity Date&#8221; is defined as the earlier of (i)&#160;eighteen months from the funding date and (ii)&#160;the successful closing of the Business Combination. This note is reported as current liabilities in the consolidated balance sheets based on the expectations that the Business Combination is expected to close in 2024. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023, the outstanding balance under this promissory note was $1,442. For the year ended December&#160;31, 2023, the interest expense accrued on this promissory note was $5. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Promissory Note with Executive and Director </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;29, 2023, the Company issued promissory notes to one of its executives and one of its directors, in the principal amount of $176 and $124, respectively, for deferred bonus. Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i)&#160;the closing of the Business Combination and (ii)&#160;June&#160;29, 2025. These promissory notes accrue interest at 5% per annum until the maturity date and 7% thereafter. These promissory notes are reported as current liabilities in the consolidated balance sheets based on the expectations that the Business Combination is expected to close in 2024. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023, the total outstanding balance under the promissory notes with executive and director was $300. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Stockholders&#8217; Equity </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s Amended and Restated Certificate of Incorporation (&#8220;Restated Charter&#8221;) authorizes the issuance of up to 40,000,000 shares in common stock and up to 11,620,248 shares in preferred stock. The Company&#8217;s Certificate of Incorporation, as amended, authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#8220;Series A&#8221;), Series B Convertible Preferred Stock (&#8220;Series B&#8221;), Series C Convertible Preferred Stock (&#8220;Series C&#8221;), Series D Convertible Preferred Stock (&#8220;Series D&#8221;), Series E Convertible Preferred Stock (&#8220;Series E&#8221;) and Series F Convertible Preferred Stock (&#8220;Series F&#8221;) collectively referred to as &#8220;Convertible Preferred Stock&#8221;. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Series F Convertible Preferred Stock Issuance </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In March, September and October 2022, the Company issued 111,111, 111,111 and 333,333 shares of Series&#160;F, respectively, at $18.00 per share, for the total proceeds of $9,991, net of financing costs of $9. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Significant terms of the Convertible Preferred Stock are as follows: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Dividends </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Dividends may be paid on the Preferred Stock when, as and if declared by the Board of Directors (the &#8220;Board&#8221;). The rights of holders of Preferred Stock to payment of any dividends shall be pro rata with the rights of holders of common stock. There have been no dividends declared by the Board through December&#160;31, 2023. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Conversion </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Each share of Preferred Stock is convertible, at the option of the holder, at any time after date of issuance of such share into the number of fully paid and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-assessable</div><div style="display:inline;"> shares of common stock, which is determined </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-51 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">by dividing the original issue price for such series by the applicable conversion price then in effect. The conversion price of Series A, Series B, Series C, Series D, Series E and Series F is $0.9323, $2.8725, $7.8441, $13.89, $9.08 and $18.00 per share, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">Each share of Preferred Stock is automatically convertible into common stock upon the earlier of a Qualified IPO defined as the net proceeds to the Company are not less than $30,000, the consummation of a transaction or series of related transactions by merger, consolidation, share exchange or otherwise of the Company with a publicly-traded special purpose acquisition company with gross proceeds of at least $30,000 from the sale of its equity securities, or by vote of the holders of a majority of the then outstanding shares of one of the classes (Series A, Series B, Series C, Series D, Series E or Series F Preferred Stock), voting each as a single class on an </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div><div style="display:inline;"> basis. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Voting </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Each holder of Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the Preferred Stock could be converted as of the record date. Except as otherwise specified in the Certificate of Incorporation, the holders of Preferred Stock and the holders of common stock vote as a single class on all matters submitted to a vote of stockholders, and not as separate classes. Series A, Series B, Series C, and Series D stockholders are collectively entitled to one elect one director. In addition, four directors may be elected by the majority of the common stock held by the founders of the Company. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Redemption Rights </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">At any time after January&#160;1, 2019, and at the election of the holders of at least a majority of the then outstanding shares of Series A, the Company shall redeem all of Series A elected by the outstanding shares of Series A that have not been previously converted into common stock. The Company is to redeem the shares of Series A by paying in cash an amount per share equal to the original issue price for such Series A of $93.23 per share, plus all declared and unpaid dividends in three equal annual installments. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Convertible Preferred Stock is redeemable upon a change in control. The occurrence of a change in control shall be deemed a Liquidation Event and the holders of shares of Convertible Preferred Stock then outstanding will be entitled to the same rights outlined in the Liquidation Preference section below. The deemed Liquidation Event was defined as (i)&#160;the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any bona fide sale of stock solely for capital raising purposes) other than a transaction or series of transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction continue to retain, immediately after such transaction or series of transactions, as a result of shares in the Company held by such holders prior to such transaction, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such surviving entity; or (ii)&#160;a sale, lease, transfer, exchange, exclusive license or other description of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by means of any transaction or series of related transactions. As such, the Convertible Preferred Stock is classified as temporary equity in the consolidated financial statements. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Liquidation Preference </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Series F, Series E and Series D are entitled to receive, prior and in preference to any distribution to the holders of the common stock or any other series of Preferred Stock, an amount per share for each share of Series F, Series E and Series D held by them equal to the sum of original issue price, and all declared but unpaid dividends (if any). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">After the payment or setting aside for payments to the Series F, Series E and Series D, the event of any liquidation, dissolution or winding up of the Company or other liquidation event, either voluntary and </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-52 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">involuntary, the holders of the Series C are entitled to receive, prior and in preference to any distribution to the holders of the common stock, Series A, or Series B, an amount per share for each share of Series C held by them equal to the sum of original issue price and all declared but unpaid dividends (if any). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">After the payment or setting aside for payment to the holders of Series F, Series E and Series D, and Series C, in the event of any liquidation, dissolution or winding up of the Company or other liquidation event, either voluntary or involuntary, the holders of the Series A and Series B are entitled to receive, prior and in preference to any distribution to the holders of the common stock, an amount per share for each share of Series A or Series B, held by them equal to the sum of original issue price and all declared but unpaid dividends (if any). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">After the payment or setting aside for payment to the holders of the Preferred Stock, in the event of any liquidation, dissolution or winding up of the Company or other liquidation event, either voluntary and involuntary, the holders of the common stock are entitled to receive remaining assets of the Company legally available for distribution on a pro rata basis. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Share-Based Compensation </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">2014 Stock Incentive Plan </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company&#8217;s 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;) provides for the Company to sell or issue restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board and consultants of the Company. The 2014 Plan is administered by the Board, or at the discretion of the Board, by a committee of the Board. Stock options granted to employees and directors typically vest over four years. Stock options granted to </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div><div style="display:inline;"> typically vest immediately at the grant date. The maximum contractual term of the stock options is ten years. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">In March 2022, the 2014 Plan was amended to reserve an additional 1,000,000 shares of common stock. As amended, a total of 6,534,395 shares of common stock may be issued under the 2014 Plan. As of December&#160;31, 2023, there were 695,921 shares available for future grants. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The summary of the Company&#8217;s stock option activity is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 50%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Number of</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Stock</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Contractual<br/>Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Aggregate</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Outstanding at December&#160;31,&#160;2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">5,464,521</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.35</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">7.1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">16,854</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Forfeited/Expired/Cancelled</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(51,673</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4.41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Outstanding at December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">5,414,848</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">34,474</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Exercisable at December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4,027,325</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">5.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">25,771</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The intrinsic value as of December&#160;31, 2023 is based on the fair value of the Company&#8217;s common stock of $9.71 per share. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-53 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock Option Valuation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The assumptions that the Company used to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Risk-free interest rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.53</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">1.82%&#8201;-&#8201;3.46</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Expected term (in years)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Expected volatility</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">71</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Expected dividend yield</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The weighted average grant date fair value of these awards was $4.26 per share and $4.82 per share for the years ended December&#160;31, 2023 and 2022, respectively. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company grants restricted stock units (&#8220;RSUs&#8221;) to various employees and directors. These RSUs cliff vest on the first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The summary of the Company&#8217;s restricted stock units activity is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 63%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Grant<br/>Date</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Remaining</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Vesting<br/>Period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Outstanding at December&#160;31,&#160;2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">83,335</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Vested</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(37,500</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Forfeited</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Outstanding at December&#160;31,&#160;2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">45,835</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3.33</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The summary of the recorded stock-based compensation expense is follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Research and development</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">118</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">214</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">General and administrative</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,187</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,804</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,305</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4,018</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023, there was approximately $3,246 of unrecognized compensation expense related to unvested stock option awards that are expected to be recognized over a weighted-average period of 1.8 years. As of December&#160;31, 2023, there was approximately $147 of unrecognized compensation cost related to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 1.2 years. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-54 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Warrants </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Common Stock Warrants </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The following presents information about warrants to purchase common stock outstanding as of December&#160;31, 2023: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">2017 Warrants</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">61,009</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">14.91</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">6.24&#160;years</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">No warrants were issued or exercised during the years ended December&#160;31, 2023 and 2022. These 2017 Warrants expire between March&#160;13, 2030 and October&#160;10, 2030 or upon the consummation of the Business Combination, unless exercised. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The components of income / (loss) before provision for / (benefit from) income taxes are: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Domestic</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,770</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(18,821</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Foreign</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,936</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Loss before Income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(16,885</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">For the year ended December&#160;31, 2023, the Company did not record a current income tax provision as no foreign withholding taxes were incurred in the period. For the year ended December&#160;31, 2022, the Company recorded a current income tax provision of $330 related to foreign withholding taxes applied against the $2,000 milestone payment received from Celltrion. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The components of the provision for income taxes are: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Current</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Federal</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">State</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Foreign</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total current provision for income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Deferred</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Federal</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">State</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Foreign</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total deferred provision for income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total provision for income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-55 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">A reconciliation of the Company&#8217;s effective income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December&#160;31, 2023 and 2022 is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net loss before tax</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(11,706</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(16,885</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Statutory U.S. federal tax rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Tax computed at federal statutory rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(2,458</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(3,546</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">State income taxes, net of federal benefit and tax credits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(825</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(1,117</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Federal research and development credit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(297</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(337</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Permanent differences</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">40</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,540</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">4,990</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Foreign withholding tax</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Income tax expense</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">330</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Significant components of the Company&#8217;s net deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">Years ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred tax assets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Operating loss carryforwards</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">20,233</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">17,930</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Tax credits</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,054</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,648</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,154</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,680</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Capitalized research expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">3,183</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">2,482</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Depreciation and amortization</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">539</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">1,025</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Lease liability</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">279</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">416</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">333</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">195</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">28,775</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">25,376</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Less: Valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(28,512</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(24,972</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Total deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">263</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">404</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Deferred tax liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div><div style="display:inline;"> asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(263</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">(404</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Net deferred income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div><div style="display:inline;"> that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">jurisdiction-by-jurisdiction</div></div><div style="display:inline;"> basis. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company continues to maintain a valuation allowance against its deferred tax assets. During the years ended December&#160;31, 2023 and 2022, management assessed the positive and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December&#160;31, 2023 </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-56 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">and 2022 will not be realized given the Company&#8217;s history of operating losses. The valuation allowance against deferred tax assets increased by approximately $3,540 and $4,965 during 2023 and 2022, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning after December&#160;31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research activities are conducted in the U.S. or outside the U.S., respectively. Effective January&#160;1, 2022, the Company has complied with the mandatory capitalization and amortization of research and experimentation expenditures. For the year ended December&#160;31, 2023, the Company capitalized $4,416 and received $1,850 of amortization deductions related to such Section&#160;174 expenditures, which on a tax effected basis represent $3,183 of the deferred tax assets shown in capitalized research expenses in the components of deferred tax assets and liabilities table above. For the year ended December&#160;31, 2022, the Company capitalized $9,790 and received $704 of amortization deductions related to such Section&#160;174 expenditures, which on a tax effected basis represent $2,482 of the deferred tax assets shown in capitalized research and development costs in the components of deferred tax assets and liabilities table above. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023, the Company had federal net operating losses of $74,871, which may be available to offset future federal income tax liabilities. As a result of the Act, for U.S. federal income tax purposes, net operating losses generated after December&#160;31, 2017 can be carried forward indefinitely, but are limited to 80% utilization against future taxable income each year. The Company&#8217;s federal net operating losses incurred prior to 2018, $22,999, expire through 2037, while its federal net operating losses incurred in 2018 and onwards, $51,872, can be carried forward indefinitely. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2022, the Company had federal net operating losses of $66,409, which may be available to offset future federal income tax liabilities. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023 and 2022, the Company had post-apportioned Massachusetts net operating losses of $71,356 and $63,042, respectively, that can generally be carried forward 20 years and will expire at various dates through 2043. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">As of December&#160;31, 2023, the Company had $1,483 and $708 of federal and state research and development credits, respectively, which will expire at various dates through 2043. As of December&#160;31, 2022, the Company had $1,185 and $571 of federal and state research and development credits, respectively, which will expire at various dates through 2042. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating losses and other carryforward tax attributes may be limited in the event a cumulative change in ownership of more than 50% that occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRS Section&#160;382. If ownership changes have occurred or occur in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company recognizes liabilities for uncertain tax positions based on a </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-step</div><div style="display:inline;"> process. First, management determines whether it is more likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company did not have any uncertain tax positions. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-57 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheets. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Employee Benefit Plan </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company has a 401(k) retirement plan available to all eligible employees. During the years ended December&#160;31, 2023 and 2022, the matching contribution to the plan were $136 and $119, respectively. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Related Parties </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On January&#160;15, 2020, the Company entered into an agreement for various consulting services, as defined in the agreement, with a member of the Company&#8217;s Board of Directors. On January&#160;1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in January 2020. During the years ended December&#160;31, 2023 and 2022, the Company incurred $250 and $435, respectively under this agreement, of which $21 and $194 remain unpaid as of December&#160;31, 2023 and 2022, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;1, 2021, the Company entered into a consulting agreement with another member of the Company&#8217;s Board of Directors. Under the agreement, the Company is obligated to pay fees for various consulting services, as defined in the agreement. During the years ended December&#160;31, 2023 and 2022, the Company incurred $0 and $280, respectively under this agreement, of which $8 remains unpaid as of both December&#160;31, 2023 and 2022, respectively. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;">In September 2022, the Company entered into a collaboration and license agreement with Celltrion, a significant investor in the Company&#8217;s Series F, as discussed in Note 5. The Company entered into </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-100</div><div style="display:inline;"> Agreement and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ABP-201</div><div style="display:inline;"> Agreement with ABI, a significant investor in the Company&#8217;s Series E and F, described in Note 5. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On October&#160;18, 2023, the Company issued a promissory note to ABI in the principal amount of up to $6,000 for expenses incurred in connection with the Business Combination and for its operating expenses, as discussed in Note 9. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">On December&#160;29, 2023, the Company issued promissory notes to one of its executives and one of its directors in the principal amount of $176 and $124, respectively, as discussed in Note 9. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Subsequent Events </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Promissory Note with ABI </div></div></div></div><div id="fin509388_106a" style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The Company received $3,315 through the issuance date of these financial statements under the promissory note with ABI. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-58 </div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_36">ANNEX A - BUSINESS COMBINATION AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BUSINESS COMBINATION AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BY AND AMONG </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ATLANTIC COASTAL ACQUISITION CORP. II, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABPRO MERGER SUB CORP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AND </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABPRO CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DATED AS OF December&#160;11, 2023 </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc1">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:10%"/>
<td style="width:77%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_1">ARTICLE I. CERTAIN DEFINITIONS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;1.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_2">Definitions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;1.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_3">Certain Defined Terms</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_4">Allocation Schedule </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_5">ARTICLE II. THE MERGER </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_6">Closing Transactions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_7">Contingency Consideration</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_8">Incentive Shares</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_9">Closing of the Transactions Contemplated by this Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_10">Allocation Schedule</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_11">Treatment of Company Options and Company RSUs</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_12">Closing Actions and Deliverables</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_13">Withholding</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;2.9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_14">Dissenting Stockholders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_15">ARTICLE III. REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANY </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_16">Organization and Qualification</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_17">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_18">Authority</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_19">Subsidiaries</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_20">Financial Statements; Undisclosed Liabilities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_21">Consents and Requisite Governmental Approvals; No Violations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_22">Permits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_23">Material Contracts</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_24">Absence of Changes</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_25">Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_26">Compliance with Applicable Law</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_27">Employee Benefit Plans</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_28">Environmental Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_29">Intellectual Property</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_30">Labor Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.16.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_31">Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.17.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_32">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.18.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_33">Brokers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.19.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_34">Real and Personal Property</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.20.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_35">Transactions with Affiliates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.21.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_36">Data Privacy and Security</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.22.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_37">Compliance with International Trade&#160;&amp; Anti-Corruption Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.23.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_38">Information Supplied</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.24.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_39">Regulatory Compliance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.25.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_40">Investigation; No Other Representations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.26.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_41">Investment Company Act</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;3.27.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_42">EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_43">ARTICLE IV. REPRESENTATIONS AND WARRANTIES RELATING TO THE SPAC PARTIES </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_44">Organization and Qualification</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_45">Authority</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_46">Consents and Requisite Governmental Approvals; No Violations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:10%"/>
<td style="width:77%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_47">Brokers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_48">Information Supplied</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_49">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_50">SEC Filings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_51">Trust Account</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_52">Transactions with Affiliates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_53">Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_54">Compliance with Applicable Law</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_55">Merger Sub Activities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_56">Internal Controls; Listing; Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_57">No Undisclosed Liabilities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_58">Employee Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.16.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_59">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.17.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_60">Investigation; No Other Representations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.18.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_61">Business Activities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.19.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_62">Investment Company Act; JOBS Act</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;4.20.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_63">EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_64">ARTICLE V. COVENANTS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_65">Conduct of Business of the Company</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_66">Efforts to Consummate</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_67">Confidentiality and Access to Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_68">Public Announcements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_69">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_70">Exclusive Dealing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_71">Preparation of Registration Statement/Proxy Statement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_72">SPAC Stockholder Approval</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_73">Merger Sub Stockholder Approval</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_74">Conduct of Business of SPAC</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_75">Nasdaq Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_76">Trust Account</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_77">Company Stockholder Approval</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_78">SPAC Indemnification; Directors&#8217; and Officers&#8217; Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_79">Company Indemnification; Directors&#8217; and Officers&#8217; Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.16.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_80">Post-Closing Directors and Officers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.17.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_81">PIPE Subscriptions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.18.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_82">Expense Statement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.19.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_83">Transaction Litigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.20.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_84">Employee Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;5.21.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_85">SPAC Extension Proposal</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_86">ARTICLE VI. CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_87">Conditions to the Obligations of the Parties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_88">Other Conditions to the Obligations of the SPAC Parties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_89">Other Conditions to the Obligations of the Company</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;6.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_90">Frustration of Closing Conditions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_91">ARTICLE VII. TERMINATION </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_92">Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;7.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_93">Effect of Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:10%"/>
<td style="width:77%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa509388_94">ARTICLE VIII. MISCELLANEOUS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_95"><span style="white-space:nowrap">Non-Survival</span></a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_96">Entire Agreement; Assignment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_97">Amendment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_98">Notices</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_99">Governing Law</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_100">Fees and Expenses</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_101">Construction; Interpretation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_102">Exhibits and Schedules</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_103">Parties in Interest</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_104">Severability</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_105">Counterparts; Electronic Signatures; Effectiveness</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_106">Knowledge of Company; Knowledge of SPAC</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_107">No Recourse</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_108">Extension; Waiver</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_109">Waiver of Jury Trial</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.16.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_110">Submission to Jurisdiction</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.17.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_111">Remedies</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.18.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_112">Trust Account Waiver</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&#160;8.19.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa509388_113">Conflicts and Privilege</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">EXHIBITS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:90%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit&#160;A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Sponsor Support Agreement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit&#160;B</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Company Support Agreement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit C</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Company <span style="white-space:nowrap">Lock-Up</span> Agreement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit&#160;D</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Amended and Restated SPAC Certificate of Incorporation</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit&#160;E</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Amended and Restated SPAC Bylaws</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BUSINESS COMBINATION AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This BUSINESS COMBINATION AGREEMENT (this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;), dated as of December&#160;11, 2023, is made by and among Atlantic Coastal Acquisition Corp. II, a Delaware corporation (&#8220;<span style="font-weight:bold">SPAC</span>&#8221;), Abpro Merger Sub Corp., a Delaware corporation (&#8220;<span style="font-weight:bold">Merger Sub</span>&#8221;), and Abpro Corporation, a Delaware corporation (the &#8220;<span style="font-weight:bold">Company</span>&#8221;). SPAC, Merger Sub and the Company shall be referred to herein from time to time collectively as the &#8220;<span style="font-weight:bold">Parties</span>&#8221; (and each a &#8220;<span style="font-weight:bold">Party</span>&#8221;). Capitalized terms used herein have the meanings set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.2</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, (a)&#160;SPAC is a blank check company incorporated as a Delaware corporation on May&#160;20, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, and (b)&#160;Merger Sub is, as of the date of this Agreement, a wholly-owned Subsidiary of SPAC that was formed for purposes of consummating the transactions contemplated by this Agreement and the Ancillary Documents; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, pursuant to the Governing Documents of SPAC, SPAC is required to provide an opportunity for its stockholders to have their outstanding shares of Series A Common Stock redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the SPAC Stockholder Approval; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, as of the date of this Agreement, SPAC&#8217;s initial stockholders, including Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;<span style="font-weight:bold">Sponsor</span>&#8221;), collectively own 7,499,999 shares of Series A Common Stock, and 1 share of Series B Common Stock; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, on the Closing Date, upon the terms and conditions set forth herein and in accordance with the General Corporation Law of the State of Delaware (the &#8220;<span style="font-weight:bold">DGCL</span>&#8221;), Merger Sub will merge with and into the Company (the &#8220;<span style="font-weight:bold">Merger</span>&#8221;), with the Company as the surviving company in the Merger and, after giving effect to such Merger, a wholly-owned Subsidiary of SPAC, and each Company Share will be converted into the right to receive the Merger Consideration, on the terms and subject to the conditions set forth in this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, prior to the Closing Date, SPAC will enter into subscription agreements, in form and substance reasonably satisfactory to the Parties (collectively, the &#8220;<span style="font-weight:bold">Subscription Agreements</span>&#8221;), with certain investors (collectively, the &#8220;<span style="font-weight:bold">Investors</span>&#8221;) pursuant to which, among other things, the Investors will agree to subscribe for and purchase, and SPAC will agree to issue and sell to the Investors, a number of shares of Series A Common Stock as set forth in each applicable Subscription Agreement in exchange for an aggregate purchase price to be determined (the &#8220;<span style="font-weight:bold">PIPE Investment Amount</span>&#8221;), on the terms and subject to the conditions set forth therein (such equity financing hereinafter referred to as the &#8220;<span style="font-weight:bold">PIPE Financing</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, pursuant to the Governing Documents of SPAC, SPAC is required to provide an opportunity for its stockholders to have their outstanding shares of Series A Common Stock redeemed pursuant to the SPAC Stockholder Redemption on the terms and subject to the conditions set forth therein in connection with obtaining the SPAC Shareholder Approval; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, concurrently with the execution of this Agreement, Sponsor will enter into an agreement with SPAC, the Company and Abpro Bio Co., Ltd (the &#8220;<span style="font-weight:bold">Sponsor Share Letter</span>&#8221;), whereby Sponsor agrees to (i)&#160;retain 2.95&#160;million shares of Series A Common Stock, (ii)&#160;divide 2,458,333 shares of Series A Common Stock held by it among the Sponsor, who will be entitled to 491,667 of the shares, the Company, who will be entitled to 983,333 of the shares, and Abpro Bio Co., Ltd, who will be entitled to 983,333 of the shares, for such party to use to obtain <span style="white-space:nowrap">non-redemption</span> commitments from SPAC stockholders or other capital for SPAC or the Surviving Corporation (with any shares unused for such purpose to be retained by such party), and (iii)&#160;forfeit the remainder of any Series A Common Stock and Series B Common Stock held by it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, concurrently with the execution of this Agreement, SPAC, the Sponsor and the Company, among others, will enter into the stockholder support agreement attached hereto as <span style="text-decoration:underline">Exhibit</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;A</span> (the &#8220;<span style="font-weight:bold">Sponsor</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-weight:bold">Support Agreement</span>&#8221;), pursuant to which, among other things, the Sponsor will agree (a)&#160;to vote its shares of SPAC Common Stock in favor of the Required Transaction Proposals, (b)&#160;not to transfer its shares of SPAC Common Stock, and (c)&#160;to waive any adjustment to the conversion ratio set forth in the Governing Documents of SPAC or any other anti-dilution or similar protection with respect to its shares of SPAC Common Stock in connection with the transactions contemplated by this Agreement, in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, concurrently with the execution of this Agreement, certain Company Stockholders will enter into stockholder support agreements in the form attached hereto as <span style="text-decoration:underline">Exhibit</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;B</span> (the &#8220;<span style="font-weight:bold">Company Support Agreements</span>&#8221;), pursuant to which, among other things, such Company Stockholders will agree (a)&#160;to, as promptly as practicable following the time at which the Registration Statement/Proxy Statement shall have been declared effective and made available to such Company Stockholders, vote their Company Shares in favor of, or execute written consents to adopt and approve, promptly following the effectiveness of the Registration Statement/Proxy Statement, this Agreement, any Ancillary Documents to which the Company is or will be a party, the Merger and the other transactions contemplated by this Agreement and any Ancillary Documents to which the Company is or will be a party, and (b)&#160;not to transfer, prior to the Closing, such Company Stockholder&#8217;s Company Shares, subject to the exceptions set forth therein; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>,<span style="font-weight:bold"> </span>prior to Closing, certain Company Stockholders will enter into <span style="white-space:nowrap">lock-up</span> agreements in the form attached hereto as <span style="text-decoration:underline">Exhibit C</span> (the &#8220;<span style="font-weight:bold">Company <span style="white-space:nowrap">Lock-up</span> Agreements</span>&#8221;), pursuant to which Company Stockholders will agree not to transfer, following the Closing, such Company Stockholder&#8217;s shares of Series A Common Stock constituting such Company Stockholder&#8217;s Merger Consideration for the period set forth therein, subject to the exceptions set forth therein; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, effective immediately after the Effective Time, the appointment of members to the board of directors of the SPAC, as approved in Required Transaction Proposals, will take effect; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, prior to the Closing, SPAC, Company and Sponsor shall enter into an escrow agreement (the &#8220;<span style="font-weight:bold">SPAC Incentive Shares Escrow Agreement</span>&#8221;), providing for an escrow account (&#8220;<span style="font-weight:bold">SPAC Incentive Share Escrow Account</span>&#8221;) into which, at Closing, SPAC shall issue and deliver 2,000,000 shares of Series A Common Stock (the &#8220;<span style="font-weight:bold">SPAC Incentive Shares</span>&#8221;), which shall be disbursed pursuant to the SPAC Incentive Share Escrow Agreement by the joint written consent of Sponsor and the Company to induce <span style="white-space:nowrap">non-redemption</span> commitments from SPAC stockholders or other capital raises for the SPAC. Any SPAC Incentive Shares that are undistributed for such purpose after 180 days following the Closing shall be forfeited and cancelled; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the board of directors of the Company (the &#8220;<span style="font-weight:bold">Company Board</span>&#8221;) has duly (a)&#160;determined that this Agreement, the Ancillary Documents to which the Company is or will be party and the transactions contemplated hereby and thereby (including the Merger) are in the best interests of, and are advisable to, the Company and the Company Stockholders, (b)&#160;approved and declared advisable this Agreement, the Ancillary Documents to which the Company is or will be party and the transactions contemplated hereby and thereby (including the Merger), and (c)&#160;resolved to recommend that the Company Stockholders adopt and approve this Agreement, the Ancillary Documents to which the Company is or will be party and the transactions contemplated hereby and thereby (including the Merger); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, no later than forty-eight (48)&#160;hours, following the date that the Registration Statement/Proxy Statement becomes effective, holders of a majority of the Company Preferred Stock, acting together as a class, and holders of a majority of the Company Common Stock shall approve an amendment to the Company Certificate of Incorporation, providing for the automatic conversion, immediately prior to the Closing, of the Company Preferred Stock into shares of Company Common Stock (the &#8220;<span style="font-weight:bold">Company Preferred Stock Conversion</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the board of directors of SPAC (the &#8220;<span style="font-weight:bold">SPAC Board</span>&#8221;) has unanimously (a)&#160;determined that this Agreement, the Ancillary Documents to which a SPAC Party is or will be party and the transactions </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby and thereby (including the Merger) are in the best interests of, and advisable to, SPAC and its stockholders, (b)&#160;approved and declared advisable this Agreement, the Ancillary Documents to which a SPAC Party is or will be party and the transactions contemplated hereby and thereby (including the Merger), and (c)&#160;resolved to recommend that its stockholders adopt this Agreement and the Ancillary Documents to which a SPAC Party is or will be party; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the board of directors of Merger Sub has unanimously (a)&#160;determined that this Agreement, the Ancillary Documents to which Merger Sub is or will be party and the transactions contemplated hereby and thereby (including the Merger) are in the best interests of, and advisable to, Merger Sub and its sole stockholder, (b)&#160;approved and declared advisable this Agreement, the Ancillary Documents to which Merger Sub is or will be party and the transactions contemplated hereby and thereby (including the Merger), and (c)&#160;recommended that its sole stockholder adopt and approve this Agreement, the Ancillary Documents to which Merger Sub is or will be party and the transactions contemplated hereby and thereby (including the Merger); and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, each of the Parties intends that, for U.S. federal income tax purposes, (a)&#160;this Agreement constitutes a &#8220;plan of reorganization&#8221; within the meaning of Section&#160;368 of the Code and Treasury Regulations promulgated thereunder, and (b)&#160;the Merger constitutes a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code (clause (b)&#160;being the &#8220;<span style="font-weight:bold">Intended Tax Treatment</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_1">ARTICLE I. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTAIN DEFINITIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_2">Section&#160;1.1. Definitions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms have the respective meanings set forth below. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Affiliate</span>&#8221; means, with respect to any Person, any other Person who directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#8220;control&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms &#8220;controlled&#8221; and &#8220;controlling&#8221; have meanings correlative thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Affordable Care Act</span>&#8221; means the Patient Protection and Affordable Care Act (Pub. L. 111&#8211;148), as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111&#8211;152), and the regulations promulgated pursuant to each of the foregoing laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Aggregate Consideration</span>&#8221; means, collectively, the Merger Consideration and, if any, the Contingency Consideration. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Ancillary Documents</span>&#8221; means the Subscription Agreements, the Sponsor Share Letter, the Sponsor Support Agreement, the Company Support Agreements, the Company <span style="white-space:nowrap">Lock-up</span> Agreements, Employment Agreements, the SPAC Incentive Share Escrow Agreement, and each other agreement, document, instrument or certificate contemplated by this Agreement executed or to be executed in connection with the transactions contemplated hereby. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Anti-Corruption Laws</span>&#8221; means, collectively, (a)&#160;the U.S. Foreign Corrupt Practices Act, (b)&#160;the UK Bribery Act 2010, and (c)&#160;any other anti-bribery or anti-corruption Laws related to combating bribery, corruption and money laundering, each as applicable. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Available Closing Cash</span>&#8221; means, as of the Closing (a)&#160;the amount of funds contained in the Trust Account (after reduction for the aggregate amount of payments made or required to be made in connection </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with the SPAC Stockholder Redemption), <span style="font-style:italic">plus</span> (b)&#160;the amount of funds available to consummate the Merger pursuant to a PIPE Financing, forward purchase agreements, an equity line of credit, convertible note financing, and other sources of financing <span style="font-style:italic">minus </span>(c)&#160;Unpaid SPAC Expenses. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business</span>&#8221; means the development of next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, including novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity, as conducted (and as contemplated to be conducted) by the Company and its Subsidiaries as of the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business Day</span>&#8221; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York are open for the general transaction of business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CARES Act</span>&#8221; means (a)&#160;the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. <span style="white-space:nowrap">116-136)</span> and any administrative or other guidance published with respect thereto by any Governmental Authority (including IRS Notices <span style="white-space:nowrap">2020-22</span> and <span style="white-space:nowrap">2020-65),</span> or any other Law or executive order or executive memorandum (including the Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing <span style="white-space:nowrap">COVID-19</span> Disaster, dated August&#160;8, 2020) intended to address the consequences of <span style="white-space:nowrap">COVID-19</span> (in each case, including any comparable provisions of U.S. state or local or <span style="white-space:nowrap">non-U.S.</span> Law and including any related or similar orders or declarations from any Governmental Authority) and (b)&#160;any extension of, amendment, supplement, correction, revision or similar treatment to any provision of the CARES Act contained in the Consolidated Appropriations Act, 2021, H.R. 133. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Change of Control Payment</span>&#8221; means (a)&#160;any success, change of control, retention, severance, transaction bonus or other similar payment payable to any Person as a result of or in connection with the consummation of the transactions contemplated by this Agreement or any Ancillary Document (but, for the avoidance of doubt, not including any <span style="white-space:nowrap">so-called</span> double-trigger payments), or (b)&#160;any payments made or required to be made pursuant to or in connection with or upon termination of, and any fees, expenses or other payments owing in respect of, any Company Related Party Transaction (in the case of clause (b), regardless of whether paid or payable prior to, at or after the Closing or in connection with or otherwise related to this Agreement or any Ancillary Document). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Code</span>&#8221; means the U.S. Internal Revenue Code of 1986, as amended. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Acquisition Proposal</span>&#8221; means (a)&#160;any transaction or series of related transactions under which any Person(s), directly or indirectly, acquires or otherwise purchases (i)&#160;the Company, or (ii)&#160;all or substantially all of the assets or businesses of the Company and its Subsidiaries (in the case of each of clause (i)&#160;and (ii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise), or (b)&#160;any material equity or similar investment in the Company or any of its Subsidiaries. Notwithstanding the foregoing or anything to the contrary herein, (i)&#160;none of this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby shall constitute a Company Acquisition Proposal, (ii)&#160;the Company may issue Company Options in the ordinary course of business, and (iii)&#160;the Company may raise capital in the form of an equity financing and/or convertible debt financing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Business Intellectual Property</span>&#8221; means collectively, the Company Owned Intellectual Property and the Company Licensed Intellectual Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Certificate of Incorporation</span>&#8221; means the Amended and Restated Certificate of Incorporation of the Company, dated as of March&#160;30, 2022. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Common Stock</span>&#8221; means common stock, par value $0.0001 per share, of the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Disclosure Schedules</span>&#8221; means the disclosure schedules to this Agreement delivered to SPAC by the Company on the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Equity Plan</span>&#8221; means the Company&#8217;s 2014 Stock Incentive Plan. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Expenses</span>&#8221; means, as of any determination time, the aggregate amount of fees, expenses, commissions or other amounts incurred by or on behalf of the Company or any of its Subsidiaries, whether </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or not due and payable, and not otherwise expressly allocated to a SPAC Party pursuant to the terms of this Agreement or any Ancillary Document, in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, including (a)&#160;the fees and expenses of outside legal counsel, accountants, advisors, brokers, investment bankers, consultants, or other agents or service providers of the Company, (b)&#160;any other fees, expenses, commissions or amounts that are expressly allocated to the Company or any of its Subsidiaries pursuant to this Agreement or any Ancillary Document, and (c)&#160;Change of Control Payments paid or payable by the Company on or before the Closing Date. Notwithstanding the foregoing or anything to the contrary herein, Company Expenses shall not include any SPAC Expenses. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Fundamental Representations</span>&#8221; means the representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.1(a)</span> (<span style="font-style:italic">Organization and Qualification</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(a) </span>(other than clause (iii)&#160;of the first sentence) and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(b)</span> (<span style="font-style:italic">Capitalization</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3</span> (<span style="font-style:italic">Authority</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.9(a)</span> (<span style="font-style:italic">Absence of Changes</span>) and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span> (<span style="font-style:italic">Brokers</span>). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company IT Systems</span>&#8221; means any and all computer systems, Software and hardware, communication systems, servers, network equipment and related documentation, in each case, owned, used, licensed, or leased by the Company or its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Licensed Intellectual Property</span>&#8221; means any and all Intellectual Property Rights owned by or licensed to any Person (other than the Company or any of its Subsidiaries) that (a)&#160;are licensed or sublicensed (or purported to be licensed or sublicensed) to or used, held for use or practiced by the Company or any of its Subsidiaries, or (b)&#160;with respect to which the Company or any of its Subsidiaries has obtained (or purported to have obtained) a covenant not to be sued. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Material Adverse Effect</span>&#8221; means any Effect that, individually or in the aggregate with any other Effect, has had or would reasonably be expected to have a material adverse effect on (a)&#160;the business, assets, results of operations or condition (financial, regulatory, clinical or otherwise) of the Company and its Subsidiaries, taken as a whole, or (b)&#160;the ability of the Company to consummate the Merger; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that in the case of clause (a), none of the following shall be taken into account in determining whether a Company Material Adverse Effect has occurred or would be reasonably expected to occur: any adverse Effect (regardless of materiality) arising from or related to (i)&#160;general business or economic conditions in or affecting the United States, European Union or Australia, or changes therein, or the global economy generally, (ii)&#160;any national or international political or social conditions in the United States, European Union or any other country, including the engagement by the United States, European Union or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&#160;changes in conditions of the financial, banking, capital or securities markets generally in the United States, European Union or any other country or region in the world, or changes therein, including changes in interest rates in the United States, European Union or any other country and changes in exchange rates for the currencies of any countries, (iv)&#160;changes or proposed changes in any applicable Laws or GAAP after the date of this Agreement, (v)&#160;any Effect that is generally applicable to the industries or markets in which the Company and its Subsidiaries operate, (vi)&#160;the execution or public announcement of this Agreement or the pendency or consummation of the transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of the Company and its Subsidiaries with employees, Contingent Workers, customers, investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees or other third parties related thereto; <span style="font-style:italic">provided</span> that the exception in this clause (vi)&#160;shall not apply to the representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.6(b)</span> to the extent that such exception&#8217;s purpose is to address the consequences resulting from the public announcement or pendency or consummation of the transactions contemplated by this Agreement, or the condition set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(a)</span> to the extent it relates to such representations and warranties), (vii)&#160;any failure by the Company and its Subsidiaries, taken as a whole, to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
account to the extent not otherwise excluded from this definition pursuant to clauses (i)&#160;through (vi) or (viii)), or (viii)&#160;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics or pandemics or the worsening of any pandemics (including <span style="white-space:nowrap">COVID-19),</span> acts of God or other natural disasters or comparable events in the United States, European Union or any other country or region in the world, or any escalation of the foregoing; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that any Effect resulting from a matter described in any of the foregoing clauses (i)&#160;through (v) or (viii)&#160;may be taken into account in determining whether a Company Material Adverse Effect has occurred or would be reasonably expected to occur to the extent, and solely to the extent, such Effect has a material and disproportionate adverse effect on the Company and its Subsidiaries, taken as a whole, relative to other participants operating in the industries or markets in which the Company and its Subsidiaries operate. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Option</span>&#8221; means, as of any reference time, each option to purchase shares of Company Common Stock granted to any current or former director, manager, officer, employee, Contingent Worker or other service provider of the Company or any of its Subsidiaries that is outstanding and unexercised. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Owned Intellectual Property</span>&#8221; means any and all Intellectual Property Rights that are owned or purported to be owned by the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Preferred Stock</span>&#8221; means the 11,620,248 shares of Preferred Stock, $0.001 par value per share, 4,444,444 shares of which are designated Series F Preferred Stock, 3,303,966 shares of which are designated Series E Preferred Stock, 1,220,261 shares of which are designated Series D Preferred Stock, 2,005,687 shares of which are designated Series C Preferred Stock, 626,636 shares of which are designated Series B Preferred Stock, and 19,254 of which are designated Series A Preferred Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Product</span>&#8221; means each product candidate that is being researched, tested, developed or manufactured by or on behalf of the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Registered Intellectual Property</span>&#8221; means any and all Registered Intellectual Property owned or purported to be owned by, or filed or registered by or in the name of the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company RSU</span>&#8221; means, as of any reference time, each restricted stock unit covering shares of Company Common Stock granted to any current or former director, manager, officer, employee, Contingent Worker or other service provider of the Company or any of its Subsidiaries that is outstanding. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Shares</span>&#8221; means shares of the Company Common Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Stockholders</span>&#8221; means the holders of Company Common Stock and the Company Preferred Stock as of any determination time prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Confidentiality Agreement</span>&#8221; means that certain Confidential Disclosure Agreement, dated as of March&#160;1, 2023, between the Company and SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Consent</span>&#8221; means any notice, authorization, qualification, registration, filing, notification, waiver, order, consent or approval to be obtained from, filed with or delivered to, a Governmental Entity or other Person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contingent Worker</span>&#8221; means any individual independent contractor, consultant, contractor, temporary employee or leased employee currently being used by the Company and its Subsidiaries and classified by them as other than an employee, or compensated other than through Form <span style="white-space:nowrap">W-2</span> wages paid by them through their payroll functions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contract</span>&#8221; or &#8220;<span style="font-weight:bold">Contracts</span>&#8221; means any written agreement, contract, license, lease, obligation, undertaking or other commitment or arrangement that is legally binding upon a Person or any of his, her or its properties or assets. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Copyrights</span>&#8221; has the meaning set forth in the definition of Intellectual Property Rights. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">COVID-19</span></span>&#8221; means <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> or <span style="white-space:nowrap">COVID-19,</span> and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Effect</span>&#8221; means any state of facts, event, change, effect, occurrence, circumstance or development. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Employee Benefit Plan</span>&#8221; means each (a) &#8220;employee benefit plan&#8221; (as such term is defined in Section&#160;3(3) of ERISA, whether or not subject to ERISA), (b) each stock option plan, stock purchase plan, equity-based plan, retention plan, profit sharing plan, bonus or incentive plan, severance pay plan, program or arrangement, deferred compensation arrangement or agreement, employment agreement, compensation plan, program, agreement or arrangement, change in control plan, program or arrangement, supplemental income arrangement, vacation plan and each other employee benefit plan, program, policy, agreement and arrangement not described in (a)&#160;above, and (c)&#160;each plan or arrangement providing compensation to employee and <span style="white-space:nowrap">non-employee</span> directors, in each case that the Company or any of its Subsidiaries maintain, sponsor or contribute to, or has any obligation to contribute to, or under or with respect to which the Company or any of its Subsidiaries has or may have any Liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Employment Agreements</span>&#8221; means the employment agreements with Ian Chan, Rob Markelewicz, Richard Mitrano and Christian Zapf. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Environmental Laws</span>&#8221; means all Laws and Orders concerning pollution, protection of the environment, or human health or safety. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Equity Securities</span>&#8221; means any share, share capital, capital stock, partnership, membership, unit, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option, warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Equity Value</span>&#8221; means $725,000,000. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Equity Value Per Share</span>&#8221; means (a)&#160;the Equity Value, <span style="font-style:italic">divided by</span> (b)&#160;the Fully Diluted Company Capitalization. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA</span>&#8221; means the Employee Retirement Income Security Act of 1974. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA Affiliate</span>&#8221; means any entity, trade or business that is, or at any applicable time was, a member of a group described in Section&#160;414(b), (c), (m) or (o)&#160;of the Code or Section&#160;4001(b)(1) of ERISA that includes the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Exchange Ratio</span>&#8221; means (a)&#160;the Equity Value Per Share, <span style="font-style:italic">divided by</span> (b)&#160;$10.00. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">FDA</span>&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">FDCA</span>&#8221; means the United States Federal Food, Drug, and Cosmetic Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Federal Securities Laws</span>&#8221; means the Exchange Act, the Securities Act and the other U.S. federal securities laws and the rules and regulations of the SEC promulgated thereunder or otherwise. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Fraud</span>&#8221; with respect to any Party, means a material false representation of material fact by such Party of the representations and warranties set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> or <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> IV</span>, as applicable, or in any certificate delivered hereunder, with the intent that another Party rely on such representations and warranties, coupled with such other Party&#8217;s detrimental reliance on such representations and warranties under circumstances that constitute common law fraud under the Laws of the State of Delaware. For the avoidance of doubt, &#8220;Fraud&#8221; does not include any claim for equitable fraud, promissory fraud, unfair dealings fraud or any torts based on negligence or recklessness. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Fully Diluted Company Capitalization</span>&#8221; means, without duplication, the sum of (a)&#160;the aggregate number of shares of Company Common Stock outstanding as of immediately prior to the Effective Time, determined on an <span style="white-space:nowrap">as-converted</span> basis (including, for the avoidance of doubt, the number of shares of Company Common Stock issuable upon conversion of a share of Company Preferred Stock and any other Equity Securities convertible into shares of Company Common Stock outstanding as of immediately prior to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Closing based on the then-applicable conversion ratio), (b) the aggregate number of Company RSUs that are outstanding as of immediately prior to the Effective Time and (c)&#160;the aggregate number of shares of Company Common Stock (on a net exercise basis) subject to Unvested Company Options and Vested Company Options as of immediately prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">GAAP</span>&#8221; means United States generally accepted accounting principles. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Good Clinical Practices</span>&#8221; means the then current standards for clinical trials, including all applicable requirements relating to protection of human subjects, as set forth in the FDCA and applicable regulations promulgated thereunder, as amended from time to time, including the applicable requirements contained in 21 C.F.R. Parts 50, 54, and 56, and such standards of good clinical practice, including all applicable requirements relating to protection of human subjects, as are required by other organizations and Governmental Entities in any other countries in which the Company Products are intended to be used or sold. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Good Laboratory Practices</span>&#8221; mean the then current standards for conducting nonclinical laboratory studies, as set forth in the FDCA and applicable regulations promulgated thereunder, as amended from time to time, including applicable requirements contained in 21 C.F.R. Part 58, and such applicable standards of good laboratory practices as are required by other organizations and Governmental Entities in any other countries in which the Company Products are intended to be used or sold. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governing Documents</span>&#8221; means the legal document(s) by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs, or other organizational documents of such Person. For example, the &#8220;Governing Documents&#8221; of a U.S. corporation are its certificate or articles of incorporation and <span style="white-space:nowrap">by-laws,</span> the &#8220;Governing Documents&#8221; of a U.S. limited partnership are its limited partnership agreement and certificate of limited partnership and the &#8220;Governing Documents&#8221; of a U.S. limited liability company are its operating or limited liability company agreement and certificate of formation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Entity</span>&#8221; means any United States or <span style="white-space:nowrap">non-United</span> States (a)&#160;federal, state, local, municipal or other government, (b)&#160;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official or entity and any court or other tribunal), or (c)&#160;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power of any nature, including any arbitral tribunal (public or private). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Healthcare Laws</span>&#8221; means all Laws relating to healthcare regulatory matters or the development, testing, research (including nonclinical and clinical research or studies), manufacture, production, analysis, distribution, approval, importation, exportation, use, handling, quality, packaging, labeling, sale or promotion of any drug or biological product (including any ingredient or component of the foregoing products), including the FDCA (21 U.S.C. &#167;&#167;&#160;301, <span style="font-style:italic">et seq</span>.), the Public Health Service Act (42 U.S.C. &#167;&#167;&#160;201, <span style="font-style:italic">et seq</span>.), all Laws relating to any federal health care program (as such term is defined in 42 U.S.C. <span style="white-space:nowrap">&#167;&#160;1320a-7b(f)),</span> including the federal Anti-Kickback Statute (42 U.S.C. <span style="white-space:nowrap">&#167;&#160;1320a-7b(b)),</span> the Physician Self-Referral Law (42 U.S.C. &#167;&#160;1395nn), the civil False Claims Act (31 U.S.C. &#167;&#160;3729, <span style="font-style:italic">et seq</span>.), the administrative False Claims Law (42 U.S.C. <span style="white-space:nowrap">&#167;&#160;1320a-7b(a)),</span> Sections <span style="white-space:nowrap">1320a-7,</span> <span style="white-space:nowrap">1320a-7a,</span> and <span style="white-space:nowrap">1320a-7b</span> of Title 42 of the United States Code and any comparable self-referral or fraud and abuse laws promulgated by any Governmental Entity, the 21st Century Cures Act (Pub. L. <span style="white-space:nowrap">114-255),</span> the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (&#8220;<span style="font-weight:bold">HIPAA</span>&#8221;) (42 U.S.C. &#167;&#160;1320d, <span style="font-style:italic">et seq</span>.), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167;&#160;17921, <span style="font-style:italic">et seq</span>.), and any state or federal Law the purpose of which is to protect the privacy of individually-identifiable patient information, Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), the Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, TRICARE (10 U.S.C. Section&#160;1071, <span style="font-style:italic">et seq</span>.), the U.S. Physician Payments Sunshine Act (42 U.S.C. <span style="white-space:nowrap">&#167;&#160;1320a-7h)</span> and similar state or foreign Laws related to the reporting of manufacturer payments or transfers of value to health care professionals, in each case including the associated rules and regulations promulgated thereunder and all of their foreign equivalents, and any other requirements of Law relating to the Business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">HSR Act</span>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Incentive Stock Option</span>&#8221; means a Company Option that is an &#8220;incentive stock option&#8221; (as defined in Section&#160;422 of the Code). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Indebtedness</span>&#8221; means, as of any time, without duplication, with respect to any Person, the outstanding principal amount of, accrued and unpaid interest on, fees and expenses arising under or in respect of (a)&#160;indebtedness for borrowed money, (b)&#160;other obligations evidenced by any note, bond, debenture or other debt security, (c)&#160;obligations for the deferred purchase price of property or assets, including &#8220;earn-outs&#8221; and &#8220;seller notes&#8221; (but excluding any trade payables arising in the ordinary course of business), (d)&#160;reimbursement and other obligations with respect to letters of credit, bank guarantees, bankers&#8217; acceptances or other similar instruments, in each case, solely to the extent drawn, (e)&#160;leases required to be capitalized under GAAP, (f)&#160;derivative, hedging, swap, foreign exchange or similar arrangements, including swaps, caps, collars, hedges or similar arrangements, (g)&#160;all &#8220;applicable employment taxes&#8221; (as defined in Section&#160;2302(d)(1) of the CARES Act) that the Group Companies have elected to defer pursuant to Section&#160;2302 of the CARES Act, (h)&#160;all Taxes (including withholding Taxes) deferred pursuant to Internal Revenue Service Notice <span style="white-space:nowrap">2020-65</span> or any related or similar order or declaration from any Governmental Entity (including, without limitation, the Presidential Memorandum, dated August&#160;8, 2020, issued by the President of the United States), and (i)&#160;any of the obligations of any other Person of the type referred to in clauses (a)&#160;through (g)&#160;above directly or indirectly guaranteed by such Person or secured by any assets of such Person, whether or not such Indebtedness has been assumed by such Person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Intellectual Property Rights</span>&#8221; means any and all intellectual property rights and related priority rights protected, created or arising under the Laws of the United States or any other jurisdiction or under any international convention, including all (a)&#160;patents and patent applications, industrial designs and design patent rights, including any continuations, divisionals, <span style="white-space:nowrap"><span style="white-space:nowrap">continuations-in-part</span></span> and provisional applications and statutory invention registrations, and any patents issuing on any of the foregoing and any reissues, reexaminations, substitutes, supplementary protection certificates or extensions of any of the foregoing (collectively, &#8220;<span style="font-weight:bold">Patents</span>&#8221;), (b)&#160;trademarks, service marks, trade names, service names, brand names, trade dress rights, logos, Internet domain names, social media accounts or identifiers, corporate names and other source or business identifiers, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals of any of the foregoing (collectively, &#8220;<span style="font-weight:bold">Marks</span>&#8221;), (c)&#160;copyrights and rights in works of authorship, design rights, mask work rights and moral rights, whether or not registered or published, and all registrations, applications, renewals, extensions and reversions of any of any of the foregoing (collectively, &#8220;<span style="font-weight:bold">Copyrights</span>&#8221;), (d)&#160;trade secrets, <span style="white-space:nowrap">know-how</span> and confidential and proprietary information, including invention disclosures, inventions and formulae, whether patentable or not, (e)&#160;rights in or to Software or other technology, (f)&#160;rights in databases and compilations, including rights in data and collections of data, whether machine readable or otherwise and (g)&#160;any other intellectual or proprietary rights protectable, arising under or associated with any of the foregoing, including those protected by any Law anywhere in the world. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Investment Company Act</span>&#8221; means the Investment Company Act of 1940. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Key Employee</span>&#8221; means the Chief Executive Officer or any individual employed by the Company or any of its Subsidiaries with a title of &#8220;vice president.&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Law</span>&#8221; means any federal, state, local, foreign, national or supranational statute, law (including common law), act, statute, ordinance, treaty, rule, code, regulation or other legally binding directive issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Liability</span>&#8221; or &#8220;<span style="font-weight:bold">liability</span>&#8221; means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental Law), Proceeding or Order and those arising under any Contract. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Lien</span>&#8221; means any mortgage, pledge, security interest, encumbrance, lien, license or <span style="white-space:nowrap">sub-license,</span> charge, covenant not to sue granted to a third party, or other similar encumbrance or interest (including, in the case of any Equity Securities, any voting, transfer or similar restrictions). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Malicious Code</span>&#8221; means disabling codes or instructions, spyware, trojan horses, worms, viruses or other software routines that facilitate or cause unauthorized access to, or disruption, impairment, disablement, or destruction of, software, information technology systems, data or other materials. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Marks</span>&#8221; has the meaning set forth in the definition of Intellectual Property Rights. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Merger Consideration</span>&#8221; means with (a)&#160;respect to each outstanding share of Company Common Stock, a number of shares of Series A Common Stock equal to the Exchange Ratio, and (b)&#160;with respect to each outstanding share of Company Preferred Stock, a number of shares of Series A Common Stock equal to (i)&#160;the aggregate number of shares of Company Common Stock that would be issued upon conversion of such Company Preferred Stock into Company Common Stock based on the applicable conversion ratio immediately prior to the Effective Time, as set forth in the Allocation Schedule, multiplied by (ii)&#160;the Exchange Ratio. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Nasdaq</span>&#8221; means the Nasdaq Global Market. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-Shelf</span></span> Software</span>&#8221; means any Software that is made generally and widely available to the public on a commercial basis and is licensed to the Company or any of its Subsidiaries on a <span style="white-space:nowrap">non-exclusive</span> basis under standard terms and conditions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Order</span>&#8221; means any outstanding writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree entered, issued or rendered by any Governmental Entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Pandemic Measures</span>&#8221; means (a)&#160;any <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;shelter-in-place,&#8221;</span></span> &#8220;stay at home,&#8221; workforce reduction, furlough, employee time off, employee leave, social distancing, shut down, closure, sequester, business or workplace reopening, or other conditions, restrictions or requirements pursuant to any Law, order, directive, pronouncement, guideline or recommendation of or by any Governmental Entity, the Centers for Disease Control and Prevention, the Occupational Safety and Health Administration, the Equal Employment Opportunity Commission or the World Health Organization in connection with or in respect of <span style="white-space:nowrap">COVID-19</span> or any other pandemic, epidemic, public health emergency or virus or disease outbreak, (b)&#160;with respect to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(a)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3(b)</span>, any acts or omissions by the Company or its Subsidiaries that have been or may be taken in a commercially reasonable manner as a reasonable good faith response to <span style="white-space:nowrap">COVID-19,</span> or to the extent necessary to avoid, mitigate or remediate a material adverse effect on the Company, its Subsidiaries or the Business as may result from <span style="white-space:nowrap">COVID-19,</span> and (c)&#160;with respect to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3(c)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span>, any acts or omissions by the SPAC Parties that have been or may be taken in a commercially reasonable manner as a reasonable good faith response to <span style="white-space:nowrap">COVID-19,</span> or to the extent necessary to avoid, mitigate or remediate a material adverse effect on the SPAC Parties as may result from <span style="white-space:nowrap">COVID-19.</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Patents</span>&#8221; has the meaning set forth in the definition of Intellectual Property Rights. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">PCAOB</span>&#8221; means the Public Company Accounting Oversight Board. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permits</span>&#8221; means any approvals, Consents, authorizations, clearances, licenses, registrations, permits or certificates of or issued by a Governmental Entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Liens</span>&#8221; means (a)&#160;mechanic&#8217;s, materialmen&#8217;s, carriers&#8217;, repairers&#8217; and other similar statutory Liens arising or incurred in the ordinary course of business for amounts that are not yet delinquent or are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established in accordance with GAAP, (b)&#160;Liens for Taxes, assessments or other governmental charges not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established in accordance with GAAP, (c)&#160;encumbrances and restrictions on real property (including easements, covenants, conditions, rights of way and similar restrictions) that do not prohibit or materially interfere with the Company&#8217;s or its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Subsidiaries&#8217; use or occupancy of such real property for the operation of the Business, (d)&#160;zoning, building codes and other land use Laws regulating the use or occupancy of real property or the activities conducted thereon which are imposed by any Governmental Entity having jurisdiction over such real property and which are not violated by the use or occupancy of such real property for the operation of the Business and do not prohibit or materially interfere with the Company&#8217;s or its Subsidiaries&#8217; use or occupancy of such real property for the operation of the Business, (e)&#160;in the case of the Leased Real Property, any Lien granted by any lessor, developer or third-party on any fee interest underlying the Leased Real Property, (f)&#160;the Real Property Leases, (g)&#160;cash deposits or cash pledges to secure the payment of workers&#8217; compensation, unemployment insurance, social security benefits or obligations arising under similar Laws or to secure the performance of public or statutory obligations, surety or appeal bonds, and other obligations of a like nature, in each case in the ordinary course of business and which are not yet due and payable, <span style="white-space:nowrap">(h)&#160;non-exclusive</span> grants by the Company or its Subsidiaries of Intellectual Property Rights in the ordinary course of business consistent with past practice and that are not material to the Company or any of its Subsidiaries, and (i)&#160;Liens listed on <span style="text-decoration:underline">Schedule 1.1(PL)</span> of the Company Disclosure Schedules. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Person</span>&#8221; means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture or other similar entity, whether or not a legal entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Personal Data</span>&#8221; means any data in the Company&#8217;s possession, custody, or control, (i)&#160;that identifies, or that could reasonably be used to identify, any natural person or device or household, or (ii)&#160;that constitutes protected health information of any natural person, in each case which data or information is regulated by Privacy Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders</span>&#8221; means the holders of SPAC Common Stock at the relevant time of determination prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Privacy Laws</span>&#8221; means all applicable Laws that govern the Processing of Personal Data or governing privacy, protected health information, data protection, data security, or data or security breach notification. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Proceeding</span>&#8221; means any lawsuit, litigation, action, audit, investigation, examination, claim, charge, complaint, proceeding, suit, arbitration or mediation (in each case, whether civil, criminal or administrative and whether public or private) pending by or before any Governmental Entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Process</span>&#8221; (or &#8220;<span style="font-weight:bold">Processing</span>&#8221; or &#8220;<span style="font-weight:bold">Processes</span>&#8221;) means the collection, use, storage, processing, recording, distribution, transfer, import, export, protection (including security measures), disposal or disclosure or other activity regarding Personal Data (whether electronically or in any other form or medium). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Real Property Leases</span>&#8221; means all leases, <span style="white-space:nowrap">sub-leases,</span> licenses or other agreements, in each case, as amended from time to time and pursuant to which the Company or, if applicable, any of its Subsidiaries, leases or <span style="white-space:nowrap">sub-leases</span> any real property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Redemption Rights</span>&#8221; means the redemption rights provided for in Sections 9.2 and 9.7 of the SPAC Certificate of Incorporation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Registered Intellectual Property</span>&#8221; means all issued Patents, pending Patent applications, registered Marks, pending applications for registration of Marks, registered Copyrights, pending applications for registration of Copyrights and Internet domain name registrations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Regulatory Permits</span>&#8221; means all Permits granted by the FDA or any comparable Governmental Entity to the Company or any of its Subsidiaries, including investigational new drug applications, Biologics License Applications, manufacturing approvals and authorizations, clinical trial authorizations and ethical reviews, or their national or foreign equivalents. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Representatives</span>&#8221; means, with respect to a Person, such Person&#8217;s Affiliates and its and such Affiliates respective directors (or equivalent), officers, managers, employees, members, owners and legal, financial, internal and independent accounting and other advisors and representatives. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Required Governing Document Proposals</span>&#8221; means the approval of the Amended and Restated Certificate of Incorporation of SPAC, in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;D</span>, and Amended and Restated Bylaws of SPAC, in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;E</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Sanctions and Export Control Laws</span>&#8221; means any applicable Law in any part of the world related to (a)&#160;import and export controls, including the U.S. Export Administration Regulations, the International Traffic and Arms Regulations, and any other equivalent or comparable export control laws and regulations of other countries, (b)&#160;economic sanctions, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the European Union, any European Union Member State, the United Nations and Her Majesty&#8217;s Treasury of the United Kingdom or (c)&#160;anti-boycott measures. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Sarbanes-Oxley Act</span>&#8221; means the Sarbanes-Oxley Act of 2002. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Schedules</span>&#8221; means, collectively, the Company Disclosure Schedules and the SPAC Disclosure Schedules. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SEC</span>&#8221; means the U.S. Securities and Exchange Commission. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Securities Act</span>&#8221; means the U.S. Securities Act of 1933, as amended. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Securities Laws</span>&#8221; means Federal Securities Laws and other applicable foreign and domestic securities or similar Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Series A Common Stock</span>&#8221; means Series A Common Stock, $0.0001 par value, of SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Series B Common Stock</span>&#8221; means Series B Common Stock, $0.0001 par value, of SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Software</span>&#8221; means any and all (a)&#160;computer programs, including any and all software implementations of algorithms, models and methodologies, whether in source code or object code, (b)&#160;databases and compilations, including any and all data and collections of data, whether machine readable or otherwise, (c)&#160;descriptions, flowcharts and other work product used to design, plan, organize and develop any of the foregoing and, to the extent embodied in any of the foregoing, screens, user interfaces, report formats, firmware, development tools, templates, menus, buttons and icons, and (d)&#160;documentation, including user manuals and other training documentation, related to any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Acquisition Proposal</span>&#8221; means any transaction or series of related transactions under which SPAC or any of its Affiliates, directly or indirectly, (a)&#160;acquires or otherwise purchases any other Person(s), (b)&#160;engages in a business combination with any other Person(s), or (c)&#160;acquires or otherwise purchases at least a majority of the voting securities of such Person(s) or all or substantially all of the assets or business of any other Person(s) (in the case of each of clauses (a), (b)&#160;and (c), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise). Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby shall constitute a SPAC Acquisition Proposal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Certificate of Incorporation</span>&#8221; means the Amended and Restated Certificate of Incorporation of SPAC, effective as of January&#160;18, 2022, as amended by that certain Amendment to Amended and Restated Certificate of Incorporation, dated April&#160;18, 2023. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Common Stock</span>&#8221; means Series A Common Stock and Series B Common Stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Disclosure Schedules</span>&#8221; means the disclosure schedules to this Agreement delivered to the Company by SPAC on the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Expenses</span>&#8221; means, as of any determination time, the aggregate amount of fees, expenses, commissions or other amounts incurred by or on behalf of any SPAC Party, whether or not due and payable, in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, including (a)&#160;the fees and expenses of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
outside legal counsel, accountants, advisors, brokers, investment bankers, consultants or other agents or service providers of any SPAC Party, (b)&#160;any other fees, expenses, commissions or amounts that are expressly allocated to any SPAC Party pursuant to this Agreement or any Ancillary Document, (c)&#160;any deferred underwriter fees, discounts and commissions in connection with SPAC&#8217;s initial public offering, (d)&#160;the fees, costs and expenses incurred in connection with the PIPE Financing, including any cash financing fees or third-party advisory expenses in connection therewith, (e)&#160;the costs and expenses associated with any filings with or notifications to any Governmental Entity in connection with the transactions contemplated by this Agreements or the Ancillary Documents, including pursuant to the HSR Act, (f)&#160;the fees, costs and expenses associated with the preparation and filing of the Registration Statement/Proxy Statement and (g)&#160;the fees, costs and expenses associated with the SPAC Stockholders Meeting. Notwithstanding the foregoing or anything to the contrary herein, SPAC Expenses shall not include any Company Expenses. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Fundamental Representations</span>&#8221; means the representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1</span> (<span style="font-style:italic">Organization and Qualification</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2</span> (<span style="font-style:italic">Authority</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span> (<span style="font-style:italic">Brokers</span>), and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(a)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(b)</span> (<span style="font-style:italic">Capitalization</span>). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Material Adverse Effect</span>&#8221; means any Effect that, individually or in the aggregate with any other Effect, has had or would reasonably be expected to have a material adverse effect on (a)&#160;the business, assets, results of operations or condition (financial, regulatory or otherwise) of the SPAC Parties, taken as a whole, or (b)&#160;the ability of SPAC or Merger Sub to consummate the Merger; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that, in the case of clause (a), none of the following shall be taken into account in determining whether a SPAC Material Adverse Effect has occurred or would be reasonably expected to occur: any adverse Effect (regardless of materiality) arising from or related to (i)&#160;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&#160;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&#160;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&#160;changes or proposed changes in any applicable Laws or GAAP after the date of this Agreement, (v)&#160;any Effect that is generally applicable to the industries or markets in which any SPAC Party operates, (vi)&#160;the execution or public announcement of this Agreement or the pendency or consummation of the transactions contemplated by this Agreement, including the impact thereof on the relationships, contractual or otherwise, of any SPAC Party with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees or other third parties related thereto; <span style="font-style:italic">provided</span> that the exception in this clause (vi)&#160;shall not apply to the representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3(b)</span> to the extent that such exception&#8217;s purpose is to address the consequences resulting from the public announcement or pendency or consummation of the transactions contemplated by this Agreement or the condition set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(a)</span> to the extent it relates to such representations and warranties), (vii)&#160;any failure by any SPAC Party to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (i)&#160;through (vi)&#160;or (viii)), (viii)&#160;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics or pandemics or the worsening of any pandemics (including <span style="white-space:nowrap">COVID-19),</span> acts of God or other natural disasters or comparable events in the United States or any other country or region in the world, or any escalation of the foregoing, (ix)&#160;any Effect relating to the Company or its Subsidiaries or the Company Stockholders, (x)&#160;any SPAC Stockholder Redemption, in and of itself, or (xi)&#160;subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.17(b)</span>, any breach of any covenants, agreements or obligations of an Investor under a Subscription Agreement (including any breach of an Investor&#8217;s obligations to fund its commitment thereunder when required); <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that any Effect resulting from a matter described in any of the foregoing clauses (i)&#160;through (v) or (viii)&#160;may be taken into account in determining whether a SPAC Material Adverse Effect </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
has occurred or would be reasonably expected to occur to the extent, and solely to the extent, such Effect has a material and disproportionate adverse effect on the SPAC Parties, taken as a whole, relative to other &#8220;SPACs&#8221; operating in the industries in which the SPAC Parties operate. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Parties</span>&#8221; means, collectively, SPAC and Merger Sub. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Stockholder Approval</span>&#8221; means the approval of each Required Transaction Proposal by the affirmative vote of the holders of the requisite number of SPAC Common Stock entitled to vote thereon, whether in person or by proxy at the SPAC Stockholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of SPAC and applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SPAC Stockholder Redemption</span>&#8221; means the right of the holders of Series A Common Stock to redeem all or a portion of their Series A Common Stock (in connection with the transactions contemplated by this Agreement or otherwise) as set forth in the SPAC Certificate of Incorporation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Subsidiary</span>&#8221; means, with respect to any Person, any corporation, limited liability company, partnership or other legal entity of which (a)&#160;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or (b)&#160;if a limited liability company, partnership, association or other business entity (other than a corporation), a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person or a combination thereof and for this purpose, a Person or Persons own a majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business entity&#8217;s gains or losses or shall be a, or control any, managing director or general partner of such business entity (other than a corporation). The term &#8220;Subsidiary&#8221; shall include all Subsidiaries of such Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax</span>&#8221; means any federal, state, local or <span style="white-space:nowrap">non-U.S.</span> income, gross receipts, franchise, estimated, alternative minimum, imputed underpayment, sales, use, transfer, value added, excise, stamp, customs, duties, ad valorem, real property, personal property (tangible and intangible), capital stock, social security, unemployment, payroll, wage, employment, severance, occupation, registration, communication, mortgage, profits, license, lease, service, goods and services, withholding, premium, unclaimed property, escheat, turnover, windfall profits or other taxes or other similar governmental fees or assessments, in each case, in the nature of taxes, together with any interest, deficiencies, penalties, additions to tax or additional amounts imposed by any Governmental Entity with respect thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax Authority</span>&#8221; means any Governmental Entity responsible for the collection or administration of Taxes or Tax Returns. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax Return</span>&#8221; means any return, information return, statement, declaration or claim for refund, together with any schedules thereto or amendments thereof, relating to Taxes required to be filed with any Tax Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Unpaid Company Expenses</span>&#8221; means the Company Expenses that are unpaid as of the relevant determination date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Unpaid SPAC Expenses</span>&#8221; means the SPAC Expenses that are unpaid as of the relevant determination date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Unvested Company Option</span>&#8221; means each Company Option outstanding as of immediately prior to the Effective Time that is not a Vested Company Option. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Unvested Company RSU</span>&#8221; means each Company RSU outstanding as of immediately prior to the Effective Time that is not a Vested Company RSU. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Vested Company Option</span>&#8221; means each Company Option outstanding as of immediately prior to the Effective Time that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby (whether at the Effective Time or otherwise). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Vested Company RSU</span>&#8221; means each Company RSU outstanding as of immediately prior to the Effective Time that is vested as of such time or will vest in connection with the consummation of the transactions contemplated hereby (whether at the Effective Time or otherwise). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">WARN Act</span>&#8221; means the Worker Adjustment Retraining and Notification Act of 1988, as well as analogous applicable foreign, state or local Laws related to plant closings, mass layoffs and employment losses. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Willful Breach</span>&#8221; means an intentional and willful breach, or an intentional and willful failure to perform, in each case, that is the consequence of an act or omission by a Party with the knowledge that the taking of such act or failure to take such act would cause a breach of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_3"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1.2.</span> <span style="font-weight:bold">Certain Defined Terms.</span><span style="font-weight:bold"> </span>Each of the following terms is defined in the Section&#160;set forth opposite such term: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Term</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Section</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Company Financial Statements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional SPAC SEC Reports</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Introduction</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" id="anxa509388_4">Allocation Schedule</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Company Financial Statements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of Merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.1(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.1(a)(vii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Filing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Press Release</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Introduction</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Board</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company D&amp;O Persons</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.15(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company D&amp;O Tail Policy</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.15(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Financial Statements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Group</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.19(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Incentive Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.3(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company <span style="white-space:nowrap">Lock-up</span> Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Preferred Stock Conversion</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Related Party</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.20</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Related Party Transactions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.20</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stockholder Written Consent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.13</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Stockholder Written Consent Deadline</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.13</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingency Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(iii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Creator</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.14(e)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DGCL</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dissenting Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Time</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.1(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enforceability Exceptions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Agent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange Fund</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.7(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Level Contingency Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outside Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Share Target</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Funded IP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.14(l)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intended Tax Treatment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Term</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Section</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interim Period</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.1(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.18</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leased Real Property</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.19(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensed Patents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.14(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Contracts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Permits</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Sub</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Introduction</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nelson Mullins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nelson Mullins Privileged Communications</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.19(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Equity Incentive Plan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parties</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Introduction</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted Transfer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(e)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investment Amount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Privacy and Data Security Policies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.21(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Privacy Requirements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.21(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Statement/Prospectus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration Statement/Proxy Statement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Released Claims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.18</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Required Transaction Proposals</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.8</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover Option</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.6(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover RSU</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.6(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Level Contingency Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Share Target</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Targets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(iii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signing Filing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signing Press Release</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Introduction</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Board</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Board Recommendation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.8</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC D&amp;O Persons</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.14(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC D&amp;O Tail Policy</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Financial Statements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.13(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Group</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.19(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Incentive Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Incentive Shares Escrow Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Incentive Shares Escrow Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Related Party</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Related Party Transactions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC SEC Reports</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.7</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPAC Stockholders Meeting</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.8</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor Support Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subscription Agreements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Recitals</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiary Securities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surviving Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.1(a)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">7.1(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Level Contingency Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(iii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Share Target</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(iii)</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Term</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Section</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction Litigation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5.19</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">8.18</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.8</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">4.8</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VWAP</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2.2(a)(i)</td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_5">ARTICLE II. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_6"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.1.</span> <span style="font-weight:bold">Closing Transactions.</span><span style="font-weight:bold"> </span>On the terms and subject to the conditions set forth in this Agreement, the following transactions shall occur in the order set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Merger</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) On the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, on the Closing Date, Merger Sub shall merge with and into the Company at the Effective Time. Following the Effective Time, the separate existence of Merger Sub shall cease and the Company shall continue as the surviving company of the Merger (the &#8220;<span style="font-weight:bold">Surviving Corporation</span>&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) At the Closing, the Parties shall cause a certificate of merger, in a form reasonably satisfactory to the Company and SPAC (the &#8220;<span style="font-weight:bold">Certificate of Merger</span>&#8221;), to be executed and filed with the Secretary of State of the State of Delaware. The Merger shall become effective on the date and time at which the Certificate of Merger is accepted for filing by the Secretary of State of the State of Delaware or at such later date or time as is agreed by SPAC and the Company and specified in the Certificate of Merger (the time the Merger becomes effective being referred to herein as the &#8220;<span style="font-weight:bold">Effective Time</span>&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The Merger shall have the effects set forth in Section&#160;251 of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all of the assets, properties, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Corporation and all Liabilities, obligations, restrictions, disabilities and duties of or applicable to each of the Company and Merger Sub shall become the Liabilities, obligations, restrictions, disabilities and duties of or applicable to the Surviving Corporation, in each case, in accordance with the DGCL. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) At the Effective Time, the Governing Documents of Merger Sub shall be the Governing Documents of the Surviving Corporation, in each case, until thereafter changed or amended as provided therein or by applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) At the Effective Time, the directors set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(v)</span> of the Company Disclosure Schedule shall be the initial directors of the Surviving Corporation, each to hold office in accordance with the Governing Documents of the Surviving Corporation until such director&#8217;s successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal. At the Effective Time, the officers of the Company immediately prior to the Effective Time shall be the initial officers of the Surviving Corporation, each to hold office in accordance with the Governing Documents of the Surviving Corporation until such officer&#8217;s successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into one share of common stock, par value $0.0001, of the Surviving Corporation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each Company Share (other than the Company Shares cancelled in accordance with clause (viii)&#160;immediately below) issued and outstanding as of immediately prior to the Effective Time </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
shall be canceled and extinguished and be converted into the right to receive a number of shares of Series A Common Stock equal to the Merger Consideration. From and after the Effective Time, the holder(s) of certificates (the &#8220;<span style="font-weight:bold">Certificates</span>&#8221;), if any, evidencing ownership of Company Shares and the Company Shares held in book-entry form issued and outstanding immediately prior to the Effective Time shall each cease to have any rights with respect to such Company Shares except as otherwise expressly provided for herein or under applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each Company Share held immediately prior to the Effective Time by the Company as treasury stock shall be canceled and extinguished, and no consideration shall be paid with respect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_7">Section&#160;2.2. Contingency Consideration. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Following the Closing, in addition to the consideration to be received pursuant to <span style="text-decoration:underline">Sections 2.1(a)(vii)</span> and <span style="text-decoration:underline">2.5</span> and as part of the overall Aggregate Consideration, Company Stockholders shall be issued additional shares of Series A Common Stock up to an aggregate amount of 14,500,000 shares (collectively, the &#8220;<span style="font-weight:bold">Earnout Shares</span>&#8221;), as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, on or before the date which is five calendar years after the Closing Date (the &#8220;<span style="font-weight:bold">Outside Date</span>&#8221;), the volume weighted average price of shares of Series A Common Stock on Nasdaq, or any other national securities exchange on which the shares of Series A Common Stock are then traded (&#8220;<span style="font-weight:bold">VWAP</span>&#8221;), is greater than or equal to $13.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;<span style="font-weight:bold">First Share Target</span>&#8221;) (such Earnout Shares, the &#8220;<span style="font-weight:bold">First Level Contingency Consideration</span>&#8221;); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, on or before the Outside Date, the VWAP is greater than or equal to $15.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;<span style="font-weight:bold">Second Share Target</span>&#8221;) (such Earnout Shares, the &#8220;<span style="font-weight:bold">Second Level Contingency Consideration</span>&#8221;); and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <span style="white-space:nowrap">one-third</span> of the total Earnout Shares, if, on or before the Outside Date, the VWAP is greater than or equal to $18.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;<span style="font-weight:bold">Third Share Target</span>&#8221; and together with the First Share Target and Second Share Target, collectively, the &#8220;<span style="font-weight:bold">Share Targets</span>&#8221;) (such Earnout Shares, the &#8220;<span style="font-weight:bold">Third Level Contingency Consideration</span>&#8221; and together with the First Level Contingency Consideration and the Second Level Contingency Consideration, collectively, the &#8220;<span style="font-weight:bold">Contingency Consideration</span>&#8221;). For the avoidance of doubt, each of the First Level Contingency Consideration, the Second Level Contingency Consideration and the Third Level Contingency Consideration is issuable only once in accordance with the terms of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(a)</span>, and the maximum amount of Contingency Consideration is 14,500,000&#160;shares of Series A Common Stock, in the aggregate. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If any of the Share Targets shall have been achieved, then within ten Business Days following the achievement of the applicable Share Target (which may be achieved at the same time or over the same or overlapping trading days), SPAC shall issue the applicable Contingency Consideration to each Company Stockholder as specified on the Allocation Schedule. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Following the Closing, if a Change of Control of SPAC shall occur on or before the applicable Outside Date set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(a)(i)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(a)(ii)</span>, or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(a)(iii)</span>, respectively, then if (i)&#160;the per share value of the consideration to be received by holders of Series A Common Stock in connection with the Change of Control exceeds $13.00 per share and the First Share Target has not been previously achieved, then the First Share Target shall be deemed to have been achieved, (ii)&#160;the per share value of the consideration to be received by holders of Series A Common Stock in connection with the Change of Control exceeds $15.00 per share and the Second Share Target has not been previously achieved, then the Second Share Target shall be deemed to have been achieved, and (iii)&#160;the per share value of the consideration to be received by holders of Series A Common Stock in connection with the Change of Control exceeds $18.00 per share and the Third Share Target has not been previously achieved, then the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Third Share Target shall be deemed to have been achieved. If any or all Share Targets are deemed to have been achieved, then any Contingency Consideration that remains unissued as of immediately prior to the consummation of such Change of Control shall immediately become payable and the Company Stockholders shall be entitled to receive such Contingency Consideration prior to the consummation of such Change of Control; provided, that any Contingency Consideration that is not deemed to be earned in connection with the Change of Control in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(c)</span> shall be forfeited by the Company Stockholder(s) for no consideration. Any Contingency Consideration shall be payable to the Company Stockholders as specified on the Allocation Schedule. For the purposes of this Agreement, a &#8220;<span style="font-weight:bold">Change of Control</span>&#8221; shall have been deemed to occur with respect to SPAC upon: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the sale, lease, license, distribution, dividend or transfer, in a single transaction or a series of related transactions, of more than 50% of the assets of SPAC and its Subsidiaries taken as a whole; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) a merger, consolidation or other business combination of SPAC (or any Subsidiary or Subsidiaries that alone or together represent more than 50% of the consolidated business of SPAC at that time) or any successor or other entity holding, directly or indirectly, 50% or more of all the assets of SPAC and its Subsidiaries that results in the stockholders of SPAC (or such Subsidiary or Subsidiaries) or any successor or other entity holding, directly or indirectly, 50% or more of the assets of SPAC and its Subsidiaries or the surviving entity thereof, as applicable, immediately before the consummation of such transaction or series of related transactions holding, directly or indirectly, less than 50% of the voting power of SPAC (or such Subsidiary or Subsidiaries) or any successor, other entity or surviving entity thereof, as applicable, immediately following the consummation of such transaction or series of related transactions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Contingency Consideration and the Share Targets shall be adjusted to reflect appropriately the effect of any stock split, reverse stock split, stock dividend (including any dividend or distribution of securities convertible into shares of Series A Common Stock), reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with respect to Series A Common Stock, occurring on or after the date hereof and prior to the time any such Contingency Consideration is delivered to the Company Stockholders, if any. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The right of the Company Stockholders to receive the Contingency Consideration (i)&#160;is solely a contractual right and will not be evidenced by a certificate and does not constitute a security or other instrument, (ii)&#160;may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than upon written notice to SPAC pursuant to a Permitted Transfer, and (iii)&#160;does not give the Company Stockholders any right to receive interest payments. There is no guaranty or other assurance of any kind that any Contingency Consideration will be payable hereunder (regardless of any projections, models, forecasts or any other financial data generated by, or provided to, the Company, SPAC or their respective Affiliates or Representatives). For purposes of this Agreement, &#8220;<span style="font-weight:bold">Permitted Transfer</span>&#8221; means (A)&#160;a transfer on death by will or intestacy, (B)&#160;a transfer by instrument to an <span style="font-style:italic">inter vivos</span> or testamentary trust for beneficiaries upon the death of the trustee, (C)&#160;a transfer made pursuant to an order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation), (D) a transfer by a partnership or limited liability company through a distribution to its partners or members, as applicable, in each case without consideration, or (E)&#160;a transfer made by operation of law (including a consolidation or merger) or as pursuant to the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If the consideration to be received by holders of Series A Common Stock in a Change of Control includes <span style="white-space:nowrap">non-cash</span> consideration, then the value of such consideration for the purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2(c)</span> shall be determined in good faith by the SPAC Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_8">Section&#160;2.3. Incentive Shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">SPAC Incentive Shares</span>. Prior to the Closing, SPAC, the Company and Sponsor shall enter into the SPAC Incentive Shares Escrow Agreement, providing for the SPAC Incentive Share Escrow Account into which, at Closing, SPAC shall issue and deliver 2,000,000 shares of Series A Common Stock, which shall </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
be disbursed pursuant to the SPAC Incentive Share Escrow Agreement by the joint written consent of Sponsor and the Company to SPAC stockholders on a pro rata basis to induce <span style="white-space:nowrap">non-redemption</span> commitments from SPAC stockholders. Any SPAC Incentive Shares that are undistributed for such purpose after 180 days following the Closing shall be forfeited and cancelled. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Company Incentive Shares</span>. Notwithstanding anything in this Agreement to the contrary, 22,500,000 shares Series A Common Stock of the total Merger Consideration (the &#8220;<span style="font-weight:bold">Company Incentive</span> <span style="font-weight:bold">Shares</span>&#8221;) to be issued to the Company Stockholders will be reduced from the Merger Consideration and equally divided among the Sponsor, the Company and Abpro Bio Co., Ltd. for each such Person to use in the PIPE Financing or to obtain capital for SPAC or the Surviving Company. Any of the Company Incentive Shares that are not used or allocated by the Sponsor, the Company or Abpro Bio Co., Ltd. to any Person by the Closing shall be deemed forfeited and shall not be issued to any other Person, including the Company Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_9"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.4.</span> <span style="font-weight:bold">Closing of the Transactions Contemplated by this Agreement.</span><span style="font-weight:bold"> </span>The closing of the transactions contemplated by this Agreement (the &#8220;<span style="font-weight:bold">Closing</span>&#8221;) shall take place at the offices of Pillsbury Winthrop Shaw Pittman LLP, 31 W. 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street, New York, New York 10019, as promptly as reasonably practicable, but in no event later than the third Business Day, following the satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in <span style="text-decoration:underline">ARTICLE VI</span> (other than those conditions that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) (the &#8220;<span style="font-weight:bold">Closing Date</span>&#8221;) or at such other place, date or time as SPAC and the Company may agree in writing, or electronically by exchange of the closing deliverables by the means provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.11</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_10"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.5.</span> <span style="font-weight:bold">Allocation Schedule.</span><span style="font-weight:bold"> </span>No later than five Business Days prior to the Closing Date, the Company shall deliver to SPAC an allocation schedule (the &#8220;<span style="font-weight:bold">Allocation Schedule</span>&#8221;) setting forth (a)&#160;(i)&#160;the number of Company Equity Securities held by each Company Stockholder, (ii)&#160;the number of shares of Company Common Stock to be issued and outstanding as of immediately prior to the Effective Time, including pursuant to outstanding Company Preferred Stock, (iii)&#160;the number of shares of Company Common Stock subject to each Company Option held by each holder thereof, including the tax status of such Company Option, whether each such Company Option will be a Vested Company Option or an Unvested Company Option and the exercise price thereof, and the holder&#8217;s employment or service status with the Company; (iv)&#160;the number of shares of Company Common Stock subject to each Company RSU held by each holder thereof, including whether each such Company RSU will be a Rollover RSU; (b)&#160;the number of shares of Series A Common Stock that will be subject to each Rollover Option or Rollover RSU, and the exercise price of each Rollover Option at the Effective Time, determined in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>, as well as reasonably detailed calculations with respect to the components and subcomponents thereof; (c)&#160;the portion of the Merger Consideration allocated to each Company Stockholder pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span>, as well as reasonably detailed calculations with respect to the components and subcomponents thereof; (d)&#160;the portion of the Contingency Consideration allocated to each Company Stockholder, in the event that any Contingency Consideration becomes payable, as well as reasonably detailed calculations with respect to the components and subcomponents thereof; and (e)&#160;a certification, duly executed by an authorized officer of the Company, that the information and calculations delivered pursuant to clauses (a), (b), (c) and (d)&#160;are, and will be as of immediately prior to the Effective Time, (i)&#160;true and correct in all respects, and (ii)&#160;in accordance with the applicable provisions of this Agreement, the Governing Documents of the Company and applicable Laws and, in the case of Company Options and Company RSUs, the Company Equity Plan and any applicable grant or similar agreement with respect to any such Company Option or Company RSU. The Company will review any comments to the Allocation Schedule provided by SPAC or any of its Representatives and consider in good faith and incorporate any reasonable comments proposed by SPAC or any of its Representatives to correct inaccuracies. Notwithstanding the foregoing or anything to the contrary herein, the aggregate number of shares of Series A Common Stock that each Company Stockholder will have a right to receive pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span> will be rounded down to the nearest whole share. Notwithstanding the foregoing or anything to the contrary herein, the SPAC Parties and the Exchange Agent will be entitled to rely upon the Allocation Schedule for purposes of allocating the transaction consideration to the Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholders under this Agreement or the agreement entered into by the Parties with the Exchange Agent, as applicable, and upon delivery, payment and issuance of the Aggregate Consideration on the Closing Date to the Exchange Agent, the SPAC and its respective Affiliates shall be deemed to have satisfied all obligations with respect to the payment of consideration under this Agreement (including with respect to the Aggregate Consideration), and none of them shall have (A)&#160;any further obligations to the Company, any Company Stockholder or any other Person with respect to the payment of any consideration under this Agreement, or (B)&#160;any Liability with respect to the allocation of the consideration under this Agreement, and the Company and the Company Stockholders hereby irrevocably waive and release the SPAC and its Affiliates (and, on and after the Closing, the Surviving Company and its Affiliates) from any and all claims arising out of or resulting from or related to such Allocation Schedule and the allocation of the Share Consideration, as the case may be, among each Company Stockholder as set forth in such Allocation Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_11">Section&#160;2.6. Treatment of Company Options and Company RSUs. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, by virtue of the Merger and without any action of any Party or any other Person, each Company Option (whether a Vested Company Option or an Unvested Company Option) shall cease to represent the right to purchase shares of Company Common Stock and shall be converted into an option to purchase shares of Series A Common Stock (each, a &#8220;<span style="font-weight:bold">Rollover Option</span>&#8221;) in an amount, at an exercise price and subject to such terms and conditions determined as set forth below. Each Rollover Option shall (i)&#160;be exercisable for, and represent the right to purchase, a number of shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Company Common Stock subject to the corresponding Company Option immediately prior to the Effective Time, <span style="font-style:italic">multiplied by</span> (B)&#160;the Exchange Ratio, and (ii)&#160;have an exercise price per share of Series A Common Stock (rounded up to the nearest whole cent) subject to such Rollover Option equal to (A)&#160;the exercise price per share of Company Common Stock applicable to the corresponding Company Option immediately prior to the Effective Time, <span style="font-style:italic">divided by</span> (B)&#160;the Exchange Ratio. Each Rollover Option shall be subject to the same terms and conditions (including applicable vesting, termination protection, expiration and forfeiture provisions) that applied to the corresponding Company Option immediately prior to the Effective Time, except for terms rendered inoperative by reason of the transactions contemplated by this Agreement or the Ancillary Documents or for such other immaterial administrative or ministerial changes as the SPAC Board (or the compensation committee of the SPAC Board) may determine in good faith are necessary to effectuate the administration of the Rollover Options. Such conversion shall occur in a manner consistent with Treasury Regulation <span style="white-space:nowrap">Section&#160;1.424-1,</span> such that such conversion will not constitute a &#8220;modification&#8221; of such Company Options for purposes of Section&#160;409A or Section&#160;424 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, by virtue of the Merger and without any action of any Party or any other Person, each Unvested Company RSU that is either (i)&#160;held by an employee of the Company as of the Effective Time or (ii)&#160;is held by a person that has been designated by the Company as a member of the Post-Closing Board, shall cease to represent the right to receive shares of Company Common Stock and shall be converted into a restricted stock unit denominated in shares of Series A Common Stock (each, a &#8220;<span style="font-weight:bold">Rollover RSU</span>&#8221;) in an amount and subject to such terms and conditions determined as set forth below. Each Rollover RSU shall represent the right to receive on settlement, a number of shares of Series A Common Stock (rounded down to the nearest whole share) equal to (A)&#160;the number of shares of Company Common Stock subject to the corresponding Company RSU immediately prior to the Effective Time, multiplied by (B)&#160;the Exchange Ratio. Each Rollover RSU shall be subject to the same terms and conditions (including applicable vesting, termination protection, expiration and forfeiture provisions) that applied to the corresponding Company RSU immediately prior to the Effective Time, except for terms rendered inoperative by reason of the transactions contemplated by this Agreement or the Ancillary Documents or for such other immaterial administrative or ministerial changes as the SPAC Board (or the compensation committee of the SPAC Board) may determine in good faith are necessary to effectuate the administration of the Rollover RSUs. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, (i)&#160;each Vested Company RSU issued and outstanding as of immediately prior to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Effective Time shall be canceled and extinguished and be converted into the right to receive a number of shares of Series A Common Stock equal to the Merger Consideration, and (ii)&#160;each Unvested Company RSU that is not converted into a Rollover RSU shall be cancelled at the Effective Time and forfeited for no consideration. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) At the Effective Time, SPAC shall assume the Company Equity Plan and (i)&#160;all Company Options shall no longer be outstanding and shall automatically be converted into Rollover Options, and each holder thereof shall cease to have any rights with respect thereto, except as otherwise expressly provided for in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>, (ii) all Company RSUs (whether vested or unvested) shall no longer be outstanding and each holder thereof shall cease to have any rights with respect thereto, except as otherwise expressly provided for in this Section&#160;2.6, (iii)&#160;all shares of Company Common Stock reserved for issuance pursuant to the Company Equity Plan shall automatically be cancelled, and (iv)&#160;no further grants shall be made pursuant to the Company Equity Plan following the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Prior to the Closing, the Company shall take, or cause to be taken, all necessary actions under the Company Equity Plan (and the underlying grant, award or similar agreements) to give effect to the provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_12">Section&#160;2.7. Closing Actions and Deliverables. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At least five Business Days prior to the Closing Date, SPAC shall appoint and engage Continental Stock Transfer&#160;&amp; Trust Company as exchange agent (the &#8220;<span style="font-weight:bold">Exchange Agent</span>&#8221;) for the purpose of exchanging Certificates, if any, representing the Company Shares, and each Company Share held in book-entry form on the stock transfer books of the Company immediately prior to the Effective Time, for the portion of the Merger Consideration issuable in respect of such Company Share pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span>, and on the terms and subject to the other conditions set forth in this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Prior to the Effective Time, SPAC shall deposit, or cause to be deposited, with the Exchange Agent, for the benefit of the Company Stockholders and for exchange in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> through the Exchange Agent, evidence of Series A Common Stock in book-entry form representing the portion of the Merger Consideration issuable pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span> in exchange for the Company Shares outstanding immediately prior to the Effective Time. All shares in book-entry form representing the portion of the Merger Consideration issuable pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span> deposited with the Exchange Agent shall be referred to in this Agreement as the &#8220;<span style="font-weight:bold">Exchange Fund</span>.&#8221; SPAC shall cause the Exchange Agent pursuant to irrevocable instructions, to deliver that portion of the Merger Consideration consisting of SPAC Common Stock out of the Exchange Fund in accordance with this Agreement. Except as contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> hereof, the Exchange Fund shall not be used for any other purpose. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Company Stockholder whose Company Shares have been converted into the right to receive a portion of the Merger Consideration pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span> shall be entitled to receive the portion of the Merger Consideration to which he, she or it is entitled on the date provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(d)</span> upon (i)&#160;surrender of a Certificate (or affidavit of loss, in lieu thereof, in the form required by the Exchange Agent) (including, for the avoidance of doubt, any documents or agreements required by the Exchange Agent) to the Exchange Agent, or (ii)&#160;delivery of an &#8220;agent&#8217;s message&#8221; in the case of Company Common Stock held in book-entry form (including, for the avoidance of doubt, any documents or agreements required by the Exchange Agent) to the Exchange Agent. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If any Certificates (or affidavit of loss, in lieu thereof, in the form required by the Exchange Agent) or an &#8220;agent&#8217;s message,&#8221; as applicable, is delivered to the Exchange Agent in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(c)</span>&#160;(i) at least one Business Day prior to the Closing Date, then SPAC and the Company shall take all necessary actions to cause the applicable portion of the Merger Consideration to be issued to the applicable Company Stockholder in book-entry form on the Closing Date, or (ii)&#160;less than one Business Day prior to or on or after the Closing Date, then SPAC and the Company (or the Surviving Corporation) shall take all necessary actions to cause the applicable portion of the Merger Consideration to be issued to the Company Stockholder in book-entry form within two Business Days after such delivery. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If any portion of the Merger Consideration is to be issued to a Person other than the Company Stockholder in whose name the surrendered Certificate is, or the transferred Company Shares in book-entry form are, registered, it shall be a condition to the issuance of the applicable portion of the Merger Consideration that (i)&#160;either such Certificate shall be properly endorsed or shall otherwise be in proper form for transfer, or such Company Shares in book-entry form shall be properly transferred, and (ii)&#160;the Person requesting such consideration pay to the Exchange Agent any transfer or similar Taxes required as a result of such consideration being issued to a Person other than the registered holder of such Certificate or Company Shares in book-entry form, or establish to the satisfaction of the Exchange Agent that such transfer or similar Taxes have been paid or are not payable. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) No interest will be paid or accrued on the Merger Consideration (or any portion thereof). From and after the Effective Time, until surrendered or transferred, as applicable, in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span>, each Company Share (other than, for the avoidance of doubt, the Company Shares cancelled in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(viii)</span>) shall solely represent the right to receive a portion of the Merger Consideration to which such Company Share is entitled pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(vii)</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) At the Effective Time, the stock transfer books of the Company shall be closed and there shall be no transfers of Company Shares that were outstanding immediately prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Any portion of the Exchange Fund that remains unclaimed by the Company Stockholders 12&#160;months following the Closing Date shall be delivered to SPAC or as otherwise instructed by SPAC, and any Company Stockholder who has not exchanged his, her or its Company Shares for the applicable portion of the Merger Consideration in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> prior to that time shall thereafter look only to SPAC for the issuance of the applicable portion of the Merger Consideration, without any interest thereon. None of SPAC, the Surviving Corporation or any of their respective Affiliates shall be liable to any Person in respect of any consideration delivered to a public official pursuant to any applicable abandoned property, unclaimed property, escheat or similar Law. Any portion of the Merger Consideration remaining unclaimed by the Company Stockholders immediately prior to such time when the amounts would otherwise escheat to or become property of any Governmental Entity shall become, to the extent permitted by applicable Law, the property of SPAC free and clear of any claims or interest of any Person previously entitled thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) None of the Exchange Agent, SPAC, the Surviving Corporation or any of their respective Affiliates shall be liable to any holder of SPAC Common Stock (or dividends or distributions with respect thereto) or cash delivered to a public official pursuant to any abandoned property, escheat or similar Law in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Notwithstanding any other provision of this Agreement, no fractional shares of SPAC Common Stock will be issued, and the number of shares of SPAC Common Stock each holder of shares of SPAC Common Stock or Company Shares, as applicable, is entitled to receive pursuant to <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> II</span> will be rounded down to the nearest whole share. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) At the Closing: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) SPAC shall deliver, or cause to be delivered to the Company, the written resignations of all of the directors and officers of SPAC and Merger Sub (other than those Persons identified as directors of SPAC immediately after the Effective Time, in accordance with the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.16</span>), effective as of the Effective Time; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) SPAC shall issue and deliver the SPAC Incentive Shares into the SPAC Incentive Share Escrow Account; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) SPAC shall issue and deliver 350,000 shares of Series A Common Stock to Pillsbury Winthrop Shaw Pittman LLP as partial compensation for services rendered in connection with the Merger, and 400,000 shares to Cantor Fitzgerald in full satisfaction of deferred underwriters fee due to Cantor; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) the Company shall deliver or cause to be delivered to SPAC (A)&#160;the Company <span style="white-space:nowrap">Lock-Up</span> Agreements, duly executed by the Persons listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(k)(ii)</span> of the Company Disclosure </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Schedules, and (B)&#160;as necessary, a duly executed certificate substantially in the form described in Treasury Regulations <span style="white-space:nowrap">Section&#160;1.1445-2(c)(3),</span> together with a notice to the Internal Revenue Service in accordance with the provisions of Treasury Regulations <span style="white-space:nowrap">Section&#160;1.897-2(h)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_13"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.8.</span> <span style="font-weight:bold">Withholding.</span><span style="font-weight:bold"> </span>SPAC, the Exchange Agent and any of their Affiliates shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any consideration payable pursuant to this Agreement and any Ancillary Document, such amounts as are required to be deducted and withheld under applicable Tax Law; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that before making any deduction or withholding pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8</span>, other than in connection with any deduction or withholding attributable to either (i)&#160;payments that are compensatory in nature or (ii)&#160;a failure of the Company to comply with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(k)(ii)</span>, SPAC shall use commercially reasonable efforts to give the Company at least three days prior written notice of any anticipated deduction or withholding to provide the Company with sufficient opportunity to provide any forms or other documentation from the applicable equity holders or take such other steps in order to avoid such deduction or withholding and shall reasonably consult and cooperate with the Company in good faith to attempt to reduce or eliminate any amounts that would otherwise be deducted or withheld pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.8</span>. To the extent that amounts are so withheld and remitted to the applicable Governmental Entity, such withheld amounts shall be treated for all purposes as having been paid to the Person in respect of which such deduction and withholding was made. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_14"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.9.</span> <span style="font-weight:bold">Dissenting Stockholders.</span><span style="font-weight:bold"> </span>Notwithstanding anything in this Agreement to the contrary, shares of Company Common Stock that are outstanding immediately prior to the Effective Time and that are held by any Person who is entitled to demand and properly demands appraisal of such shares (the &#8220;<span style="font-weight:bold">Dissenting Shares</span>&#8221;) pursuant to, and who complies in all respects with, Section&#160;262 of the DGCL shall not be converted into the right to receive such Persons&#8217; portions of the Merger Consideration, but rather the holders of such Dissenting Shares shall be entitled to payment by the Surviving Corporation of the &#8220;fair value&#8221; of such Dissenting Shares in accordance with Section&#160;262 of the DGCL; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that if any such holder shall fail to perfect or otherwise shall waive, withdraw or lose the right to appraisal under Section&#160;262 of the DGCL, then the right of such holder to be paid the fair value of such holder&#8217;s Dissenting Shares shall cease and such Dissenting Shares shall be deemed to have been converted as of the Effective Time into, and to have become exchangeable solely for, the right to receive the Merger Consideration (for the avoidance of doubt, without any interest thereon), upon proper delivery to the Exchange Agent of such Person&#8217;s Certificates (or affidavit of loss, in lieu thereof, in the form required by the Exchange Agent) or an &#8220;agent&#8217;s message,&#8221; as applicable (including, for the avoidance of doubt, any documents or agreements required by the Exchange Agent). The Company shall provide prompt notice to SPAC of any demands received by the Company for appraisal of any shares of Company Common Stock, withdrawals of such demands and any other instruments served pursuant to Section&#160;262 of the DGCL received by the Company. To the extent permitted by applicable Law, SPAC shall have the opportunity to participate with the Company in any and all negotiations and proceedings with respect to such demands. Prior to the Effective Time, neither the Company nor SPAC shall, without the prior written consent of the other party, voluntarily make any payment with respect to, or settle or offer to settle, any such demands or applications, waive any failure to timely deliver a written demand for appraisal, or agree to do any of the foregoing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_15">ARTICLE III. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.8</span>, except as set forth in the Company Disclosure Schedules, the Company hereby represents and warrants to the SPAC Parties, as of the date hereof and as of the Closing Date, as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_16">Section&#160;3.1. Organization and Qualification. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries are corporations duly organized or formed, as applicable, validly existing and in good standing under the Laws of their jurisdiction of incorporation. The Company and its Subsidiaries have the requisite corporate power and authority to own, lease and operate their properties and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to carry on the Business as presently conducted, except where the failure to have such power or authority would not, and would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) True and complete copies of the Governing Documents of the Company and its Subsidiaries have been made available to SPAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of the Company and its Subsidiaries are in full force and effect and neither the Company nor its Subsidiaries is in breach or violation of any provision set forth in its Governing Documents. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company and its Subsidiaries are duly qualified or licensed to transact business and are in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets owned, leased or operated by them, or the nature of the business conducted by them, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing (or the equivalent thereof) would not, and would not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_17">Section&#160;3.2. Capitalization. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(a)</span>&#160;of the Company Disclosure Schedules sets forth, as of the date of this Agreement, a true and complete statement of (i)&#160;the number and class or series (as applicable) of all of the Equity Securities of the Company issued and outstanding, (ii)&#160;the identity of the Persons that are the record and beneficial owners thereof (which does not include any Subsidiary of the Company), (iii)&#160;with respect to each Company Option, (A)&#160;the date of grant, (B)&#160;any applicable exercise (or similar) price, (C)&#160;the expiration date, (D)&#160;any applicable vesting schedule (including acceleration provisions), (E) the number of shares of Company Common Stock subject to the Company Option, (F)&#160;whether the Company Option is an Incentive Stock Option. All of the Company Shares have been duly authorized and validly issued and are fully paid and <span style="white-space:nowrap">non-assessable.</span> The Company Shares (1)&#160;were not issued in violation of the Governing Documents of the Company or any other Contract to which the Company is party or bound, (2)&#160;were not issued in violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person, (3)&#160;have been offered, sold and issued in compliance with applicable Law, including Securities Laws, and (4)&#160;are free and clear of all Liens (other than transfer restrictions under applicable Securities Law). Except for the Company Options set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(a)</span> of the Company Disclosure Schedules, as of the date of this Agreement, the Company has no outstanding (x)&#160;equity appreciation, phantom equity or profit participation rights, or (y)&#160;options, restricted stock, phantom stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts, in the case of each of clause (x)&#160;and (y), that would require the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of the Company or any of its Subsidiaries. There are no voting trusts, proxies or other Contracts with respect to the voting or transfer of the Company Shares. No Company Shares are held by a Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Other than the Equity Securities it holds in each of its Subsidiaries, the Company does not own or hold (of record, beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person or the right to acquire any such Equity Securities, and the Company is not a partner or member of any partnership, limited liability company or joint venture. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(c)</span> of the Company Disclosure Schedules sets forth a list of all Indebtedness of the Company and its Subsidiaries as of the date of this Agreement, including the principal amount of such Indebtedness, the outstanding balance as of the date of this Agreement and the debtor and creditor thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(d)</span> of the Company Disclosure Schedules sets forth a list of all Change of Control Payments of the Company and its Subsidiaries, identifying for each such Change of Control Payment (i)&#160;the Person eligible to receive such Change of Control Payment, (ii)&#160;an estimate of the total potential amount of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such Change of Control Payment, and (iii)&#160;the Contract or other arrangement pursuant to which such Change of Control Payment is payable or required to be made. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(e)</span> of the Company Disclosure Schedules, each Company Option and each Company RSU was granted in compliance in all material respects with all applicable Laws and all of the terms and conditions of the applicable Company Equity Plan, and each Company Option has an exercise price per share that is equal to or greater than the fair market value of a share of Company Common Stock on the date of such grant, determined in a manner consistent with Section&#160;409A of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_18"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.3.</span> <span style="font-weight:bold">Authority.</span><span style="font-weight:bold"> </span>The Company has the requisite corporate power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. Subject to obtaining the Company Stockholder Written Consent, the execution and delivery of this Agreement, the Ancillary Documents to which the Company is or will be a party and the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate action on the part of the Company. Subject to obtaining the Company Stockholder Written Consent, this Agreement and each Ancillary Document to which the Company is or will be a party has been or will be, upon execution thereof, as applicable, duly and validly executed and delivered by the Company and constitutes or will constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding agreement of the Company (assuming that this Agreement and the Ancillary Documents to which the Company is or will be a party are or will be upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto, as applicable), enforceable against the Company in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#8217; rights and subject to general principles of equity (&#8220;<span style="font-weight:bold">Enforceability Exceptions</span>&#8221;). On or prior to the date of this Agreement, the Company Board has duly adopted resolutions (i)&#160;determining that this Agreement and the transactions contemplated hereby and thereby are advisable and fair to, and in the best interest of the Company, and the Company Stockholders, (ii)&#160;approving the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby and thereby and (iii)&#160;resolving to recommend the approval of this Agreement and the transactions contemplated hereby and thereby by the holders of Company Shares entitled to vote thereon. No other corporate action or vote is required under applicable Law, the Governing Documents of the Company, on the part of the Company or any Company Stockholders, to enter into this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby, or to approve the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_19">Section&#160;3.4. Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.4(a)</span> of the Company Disclosure Schedules is a list of the Company&#8217;s Subsidiaries, together with their jurisdiction of incorporation, and a true and complete statement of the number and class or series (as applicable) of all of the Equity Securities of each Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All of the issued share capital, stock or other voting or equity securities of each Subsidiary have been duly authorized and validly issued and are fully paid and <span style="white-space:nowrap">non-assessable.</span> All of the ownership interests in each Subsidiary are owned by the Company, directly or indirectly, free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such ownership interests) and have not been issued in violation of preemptive or similar rights. There are no outstanding (i)&#160;subscriptions, calls, options, warrants, rights (including preemptive rights), puts or other securities of any Subsidiary convertible into or exchangeable or exercisable for shares or voting or equity securities of any Subsidiary, or any other Contracts to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound obligating the Company or any Subsidiary to issue or sell any shares of, other equity interests in or debt securities of, any Subsidiary, or (ii)&#160;equity equivalents, phantom stock, options, appreciation rights, stock units, profits interests or other rights to acquire from the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company or any Subsidiary, or other obligation of the Company or any Subsidiary to issue, any shares, voting or equity securities or securities convertible into or exchangeable for shares or voting or equity securities of any Subsidiary (the items in clauses (i)&#160;and (ii)&#160;being, collectively, &#8220;<span style="font-weight:bold">Subsidiary Securities</span>&#8221;). There are no outstanding obligations of the Company or any Subsidiary to repurchase, redeem or otherwise acquire any outstanding Subsidiary Securities. None of the Subsidiaries owns any equity, ownership, profit, voting or similar interest in, or any interest convertible, exchangeable or exercisable for, any equity, profit, voting or similar interest in, any Person. No Subsidiary is party to any shareholders agreement, voting agreement, proxies, registration rights agreement or other similar agreements relating to its equity interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_20">Section&#160;3.5. Financial Statements; Undisclosed Liabilities. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to SPAC true and complete copies of the audited consolidated balance sheets of the Company and its Subsidiaries as of December&#160;31, 2022 and December&#160;31, 2021 and the related audited consolidated statements of operations and comprehensive loss, and stockholders&#8217; deficit and cash flows of the Company and its Subsidiaries for each of the years then ended (collectively, the &#8220;<span style="font-weight:bold">Audited</span> <span style="font-weight:bold">Company Financial Statements</span>&#8221;), and the unaudited, consolidated balance sheets of the Company as of September&#160;30, 2023 and the related unaudited, consolidated statements of operations and comprehensive loss of the Company and its Subsidiaries for the fiscal year to date period then ended (the &#8220;<span style="font-weight:bold">Unaudited Company </span><span style="font-weight:bold">Financial Statements</span>&#8221; and, together with the Audited Company Financial Statements, the &#8220;<span style="font-weight:bold">Company Financial Statements</span>&#8221;). The Company Financial Statements (including the notes thereto) and, when delivered pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.7</span>, the Additional Company Financial Statements and any pro forma financial statements, (i)&#160;were prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto), (ii)&#160;fairly present, in all material respects, as applicable, the financial position, results of operations and cash flows of the Company and its Subsidiaries as at the date thereof and for the period indicated therein, except as otherwise specifically noted therein, (iii)&#160;in the case of the Audited Company Financial Statements and the Additional Company Financial Statements, when delivered pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.7</span>, were audited in accordance with the standards of the PCAOB and contain an unqualified report of the Company&#8217;s auditors, and (iv)&#160;comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the date hereof (including Regulation <span style="white-space:nowrap">S-X</span> or Regulation <span style="white-space:nowrap">S-K,</span> as applicable); <span style="font-style:italic">provided that</span>, the Unaudited Company Financial Statements do not include all of the notes or the information contained in such notes as required by GAAP for complete financial statements and are subject to normal <span style="white-space:nowrap">year-end</span> adjustments. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except (i)&#160;as set forth in the Company Financial Statements, (ii)&#160;for Liabilities incurred in the ordinary course of business as of September&#160;30, 2023 (none of which is a Liability for breach of contract, breach of warranty, tort, infringement or violation of Law), (iii)&#160;for Liabilities incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of the respective covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, (iv)&#160;either permitted to be incurred pursuant to or incurred in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>, (v)&#160;as set forth on the Company Disclosure Schedules, and (vi)&#160;for Liabilities that are not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole, the Company and its Subsidiaries have no Liabilities required by GAAP to be reflected or reserved against in the consolidated balance sheet as of September&#160;30, 2023 included in the Company Financial Statements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company has established and maintains a system of internal accounting controls that is designed to provide, in all material respects, reasonable assurance that (i)&#160;all transactions are executed in accordance with management&#8217;s authorization, and (ii)&#160;all transactions are recorded as necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for the Company&#8217;s and its Subsidiaries&#8217; assets. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in Section&#160;3.5(d) of the Company Disclosure Schedules, in the past three years, neither the Company nor any of its Subsidiaries has received any written complaint, allegation, assertion or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
claim, written or otherwise, that there is (i)&#160;a &#8220;significant deficiency&#8221; in the internal controls over financial reporting of the Company and its Subsidiaries, (ii)&#160;a &#8220;material weakness&#8221; in the internal controls over financial reporting of the Company and its Subsidiaries, or (iii)&#160;fraud, whether or not material, that involves management or other employees of the Company or its Subsidiaries who have a significant role in the internal controls over financial reporting of the Company and its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_21">Section&#160;3.6. Consents and Requisite Governmental Approvals; No Violations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval, waiver or authorization of, or designation, declaration or filing with, any Person or Governmental Entity is required on the part of the Company with respect to the Company&#8217;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which the Company is or will be party or the consummation of the transactions contemplated hereby or thereby, except for (i)&#160;compliance with and filings under the HSR Act or any filings with or approvals or clearances from any Governmental Entities that the Parties determine (acting reasonably) are required and advisable to consummate the transactions contemplated hereby and thereby, (ii)&#160;the filing with the SEC of (A)&#160;the Registration Statement/Proxy Statement and the declaration of the effectiveness thereof by the SEC, and (B)&#160;such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, (iii)&#160;such filings with and approvals of Nasdaq to permit Series A Common Stock to be issued in accordance with this Agreement to be listed on Nasdaq, (iv)&#160;filing of the Certificate of Merger and filing of the charter amendment to effect the conversion of the Company Preferred Stock, (v)&#160;obtaining the Company Stockholder Written Consent, or (vi)&#160;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a Company Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.6(a)</span>, neither the execution, delivery or performance by the Company of this Agreement nor the Ancillary Documents to which the Company is or will be a party, nor the consummation of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of time or both) (i)&#160;result in any breach of any provision of the Company&#8217;s Governing Documents, (ii)&#160;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of (A)&#160;any Material Contract to which the Company or any of its Subsidiaries is a party, or (B)&#160;any Material Permits, (iii)&#160;violate, or constitute a breach under, any Order or applicable Law to which the Company or any of its Subsidiaries or any of their respective properties or assets are bound, or (iv)&#160;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) or Equity Securities of the Company or any of its Subsidiaries, except, in the case of any of clauses (ii)&#160;through (iv)&#160;above, as would not be material to the Company and its Subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_22"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.7.</span> <span style="font-weight:bold">Permits.</span><span style="font-weight:bold"> </span>The Company and its Subsidiaries have all Permits that are required to own, lease or operate their properties and assets and to conduct the Business as currently conducted, except where the failure to obtain the same would not result in a Company Material Adverse Effect (the &#8220;<span style="font-weight:bold">Material Permits</span>&#8221;). Except as is not and would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole, (a)&#160;each Material Permit is in full force and effect in accordance with its terms, and (b)&#160;no written notice of revocation, cancellation or termination of any Material Permit has been received by the Company or any of its Subsidiaries. The Company and its Subsidiaries are, and (where applicable) have been for the past three (3)&#160;years prior to the date hereof, in all material respects fulfilling and performing their obligations under each of the Material Permits held by them or to which they are bound. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_23">Section&#160;3.8. Material Contracts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.8(a)</span> of the Company Disclosure Schedules sets forth a list of the following Contracts to which the Company or any of its Subsidiaries is, as of the date of this Agreement, a party (each Contract required to be set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.8(a)</span> of the Company Disclosure Schedules, together with each of the Contracts entered into after the date of this Agreement that would be required to be set forth on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.8(a)</span> of the Company Disclosure Schedules if entered into prior to the execution and delivery of this Agreement, collectively, the &#8220;<span style="font-weight:bold">Material Contracts</span>.&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any Contract relating to Indebtedness of the Company or any of its Subsidiaries or to the placing of a Lien (other than any Permitted Lien) on any assets or properties of the Company or any of its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) any Contract under which the Company or any of its Subsidiaries is lessee of or holds or operates, in each case, any tangible property (other than real property), owned by any other Person, except for any lease or agreement under which the aggregate annual rental payments do not exceed $250,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) any Contract under which the Company or any of its Subsidiaries is lessor of or permits any third party to hold or operate, in each case, any tangible property (other than real property), owned or controlled by the Company or any of its Subsidiaries, except for any lease or agreement under which the aggregate annual rental payments do not exceed $250,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) any joint venture, profit-sharing, partnership, collaboration, <span style="white-space:nowrap">co-promotion,</span> commercialization, material research and development or other similar, Contract (including any such Contract that governs the research, development, ownership, enforcement, use, or other exploitation of any Intellectual Property Rights or other assets material to the Business); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) any Contract that (A)&#160;limits or purports to limit, in any respect, the freedom of the Company or any of its Subsidiaries to engage or compete in any line of business or with any Person or in any area or that would so limit or purport to limit, in any respect, the operations of SPAC or any of its Affiliates after the Closing, (B)&#160;contains any exclusivity, &#8220;most favored nation&#8221; or similar provisions, obligations or restrictions, or (C)&#160;contains any other provisions restricting or purporting to restrict the ability of the Company or any of its Subsidiaries to sell, manufacture, develop, commercialize, test or research the Company Products, directly or indirectly through third parties, in any respect or that would so limit or purports to limit, in any respect, SPAC or any of its Affiliates after the Closing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) any Contract requiring any future capital commitment or capital expenditure (or series of capital expenditures) by the Company or any of its Subsidiaries in an amount in excess of (A) $500,000 annually, or (B) $1,500,000 over the life of the agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) any Contract requiring the Company or any of its Subsidiaries to guarantee the Liabilities of any Person (other than the Company or a Subsidiary) or pursuant to which any Person (other than the Company or a Subsidiary) has guaranteed the Liabilities of the Company or any of its Subsidiaries, in each case in excess of $500,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) any Contract under which the Company or any of its Subsidiaries has, directly or indirectly, made or agreed to make any loan, advance, or assignment of payment to any Person or made any capital contribution to, or other investment in, any Person, in each case in excess of $500,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) any Contract required to be disclosed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20</span> of the Company Disclosure Schedules; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) any Contract with any Person (A)&#160;pursuant to which the Company or any of its Subsidiaries (or SPAC or any of its Affiliates after the Closing) may be required to pay milestones, royalties or other contingent payments based on any research, testing, development, regulatory filings or approval, sale, distribution, commercial manufacture or other similar occurrences, developments, activities or events, in each case, relating to Company Products, or (B)&#160;under which the Company or any of its Subsidiaries grants to any Person any right of first refusal, right of first negotiation, option to purchase, option to license or any other similar rights with respect to any Company Product or any Company Business Intellectual Property; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) any Contract entered into by the Company or any of its Subsidiaries that constitutes a collective bargaining agreement or any other agreement executed between the Company or its Subsidiary, as applicable, and a union or similar organization; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) any Contract governing the terms of the employment, engagement or services of any current director, manager, officer, employee, or Contingent Worker of the Company whose annual base salary (or, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in the case of a Contingent Worker, actual or anticipated annual base compensation) is in excess of $150,000, excluding any such Contract that either (A)&#160;is terminable by the Company at will or (B)&#160;that provides for severance of 30 days or less; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) any Contract providing for any Change of Control Payment of the type described in clause (a)&#160;of the definition thereof; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) any Contract for the disposition of any portion of the assets or business of the Company or any of its Subsidiaries or for the acquisition by the Company or any of its Subsidiaries of the assets or business of any other Person (other than acquisitions or dispositions made in the ordinary course of business), or under which the Company or any of its Subsidiaries has any continuing obligation with respect to an <span style="white-space:nowrap">&#8220;earn-out,&#8221;</span> contingent purchase price or other contingent or deferred payment obligation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) any Contract pursuant to which the Company or any of its Subsidiaries (A)&#160;obtains any right to, or covenant not to be sued under, any Intellectual Property Right (other than any license for <span style="white-space:nowrap"><span style="white-space:nowrap">Off-the-Shelf</span></span> Software), or (B)&#160;grants any right to, or covenant not to be sued under, any Intellectual Property Right; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) any settlement, conciliation or similar Contract (A)&#160;the performance of which would be reasonably likely to involve any payments after the date of this Agreement by the Company or any of its Subsidiaries, (B)&#160;with a Governmental Entity or which relates to alleged criminal wrongdoing, (C)&#160;that imposes or is reasonably likely to impose, at any time in the future, any material, <span style="white-space:nowrap">non-monetary</span> obligations on the Company or any of its Subsidiaries (or SPAC or any of its Affiliates after the Closing), or (D)&#160;which requires the Company or any of its Subsidiaries to accept or concede material injunctive relief; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) any other Contract the performance of which requires either (A)&#160;annual payments by the Company or any of its Subsidiaries in excess of $500,000, or (B)&#160;aggregate payments by the Company or any of its Subsidiaries in excess of $1,500,000 over the life of the agreement and, in each case, that is not terminable by the Company or its Subsidiary, as applicable, without penalty upon less than 30 days&#8217; prior written notice. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.8(b)</span> of the Company Disclosure Schedules, (i)&#160;each Material Contract is valid and binding on the Company or its Subsidiary, as applicable, and, to the knowledge of the Company, the counterparty thereto, and is in full force and effect, and (ii)&#160;the Company and its Subsidiaries and, to the knowledge of the Company, the counterparties thereto, are not in material breach of, or default under, any Material Contract, and, to the knowledge of the Company, there are no facts or circumstances which would, or which would reasonably be expected to, lead to such breach or default. As of the date of this Agreement, no written notice of termination has been received by the Company with respect to any Material Contract, and to the knowledge of the Company, none of the other parties to any Material Contract has indicated to the Company that it intends to terminate the Material Contract or to terminate or reduce its business dealings with the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_24"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.9.</span> <span style="font-weight:bold">Absence of Changes.</span><span style="font-weight:bold"> </span>During the period beginning on September&#160;30, 2023 and ending on the date of this Agreement, (a)&#160;except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.9(a)</span> of the Company Disclosure Schedules, no Company Material Adverse Effect has occurred, and (b)&#160;except as expressly contemplated by this Agreement, any Ancillary Document, in connection with the transactions contemplated hereby and thereby, (i)&#160;the Company and its Subsidiaries have conducted the Business in the ordinary course in all material respects (including, for the avoidance of doubt, recent past practice in light of <span style="white-space:nowrap">COVID-19),</span> and (ii)&#160;neither the Company nor any of its Subsidiaries has taken any action that would require the consent of SPAC if taken during the period from the date of this Agreement until the Closing pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)(i)</span>, <span style="text-decoration:underline">(ii)</span>, <span style="text-decoration:underline">(iv)</span>, <span style="text-decoration:underline">(v)</span>, <span style="text-decoration:underline">(vii)</span>, <span style="text-decoration:underline">(ix)</span>, <span style="text-decoration:underline">(x)</span> (solely relating to the Company&#8217;s directors and officers), <span style="text-decoration:underline">(xii)</span>, <span style="text-decoration:underline">(xiii),</span> <span style="text-decoration:underline">(xiv)</span>, <span style="text-decoration:underline">(xv)</span><span style="text-decoration:underline"></span>&#160;and <span style="text-decoration:underline">(xviii)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_25"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.10.</span> <span style="font-weight:bold">Litigation.</span><span style="font-weight:bold"> </span>Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.10</span> of the Company Disclosure Schedules, there is (and for the past three years there has been) (a)&#160;no Proceeding pending or, to the Company&#8217;s knowledge, threatened against the Company, any of its Subsidiaries or any of their respective directors or officers, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affecting any of the Company&#8217;s or its Subsidiaries&#8217; respective assets or properties, that if adversely decided or resolved, has been or would reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries taken as a whole, and, to the Company&#8217;s knowledge, no facts exist that would reasonably be expected to form the basis for any such Proceeding; (b)&#160;no material Order to which the Company, its Subsidiaries, their respective directors and officers or any of the Company&#8217;s or its Subsidiaries&#8217; respective properties or assets is subject; (c)&#160;no Proceeding by the Company or any of its Subsidiaries against any other Person, and no such Proceeding is or has been threatened in writing; (d)&#160;no settlement or similar agreement that imposes any material ongoing obligation or restriction on the Company or any of its Subsidiaries or the operation of the Business; and (e)&#160;no pending or, to the Company&#8217;s knowledge, threatened, audit, examination or investigation by any Governmental Entities in respect of the Company or any of its Subsidiaries or any of their respective properties or assets, or any of the directors or officers of the Company or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_26"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.11.</span> <span style="font-weight:bold">Compliance with Applicable Law.</span><span style="font-weight:bold"> </span>The Company and its Subsidiaries (a)&#160;conduct (and for the past three years have conducted) the Business in accordance with all Laws and Orders applicable to them and are not in violation of any such Law or Order, and (b)&#160;have not received any written communications from a Governmental Entity and, to the Company&#8217;s knowledge, there is no such pending communication, that alleges that the Company or any of its Subsidiaries is not in compliance with any such Law or Order, except in each case of clauses (a)&#160;and (b), as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_27">Section&#160;3.12. Employee Benefit Plans. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(a)</span> of the Company Disclosure Schedules sets forth a true and complete list of all material Employee Benefit Plans. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) True, complete and correct copies of the following documents, with respect to each material Employee Benefit Plan, where applicable, have been delivered to SPAC (i)&#160;all documents embodying or governing such Employee Benefit Plan (or for unwritten Employee Benefit Plans, a written description of the material terms of such Employee Benefit Plan) and any funding medium for the Employee Benefit Plan, (ii)&#160;the most recent Internal Revenue Service determination or opinion letter, (iii)&#160;the most recently filed Form 5500, (iv)&#160;the most recent actuarial valuation report, (v)&#160;the most recent summary plan description (or other descriptions provided to employees) and all modifications thereto, (vi)&#160;the last three years of <span style="white-space:nowrap">non-discrimination</span> testing results, and (vii)&#160;all <span style="white-space:nowrap">non-routine</span> correspondence to and from any Governmental Entity in the last three years. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Employee Benefit Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or approval letter from the Internal Revenue Service with respect to such qualification, or may rely on an opinion letter issued by the Internal Revenue Service with respect to a prototype plan adopted in accordance with the requirements for such reliance and, to the Company&#8217;s knowledge, no event or omission has occurred that would be reasonably likely to cause any such Employee Benefit Plan to lose such qualification. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each Employee Benefit Plan is and has been established, operated and administered in all material respects in accordance with applicable Laws and with its terms, including ERISA, the Code and the Affordable Care Act. No Employee Benefit Plan is, or since its inception has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance or similar program, or been the subject of any self-correction under any such program. As of the date hereof, no litigation or governmental administrative proceeding or audit (other than those relating to routine claims for benefits) is pending or, to the knowledge of the Company, threatened with respect to any Employee Benefit Plan. All payments or contributions required to have been made with respect to all Employee Benefit Plans either have been timely made in all material respects or have been accrued in all material respects in accordance with the terms of the applicable Employee Benefit Plan and applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company, its Subsidiaries nor any ERISA Affiliate (or any predecessor thereof) has, since the date the Company was organized, maintained, contributed to, or been required to contribute to or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
had any liability (whether contingent or otherwise, including on account of any ERISA Affiliate) with respect to (i)&#160;any employee benefit plan that is or was subject to Title IV of ERISA, Section&#160;412 of the Code or Section&#160;302 of ERISA, (ii)&#160;a &#8220;multiemployer plan&#8221; (within the meaning of Section&#160;3(37) of ERISA), (iii)&#160;any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv)&#160;any &#8220;multiple employer plan&#8221; (within the meaning of Section&#160;210 of ERISA or Section&#160;413(c) of the Code), or (v)&#160;any &#8220;multiple employer welfare arrangement&#8221; (as such term is defined in Section&#160;3(40) of ERISA). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(f)</span> of the Company Disclosure Schedules, neither the Company nor its Subsidiaries provide or has any obligation to provide health care or any other <span style="white-space:nowrap">non-pension</span> benefits to any employees after their employment is terminated (other than as required by Part 6 of Subtitle B of Title I of ERISA, Section&#160;4980B of the Code and any similar state Law and for which the recipient pays the full cost of coverage). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Employee Benefit Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of Section&#160;409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section&#160;409A of the Code and applicable guidance thereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.12(h)</span> of the Company Disclosure Schedules, neither the execution or delivery of this Agreement or any Ancillary Document to which the Company is or will be a party, the approval of this Agreement by the Company Stockholders, nor the consummation of the transactions contemplated by this Agreement or any Ancillary Document to which the Company is or will be a party, could (either alone or in combination with any other event) reasonably be expected to (i)&#160;result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to, or result in the forgiveness of any indebtedness of, any current or former director, manager, officer, employee, individual independent contractor or other individual service provider of the Company or any of its Subsidiaries under any Employee Benefit Plan, (ii)&#160;further restrict any rights of the Company or its Subsidiaries to merge, amend or terminate any Employee Benefit Plan, or (iii)&#160;result in any &#8220;parachute payment&#8221; as defined in Section&#160;280G(b)(2) of the Code (whether or not such payment is considered to be reasonable compensation for services rendered). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries has any obligation to make any tax <span style="white-space:nowrap">&#8220;gross-up&#8221;</span> or similar &#8220;make whole&#8221; payments to any service provider with respect to any tax under Section&#160;4999 or 409A of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) No Employee Benefit Plan is subject to the laws of any jurisdiction outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_28"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.13.</span> <span style="font-weight:bold">Environmental Matters.</span><span style="font-weight:bold"> </span>Except as would not have a Company Material Adverse Effect: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company is (and where still relevant, was) in compliance with all applicable material Environmental Laws (including whether applicable to its operations and the use or condition of any real property currently or formerly owned or leased). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its Subsidiaries has received any written notice or communication from any Governmental Entity or any other Person regarding any actual, alleged or potential violation or remediation requirement in any respect of, or a failure to comply in any respect with, any Environmental Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There is (and for the past three years there has been) no Proceeding pending or, to the Company&#8217;s knowledge, threatened against the Company, any of its Subsidiaries or any of their respective directors and officers pursuant to Environmental Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) To the knowledge of the Company, there are no underground storage tanks, landfills, current or former waste disposal areas or polychlorinated biphenyls or any other condition or contamination at or on any material real property currently or formerly owned or leased by the Company that require reporting, investigation, cleanup, remediation or any other type of response action by a Group Company pursuant to any Environmental Laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) There has not been, whether by the Company or any of its Subsidiaries, any manufacture, release, treatment, storage, disposal, arrangement for disposal, transport or handling of, contamination by, or exposure of any Person to, any hazardous, toxic, explosive or radioactive material, substance, waste or other pollutant that is regulated by, or may give rise to Liability pursuant to any Environmental Law, including any petroleum products or byproducts, asbestos, lead, polychlorinated biphenyls, <span style="white-space:nowrap">per-</span> and poly-fluoroakyl substances, or radon. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company has made available to SPAC copies of all material environmental, health and safety reports and documents that were prepared for the Company or its Subsidiaries by third parties and are in the Company&#8217;s or its Subsidiaries&#8217; possession relating to the operations, properties or facilities of the Company and its Subsidiaries in the past three (3)&#160;years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_29">Section&#160;3.14. Intellectual Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.14(a)</span> of the Company Disclosure Schedules sets forth a true and complete list of (i)&#160;all currently issued or pending Company Registered Intellectual Property, and (ii)&#160;any Patent included in the Company Licensed Intellectual Property that is exclusively licensed (including by field of use, territory or other manner) to the Company or any of its Subsidiaries (&#8220;<span style="font-weight:bold">Licensed Patents</span>&#8221;), specifying as to each such item, as applicable, (A)&#160;the record owner of such item, (B)&#160;the jurisdictions in which such item has been issued, registered or filed, (C)&#160;the issuance, registration or application date, as applicable, for such item, and (D)&#160;the issuance, registration or application number, as applicable, for such item. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All fees and filings necessary as of the date of this Agreement to maintain any application or registration, issuance, or grant of any Company Registered Intellectual Property and, to the Company&#8217;s knowledge, any Licensed Patents, have been timely submitted to the relevant patent office or other Governmental Entity, as applicable. As of the date of this Agreement, no item of the Company Registered Intellectual Property or, to the Company&#8217;s knowledge, Licensed Patents are lapsed, abandoned or cancelled. As of the date of this Agreement, the Company Registered Intellectual Property and, to the Company&#8217;s knowledge, Licensed Patents are not the subject of any pending Proceedings, including litigation, interference, <span style="white-space:nowrap">re-examination,</span> <span style="font-style:italic">inter parties</span> review, reissue, opposition, nullity or cancellation proceedings and, to the Company&#8217;s knowledge, no such Proceedings are threatened by any Governmental Entity or any other Person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.14(c)</span> of the Company Disclosure Schedules, the Company and its Subsidiaries exclusively own all right, title and interest in and to all Company Owned Intellectual Property, free and clear of all Liens (other than Permitted Liens) and hold all right, title and interest in and to all of the Company&#8217;s or its applicable Subsidiary&#8217;s rights under all Company Licensed Intellectual Property free and clear of any Lien (other than Permitted Liens). For each Patent included in the Company Owned Intellectual Property, each inventor listed or required to be listed on the Patent has assigned his or her rights to the Company or the relevant Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company Business Intellectual Property, to the Company&#8217;s knowledge, constitutes all of the Intellectual Property Rights that are necessary to enable the Company and its Subsidiaries to conduct the Business as currently conducted and as currently contemplated to be conducted. The Company Registered Intellectual Property and Licensed Patents are currently in compliance with formal legal requirements of the applicable intellectual property office and are not subject to any maintenance fees or taxes or actions falling due within 90 days after the Closing Date, with the exception of responses, patent maintenance fees, and other filings due in the ordinary course of intellectual property prosecution with the applicable intellectual property offices. All Company Registered Intellectual Property and, to the knowledge of the Company, Licensed Patents are subsisting, and if registered, issued or granted, are valid and enforceable. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company&#8217;s and its Subsidiaries&#8217; former and current employees, consultants, advisors and independent contractors who independently or jointly contributed to or otherwise participated in the authorship, invention, creation, improvement, modification or development of any Intellectual Property Rights for or on behalf of the Company (each such person, a &#8220;<span style="font-weight:bold">Creator</span>&#8221;) have executed written agreements </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
assigning to the Company or its relevant Subsidiary, as applicable, all Intellectual Property Rights authored, invented, created, improved, modified or developed by such person in the course of such Creator&#8217;s employment or other engagement with the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company and its Subsidiaries have taken reasonable steps to safeguard and maintain the secrecy of any trade secrets, confidential <span style="white-space:nowrap">know-how</span> and other confidential information owned by or licensed to the Company and its Subsidiaries. Without limiting the foregoing, the Company and its Subsidiaries have not disclosed any material trade secrets, confidential <span style="white-space:nowrap">know-how</span> or confidential information to any other Person unless such disclosure was under an appropriate written agreement containing appropriate limitations on use, reproduction and disclosure of such trade secret, confidential <span style="white-space:nowrap">know-how</span> or confidential information or was otherwise made subject to an appropriate duty of confidence. To the Company&#8217;s knowledge, as of the date of this Agreement there has been no violation or unauthorized access to or disclosure of any trade secrets, confidential <span style="white-space:nowrap">know-how</span> or confidential information of or in the possession of the Company or any of its Subsidiaries, or of any written obligations with respect to such. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) None of the Company Owned Intellectual Property and, to the Company&#8217;s knowledge, none of the Company Licensed Intellectual Property is subject to any outstanding Order that restricts in any manner the use, sale, transfer, licensing or exploitation thereof by the Company and its Subsidiaries or affects the validity, use or enforceability of any such Company Business Intellectual Property. The consummation of the transactions contemplated by this Agreement will not alter, encumber, impair or extinguish any Company Owned Intellectual Property or the Company&#8217;s or its applicable Subsidiary&#8217;s rights under any Company Licensed Intellectual Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) To the Company&#8217;s knowledge, neither the Company nor its Subsidiaries nor any actual or currently contemplated design, development, manufacturing, reproduction, use, marketing, offer for sale, sale, importation, exportation, distribution or other exploitation of any Company Product infringes, misappropriates or otherwise violates (or in the past infringed, misappropriated or otherwise violated) any Intellectual Property Rights of any other Person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the past three years, there has been no Proceeding pending against the Company or any of its Subsidiaries nor has the Company or any of its Subsidiaries received any written communications nor, to the knowledge of the Company, is any Proceeding threatened against the Company or any of its Subsidiaries (i)&#160;alleging that the Company or any of its Subsidiaries has infringed, misappropriated or otherwise violated any Intellectual Property Rights of any other Person, or (ii)&#160;challenging the validity, enforceability, use or exclusive ownership of any Company Owned Intellectual Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.14(j)</span> of the Company Disclosure Schedules, to<span style="font-weight:bold"> </span>the Company&#8217;s knowledge, no Person is (or was at any time in the past three years) infringing, misappropriating or otherwise violating any Company Owned Intellectual Property or the Licensed Patents. For the past three years, neither the Company nor any of its Subsidiaries has made any claim against any Person alleging any infringement, misappropriation or other violation of any Company Owned Intellectual Property or Licensed Patents. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company and its Subsidiaries own or have obtained, possess and are in compliance with valid licenses to use all of the Software present on the computers and other Software-enabled electronic devices that they own or lease or that are otherwise under the control of the Company and its Subsidiaries and used by them in connection with the Business, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries taken as a whole. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.14(l)</span> of the Company Disclosure Schedules contains a true and complete list of any and all Company Owned Intellectual Property or Licensed Patent that was created, developed or reduced to practice, or is being created, developed or reduced to practice, (i)&#160;pursuant to, or in connection with, any Contract with any Governmental Entity or Governmental Entity-affiliated entity, or university, college or other educational institution, or (ii)&#160;using any funding or facilities of any Governmental Entity or Governmental Entity-affiliated entity, or university, college or other educational institution (collectively, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#8220;<span style="font-weight:bold">Government Funded IP</span>&#8221;). To the Company&#8217;s knowledge, the applicable licensors of the Licensed Patents included in the Government Funded IP, have taken any and all actions necessary to obtain, secure, maintain, enforce and protect the Company&#8217;s or its applicable Subsidiary&#8217;s right, title and interest in, to and under all Government Funded IP, and the Company and its Subsidiaries, and to the Company&#8217;s knowledge the applicable licensors of any Government Funded IP, have complied with any and all any Intellectual Property Rights disclosure and/or licensing obligations under any applicable contract referenced in clause (i)&#160;above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_30">Section&#160;3.15. Labor Matters. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(a)</span><span style="text-decoration:underline"></span>&#160;of the Company Disclosure Schedules contains a complete and accurate list of all employees of the Company and its Subsidiaries as of the date of this Agreement, setting forth for each employee: (i)&#160;the employee&#8217;s position or title, (ii)&#160;the entity that employs the individual, (iii)&#160;whether classified as exempt or <span style="white-space:nowrap">non-exempt</span> for wage and hour purposes, (iv)&#160;the employee&#8217;s actual annual base salary (if paid on a salary basis), hourly rate (if paid on an hourly basis) or commission rate (if paid on a purely commission basis), as applicable, (v)&#160;bonus and commission potential, (vi)&#160;for any part-time employee, average scheduled hours per week, (vii)&#160;date of hire, (viii)&#160;business location, (ix)&#160;status (<span style="font-style:italic">i.e.</span>, active or inactive and if inactive, the type of leave and estimated duration), and (x)&#160;any visa or work permit status and the date of expiration, if applicable. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and its Subsidiaries are, and for the past three years have been, in compliance in all material respects with all applicable Laws and regulations respecting labor and employment matters, including fair employment practices, pay equity, the classification of independent contractors, workplace safety and health, work authorization and immigration, unemployment compensation, workers&#8217; compensation, affirmative action, terms and conditions of employment, employee leave and wages and hours, including payment of minimum wages and overtime. Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(b)</span> of the Company Disclosure Schedules, the Company and its Subsidiaries are not delinquent in any payments to any employee or Contingent Worker for any wages, salaries, commissions, bonuses, severance, fees or other direct compensation, as applicable, due with respect to any services performed for it or amounts required to be reimbursed to such employees or Contingent Workers, in each case, except as would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Currently and within the three years preceding the date of this Agreement, the Company and its Subsidiaries have not been party to or, to the Company&#8217;s knowledge, the subject of any litigation, arbitration, mediation, governmental audit, administrative agency proceeding, private dispute resolution proceeding or governmental investigation, in each case relating to employment or labor matters concerning the employees or Contingent Workers of the Company and its Subsidiaries, in each case, except as would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole, and the Company and its Subsidiaries have not conducted an internal investigation or authorized a third-party investigation (including those concerning allegations of employment discrimination, retaliation, noncompliance with wage and hour Laws, the misclassification of independent contractors, violation of restrictive covenants, sexual harassment or misconduct, other unlawful harassment, or unfair labor practices), in each case, except as would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the past three years, the Company and its Subsidiaries have not experienced a &#8220;plant closing,&#8221; &#8220;business closing,&#8221; or &#8220;mass layoff&#8221; or similar group employment loss as defined in the federal WARN Act or any similar state or local Law affecting any site of employment of the Company or its Subsidiaries or one or more facilities or operating units within any site of employment or facility of the Company or its Subsidiaries. During the <span style="white-space:nowrap">90-day</span> period preceding the date of this Agreement, no employee has suffered an &#8220;employment loss&#8221; as defined in the WARN Act with respect to the Company or its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and its Subsidiaries are not a party to any collective bargaining agreements or other agreements with any labor organization, labor union, works council or other employee representative or any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
other Contract with a labor union, labor organization, works council, employee delegate, representative or other employee collective group, nor to the knowledge of the Company is there any duty on the part of the Company or any of its Subsidiaries to bargain with any labor union, labor organization, works council, employee delegate, representative or other employee collective group. For the past three years, there has been no actual or, to the Company&#8217;s knowledge, threatened unfair labor practice charges, material grievances, arbitrations, strikes, lockouts, work stoppages, slowdowns, picketing, hand billing or other material labor disputes against the Company or any of its Subsidiaries. To the Company&#8217;s knowledge, for the past three years, there have been no labor organizing activities with respect to any employees of the Company or any of its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.15(f)</span> of the Company Disclosure Schedules, to the knowledge of the Company, no Key Employee has provided written notice, as of the date of this Agreement, of a plan to terminate his or her employment with such entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) In the last three years, to the knowledge of the Company, no allegations of sexual harassment or sexual misconduct have been made to the Company or any of its Subsidiaries against any officer, executive or management-level employee of the Company or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_31"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.16.</span> <span style="font-weight:bold">Insurance.</span><span style="font-weight:bold"> </span><span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.16</span> of the Company Disclosure Schedules sets forth a list of all material policies of fire, liability, workers&#8217; compensation, property, casualty and other forms of material insurance owned or held by the Company or its Subsidiaries as of the date of this Agreement. All such policies are in full force and effect, all premiums due and payable thereon as of the date of this Agreement have been paid in full as of the date of this Agreement and true and complete copies of all such policies have been made available to SPAC. Neither the Company nor any of its Subsidiaries is in breach or otherwise in default under the terms of such policies and, to the Company&#8217;s knowledge, no facts or circumstances exist which would result in any such breach or default, in each case, which has voided, would void, or which might reasonably be expected to void, any coverages under such policies. As of the date of this Agreement, no claim by the Company or any of its Subsidiaries is pending under any such policies as to which coverage has been questioned, denied or disputed, or rights reserved to do so, by the underwriters thereof, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole. The coverages provided by such policies are usual and customary in amount and scope for the Business as currently conducted and sufficient to comply with any insurance required to be maintained under Material Contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_32">Section&#160;3.17. Tax Matters. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries have prepared and filed all material Tax Returns required to have been filed by them, all such Tax Returns are true and complete in all material respects and prepared in compliance in all material respects with all applicable Laws, and the Company and its Subsidiaries have paid all material Taxes required to have been paid by them regardless of whether shown on a Tax Return. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and its Subsidiaries have timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and paid in connection with amounts paid or owing to any employee, individual independent contractor, other service provider, equity interest holder or other third-party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company and its Subsidiaries are not currently the subject of a Tax audit or examination, and have not been informed in writing of the commencement or anticipated commencement of any Tax audit or examination that has not been resolved or completed, in each case, with respect to material Taxes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company and its Subsidiaries have not consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax Returns obtained in the ordinary course of business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> income Tax Law), private letter ruling, technical advice memoranda or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
similar agreement or ruling has been entered into or issued by any Tax Authority with respect to the Company or any of its Subsidiaries which agreement or ruling would be effective after the Closing Date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company and its Subsidiaries are not nor have they been a party to any &#8220;listed transaction&#8221; as defined in Section&#160;6707A of the Code and Treasury Regulations <span style="white-space:nowrap">Section&#160;1.6011-4</span> (or any corresponding or similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> income Tax Law). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for Taxes on any assets of the Company or its Subsidiaries other than Permitted Liens. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor any of its Subsidiaries has been a distributing corporation or a controlled corporation in a transaction purported or intended to be governed by Section&#160;355 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Neither the Company nor any of its Subsidiaries (i)&#160;has been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was the Company), or (ii)&#160;has any material Liability for the Taxes of any Person (other than the Company or any of its Subsidiaries, as applicable) under <span style="white-space:nowrap">Section&#160;1.1502-6</span> of the Treasury Regulations (or any similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> Law), as a transferee or successor, by Contract or otherwise (other than any Contract entered into in the ordinary course of business, the principal purpose of which does not relate to Taxes). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by any Tax Authority in a jurisdiction where the Company and its Subsidiaries do not file a particular type of Tax Return or pay a particular type of Tax that the Company or any of its Subsidiaries is or may be required to file such type of Tax Return in or pay such type of Tax to that jurisdiction, which claims have not been resolved or withdrawn. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreement (other than one that is included in a Contract entered into in the ordinary course of business that is not primarily related to Taxes) and neither the Company nor any of its Subsidiaries is a party to any joint venture, partnership or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company and its Subsidiaries are tax residents only in their respective jurisdiction of formation, and are not managed or controlled outside such jurisdiction for income Tax purposes, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Neither the Company nor any of its Subsidiaries has a branch, permanent establishment (within the meaning of an applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country in which it is organized, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company and its Subsidiaries will not be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&#160;change in, or use of improper, method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing Date; (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law) executed on or prior to the Closing Date; (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;deferred revenue or prepaid amount received on or prior to the Closing Date outside of the ordinary course of Business; (v)&#160;intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law); or (vi)&#160;election under Section&#160;965(h)&#160;of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) Neither the Company nor any of its Subsidiaries has deferred any material Taxes under the CARES Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) All related party transactions involving the Company or any of its Subsidiaries are at arm&#8217;s length in material compliance with Section&#160;482 of the Code, the Treasury Regulations promulgated thereunder and any similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> Law, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) Neither the Company nor any of its Subsidiaries (i)&#160;knows of any fact or circumstance, or (ii)&#160;has taken or agreed to take any action, that, alone or in combination, could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_33"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.18.</span> <span style="font-weight:bold">Brokers.</span><span style="font-weight:bold"> </span>Except for fees (including the amounts due and payable assuming the Closing occurs) set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.18</span> of the Company Disclosure Schedules (which fees shall, if applicable, be subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.6</span>), no broker, finder, investment banker or other Person is entitled to any brokerage fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company, any of its Subsidiaries or any of their respective Affiliates for which the Company or its Subsidiaries has any obligation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_34">Section&#160;3.19. Real and Personal Property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <span style="font-style:italic">Owned Real Property</span>. The Company does not own any real property. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <span style="font-style:italic">Leased Real Property</span>. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.19(b)</span> of the Company Disclosure Schedules sets forth a true and complete list (including street addresses) of all real property leased or otherwise occupied by the Company and its Subsidiaries (the &#8220;<span style="font-weight:bold">Leased Real Property</span>&#8221;) and all Real Property Leases pursuant to which the Company or any of its Subsidiaries is a tenant or landlord (or <span style="white-space:nowrap">sub-tenant</span> or <span style="white-space:nowrap">sub-landlord)</span> as of the date of this Agreement. True and complete copies of all such Real Property Leases have been made available to SPAC. Each Real Property Lease is in full force and effect and is a valid, legal and binding obligation of the Company or its Subsidiary (as applicable), enforceable in accordance with its terms against the Company or its Subsidiary (as applicable) and, to the Company&#8217;s knowledge, each other party thereto, subject to the Enforceability Exceptions. There is no material breach or default by the Company or its Subsidiary (as applicable) or, to the Company&#8217;s knowledge, any third party under any Real Property Lease. The Company has not leased, subleased, licensed or granted occupancy rights in any parcel or any portion of any parcel of Leased Real Property to any other Person and no other Person has any rights to the use, occupancy or enjoyment thereof pursuant to any lease, sublease, license, occupancy or other agreement, nor has the Company assigned its interest under any Real Property Lease to any third party, in each case, in any material respects. No other Person is otherwise interfering with the unrestricted use of such property by the Company in all material respects. The Leased Real Property constitutes all of the material real property used or occupied by the Company in connection with the conduct of the Business. Other than the expiry or other possible future termination of the relevant Real Property Lease in accordance with its terms, there is no other covenant, restriction or obligation other than set forth under the relevant Real Property Lease which materially adversely affects, or may materially adversely affect in the future, the use of any Leased Real Property by the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <span style="font-style:italic">Personal Property</span>. Except as set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.19(c)</span> of the Company Disclosure Schedules, the Company and its Subsidiaries have good, valid and indefeasible title to, or a valid leasehold interest in or license or right to use, all of the material tangible assets and properties of the Company and its Subsidiaries reflected in the Company Financial Statements or thereafter acquired by the Company or any of its Subsidiaries prior to the date hereof, except for assets disposed of in the ordinary course of business. Such assets and properties are free and clear of any Liens (other than Permitted Liens or Liens that do not materially and adversely affect the operation of the businesses of the Company). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="font-style:italic">Tangible Assets</span>. The tangible assets owned, leased or otherwise used by the Company are in good condition (except for ordinary wear and tear). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_35"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.20.</span> <span style="font-weight:bold">Transactions with Affiliates.</span><span style="font-weight:bold"> </span><span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20</span> of the Company Disclosure Schedules sets forth all Contracts between (a)&#160;the Company or any of its Subsidiaries, on the one hand, and (b)&#160;any officer, director, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee, partner, member, manager, direct or indirect equityholder or Affiliate of the Company or any of its Subsidiaries, or, to the Company&#8217;s knowledge, any family member of the foregoing Persons, on the other hand (each Person identified in this clause (b), a &#8220;<span style="font-weight:bold">Company Related Party</span>&#8221;), other than (i)&#160;Contracts with respect to a Company Related Party&#8217;s employment with or service as a director to (including benefit plans and other ordinary course compensation from) the Company or any of its Subsidiaries entered into in the ordinary course of business and (ii)&#160;Contracts entered into after the date of this Agreement that are either permitted pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span> or entered into in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span>. No Company Related Party (A)&#160;owns any interest in any material asset used in the Business, (B)&#160;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a supplier, lender, partner, lessor, lessee or other material business relation of the Company or any of its Subsidiaries, or (C)&#160;owes any material amount to, or is owed any material amount by, or has any claim or cause of action against the Company or any of its Subsidiaries (other than ordinary course accrued compensation, employee benefits, employee or director expense reimbursement or other transactions that, if entered into after the date of this Agreement, are either permitted pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span> or entered into in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span>). All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20</span> are referred to herein as &#8220;<span style="font-weight:bold">Company Related Party Transactions</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_36">Section&#160;3.21. Data Privacy and Security. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and its Subsidiaries have at all times complied in all material respects with all applicable Privacy Laws, Privacy and Data Security Policies (as defined below) and contractual commitments relating to the Processing of Personal Data (collectively, the &#8220;<span style="font-weight:bold">Privacy Requirements</span>&#8221;). The Company has adopted written policies relating to the Processing of Personal Data as and to the extent required by applicable Law (&#8220;<span style="font-weight:bold">Privacy and Data Security Policies</span>&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) There is no pending, nor has there been any Proceeding against the Company or any of its Subsidiaries initiated by (i)&#160;any Person, (ii)&#160;the United States Federal Trade Commission, any state attorney general or similar state official, (iii)&#160;any other Governmental Entity, foreign or domestic, or (iv)&#160;any regulatory or self-regulatory entity, alleging that any Processing of Personal Data by or on behalf of the Company or any of its Subsidiaries is in violation of any Privacy Requirements or Privacy Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company has implemented and maintained, consistent with practices reasonable for similarly-situated companies in the industry in which the Company operates and its respective obligations to third parties, reasonable security and other measures designed to be adequate to protect the Company IT Systems used by the Company to store, process or transmit Intellectual Property Rights of the Company or Personal Data from loss, theft, unauthorized access, use, disclosure or modification, including reasonable measures (no less than reasonable for similarly-situated companies in the industry in which the Company operates) designed to be adequate to (i)&#160;secure Company IT Systems from unauthorized access and use by any Person; (ii)&#160;defend Company IT Systems against Malicious Code, denial of service attacks, distributed denial of service attacks, hacking attempts, and like attacks and activities by any other Person; and (iii)&#160;ensure the continued and uninterrupted operation of Company IT Systems, including by employing reasonable security, maintenance, disaster recovery, redundancy, backup, archiving, and anti-virus systems (no less than reasonable for similarly-situated companies in the industry in which the Company operates) designed to be adequate to maintain and protect the performance, confidentiality, integrity and security of all Company IT Systems (and all software, information and data stored or contained therein or transmitted thereby). To the Company&#8217;s knowledge, none of the Company IT Systems contain any (A)&#160;devices, errors, contaminants or effects that materially disrupt or adversely affect the functionality of any Company IT Systems (or any software stored or contained therein), or enable or assist any Person to access any Company IT Systems (or any software, information or data stored or contained therein or transmitted thereby) without authorization, or (B)&#160;Malicious Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) There has been no breach of security resulting in unauthorized access, use or disclosure of Personal Data in the possession or control of the Company or any of its Subsidiaries or, to the Company&#8217;s knowledge, any of its contractors with regard to any Personal Data obtained from or on behalf of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company or any of its Subsidiaries, or any unauthorized intrusions or breaches of security into the Company&#8217;s or its Subsidiaries&#8217; systems. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company and its Subsidiaries own or have license to use the Company IT Systems as currently conducted. To the Company&#8217;s knowledge, none of the Company IT Systems contain any worm, bomb, backdoor, clock, timer or other disabling device, code, design or routine that causes the Software of any portion thereof to be erased, inoperable or otherwise incapable of being used, either automatically, with the passage of time or upon command by any unauthorized person. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor, to the Company&#8217;s knowledge, any third party acting at the direction or authorization of the Company has paid (i)&#160;any perpetrator of any data breach incident or cyber-attack; or (ii)&#160;any third party with actual or alleged information about a data breach incident or cyber-attack, in each case, pursuant to a request for payment from or on behalf of such perpetrator or other third party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company has taken commercially reasonable organizational, physical, administrative and technical measures required by Privacy Requirements, and consistent with standards typical for similarly-situated companies in the industry in which the Company operates, designed to protect the integrity, security and operations of the Company IT Systems. The Company and its Subsidiaries have implemented commercially reasonable procedures, satisfying the requirements of applicable Privacy Laws in all material respects, designed to protect Personal Data against loss and against unauthorized access, use, modification, disclosure or other misuse. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The consummation of any of the transactions contemplated hereby or pursuant to any Ancillary Document will not violate any applicable Privacy Requirements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) There have not been any Proceedings related to any data security incidents or any violations of any Privacy Requirements that have been asserted against the Company or any of its Subsidiaries and, to the Company&#8217;s knowledge, neither the Company nor any of its Subsidiaries has received any information relating to, or notice of any Proceedings with respect to, alleged violations by the Company or any of its Subsidiaries of any Privacy Requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_37">Section&#160;3.22. Compliance with International Trade&#160;&amp; Anti-Corruption Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither the Company nor any of its Subsidiaries nor their directors or officers nor, to the Company&#8217;s knowledge, any of their respective Representatives acting for or on their behalf, is or has been, for the past three years, (i)&#160;a Person named on any Sanctions and Export Control Laws-related list of designated Persons maintained by a Governmental Entity, (ii)&#160;located, organized or resident in a country or territory which is itself the subject or target of any Sanctions and Export Control Laws, (iii)&#160;an entity owned, directly or indirectly, by one or more Persons described in clause (i)&#160;or (ii), or (iv)&#160;otherwise engaging in dealings with or for the benefit of any Person described in clauses (i)&#160;through (iii) or any country or territory which is or has, or the past three years, been the subject or target of any Sanctions and Export Control Laws (at the time of this Agreement, the Crimea region of Ukraine, Cuba, Iran, North Korea, Venezuela, Sudan and Syria). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the Company nor any of its Subsidiaries nor, to the Company&#8217;s knowledge, any of their respective Representatives acting for or on their behalf, has (i)&#160;made, offered, promised, paid or received any unlawful bribes, kickbacks or other similar payments to or from any Person, (ii)&#160;made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate or (iii)&#160;otherwise violated any Anti-Corruption Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) None of the Company, their directors and officers or, to the Company&#8217;s knowledge, any of their other Representatives or any other Persons acting for or on behalf of any of the foregoing has, directly or indirectly, violated any, or been subject to actual or, to the knowledge of the Company, pending or threatened Proceedings, demand letters, settlements or enforcement actions relating to any Anti-Corruption Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) During the last three years, the Company has complied with all applicable Anti-Corruption Laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_38"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.23.</span> <span style="font-weight:bold">Information Supplied.</span><span style="font-weight:bold"> </span>None of the information supplied or to be supplied by or on behalf of the Company expressly for inclusion or incorporation by reference prior to the Closing in the Registration Statement/Proxy Statement will, when the Registration Statement/Proxy Statement is declared effective, when the Registration Statement/Proxy Statement is mailed to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders, or at the time of the SPAC Stockholders Meeting, and in the case of any amendment thereto, at the time of such amendment, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_39">Section&#160;3.24. Regulatory Compliance. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company, its Subsidiaries and the Company Products are in compliance in all respects with all Regulatory Permits. To the knowledge of the Company, no Governmental Entity is considering limiting, suspending or revoking any Regulatory Permit held by the Company or any of its Subsidiaries, if any. To the Company&#8217;s knowledge, each third party that is a sublicensee, manufacturer, contractor or agent for the Company or any of its Subsidiaries is in compliance in all respects with all Regulatory Permits, if any, required by all applicable Healthcare Laws insofar as they reasonably pertain to the Company Products. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Since the date the Company was organized, neither the Company nor any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of their sublicensees, has received any written notice that the FDA, any similar foreign Governmental Entity, or any institutional animal care and use committee (or similar body responsible for oversight of animal research), has initiated, or threatened to initiate, any Proceeding to restrict or suspend nonclinical or clinical research of any Company Product or in which the Governmental Entity alleges or asserts a failure to comply with applicable Healthcare Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) There are no Proceedings pending or, to the Company&#8217;s knowledge, threatened, with respect to any alleged violation by the Company or any of its Subsidiaries, or any of their sublicensees, of any applicable Healthcare Law as it relates to a Company Product. Neither the Company nor any of its Subsidiaries is party to or subject to any corporate integrity agreement, monitoring agreement, consent decree, deferred prosecution agreement, settlement order or similar Contract with or imposed by any Governmental Entity related to any applicable Healthcare Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All Company Products are, as applicable, being researched, developed, tested, investigated, manufactured, prepared, packaged, labeled, stored and distributed in compliance in all respects with applicable Healthcare Laws. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Since the date the Company was organized, neither the Company nor any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of their sublicensees, has distributed (including for the purposes of any clinical trial) any Company Product that were upon their shipment adulterated or misbranded in violation of 21 U.S.C. &#167;&#160;331. No Company Products have been seized, withdrawn, recalled, detained or subject to a suspension (other than in the ordinary course of business) of research, development, testing, manufacturing or distribution, and, to the Company&#8217;s knowledge, there are no facts or circumstances reasonably likely to cause the seizure, withdrawal, recall, or detention, or suspension (other than in the ordinary course of business) of research, development, testing, manufacturing, or distribution of any Company Product. There are no proceedings against the Company or any of its Subsidiaries, or, to the Company&#8217;s knowledge, their sublicensees, pending or threatened in writing seeking the withdrawal, recall, revocation, suspension, import detention or seizure of any Company Product. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of the Company&#8217;s or its Subsidiaries&#8217; sublicensees, or representative of the Company or any of its Subsidiaries or their sublicensees, has, made any untrue statement of a material fact or a fraudulent statement to the FDA or any other Governmental Entity responsible for enforcement or oversight with respect to applicable Healthcare Laws, or failed to disclose a material fact required to be disclosed to the FDA or such other Governmental Entity that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; set forth in 56 Fed. Reg. 46191 (September 10, 1991), or for any other Governmental </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Entity to invoke a similar policy. Neither the Company nor any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of the Company&#8217;s or its Subsidiaries&#8217; sublicensees, or any representative of the Company or any of its Subsidiaries or their sublicensees, has been convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. &#167;&#160;335a(a) or any similar Laws or authorized by 21 U.S.C. &#167;&#160;335a(b) or any similar Laws. Neither the Company nor any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of the Company&#8217;s or its Subsidiaries&#8217; sublicensees, any employee, agent, officer, director, or owner of more than 5% equity of the Company or any of its Subsidiaries or their sublicensees, has been convicted of any crime or engaged in any conduct for which such person or entity could be excluded from participating in any U.S. federal health care programs under 42 U.S.C. <span style="white-space:nowrap">Section&#160;1320a-7</span> or any similar Law. No debarment or exclusionary claims, actions, proceedings or investigations are pending or threatened in writing against the Company or any of its Subsidiaries, nor, to the Company&#8217;s knowledge, any of the Company&#8217;s or its Subsidiaries&#8217; sublicensees or respective representatives. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All nonclinical studies and clinical trials conducted or being conducted with respect to all Company Products by or at the direction of the Company or any of its Subsidiaries or, to the Company&#8217;s knowledge, their sublicensees have been and are being conducted in compliance with accepted professional scientific standards and all applicable Healthcare Laws, including the applicable requirements of Good Laboratory Practices and Good Clinical Practices. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) All material reports, documents, claims, permits and notices required to be filed, maintained or furnished to the FDA or any other foreign Governmental Entity by the Company or any of its Subsidiaries under applicable Healthcare Laws have been so filed, maintained or furnished. All such reports, documents, claims, permits and notices were complete and accurate in all material respects on the date filed (or were corrected or supplemented by a subsequent filing). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company and its Subsidiaries and, to the Company&#8217;s knowledge, any of their sublicensees or Person acting for or on behalf of the Company or its Subsidiaries or their sublicensees are and have been in compliance with all applicable Healthcare Laws, except as would not have or be reasonably expected to have a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_40">Section&#160;3.25. Investigation; No Other Representations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that (i)&#160;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning the business, assets, condition, operations and prospects of the SPAC Parties, and (ii)&#160;it has been furnished with or given access to such documents and information about the SPAC Parties and their respective businesses and operations as it and its Representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Documents to which it is or will be a party and the transactions contemplated hereby and thereby. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In entering into this Agreement and the Ancillary Documents to which it is or will be a party, the Company has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;IV</span> and in the Ancillary Documents and no other representations or warranties of any SPAC Party or any other Person, either express or implied, and the Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;IV</span> and in the Ancillary Documents, (i)&#160;none of the SPAC Parties nor any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, and (ii)&#160;the Company hereby disclaims reliance on any other documentation or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_41"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.26.</span> <span style="font-weight:bold">Investment Company Act.</span><span style="font-weight:bold"> </span>The Company is not an &#8220;investment company&#8221; or a Person directly or indirectly &#8220;controlled&#8221; by or acting on behalf of a person subject to registration and regulation as an &#8220;investment company,&#8221; in each case, within the meaning of the Investment Company Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_42">Section&#160;3.27. EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO ANY SPAC PARTY OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <span style="text-decoration:underline">ARTICLE III</span> OR THE ANCILLARY DOCUMENTS, NEITHER THE COMPANY NOR ANY OTHER PERSON MAKES, AND THE COMPANY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF THE COMPANY AND ITS SUBSIDIARIES THAT HAVE BEEN MADE AVAILABLE TO ANY SPAC PARTY OR ANY OF THEIR REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF THE COMPANY AND ITS SUBSIDIARIES BY OR ON BEHALF OF THE MANAGEMENT OF THE COMPANY OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY ANY SPAC PARTY OR ANY OF THEIR REPRESENTATIVES IN EXECUTING, DELIVERING AND PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN <span style="text-decoration:underline">ARTICLE IV</span> OR THE ANCILLARY DOCUMENTS, IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF ANY SPAC PARTY ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF ANY SPAC PARTY, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY OF ITS REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_43">ARTICLE IV. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REPRESENTATIONS AND WARRANTIES RELATING TO THE SPAC PARTIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.8</span>, except as set forth on the SPAC Disclosure Schedules or as set forth in any SPAC SEC Reports filed or furnished with the SEC at least one Business Day prior to the date hereof (excluding (i)&#160;any disclosures in any &#8220;risk factors&#8221; section that do not constitute statements of fact, disclosures in any forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature, and (ii)&#160;any matters required to be disclosed for purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1</span> (<span style="font-style:italic">Organization and Qualification</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2</span> (<span style="font-style:italic">Authority</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span> (<span style="font-style:italic">Brokers</span>), <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(a)</span> (<span style="font-style:italic">Capitalization</span>) and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.8</span> (<span style="font-style:italic">Trust Account</span>)), each SPAC Party hereby represents and warrants to the Company, as of the date hereof and as of the Closing Date, as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_44"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1.</span> <span style="font-weight:bold">Organization and Qualification.</span><span style="font-weight:bold"> </span>Each SPAC Party is a corporation, duly organized, incorporated or formed, as applicable, and validly existing in good standing under the Laws of its jurisdiction of incorporation. True and complete copies of the Governing Documents of Merger Sub have been made available to the Company, as amended and in effect as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_45"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.2.</span> <span style="font-weight:bold">Authority.</span><span style="font-weight:bold"> </span>Each SPAC Party has the requisite corporate power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder (subject to the SPAC Stockholder Approval and the stockholder approval contemplated </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9</span>) and to consummate the transactions contemplated hereby and thereby. Subject to obtaining the SPAC Stockholder Approval and the approvals and consents to be obtained by Merger Sub pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9</span>, the execution and delivery of this Agreement, the Ancillary Documents to which a SPAC Party is or will be a party and the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate action on the part of such SPAC Party. Subject to obtaining the SPAC Stockholder Approval, this Agreement and each Ancillary Document to which a SPAC Party is or will be a party has been or will be, upon execution thereof, as applicable, duly and validly executed and delivered by such SPAC Party and constitutes or will constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding agreement of such SPAC Party (assuming that this Agreement and the Ancillary Documents to which such SPAC Party is or will be a party are or will be upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto, as applicable), enforceable against such SPAC Party in accordance with their terms, subject to Enforceability Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_46">Section&#160;4.3. Consents and Requisite Governmental Approvals; No Violations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval, waiver or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of any SPAC Party with respect to such SPAC Party&#8217;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which it is or will be party or the consummation of the transactions contemplated hereby or thereby, except for (i)&#160;compliance with and filings under the HSR Act or any filings with or approvals or clearances from any Governmental Entities that the Parties determine (acting reasonably) are required and advisable to consummate the transactions contemplated hereby and thereby, (ii)&#160;the filing with the SEC of (A)&#160;the Registration Statement/Proxy Statement and the declaration of the effectiveness thereof by the SEC, and (B)&#160;such reports under Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, (iii)&#160;such filings with and approvals of Nasdaq to permit Series A Common Stock to be issued in accordance with this Agreement to be listed on Nasdaq, (iv)&#160;filing of the Certificate of Merger, (v)&#160;the approvals and consents to be obtained by Merger Sub pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.9</span>, (vi)&#160;the SPAC Stockholder Approval, or (vii)&#160;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a SPAC Material Adverse Effect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3(a)</span>, neither the execution, delivery or performance by any SPAC Party of this Agreement nor the Ancillary Documents to which any SPAC Party is or will be a party, nor the consummation of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of time or both) (i)&#160;result in any breach of any provision of the Governing Documents of any SPAC Party, (ii)&#160;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any Contract to which any SPAC Party is a party, (iii)&#160;violate, or constitute a breach under, any Order or applicable Law to which any such SPAC Party or any of its properties or assets are bound, or (iv)&#160;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) or Equity Securities of any SPAC Party, except, in the case of any of clauses (ii)&#160;through (iv) above, as would not be material to the SPAC Parties taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_47"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.4.</span> <span style="font-weight:bold">Brokers.</span><span style="font-weight:bold"> </span>Except for fees (including the amounts due and payable assuming the Closing occurs) set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span> of the SPAC Disclosure Schedules (which fees shall, if applicable, be subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.6</span>), no broker, finder, investment banker or other Person is entitled to any brokerage fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of any SPAC Party or any of its Affiliates for which any SPAC Party has any obligation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_48"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.5.</span> <span style="font-weight:bold">Information Supplied.</span><span style="font-weight:bold"> </span>None of the information supplied or to be supplied by or on behalf of either SPAC Party expressly for inclusion or incorporation by reference prior to the Closing in the Registration Statement/Proxy Statement will, when the Registration Statement/Proxy Statement is declared effective, when </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Registration Statement/Proxy Statement is mailed to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders or at the time of the SPAC Stockholders Meeting, and in the case of any amendment thereto, at the time of such amendment, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_49">Section&#160;4.6. Capitalization. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of SPAC consists of (i)&#160;100,000,000 shares of Series A Common Stock, (ii)&#160;10,000,000 shares of Series B Common Stock, and (iii)&#160;1,000,000 shares of preferred stock, in each case, par value $0.0001 per share. As of the date of this Agreement, (A) 10,935,691 shares of Series A Common Stock and 1 share of Series B Common Stock are issued and outstanding includes 3,435,692 shares subject to Redemption Rights), all of which are validly issued, fully paid and <span style="white-space:nowrap">non-assessable,</span> and (B)&#160;no shares of SPAC Common Stock are held in the treasury of SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(b)</span> of the SPAC Disclosure Schedules and for this Agreement, the Ancillary Documents or the transactions contemplated hereby and thereby, or as mutually agreed to by the Parties, there are no outstanding (i)&#160;equity appreciation, phantom equity or profit participation rights, or (ii)&#160;options, restricted stock, phantom stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts that would require SPAC, and, except as expressly contemplated by this Agreement, the Ancillary Documents or as mutually agreed in writing by the Parties, there is no obligation of SPAC, to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of SPAC. There are no voting trusts, proxies or other Contracts with respect to the voting or transfer of SPAC Equity Securities to which SPAC, the Sponsor or, to SPAC&#8217;s knowledge, any other Person is a party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Equity Securities of Merger Sub outstanding as of the date of this Agreement (i)&#160;have been duly authorized and validly issued and are fully paid and <span style="white-space:nowrap">non-assessable,</span> (ii)&#160;were issued in compliance in all material respects with applicable Law, and (iii)&#160;were not issued in breach or violation of any preemptive rights or Contract to which SPAC is a party or bound. All of the outstanding Equity Securities of Merger Sub are owned directly by SPAC free and clear of all Liens (other than transfer restrictions under applicable Securities Laws). As of the date of this Agreement, SPAC has no Subsidiaries other than Merger Sub and does not own, directly or indirectly, any Equity Securities in any Person other than Merger Sub. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6(d)</span><span style="text-decoration:underline"></span>&#160;of the SPAC Disclosure Schedules sets forth a list of all Indebtedness of SPAC as of the date of this Agreement, including the principal amount of such Indebtedness, the outstanding balance as of the date of this Agreement and the debtor and the creditor thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_50"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.7.</span> <span style="font-weight:bold">SEC Filings.</span><span style="font-weight:bold"> </span>Except for the quarterly reports on Form <span style="white-space:nowrap">10-Q</span> for the periods ended June&#160;30, 2023 and September&#160;30, 2023, SPAC has timely filed or furnished, in all material respects, all statements, forms, reports and documents required to be filed or furnished by it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#8220;<span style="font-weight:bold">SPAC SEC Reports</span>&#8221;), and will file or furnish all other statements, forms, reports and other documents required to be filed or furnished by it subsequent to the date of this Agreement with the SEC pursuant to Federal Securities Laws (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as they may be supplemented, modified or amended after the time of filing, but excluding the Registration Statement/Proxy Statement, the &#8220;<span style="font-weight:bold">Additional SPAC SEC Reports</span>&#8221;). Each of the SPAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing, complied in all material respects, and each of the Additional SPAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that supersedes the initial filing, will comply in all material respects, with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder) applicable to the SPAC SEC Reports or the Additional SPAC SEC Reports; <span style="font-style:italic">provided</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that, for purposes of the Additional SPAC SEC Reports, the representation and warranty in this sentence is subject to the representation and warranty set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.23</span> being true and correct in all respects with respect to all information supplied by or on behalf of the Company expressly for inclusion or incorporation by reference therein. As of their respective dates of filing, the SPAC SEC Reports did not (a)&#160;contain any untrue statement of a material fact, or (b)&#160;omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made or will be made, as applicable, not misleading in any material respect. As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the SPAC SEC Reports. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_51"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.8.</span> <span style="font-weight:bold">Trust Account.</span><span style="font-weight:bold"> </span>As of the date of this Agreement, SPAC has an amount in cash in the Trust Account equal to at least $36,466,121. The funds held in the Trust Account are (a)&#160;invested in United States &#8220;government securities&#8221; within the meaning of Section&#160;2(a)(16) of the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule <span style="white-space:nowrap">2a-7</span> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, and (b)&#160;held in trust pursuant to that certain Investment Management Trust Agreement, dated January&#160;13, 2022, between SPAC and Continental Stock Transfer&#160;&amp; Trust Company, as trustee (the &#8220;<span style="font-weight:bold">Trustee</span>&#8221;) (the &#8220;<span style="font-weight:bold">Trust Agreement</span>&#8221;). There are no separate agreements, side letters or other understandings (whether written or unwritten, express or implied) that would cause the description of the Trust Agreement in the SPAC SEC Reports to be inaccurate in any material respect or, to SPAC&#8217;s knowledge, that would entitle any Person to any portion of the funds in the Trust Account (other than (i)&#160;in respect of deferred underwriting commissions or Taxes, (ii)&#160;the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders who shall have elected to redeem their Series A Common Stock pursuant to the Governing Documents of SPAC, or (iii)&#160;if SPAC fails to complete a business combination within the allotted time period set forth in the Governing Documents of SPAC and liquidates the Trust Account, subject to the terms of the Trust Agreement, SPAC (in limited amounts to permit SPAC to pay the expenses of the Trust Account&#8217;s liquidation, dissolution and winding up of SPAC) and then the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders). Prior to the Closing, none of the funds held in the Trust Account are permitted to be released, except in the circumstances described in the Governing Documents of SPAC and the Trust Agreement. SPAC has performed all material obligations required to be performed by it to date under, and is not in material default or delinquent in performance or any other respect (claimed or actual) in connection with the Trust Agreement, and, to the knowledge of SPAC, no event has occurred which, with due notice or lapse of time or both, would constitute such a material default thereunder. As of the date of this Agreement, there are no claims or proceedings pending with respect to the Trust Account. Since January&#160;13, 2022, SPAC has not released any money from the Trust Account (other than (i)&#160;interest income earned on the funds held in the Trust Account as permitted by the Trust Agreement and (ii)&#160;funds pursuant to stockholder redemptions in connection with the amendment to the SPAC Certificate of Incorporation on April&#160;18, 2023). Upon the consummation of the transactions contemplated hereby, including the distribution of assets from the Trust Account (A)&#160;in respect of deferred underwriting commissions or Taxes, or (B)&#160;to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders who have elected to redeem their Series A Common Stock pursuant to the Governing Documents of SPAC, each in accordance with the terms of and as set forth in the Trust Agreement, SPAC shall have no further obligation under either the Trust Agreement or the Governing Documents of SPAC to liquidate or distribute any assets held in the Trust Account, and the Trust Agreement shall terminate in accordance with its terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_52"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.9.</span> <span style="font-weight:bold">Transactions with Affiliates.</span><span style="font-weight:bold"> </span><span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.9</span> of the SPAC Disclosure Schedules sets forth all Contracts between (a)&#160;SPAC, on the one hand, and (b)&#160;any officer, director, employee, partner, member, manager, direct or indirect equityholder (including the Sponsor) or Affiliate of either SPAC or the Sponsor or any family member of the forgoing Persons, on the other hand (each Person identified in this clause (b), a &#8220;<span style="font-weight:bold">SPAC Related Party</span>&#8221;), that have not already been disclosed in the SPAC SEC Reports, other than (i)&#160;Contracts with respect to a SPAC Related Party&#8217;s employment with, or the provision of services to, SPAC entered into in the ordinary course of business, and (ii)&#160;Contracts entered into after the date of this Agreement that are either permitted pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span> or entered into in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span>. No SPAC Related Party (A)&#160;owns any interest in any material asset used in the business of SPAC, (B)&#160;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a client, supplier, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lender, partner, customer, lessor, lessee or other material business relation of SPAC or (C)&#160;owes any material amount to, or is owed any material amount by, SPAC. All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.9</span> are referred to herein as &#8220;<span style="font-weight:bold">SPAC Related Party Transactions.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_53"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.10.</span> <span style="font-weight:bold">Litigation.</span><span style="font-weight:bold"> </span>There is (and since its organization, incorporation or formation, as applicable, there has been) no Proceeding pending or, to SPAC&#8217;s knowledge, threatened against any SPAC Party or any of their respective directors or officers that, if adversely decided or resolved, would be material to the SPAC Parties, taken as a whole, and, to SPAC&#8217;s knowledge, no facts exist that would reasonably be expected to form the basis for any such Proceeding. None of the SPAC Parties nor any of their respective properties or assets is subject to any material Order. As of the date of this Agreement, there are no material Proceedings by any SPAC Party pending against any other Person. There is (and since its organization, incorporation or formation, as applicable, there has been) no (a)&#160;settlement or similar agreement that imposes any material ongoing obligation or restriction on SPAC or the operation of its business, and (b)&#160;pending or, to SPAC&#8217;s knowledge, threatened, audit, examination or investigation by any Governmental Entities in respect of SPAC or any of its directors or officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_54"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.11.</span> <span style="font-weight:bold">Compliance with Applicable Law.</span><span style="font-weight:bold"> </span>Each SPAC Party is (and since its incorporation has been) in compliance with all applicable Laws, except as would not be material to the SPAC Parties, taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_55"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.12.</span> <span style="font-weight:bold">Merger Sub Activities.</span><span style="font-weight:bold"> </span>Merger Sub was organized solely for the purpose of entering into this Agreement, the Ancillary Documents and consummating the transactions contemplated hereby and thereby and has not engaged in any activities or business, other than those incident or related to or incurred in connection with its incorporation or the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby. Merger Sub does not have any Indebtedness. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_56">Section&#160;4.13. Internal Controls; Listing; Financial Statements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as not required in reliance on exemptions from various reporting requirements by virtue of SPAC&#8217;s status as an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended, or &#8220;smaller reporting company&#8221; within the meaning of the Exchange Act, since its initial public offering, (i)&#160;SPAC has established and maintained a system of internal controls over financial reporting (as defined in <span style="white-space:nowrap">Rule&#160;13a-15</span> and <span style="white-space:nowrap">Rule&#160;15d-15</span> under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of SPAC&#8217;s financial reporting and the preparation of SPAC&#8217;s financial statements for external purposes in accordance with GAAP, and (ii)&#160;SPAC has established and maintained disclosure controls and procedures (as defined in <span style="white-space:nowrap">Rule&#160;13a-15</span> and <span style="white-space:nowrap">Rule&#160;15d-15</span> under the Exchange Act) designed to ensure that information relating to SPAC is made known to SPAC&#8217;s principal executive officer and principal financial officer by others within SPAC. Such disclosure controls and procedures are effective in timely alerting SPAC&#8217;s principal executive officer and principal financial officer to material information required to be included in SPAC&#8217;s periodic reports required under the Exchange Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each director and executive officer of SPAC has filed with the SEC on a timely basis all statements required by Section&#160;16(a)&#160;of the Exchange Act and the rules and regulations promulgated thereunder. SPAC has not taken any action prohibited by Section&#160;402 of the Sarbanes-Oxley Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Since its initial public offering, SPAC has complied in all material respects with all applicable listing and corporate governance rules and regulations of Nasdaq. The class of securities representing issued and outstanding Series A Common Stock are registered pursuant to Section&#160;12(b)&#160;of the Exchange Act and are listed for trading on Nasdaq. There is no Proceeding pending or, to the knowledge of SPAC, threatened against SPAC by Nasdaq or the SEC with respect to any intention by such entity to deregister the Series A Common Stock or prohibit or terminate the listing of Series A Common Stock on Nasdaq. SPAC has not taken any action that is designed to terminate the registration of Series A Common Stock under the Exchange Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) (i)&#160;The SPAC SEC Reports contain true and complete copies of the financial statements (including all related notes and schedules thereto) of SPAC (the &#8220;<span style="font-weight:bold">SPAC Financial Statements</span>&#8221;). The SPAC Financial Statements (A)&#160;fairly present in all material respects the financial position of SPAC as at the respective dates thereof, and the results of its operations and cash flows for the respective periods then ended and fairly present, in all material respects, its stockholders&#8217; equity, (B)&#160;were prepared in conformity with GAAP applied on a consistent basis during the periods involved, and (C)&#160;comply, in all material respects, with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <span style="white-space:nowrap">S-X</span> or Regulation <span style="white-space:nowrap">S-K,</span> as applicable). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) SPAC has established and maintains systems of internal accounting controls that are designed to provide, in all material respects, reasonable assurance that (i)&#160;all transactions are executed in accordance with management&#8217;s authorization, and (ii)&#160;all transactions are recorded as necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for SPAC&#8217;s and its Subsidiaries&#8217; assets. SPAC maintains and, for all periods covered by the SPAC Financial Statements, has maintained, in all material respects in accordance with GAAP and applicable Law, books and records of SPAC in the ordinary course of business that are accurate and complete and reflect the revenues, expenses, assets and Liabilities of SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) There are no outstanding loans or other extensions of credit made by SPAC to any executive officer (as defined in <span style="white-space:nowrap">Rule&#160;3b-7</span> under the Exchange Act) or director of SPAC. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.13(g)</span> of the SPAC Disclosure Schedules, since its incorporation, neither SPAC (including any employee thereof) nor, to the knowledge of SPAC, SPAC&#8217;s independent auditors, has received any written complaint, allegation, assertion or claim that there is, or there has been, (i)&#160;a &#8220;significant deficiency&#8221; in the internal controls over financial reporting of SPAC, (ii)&#160;a &#8220;material weakness&#8221; in the internal controls over financial reporting of SPAC, or (iii)&#160;fraud, whether or not material, that involves management or other employees of SPAC who have a role in the internal controls over financial reporting of SPAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_57"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.14.</span> <span style="font-weight:bold">No Undisclosed Liabilities.</span><span style="font-weight:bold"> </span>Except for the Liabilities (a)&#160;set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.14</span> of the SPAC Disclosure Schedules, (b)&#160;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby (including, for the avoidance of doubt, the SPAC Expenses and any Liabilities arising out of, or related to, any Proceeding related to this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, including any stockholder demand or other stockholder Proceedings (including derivative claims) arising out of, or related to, any of the foregoing), (c)&#160;set forth or disclosed in the SPAC Financial Statements, (d)&#160;that have arisen since the date of the most recent balance sheet included in the SPAC SEC Reports in the ordinary course of business (none of which is a Liability for breach of contract, breach of warranty, tort, infringement or violation of Law), (e)&#160;either permitted to be incurred pursuant to or incurred in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span>, or (f)&#160;that are not, and would not reasonably be expected to be, individually or in the aggregate, material to SPAC, SPAC does not have any Liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_58"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.15.</span> <span style="font-weight:bold">Employee Matters.</span><span style="font-weight:bold"> </span>SPAC does not have any current or former employees, and does not maintain, sponsor, contribute to or have any present or future Liability with respect to (other than as a result of the transactions contemplated by this Agreement) any &#8220;employee benefit plan&#8221; (as such term is defined in Section&#160;3(3) of ERISA). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_59">Section&#160;4.16. Tax Matters. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each SPAC Party has prepared and filed all material Tax Returns required to have been filed by it, all such Tax Returns are true and complete in all material respects and prepared in compliance in all material respects with all applicable Laws, and each SPAC Party has paid all material Taxes required to have been paid or deposited by it regardless of whether shown on a Tax Return. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each SPAC Party has timely withheld and paid to the appropriate Tax Authority all material amounts required to have been withheld and paid in connection with amounts paid or owing to any employee, individual independent contractor, other service providers, equity interest holder or other third-party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No SPAC Party is currently the subject of a Tax audit or examination, and has not been informed in writing of the commencement or anticipated commencement of any Tax audit or examination that has not been resolved or completed, in each case with respect to material Taxes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) No SPAC Party has consented to extend or waive the time in which any material Tax may be assessed or collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax Returns obtained in the ordinary course of business. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by any Tax Authority with respect to any SPAC Party which agreement or ruling would be effective after the Closing Date. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) None of the SPAC Parties is and none of the SPAC Parties has been a party to any &#8220;listed transaction&#8221; as defined in Section&#160;6707A of the Code and Treasury Regulations <span style="white-space:nowrap">Section&#160;1.6011-4</span> (or any corresponding or similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> income Tax Law). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) There are no Liens for Taxes on any assets of any SPAC Party other than Liens for Taxes not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established in accordance with GAAP. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) No SPAC Party has been a distributing corporation or a controlled corporation in a transaction purported or intended to be governed by Section&#160;355 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No SPAC Party (i)&#160;has been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was SPAC) or (ii)&#160;has any material Liability for the Taxes of any Person (other than the SPAC Parties) under <span style="white-space:nowrap">Section&#160;1.1502-6</span> of the Treasury Regulations (or any similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> Law), as a transferee or successor, by Contract or otherwise (other than any Contract entered into in the ordinary course of business the principal purpose of which does not relate to Taxes). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) No written claims have ever been made by any Tax Authority in a jurisdiction where a SPAC Party does not file a particular type of Tax Return or pay a particular type of Tax that such SPAC Party is or may be required to file such type of Tax Return in or pay such type of Tax to that jurisdiction, which claims have not been resolved or withdrawn. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) No SPAC Party is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than one that is included in a Contract entered into in the ordinary course of business that is not primarily related to Taxes) and no SPAC Party is a party to any joint venture, partnership or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Each SPAC Party is a tax resident only in its jurisdiction of organization, incorporation or formation, as applicable, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) No SPAC Party has a branch, permanent establishment (within the meaning of an applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country in which it is organized, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) No SPAC Party will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i)&#160;change in, or use of improper, method of accounting for a taxable period ending </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
on or prior to the Closing Date, (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of U.S. state or local or foreign income Tax Law) executed on or prior to the Closing Date, (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&#160;deferred revenue or prepaid amount received on or prior to the Closing Date, outside of the ordinary course of business (v)&#160;intercompany transaction or excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of U.S. state or local or <span style="white-space:nowrap">non-U.S.</span> income Tax Law), or (vi)&#160;election under Section&#160;965(h)&#160;of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) No SPAC Party has deferred any material Taxes under the CARES Act. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) All related party transactions involving the SPAC Parties are at arm&#8217;s length in material compliance with Section&#160;482 of the Code, the Treasury Regulations promulgated thereunder and any similar provision of state, local or <span style="white-space:nowrap">non-U.S.</span> Law, but only to the extent that the failure of this representation to be true could reasonably be expected to give rise to a material Tax liability. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) None of the SPAC Parties (i)&#160;knows of any fact or circumstance, or (ii)&#160;has taken or agreed to take any action, that, alone or in combination, could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_60">Section&#160;4.17. Investigation; No Other Representations. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each SPAC Party, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that (i)&#160;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning the business, assets, condition, operations and prospects of, the Company and its Subsidiaries, and (ii)&#160;it has been furnished with or given access to such documents and information about the Company, its Subsidiaries and the Business as it and its Representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Documents to which it is or will be a party and the transactions contemplated hereby and thereby. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In entering into this Agreement and the Ancillary Documents to which it is or will be a party, each SPAC Party has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in <span style="text-decoration:underline">ARTICLE III</span> and in the Ancillary Documents and no other representations or warranties of the Company or any other Person, either express or implied, and each SPAC Party, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in <span style="text-decoration:underline">ARTICLE III</span> and in the Ancillary Documents, (i)&#160;neither the Company nor any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, and (ii)&#160;each SPAC Party hereby disclaims reliance on any other documentation or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_61">Section&#160;4.18. Business Activities. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Since its incorporation, SPAC has not conducted any business activities other than activities related to the SPAC&#8217;s initial public offering or directed toward the accomplishment of a business combination. Except as set forth in its Governing Documents or as otherwise contemplated by this Agreement or the Ancillary Documents and the transactions contemplated hereby, there is no Contract to which SPAC is a party which has or would reasonably be expected to have the effect of prohibiting or impairing in any material respect any business practice of SPAC or any acquisition of property by SPAC or the conduct of business by SPAC as currently conducted or as contemplated to be conducted as of the Closing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SPAC does not own or have a right to acquire, directly or indirectly, any interest or investment (whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except for this Agreement, the Ancillary Documents and the other documents and transactions contemplated hereby and thereby (including with respect to expenses and fees incurred in connection </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
therewith and the Unpaid SPAC Expenses) or any Contracts that are exhibits to the SPAC SEC Reports, SPAC is not a party to any Contract with any other Person that (i)&#160;obligates SPAC to make payments of $50,000 or more as of the date of this Agreement or (ii)&#160;will remain in effect immediately following the Closing and limit the right of the Company to engage in any line of business or in any geographic area in any material respect. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) SPAC does not own, lease, license or otherwise occupy any real property. SPAC does not own or license any Intellectual Property Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_62"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.19.</span> <span style="font-weight:bold">Investment Company Act; JOBS Act.</span><span style="font-weight:bold"> </span>SPAC is not an &#8220;investment company&#8221; or a Person directly or indirectly &#8220;controlled&#8221; by or acting on behalf of an &#8220;investment company,&#8221; in each case within the meaning of the Investment Company Act. SPAC constitutes an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups (JOBS) Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_63">Section&#160;4.20. EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <span style="text-decoration:underline">ARTICLE IV</span> OR THE ANCILLARY DOCUMENTS, NONE OF THE SPAC PARTIES NOR ANY OTHER PERSON MAKES, AND EACH SPAC PARTY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF ANY SPAC PARTY THAT HAVE BEEN MADE AVAILABLE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF ANY SPAC PARTY BY OR ON BEHALF OF THE MANAGEMENT OF SUCH SPAC PARTY OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY OF ITS REPRESENTATIVES IN EXECUTING, DELIVERING AND PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN <span style="text-decoration:underline">ARTICLE III</span> OR THE ANCILLARY DOCUMENTS, IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF THE COMPANY, ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF THE COMPANY, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY ANY SPAC PARTY OR ANY OF ITS REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_64">ARTICLE V. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COVENANTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_65">Section&#160;5.1. Conduct of Business of the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) From and after the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms (the &#8220;<span style="font-weight:bold">Interim Period</span>&#8221;), the Company shall, and shall cause its Subsidiaries to, except as expressly contemplated by this Agreement, any Contract disclosed on the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company Disclosure Schedules or any Ancillary Document, as required by applicable Law, as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(a)</span> of the Company Disclosure Schedules, to reasonably comply with any applicable Pandemic Measures or as expressly consented to in writing by SPAC (it being agreed that any request for a consent shall not be unreasonably withheld, conditioned or delayed), (i)&#160;operate the Business in the ordinary course and, where applicable, consistent with past practice, in all material respects, and (ii)&#160;use commercially reasonable efforts to maintain and preserve intact the business organization, assets, properties and material business relations of the Company and its Subsidiaries; <span style="font-style:italic">provided</span> that in no event shall the Company&#8217;s and its Subsidiaries&#8217; compliance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span> constitute a breach of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(a)</span>; <span style="font-style:italic">and provided further</span>, that any action taken, or omitted to be taken, by the Company or any of its Subsidiaries, or by the Company Board or the board of directors of any Subsidiary, to the extent such act or omission is reasonably determined by the Company, its Subsidiary, the Company Board or the board of directors of the relevant Subsidiary to be reasonably necessary or advisable to comply with any Pandemic Measures, shall in no event be deemed to constitute a breach of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>; <span style="font-style:italic">provided, however</span>, (1)&#160;that the Company shall give SPAC prior written notice of any such act or omission to the extent reasonably practicable and, in the event that it is not reasonably practicable for the Company to give the prior written notice described in this clause (1), the Company shall instead give such written notice to SPAC promptly after such act or omission, and (2)&#160;in no event shall any act or omission taken in accordance with this sentence be deemed to not constitute a breach of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> if the act or omission is of the type described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;(i)</span>, <span style="text-decoration:underline">(ii)</span>, <span style="text-decoration:underline">(iv)</span>, <span style="text-decoration:underline">(v)</span>, <span style="text-decoration:underline">(xii)</span>, <span style="text-decoration:underline">(xiv)</span>, <span style="text-decoration:underline">(xv)</span> and <span style="text-decoration:underline">(xviii))</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing, during the Interim Period, the Company shall, except as expressly contemplated by this Agreement, any Contract disclosed on the Company Disclosure Schedules or any Ancillary Document, as required by applicable Law, as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span> of the Company Disclosure Schedules or as expressly consented to in writing by SPAC (such consent not to be unreasonably withheld, conditioned or delayed), not do, and shall cause its Subsidiaries not to do, any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) declare, set aside, or make any <span style="white-space:nowrap">non-cash</span> distribution in respect of, any of its issued and outstanding Equity Securities, or repurchase, cancel, redeem, facilitate a capital reduction in respect of or otherwise acquire any of its issued and outstanding Equity Securities or any securities convertible into (whether currently convertible or convertible only after the passage of time or the occurrence of certain events) or exchangeable for its Equity Securities, or offer to do any of these things; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) (A) merge, consolidate, combine or amalgamate with any Person, or (B)&#160;purchase or otherwise acquire (whether by merging or consolidating with, purchasing any Equity Securities in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, limited liability company, joint venture, association or other business entity or organization or division thereof; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) adjust, split, combine, subdivide, recapitalize, reclassify or otherwise effect any change in respect of any of its Equity Securities or issue any other security in respect of, in lieu of or in substitution for its Equity Securities; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) adopt or propose that its stockholders approve or adopt any amendments, supplements, restatements or modifications to its Governing Documents except as required to effect the conversion of the Company Preferred Stock; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) (A) sell, assign, transfer, convey, abandon, lease, license, allow to lapse or expire or otherwise dispose of any material assets or properties (including the Leased Real Property but excluding Intellectual Property Rights), other than obsolete assets or properties or in the ordinary course of business, or (B)&#160;create, subject to or incur any Lien (other than a Permitted Lien) in respect of any material assets or properties (including the Leased Real Property but excluding Intellectual Property Rights); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) transfer, issue, deliver, sell, pledge, grant or otherwise directly or indirectly dispose of, or subject to a Lien, (A)&#160;any of its Equity Securities or the Equity Securities of any Subsidiary, as applicable, or (B)&#160;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating it to transfer, issue, deliver, sell, pledge, grant or otherwise directly or indirectly dispose of, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subject to a Lien, any of its Equity Securities or the Equity Securities of any Subsidiary, as applicable; provided that the Company may grant Equity Securities to current and new employees pursuant to the Company Equity Plan, subject to providing SPAC and its legal counsel prior notice and an opportunity to review such proposed grants at least five (5)&#160;Business Days prior to any such proposed approval and any such proposed grants are made in compliance with all applicable Laws, including Section&#160;409A or Section&#160;424 of the Code, and at a valuation determined by an independent third party valuation firm with all material information relating to the Company, including the transactions contemplated by this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) incur, create, assume or otherwise become liable for (whether directly, contingently or otherwise), or guarantee for the benefit of another Person, any Indebtedness in excess of $500,000 (other than equipment financing and trade payables incurred in the ordinary course of Business), individually or in the aggregate; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) enter into, amend, modify, waive any material benefit or right under, novate, assign, assume or terminate or rescind any Material Contract (excluding, for the avoidance of doubt, any expiration or automatic extension or renewal of any such Material Contract pursuant to its terms, or entering into additional work orders pursuant to, and in accordance with the terms of, any Material Contract); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) make any loans, advances or capital contributions of money or other property to, or guarantees for the benefit of, or any investments in, any Person in excess of $250,000, individually or in the aggregate, other than (A)&#160;the reimbursement of expenses of employees and other service providers in the ordinary course of business, and (B)&#160;prepayments and deposits paid to suppliers of the Company and its Subsidiaries in the ordinary course of business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) except pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.20</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.21</span> and as required under the terms of any Employee Benefit Plan or by applicable Law, (A)&#160;amend or modify in any material respect, adopt, enter into, or terminate or rescind any material Employee Benefit Plan or any benefit or compensation plan, policy, program or Contract that would be a material Employee Benefit Plan if in effect as of the date of this Agreement, (B)&#160;increase or agree to increase the compensation or bonus payable, or pay or agree to pay any bonus to, any current or former Key Employee or Contingent Worker, other than, in each case, individual annual and merit-based raises of up to three percent (3%) in the salary or wages of any such Key Employee or Contingent Worker and bonus payments made in the ordinary course of business and consistent with past practice, as applicable, (C)&#160;take any action to accelerate any payment, right to payment or benefit, or the vesting or funding of any payment, right to payment or benefit, payable or to become payable to any current or former Key Employee or Contingent Worker, (D)&#160;waive or release any noncompetition, <span style="white-space:nowrap">non-solicitation,</span> <span style="white-space:nowrap">no-hire,</span> nondisclosure or other restrictive covenant obligation of any current or former Key Employee, (E)&#160;increase the severance or change in control pay or benefits of any current or former executive director, manager, officer or employee, or (F)&#160;hire or terminate (other than for cause) or furlough the employment of any Key Employee (or person who would be a Key Employee, were they hired by the Company or any of its Subsidiaries), or terminate any group of employees if such group termination, when taken alone, would trigger the WARN Act; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) enter into, assume, assign, amend any material term of or terminate (excluding any expiration in accordance with its terms) any collective bargaining or similar agreement (including agreements with works councils and trade unions and side letters) to which it is a party or by which it is bound, other than in the ordinary course of business consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) make, change or revoke any material Tax election or material Tax accounting method, file any material Tax Return in a manner inconsistent with past practice, amend any material Tax Return, enter into any agreement with a Governmental Entity with respect to a material amount of Taxes, settle or compromise any claim or assessment by a Governmental Entity in respect of any material amount of Taxes, surrender any right to claim a refund of a material amount of Taxes, consent to any extension or waiver of the statutory period of limitation applicable to any material Tax claim or assessment or enter into any Tax sharing or similar agreement (other than any agreement entered into in the ordinary course of business, the primary purpose of which does not relate to Taxes); </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) waive, release, compromise, settle or satisfy any pending or threatened claim or compromise or settle any Liability, whether by Contract or otherwise, the performance of which would, at any time (A)&#160;involve the payment of more than $250,000 in the aggregate, (B)&#160;impose any material, <span style="white-space:nowrap">non-monetary</span> obligations on it (or SPAC or any of its Affiliates after the Closing), (C) require it to accept or concede material injunctive relief or (D)&#160;involve a Governmental Entity or alleged criminal wrongdoing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) change the Company&#8217;s accounting principles, policies, procedures, practices or methods in any material respect, or make any change which would materially affect the reported consolidated assets, liabilities or results of operations of the Company and its Subsidiaries, other than changes that are made in accordance with GAAP or PCAOB standards; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) enter into any Contract with any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) enter into any Contract or other arrangement that materially restricts its or its Affiliates&#8217; ability to engage or compete in any material line of business or enter into a new material line of business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) make any capital expenditure that in the aggregate exceeds $1,000,000, other than any capital expenditure (or series of related capital expenditures) consistent with the capital expenditures budget set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)(xviii)</span><span style="text-decoration:underline"></span>&#160;of the Company Disclosure Schedules; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix) voluntarily fail to maintain in full force and effect material insurance policies covering it and its Affiliates and their respective properties, assets and businesses in a form and amount consistent with past practice; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx) enter into any transaction or amend in any material respect any existing Contract with any Company Related Party excluding, to the extent permitted under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)(x)</span>, ordinary course payments of annual compensation, provision of benefits or reimbursement of expenses; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi) sell, assign, transfer, convey, abandon, lease, license, or otherwise dispose of, or create or incur any Lien (other than Permitted Liens) on, any Intellectual Property Rights, except granting <span style="white-space:nowrap">non-exclusive</span> licenses pursuant to contract research agreements, clinical trial agreements, or supply agreements in which research, clinical trials, or supply services are being performed for the Company or any of its Subsidiaries, in each case, that are entered into by the Company or any of its Subsidiaries in the ordinary course of business and where the grant of rights to use any Intellectual Property Rights are incidental, and not material to, any performance under each such agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii) allow to lapse or expire or fail to take any action necessary to maintain any Intellectual Property Rights, except for the intentional abandonment of Intellectual Property rights that in the reasonable judgement of management of the Company are immaterial to the business of the Company or its Subsidiaries; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiii) enter into any Contract to take or cause to be taken, or otherwise become obligated to take or cause to be taken, any of the actions set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span> or this Agreement to the contrary, nothing set forth in this Agreement shall (i)&#160;give SPAC, directly or indirectly, the right to control or direct the operations of the Company prior to the Closing, or (ii)&#160;prohibit, or otherwise restrict the ability of, the Company or its Subsidiaries from using, paying or discharging any Indebtedness, Company Expenses or Liabilities of the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_66">Section&#160;5.2. Efforts to Consummate. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective, as promptly as reasonably practicable, the transactions contemplated by this Agreement (including (i)&#160;the satisfaction, but not waiver, of the Closing conditions set forth in <span style="text-decoration:underline">Article 6</span> and, in the case of any Ancillary Document to which such Party will be a party after the date of this Agreement, to execute and deliver such Ancillary Document when required pursuant to this Agreement, (ii)&#160;using reasonable best efforts to solicit proxies in connection with the SPAC Stockholder Approval, and (iii)&#160;using reasonable best efforts to obtain the PIPE Financing on the terms and subject to the conditions set forth in the Subscription Agreements, (iv)&#160;the Company taking, or causing to be taken, all actions necessary or advisable to cause the agreements set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2(a)</span> of the Company Disclosure Schedules to be terminated effective as of the Closing without any further obligations or liabilities to the Company or any of its Affiliates (including, from and after the Effective Time, SPAC) and (v)&#160;making all such filings with and obtaining all such approvals of Nasdaq to permit Series A Common Stock to be issued in accordance with this Agreement to be listed on Nasdaq). Without limiting the generality of the foregoing, each of the Parties shall use reasonable best efforts to obtain, file with or deliver to, as applicable, any Consents of any Governmental Entities necessary, proper or advisable to consummate the transactions contemplated by this Agreement or the Ancillary Documents. The costs incurred in connection with obtaining such Consents, including the HSR Act filing fee, shall be borne by SPAC; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that each Party shall, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.6</span>, bear its <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs and expenses in connection with the preparation of any such Consents. Each Party shall (A)&#160;make any appropriate filings pursuant to the HSR Act with respect to the transactions contemplated by this Agreement promptly (and in any event within ten Business Days) following the date of this Agreement, and (B)&#160;respond as promptly as reasonably practicable to any requests by any Governmental Entity for additional information and documentary material that may be requested pursuant to the HSR Act. SPAC shall promptly inform the Company of any communication between any SPAC Party, on the one hand, and any Governmental Entity, on the other hand, and the Company shall promptly inform SPAC of any communication between the Company or any of its Affiliates, on the one hand, and any Governmental Entity, on the other hand, in either case, regarding any of the transactions contemplated by this Agreement or any Ancillary Document. Without limiting the foregoing, each Party and their respective Affiliates shall not extend any waiting period, review period or comparable period under the HSR Act or enter into any agreement with any Governmental Entity not to consummate the transactions contemplated hereby or by the Ancillary Documents, except with the prior written consent of SPAC and the Company. Nothing in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> obligates any Party or any of its Affiliates to agree to (1)&#160;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of, any entities, assets or facilities, (2)&#160;terminate, amend or assign existing relationships and contractual rights or obligations, including licenses, or (3)&#160;enter into new licenses or other agreements. No Party shall agree to any of the foregoing measures with respect to any other Party, except with SPAC&#8217;s and the Company&#8217;s prior written consent. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During the Interim Period, and unless prohibited by applicable Law, the SPAC Parties, on the one hand, and the Company, on the other hand, shall give counsel for the Company (in the case of any SPAC Party) or SPAC (in the case of the Company) a reasonable opportunity to review in advance, and consider in good faith the views of the other in connection with, any proposed written communication to any Governmental Entity relating to the transactions contemplated by this Agreement or the Ancillary Documents. Each of the Parties agrees not to participate in any substantive meeting or discussion, either in person or by telephone, with any Governmental Entity in connection with the transactions contemplated by this Agreement unless it consults with, in the case of any SPAC Party, the Company, or, in the case of the Company, SPAC in advance. The Parties agree to consult and cooperate with one another in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any Party in connection with judicial proceedings under or relating to the HSR Act or any Foreign Antitrust Law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in the Agreement, in the event that this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span> conflicts with any other covenant or agreement in this <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> V</span> that is intended to specifically address certain subject matter, then such other covenant or agreement shall govern and control solely to the extent of such conflict. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Without limiting the generality of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span>, SPAC will (and shall cause the Sponsor to) use commercially reasonable efforts to cause the satisfaction of the condition set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(c)</span>, which may include, during the Interim Period and subject to applicable Law, using commercially reasonable efforts to obtain from Persons who have not previously entered into a Subscription Agreement on the date hereof, Subscription Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_67">Section&#160;5.3. Confidentiality and Access to Information. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties hereby acknowledge and agree that the information being provided in connection with this Agreement and the consummation of the transactions contemplated hereby is subject to the terms of the Confidentiality Agreement, the terms of which are incorporated herein by reference, <span style="font-style:italic">mutatis mutandis</span>. Notwithstanding the foregoing or anything to the contrary in this Agreement, in the event that this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3(a)</span> or the Confidentiality Agreement conflicts with any other covenant or agreement contained herein that contemplates the disclosure, use or provision of information or otherwise, then such other covenant or agreement contained herein shall govern and control to the extent of such conflict. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During the Interim Period, upon reasonable advance written notice, the Company shall provide, or cause to be provided, to SPAC and its Representatives during normal business hours reasonable access to the directors, officers, books and records of the Company (in a manner so as to not interfere with the normal business operations of the Company or, in light of <span style="white-space:nowrap">COVID-19</span> or any Pandemic Measures, jeopardize the health or safety of any employee of the Company (which may require remote and telephonic meetings)). Notwithstanding the foregoing, the Company shall not be required to provide, or cause to be provided, to SPAC or any of its Representatives any information (i)&#160;if, and to the extent, doing so would (A)&#160;violate any Law to which the Company is subject, (B)&#160;result in the disclosure of any trade secrets, (C)&#160;violate any legally-binding obligation of the Company with respect to confidentiality, <span style="white-space:nowrap">non-disclosure</span> or privacy or (D)&#160;jeopardize protections afforded to the Company under the attorney-client privilege or the attorney work product doctrine (<span style="font-style:italic">provided</span> that, in case of each of clauses (A)&#160;through (D), the Company shall use commercially reasonable efforts to (x)&#160;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law, and (y)&#160;provide such information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&#160;if the Company, on the one hand, and any SPAC Party or any of its Representatives, on the other hand, are adverse parties in a litigation and such information is reasonably pertinent thereto; <span style="font-style:italic">provided</span> that the Company shall, in the case of clause (i)&#160;or (ii), provide prompt written notice of the withholding of access or information on any such basis. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) During the Interim Period, upon reasonable advance written notice, SPAC shall provide, or cause to be provided, to the Company and its Representatives during normal business hours reasonable access to the directors, officers, books and records of the SPAC Parties (in a manner so as to not interfere with the normal business operations of the SPAC Parties or, in light of <span style="white-space:nowrap">COVID-19</span> or any Pandemic Measures, jeopardize the health or safety of any employee of the SPAC Parties (which may require remote and telephonic meetings)). Notwithstanding the foregoing, SPAC shall not be required to provide, or cause to be provided, to the Company or any of its Representatives any information (i)&#160;if and to the extent doing so would (A)&#160;violate any Law to which any SPAC Party is subject, (B)&#160;result in the disclosure of any trade secrets, (C)&#160;violate any legally-binding obligation of any SPAC Party with respect to confidentiality, <span style="white-space:nowrap">non-disclosure</span> or privacy or (D)&#160;jeopardize protections afforded to any SPAC Party under the attorney-client privilege or the attorney work product doctrine; <span style="font-style:italic">provided</span> that, in case of each of clauses (A)&#160;through (D), SPAC shall use, and shall cause the other SPAC Parties to use, commercially reasonable efforts to (x)&#160;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law, and (y)&#160;provide such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&#160;if a SPAC Party, on the one hand, and the Company or any of its Representatives, on the other hand, are adverse parties in a litigation and such information is reasonably pertinent thereto; <span style="font-style:italic">provided</span> that SPAC shall, in the case of clause (i)&#160;or (ii), provide prompt written notice of the withholding of access or information on any such basis. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Parties hereby acknowledge and agree that the Confidentiality Agreement shall be automatically terminated effective as of the Closing without any further action by any Party or any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_68">Section&#160;5.4. Public Announcements. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.7</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.8</span>, none of the Parties or any of their respective Representatives or Affiliates shall issue any press releases or make any public announcements with respect to this Agreement or the transactions contemplated hereby without the prior written consent of, prior to the Closing, the Company and SPAC or, after the Closing, SPAC; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that each Party may make any such announcement or other communication (i)&#160;if such announcement or other communication is required by applicable Law, in which case (A)&#160;prior to the Closing, the disclosing Party and its Representatives shall, where permitted under applicable Law and feasible with regard to any time limits imposed thereby in relation to making such announcement or other communication, use reasonable best efforts to consult with the Company, if the disclosing party is any SPAC Party, or with SPAC, if the disclosing party is the Company, prior to making such announcement or other communication, to review such announcement or communication and to give such <span style="white-space:nowrap">non-disclosing</span> party the opportunity to comment thereon, in which case the disclosing Party shall consider such comments in good faith, or (B)&#160;after the Closing, the disclosing Party and its Representatives shall, where permitted under applicable Law and feasible with regard to any time limits imposed thereby in relation to making such announcement or other communication, use reasonable best efforts to consult with SPAC prior to making such announcement or other communication and to consider any comments of SPAC thereon in good faith, (ii)&#160;to the extent such announcements or other communications contain only information previously disclosed in a public statement, press release or other communication previously approved in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4</span>, and (iii)&#160;to Governmental Entities in connection with any Consents required to be made under this Agreement, the Ancillary Documents or in connection with the transactions contemplated hereby or thereby. Notwithstanding anything to the contrary in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4</span> or otherwise in this Agreement, the Parties agree that the SPAC Parties, the Sponsor and their respective Representatives may provide general information about the subject matter of this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby to any direct or indirect current or prospective investor or in connection with normal fund raising or related marketing or informational or reporting activities. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The initial press release concerning this Agreement and the transactions contemplated hereby shall be a joint press release in the form agreed by the Company and SPAC prior to the execution of this Agreement and such initial press release (the &#8220;<span style="font-weight:bold">Signing Press Release</span>&#8221;) shall be released as promptly as reasonably practicable after the execution of this Agreement. Promptly after the execution of this Agreement, SPAC shall file a current report on Form <span style="white-space:nowrap">8-K</span> (the &#8220;<span style="font-weight:bold">Signing Filing</span>&#8221;) with the Signing Press Release and a description of this Agreement as required by, and in compliance with, the Securities Laws, which the Company shall have the opportunity to review and comment upon prior to filing and SPAC shall consider such comments in good faith. The Company, on the one hand, and SPAC, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or SPAC, as applicable) a press release announcing the consummation of the transactions contemplated by this Agreement (the &#8220;<span style="font-weight:bold">Closing Press Release</span>&#8221;) prior to the Closing, and, on the Closing Date, the Parties shall cause the Closing Press Release to be released. Promptly after the Closing (but in any event within four (4)&#160;Business Days after the Closing), SPAC shall file a current report on Form <span style="white-space:nowrap">8-K</span> (the &#8220;<span style="font-weight:bold">Closing Filing</span>&#8221;) with the Closing Press Release, a description of the Closing and the required pro forma financial statements and the historical financial statements prepared by the Company and its accountants, in each case, as required by Securities Laws, which the Company shall have the opportunity to review and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
comment upon prior to filing and SPAC shall consider such comments in good faith. In connection with the preparation of each of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing Filing, each Party shall, upon written request by any other Party, furnish such other Party with all information concerning itself, its directors, officers and equityholders, and such other matters as may be reasonably necessary for such press release or filing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event that <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(a)</span><span style="text-decoration:underline"></span>&#160;conflicts with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(b)</span>, then <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4(b)</span> shall govern and control solely to the extent of such conflict. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_69">Section&#160;5.5. Tax Matters. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties intend that the Merger shall constitute a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Each Party shall, and shall cause its respective Affiliates to, use reasonable best efforts to so qualify and shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), such treatment unless required to do so pursuant to a &#8220;determination&#8221; (within the meaning of Section&#160;1313(a) of the Code) that is final. None of the Parties knows of any facts or circumstances and shall not knowingly take any action, or knowingly fail to take any action, that would reasonably be expected to prevent or impede the Intended Tax Treatment. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Parties hereby adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections <span style="white-space:nowrap">1.368-2(g)&#160;and</span> <span style="white-space:nowrap">1.368-3(a),</span> for purposes of Sections 354, 361 and 368 of the Code. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Parties shall cooperate fully, as and to the extent reasonably requested by each of them, in connection with the filing or amendment of any Tax Returns or any audit or other proceeding with respect to Taxes of the Surviving Corporation, and with each other and their respective counsel to document and support the Tax treatment of the Merger in a manner consistent with the Intended Tax Treatment, including by providing reasonable and customary factual support letters. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If, in connection with the preparation and filing of the Registration Statement/Proxy Statement, the SEC requests or requires that tax opinions be prepared and submitted in such connection, SPAC and the Company shall deliver customary Tax representation letters, dated and executed as of the date the Registration Statement/Proxy Statement shall have been declared effective by the SEC and such other date(s) as determined reasonably necessary in connection with the preparation and filing of the Registration Statement/Proxy Statement, and, if required, the Parties shall cause Marcum (or such other nationally recognized tax counsel to the Company reasonably satisfactory to SPAC) to furnish an opinion, subject to customary assumptions and limitations, to the effect that the Intended Tax Treatment should apply to the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_70">Section&#160;5.6. Exclusive Dealing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Interim Period, the Company shall not, and shall direct its Representatives and Affiliates not to, directly or indirectly (i)&#160;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition Proposal, (ii)&#160;furnish or disclose any <span style="white-space:nowrap">non-public</span> information to any Person (other than to the Parties and their respective Representatives) in connection with, or that would reasonably be expected to lead to, a Company Acquisition Proposal, (iii)&#160;enter into any Contract or other arrangement or understanding regarding a Company Acquisition Proposal, (iv)&#160;other than in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, prepare or take any steps in connection with a public offering of any Equity Securities of the Company (or any Affiliate or successor of the Company), or (v)&#160;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company shall (i)&#160;notify SPAC promptly upon receipt of any Company Acquisition Proposal by the Company, describing the terms and conditions of any such Company Acquisition Proposal in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
reasonable detail (including the identity of the Person(s) making such Company Acquisition Proposal, unless the Company is bound by any confidentiality obligation entered into prior to the date hereof prohibiting the disclosure of such identity), and (ii)&#160;keep SPAC reasonably informed on a reasonably current basis of any modifications to such offer or information. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) During the Interim Period, the SPAC Parties shall not, and each of them shall direct their Representatives not to, directly or indirectly (i)&#160;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a SPAC Acquisition Proposal, (ii)&#160;furnish or disclose any <span style="white-space:nowrap">non-public</span> information to any Person (other than to the Parties and their respective Representatives) in connection with, or that would reasonably be expected to lead to, a SPAC Acquisition Proposal, (iii)&#160;enter into any Contract or other arrangement or understanding regarding a SPAC Acquisition Proposal, (iv)&#160;other than in connection with this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby, prepare or take any steps in connection with an offering of any securities of any SPAC Party (or any Affiliate or successor of any SPAC Party), or (v)&#160;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any of the foregoing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) SPAC agrees to (i)&#160;notify the Company promptly upon any SPAC Party obtaining any SPAC Acquisition Proposal, and to describe the terms and conditions of any such SPAC Acquisition Proposal in reasonable detail (including the identity of any Person making such SPAC Acquisition Proposal), and (ii)&#160;keep the Company reasonably informed on a reasonably current basis of any modifications to such offer or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_71"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.7.</span> <span style="font-weight:bold">Preparation of Registration Statement/Proxy Statement.</span><span style="font-weight:bold"> </span>As promptly as practicable following the date of this Agreement, (a)&#160;SPAC and the Company shall jointly prepare and SPAC shall file with the SEC, mutually acceptable materials which shall include the proxy statement/prospectus (as amended or supplemented from time to time, the &#8220;<span style="font-weight:bold">Proxy Statement/Prospectus</span>&#8221;) to be sent to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders soliciting proxies from such stockholders to obtain the SPAC Stockholders Approval at the SPAC Stockholders Meeting, and (b)&#160;SPAC shall prepare and file with the SEC a registration statement on Form <span style="white-space:nowrap">S-4</span> or such other applicable form, in which the Proxy Statement/Prospectus will be included as a prospectus, in connection with the registration under the Securities Act of, to the extent permitted by the rules and regulations promulgated by the SEC, the Series A Common Stock issuable in connection with the Merger (together with the Proxy Statement/Prospectus, the &#8220;<span style="font-weight:bold">Registration Statement/Proxy Statement</span>&#8221;). Any lodgement or filing fees in connection with the filing of the Registration Statement/Proxy Statement with the SEC shall be borne by SPAC. Each of SPAC and the Company shall use its reasonable best efforts to (i)&#160;cause the Registration Statement/Proxy Statement to comply in all material respects with the applicable rules and regulations promulgated by the SEC (including, with respect to the Company and its Subsidiaries, by the provision of audited financial statements (in accordance with PCAOB standards) of, and any other information with respect to, the Company and its Subsidiaries for all periods, and in the form, required to be included in the Registration Statement/Proxy Statement under Securities Laws (after giving effect to any waivers received) or in response to any comments from the SEC) and using reasonable best efforts to cause the Company&#8217;s auditors to deliver the required audit opinions and consents, and (ii)&#160;promptly notify the other Party of, reasonably cooperate with each other with respect to and respond promptly to any comments of the SEC or its staff; and SPAC shall use its reasonable best efforts to (A)&#160;have the Registration Statement/Proxy Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC, and (B)&#160;keep the Registration Statement/Proxy Statement effective through the Closing in order to permit the consummation of the transactions contemplated by this Agreement. SPAC, on the one hand, and the Company, on the other hand, shall promptly furnish, or cause to be furnished, to the other all information or representations concerning such Party and its Representatives that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.7</span> or for including in any other statement, filing, notice or application made by or on behalf of SPAC to the SEC or Nasdaq in connection with the transactions contemplated by this Agreement and the Ancillary Documents, including, for the avoidance of doubt, the Company providing for the Registration Statement/Proxy Statement its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
audited consolidated balance sheets as of December&#160;31, 2022 and December&#160;31, 2021 and its related consolidated statements of income (loss), changes in shareholders&#8217; equity and cash flows for the fiscal years then ended, audited in accordance with applicable PCAOB auditing standards (the &#8220;<span style="font-weight:bold">Additional Company Financial Statements</span>&#8221;), its unaudited consolidated balance sheet as of September&#160;30, 2023 and the related unaudited consolidated statement of operations and comprehensive loss for the quarterly periods then ended, and necessary pro forma financial statements. If any Party becomes aware of any information that should be disclosed in an amendment or supplement to the Registration Statement/Proxy Statement, then (1)&#160;such Party shall promptly inform, in the case of any SPAC Party, the Company, or, in the case of the Company, SPAC thereof, (2)&#160;such Party shall prepare and mutually agree upon with, in the case of SPAC, the Company, or, in the case of the Company, SPAC (in either case, such agreement not to be unreasonably withheld, conditioned or delayed), an amendment or supplement to the Registration Statement/Proxy Statement, (3)&#160;SPAC shall promptly file such mutually agreed upon amendment or supplement with the SEC, and (4)&#160;the Parties shall reasonably cooperate, if appropriate, in promptly mailing such amendment or supplement to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders. The Proxy Statement/Prospectus shall include materials for the adoption and approval by the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders of a new equity incentive plan (the &#8220;<span style="font-weight:bold">New Equity Incentive Plan</span>&#8221;), which will initially reserve a number of shares of Series A Common Stock equal to 10.0% of the aggregate number of shares of Series A Common Stock issued and outstanding immediately after the Closing (and, for the avoidance of doubt, without accounting for any shares of Series A Common Stock subject to Rollover Options). The Company shall provide a proposed form of the New Equity Incentive Plan within 30 days after the date of this Agreement. SPAC shall have a right to review and approve the New Equity Incentive Plan in advance, such approval not to be unreasonably withheld, conditioned or delayed, and the Parties shall otherwise cooperate to include such terms and conditions as are customary and appropriate for the New Equity Incentive Plan. SPAC shall as promptly as reasonably practicable advise the Company of the time of effectiveness of the Registration Statement/Proxy Statement, the issuance of any stop order relating thereto or the suspension of the qualification of Series A Common Stock for offering or sale in any jurisdiction, and SPAC and the Company shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the Parties hereto shall use reasonable best efforts to ensure that none of the information related to it or any of its Representatives, supplied by or on its behalf for inclusion or incorporation by reference in the Registration Statement/Proxy Statement will, at the time the Registration Statement/Proxy Statement is filed with the SEC, at each time at which it is amended, or at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_72"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.8.</span> <span style="font-weight:bold">SPAC Stockholder Approval.</span><span style="font-weight:bold"> </span>As promptly as reasonably practicable following the time at which the Registration Statement/Proxy Statement is declared effective under the Securities Act, SPAC shall (a)&#160;establish the record date for, duly call, give notice of, and (b)&#160;in any case within 30 days of such effectiveness, duly convene and hold a meeting of its stockholders (the &#8220;<span style="font-weight:bold">SPAC Stockholders Meeting</span>&#8221;) in accordance with the Governing Documents of SPAC, for the purposes of obtaining the SPAC Stockholder Approval and, if applicable, any approvals related thereto, and providing its stockholders with the opportunity to elect to effect a SPAC Stockholder Redemption. Except as required by applicable Law, SPAC shall, through the unanimous approval of its board of directors, recommend to its stockholders (the &#8220;<span style="font-weight:bold">SPAC Board Recommendation</span>&#8221;): (i)&#160;the adoption and approval of this Agreement and each Ancillary Document to which SPAC is a party and the transactions contemplated hereby and thereby (including the Merger), (ii)&#160;the adoption and approval of the issuance of Series A Common Stock in connection with the transactions contemplated by this Agreement, as required by Nasdaq listing requirements, (iii)&#160;the adoption and approval of the Required Governing Document Proposals, (iv)&#160;the adoption of the New Equity Incentive Plan, (v)&#160;the election of directors to be nominated in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.16</span>, (vi)&#160;the issuance of the SPAC Incentive Shares and Company Incentive Shares, (vii)&#160;the adoption and approval of each other proposal that either the SEC or Nasdaq (or the respective staff members thereof) indicates is necessary in its comments to the Registration Statement/Proxy Statement or in correspondence related thereto, (viii)&#160;the adoption and approval of each other proposal reasonably agreed by SPAC and the Company as necessary or appropriate in connection with the consummation of the transactions contemplated by this Agreement or the Ancillary Documents, and (xi)&#160;the adoption and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of a proposal for the adjournment of the SPAC Stockholders Meeting, if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt any of the foregoing (such proposals in clauses (i)&#160;through (xi)&#160;together, the &#8220;<span style="font-weight:bold">Required Transaction Proposals</span>&#8221;); <span style="font-style:italic">provided</span> that SPAC may postpone or adjourn the SPAC Stockholders Meeting (A)&#160;to solicit additional proxies for the purpose of obtaining the SPAC Stockholder Approval, (B)&#160;for the absence of a quorum, (C)&#160;to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosures that SPAC has determined, based on the advice of outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders prior to the SPAC Stockholders Meeting, or (D)&#160;if the holders of Series A Common Stock have elected to redeem a number of shares of Series A Common Stock as of such time that would reasonably be expected to result in the condition set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(c)</span>&#160;not being satisfied; <span style="font-style:italic">provided</span> that, without the consent of the Company, (i)&#160;SPAC may only adjourn the SPAC Stockholders Meeting two (2)&#160;times, and (ii)&#160;in no event shall SPAC adjourn the SPAC Stockholders Meeting for more than ten (10)&#160;Business Days later than the most recently adjourned meeting or to a date that is beyond the Termination Date. Except as required by applicable Law, the SPAC Board Recommendation shall be included in the Registration Statement/Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_73"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.9.</span> <span style="font-weight:bold">Merger Sub Stockholder Approval.</span><span style="font-weight:bold"> </span>As promptly as reasonably practicable (and in any event within one Business Day) following the date of this Agreement, SPAC, as the sole stockholder of Merger Sub, will approve and adopt this Agreement, the Ancillary Documents to which Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the Merger). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_74"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.10.</span> <span style="font-weight:bold">Conduct of Business of SPAC.</span><span style="font-weight:bold"> </span>During the Interim Period, SPAC shall operate in the ordinary course in all material respects and not, except as expressly contemplated by this Agreement or any Ancillary Document (including, for the avoidance of doubt, in connection with the PIPE Financing), as required by applicable Law, as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span> of the SPAC Disclosure Schedules, to reasonably comply with any applicable Pandemic Measures or as expressly consented to in writing by the Company (such consent not to be unreasonably withheld, conditioned or delayed if such matter is in furtherance of the transactions contemplated by this Agreement or any Ancillary Document), do any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) seek an approval from the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders, or otherwise adopt any amendments, supplements, restatements or modifications to the Trust Agreement, or the Governing Documents of any SPAC Party or any of their Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any issued and outstanding Equity Securities of SPAC or any of its Subsidiaries, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any issued and outstanding Equity Securities of SPAC or any of its Subsidiaries, as applicable; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) split, combine or reclassify any of its capital stock or other Equity Securities or issue any other security in respect of, in lieu of or in substitution for shares of its capital stock; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) incur, create, guarantee or assume (whether directly, contingently or otherwise) any Indebtedness, except for Indebtedness for borrowed money in an amount not to exceed $1,000,000 in the aggregate; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) make any loans or advances to, or capital contributions in, any other Person, other than to, or in, SPAC or any of its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) issue any Equity Securities of SPAC or any of its Subsidiaries or grant any options, warrants or stock appreciation rights with respect to Equity Securities of SPAC or any of its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) enter into, renew, modify or revise any SPAC Related Party Transaction (or any Contract or agreement that if entered into prior to the execution and delivery of this Agreement would be a SPAC Related Party Transaction), other than the entry into any Contract with a SPAC Related Party with respect to the incurrence of Indebtedness permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10(d)</span>; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) engage in any activities or business, or incur any material Liabilities, other than with respect to any activities, business or Liabilities that are (i)&#160;either otherwise permitted under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span> (including, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
for the avoidance of doubt, any activities, business or Liabilities contemplated by, or Liabilities incurred in connection with, or that are otherwise incidental or attendant to, this Agreement or any Ancillary Document, the performance of any covenants or agreements hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby) or in accordance with or consented to by the Company pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span>, (ii)&#160;in connection with or incidental or related to its continuing corporate (or similar) existence or it being (or continuing to be) a public company listed on Nasdaq, or (iii)&#160;which are administrative or ministerial in nature and, in the case of this clause (iii), which are not material; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction involving SPAC or its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) enter into any Contract with any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage fee, finder&#8217;s fee or other commission in connection with the transactions contemplated by this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) make, change or revoke any material Tax election or material Tax accounting method, file any material Tax Return in a manner inconsistent with past practice, amend any material Tax Return, enter into any agreement with a Governmental Entity with respect to a material amount of Taxes, settle or compromise any claim or assessment by a Governmental Entity in respect of any material amount of Taxes, surrender any right to claim a refund of a material amount of Taxes, consent to any extension or waiver of the statutory period of limitation applicable to any material Tax claim or assessment, or enter into any Tax sharing or similar agreement (other than any agreement entered into in the ordinary course of business, the primary purpose of which does not relate to Taxes); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) waive, release, compromise, settle or satisfy any pending or threatened material claim (which shall include, but not be limited to, any pending or threatened Proceeding); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) make any change in any method of financial accounting or financial accounting principles, policies, procedures or practices except changes that are made (i)&#160;in accordance with PCAOB standards, or (ii)&#160;as required by any Securities Law or any Order, directive, guideline, recommendation, statement, comment or guidance issued, passed, approved, published, promulgated or released by, the SEC, following reasonable prior consultation with the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) make or permit to be made any distribution of amounts held in the Trust Account (other than interest income earned on the funds held in the Trust Account as permitted by the Trust Agreement); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) create any new Subsidiary; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) (A) merge, consolidate, combine or amalgamate with any Person, or (B)&#160;purchase or otherwise acquire (whether by merging or consolidating with, purchasing any Equity Securities in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, limited liability company, joint venture, association or other business entity or organization or division thereof; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) enter into any Contract to take, or cause to be taken, or otherwise become obligated to take or cause to be taken, any of the actions set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.10</span> or this Agreement to the contrary, (i)&#160;nothing set forth in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of SPAC, and (ii)&#160;nothing set forth in this Agreement shall prohibit, or otherwise restrict the ability of, SPAC from using the funds held by SPAC outside the Trust Account to pay any SPAC Expenses or any Liabilities of SPAC or from otherwise distributing or paying over any funds held by SPAC outside the Trust Account to the Sponsor or any of its Affiliates, in each case, prior to the Closing; <span style="font-style:italic">provided</span>, that prior to any distribution or payment of any funds to the Sponsor or any of its Affiliates pursuant to the foregoing sentence, SPAC shall cause any Indebtedness of SPAC payable or owing to the Sponsor or any of its Affiliates to be paid in full and discharged with no further Liability or obligation of SPAC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_75"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.11.</span> <span style="font-weight:bold">Nasdaq Listing.</span><span style="font-weight:bold"> </span>From the date hereof through the Effective Time, SPAC shall ensure SPAC remains listed as a public company on Nasdaq. SPAC shall use its reasonable best efforts to, as promptly as reasonably practicable after the date of this Agreement (and in any event, as of immediately prior to or at the Effective Time), (a)&#160;cause the Series A Common Stock issuable in accordance with this Agreement to be approved for listing on Nasdaq (and the Company shall reasonably cooperate in connection therewith), subject to official notice of issuance prior to the Effective Time, (b)&#160;satisfy any applicable initial and continuing listing requirements of Nasdaq, (c)&#160;cause the name of SPAC to be changed to &#8220;Abpro Corporation&#8221; with effect from the Closing Date, and (d)&#160;cause the ticker under which the Series A Common Stock is listed for trading on Nasdaq to be changed to &#8220;ABP&#8221; and have the Series A Common Stock listed for trading with such trading ticker. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_76"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.12.</span> <span style="font-weight:bold">Trust Account.</span><span style="font-weight:bold"> </span>Upon satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> VI</span> and provision of notice thereof to the Trustee, (a)&#160;at the Closing, SPAC shall (i)&#160;cause the documents, certificates and notices required to be delivered to the Trustee pursuant to the Trust Agreement to be so delivered, and (ii)&#160;make all appropriate arrangements to cause the Trustee to (A)&#160;pay as and when due all amounts, if any, payable to the SPAC&#8217;s public stockholders pursuant to the SPAC Stockholder Redemption, (B)&#160;pay any Unpaid SPAC Expenses and (C)&#160;immediately thereafter, pay all remaining amounts then available in the Trust Account to SPAC in accordance with the Trust Agreement, and (b)&#160;thereafter, the Trust Account shall terminate, except as otherwise provided therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_77"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.13.</span> <span style="font-weight:bold">Company Stockholder Approval.</span><span style="font-weight:bold"> </span><span style="font-weight:bold"></span>As promptly as reasonably practicable (and in any event within forty eight (48)&#160;hours) following the date that the Registration Statement/Proxy Statement becomes effective (the &#8220;<span style="font-weight:bold">Company Stockholder Written Consent Deadline</span>&#8221;), the Company shall obtain and deliver to SPAC a true and correct copy of a written consent (in form and substance reasonably satisfactory to SPAC) approving this Agreement, the Ancillary Documents to which the Company is or will be a party and the transactions contemplated hereby and thereby (including the Merger, the amendment to the Company Certificate of Incorporation to provide for the Company Preferred Stock Conversion to occur automatically immediately prior to the Closing, the Company Preferred Stock Conversion and the amendment of the Company&#8217;s Governing Documents pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.1(a)(iv)</span>) that is duly executed by the Company Stockholders that hold at least the requisite number of issued and outstanding Company Common Stock and Company Preferred Stock required to approve and adopt such matters in accordance with the DGCL and the Company&#8217;s Governing Documents (the &#8220;<span style="font-weight:bold">Company Stockholder Written Consent</span>&#8221;). The Company shall recommend to the Company Stockholders the approval and adoption of this Agreement and the Ancillary Documents to which the Company is or will be a party and the transactions contemplated hereby and thereby (including the Merger). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_78">Section&#160;5.14. SPAC Indemnification; Directors&#8217; and Officers&#8217; Insurance. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that (i)&#160;all rights to advancement, indemnification, limitations on liability or exculpation now existing in favor of the directors and officers of each SPAC Party, as provided in the applicable SPAC Party&#8217;s Governing Documents in effect as of immediately prior to the Effective Time, in either case, solely with respect to any acts, errors or omissions occurring on or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective Time for a period of six (6)&#160;years, and (ii)&#160;SPAC will perform and discharge, or cause to be performed and discharged, all obligations to provide such advancement, indemnity, limitations on liability and exculpation during such six (6)-year period. To the maximum extent permitted by applicable Law, during such six (6)-year period, SPAC shall advance, or caused to be advanced, expenses in connection with such indemnification as provided in the applicable SPAC Party&#8217;s Governing Documents or other applicable agreements in effect as of the date hereof. The advancement, indemnification and liability limitation or exculpation provisions of the SPAC Parties&#8217; Governing Documents or in other applicable agreements in effect as of immediately prior to the Effective Time shall not, during such six (6)-year period, be amended, repealed or otherwise modified after the Effective Time in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior to the Effective Time or at any time prior to such time, were directors or officers of any SPAC Party (the &#8220;<span style="font-weight:bold">SPAC D&amp;O Persons</span>&#8221;) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to receive advancement, be so indemnified, have their liability limited or be exculpated with respect to any act, error or omission occurring on or prior to the Effective Time by reason of the fact that such SPAC D&amp;O Person was a director or officer of any SPAC Party prior to the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. If any claims are made or asserted within such six (6)-year period, all rights in respect of any such claims will continue until the full disposition of all such claims. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SPAC shall not have any obligation under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span> to any SPAC D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <span style="white-space:nowrap">non-appealable)</span> that the indemnification of such SPAC D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Surviving Company shall purchase at or prior to Closing and maintain in effect for a period of six (6)&#160;years after the Effective Time, without lapses in coverage, a &#8220;tail&#8221; policy or policies providing directors&#8217; and officers&#8217; liability insurance coverage for the benefit of those Persons who are currently covered by any comparable insurance policies of the SPAC Parties as of the date of this Agreement with respect to any acts, errors or omissions occurring on or prior to the Effective Time (the &#8220;<span style="font-weight:bold">SPAC D&amp;O Tail Policy</span>&#8221;). Such &#8220;tail&#8221; policy or policies shall be included in the Company&#8217;s directors&#8217; and officers&#8217; liability insurance coverage and provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under SPAC&#8217;s directors&#8217; and officers&#8217; liability insurance policies as of the date of this Agreement; provided that SPAC shall not be required to pay a premium for such &#8220;tail&#8221; policy or policies in excess of three hundred seventy-five percent (375%) of the most recent premium paid by SPAC prior to the date of this Agreement and, if the requisite cover is not available for such a premium, SPAC shall purchase the maximum coverage available for three hundred seventy-five percent (375%) of the most recent premium paid by SPAC prior to the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If, following the Closing, SPAC (i)&#160;shall merge or consolidate with or merge into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger, or (ii)&#160;shall transfer all or substantially all of its properties and assets as an entity in one or a series of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of SPAC shall assume all of the obligations set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The SPAC D&amp;O Persons entitled to the advancement, indemnification, liability limitation, exculpation and insurance set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span> are intended to be third-party beneficiaries of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span>. This <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span> shall survive the consummation of the transactions contemplated by this Agreement and shall be binding on all successors and assigns of SPAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_79">Section&#160;5.15. Company Indemnification; Directors&#8217; and Officers&#8217; Insurance. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Each Party agrees that (i)&#160;all rights to advancement, indemnification, limitations on liability or exculpation now existing in favor of the directors and officers of the Company, as provided in any indemnification agreements or in the Company&#8217;s Governing Documents in effect as of immediately prior to the Effective Time, in either case, solely with respect to any acts, errors or omissions occurring on or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective Time for a period of six (6)&#160;years, and (ii)&#160;SPAC will perform and discharge, or cause to be performed and discharged, all obligations to provide such advancement, indemnity, limitations on liability and exculpation during such six (6)-year period. To the maximum extent permitted by applicable Law, during such six (6)-year period, SPAC shall advance, or caused to be advanced, expenses in connection with such indemnification as provided in the Company&#8217;s Governing Documents or other applicable agreements in effect as of the date hereof. The advancement, indemnification and liability limitation or exculpation provisions of the Company&#8217;s Governing Documents or in other applicable agreements in effect as of immediately prior to the Effective Time shall not, during such six (6)-year period, be amended, repealed or otherwise modified after the Effective Time in any manner that would materially and adversely affect the rights thereunder of individuals who, as of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
immediately prior to the Effective Time or at any time prior to such time, were directors or officers of the Company (the &#8220;<span style="font-weight:bold">Company D&amp;O Persons</span>&#8221;) to receive advancement, be so indemnified, have their liability limited or be exculpated with respect to any act, error or omission occurring on or prior to the Effective Time by reason of the fact that such Company D&amp;O Person was a director or officer of the Company prior to the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. If any claims are made or asserted within such six (6)-year period, all rights in respect of any such claims will continue until the full disposition of all such claims. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither the SPAC nor the Company shall have any obligation under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> to any Company D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <span style="white-space:nowrap">non-appealable)</span> that the indemnification of such Company D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall purchase, at or prior to the Effective Time, and SPAC shall maintain, or cause to be maintained, in effect for a period of six (6)&#160;years after the Effective Time, without lapses in coverage, a &#8220;tail&#8221; policy or policies providing directors&#8217; and officers&#8217; liability insurance coverage for the benefit of those Persons who are currently covered by any comparable insurance policies of the Company immediately prior to the Effective Time with respect to any acts, errors or omissions occurring on or prior to the Effective Time (the &#8220;<span style="font-weight:bold">Company D&amp;O Tail Policy</span>&#8221;). Such Company D&amp;O Tail Policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under the Company&#8217;s directors&#8217; and officers&#8217; liability insurance policies in effect immediately prior to the Effective Time; provided that the Company shall not be required to pay a premium for such &#8220;tail&#8221; policy or policies in excess of three hundred seventy-five percent (375%) of the most recent premium paid by the Company prior to the Effective Time and, if the requisite cover is not available for such a premium, the Company shall purchase the maximum coverage available for three hundred seventy-five percent (375%) of the most recent premium paid by the Company prior to the Effective Time. Notwithstanding the foregoing in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15(c)</span>, the Company in its sole discretion, in lieu of purchasing the Company D&amp;O Tail Policy, may choose to maintain (and if so chosen, SPAC shall maintain or cause to be maintained) for a period of six (6)&#160;years after the Closing, without any lapses in coverage, directors&#8217; and officers&#8217; liability insurance for the benefit of those Persons who are currently covered by any comparable insurance policies of the Company immediately prior to the Effective Time with respect to any acts, errors or omissions occurring on or prior to the Effective Time. Such insurance policies shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under the Company&#8217;s directors&#8217; and officers&#8217; liability insurance policies immediately prior to the Effective Time. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If, following the Closing, SPAC (i)&#160;shall merge or consolidate with or merge into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger, or (ii)&#160;shall transfer all or substantially all of its properties and assets as an entity in one or a series of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of SPAC shall assume all of the obligations set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company D&amp;O Persons entitled to the advancement, indemnification, liability limitation, exculpation and insurance set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> are intended to be third-party beneficiaries of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span>. This <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> shall survive the consummation of the transactions contemplated by this Agreement and shall be binding on all successors and assigns of SPAC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_80"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.16.</span> <span style="font-weight:bold">Post-Closing Directors and Officers.</span><span style="font-weight:bold"> </span>The Parties shall take all necessary action, including causing the SPAC&#8217;s directors to resign, so that effective as of the Closing, the SPAC&#8217;s board of directors (the &#8220;<span style="font-weight:bold">Post-Closing Board</span>&#8221;) will consist of five individuals. At the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Board, one person designated prior to the Closing by the SPAC, who shall qualify as an independent director under Nasdaq requirements; and four persons designated prior to the Closing by the Company in the Company&#8217;s sole discretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_81">Section&#160;5.17. PIPE Subscriptions. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Closing, SPAC and/or the Company may execute Subscription Agreements with potential sources of PIPE Financing. The Company agrees, and shall cause the appropriate officers and employees thereof, to use commercially reasonable efforts to cooperate in connection with the arrangement of such PIPE Financing (including the satisfaction of the conditions precedent set forth therein) as may be reasonably requested by SPAC, including by (a)&#160;participating in a reasonable number of meetings, presentations, due diligence sessions, drafting sessions and sessions with rating agencies at mutually agreeable times and locations and upon reasonable advance notice, (b)&#160;assisting with the preparation of customary materials for actual and potential investors, rating agency presentations, offering documents, private placement memoranda, bank information memoranda, prospectuses and similar documents required in connection with such financing (which shall not include pro forma financial information); provided, that, the Company shall have the right to review and approve (which approval shall not be unreasonably conditioned, withheld or delayed) any such materials prior to their distribution, (c)&#160;executing and delivering any pledge and security documents, other definitive financing documents, or other certificates, or documents as may be reasonably requested by SPAC or otherwise reasonably facilitating the pledging of collateral, provided, that, such documents will not take effect until the Closing, (d)&#160;taking or appointing a representative of SPAC to take all corporate actions, subject to the occurrence of the Closing, reasonably requested by SPAC to permit the consummation of the PIPE Financing immediately prior to or following the Closing Date, (e)&#160;providing the Company Financial Statements and such other financial information regarding the Company that is readily available or within the Company&#8217;s possession and as is reasonably requested in connection with arrangement of such financing, (f)&#160;executing and delivering reasonable and customary certificates and other documentation required by any such equity investor and the subscription agreement, provided, that no such certificates, letters or other documentation shall be effective prior to the consummation of the transactions contemplated by the subscription agreement, (g)&#160;furnishing SPAC with all documentation and other information required by bank regulatory authorities under applicable &#8220;know-your-customer&#8221; and anti-money laundering rules and regulations, including the Patriot Act and (h)&#160;otherwise reasonably cooperating in SPAC&#8217;s efforts to obtain such PIPE Financing. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SPAC shall use its reasonable best efforts to take, or to cause to be taken, all actions required, necessary or that it otherwise deems to be proper or advisable to consummate the transactions contemplated by the Subscription Agreements on the terms described therein. Without limiting the generality of the foregoing, SPAC shall give the Company prompt written notice (i)&#160;of any requested amendment to any Subscription Agreement, (ii)&#160;of any breach or default, to the knowledge of SPAC, by any party to any Subscription Agreement, (iii)&#160;of the receipt of any written notice or other written communication from any party to any Subscription Agreement with respect to any actual, or to the knowledge of SPAC, potential, threatened or claimed expiration, lapse, withdrawal, breach, default, termination or repudiation by any party to any Subscription Agreement or any provisions of any Subscription Agreement, and (iv)&#160;if SPAC does not expect to receive all or any portion of the applicable purchase price under any Investor&#8217;s Subscription Agreement in accordance with its terms. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any other provision of this Agreement, SPAC agrees, for the benefit of the Company, to take all necessary, legally available steps to enforce against any Investor the terms of that Investor&#8217;s Subscription Agreement if the Investor is in material breach of its obligations thereunder, including any breach caused by the Investor&#8217;s failure to fund its Subscription Amount (as defined in its Subscription Agreement) at the time and in the amount required pursuant to its Subscription Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_82"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.18.</span> <span style="font-weight:bold">Expense Statement.</span><span style="font-weight:bold"> </span>At least three Business Days prior to the contemplated Closing Date, SPAC and the Company shall each deliver to the other a written statement setting forth a complete and accurate schedule of its good faith estimate of, in respect of SPAC, each Unpaid SPAC Expense, and in respect of the Company, each Unpaid Company Expense, as of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_83"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.19.</span> <span style="font-weight:bold">Transaction Litigation.</span><span style="font-weight:bold"> </span>During the Interim Period, SPAC, on the one hand, and the Company, on the other hand, shall each notify the other promptly after learning of any stockholder demand (or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
threat thereof) or other stockholder Proceeding, claim, investigation, examination or inquiry, whether or not before any Governmental Entity (including derivative claims), relating to this Agreement, or any of the transactions contemplated hereby (collectively, &#8220;<span style="font-weight:bold">Transaction Litigation</span>&#8221;) commenced or, to the knowledge of SPAC or to the knowledge of the Company, as applicable, threatened in writing against (a)&#160;in the case of SPAC, SPAC, any of SPAC&#8217;s Affiliates or any of their respective Representatives or stockholders (in their capacity as such), or (b)&#160;in the case of the Company, the Company, any of the Company&#8217;s Affiliates or any of their respective Representatives or stockholders (in their capacity as such). SPAC and the Company shall each (i)&#160;keep the other reasonably informed regarding any Transaction Litigation, (ii)&#160;give the other the opportunity to, at its own cost and expense, participate in the defense, settlement and compromise of any such Transaction Litigation and reasonably cooperate with the other in connection with the defense, settlement and compromise of any such Transaction Litigation, (iii)&#160;consider in good faith the other&#8217;s advice with respect to any such Transaction Litigation, and (iv)&#160;reasonably cooperate with each other with respect to any Transaction Litigation; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that in no event shall (x)&#160;the Company, any of the Company&#8217;s Affiliates or any of their respective Representatives settle or compromise any Transaction Litigation without the prior written consent of SPAC (such consent not to be unreasonably withheld, conditioned or delayed) or (y)&#160;SPAC, any of SPAC&#8217;s Affiliates or any of their respective Representatives settle or compromise any Transaction Litigation without the Company&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_84"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.20.</span> <span style="font-weight:bold">Employee Matters.</span><span style="font-weight:bold"> </span>Prior to the Closing, the SPAC Board will approve and adopt the New Equity Incentive Plan, subject to the SPAC Stockholder Approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_85"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.21.</span> <span style="font-weight:bold">SPAC Extension Proposal.</span><span style="font-weight:bold"> </span>If a definitive proxy relating to the approval of the Contemplated Transactions has not been mailed to <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders by December&#160;8, 2023, SPAC shall use its best efforts to take all actions necessary to obtain the approval of the SPAC Extension Proposal. In connection with obtaining the approval, SPAC will prepare, file and mail all required proxy materials to be sent to the <span style="white-space:nowrap">Pre-Closing</span> SPAC Stockholders seeking approval of the SPAC Extension Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_86">ARTICLE VI. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTEMPLATED BY THIS AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_87"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.1.</span> <span style="font-weight:bold">Conditions to the Obligations of the Parties.</span><span style="font-weight:bold"> </span>The obligations of the Parties to consummate, or cause to be consummated, the transactions contemplated by this Agreement (including the Closing) are subject to the satisfaction or, if permitted by applicable Law, waiver by the Party for whose benefit such condition exists, of the following conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) each applicable waiting period (and any extensions thereof, or any timing agreements, understandings or commitments obtained by request or other action of the United States Federal Trade Commission or the Antitrust Division of the United States Department of Justice, as applicable) or Consent under the HSR Act shall have expired, been terminated or obtained (or deemed, by applicable Law, to have been obtained), as applicable; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) no Order or Law issued by any court of competent jurisdiction or other Governmental Entity or other legal restraint or prohibition preventing the consummation of the transactions contemplated by this Agreement (including the Closing) shall exist, and the Parties shall act reasonably and in good faith and consult each other when assessing the application of any such restraint or prohibition; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Registration Statement/Proxy Statement shall have become effective in accordance with the provisions of the Securities Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement/Proxy Statement, and no proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Company Stockholder Written Consent shall have been obtained; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the SPAC Stockholder Approval shall have been obtained; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) SPAC&#8217;s initial listing application with Nasdaq in connection with the transactions contemplated by this Agreement shall have been approved and, immediately following the Effective Time, SPAC shall be able to satisfy any applicable initial and continuing listing requirements of Nasdaq, and SPAC shall not have received any notice of <span style="white-space:nowrap">non-compliance</span> therewith that has not been cured or would not be cured at or immediately following the Effective Time, and the Series A Common Stock (including the Series A Common Stock to be issued hereunder) shall have been approved for listing on Nasdaq, subject only to official notice of issuance thereof; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) after giving effect to the transactions contemplated hereby (including the SPAC Stockholder Redemption and the PIPE Financing), SPAC shall have at least $5,000,001 of net tangible assets (as determined in accordance with <span style="white-space:nowrap">Rule&#160;3a51-1(g)(1)</span> of the Exchange Act) immediately after the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_88"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.2.</span> <span style="font-weight:bold">Other Conditions to the Obligations of the SPAC Parties.</span><span style="font-weight:bold"> </span>The obligations of the SPAC Parties to consummate the transactions contemplated by this Agreement (including the Closing) are subject to the satisfaction or, if permitted by applicable Law, waiver by SPAC (on behalf of itself and the other SPAC Parties), of the following further conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) (i)&#160;the Company Fundamental Representations shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all material respects as of such earlier date), and (ii)&#160;the representations and warranties of the Company set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> (other than the Company Fundamental Representations) shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; or any similar limitation set forth therein) as of such earlier date), except, in the case of this clause (ii), where the failure of such representations and warranties to be true and correct, taken as a whole, does not, and would not reasonably be expected to, cause a Company Material Adverse Effect; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Company shall have performed and complied in all material respects with the covenants and agreements required to be performed or complied with by the Company under this Agreement at or prior to the Closing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, no Company Material Adverse Effect has occurred and is continuing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) at or prior to the Closing, the Company shall have delivered, or caused to be delivered, to SPAC a certificate duly executed by an authorized officer of the Company, dated as of the Closing Date, to the effect that the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(c)</span> are satisfied, in form and substance reasonably acceptable to SPAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) each Ancillary Document to which the Company is or is to be a party pursuant hereto shall have been executed and delivered by the Company and shall be in full force and effect; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the Company Preferred Stock Conversion shall have been duly authorized; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) each of the agreements set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(g)</span> of the Company Disclosure Schedule has been terminated as of immediately prior to Closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_89"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.3.</span> <span style="font-weight:bold">Other Conditions to the Obligations of the Company.</span><span style="font-weight:bold"> </span>The obligations of the Company to consummate the transactions contemplated by this Agreement (including the Closing) are subject to the satisfaction or, if permitted by applicable Law, waiver by the Company, of the following further conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) (i)&#160;the SPAC Fundamental Representations shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) as of such earlier date), and (ii)&#160;the representations and warranties of the SPAC Parties (other than the SPAC Fundamental Representations) contained in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline">&#160;IV</span> of this Agreement shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) in all respects as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;SPAC Material Adverse Effect&#8221; or any similar limitation set forth therein) as of such earlier date), except, in the case of this clause (ii), where the failure of such representations and warranties to be true and correct, taken as a whole, does not, and would not reasonably be expected to, cause a SPAC Material Adverse Effect; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the SPAC Parties shall have performed and complied in all material respects with the covenants and agreements required to be performed or complied with by the SPAC Parties under this Agreement at or prior to the Closing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) there being at least $8,700,000 in Available Closing Cash; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) since the date of this Agreement, no SPAC Material Adverse Effect has occurred and is continuing; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Employment Agreements shall have been signed by the respective executives party thereto in form reasonably satisfactory to the Parties, with approval of the form Employment Agreement not to be unreasonably withheld, conditioned or delayed by the SPAC; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) at or prior to the Closing, SPAC shall have delivered, or caused to be delivered, to the Company a certificate duly executed by an authorized officer of SPAC, dated as of the Closing Date, to the effect that the conditions specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(a)</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(d)</span> are satisfied, in a form and substance reasonably satisfactory to the Company; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) each Ancillary Document to which SPAC or Sponsor is or is to be a party pursuant hereto shall have been executed and delivered by SPAC or Sponsor and shall be in full force and effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_90">Section&#160;6.4. Frustration of Closing Conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may not rely on the failure of any condition set forth in this <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> VI</span> to be satisfied if such failure was proximately caused by the Company&#8217;s or any one of its Subsidiaries&#8217; failure to use reasonable best efforts to cause the Closing to occur, as required by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span>, or a material breach of any of its other obligations under this Agreement. None of the SPAC Parties may rely on the failure of any condition set forth in this <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> VI</span> to be satisfied if such failure was proximately caused by any SPAC Party&#8217;s failure to use reasonable best efforts to cause the Closing to occur, as required by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span>, or a material breach of any of its other obligations under this Agreement. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_91">ARTICLE VII. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TERMINATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_92"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;7.1.</span> <span style="font-weight:bold">Termination.</span><span style="font-weight:bold"> </span>This Agreement may be terminated and the transactions contemplated by this Agreement may be abandoned at any time prior to the Closing: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of SPAC and the Company; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) by SPAC, if any of the representations or warranties set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> shall not be true and correct, or if the Company has failed to perform any covenant or agreement on the part of the Company set forth in this Agreement (including an obligation to consummate the Closing), such that the condition to Closing set forth in either <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(b)</span> will not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&#160;30 days after written notice thereof is delivered to the Company by SPAC, and (ii)&#160;the Termination Date; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that none of the SPAC Parties is then in breach of this Agreement so as to prevent the condition to Closing set forth in either <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(b)</span> from being satisfied; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) by the Company, if any of the representations or warranties set forth in <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> IV</span> shall not be true and correct, or if any SPAC Party has failed to perform any covenant or agreement on the part of such applicable SPAC Party set forth in this Agreement (including an obligation to consummate the Closing), such that the condition to Closing set forth in either <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(b)</span> will not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&#160;30 days after written notice thereof is delivered to SPAC by the Company, and (ii)&#160;the Termination Date; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that the Company is not then in breach of this Agreement so as to prevent the condition to Closing set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(a)</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(b)</span> from being satisfied; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) by either SPAC or the Company, if the transactions contemplated by this Agreement (including the Closing) shall not have been consummated on or prior June&#160;1, 2024 (the &#8220;<span style="font-weight:bold">Termination Date</span>&#8221;); <span style="font-style:italic">provided</span>, that (i)&#160;the right to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1(d)</span> shall not be available to SPAC if any SPAC Party&#8217;s breach of any of its covenants or obligations under this Agreement shall have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date, and (ii)&#160;the right to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1(d)</span> shall not be available to the Company if the Company&#8217;s breach of its covenants or obligations under this Agreement shall have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) by either SPAC or the Company, if any Governmental Entity shall have issued an Order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by this Agreement and such Order or other action shall have become final and nonappealable; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) by either SPAC or the Company, if the SPAC Stockholders Meeting has been held (including any adjournment or postponement thereof), has concluded, SPAC&#8217;s stockholders have duly voted and the SPAC Stockholder Approval was not obtained; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) by SPAC, if the Company does not deliver or cause to be delivered to SPAC the Company Stockholder Written Consent in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.13</span> on or prior to the Company Stockholder Written Consent Deadline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_93"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;7.2.</span> <span style="font-weight:bold">Effect of Termination.</span><span style="font-weight:bold"> </span>In the event of the termination of this Agreement pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1</span>, this entire Agreement shall forthwith become void (and there shall be no Liability or obligation on the part of the Parties and their respective Representatives) with the exception of (a)<span style="text-decoration:underline">&#160;Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.3(a)</span>, this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span>, <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> VIII</span> and <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> I</span> (to the extent related to the foregoing), each of which shall survive such termination and remain valid and binding obligations of the Parties, and (b)&#160;the Confidentiality Agreement, which shall survive such termination and remain valid and binding obligations of the parties thereto in accordance with its terms. Notwithstanding the foregoing, the termination of this Agreement pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1</span> shall not affect any Liability on the part of any Party for the Willful Breach of this Agreement by, or any Fraud of, such Party. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="anxa509388_94">ARTICLE VIII. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">MISCELLANEOUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_95"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.1.</span> <span style="font-weight:bold"><span style="white-space:nowrap">Non-Survival.</span></span><span style="font-weight:bold"> </span>The representations, warranties, agreements and covenants in this Agreement, or in any instrument, document or certificate delivered pursuant to this Agreement, shall terminate at the Effective Time, except for (a)&#160;those covenants and agreements that, by their terms, contemplate performance after the Effective Time, and (b)&#160;those representations and warranties set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.25</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.27</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.17</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.20</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_96"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.2.</span> <span style="font-weight:bold">Entire Agreement; Assignment.</span><span style="font-weight:bold"> </span>This Agreement (together with the Ancillary Documents and the Confidentiality Agreement) constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, undertakings, representations and other arrangements, both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may not be assigned by any Party (whether by operation of law or otherwise) without the prior written consent of (a)&#160;prior to the Closing, SPAC and the Company, and (b)&#160;from and after the Closing, SPAC and the Sponsor. Any attempted assignment of this Agreement not in accordance with the terms of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.2</span> shall be void, <span style="font-style:italic">ab initio</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_97"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.3.</span> <span style="font-weight:bold">Amendment.</span><span style="font-weight:bold"> </span>This Agreement may be amended or modified only (a)&#160;prior to the Closing, by a written agreement executed and delivered by SPAC and the Company, and (b)&#160;after the Closing, by a written agreement executed and delivered by SPAC and the Sponsor. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any purported amendment by any Party or Parties effected in a manner which does not comply with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> shall be void, <span style="font-style:italic">ab initio</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_98"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.4.</span> <span style="font-weight:bold">Notices.</span><span style="font-weight:bold"> </span>All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given) by delivery in person, <span style="white-space:nowrap">e-mail</span> (having obtained electronic delivery confirmation thereof) or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If to any SPAC Party, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Atlantic Coastal Acquisition Corp. II </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6 St. Johns Lane, Floor 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Shahraab Ahmad </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pillsbury Winthrop Shaw Pittman LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">31 W 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Oresman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If to the Company, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abpro Corporation </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">68 Cummings Park Drive </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Woburn, MA 01801 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Legal Department </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: <span style="text-decoration:underline">*******</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nelson Mullins Riley&#160;&amp; Scarborough LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">101 Constitution Avenue, NW, Suite 900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20001 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Talcott; E. Peter Strand </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">E-mail:</span> <span style="text-decoration:underline">*******; *******</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth above. All such notices, requests, claims, demands and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in the place of receipt and such day is a Business Day; otherwise, any such notice, request, claim, demand or other communication shall be deemed not to have been received until the next succeeding Business Day. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_99"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.5.</span> <span style="font-weight:bold">Governing Law.</span><span style="font-weight:bold"> </span>This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby, including the applicable statute of limitations, shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Law of any jurisdiction other than the State of Delaware. Notwithstanding the foregoing, the Merger shall be governed by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_100"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.6.</span> <span style="font-weight:bold">Fees and Expenses.</span><span style="font-weight:bold"> </span>Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; <span style="font-style:italic">provided</span> that, for the avoidance of doubt, in the event the Closing occurs, Unpaid Company Expenses and Unpaid SPAC Expenses shall be borne by the Trust Account (provided, however, that the effect of such payment shall be disregarded for the purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1(g)</span>, but not, for the avoidance of doubt, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(c)</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_101"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.7.</span> <span style="font-weight:bold">Construction; Interpretation.</span><span style="font-weight:bold"> </span>The term &#8220;this Agreement&#8221; means this Business Combination Agreement together with the Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions hereof, and all provisions of this Agreement shall be construed according to their fair meaning and not strictly for or against any Party. Unless otherwise indicated to the contrary herein by the context or use thereof (a)&#160;the words, &#8220;herein,&#8221; &#8220;hereto,&#8221; &#8220;hereof&#8221; and words of similar import refer to this Agreement as a whole, including the Schedules and Exhibits, and not to any particular section, subsection, paragraph, subparagraph or clause set forth in this Agreement, (b)&#160;masculine gender shall also include the feminine and neutral genders, and vice versa, (c)&#160;words importing the singular shall also include the plural, and vice versa, (d)&#160;the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation,&#8221; (e)&#160;references to &#8220;$&#8221; or &#8220;dollar&#8221; or &#8220;US$&#8221; shall be references to United States dollars, (f)&#160;the word &#8220;or&#8221; is disjunctive but not necessarily exclusive, (g)&#160;the words &#8220;writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form, (h)&#160;the word &#8220;day&#8221; means calendar day unless Business Day is expressly specified, (i)&#160;the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase shall not mean simply &#8220;if,&#8221; (j)&#160;all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement, (k)&#160;the words &#8220;provided&#8221; or &#8220;made available&#8221; or words of similar import (regardless of whether capitalized or not) shall mean, when used with reference to documents or other materials required to be provided or made available to any SPAC Party, any documents or other materials posted to datasite electronic data room maintained by or on behalf of the Company as of 5:00 p.m., Eastern Time, at least one day prior to the date of this Agreement, (l)&#160;all references to any Law will be to such Law as amended, supplemented, restated or otherwise modified or <span style="white-space:nowrap">re-enacted</span> from time to time, and (m)&#160;all references to any Contract are to such Contract as amended or modified from time to time in accordance with the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement). If any action under this Agreement is required to be done or taken on a day that is not a Business Day, then such action shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_102"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.8.</span> <span style="font-weight:bold">Exhibits and Schedules.</span><span style="font-weight:bold"> </span>All Exhibits and Schedules, or documents expressly incorporated into this Agreement, are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in full in this Agreement. The Schedules shall be arranged in sections and subsections corresponding to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
numbered and lettered Sections and subsections set forth in this Agreement. Any item disclosed in the Company Disclosure Schedules or in the SPAC Disclosure Schedules corresponding to any Section&#160;or subsection of <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> (in the case of the Company Disclosure Schedules) or <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> IV</span> (in the case of the SPAC Disclosure Schedules) shall be deemed to have been disclosed with respect to every other Section&#160;and subsection of <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> (in the case of the Company Disclosure Schedules) or <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> IV</span> (in the case of the SPAC Disclosure Schedules), as applicable, where the relevance of such disclosure to such other Section&#160;or subsection is reasonably apparent on the face of the disclosure. The information and disclosures set forth in the Schedules that correspond to the Sections or subsections of <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> III</span> or <span style="text-decoration:underline">ARTICLE</span><span style="text-decoration:underline"> IV</span> may not be limited to matters required to be disclosed in the Schedules, and any such additional information or disclosure is for informational purposes only and does not necessarily include other matters of a similar nature. Without limiting the generality of the foregoing, the fact that any disclosure on any of the Schedules is not required to be disclosed in order to render the applicable representation or warranty to which it relates true, or that the absence of such disclosure on the Schedules would not constitute a breach of such representation or warranty, (i)&#160;shall not be deemed or construed to expand the scope of any representation or warranty hereunder or to establish a standard of materiality disclosure in respect of any representation or warranty or create any covenant and (ii)&#160;shall not constitute, or be deemed to be, an admission to any third party concerning such item or an admission of default or breach under any agreement or document. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_103"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.9.</span> <span style="font-weight:bold">Parties in Interest.</span><span style="font-weight:bold"> </span>This Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns and, except as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.14</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.15</span> and, with respect thereto, this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.9</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.14</span>, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. The Sponsor shall be an express third-party beneficiary of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.2</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.3</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.13</span> and, with respect thereto, this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.9</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.14</span>. Nelson Mullins Riley&#160;&amp; Scarborough LLP (&#8220;<span style="font-weight:bold">Nelson Mullins</span>&#8221;) shall be an express third-party beneficiary of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.19</span> and, with respect thereto, this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.9</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.14</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_104"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.10.</span> <span style="font-weight:bold">Severability.</span><span style="font-weight:bold"> </span>Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, then all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_105"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.11.</span> <span style="font-weight:bold">Counterparts; Electronic Signatures; Effectiveness.</span><span style="font-weight:bold"> </span>This Agreement and each Ancillary Document (including any of the Closing deliverables contemplated hereby) may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement or any Ancillary Document (including any of the Closing deliverables contemplated hereby) by <span style="white-space:nowrap">e-mail,</span> or scanned pages shall be effective as delivery of a manually executed counterpart to this Agreement or any such Ancillary Document or Closing deliverable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_106"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.12.</span> <span style="font-weight:bold">Knowledge of Company; Knowledge of SPAC.</span><span style="font-weight:bold"> </span>For all purposes of this Agreement, the phrase &#8220;<span style="font-weight:bold">to the Company</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold">s knowledge</span>&#8221; and &#8220;<span style="font-weight:bold">known by the Company</span>&#8221; and any derivations thereof shall mean, as of the applicable date, the actual knowledge of the individuals set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.12</span> of the Company Disclosure Schedules after reasonable inquiry. For all purposes of this Agreement, the phrase &#8220;<span style="font-weight:bold">to SPAC</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold">s knowledge</span>&#8221; and &#8220;<span style="font-weight:bold">to the knowledge of SPAC</span>&#8221; and any derivations thereof shall mean, as of the applicable date, the actual knowledge of the individuals set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.12</span> of the SPAC Disclosure Schedules. For the avoidance of doubt, none of the individuals set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.12</span> of the Company Disclosure Schedules or the SPAC Disclosure Schedules shall have any personal Liability or obligations regarding such knowledge. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_107"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.13.</span> <span style="font-weight:bold">No Recourse.</span><span style="font-weight:bold"> </span>This Agreement may only be enforced against, and any action for breach of this Agreement or related to the transactions contemplated hereby, may only be made against, the Parties (and then only with respect to the specific obligations of such Parties, as set forth herein), and none of the Representatives of any SPAC Party (including the Sponsor) or the Company (and including the Parties&#8217; stockholders) shall have any Liability arising out of or relating to this Agreement or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein. For the avoidance of doubt, nothing in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.13</span> shall limit the enforcement of, or recovery under, Ancillary Documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_108"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.14.</span> <span style="font-weight:bold">Extension; Waiver.</span><span style="font-weight:bold"> </span>The Company (prior to the Closing) or the Sponsor (after the Closing) may (a)&#160;extend the time for the performance of any of the obligations or other acts of the SPAC Parties set forth herein, (b)&#160;waive any inaccuracies in the representations and warranties of the SPAC Parties set forth herein or (c)&#160;waive compliance by the SPAC Parties with any of the agreements or conditions set forth herein. SPAC may (i)&#160;extend the time for the performance of any of the obligations or other acts of the Company set forth herein, (ii)&#160;waive any inaccuracies in the representations and warranties of the Company set forth herein or (iii)&#160;waive compliance by the Company with any of the agreements or conditions set forth herein. Any agreement on the part of any such Party to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such Party. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its rights, powers or privileges hereunder shall not constitute a waiver of such rights, powers or privileges, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_109"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.15.</span> <span style="font-weight:bold">Waiver of Jury Trial.</span><span style="font-weight:bold"> </span>THE PARTIES EACH HEREBY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING (I)&#160;ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT, OR (II)&#160;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE. THE PARTIES EACH HEREBY AGREE AND CONSENT THAT ANY SUCH PROCEEDING SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&#160;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&#160;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&#160;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D)&#160;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION 8.15</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_110"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.16.</span> <span style="font-weight:bold">Submission to Jurisdiction.</span><span style="font-weight:bold"> </span>Each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of the state and federal courts located in New Castle County, State of Delaware for the purposes of any Proceeding (a)&#160;arising under this Agreement or under any Ancillary Document, or (b)&#160;in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or thereby, and irrevocably and unconditionally waives any objection to the laying of venue of any such Proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Proceeding has been </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
brought in an inconvenient forum. Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Proceeding (i)&#160;arising under this Agreement or under any Ancillary Document, or (ii)&#160;in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or thereby, (A)&#160;any claim that it is not personally subject to the jurisdiction of the courts as described in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.16</span> for any reason, (B)&#160;that it or its property is exempt or immune from the jurisdiction of any such court or from any Proceeding commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (C)&#160;that (x)&#160;the Proceeding in any such court is brought in an inconvenient forum, (y)&#160;the venue of such Proceeding is improper or (z)&#160;this Agreement, or any Ancillary Document, or the subject matter hereof or thereof, may not be enforced in or by such courts. Each Party agrees that service of any process, summons, notice or document by registered mail to such Party&#8217;s respective address set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.4</span> shall be effective service of process for any such Proceeding. Notwithstanding the foregoing, a party may seek the remedies contemplated by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.17</span> in any court of competent jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_111"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.17.</span> <span style="font-weight:bold">Remedies.</span><span style="font-weight:bold"> </span>Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage, for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of this Agreement (including failing to take such actions as are required of them hereunder to consummate the transactions contemplated by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without proof of damages, and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that (a)&#160;the other Parties have an adequate remedy at law, or (b)&#160;an award of specific performance is not an appropriate remedy for any reason at law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa509388_112"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.18.</span> <span style="font-weight:bold">Trust Account Waiver.</span><span style="font-weight:bold"> </span>Reference is made to the final prospectus of SPAC, filed with the SEC (File <span style="white-space:nowrap">No.&#160;333-262159)</span> on January&#160;18, 2022 (the &#8220;<span style="font-weight:bold">Prospectus</span>&#8221;). The Company acknowledges, agrees and understands that SPAC has established a trust account (the &#8220;<span style="font-weight:bold">Trust Account</span>&#8221;) containing the proceeds of its initial public offering (the &#8220;<span style="font-weight:bold">IPO</span>&#8221;) and certain proceeds of the private placement (including interest accrued from time to time thereon) for the benefit of SPAC&#8217;s public stockholders. The Company hereby agrees that it does not now and shall not at any time hereafter have any right, title, interest or claim of any kind in or to any assets held in the Trust Account, and shall not make any claim against the Trust Account, regardless of whether such claim arises as a result of, in connection with or relating in any way to this Agreement, the transactions contemplated hereby or any proposed or actual business relationship between SPAC or any of its Representatives or Affiliates, on the one hand, and the Company or any of its Representatives or Affiliates, on the other hand or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to hereafter as the &#8220;<span style="font-weight:bold">Released Claims</span>&#8221;). The Company hereby irrevocably waives (on its own behalf and on behalf of its Company Related Parties) any Released Claims that it may have against the Trust Account now or in the future as a result of, or arising out of, any discussions, contracts or agreements with SPAC and will not seek recourse against the Trust Account for any reason whatsoever. Notwithstanding anything herein or otherwise to the contrary (a)&#160;nothing herein shall serve to limit or prohibit the Company&#8217;s right to pursue a claim against SPAC for legal relief against monies or other assets held outside the Trust Account, for specific performance or other equitable relief in connection with the consummation of the transactions contemplated hereby (including a claim for SPAC to specifically perform its obligations under this Agreement and cause the disbursement of the balance of the cash remaining in the Trust Account (after giving effect to the SPAC Shareholder Redemption) to the Company in accordance with the terms </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Agreement and the Trust Agreement), or for Fraud and (b)&#160;nothing herein shall serve to limit or prohibit any claims that the Company may have in the future against SPAC&#8217;s (or its successors&#8217;) assets or funds that are not held in the Trust Account (including any funds that have been released from the Trust Account and any assets that have been purchased or acquired with any such funds). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="anxa509388_113">Section&#160;8.19. Conflicts and Privilege. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) SPAC and Merger Sub, on behalf of their respective successors and assigns (including, after the Closing, the Surviving Corporation), hereby agree that, in the event a dispute with respect to this Agreement or the transactions contemplated hereby arises after the Closing between or among (i)&#160;the Sponsor, the stockholders or holders of other equity interests of SPAC, or any of their respective directors, members, partners, officers, employees or Affiliates (other than the Surviving Corporation) (collectively, the &#8220;<span style="font-weight:bold">SPAC Group</span>&#8221;), on the one hand, and (ii)&#160;any <span style="white-space:nowrap">pre-Closing</span> stockholders, directors, members, partners, officers or employees of the Company or Affiliates (the &#8220;<span style="font-weight:bold">Company Group</span>&#8221;), on the other hand, Nelson Mullins, may represent any member of the Company Group in such dispute even though the interests of such Persons may be directly adverse to SPAC or the Surviving Corporation, and even though Nelson Mullins may be handling ongoing unrelated matters for SPAC, the Surviving Corporation or the members of the Company Group. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) SPAC and Merger Sub, on behalf of their respective successors and assigns (including, after the Closing, the Surviving Corporation), further agree that, as to all legally privileged communications made prior to the Closing (in each case, including to the extent made in connection with the negotiation, preparation, execution, delivery and performance under, or any dispute or Proceeding arising out of or relating to, this Agreement, any Ancillary Documents or the transactions contemplated hereby or thereby) between or among the Company, its Affiliates or any member of the Company Group, on the one hand, and Nelson Mullins, on the other hand (the &#8220;<span style="font-weight:bold">Nelson Mullins Privileged Communications</span>&#8221;), the attorney/client privilege, attorney work-product protection, and the expectation of client confidence shall survive the Merger and belong to the <span style="white-space:nowrap">pre-Closing</span> stockholders of the Company after the Closing, and shall not pass to or be claimed or controlled by the Surviving Corporation or any other member of the SPAC Group. Notwithstanding the foregoing, in the event that a dispute arises between SPAC or the SPAC Group, on the one hand, and a third party other than the Company, its Affiliates or any member of the Company Group, on the other hand, SPAC (or such other member of the SPAC Group, as applicable) may assert the attorney-client privilege to prevent the disclosure of the Nelson Mullins Privileged Communications to such third party; provided, however, that neither SPAC nor the SPAC Group may waive such privilege with respect to Nelson Mullins Privileged Communications without the prior written consent of Nelson Mullins. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, any privileged communications or information shared by or on behalf of the Company prior to the Closing with SPAC or the Sponsor shall remain the privileged communications (the attorney/client privilege, attorney work-product protection, and the expectation of client confidence shall survive the Merger and belong to the <span style="white-space:nowrap">pre-Closing</span> stockholders of the Company after the Closing, and shall not pass to or be claimed or controlled by the Surviving Corporation or any other member of the SPAC Group), and SPAC agrees, on its own behalf and on behalf of the other members of the SPAC Group, not to assert that any privilege has been waived as to the Nelson Mullins Privileged Communications, by virtue of the same having been shared. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) SPAC agrees on behalf of itself and the other members of the SPAC Group, (i)&#160;to the extent that SPAC or, after the Closing, the Surviving Corporation receives or takes physical possession of any Nelson Mullins Privileged Communications, (A)&#160;such physical possession or receipt shall not, in any way, be deemed a waiver by the Company or the Company&#8217;s <span style="white-space:nowrap">pre-closing</span> stockholders of the privileges or protections described in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.19</span>, and (B)&#160;neither SPAC nor the SPAC Group shall assert any claim that the Company, or the Company&#8217;s <span style="white-space:nowrap">pre-closing</span> stockholders or any other Person waived the attorney-client privilege, attorney work-product protection or any other right or expectation of client confidence applicable to any such materials or communications, (ii)&#160;not to access or use the Nelson Mullins Privileged Communications, including by way of review of any electronic data, communications or other information, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by seeking to have the Company or the Company&#8217;s <span style="white-space:nowrap">pre-closing</span> stockholders waive the attorney-client or other privilege or otherwise and (iii)&#160;not to seek to obtain the Nelson Mullins Privileged Communications from Nelson Mullins as long as such Nelson Mullins Privileged Communications would be subject to a privilege or protection if they were being requested in a proceeding by an unrelated third party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To the extent that files or other materials maintained by Nelson Mullins constitute property of its clients, such property rights (and the attorney/client privilege, attorney work-product protection, and the expectation of client confidence with respect thereto) shall survive the Merger and belong to the <span style="white-space:nowrap">pre-</span> Closing stockholders of the Company after the Closing, and shall not pass to or be claimed or controlled by the Surviving Corporation or any other member of the SPAC Group, and Nelson Mullins shall have no duty to reveal or disclose to any Person any such files or other materials or any Nelson Mullins Privileged Communications, as long as such files or other materials would be subject to a privilege or protection if they were being requested in a proceeding by an unrelated third party. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) SPAC on behalf of itself and the SPAC Group, hereby acknowledges that it has had the opportunity to discuss and obtain adequate information concerning the significance and material risks of, and reasonable available alternatives to, the waivers, permissions and other provisions of this Agreement. This <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.19</span> shall be irrevocable, and no term of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8.19</span> may be amended, waived or modified, without the prior written consent of Nelson Mullins (not to be unreasonably withheld, conditioned or delayed). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">* * * * * </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, each of the Parties has caused this Business Combination Agreement to be duly executed on its behalf as of the day and year first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:43%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="text-decoration:underline">COMPANY</span>:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ABPRO CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ian Chan</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:&#8201;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Ian Chan</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="text-decoration:underline">SPAC</span>:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION CORP. II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shahraab Ahmad</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Shahraab Ahmad</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">CEO</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="text-decoration:underline">MERGER SUB</span>:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ABPRO MERGER SUB CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shahraab Ahmad</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Shahraab Ahmad</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President</td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">[</span><span style="font-weight:bold"><span style="font-style:italic">Signature Page to Business Combination Agreement</span></span><span style="font-weight:bold">] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="ii509388_4"><span style="text-decoration:underline">Exhibit A </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Sponsor Support Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(attached) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SPONSOR SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This SPONSOR SUPPORT AGREEMENT, dated as of December&#160;11, 2023 (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;), by and among ATLANTIC COASTAL ACQUISITION MANAGEMENT II LLC, a Delaware limited liability company (&#8220;<span style="text-decoration:underline">Supporter</span>&#8221;), ATLANTIC COASTAL ACQUISITION CORP. II, a Delaware corporation (&#8220;<span style="text-decoration:underline">SPAC</span>&#8221;), and ABPRO CORPORATION, a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;). Terms used but not defined in this Agreement shall have the meanings ascribed to them in the BCA (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, contemporaneously with the execution of this Agreement, SPAC, the Company, and Abpro Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of SPAC (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), are entering into that certain Business Combination Agreement (the &#8220;<span style="text-decoration:underline">BCA</span>&#8221;), a copy of which has been made available to Supporter and pursuant to which, subject to the terms and conditions thereof, Merger Sub will merge with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;), and the Company&#8217;s securityholders will receive shares of SPAC&#8217;s Series A common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Series A Common Stock</span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, Supporter owns 6,374,774 shares of Series A Common Stock and 1 share of SPAC&#8217;s Series B common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Series B Common Stock</span>&#8221;) (all such SPAC shares and any SPAC shares of which ownership of record or the power to vote is hereafter acquired by Supporter prior to the termination of this Agreement being referred to herein as the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;); and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce the Company and SPAC to enter into the BCA, Supporter is executing and delivering this Agreement to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, Supporter, the Company, and SPAC hereby agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Agreement to Vote</span>. Supporter, with respect to the Shares, hereby agrees (and agrees to execute such documents or certificates evidencing such agreement as SPAC and/or the Company may reasonably request in connection therewith) to vote at any meeting of the stockholders of SPAC, and in any action by written consent of the stockholders of SPAC, to approve the BCA, all of the Shares (a)&#160;in favor of the approval and adoption of the BCA, the transactions contemplated by the BCA and this Agreement, (b)&#160;in favor of any other matter reasonably necessary to the consummation of the transactions contemplated by the BCA and considered and voted upon by the stockholders of SPAC (including each Required Transaction Proposal), (c) in favor of the approval and adoption of the new equity incentive plan, (d)&#160;for the appointment, and designation of classes, of the members of the Post-Closing Board and (e)&#160;against any action, agreement or transaction (other than the BCA or the transactions contemplated thereby) or proposal that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of SPAC under the BCA or that would reasonably be expected to result in the failure of the transactions contemplated by the BCA from being consummated. Supporter acknowledges receipt and review of a copy of the BCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Transfer of Shares</span>. Supporter agrees that it shall not, directly or indirectly, except as otherwise contemplated pursuant to the BCA and the Ancillary Documents, (a)&#160;sell, assign, transfer (including by operation of law), redeem, lien, pledge, distribute, dispose of or otherwise encumber any of the Shares or otherwise agree to do any of the foregoing (unless the transferee agrees to be bound by this Agreement), (b) deposit any Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement, (c)&#160;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law), redemption or other disposition of any Shares (unless the transferee agrees to be bound by this Agreement) or (d)&#160;take any action that would have the effect of preventing or disabling Supporter from performing its obligations hereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Waiver</span>. Except as otherwise contemplated pursuant to the BCA and the Ancillary Documents, Supporter hereby waives (and agrees to execute such documents or certificates evidencing such waiver as SPAC and/or the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company may reasonably request) any adjustment to the conversion ratio set forth in the SPAC Certificate of Incorporation or any other anti-dilution or similar protection with respect to the Shares (whether resulting from the transactions contemplated hereby, by the BCA or any Ancillary Document or by any other transaction consummated in connection with the transactions contemplated hereby and thereby). </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Representations and Warranties</span>. Supporter represents and warrants for and on behalf of itself to SPAC and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution, delivery and performance by Supporter of this Agreement and the consummation by Supporter of the transactions contemplated hereby do not and will not (i)&#160;conflict with or violate any Law or Order applicable to Supporter, (ii)&#160;require any consent, approval or authorization of, declaration, filing or registration with, or notice to, any person or entity, (iii)&#160;result in the creation of any Lien on any Shares (other than pursuant to this Agreement or transfer restrictions under applicable securities laws or the Governing Documents of Supporter) or (iv)&#160;conflict with or result in a breach of or constitute a default under any provision of Supporter&#8217;s Governing Documents. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as contemplated pursuant to the BCA and the Ancillary Documents, Supporter owns of record and has good, valid and marketable title to the Shares free and clear of any Lien (other than pursuant to this Agreement or transfer restrictions under applicable securities Laws or the Governing Documents of Supporter) and has the sole power (as currently in effect) to vote and has the full right, power and authority to sell, transfer and deliver such Shares, and Supporter does not own, directly or indirectly, any other Shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Supporter has the power, authority and capacity to execute, deliver and perform this Agreement and that this Agreement has been duly authorized, executed and delivered by Supporter. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Termination</span>. This Agreement and the obligations of Supporter under this Agreement shall automatically terminate upon the earliest of: (a)&#160;the Effective Time; (b)&#160;the termination of the BCA in accordance with its terms; and (c)&#160;the mutual agreement of the Company and SPAC. Upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; provided, however, such termination or expiration shall not relieve any party from liability for any willful breach of this Agreement occurring prior to its termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Miscellaneous</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise provided herein or in the BCA or any Ancillary Document, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the transactions contemplated hereby are consummated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by telecopy or <span style="white-space:nowrap">e-mail</span> or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this <span style="text-decoration:underline">paragraph 6(b)</span>): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to SPAC or Supporter, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Atlantic Coastal Acquisition Corp. II </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6 St. Johns Lane, Floor 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Shahraab Ahmad </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Pillsbury Winthrop Shaw Pittman LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">31 W 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Oresman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Abpro Corporation </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">68 Cummings Park Drive </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Woburn, MA 01801 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Legal Department </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Nelson Mullins Riley&#160;&amp; Scarborough LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">101 Constitution Avenue, NW, Suite 900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20001 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Talcott; E. Peter Strand </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">E-mail:</span> ******* ; ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement, the BCA and the Ancillary Documents constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise). </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The parties hereto agree that irreparable damage may occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity. Each of the parties agrees that it shall not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity. Any party seeking an injunction or injunctions to prevent breaches or threatened breaches of, or to enforce compliance with this Agreement when expressly available pursuant to the terms of this Agreement shall not be required to provide any bond or other security in connection with any such Order. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware. Without prejudice to the ability of any party to enforce this Agreement in any other proper jurisdiction, each of the parties irrevocably and unconditionally submits and attorns to the <span style="white-space:nowrap">non-exclusive</span> jurisdiction of the courts of the State of Delaware to determine all issues, whether at law or in equity, arising from this Agreement. To the extent permitted by applicable law, each party: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) irrevocably waives any objection, including any claim of inconvenient forum, that it may now or in the future have to the venue of any legal proceeding arising out of or relating to this agreement in the courts of the State of Delaware, or that the subject matter of this agreement may not be enforced in those courts; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) irrevocably agrees not to seek, and waives any right to, judicial review by any court that may be called upon to enforce the judgment of the courts referred to in this <span style="text-decoration:underline">paragraph 6(g)</span>, of the substantive merits of any suit, action or proceeding; and </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to the extent that party has or may acquire any immunity from the jurisdiction of any court or from any legal process, whether through service or notice, attachment before judgment, attachment in aid of execution, execution or otherwise, with respect to itself or its property, irrevocably waives that immunity in connection with its obligations under this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) This Agreement may be executed and delivered (including by facsimile or portable document format (pdf) transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Without further consideration, each party shall use commercially reasonable efforts to execute and deliver or cause to be executed and delivered such additional documents and instruments and take all such further action as may be reasonably necessary or desirable to consummate the transactions contemplated by this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) This Agreement shall not be effective or binding upon Supporter until such time as the BCA is executed by each of the parties thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) If, and as often as, there are any changes in the SPAC Common Stock by way of stock split, stock dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or business combination, or by any other means, equitable adjustment shall be made to the provisions of this Agreement as may be required so that the rights, privileges, duties and obligations hereunder shall continue with respect to SPAC, Supporter and the Shares as so changed. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Each of the parties hereto hereby waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement. Each of the parties hereto (i)&#160;certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii)&#160;acknowledges that it and the other parties hereto have been induced to enter into this Agreement and the transactions contemplated hereby, as applicable, by, among other things, the mutual waivers and certifications in this <span style="text-decoration:underline">paragraph 6(l)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature pages follow] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="text-decoration:underline">SPAC</span></span><span style="font-weight:bold"><span style="font-style:italic"><span style="text-decoration:underline">: </span></span></span><span style="font-weight:bold"><span style="text-decoration:underline"></span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION CORP.&#160;II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="text-decoration:underline">COMPANY:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ABPRO CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Sponsor Support Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="text-decoration:underline">SUPPORTER:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION MANAGEMENT II LLC</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Sponsor Support Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="ii509388_5"><span style="text-decoration:underline">Exhibit B </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Company Support Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(attached) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COMPANY SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This COMPANY SUPPORT AGREEMENT, is entered into as of December&#160;11, 2023 (this &#8220;<span style="font-weight:bold"><span style="font-style:italic">Agreement</span></span>&#8221;), by and among <span style="font-weight:bold">Atlantic Coastal Acquisition Corp. II</span>, a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">SPAC</span></span>&#8221;), <span style="font-weight:bold">Abpro Corporation</span>,<span style="font-weight:bold"> </span>a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;), and each of the shareholders of the Company whose names appear on the signature pages of this Agreement (each, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company Shareholder</span></span>&#8221; and, collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company Shareholders</span></span>&#8221;). The SPAC, the Company and each Company Shareholder may be referred to herein individually as a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Party</span></span>&#8221; and collectively as the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Parties</span></span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, contemporaneously with the execution of this Agreement, the SPAC, the Company, and Abpro Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of the SPAC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Sub</span></span>&#8221;), are entering into that certain Business Combination Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">BCA</span></span>&#8221;), pursuant to which, subject to the terms and conditions thereof, Merger Sub will merge with and into the Company and become a wholly-owned subsidiary of the SPAC (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger</span></span>&#8221;), and the Company&#8217;s securityholders will receive shares of the SPAC&#8217;s Series A Common Stock; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, as of the date hereof, each Company Shareholder owns of record the number of equity securities of the Company as set forth opposite such Company Shareholder&#8217;s name on <span style="font-weight:bold"><span style="font-style:italic">Exhibit A</span></span> hereto (all such securities and any underlying securities of the Company of which ownership of record or the power to vote is hereafter acquired by the Company Shareholders prior to the termination of this Agreement being referred to herein as the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Securities</span></span>&#8221;); and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, in order to induce the SPAC, Merger Sub, and the Company to enter into the BCA, the Company Shareholders are executing and delivering this Agreement to the SPAC and the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and intending to be legally bound hereby, each of the Company Shareholders (severally and not jointly), the SPAC and the Company hereby agrees as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Agreement to Vote</span>. Each Company Shareholder, by this Agreement, with respect to its Securities, severally and not jointly, hereby agrees (and agrees to execute such documents and certificates evidencing such agreement as the SPAC may reasonably request in connection therewith), if (and only if) the Approval Condition (as defined below) shall have been satisfied, to vote, at any meeting of the members of the Company, and in any action by written consent of the members of the Company, all of such Company Shareholder&#8217;s Securities (a)&#160;in favor of the approval and adoption of the BCA, the transactions contemplated by the BCA and this Agreement, including, no later than forty-eight (48)&#160;hours following the date that the Registration Statement/Proxy Statement (as defined in the BCA) becomes effective, an amendment to the Company Certificate of Incorporation (as defined in the BCA), providing for the automatic conversion, immediately prior to the Closing, of the Company Preferred Stock (as defined in the BCA) into shares of Company Common Stock (as defined in the BCA)&#160;(b) in favor of any other matter reasonably necessary to the consummation of the transactions contemplated by the BCA and considered and voted upon by the stockholders of the Company, including the conversion of the Company&#8217;s preferred stock, (c)&#160;in favor of the approval and adoption of the new equity incentive plan (as contemplated by the BCA) and (d)&#160;against any action, agreement or transaction (other than the BCA or the transactions contemplated thereby) or proposal that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of the Company under the BCA or that would reasonably be expected to result in the failure of the transactions contemplated by the BCA from being consummated. Each Company Shareholder acknowledges receipt and review of a copy of the BCA. For purposes of this Agreement, &#8220;<span style="font-weight:bold"><span style="font-style:italic">Approval Condition</span></span>&#8221; shall mean that (i)&#160;the BCA and the transactions as set forth therein shall have been approved by the Board of Directors of the Company and such approval shall not have been withdrawn and (ii)&#160;the BCA shall not have been amended or modified to change the Merger Consideration payable under the BCA to the Company Shareholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Waiver of Appraisal Rights</span>. Each Company Shareholder hereby unconditionally waives, and agrees not to exercise, assert or perfect, any rights of appraisal or any dissenters&#8217; rights that such Company Shareholder may have (whether under applicable Law or otherwise) or could potentially have or acquire in connection with the Merger. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Transfer of Securities</span>. Except as may be required by or permitted in the BCA, each Company Shareholder, severally and not jointly, agrees that it shall not, directly or indirectly, (a)&#160;sell, assign, transfer (including by operation of law), lien, pledge, dispose of or otherwise encumber any of the Securities or otherwise agree to do any of the foregoing (unless the transferee agrees to be bound by this Agreement), (b) deposit any Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement, (c)&#160;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law) or other disposition of any Securities (unless the transferee agrees to be bound by this Agreement), or (d)&#160;take any action that would have the effect of preventing or disabling the Company Shareholder from performing its obligations hereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Representations and Warranties</span>. Each Company Shareholder, severally and not jointly, represents and warrants for and on behalf of itself to the SPAC as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The execution, delivery and performance by such Company Shareholder of this Agreement and the consummation by such Company Shareholder of the transactions contemplated hereby do not and will not (i)&#160;conflict with or violate any Law (with this and any other defined term used herein without definition having the meaning as given in the BCA) or other Order applicable to such Company Shareholder, (ii)&#160;require any consent, approval or authorization of, declaration, filing or registration with, or notice to, any person or entity, (iii)&#160;result in the creation of any Lien on any Securities (other than pursuant to this Agreement, the BCA or transfer restrictions under applicable securities laws or the Governing Documents of the Company or such Company Shareholder) or (iv)&#160;conflict with or result in a breach of or constitute a default under any provision of such Company Shareholder&#8217;s Governing Documents if such Company Shareholder is an entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Such Company Shareholder owns of record and has good, valid and marketable title to the Securities set forth opposite the Company Shareholder&#8217;s name on <span style="text-decoration:underline">Exhibit</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;A</span> free and clear of any Lien (other than pursuant to this Agreement or transfer restrictions under applicable securities Laws or the Governing Documents of such Company Shareholder) and has the sole power (as currently in effect) to vote and the full right, power and authority to sell, transfer and deliver such Securities, and such Company Shareholder does not own, directly or indirectly, any other Securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Such Company Shareholder has the power, authority and capacity to execute, deliver and perform this Agreement, and that this Agreement has been duly authorized, executed and delivered by such Company Shareholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Termination</span>. This Agreement and the obligations of the Company Shareholders under this Agreement shall automatically terminate upon the earliest of (a)&#160;the Effective Time; (b)&#160;the termination of the BCA in accordance with its terms; or (c)&#160;the mutual agreement of the SPAC and the Company. Upon termination or expiration of this Agreement, no Party shall have any further obligations or liabilities under this Agreement;<span style="text-decoration:underline"> provided</span>, <span style="text-decoration:underline">however</span>, such termination or expiration shall not relieve any Party from liability for any willful breach of this Agreement occurring prior to such termination of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Miscellaneous</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise provided herein, in the BCA or in any Ancillary Document, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such costs and expenses, whether or not the transactions contemplated hereby are consummated. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All notices, consents, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered (i)&#160;in person, (ii)&#160;by <span style="white-space:nowrap">e-mail,</span> with affirmative confirmation of receipt, (iii)&#160;one Business Day after being sent, if sent by reputable, nationally recognized overnight courier service or (iv)&#160;three (3) Business Days after being mailed, if sent by registered or certified mail, <span style="white-space:nowrap">pre-paid</span> and return receipt requested, in each case to the applicable Party at the following addresses (or at such other address for a Party as shall be specified by like notice in accordance with this <span style="text-decoration:underline">paragraph 5(b)</span>): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the SPAC, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Atlantic Coastal Acquisition Corp. II </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6 St. Johns Lane, Floor 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Shahraab Ahmad </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Pillsbury Winthrop Shaw Pittman LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">31 W 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Oresman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Abpro Corporation </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">68 Cummings Park Drive </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Woburn, MA 01801 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Legal Department </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">with a copy (which shall not constitute notice) to</span>: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Nelson Mullins Riley&#160;&amp; Scarborough LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">101 Constitution Avenue, NW, Suite 900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20001 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Talcott; E. Peter Strand </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">E-mail:</span> *******; ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to a Company Shareholder, to the address set forth for such Company Shareholder on the signature page hereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement, the BCA and the Ancillary Documents constitute the entire agreement among the Parties and the other parties thereto with respect to the subject matter hereof and thereof, and supersede all prior agreements and undertakings, both written and oral, among the Parties and the other parties thereto, or any of them, with respect to the subject matter hereof and thereof. This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise) without the prior written consent of each of the Parties, and any attempt to do so without such consent shall be void ab initio. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) This Agreement shall be binding upon and inure solely to the benefit of each Party, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. No Company Shareholder shall be liable for the breach of this Agreement by any other Company Shareholder. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Parties agree that irreparable damage may occur in the event any provision of this Agreement is not performed in accordance with the terms hereof and that the Parties shall be entitled to seek specific performance of the terms hereof, in addition to any other remedy at law or in equity. Each of the Parties agrees that it shall not oppose the granting of an injunction, specific performance or other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or equity. Any Party seeking an injunction or injunctions to prevent breaches or threatened breaches of, or to enforce compliance with, this Agreement, when expressly available pursuant to the terms of this Agreement, shall not be required to provide any bond or other security in connection with any such Order. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) This Agreement shall be governed by, and construed and interpreted in accordance with, the Laws of the State of Delaware. Without prejudice to the ability of any Party to enforce this Agreement in any other proper jurisdiction, each of the Parties irrevocably and unconditionally submits and attorns to the <span style="white-space:nowrap">non-exclusive</span> jurisdiction of the courts of the State of Delaware to determine all issues, whether at law or in equity, arising from this Agreement. To the extent permitted by applicable Law, each of the Parties: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) irrevocably waives any objection, including any claim of inconvenient forum, that it may now or in the future have to the venue of any legal proceeding arising out of or relating to this Agreement in the courts of the State of Delaware, or that the subject matter of this Agreement may not be enforced in those courts; </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) irrevocably agrees not to seek, and waives any right to, judicial review by any court that may be called upon to enforce the judgment of the courts referred to in this <span style="text-decoration:underline">paragraph 5(g)</span>, of the substantive merits of any suit, action or proceeding; and </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to the extent that the Party has or may acquire any immunity from the jurisdiction of any court or from any legal process, whether through service or notice, attachment before judgment, attachment in aid of execution, execution or otherwise, with respect to itself or its property, irrevocably waives that immunity in connection with its obligations under this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) This Agreement may be executed and delivered (including by facsimile or portable document format (pdf) transmission) in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Without further consideration, each Party shall use commercially reasonable efforts to execute and deliver or cause to be executed and delivered such additional documents and instruments and take all such further action as may be reasonably necessary or desirable to consummate the transactions contemplated by this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) This Agreement shall not be effective or binding upon any Company Shareholder until such time as the BCA is executed by each of the parties thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) If, and as often as, there are any changes in the Company or the Company Shareholder&#8217;s Securities by way of stock split, stock dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or business combination, or by any other means, equitable adjustment shall be made to the provisions of this Agreement as may be required so that the rights, privileges, duties and obligations hereunder shall continue with respect to the Company Shareholder and its Securities as so changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Each of the Parties hereby waives to the fullest extent permitted by applicable law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement. Each of the Parties hereto (i)&#160;certifies that no representative, agent or attorney of any other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party has represented, expressly or otherwise, that such other Party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii)&#160;acknowledges that it and the other Parties have been induced to enter into this Agreement and the transactions contemplated hereby, as applicable, by, among other things, the mutual waivers and certifications in this <span style="text-decoration:underline">paragraph 5(l)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signatures appear on following pages] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the Parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION CORP. II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ABPRO CORPORATION</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Voting Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the Parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">COMPANY SHAREHOLDERS</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Shareholder Name:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">ABPRO BIO INTERNATIONAL, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Address for Notices:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Email: *******</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Voting Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the Parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">COMPANY SHAREHOLDERS</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Shareholder Name:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">APEX PARTNERS II LTD.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Address for Notices:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Email: *******</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Voting Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the Parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">COMPANY SHAREHOLDERS</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Shareholder Name:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">IAN CHAN</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Name: Ian Chan</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Address for Notices:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Email: *******</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Voting Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the Parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">COMPANY SHAREHOLDERS</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Shareholder Name:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">FV DYNASTY TRUST</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;&#8195;&#8195;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Address for Notices:</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Email: *******</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Voting Agreement] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">EXHIBIT A </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">THE COMPANY SHAREHOLDERS </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Company Shareholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Company Securities</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ian Chan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">4,477,913 common (approx. 47.8%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FV Dynasty Trust</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">556,118 common (approx. 5.94%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abpro Bio International, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3,748,410&#160;preferred&#160;(approx.&#160;48.4%)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apex Partners II Ltd.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">892,391&#160;preferred&#160;(approx.&#160;11.5%)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="ii509388_6"><span style="text-decoration:underline">Exhibit C</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Company Lock-Up Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(attached) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">FORM OF <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT (this &#8220;<span style="font-weight:bold"><span style="font-style:italic">Agreement</span></span>&#8221;) is made and entered into as of [&#9679;], 2023, by and between (i)&#160;Atlantic Coastal Acquisition Corp. II,<span style="font-weight:bold"> </span>a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;), (ii) Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Sponsor</span></span>&#8221;), and (iii)&#160;the undersigned (each, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Holder</span></span>&#8221;). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the BCA (as defined herein). Company, Sponsor and each Holder may be referred to herein individually as a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Party</span></span>&#8221; and collectively as the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Parties</span></span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the Company, Abpro Corporation, a Delaware corporation (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Abpro</span></span>&#8221;), and Abpro Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Sub</span></span>&#8221;), have entered into that certain Business Combination Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">BCA</span></span>&#8221;), pursuant to which, subject to the terms and conditions thereof, Merger Sub will merge with and into Abpro, with Abpro&#8217;s securityholders receiving shares of the Company&#8217;s Series A common stock, par value $0.0001 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Series A Common Stock</span></span>&#8221;); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, immediately prior to the Closing, Holder is a holder of equity or equity-linked securities of Abpro and upon the Closing, Holder will be a holder of Series A Common Stock or options to acquire Series A Common Stock; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, pursuant to the BCA, and in view of the valuable consideration to be received by each Holder thereunder, the Parties desire to enter into this Agreement, pursuant to which the shares of Series A Common Stock and options to acquire shares of Series A Common Stock (all such securities, together with any securities paid as dividends or distributions with respect to such securities or into which such securities are exchanged or converted, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restricted Securities</span></span>&#8221;) shall become subject to limitations on disposition as set forth herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth below, and intending to be legally bound hereby, the Parties hereby agree as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Provisions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Holder hereby agrees not to, during the period commencing from the Closing and ending on the earlier of (x)&#160;the twelve month anniversary of the date of the Closing, (y)&#160;if the reported last sale price of the shares of Series A Common Stock equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, right issuances, reorganizations, recapitalizations and the like) for any twenty (20)&#160;trading days within any thirty (30)&#160;trading day period commencing at least <span style="white-space:nowrap">one-hundred</span> and fifty (150)&#160;days after the Closing, and (z)&#160;the date after the Closing on which the Company consummates a liquidation, merger, capital stock exchange, reorganization or other similar transaction with an unaffiliated third party that results in all of the Company&#8217;s shareholders having the right to exchange their common stock of the Company for cash, securities or other property (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Period</span></span>&#8221;): (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Restricted Securities, (ii)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii)&#160;publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii) or (iii)&#160;above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii) or (iii), a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Prohibited Transfer</span></span>&#8221;). The foregoing restrictions shall not apply to the transfer of any or all of the Restricted Securities owned by a Holder (I)&#160;by gift, will or intestate succession upon the death of Holder, (II)&#160;to any Permitted Transferee (as defined below) or (III)&#160;pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of marriage or civil union; provided, however, that in any of cases (I), (II) or (III)&#160;it shall be a condition to such transfer that the transferee executes and delivers to the Company an agreement stating that the transferee is receiving and holding the Restricted Securities subject to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of this Agreement applicable to Holder, and there shall be no further transfer of such Restricted Securities except in accordance with this Agreement. The forgoing restrictions shall also not apply to the exercise of stock options existing on the date hereof, provided that the shares of Series A Common Stock received upon such exercise shall be Restricted Securities subject to the forgoing restrictions. As used in this Agreement, the term &#8220;<span style="font-weight:bold"><span style="font-style:italic">Permitted Transferee</span></span>&#8221; shall mean: (1)&#160;the members of Holder&#8217;s immediate family (for purposes of this Agreement, &#8220;immediate family&#8221; shall mean with respect to any natural person, any of the following: such person&#8217;s spouse or domestic partner, the siblings of such person and his or her spouse or domestic partner, and the direct descendants and ascendants (including adopted and step children and parents) of such person and his or her spouses or domestic partners and siblings), (2) any trust for the direct or indirect benefit of Holder or the immediate family of Holder, (3)&#160;if Holder is a trust, to the trustor or beneficiary of such trust or to the estate of a beneficiary of such trust, (4)&#160;in the case of an entity, partners, members, managers, investment managers or stockholders of such entity that receive such transfer as a distribution, (5)&#160;to any affiliate of Holder, (6)&#160;any charitable foundation controlled by the undersigned, its members or stockholders or any of their respective immediate family, (7)&#160;any transferee to satisfy any U.S. federal, state, or local income tax obligations of a Holder (or its direct or indirect owners) arising from such Holder&#8217;s ownership (including prior to and after the Closing) of the Restricted Securities or any interests in the Company, in each case solely and to the extent necessary to cover any tax liability as a direct result of such ownership of the Restricted Securities or any interests in the Company, and (8)&#160;any transferee whereby there is no change in beneficial ownership. Holder further agrees to execute such agreements as may be reasonably requested by the Company that are consistent with the foregoing or that are necessary to give further effect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If any Prohibited Transfer is made or attempted contrary to the provisions of this Agreement, such purported Prohibited Transfer shall be null and void <span style="font-style:italic">ab initio</span>, and the Company shall refuse to recognize any such purported transferee of the Restricted Securities as one of its equity holders for any purpose. In order to enforce this<span style="text-decoration:underline">&#160;Section 1</span>, the Company may impose stop-transfer instructions with respect to the Restricted Securities of Holder (and Permitted Transferees and assigns thereof) until the end of the <span style="white-space:nowrap">Lock-Up</span> Period except in compliance with the foregoing restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) During the <span style="white-space:nowrap">Lock-Up</span> Period, each certificate evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend in substantially the following form, in addition to any other applicable legends: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#8220;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER SET FORTH IN A <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT, DATED AS OF [&#9679;], 2023, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &#8220;ISSUER&#8221;) AND THE ISSUER&#8217;S SECURITY HOLDER NAMED THEREIN, AS AMENDED. A COPY OF SUCH <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For the avoidance of any doubt, Holder shall retain all of its rights as a stockholder of the Company during the <span style="white-space:nowrap">Lock-Up</span> Period, including the right to vote any Restricted Securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Miscellaneous</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Binding Effect; Assignment</span>. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns. This Agreement and all obligations of Holder are personal to Holder and may not be transferred or delegated by Holder at any time. The Company may freely assign any or all of its rights under this Agreement, in whole or in part, to any successor entity (whether by merger, consolidation, equity sale, asset sale or otherwise) without obtaining the consent or approval of Holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Third Parties</span>. Nothing contained in this Agreement or in any instrument or document executed by any Party in connection with the transactions contemplated hereby shall create any rights in, or be deemed to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have been executed for the benefit of, any person or entity that is not a Party or thereto or a successor or permitted assign of such a Party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Governing Law; Jurisdiction</span>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby, including the applicable statute of limitations, shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Law of any jurisdiction other than the State of Delaware. To the extent permitted by applicable Law, each Party: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">irrevocably waives any objection, including any claim of inconvenient forum, that it may now or in the future have to the venue of any legal proceeding arising out of or relating to this agreement in the courts of that Province, or that the subject matter of this agreement may not be enforced in those courts; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">irrevocably agrees not to seek, and waives any right to, judicial review by any court that may be called upon to enforce the judgment of the courts referred to in this section 2(c), of the substantive merits of any suit, action or proceeding; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to the extent that party has or may acquire any immunity from the jurisdiction of any court or from any legal process, whether through service or notice, attachment before judgment, attachment in aid of execution, execution or otherwise, with respect to itself or its property, irrevocably waives that immunity in connection with its obligations under this Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">WAIVER OF JURY TRIAL</span>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO (i)&#160;CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (ii)&#160;ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS<span style="text-decoration:underline">&#160;SECTION 2(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">Interpretation</span>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. In this Agreement, unless the context otherwise requires: (i)&#160;any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns, pronouns and verbs shall include the plural and vice versa; (ii) &#8220;including&#8221; (and with correlative meaning &#8220;include&#8221;) means including without limiting the generality of any description preceding or succeeding such term and shall be deemed in each case to be followed by the words &#8220;without limitation&#8221;; (iii) the words &#8220;herein,&#8221; &#8220;hereto,&#8221; and &#8220;hereby&#8221; and other words of similar import in this Agreement shall be deemed in each case to refer to this Agreement as a whole and not to any particular section or other subdivision of this Agreement; and (iv)&#160;the term &#8220;or&#8221; means &#8220;and/or&#8221;. The Parties have participated jointly in the negotiation and drafting of this Agreement. Consequently, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline">Notices</span>. All notices, consents, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered (i)&#160;in person, (ii)&#160;by facsimile, email or other electronic means, with affirmative confirmation of receipt, (iii)&#160;one Business Day after being sent, if sent by reputable, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nationally recognized overnight courier service or (iv)&#160;three (3) Business Days after being mailed, if sent by registered or certified mail, <span style="white-space:nowrap">pre-paid</span> and return receipt requested, in each case to the applicable Party at the following addresses (or at such other address for a Party as shall be specified by like notice): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Abpro Corporation </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">68 Cummings Park Drive </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Woburn, MA 01801 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Legal Department </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Nelson Mullins Riley&#160;&amp; Scarborough LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101 Constitution Avenue, NW, Suite 900 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20001 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Jonathan Talcott; E. Peter Strand </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">E-mail:</span> *******; ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">and: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Atlantic Coastal Acquisition Corp. II </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6 St. Johns Lane, Floor 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Shahraab Ahmad </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pillsbury Winthrop Shaw Pittman LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">31 W 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Matthew Oresman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: ******* </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">If to a Holder or Sponsor, to</span>: the address set forth below Holder&#8217;s or Sponsor&#8217;s name on the signature page to this Agreement. </p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Amendments and Waivers</span>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company, Sponsor and Holder. No failure or delay by a Party in exercising any right hereunder shall operate as a waiver thereof. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <span style="text-decoration:underline">Authorization on Behalf of the Company</span>. The Parties acknowledge and agree that notwithstanding anything to the contrary contained in this Agreement, any and all determinations, actions or other authorizations under this Agreement on behalf of the Company, including enforcing the Company&#8217;s rights and remedies under this Agreement, or providing any waivers with respect to the provisions hereof, shall solely be made, taken and authorized by the majority of the Company&#8217;s disinterested directors (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Disinterested Directors</span></span>&#8221;). In the event that the Company at any time does not have any Disinterested Directors, so long as Holder has any remaining obligations under this Agreement, the Company will promptly appoint one in connection with this Agreement. Without limiting the foregoing, in the event that Holder or Holder&#8217;s Affiliate serves as a director, officer, employee or other authorized agent of the Company or any of its current or future Affiliates, Holder and/or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder&#8217;s Affiliate shall have no authority, express or implied, to act or make any determination on behalf of the Company or any of its current or future Affiliates in connection with this Agreement or any dispute or Action with respect hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <span style="text-decoration:underline">Severability</span>. In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties will substitute for any invalid, illegal or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid, illegal or unenforceable provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <span style="text-decoration:underline">Specific Performance</span>. Holder acknowledges that its obligations under this Agreement are unique, recognizes and affirms that in the event of a breach of this Agreement by Holder, money damages will be inadequate and Company will have no adequate remedy at law, and agrees that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed by Holder in accordance with their specific terms or were otherwise breached. Accordingly, the Company shall be entitled to an injunction or restraining order to prevent breaches of this Agreement by Holder and to enforce specifically the terms and provisions hereof, without the requirement to post any bond or other security or to prove that money damages would be inadequate, this being in addition to any other right or remedy to which the Company may be entitled under this Agreement, at law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <span style="text-decoration:underline">Entire Agreement</span>. This Agreement constitutes the full and entire understanding and agreement among the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the Parties is expressly canceled;<span style="text-decoration:underline">&#160;provided</span>, that, for the avoidance of doubt, the foregoing shall not affect the rights and obligations of the Parties under the BCA or any Ancillary Document or under the Letter Agreement, dated as of January&#160;13, 2022, by and among Sponsor, the undersigned thereto, and the Company. Notwithstanding the foregoing, nothing in this Agreement shall limit any of the rights or remedies of the Company or any of the obligations of Holder under any other agreement between Holder and the Company or any certificate or instrument executed by Holder in favor of the Company, and nothing in any other agreement, certificate or instrument shall limit any of the rights or remedies of the Company or any of the obligations of Holder under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <span style="text-decoration:underline">Further Assurances</span>. From time to time, at another Party&#8217;s request and without further consideration (but at the requesting Party&#8217;s reasonable cost and expense), each Party shall execute and deliver such additional documents and take all such further action as may be reasonably necessary to consummate the transactions contemplated by this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <span style="text-decoration:underline">Counterparts; Facsimile.</span>&#160;This Agreement may also be executed and delivered by facsimile signature or by email in portable document format in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <span style="text-decoration:underline">Effectiveness</span>. This Agreement shall be binding upon the Holder upon the Holder&#8217;s execution and delivery of this Agreement, but this Agreement shall only become effective upon the consummation of the Merger. In the event that the BCA is validly terminated in accordance with its terms prior to the consummation of the Merger, this Agreement shall automatically terminate and become null and void, and the Parties shall have no obligations hereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">[Remainder of Page Intentionally Left Blank; Signature Pages Follow]</span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the parties have executed this Agreement as of the date first written above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic">Company:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION CORP. II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic">Sponsor:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ATLANTIC COASTAL ACQUISITION MANAGEMENT II LLC</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic">Address for Notice:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">{Additional Signature on the Following Page} </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">{Signature Page to <span style="white-space:nowrap">Lock-Up</span> Agreement} </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, the parties have executed this <span style="white-space:nowrap">Lock-Up</span> Agreement as of the date first written above.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:66%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic"><span style="text-decoration:underline">Holder:</span></span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name&#160;of&#160;Holder:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr></table>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr></table>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic">Number of Series A Common Stock and Options:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold"><span style="font-style:italic">Address for Notice:</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr></table>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Email:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">{Signature Page to <span style="white-space:nowrap">Lock-Up</span> Agreement} </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit D</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Amended and Restated SPAC Certificate of Incorporation </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(attached) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECOND AMENDED AND RESTATED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTIFICATE OF INCORPORATION </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ATLANTIC COASTAL ACQUISITION CORP. II </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad hereby certifies that: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">ONE:</span> He is the duly elected and acting Chief Executive Officer of Atlantic Coastal Acquisition Corp. II, a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Corporation</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">TWO:</span> The date of filing of said corporation&#8217;s original certificate of incorporation with the Secretary of State of the State of Delaware was May&#160;20, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THREE:</span> The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on January&#160;18, 2022 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Amended Certificate</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FOUR: </span>This Second Amended and Restated Certificate of Incorporation amends and restates the Amended Certificate in its entirety. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIVE</span>: This Second Amended and Restated Certificate of Incorporation has been duly approved and adopted by the Board of Directors of the Corporation on [&#9679;], and by the stockholders of the Corporation on [&#9679;], in accordance with the provisions of Sections 141, 228, 242 and 245 of the General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIVE: </span>The Amended Certificate is hereby amended and restated to read in its entirety as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">I. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Abpro Corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">II. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of the Company in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of the registered agent at such address is The Corporation Trust Company. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CIII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (&#8220;<span style="font-weight:bold"><span style="font-style:italic">DGCL</span></span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">IV. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The Company is authorized to issue two classes of stock to be designated, respectively, &#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221; and &#8220;<span style="font-weight:bold"><span style="font-style:italic">Preferred Stock</span></span>.&#8221; The total number of shares which the Company is authorized to issue is 111,000,000 shares. 110,000,000 shares shall be Common Stock, each having a par value of $0.0001. 1,000,000 shares shall be Preferred Stock, each having a par value of $0.0001. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Board of Directors</span></span>&#8221;) is hereby expressly authorized to provide for the issue of any or all of the unissued and undesignated shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; <span style="font-style:italic">provided, however</span>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Second Amended and Restated Certificate of Incorporation (this &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restated Certificate</span></span>&#8221;) (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon by law or pursuant to this Restated Certificate (including any certificate of designation filed with respect to any series of Preferred Stock). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">V. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The management of the business and the conduct of the affairs of the Company shall be vested in its Board of Directors. The number of directors that shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&#160;I directors shall expire and Class&#160;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&#160;II directors shall expire and Class&#160;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&#160;III directors shall expire and Class&#160;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Subject to the rights of any series of Preferred Stock that may be designated from time to time to elect additional directors under specified circumstances, neither the Board of Directors nor any individual director may be removed without cause. Subject to any limitations imposed by applicable law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">D.</span> Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Preferred Stock that may be designated from time to time, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">E.</span> The Board of Directors is expressly empowered to adopt, amend or repeal the Amended and Restated Bylaws of the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Bylaws</span></span>&#8221;).<span style="font-weight:bold"> </span>Any adoption, amendment or repeal of the Bylaws by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders shall also have power to adopt, amend or repeal the Bylaws; <span style="font-style:italic">provided, however, </span>that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Restated Certificate, such action by stockholders shall require the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">F.</span> The directors of the Company need not be elected by written ballot unless the Bylaws so provide. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">G.</span> No action shall be taken by the stockholders of the Company except at an annual or special meeting of stockholders called in accordance with the Bylaws. No action shall be taken by the stockholders of the Company by written consent or electronic transmission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">H.</span> Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VI. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The liability of a director of the Company for monetary damages shall be eliminated to the fullest extent under applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval by the stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (A)&#160;any derivative claim or cause of action brought on behalf of the Company; (B)&#160;any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the Company, to the Company or the Company&#8217;s stockholders; (C)&#160;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, arising out of or pursuant to any provision of the DGCL, this Restated Certificate or the Bylaws of the Company (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Restated Certificate or the Bylaws of the Company (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&#160;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, governed by the internal-affairs doctrine or otherwise related to the Company&#8217;s internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1933 Act</span></span>&#8221;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Unless the Company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters for any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Any person or entity holding, owning or otherwise acquiring any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Restated Certificate. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VIII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The Company reserves the right to amend, alter, change or repeal any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by statute, except as provided in Section B of this Article VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Notwithstanding any other provisions of this Restated Certificate or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class or series of the Company required by law or by this Restated Certificate or any certificate of designation filed with respect to a series of Preferred Stock that may be designated from time to time, subject to the rights of the holders of any series of Preferred Stock, the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII of this Restated Certificate.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">* * * * </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">SIX: </span>This Restated Certificate has been duly adopted and approved by the Board of Directors and by written consent of the stockholders in accordance with Sections 228, 242 and 245 of the DGCL and written notice of such action has been given as provided in section 228 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature page follows] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, Atlantic Coastal Acquisition Corp. II has caused this Second Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this [&#9679;]th day of [&#9679;], [&#9679;]. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">TLANTIC</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OASTAL</small> A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">CQUISITION</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ORP</small>. II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Shahraab Ahmad</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its: Chief Executive Officer</p></td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit E</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Amended and Restated SPAC Bylaws </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(attached) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECOND AMENDED AND RESTATED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BYLAWS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABPRO HOLDINGS, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OFFICES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1.</span> <span style="font-weight:bold">Registered Office.</span> The registered office of the corporation in the State of Delaware shall be at 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the registered agent at such address is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.</span> <span style="font-weight:bold">Other Offices.</span> The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation&#8217;s Board of Directors (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Board of Directors</span></span>&#8221;), and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CORPORATE SEAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.</span> <span style="font-weight:bold">Corporate Seal.</span> The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, &#8220;Corporate Seal-Delaware.&#8221; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">STOCKHOLDERS&#8217; MEETINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.</span> <span style="font-weight:bold">Place of Meetings.</span> Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">DGCL</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;5. Annual Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&#160;pursuant to the corporation&#8217;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or at the direction of the Board of Directors; or (iii)&#160;by any stockholder of the corporation who was a stockholder of record at the time of giving the stockholder&#8217;s notice provided for in Section&#160;5(b) of these Second Amended and Restated Bylaws (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Bylaws</span></span>&#8221;), who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section&#160;5. For the avoidance of doubt, clause (iii)&#160;above shall be the exclusive means for a stockholder to make nominations </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule <span style="white-space:nowrap">14a-8</span> under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1934 Act</span></span>&#8221;)) before an annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> At an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under Delaware law and as shall have been properly brought before the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&#160;of Section&#160;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&#160;5(b)(iii) of these Bylaws and must update and supplement such written notice on a timely basis as set forth in Section&#160;5(c) of these Bylaws. Such stockholder&#8217;s notice shall set forth: (A)&#160;as to each nominee such stockholder proposes to nominate at the meeting: (1)&#160;the name, age, business address and residence address of such nominee; (2)&#160;the principal occupation or employment of such nominee; (3)&#160;the class and number of shares of each class of capital stock of the corporation which are owned of record and beneficially by such nominee; (4)&#160;the date or dates on which such shares were acquired and the investment intent of such acquisition; (5)&#160;with respect to each nominee for election or <span style="white-space:nowrap">re-election</span> to the Board of Directors, include a completed and signed questionnaire, representation and agreement required by Section&#160;5(e) of these Bylaws; and (6)&#160;such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section&#160;14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&#8217;s written consent to being named as a nominee and to serving as a director if elected); and (B)&#160;the information required by Section&#160;5(b)(iv) of these Bylaws. The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&#8217;s understanding of the independence, or lack thereof, of such proposed nominee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> Other than proposals sought to be included in the corporation&#8217;s proxy materials pursuant to Rule <span style="white-space:nowrap">14(a)-8</span> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&#160;of Section&#160;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&#160;5(b)(iii) of these Bylaws, and must update and supplement such written notice on a timely basis as set forth in Section&#160;5(c) of these Bylaws. Such stockholder&#8217;s notice shall set forth: (A)&#160;as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the corporation&#8217;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&#160;the information required by Section&#160;5(b)(iv) of these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iii)</span> To be timely, the written notice required by Section&#160;5(b)(i) or 5(b)(ii) of these Bylaws must be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting; <span style="font-style:italic">provided, however,</span> that, subject to the last sentence of this Section&#160;5(b)(iii), in the event that the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year&#8217;s annual meeting, notice by the stockholder to be timely must be so received not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment or a postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#8217;s notice as described above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iv)</span> The written notice required by Section&#160;5(b)(i) or 5(b)(ii) of these Bylaws shall also set forth, as of the date of the notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Proponent</span></span>&#8221; and collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Proponents</span></span>&#8221;): (A) the name and address of each Proponent, as they appear on the corporation&#8217;s books; (B)&#160;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&#160;a description of any agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the agreement, arrangement or understanding, with any of the foregoing; (D)&#160;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting and intend to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section&#160;5(b)(i) of these Bylaws) or to propose the business that is specified in the notice (with respect to a notice under Section&#160;5(b)(ii) of these Bylaws); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#8217;s voting shares to elect such nominee or nominees (with respect to a notice under Section&#160;5(b)(i) of these Bylaws) or to carry such proposal (with respect to a notice under Section&#160;5(b)(ii) of these Bylaws); (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#8217;s notice; and (G)&#160;a description of all Derivative Transactions (as defined below) by each Proponent during the previous 12 month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Sections 5 and 6 of these Bylaws, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Derivative Transaction</span></span>&#8221; means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(w) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the corporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(x) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the corporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(y) the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price changes; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(z) which provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, with respect to any securities of the corporation, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> A stockholder providing written notice required by Section&#160;5(b)(i) or (ii)&#160;of these Bylaws shall update and supplement such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&#160;the record date for the meeting and (ii)&#160;the date that is five business days prior to the meeting and, in the event of any adjournment or postponement thereof, five business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i)&#160;of this Section&#160;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than five business days after the record date for the meeting. In the case of an update and supplement pursuant to clause (ii)&#160;of this Section&#160;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
later than two business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two business days prior to such adjourned or postponed meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> Notwithstanding anything in Section&#160;5(b)(iii) of these Bylaws<span style="font-weight:bold"> </span>to the contrary, in the event that the number of directors in an Expiring Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the corporation at least 10 days before the last day a stockholder may deliver a notice of nomination in accordance with<span style="font-weight:bold"> </span>Section&#160;5(b)(iii) of these Bylaws, a stockholder&#8217;s notice required by this Section&#160;5 and which complies with the requirements in Section&#160;5(b)(i) of these Bylaws, other than the timing requirements in Section&#160;5(b)(iii) of these Bylaws, shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class&#160;created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the corporation. For purposes of this Section&#160;5, an &#8220;<span style="font-weight:bold"><span style="font-style:italic">Expiring Class</span></span>&#8221; shall mean a class of directors whose term shall expire at the next annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> To be eligible to be a nominee for election or <span style="white-space:nowrap">re-election</span> as a director of the corporation pursuant to a nomination under clause (iii)&#160;of Section&#160;5(a) of these Bylaws, such proposed nominee or a person on such proposed nominee&#8217;s behalf must deliver (in accordance with the time periods prescribed for delivery of notice under Section&#160;5(b)(iii) or 5(d) of these Bylaws, as applicable) to the Secretary at the principal executive offices of the corporation a written questionnaire with respect to the background and qualification of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that such person (i)&#160;is not and will not become a party to (A)&#160;any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Voting Commitment</span></span>&#8221;) that has not been disclosed to the corporation in the questionnaire or (B)&#160;any Voting Commitment that could limit or interfere with such person&#8217;s ability to comply, if elected as a director of the corporation, with such person&#8217;s fiduciary duties under applicable law; (ii)&#160;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the corporation that has not been disclosed therein; and (iii)&#160;in such person&#8217;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> A person shall not be eligible for election or <span style="white-space:nowrap">re-election</span> as a director unless the person is nominated either in accordance with clause (ii)&#160;of Section&#160;5(a) of these Bylaws, or in accordance with clause (iii)&#160;of Section&#160;5(a) of these Bylaws. Except as otherwise required by law, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E) of these Bylaws, to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect of such nominations or such business may have been solicited or received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> Notwithstanding the foregoing provisions of this Section&#160;5, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders&#8217; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#8217;s proxy statement pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the 1934 Act; <span style="font-style:italic">provided, however,</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-style:italic"></span>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section&#160;5(a)(iii) of these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(h)</span> For purposes of Sections 5 and 6 of these Bylaws, </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> &#8220;<span style="font-weight:bold"><span style="font-style:italic">public announcement</span></span>&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&#160;13, 14 or 15(d) of the 1934 Act; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> &#8220;<span style="font-weight:bold"><span style="font-style:italic">affiliates</span></span>&#8221; and &#8220;<span style="font-weight:bold"><span style="font-style:italic">associates</span></span>&#8221; shall have the meanings set forth in Rule 405 under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1933 Act</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;6. Special Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action under Delaware law, by (i)&#160;the Chairman of the Board of Directors, (ii)&#160;the Chief Executive Officer, or (iii)&#160;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&#160;7 of these Bylaws. No business may be transacted at such special meeting otherwise than specified in the notice of meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected (i)&#160;by or at the direction of the Board of Directors or (ii)&#160;by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section&#160;5(b)(i) of these Bylaws. In the event the corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporation&#8217;s notice of meeting, if written notice setting forth the information required by Section&#160;5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under Section&#160;5(c) of these Bylaws. In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#8217;s notice as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> Notwithstanding the foregoing provisions of this Section&#160;6, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&#160;6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#8217;s proxy statement pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the 1934 Act; <span style="font-style:italic">provided, however, </span>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to Section&#160;6(c) of these Bylaws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;7.</span> <span style="font-weight:bold">Notice of Meetings.</span> Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the corporation. If sent via electronic transmission, notice is deemed given as of the sending time recorded at the time of transmission. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.</span> <span style="font-weight:bold">Quorum.</span> At all meetings of stockholders, except where otherwise provided by statute or by the corporation&#8217;s Second Amended and Restated Certificate of Incorporation (as amended or restated from time to time, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Certificate of Incorporation</span></span>&#8221;), or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.</span> <span style="font-weight:bold">Adjournment and Notice of Adjourned Meetings.</span> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;10.</span> <span style="font-weight:bold">Voting Rights.</span> For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section&#160;12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote<span style="font-weight:bold"> </span>shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;11.</span> <span style="font-weight:bold">Joint Owners of Stock.</span> If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a)&#160;if only one votes, his act binds all; (b)&#160;if more than one votes, the act of the majority so voting binds all; or (c)&#160;if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section&#160;217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of clause (c)&#160;of this Section&#160;11 shall be a majority or even-split in interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;12.</span> <span style="font-weight:bold">List of Stockholders.</span> The Secretary shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&#160;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&#160;during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;13.</span> <span style="font-weight:bold">Action Without Meeting. </span>No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;14. Organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, if applicable, the Lead Independent Director (as defined below), or, if the Lead Independent Director is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE IV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIRECTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;15.</span> <span style="font-weight:bold">Number and Term of Office.</span> The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.</span> <span style="font-weight:bold">Powers.</span> The business and affairs of the corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;17.</span> <span style="font-weight:bold">Classes of Directors. </span>Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&#160;I directors shall expire and Class&#160;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&#160;II directors shall expire and Class&#160;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&#160;III directors shall expire and Class&#160;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&#160;17, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;18.</span> <span style="font-weight:bold">Vacancies. </span>Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <span style="font-style:italic">provided, however</span>, that whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;19.</span> <span style="font-weight:bold">Resignation.</span> Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor shall have been duly elected and qualified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;20. Removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances,<span style="font-weight:bold"> </span>neither the Board of Directors nor any individual director may be removed without cause. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> Subject to any limitation imposed by law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all then outstanding shares of capital stock of the corporation entitled to vote generally at an election of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;21. Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Regular Meetings.</span> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Special Meetings. </span>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Meetings by Electronic Communications Equipment. </span>Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Notice of Special Meetings. </span>Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three days before the date of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Waiver of Notice. </span>The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been transacted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;22. Quorum and Voting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification arising under Section&#160;45 of these Bylaws for which a quorum shall be <span style="white-space:nowrap">one-third</span> of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <span style="font-style:italic">provided, however,</span> at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;23.</span> <span style="font-weight:bold">Action Without Meeting.</span> Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;24.</span> <span style="font-weight:bold">Fees and Compensation.</span> Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;25. Committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Executive Committee.</span> The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&#160;approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&#160;adopting, amending or repealing any Bylaw of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Other Committees.</span> The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Term.</span> The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections (a)&#160;or (b) of this Section&#160;25, may at any time increase or decrease the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Meetings.</span> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&#160;25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director<span style="font-weight:bold"> </span>who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;26.</span> <span style="font-weight:bold">Duties of Chairman of the Board of Directors.</span> The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;27. Lead Independent Director</span>. The Chairman of the Board of Directors, or if the Chairman is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Lead Independent Director</span></span>&#8221;) to serve until replaced by the Board of Directors. The Lead Independent Director will: with the Chairman of the Board of Directors, establish the agenda for regular Board meetings and serve as chairman of Board of Directors meetings in the absence of the Chairman of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is presented or discussed; and perform such other duties as may be established or delegated by the Chairman of the Board of Directors.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;28.</span> <span style="font-weight:bold">Organization.</span> At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary or other officer or director directed to do so by the Chairman, shall act as secretary of the meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE V </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OFFICERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;29.</span> <span style="font-weight:bold">Officers Designated.</span> The officers of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;30. Tenure and Duties of Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">General.</span> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Duties of Chief Executive Officer.</span> The Chief Executive Officer shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Duties of President.</span> The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation.<span style="font-weight:bold"> </span>The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Duties of Vice Presidents.</span> The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Duties of Secretary.</span> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. The President </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Duties of Chief Financial Officer.</span> The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> <span style="font-weight:bold">Duties of Treasurer.</span> Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.<span style="font-weight:bold"> </span>The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;31.</span> <span style="font-weight:bold">Delegation of Authority.</span> The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;32.</span> <span style="font-weight:bold">Resignations.</span> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;33.</span> <span style="font-weight:bold">Removal.</span> Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VI </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;34.</span> <span style="font-weight:bold">Execution of Corporate Instruments.</span> The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;35.</span> <span style="font-weight:bold">Voting of Securities Owned by the Corporation.</span> All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SHARES OF STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;36.</span> <span style="font-weight:bold">Form and Execution of Certificates.</span> The shares of the corporation shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock of the corporation, if any, shall be in such form<span style="font-weight:bold"> </span>as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by certificate<span style="font-weight:bold"> </span>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, the Chief Executive Officer, or the President or any Vice President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;37.</span> <span style="font-weight:bold">Lost Certificates.</span> A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#8217;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;38. Transfers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;39. Fixing Record Dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <span style="font-style:italic">provided, however,</span> that the Board of Directors may fix a new record date for the adjourned meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;40.</span> <span style="font-weight:bold">Registered Stockholders.</span> The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VIII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OTHER SECURITIES OF THE CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;41.</span> <span style="font-weight:bold">Execution of Other Securities.</span> All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section&#160;36 of these Bylaws), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; <span style="font-style:italic">provided, however,</span> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE IX </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIVIDENDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;42.</span> <span style="font-weight:bold">Declaration of Dividends.</span> Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;43.</span> <span style="font-weight:bold">Dividend Reserve.</span> Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE X </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FISCAL YEAR </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;44.</span> <span style="font-weight:bold">Fiscal Year.</span> The fiscal year of the corporation shall be fixed by resolution of the Board of Directors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XI </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INDEMNIFICATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;45. Indemnification of Directors, Officers, Employees and Other Agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Directors and Officers. </span>The corporation shall indemnify its directors and officers to the extent not prohibited by the DGCL or any other applicable law; <span style="font-style:italic">provided, however,</span> that the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, <span style="font-style:italic">provided, further,</span> that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&#160;such indemnification is expressly required to be made by law, (ii)&#160;the proceeding was authorized by the Board of Directors of the corporation, (iii)&#160;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or (iv)&#160;such indemnification is required to be made under subsection (d). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Employees and Other Agents.</span> The corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person (except for officers) or other persons as the Board of Directors shall determine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Expenses.</span> The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer<span style="font-weight:bold"> </span>in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
director or officer<span style="font-weight:bold"> </span>(and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an &#8220;<span style="font-weight:bold"><span style="font-style:italic">undertaking</span></span>&#8221;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<span style="font-weight:bold"><span style="font-style:italic">final adjudication</span></span>&#8221;) that such indemnitee is not entitled to be indemnified for such expenses under this Section&#160;45 or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e)&#160;of this Section&#160;45, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&#160;by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii)&#160;by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii)&#160;if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Enforcement. </span>Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Section&#160;45 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or advances granted by this Section&#160;45 to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&#160;the claim for indemnification or advances is denied, in whole or in part, or (ii)&#160;no disposition of such claim is made within 90 days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because the director or officer has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this Section&#160;45 or otherwise shall be on the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold"><span style="white-space:nowrap">Non-Exclusivity</span> of Rights. </span>The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Survival of Rights. </span>The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director or officer, or, if applicable, employee or other agent,<span style="font-weight:bold"> </span>and shall inure to the benefit of the heirs, executors and administrators of such a person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> <span style="font-weight:bold">Insurance. </span>To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section&#160;45. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(h)</span> <span style="font-weight:bold">Amendments. </span>Any repeal or modification of this Section&#160;45 shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> <span style="font-weight:bold">Saving Clause. </span>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Section&#160;45 that shall not have been invalidated, or by any other applicable law. If this Section&#160;45 shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer<span style="font-weight:bold"> </span>to the full extent under any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(j)</span> <span style="font-weight:bold">Certain Definitions. </span>For the purposes of this Bylaw, the following definitions shall apply: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> The term &#8220;<span style="font-weight:bold"><span style="font-style:italic">proceeding</span></span>&#8221; shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> The term &#8220;<span style="font-weight:bold"><span style="font-style:italic">expenses</span></span>&#8221; shall be broadly construed and shall include, without limitation, court costs, attorneys&#8217; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iii)</span> The term the &#8220;<span style="font-weight:bold"><span style="font-style:italic">corporation</span></span>&#8221; shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section&#160;45 with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iv)</span> References to a &#8220;<span style="font-weight:bold"><span style="font-style:italic">director</span></span>,&#8221; &#8220;<span style="font-weight:bold"><span style="font-style:italic">officer</span></span>,&#8221; &#8220;<span style="font-weight:bold"><span style="font-style:italic">employee</span></span>,&#8221; or &#8220;<span style="font-weight:bold"><span style="font-style:italic">agent</span></span>&#8221; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(v)</span> References to &#8220;<span style="font-weight:bold"><span style="font-style:italic">other enterprises</span></span>&#8221; shall include employee benefit plans; references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#8220;<span style="font-weight:bold"><span style="font-style:italic">serving at the request of the corporation</span></span>&#8221; shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;<span style="font-weight:bold"><span style="font-style:italic">not opposed to the best interests of the corporation</span></span>&#8221; as referred to in this Section&#160;45. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;46. Notices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Notice to Stockholders. </span>Written notice to stockholders of stockholder meetings shall be given as provided in Section&#160;7 of these Bylaws. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by facsimile, telegraph or telex, or by electronic mail or other electronic means. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Notice to Directors. </span>Any notice required to be given to any director may be given by the method stated in subsection (a), or as otherwise provided in these Bylaws, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Affidavit of Mailing. </span>An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Methods of Notice. </span>It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Notice to Person With Whom Communication is Unlawful. </span>Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Notice to Stockholders Sharing an Address. </span>Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within 60 days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XIII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;47.</span> <span style="font-weight:bold">Amendments.</span> Subject to the limitations set forth in Section&#160;45(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; <span style="font-style:italic">provided, however, </span>that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XIV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">LOANS TO OFFICERS OR EMPLOYEES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;48.</span> <span style="font-weight:bold">Loans to Officers or Employees.</span> Except as otherwise prohibited by applicable law, the corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">MISCELLANEOUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;49. Forum. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (A)&#160;any derivative claim or cause of action brought on behalf of the corporation; (B)&#160;any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the corporation, to the corporation or the corporation&#8217;s stockholders; (C)&#160;any claim or cause of action against the corporation or any current or former director, officer or other employee of the corporation, arising out of or pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws of the corporation (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws of the corporation (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&#160;any claim or cause of action against the corporation or any current or former director, officer or other employee of the corporation, governed by the internal-affairs doctrine or otherwise related to the corporation&#8217;s internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section&#160;49 of Article XV shall not apply to claims or causes of action brought to enforce a duty or liability created by the 1933 Act or the 1934 Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the corporation, its officers and directors, the underwriters for any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_37"><span id="ii509388_2"></span>ANNEX B - FORM OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECOND AMENDED AND RESTATED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTIFICATE OF INCORPORATION </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ATLANTIC COASTAL ACQUISITION CORP. II </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad hereby certifies that: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">ONE:</span> He is the duly elected and acting Chief Executive Officer of Atlantic Coastal Acquisition Corp. II, a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Corporation</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">TWO:</span> The date of filing of said corporation&#8217;s original certificate of incorporation with the Secretary of State of the State of Delaware was May&#160;20, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THREE:</span> The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on January&#160;18, 2022 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Amended Certificate</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FOUR: </span>This Second Amended and Restated Certificate of Incorporation amends and restates the Amended Certificate in its entirety. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIVE</span>: This Second Amended and Restated Certificate of Incorporation has been duly approved and adopted by the Board of Directors of the Corporation on [&#9679;], and by the stockholders of the Corporation on [&#9679;], in accordance with the provisions of Sections 141, 228, 242 and 245 of the General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">FIVE: </span>The Amended Certificate is hereby amended and restated to read in its entirety as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">I. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Abpro Holdings, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">II. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of the Company in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of the registered agent at such address is The Corporation Trust Company. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CIII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (&#8220;<span style="font-weight:bold"><span style="font-style:italic">DGCL</span></span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">IV. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The Company is authorized to issue two classes of stock to be designated, respectively, &#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221; and &#8220;<span style="font-weight:bold"><span style="font-style:italic">Preferred Stock</span></span>.&#8221; The total number of shares which the Company is authorized to issue is 111,000,000 shares. 110,000,000 shares shall be Common Stock, each having a par value of $0.0001. 1,000,000 shares shall be Preferred Stock, each having a par value of $0.0001. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Board of Directors</span></span>&#8221;) is hereby expressly authorized to provide for the issue of any or all of the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unissued and undesignated shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; <span style="font-style:italic">provided, however</span>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Second Amended and Restated Certificate of Incorporation (this &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restated Certificate</span></span>&#8221;) (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled, either separately or together as a class with the holders of one or more other such series of Preferred Stock, to vote thereon by law or pursuant to this Restated Certificate (including any certificate of designation filed with respect to any series of Preferred Stock). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">V. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The management of the business and the conduct of the affairs of the Company shall be vested in its Board of Directors. The number of directors that shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&#160;I directors shall expire and Class&#160;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&#160;II directors shall expire and Class&#160;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&#160;III directors shall expire and Class&#160;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Subject to the rights of any series of Preferred Stock that may be designated from time to time to elect additional directors under specified circumstances, neither the Board of Directors nor any individual director may </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be removed without cause. Subject to any limitations imposed by applicable law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">D.</span> Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Preferred Stock that may be designated from time to time, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">E.</span> The Board of Directors is expressly empowered to adopt, amend or repeal the Amended and Restated Bylaws of the Company (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Bylaws</span></span>&#8221;).<span style="font-weight:bold"> </span>Any adoption, amendment or repeal of the Bylaws by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders shall also have power to adopt, amend or repeal the Bylaws; <span style="font-style:italic">provided, however, </span>that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Restated Certificate, such action by stockholders shall require the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">F.</span> The directors of the Company need not be elected by written ballot unless the Bylaws so provide. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">G.</span> No action shall be taken by the stockholders of the Company except at an annual or special meeting of stockholders called in accordance with the Bylaws. No action shall be taken by the stockholders of the Company by written consent or electronic transmission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">H.</span> Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VI. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The liability of a director of the Company for monetary damages shall be eliminated to the fullest extent under applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (A)&#160;any derivative claim or cause of action brought on behalf of the Company; (B)&#160;any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the Company, to the Company or the Company&#8217;s stockholders; (C)&#160;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, arising out of or pursuant to any provision of the DGCL, this Restated Certificate or the Bylaws of the Company (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Restated Certificate or the Bylaws of the Company (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&#160;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, governed by the internal-affairs doctrine or otherwise related to the Company&#8217;s internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1933 Act</span></span>&#8221;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Unless the Company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters for any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">C.</span> Any person or entity holding, owning or otherwise acquiring any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Restated Certificate. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VIII. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">A.</span> The Company reserves the right to amend, alter, change or repeal any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by statute, except as provided in Section B of this Article VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">B.</span> Notwithstanding any other provisions of this Restated Certificate or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Company required by law or by this Restated Certificate or any certificate of designation filed with respect to a series of Preferred Stock that may be designated from time to time, subject to the rights of the holders of any series of Preferred Stock, the affirmative vote of the holders of at least <span style="white-space:nowrap">sixty-six</span> and <span style="white-space:nowrap">two-thirds</span> percent (66 2/3%)<span style="font-weight:bold"> </span>of the voting power of all of the then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII of this Restated Certificate.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">* * * * </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">SIX: </span>This Restated Certificate has been duly adopted and approved by the Board of Directors and by written consent of the stockholders in accordance with Sections 228, 242 and 245 of the DGCL and written notice of such action has been given as provided in section 228 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[Signature page follows] </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, Atlantic Coastal Acquisition Corp. II has caused this Second Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this [&#9679;]th day of [&#9679;], [&#9679;]. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">TLANTIC</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OASTAL</small> A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">CQUISITION</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ORP</small>. II</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Shahraab Ahmad</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its: Chief Executive Officer</p></td></tr>
</table></div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx509388_38"><span id="ii509388_3"></span>ANNEX C - FORM OF AMENDED AND RESTATED BYLAWS </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECOND AMENDED AND RESTATED </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BYLAWS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABPRO CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OFFICES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1.</span> <span style="font-weight:bold">Registered Office.</span> The registered office of the corporation in the State of Delaware shall be at 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the registered agent at such address is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.</span> <span style="font-weight:bold">Other Offices.</span> The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation&#8217;s Board of Directors (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Board of Directors</span></span>&#8221;), and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CORPORATE SEAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.</span> <span style="font-weight:bold">Corporate Seal.</span> The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, &#8220;Corporate Seal-Delaware.&#8221; Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">STOCKHOLDERS&#8217; MEETINGS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.</span> <span style="font-weight:bold">Place of Meetings.</span> Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">DGCL</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;5. Annual Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&#160;pursuant to the corporation&#8217;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or at the direction of the Board of Directors; or (iii)&#160;by any stockholder of the corporation who was a stockholder of record at the time of giving the stockholder&#8217;s notice provided for in Section&#160;5(b) of these Second Amended and Restated Bylaws (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Bylaws</span></span>&#8221;), who is entitled to vote at the meeting and who complied with the notice procedures set forth in this Section&#160;5. For the avoidance of doubt, clause (iii)&#160;above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters properly included in the corporation&#8217;s notice of meeting of stockholders and proxy statement under Rule <span style="white-space:nowrap">14a-8</span> under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1934 Act</span></span>&#8221;)) before an annual meeting of stockholders. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> At an annual meeting of the stockholders, only such business shall be conducted as is a proper matter for stockholder action under Delaware law and as shall have been properly brought before the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&#160;of Section&#160;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&#160;5(b)(iii) of these Bylaws and must update and supplement such written notice on a timely basis as set forth in Section&#160;5(c) of these Bylaws. Such stockholder&#8217;s notice shall set forth: (A)&#160;as to each nominee such stockholder proposes to nominate at the meeting: (1)&#160;the name, age, business address and residence address of such nominee; (2)&#160;the principal occupation or employment of such nominee; (3)&#160;the class and number of shares of each class of capital stock of the corporation which are owned of record and beneficially by such nominee; (4)&#160;the date or dates on which such shares were acquired and the investment intent of such acquisition; (5)&#160;with respect to each nominee for election or <span style="white-space:nowrap">re-election</span> to the Board of Directors, include a completed and signed questionnaire, representation and agreement required by Section&#160;5(e) of these Bylaws; and (6)&#160;such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section&#160;14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&#8217;s written consent to being named as a nominee and to serving as a director if elected); and (B)&#160;the information required by Section&#160;5(b)(iv) of these Bylaws. The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&#8217;s understanding of the independence, or lack thereof, of such proposed nominee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> Other than proposals sought to be included in the corporation&#8217;s proxy materials pursuant to Rule <span style="white-space:nowrap">14(a)-8</span> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&#160;of Section&#160;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&#160;5(b)(iii) of these Bylaws, and must update and supplement such written notice on a timely basis as set forth in Section&#160;5(c) of these Bylaws. Such stockholder&#8217;s notice shall set forth: (A)&#160;as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the corporation&#8217;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&#160;the information required by Section&#160;5(b)(iv) of these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iii)</span> To be timely, the written notice required by Section&#160;5(b)(i) or 5(b)(ii) of these Bylaws must be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting; <span style="font-style:italic">provided, however,</span> that, subject to the last sentence of this Section&#160;5(b)(iii), in the event that the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year&#8217;s annual meeting, notice by the stockholder to be timely must be so received not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment or a postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#8217;s notice as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iv)</span> The written notice required by Section&#160;5(b)(i) or 5(b)(ii) of these Bylaws shall also set forth, as of the date of the notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Proponent</span></span>&#8221; and collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Proponents</span></span>&#8221;): (A) the name and address of each Proponent, as they appear on the corporation&#8217;s books; (B)&#160;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&#160;a description of any </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the agreement, arrangement or understanding, with any of the foregoing; (D)&#160;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting and intend to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section&#160;5(b)(i) of these Bylaws) or to propose the business that is specified in the notice (with respect to a notice under Section&#160;5(b)(ii) of these Bylaws); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#8217;s voting shares to elect such nominee or nominees (with respect to a notice under Section&#160;5(b)(i) of these Bylaws) or to carry such proposal (with respect to a notice under Section&#160;5(b)(ii) of these Bylaws); (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#8217;s notice; and (G)&#160;a description of all Derivative Transactions (as defined below) by each Proponent during the previous 12 month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Sections 5 and 6 of these Bylaws, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Derivative Transaction</span></span>&#8221; means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(w) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the corporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(x) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the corporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(y) the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price changes; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(z) which provides the right to vote or increase or decrease the voting power of, such Proponent, or any of its affiliates or associates, with respect to any securities of the corporation, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> A stockholder providing written notice required by Section&#160;5(b)(i) or (ii)&#160;of these Bylaws shall update and supplement such notice in writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&#160;the record date for the meeting and (ii)&#160;the date that is five business days prior to the meeting and, in the event of any adjournment or postponement thereof, five business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i)&#160;of this Section&#160;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than five business days after the record date for the meeting. In the case of an update and supplement pursuant to clause (ii)&#160;of this Section&#160;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than two business days prior to the date for the meeting, and, in the event of any adjournment or postponement thereof, two business days prior to such adjourned or postponed meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> Notwithstanding anything in Section&#160;5(b)(iii) of these Bylaws<span style="font-weight:bold"> </span>to the contrary, in the event that the number of directors in an Expiring Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the corporation at least 10 days before the last day a stockholder may deliver a notice of nomination in </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with<span style="font-weight:bold"> </span>Section&#160;5(b)(iii) of these Bylaws, a stockholder&#8217;s notice required by this Section&#160;5 and which complies with the requirements in Section&#160;5(b)(i) of these Bylaws, other than the timing requirements in Section&#160;5(b)(iii) of these Bylaws, shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class&#160;created by such increase, if it shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the corporation. For purposes of this Section&#160;5, an &#8220;<span style="font-weight:bold"><span style="font-style:italic">Expiring Class</span></span>&#8221; shall mean a class of directors whose term shall expire at the next annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> To be eligible to be a nominee for election or <span style="white-space:nowrap">re-election</span> as a director of the corporation pursuant to a nomination under clause (iii)&#160;of Section&#160;5(a) of these Bylaws, such proposed nominee or a person on such proposed nominee&#8217;s behalf must deliver (in accordance with the time periods prescribed for delivery of notice under Section&#160;5(b)(iii) or 5(d) of these Bylaws, as applicable) to the Secretary at the principal executive offices of the corporation a written questionnaire with respect to the background and qualification of such proposed nominee and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that such person (i)&#160;is not and will not become a party to (A)&#160;any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the corporation, will act or vote on any issue or question (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Voting Commitment</span></span>&#8221;) that has not been disclosed to the corporation in the questionnaire or (B)&#160;any Voting Commitment that could limit or interfere with such person&#8217;s ability to comply, if elected as a director of the corporation, with such person&#8217;s fiduciary duties under applicable law; (ii)&#160;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the corporation that has not been disclosed therein; and (iii)&#160;in such person&#8217;s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> A person shall not be eligible for election or <span style="white-space:nowrap">re-election</span> as a director unless the person is nominated either in accordance with clause (ii)&#160;of Section&#160;5(a) of these Bylaws, or in accordance with clause (iii)&#160;of Section&#160;5(a) of these Bylaws. Except as otherwise required by law, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E) of these Bylaws, to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect of such nominations or such business may have been solicited or received. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> Notwithstanding the foregoing provisions of this Section&#160;5, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders&#8217; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#8217;s proxy statement pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the 1934 Act; <span style="font-style:italic">provided, however, </span>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be considered pursuant to Section&#160;5(a)(iii) of these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(h)</span> For purposes of Sections 5 and 6 of these Bylaws, </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> &#8220;<span style="font-weight:bold"><span style="font-style:italic">public announcement</span></span>&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&#160;13, 14 or 15(d) of the 1934 Act; and </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> &#8220;<span style="font-weight:bold"><span style="font-style:italic">affiliates</span></span>&#8221; and &#8220;<span style="font-weight:bold"><span style="font-style:italic">associates</span></span>&#8221; shall have the meanings set forth in Rule 405 under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">1933 Act</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;6. Special Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action under Delaware law, by (i)&#160;the Chairman of the Board of Directors, (ii)&#160;the Chief Executive Officer, or (iii)&#160;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&#160;7 of these Bylaws. No business may be transacted at such special meeting otherwise than specified in the notice of meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected (i)&#160;by or at the direction of the Board of Directors or (ii)&#160;by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section&#160;5(b)(i) of these Bylaws. In the event the corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the corporation&#8217;s notice of meeting, if written notice setting forth the information required by Section&#160;5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the later of the 90th day prior to such meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under Section&#160;5(c) of these Bylaws. In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#8217;s notice as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> Notwithstanding the foregoing provisions of this Section&#160;6, a stockholder must also comply with all applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&#160;6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#8217;s proxy statement pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the 1934 Act; <span style="font-style:italic">provided, however, </span>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to Section&#160;6(c) of these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;7.</span> <span style="font-weight:bold">Notice of Meetings.</span> Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the corporation. If sent via electronic transmission, notice is deemed given as of the sending time recorded at the time of transmission. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8.</span> <span style="font-weight:bold">Quorum.</span> At all meetings of stockholders, except where otherwise provided by statute or by the corporation&#8217;s Second Amended and Restated Certificate of Incorporation (as amended or restated from time to time, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Certificate of Incorporation</span></span>&#8221;), or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9.</span> <span style="font-weight:bold">Adjournment and Notice of Adjourned Meetings.</span> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;10.</span> <span style="font-weight:bold">Voting Rights.</span> For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section&#160;12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote<span style="font-weight:bold"> </span>shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three years from its date of creation unless the proxy provides for a longer period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;11.</span> <span style="font-weight:bold">Joint Owners of Stock.</span> If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a)&#160;if only one votes, his act binds all; (b)&#160;if more than one votes, the act of the majority so voting binds all; or (c)&#160;if more than one votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chancery for relief as provided in the DGCL, Section&#160;217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of clause (c)&#160;of this Section&#160;11 shall be a majority or even-split in interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;12.</span> <span style="font-weight:bold">List of Stockholders.</span> The Secretary shall prepare and make, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, (a)&#160;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&#160;during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;13.</span> <span style="font-weight:bold">Action Without Meeting. </span>No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;14. Organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, if applicable, the Lead Independent Director (as defined below), or, if the Lead Independent Director is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE IV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIRECTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;15.</span> <span style="font-weight:bold">Number and Term of Office.</span> The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;16.</span> <span style="font-weight:bold">Powers.</span> The business and affairs of the corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;17.</span> <span style="font-weight:bold">Classes of Directors. </span>Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class&#160;I directors shall expire and Class&#160;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class&#160;II directors shall expire and Class&#160;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class&#160;III directors shall expire and Class&#160;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&#160;17, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;18.</span> <span style="font-weight:bold">Vacancies. </span>Unless otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <span style="font-style:italic">provided, however</span>, that whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;19.</span> <span style="font-weight:bold">Resignation.</span> Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor shall have been duly elected and qualified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;20. Removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances,<span style="font-weight:bold"> </span>neither the Board of Directors nor any individual director may be removed without cause. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> Subject to any limitation imposed by law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all then outstanding shares of capital stock of the corporation entitled to vote generally at an election of directors. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;21. Meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Regular Meetings.</span> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Special Meetings. </span>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Meetings by Electronic Communications Equipment. </span>Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Notice of Special Meetings. </span>Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business hours, at least 24 hours before the date and time of the meeting. If notice is sent by U.S. mail, it shall be sent by first class mail, charges prepaid, at least three days before the date of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Waiver of Notice. </span>The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;22. Quorum and Voting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification arising under Section&#160;45 of these Bylaws for which a quorum shall be <span style="white-space:nowrap">one-third</span> of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <span style="font-style:italic">provided, however,</span> at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;23.</span> <span style="font-weight:bold">Action Without Meeting.</span> Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;24.</span> <span style="font-weight:bold">Fees and Compensation.</span> Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;25. Committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Executive Committee.</span> The Board of Directors may appoint an Executive Committee to consist of one or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&#160;approving or adopting, or recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&#160;adopting, amending or repealing any Bylaw of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Other Committees.</span> The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Term.</span> The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections (a)&#160;or (b) of this Section&#160;25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Meetings.</span> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&#160;25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director<span style="font-weight:bold"> </span>who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;26.</span> <span style="font-weight:bold">Duties of Chairman of the Board of Directors.</span> The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;27. Lead Independent Director</span>. The Chairman of the Board of Directors, or if the Chairman is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Lead Independent Director</span></span>&#8221;) to serve until replaced by the Board of Directors. The Lead Independent Director will: with the Chairman of the Board of Directors, establish the agenda for regular Board meetings and serve as chairman of Board of Directors meetings in the absence of the Chairman of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is presented or discussed; and perform such other duties as may be established or delegated by the Chairman of the Board of Directors.<span style="font-weight:bold"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;28.</span> <span style="font-weight:bold">Organization.</span> At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent, the Chief Executive Officer (if a director), or, if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, any Assistant Secretary or other officer or director directed to do so by the Chairman, shall act as secretary of the meeting. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE V </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OFFICERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;29.</span> <span style="font-weight:bold">Officers Designated.</span> The officers of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;30. Tenure and Duties of Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">General.</span> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Duties of Chief Executive Officer.</span> The Chief Executive Officer shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive Officer. The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Duties of President.</span> The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive Officer of the corporation, the President shall be the Chief Executive Officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation.<span style="font-weight:bold"> </span>The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Duties of Vice Presidents.</span> The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Duties of Secretary.</span> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Duties of Chief Financial Officer.</span> The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed references to the Chief Financial Officer. The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> <span style="font-weight:bold">Duties of Treasurer.</span> Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.<span style="font-weight:bold"> </span>The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;31.</span> <span style="font-weight:bold">Delegation of Authority.</span> The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;32.</span> <span style="font-weight:bold">Resignations.</span> Any officer may resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;33.</span> <span style="font-weight:bold">Removal.</span> Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VI </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;34.</span> <span style="font-weight:bold">Execution of Corporate Instruments.</span> The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;35.</span> <span style="font-weight:bold">Voting of Securities Owned by the Corporation.</span> All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SHARES OF STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;36.</span> <span style="font-weight:bold">Form and Execution of Certificates.</span> The shares of the corporation shall be represented by certificates, or shall be uncertificated if so provided by resolution or resolutions of the Board of Directors. Certificates for the shares of stock of the corporation, if any, shall be in such form<span style="font-weight:bold"> </span>as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by certificate<span style="font-weight:bold"> </span>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, the Chief Executive Officer, or the President or any Vice President and by the Chief Financial Officer, Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;37.</span> <span style="font-weight:bold">Lost Certificates.</span> A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#8217;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;38. Transfers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;39. Fixing Record Dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable law, not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <span style="font-style:italic">provided, however,</span> that the Board of Directors may fix a new record date for the adjourned meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;40.</span> <span style="font-weight:bold">Registered Stockholders.</span> The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE VIII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OTHER SECURITIES OF THE CORPORATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;41.</span> <span style="font-weight:bold">Execution of Other Securities.</span> All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section&#160;36 of these Bylaws), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; <span style="font-style:italic">provided, however,</span> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE IX </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIVIDENDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;42.</span> <span style="font-weight:bold">Declaration of Dividends.</span> Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;43.</span> <span style="font-weight:bold">Dividend Reserve.</span> Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE X </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FISCAL YEAR </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;44.</span> <span style="font-weight:bold">Fiscal Year.</span> The fiscal year of the corporation shall be fixed by resolution of the Board of Directors. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XI </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INDEMNIFICATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;45. Indemnification of Directors, Officers, Employees and Other Agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Directors and Officers. </span>The corporation shall indemnify its directors and officers to the extent not prohibited by the DGCL or any other applicable law; <span style="font-style:italic">provided, however,</span> that the corporation may modify the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent of such indemnification by individual contracts with its directors and officers; and, <span style="font-style:italic">provided, further,</span> that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&#160;such indemnification is expressly required to be made by law, (ii)&#160;the proceeding was authorized by the Board of Directors of the corporation, (iii)&#160;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or any other applicable law or (iv)&#160;such indemnification is required to be made under subsection (d). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Employees and Other Agents.</span> The corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person (except for officers) or other persons as the Board of Directors shall determine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Expenses.</span> The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer<span style="font-weight:bold"> </span>in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a director or officer<span style="font-weight:bold"> </span>(and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (hereinafter an &#8220;<span style="font-weight:bold"><span style="font-style:italic">undertaking</span></span>&#8221;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<span style="font-weight:bold"><span style="font-style:italic">final adjudication</span></span>&#8221;) that such indemnitee is not entitled to be indemnified for such expenses under this Section&#160;45 or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e)&#160;of this Section&#160;45, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&#160;by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii)&#160;by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii)&#160;if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Enforcement. </span>Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Section&#160;45 shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or advances granted by this Section&#160;45 to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i)&#160;the claim for indemnification or advances is denied, in whole or in part, or (ii)&#160;no disposition of such claim is made within 90 days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because the director or officer has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this Section&#160;45 or otherwise shall be on the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold"><span style="white-space:nowrap">Non-Exclusivity</span> of Rights. </span>The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Survival of Rights. </span>The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director or officer, or, if applicable, employee or other agent,<span style="font-weight:bold"> </span>and shall inure to the benefit of the heirs, executors and administrators of such a person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(g)</span> <span style="font-weight:bold">Insurance. </span>To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Section&#160;45. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(h)</span> <span style="font-weight:bold">Amendments. </span>Any repeal or modification of this Section&#160;45 shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> <span style="font-weight:bold">Saving Clause. </span>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Section&#160;45 that shall not have been invalidated, or by any other applicable law. If this Section&#160;45 shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and officer<span style="font-weight:bold"> </span>to the full extent under any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(j)</span> <span style="font-weight:bold">Certain Definitions. </span>For the purposes of this Bylaw, the following definitions shall apply: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(i)</span> The term &#8220;<span style="font-weight:bold"><span style="font-style:italic">proceeding</span></span>&#8221; shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(ii)</span> The term &#8220;<span style="font-weight:bold"><span style="font-style:italic">expenses</span></span>&#8221; shall be broadly construed and shall include, without limitation, court costs, attorneys&#8217; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iii)</span> The term the &#8220;<span style="font-weight:bold"><span style="font-style:italic">corporation</span></span>&#8221; shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section&#160;45 with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(iv)</span> References to a &#8220;<span style="font-weight:bold"><span style="font-style:italic">director</span></span>,&#8221; &#8220;<span style="font-weight:bold"><span style="font-style:italic">officer</span></span>,&#8221; &#8220;<span style="font-weight:bold"><span style="font-style:italic">employee</span></span>,&#8221; or &#8220;<span style="font-weight:bold"><span style="font-style:italic">agent</span></span>&#8221; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(v)</span> References to &#8220;<span style="font-weight:bold"><span style="font-style:italic">other enterprises</span></span>&#8221; shall include employee benefit plans; references to &#8220;fines&#8221; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#8220;<span style="font-weight:bold"><span style="font-style:italic">serving at the request of the corporation</span></span>&#8221; shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;<span style="font-weight:bold"><span style="font-style:italic">not opposed to the best interests of the corporation</span></span>&#8221; as referred to in this Section&#160;45. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;46. Notices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> <span style="font-weight:bold">Notice to Stockholders. </span>Written notice to stockholders of stockholder meetings shall be given as provided in Section&#160;7 of these Bylaws. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than stockholder meetings may be sent by U.S. mail or nationally recognized overnight courier, or by facsimile, telegraph or telex, or by electronic mail or other electronic means. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> <span style="font-weight:bold">Notice to Directors. </span>Any notice required to be given to any director may be given by the method stated in subsection (a), or as otherwise provided in these Bylaws, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(c)</span> <span style="font-weight:bold">Affidavit of Mailing. </span>An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(d)</span> <span style="font-weight:bold">Methods of Notice. </span>It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(e)</span> <span style="font-weight:bold">Notice to Person With Whom Communication is Unlawful. </span>Whenever notice is required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(f)</span> <span style="font-weight:bold">Notice to Stockholders Sharing an Address. </span>Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or the Bylaws shall be effective </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within 60 days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XIII </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;47.</span> <span style="font-weight:bold">Amendments.</span> Subject to the limitations set forth in Section&#160;45(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. Any adoption, amendment or repeal of the Bylaws of the corporation by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the corporation; <span style="font-style:italic">provided, however, </span>that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XIV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">LOANS TO OFFICERS OR EMPLOYEES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;48.</span> <span style="font-weight:bold">Loans to Officers or Employees.</span> Except as otherwise prohibited by applicable law, the corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE XV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">MISCELLANEOUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;49. Forum. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(a)</span> Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (A)&#160;any derivative claim or cause of action brought on behalf of the corporation; (B)&#160;any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the corporation, to the corporation or the corporation&#8217;s stockholders; (C)&#160;any claim or cause of action against the corporation or any current or former director, officer or other employee of the corporation, arising out of or pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws of the corporation (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws of the corporation (as </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&#160;any claim or cause of action against the corporation or any current or former director, officer or other employee of the corporation, governed by the internal-affairs doctrine or otherwise related to the corporation&#8217;s internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section&#160;49 of Article XV shall not apply to claims or causes of action brought to enforce a duty or liability created by the 1933 Act or the 1934 Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">(b)</span> Unless the corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the corporation, its officers and directors, the underwriters for any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Section&#160;102(b)(7) of the DGCL, ACAB&#8217;s charter provides that a director will not be personally liable to ACAB or ACAB&#8217;s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&#160;for any breach of the director&#8217;s duty of loyalty to ACAB or ACAB&#8217;s stockholders, (ii)&#160;for acts of bad faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. No such provision shall eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective. Accordingly, these provisions will have no effect on the availability of equitable remedies such as an injunction or rescission based on a director&#8217;s breach of his or her duty of care. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB&#8217;s charter provides that ACAB will indemnify its present and former directors and officers to the fullest extent permitted by the DGCL and that such indemnification will not be exclusive of any other rights to which those seeking indemnification may have or hereafter acquire under law, the ACAB charter, the Bylaws, an agreement, a vote of stockholders or disinterested directors, or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACAB has entered into indemnification agreements with each of its current directors and executive officers. These agreements require ACAB to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to ACAB, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. ACAB also intends to enter into indemnification agreements with future directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exhibits and Financial Statement Schedules </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exhibit Index </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#tx509388_36">Business Combination Agreement, dated as of December&#160;11, 2023 (included as Annex A to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312523105078/d450777dex31.htm">Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on April&#160;18, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312523297729/d416489dex31.htm">Amendment No.&#160;2 to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on December&#160;18, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312521362526/d482235dex33.htm">Amended and Restated By Laws (incorporated by reference to ACAB&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1/A</span> filed with the SEC on December&#160;20, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii509388_2">Form of the Post-Combination Company&#8217;s Charter (included as Annex B to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii509388_3">Form of the Post-Combination Company&#8217;s Bylaws (included as Annex C to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312521362526/d482235dex41.htm">Specimen Unit Certificate (incorporated by reference to ACAB&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1/A</span> filed with the SEC on December&#160;20, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312521362526/d482235dex42.htm">Specimen Series A Common Stock Certificate (incorporated by reference to ACAB&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1/A</span> filed with the SEC on December&#160;20, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex42.htm">Specimen Public Warrant Certificate (included in Exhibit 4.4) (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex42.htm">Public Warrant Agreement, dated January&#160;13, 2022, between ACAB and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex41.htm">Specimen Private Warrant Certificate (included in Exhibit 4.6) (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex41.htm">Private Warrant Agreement, dated January&#160;13, 2022, between ACAB and Continental Stock Transfer &amp; Trust Company (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Opinion of Pillsbury Winthrop Shaw Pittman LLP as to the validity of the securities being registered.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex102.htm">Investment Management Trust Agreement, dated January&#160;13, 2022, by and between ACAB and Continental Stock Transfer&#160;&amp; Trust Company, as trustee (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312521346558/d482235dex103.htm">Securities Subscription Agreement, dated October&#160;25, 2021, between ACAB and the Sponsor (incorporated by reference to Exhibit 10.3 to ACAB&#8217;s registration statement on Form <span style="white-space:nowrap">S-1</span> filed with the SEC on December&#160;2, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex101.htm">Private Placement Warrant Purchase Agreement, dated January&#160;13, 2022, by and between ACAB and the Sponsor (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312521362526/d482235dex106.htm">Form of Indemnity Agreement (incorporated by reference to ACAB&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1/A</span> filed with the SEC on December&#160;20, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex105.htm">Expense Advancement Agreement, dated January&#160;13, 2022, between ACAB and the Sponsor (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:88%"/></tr>



<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex104.htm">Letter Agreement, dated January&#160;13, 2022, among ACAB and its officers, directors, and the Sponsor (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex103.htm">Registration Rights Agreement, dated January&#160;13, 2022, among ACAB, the Sponsor and certain securityholders of ACAB (incorporated by reference to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii509388_4">Form of Sponsor Support Agreement (included as Exhibit A of Annex A to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii509388_5">Form of Abpro Support Agreement (included as Exhibit B of Annex A to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011224/d692726dex101.htm">Amended Sponsor Letter Agreement, dated as of January&#160;18, 2024, by and among ACAB, Abpro, the Sponsor and directors and officers of ACAB (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on January&#160;19, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii509388_6">Form of Abpro <span style="white-space:nowrap">Lock-Up</span> Agreement (included as Exhibit C of Annex A to this proxy statement/prospectus). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Director and Officer Indemnification Agreement.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13+*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Abpro Holdings, Inc. 2024 Incentive Award Plan.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14+&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1014.htm">Employment Agreement, dated as of January 15, 2020, by and between Abpro and Ian Chan. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15+&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1015.htm">Offer Letter, dated June 11, 2018, by and between Abpro and Rob Markelewicz. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16+&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1016.htm">Offer Letter, dated November 5, 2020, by and between Abpro and Christian Zapf. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1017.htm">Promissory Note, dated October 18, 2023, by and between Abpro and Abpro Bio International, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1018.htm">Consulting Agreement, dated January 1, 2023, by and between the Company and NEM LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1019.htm">Commercial Lease Agreement, dated July 2, 2014, by and between Abpro and Cummings Properties, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1020.htm">Lease Extension #1 to Commercial Lease Agreement, dated May 22, 2017, by and between Abpro and Cummings Properties, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1021.htm">Lease Extension #2 to Commercial Lease Agreement, dated March 9, 2021, by and between Abpro and Cummings Properties, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1022.htm">Collaboration and License Agreement, dated August 26, 2016, as amended by the First Amendment to License Agreement dated November 11, 2016, as amended by the Second Amendment to License Agreement dated November 1, 2017, as amended by the Third Amendment to License Agreement dated March 5, 2018, and as amended by the Fourth Amendment to License Agreement dated December 9, 2019, by and between Abmed Corporation, MedImmune Limited and Abpro. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1023.htm">Side Letter Agreement, dated August 8, 2017, by and among the Company, AbMed Corporation, and MedImmune Limited.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.24#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1024.htm">Patent License Agreement, dated August 29, 2017, as amended by the First Amendment, dated May 20, 2020, and as amended by the Second Amendment, dated October 13, 2023, by and between Abpro and The U.S. Department of Health and Human Services, as represented by The National Cancer Institute. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.25#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1025.htm">Collaboration Agreement, dated as of January 30, 2019, by and between Abpro and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. </a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.26#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1026.htm">Collaboration and License Agreement, dated December 14, 2019, by and between Abpro and Abpro Bio International, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.27#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1027.htm">Collaboration and License Agreement, dated January 15, 2020, by and between Abmed Corporation and Abpro Bio International, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.28#&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001893219/000119312524084816/d509388dex1028.htm">Collaboration Agreement, dated September 21, 2022, by and between Abpro and Celltrion. Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524097954/d691589dex101.htm">Subscription Agreement, effective as of April 10, 2024, by, between and among ACAB, Polar Multi-Strategy Master Fund, and the Sponsor (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on April 16, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d509388dex231.htm">Consent of Marcum LLP.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d509388dex232.htm">Consent of Wolf&#160;&amp; Company, P.C. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Pillsbury Winthrop Shaw Pittman LLP (included in Exhibit 5.1 hereto).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388ds4a.htm#ii509388_7">Power of Attorney (included on the signature page to this Registration Statement). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Proxy Card to be used by Atlantic Coastal Acquisition Corp II.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Consent to be used by holders of Abpro Corporation common stock and preferred stock.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Letter of Transmittal.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107&#167;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dexfilingfees.htm">Filing Fee Table </a></td></tr>
</table> </div> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#167;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><sup style="font-size:75%; vertical-align:top">#</sup>&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the Registrant if publicly disclosed. The Registrant agrees to furnish supplementally a copy of any such omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Undertakings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">A.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by section 10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td align="left" style="vertical-align:top">
prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Filing Fees Tables&#8221; or &#8220;Calculation of Registration Fee&#8221; table, as applicable, in the effective registration statement. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">B.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">C.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">D.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">E.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">F.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">G.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That every prospectus (i)&#160;that is filed pursuant to paragraph (F)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of section 10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">H.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">I.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="ii509388_7">SIGNATURES </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form <span style="white-space:nowrap">S-4</span> to be signed on its behalf by the undersigned, thereunto duly authorized, in New York City, New York, on April&#160;30, 2024. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Atlantic Coastal Acquisition Corp. II</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Shahraab Ahmad</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:41%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shahraab Ahmad</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shahraab Ahmad</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman and Chief Executive Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal executive officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Chryssicas</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jason Chryssicas</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal financial and accounting officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anthony D. Eisenberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Burt Jordan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Joanna Lord</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bryan Dove</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Curtis Collar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:41%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Darren Stanwood</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dominick J. Schiano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;30, 2024</td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Signed pursuant to Power of Attorney dated January&#160;19, 2024, included as part of the signature page to the Registration Statement on Form S-4 for Atlantic Coastal Acquisition Corp. II filed on January&#160;19, 2024. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shahraab Ahmad</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Shahraab Ahmad</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Attorney-in-Fact</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d509388dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of Atlantic Coastal Acquisition Corp. II (the &#147;Company&#148;) on Amendment #2 to Form <FONT
STYLE="white-space:nowrap">S-4</FONT> of our report dated March&nbsp;28, 2024, which includes an explanatory paragraph as to the Company&#146;s ability to continue as a going concern, with respect to our audits of the financial statements of
Atlantic Coastal Acquisition Corp. II<B> </B>as of December&nbsp;31, 2023 and 2022 and for the years ended December&nbsp;31, 2023 and 2022, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the
reference to our Firm under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum <SMALL>LLP</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum, <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">East Hanover, NJ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d509388dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Amendment No.&nbsp;2 to Registration Statement <FONT STYLE="white-space:nowrap">(No.&nbsp;333-276618)</FONT> on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> of Atlantic Coastal Acquisition Corp. II of our report dated March&nbsp;1, 2024, relating to the consolidated financial statements of Abpro Corporation and Subsidiary, appearing in the Prospectus,
which is part of this Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to our firm under the caption &#147;Experts&#148; in such Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Wolf&nbsp;&amp; Company, P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wolf&nbsp;&amp; Company,
P.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acab-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-April-2024 [10:25:30] {PM}-->
<schema targetNamespace="http://www.atlanticcoastalacquisition.com/20231231" elementFormDefault="qualified" xmlns:acab="http://www.atlanticcoastalacquisition.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Consolidated Statements Of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" id="ConsolidatedStatementsOfChangesInStockholdersDeficit">
<link:definition>1005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" id="ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical">
<link:definition>1006 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements Of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations" id="OrganizationAndPlanOfBusinessOperations">
<link:definition>1008 - Disclosure - Organization And Plan Of Business Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary Of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering" id="InitialPublicOffering">
<link:definition>1010 - Disclosure - Initial Public Offering</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>1011 - Disclosure - Private Placement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1012 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/Commitments" id="Commitments">
<link:definition>1013 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit" id="StockholdersDeficit">
<link:definition>1014 - Disclosure - Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1015 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1016 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1017 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1018 - Disclosure - Summary Of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1019 - Disclosure - Summary Of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1020 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails" id="OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails">
<link:definition>1022 - Disclosure - Organization And Plan Of Business Operations - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails">
<link:definition>1023 - Disclosure - Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails">
<link:definition>1024 - Disclosure - Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1025 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails" id="InitialPublicOfferingAdditionalInformationDetails">
<link:definition>1026 - Disclosure - Initial Public Offering - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails" id="PrivatePlacementAdditionalInformationDetails">
<link:definition>1027 - Disclosure - Private Placement - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1028 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails" id="CommitmentsAdditionalInformationDetails">
<link:definition>1029 - Disclosure - Commitments - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails" id="StockholdersDeficitAdditionalInformationDetails">
<link:definition>1030 - Disclosure - Stockholders' Deficit - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<link:definition>1031 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails" id="IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails">
<link:definition>1032 - Disclosure - Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<link:definition>1033 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1034 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails" id="FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails">
<link:definition>1035 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1036 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="acab-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="acab-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="acab-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="acab-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_AccruedOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExciseTaxPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_ExciseTaxPayableCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassificationOfCommonStockAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_ClassificationOfCommonStockAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ClassificationOfCommonStockDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_ClassificationOfCommonStockDomain" substitutionGroup="xbrli:item" />
<element name="NonRedeemableCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_NonRedeemableCommonStockMember" substitutionGroup="xbrli:item" />
<element name="RedeemableCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_RedeemableCommonStockMember" substitutionGroup="xbrli:item" />
<element name="ClassAAndClassBCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_ClassAAndClassBCommonStockMember" substitutionGroup="xbrli:item" />
<element name="InvestmentIncomeExpenseNonoperating" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_InvestmentIncomeExpenseNonoperating" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PenaltiesAndInterestOnTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PenaltiesAndInterestOnTaxes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperationAndFormationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_OperationAndFormationCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalExciseTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockholderNonRedemptionAgreementAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_StockholderNonRedemptionAgreementAdjustment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockholderNonRedemptionAgreementAdjustmentReduction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_StockholderNonRedemptionAgreementAdjustmentReduction" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="DeferredOfferingCostsIncludedInAccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromTrustAccountInConnectionWithRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ProceedsFromTrustAccountInConnectionWithRedemption" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisclosureOfInitialPublicOffering" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_DisclosureOfInitialPublicOffering" substitutionGroup="xbrli:item" />
<element name="DisclosureOfPrivatePlacement" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_DisclosureOfPrivatePlacement" substitutionGroup="xbrli:item" />
<element name="AssetsHeldInTrustAccountPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AssetsHeldInTrustAccountPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_EmergingGrowthCompanyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TemporaryEquityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantsDisclosurePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_WarrantsDisclosurePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" substitutionGroup="xbrli:item" />
<element name="AmountToBeDepositedInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AmountToBeDepositedInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsIssuePricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_ClassOfWarrantsOrRightsIssuePricePerUnit" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesRedeemable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_CommonStockSharesRedeemable" substitutionGroup="xbrli:item" />
<element name="CommonStockValueRedeemable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_CommonStockValueRedeemable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfPermanentEquityIntoTemporaryEquityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" substitutionGroup="xbrli:item" />
<element name="DeferredUnderwritingCommissionNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_DeferredUnderwritingCommissionNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromInitialPublicOffer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_GrossProceedsFromInitialPublicOffer" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MinimumNetWorthNeededToConsummateBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_MinimumNetWorthNeededToConsummateBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" substitutionGroup="xbrli:item" />
<element name="OtherOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_OtherOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfFederalExciseTaxOnStockBuyBack" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfFederalExciseTaxOnStockBuyBack" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesRedeemable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfSharesRedeemable" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" substitutionGroup="xbrli:item" />
<element name="PerShareAmountAvailableForDistribution" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PerShareAmountAvailableForDistribution" substitutionGroup="xbrli:item" />
<element name="PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" substitutionGroup="xbrli:item" />
<element name="PerSharePaymentMadeToAcquireRestrictedInvestments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PerSharePaymentMadeToAcquireRestrictedInvestments" substitutionGroup="xbrli:item" />
<element name="PerShareValueOfTheAmountToBeDepositedInTrustAccount" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" substitutionGroup="xbrli:item" />
<element name="ReimbursementByUnderwriters" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ReimbursementByUnderwriters" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TemporaryEquityStockRedeemedDuringThePeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TemporaryEquityStockRedeemedDuringThePeriodShares" substitutionGroup="xbrli:item" />
<element name="TermOfRestrictedInvestments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TermOfRestrictedInvestments" substitutionGroup="xbrli:item" />
<element name="TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" substitutionGroup="xbrli:item" />
<element name="TransactionCostsOfIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TransactionCostsOfIssuance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnderwritingFeesNetOfReimbursementByUnderwriters" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_UnderwritingFeesNetOfReimbursementByUnderwriters" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WorkingCapitalLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_WorkingCapitalLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_SponsorMember" substitutionGroup="xbrli:item" />
<element name="PostBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PostBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="CommonStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_CommonStockIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_GrossProceeds" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsAllocatedToPublicWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ProceedsAllocatedToPublicWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TemporaryEquityRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_TemporaryEquityRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BasicAndDilutedLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_BasicAndDilutedLossPerShareAbstract" substitutionGroup="xbrli:item" />
<element name="BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" substitutionGroup="xbrli:item" />
<element name="OfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_OfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfferingCostsAllocatedInShareholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_OfferingCostsAllocatedInShareholdersEquity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OfferingCostsAllocatedInTemporaryEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_OfferingCostsAllocatedInTemporaryEquity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PublicWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PublicWarrantMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PrivatePlacementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PrivatePlacementWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PrivatePlacementWarrantMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PrivatePlacementLineItems" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." substitutionGroup="xbrli:item" />
<element name="ProceedsFromTheIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ProceedsFromTheIssuanceOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasisAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_BasisAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BasisDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_BasisDomain" substitutionGroup="xbrli:item" />
<element name="RestrictionOnTransferOfSponsorSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_RestrictionOnTransferOfSponsorSharesMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalLoansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_WorkingCapitalLoansMember" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentConversionPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_DebtInstrumentConversionPricePerShare" substitutionGroup="xbrli:item" />
<element name="LockInPeriodOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_LockInPeriodOfShares" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="NumberOfTradingDaysForDeterminingSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfTradingDaysForDeterminingSharePrice" substitutionGroup="xbrli:item" />
<element name="WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalLoansConvertibleIntoEquityWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WorkingCapitalLoansOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_WorkingCapitalLoansOutstanding" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FeeSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_FeeSharesMember" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="AdvisoryServiceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AdvisoryServiceFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingDiscountPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_DeferredUnderwritingDiscountPerShare" substitutionGroup="xbrli:item" />
<element name="InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" substitutionGroup="xbrli:item" />
<element name="MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfSharesNotAvailableForRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_NumberOfSharesNotAvailableForRedemption" substitutionGroup="xbrli:item" />
<element name="PaymentOfUnderwritingDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PaymentOfUnderwritingDiscount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfAdvisoryServiceFee" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PercentageOfAdvisoryServiceFee" substitutionGroup="xbrli:item" />
<element name="ThresholdDateForConsummationOfBusinessCombinationOne" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ThresholdDateForConsummationOfBusinessCombinationOne" substitutionGroup="xbrli:item" />
<element name="ThresholdDateForConsummationOfBusinessCombinationThree" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ThresholdDateForConsummationOfBusinessCombinationThree" substitutionGroup="xbrli:item" />
<element name="ThresholdDateForConsummationOfBusinessCombinationTwo" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ThresholdDateForConsummationOfBusinessCombinationTwo" substitutionGroup="xbrli:item" />
<element name="UnderwritingDiscountPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_UnderwritingDiscountPerShare" substitutionGroup="xbrli:item" />
<element name="AbproBioCoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AbproBioCoMember" substitutionGroup="xbrli:item" />
<element name="AbproMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AbproMember" substitutionGroup="xbrli:item" />
<element name="NonRedemptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_NonRedemptionAgreementMember" substitutionGroup="xbrli:item" />
<element name="AdjustedExercisePriceOfWarrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AdjustedExercisePriceOfWarrantsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AdjustedExercisePriceOfWarrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AdjustedExercisePriceOfWarrantsDomain" substitutionGroup="xbrli:item" />
<element name="AdjustedExercisePriceOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AdjustedExercisePriceOneMember" substitutionGroup="xbrli:item" />
<element name="AdjustedExercisePriceTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AdjustedExercisePriceTwoMember" substitutionGroup="xbrli:item" />
<element name="AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsLockInPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ClassOfWarrantsOrRightsLockInPeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsRedemptionPricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" substitutionGroup="xbrli:item" />
<element name="MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" substitutionGroup="xbrli:item" />
<element name="NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" substitutionGroup="xbrli:item" />
<element name="NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" substitutionGroup="xbrli:item" />
<element name="NumberOfTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_NumberOfTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommonStockIssuedAndOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PercentageOfCommonStockIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="PeriodAfterWhichTheWarrantsAreExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PeriodAfterWhichTheWarrantsAreExercisable" substitutionGroup="xbrli:item" />
<element name="PerShareRedemptionTriggerPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_PerShareRedemptionTriggerPrice" substitutionGroup="xbrli:item" />
<element name="ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" substitutionGroup="xbrli:item" />
<element name="SharesAreSubjectToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_SharesAreSubjectToForfeiture" substitutionGroup="xbrli:item" />
<element name="VolumeWeightedAveragePriceOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_VolumeWeightedAveragePriceOfShares" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PeriodAfterWhichTheWarrantsAreExercisableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodAfterWhichTheWarrantsAreExercisableDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" substitutionGroup="xbrli:item" />
<element name="FromTheCompletionOfBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_FromTheCompletionOfBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="FromTheCompletionOfInitialPublicOfferMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_FromTheCompletionOfInitialPublicOfferMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" substitutionGroup="xbrli:item" />
<element name="FederalAndStateAuthorityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_FederalAndStateAuthorityMember" substitutionGroup="xbrli:item" />
<element name="AssetsHeldInTrustMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AssetsHeldInTrustMember" substitutionGroup="xbrli:item" />
<element name="InvesteeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_InvesteeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvesteeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_InvesteeDomain" substitutionGroup="xbrli:item" />
<element name="AdvisorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_AdvisorMember" substitutionGroup="xbrli:item" />
<element name="UnderwriterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="acab_UnderwriterMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" substitutionGroup="xbrli:item" />
<element name="UnderwriterFeeWaivedOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="acab_UnderwriterFeeWaivedOff" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>acab-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-April-2024 [10:25:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ExciseTaxPayableCurrent" xlink:label="loc_ACAB_ExciseTaxPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ACAB_ExciseTaxPayableCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_TaxesPayableCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AccruedOfferingCosts" xlink:label="loc_ACAB_AccruedOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ACAB_AccruedOfferingCosts" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PenaltiesAndInterestOnTaxes" xlink:label="loc_ACAB_PenaltiesAndInterestOnTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ACAB_PenaltiesAndInterestOnTaxes" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvestmentIncomeExpenseNonoperating" xlink:label="loc_ACAB_InvestmentIncomeExpenseNonoperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ACAB_InvestmentIncomeExpenseNonoperating" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OperationAndFormationCosts" xlink:label="loc_ACAB_OperationAndFormationCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_ACAB_OperationAndFormationCosts" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromOtherDebt" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="loc_ACAB_ProceedsFromTrustAccountInConnectionWithRedemption" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ACAB_ProceedsFromTrustAccountInConnectionWithRedemption" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xlink:label="loc_ACAB_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACAB_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="loc_ACAB_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ACAB_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xlink:label="loc_ACAB_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ACAB_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="5" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>acab-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-April-2024 [10:25:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#CoverPage" roleURI="http://www.atlanticcoastalacquisition.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#InitialPublicOfferingAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#PrivatePlacementAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#CommitmentsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#StockholdersDeficitAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1426133" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1426119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_DocumentInformationTable_1426119" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426124" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426124" xlink:to="loc_us-gaap_ClassOfStockDomain_1426126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426124" xlink:to="loc_us-gaap_ClassOfStockDomain_1426126_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426129" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426129" xlink:to="loc_us-gaap_EquityComponentDomain_1426130" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426129" xlink:to="loc_us-gaap_EquityComponentDomain_1426130_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1702003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1702003" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1702004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1702003" xlink:to="loc_dei_AddressTypeDomain_1702004" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1702004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1702003" xlink:to="loc_dei_AddressTypeDomain_1702004_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1702005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1702004" xlink:to="loc_dei_BusinessContactMember_1702005" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1426137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_AmendmentFlag_1426137" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1426167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_CityAreaCode_1426167" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1426135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_DocumentType_1426135" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1426145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityRegistrantName_1426145" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1426146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityCentralIndexKey_1426146" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1426148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityFilerCategory_1426148" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1426159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1426159" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1426160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressAddressLine1_1426160" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1426161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressCityOrTown_1426161" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1426162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressStateOrProvince_1426162" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1426163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressPostalZipCode_1426163" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1426166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityTaxIdentificationNumber_1426166" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1426168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_LocalPhoneNumber_1426168" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1426169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntitySmallBusiness_1426169" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1426171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityEmergingGrowthCompany_1426171" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1426173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityExTransitionPeriod_1426173" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1702002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityPrimarySicNumber_1702002" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1702006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_ContactPersonnelName_1702006" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426230" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1426230" xlink:to="loc_us-gaap_StatementTable_1426222" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426222" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426223" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426223" xlink:to="loc_us-gaap_ClassOfStockDomain_1426224" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426224_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426223" xlink:to="loc_us-gaap_ClassOfStockDomain_1426224_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426224" xlink:to="loc_us-gaap_CommonClassAMember_1426225" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426224" xlink:to="loc_us-gaap_CommonClassBMember_1426226" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426222" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" xlink:to="loc_us-gaap_RelatedPartyDomain_1701881" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701881_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" xlink:to="loc_us-gaap_RelatedPartyDomain_1701881_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1701882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701881" xlink:to="loc_us-gaap_RelatedPartyMember_1701882" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1426231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426230" xlink:to="loc_us-gaap_AssetsAbstract_1426231" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1426233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1426233" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426235" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1426237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1426237" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_1701888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_1701888" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1426244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_AssetsCurrent_1426244" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1426255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1426255" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1426259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_Assets_1426259" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426230" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1426270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1426270" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ExciseTaxPayableCurrent" xlink:label="loc_acab_ExciseTaxPayableCurrent_1701815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_acab_ExciseTaxPayableCurrent_1701815" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AccruedOfferingCosts" xlink:label="loc_acab_AccruedOfferingCosts_1426278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_acab_AccruedOfferingCosts_1426278" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1568256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_TaxesPayableCurrent_1568256" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701877" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1701878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_NotesPayableCurrent_1701878" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1701879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1701879" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1426280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_LiabilitiesCurrent_1426280" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426282" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1426285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_Liabilities_1426285" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1426297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1426297" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426299" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1426301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1426301" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_1426303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_PreferredStockValue_1426303" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1426305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_CommonStockValue_1426305" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1426307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1426307" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1426310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1426310" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1426313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_StockholdersEquity_1426313" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1426316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1426316" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_StatementTable_1426353" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426355" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426355" xlink:to="loc_us-gaap_ClassOfStockDomain_1426356" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426356_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426355" xlink:to="loc_us-gaap_ClassOfStockDomain_1426356_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426356" xlink:to="loc_us-gaap_CommonClassAMember_1426357" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426356" xlink:to="loc_us-gaap_CommonClassBMember_1426358" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426365" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426365" xlink:to="loc_us-gaap_EquityComponentDomain_1426366" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426365" xlink:to="loc_us-gaap_EquityComponentDomain_1426366_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426402" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1426403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1426403" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1426405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesIssued_1426405" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701887" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1426373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1426373" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1426376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1426376" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426377" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426398" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1426399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1426399" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1426400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1426400" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1426401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1426401" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426406" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_StatementTable_1426489" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426489" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426490" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426490" xlink:to="loc_us-gaap_ClassOfStockDomain_1426491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426491_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426490" xlink:to="loc_us-gaap_ClassOfStockDomain_1426491_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_us-gaap_CommonClassAMember_1426493" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_us-gaap_CommonClassBMember_1426495" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassAAndClassBCommonStockMember" xlink:label="loc_acab_ClassAAndClassBCommonStockMember_1701898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_acab_ClassAAndClassBCommonStockMember_1701898" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockAxis" xlink:label="loc_acab_ClassificationOfCommonStockAxis_1701894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426489" xlink:to="loc_acab_ClassificationOfCommonStockAxis_1701894" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701894" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701895" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701895_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701894" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701895_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RedeemableCommonStockMember" xlink:label="loc_acab_RedeemableCommonStockMember_1701896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701895" xlink:to="loc_acab_RedeemableCommonStockMember_1701896" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedeemableCommonStockMember" xlink:label="loc_acab_NonRedeemableCommonStockMember_1701897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701895" xlink:to="loc_acab_NonRedeemableCommonStockMember_1701897" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OperationAndFormationCosts" xlink:label="loc_acab_OperationAndFormationCosts_1426497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_acab_OperationAndFormationCosts_1426497" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1426498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_OperatingIncomeLoss_1426498" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1426503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_InterestIncomeOther_1426503" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvestmentIncomeExpenseNonoperating" xlink:label="loc_acab_InvestmentIncomeExpenseNonoperating_1426505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_acab_InvestmentIncomeExpenseNonoperating_1426505" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PenaltiesAndInterestOnTaxes" xlink:label="loc_acab_PenaltiesAndInterestOnTaxes_1701840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_acab_PenaltiesAndInterestOnTaxes_1701840" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_1426506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_1426506" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1426510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1426510" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1568240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1568240" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1568241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1568241" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_NetIncomeLoss_1426511" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568468" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568469" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1568470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_EarningsPerShareBasic_1568470" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1568471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1568471" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426548" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StatementTable_1426539" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426539" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426540" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426540" xlink:to="loc_us-gaap_EquityComponentDomain_1426541" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426540" xlink:to="loc_us-gaap_EquityComponentDomain_1426541_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1429592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_CommonStockMember_1429592" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1426545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1426545" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1426546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_RetainedEarningsMember_1426546" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1429578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426539" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1429578" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1429580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1429578" xlink:to="loc_us-gaap_ClassOfStockDomain_1429580" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1429580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1429578" xlink:to="loc_us-gaap_ClassOfStockDomain_1429580_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1429588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1429580" xlink:to="loc_us-gaap_CommonClassAMember_1429588" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1429589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1429580" xlink:to="loc_us-gaap_CommonClassBMember_1429589" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1426552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1426552" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron_1426556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron_1426556" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_1426557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_1426557" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1426558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1426558" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax_1701796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax_1701796" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1426549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_SharesOutstanding_1426549" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1426551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockholdersEquity_1426551" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426554" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426559" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustment" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustment_1701792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_StockholderNonRedemptionAgreementAdjustment_1701792" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustmentReduction" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction_1701793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction_1701793" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1701795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1701795" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1701794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1701794" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_NetIncomeLoss_1426560" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426573" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1426573" xlink:to="loc_us-gaap_StatementTable_1426568" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1426568" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426572" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1426573" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426576" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1426630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1426630" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426631" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_StatementTable_1701883" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts_1701893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts_1701893" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xlink:label="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption_1426639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption_1426639" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xlink:label="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities_1426641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities_1426641" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_NetIncomeLoss_1426586" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xlink:label="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount_1428003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount_1428003" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1568234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_us-gaap_ShareBasedCompensation_1568234" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1426607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1426607" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1426608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1426608" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1568230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1568230" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1426609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1426609" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426612" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1701797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1701797" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption_1701799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption_1701799" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1426613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1426613" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1426620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1426620" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426622" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1426625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1426625" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1701889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1701889" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_1426626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_1426626" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_1701890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_1701890" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1426628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1426628" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1701800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1701800" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1426629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1426629" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1701892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1701892" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426705" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426705" xlink:to="loc_us-gaap_ClassOfStockDomain_1426706" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426705" xlink:to="loc_us-gaap_ClassOfStockDomain_1426706_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426706" xlink:to="loc_us-gaap_CommonClassAMember_1426707" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1701781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426706" xlink:to="loc_us-gaap_CommonClassBMember_1701781" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1426713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_IPOMember_1426713" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426714" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1426717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_PrivatePlacementMember_1426717" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426731" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1426733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_srt_RangeAxis_1426733" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1426734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1426733" xlink:to="loc_srt_RangeMember_1426734" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1426734_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1426733" xlink:to="loc_srt_RangeMember_1426734_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1426737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1426734" xlink:to="loc_srt_MinimumMember_1426737" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1698256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1698256" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1698256_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1698256_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PostBusinessCombinationMember" xlink:label="loc_acab_PostBusinessCombinationMember_1701777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1698256" xlink:to="loc_acab_PostBusinessCombinationMember_1701777" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" xlink:to="loc_us-gaap_RelatedPartyDomain_1701785" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" xlink:to="loc_us-gaap_RelatedPartyDomain_1701785_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1701786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701785" xlink:to="loc_acab_SponsorMember_1701786" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701822" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701822" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701823" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701822" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701823_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_1701824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1701823" xlink:to="loc_us-gaap_UnsecuredDebtMember_1701824" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1701825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1701825" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1701826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1701825" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1701826" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1701826_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1701825" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1701826_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetHeldInTrustMember" xlink:label="loc_us-gaap_AssetHeldInTrustMember_1701827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1701826" xlink:to="loc_us-gaap_AssetHeldInTrustMember_1701827" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701828" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701828" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701829" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701829_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701828" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701829_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceedsFromInitialPublicOffer" xlink:label="loc_acab_GrossProceedsFromInitialPublicOffer_1426754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_GrossProceedsFromInitialPublicOffer_1426754" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits_1426768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits_1426768" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit_1426774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit_1426774" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingCommissionNonCurrent" xlink:label="loc_acab_DeferredUnderwritingCommissionNonCurrent_1426784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_DeferredUnderwritingCommissionNonCurrent_1426784" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426786" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xlink:label="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments_1426788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments_1426788" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xlink:label="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected_1426793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected_1426793" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1426797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1426797" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1426809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1426809" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction_1426813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction_1426813" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated_1426818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated_1426818" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_1426828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_1426828" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xlink:label="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed_1426834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed_1426834" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountAvailableForDistribution" xlink:label="loc_acab_PerShareAmountAvailableForDistribution_1426838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareAmountAvailableForDistribution_1426838" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xlink:label="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution_1426848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution_1426848" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OtherOfferingCosts" xlink:label="loc_acab_OtherOfferingCosts_1427335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_OtherOfferingCosts_1427335" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1427365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_Cash_1427365" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack_1697936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack_1697936" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack_1697944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack_1697944" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xlink:label="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares_1701780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares_1701780" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_1701782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_1701782" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1701783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1701783" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockSharesRedeemable" xlink:label="loc_acab_CommonStockSharesRedeemable_1701788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_CommonStockSharesRedeemable_1701788" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockValueRedeemable" xlink:label="loc_acab_CommonStockValueRedeemable_1701789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_CommonStockValueRedeemable_1701789" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemable" xlink:label="loc_acab_PercentageOfSharesRedeemable_1701791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesRedeemable_1701791" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1701831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1701831" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701833" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AmountToBeDepositedInTrustAccount" xlink:label="loc_acab_AmountToBeDepositedInTrustAccount_1701899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_AmountToBeDepositedInTrustAccount_1701899" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xlink:label="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount_1701900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount_1701900" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426745" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426750" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426777" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TransactionCostsOfIssuance" xlink:label="loc_acab_TransactionCostsOfIssuance_1426778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TransactionCostsOfIssuance_1426778" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xlink:label="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters_1426779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters_1426779" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ReimbursementByUnderwriters" xlink:label="loc_acab_ReimbursementByUnderwriters_1426782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ReimbursementByUnderwriters_1426782" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TermOfRestrictedInvestments" xlink:label="loc_acab_TermOfRestrictedInvestments_1426789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TermOfRestrictedInvestments_1426789" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426799" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xlink:label="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering_1426824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering_1426824" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoan" xlink:label="loc_acab_WorkingCapitalLoan_1438280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_WorkingCapitalLoan_1438280" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xlink:label="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares_1701779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares_1701779" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1701787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1701787" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1701790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1701790" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701980" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1701981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharePrice_1701981" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xlink:label="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses_1701903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses_1701903" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701982" use="optional" order="85" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1426791" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1426790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1426790" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceeds" xlink:label="loc_acab_GrossProceeds_1428166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_GrossProceeds_1428166" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsAllocatedToPublicWarrants" xlink:label="loc_acab_ProceedsAllocatedToPublicWarrants_1426794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_ProceedsAllocatedToPublicWarrants_1426794" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockIssuanceCosts" xlink:label="loc_acab_CommonStockIssuanceCosts_1428122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_CommonStockIssuanceCosts_1428122" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityRedemptionValue" xlink:label="loc_acab_TemporaryEquityRedemptionValue_1701798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_TemporaryEquityRedemptionValue_1701798" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1701957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1701957" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426796" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426798" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426804" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426804" xlink:to="loc_us-gaap_ClassOfStockDomain_1426805" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426805_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426804" xlink:to="loc_us-gaap_ClassOfStockDomain_1426805_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426805" xlink:to="loc_us-gaap_CommonClassAMember_1426806" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426805" xlink:to="loc_us-gaap_CommonClassBMember_1426807" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockAxis" xlink:label="loc_acab_ClassificationOfCommonStockAxis_1701953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xlink:to="loc_acab_ClassificationOfCommonStockAxis_1701953" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701953" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701954" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701954_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701953" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701954_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RedeemableCommonStockMember" xlink:label="loc_acab_RedeemableCommonStockMember_1701955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701954" xlink:to="loc_acab_RedeemableCommonStockMember_1701955" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedeemableCommonStockMember" xlink:label="loc_acab_NonRedeemableCommonStockMember_1701956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701954" xlink:to="loc_acab_NonRedeemableCommonStockMember_1701956" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedLossPerShareAbstract" xlink:label="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" xlink:to="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1426812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1426812" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1426812" xlink:to="loc_us-gaap_NetIncomeLoss_1426814" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xlink:label="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" xlink:to="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568482" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568483" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1568486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_EarningsPerShareBasic_1568486" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1568488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1568488" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1426850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_1426850" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426852" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_1426853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashFDICInsuredAmount_1426853" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1426861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1426861" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCosts" xlink:label="loc_acab_OfferingCosts_1438285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCosts_1438285" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInTemporaryEquity" xlink:label="loc_acab_OfferingCostsAllocatedInTemporaryEquity_1438294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCostsAllocatedInTemporaryEquity_1438294" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInShareholdersEquity" xlink:label="loc_acab_OfferingCostsAllocatedInShareholdersEquity_1438295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCostsAllocatedInShareholdersEquity_1438295" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_1438300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_DeferredOfferingCosts_1438300" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_StatementTable_1701841" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" xlink:to="loc_us-gaap_RelatedPartyDomain_1701847" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" xlink:to="loc_us-gaap_RelatedPartyDomain_1701847_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701843" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701844" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701844_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701844_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1701849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_CreditFacilityAxis_1701849" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1701849" xlink:to="loc_us-gaap_CreditFacilityDomain_1701850" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701850_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1701849" xlink:to="loc_us-gaap_CreditFacilityDomain_1701850_default" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1426147" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1426144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1426194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" xlink:to="loc_us-gaap_IPOMember_1426194" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426195" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantMember" xlink:label="loc_acab_PublicWarrantMember_1426199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" xlink:to="loc_acab_PublicWarrantMember_1426199" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426200" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426200" xlink:to="loc_us-gaap_ClassOfStockDomain_1426201" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426201_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426200" xlink:to="loc_us-gaap_ClassOfStockDomain_1426201_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426201" xlink:to="loc_us-gaap_CommonClassAMember_1426202" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426152" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1426153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_CommonStockConversionBasis_1426153" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426156" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426158" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426149" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementLineItems" xlink:label="loc_acab_PrivatePlacementLineItems_1426252" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementTable" xlink:label="loc_acab_PrivatePlacementTable_1426247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_PrivatePlacementTable_1426247" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" xlink:to="loc_us-gaap_RelatedPartyDomain_1426304" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426304_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" xlink:to="loc_us-gaap_RelatedPartyDomain_1426304_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1426312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1426304" xlink:to="loc_acab_SponsorMember_1426312" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426314" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426314" xlink:to="loc_us-gaap_ClassOfStockDomain_1426315" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426315_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426314" xlink:to="loc_us-gaap_ClassOfStockDomain_1426315_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426315" xlink:to="loc_us-gaap_CommonClassAMember_1426317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantMember" xlink:label="loc_acab_PrivatePlacementWarrantMember_1426320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" xlink:to="loc_acab_PrivatePlacementWarrantMember_1426320" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits_1426256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits_1426256" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant._1426258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant._1426258" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTheIssuanceOfWarrants" xlink:label="loc_acab_ProceedsFromTheIssuanceOfWarrants_1426262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ProceedsFromTheIssuanceOfWarrants_1426262" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426290" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426295" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426855" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426855" xlink:to="loc_us-gaap_EquityComponentDomain_1426857" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426855" xlink:to="loc_us-gaap_EquityComponentDomain_1426857_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FounderSharesMember" xlink:label="loc_acab_FounderSharesMember_1426859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426857" xlink:to="loc_acab_FounderSharesMember_1426859" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FeeSharesMember" xlink:label="loc_acab_FeeSharesMember_1426901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426857" xlink:to="loc_acab_FeeSharesMember_1426901" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426864" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426864" xlink:to="loc_us-gaap_ClassOfStockDomain_1426865" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426865_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426864" xlink:to="loc_us-gaap_ClassOfStockDomain_1426865_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426865" xlink:to="loc_us-gaap_CommonClassBMember_1426866" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426865" xlink:to="loc_us-gaap_CommonClassAMember_1426897" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" xlink:to="loc_us-gaap_RelatedPartyDomain_1426912" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" xlink:to="loc_us-gaap_RelatedPartyDomain_1426912_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1426913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1426912" xlink:to="loc_acab_SponsorMember_1426913" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1701816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1426912" xlink:to="loc_us-gaap_RelatedPartyMember_1701816" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1426882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1426882" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1426883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1426882" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1426883" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1426883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1426882" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1426883_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansMember" xlink:label="loc_acab_WorkingCapitalLoansMember_1426884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1426883" xlink:to="loc_acab_WorkingCapitalLoansMember_1426884" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PromissoryNoteMember" xlink:label="loc_acab_PromissoryNoteMember_1426886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1426883" xlink:to="loc_acab_PromissoryNoteMember_1426886" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426893" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisAxis" xlink:label="loc_acab_BasisAxis_1426906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_acab_BasisAxis_1426906" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisDomain" xlink:label="loc_acab_BasisDomain_1426907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_BasisAxis_1426906" xlink:to="loc_acab_BasisDomain_1426907" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisDomain" xlink:label="loc_acab_BasisDomain_1426907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_BasisAxis_1426906" xlink:to="loc_acab_BasisDomain_1426907_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_acab_RestrictionOnTransferOfSponsorSharesMember_1426908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_BasisDomain_1426907" xlink:to="loc_acab_RestrictionOnTransferOfSponsorSharesMember_1426908" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1438307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_srt_TitleOfIndividualAxis_1438307" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1438307" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1438307" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1438309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" xlink:to="loc_srt_DirectorMember_1438309" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701983" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701983" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701984" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701984_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701983" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701984_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_1701985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1701984" xlink:to="loc_us-gaap_LoansPayableMember_1701985" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426748" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1426760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_SharePrice_1426760" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_LockInPeriodOfShares" xlink:label="loc_acab_LockInPeriodOfShares_1426765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_LockInPeriodOfShares_1426765" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingSharePrice_1426781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_NumberOfTradingDaysForDeterminingSharePrice_1426781" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426785" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426821" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1426822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1426822" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1426823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1426823" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_1701962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_AssetsHeldInTrust_1701962" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701963" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_1701964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_NotesPayable_1701964" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1426825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_NotesPayableCurrent_1426825" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLoansPayable" xlink:label="loc_us-gaap_OtherLoansPayable_1426826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_OtherLoansPayable_1426826" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DebtInstrumentConversionPricePerShare" xlink:label="loc_acab_DebtInstrumentConversionPricePerShare_1426835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_DebtInstrumentConversionPricePerShare_1426835" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_1701988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_OtherCommitment_1701988" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1426744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1426744" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1426746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1426746" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426747" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426749" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_1426787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_1426787" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xlink:label="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants_1426831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants_1426831" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansOutstanding" xlink:label="loc_acab_WorkingCapitalLoansOutstanding_1426837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WorkingCapitalLoansOutstanding_1426837" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1438301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1438301" use="optional" order="60" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1426662" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1426660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_OtherCommitmentsTable_1426660" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1701802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1701802" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701802" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701802" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedemptionAgreementMember" xlink:label="loc_acab_NonRedemptionAgreementMember_1701804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" xlink:to="loc_acab_NonRedemptionAgreementMember_1701804" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701805" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701805" xlink:to="loc_us-gaap_ClassOfStockDomain_1701806" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701805" xlink:to="loc_us-gaap_ClassOfStockDomain_1701806_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1701807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1701806" xlink:to="loc_us-gaap_CommonClassAMember_1701807" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" xlink:to="loc_us-gaap_RelatedPartyDomain_1701970" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" xlink:to="loc_us-gaap_RelatedPartyDomain_1701970_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1701971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_SponsorMember_1701971" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproBioCoMember" xlink:label="loc_acab_AbproBioCoMember_1701973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_AbproBioCoMember_1701973" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproMember" xlink:label="loc_acab_AbproMember_1701974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_AbproMember_1701974" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PaymentOfUnderwritingDiscount" xlink:label="loc_acab_PaymentOfUnderwritingDiscount_1426676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_PaymentOfUnderwritingDiscount_1426676" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingDiscountPerShare" xlink:label="loc_acab_DeferredUnderwritingDiscountPerShare_1426677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_DeferredUnderwritingDiscountPerShare_1426677" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426679" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfAdvisoryServiceFee" xlink:label="loc_acab_PercentageOfAdvisoryServiceFee_1426680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_PercentageOfAdvisoryServiceFee_1426680" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisoryServiceFee" xlink:label="loc_acab_AdvisoryServiceFee_1426683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_AdvisoryServiceFee_1426683" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfSharesNotAvailableForRedemption" xlink:label="loc_acab_NumberOfSharesNotAvailableForRedemption_1701801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_NumberOfSharesNotAvailableForRedemption_1701801" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xlink:label="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders_1701813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders_1701813" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1701989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1701989" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination_1701990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination_1701990" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1701967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1701967" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1701972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_CommonStockSharesIssued_1701972" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingDiscountPerShare" xlink:label="loc_acab_UnderwritingDiscountPerShare_1426673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_UnderwritingDiscountPerShare_1426673" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationOne" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne_1701809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne_1701809" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo_1701811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo_1701811" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationThree" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree_1701812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree_1701812" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1426211" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1426210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426271" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426271" xlink:to="loc_us-gaap_ClassOfStockDomain_1426272" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426271" xlink:to="loc_us-gaap_ClassOfStockDomain_1426272_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426272" xlink:to="loc_us-gaap_CommonClassAMember_1426273" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1426272" xlink:to="loc_us-gaap_CommonClassBMember_1426291" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426326" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426329" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426329" xlink:to="loc_us-gaap_EquityComponentDomain_1426330" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426329" xlink:to="loc_us-gaap_EquityComponentDomain_1426330_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FounderSharesMember" xlink:label="loc_acab_FounderSharesMember_1426333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1426330" xlink:to="loc_acab_FounderSharesMember_1426333" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantsMember" xlink:label="loc_acab_PublicWarrantsMember_1426350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" xlink:to="loc_acab_PublicWarrantsMember_1426350" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426611" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfBusinessCombinationMember" xlink:label="loc_acab_FromTheCompletionOfBusinessCombinationMember_1426487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" xlink:to="loc_acab_FromTheCompletionOfBusinessCombinationMember_1426487" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfInitialPublicOfferMember" xlink:label="loc_acab_FromTheCompletionOfInitialPublicOfferMember_1426520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" xlink:to="loc_acab_FromTheCompletionOfInitialPublicOfferMember_1426520" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAxis" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsDomain" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsDomain" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOneMember" xlink:label="loc_acab_AdjustedExercisePriceOneMember_1426578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" xlink:to="loc_acab_AdjustedExercisePriceOneMember_1426578" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceTwoMember" xlink:label="loc_acab_AdjustedExercisePriceTwoMember_1426599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" xlink:to="loc_acab_AdjustedExercisePriceTwoMember_1426599" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1426212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1426212" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426214" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1426215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1426215" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1426216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1426216" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1426228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1426228" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426229" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1426236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockVotingRights_1426236" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1426239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesIssued_1426239" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426241" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SharesAreSubjectToForfeiture" xlink:label="loc_acab_SharesAreSubjectToForfeiture_1426322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_SharesAreSubjectToForfeiture_1426322" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfCommonStockIssuedAndOutstanding" xlink:label="loc_acab_PercentageOfCommonStockIssuedAndOutstanding_1426321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PercentageOfCommonStockIssuedAndOutstanding_1426321" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1426340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockConversionBasis_1426340" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1426344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1426344" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable_1426480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable_1426480" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xlink:label="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered_1426501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered_1426501" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xlink:label="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective_1426507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective_1426507" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit_1426531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit_1426531" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_1426535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_1426535" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1426536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_SharePrice_1426536" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice_1426542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice_1426542" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426547" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426550" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xlink:label="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal_1426555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal_1426555" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice_1426565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice_1426565" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareRedemptionTriggerPrice" xlink:label="loc_acab_PerShareRedemptionTriggerPrice_1426579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PerShareRedemptionTriggerPrice_1426579" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsLockInPeriod" xlink:label="loc_acab_ClassOfWarrantsOrRightsLockInPeriod_1426619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ClassOfWarrantsOrRightsLockInPeriod_1426619" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1426245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1426245" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426328" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426338" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_VolumeWeightedAveragePriceOfShares" xlink:label="loc_acab_VolumeWeightedAveragePriceOfShares_1426562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_VolumeWeightedAveragePriceOfShares_1426562" use="optional" order="59" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1701946_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1701946_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FederalAndStateAuthorityMember" xlink:label="loc_acab_FederalAndStateAuthorityMember_1701947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" xlink:to="loc_acab_FederalAndStateAuthorityMember_1701947" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1701949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1701949" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701950" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1426183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1426183" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1426183" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1426183" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AssetsHeldInTrustMember" xlink:label="loc_acab_AssetsHeldInTrustMember_1426185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" xlink:to="loc_acab_AssetsHeldInTrustMember_1426185" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1426188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1426188" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1426190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1426190" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1701758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1701747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_us-gaap_SubsequentEventTable_1701747" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701748" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701748" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701749" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701749_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701748" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701749_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1701750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1701749" xlink:to="loc_us-gaap_SubsequentEventMember_1701750" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1701751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1701751" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701751" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701751" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1701868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_TaxPeriodAxis_1701868" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1701869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1701868" xlink:to="loc_us-gaap_TaxPeriodDomain_1701869" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1701869_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1701868" xlink:to="loc_us-gaap_TaxPeriodDomain_1701869_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701754" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701754" xlink:to="loc_us-gaap_ClassOfStockDomain_1701755" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701754" xlink:to="loc_us-gaap_ClassOfStockDomain_1701755_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1701756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1701755" xlink:to="loc_us-gaap_CommonClassAMember_1701756" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" xlink:to="loc_us-gaap_RelatedPartyDomain_1701774" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701774_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" xlink:to="loc_us-gaap_RelatedPartyDomain_1701774_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterMember" xlink:label="loc_acab_UnderwriterMember_1701992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1701774" xlink:to="loc_acab_UnderwriterMember_1701992" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701837" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701837" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701838" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701838_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701837" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701838_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1701856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_CreditFacilityAxis_1701856" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1701856" xlink:to="loc_us-gaap_CreditFacilityDomain_1701857" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1701856" xlink:to="loc_us-gaap_CreditFacilityDomain_1701857_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeAxis" xlink:label="loc_acab_InvesteeAxis_1701995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_acab_InvesteeAxis_1701995" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeDomain" xlink:label="loc_acab_InvesteeDomain_1701996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_acab_InvesteeAxis_1701995" xlink:to="loc_acab_InvesteeDomain_1701996" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeDomain" xlink:label="loc_acab_InvesteeDomain_1701996_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_acab_InvesteeAxis_1701995" xlink:to="loc_acab_InvesteeDomain_1701996_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisorMember" xlink:label="loc_acab_AdvisorMember_1701997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_acab_InvesteeDomain_1701996" xlink:to="loc_acab_AdvisorMember_1701997" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xlink:label="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors_1701976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors_1701976" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1702001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1702001" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterFeeWaivedOff" xlink:label="loc_acab_UnderwriterFeeWaivedOff_1701977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_acab_UnderwriterFeeWaivedOff_1701977" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1701993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1701993" use="optional" order="33" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>acab-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-April-2024 [10:25:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related Party [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related party [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Series A common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Series A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Series B common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Series B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Asset, Held-in-Trust, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Cash and marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustCurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Assets Held-in-trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Cash and marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments (Note 6)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred underwriting fee payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred underwriting commission</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AccruedOfferingCosts" xlink:label="loc_acab_AccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AccruedOfferingCosts" xml:lang="en-US">Accrued Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AccruedOfferingCosts" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AccruedOfferingCosts" xlink:to="lab_acab_AccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AccruedOfferingCosts" xml:lang="en-US">Accrued offering costs.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ExciseTaxPayableCurrent" xlink:label="loc_acab_ExciseTaxPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ExciseTaxPayableCurrent" xml:lang="en-US">Excise Tax Payable Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ExciseTaxPayableCurrent" xml:lang="en-US">Excise tax payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ExciseTaxPayableCurrent" xlink:to="lab_acab_ExciseTaxPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ExciseTaxPayableCurrent" xml:lang="en-US">Excise tax payable current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Extension promissory note - related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable to related party classified as current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Advance from related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xml:lang="en-US">Common stock to be redeemed (2,768,301 shares of Series A common stock)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xml:lang="en-US">Common stock to be redeemed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Series A common stock subject to possible redemption; 667,391 and 30,000,000 shares issued and outstanding at December 31, 2023 and 2022 at redemption value of $10.93 and $10.30 per share, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Plus: Series A common stock subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xml:lang="en-US">Common stock to be redeemed (2,768,301 shares of Series A common stock)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xml:lang="en-US">Temporary equity shares subject to redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary equity, redemption price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary equity, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary equity, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary equity shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockAxis" xlink:label="loc_acab_ClassificationOfCommonStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassificationOfCommonStockAxis" xml:lang="en-US">Classification Of Common Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassificationOfCommonStockAxis" xlink:to="lab_acab_ClassificationOfCommonStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassificationOfCommonStockAxis" xml:lang="en-US">Classification of common stock [axis].</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassificationOfCommonStockDomain" xml:lang="en-US">Classification Of Common Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassificationOfCommonStockDomain" xlink:to="lab_acab_ClassificationOfCommonStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassificationOfCommonStockDomain" xml:lang="en-US">Classification of common stock.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedeemableCommonStockMember" xlink:label="loc_acab_NonRedeemableCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NonRedeemableCommonStockMember" xml:lang="en-US">Non Redeemable common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NonRedeemableCommonStockMember" xml:lang="en-US">Nonredeemable common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NonRedeemableCommonStockMember" xlink:to="lab_acab_NonRedeemableCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NonRedeemableCommonStockMember" xml:lang="en-US">Non Redeemable common stock [member].</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RedeemableCommonStockMember" xlink:label="loc_acab_RedeemableCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_RedeemableCommonStockMember" xml:lang="en-US">Redeemable common stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_RedeemableCommonStockMember" xml:lang="en-US">Redeemable common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_RedeemableCommonStockMember" xlink:to="lab_acab_RedeemableCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_RedeemableCommonStockMember" xml:lang="en-US">Redeemable common stock.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassAAndClassBCommonStockMember" xlink:label="loc_acab_ClassAAndClassBCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassAAndClassBCommonStockMember" xml:lang="en-US">Class A And Class B Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ClassAAndClassBCommonStockMember" xml:lang="en-US">Series A and Series B common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassAAndClassBCommonStockMember" xlink:to="lab_acab_ClassAAndClassBCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassAAndClassBCommonStockMember" xml:lang="en-US">Class A and Class B common stock [member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic and diluted income (loss) per share, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Basic and diluted income (loss) per share, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Allocation of net income, as adjusted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income &#8211; bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvestmentIncomeExpenseNonoperating" xlink:label="loc_acab_InvestmentIncomeExpenseNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InvestmentIncomeExpenseNonoperating" xml:lang="en-US">Investment Income Expense Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_InvestmentIncomeExpenseNonoperating" xml:lang="en-US">Interest earned on Cash and marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InvestmentIncomeExpenseNonoperating" xlink:to="lab_acab_InvestmentIncomeExpenseNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InvestmentIncomeExpenseNonoperating" xml:lang="en-US">Investment income expense nonoperating.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PenaltiesAndInterestOnTaxes" xlink:label="loc_acab_PenaltiesAndInterestOnTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PenaltiesAndInterestOnTaxes" xml:lang="en-US">Penalties And Interest On Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_acab_PenaltiesAndInterestOnTaxes" xml:lang="en-US">Penalties and interest on taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PenaltiesAndInterestOnTaxes" xlink:to="lab_acab_PenaltiesAndInterestOnTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PenaltiesAndInterestOnTaxes" xml:lang="en-US">Penalties and interest on taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OperationAndFormationCosts" xlink:label="loc_acab_OperationAndFormationCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OperationAndFormationCosts" xml:lang="en-US">Operation and Formation Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_OperationAndFormationCosts" xml:lang="en-US">Operation and formation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OperationAndFormationCosts" xlink:to="lab_acab_OperationAndFormationCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OperationAndFormationCosts" xml:lang="en-US">Operation and formation costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xml:lang="en-US">Adjustments To Additional Paid In Capital Compensation Expense for Fair value of assigned founder shares to Apeiron</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xml:lang="en-US">Compensation Expense &#8211; Fair value of assigned Founder Shares to Apeiron</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xlink:to="lab_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xml:lang="en-US">Adjustments to additional paid in capital compensation expense for fair value of assigned founder shares to apeiron.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xml:lang="en-US">Adjustments To Additional Paid In Capital Excise Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xml:lang="en-US">Excise tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xlink:to="lab_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xml:lang="en-US">Adjustments to additional paid in capital excise tax.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xml:lang="en-US">Adjustments to Additional Paid in Capital, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xml:lang="en-US">Fair value of Public Warrants at issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Allocated value of transaction costs to Series A common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Sale of 13,850,000 Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustment" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustment" xml:lang="en-US">Stockholder Non Redemption Agreement Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustment" xml:lang="en-US">Stockholder non-redemption agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_StockholderNonRedemptionAgreementAdjustment" xlink:to="lab_acab_StockholderNonRedemptionAgreementAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustment" xml:lang="en-US">Stockholder non-redemption agreement adjustment.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustmentReduction" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustmentReduction" xml:lang="en-US">Stockholder Non Redemption Agreement Adjustment Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustmentReduction" xml:lang="en-US">Stockholder non-redemption agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction" xlink:to="lab_acab_StockholderNonRedemptionAgreementAdjustmentReduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_StockholderNonRedemptionAgreementAdjustmentReduction" xml:lang="en-US">Stockholder&#160;non-redemption&#160;agreement adjustment reduction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Series Class B shares to Series Class A Non-redeemable shares, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Forfeiture of Founder Shares, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Series Class B shares to Series Class A Non-redeemable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xml:lang="en-US">Remeasurement of Series A common stock to redemption amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xml:lang="en-US">Plus: Remeasurement of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PrivatePlacementWarrantsMember" xlink:to="lab_acab_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PrivatePlacementWarrantsMember" xml:lang="en-US">Private placement warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during the period shares new issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during period shares new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash &#8211; Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash &#8211; Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net Change in Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred offering costs included in accrued offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred offering costs included in accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:to="lab_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Deferred offering costs included in accrued offering costs.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xlink:label="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xml:lang="en-US">Deferred Underwriting Fee Payable As Non CashInvesting and Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xlink:to="lab_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xml:lang="en-US">Deferred underwriting fee payable as non cash investing and financing activities.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xlink:label="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xml:lang="en-US">Initial Classification Of Series A Common Stock Subject To Possible Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xml:lang="en-US">Initial classification of Series A common stock subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xlink:to="lab_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xml:lang="en-US">Initial classification of Series A common stock subject to possible redemption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows from Financing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Redemption of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from convertible promissory note - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from sale of Units, net of underwriting discounts paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from sale of Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xml:lang="en-US">Proceeds from Other Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt" xlink:to="lab_us-gaap_ProceedsFromOtherDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from extension promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows from Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xml:lang="en-US">Payments to Acquire Restricted Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xml:lang="en-US">Investment of cash in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xml:lang="en-US">Cash deposited in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xml:lang="en-US">Proceeds from Sale of Restricted Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xml:lang="en-US">Cash withdrawn from Trust Account to pay franchise and income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ProceedsFromTrustAccountInConnectionWithRedemption" xml:lang="en-US">Proceeds from Trust Account in connection with redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ProceedsFromTrustAccountInConnectionWithRedemption" xml:lang="en-US">Cash withdrawn from Trust Account in connection with redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:to="lab_acab_ProceedsFromTrustAccountInConnectionWithRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ProceedsFromTrustAccountInConnectionWithRedemption" xml:lang="en-US">Proceeds from trust account in connection with redemption.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows from Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xlink:label="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xml:lang="en-US">Interest Earned on Marketable Securities Held in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xml:lang="en-US">Interest earned on Cash and marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xlink:to="lab_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xml:lang="en-US">Interest earned on marketable securities held in trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Compensation expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplementary&#160;cashflow&#160;information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Organization And Plan Of Business Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary Of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DisclosureOfInitialPublicOffering" xlink:label="loc_acab_DisclosureOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DisclosureOfInitialPublicOffering" xml:lang="en-US">Disclosure Of Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DisclosureOfInitialPublicOffering" xml:lang="en-US">Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DisclosureOfInitialPublicOffering" xlink:to="lab_acab_DisclosureOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DisclosureOfInitialPublicOffering" xml:lang="en-US">Disclosure Of Initial Public Offering.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DisclosureOfPrivatePlacement" xlink:label="loc_acab_DisclosureOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DisclosureOfPrivatePlacement" xml:lang="en-US">Disclosure Of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DisclosureOfPrivatePlacement" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DisclosureOfPrivatePlacement" xlink:to="lab_acab_DisclosureOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DisclosureOfPrivatePlacement" xml:lang="en-US">Disclosure of private placement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AssetsHeldInTrustAccountPolicyTextBlock" xlink:label="loc_acab_AssetsHeldInTrustAccountPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AssetsHeldInTrustAccountPolicyTextBlock" xml:lang="en-US">Assets Held in Trust Account [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AssetsHeldInTrustAccountPolicyTextBlock" xml:lang="en-US">Cash and Marketable Securities Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AssetsHeldInTrustAccountPolicyTextBlock" xlink:to="lab_acab_AssetsHeldInTrustAccountPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AssetsHeldInTrustAccountPolicyTextBlock" xml:lang="en-US">Assets Held in Trust Account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Income per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_acab_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_EmergingGrowthCompanyPolicyTextBlock" xlink:to="lab_acab_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging growth company .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityPolicyTextBlock" xlink:label="loc_acab_TemporaryEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Temporary Equity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Series A Common Stock Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TemporaryEquityPolicyTextBlock" xlink:to="lab_acab_TemporaryEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Temporary equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WarrantsDisclosurePolicyTextBlock" xlink:label="loc_acab_WarrantsDisclosurePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WarrantsDisclosurePolicyTextBlock" xml:lang="en-US">Warrants Disclosure [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_WarrantsDisclosurePolicyTextBlock" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WarrantsDisclosurePolicyTextBlock" xlink:to="lab_acab_WarrantsDisclosurePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WarrantsDisclosurePolicyTextBlock" xml:lang="en-US">Warrants disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xml:lang="en-US">Schedule of the calculation of basic and diluted net income per common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Schedule of Series A common stock reflected in the consolidated balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value Measurements, Recurring and Nonrecurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xml:lang="en-US">Organization Consolidation And Presentation Of Statement Of Finanacial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xlink:to="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xml:lang="en-US">Organization consolidation and presentation of statement of financial statements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetHeldInTrustMember" xlink:label="loc_us-gaap_AssetHeldInTrustMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetHeldInTrustMember" xml:lang="en-US">Asset, Held-in-Trust [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetHeldInTrustMember" xlink:to="lab_us-gaap_AssetHeldInTrustMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xlink:to="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xml:lang="en-US">Organization consolidation and presentation of statement of financial statements.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AmountToBeDepositedInTrustAccount" xlink:label="loc_acab_AmountToBeDepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AmountToBeDepositedInTrustAccount" xml:lang="en-US">Amount To Be Deposited In Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AmountToBeDepositedInTrustAccount" xml:lang="en-US">Amount to be deposited in trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AmountToBeDepositedInTrustAccount" xlink:to="lab_acab_AmountToBeDepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AmountToBeDepositedInTrustAccount" xml:lang="en-US">Amount to be deposited in trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xml:lang="en-US">Class of warrants or rights issued during the period units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xlink:to="lab_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xml:lang="en-US">Class of warrants or rights issued during the period units.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:to="lab_acab_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockSharesRedeemable" xlink:label="loc_acab_CommonStockSharesRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_CommonStockSharesRedeemable" xml:lang="en-US">Common Stock Shares Redeemable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_CommonStockSharesRedeemable" xml:lang="en-US">Common stock shares redeemable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_CommonStockSharesRedeemable" xlink:to="lab_acab_CommonStockSharesRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_CommonStockSharesRedeemable" xml:lang="en-US">Common stock shares redeemable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockValueRedeemable" xlink:label="loc_acab_CommonStockValueRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_CommonStockValueRedeemable" xml:lang="en-US">Common Stock Value Redeemable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_CommonStockValueRedeemable" xml:lang="en-US">Common stock value redeemable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_CommonStockValueRedeemable" xlink:to="lab_acab_CommonStockValueRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_CommonStockValueRedeemable" xml:lang="en-US">Common stock value redeemable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xlink:label="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xml:lang="en-US">Conversion Of Permanent Equity Into Temporary Equity Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xml:lang="en-US">Conversion of permanent equity into temporary equity shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xlink:to="lab_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xml:lang="en-US">Conversion of permanent equity into temporary equity shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Common stock, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingCommissionNonCurrent" xlink:label="loc_acab_DeferredUnderwritingCommissionNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DeferredUnderwritingCommissionNonCurrent" xml:lang="en-US">Deferred Underwriting Commission Non Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DeferredUnderwritingCommissionNonCurrent" xlink:to="lab_acab_DeferredUnderwritingCommissionNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DeferredUnderwritingCommissionNonCurrent" xml:lang="en-US">Deferred underwriting commission non current.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Effective date for Levy of Federal Excise Tax on Stock Buy Back</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Effective date for levy of federal excise tax on stock buy back</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xlink:to="lab_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Effective date for levy of federal excise tax on stock buy back.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceedsFromInitialPublicOffer" xlink:label="loc_acab_GrossProceedsFromInitialPublicOffer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_GrossProceedsFromInitialPublicOffer" xml:lang="en-US">Gross Proceeds From Initial Public Offer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_GrossProceedsFromInitialPublicOffer" xml:lang="en-US">Gross proceeds from initial public offer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_GrossProceedsFromInitialPublicOffer" xlink:to="lab_acab_GrossProceedsFromInitialPublicOffer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_GrossProceedsFromInitialPublicOffer" xml:lang="en-US">Gross proceeds from initial public offer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xml:lang="en-US">Liquidation Basis of Accounting, Accrued Costs to Dispose of Assets and Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xml:lang="en-US">Expenses payable on liquidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_MinimumNetWorthNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum Net worth Needed To Consummate Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_MinimumNetWorthNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum value of net tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:to="lab_acab_MinimumNetWorthNeededToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_MinimumNetWorthNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum net worth needed to consummate business combination.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xlink:label="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xml:lang="en-US">Number Of Days Within Which Public Shares Shall Be Redeemed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xlink:to="lab_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xml:lang="en-US">Number of days within which public shares shall be redeemed.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OtherOfferingCosts" xlink:label="loc_acab_OtherOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OtherOfferingCosts" xml:lang="en-US">Other offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_OtherOfferingCosts" xml:lang="en-US">Other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OtherOfferingCosts" xlink:to="lab_acab_OtherOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OtherOfferingCosts" xml:lang="en-US">Other offering costs.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Percentage of Federal Excise Tax on Stock Buy Back</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PercentageOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Percentage of Federal excise tax on share buy back</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack" xlink:to="lab_acab_PercentageOfFederalExciseTaxOnStockBuyBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfFederalExciseTaxOnStockBuyBack" xml:lang="en-US">Percentage of Federal excise tax on share buy back.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xlink:label="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xml:lang="en-US">Percentage of net assets in the trust account for which the business combination shall be effected</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xlink:to="lab_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xml:lang="en-US">Percentage of net assets in the trust account of the acquiree for which business combination shall be effected.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemable" xlink:label="loc_acab_PercentageOfSharesRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfSharesRedeemable" xml:lang="en-US">Percentage Of Shares Redeemable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PercentageOfSharesRedeemable" xml:lang="en-US">Percentage of shares redeemable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfSharesRedeemable" xlink:to="lab_acab_PercentageOfSharesRedeemable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfSharesRedeemable" xml:lang="en-US">Percentage of shares redeemable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xml:lang="en-US">Percentage Of Shares Redeemable In Case Business Combination Is Not Consummated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xlink:to="lab_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xml:lang="en-US">Percentage of shares redeemable in case business combination is not consummated.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xml:lang="en-US">Percentage Of Shares That Can Be Transferred Without Any Restriction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xlink:to="lab_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xml:lang="en-US">Percentage of shares that can be transferred without any restriction.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountAvailableForDistribution" xlink:label="loc_acab_PerShareAmountAvailableForDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PerShareAmountAvailableForDistribution" xml:lang="en-US">Per share amount available for distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PerShareAmountAvailableForDistribution" xlink:to="lab_acab_PerShareAmountAvailableForDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PerShareAmountAvailableForDistribution" xml:lang="en-US">Per share amount available for distribution.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xlink:label="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xml:lang="en-US">Per share amount to be maintained in the trust account for distribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xlink:to="lab_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xml:lang="en-US">Per share amount to be maintained in the trust account for distribution.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xlink:label="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xml:lang="en-US">Per share payment made to acquire restricted investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xlink:to="lab_acab_PerSharePaymentMadeToAcquireRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xml:lang="en-US">Per share payment made to acquire restricted investments.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xlink:label="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xml:lang="en-US">Per share value of the amount to be deposited in trust account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xml:lang="en-US">Per share value of the amount to be deposited in trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xlink:to="lab_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xml:lang="en-US">Per share value of the amount to be deposited in trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xlink:label="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xml:lang="en-US">Proceeds from Sale of Trust Assets to Pay Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xml:lang="en-US">Proceeds from sale of trust assets to pay expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xlink:to="lab_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ReimbursementByUnderwriters" xlink:label="loc_acab_ReimbursementByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ReimbursementByUnderwriters" xml:lang="en-US">Reimbursement By Underwriters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ReimbursementByUnderwriters" xlink:to="lab_acab_ReimbursementByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ReimbursementByUnderwriters" xml:lang="en-US">Reimbursement by underwriters.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Excise tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xlink:label="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xml:lang="en-US">Temporary Equity Stock Redeemed During The Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xml:lang="en-US">Temporary equity stock redeemed during the period shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xlink:to="lab_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xml:lang="en-US">Temporary equity stock redeemed during the period shares.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TermOfRestrictedInvestments" xlink:label="loc_acab_TermOfRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TermOfRestrictedInvestments" xml:lang="en-US">Term of restricted investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TermOfRestrictedInvestments" xlink:to="lab_acab_TermOfRestrictedInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TermOfRestrictedInvestments" xml:lang="en-US">Term of restricted investments.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xlink:label="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xml:lang="en-US">Time Limit Within Which Business Combination Shall Be Consummated From The Date Of Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xlink:to="lab_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xml:lang="en-US">Time limit within which business combination shall be consummated from the date of initial public offering.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TransactionCostsOfIssuance" xlink:label="loc_acab_TransactionCostsOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TransactionCostsOfIssuance" xml:lang="en-US">Transaction Costs Of Issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TransactionCostsOfIssuance" xlink:to="lab_acab_TransactionCostsOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TransactionCostsOfIssuance" xml:lang="en-US">Transaction costs of issuance.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xlink:label="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xml:lang="en-US">Underwriting Fees Net Of Reimbursement By Underwriters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xlink:to="lab_acab_UnderwritingFeesNetOfReimbursementByUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xml:lang="en-US">Underwriting fees net of reimbursement by underwriters.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoan" xlink:label="loc_acab_WorkingCapitalLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WorkingCapitalLoan" xml:lang="en-US">Working Capital Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_WorkingCapitalLoan" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WorkingCapitalLoan" xlink:to="lab_acab_WorkingCapitalLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WorkingCapitalLoan" xml:lang="en-US">Working capital loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_SponsorMember" xlink:to="lab_acab_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_SponsorMember" xml:lang="en-US">Sponsor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PostBusinessCombinationMember" xlink:label="loc_acab_PostBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PostBusinessCombinationMember" xml:lang="en-US">Post Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PostBusinessCombinationMember" xml:lang="en-US">Post Business Combination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PostBusinessCombinationMember" xlink:to="lab_acab_PostBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PostBusinessCombinationMember" xml:lang="en-US">Post Business Combination [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockIssuanceCosts" xlink:label="loc_acab_CommonStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_CommonStockIssuanceCosts" xml:lang="en-US">Common Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_CommonStockIssuanceCosts" xml:lang="en-US">Less: Series A common stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_CommonStockIssuanceCosts" xlink:to="lab_acab_CommonStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_CommonStockIssuanceCosts" xml:lang="en-US">Common stock issuance costs.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceeds" xlink:label="loc_acab_GrossProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_GrossProceeds" xml:lang="en-US">Gross Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_GrossProceeds" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_GrossProceeds" xlink:to="lab_acab_GrossProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_GrossProceeds" xml:lang="en-US">Gross proceeds</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsAllocatedToPublicWarrants" xlink:label="loc_acab_ProceedsAllocatedToPublicWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ProceedsAllocatedToPublicWarrants" xml:lang="en-US">Proceeds allocated to Public Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ProceedsAllocatedToPublicWarrants" xml:lang="en-US">Less: Proceeds allocated to Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ProceedsAllocatedToPublicWarrants" xlink:to="lab_acab_ProceedsAllocatedToPublicWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ProceedsAllocatedToPublicWarrants" xml:lang="en-US">Proceeds allocated to Public Warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Less:Redemptions (redeemed in December 2023, paid in January 2024)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityRedemptionValue" xlink:label="loc_acab_TemporaryEquityRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_TemporaryEquityRedemptionValue" xml:lang="en-US">Temporary Equity Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_TemporaryEquityRedemptionValue" xml:lang="en-US">Less: Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_TemporaryEquityRedemptionValue" xlink:to="lab_acab_TemporaryEquityRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_TemporaryEquityRedemptionValue" xml:lang="en-US">Temporary equity redemption value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedLossPerShareAbstract" xlink:label="loc_acab_BasicAndDilutedLossPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_BasicAndDilutedLossPerShareAbstract" xml:lang="en-US">Basic and Diluted Loss Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_BasicAndDilutedLossPerShareAbstract" xml:lang="en-US">Basic and diluted net loss per common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_BasicAndDilutedLossPerShareAbstract" xlink:to="lab_acab_BasicAndDilutedLossPerShareAbstract" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xlink:label="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xml:lang="en-US">Basic and Diluted Weighted Average Number Of Share Outstanding [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xlink:to="lab_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Federal Deposit Insurance Corporation coverage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCosts" xlink:label="loc_acab_OfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OfferingCosts" xml:lang="en-US">Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_OfferingCosts" xml:lang="en-US">Offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OfferingCosts" xlink:to="lab_acab_OfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OfferingCosts" xml:lang="en-US">Offering costs.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInShareholdersEquity" xlink:label="loc_acab_OfferingCostsAllocatedInShareholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OfferingCostsAllocatedInShareholdersEquity" xml:lang="en-US">Offering Costs Allocated In Shareholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_OfferingCostsAllocatedInShareholdersEquity" xml:lang="en-US">Offering costs allocated in shareholders equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OfferingCostsAllocatedInShareholdersEquity" xlink:to="lab_acab_OfferingCostsAllocatedInShareholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OfferingCostsAllocatedInShareholdersEquity" xml:lang="en-US">Offering costs allocated in shareholders equity.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInTemporaryEquity" xlink:label="loc_acab_OfferingCostsAllocatedInTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_OfferingCostsAllocatedInTemporaryEquity" xml:lang="en-US">Offering Costs Allocated In Temporary Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_OfferingCostsAllocatedInTemporaryEquity" xml:lang="en-US">Offering costs allocated in temporary equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_OfferingCostsAllocatedInTemporaryEquity" xlink:to="lab_acab_OfferingCostsAllocatedInTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_OfferingCostsAllocatedInTemporaryEquity" xml:lang="en-US">Offering costs allocated in temporary equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrants or rights exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConversionBasis" xlink:to="lab_us-gaap_CommonStockConversionBasis" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantMember" xlink:label="loc_acab_PublicWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PublicWarrantMember" xml:lang="en-US">Public Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PublicWarrantMember" xlink:to="lab_acab_PublicWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PublicWarrantMember" xml:lang="en-US">Public warrant.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementTable" xlink:label="loc_acab_PrivatePlacementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PrivatePlacementTable" xml:lang="en-US">Private Placement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PrivatePlacementTable" xlink:to="lab_acab_PrivatePlacementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PrivatePlacementTable" xml:lang="en-US">Private Placement.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantMember" xlink:label="loc_acab_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PrivatePlacementWarrantMember" xlink:to="lab_acab_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PrivatePlacementWarrantMember" xml:lang="en-US">Private placement warrant.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementLineItems" xlink:label="loc_acab_PrivatePlacementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PrivatePlacementLineItems" xml:lang="en-US">Private Placement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PrivatePlacementLineItems" xlink:to="lab_acab_PrivatePlacementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PrivatePlacementLineItems" xml:lang="en-US">Private placement.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xml:lang="en-US">Class of Warrants or Rights Warrants Issued During the Period Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xml:lang="en-US">Class of warrants or rights warrants issued during the period units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xlink:to="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xml:lang="en-US">Class of warrants or rights warrants issued during the period units.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xml:lang="en-US">Class of Warrants or Rights Warrants Issued Issue Price Per Warrant.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xml:lang="en-US">Class of warrants or rights warrants issued issue price per warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xlink:to="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xml:lang="en-US">Class of warrants or rights warrants issued issue price per warrant.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTheIssuanceOfWarrants" xlink:label="loc_acab_ProceedsFromTheIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ProceedsFromTheIssuanceOfWarrants" xml:lang="en-US">Proceeds from the Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ProceedsFromTheIssuanceOfWarrants" xml:lang="en-US">Proceeds from the issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ProceedsFromTheIssuanceOfWarrants" xlink:to="lab_acab_ProceedsFromTheIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ProceedsFromTheIssuanceOfWarrants" xml:lang="en-US">Proceeds from the issuance of warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisAxis" xlink:label="loc_acab_BasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_BasisAxis" xml:lang="en-US">Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_BasisAxis" xlink:to="lab_acab_BasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_BasisAxis" xml:lang="en-US">Basis.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisDomain" xlink:label="loc_acab_BasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_BasisDomain" xml:lang="en-US">Basis [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_BasisDomain" xlink:to="lab_acab_BasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_BasisDomain" xml:lang="en-US">Basis.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_acab_RestrictionOnTransferOfSponsorSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_RestrictionOnTransferOfSponsorSharesMember" xml:lang="en-US">Restriction on Transfer of Sponsor Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_RestrictionOnTransferOfSponsorSharesMember" xlink:to="lab_acab_RestrictionOnTransferOfSponsorSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_RestrictionOnTransferOfSponsorSharesMember" xml:lang="en-US">Restriction on transfer of sponsor shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayableMember" xml:lang="en-US">Loans Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansPayableMember" xml:lang="en-US">Loans payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PromissoryNoteMember" xlink:label="loc_acab_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PromissoryNoteMember" xml:lang="en-US">Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PromissoryNoteMember" xlink:to="lab_acab_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PromissoryNoteMember" xml:lang="en-US">Promissory note .</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansMember" xlink:label="loc_acab_WorkingCapitalLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WorkingCapitalLoansMember" xml:lang="en-US">Working Capital Loans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WorkingCapitalLoansMember" xlink:to="lab_acab_WorkingCapitalLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WorkingCapitalLoansMember" xml:lang="en-US">Working capital loans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock- based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Asset, Held-in-Trust, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Common stock held in trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrust" xlink:to="lab_us-gaap_AssetsHeldInTrust" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DebtInstrumentConversionPricePerShare" xlink:label="loc_acab_DebtInstrumentConversionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DebtInstrumentConversionPricePerShare" xml:lang="en-US">Debt Instrument Conversion Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DebtInstrumentConversionPricePerShare" xml:lang="en-US">Debt instrument conversion price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DebtInstrumentConversionPricePerShare" xlink:to="lab_acab_DebtInstrumentConversionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DebtInstrumentConversionPricePerShare" xml:lang="en-US">Debt instrument conversion price per share.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_LockInPeriodOfShares" xlink:label="loc_acab_LockInPeriodOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_LockInPeriodOfShares" xml:lang="en-US">Lock in Period of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_LockInPeriodOfShares" xml:lang="en-US">Lock in period of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_LockInPeriodOfShares" xlink:to="lab_acab_LockInPeriodOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_LockInPeriodOfShares" xml:lang="en-US">Lock in period of shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Debt instrument, unused borrowing capacity, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:to="lab_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number of Trading Days for Determining Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number of trading days for determining share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfTradingDaysForDeterminingSharePrice" xlink:to="lab_acab_NumberOfTradingDaysForDeterminingSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number of trading days for determining share price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitment" xml:lang="en-US">Other Commitment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCommitment" xml:lang="en-US">Other Commitment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLoansPayable" xlink:label="loc_us-gaap_OtherLoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLoansPayable" xml:lang="en-US">Other Loans Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLoansPayable" xml:lang="en-US">Other Commitment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLoansPayable" xlink:to="lab_us-gaap_OtherLoansPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock split ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock shares issued during the period for services shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock shares issued during the period for services value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting Period after which the Share Trading Days are Considered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting period after which the share trading days are considered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:to="lab_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting period after which the share trading days are considered.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xlink:label="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xml:lang="en-US">Working Capital Loans Convertible into Equity Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xml:lang="en-US">Working capital loans convertible into equity warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xlink:to="lab_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xml:lang="en-US">Working capital loans convertible into equity warrants.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansOutstanding" xlink:label="loc_acab_WorkingCapitalLoansOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_WorkingCapitalLoansOutstanding" xml:lang="en-US">Working Capital Loans outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_WorkingCapitalLoansOutstanding" xml:lang="en-US">Working Capital Loans outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_WorkingCapitalLoansOutstanding" xlink:to="lab_acab_WorkingCapitalLoansOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_WorkingCapitalLoansOutstanding" xml:lang="en-US">Working capital loans outstanding.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FeeSharesMember" xlink:label="loc_acab_FeeSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_FeeSharesMember" xml:lang="en-US">Fee Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_FeeSharesMember" xlink:to="lab_acab_FeeSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_FeeSharesMember" xml:lang="en-US">Fee shares.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FounderSharesMember" xlink:label="loc_acab_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_FounderSharesMember" xml:lang="en-US">Founder Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_FounderSharesMember" xlink:to="lab_acab_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_FounderSharesMember" xml:lang="en-US">Founder shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable" xml:lang="en-US">Other Commitments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xml:lang="en-US">Other Commitments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisoryServiceFee" xlink:label="loc_acab_AdvisoryServiceFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdvisoryServiceFee" xml:lang="en-US">Advisory service fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AdvisoryServiceFee" xml:lang="en-US">advisory service fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdvisoryServiceFee" xlink:to="lab_acab_AdvisoryServiceFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdvisoryServiceFee" xml:lang="en-US">Advisory service fee.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingDiscountPerShare" xlink:label="loc_acab_DeferredUnderwritingDiscountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DeferredUnderwritingDiscountPerShare" xml:lang="en-US">Deferred underwriting discount per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DeferredUnderwritingDiscountPerShare" xml:lang="en-US">Deferred underwriting discount per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DeferredUnderwritingDiscountPerShare" xlink:to="lab_acab_DeferredUnderwritingDiscountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DeferredUnderwritingDiscountPerShare" xml:lang="en-US">Deferred underwriting discount per share.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xlink:label="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xml:lang="en-US">Interse Transfer Of Shares Transferrable By Sponsor To Non Redemption Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xml:lang="en-US">Interse transfer of shares to be made</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xlink:to="lab_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xml:lang="en-US">Interse transfer of shares transferrable by sponsor to non redemption holders.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum Cash and Cash Equivalents Needed To Consummate Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xlink:to="lab_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xml:lang="en-US">Minimum cash and cash equivalents needed to consummate business combination.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfSharesNotAvailableForRedemption" xlink:label="loc_acab_NumberOfSharesNotAvailableForRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfSharesNotAvailableForRedemption" xml:lang="en-US">Number of Shares Not Available for Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfSharesNotAvailableForRedemption" xml:lang="en-US">Number of shares not available for Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfSharesNotAvailableForRedemption" xlink:to="lab_acab_NumberOfSharesNotAvailableForRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfSharesNotAvailableForRedemption" xml:lang="en-US">Number of shares not available for Redemption.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PaymentOfUnderwritingDiscount" xlink:label="loc_acab_PaymentOfUnderwritingDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PaymentOfUnderwritingDiscount" xml:lang="en-US">Payment of underwriting discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_acab_PaymentOfUnderwritingDiscount" xml:lang="en-US">Payment of underwriting discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PaymentOfUnderwritingDiscount" xlink:to="lab_acab_PaymentOfUnderwritingDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PaymentOfUnderwritingDiscount" xml:lang="en-US">Payment of underwriting discount.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfAdvisoryServiceFee" xlink:label="loc_acab_PercentageOfAdvisoryServiceFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfAdvisoryServiceFee" xml:lang="en-US">percentage of advisory service fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PercentageOfAdvisoryServiceFee" xml:lang="en-US">percentage of advisory service fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfAdvisoryServiceFee" xlink:to="lab_acab_PercentageOfAdvisoryServiceFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfAdvisoryServiceFee" xml:lang="en-US">percentage of advisory service fee.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationOne" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationOne" xml:lang="en-US">Threshold Date For Consummation Of Business Combination One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationOne" xml:lang="en-US">Threshold date for consummation of business combination one</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne" xlink:to="lab_acab_ThresholdDateForConsummationOfBusinessCombinationOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationOne" xml:lang="en-US">Threshold date for consummation of business combination one.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationThree" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationThree" xml:lang="en-US">Threshold date for consummation of business combination three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationThree" xml:lang="en-US">Threshold date for consummation of business combination three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree" xlink:to="lab_acab_ThresholdDateForConsummationOfBusinessCombinationThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationThree" xml:lang="en-US">Threshold date for consummation of business combination three.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xml:lang="en-US">Threshold date for consummation of business combination two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xml:lang="en-US">Threshold date for consummation of business combination two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xlink:to="lab_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xml:lang="en-US">Threshold date for consummation of business combination two.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingDiscountPerShare" xlink:label="loc_acab_UnderwritingDiscountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_UnderwritingDiscountPerShare" xml:lang="en-US">Underwriting discount per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_UnderwritingDiscountPerShare" xml:lang="en-US">Underwriting discount per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_UnderwritingDiscountPerShare" xlink:to="lab_acab_UnderwritingDiscountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_UnderwritingDiscountPerShare" xml:lang="en-US">Underwriting discount per share.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproBioCoMember" xlink:label="loc_acab_AbproBioCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AbproBioCoMember" xml:lang="en-US">Abpro Bio Co [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AbproBioCoMember" xlink:to="lab_acab_AbproBioCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AbproBioCoMember" xml:lang="en-US">Abpro Bio Co</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproMember" xlink:label="loc_acab_AbproMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AbproMember" xml:lang="en-US">Abpro [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AbproMember" xlink:to="lab_acab_AbproMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AbproMember" xml:lang="en-US">Abpro</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedemptionAgreementMember" xlink:label="loc_acab_NonRedemptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NonRedemptionAgreementMember" xml:lang="en-US">Non Redemption Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NonRedemptionAgreementMember" xml:lang="en-US">Non Redemption Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NonRedemptionAgreementMember" xlink:to="lab_acab_NonRedemptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NonRedemptionAgreementMember" xml:lang="en-US">Non redemption agreement.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAxis" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsAxis" xml:lang="en-US">Adjusted Exercise Price Of Warrants [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsAxis" xlink:to="lab_acab_AdjustedExercisePriceOfWarrantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsAxis" xml:lang="en-US">Adjusted exercise price of warrants .</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsDomain" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsDomain" xml:lang="en-US">Adjusted Exercise Price Of Warrants [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsDomain" xlink:to="lab_acab_AdjustedExercisePriceOfWarrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsDomain" xml:lang="en-US">Adjusted exercise price of warrants.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOneMember" xlink:label="loc_acab_AdjustedExercisePriceOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustedExercisePriceOneMember" xml:lang="en-US">Adjusted Exercise Price One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustedExercisePriceOneMember" xlink:to="lab_acab_AdjustedExercisePriceOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustedExercisePriceOneMember" xml:lang="en-US">Adjusted exercise price one member</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceTwoMember" xlink:label="loc_acab_AdjustedExercisePriceTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustedExercisePriceTwoMember" xml:lang="en-US">Adjusted Exercise Price Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustedExercisePriceTwoMember" xlink:to="lab_acab_AdjustedExercisePriceTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustedExercisePriceTwoMember" xml:lang="en-US">Adjusted exercise price two member.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xml:lang="en-US">Adjusted exercise price of warrants as a percentage of newly issued price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xml:lang="en-US">Adjusted exercise price of warrants as a percentage of newly issued price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xlink:to="lab_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xml:lang="en-US">Adjusted exercise price of warrants as a percentage of newly issued price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsLockInPeriod" xlink:label="loc_acab_ClassOfWarrantsOrRightsLockInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsLockInPeriod" xml:lang="en-US">Class of warrants or rights lock in period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ClassOfWarrantsOrRightsLockInPeriod" xml:lang="en-US">Class of warrants or rights lock in period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsLockInPeriod" xlink:to="lab_acab_ClassOfWarrantsOrRightsLockInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsLockInPeriod" xml:lang="en-US">Class of warrants or rights lock in period.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xml:lang="en-US">Class of warrants or rights redemption price per unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xml:lang="en-US">Class of warrants or rights redemption price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xlink:to="lab_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xml:lang="en-US">Class of warrants or rights redemption price per unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xml:lang="en-US">Minimum notice period to be given to the holders of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xml:lang="en-US">Minimum notice period to be given to the holders of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:to="lab_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xml:lang="en-US">Minimum notice period to be given to the holders of warrants.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xlink:label="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xml:lang="en-US">Number Of Days After Consummation Of Business Combination With in Which The Securities Shall Be Registered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xml:lang="en-US">Number of days after consummation of business combination within which the securities shall be registered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xlink:to="lab_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xml:lang="en-US">Number of days after consummation of business combination with in which these curities shall be registered.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xlink:label="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xml:lang="en-US">Number Of Days After Which Business Combination With in Which Securities Registration Shall Be Effective</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xml:lang="en-US">Number of days after which business combination within which securities registration shall be effective</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xlink:to="lab_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xml:lang="en-US">Number of days after which business combination with in which securities registration shall be effective.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="lab_acab_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfCommonStockIssuedAndOutstanding" xlink:label="loc_acab_PercentageOfCommonStockIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfCommonStockIssuedAndOutstanding" xml:lang="en-US">Percentage of common stock issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PercentageOfCommonStockIssuedAndOutstanding" xml:lang="en-US">Percentage of common stock issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfCommonStockIssuedAndOutstanding" xlink:to="lab_acab_PercentageOfCommonStockIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfCommonStockIssuedAndOutstanding" xml:lang="en-US">Percentage of common stock issued and outstanding.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisable" xml:lang="en-US">Period after which the warrants are exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisable" xml:lang="en-US">Period after which the warrants are exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable" xlink:to="lab_acab_PeriodAfterWhichTheWarrantsAreExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisable" xml:lang="en-US">Period after which the warrants are exercisable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareRedemptionTriggerPrice" xlink:label="loc_acab_PerShareRedemptionTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PerShareRedemptionTriggerPrice" xml:lang="en-US">per share redemption trigger price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PerShareRedemptionTriggerPrice" xml:lang="en-US">per share redemption trigger price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PerShareRedemptionTriggerPrice" xlink:to="lab_acab_PerShareRedemptionTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PerShareRedemptionTriggerPrice" xml:lang="en-US">Per share redemption trigger price.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xlink:label="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xml:lang="en-US">Proceeds from equity used for funding business combination as a percentage of the total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xml:lang="en-US">Proceeds from equity used for funding business combination as a percentage of the total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xlink:to="lab_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xml:lang="en-US">Proceeds from equity used for funding business combination as a percentage of the total.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SharesAreSubjectToForfeiture" xlink:label="loc_acab_SharesAreSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_SharesAreSubjectToForfeiture" xml:lang="en-US">shares are subject to forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_SharesAreSubjectToForfeiture" xml:lang="en-US">shares are subject to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_SharesAreSubjectToForfeiture" xlink:to="lab_acab_SharesAreSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_SharesAreSubjectToForfeiture" xml:lang="en-US">Shares are subject to forfeiture.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_VolumeWeightedAveragePriceOfShares" xlink:label="loc_acab_VolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_VolumeWeightedAveragePriceOfShares" xml:lang="en-US">Volume weighted average price of shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_VolumeWeightedAveragePriceOfShares" xml:lang="en-US">Volume weighted average price of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_VolumeWeightedAveragePriceOfShares" xlink:to="lab_acab_VolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_VolumeWeightedAveragePriceOfShares" xml:lang="en-US">Volume weighted average price of shares.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantsMember" xlink:label="loc_acab_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PublicWarrantsMember" xlink:to="lab_acab_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PublicWarrantsMember" xml:lang="en-US">Public warrants.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xml:lang="en-US">Period After Which The Warrants Are Exercisable [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xlink:to="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xml:lang="en-US">Period after which the warrants are exercisable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xml:lang="en-US">Period After Which The Warrants Are Exercisable [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xlink:to="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xml:lang="en-US">Period after which the warrants are exercisable.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfBusinessCombinationMember" xlink:label="loc_acab_FromTheCompletionOfBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_FromTheCompletionOfBusinessCombinationMember" xml:lang="en-US">From The Completion Of Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_FromTheCompletionOfBusinessCombinationMember" xml:lang="en-US">From The Completion Of Business Combination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_FromTheCompletionOfBusinessCombinationMember" xlink:to="lab_acab_FromTheCompletionOfBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_FromTheCompletionOfBusinessCombinationMember" xml:lang="en-US">From the completion of business combination.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfInitialPublicOfferMember" xlink:label="loc_acab_FromTheCompletionOfInitialPublicOfferMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_FromTheCompletionOfInitialPublicOfferMember" xml:lang="en-US">From The Completion Of Initial Public Offer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_FromTheCompletionOfInitialPublicOfferMember" xlink:to="lab_acab_FromTheCompletionOfInitialPublicOfferMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_FromTheCompletionOfInitialPublicOfferMember" xml:lang="en-US">From the completion of initial public offer .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="loc_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up And Organization Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xml:lang="en-US">Startup/Organization Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:to="lab_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xml:lang="en-US">Deferred tax assets capitalized start up and organization costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory federal income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xlink:label="loc_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Expense Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xml:lang="en-US">Business combination expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xlink:to="lab_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xml:lang="en-US">Effective income tax rate reconciliation non deductible expense business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xml:lang="en-US">Meals&#160;&amp; entertainment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xml:lang="en-US">Fines and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FederalAndStateAuthorityMember" xlink:label="loc_acab_FederalAndStateAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_FederalAndStateAuthorityMember" xml:lang="en-US">Federal And State Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_FederalAndStateAuthorityMember" xml:lang="en-US">Federal And State Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_FederalAndStateAuthorityMember" xlink:to="lab_acab_FederalAndStateAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_FederalAndStateAuthorityMember" xml:lang="en-US">Federal and state authority.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AssetsHeldInTrustMember" xlink:label="loc_acab_AssetsHeldInTrustMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AssetsHeldInTrustMember" xml:lang="en-US">Assets Held In Trust [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AssetsHeldInTrustMember" xml:lang="en-US">Asset Held In Trust [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AssetsHeldInTrustMember" xlink:to="lab_acab_AssetsHeldInTrustMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AssetsHeldInTrustMember" xml:lang="en-US">Assets held in trust member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeAxis" xlink:label="loc_acab_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InvesteeAxis" xml:lang="en-US">Investee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InvesteeAxis" xlink:to="lab_acab_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InvesteeAxis" xml:lang="en-US">Investee.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeDomain" xlink:label="loc_acab_InvesteeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_InvesteeDomain" xml:lang="en-US">Investee [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_InvesteeDomain" xlink:to="lab_acab_InvesteeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_InvesteeDomain" xml:lang="en-US">Investee.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisorMember" xlink:label="loc_acab_AdvisorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_AdvisorMember" xml:lang="en-US">Advisor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_AdvisorMember" xml:lang="en-US">Advisor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_AdvisorMember" xlink:to="lab_acab_AdvisorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_AdvisorMember" xml:lang="en-US">Advisor.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterMember" xlink:label="loc_acab_UnderwriterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_UnderwriterMember" xml:lang="en-US">Underwriter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_UnderwriterMember" xml:lang="en-US">Underwriter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_UnderwriterMember" xlink:to="lab_acab_UnderwriterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_UnderwriterMember" xml:lang="en-US">Underwriter.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Number of shares issuable on acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xlink:label="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xml:lang="en-US">Percentage Of Gross Amount Payable to Sponsor Raised from Investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xml:lang="en-US">Percentage of gross amount payable to sponsor raised from investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xlink:to="lab_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xml:lang="en-US">Percentage of gross amount payable to sponsor raised from investors.</label>
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterFeeWaivedOff" xlink:label="loc_acab_UnderwriterFeeWaivedOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_acab_UnderwriterFeeWaivedOff" xml:lang="en-US">Underwriter Fee Waived Off</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_acab_UnderwriterFeeWaivedOff" xml:lang="en-US">Underwriter fee waived off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_acab_UnderwriterFeeWaivedOff" xlink:to="lab_acab_UnderwriterFeeWaivedOff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_acab_UnderwriterFeeWaivedOff" xml:lang="en-US">Underwriter fee waived off.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>acab-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-April-2024 [10:25:30] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#CoverPage" roleURI="http://www.atlanticcoastalacquisition.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficit" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#OrganizationAndPlanOfBusinessOperations" roleURI="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#InitialPublicOffering" roleURI="http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#PrivatePlacement" roleURI="http://www.atlanticcoastalacquisition.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#RelatedPartyTransactions" roleURI="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#Commitments" roleURI="http://www.atlanticcoastalacquisition.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#StockholdersDeficit" roleURI="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxes" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#FairValueMeasurements" roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SubsequentEvents" roleURI="http://www.atlanticcoastalacquisition.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesTables" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#FairValueMeasurementsTables" roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#InitialPublicOfferingAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#PrivatePlacementAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#CommitmentsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#StockholdersDeficitAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails" />
<roleRef xlink:type="simple" xlink:href="acab-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1426117" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1426119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1426117" xlink:to="loc_dei_DocumentInformationTable_1426119" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426124" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426124" xlink:to="loc_us-gaap_ClassOfStockDomain_1426126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426129" xlink:to="loc_us-gaap_EquityComponentDomain_1426130" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1702003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1702003" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1702004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1702003" xlink:to="loc_dei_AddressTypeDomain_1702004" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1702005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1702004" xlink:to="loc_dei_BusinessContactMember_1702005" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1426133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1426119" xlink:to="loc_dei_DocumentInformationLineItems_1426133" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1426135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_DocumentType_1426135" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1426137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_AmendmentFlag_1426137" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1426145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityRegistrantName_1426145" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1426146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityCentralIndexKey_1426146" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1426148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityFilerCategory_1426148" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1426159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1426159" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1426160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressAddressLine1_1426160" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1426161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressCityOrTown_1426161" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1426162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressStateOrProvince_1426162" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1426163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityAddressPostalZipCode_1426163" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1426166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityTaxIdentificationNumber_1426166" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1426167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_CityAreaCode_1426167" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1426168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_LocalPhoneNumber_1426168" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1426169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntitySmallBusiness_1426169" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1426171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityEmergingGrowthCompany_1426171" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1426173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityExTransitionPeriod_1426173" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1702002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_EntityPrimarySicNumber_1702002" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1702006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1426133" xlink:to="loc_dei_ContactPersonnelName_1702006" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1426221" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1426221" xlink:to="loc_us-gaap_StatementTable_1426222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426222" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426223" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426223" xlink:to="loc_us-gaap_ClassOfStockDomain_1426224" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426224" xlink:to="loc_us-gaap_CommonClassAMember_1426225" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426224" xlink:to="loc_us-gaap_CommonClassBMember_1426226" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426222" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701880" xlink:to="loc_us-gaap_RelatedPartyDomain_1701881" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1701882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701881" xlink:to="loc_us-gaap_RelatedPartyMember_1701882" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426222" xlink:to="loc_us-gaap_StatementLineItems_1426230" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1426231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426230" xlink:to="loc_us-gaap_AssetsAbstract_1426231" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1426233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1426233" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426235" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1426237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1426237" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_1701888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_1701888" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1426244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1426233" xlink:to="loc_us-gaap_AssetsCurrent_1426244" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1426255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1426255" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1426259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1426231" xlink:to="loc_us-gaap_Assets_1426259" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426230" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1426270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1426270" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ExciseTaxPayableCurrent" xlink:label="loc_acab_ExciseTaxPayableCurrent_1701815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_acab_ExciseTaxPayableCurrent_1701815" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AccruedOfferingCosts" xlink:label="loc_acab_AccruedOfferingCosts_1426278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_acab_AccruedOfferingCosts_1426278" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1568256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_TaxesPayableCurrent_1568256" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701877" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1701878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_NotesPayableCurrent_1701878" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1701879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1701879" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1426280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1426264" xlink:to="loc_us-gaap_LiabilitiesCurrent_1426280" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426282" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1426285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_Liabilities_1426285" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1426297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1426297" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426299" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1426301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1426301" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_1426303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_PreferredStockValue_1426303" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1426305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_CommonStockValue_1426305" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1426307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1426307" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1426310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1426310" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1426313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1426301" xlink:to="loc_us-gaap_StockholdersEquity_1426313" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1426316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1426260" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1426316" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1426348" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1426348" xlink:to="loc_us-gaap_StatementTable_1426353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426355" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426355" xlink:to="loc_us-gaap_ClassOfStockDomain_1426356" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426356" xlink:to="loc_us-gaap_CommonClassAMember_1426357" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426356" xlink:to="loc_us-gaap_CommonClassBMember_1426358" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426361" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426362" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426365" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426365" xlink:to="loc_us-gaap_EquityComponentDomain_1426366" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426353" xlink:to="loc_us-gaap_StatementLineItems_1426371" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701887" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1426373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1426373" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1426376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1426376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426377" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426398" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1426399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1426399" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1426400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1426400" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1426401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1426401" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426402" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1426403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1426403" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1426405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesIssued_1426405" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426371" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426406" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1426488" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1426488" xlink:to="loc_us-gaap_StatementTable_1426489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426489" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426490" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426490" xlink:to="loc_us-gaap_ClassOfStockDomain_1426491" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_us-gaap_CommonClassAMember_1426493" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_us-gaap_CommonClassBMember_1426495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassAAndClassBCommonStockMember" xlink:label="loc_acab_ClassAAndClassBCommonStockMember_1701898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426491" xlink:to="loc_acab_ClassAAndClassBCommonStockMember_1701898" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockAxis" xlink:label="loc_acab_ClassificationOfCommonStockAxis_1701894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426489" xlink:to="loc_acab_ClassificationOfCommonStockAxis_1701894" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701894" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RedeemableCommonStockMember" xlink:label="loc_acab_RedeemableCommonStockMember_1701896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701895" xlink:to="loc_acab_RedeemableCommonStockMember_1701896" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedeemableCommonStockMember" xlink:label="loc_acab_NonRedeemableCommonStockMember_1701897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701895" xlink:to="loc_acab_NonRedeemableCommonStockMember_1701897" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426489" xlink:to="loc_us-gaap_StatementLineItems_1426496" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OperationAndFormationCosts" xlink:label="loc_acab_OperationAndFormationCosts_1426497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_acab_OperationAndFormationCosts_1426497" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1426498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_OperatingIncomeLoss_1426498" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1426503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_InterestIncomeOther_1426503" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvestmentIncomeExpenseNonoperating" xlink:label="loc_acab_InvestmentIncomeExpenseNonoperating_1426505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_acab_InvestmentIncomeExpenseNonoperating_1426505" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PenaltiesAndInterestOnTaxes" xlink:label="loc_acab_PenaltiesAndInterestOnTaxes_1701840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_acab_PenaltiesAndInterestOnTaxes_1701840" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_1426506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_1426506" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1426510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1426502" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1426510" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1568240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1568240" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1568241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1568241" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_NetIncomeLoss_1426511" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568468" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568469" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1568470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_EarningsPerShareBasic_1568470" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1568471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426496" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1568471" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1426538" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1426538" xlink:to="loc_us-gaap_StatementTable_1426539" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426539" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426540" xlink:to="loc_us-gaap_EquityComponentDomain_1426541" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1429592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_CommonStockMember_1429592" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1426545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1426545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1426546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426541" xlink:to="loc_us-gaap_RetainedEarningsMember_1426546" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1429578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426539" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1429578" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1429580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1429578" xlink:to="loc_us-gaap_ClassOfStockDomain_1429580" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1429588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1429580" xlink:to="loc_us-gaap_CommonClassAMember_1429588" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1429589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1429580" xlink:to="loc_us-gaap_CommonClassBMember_1429589" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426539" xlink:to="loc_us-gaap_StatementLineItems_1426548" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1426549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_SharesOutstanding_1426549" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1426551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockholdersEquity_1426551" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1426552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1426552" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426554" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron_1426556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron_1426556" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_1426557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_1426557" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1426558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1426558" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426559" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustment" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustment_1701792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_StockholderNonRedemptionAgreementAdjustment_1701792" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_StockholderNonRedemptionAgreementAdjustmentReduction" xlink:label="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction_1701793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_StockholderNonRedemptionAgreementAdjustmentReduction_1701793" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustmentsToAdditionalPaidInCapitalExciseTax" xlink:label="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax_1701796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax_1701796" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1701795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1701795" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1701794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1701794" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_NetIncomeLoss_1426560" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1426561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_SharesOutstanding_1426561" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1426564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426548" xlink:to="loc_us-gaap_StockholdersEquity_1426564" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1426567" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1426568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1426567" xlink:to="loc_us-gaap_StatementTable_1426568" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426568" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426570" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1426573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1426568" xlink:to="loc_us-gaap_StatementLineItems_1426573" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1426573" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426576" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1426583" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1426583" xlink:to="loc_us-gaap_StatementTable_1701883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701883" xlink:to="loc_us-gaap_StatementLineItems_1701884" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_NetIncomeLoss_1426586" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount" xlink:label="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount_1428003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount_1428003" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1568234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_us-gaap_ShareBasedCompensation_1568234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1426587" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1426607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1426607" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1426608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1426608" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1568230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1426602" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1568230" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1426609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1426585" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1426609" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426612" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1701797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1701797" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTrustAccountInConnectionWithRedemption" xlink:label="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption_1701799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_acab_ProceedsFromTrustAccountInConnectionWithRedemption_1701799" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1426613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1426610" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1426613" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1426620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1426620" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426622" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1426625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1426625" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1701889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1701889" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_1426626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_1426626" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_1701890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_1701890" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1426628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1426628" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1701800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1701800" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1426629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1426618" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1426629" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1426630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1426630" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426631" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1426632" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1701892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1701891" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1701892" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701884" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts_1701893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts_1701893" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption" xlink:label="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption_1426639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption_1426639" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities" xlink:label="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities_1426641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1426634" xlink:to="loc_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities_1426641" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1426670" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1426671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1426670" xlink:to="loc_us-gaap_NatureOfOperations_1426671" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1426710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426708" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1426710" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426120" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DisclosureOfInitialPublicOffering" xlink:label="loc_acab_DisclosureOfInitialPublicOffering_1426125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426120" xlink:to="loc_acab_DisclosureOfInitialPublicOffering_1426125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426234" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DisclosureOfPrivatePlacement" xlink:label="loc_acab_DisclosureOfPrivatePlacement_1426238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426234" xlink:to="loc_acab_DisclosureOfPrivatePlacement_1426238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1426351" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1426352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1426351" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1426352" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/Commitments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1426646" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1426647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1426646" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1426647" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426204" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1426205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426204" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1426205" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1701909" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1701910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701909" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1701910" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1426121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1426123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1426121" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1426123" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1426109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1426110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1426109" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1426110" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426719" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1426720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1426720" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_acab_EmergingGrowthCompanyPolicyTextBlock_1426721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_acab_EmergingGrowthCompanyPolicyTextBlock_1426721" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1426723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_UseOfEstimates_1426723" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1701958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1701958" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1426724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1426724" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AssetsHeldInTrustAccountPolicyTextBlock" xlink:label="loc_acab_AssetsHeldInTrustAccountPolicyTextBlock_1426725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_acab_AssetsHeldInTrustAccountPolicyTextBlock_1426725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityPolicyTextBlock" xlink:label="loc_acab_TemporaryEquityPolicyTextBlock_1426726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_acab_TemporaryEquityPolicyTextBlock_1426726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_1438283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_1438283" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1426728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1426728" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1426729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1426729" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1426730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1426730" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1426732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1426732" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1426735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1426735" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WarrantsDisclosurePolicyTextBlock" xlink:label="loc_acab_WarrantsDisclosurePolicyTextBlock_1571431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_acab_WarrantsDisclosurePolicyTextBlock_1571431" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1438284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1438284" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1426736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426719" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1426736" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426764" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_1426769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426764" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_1426769" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_1426775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426764" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_1426775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1701912" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1701913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701912" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1701913" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1701914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701912" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1701914" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1701915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701912" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1701915" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1426170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1426172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1426170" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1426172" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1426686" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1426686" xlink:to="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426705" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426705" xlink:to="loc_us-gaap_ClassOfStockDomain_1426706" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426706" xlink:to="loc_us-gaap_CommonClassAMember_1426707" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1701781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426706" xlink:to="loc_us-gaap_CommonClassBMember_1701781" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426711" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1426713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_IPOMember_1426713" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426714" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1426717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426712" xlink:to="loc_us-gaap_PrivatePlacementMember_1426717" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426727" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426731" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1426733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_srt_RangeAxis_1426733" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1426734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1426733" xlink:to="loc_srt_RangeMember_1426734" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1426737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1426734" xlink:to="loc_srt_MinimumMember_1426737" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1698256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1698255" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1698256" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PostBusinessCombinationMember" xlink:label="loc_acab_PostBusinessCombinationMember_1701777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1698256" xlink:to="loc_acab_PostBusinessCombinationMember_1701777" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701784" xlink:to="loc_us-gaap_RelatedPartyDomain_1701785" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1701786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701785" xlink:to="loc_acab_SponsorMember_1701786" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701822" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701822" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701823" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_1701824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1701823" xlink:to="loc_us-gaap_UnsecuredDebtMember_1701824" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1701825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1701825" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1701826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1701825" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1701826" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetHeldInTrustMember" xlink:label="loc_us-gaap_AssetHeldInTrustMember_1701827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1701826" xlink:to="loc_us-gaap_AssetHeldInTrustMember_1701827" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701828" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701828" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701829" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems" xlink:label="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable_1426691" xlink:to="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426745" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426750" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceedsFromInitialPublicOffer" xlink:label="loc_acab_GrossProceedsFromInitialPublicOffer_1426754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_GrossProceedsFromInitialPublicOffer_1426754" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits_1426768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits_1426768" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit_1426774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ClassOfWarrantsOrRightsIssuePricePerUnit_1426774" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1426777" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TransactionCostsOfIssuance" xlink:label="loc_acab_TransactionCostsOfIssuance_1426778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TransactionCostsOfIssuance_1426778" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingFeesNetOfReimbursementByUnderwriters" xlink:label="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters_1426779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_UnderwritingFeesNetOfReimbursementByUnderwriters_1426779" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ReimbursementByUnderwriters" xlink:label="loc_acab_ReimbursementByUnderwriters_1426782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ReimbursementByUnderwriters_1426782" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingCommissionNonCurrent" xlink:label="loc_acab_DeferredUnderwritingCommissionNonCurrent_1426784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_DeferredUnderwritingCommissionNonCurrent_1426784" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_1426786" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerSharePaymentMadeToAcquireRestrictedInvestments" xlink:label="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments_1426788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerSharePaymentMadeToAcquireRestrictedInvestments_1426788" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TermOfRestrictedInvestments" xlink:label="loc_acab_TermOfRestrictedInvestments_1426789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TermOfRestrictedInvestments_1426789" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected" xlink:label="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected_1426793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected_1426793" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1426797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1426797" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_1426799" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1426809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1426809" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction_1426813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction_1426813" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated_1426818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated_1426818" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering" xlink:label="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering_1426824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering_1426824" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_1426828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_1426828" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed" xlink:label="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed_1426834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed_1426834" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountAvailableForDistribution" xlink:label="loc_acab_PerShareAmountAvailableForDistribution_1426838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareAmountAvailableForDistribution_1426838" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution" xlink:label="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution_1426848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution_1426848" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OtherOfferingCosts" xlink:label="loc_acab_OtherOfferingCosts_1427335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_OtherOfferingCosts_1427335" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1427365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_Cash_1427365" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoan" xlink:label="loc_acab_WorkingCapitalLoan_1438280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_WorkingCapitalLoan_1438280" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack_1697936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfFederalExciseTaxOnStockBuyBack_1697936" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack" xlink:label="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack_1697944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack_1697944" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityStockRedeemedDuringThePeriodShares" xlink:label="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares_1701779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_TemporaryEquityStockRedeemedDuringThePeriodShares_1701779" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ConversionOfPermanentEquityIntoTemporaryEquityShares" xlink:label="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares_1701780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares_1701780" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_1701782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_1701782" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1701783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1701783" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1701787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1701787" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockSharesRedeemable" xlink:label="loc_acab_CommonStockSharesRedeemable_1701788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_CommonStockSharesRedeemable_1701788" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockValueRedeemable" xlink:label="loc_acab_CommonStockValueRedeemable_1701789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_CommonStockValueRedeemable_1701789" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1701790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_1701790" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfSharesRedeemable" xlink:label="loc_acab_PercentageOfSharesRedeemable_1701791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PercentageOfSharesRedeemable_1701791" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1701831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1701831" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701833" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AmountToBeDepositedInTrustAccount" xlink:label="loc_acab_AmountToBeDepositedInTrustAccount_1701899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_AmountToBeDepositedInTrustAccount_1701899" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount" xlink:label="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount_1701900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount_1701900" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_1701980" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1701981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharePrice_1701981" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses" xlink:label="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses_1701903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses_1701903" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems_1426743" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_1701982" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426783" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1426790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426783" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1426790" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1426791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1426790" xlink:to="loc_us-gaap_TemporaryEquityLineItems_1426791" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_GrossProceeds" xlink:label="loc_acab_GrossProceeds_1428166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_GrossProceeds_1428166" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsAllocatedToPublicWarrants" xlink:label="loc_acab_ProceedsAllocatedToPublicWarrants_1426794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_ProceedsAllocatedToPublicWarrants_1426794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_CommonStockIssuanceCosts" xlink:label="loc_acab_CommonStockIssuanceCosts_1428122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_CommonStockIssuanceCosts_1428122" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_TemporaryEquityRedemptionValue" xlink:label="loc_acab_TemporaryEquityRedemptionValue_1701798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_acab_TemporaryEquityRedemptionValue_1701798" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1701957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_1701957" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_1426796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1426791" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1426798" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426802" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426804" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426804" xlink:to="loc_us-gaap_ClassOfStockDomain_1426805" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426805" xlink:to="loc_us-gaap_CommonClassAMember_1426806" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426805" xlink:to="loc_us-gaap_CommonClassBMember_1426807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockAxis" xlink:label="loc_acab_ClassificationOfCommonStockAxis_1701953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xlink:to="loc_acab_ClassificationOfCommonStockAxis_1701953" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassificationOfCommonStockDomain" xlink:label="loc_acab_ClassificationOfCommonStockDomain_1701954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockAxis_1701953" xlink:to="loc_acab_ClassificationOfCommonStockDomain_1701954" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RedeemableCommonStockMember" xlink:label="loc_acab_RedeemableCommonStockMember_1701955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701954" xlink:to="loc_acab_RedeemableCommonStockMember_1701955" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedeemableCommonStockMember" xlink:label="loc_acab_NonRedeemableCommonStockMember_1701956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_ClassificationOfCommonStockDomain_1701954" xlink:to="loc_acab_NonRedeemableCommonStockMember_1701956" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1426803" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedLossPerShareAbstract" xlink:label="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1426808" xlink:to="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1426812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1426812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1426814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1426812" xlink:to="loc_us-gaap_NetIncomeLoss_1426814" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract" xlink:label="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedLossPerShareAbstract_1426810" xlink:to="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1568482" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1568483" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1568486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_EarningsPerShareBasic_1568486" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1568488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract_1426815" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1568488" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1426841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1426841" xlink:to="loc_us-gaap_StatementTable_1701841" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701846" xlink:to="loc_us-gaap_RelatedPartyDomain_1701847" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701843" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701843" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701844" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1701849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_CreditFacilityAxis_1701849" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1701849" xlink:to="loc_us-gaap_CreditFacilityDomain_1701850" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701841" xlink:to="loc_us-gaap_StatementLineItems_1701842" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1426850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_1426850" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1426852" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_1426853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_CashFDICInsuredAmount_1426853" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1426861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1426861" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCosts" xlink:label="loc_acab_OfferingCosts_1438285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCosts_1438285" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInTemporaryEquity" xlink:label="loc_acab_OfferingCostsAllocatedInTemporaryEquity_1438294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCostsAllocatedInTemporaryEquity_1438294" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_OfferingCostsAllocatedInShareholdersEquity" xlink:label="loc_acab_OfferingCostsAllocatedInShareholdersEquity_1438295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_acab_OfferingCostsAllocatedInShareholdersEquity_1438295" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_1438300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701842" xlink:to="loc_us-gaap_DeferredOfferingCosts_1438300" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426141" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1426144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426141" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1426144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426192" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1426194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" xlink:to="loc_us-gaap_IPOMember_1426194" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426193" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426195" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426196" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantMember" xlink:label="loc_acab_PublicWarrantMember_1426199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426197" xlink:to="loc_acab_PublicWarrantMember_1426199" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426200" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426200" xlink:to="loc_us-gaap_ClassOfStockDomain_1426201" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426201" xlink:to="loc_us-gaap_CommonClassAMember_1426202" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1426147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426144" xlink:to="loc_us-gaap_ClassOfStockLineItems_1426147" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1426149" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426152" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1426153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_CommonStockConversionBasis_1426153" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426156" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426158" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426243" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementTable" xlink:label="loc_acab_PrivatePlacementTable_1426247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426243" xlink:to="loc_acab_PrivatePlacementTable_1426247" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426302" xlink:to="loc_us-gaap_RelatedPartyDomain_1426304" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1426312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1426304" xlink:to="loc_acab_SponsorMember_1426312" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426314" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426314" xlink:to="loc_us-gaap_ClassOfStockDomain_1426315" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426315" xlink:to="loc_us-gaap_CommonClassAMember_1426317" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426318" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantMember" xlink:label="loc_acab_PrivatePlacementWarrantMember_1426320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426319" xlink:to="loc_acab_PrivatePlacementWarrantMember_1426320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementLineItems" xlink:label="loc_acab_PrivatePlacementLineItems_1426252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementTable_1426247" xlink:to="loc_acab_PrivatePlacementLineItems_1426252" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits" xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits_1426256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits_1426256" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant." xlink:label="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant._1426258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant._1426258" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromTheIssuanceOfWarrants" xlink:label="loc_acab_ProceedsFromTheIssuanceOfWarrants_1426262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_acab_ProceedsFromTheIssuanceOfWarrants_1426262" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1426290" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PrivatePlacementLineItems_1426252" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1426295" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1426372" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1426372" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426855" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426855" xlink:to="loc_us-gaap_EquityComponentDomain_1426857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FounderSharesMember" xlink:label="loc_acab_FounderSharesMember_1426859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426857" xlink:to="loc_acab_FounderSharesMember_1426859" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FeeSharesMember" xlink:label="loc_acab_FeeSharesMember_1426901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426857" xlink:to="loc_acab_FeeSharesMember_1426901" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426864" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426864" xlink:to="loc_us-gaap_ClassOfStockDomain_1426865" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426865" xlink:to="loc_us-gaap_CommonClassBMember_1426866" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426865" xlink:to="loc_us-gaap_CommonClassAMember_1426897" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1426912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1426867" xlink:to="loc_us-gaap_RelatedPartyDomain_1426912" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1426913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1426912" xlink:to="loc_acab_SponsorMember_1426913" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1701816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1426912" xlink:to="loc_us-gaap_RelatedPartyMember_1701816" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1426882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1426882" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1426883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1426882" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1426883" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansMember" xlink:label="loc_acab_WorkingCapitalLoansMember_1426884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1426883" xlink:to="loc_acab_WorkingCapitalLoansMember_1426884" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PromissoryNoteMember" xlink:label="loc_acab_PromissoryNoteMember_1426886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1426883" xlink:to="loc_acab_PromissoryNoteMember_1426886" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426891" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426892" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426893" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisAxis" xlink:label="loc_acab_BasisAxis_1426906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_acab_BasisAxis_1426906" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_BasisDomain" xlink:label="loc_acab_BasisDomain_1426907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasisAxis_1426906" xlink:to="loc_acab_BasisDomain_1426907" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_acab_RestrictionOnTransferOfSponsorSharesMember_1426908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_BasisDomain_1426907" xlink:to="loc_acab_RestrictionOnTransferOfSponsorSharesMember_1426908" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1438307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_srt_TitleOfIndividualAxis_1438307" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1438307" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1438309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1438308" xlink:to="loc_srt_DirectorMember_1438309" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701983" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701983" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701984" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaap_LoansPayableMember_1701985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1701984" xlink:to="loc_us-gaap_LoansPayableMember_1701985" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1426374" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1426744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1426744" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1426746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1426746" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426747" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426748" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426749" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1426760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_SharePrice_1426760" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_LockInPeriodOfShares" xlink:label="loc_acab_LockInPeriodOfShares_1426765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_LockInPeriodOfShares_1426765" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingSharePrice_1426781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_NumberOfTradingDaysForDeterminingSharePrice_1426781" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426785" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_1426787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_1426787" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426821" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1426822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1426822" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1426823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1426823" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_1701962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_AssetsHeldInTrust_1701962" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1701963" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_1701964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_NotesPayable_1701964" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1426825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_NotesPayableCurrent_1426825" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLoansPayable" xlink:label="loc_us-gaap_OtherLoansPayable_1426826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_OtherLoansPayable_1426826" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansConvertibleIntoEquityWarrants" xlink:label="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants_1426831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants_1426831" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DebtInstrumentConversionPricePerShare" xlink:label="loc_acab_DebtInstrumentConversionPricePerShare_1426835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_DebtInstrumentConversionPricePerShare_1426835" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_WorkingCapitalLoansOutstanding" xlink:label="loc_acab_WorkingCapitalLoansOutstanding_1426837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_acab_WorkingCapitalLoansOutstanding_1426837" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1438301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1438301" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_1701988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1426375" xlink:to="loc_us-gaap_OtherCommitment_1701988" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1426655" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1426660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1426655" xlink:to="loc_us-gaap_OtherCommitmentsTable_1426660" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1701802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1701802" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701802" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NonRedemptionAgreementMember" xlink:label="loc_acab_NonRedemptionAgreementMember_1701804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701803" xlink:to="loc_acab_NonRedemptionAgreementMember_1701804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701805" xlink:to="loc_us-gaap_ClassOfStockDomain_1701806" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1701807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1701806" xlink:to="loc_us-gaap_CommonClassAMember_1701807" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701969" xlink:to="loc_us-gaap_RelatedPartyDomain_1701970" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SponsorMember" xlink:label="loc_acab_SponsorMember_1701971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_SponsorMember_1701971" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproBioCoMember" xlink:label="loc_acab_AbproBioCoMember_1701973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_AbproBioCoMember_1701973" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AbproMember" xlink:label="loc_acab_AbproMember_1701974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701970" xlink:to="loc_acab_AbproMember_1701974" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1426662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1426660" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_1426662" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwritingDiscountPerShare" xlink:label="loc_acab_UnderwritingDiscountPerShare_1426673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_UnderwritingDiscountPerShare_1426673" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PaymentOfUnderwritingDiscount" xlink:label="loc_acab_PaymentOfUnderwritingDiscount_1426676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_PaymentOfUnderwritingDiscount_1426676" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredUnderwritingDiscountPerShare" xlink:label="loc_acab_DeferredUnderwritingDiscountPerShare_1426677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_DeferredUnderwritingDiscountPerShare_1426677" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1426679" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfAdvisoryServiceFee" xlink:label="loc_acab_PercentageOfAdvisoryServiceFee_1426680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_PercentageOfAdvisoryServiceFee_1426680" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisoryServiceFee" xlink:label="loc_acab_AdvisoryServiceFee_1426683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_AdvisoryServiceFee_1426683" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfSharesNotAvailableForRedemption" xlink:label="loc_acab_NumberOfSharesNotAvailableForRedemption_1701801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_NumberOfSharesNotAvailableForRedemption_1701801" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationOne" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne_1701809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationOne_1701809" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationTwo" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo_1701811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationTwo_1701811" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ThresholdDateForConsummationOfBusinessCombinationThree" xlink:label="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree_1701812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_ThresholdDateForConsummationOfBusinessCombinationThree_1701812" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders" xlink:label="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders_1701813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders_1701813" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNetWorthNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1701989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_MinimumNetWorthNeededToConsummateBusinessCombination_1701989" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination" xlink:label="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination_1701990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination_1701990" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1701967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1701967" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1701972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1426662" xlink:to="loc_us-gaap_CommonStockSharesIssued_1701972" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1426209" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1426210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1426209" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1426210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1426271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1426271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1426272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1426271" xlink:to="loc_us-gaap_ClassOfStockDomain_1426272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1426273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426272" xlink:to="loc_us-gaap_CommonClassAMember_1426273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1426291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1426272" xlink:to="loc_us-gaap_CommonClassBMember_1426291" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1426324" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1426326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1426325" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1426326" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1426329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1426329" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1426330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1426329" xlink:to="loc_us-gaap_EquityComponentDomain_1426330" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FounderSharesMember" xlink:label="loc_acab_FounderSharesMember_1426333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1426330" xlink:to="loc_acab_FounderSharesMember_1426333" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1426347" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PublicWarrantsMember" xlink:label="loc_acab_PublicWarrantsMember_1426350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" xlink:to="loc_acab_PublicWarrantsMember_1426350" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PrivatePlacementWarrantsMember" xlink:label="loc_acab_PrivatePlacementWarrantsMember_1426611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1426349" xlink:to="loc_acab_PrivatePlacementWarrantsMember_1426611" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableAxis" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisableDomain" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis_1426482" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfBusinessCombinationMember" xlink:label="loc_acab_FromTheCompletionOfBusinessCombinationMember_1426487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" xlink:to="loc_acab_FromTheCompletionOfBusinessCombinationMember_1426487" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FromTheCompletionOfInitialPublicOfferMember" xlink:label="loc_acab_FromTheCompletionOfInitialPublicOfferMember_1426520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_PeriodAfterWhichTheWarrantsAreExercisableDomain_1426486" xlink:to="loc_acab_FromTheCompletionOfInitialPublicOfferMember_1426520" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAxis" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsDomain" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsAxis_1426571" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOneMember" xlink:label="loc_acab_AdjustedExercisePriceOneMember_1426578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" xlink:to="loc_acab_AdjustedExercisePriceOneMember_1426578" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceTwoMember" xlink:label="loc_acab_AdjustedExercisePriceTwoMember_1426599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_AdjustedExercisePriceOfWarrantsDomain_1426575" xlink:to="loc_acab_AdjustedExercisePriceTwoMember_1426599" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1426211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1426210" xlink:to="loc_us-gaap_ClassOfStockLineItems_1426211" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1426212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1426212" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1426214" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1426215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1426215" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1426216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1426216" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1426228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1426228" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1426229" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1426236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockVotingRights_1426236" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1426239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesIssued_1426239" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1426241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1426241" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1426245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1426245" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_SharesAreSubjectToForfeiture" xlink:label="loc_acab_SharesAreSubjectToForfeiture_1426322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_SharesAreSubjectToForfeiture_1426322" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfCommonStockIssuedAndOutstanding" xlink:label="loc_acab_PercentageOfCommonStockIssuedAndOutstanding_1426321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PercentageOfCommonStockIssuedAndOutstanding_1426321" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1426328" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1426338" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_1426340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_CommonStockConversionBasis_1426340" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1426344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1426344" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PeriodAfterWhichTheWarrantsAreExercisable" xlink:label="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable_1426480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PeriodAfterWhichTheWarrantsAreExercisable_1426480" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered" xlink:label="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered_1426501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered_1426501" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective" xlink:label="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective_1426507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective_1426507" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit" xlink:label="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit_1426531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit_1426531" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants" xlink:label="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_1426535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants_1426535" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1426536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_SharePrice_1426536" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice_1426542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfTradingDaysForDeterminingTheSharePrice_1426542" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_1426547" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1426550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1426550" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal" xlink:label="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal_1426555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal_1426555" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_VolumeWeightedAveragePriceOfShares" xlink:label="loc_acab_VolumeWeightedAveragePriceOfShares_1426562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_VolumeWeightedAveragePriceOfShares_1426562" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice" xlink:label="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice_1426565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice_1426565" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PerShareRedemptionTriggerPrice" xlink:label="loc_acab_PerShareRedemptionTriggerPrice_1426579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_PerShareRedemptionTriggerPrice_1426579" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_ClassOfWarrantsOrRightsLockInPeriod" xlink:label="loc_acab_ClassOfWarrantsOrRightsLockInPeriod_1426619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1426211" xlink:to="loc_acab_ClassOfWarrantsOrRightsLockInPeriod_1426619" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1701918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1701918" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts" xlink:label="loc_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_1701920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" xlink:to="loc_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts_1701920" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1701921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1701921" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1701922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1701922" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1701923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1701917" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1701923" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1701925" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701925" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701926" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1701927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701926" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1701927" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1701928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701926" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1701928" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701925" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1701930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1701930" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1701931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1701931" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701932" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1701933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1701929" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1701933" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1701937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1701937" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_1701939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_1701939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination" xlink:label="loc_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination_1701951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination_1701951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1701979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1701979" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1701940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1701940" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1701941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701936" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1701941" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1701943" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1701943" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1701945" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_FederalAndStateAuthorityMember" xlink:label="loc_acab_FederalAndStateAuthorityMember_1701947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1701946" xlink:to="loc_acab_FederalAndStateAuthorityMember_1701947" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1701944" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1701949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1701949" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1701948" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1701950" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1426180" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1426180" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1426183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1426183" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1426183" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AssetsHeldInTrustMember" xlink:label="loc_acab_AssetsHeldInTrustMember_1426185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1426184" xlink:to="loc_acab_AssetsHeldInTrustMember_1426185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1426186" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1426188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1426187" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1426188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1426181" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1426190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1426189" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1426190" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1701745" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1701747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1701745" xlink:to="loc_us-gaap_SubsequentEventTable_1701747" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1701748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1701748" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1701748" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1701749" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1701750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1701749" xlink:to="loc_us-gaap_SubsequentEventMember_1701750" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1701751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1701751" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1701751" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1701752" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1701868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_TaxPeriodAxis_1701868" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1701869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1701868" xlink:to="loc_us-gaap_TaxPeriodDomain_1701869" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701754" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701754" xlink:to="loc_us-gaap_ClassOfStockDomain_1701755" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1701756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1701755" xlink:to="loc_us-gaap_CommonClassAMember_1701756" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1701774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1701773" xlink:to="loc_us-gaap_RelatedPartyDomain_1701774" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterMember" xlink:label="loc_acab_UnderwriterMember_1701992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1701774" xlink:to="loc_acab_UnderwriterMember_1701992" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1701837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1701837" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1701838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1701837" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1701838" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1701856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_CreditFacilityAxis_1701856" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1701857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1701856" xlink:to="loc_us-gaap_CreditFacilityDomain_1701857" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeAxis" xlink:label="loc_acab_InvesteeAxis_1701995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_acab_InvesteeAxis_1701995" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_InvesteeDomain" xlink:label="loc_acab_InvesteeDomain_1701996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_InvesteeAxis_1701995" xlink:to="loc_acab_InvesteeDomain_1701996" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_AdvisorMember" xlink:label="loc_acab_AdvisorMember_1701997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_acab_InvesteeDomain_1701996" xlink:to="loc_acab_AdvisorMember_1701997" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1701758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1701747" xlink:to="loc_us-gaap_SubsequentEventLineItems_1701758" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors" xlink:label="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors_1701976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors_1701976" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="acab-20231231.xsd#acab_UnderwriterFeeWaivedOff" xlink:label="loc_acab_UnderwriterFeeWaivedOff_1701977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_acab_UnderwriterFeeWaivedOff_1701977" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1701993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1701993" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1702001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1701758" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_1702001" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g509388g00n37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g00n37.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1884&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?R^5B@X0DE-! 0      $ < 5H  QLE1QP"   "   < E  "')R,CDU
M-38R' (% !]-:6-R;W-O9G0@5V]R9" M(%)I9&5R(#$W,BYD;V-X.$))300E
M       07HH]R9@0,"4V0^GJSMF(;3A"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $
ME,S,  $  3A"24T$)@      #@             _@   .$))300-       $
M    6CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))301$       0
M @   D    )      #A"24T$'@      !      X0DE-!!H      T<    &
M              )Y   &CP    D 4@!I &0 90!R "  ,0 W #(    !
M                      $             !H\   )Y
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   )Y     %)G:'1L;VYG
M   &CP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   ">0    !29VAT;&]N9P  !H\    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M"VX    !    GP   #P   '@  !P@   "U( &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( #P GP,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MM\?_V@ , P$  A$#$0 _ ,BR[*?D9$YKZMMKP&L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #_X4$M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP
M86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)!9&]B92!835 @0V]R92 Y+C$M8S P,2 W.2XQ-#8R.#DY+" R,#(S
M+S V+S(U+3(P.C Q.C4U(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIP:&]T
M;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z=&EF
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO
M;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF
M>41A=&4^,C R-"TP,RTR-E0Q,3HU,CHP,2LP-3HS,#PO>&UP.DUO9&EF>41A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(T+3 S+3(V5#$Q.C S
M.C V*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C R-"TP,RTR-E0Q,3HU,CHP,2LP-3HS,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I
M;&QE<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" @
M(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7
M;W)D("T@4FED97(@,3<R+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E
M871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^<G(R.34U-C(\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^
M:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \>&UP
M34TZ26YS=&%N8V5)1#YX;7 N:6ED.C5E.31D9&(P+3 U,6$M.#<T,RUA96,Y
M+3)D9F4X8V,X,C9D8SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.CAF.3=B,#EF
M+3%F,C8M,V(T,BUB,V4U+3-C,S4T,#4R8V4T9#PO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED
M.C9F9# Q,C,V+6,P.3,M,#$T92TY-S4Y+6%C.#AF,#,R-S U,SPO>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-F9D,#$R,S8M8S Y
M,RTP,31E+3DW-3DM86,X.&8P,S(W,#4S/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3 S+3(V5#$Q.C0Y
M.C4V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C4N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F$T86$U9#=E+3<X-&0M.#(T-2UA,#DU
M+3-F,&-E,&-E868S,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R-"TP,RTR-E0Q,3HU,CHP,2LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(U+C @*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C5E
M.31D9&(P+3 U,6$M.#<T,RUA96,Y+3)D9F4X8V,X,C9D8SPO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP
M,RTR-E0Q,3HU,CHP,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(U
M+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z831A835D-V4M-S@T9"TX,C0U
M+6$P.34M,V8P8V4P8V5A9C,S/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C9F9# Q,C,V+6,P.3,M
M,#$T92TY-S4Y+6%C.#AF,#,R-S U,SPO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9F
M9# Q,C,V+6,P.3,M,#$T92TY-S4Y+6%C.#AF,#,R-S U,SPO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T
M:6]N/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXS,# P,# P+S$P,# P
M/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI94F5S;VQU=&EO
M;CXS,# P,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@
M(" @(" @(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A
M8V4^"B @(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ-C<Y/"]E>&EF
M.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS
M:6]N/C8S,SPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^
M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_\  $0@ RP(9 P$1  (1 0,1 ?_$ !\  0$   <! 0$            !
M @0%!@<("0H#"__$ 'H0   "" ,$ P@*" P.#0D)  $% @,$!@<1(3$ 05$(
M87&!D:'P"1(4&5BQP=$3%1884Y67UN'Q%QHE)S(W5]<*(B,S-4=258>3TM4F
M*#8X0D-%1E9B9W>6TR0Y2%1E9G)S=7:%E+4T1&.#I[*VM\1D>(*2HJ2HPL?_
MQ  > 0$!  ,  P$! 0           0(#! 4&!PD("O_$ &H1  $"! (&! @&
M"!$(!P8' 0$1(0 ",4$#400%$F%Q@0:1H? 3%")2DK'!T0<5,E/2X187)$)5
M8I/Q"!@C)28S-#4V0T1&5%9RE*)%9&6"E9;4U6-F=':$A=,W<X;"Q-8G1U>#
MIK*TI/_:  P# 0 "$0,1 #\ Y$V_^Z?;>\*=M3:9AQ#W:6?9UW(<R+SVD#KN
MZPE[HK&,F)F!O25,; S)MCN-+4FI9U8 @@DT-"Y:(526)#7'GM&T31L3 PIY
M\(&8RA3M3 DU4H0(T&:<3S $($1A<+]7=^H'C?\ NE/E:1!^+'(^:N-_B.B?
M,CTI_I0VI_.'HB'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G\Y.$H]JP\;_P!T
MI\K2(/Q8Y'S5P\1T3YD>E/\ 2AM3^=_A"^[LKN:'C?\ NE/E:1!^+'(^:N'B
M.B?,CTI_I0VY[3#J&[MN./.'C?\ NE/E:1!^+'(^:N'B.B_,CTI_I0VIO.[!
M[N[[D>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J?SO\(R]:OENAXW_NE/E:1!^+
M'(^:N'B.B?,CTI_I0VI_.'HCWP\;_P!TI\K2(/Q8Y'S5P\1T3YD>E/\ 2B;4
M_GY5E'L2L/&_]TI\K2(/Q8Y'S5P\1T3YD>E/]*+M3I\H+F@]4/&_]TI\K2(/
MQ8Y'S5P\1T3YD>E/]*!FG\Y/]4>U8>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J
M?,=7?K[(>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J?SK9"N??.'C?^Z4^5I$'X
ML<CYJX>(Z)\R/2G^E#:G\X>B.[^V'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G
M\X>B(>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J?SNR7W5Y)N5X>-_[I3Y6D0?B
MQR/FKAXCHGS(]*?Z4-J>TW6 ?4D/&_\ =*?*TB#\6.1\U</$=$^9'I3_ $H;
M4_G?X0W=^X=XW_NE/E:1!^+'(^:N'B.B?,CTI_I0VI_.'HCM>O!J\GC?^Z4^
M5I$'XL<CYJX>(Z)\R/2G^E#:G5IFX ^X_GK8/&_]TI\K2(/Q8Y'S5P\1T3YD
M>E/]*&U/YP]$=GUK[GC?^Z4^5I$'XL<CYJX>(Z)\R/2G^E$VI_/_ ,([_7N:
M'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E%VI_.YB4+[1V?4\;_W2GRM(@_%CD?-7
M#Q'1/F1Z4_TH;4ZGRFX!1S]X,/&_]TI\K2(/Q8Y'S5P\1T3YD>E/]*&U/YW^
M$0\;_P!TI\K2(/Q8Y'S5P\1T3YD>E/\ 2B":?SAZ(]B>V'C?^Z4^5I$'XL<C
MYJX>(Z)\R/2G^E%,T_G"OFBG;WRAXW_NE/E:1!^+'(^:N'B.B?,CTI_I0$T]
MY@?]4=^R'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G'WRT^]'L[BZUAXW_ +I3
MY6D0?BQR/FKAXCHGS(]*?Z4-J=_*_P (6W%>JO*'C?\ NE/E:1!^+'(^:N'B
M.B?,CTI_I0VIV\KL"'N=\/&_]TI\K2(/Q8Y'S5P\1T3YD>E/]*&U/YW^$=^+
M\$AXW_NE/E:1!^+'(^:N'B.B?,CTI_I1-J?SM_R1U<.W?#QO_=*?*TB#\6.1
M\U>W1AXCHGS(]*?Z47;GS_PVW]^4/&_]TI\K2(/Q8Y'S5P\1T3YD>E/]*&U/
MYW^$?7ZNQH>-^[I3Y6D0?BQR/FKOP\1T3YD>E/\ 2AM3+\K*P]U"GN(AXW_N
ME/E:1!^+'(^:N'B.B?,CTI_I0VIW\K_"-_?==:P\;_W2GRM(@_%CD?-7#Q'1
M/F1Z4_TH;4_G#T1[X>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4#-.K3)NV0?KAXW
M_NE/E:1!^+'(^:N'B.B_,CTI_I0$T_G#T?KAXW_NE/E:1!^+'(^:N'B.B?,C
MTI_I0VI_._PA/?V\E>'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G\X>B.WZDAX
MW_NE/E:1!^+'(^:N'B.B?,CTI_I0VIK37=I>JG5VK#QO_=*?*TB#\6.1\U</
M$=$^9'I3_2AM3^=G24>X]M1O>'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G\X>
MB._'L2'C?NZ4^5I$'/\ N8Y'S5[93P\1T3YD>E/]*&W/YW^&Y6K<%1.0AXW_
M +I3Y6D0?BQR/FKAXCHGS(]*?Z4-J?SKY!QWX.*)#QO_ '2GRM(@_%CD?-7#
MQ'1?F1Z4_P!*)M3K\I-VR/7[H>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z47:G\X>
MC]</&_\ =*?*TB#\6.1\U</$=$^9'I3_ $H;4_G=@RX5O[ (>-_[I3Y6D0?B
MQR/FKAXCHGS(]*?Z43:G\_\ PCNO9NAXW_NE/E:1!^+'(^:N'B.B?,CTI_I1
M=J?SN2!/4O!^N'C?^Z4^5I$'XL<CYJX>(Z)\R/2G^E#:G\X>B/?#QO\ W2GR
MM(@_%CD?-7#Q'1/F1Z4_THFU/YP+WE%&RY_5#QO_ '2GRM(@_%CD?-7#Q'1/
MF1Z4_P!*+MS^=_A[\_9#QO\ W2GRM(@_%CD?-7#Q'1/F1Z4_TH;4_G?X1[5Y
M=JP\;_W2GRM(@_%CD?-7#Q'1/F1Z4_TH;4_G=@[K[+ O#QO_ '2GRM(@_%CD
M?-7#Q'1/F1Z4_P!*&U/GV!J[GLW:8>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J
M?SNP=^]4:'C?^Z4^5I$'XL<CYJX>(Z+\R/2G^E#:G\X>B.SZUAXW_NE/E:1!
M^+'(^:N'B.B?,CTI_I0VI_.[)?=?W;U>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4
M-J?SO\([][W>-_[I3Y6D0?BQR/FKAXCHGS(]*?Z4-J?SO\([JO+=#QO_ '2G
MRM(@_%CD?-7#Q'1/F1Z4_P!*&U/YPIYHKG#QO_=*?*TB#\6.1\U</$=$^9'I
M3_2AM3K\JU-D5SSY0\;_ -TI\K2(/Q8Y'S5P\1T3YD>E/]*&U/YP]$1O&'G=
M;NZ.&[_N,4F6U:_S47F;X.T7-[*L+'*!!H8VPZ8F9I9TQ0==%,$%RE:FK2[U
M)%*20]ZD"50QGT+199)IA@A1*2/*GRJ\Q#5I$$TZCR@A(^]#J4[ ]>+1_1"Q
MZY'1'\UCNH/^V%[8'^?5^/\ Q-/'LVA?N;"_LCU"-$Q\J;($?_U!CH?(93E3
M'5&*BG?+UQ)>GJP@H'9VTBR'T\K3W8182'MZ.BLL(A(%?JYVZX2'2?"OFP@"
M#?V;[[HDAMGA%AV[5[3X21._KW=TXJPBQ0 1Y<O/A$) J8DATPBPEV&F$%3U
M0PAPYQ9#>6<N=\(BCL7E#M7EY\MW">$.]./?\Z1,(L.WUX0[_FAV[5[:#A#O
MW;OF(80AA"$NW#""Q9#IT]N'2&N$11GU=^?!Z1.B^[M+JP0Y;N>4% / +>G?
MG%D.ZN\-^_=BH<CU&)M2Y]^_U1,2,H80A:U\(5K2&$(=AWX0[C=#TX1"@<VB
MR'C6TZSWA?""AP+;J>R A+ZP[<L(+[G!'KA(:4O4,(JKR:)+/MEZPPAW[]46
M0AY^B?TSZ\(@(-+-$PBPPA#L&$.YBB A<!#CA#OW[82'0:VIA!1G"0]4^WIT
MPB**75/;$D(V#"+#"$60Z=J4]6L\\(GU0D/;MT:Y8049]^]<KQ,(L,(0E,:>
MK"(2@4Q9#;ET7Z,(L3"%*GF82[=NUM<(>R&$(80AA"&$(2&^78,(BCOW[J,X
MLAY#T:<,\(**Y?G]3PD-;4O4,O1PH.$%#5>C&_9[HF$5:[JPPA"W;U=>$*]_
M?V0P@2CF+(<P&\NV_G7")O&3=_JB2'0<(L60]NVDIZ9X1%'6HZK=^420]NW3
MIA%6T;^A3^-"&_\ U\=#_P"("_&O%_:L3^R8EY?[<OKC^JUCU..F/YK'=0?]
ML*VP/\^K\_\ B2>/9M"_<V%_9'J$<\P\N<[Y>P ^WLC9>QV^T*W%?]6<Q52=
MM$J9WP@F9J0>=VP>DO3+W?C>X+P/>"XL6%)PI:&('-+3U(V8E[*L5&Y6#64I
ML[<#9X$OSQQ.94DVEV<0>20""<.82W#[1"$4+L7BRHKT0!$HX7L[O'/3/$.
M(.:2-$-'GAO#9Y#]WB<[>4C?=QC%XBUR3%KBN>FKZ0_31:G.>X7R=UF*?!FM
MVV9) X7FC@M)&0&[6O>!E-F1#69,3:\L3SB4G9,LPEVUDE$LU91*5$VTB 3J
M0$C%0Q"<P2 %>Q-N)R,91?$F RY@($(4G<.X9F+.V.DT-[1$1Q5SU,ZF&S'$
M_:'-#IRSIE]RKP"\YBI=IXH5K7D)E:U-)^2MD+BA69-*9(L96=LXJ^7+/.#+
M,/)GV?U39PTF43 @++.)3]X2M3%4&B!P74MY3(I0J>Q'1#L=-_8#N\Y<#&!R
M3Y4QQ!A*\+E-SU'BUP&-B87P*8DLS4=1<96EX$C [,7Q%P31,E<XJ9CMVB!0
MH)&0Z7D*9T@UBUKJ9<4S8AFE)DQ!-LRB8K(9 F&4\G9VP3-Y,Q6;94!(,1*0
M5((= CJN]F50P4!8UEBBQ#0\*G^:%KS.<514-GICNG#A\#QU !@=UE,GBV8T
MG':VAH9W6;U)8SM\/'2C&[#K- ER])W30T6K5ZLC3-D#E6.'.-@;,^PF%X24
M3$$G9QA-684G,AF *($<!($@@@("=H[K)10A4U6M'4;R/(H;*!XP/"1IJ7,+
M#$J=':?/W5?$BAZTEK(\,0WJA0>N>6NPU%:HC85I4Z#[/8U,;\0H27EJM7"P
MT*BXI0+7997C.&LF@EQY2*D&;!!!F5)1.)C,'F\J4#8G7Y8)*D2A3945 *JA
M&X(ZBX(CS QUPAA".R.SI$!R(=(1G-GQ5MZYM,(2L90Y+.3+RA@/U[U+(SP>
M,VI61G!^YK]DY*U^X@J?)-L;&\A6*VLD1-B9!H5KS54J7ZL66:<2"5$VUF54
MV=B<#:V9I)DVC*&+%"C, "DFX %,U95MNI2.Y:C:%V6GE+')3.W+=5W/96TB
M>AYW/7N\5'+A.BR&6UM$1]#PJ=LB*H;%QVVOJ[L.VYPR]K$7C%RWM@XTO8Z*
MAWB\]+G>*0Y_!8P,WE3*\H.T=J8C EEE,RS$"6:<3O63$28G9,7:E1PES<!R
M0%"&X6Q!ND;'(XAPR5J'>9#1_P"&:<5U#"XR+[Q)8G28F8C/'8+W]BZ8/*ZS
M$8&T*3HL;GE3=X[A.UF;>W.:FRO(ZCL-4/TS-J39?:4TRFDG(*23>#68R2&8
MDRS&7#0S;,XF3:&(PF.R9EV140*HI92@1%F)9"!4!7*"-3:(@;)Y^YKBN ;&
MG>D[L+G);GJ-UCO,*OVT=$EB+%0_?!D<,J+G))WA)(JG[M"XA BB<OTUND;E
M#QM"IL$J:G;8FE@AEQA---+*=J;:$H!+3'#PQ*9B9MF:3:,TS2B83!1D7DFO
MXJTH"Z(A!K=*FL9E:_FR ^A8_BA[3<J8&.+3R0JB:VM9="]6Y;T.*\\/G??K
M[)9"4$CK"\A00%<5VHM-2XB=AVWE:72+#.+</#0T39&5PS% GFSI$NSL@DR2
MXD@\O:$TLQEV)B9@%FD!!,YE!(PYQ6929ZA2"I0.&1!:9 CW<-'2W:.>QV7[
MC6_;XN>S$#$[[QMI8:LC$ZI*B[KN,30TN^4I&S(2D:#*Q*RQ@93@&]G4,JME
M5*E:*J:OOU8HK$NG!$TN%()EV@"#M%3\J9%-V1U,"BDA$;U!DLY8+?F>$<;(
M0PA#7KRPAEV7AA"&$([$.!$(&&#K\0Z7/07$#6\T0(:LY<N;R=4UI,+J-Y7$
M8NB$V^V2HI;F]E+%:QK<]<;LK*T(M;6"AB6,+*T+&-/V+5/)M8DLPE) EG5"
M0LWD[ J I\I%WJ8C!7>J-1U-KI?VF.Z)?&+8Y+'B>1[B=8>L+OC#,JA PD1>
MXKHN>_RUE<N/D'6YWWY9@,2B+;F&YP;P*$](WF,S-23F[]-3BO3[?,Y(VOFH
M7F7/-AXY$LI 7;,YF,YFE\O"Q!-(VQ, ,79( 42;4J&82QDLKDN$ 0#*:J.J
MC<%0J!&1=Z(VSU[=.\V&CRPP=YRR=Z7#,#!QR)Q4&XG:WK+]K)D>%]6Q0S&\
M.6]XDG7;(-M+6:.V]K,\3$VLCB$BF$1P3-J9J)(K&3%*I+B&8RS S33(1+XN
M9902)]E1BH)A-(%F.V)@C0$$L0 H* !R9MJ8%0J;)9#2RM'$QS&DI)V?:%8"
MY[&5<K>2$3L,T.46PT)XBMR#Z(QLA2M.E9>\[-"B':@L,DH:L+_ F(N\7JU!
M"U-A6)LWM9@J9UN<N&O@B92$Q"9_E2++X.>H\),4V]E$/  +#S@"' 2Z%:_)
M!?A5:QT-[=NO'5#OW[(80AA"&$(80CG39U>YT7&B0O>5]06B3L<.HPLS(BRB
MQJV]-YC6$[YE3G(%348N^]3 7&Z;UMI,@5&K80F#,5& LY@M04H,PM"G7BB:
M:1)0I,V'PV1B2F8D A0)5)"A0$@$%=_-B 'WHF^.X+!M![/CRN*V,AFZ["ZK
MR&RQ\VIG)3!E=8W=<6@O(X'.\5FS] 40E*F]N?5X"]W(DON[KQ.:WNH5,<2V
MA%A.'<5.T\AK[-H.#BB<$>4 9"H,PF>;&)$JSS!!M8<LPFVB94290$$R\%4H
M411LDN N9R6XM^S]Q,AD91!B.8.(_P##YVV@QB"Y)FZKQORI98FD"J$Q<?Q9
M:7W=ID8F&!SK(%A>:)'$-3-=#M<[C6W'!$1MI(+RF7?^TJZ22S;&&)Y)RDLP
MFEE!D(G(P]F8KB),5$X,ZH"5,H!)BE%*(Y[.IJTJQ<?)/&3,<0487M9GP7O'
M#QJ=XR@)"UUD"%F(S-(R+7_)'3AFPO2N;R1:[R3,R-:9L1/0+0;*FUL%M6KE
MR\6UJ]L!7+LOU4R[.SB C%F)*A#),9R ")@H<,UF "Q$#NJRAM_WS9/ZGCF-
M\(L;'YXPG3R,Q8[;*V/3$6-)T^+B%+EK2Q2H9&M^MF=$C7.*ULQ4RLA8[;^.
MDZ$0WD=\C4-).#C&QH^+L,S"4%"PD7&^$LFD @$S#9DPP"34[&.NT%0S2S&0
M3'[YBY$4&7K,Q3<LM^ 9,R JJ=BN[$2#3NOZU/[&%](?Q.9R-D><N=%W8;0<
M+C%4WDS[O.7%BU@."@^988D %1?#1-_P==D6-"@YA6>'CG-A0@O:RX"8@R,F
M(9-B26>13*9IIYR"#)*2Q!G()GV=HH!. 06>8$557@&()X -:J,N[@:/A1#5
M2[\*T(</\Y3UJ7+<L\<<_6%# <DKP'YJR1KC"9E+TMI<8D!<#2K-7%-'-;46
MMH;5[<S,32P%"]!6M+%K*R;,(SK/X22:4S3"<.#* <.0&4':*),)@G.\0HWN
MJ5+]2!THF4=8<;X0PA'J="R*FR:J98/.O$%4Y[.P)/ML^'CT/:@Y+6V&KE-D
M.X<NJ)\U&B+*1)M3QND\#Q*'I<Y_7>5)&"HS$]1?567'9D[),BT\4\F.#.9=
MLI)BB64S-/M8IV4)/DS ;,TLS()3*P)$7R2BBXR*$"XN"MBMXX1B$^L'3-PB
MPM-C8D>5B!V-GUE=1WW%)F<C?ESSAVX-B4197&3R&;DH,2@N-7^[P38G3,C?
MW3&B:MXV=4K28D3)9LEDQ-M0LI!Q1,9IC-),#B#8243*TBD3,@0%42,20CJ9
M4%&- "2:IN4NI,<VG\9-GAG7OHL,E)$^3E'<!G;<@O=A6WL!P8J#YO?;9W5O
M69P_+ A,YR<,'Q(G6(X@G9&WFKR/<I:S4K39FHW6L+<U%SP:Y),4B5-J688L
MTQ,P(""7&V1,=N;;DF)PP0)948HHVHK!:(@"* ZRJ04"%%SXDF-NOP\NR0K+
MXO.>2O45'9F^YNF\#IOL60N6,[O%2F%9.ZR+@*%!D9-A2]3F-C_M!=%@H/2)
M@=(]*#A7$%Q#)YFTM:G5%H8<I)<=<,S @22I-+-,JF>:;;4 ':$H.&020AEF
M$H(F840BJT6EDN3F2C7LL;ECV^6SK$=*+9:Y[UPZ*3<Y+'P4.D:&BAI;5"3$
M.T$X+U.L+,]93"5R?:5)<X"EZ6$J<Y,@,%[I$I8O8&M^#A-ZE3OD6.%+BR;!
MFEGV=J7: K^U32S'9.),3Y6R221M$KLC9)BD@T(%2-X!!R9507#NB1^KCQ3V
M2T6.$CL/F@YZA L>4@>HX?!E<EH:VL@-W,V6=EIWD21X4$'?3:7A<M_'_(8V
M.T;ES.BTBSOZB51":$A*E+8D\MGEQDGFDVBLIE$I(?;Q<53*XV9Y)3AE?,65
MR6@1MHA54$.C2AA<$KPKG'6J,CS0Y/(3E;.[+RN\FM9&V#RIU',+2$O930C+
M2V$K:41+ V:?<*5&Q::*(@,ZEJ/C 'R-"N)K>=L;RHEK0UN^F9H;9)9AB3$R
MD ^$VIMIB3B+AD#;((V"0!LB:1!*25( $$!#E:P"&S%:N5<C=T_QOA#"$<X;
M/CVNFX\0&MY'R!H$J9(?1396)%B38E)DF\AG#AYRUU4"IL,G>>HO+C5-XFHM
M1+C-L(6]G+FL536L14HJ1:%6K%EFFE EJ9Y%JFR)P9E ,I(0%0)@30%8"J&X
MFIV5!SKSCL\7QGV:'F6E1X\<.UCOO$TET?&54+.?.ZB4D[0V[/[MN6X9J^Y*
M6P94,SZ/"]S]%)D\:UO=YK<<N*'M.S$W5%12RI(K%FKP>-*HEF,TH&$R$DIB
MS33B0G$6422$#RMHF4 .R4D*"C^4"J,H %*J0S5RC7O=MLS,!DY(.:\)$UF<
M,7:/82-C4=N:JALH?,J7N^3M#*_[A/LQE,3$F5ZFM_T(K/&Q1 B:XZ@T+29]
M''<]>[3,7$RMK(X9<8B;:EF GF$Z";;,J$K)/*LGD[.R#+),5,LTROLQ&5BR
M&U55""GUN,EC9^T,^\*3B&+*20X>\G.VEG-'P6'BXE1*7"8SY8UQPB">%38G
M#!CA 6>SMBUU#)U&MF.RQ^W<*F4F4,A2H<LN$J2+<9X0F$X,TLP264#:6=$P
MP#Y9Q,P?)FDF?[XUB$)<.2X6Y5FN%HB)0"G6>*SU$+U._ U,L5N^J.R*$*YW
MGU5N\[!2ZRM%XF*+L6&DL]M6<D*2=@-3A-PVYS%K4>@K;FTQ4K&7VU,FHT4M
M@*ML@(.(NTAG4;4QF8R2*BDD#:VFH"J!(N5&8I9RG-$]D<-XSA#"$<V;.;Q.
M>Z4:W!>5_A4HNB3&3:V'(KV96UH>Q($YDBS @I6E9VI\(2;DV5%D7+R@Q4,S
M4*EI7,BY6J21'7C2S38<\LGRB&3B%N++<'(P4 A:*X-P[1W$=*/>RZ\K7!DT
MB)#9H86UVXZN.N/&M%X775'#6Z!,SD:PY?F*;05P,6%402]K:$VAA7NP1E#K
M-[04$2M08-1P<-[6?MFB;#QI1.)9E!PIRFR4VB2!+(N(LI(=29O*- &!1M!0
M449FVX)FQL%C;SKOGLVE3JP6*"TT=9)]H4JE)H?&3Y0_7E[O/J8Q/<IY#!^F
M-<^)0#V'IJ<P\>U<XSK0_-3]PV,D<IO)C-\&5E>DK6-2#8FEQMK%*3;&(2)1
M)/Y4HDF&R=F8B4"<*9I1,=M465@#,SA'1G57*GFC#-HS\7G^@\WP;>,A<E[R
MXR>QK?0_-#):S&1&[+8UE+?"G9W8F8K.E!? PN9HKM)8]!!$HB5O64&L+A/3
M]E.H@-I.L3?,0:;)).,24SRG9V0C3$!,3%SQ3L++-+-LS#$V0)9 ?)6)8N][
M(H#T=""*@;FCK_$EX21? J&)"S/'#]YS])>6&QJSD!(H)3EP&)@(FTB+W/5H
M*W7*5YBU&B*I)ZXEO$T'9JSO ];>0*V%F!I)#8[/=D@/A<29)P' VIB1.203
M,Y8!Y9)4!$JD_*"* +FS!0Q0-S)/)@'ZPXW1880CFG9T>%SW4C?#9Y'^%F!S
MB5XU+>?BULJ#:I\!4,[0,A9EA:<JTU@KO8@4)+2HP5*EXJURUD7*U:2 Z\83
M384XD!,Q"2@,25%''K@$!"T5^$=O'0CULQO(8PJ,HC0V;F->[D:H3)FK8+S.
MHK.S)U2)M-6YZ7YB<V%4"DRI^BY(#1D)VIUR@D=LQ;B%WBYF;6\Z,TVDX7:3
MAXTLLXEG!!P\0@;,R;1 V991X592Q.T9IG/DR@- (S%%E9@P*DENQNN-)=)\
M]FXJ=*#I,Q&SJK7WA@M8'I.F]]X<KV9U7N-8E.X\;2_9.N>\F2>=Y38T<<V:
MH8.TZ32\#C*'<<HU<YYWS*5+S,!BTLQHFEQ3-B%)]F8S ;$Y,TLN&1LG8(E
M$Z3DB6=9]J6192A@" E%5'!=050H:%$;9 "@$L-9BS$"#3=!1XR!RWQ+#!]&
MM\WE-#-8SF1"[IBT$K="79^+F(G/6A@@6P,L8%Y>\I!$<E4O,4-T+%AL?JCI
M]FYA:UCW"U-4PY<08@,TI$NQ* QF (GQ24/A"<-0921-MH$E4;,&3>O8@R 5
MPEB:FJ#KT_+S.:V;.CE.XB=NJ;OTQ/2[K8SJR8L5,S>5NLK=1XV4X*5ZA4X+
MJK7?;V ^7E?NL:VYZ'^2B@:-16\3"UDBMU6OV]VRB?PT\QEFED0AR$,Q,I!
M$\RRHNPDL@D!,J$DI B ,0R$614%+9J5041^&H4_C0AQ_P!?'0_^("_&6+^U
M8G]DPO(_W\O-X_JM8]3CIC^:QW4'_;"ML#_/J_'_ (FGCV;0OW+A?V?8+=^R
M-$WRYO\ 57J^JGOCH=CJB0PA#"$,(0PA#"$,(0^CZ<NV_"'U_5?ONAA"&_SY
M]M^$-WJMWW0PA#"$,(0PA#"$,(0X9>OMIA$XW[]ZPPBPPA#"$,(0PA#"$,(0
MPA#MKA#OE#"$,(0PA#"$,(0[=NWHPAW[]_;#MVGVG;"'?NG=*PPA#"$,(0PA
M#"$,(0PA#"$,(0EZ^W.G'""^[OR?A#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0P
MA#"$,(0PA#"$.W;L&6F$._?N;YP[<,(=^,,(0PA#EZ>W/7")S]F?=LH=M.K"
M+WS[8W]"G\:$-_\ KXZ'_P 0%^->+^U8G]D]Z>[C$O+_ &Y?7']5K'J<=,?#
MEMZ=R7[H%&';+VE(HPZV?VEXG%?J+3UO&ZIZA$2$Q:@:DIBW)+F-M!@.'\+S
M1C!<K$!!0WL3*TH66J4!H'GM%TK DP,*2:<[0E0@23E#0AI2"B*V=XYYU$TQ
M9#LU*(W"G>XCJ/XD[NFODS-?RHP4_.1CI\<T?SS^3Q/H1CM?V?2'N3KYP\2=
MW37R9FOY48*5X??(\^'CFC^>?R>)]""D>;6TX;W\1PAXD_NFWDS-?RI04ZOO
MD>K#QS1_//Y/$^A!7;9],#K[D]4/$G]TVO[V9K^5&"GYR,/'-'^</Y/$^A '
M+9])!ZDAXD[NFWDS-?RHP4'.642-^'CFC_.'\GB?0BJ?Q3PG'NY-<@0\2=W3
M6_O9FOY48*5_]I&6>'CFC_.'\GB?0B+_ &;OM!&Y>I8>)/[IMY,S7\J,%)?_
M #(D':6'CFC_ #A_)XGT(JM66P^6+\N[K0P\2?W36G]+*U_*C!.O_M(^KC/#
MQS1_G#^3Q/H1%(KL^EQLG6<^0B^).[IM;WLS7I^-&"FO^<C#QS1Z[9_)XGT(
M*?Q3NVPMZCL>Y$/$G=TV\F9KK/\ ;1@IEPB1]6'CFC_.&W\7B7_U(JEODG+R
ME5*NCIU\8>).[IKY,S6'&*,%/1$C#QS1_//Y/$^A$7^R2])A3JW/UQ/$G=TV
M\F5KR'\:,%+#_"1VIKAXYH_SA_)XGT(K_BT7Y0]U[9V6'B3NZ;9;,S7\J,$_
MSD8>.:/\X?R>)]"(O]GTKK2G?*+XD[NFWDS-?#[*,%-TOVR,Y]J3GCFC^>?0
MQ++^+N[O!2J(/2^KNHB>).[IMY,S7\J,$_SD8OCFC_.'\GB?0@I_%M]]G2V^
M'B3NZ:^3,U_*C!3\Y';IP\;T?SS^3Q/H04_BO^./<N?=(>).[IMY,S73_*C!
M3\Y&O6.'CFC_ #A_)XGT(+_9W^5P#MWI5!#Q)W=-?)F:_E1@I^<C#QS1_//Y
M/$^A!3;9+I\H<JB].,/$G=TU\F9K^5&"?YR,/&]'\\_D\3Z$%WR>F/=#Q)W=
M-O)F:_E1@IO_ ,I&[#QS1_G#^3Q/H15.4O$3*.L"+XD[NFL_ZV9KE_G2@I^<
MCT<L/'-'\\_D\3Z$12GWJHORA>F[DM*Q/$G=TV\F9KS'\:,%/SD9T##QS1_G
M#^3Q/H15-?)LJ3C?NX_G(AXD[NFWDS-?RHP4_.1AXYH_SA_)XGT(*?Q>&T_4
MBVB^).[IMELS-8\(HP4_.1AXYHWSA]#$^A $D* /2^KOSB>).[IKY,S7\J,%
M/SD8>.:/YY_)XGT(BG\7?Y8;K"]2P\2?W37R9FOY48)_G(IY\/'-'\\_D\3Z
M$%-]GTOJ=58TZH>).[IMY,S6/\*,%/SD8>.:/\X1_P#MXGT(JE4\GT@^^F;#
M.U1#Q)W=-O)F:Z_Y48*?G(\VN'CFC_.'\GB?0B*?Q6_&=^7?F(>).[IKY,S6
M/\*,%/3$C#QO1_//Y/$^A!3^+Z8/J7N4JT/$G=TU\F9KS_;1@IE_"1OP\<T?
MYP_D\3Z$53D#PF^JU\N+0\2=W37R9FOY48)_G(P\;T?SS^3Q/H1%+?)*Y3#W
M=E=T/$G=TVE_6S-<O\Z,$_/]DC#QS1_G#^3Q/H057&SZ6_)*]L7Q)W=-?)F:
M_E1@II/\I&>7JKAXYH_GG\GB?0M>"E4(E'&8#MHU_>T3Q)W=-O)F:_E1@G^<
MC#QS1_G#^3Q/H0!7S?2^J+XD[NFODS->7[:,%*;_ ,9'3QH&'CFC^>?R>)]#
MND%-MD_ZPY"F]C3,YSQ)W=-O)E:_E1@I^<C#QS1_G#^3Q/H17_%M]\+\OS7B
M^)/[IMY,K7I^-&"G1^,C/L(!/#QS1_G#G^UXC_X(CJR<-KULR(6YH2D3Q)W=
M-?)F:_E1@I^<C+ZIX>.:/YY_)XGT(*6^2_XX[IOZTAXD[NFWDS-?RHP4T#_*
M1O /HP\<T?YP_D\3?^)N[O%4HJ2^D'[@KU"K!XD[NFODS-?RHP3_ #D8>-Z/
MYY_)XGT(*?Q7_'&[=O[H8>)/[IMY,S7\J,$_SDX>-Z/YY_)XGT(A/]GTE[4W
MP\2=W3;R9FOY48*9_P )&[GYGCFC_.'\GB?0BO\ B\=H4ZG941;\WB3NZ;2_
MK9FOY48)R_\ F1E/KP\<T?YP_D\3Z$'KY*.^UE5T[I>'B3NZ:^3,U_*C!3\Y
M&>6'CFC_ #A_)XGT(FU_9M]]GR[VAXD[NFWDS-?RHP4_.1AXYH_GG\GB?0@I
M_%]+ZNZB'B3NZ;>3,UT#**,%/SD>O(,/'-'\\_D\1_\ !%4_B\YOJ9*&B&L/
M$G=TU\F9KU_&C!2TY?E(UW_2\<T?YPY?M>)DOF1%/XIX3+2]*6:_9?$G=TV\
MF9K'A%&"F7\)';.N'CFC_.'+]KQ'_P $ 3N:OE==C3NT3Q)W=-O)F:_E1@I^
M<C/#QS1_G#^3Q/H07^S;[[/EOB^).[IMY,S6(9C]E&"GYR)[LNK#QS1_G"]O
M!XGT(KU\GTQFBFR77(%+Q/$G=TU\F9KM^5&"GIB1K?#QS1_G#^3Q/H1%)\WT
MF:KHG-65X>).[IKY,S7\J,%/SD8>.:/YY_)XGT(*?Q:+\H4ZKJ-\/$G=TVG+
MWLS6/\*,%,_X2-_/>&'CFC_.'\GB?0BJ?Q:@?*'*UTZHOB3NZ;5_I9FOY48*
M2TG^,C?V'#QS1_//Y/$ZODUB+_9](-Q9G0=5GB>).[IJ'^YF:Q_A1@IZ8D8>
M.:/YY_)XGT(*;H/]9\K!O7#Q)W=-?)F:_E1@I7A]\C#QS1_//Y/$;_!!3^+1
M?EAAR"5;C#Q)W=-O)F:_E1@I^<C#QS1_G#^3Q/H15-?)3^V+KNW<8>).[IKY
M,S7I^-&"G32)&'C>C^>?R>)]"(MUE],/V=^$/$G=TU\F9K^5&"G3^,B>'CFC
M^>?R>)]""G\7TQ[D[4NJ P\2?W3;R9FO?]]*"GYR.TL/&]'\\_D\3Z$%WR[E
MF ]F_P!>^'B3NZ:^3,U_*C!3\Y&7U3P\<T?SS^3Q/H04_BT7Y8S3MWTND/$G
M]TU\F9K^5&"?YR,/&]'\\_D\3Z$5?[-OOQ?ENAXD[NFWDS-8?PHP4_.1]$Z3
MIAXYH_GG\GB?0@2B?)=/OAPR1-^3P\2?W37R9FOY48)_G(P\;T?SS^3Q/H04
M_B/^./=3?2'B3^Z:^3,U_*C!0/\ _2 URTP\;T?SS^3Q/H1%WRV^_!]A/&\;
MOA]W&'NE)*_KD')ELV-;,7%+W.V9-[0,3H,+ 9V)A.6)I:UXJU,15JY9["H5
MIK/8U2M8M3[WO4$$DQ !PQ-+T<X<X\(YE-</$R:LC*D4*3+1-H%IEH<DI^>/
MZ"V/6XZ8T!I_7EHB-EB4NA$/-GNWXZ<'Y-%_.?S)OW&.;% $V3^M%KUK;U9?
MMY^K&_/OW,:L^!2I9:"C9U(0EC#S?5PK2NNN)Z_S\6=LLH$C)N2IN 1]^Y%1
M54 >F_.6N[UA? J1U4Y+EO\ <:05UN%)5G[:LV=#D'SUJ.\0K, J%9X"^YF&
MX%D)8LD#8*7<K3)V#AU-ZWA,)6MT#/6O7<::8(5K7K"9-V4#YP/()DX-T*$N
MW-J(L--U?,%9 &G6&<\,][>LW)S[#9(+9TN.QT R'7G :UZ1Z.OK&^N%&ZAU
M]G8*9015J2M60MVNY.2DPH%N6M,QRKQ&0:C@YKSR>PNW *<A%:H= Q%DH2K6
M;=52\)#H-=P]5M_:N"C,=8^OOU03<71<Q1J"B'=3()IJ1R3H"*M,V+$$T!$$
MD$S!D131&=02127 DC+00#,<:CC8(F(.+A@W!GE5N=?J"1T2Z'ID\HFET729
MI464C!Q"#9CLHC,*5>Q@'A*']V"K=]T6.D\I>S6&<A =<0X^!\]A[_+E?FM1
M9(R\1TW^B:4<EP<5JH$V4+5L]*@SV\)93$X*Y9_=%CM>7Z]K]4[WP^!\]A>G
M+6BJN7YX>(::WW)I*?\ N,3.GR**[JUE:*!V26]N2N8?\(LD@F%/[=.8"&5*
M2Q#I&#\[A(?QY5+O=$(6KNL7Q'33_)-)5?F<7*_DU5*!&8 1/;LE#^[!2/\
MVBQYT^&Z,I\\7QC /\=AC_7EL^=^LTC'Q'3@GW'I!12^!B5/^J,A[X>WA+(!
M]N"J@?OBQ@(2G_Z:>'A\!QX7"<^?*A7FG&'B&G-]R:2U/U#$9_[/-E]SV\)/
MWY*I!?[HL<P&5OU^LI:T#2H8GC&!\[A^F$KV;V7DAAXCII1=$TFGS&(H=?-Z
MD(;F(OMX26]N"H<@^Z+&%P 1G^K3$;4L$KC+#P^"J^%PAGY8)941VOO*T"Q3
MH.FVT/2CN.!B([E4E"NC4:J-$]NR7]^"G3]D6(+?^NZ<7QC ^>P_3'OB>(::
MRZ'I.38$_P!#+FKK #LER.2JPV,6+.GP^=0W=6(=(P/G<.WWX]]FXTWP\1TU
M_N/277^(GY?>]:) #LE_?DJN(?LBQT&WPU]*Z3H(8ITC ^=P[??R^_>_-'B^
M(:::Z)I2/7!Q%HE=BM$LSQ0/"6_MR4B'_2+&(9A+]>WRIKB''T<_QN&/]>7<
M5KGVQ/$=.'\DTD\<#$.83Y.1-,X>WA*']V"N^1DQTME[->FLK8>'P"?VW";.
M:5V-UWT1:VBC0=-#^)Z5;^)Q*J%K*Y**N:9+$]NR7]^"H,OV18]<_P!6]&E)
MCB^,8'SV&?\ 7E'4^>_FT/$=-_HFD"W[1B.I+_("-N7=5'MX2W]N"K=]T6,;
MVE^KSTE?#P^ P&-A^G*/J>](>(Z:_P!R:2__ $&(@-/-L*518>WA)F<E,QG_
M '28Y[Q_7LAOG??)XQ@?/8;?CR^I<N0ZHAT#37^X])?_ *'$K?[TW2X*-OA[
M>$H_W8*J9>V+'+?*2X,].&6'A\#Y[#>^W*NY7+C? Z#IW]$TE,O XJ6*?)8*
M+=</;PDF/W9*I[S%C&O\=N$;#36=7A\!OU7#Y3RA&:_ 6=V1GB.G?T32>>!B
M&^>S=23N8JL7V[):3-RK3]DF/J_5NK6MJ8GC& Z8V'G\J7M?MR:KP\1TU0NA
MZ2@"-@XG7\D5J]\Z1/;PDK,Y*?C)CX_##.@]=1Q?&, )^K8?IR\,PGNH*0\1
MTTG]R:3^0Q,U\U2O$%W*/ #PE$ ^[!5*M0,6/2D_U:U//GAXQ@*?U;#M]_+1
M;/?V;H>(Z8$71-(YX&(MOQ4(5JW-(HG9*(U.2H;V,6.]9?V[ARIEB#2, !L7
M#%*SBC+?CS>\0Z%IAKHND$O_ !.)R^]Y\&M 3LE_?@J^,6.G#]7SOQM@-(P/
MGL/TY7X\*<*P\2TS^BZ3RP<3L9ENW ) 3PEE^RY501D'MBR#TR73GOG*E@H&
M Q\%?V[#<.=N49T4HFY%>I<Q?$M,_HFD7*>!Q/9**\4:E!$]NR7]^"K?]T6/
M_78OC&!\]A[O*'OB'0M,?[DT@N7\%B*<OO?8N^+[=DH#^S!4-@_9%CX!==6@
M:4H(XGA\ _QV&*GY<JYFA9SF[@1EXEIG]&TCAX'%1B$^\=ADM#6@3LE_?@JY
MF+'J/_IM]=^ TC ^>P_2&0J^YMT3Q+3&^Y=(W_J.(H0G\4!QUER\/;LF_?DJ
M#_M%CR_]=G(!IG+2CQC ^=PS_KRWYV4A[+F[Q+3+:+I H_@L1FHTBNG UX0#
MLEG4X*OC%C_UWKSH,L4Z1@(V-A^G+[_=Q"Q/$=,53HND.[X.(+[AUY.@*10.
MR6DS@JY&+'0/X[G;G6D.D8#IBX?.<.>OE7DSWQ+3"BZ+I%5_:<1N'D\Z$GSE
M:'MV2U#VX*@EJ8LE9Z?JLLJ\K8>,8#'PN&5RGE9,_*6[<ZQ/$M,?[ETCGA8A
M7+[VH09!AOA[=DM9'!5*?[XL>^0_KVG"H[L/&,!EQ<-4\\;E%<^--\#H6EN/
M%=(11_$SV5_DNW!\ZP]O"6OW8*N'MBQ\1E^K;@MZ,/#X#?JN'QVY> 5]YK[8
MOB>F_P!%T@63P.(@!#IY+(@W\8S;.ULC6BDFR-+,U((CWJ23.O5+T41N$TE2
M:8(B,K3K4 &E,Y<22?Y,\I =1,#56]R[B0;Z9\'%PBF+A8F&2$ Q))I"0U%=
MU>SD*(S 4XARSYS[4D XSKP*O44W(GU5!(C6B=>X4.]>U"!F%A325\YW"@9V
M[2P?-:62A<VKW6'!KUS#9THM5+D&B>0RM3SWD(UXW'(,$N%J_JHH#<+7,6R%
M&#+2@.2KF,T9%BWOD$K6D RG*O:T@PI2Y6M5(5%;O53"K$);<$'6K&I=J@")
MNG*M>JX3]',<F]%9NVZ>WD+RC657R!2B]816W,Y]J=?JSQ>7=^SWV@I*(N9S
M<V.;@%K"HAVMV^G=AWKW^K?$7)&W!V+YM]9<PZ!Y\=/6 [AQ.L<N&?N(WB*>
MOCSN";JRC@58._GQK<1GT!0=PX#=RX-0!.LN-X@;CK3/>31WR]<.W:@XI[]U
M$/>5=2A:J'KNK0#H#EEVY[QQ#UGG?ORW""9HU;\+Y+1*,I:*(T"M=V_L.\9U
MH 3@#EFW[NXW!&<E*41BM4W MUF[+=4#MUK@(B,AED TM72NX HWUH0 %>Y#
MU;-MY+V]@C/E8'<AN[&B+ *]ISO.@W&HB%NFN!;NB41Q0, :]31B%-ZYE2U6
MS=D0HN:E0!"=0TSSS#IO6EPD.#D%&.=K6/51GH5$&!="Z(P(>K6XD=0!AG,;
M3J$PYB%<Q"LLI5EA9!5&*'D"U@66ZLL#5Z*[C@HXU*"B9K$G?*F75V'2<YXJ
M4N]^WN,T1(JUHI!!'UEZEZ@N5-DYTZQY=%LN%<R(_8.)ZZWXM82B40*A8K1W
M6B<4:H@ 5O(-=,PMGSI@2U%.6=C6W)X@2["JBRT9W*4"(]@R=.GL&G .>4B/
MU=SGQ/*ZVP^H %12@HK)5RH0PS[>KT8MN_O]L0!2BBPRN-S<2'+.L4<YUH'2
M,AW_ %8F2,YZ@HW?G@=]P$XE"RDEF"LH!"K7&K_"1#_&0I*?]DB C;*TMX\1
MUXGR3O!=>) J>/(<!G(B]J4R%4 8CK)XG<>.2.N- :?U]8%_U4;3_P 72L\J
M<L=.%\@\#ON8YL5=L<:<@[+UU$;3+'S<\Y9D6PG>QVC5D3-$2-!K+#XK;F9,
M[2#OD"=%>S-2Q4F:I!^F0+T4Q:Q1$4@5) $\;27<$-0REPM1=,U8I:,-DV"<
M""G%4<$@ A*U,98Y?]Q'=335O ^KHD2:IN]K%B!R\A,5IJS(&-D,1+DT6YM9
MTD6X"]O8&X61( : 8VUC:?8P4-*E--R+ATE)'&A'4H-UB;,V5*/9:*Q3U62-
M87'Q&SM#4QKSHI4-;$BSIMK*N,6-6TL:+4DH5,B;4H37@M9T6I:ULRIG27((
M(KEC2SH*Q227*D4FT*]5:*]@J!#>XWF[!&Y=S%%%55]PO:V>4M;(T*EJ]G:F
M9>I4+FEG7KE*]4FJ4M#$N6,[8I6+$$TD%:UD:%*U0U*E@HK%"Y6L5+44%B"0
M!-H7;BZC?Q!5ES)B;)RYAGJH=$"9"M%B+VQD94V14U-;*S+#!I\#8%2]>J4+
M&YL\&:6P61C06)(I-+2#(QMC4+.I!-8#,RM*_O/8E*U-&K*#0[RY HA/%G<T
M6*)9B.M@@6JO9%+4R55C(B?D(,REK$[)P96@Q:"A0T^V3$#.O-V1H:61J*U2
M[V?V):8,S4PMK,O8D$A:E+0QM:E8J16J%J*+:"W[2$<K3>%LA"&&R3;A3JKS
M#U556(1O"0/0P(FSM'A,\)4FM6*4#(B-&(W+TEJH0!:I0;"]>T,Z2Q4*0 L5
MHK130$0!($1&I49U2A"$[R2+H$7GN$$.0'-W %T"YK1;HD:OSXY3SJ.0]4PS
MJ.!*"@8*!D@1MW:A-*1+NZMN<\2]4K3:=5CK"0N\JVA6@T?-]VEK;H3JS<[(
MX?0Z9C%J979>PF)3!I)6M_'_ &9C39P?%2]!@Q-K6ZKM&JUO=!E=$20Y:"AK
M>$Q6KROP>%ARZV.)I.DS33:#X7$P]%T26>88./)ASS8<VDZ4))AXQ+C32SG
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M!0RLJ"AD9&=6'Z10RLBA0S,ZL$52A2K5HHHA\0GQ)\2>;$Q"#/.3-,=D!6*
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ME26=AZ@GUC@E5=;5':4[!$6@#.7IDY2F]S1[19#/*8B(2GZZ2GOG.U:X*-Z
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M,'GQ<O 7#C-*7V>!"E90P=09UU\,&F5[TW \5UG^%#5ON/ ^G6O+<\7XZZ)
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MV@--+=$PWZ85SKUH=V</OG8D;RBNKNHJ2K9VBSOGJ(7SG>M0&\@T$*UB.+9
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MEKR"FN^^>N%SQSK12^6ZELH.B[N8J10,#Q!).4)C>M!N YB'T5'/!!1G%"+
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M'"$N';S\L5>/?U<XAZB&/:"6"9! L*]MU?IQ&[[V^J%2BJ4JH3-:,CK<G)3
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MWA$Z9@ C65NCS:\AP1[$@,M;W]>7,1<T<$FE+4!N'0;@E(5ENS"<^<LI]J"
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M7WO,,@I[#$"89?9EC-:M9>[V8!2PRIA\4:"M=(3_ +?IR\/W5VA1#[.ND/\
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M6HE^]C$-0KK>JCFO 4I0& SEJ&LA"P=%*@&=YX!%R+LH-3UNQ-J)&3LC@H%
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M%-*)3:&-HLTV%I"CSL6>2:<6G$\LX628$^[_  @CPG2_7&GR+XIKG'&O=63
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M5G+&H6AA]K>1N\H^%/\ HT^'^IRN.[#[5^M$3XQT"P^3I'+[W?[J"(/T?'1
ME1T"Z2 U_?#5;+6VX+NXF)]K>QO\H^%&7][3X9_^IRZ+5K1]J_6IKK'0#_JZ
M12_WK'UAJ4?I^.AX"CH%TDLWQAJO>E0Z(<W>L7[6\C?*NTA"C_1I\/\ 4@/.
M0!6^'VK]:+^^&@%R?D:01D?O47=P9HI_1\=#Q3H)TEH!^^.JP<P@K1'.=8GV
MM['#RCH45&0?T-OA7C^HTOO];[6&M0I.L-7L&\G2"SU\F[N]^<_3[]$&'V!=
M)7/X1U6Y!1B&Y*C+E#[6]C?Y1\*/]&GPY64B'JTP^U=K1/WPT#+Y.D@%&R/*
MJ6B_I^.B!_F'TEW#XPU6KO4"I[;I%#]#>1O&7],A"C_1I\;Z?K-</M7:T53K
M#5]'\C'0'/Y*=>5*P_3\=$$ ^P/I+_M'5BV90+;N$0?T-[&\/]T?"BT_ZFGP
MZ_U'#[6&M3_E'0"A99-(YOL9\7&Y!/T^_0\4Z!=)?* ;XQU7]67-4"UCDZ%/
MZ&_;5#TL+9&S:++F]SF5>J7-I%#5UFUE/3E2B,TV1!X'D:!9"-%,9 DTHD1T
MFDAWR*"I2FDBM0ZM$^"[&.*#I^L\(8,I&U)HF#,<2<*LP&)C'9PC^,</%+GR
M50CU[I+^CVPI]78V#T0Z"Z1H^M<62:7!TS7^L<'%T71)D27$.A:#A#$TP@$[
M.'-I>BRB8 F:8+*?I?A7"UPH)P^=6%D,';8'4<5S"M44D!&7H) J9F96FFO7
M+5Z]:DFT-I@W-:YH;S,Q:UJYL,3!J:FUK7+6AH6)I?6- T#1=6Z)@Z%H>$,'
M P)/!X<DI)0$DF:8DF:>>>8F>>><F:><S33%23'Y^=).DFNNENO-8](^D.G8
MNL];ZVTF;2M-TS'(V\3%(EEEEEE $F%@X.'))@8&!A2286#H\F'@X4DLDLDH
MY IYL\AY7Z>&.Q_7:XYTZN,>".1W$NSHZ(JH?J1H!T=AZ UZ:X'K[CK.74T&
MI2G'F69$)KF!864\@MTT&0Z<><["(14N:]3A1GP[*@&C/=7-14JQNH9U4HJ2
M5AEJ,[A3ERKBK4+D$H7Y\VWQ*6YE"+@T&:.ZE"83WCV^L>PXJ;AW_,.X@IS<
M$FR*#4/[-PA(;"%J[QW9UTGK+0,114&K;AOLV:9+F8KJA&_>747*%R!Q3*)V
M^OMYA#%[_F[^L&(713N5LZFZHF5'-0,7'SR&5I!25,^$@E(<3AZE>JEU>W%2
MJB*]_<2&" !0S*.5C$N$A&4K4UD&7"=JUPH5 5:ODIOQ2K-$!WIPY TRKO>\
M*2L,[UM*<LM<ZY4'+!UJ$HU51;Y6:[B\+$(6=V8%*<RH6M"K0RWT'*U0[!NG
MA?<XO5CW.](<:J#9 %SVKJ'-DLA#36<Y[MW"NGJ&^2(ASW\6S]Y:)95(=MRN
MP[$4LSM?CG;HOD&'>G"U>NCJ87R/$DU7,@T:@),!#L/5:=];5TJ('OZZI3*K
M9L!97<J#P8CKIER>'HRS"N?3>0Z<'MO8M;JHHSXUT*]2A7(53G1T(]4 K2HV
MIE.8!Q&FE>C L["KW1"> ?-NN#DE3OW*J(BJAI10HM"6X=];VW4OG]9=XW-2
MN]Z6_,+\**;O951RY4H*NQ6TGKVF #I*PSGN5S3+NA(S6K)OBI<70Y*A5KY$
M*B)1"%YC0,Y<\N&%$#FR\K\8(2ZV8<2B!%0?F2$NKURTJ(3G>U)A@O;[ES8%
M$I5T,*AUN3ZJ&I<.M-\700R'30 KOSG;?*>)F#<7.9+;K)7<J1;KD7K4!T=U
MN;7K&)7^&CQ1IP21W2KSWSSQQ/D'GV@YOWY1E($F':78@HM@Z+56K&Y,<<=<
M: U?KZW+].EYD=.GZ<=6#\FB]YOS<XYL4G:8I7/<-]/K$9>6^H<,I!EZJU&>
M-J[F/&ZF_O9@D:JDEJD(4IN.8SYJ7BWSRW96IK.?(9YCA2U]]ZODB<PEA%%"
M-UT9%0)8JJJ13:+*(FHZ[^=<Q]>&0RW<FL/=$5C>KDKE-1\GL[P&LY6O+2>@
M>KJP#(M:+FF9]_; YAKD,UD2ZW;);PE81$0WYT !"59^BV"U  .ZSD@JR<;U
M@ER2$;>PJ%*U3*HI9?6@!E0* $[\NO=A3)R;N7)2G/LWP*'LH&##ZAV[H!3K
MRGY^V5 &>!?LNGJ[W<A((CDU#-FN>[==R 5A4:7R#A;/EI@P>ESQK;GG%<@7
M ('7R+9+S% &8^O7IYA4<+#W9=7(L(Q1^/M;?F%#ETK%I4>@!GF-YSN&^G'!
MV'60EA1$H=S\(IN3R52QHZU3ES5&@7"@CE.MA'( &E>.DIF:%P+HU0+DAVX9
MK02@2C4926(5&W*=^2!"XB-;C3?+.7*7.6 -  U _.R\UY+ BI)-K5SL%=$R
M8%+2G:0TKZ@SZ0'%?NH=O>;=1$8H']CW+9*WG4SA(>&5Y;O3Y]^"CC>B[_9Z
MMT4!3D7R&3 %,Z-V(6E?H^OSSGKAFWU_F]2)E$RIDXIR1$-F5RN< OEZ)\0X
MY"'5+ TO?BG \+@]JQD&)!140Y*K%@P#*XZQ :] 6X!+II/JG@&ZS7B5ZG]J
M1*WL&3<$3B@!+;E$!KG,>UQGO"]<J2JI9 _=$W&C7=65J_4OI/F*Y(R!:-!X
M9A,.GCN&D[C0,0..-BAZN&\.E YBT*41E#4*;MRH5<N0PG/=?3+26>>6+RWT
MSOFMK7B*AW J^0<#)"BLJLBHD)]J!;SVZ=]R=W-?57JW4$A2G8@9C5-S7!WA
MV67II/B.?.0#8,+W]C]0MR)(J865NH+?C?<& 1'2TI>8 /GGE4,^H:!B.IHA
M(]278V[0Y@Q%2J+=6)-KU<[BRF)+.4@KGQEORE/73%6RJ>'7NNJ99Q44*@W4
MS:VY'54-(4#HKQ#*>@WIP"5\'/6W W3,4?B5I!N98A['<J*0K+5 @<JRE]/6
M%->D99X,J_5V%\NH+:(Y#D.4S>M@>Y.9@$ZRTXTF&6OHP*,N?!T-3E[8J51U
M!MO1@A-1N3<QBR"F@A>XY=4P&TAUT$I?,&E!?M0BJC+,*!P0H0GCGDAL'(KD
M937>(^CCU5YX.[;@/;P[6Y1&93O6M[L_.K"CPSTOZ:>C#MI[']L6BHHYT9JH
M7:N2E0&4Z;3R"T^JM+<L'ZJI<U3M9Z\XF2*Y:R%:MU)S9HM:@$K[LJ5$94M*
M<JA2N(S$K3?=V 5ZJBL7:+U,4*V1D)=BQ=*% "D0>4]TM->H KRSHYIO7/+M
M);G85.XUXLM:(S/0&X>WI^Y#S<=XR#=EA1_./KX;@IWW@0I=T#HS#LW!*7"Q
M.<] ]6>F5>6&;)F??;.[<XG,U1 2N],A2H4N++"TNVLYW^K(9X57ODB4_/<)
M"CH^[((_,=CD%85&>5*WM:68Z?5@P2[M2KE;#/\ /!"7&2$!:6M>SGJ!2@.5
MPN/89 &@CQK(98A%30T'<*3F!P90L :"P0OQ5'85<G>Y""%9"$L@'B%^^TL
M;YB-<L&4%;D<#39SJ3N0!KQ48C,*,BB/D& K<N8FH;^L!EG+4>UKD=W80MER
M'>JZ$$FZWMDJ.2"Y&\!0R .<QZ)3W2EI/A/"Y/)!UJF]5S3BD'1U5RI9VN7"
M-D"35 X M]&5ZC3IYY3$U^N]&#]7*Z061G)KDA+EA1KI5JI]JTE:7( "L]XZ
M$[LZU7F263<,QON[$%10A@C@[S2'5QUSIOEI2DQP[>&2L^Y<W=!$W)UFZ%63
MAP2HK#TRX5G+,0L.=0UI5[%XLBV!J+,<G:VM6XS!(5206S4A>L._?*VHZ3"\
M^TL!NW+7(9H:)W6*<R=W)6< AC4/VB VRURW]6?H"DPK?*^[MM[2Z1RHNRA'
M^H,"50!D:MD,@K.=)3I00WAKG*XCOQ%"ED1U1W!W'*RT W12"@1P32@K9Z9
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MJ8LM*<[B$K;ZSO3E@N;\J K7<R4?G!$<('L2A-*\UK0[C&)7^$C/-)$0&?\
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M7GK>LPSW:C7.V# /1,J,AMOR#6K"K7VC<!7'$]I<5)01!'(* ._M2=9#:^>
M%RY&[NZ,HK2T161$7>W#K="6LBO9R&<YUO,0&M]=)#2<AWAB(H1$:B AJ99J
M'11N,6ER4->*GB ;YAW4))ZZ#+=RG*=!T$1K6F*1EF%W\T5'"U #,\2R)0<A
MR9P]7)O2+,*R =P5I4-!UZY5'$0LI&\L[',9=BL(K*46R5"*061"CY51*PG(
M>J0TI/.H>?C3%(4=JAW2S'U<'@"A0BK.$0*,D15)O;)2&EZB%Z9SUSIK/KI
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MV7Y",L/Y7'WA-Q/*M8W)CCCKC0&K]?63&7ZHE>8Y([NCEQQU8/R2@7\YCFQ
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MXF5RKR@.TMLX>4' \:V^RRX.=[O!N#6^[#X]U+^%]6!JG3M%M2F+O.5-\4]
M.G=?L+Z6'=]CNN'507.AFR5J-\/?+[.'E!0/K27V67!MO^[\N>N'Q[J3\+ZL
MX^/:+5_^E7ZF@>@'3O\ J7TLX?8[K=*B_B8J+HJAX\H.ZQP*V>]NN$3OMC@;
M1NSZ61OA.T&IDXJ9M%Z'[(6/44G*IE1>!R30P$^2 M3,5A<6MY&9KO9&1B-6
M(65K\$839M,&3TOICHNI^D&AX<VBZXU3+I^B&>; V]/T263&P\0#PN 9_"^2
MIEEFPYIALRSC9F26>:>7^E_T-'37IM\#G2?3,+7?0;III'1'I))HV!K@:-T;
MUQBZ1JW2=$GQ/$M;X&!XH/#C!EQ\?!TS1\,C%QM'Q1B87A,;1L' Q?C2?*&K
M[N ?MCLO01+&4V84TD5H%S:6O"7+D44TE?LS =NZV&I(9LJ:2"7L;67&#4S+
M0DDK6I(B C\1QL&? Q)L+$$DL\A0B7$DQ951%EGPYIY)A0[4LTTLP0JQC]6]
M4](M3Z[T+"UAJ[3I<;1L8+*<;#QM!TB5I9MC'T/3L/1M+T;$0OA8^!A8DA)E
M,@*B-K>U)K^]AA_W)I_U>-03,%& ) 1R5N"MJASE'DSIFBJ?NG "D%1BR&P;
MY0.:T+<H>U)K^]AA_P!R:?\ 5X(*-92HMDZH;D(F3$0\;T:OC6!=!X617S\I
M%%@5&\!##VI-?WL,/^YM/^KQ3Q!HRBR%B7N<T=[1!I>B@KXS@"K^%PUO4"=&
M:P5FO%1)S=-)%!$K,4DDT@11118FD4DDDA $440!5,12$0  "HB,@Q% 5P+
MJ*<BJL#<DT >!TS144Z3@ #RIEQL, (Y4F9 '(= +E$CV2[F3W*Z,>T3%IS(
MCQ7<<\<;9]<\Z+GE.C-Z6!>4-+_"5+U3>Q.NZY>VJD&HS9#9I5*5!N;H*D"M
M@*_#@!M2,_ V%I]UZ*]$]-UQIF!C8^CXNCZKP<63%QL;&D.'XT)#+,,# EG
MFQ!BD 8F+++X*3#$XVC/LRG^4_T0GZ)'HKT%Z,ZVU%T:UQH6NNF^M=#Q]7Z)
MH^KL?#TO!U)XS)-@XNL=8X^%/-A8&+HV%-B3:+HIGFTG%TGP4TV%+H_A<?#^
MX[*4@1"0 %)?I0G(*!*02  E(+4I3^AI0 B.E4H"PW=Z)0_CV9B2INX6]2ZU
MRJ I98L^ 2G< &]Y!*],]P8)Q*Y$BE%*T>V\Q%6K'(A:[DJJ(I#(-Y!Y]XT
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M047LBJR*@ 9$<U8V=%"V "K"W/,9ROP <LM^=E>5F6G$B][I:L:BDKFJ-EU
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MDND?,(WW9VP(E14'?>+;[5@I6IZU.89:V1=R&[OTPNDE4/W0YA3,>OJO@@-
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M4I1KY!!F%@,[VH A271+Z-< E*N077K7Z\H%55P6("#.B<=SU2 !6F0UK+,
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M2,J@,]#94"KGQY(""EF&@C*=0O:PT /K#$6QS148TK4.3^8P:H1<E8!UHZA
MI!=<C ;3Y7#*7/U!><\6Z<Z&Z\O>:(D3>PM4%$%K\$<!W:)0*SK>0<=?5/>
M2P<LC44\,O>FXE8,'NQ0'?1>"44AU@$NC+6V8SXV]&!7KOE6P3A7VQ0C612&
M5=ZE4+5V0PX0K/>//UUZYZ8,FX<O<W8F<1R5"*>"T54="=U[PR^J>[>(#NM?
M"_Y^>X$;ZT@R!;"F] X7.X#,KW6[:SI/>&73;"O?)'3<;]58"WU7!:A5GYH
MH@&^E->&6>ZT]:#@=SOEQO;?5,G$ H8JB<.RI#EF!*NRPJ Z#VS[!@QWCO;N
M5@^9XV!-%-"UPC(1 *\],QTRI@6Y9V&=W@-ROPS9V2@?LBANOE0,L]9TRSJ
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MX>>F*3>H>A>X$.726Q!?=@4,C6\**XW0=IRW)93!2FO+4WT>X2\Z7L1@:J$
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M4#5!=6.F9-:_NL3%$OP?L/#=,A4?N74F:?TIWSH:/#V7:7_WA KXW?\ W_\
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M'2:9H&#I.NNF>FZDTW%DEFFU?@:OT36TVC&8 G"TC2<+2M$P#CR?)Q!HQTG
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MK_\ C<FY#G??00(_* S2G;VD>;^9KRSEB?'VJOZ5(J5V,7_TZ+4+%^UWTP_
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ME>&)UU.X N5*(QWEVXPOP"9DBP%0#FE"I"AH;AR&\J7N(=5LZC0 PWBXHK\
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M<I-"6L"K&AS:X+\ J28YB(AQ&H9[Y#+%V1D 4R#>R"E7+*K'>[5X#GG%F/\
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M\$AT;I>;#:F\Z;K/OAL2^:,N_?+*'@S/\$AT:8;<_G3>D??#8D#B4"'@S/\
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%&,X__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g509388g01j05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g01j05.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1EJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &4Z^9'@X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#,T' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $(6XH4IXI%G@[F@1
M%<2$W($X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 5\            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$1       $     (   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              ?P   'D
M   & &< ,  Q &H ,  U     0                         !
M      !Y    ?P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    ?P    !29VAT;&]N9P   'D    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   '\
M4F=H=&QO;F<   !Y     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    %.$))300,      ZJ     0   %L   !@   !%   9X
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MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#L\CZQY=.
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MDXNVI@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ @ !Z P$1  (1 0,1 ?_$ !\
M  (" @,! 0$            )" H&!P$$!0(#"__$ #40   '  $# P,# P(&
M P    $" P0%!@<( !$2"1,A%!4Q%B)!(U%Q,V$7)#(T0I&!P='_Q  = 0$
M 04! 0$              0(#! 8'!0@)_\0 -A$  0," P8$!00" P$!
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M_P#5/W9Y:3G5JXSG+'..7[DC!%ZP9M&3*5?(JZS0\.X3 ?-3WWN+IEX9:)D
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MEKU=CM5:Z/=&-CLE:BV#]-O#2M=9QU.*U3BTV[-B+ADL1$AW)C&QV81C"2+
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M1 H  "/Y'L !_;J29)/$RJ0( ' (,7O_ "(?';X_'_KJ@MDYVX=]Z*5R =@
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MC:KU]L[*@46C%BQ: ("3K7Z. QE1CGFDXMG, Q$Q;*1;TDW*V5N(HO  < Z
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M)RK58\:DHKV$I?K3MEDT2#V$YTC 7O\ /8B5_P Y[K'TU7BX61*)2ON3= 5
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M^!*)!\0,;Y^8 B>=_-)Y1Z?;OC?/<W*AP">)7!  ,=>4=U&*8E /(RTK)7*
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@#\" ]OP/81#X_P C_D?ST1<]$1T1'1$=$1T1'1%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g509388g02p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g02p02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!E<*/@        "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$
M)@      #@             _@   .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              <\   0P    !@!G #  ,@!P #  ,@    $
M                     0             $,    <\
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   <\     4F=H=&QO;F<
M  0P    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   '/     %)G:'1L;VYG   $,     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $    !#A"24T$#      1
M60    $   "@    10   >   (%@   1/0 8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ 10"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M'
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0LF4]8VYZ"$A!!IIN*MC,5:G4NH(JN-P>!$K9@ZRV#.U-9F]E1_$&[,]U*%
MVAJ25>M/3*GV6BUZ!8M.[-HZK2.G6#(]BN#9D6VAC I^.2B,R88UE><+:(ME
M5SPEMVZ21U]VIU;WKH33_9;4M-W?K>XS1_6>&*T!<Z+O"VQ[M(&"-6UBX"R5
M<)Z]/#0KM9/O6(L4L:!ZE7-\F[,EK=(L2O/@(T"SZ2Z Z:'[@GQVNIE_+E]T
MV2=7/*=V5UKL390_<&Y-9&8HLK!8"AKE?1<*4):E+-0P(UOW=46=(Q[RHBPS
MO1X&NT.V78+?6VZ_O_38H'NLQHVRB'MKZ&E[-VIIE_2K8-I%&T[>U7<2Q0]>
MW)\-DM9XP$1",SY<N5!?EO094G+A%NFS>$9M&V][0W:HIV"UW K@??<[<WRY
M3=(0===E3=)F""PU'6BZ[0H!^MU+8NG6,%&HF2U^HECV%+#BAT&=8Y3B79#A
M%Z&G/"P[+:YUH4ZBE^ZT:3T1&:[[,:TI^J:OIT.(VA8*OV'&74>-$[6V03+E
MV"\34KUY(DJL[30]2EG9<(>W8G7X;:XV2+0=:\%GM,5 & &Z>WVJ[E$$^&AO
M+PX-6(J>C#%457:QLV+7X=<V#:9#U]*.60N*9"(P>&Q6Q,:8EN*D:[$<]\?D
MDV='N(]JP?L]X >UM\V"WR1_9/3[X>Z:HZO4..5VOH.;L?8FHIW6T16A[L#0
M=J=O0]G6-/V;/K^3%S9$#T'IF)DL0^1EPIT]V213*O/A.6VZ]9?$HT(YNNO0
MBW?GL9#WP,LZ:42<'ZY98<TX\_7IXK-A3(L#KCFKY>&Y\:<,0A)B/ZHRLPW/
M>"+^U7P]>Z=4[^W/N@OLUU^ND&QQZCK6JUV^Z%N!FW:@ZY5LCF23U=JBPPMJ
M# -:+VU#TLA:+:]6B,PS8'&Y<MI8UO(I1%&OJ]X&6TM =I-$[W/]@].W83HV
M\=@#\@^QH>8*[#[I%;UKA\.J1NK=,N[E)UKL5/=)#VZ^WD<@!"@-%_=AS,HK
MAR,1;(Z\>#-L'6U?Z9Z^VQOVF[ UUT\KW<K6 :#6==F*M8+GJ/M+K<M0QXXL
M2E6HK$A6ZKOV$V0)%HL)4 E$=@P8L*,_%=G22+'PW@O;U/5"CZNW7VUJ6P-:
M=9.L/9WKEU!@A-.N56P G>Q6I3NEF+UNLDFUD(UT(T:@EHP@>,K,:MQ2,@>T
M7?=9GNR,OD4U=%^'@=T_OWIWN>7M 2=B=7>@<GI>1 QZS,@R;@7?,:Z*8OL*
M<X8DM"!J4T9YG(%^-.DY40:7@EC$=:72+4_87PI[)N[/BHYA[E!U_P#LBPCJ
MB, ^\TZ>0^Y:KK?"S%GO%_9'XOSHQ:E9]<-$/Y&R+Q]Z\J;GX\;>GW >Q%C'
M9+P?3F^=R[7W>*WU#H=U+U/I3-TH19HRCV-=;CZ7VZR7"M6^R0)IQF#;:M9Y
M1[(Z=6T(&R(D7+[^"$E_#"4E'V]>K?S+%K3X/^Y-G MM[AV3V<J*^]=][+=;
M.SE/V[4-3/#-/:]L?4H5* Z<J#&LBEG*&3]:2+-VMRS2"=HS.($CS<EE"&QB
M&I92M4W_ ,"W9^[JQO.R;U[%ZHO._=H=M=7]N@!K&AY/W%X-AH.LLZQ(ZTN6
MKREX(R;1K\Z!<Q$4XBP0CB$0($Q^4_,7-4^12&ZT^$<;T9NOJ)NV7>-&"9_7
MNX=J;G<:3H_0<;4%)LTCL1K('K4(+K<"!92DIC%(@@8CTNQ6V38;#8V,HB2)
M49,6.O!%D?B%>%59>[>PM]W</N0'K]G<O1JH]0H@XE3IY]P"4K/9)>^'+O)D
M13PQ,X?+A+^;: C34:0S*Q\HJ(N-?ZDX12UU;T_*Z[[S]@>W[]Y'E!6Z]#Z&
MTY#H[(.1%(5^7IR5;)$L[)-K(O1Y\<]BR-)CP6AT5R#F(O+LF3[5/H(H=7OP
MG[K;>K_B%Z $=A\U SW7[:WOLX$MH:LDF8=1&VRX52U)UE<!L>Q19UJ D&*T
MZ M+PPH#P5&$G4)C):2]%DD45Z_X%6UP^HNW-4B[TZ_4J[=A]L=0MWT2+J#K
MF]K?36K+IU2(CY\ (WK@;<Y/RC6+1@9'P2EQR,$[.+2"=F-2"98I-]J1;HV[
MX1N]MT=L:#V0M'9#4XR:#V/IO:)B\4O0+%#[$UYW74$+BWZEH>W*7:0*CNGK
M\3%RO9C=S"=DV"M@RCP:.5GQV6O,BOMX1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6!0]EU"=LP[J&-/D+O=<IE=OY88H:0
M;BL5BU&+"!"S6RRXZ1DE^02JYEEV!'E.38J([3\EAIF5&6Z19[PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G"+2W9 $#L_7W=M<L^Q)>HJX=U5?1)W:<&<@9-UR)GUDE&(7:*16_%1!
MD5F*XZ8:E*DQ\,KAX<R\UZ?6DBSG7L2&/H-(@#C[MJ'PJC7(D&SON^W>L<2.
M'ALQCKK_ *W/;.%V4(GK=]HY[14C*_6OS]62+,.$3A$X1.$7R:?8?]7L7FGO
M1GTK]DXASTJ^Q7HSGTY_)GRSPB^O"+_/J3\<^I/EC/ISGSQ\%>>,>G/Q^GSS
MC'E]/GG&.$7^N$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%&']-/4H/
M8JR==+/5[33"8'6,W;438-FDU&%K\[3Q),$&,D(DYFT230MD>4/L0L2+&%#1
MYCT OF*XXS ]J\1;MJ.Q-?W]N8]0[U3KLT.6TV0=J-F"61N X^E2F6YBPTZ:
MF*MY*%J:0_E"G$I5E&,X3G."+,>$3A$X1.$3A%I2Q;WJ%8M=@JQ(?9%?-/YC
MYLYZ,.BO 0:-ASI(VM/3'LD$$%QW9L;+,Y^*.D-C\/,/2,X8RZXT1>M%WEIZ
M<]-CQ-E4UY\=B>J:TD[!PJ.@7 D%"#J\*=QYM11L27.==3ZFL1HTAW"\H9<R
MDB_99MFBJO8Z+6WPYXH_L(FH6!F!F1LN(EQH=*+2ILY#I2-.8%P8$7+TT@W#
M?98R_%:^^=DM(41;)X1.$3A$X1.$6B1.TK)/[)WC3+]5Q'J59TYKW8HZZ>R(
M8R4/6RW7^OE:YEY;6!:\!X-5%$<-1WE3F_E?U26TLNQE*(M[<(G")PB<(M0;
M(V66IEAHM6 5>/93-Y7:<1$33OR#$BHJ]??.O87(2+++<>FX:1$83[!MMM3F
M7G7<)1Z5-]_2BU6,[J:'E9KD,I8I8(U8@2#C(::,FO2(Z&X;<PBPIR(R\F0@
M6TIY4J='2X/PB+)SB3A;#S39%F&Q.PX"F:M:VQ7:W8MB5]ZS0:WCYN('Q,1D
M/V?YK3C\Q\Y-')P %SD/K?E0D3Y4IMM'N$.5AY*L$V+TZ)O2N["VMM#5P(:2
MRO5T*M/D+.[F-@*:FGI)V),'A?0ZN2\H!+!/0R<EUIIC,QQ4>,IW,=Y6"+>'
M")PB<(G")PB<(G")PB<(J(]*5[N[54=WHA(#V$8N6P*C9JOKPS;3Y"SU67V#
MF'=]E =YU=F=9RP^AZQ;UZ[J ,DF/B5VK0SC(R [!;.13#JV^^K?'4BBD&H/
M<ED#I"MQZYX@M.,*V;93M LYNY;*N,?5]5A(IBW!FV8 RUFT6POL38$2T"QK
MVW#!RGTK5A0R=A#8\S->9S&S?V^_V@I)=7:!XI=>T1=$:YL0S5]G:N]9(38W
M>O&Q-O&2,P=J2N1=S$*<\$OL\H,K-BW7'LIFII<)_-U89];M;&P TB RB=]Z
M)OO56">&;V/V3VSZ6Z>WSMZ/5HNQ+FU;&;*S2A\X76?>Z[<S]:0X*@DIY.;'
M8>8$M/93(FO+RXM:OO,9PA)0-?0?8#[5//A2G")PB<(O)/XEY!&L0/;>_9$D
M<0_=\JQ(][S#>]W]AE'DO#WMO1[+*<^K"_3Z?CY<(J4'+]V(UO1(IG0-7[2%
MRLG7M4"[)3LBE;HM+$#<DD@^ZX1K0;:]<M=IP/<CQY(^TG:!3K12HT>>"4EB
M,M$DN+;^O?[U&/W>WT=O1G+OJYN+?NW;/;J/N4+'"QZ1K"FE;HH6-?!SY5PV
MO7A1Z+4V%QY314 ;UZQ M$ W#RB(25\L5N<O$=Q3>7&^SW>]*^W5LWPVK=W4
MVC'*;JYV;9'KPT6N]HL%R^;M[M-NM12F"2<U3->J;,FZE"QJ(V*!Q8'OD9V2
ME*RKT^3[%I3^4)*=]]\5)SA$X1.$3A%H/M4$UI9>LV_Z]N>R3:=J,YIW8HG9
MEL&^K)"M44A5"D6TG86$#RR\RA89V9-8PD80SEUE./<I/^XK(MCZUAUX=KJA
M0*E/=*56#3*O$K)-_P _;D0$8)!9#SWO4S&5[66.1'D.><=C/K<SYLM9^\21
M9KPB<(G"+\1)EV0.GL,X]3S\*4RTGU83ZG7&'$-X]2LX2GS6K&/5G.,8^G.<
M8^/";[Y*DMS079ZKTB%]P3KG8]&6J+KT;2-@O538.DJB;VA9Y%K%$G;]#:IF
MR<ARK@2$.)KF&K39Z7>"<.Q2(4-]>4R8;Q-]_L4I>H4WLR5OUAK&[K,6)#]:
M:XI+%BDJE#WTS]O7VLUV1;ZO*G!LOBI;VN7*W+*Q70\^;"2C93"<R77(J/9M
M_NRJBT[<NJO:MEO7@37,@.]KVG]N"6X#E?N>TK4JX6,)(V;7C0BQ2["ERP?.
M$0(K:;--73K 7BOO$I(_/N#ZQD""DBM^X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$42S_3+4MUV[:MK['F7#:$>TU*RTO&KMBG&K7J8 $NL*N#KI$
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MG")PB<(G")PB<(G")PB<(G"*!OB-E]6,=:C]=VF5K\:!9S !@0%,L:')RCY
M46AE5,B '8PL'UH8DCFH_P HOI(2<S(+#"IHY.)C3.>$V;TP/W=JQ3IW0!%_
MZ "=?W6F:\O%6M ?8XQNDB5ZS#5"R565;;$JKC2R]+.%]=5XQ-$)%+L3M,DE
M(P.P9F/Q9+\N+ZN$KZ%^3H#6P==DWU O4FM=43U!*T%)B]>;&7LUAL?3SEOK
M=5$22CPD.NNQA8>)E^-6VX:6Y4XB6MLEQXI92#F8Z=NO:B^FM/$;K-X@=ESQ
MW5]CJ%:T'KPYM\"44>$G)&S=9 K%L^H23<4=#9CNU8N[8M3V)EH"5=DN?)\X
M-.S+];\J-$5WWZD6!U;Q1XI$3K*3;NO%]J92W;:M>JKRW%LE<LE<UI-KVIYV
MXQLN998N(.+)*LM3:@Y'B0XSVT:4Z01/D,('H5,#??>N8P1?FIWBU]>2>I+1
M>.PJVNLN43Z^)!C;::Q;6["*V5K$5M77Y.(0JXIU#$XK2+! E%P[\;"P91N6
M.5,FH::E/2GV^A89X,DV,2\(S41&$\F1#GU?=4V(^G"DI?C2;[?7V'DX6E*D
MI<;6E>,*2E6,9QYXQGSQ@E:D]?L!]J^GZ']_%.]6?VOOG](]K_\ #A13/I-?
M0![%D'B5X_UR/A-9\_\ \]Z5CZ?+R_O*;(^/_?Y?#A": ] KZUXGC4)CJT?H
M;$N0<B1<]G->XD2JR-;,6*,QD>?]J^"$NQY;1(NTCU.#H#L60W+E):86PZE>
M4*R]P-WN[=N7&P'O_!JT+K9J)Q,NYW&2]T1XH<PPX1=01'AS2UA)J%1+?^32
MQ)>T">EJNA,OQ +YQALNNO/&;10U(I15VF-/Z5,W(/>GNRWBA,'JY#/# *XO
M4W7R8HL;:'!+AN"TP_U\?]Y:EJ!BO)R>N7*8]T3AB0WEV1ERL1I"WHLTV9;^
M"$ -$0-EH6E,MR<-B7"YM(D6)%<!Q;0TNBEP!/.QJ#9R6:T-,*??@T%SK/F+
MQH"*DMA!M2<[K6](HI:^$^V)9[7]V6P9K8MB%I"ZAQ&,;7J<>CWV;CY,F>T6
M>K$4. CC'&WO:-1,-B8F),!$65Z%9>RXOCPIF*=%]"S'@V=+Q3%M8NA65-NG
M9%O?64XB9?%CNB MH7UBNNO)9A2@Z+&+3/VJ6NC.!Y+0S$(08N$-U0Y@APL
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M'AK*5-XC,-(:8PVI'WF48;2G"<I^]SCZ/AR47Y#YAFO RYY^$6),!ALTF\/
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MY.F.K4VY-EY0G+C[N5Y0GU>6/59VDM@VM',K9MJ2LY,"&Z*84)[B_BV%K7/
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MV_7]GP^&//./^_Z<_DYL%T;*;3[!7K\X5DC'&F>K#  D=>.>)J=55W&^#?\
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M'3&5A2'U)SEG@PFC)2VF4T)^+9A@V-*NY=!DV3\67K/PVE[).)S(Y(-TM=@
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M\H4I$*&I>8N4YA8PO+_LDQL,LMBH[;((5C7A=K^#=@5-?QQ/G,G.5A$$"^\
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M%6A>$Q^$F8^'_HX/?3]7]L _T9_?^/\ +]6<E\%'E4[Z+G.KXV5WV]&9&=>
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M*RBS(\IN+"_1JZWDS%RKS@0\SU9D(7)],=>48RWTV'*L@LMU[; T-LT_@Y;
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MMDO;UI03IIHQ9YAQ[O(IO1+ELU+TAL[W'F^Y\3CX@S+^,=6H%:"@M>3EB96
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MQAM/LYZY3?E][RW>%*)QUGZ%1.4VO-WK/M0B8MV'Q5J1/A<$5FF5-'#)N.+
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M)D;?YY_WGK7S_P!)S3232#,?CBT*D''Y9%U#HZ,^L!>30?\ #NE?Y6US]_\
MMQ#YT2WRB /[Z%^\;G3'S8KS6)46Q9&7C.SSJ#16:@ZP:C7CD<10UQ[5V?\
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M[)*(1+Y881;[\@N+8L$T%>,9@3=J6N:!0DL '-;4ES0VAY\/BG&5Z(E##B#
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M!$J+A=E>J*$@UPJ- ?I=C>/_ *.S?G_]PTC_ /\ 2Y_ES^?E>[OP/^<*P_\
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M@%V!&RB7R$H.388_M=!DY1[4;/2I>$H5#D85[)>.^#^VI&P-)Y.U+2B1($K
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MAV,CZHF,U^YCXEI@6NCUT!/>K-'HC]^I$V;;"NJ]I:>L)EZHULP2J^SA5O\
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MV8HZ(X3.GS9>:P+ UBL!H^?>SMFL1:5%% PT)*I1 A)98;QCU*4DBIYH6O\
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M#%.>!FP;Y(BZ1=5:\C:XH-"J3R:_/+4ND :6LZ"JPZI1)D4+"CQE8&@QZY#
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M:<ZMZHT?>]P[+IT(U)NV[K;-MEP-V,[/.O0L37\S55JJ,3'%1:M46RCLLND
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MVNL<[AZ_;#@W[7S)L]6B!CY*L-8FA+%5Y'NMA!6*NW$17[+72HEWTYE0C8B
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CU>Q;<6I+7J5Z,)\\^9%^OA$X1.$3A$X1.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g509388g03k03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g03k03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1?D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %\B^8(@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     !  E,S,  $  0"4S,P  0 !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!$0      !     "   "0    D      .$))300>       $     #A"
M24T$&@     #00    8              %    #,    !@!G #  ,P!K #
M,P    $                          0              S    %
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   %
M4F=H=&QO;F<   #,    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   !0     %)G:'1L;VYG    S
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]5220,W+JPL6W*N,5TM+G?+LD@D
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M$P;LO+_KV-^S8E?_ %MMMM__ &PNWS\VCI^%?G9!VTXU;@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0UF!M*3HAU7[@%=LD$_9A&4+D4[#O_:S$[:M-N?NQ)(%:P! -^"6+9HW_1;
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M%G$1[2-:"NIA%Y*HL+=FBBB*IRID*=02><Q2$ QA H=H6B3=M29_2)_F%2N
M"V\0/4;_ "GI23<R)JTR''?AY@5:M<[0FG+W:,2XXWN\5626A+;7LODLKO6K
M:0UJD^W_ +:O6.[U')I7-(JPMBB^A'-U+)10I2S9@NE.V!GN.1F[M6=0=BP9
M54D#D"TD3!B)J+SD108SE5)\""2/>!'OI[M1XXX#0\F0P>HXQF,)C",22$/F
M#:E5]6DOXT$2(*HS, Z8KL)U9Z4@*2;V:1?OI5R95Y)N7;M998]1=RV<LV;[
MTF?CRCETJ850("B-HBL?QSX[TKB]GSC*LUEKDXSMM:K#/TJJVV?"PL<P@9]P
MF\1S//W*K)O)QV:UET#HU0KTP_G'5=:/U89C*E@64-%19W+G,P$QJ0(S'J8T
MD\SI-%4((!,22 >0Z#P'*9^$ +SU&I51E_:A^6K[8]OR_@A1)(ZU2Q5-GJ.Q
M$:*B9L^U:W1!TZ5 /2 '85J3G\FO,@8AS(JJZ2=NN4'40 )\G@DRJUT[MHO@
MHW.NFI\.4@CGI8AY=4 G+J?%N6XV &I!YF=JC7U+@3R;YJYAP%I/&+*)W3+3
M#YC;ZM:G#,["(K%,B89[54(F6N%JF73"O5MBL9.9304E))!S*.6OLHAJ_D5"
M,S]OXX43AG!;TJMO[.%+:R7.&PBD#?-!LMM&H)@#;Y=]!^"."](OIKLWGN'&
MX[M-CKZ6"%[M<'8[:=NL<EY6RH0SV^T.&S R,HMY6)#.TR/#S]DJI,2A%6CG
M'O4I;97RI.763X&48"L-U@],_LIC3K1%JV&>:J 91%XW@:A3'**A ,RL"Z9O
M./3;F.Y6TC?UFUT\%&Q\R?*OJ-,+K+L#_97\_AL!S$Q5ESC3X<W!SB BR'CO
MQDRK/IE@4I4+J%?)9](,!2"3LOIEP5L%^<$'S'-Z*MB,@0RB@II$\YN^F]Z[
M<G,[$'E,+^Z('RFME;:)[*@<YB3\3K[AH.510?M)OB"+<2N&G[AL^G",-IY;
M$G*(B=HL4).L8TT:)HZC8R>FIZK)S/MY*.H$0LJDF99&Q6&2BG))"MB9+:P
M=;RWU.4VCF1N:W(]5E/ZKI[:./61PK*0P!&ICTMW[#8:ZN>W>$74)(6Y;!!:
MW< C/:N@=W=M--N];9[5Q6MNRGFV#_K_ %_L_7T^?)5K?4'IN#R^7\8I:L7N
M2U=GT&QE1(BNH!D^XB  ;O\ G*'T^H]C?<1'O]N_62 RE3]&=#\"0>40*R-(
M.AY'QF#KUB==/#4D"IY.-.FBW<1R@.?R'%(H_G[?<!#Y /V[B _3["'6C=20
M3S$S$R8]QC;PJY3XGI,\HW\>L:ZZ5=@\,W60T3!W%=<.O</Z!-"T3#OYC$@[
M 164C1.81\PF-(ISQ"AV\I44DB$_*4 #0N"&G:>7T!M,:R9'N&Y;,@^!_'ZG
MW^^I&>JZLJ,O9.#L[RIY</-:VVXZ91,MP_.8BE<7$L%W?2,=O*EJT$'<IR!T
M*SV/+YFIV*-++,V%!SF"KP3;IFYB:S/2SU'M--$T;EN!+>50"S$FYF4,(7V
M T@\R3&DBJBA9R6)"J %RF#)]HR-?"-M*33<_# !I7ZYJG'G9.3UGY,8+=:Y
ML&!-N17,CD9KF9.;E6'Q$YVIS\!I-ZN,+&1FI9\]N&4S5@9Q1).)A;M(.$7
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MHH8[5XAYA,@Z160/V.F8 \GXE@,3PK'XSAN+0V\3@L1=PUY=8SVG*YE)]I'
M#VV&CHRL"00:^J>!<:P':+@W"^.\,NB]@.+X'#8_"OIF[K$VEN!+@!.2]:+&
MU>MDYK=U'MM#*0*S7[3UXAA>//&*-X<YW."UUOE0P<C=SL')DI"K8!'O#-+
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MM_5,-G_I&VU(8RN_L+KI51"LK.& =F#KZPD9/97<Z$#4#34^=2<2[7,?%&X
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,CI2CI2CI2CI2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g509388g03p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g03p03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1Q:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#Z^<C X0DE-! 0      "$< 5H  QLE1QP"   "   < @4 #7!R:6YT
M;6=R(&9I;&4 .$))300E       0"<2=# TR":T*.P^V)B,ZT3A"24T$.@
M    [P   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L
M 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %  1  M #(
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q =>            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$1       $     (   )    "0      X0DE-!!X
M      0     .$))300:      -!    !@             $?P  "(P    &
M &< ,  S '  ,  S     0                         !
M  B,   $?P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   $?P    !29VAT;&]N9P  "(P    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !'\     4F=H
M=&QO;F<   B,     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MN-!3[/TM=F1[/\-?9_@_T:@.I?4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!/ )8 P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
M       &!P4( 00) P(*"__$ '@0  $$ @$! @<&#0L-"@@)#04" P0& 0<
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M  :"?9J]GLT3QVW9L8R<CC@PV))])-QLD8Y47Q4V,:YPKLJ8L/W.D 6N>XF
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M>&^Z6[( U+8Y-+V]78>PZ#U';+NL4R)JOI/1E2Z:9Q@9:96T1\&V3)+,ZUE
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M$FYB8XF5HF(&I(%_7%O1O4*3U9]470CKS=9WPB<8-N6LUZ^ZWI?3%M#0M5
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M-OU.OP@4(T4%-%&PT=IQAN6VY$&O8PYC&'T [:JM&F6L#75,())$,!.$&YF
M8DWWJS#9-[>/W^K15_;O#1=/UDA7ZAZN'[55L-C975-HP*:!UVAGWZ\6Z<M5
M3-AV'=D8&=N4 <=UZV.3F?669[S$D]-'.CR@T?%<4_RC8Z@PN?A#"RE4N2)%
M5X:&2!9TYQD+@DV0NSC.XOP$E:D@O"U=234;I9U:!I-HVK"W=T,["W63Z@C]
M,UW1]C3+97@-Q4C8L6E@=ED=> *U19@2,0O-?]$GITM##F*Q%-9?\UQR.V6G
M]V>7-9YNN*?FP7.: 3\6<(<9^])(UF+3 XR!!,C.(_=UWUMN.QG@P/"FD]Y
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MC+F[**0X<>*BJ^5?=EPBS$7R%A9$-O").JNV^<\Y%%K'5C3-1V)SI;3C"((
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MD)D&XC.UYC>E[G=>9RX]95E9V3TBMV4=*BM:?>$J,["?H#$C51,*K6^M2=1
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M^/O[<\&(SRD1UZSJ",_1: IG<^C</H UOEUK_1&_J?O_ ,E/T\?#_9)O[O\
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M5G@#EF-Q]&Z!:%Q]2K,?9UN]_P 'T,J.SX_L@?C[\_'RX1O-M;3NW;K<$D^
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ML:;M%KKY*/!'B+2"8UM4[%IKIJN[E*G6LDVW!NEEK97:NSB4L\,%H>.,ZLL
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M=67O*3>GV;7-1$R.T6*IM-X)L<=+-!*28O\ ' 6J6.L=:%+$A[&,J8!4(F]
M=IL^7:XT/-Z$V=VK4NXD7KUPBI_3?][[_P#?@V=_G/+X\>WT^E%E]R0-CE-2
M;/':=/1*OMN90+='UA8B(\>5&AM@N 9^*<1)C"S$D=/&1K#Z/<(PYC*F9$+#
M[6<MY5AQ!%X52.O+KWGUK6V[!^O;-5*SN"R&[#!UM<=0$Y+&JM1TWJ*Z#^GR
MSLWH$)JK&QTVDFB[]2FU01N9<8$(;KUV84?K1X>%"E*J12V5X4GK;"1M7K+=
M Q,JN]=*=4ZB#A&NS+JH#5R-\IM_NK(!>9=;7;"*]4I TJJ;5!#*?/LC)NUS
M9D9H.W'J N]D7P(>%HZF8<141KI$DR3;IZR10A/T+MJ#3;AKX!7-VNP=U5\Z
M7IXT>/I-R.ZPK9.KQ+B3J[#%:NL5=KM%:$QIEW@CXM/CQ9%[(].FS#FYM$ZF
MVM9:Q(I=@V!1:_:#-5DPR\!X$1*P6Y$H>J(>A0"C2&75*\EYPPXVMI2'(DTE
M"7'(RB+Z[9_OGIK[\0;L^2%VX\%%<7"+4[KFO>VM:=*6X;MHILH[MD*(!^XM
M 0&+L9?) E;Z\(E9'!C@TP&ERT"Y\Y;*BPN<.B*3B9-CKCQW.PB\79GA*?"3
M5FEW;7,'I:LUMV77-6]4%K%[5M=)>=(0CFK[1U/L4RMV&H4D?6*Q>+Q71>G=
M95FV1]9B&JE=SFV0EQJ$F%49M%;V>163$\*)U<U:3LA$[IE,; J58W)O:@ [
M>X OK1PU##3>IRSZ]MPL)7]<!!;6JXP'2U9 0W2TC)1(J]5B?;MANOPREP.D
M7K]TD[GM74)T[:QW#>-?D-6V^Y"BCEBH1-J:Q-KY4+8C-<E-.1R++,Z*W.6'
M]*1HLG#SD:+.98S,GX;Q-D.M%L9PBJ#3']Y+I]]_;W^D ]PBM_A%65[_ ,*]
M+??)+_Z'MJ\(J2Z^-SW?IUZ+NIK>>MLC,7[5>GKC=*CDR.27%^G@HUR2/\^&
M+F#T3X^7TIPN*N=$0[W)5(:3G*\$7CU=_""^$-TMM_6>H=WU"N:ZIVP9!TB7
MW;;*'3&S&G])(WAT_P"O N]-Q4?7NX-EU,-,GE=@6W5T(2"N1.N!,':/MW8>
M:R!!V\"T1;6=2GA;1?3;U#;=TL;UG330;5-8-%I)I.X9L6^/2!W361ZBXMF/
M:P%:ML9"OZ>4@/(UV9V9#,6!X3;BM?;15)R)SC#)%4%?\-K+LVO+3LF#HO6X
MNMTJL4Q!XW8NHN?'JSVR;YUA;UZ1*Z'"VL#I"QC).M9A705GO*=HET@F&Q!R
ML0)->C-3"!H811<MX<ZUOTE.T*7TIUTM0<ZHA;/6JR[^(5ZVM^0Z+*=UOV<'
M@*+TE: [BAM ,V"FA"/ND;P;N8T,J="KP0I/(!R*4S?#'7NT;:>H-#TGKFIU
MNG]9M,Z=;[8MG;D8]TT:G&+]MW61"4:UZ&KD<YK&_P!KL&N!)S4D4Z_9:K=:
M[;0L=)J.>FY'12*Q>DWPMMIZN;/IJMT_IRK5;5M;8-@"SY9?J &EW*-2JOKX
M)LFP8L8:O:ZG'16ZZX))2:_9-/6(;71XNTMP&&=ASQ,N84&$7JWO']I7;_WK
MM@?YIEN$5H\(G")PB\$.K/PJNQ.F'8_4!741J%<RNE.IHVU$TOF4P"V):.E2
ML^# >ZH2-P2O"BY<:"E=1<.73<[9Q5R%;'^+FFK8D%VLX618B[^%AWP-O,X*
M-UOJ&F2Z+M;56I=M#[QLXF0U;7HY?KSQTJWB[ ]ALZUJUD6Q+K\X.1@$K,$!
MA:GYW.+SJ_8G030FT$7] W")PB<(JETK_@<9^^UOW_3KL?A%;7"+#V(@\(KY
MTK'PUE\8')D&,/QR,MC+T*$_);P]$$1II:4UE;2?*1Q<.61>1VMPHS\E332R
M+^;#7?ANMDT74^#^TPVK.H6[3]AURJR"NOK13M.Z9KTN=I>7M0S6P>YV[MN.
MBV0U9Y N2.TY2KZ_J3:4?$AT?O.NZW?&LERY%M;8_#"R:.95&OFD*C5@UJV)
MO77>G'I^\VV;%L4SH;K;U/T;V$4X"GZV'0H5MGYV!9MJQZG6#]XE1:G1)'G,
MS#!&63!$7<Z:O"R7S>FTM&4NR]-U2I%4WB;UF&%V4)O,O<K #SN/0/4-O>A2
M)M6G:5IX^5AJ%TR7\#;FV+8C(:2=ILH.JRMOG$""+VNX1.$51A_V^-B_>CTQ
M_GEOKA%;G"+5KK5Z@9/2_P!+^WMSAQ2[%=:]7&PVK:DP,+')EUW#=B4&DZCI
M<(%7XLZP&Y%IV-8:T&]%@8$XQ*9EO8@1'WTI1DB\<ZUX<:R!0U"I=JTR#M6W
MPE:9J^X11^T6C0FQ#VX19[J)JQ+&MNGRXZU-7A(*8UTZ8O9\3:)U?LU  [JU
M:/(A9TV5+3@BL85X<NJ6F\Z[JM%TP NH2^[B'ZPA7<7ONHQ:N8;7K7I!NIJ%
MKXW.KK=<O6U!!GJL?"M:KP?!22(_5-GG-6)HX2B5B(11][P\-;#U>Q6ZUZ7J
M(((.JMIM@\GC?8]\4+*,Z)ZB-OT316RRD[7PF'0.J0L;Z?G*%=](X</SZ9/V
M!3Y8LU<9<K 9TBWVZ(^O=KK!V#U"T!ZC5BD$='%0S34<#LI6R2),"<MNS:B+
M*V20)I@FF5LD1D:R(3T5@-=;C80.94H#>1]1L(9V#.> B]%>$51[0_OYI;[[
MC'^CO8O"*K]=2=JMV#=:*L'U],#8W18_(/V"R6,<34YFNU++^'H@ZJ%8J$)=
M\;#*D3'%+;PE2TH5G*<$5H^>;W^MW4GRSN/Z!\(L*##[5J\>=$K6O]%UZ(3-
M&[(1C S]D%1R%BLI.2;L9Z:S UY';E&CYF;,+&BCZ5SBI.7)GSGWY3[KJR+-
M>>;W^MW4GRSN/Z!\(GGF]_K=U)\L[C^@?")YYO?ZW=2?+.X_H'PBJS:DO>.8
M]"\M7]4)_93HN6_)W"WK[7O2:O)I7XU&1XK><_VZT^,I..]*%9[N$5I^>;W^
MMW4GRSN/Z!\(GGF]_K=U)\L[C^@?")YYO?ZW=2?+.X_H'PB>>;W^MW4GRSN/
MZ!\(GGF]_K=U)\L[C^@?")YYO?ZW=2?+.X_H'PBK#6$S>/B7_P C7M49_9/N
M/E?*7"WI['O+Q?*8;\2C+\9O&>SQ5J\52NW/C(3\,'CO**S_ #S>_P!;NI/E
MG<?T#Y43SS>_UNZD^6=Q_0/A$\\WO];NI/EG<?T#X1//-[_6[J3Y9W'] ^$3
MSS>_UNZD^6=Q_0/A%2^Y)>\,NZC\O7]5)[-T4W+/D;?;E^,_YD>\FEWQZ.WX
MC.<>-XZT>.O'9C"6U=N>PBNCSS>_UNZD^6=Q_0/A$\\WO];NI/EG<?T#X184
M.&VK7GCD@!K_ $4$D6<T]9+(^(/V0:]8+%(@CQ;YXV[#UXRLJ:>&"10YTI.4
M_.<@C1\1;^8\..VV19KSS>_UNZD^6=Q_0/A$\\WO];NI/EG<?T#X1//-[_6[
MJ3Y9W'] ^$52:@E[PP/OGD*_JE6/?;V7EWRMPMR,X?S9I>74H\2C.>,TE7<V
MM64K6GO4A&?U.)[?X]7@HK;\\WO];NI/EG<?T#Y43SS>_P!;NI/EG<?T#X1/
M/-[_ %NZD^6=Q_0/A$\\WO\ 6[J3Y9W'] ^$3SS>_P!;NI/EG<?T#X15'M27
MO#)+4'EZ_JI.<;<$98\E<+<O"G_<G<_%2]E=&1E#.4>4SE:,+7A>$)PC*5*4
MDBMSSS>_UNZD^6=Q_0/A$\\WO];NI/EG<?T#X1//-[_6[J3Y9W'] ^$3SS>_
MUNZD^6=Q_0/A$\\WO];NI/EG<?T#X1//-[_6[J3Y9W'] ^$6(T LRNI6A=@8
M&1C*MM[?S/8#2Y4X8V[[XE@PG$27-A#Y3S>6O)YRIZ$PK#F5IPG*4X6HBO+A
M%2&Y+=6*05TT>MYT97 S6SR$9PF7E-0X:'Y.H=K(CLJ?>4E&''EXREM/;VJS
MCLQ\/"+Y/=2'3U(:<8D;:UX^PZG*'67CPYUIQ"N[*'&UK4A:<X]:58SC/PXX
M1?%_J)Z<Y65YD[4UO(RXPN*YE\T+>RN,XI*W(Z_**5XS#BT(6ME7:VM2$J4G
M.4XS@BA838G1_7;A?+\&NVKH=PV<\&>O1[W01WYEA77Z^.JPA,G$J4]'C,1
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M\&S_ /.B7PBN#A%YX7KZ(\'>A,$!,V<:K<7:9]Z)+Q"FS73 I\UT_3!X]<H
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MV46]RB(,DE!F!"5=<D@ ,/:DD+,V2D+7)EK!$WR! "V%FYU,6,38CVO(DZO
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M)P6*+NPU%1 \UC):&,FQ(Y%2IC;RLD5I<(G"*H]H?W\TK]]R/_H[V+PBK/7
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M:OX7TA\\G"*+6Z:_>QT87:.G;:9&/!(L&!DAFQ:?%E0IB*U(CQS (X(W; -
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MM3X'ODC_ *;G=^FMC_9"Y^G(>$5]OD?\4VE?FZ_>X]]'G,/O.3=1?9*H[_\
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M8\;?M3-F-0[0SE7:W--(/QAOF78R,)+9D></A [D$JW7]X0 8<'JFLW?%0K
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M9Q7]MG[N?A_I\7^7[?.OG&^P]>_*++U'9GK/K7YQ\/?_ !?;SC_O_P!7)O\
MHL.[OW*)G/=Z_M^O'[W\/JY;>@=^OJ.^T;T3/[_Q?]N,_P"OO]79COY/XHG9
MZOZ?!Z_5V=O;G/P?;^URB#PX^.Z!&B)CN_>[_A_R=^<]O?Z\Y[_XAMQ\>-W=
MF7/^7^/^GKXSMNX"?:>_U(KN#7FOM:WBTHHV)>1YKLB4_P"=5F#-*QC)*%7E
MU%<"PNC'RHU&28A>5)%D8L?Q%2&RN%Q9:FW/3I[52&QMV:H*1AFV$XJ#'/%1
M[:/VO@K%A>P8J<_<WM;\;'+70?D-JY'VU_+U3E:@=I8?/<A4V>;Y0K4MG?LE
M!^VMY2%;8F[0W9ZY\SM#1.T4*C[,.SD5*<C7:O\ ][WO_7MK_P ZC?\ 3NYU
MML_E6?[KL)S_ -2V;07\:05[/(G\QJ?\6YQ?_P#1<K+,XSVX]6?7GM^#LQVY
MQ_#]K'J^UW<ZN?9?QZ.P+UESG[GK[L_'_3U_;^+DST]?C^*+9+7-ZJ 361,,
M9(#F3,5>W7H$>9$M#IEIR^:V#5,7[D/1#"JE*P7)#,#[PC8:W6H%=8BRJ2B$
M=>G27O<V+:MGH["^G4>UM5IY1+&O;7-2=JV.EL[/M<TP=G/G'T\&U#;)#*(:
M[9@VJ7$_!<O<C<I[9R_L^U;+0K/V2HWFTRL^E5Y/9LSF\D<N[5RCM/\ E([2
M\<I4CLVS[1Y[DH\B!KJVVOJ4^5#5V1M*FW]7N^5.RRZ=.&V"4 *1;A8=GV@R
M,?L1Z0-.WDI1<SAE1;*!:JM)"KJ"$3T8;+=CBT):<B,[!L$]V*ZMM6U[-7=L
M[J=4T:C=HK;?7JTS6JN96VI^RE]/9P^E0(=0--]9K'$,$%HVNJ\M<<\C<B\I
M\GTN5:-?8J>V[/4Y,V/F_P G[+7I[#L;-HV/DG9N5O,[1RF=FVOE &CRA]M4
M=CJ5Z8?M!+A4?R/L=%M1HA&US@$HU0!0(F)+8JE.?!D)5>9M;=>7-DV^TV!;
MHYR\Q(=K??EMFT32ZB#"8;961+9#H9&-QX[/5Y0K4G_:C*3Z=3S&S&D]U(;0
M*.)VT5ZTL^VFMKDO%7'5QC#YQSA3Z  'L<VMBVS97<M;1M>S[1LPY1Y49M="
MGMKN3CMHHT^3.3]B#:[>2*E3DYC*3ME-+910<:KMF93=M1=7+WNJ+U?!ZNS[
M?=W=OV^W_+W>OU<\[LS\?Q[N"^G3_N_[?Z=O?W<7U':?WYR/5;62PD?_  D,
M=O[AUOU?_P _:N_O[N[U_:^WSMU).P[-.?VWMLW_ /VM@TTZNU>/0_Y_Y5_X
M/R!_ZWG*LW_J^[_3_+V?;YU.V#V]^N_AEJ2O83[G\?;\'VOA_P!?=^\!OD.K
MO[?3?*Z)]OXNWU_P?O8^'N[/M_#QW>L">_+M[PBW/E[)U<6E8(2)M2;ESZRF
MM5N"\!O0P-5JSBF0P$NJ;.(5H>U9C'B2V4RZZ3HTLZ\B?#5'(S1M5*N!('TS
MMOV&H<9?LX<^AYBBQU':F4J%#[6;2=0VY]%GGZG2$T7[*ZJ0YI:]S*%3S3/R
M>GR!SAV:GYBG1Y2=2H\H';]OK-VWDC:-JY1Y0/*E7;*?*7(%';Z[M@V6:3C2
MVW9^5J>R,=2J^<HTJ_*.SMVRMK7LXV,L=_M!T0_YR/*$URV74M2VHRG%LLXE
M)'8(XP66';EX?;"OFTI/R1"84@^G!AR=C'B;?5IUMLKUJ1Q,J/Q PX-D@8L.
M,"H:>*?-FI%4T\)J_=2]??\ -[8]HV#D7D[8]J8*=;9]G%-S,5-SPT/=YLUS
M1G9QM3J18[:V;(3L;-I-5FQD[*VD5!,Y^[]W^#&/\OP_#CU=G?SJ ?QW>+3U
MKV5QV_Q=GQ_;[?N]V,]G;\..WXN)]'49]6G'MR@O1+P2_P#Y1GI;_P#:'8_Q
M]G[1NTO5V_T_A[_OO)K_ -*ME_W7;=9OYATQ%MTZY+^:_LLO^ICEC_C'-_\
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M^3_U++J^@0^DG^#7]@UD_*$ZE/G?X]Q'-3Y%V7\:O]:I\('RS?.!RU^)R?\
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M5DE,@$M9%QLLC 'NSHH@@N'B<*:*%D09#*2,K#A%P5)Z@.'[%:"U4ZDY5@L
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M]AK&?$=:6M"NS.,^*K/9G'"+6R %Z<8=5@ %]1.KY)%>0D&S%W;W3E,6*OP
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M'2*RNDX1OBIFKS$W-55B&]J,0]W,2&+T6V(Q7MA66?,C[&UZY-F56MPZ<"K
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M]K6'5W\9A$348XV2)F1%?%F:U&D$7Z.]8-AC0[O%#:T">Z.C"M@^EVSE^D0
MK!S7Y"\P9TR))53FIYJ@RU4(M'BVB'#CEUF%9%OU6)$%60R#(I*KJL;A(MBI
MP>K>)6KA9:0WB;>&PQDB?A7&370,J'5T C)6?0Y?E!PF3=0JBY;%B0383140
M($V9$(K*3NIHWT\V7=-99%>?B-<6FV-"W9_ID7#. *[.+H'RY<3(N3,&NO1X
M[[+^6@\V>&E19OFPU<M#;1%@[COE(&9MB.)(4\@FE:8I^Q*[ER?A[$LN<*;<
MA''"68A/"I=? Q*"+)3&AS<>=%BX-+>FK\I%\S(K9UZ:)F!YELM9JE;I08_(
M$^FZ="EC8#S:1@HCB-.'R2AUJ(6A+(KBRT0#9.(ZTU&DJ7 FOS XTBGW")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBA=RIN;=BNNL
MV0_52-7/.6$65KS==?EXE/5\]6GX\ABS@+&->B/#;%/RI.(")")"(SK4EM+;
MC;I%@O<#;O;=LO\  VF_FHX1/<#;O;?LO\#:;^:?A$]P-N]M^R_P-IOYI^$3
MW V[VW[+_ VF_FGX1/<#;O;?LO\  VF_FGX1/<#;O;=LO\#:;^:CA$]P-N]M
M^R_P-IOYI^$6'L6I#UIKYVL%]U[/<%6,,4 DVV1>G6'G!Y>$^/FH:>1JCQV7
M51I#B6W4_JFU^*O'?CA%F/<#;O;=LO\  VF^[_[*/\O;PB>X&W>V_9?X&TW\
MT_")[@;=[;ME_@;3?S4<(GN!MWMNV7^!M-_-1PB>X&W>V_9?X&TW\T_")[@;
M=[;ME_@;3?S4<(GN!MWMNV7^!M-_-1PB>X&W>V_9?X&TW\T_"+"5_4!RLP)
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M1.$3A$X1.$3A$X1.$4%O^RZ/JT1$/7T^Q7 \TN) QI\F+/D,+,'B,0.%@*S
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M.?*=F4>/C*/&QW>-^I[>WNY/;';NZTSRW ]AR/4=#JHTWL6DNV8O3TV&$FQ
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MJFZ\XXF>&&), ![JEKR#C=,@@RUO];%EK&L;A;823N))ILI'*+%C(@0.D[2
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MGI,YZWUV+,(3-CF\6"T)DMBX4 :RETCXJATD>/A$1#?C)'3H[CKKCG&0#:!
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MKRZ_8B%-)S8I6M1=,-B"CT:90*DX*E3(SCPE AED>MAI3B%T.<T'"3T@T$3
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M43S4*E(B-Y!YOR Q*8#7BQ,8:Q9<"Z"8=G<RZ[CTM]W.-R;N<<R9EB "XP!
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MYP0 25;0XN<&M:UQ)()ET$4V6!@U*IIT@38%X)RA9)O;%&B0(CQ>V!4R%$'
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M00-& YP:<0!(!B)C.)S$R)R,2+*P^11:L=:]<NMQZ8=L5+7>KX&X;I9P<<
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M, <['?HEK2USI (Q-.1!6C +@7"U-M09G&UY+6X1%\3@YH,P2UPF1"N4ELN
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MTRQUA+OB,1?/Y&?+M>7Q R]BX7!N+(.%KW<TE[+\"65&P=QM#KX(B-TV/]:
M[OATSH9&:N&'7 (Z6B=!$#XDMJ.]%8>CQ6FE1HTA[$B2Q%PA.$Q6I+Z4.R41
MTMID+:94]A>66O$QK.IS.MS)OQ-^M.&F[T>JRS7")PB<(G")PB<(G")PB<(N
MB2%C3$1R 6@0R4%U;3CD2=':E1U.,.H?8<RT\A:/*,/MMO,N=GCM/-H=;4E:
M$JP\?1ZK(HL5H=$?"EAY*G@2 >7#4DD+D"H4F-.AQ1[\)J$Y&D(RPY&9'NOP
M(D-?BQ(\5YR,RAIE:DYA, S< $Q_&VBH$D1G, Z[OI]*T\D=6_31!I5:D2JC
M/A5: $#R@ IVK0?-0#<NK:YM>1V8D)V5%$M":[L^EO39C65"HV9$U&9>&!<J
M0@3\5SP1B&*3<M$"2XB8$N#9)$DC0@K3*9<.C  (%S%\3VQ&9(P/<8F&@E7K
MG:FK;-L6JTDA7'9=A.5Y2:X1* X4J-D;:*JY<)PV'-RN3AP9.!U]22LV N0$
M<)C6!+\MR8F,WGD%-P+W" ZF'AQQ870RI1:0!9Q&.HPCBUQ@%JP#B8UPDM.%
MPO:7!X!B<X#A:;&18RK/?UKKV23!&I%)JSY:L.N/UPBZ#'+F GG41FW71,A4
M?+D!QQ$*)A:XRFU+S&84K.5-(SC&XZ@81_LVMU6%M  $]L]N4]:FW")PB<(G
M")PB<(G")PB<(G"*,+I-/<RK*ZN 5E9**85G(F#G.2L*9((PR.?UC_QR*0ER
MYS$C^Z-3)4F4A6'WW5K996M'8 0!U $B-Q.] 2+ F+G/\(@N[R 3O@;@H_<9
M=<UO4;3:F:@DA'CCG))<37AXY)8[':2[VCXT=U45)4C+S(?CC!BW?*$B4U$1
MO*79JW.#>!F"0V"0 ,1 ),Z7N,SD!*MSKQ$DY@ <8L )T &Y5M)V;JT34K\S
M[BIC0 -?XVIK0$R"&(@DC%A$UU[*I[7G2Q[=>?AVJ#"GSC#D5EM?G$:2SA.6
MO+1S06EKH(+*W1.1;3;5+F_@]-M-V 9.Q-;\9T"4W$NZ)PN8YD$V(+BS"1K(
M+A-I:0[02K'J([7-SJP&Y JL%4&N=?JMA@+F5^%&E/B\@V_<UB;%=8RMIX:&
MG>8QV'.W,&.Z]#;REE2DJV]I:^HUQ#CC<'$'$'.D F=02T&=8!-PHT!H$##A
M : +%H$@-MD!)$"T$Z%3.""##)+TP>+A0Y<B.Q#>DL1VVWW(D5Q]Z-$R[A/C
MXBL/2I3S,?"L,MO27W4HPX\XI6?'<JLMPBJW<.Q*KK&GQ;#<X+1 "3NNNJ.\
MQ(6*;BHG;%OE=H@>5+R:D1H*HL,O884J0WEQ<IUIE3<%B1,4PPX4/\-_9Q6O
M8OKQZ)3T5@H.W/2)#(6-#ECW7PIZ')B#RA#780>0#QY]?C2UC":]L:U>@$!C
M2X,\'<@1V*^\ E8((*K-WGJ8TT'T[K/> &L3=G:VV;LC45#K9@#7QT!$5W;F
MQ0.L:S;9D"ZJKA%L#%-V>&\X_"@2R4@>]YT-A28KZ7\D\>-Z^.A^J;3O4<0W
M2/U\)$D8NJKM8*;-;].:\FG+<>$%K/53TAJH0+#*/5^.0-U$P,"2;S$KSMIA
MLX(16_,$O+9(M;PGA*.GZ<>T""1J&W"#&\(K<"NQI<76<*< GGMD;"U37*RF
M.NVLR#\D[=J&?A%L4W!D55818*7M,P>/-H?P18M'A#NG+8[8W6U[T=:(@ K;
MG=7[9C6.)K<M1]<.CMW6/2-4782 ^TS1EOJ![:U+,0!LZFH/P!D>"^1,LCT-
M.LX(MVNE[J3JO55K.5M*FUVTUD"U=KE3HD*X18,(O.14C+HQ@^B) G$$1AEB
MAIC&A3$IYHDS FL-$H<*:AZ,T1;%\(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G"*IMR&Z/5ZM"LU\KTH^-#V(,V,P.A-S"@X^??551$@7G,J')8G$9!W
M%>:5!?Q*DX-*@>(Y'EOIR'QFB+O(I@D2!YSH'$8(:T@](FT*Z.W!I>1<R*8\
MYD)DC#(FT@3"J1[H]TR<,/6]X;<!!,S/GFR@Y%D=8CR)99]J5(C%!S?G<"0R
MRIO#"(:EOQD1E.Q,Y=CN+0J 801)(@MO>QB8L/P<]Y<<W$HXXB'&)&$V 'Q<
M0'_S>ANX+\[3IV@=>:ZU]0MF,DW-=+MT./%47GRR8],JKT6R&?+W&=(=5(Q7
MV:S62CA>1GL;DN-8>**6W)G/N4NQ5&#-S_.-:($'%2J!X(UEA? B <@!90-A
MCC>&FD29,@BJSS9!&73#1)TS,K\ZHTQT_&I&PK!6P)DN@L>L-7L4>SS3#@>0
MXP;9(S'A@1Y]H.IF3*C0O-3R(63<H9"@0I<]<>*VRF@G"QPR+G/:;2'-JN+C
M'WI\ZTN( &)P#W F"H2#+#]X&M(_JFF($Z@,<&@9 6 A6Q!T#IL7-R3%Z^ C
M"66I;."(]I^'-2B<U6V)>,26'T._K[-/J[;N<JSXZ (U"NU,9&.9@23J6X"=
M2T8 !.X"FP#_ &0J.BUK!\5CL36Y@.Z=X.9^Z5,Y^.=ZLT('@5X,( "FW&1@
M,9 #C677WY3K4 9%:A0VG),EQV1(6W'8;0M]]UQYU6,N.N+6I2LZ)+B7'-Q)
M/63)4    R  '4++)\BJ<(G")PB<(G")PB<(G")PB<(NB2&PR\"6,(-*?@SF
M'(TMA+KS'EX[J<H=94XPXT[AMU&5-N)2O&%MJ4A7:E6<9A ((-P;$;QN5!(,
MC/QZ=QS!N+JG2=9TS4+#2ZNY2 T"=>RQ""!CC03#8M^?76R^PG&2+<;#<9F,
MQ-;+6&$T^PN'Z=6N:A""+K;JM %Q,22UIJFYB X-)-X)Q5K3^$862X,PY /=
MYL6U<QSHRM+:4'*0T#(*RA-,J@(G,-"*^+'ER#669Q2/$;3/EM*Q%PM,B7G&
M7W?*^8PO+Y6O*G\PXF7LN9C,Y0))$$F-VEI]-S?.YWJ]_>>'L"DW(B<(G")P
MB<(G")PB<(G")PB<(OPXVAUM;3B<+;<0IMQ&?4I"TY2I.?M*3G.,_:SR$ @@
MY$0>HIDM8[W$Z:=,CPJ+-4ZD&B"PLAT.PP$9?>&!*H%@PWI,1MIM;\>,,KXD
M?#F34>(B)7!'CDY#((.^Y%HB") &$4S/X+\-(3 -CT6DG<#,B10'1B$PQP=,
MY.!?4$2<P2]P&A)BYO:.MVM=62O56_489!]$3@;Z:G.:91EN$ )R&GWXX+Q7
M'XL,00<A17F\"',#9L2- =B+>@MPU8TX.#CB))(;-YD1(U(F#+M2Z2Z725D
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MD-NX8EXBNJ\12$O,)RSF0VUB0QY1/2<W5F'&/P<6+""<I.!T"="5F?BZ8@2
M;$@$ F#>Q(!XE3#E53A$X1.$3A$X1.$3A$X15;-W5K$? P5EVF.T,P3NH9R?
MB"5<C,%-=LG)%RA2%MP5Y8>!MULYY?+J4H?<'K8B+D//16WY, .O!8:@,&[
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JA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g509388g04p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g04p03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:44&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GB^5U(X0DE-! 0      #P< 5H  QLE1QP"   "   < E  #$UE;F=S
M:&$@5V%N9QP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'7@
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4
M @ !.$))300F       .             #^    X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -!    !@             #30  ")8    & &< ,  T '  ,  S
M     0                         !              B6   #30
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #30    !2
M9VAT;&]N9P  ")8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   TT     4F=H=&QO;F<   B6
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ^ * # 2(  A$! Q$!_]T
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MGP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT]37\ HD)3(W1%AV@1A%9*''\3-"986DM<'_Q  < 0$!  (# 0$
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M(C5Q_=5/K_8_21?4,S<6K*PM23EQU.R:)2'ST. G,=]T:99KI[W61F5@5F/
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MG!5+;=89GMMIC,Y WX< < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
MCC;.H-8[VHQ/6>X:/7MBT U,!D"M2M$%!$+/FUDZ.LP"5)B+SA+CPD^(&%H2
M\Y\V9L&.]CZT8X!(_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' (R :9U75MFW[
M<]?H=<%;6VD-K ?8.P(T!'S1:A%+B/0:J**%',KD+&@XS[S<" RIJ*VIQ3N6
ME/9]IP"3> . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M<IEI8'P-]R>IE9'Z\*V/LIH\ +VV+%F]7D36SJ@+@[!#&R40.(*T^5-+,,6
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MUVS!39BGEG4+<:%VD:,FRIM?(NH:=6W!+,1)*T-K4EK.$*S@#,. . . . .
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M&28(&2Z>6NTFXI.!$$7KK7=X\P;>N . . . . . . . . . . . . . . .
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M1>"]RZY_)07.Y0. . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . 4X\0C]11V4_P 5QS^F/P"X_ ' ' ' ' ' ' ' ' '
M' ' ' ' (.["QRKNO$.AK7:*?.:NFN8OQ2ID6!I%R&<OU;KI.&Z](ASFU1I(
MTO+3E'L<*2][%Y"TJ:QY@3/!C9A0HD/,F5,S$BL1LRYSN'ILKV#2&O>);R4-
MI>E/>CVC[N&T8<=4M>$)\_+ '*X X X X X X X X X X X X X X X X X
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M;NU1=@ "S?Q%X=+ZYV[N(U;7WMEYR#1N[R]@WMG7X77DR+:)H^#-G1I]YK"
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MU.?=UU?5[(AN/Y2%,_$!_4IWS_S9I+_3OK3D7@O/+AU!<SE X X X X X X
MX X X X X X X X X!PR,5V</G0F)TL6_,ARHK).!B+F<.=D,+:;G0L3HTV%
MF7$6O$B/B9#EQ<O-HQ(C/M>MI?.-R,D8]S&2M8]KECDWMR1&N158_<<Q^X]$
MW7;CV.LJ[KFK94BYHMELMLEZ=N>67::H)OAY;VD=O1.^T=S]LYJD&B/5MXD[
MFH8VDAY<.9$Q7XL1FA-ZIS57)4E!IQV5279F)B'/*%DM[O8F/4F;?X&W9*7
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MQ69+O,P]CJ9SG(EU3X=:Y%7=_:YW[%UYSO8M@/[9<4VO]HU?'?>I\ HJ?93
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M@B$:1<+/7G8)EB;#3"-SE-LHD*;>; J/V\U)KW5'2NR5"CUN*,# KIJJ:/\
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MMDK1IA$<H%+Q6Y<"8VV\U)8RXRYC.$O1I;#$R)(;RB1#F1X\N*ZU)8:=1WC
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MR0Y3FGCX:X7[;<R%Q.4%./$'_44=E/\ %<=_IC\ N/P"'=E?W[Z"_P :!O\
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M.;(JYK>2-'*O^3^9$_9CO/KZK:$V_7-S:^V_H^YGM8W2OB05UIJYHHV=.@2
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M#BA>"Y1[T84N7/P''!Q>)#F59]>((R#'QY8PW'1C'UAK5SO/:-_LT?SD_EX
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M+Q+'2,RLQ8F)&7$Q(V&@)%X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X!U9P7@V%,!<RWX&"XL@,S.BM07Y,+$^([%S+CL$
MXA :\_']K[9EHA FPG'$)1*B2&,N,K U?=S.J'7RD]27\Q]2:W,G]>W'6<NI
M7$WKVC/V>NSK;V3I5FM$FL38==A,4Y@R>.F"3XBGQ0(.,X0?9@#(D7*6$Q>"
M]>7?R\UMEP4>/'C^39-]'U#^\JI?=_O<$?;]W^X^<KKU7S!Y^C^A_;\E5+[O
M][@?_8^+KU7S4'CZ/J']Y-2_%P/_ +'Q=>J^8'T?4/[R:E^+@?\ V/BZ]5\P
M5'[S6/5VDNL.T[.1H54G2S5>F4@(-:%@($F87N;#E?8>9<>AK<<0*9G/F9;<
M9E^1F' ?RA"<84ZWK&V&TT.R>!5>-30K5.@6*."D29L+JB::5L;&(]R/5&MN
MLDBLCD<V-CWHQ=T]0]CWLQK?:YMWAFQM)6_I455'5U5?BRT<E:S#Z*CIY)Y)
M70,DA:Z29[8Z6G;+44\;ZB>-JRHJHUTLZ#.:HWKI^A[5 T.JPX5N!1ISPQT.
M F2!!%G*XA,5*?CP\-K?@3X\B.I>6V5N(0AU3#.7/9I[^S^-0;08-A^,4R.C
MBKZ=DRQ*]'OAD7]LL+W-R5\4B.8JV15M=6I>R8/VB;$U_LZVTV@V-Q*5*BHP
M.O?3,K&PR01UU,YK9:2MBBDNYL=33R1RHU'R-8YSF))(C=]9@^C^A_>54_Q=
M$?['S,77JOFII8^C^A_>54_K^W^UT1]?_P##XNJ\55?$#Z/Z']Y52_%T1_L?
M%UM:ZVZ<@>/H^H7WDU+\7 _^Q\77JOFH'T?4/[RJE^+@C_8^+KU7S4'GZ/Z'
M]Y53_%T1_L?%UZKYJ#Q]'U#^\JI?<_O<$?9]S^X^+KU7S4#Z/J']Y52_%P1^
MM]G_ '/BZ]5\U ^CZA_>54OQ<$?['_%C^3BZ]5\U ^CZA_>54OQ<$?['Q=>J
M@RMEEF,RU'CM-,,,-H9889;2TRRTVG"&VFFD82AMMM&,)0A"<)2G&$IQC&,8
MY ?3@#@#@#@#@#@#@#@#@#@#@#@#@%!=JC]^.=F*R_4:)O,EIEPE2UW;Y6V/
MU_#ZKL<MIZ*AX_8P%N#R=UM)K#'NN3PNC&Q<"W0P(Z"J+*2LI'GM:] 7ZX X
M!3CQ!_U%'93_ !7'/Z8_ +C\ < < < B?7M M-/LFR#AR],6J'?[.S:&!3=4
MB@<U^5'KP"K-169\<K.<)1O@]:%I7F4PVZJ;[U*2M#3Z(K($L< BG>53M5]U
M%L2B4Q5?:/W:H6&HQI5GED88>"U8Q,P/(GON"AQ.:ZN$U,5)9BMQDIE.-X87
M)C)7E] $@ E&U!Q^;)'%13ONR/B<<),ED!+4K'GA28$V?!&3)#'EA.4N2($5
MS.<YQEK&,8SD#MN . . . . . . . . . . . . . . . . . . . . . .
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M:QC&-17/>YRHC6M15551$15'"ZJJ(B(JJJK9$1,U557)$1,U5<D0XU<LE>N
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MM:[@7CX X X X X X X X X X X X X X X X X X X X X X X X X X X
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M7.R<X<,@ABCB22J5&,:Q%^,J67LB9[K)FL;?C9K41O!J(B6,Y^:M!?\ A_\
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M6252MC8C&JM;4-NC4M?=9,UC;\=UC6M3DF1*'S7H'_P_>+[^"]Y<?_4G]?\
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M*JS$YC";;79<N?3;/)KDLG2+.3KCEUHQ%=5LPN'! N!P#7QVD[2;"JKY:O\
M6"NR]J;LTCL+6I/:'7U^ND8)[:6IMA!3,!O-(L!",Q"'0,EY;4B#LR,[,J(2
MW48M4[9(C,9*-( OX/E+G0(4UR))@.3(D:4N#,2E$R&N0RAU426A"EH1)CJ7
MEE]*5K2EU"\)4K&,9R!R^ . . . . . . . . . . . . . . . . . . .
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MB2_ERP#"^ @<VH8MO$*'.P/F/!1!X=AF )K/LUK(M)P4< < < < < < < <
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MK*PQY=>OM((6#WQ,N6"'@C;6N TFM6[;Y9KUFZDT/15<@DY8<9.VH>F5ZZ[
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M%.JMI+6&M/6:1 CE;&Z,=,S7RN)K1HE2:UQL6/X X X X X X X X X X X
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MTPPRVC&$-M--(2VVA.,)0A.$IQC&,8X!]^ 5^H_6G6>N]P[)W/5(A$::V@[
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M.1'GF4..Q5NQG7XSJXZU*:4Y'>>86I&5-.N-Y2O-!R^ . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . :7>R?3'8-DW'W>V)JC2M
M844V1U"UY4-)VJ.C7,&5,W]"MV^Y]WGO),RVWX+ID+MD;$/&3L3$&RBUGQ$Y
M<R.AF--:TGGGW<1RU?S_ "8'#UMXLD?8UNE ;/<1H.=8-\?*4BZ;!UV>IXL7
M8'N[&=0.RPC4TL7S$ M6#IQA3'N<R0/^5S:<L2,-'OC$SZ]?QY?0N7;P3SRO
MYYZX8TP)\1@IN.^:BUMN>X2[I0>NU!LECDWRQ5EBO@CVT-9]T!P4 H2P0MS<
MRXP-DPNO"HMH8F%V6@]&G'CA5R2=FQ#]\2'-V'I?Q0\3[)8*+.N#9\E4A8T0
M6&;"UM!L*H08'WN>HU;M)8@0:68EU8E?NIS=G?><F#"5B#VPR.D$$.'B!B+?
MEKT77DMRUX=J=O//HG$VC]5]=;.H#O823M&27F3K]V'N5_JLDG;'K,QBCFP-
M48 01L5R7);K441B!*$*!1VXD6,[!4N*RY$7'DOTGCK7\(6OX X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MC&$MMMMI2A"$XPE*4X3C&,8QCE!]> . . . . . . . . . . . . . . .
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ME'D$9-@CVEY!(#F.<#!W:9<-<4>Q0K#.'27\AI@P[M*LXGHE,X:&0FR\TJ]
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/$83CE!WW ' ' ' ' /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g509388g05p04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g05p04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#"^<A8X0DE-! 0      #P< 5H  QLE1QP"   "   < E  #$UE;F=S
M:&$@5V%N9QP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VXX0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'7@
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4
M @ !.$))300F       .             #^    X0DE- _(       H  /__
M_____P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M! D   B6    !@!G #  -0!P #  -     $
M 0             (E@  ! D                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  ! D     4F=H=&QO;F<   B6    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      1K@    $   "@    2P
M >   (R@   1D@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 2P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MMV_H?H;]GOM_TBUDDE.?;T;'>7.KMOH>ZMM7J5V'>&ML.1[;+/4?N>]VU_\
MP:;IO1F=.M=8S+RLC>W:YF1;ZC9G^=^B/TO\M:!< 8.FD^6B@^^MNWEVYP;[
M 7:G][;^:@2!N4@$[!(DHM>UWT2#Y*2*%))))*<9GUJZ:[J'V!S+Z[0YS2Y]
M9# 6N=5[GZ_2>WV+96+UCJW3G.?TL7M^W!]#C1KNCU*K/ZOT/<H]9HQ;V@7]
M:?@>ZT2RYE)@AC7U>TU[OL_M>QUGJ65^HDI/F?5[&S,IV3;D90WF75,N<UG^
M#TK:W^9W>C_@=G^$46?5RMC"UF=EM<2PML:]C7#9ZT?0J;ZF[[4_U/6]7?\
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M[C=ZA#+/U>+*V>_T7P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M##H^0.7-3"M5?X;2V.[[%Y>H6"QC22'$301RNV"D%B;'4B-?_C1V0?O]_O\
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M,5<[LMR@5\\$D-D,NQSMPS616W(LG\1/$52_RU]JV?R' >=8]3CG(&?=,=#
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M2=Q-I'A#0.#C+$*-$LT$R+(B_P 8% L0U'-:3E]T<Q2OGP)8D9@EFTC-QO\
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M8<<+FD8$/G;)O*5]UME_$5@M;U]%*FKR"59!!VP>$UM#HS H>)W=.GVXR+Q
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M.RY]37R*RJ@:W[DD0HQ<M:QGF^M99(<,&$ 8URZ'1JTI=(GIF/O'L?0?)IF
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M;N3\XW$VV8MFA<A4\C=L5.92M!(X-*410]1F9MI!C(B=@+?<"Y.Q@XFW8F5
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MQQ0$1BSR^*P>2S,\<-*#=CYOUI2:*  A!Y)Y3E/86AK1"4UJ;^BJ0"<]DXH
M.0<$$1"T[@37(7.LG!8(]UWT'TU#2CW4@58;9VUU6LZ=(Z#2[[5VG]JFT.C"
M,=&)MU-A\G<2+11PP1QJ5V6T,DA8L*U*42""/+116,C8C+CM-:HL4U#'!(W/
MC1D+)6NF\,T]BA8>?'12MR;$8$HX<)9+)Y>)V*QG'%@I59F[O%A8"W*8XG9F
M?*V'V>1C>A P##>EV"G1%/H+BW+2OH\/5!M7+ '@8V4%H@V+W1KH\9!6XY5L
MW$M'FK%GATV')-D'&6J&5M-]D]<XP+F!Q=^2W+;@FF.]+#-;=[MX!L2UP..
MY(X[(1N\02&,;<686,MFW=8\6KM1PQ](,I,X=W+J15YCD<C(W*62:&224G,B
M+E*9EN[[/W6:R28Q>'H-EI*<8"?WE=FPQJX6^\D7=Z)Y4RQ""D,*DS1#;3&=
MDQXIH\>JXQ_MH;Y_M[.M7:E$0*U/'"QNX1"1;R3&S;]."(=Y9Y-N[1Q 9O\
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M+([1KT!JK-X# Y:;$Z<I6=09?=QJT[$T111"!/$=^V<<?1K8YIP/C=O"<<X
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M%]&J6^VJCC=%NFHNKJCKOLFCINKOC&FNVV"+D^(GB)XB>(N 5*BP0P@;.$F
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M'QUU""[C'=E(A9'?Q'M*Q2/(;;:%3@%,"4[K"4:7@NI8-P$F3I'(;G?^"V*
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M_P#Z8(CU&(MPE_$;,DULBV**^-T6Z6NA%".A/C2 5'2_9<&FMSRVXKB[Q<V
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M/K_F=_UX6W37W_-M_NZ?G^W7.,)Z>DUJ*8I[Y /KIG/;U+9QAVHMOC_)0O\
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M6V,23.SMNSL[/Z.WH[+4R$A)Q(7$A=V(29V(79]G9V?9V=G[.S]V=;#WI[Y
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ML9 Y:GDX,QI]G"$9HR&7R;N?5=NL?'8)XXKF6YS]=[VM=37_ +Z9%TFGC/\
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M3I)5N^0063WTU(N@Z9Z6AW,,/ADDE D]*35F6[6=&5I!HJFP4DLWLFU)&@!
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M*-KK<6&5A[MI66]+N(KJ&^UJB^>E$VN-U&Y%D<6^+J[!$)A,T_RN#6E]L?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g509388g09g09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g09g09.jpg
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M]/9S23\&.W7 G)ZJZ]8KH( A)^K5SURXQBR&D@D19!FVTB2;9U0DY):]N5D
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M.]?#28GOWS9LJ2I4J%*F0H4R=&B1IR4J-&E)+3I4J5.6$E.F3)R0@*(3D%
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M-B^(UR?M"0L:S2QS$\$;*<2>8XZY$0:/$&$MUMN-C/6E+#'#69-M_P"6=O\
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MY0\(&)F(<I*]MT9CR YS<U"9&4L?)$[M3$TIAG!-<'=R0MR0!JM604,,EP&
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M6A;W/=7LDG./FZVJ%<413IJB,'D@X98TV&YJV".I&EW=XN:TQQ]G$UX.>/\
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MS^B:DL'\C+KU-XS'4%<2*YR8U%I:\P>+0?F$-T+VV&,\[:GZ#BG<Z5UT@B;
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MV] 7-3B4'85C,_-1^]HWN//*9 ^,:\LYO=V]$N).3@)99NDW"& P& P& P&
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M)&PA@,!@,!@,!@," ;DZIYPY\&C2W-===5^\NOI"Q1-ZDK>*=2<XS6Q%)(C
M$)JR:RY><$(A$MT9875<<$ Q%)QZ"+>BR6[*]#Z?Z5NC>T7*O*<E9&!6 82;
MV[(T]4'!4Y8A:V6XQZD-MSATG-#0D?O@IHEL)I%I<=&IRB9PFWM28E&)-[Z:
M_P!>]1Y1G+#-=CP78G;$WD'2U_U?)BT[O54W0M[!SI1TY1  XMKI4E M C(F
M]-RU"H122MK>M4^S;1.8UB)21*HL[E.\99A;TF)CSOC?M,33;+:-]WW80P&
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M<[5!%-#Z\_GJM!@,!@,!@,!@,!@,!@,!@,!@5_F/Z3I.BR?O^%6=_K__ &^
MZT@A]7^[Z4]/G]_V_+[M[PO*^,^ZP&$,!@,!@,!@,!@,!@,!@,#I.3DW,S<X
M/#PO1-32U(E3DZ.CDJ(0MS:W(2#%2U>O6JC"DR-$C3%&J%2I0:60G(+,.-,
M6 0M!7>#-KC<\J:;IEJ!:VP>/F*%%#0AW2G(UNP+4BAO477+VE664H;I1)FE
M8K05]'5Q);K"(&Y+%SZ6WS&</L6A0^?/\ZK*X# 8# 8# 8# 8# 8# 8# 8#
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MTL]FE,9<WV'R5$YQB0O36M#Q:FL9QEY#W%9J@11ZVJ_.0MMA1I"(_P"C3-N
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M*7)[1-C/*9(+\^?.N$W8# 8# 8# 8# 8$$ _2].*?NW\E1"+R^[SU])V"O\
M/\/5K0OHG7X^6_3]WGK!\^>OS"=\!@,!@,!@,!@,"JZ;_&5E1#B+R-YV@$@+
M4,X-_:37M8L:<=&$OH@^Y:FGZZ?$6C(\(>A@LJP&X$C3 (@L-CKE99?GA_?T
M\=K480P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P(=MVMG&9)V.5PEQ11RW:].7.==2=< _;:9MP F#((),
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M# 8# 8# 8$%Q_P OW2]M[_'\A?._\WW:G_4/E^/G^._OUY?S;W[^0^?/=.F
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MJEE8C3S%LEDYB5$X6%,CW*3JT3,R!B<.B!;W;?-?GONG'"& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M3PYXO/P2P1VG2JB&M,Z+-E7T$\]7NG&:+8F'6EF[G:+N?.?U91J?YW>BXO\
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M?^F,DPO#O/&?5?,G^"*_T8/^'6$<F P& P& P& P& P& P& P& P& P& P&
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M&DI$!@\-<.\Z36^$U;"0AT$(0Z^X.M!U_P"VM>6O_P 89?N P& P& P& P&
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M.?T8U[_9[!V.'I[W\GYY+OO]J<<_HQKW^SV#L</3WOY/SR7??[4XY_1C7O\
M9[!V.'I[W\NXW^,3WPL7HDAEJQ\!:I6G3C&56-=Z,  XT!8A%['&S :&'0M[
M#L8!A]6M>H(M>>MCL</3WK^CKD?GEF<?J;UG:T^LF_;^DD,4)&&;VTXQ4Y#5
M,=D(B_IR+T]!(!#X#7-?(GL*-(1(G]IB.YY*TB5*@EDO?$*5,F*.?%=Y-)G&
H)G7'.];].6&P/#)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g509388g10g10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g10g10.jpg
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M 0$! 0$! 0'_P  1" &5 E\# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
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M!29EET;</1H.S I'M@6KVT\97J#HTLM2(90MZ"8$(OAA)B8PF*G:7;X# 8#
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M*- $PHTL01EF%C#H0#"QAWL(P##O0@B#O81!WK>M[UO6\ ::6068<<8 DDD
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ML["!+['6BO=P-2-($G96M%[+T'T?1\L([O 8'Y&,!8!F&#"666$0S#!BT
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M:_<5[TVUZNDI%FN 7]I:5-;DSE&Z1QE$1=XQ=Q'6\,/G+CO,4[\1JG(:5(9
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MW#T+8$[@:Q^<RT:52K>RJ\=(>V.!"H2@39MK(9RU!R=L3BT29OI$=(A;K"&
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M>WQ"'1EG;V6,1M,V,Z4L[:4Q6HI,WWLGW"(0O;HBK>=(RAD-CO*L+A(7'3!
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MH.& PX\)!6CC3"R1)RQF&Z#H9@RTXA$ $(6Q!)$(H.] WL.$?S:-+L9!FDY
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M<;D-X/;'L\&G(VL:)B4C.KUID*ELVH4Q19>-WQ$"-Y"@1S.NTR,UP]R%1O\
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M87RS_7_W>'[; />-6*B_6TU%VL["WKZ)6^">QX\,>_VM:',Z3C) ?/ZO48<
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M^%):];'E;&@"]N^[RZVG/"& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P&!%,XJ&.S!U(EK>N>('9"!$6W-EEPDY&
MW2DMN)-./*9'LM<B<F";1<!RE4>7%)RRR./)%JD;RVMR!_(1.Z0.-#;,GK'>
MD/0+:UMC&6+1:>\8BF7%5:H!ORT R>-*Y8ZO=,*OHGB/6R%TD5:DD%(]FV@G
M>WA+%TY<\N&&OI]9\\5A"C2E!11Y!I9Q!Q8#23BAA,*-*,#H99I1@-B 868
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M:VU(0@;FYO1D@3HT*!$E+*3(T:5.660F3)RBR2"0 **   0AT1FX# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8$132GF61O0IO&G1TKBS@I4Z0%@1'20E<[)$7KTA9YRR+"%,
M>L..I@&J4Z1LEC>O5,!+@Y*X6Z11^5 >R![N8(N![KXXEHZ!:FR*$#-+2M]P
MQ[WO=./I@QA3I_EY0X'JG.GGI>?Z- 9)TM71/:I>U,,;M"9R!48@(+5Y=-?3
M?O"%@];UO6MZWK>MZUO6];\];UOXZWK>OAO6]?5O"/[@,#BK!@C/8\671=X-
M7(='&HW%H?&@XI,_1>1LZLIRCLJCJL\A40E?8Z[IDCHVF*4JM"8>FTF<D*]M
M4+$*D.6JF>/#^![A,\*0M]K5\) CF2-O*-2-4@;G+2L,9LF*HU*A4I*AT[);
M7 ]$F,5N.XY(FN4P54[NSG$7!Q4A+V P& P& P*\O/G;%OI8H#[]7]'N++*)
MG^VED5P*$:5^KZ(G %ZRE*6N69:W6H])SR"A$RIZIMV9W 1[&_H2RY>L?G]5
MR6&PA@8JU:B;$2MQ<5:5O;T"8]:O7K5!21$B1I2AGJE:M4>,LA,F3$%C.//.
M, 424 9A@P@#O>@@C[($TM7]:TPF)9(<?]!3=LJ;#CFQ<E,^/MJDB"@213.A
M'D:$)OG3X8TUP "UID$<W:[<!R8@#OOO\7WT%K&+P$3DX-X5[S*W\*;<JGDG
M6?+,UE1J39PT^G=Z,**T2V(SE2PYGB[(F:(=&0K52.*QUC;C-(PA(> P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P*)6^Y6!T)>[QRQ!)R_576->5]%I[T=84),1I;%DA
MEF.,I;*^H^ /RY(O*A(75HADFEEIS5N1BF#1&UT&9H.O8G66K)1'2Q41><W4
M1IEC,]8J.=X83D,'AQ<EQAE:X\RQ.T$C0S(4[:VI1]-]0*MID20L)*<@)ZNX
MSU @%%!" &AFB]( Z"'R#K6M"YX=(^FW^Y_\O?\ #=G?G)]+_P#E[!<\.D?1
M]S_Y>_X;L[\Y/I?_ ,O8+GATCZ/N?_+W_#=G?G)]+_\ E[!<\.D?3"%X=O)H
MW$IX'"[!$[)T2AM(=!=$=("<26Y6>E5*T!2[=M;4EHE2E$B4*$H#0D''I$IQ
MA8C$Y0@#S3PZ1],W[G_R]_PW9WYR?2__ )>P7/#I'T?<_P#E[_ANSOSD^E__
M "]@N>'2/H^Y_P#+W_#=G?G)]+_^7L%SPZ1]'W/_ )>_X;L[\Y/I?_R]@N>'
M2/H^Y_\ +W_#=G?G)]+_ /E[!<\.D?1]S_Y>_P"&[._.3Z7_ /+V"YX=(^F&
MB\.[D]M"H W0VPD %:Q4XJ@(NB>D$H5+@N.$H7+E 2+;+T<L6*!C/5*C-"/4
M'"$:<,8Q;%L7/#I'TS/N?_+W_#=G?G)]+_\ E[!<\.D?1]S_ .7O^&[._.3Z
M7_\ +V"YX=(^FG?O#AY*DS8<SO,2L]4A.-1J?2#IKI](H3K&Y8G<6U>B6)+C
M(5H7!M<4B5P;EZ0\E6A7)DZM,<4>26,(\T\.D?3^52\6/0M_-W,=A3Z16U6]
MEP.5V%SQ8\[4)G"S&!97#E&$%C4K8LD2I46IV)$V3..S"KYPZ)?GF\1]%/&>
M=N+^[11%*)$,)B];C#KC'3&..&T7GPA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"FU
M(ZU]MKV\+RUZMJ^<M;WY:\]ZU5!^]:WOZ]ZUL0MZU]6M[WY?7O"SEX>7YE<<
M8P%@&88,)9981#,,&+0   #6Q"&,0MZ"$(0ZWL0M[UK6M;WO>M:PCQZ:_%">
MY3ROVO?#=6+)"Y'SK#!W33[5*'M>_L5M<U3N/N4AY^O9T A3QEQ9FNS4L9FA
M*Z-HUB@3,JBRTE/(G )@3PFJQB,<9J<*J;QB)UK#JME]T*Y2)CLKDKI-YC'"
M(7+*ZA;ZPRJDKRB\\T^7 8H(J7;16K]7#?8,C:K.5(UJ"!/L>C+HS2AV0KV5
MI7*7A L0$$J>O&*PSQR?)=XAO*S?%8U*5$LGQA\NL665"Q0)#0U\NMQJ+4@S
M..12JO%-)M=:K+9;):TQL'SG&TN<.1G*8L,J4(O>8^<4Y#%3[7G%5SR=E'^T
MN=91:2.H6:7R Z3.LUF%:1]\5UE:+75TJLRODKVLG-;Q"YW2&HZDE<]BA$8E
M(7J)Q^:.+VE5Q.7-ND9CE$I,C:14U?KG%],^[R<M,^V:GJ_J":\]6Y-*NJEO
MC_/M2W9&Y=8EFQN%G2]?8MAWK"'B+MC7)CVLA0"+D5$TN9S@@<5QQ@I8!.J0
M(@)DQZXOEFHF+FYF,MHB?>_9&->>)E1#CS_0%PVR;((1(;>YCK'J*:1*#U_:
M]RME,UY8<?*<Q2RRI375?O:&"5\B<T\A;D<XGY43:G--%90Z$["AC$E/:$91
MHGEFYC:9C&HQCFZ9%W1"HW,>EVZTE)2:,UETE6-!4P56L-GUG3NUUUB<FTET
M:0B9H97S=-9-,I#H<_G#@#</CH4#?7\5$_.I)*-G>WTP5E6USPQF/33UE&5.
M^(_%9A$Q6?8CQ!X;625)XD\[7K-QVWDDT^PSPKT*@K1/.D<1,A[N,DU+7[FV
M/EFQZ1+X[.?G2[M:&#0-S*+DK?&7-9\,Q_\ ';/Q1<8_"?&OOOEUW8)S($LR
MEY)5?KZQ;W5B=*9NIEFSZ*[7=5'Z:75[7[Q7R&;V>R6L^('-JKY_KQ@DS+*5
MC2\ :EYX6AR&E)4X98WK&F=XX>M/A'/$ YHER.)J(TZVT\KII)[2B;)&$?-?
M2 IP%PH^3QV$7$XNT#'5 )BPQ6LYM*X_#)E,WEC0Q-GEKB&-G/.WE.K1$#RS
MPTUC6ZUUI<XP7H ,?EY^@ A>7U>?IUO?EY_M>?EA'FA O%+YU/HRC+/N1P?:
MZEUI<K5!UE,(9%J\MVUVNK:OM-K7''S26R^"UVZM+%743>65_;)).I1N/M,>
M3H4;E)1,J5X:AJR^6;J-YC.(NN<^W1:]/U%3:ZY5E#-3O+'Z?M2] S2!1'*N
MM&15[%)$ZQ$F?-45F-OLD-7U/$)8Y0M4WR9%&9)-&Q[-:GB.G>Y!%)XX6ZBM
M>]E@\(I#?G[,3@;?[?RSTMKS_P#QNDU.]Z__ ,WL(=[U]7F'6_KUK"Z3SCX\
M2[V$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4WI+]EIV[_P YSG_=.=A9R\/+\RF/
MHBMI-<E%VQ4D0G!E:OUFP20P)-/D[8)X7Q))+&\UC>'MH0A7MGK?43,N<#&!
M2-8 E ]>X+SRE1*8Q*>(PF)F+K3=YX6CX3<*7MLQ9*%M2P*L9+%Y,GO)DR:[
M&GUT=&I115:OC+Q33I%/LPVW(38:12SB@FI+/%H^8BCCJUV-($QJ)$H)2*PF
MO/,YQ&<3A$1SNHQOC]N2OWC?J9X<AW(994$GO1,WOS@AF2O<(IEYC]9UQ4O+
MULSN:H)-(J^>K>?Y!*1F/MN6!*)]I'8; 9IA4M<9CBAN/9=2%P=]]^F\N,JP
MCS83-S<Q6<1&T:9K$5=P[+8O:<+O*>VK'I+91?2%Q=(V<7%H$OB\0?'JRN<V
M?FF/12%M;E,Y*Z1MIA4$B,+$I<WAVD:^4NS8\N9I+-M[+2-C\I?#2HX8W][-
M5 >%+!BTGJR+OERQ-[YQHKI&S^GJQAJ&L75JMI5+;$<[;?FF'SFR3[$<XVZQ
M&!/MSRI<B6LE=L4CE*=IB"!Z<$X6^2*)<6\\,9B(N]JTK6M]5C5/,K [=06%
MT3)!QV2I9ISY3]'M\1>HFB<S6!36%A7S.5DF)>5ZA26:7(2[E1MGR60UI#$8
MHR)4:XK0N!2= 2\(C:9GK$1[5[J,Q/PTK>JVJ&FJJGZ*@S0AEW#%$\.WF\3"
MEW>5+7)FHN,V%$V>U*E3H;5CJ6(2EQ9+5FB4^-S ,[C(%I<5=A .^2'MME2,
MHU7S<-9F,=ZSPQRWA("OP\9'$9<.QZ4MB/1F:1'I6 7S4Z2>P-UF<3:V&*\'
MP_@Y^KN<HVF<1-XD6WZ$LKW,&Z6,SM'5K)(5;(G,;G1"@="WDE\-*][P^-?K
MA7'POY<_5C)X9);]9W653&DO%8K"12U%5Q[*V*I/XFELQ.U5,N01C4\<AMC3
M5JZ/+4 8P)]<#Y(G<$_ID#0-"88LDQ<3&\4OFX:^&<__ !B8][O\-9WUQ[9L
MG4R.TJX6R>1J9BEX#KU\:8(R.YDQKZ.<F7=?]NNUILP(O9M8SZ4*G!9;[&W(
MHW6,_KN?,!S&9(FR5/J3WV+JZ1.4;>:;PQN(B(QPTUW<O"N,+WNKG>"PYQ05
MKS6]5U:=Q.->6L;6]MI^EFQJF\R;)<9?D/DBSJR:S:NK2L9Z43%QL>+VO8-M
MD66XJ8_*[,0%D:=JT4%F8N\\KBXK*8F*\L1M5148U>$O5BG55RNK5/U]S-C!
M'U2VU+!)K:/LVDYJ]HI]M=/D. G2U<A>7ML<93)43:IFJL;:J3E-K;)FJ/K4
M29X9W+0C,UA6V/-0&)>&<Y1CGV74>*X4*T^3^%I6_AQ!D@8.>04C<8%&KE8#
M;;$U;E1PST3F*UB50(7I>4>E"R&%"DZC;@$Q'*QOA$=+^R9OAC,]:^D\UAS/
M=U*VE:+K7%R5R53UPSA-;,KB<LJ%_?K";+"*IJ%U0N11F;M]KL#"1"W=?7<4
MFAJ1XA+L^MP]R2,(77W-X9W6+4F;B,[B*N^.U?E<&$(Y>W0N(M]@OK+*)XAC
M+$CFLECC HBL>D,L3-:4F1/C%&%;S(U4=9W5W L7-K&ID#X>U(SR4)KLXF$"
M5G$5)OW]F'P-_P!:Z6_N25872><?'B7>PA@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M"F])?LM.W?\ G.<_[ISL+.7AY?F5R,(8# U[NZH&)J<WMU4@1M;,WK75R5F>
M?LTJ!N3&JUBDSTZWOT$)R3#1^6M[](=^6M[^&!Y70+KWJZSTO'3! 8-1VYYU
M!RI;G8CF79+K.8PQQ2&LTVH4NOJT(%$T$N7:DB>)]$QQKE4F4)ER,QXB;JYH
MV4);D2VD&JSF\IB.MXZ;3\<4JPGQ&:L<ZVC<CGL0L&-VB>Y7LP3^EJ]A\PO*
M3P!VY@L175=\/2E17D75'.-=1.8IT93)-#VAG-F#=(8S\CL.WYU%'TI)C\:Q
MK%QKUV;J&]GHGZ>]">AK<K JR!).<'*HU]+5[.;(E\W:[TK,V>%.BE#%BW[2
MAG/#[NK;7\39'&%I9S@F/KEZC"E.Q6FL9W,0V1_B*\G(Z^EEG.4]>&>*0BFI
M/>LF&]0.<,[PVPN#6')JDG+>*/.+ F>SIO"[.B;G!9/!"$)DH:I$H9T1S;O3
MVU&*A4S-5K7?#CDD%ZZ[J)O5R1NCR>R+.=8L56YKFV5#5-@V<H"&UXM()O#1
M:/B,?<F].0KB$=4/Z]>XK4+:U)G>))%ZTAUF46;W<E=]]]''-W?W,[X\U6QQ
MV23"2*[@K)GNB,G,=76,M;F6IG9W<&%18-BN7S9+1U=&HT]-QS7,E=@G1PV)
MKS"$KX0C.&( "^6=M:TS_/IFCJ=][12245>4YY\)D*JQJKH97TY#XM:U6V%
M4MN5(P 5/XGR"AE[9%37QBG+8P.45;'Q"HVIBCM(8P]2)H3H'1E*>7>Q4W$3
MK-:3\<U_(Y(&J61YAE+$ITL9)*RM<@9U>@[!I4U/*$AQ;U.@B^D'1Z122;H(
MOB'U>6_CK"-S@,!@4AOW]F'P-_UKI;^Y)5A=)YQ\>)=["& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P*:4B87OKCM\G0P[- HYO-&7ZM>T"4;52L!1@@>?JT P9!X #
MWKTB$2:$.][ +6BSEX>7YE<O"& P-')H^@ED;D,6==&":Y*QNT?<@E"T T2!
MY0*&Y9HH>]"T S:=29H MAWH(O+>];\O+!D\M:?Y'ZA;8/Q5,6BT8!25V<Q\
MH3_CB;-U@4VKO"/S9C5R2D&\5D1?</OJJ"XTM?\ ?-D=F,7 [*I406PSH;?(
MHT@>&\Y&2:F8_E&,Q,Q.V5X93O[,.2>%%#Q"JA]C4EJR;SN%,EVMM@/'6'/C
M;T3&+7?N@K4(NZQ+%61!AL"ES(?/#+-,?5[*JCL@#'$$5DKG#3HVK1HV!>RC
MS<-LIJ<(JM=,[B<<=[[.<^'2O>TDK*@]K1""I))(N9'45>@IQ>91RV-<YU>Z
M5D"JY5642MB"*W^J)(2XI)"V0EOF$<;HLY1B*(5>Y6RMBMO<R1-3>?SSB<<>
M+C&;PHX\WPOE2'K+61C2\\V[<TYF:5BJMMCL8N"M;AZ;2]:J:0,BH)<XI85$
M&*W8=42E.84MDR5;'Z_7,(F-*BERL+86?%<SQB(SVCRWECA=\V!$_"N>(%1L
M(J5AZ"02MQC%V&69*%5NU.[36N+:A;#3!'.]3UA:=:1ZX8$XRY%4=2QFL"(\
MYN-@&M3M.Z\23A[B:A6Y!0M8\V-UI6&>=S,3-UC?I-)<HKPYX[44900Q\L=3
M-(R'CD_CYY0H(@FAA[E'UTYG<M<94A.1O[PE9#ST$X/8TK$F0GID D!;@2X"
M+."W)B3-S=:S,>NF^D(71>'_ #F@>7.@('5<>YFFMIS3FQVYMK*5U9S&R\_V
M2M#+6T$*3RVZ)^JN&7M<T1LXE37.YHAC3# $#DJCKPYL\?.<%K(PMQ;B9C.K
MNIFX^.GON]98/$VZ!0N(09H$:-IAD7C\3:QG^6SA-T=:4C.B$=L.M!]J),C*
MV9Z=:UZ][\M>6&748# 8%(;[^EV+P.$/Q$%UZ8.$'7Q$$D%+&$C-WK7QT6$Y
M0G*$/?T=&'E WO0C :V72><?E=["& P& P& P& P& P& P& P& P& P& P&
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M:9;G^2X/+_;P]3[>2,_BX]M?FF6Y_DN#R_V\/4^WDC/XN/;7YIEN?Y+@\O\
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M,=^<7EPJ=>D+K80P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!#G[H'7
M\SF_[;!P)CP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P(<_= Z_F<W_;8.!,> P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P&!#G[H'7\SF_P"VP<"8\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,"'/W0.OYG-_VV#@3'@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0Y^Z!U_,YO^VP<"8\!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"'/W0.OYG-_VV#@3'@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,",%=W4P@4GHEUNU@B6)31D*DB
MN?11.I3'EBV$PD\@YV :2:6+6PC+, $8!:WH6M;UY8&/]GFC?XYJH_*)$/\
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MN!<7?&]?&4Q9\-7C$^6:GGC]2]#\,J0W[^S#X&_ZUTM_<DJPND\X^/$N]A#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M=J"KV'X>\:;-QYYVW^V\O:>Y;=W/W;U>R]_5>GVPR_P_M[/U[UXCG\!<3?\
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M@*T;Y>[L%)L7PTH$UZC[+MPT3Y^T]RT[MFU/I]E[^E]?M@#^']O9WM&<]O,
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M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0Y^Z!U_,YO\ ML'
M^ET7C!*&CK%()P*0JS9;+V>OH5&8?&7J8S":SA_(<%C7&(S'6%(L7+G UN9W
MAW5GFZ3-C2RL[J]/"] UMRM646(F<N<[1&\SWMF@5Y[\HEHJMJN$AEO21Q!2
MJM-')"X?SU<4I?JS44=(E$3N$BU&-FAZI; EL D2-<V.#2^A(>'X3<Y+(4W2
M=N;EJP@>69FL+PUC&\JQIVK;V5S\\6*SUNV3!2K5OS8B7-<P PO1=:J%[E5A
MEYH(T*P#D9<:(DRJEB3;4 UJ%I7HA8-N1QY9HBTPQ4]\Z^</]IIK*Q&"VH%&
M;)B93N"*S)OV]1E0]M:EE6NT>4*#PLDA*;5F@K4S5)FPM+(6+:XE*N/8W-N4
M+$2%2<:C()D[O 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# A
MS]T#K^9S?]M@X%8_$1JRP+=K2I(Y#X/,YQ&6GH&#S*URZA?HA$^@8U!HFPS%
MV:Y104NFTEAS7%9XBLHJ ('U]:I0RS%/5CG8B6$J]2A8V:PUX9J;X:Q<3SC:
MKWQK11Q- ^S8!R!!.4VGFR[GRO;,GM_LUF3*&ROE[72<&YB>YHZNS&U38YZN
MVO*_D73]]-,H=$\UN&-2B2&1T2R1V+(C'^W5H1*"Q,7=QA57=3.]5E&W*L,I
M5Z5XQ4W,D:Q4K0JVJGO7/ZV8/*6=3$08NLG+)4ZRMJ6YS=:WCMBRBG3'U<D3
MHX'?]FMR)\$?S^Q*Z.03230NU5BN/DB:UUJZQJ[F;F+XQ&$WCSO#R"5?!-<R
M(N^?GOI?J?NOV.BK1^Q3]E(BM]1^+Z2DV!]A+_TU^5@334WVR:C^Q&!A.XH!
MXWIZ"XA"2:T]:NO?%:S"& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P(<_= Z_F<W_ &V#@3'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@0Y^Z!U_,YO^VP<"8\!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,"'/W0.OYG-_VV#@3'@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@8B]>A:D*QS=%J1M;6],>M7N"]22C0H4:4H1RE6L5
MJ!ED)DR<D S3SSC %%% $88,(0[WH*D*O$-X"0J3T:WN3CU&K2FC(4I573%+
M)U*<\H6P&$GD&S8!I1I8M;",LP(1@%K81:UO6]86IVGI+X?=%_#X_'LXV_.>
MI+].,%3M/23[HOX?'X]G&WYSU)?IQ@J=IZ2?=%_#X_'LXV_.>I+].,%3M/23
M[HOX?'X]G&WYSU)?IQ@J=IZ2?=%_#X_'LXV_.>I+].,%3M/23[HOX?'X]G&W
MYSU)?IQ@J=IZ2B?[H/P/]G+3K]N_R#\F?8GVW_*7VRM,>X>__._2GW+WSYZ>
M[^]^[_?_ ';VGMO8_??1Z/I8*G:>DI8^Z+^'Q^/9QM^<]27Z<8*G:>DGW1?P
M^/Q[.-OSGJ2_3C!4[3TD^Z+^'Q^/9QM^<]27Z<8*G:>DGW1?P^/Q[.-OSGJ2
M_3C!4[3TD^Z+^'Q^/9QM^<]27Z<8*G:>DGW1?P^/Q[.-OSGJ2_3C!4[3TE]D
MWB'< +%!"1)W+QXJ5JCBTZ5*FZ9I8]0I4'#T620005-A&G'&F"" LHL(AF#%
MH(0[%O6L%3M/25N4*]"Z(DCDV+$CBW."8A:@<$*@E6B7(U103DRM(J3C,(4I
ME!(P&D'DF#*-*&$PL8@"UO9&5@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>>\R@[1
MUAUA-:SM5 7).?\ F&'U8^:JET#M3#;3O2S#I1(BWZRV$W6V^8QNI(9'8BI@
MD6>P+XR?,YR_2=Z953Y"X,XM1<HB=9OG4?%S?3G=^434UMB1,WMK:@;T",DM
M.D1(D:=(D2IR@Z 40F3$%EDD$E@UH)910 @ '6@A#K6M:PC*]@1^\E?T8/\
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M:?G,]>_?*>V #Q(3FQ ((1>,348;16.EU6M+[)DR=&G3I$A):=*E)*3)DY(
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C$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g509388g11g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g11g11.jpg
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MN"4S0F&1)S1$4G&AT0HF*#4W0T538W1VL[7_Q  8 0$! 0$!
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MZ6?"H\,S.,XSP#Q[Y9QG&?+GBK-<^6<>7PVUC&-L9_U9QG&<9^.,XR!V^/\
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M<87C&=S66+3VR7'<O&,-V[DKWT1Y&.'E<>,\.F?XTGAG+(%WYRW-Y8WUP[6
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M24I"UL[.A2MC6VHB-<:$(T#>B*(2(TI.F,:%)TY)91>N,:Z::XQY R](
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MU.U:GI$Y+?":V8#<[$0:IH:G:H-#&_70MO;3W0YS>7(6VZ<NG+_WONO>M6"
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MN4:FS'')$D3.;>=HM:EYS7H@=4N=CVY2I*+,VU+99O\ -<?PFT$
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M>GN9KBK]\=]=?V1)1EBWY4D7-49].F"Y1N5ZMMS-"C#4VXKW2>=LOM*OX#(
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M85GS=S]3M+IB]>[D:*'!9N6D;T"9"Q,*!GCK6U-"$EN?]:2>7SK=4[ @
M   "@%S\_P!L5C9[[U5QJ4RJ;$DQ;?O?_.,E=M8W6_43>QHB6YN?4#_L4H1U
M?T4PLB4AEBMGF(E$?E[.D;(1:B10RM\9E,'++IB]=\:SN\.[KK.<LR\[]:5#
MTF4_-,36/,1M.#;$)K4H6RVO,,NZJ'([&N-$LV@:XXQ9HUJC-O\ H*:,)[Y
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M*,Z9O.>WA1\5C_)73&N[M*9(X;YR:YR21KW1]<S]MSW!P4G;[&9,YMWN4N
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M+W;KE,4@890UI7R,O;1(F5=I@U$[L3DB=VM87G[QB5P;SE"11IG\6Y1V^O\
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M[IGO]'5U[/Z8),R4X>%7VD7OCX>;;9'!+J5G/_<=IV0FT\O/\><X\\>>?+X
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M;%*$AQZK[&%BKUAA+:D971>JB4T<%+;B#20Z0/)]?1HOS?7YX;<UAP0
M                  ! /5^N=N6^E-<??VH&X]<?^W-=R/&/_>"S2R]+$_ @
M                  *KV&^/5V2]XH:OW9Q98A']TJ?H>R6%8H;W)I2.*),Y
M):3@KXB,*4-EB3!F6HW"9R)L4%O-9UXZ)%;0>SS><0B1QXNVOIW_ .I][IKK
MBRC&QLL896B-QQI;F&/1]K0,C$QLZ).W-+,SM24I"V-36WI"RDJ%O;T1!*1$
MC3%%ITR<HLDDO0O377!'J
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M%CPT:FZHGC9KRI;"G,E60W.#FB*(<51EF@
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M]<5TK)C1K"FEJC,E(=2RR7YC;Y\FBW (
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M324+W^<NK8TJGXIB9B_QW:WQ3B"
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M;15:XM;$^S"P"]T\^_\ U.7/VECP0
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MOL.;:L+MX\_Q^?3QM8"
M              CJPZPC5D)6W9TV<F621T\]?#)Y&%1;5-H.ZJ"]"S7&-/.Z
M=47H6KT*)(>F%V1NL3EC;ILQ3"/R"/J5C4H"/F>SY)7[LV0F^<-J,QU7I&>&
M7(SI3&VO9RO7G:)&MBDB4]0KS6%BKEAA+<D879P5169KU+;B"256_NZJ QDN
M)O/2[_[^:<UA@0             05U%Y?:S]$^?WOL%6YY^7W_+Y@2 !.H
M          "ICG_]*"3KXV5^N<W09]4MLQ4Z_%+?D\CR_=.O@9!G[!93D%>$
MAB2PL%9W367,T)U>+3<PB,S]BG9=O'EW?[Z=-^E6S!
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MF9VI*4A;6ML0)2RDR) @1D$I4B1.662G(*+**TUTTUQ@CU@
M                                               $#RNJ'AI?W.R*
M5<FV)3MT.+6RN,.WO6E9VT<G)*3:_/9 W$*54>EQB @EK06O&4)\F;R$S.5*
MFBQHS'&N& ,EKRUFB=*7*.+VURA-CQPA.?+*VD_NI4C9TRHS<E(^-QR0]0V2
MN&.IQ1Q3+-8RL<H^M4IUK,I4H),SO[ T!",P\0O@>O9 X1.=]M<EPV4M)YB5
MVC<GZ*J)D?6M45MG0U,Y-+C+TZ] I+WUVUW(5IR3=-L9QMICR!<7?%QUQ6,?
MJH'AL?P@/%OYSU+?IH!B]+Z4_50/#8_A >+?SGJ6_30#%Z7TI^J@>&Q_" \6
M_G/4M^F@&+TOI3]5 \-C^$!XM_.>I;]- ,7I?2GZJ!X;'\(#Q;^<]2WZ: 8O
M2^E/U4#PV/X0'BW\YZEOTT Q>E]*?JH'AL?P@/%OYSU+?IH!B]+Z5#O1'B6>
M'2^<_P!YLK/WAQT\.SQ3MFM;6T-O2=.N#BZ.+A"GM(B;D"!+,35*U:N4G%)D
MJ1.4:>I/-+)*+W,WUUR62YFEWG*IB_50/#8_A >+?SGJ6_30$Q>E]*?JH'AL
M?P@/%OYSU+?IH!B]+Z4_50/#8_A >+?SGJ6_30#%Z7TI^J@>&Q_" \6_G/4M
M^F@&+TOI3]5 \-C^$!XM_.>I;]- ,7I?2GZJ!X;'\(#Q;^<]2WZ: 8O2^E/U
M4#PV/X0'BW\YZEOTT Q>E]*?JH'AL?P@/%OYSU+?IH!B]+Z5B[GXA7,UQR:+
M43REUAS=8EQV9LO(1.T+MZLIZGKN-MV49;_,#6ELD3B5(983JXI$-?0+0E8L
MD\E5DKW%N^8T=FSLT#LW>RX\+^/_ #T7<KZ 1JL8DUPR*)3R&IL][/,4KU9[
MD\O3PZK5#J_R:1O"O8Q<^RB3O:U>_25_<33G%[>W!<YKCC52HW?)&:
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MZH![HD_<R?\ D2_ZH![HD_<R?^1+_J@'NB3]S)_Y$O\ J@'NB3]S)_Y$O^J
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M=+MC,QFR3:667QSC1?X&0
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MUS;"W9JRH+RF=F5::W/#,Z-ZXA(Z,KTTKR#4CDSNZ)"YH3]?0J2%9VU\R)(
M:_HY^%0N3_O\/[FGS_[_ "Z+ZQ\O_#SSY?ZO//\ K!>4\;[<+8""
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MRGC?;A; 00
M            %$Z__"8=9?[#_A__ /'7Q)0:OZ.'_MQ>W O8#(  //):6M,Y
M+WA.VMY#NZ)T"1S=24:8IR<4C5LLV:TJ]=H7JJ5IVW9Q<-D!*@TPM'LN693Z
MEY5'^L.G)Y*PPR-R&82ET2,<8BC&[261O2\SV2%G86) H='=T6F^6?9I&]O2
MJ%:@SRSZ"2=]O+/EY *DR7Q!^3H&R54[V19FU<*[CJQFN>'QF61:6:2HJNWM
M.@/(?I,SLK*];14E'NY)43KA^.1:MKADU&JWT.(-UT+BZ]UQYK20*?P:TX='
MK#K281J?P.6MI3O%YE#GMND<9D#6?G;4M<T/32H5-Z]-DPLPK8U,H,UT.*-)
MW])I9FFI&.2RXX%";*J:I9"YJDLWNTR<EUXW%-B]4F==ZYCI<JE>%;BG(,0M
M6$+*;HH(RX')\+3,^[I/:G8SI@?PE$   &.RB'Q*;MN&::1:.2YGPH*5X:I0
MR-C^VX5$XWP2IPA=4JM+A03C??!1WLO:%XWWQIMC&V?,,+MNT8'SK4<LM6:%
MJ6:M:OC^CU)CV%HV6%QB'MAB8AS>LM:'4O)+!%6K8UY>=TI><-D?;%ZPL@S5
M+@G8LEMQO;]ZE,LPLTO0TK?0THW34PLPO;7<LPO?7&VF^F^N<Z[Z;ZYQMKMK
MG.NVN<9QG.,@C[     :_HY^%0N3_=_<U?\ ,7U@"\IXWVX6P$$
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MY[SEUV5Y/]?W?M?7ZONO,&>+>XVS??S]UI00   !K^CGX5"Y/]W]S5_S%]8
MO*>-]N%L!!
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M@H(
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MN!
M                 0ATU^UNZ#_B0M?^@;^"\.\\9[IO!
M
M             $(=-?M;N@_XD+7_ *!OX+P[SQGNF\$
M
M           0ATU^UNZ#_B0M?^@;^"\.\\9[IO!
M
M       $(=-?M;N@_P")"U_Z!OX+P[SQGNF\$
M
M     0ATU^UNZ#_B0M?^@;^"\.\\9[IO!
M
M $(=-?M;N@_XD+7_ *!OX+P[SQGNF\$
M                                                           0
MATU^UNZ#_B0M?^@;^"\.\\9[IO!
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MMG&/B E@
M            !KNZ//E_1/1\2XHCDSDU>5@UU.7T!U3)(&^.$5L*3P20RYW@
M-14E%I@S*$K]"&FTY'$++=[#EL;6-<L*B-<&1*..S4;-%KNV&II,Z77$EU\\
M;7'\IRA_$O', 8T<;AW*_/3"SHB\:%)D=/P'8T\SSSL:L<%RAA.7NKDJ-VW4
M+W5T5+')Q5FG+%RM0J.-.W);;O;?'5E'VK7,?T<Z(^J&O_T>!#[5KF/Z.=$?
M5#7_ .CP!]JUS']'.B/JAK_]'@#[5KF/Z.=$?5#7_P"CP!]JUS']'.B/JAK_
M /1X ^U:YC^CG1'U0U_^CP!]JUS']'.B/JAK_P#1X ^U:YC^CG1'U0U_^CP!
M]JUS']'.B/JAK_\ 1X ^U:YC^CG1'U0U_P#H\ ?:M<Q_1SHCZH:__1X ^U:Y
MC^CG1'U0U_\ H\ ?:M<Q_1SHCZH:_P#T> /M6N8_HYT1]4-?_H\ ?:M<Q_1S
MHCZH:_\ T> /M6N8_HYT1]4-?_H\ P2P.$.,[.9=F.7<Q4H<669HI;'IBKZ.
MP^8QIR)V]:5[AL[B"%BFD*D2$S]=;Y#$WYF>T!OW:1>3MG.<EELVOER\YM?-
M'_(LML2&6/>W'%M3-ZLQ^H%%6T_JFTY6<6HG%A<XW-F;-]?;V$N**3E2"PZ_
MF57V77$EEA1)1\O:X[%)@^%:221N^YT[NGM\E+C2S3.<SI9_&L7R%0
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M>-]N%L!!
M           43K_\)AUE_L/^'_\ \=?$E!J_HX?^W%[<"]@,J7=_U#:G0_,T
MJYYJE08SF7O((55-H3!.Z-+<O@M!2N4-J:^)&SD/.AR5Z?CZK+E$9C[+A*L]
MZ>I$@/5)#FU*NU!>'$N;RS?/EUYM?-V>'WU"P/?4!M:VM,.DF7KKPZ+\Y:G>
M;/(YYJ]9$[+B4/D)/**IK;:?K"F8PZ,:S:R[7@KPY.+$X.[ G=(X:L>=(TV$
MI6Z7-EG67UY-=J7$Q)V>+,QVN>^]O2=.:/+_ *6Z6DU2V/9]QTG%Z!B_(WA+
M]N\_$&1^RHW/];EF%HUC7VIBJ(DQQ$@6L]20UHI'9R:=9VV165J7V5IDQ<01
MIFE4X*7%M?"^Q+-I;<\7#<V:Z9W[]=<>NKUFGGKJGJ*OZJ?WRBHK2;93OAB=
M%\\P$Q!:,5E15XV%TO5=3QN*IXL6T)6Q3#ZHC[?6Y#LH.L1%&'_20OS6B*C!
M:!B6/:F\_GSYRYK9+=<_7+MMC._?KRRM!+.>;VJ\_P -BVJRJ5IM1RX_I*;T
MO8=%LLPA\)=\$6=5E51C>75L\RI4TU\I>H"]5?LPY;G-_CJ9PB$TD6[0[9.*
MT;W DLQ9;O9<XSMGSUST3IQOSY.81570.MU,K3$Y-U)T!=]YR.MXP_E2)%6C
M/;);8R(87B4I$:)O>I'HP,:5^F#LSH\,QDY?Y%\DJ75 4G=W EOVDGCCYIW8
M0IQ^P=O<\512W%TKYXB\DB%*L4>I=%U<S7E%V.(O=)0I,7'(K,TM:[,CI9Z"
MVB8$A:4BR#GL?S1.F:90HTLHAC/T4%%XK+;Q9LMMN,9W[^GS"!Z*Y2ZM(K_P
M\^4[#I>+0"&\"VK#9Y).CFVR8J_LMOM].0.P8/$3*O@S5G>P&J26ZHEZ!YLH
MRPVV))(XVGS%O1K)DL<46YI;9GBN<YSB8NF>O+$Y;\MMY'=U4=9G.'A/<[5$
M[P6'J;9CO=/*;GK!EK\A20^22:7^)1#YG'FV0R=E:Y"G2MTH+?VG21/)+,^J
MD!3@M./:W%4F,1&EEEX[>79XO_Q6;V-R5UI>$TO7JM33L9K:>+K?\/>=5WS-
M*K.BSJILQAX9GTXG\B^?L\AVLB@D=DEBG68YME=FY5/R1F45[!W"6F-):U20
MROGSY_J3BDTWGU3.L_5B;=))MSMOB[%V\@]+=2)NNK8DE+LM6/E\D>'G645H
MF03R"RAX<X/RIU0==-C6!:+U&ESK7675YCTVD;%&XXUR.1G;1N')DRU7\H2$
MAE0OGSY_I.*3LS.9,W/C)I/3NW97XE="=R]!&]#U9639,9=2MK<E.5:5(RP2
MYJ[IN'QBY)*@L]FL9UZ)*D#8=84^CCTPNU>)H.QQ!4YQ4W+;(F24M$;^6S9J
MD'#9,9QOF[YQIC'*:Y_G,T9<]\Z]',MK]<(V>KTLMA/5W"U35"W3]'/8BV%5
M[:=/5AT-&%$:E4=>EZ1_=$TP=[&B9+#((VG=&E'H<ZJ']0V$H--E1,RR3G+?
M2_B^["8#0_77,$CD,AAO.T<Z,TNWB;DJC'5O-M6#0O-16ASO YW#GB.3?:6F
MX*DE,24Z=ZO>SO7V\GD2)S32DK6$.I3JVKMW/T_DMEYXUMVY7'3GX^K*.:N"
M+/H64QUF>-F*:L$(\)*A>*$DZRN1XVD%H5[*K86RYO1-;AG#TW1%6BD$84H#
MUY!2,U%E$A/V-5M1VI(XN*6;8^KBXNZ3B[.)Y8Z+W\25G,J6XSY)IRQ4A#?8
M%3\S416LX0)G!,[)D,N@M71:,2-&G=$1IZ-R(2O#6L()7I#CDJLLO50G-,*,
MTWR3BN>+BLVMMGG5G@1K^CGX5"Y/]W]S5_S%]8 O*>-]N%L!!
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M> 'Z     U_1S\*A<G^[^YJ_YB^L 7E/&^W"V @@
M                                          *)U_\ A,.LO]A_P_\
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M[7U^KX^8,W>XZU8\$    :_HY^%0N3_=_<U?\Q?6 +RGC?;A; 00
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M2&Z8-7],[[;Y:3/G99Y-A0,@
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M3*4OBI?()?-)8^+%KY*)5('!>\O;LL4+%RLS??&-3-N=TL
M
M  A#IK]K=T'_ !(6O_0-_!>'>>,]TW@@
M                                                           "
M$.FOVMW0?\2%K_T#?P7AWGC/=-X(
M                                                        A#IK
M]K=T'_$A:_\ 0-_!>'>>,]TW@@
M                                                     "$.FOVM
MW0?\2%K_ - W\%X=YXSW3>"
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MDLGKYDW;XW-),4:2D?Y>B?'1J0-;,I;6U(93L
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MI;T,;C^S[*3F<U_7%MSUY_>VXGKO[-@0(
M                                                      (0Z:_:
MW=!_Q(6O_0-_!>'>>,]TW@@
M                                                  "$.FOVMW0?
M\2%K_P! W\%X=YXSW3>"
M                                                (0Z:_:W=!_Q(
M6O\ T#?P7AWGC/=-X(
M                                              A#IK]K=T'_ !(6
MO_0-_!>'>>,]TW@@
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M9!2I:V.3>J;9#'G-YC3RSO"\68_B]9UB<00
M                                     % V!O+E'BB6TY/'I69I;A/G
M=/ "CM<F88C^C;ZZCVM-8AQOMG1,HD:?F:ITBXTHO4X]/'$I.YN2M<EY-?\
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M
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MN8IN8AA+LJ5MSZ8OC"%*XMR!J)9,2S.^+GGIG/=X:\NF;LH!EK^CGX5"Y/\
M=_<U?\Q?6 +RGC?;A; 00
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MZ;J8L*4,^D=8/0\2^"O"I?NQLISMNX',[88D,YNV?SBZ8SOCNSC?K4CO_*-
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M51!XS<8Y9SYI3!&OZ.?A4+D_W?W-7_,7U@"\IXWVX6P$$
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MJ.Y,S'[#AD7G+%D[T^VRSRUC0O[9DWTYSK[3*)P(]IZ<YU]7GY9S@&69@
M -?T<_"H7)_N_N:O^8OK %Y3QOMPM@((
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M (^6?_#(+RGC?;A; 00
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M%_ 0
M       !_DU^-=^$)O/_ /E#M_\ Z2H'K_\ X_HGC6IL'4
M     !_0O_\ )K_PAL"__<E__P!"D3G/"^_"\_\ _?EY?R_TX17G
6                         '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g509388g15x15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g15x15.jpg
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M 1$  A$! Q$!_\0 'P !  (" @,! 0            <(!@D%"P(#"@0!_\0
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MMYC'IM'SA#!HP( .\;<')!\+[&_796S]&!^G0@:WK>M"--9IKG8D7!!@# &
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MF(1HTA)29*D2DEITR9.2 )9)"<@H("B222PA+**+ $!8 A" .@ZUK!D]^ ,
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M^JR*5;&G5Y4R)[2QQ&9I?(Y$L 64ID$I?G ]:_RE\.()(3"=Y"Z.3CI(G3I
MJ=)DY)0 ;;<MR3E@@P!@# & , 8 P"K'<53);TXZZ;J=1H85,SI&Q4#$L)'L
MM4SR])&G!UA,A0'!_.(<XU+T#(_M:@/YR=Q;4IX?SB]8*G#3X\CX\_\ 6E;"
M_P#LV;_T5)_[L'W_ *./G_A]3'B9-^3^!Z.KA5O9;]0&["YEE;>;^:K:I+SC
M9TQIEQ1+2M_G$GF!AB=P*"+7H<A7)%16Q$*"AB'QJS?&_6_[\,C8W@R, 8 P
M!@&LJ7^2]L26A;T!ISDGK/IV-<\3,%=7M:5%Q*NG>*0J?@9VE]>(3'V.5V;$
MY_:$IB36^-:F7LU=Q%_5-'QY*F2Z<UZ@I((:PV4NE2I2<W5]DTLM6BZQE\5:
M5?:+F0<C,#=3A4#C?"6(;97WX,RK6F9M5?KY'N0Z;=QHLPF6/;:V:93'<+Z8
M$_:XIM&@).5%B0XG28GB2_@@P"I5\]1[I*^N-:1^9'SEUUK95DU[N3?./Y'^
M8.J^IV7VOIWTS_(3G\Z-NPXN%AVAVZ1_2 *X3G\<6;3:;U TE*J<_*D^<M+]
MCLGJ/\DJN8#/_F1\_OGOT'05%;:OG'\V/DP-WV:P5V.4?'OD*0?'-QD#V)W"
MR_%$NG@2;2#;JUZ.VL*"E8IO$4M]%,%M<&1@%28=U)\[.T[MY!^9'Q#5.T=3
M5RZL#YQ_&MR'=M2*Q&$4=W%OD)/\E:8-00M4%V^<+CMTVZ#(VVM^D0358K4)
M/>?*.Y[NK.H \QCYI *$;FOY1'6%1<OZWJ1ZCOS1%:J>4'ZF^];8GSY>TQ;C
M?L[CFML^W+XY[6GU!\7]#XW$<7 2F>";Z%L,I!@# & , 8 P!@%=>O;/:Z4Y
M3Z2MQY/*(;ZWHNU9D;LW?^_.880]N"-"4'7J(Y4XK24Z!$F+T(U4K4D)R0#-
M- '8J4M):N.I\ G^K9]0_P#E.1__ ,&O_CP??^W_ ,O+_#[2(HOUR#WI-X ^
M"TVT/Y"'@-I50\F["0RQ3L.)Q!"R6]5JE0+6RD2B\:YB4;MB#$G'$!>9C$+A
M3IBC7-Q0DJ1\7>E;TV?*;/P=GI\L9LV>X,C & , 8!H*Z_K"Q^&6_K'R6<&=
M*0]KB9+G)[DZNY-M/33,N?[?GT 3)XS8:N%2UH7)9?3%\.Y4=^;BU&UKG5+)
MY^C9V!^:$>TY*(H;7Q135RI>JEVE:J7S4N'DB-B.=^:ND?,Y35L3>F@IEEP>
M+5OZG4,C^^RE$[H;707Q3#9'')P+;WMO*V]Q&)*4[ M:TQ!+,:),-6N:350M
MJ-O?OJ68H:3_ .:RVBKR.)J#G7G'MV,^33H7M1>XO=QU'UGUC537-GFPI7'7
M;D"JJ,]452EU:2UR%J;ZW"T15*DLTV4MB%&?-7=W6/+TK>$9FR0@VZ73AU5+
MNE\3><[J6UX>)&=&O4L[MDOAWHWO)?(9)6EF^.^S>AGN#R%_?(\T=+WS%'>M
MHQ%5=B)VQ>TG3Q:QU&\KK<+9%1IJ,US?E<B7H5*?8- %:5.-TYJM4[Q3?>=5
MGG;BYD7R+P60\T/'C0AGCL866<6%6UX=O#I&OII8DAG#"U3_ %RA=;HJ@)+N
M_/+^Z)RHTY*G!'%J]<'EM:4"Y.U0P]?%F,8US8%-U7BF&J9C.,2(KN>+4787
MB(Y^>J<L^UI6Z] ]\\?.]]W++'D]BZ/-Z"DG14*C=K*ID, E&ZULNOWXDYA8
MXHT$%L< (8F,F-$KFHM(ZN@4RJJI2M15"TB+1NN,MO5EK&2GXIPCY-W""\D1
MAZC<7M;QEWU;4JJG<LFDM8+!NZF[6KQ# )\YI90_/CBOL%Q0RMVC3Q(-K!.3
M^E<S37 :ER/.6FC,XJ6W$JJF\+)JJ59*UICH4"?J;I=M\*,4\H,:FTF7^0EP
M@=?7DW=9DV'+'"V9!TO(K%9$SK4X@%/PFEVC"F3KG.F-TV6R#BQ3(2-N!&P.
M"8:L,MG/GX&L_P"3#;#,1IAT>MXO.;>;+A]'V5:-6]2>8BV*\+4,UNP?P^4C
M-(X:V:^-*HU,&<OIIT [-P?0W2E1%EI1CLC"()P#C6TO0P&@$( J10U_$GDZ
MJIY325\LWDOD6C(CX1K;IE_="K2NCM3BI]E$@-MN42!;TR!]BCI*Y5;$]CCY
M(W5#.)0U/SBB7IING;RED0*FBN.I5B%E?T[2+-6FMUZY^]RS4\<Y)/-).F^7
M#BO*UOTJ*8NWNV^_)JJD7,U3WY8%:=03V@*?L*S>U[.H6>\KPB*U_$C:>>*9
MK.(T%9*6';=!O!MKEV0SRIE<K%D3FZ(7$G:2/C,5Z):G#FDTF_A3F[F9:G:,
MO4G.UN<)5>O77B5YP[2F+G8+A^0-T%OIAM@$]D[7"+ZF,'_)LVZ$2QV:-1AY
MD\->YLG131P2 *927]Q:T1"Y,)A4KVA8$I*MTJ)J24JZ3QY;.+>EX9^'K>@(
M5QM>LQZZO*@6CIOAZ$M',4$K^21JXY<TWIXZF:K6B)5DF102&.CZBW,8;()2
MJ8YL^.L(G#3:JA>]N@)"T2IM)3'G@GB4)P[MIY53R5FEO*V:/I2P?,8 P!@#
M -878"X/45]T[P)&!:<XL@>X1TWV>N3["<@CM(UQ*R9'4]2/!@?0!3]T1<$9
M94XF7:@M6IJ2!V@K4)]HUS>-4-*RQ;RETNUR_><FSW!D@[HWGV =/5))*@L0
M#HF:WD;8[,,GC:\;--:]G,:<$[["+)@$A(")3'9S!9*A;I%&G@C0]$+T0"%A
M"QM4K4*D5.')6#F?IR>QV?)N->S#FMAZ@9VQ<JK2RDB(##6_9E>L  !,LRKP
M",&B9[,:4(DQMTTD%2-YA3L8=(XT2[5RY-CJD%:M*RUX-Z/SAZK.'*-B&#(P
M!@# *%2CQ=^/J:VTXWA*N3ZD>[(>I7J=O[HL9E6V223?XV)>9,9/!BUQ<#DL
MH4N QN*Q_?HTX.JYQ,,7K%9ZPP9PAK%5E+RCPRA;+D3%=O'W,_1TKK:=793T
M4G\RJ%<:OKJ3.87%&]1H:A8WN"E$2O9U[:>X,JI<UMZM7'G<;@PJE"4LU0VF
M#]K8A$VIAQ.?O]D:V[XW.%KYLQ;<-N\RUI-[$>-,VI,_.2!>F)F^H]HD#'JQ
M&%L<$,<L;362G3)$6ITT2'1*%,F0!_D2<D@ 8FE$V[YQM,(D^_>0^:>HHE&(
M/?5-PZPXW!W EUA"9>D4M3A"7!.E A IAK]'53._Q00D)12$\# Z-Q2I&20E
M4@.3DE%@!-JZ<:>&QZH;QYS#7;92;-!:3@L2:^<GN42:E$+"V#;B(#))LRO4
M>F,@;0ISP;6O<H:I&^DO[J\[<E[LH=5CBM4'.1NU>!+<RVYSES,93T/0JXTY
M>6G3@T^EXAK5DW)#NA9PE3E."1ND-WP)>U.D7L]6UI%Q#:5+T;FQM+@N=4B5
M.:_+4)"J0:=#M"&()>[R:\'-N5V2HLJ.ME]KLEY+(BU*+:C<%?JS8YR/2CY9
M;8))WMED;]&4^]'Z2_)[F]QUE<3_ (1,,_1Z K11Q98S@&"3:-,^DQZLK S>
M-#@N/V^5>[-RW5C?9J>8'6&C=R6E7MD;K!/-$H,GK5!3%PX$U3?:L0EX):VQ
MA+("G'>W$IQ N_E&"XG$2X]VY<"RQ%+U6GL::VV7!F$5BV/"H]7,ZE!Z<:I9
M*(-%%+\KC\8=DZDTUO4-3<HE#^,!'Q,.SPN9Y2L1Y02@%A+LIRNN$_\ 15RN
MO&!P!4L@;9577*U6Q61,<R89[''= WN)JR)R2,/!\A8C(:8M<E6H<S-[XH&[
M BL8"TQ4Y>!.J4LIQJ1((D'54\V^N^^_B9+=?CSXOZ(GRBTKAY^ALLL)P:43
M"^RTH^01EWEC(V%_ -K1-SHB],()RVMZ;6D:%%,"WM.D0A"A(++1A"1H555+
M)M1E[\";4//]+M<MJ^<M5;Q=JE%*5^\554[DU(/DT$ KE_)C:9UAL:;D(R&M
MO8E":(1I*6B BV!&F9TJ=%M,3\( P9E[YW?/?S?4A::^/?BZQ;A.ON<<\P.3
M6FK?X[*W1_<RG4UM?I5$4R!'%Y1)H<%S!"9/)(^F:FLEH?I#'7-V0!;&_P"+
M*RQ(DVRA<3B)<9>&W"9<[ZER<$& , 8!27JOK574CK':)HR+HKG['M=N5**L
MIX*XU.RQAA+/TWN-VWH](=&G5]1L-5&!&ZO2@('J9NI94'K]&[RA?[" 5+5Y
M:]EQ]NQF7)G,B/FJ#/A3Y*UMI7;:LF/LKH6[7I&6B?;7M!S1)$*IS @+,.)C
M4*C+4B;XA6<#;SA-$'@[,T,B/:A4!Q<W$&YY*R6R]WYEJ,$& 0?T%SI4O3U?
M'UO;\;&]-!;FWR*-O;4XKXY-J_FC*9M1'9_7$U9#T4C@TZC:O?QEDDT><$3B
MEV(Y*:8>WK%J-2*FUD4?379TUPIK3!UFAE'3?,3;Z$,/9M;Q(QUMBN60L7Z
MGK:F(>B,7NB1I1Z$!PONF6-P9%A"3;K/:Z@VS%;VJ%A590GLWZ-^C<WM.FQJ
MNK*KVWH8Q6+5<WBEC0*4(PN$=F,)?FR31IY1BWL/PS<\-"E6A4Z+,"(HX)9V
MS$YX#"#P%G%C $9,VP!@# & , 8 P!@# & , 8 P!@# & , XM\?&2,L[I(I
M(\-<?C[(A4NCR^/C@D:6=H;$10E"QQ='-><G1($*0@ SE*M6>4G(* (PTP
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M-YM^.GA$ZS:-CJ5*E0I4R)$F(1HD9!*5(D2DEITJ5*G+"2G3)DY(0%$$$%
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M'00AUK00AUK00ZU]&M:UKTUK6M?1K6OHU@A_< 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@%>9+_P 5]+?L\]/?\R>1< L-@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@%>9+_Q7TM^SST]_S)Y%P"PV , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & 5YDO_%?2W[//3W_ #)Y%P"PV ,
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M6_\ )ZG]X2/_ )3!]/ZGQ_%]S;9XCM:UXP.!_36M?_13I;?T?1].X2T[WO\
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MP-^RE2O^2&G!PU_/5]U7JS8C@R, 8 P!@# *"53S--*J[=[ LY G97#GOKZ
M5#,9 CVZ#2O<8Z K=F<:JE:9.Q%$@T?'[&J\N$NRI\(6@4$2**N1)Z8L;@0K
M4BMRENI7AFNCF>:XD80CPP^.R"D1-K34Q+9=$X(K0+H=6]I= =$VU4<?4M:G
MXXW#25!9%J2>L5 $2K6CTI#A$UI!!NOA"B@#$(0A774]<\VDDWS:2;ZEJ^C>
M/*'ZG! U5JQ^1IY753BYNU6656M@SRH+5K=<^(26Q]W#+)J^1Q27LR)^;DZ9
M&^,Y3L-E>"DB$3BW*36]"8F$3:RCDTFGS3L8D#@7FLVB9!SF^,5A3:MY=8L2
MMJ7&6-=MS6+.918<(DL(EL=D;U9<VG;[/CQHGNN8>;\E$R(AB$D:=-VFL*!6
MM3J ES-DX:LDK-0[)1DS';@\;7)5YVC,[<GT.F_SCM)ECL>N=EB%T7'7E?7H
MSP]N$T1)#=M;P2=1V$6D3'&H7R4W@F#&Z!.: $LSF%>T$$(2P535EZ)M3:S:
ME>'/,YFTO'GR1=/*U?\ %EEU:*3<Z5<V5XT0:$G2^:H5S$BJUJ+8H;HF7MDA
M1S \]$R -:%JI4^G*7=O6KTSH:K M/\ ;%533=2=W,N%K[\-#-9%QIS=*NFZ
MM[#>ZU0J>A:7@+M65;3HIU?D8(Y"WDB1I%+25&T;F1%U@DZ.82M&V+E[,J7-
M:61.Q*!00!1K0!,3ATS9W:]\ET1"]L^+KC6[)W9\\GD&G)IEW@0F75!XU=UT
MPBI+>>&AE)C[+)K)J.&SUCKJ829G:DR0E"\/,<4J/C*)&Y*OC+FE(6%BJIJ(
M>65E*O-G$Y_O=D_L'*E&QF>4O9;-$5"69<^TR[4!5#H*22907'*K>PP\#C'C
MV]2[FMSV>:""1H(7M\2N+V5I&;LMP")8JV:)+AJ;-R^=[^;(VO'@/G._++)N
M>1H[2@5N[C*2$N]E4+>US<]S&6PE J/6HHE-W>FIQ"S)BR(5*D\;<5(@N"MK
M :80V*T:<8RA FUMXI-=&G&2(JZ+XM76&S</\\UJW)F;F6E.B(7==P"DDSD4
MIDSE'**2.\UK*" 4RY?()-.#YM<IT4=I<]R20*5A3/''0]<L<%CB00<*G$O5
MIJUL[9<I\;FR?!D8 P!@# & 8;8O]'T[_N;)_P#!%V =)S@] [>?Q'_U8' W
M[*5*_P"2&G!PU_/5]U7JS8C@R, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)?MMGL,<"1_!*F6?5V]%MLY@3^A.]25S%+X^RNJ0WT"<D!H0-B$::S+"8(,
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MB_DJ:R<IYE#6$(OI]AO=DP-[T'>P[V$/H#J;4-N-IMT+DX(, 8 P!@# & ,
M8 P!@# & , KS)?^*^EOV>>GO^9/(N 6&P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P"O,E_XKZ6_9YZ>_P"9/(N 5L\I4RF4&Y8"\0>6R=B<
MS[CI-L=8;7,GD<,N2\XDLL-FW+Z#HV4PPDV:,ENVA'"G%FB*R*&M;O[8%96Y
M)$F\U?*V4:I4OK?16S?!9E8^*D2&^*AZ\B4^N3J2EZRA?2)RM)35F7]:\9ZK
MYMJZ.5I#%*Z&7+><FDR^V&*)V8^(9+<<=5Q.VWYI;:YD;0W1>WG%I+>FMN>_
M?MBJT-0[9I*'R4:9/6;YD9U9%^GK#Y?CCS"'7JFYN;U?;5Q2VNV1KZ$>*ZZD
ML#A514,]C5**D-ZV#:-73IPCF^A3X[:T</F-K-4PD5'!BXG)?)$!1D4?V7ON
M6R>B:6R:Q3M=96=G?JLKXQZX'.Y]0!72%R2A7(H;3=0TM! 1IBL5?6=S7;/(
M^HBLZZ1LN?1N.ZK9,WW785;3J%\D,TW=VD$IC#1(K2CB!:5=-;A0 UG"LY=V
MI26BF[:UCEHS>M@P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7F2_P#%
M?2W[//3W_,GD7 /;T9SE#^E8G%8[)Y#-X2]U[8D:MJM+$K=W;&><5Y8\2(=$
M3/*8^8_LDHBR\W32^OS(X,\LBTEC;LSO3BB<F94 T BGOW_I4X]+E5)KXP*M
ML>L+;KZ<WETI(I%?D^KN>W9<*F3U<DL.SBZJ;4S5!Z_DS(VU"BIK=4M:1(G"
MLKQLJ9NC[^+XU\XD[L%T=@KQ54U%E90E?OF3D3R:H5TG.Z,F?2?1]DQZQ%+>
ME?9-+GNKFV;HX2 UK)DM<1]YKFIX D8XK-F%$X1E^6)&OYX(&J0O!\4E,<>
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MG=H2QS4[4&'$C+&JK0KPEYN[[<4D;,,&1@# & , 8 P!@# & , 8 P!@# &
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MQK9FK%P-H2J)2*4/;HUZV]2N)-[BK2GM=8/:\%:-AH)BZG,#B[2Y:N0/?O\
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M=".;7(*0T:EF>D0M[(<V)W(0O+4K :C<D*562:2 1IK--<[$J8(, 8 P!@#
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g509388g16p07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g16p07.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1364&AO=&]S:&]P(#,N,  X0DE-! 0
M    %+J^4P8X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 5\            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$1       $     (   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              >@   %<
M   & &< ,0 V '  ,  W     0                         !
M      !7    >@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    >@    !29VAT;&]N9P   %<    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   'H
M4F=H=&QO;F<   !7     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,      H6     0   $(   !<    R   1^
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M]*6U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M /_A04-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX
M.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D
M;V)E(%A-4"!#;W)E(#DN,2UC,# Q(#<Y+C$T-C(X.3DL(#(P,C,O,#8O,C4M
M,C Z,#$Z-34@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @
M(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @
M('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C R-"TP,2TP-50Q-#HP,3HS-2LP-3HS,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C
M<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C0M,#$M,#54,30Z,S Z,#8K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(T+3 Q+3 U5#$T.C,P.C V*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P
M+C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/&1C.F-R
M96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/G)R-#$U,#0U/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@06)P<F\@
M+2!3+31?,C R-%\@-#@Y,"TU,S@V+3(U,S0@=BXQ,"YD;V,\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R
M36]D93X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-S4V
M,64R."TQ8V,U+6)C-&0M.3)E-"TW8V-A-6$R,3-F9C$\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED
M.G!H;W1O<VAO<#HX-#EC.#9B."TR,V8Q+35A-#<M8C,P-2TU8C$S,C)B.# P
M.3 \+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HY,#0W9C=B8RTT,V,R+64Q-#$M.6$X,RUE
M96-C-S9B,V)D,S$\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.CDP-#=F-V)C+30S8S(M93$T,2TY83@S+65E8V,W-F(S8F0S,3PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R-"TP,2TP-50Q-#HR.3HS-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P(#(T+C<@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP965F
M8F(U92TU.3DX+3(Y-#<M.3DY9BUC.31B,#@Q93EC9&8\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#$M
M,#54,30Z,S Z,#8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XW
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#IB-S4V,64R."TQ8V,U+6)C-&0M.3)E-"TW8V-A
M-6$R,3-F9C$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C0M,#$M,#54,30Z,S Z,#8K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R-"XW("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C!E969B8C5E+34Y.3@M,CDT-RTY.3EF+6,Y-&(P.#%E.6-D9CPO<W12968Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#HY,#0W9C=B8RTT,V,R+64Q-#$M.6$X,RUE96-C-S9B,V)D,S$\+W-T
M4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^>&UP+F1I9#HY,#0W9C=B8RTT,V,R+64Q-#$M.6$X,RUE96-C
M-S9B,V)D,S$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'1I9F8Z3W)I96YT871I
M;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L
M=71I;VX^.34P,# P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @
M(" \=&EF9CI94F5S;VQU=&EO;CXY-3 P,# O,3 P,# \+W1I9F8Z65)E<V]L
M=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z
M4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U
M,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM
M96YS:6]N/C@W/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X
M:68Z4&EX96Q91&EM96YS:6]N/C$R,CPO97AI9CI0:7AE;%E$:6UE;G-I;VX^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ >P!8 P$1  (1 0,1 ?_$ !\   (!
M! ,! 0             )"@,%!@@"! <!"__$ #80  $%  $# @4"! 0' 0
M  0! @,%!@< "!$2(1,4%2(Q"5$606&A)#)Q@0H7,T)#8I'P_\0 '0$!  $%
M 0$!              $" P4&!P@$"?_$ #81  $# P(#!0@" 00#      $
M A$#(3$$!1)!409A<8'P!Q,BD:&QP>$RT?$(%!5"%S-2_]H # ,!  (1 Q$
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$N(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g509388g17p00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g17p00.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[24>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )0*^E'0X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 6             IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$1       $     (   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              X@   -(
M   & &< ,0 W '  ,  P     0                         !
M      #2    X@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    X@    !29VAT;&]N9P   -(    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .(
M4F=H=&QO;F<   #2     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,     !I>     0   )4   "@   !P  !&
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MLS"^L/5<.W]/8_.QY_25V;!:/%]%E;:6;_\ @+&_I/\ @TR62,2 >JR62,2
M>KVX*2!AY5&7CLRL>P64VC<QXF"/G]%S?SV.^@]!ZAU;I_3:?7S<AM+"X,:"
M9<]Q]S:JJJ]]MUKOS:J6>HGKV@>KX5SZAZ8=AY0<TV>UK@YCMN^Z7,?77N]1
MG^D98GJZUA,;6QF.YE;R8: T!FTGU7N=O]_Z5OYJ)@Y?5L[)%IPFX73H<?UD
M3E6DANQ_V>L^GA5_^&;+LA__ ''QTL[*ZM@9#K6X3<WIQ )&-IEUN <7N^SV
MGTLVMSO?^@?1D?\ =?(24ZX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X4%$:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C$M
M8S P,2 W.2XQ-#8R.#DY+" R,#(S+S V+S(U+3(P.C Q.C4U(" @(" @(" B
M/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*
M(" @(" @(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T
M:69F+S$N,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA
M9&]B92YC;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E
M/C(P,C0M,#$M,#54,30Z,#$Z,S4K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N
M(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(T+3 Q+3 U5#$T.C4P.C(T*S U.C,P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-"TP,2TP-50Q-#HU
M,#HR-"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XP+C @*%=I;F1O=W,I/"]P
M9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C0Q-3 T-3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CY-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X.3 M
M-3,X-BTR-3,T('8N,3 N9&]C/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA
M=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z
M0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QX
M;7!-33I);G-T86YC94E$/GAM<"YI:60Z8F0Q,#$X8C0M,39D,2TR,S0U+6)E
M-V,M,S=F.#9A93EF9#<Y/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z-V,W-V4Q
M,V$M.3@Y,RTQ,C0Y+6(S-F,M9CAB,3 V931C83%F/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z,#8S-#0S83,M,S@U,RTR.#1D+3@S8C8M-C!B83EA8S,R8F$Q/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP-C,T-#-A,RTS
M.#4S+3(X-&0M.#-B-BTV,&)A.6%C,S)B83$\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C0M,#$M,#54,30Z
M-3 Z,#(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XW("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.#@V9F4R-F,M,3@X8BTT9C0P+6$U
M-3<M9#,U869C-#@P,60P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3 Q+3 U5#$T.C4P.C(T*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N-R H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R
M86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M8F0Q,#$X8C0M,39D,2TR,S0U+6)E-V,M,S=F.#9A93EF9#<Y/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T
M+3 Q+3 U5#$T.C4P.C(T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @
M,C0N-R H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E
M<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HX.#9F93(V8RTQ.#AB+31F
M-# M834U-RUD,S5A9F,T.# Q9# \+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,#8S-#0S83,M,S@U
M,RTR.#1D+3@S8C8M-C!B83EA8S,R8F$Q/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M,#8S-#0S83,M,S@U,RTR.#1D+3@S8C8M-C!B83EA8S,R8F$Q/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT
M871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/CDV,# P,"\Q,# P
M,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I
M;VX^.38P,# P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@
M(" @(" @(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A
M8V4^"B @(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXR,3 \+V5X:68Z
M4&EX96Q81&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I
M;VX^,C(V/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" #B -(# 1$  A$! Q$!_\0 'P !  (" P$! 0$           @)
M! <#!08* @$+_\0 /1   04!  (" 0,"!0(#! L  P$"! 4&!P ($1(3"10A
M%2(6%R,Q05%A&#)Q)#.AH@I"4V)R@I&QP='P_\0 ' $! 0 !!0$
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M29]EK*Z598>;(+,WA]?_ (K%.@.2(%.7??YT3S]/+OH5.3V!Y;I'^V&>-@:
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MMQPWIG9\;;P3[&HT7]0OL9[&W>>XDV++?)_/EZ.'-FJ<\F28\L#PG,DG//\
M64IG%<JD4])MY\%V MG[&L/;;7I51=#2+U7 Z.)0Z?F-3)PF"Y\[TIJKK67
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MHFQXUAG;JL*$@YE;:102OWC2)]4 \+4[ \,\0P?$-EP=HPW2,7>BU"'.;!B
M-TM(J!)!@Q;GVQ^*X.WL;C8+PYK@)MO-,1#A! J" 07-<02T[H4@@O?^ /RY
M5^PT55<B(YW\JGV<WX^&.=\?9S&_"-<JHB)\>;@1,C(]\:_0K=&F0#>>\H]%
MCFF$"CU_*,;1M1'?F>,(U1SU^2,/]"HTZ?/U;'*-?R(GW:B_**L @ =W5.<=
M HP^R/</63@])6](]C=+B,P)LR108EFCIUO=ULKFZA-A%Q_,L=6P+?>;N]O
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MJK78OC6.EUYID:!-[:Z1#-W+5["KMH-A-UV:S]?SLDO//=A@ESTX=G;Y";Z
MQ0^=*<Y/2P4@XF_AB8 FUI )L">IIJ0OF\_7GYI=9?VDYQUEH)D;.=0XE&S
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M !N8,OV5BHG5NR[1C;#M38<\-:^ 09I,DY3()(D<Q)A<>V?:G[)M#1)W6OJ
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M\:MB?*D<\CD0,9C6N>YSW-1'$<KE55[0:W<8UF30/..Z>@LO=&P[,-EV39\
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M0CNK6U$"HSMG+(S '&\F($USO$>R<>D0 .E- ;38T)"N,]:.'P>%\:R. D3
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M]?PI5J_[*I$:HG&1"D8CG.>(AGLDR0?F55(Y'2&L9+57K^^_:Q_WBG0 48$
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1A$\(GA$\(GA$\(GA$\(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g509388g17p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g17p01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1PD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ' B^<78X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 5\            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$1       $     (   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              IP   ),
M   & &< ,0 W '  ,  Q     0                         !
M      "3    IP                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    IP    !29VAT;&]N9P   ),    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   *<
M4F=H=&QO;F<   "3     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,     !%D     0   &\   !^   !4   I6
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MKW/L(V/R++,7Z&SWUX]F/9ZNS]/]#TZU-_UJN=5NKHK:]C\-M[77M=L^V.Q
M7?H=S;L:NO-=MRZG>EZF/_HUOWXK,AK66C<&O;8();#F'<QTL+?HN2HQ*,>I
MM-%;*JV@!K&@  3N_P"J=O\ ZZ2G&Z_UC*Z?D8UM)=]EQ[:OVF-K2T4Y#SB5
MO<XGUF>E9^L_H*_Z_P"C6^2%#T]9TG^Y ZF+1TW*]$D6BFSTBPPX.V.V;2?S
MMR!V4RHS,;(+A1>RUU9AX8X.V_UMJL#4+EC0<3%HS\-FVW%J:]@: W?6&A]V
M*[_@[J_^VLCT[_S/?T]3V/J:]AW,< YKAW!U:Y0\OG]T'3A,31"^<>$^;-))
M)3K%))))*?_0[G)P,ZO.NNQV5Y%%S@\L+_2L:Z '^[;:R]CMC?\ 0O8F;>RP
M/9M?3D4D"ZET>HPD;F._1ES7UV-'Z*UCO_!/4]/<(',:K+ZU@478=V2['];(
MQZ7NI#7/K<2&E[:?5H=79Z=CV_S:IYN2A+BE'TR.I+)'*15Z@-?ZO[F79U=0
MC%8YA:P1L;<X.?DMJV_0]II=8QOZ/U/^N+<;PN"R@'7X9>RL4^D6XF5B[JP'
MN/VIKZ][GVX^3D,<]_J^M;]K_P ,NFZ%U.W,QW59#]V7C$-M<!M%C7#=5D-:
M/;^F:UW_ %^NY'E,T"!C$N(@:2/Z2[)CD!QUH?P=A)0;,J:ML*TZK,Z_:6]-
M>PG97<^JFY_A7;8VF[75K?T;MN__  :GUCJ'[/Q'WL ?:YPKIK),.>[Z.Z/H
ML9_.V_\ !L7*4FY_5&OVMR\DUO.5D7"6[;1Z5=5K!].BW=:^KIT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%18R46$C<8$70I&AL<'1)#/P"AE2@I+_Q  = 0$  04! 0$
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M@^GX/WM#9)+[-S!,Q)VF6EIC)+MS;ZYD>K2OWC=I1X3\.Y3E8Z:M4:D+@_J
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M&(!?%.&?]1WB/&N%I*6S',)1_2Y <#FPTMU?>8GP;(ES1+0018%P*L%$5<N
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M8^(OPWX;XOQIQ<R6DXU4F1)*S+"_^W+L 2"0H)L+5J+OU/!?$.)X9(^1+_\
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MT8W!%Y&(\0,W[BZ[1.82B [ P#H>[S["(B/CZ<]^D@"@4X+DL:9B0[-M'+$
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M0<0@XA!Q"#B$'$(ME&;98QSJ(D,8Y2E.;R F @[* B @(Z^@^^O'MXY!2DW
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MS&MDR? TJ]7NTQ,PA:E:RMC:+JC=M'RBE6MTDH[?NY"87@92U.F+,18"A.H
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M,</R@ AX P!KY0 P!X.'@P&#P.&F0%39BE?I6@)(N"&8@BS;ZFSM%04Q2?\
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M/;LQIC-N-6&6<?6ZARYR(1]DASLB./2%56.>MSI/(B213%PD4SB,F$&DD0
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M"."4ER\ND\^LM ;T")BITR$&5Z>O8Z=NWD%"23=.L%9.$GCEXN^EI'L33,Z
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M93  '( ^ \" #K6Q  ']-B.]>_UXA3OO^XNT #1M>-B'@/ >"@ : / > #V
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20<0@XA!Q"#B$'$(.(0<0C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g509388g17p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g17p03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2 L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (!"^@@@X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 6             IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8
M  X             /X   #A"24T#\@      "@  ________   X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!$0
M !     "   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              .<   "V    !@!G #$ -P!P #  ,P    $
M                     0              M@   .<
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   .<     4F=H=&QO;F<
M  "V    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #G     %)G:'1L;VYG    M@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ H !^ P$B  (1 0,1 ?_=  0 "/_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M 0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B
M\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>W
MQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*7.]4ZAU.O*R[,1Q<<0MKK
MQP!M>#6RRZSW;=SV_:?4_P#0/9_VI71+E.N5A^?DX._TVYAKN?D.^A66U_S5
MO_'?L]OZ/_"U69"2G6Z%E67"^MUSLBMGIV46OC<:[6[AO]K/\(RU:JQ_JZ?5
M9D918:76O:T8[Q#ZVL:W8RP?R_4?<S_@[%L)*4DDDDI22222E))))*?_T/54
MDDDE*22224I)),3"2EUR77?3GJ8MDL^TX^\:_1C W;?Y&S?O_P"O+JR\!<Q]
M8,[!PNNXK[\>W*99C7&^BEH<2[=53B76L>^MGLJMZA4UW_"_]MI3I=%'ZWGD
M#\ZK>?Y>S7_P'T%KK#^J%K;.B5WG>7VV7>H;=;"66V4-]:?SV4U5,6UN"2F2
M2222E))))*4DDDDI_]'U5)8?5L#(LZGC9./C^O4VO(.2W< '/-=;<1C][F?G
MU_H_]#]/]&JMF5]9,?'-V2"T-+6,86T[K#;DOK]U@/I56,P#C^_V4>MZOK,2
M4],DN:Q\CZS9 QG@/;7ZN/ZS_3JK-E!K'VJWTKW664O^U[VW8_\ H?2^S7?Z
M:WD5=5/6\7-H8?LM9?BWU[N:;&>M]L#'.;7^BRZJ:?\ 3^CZJ2G9)0LC(KQZ
M++[#%=32]QB8 $GA2! 6#UWJY MQ\5K+#C%MEUEA(8'5EM[<=NR-]FYK/5?_
M ('_ (2U-G.,!<C71=&)D: M65F95-F+9=ZAS,BPFO"K=%==3&EUK;O\%9MW
MTUY63=ZGIVV_JC/])9Z'798<KJ.00<G)M=5[2XL93CE]./10ZT,]1G\[>^ST
MZ_4OON_X-9.'8.H]0S3@W')O<]E;\LB*JJ6M]CZ6_P"B]5V1Z%%7J^OD5>K=
M;_A5U.+CU8N-7CTB*ZFAK9YT_.=_+=])Z<#>H000:.A</+;E=.ZEDC! =5U*
MIV0^L&'5Y#/3Q7Y&,"WTKO68^I]E%ME/Z7']7?\ I[$;IV=MHQ<JMUEF%E;6
MN;<YS[*;7'TH=98?5=7]H_5LAEG\QD?\!_-WNJX3LJEKJ2UN322ZESOHF1M?
M38Z'.;5<WVOV?S?LN_P2Y>W+IJNZAB,M^SY.0*A=AW@QZEA]"Y]3F.V_:6T?
M9\A_HW;,AGZ7_ADB:!/0;J&I [O:2AWY5..W??:REFONL<&C0;G:N(^BU4NE
M]3&9OKM:*LFH3;6"2""?;=3/TJGQ_P 95;^C>B]7PK,_I69A5;6V9-%E+'/^
MB"]IKW.B7?G)L9"0!!L%1!!HMFJZNX;JWML;)&YA#A([;FHJP\GI75[LQSVY
M HPR*F>G7;8TEC'XUMWT6[:WO97F4?H=GZ.U5>FX?UB?<UV198*!:UUC;;B'
M.8W>UNSTZ_9=7MKLR*V?JF7ZWLLJ]).0[]V531'K6LJ#I#=[@V8!>Z-Q'T6-
MW(@>=I=X?D7/9'U<SLCH_2\&Y]=MV$Q[<E[WO/J%^+?@/<VTM-WZ1^3ZUGJ?
M\4M<8>1^R#@^HSU_L_H>KZ;?3W[/2]7[)_->EO\ ?]G^AL_1I*?_TO5"V3,I
MM@4DDE,=@2V#NI))*09-@IJ?87-:&-<[?888($[K'_FL_>7GO7#DXU6/@Y=9
MH]5IMN986NLM(<WZ?HNMK_2Y3GOVL>]]UGIKH/KU:]S,'"/\QD6.?<.SO2#7
M5UO_ 'O?9ZWI_P# H&,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,E%A)$)Q@;$8,U)BH? F-&-RP7.1T>'Q_\0 '0$!  $% 0$!
M  $" P4&!P0("?_$ #@1  $# P(#!@4#! (# 0$   $  A$#(3$2000%408B
M87&!\!.1H;'!!S+1%4+A\112(V)R,X+_V@ , P$  A$#$0 _ /?QZ(GHB>B)
MZ(GHB>B)Z(GHB>B)Z(M,/+3M^RYN0Y?@>>DJ@+2=$MZ4Z9T=H56,V<]SC 0A
MZ^I)9T7>9*.+:BSJ]KS@%3'$()ZZ!#6B)LB_-#*TL3P_V@ZQ/AM]+[=5I'2\
MWN_[Z0GS_*G,IDNB<5%6JG4#MK*UM(#T^ZT1(S/QJO?'16HK8[+:+G%',]!W
MP;,PC=->L]##"\-H0D6:/PS/53;IGS$#>-LXF<875KBG1F==Y1S_ *=%1E%,
MW>1SFJ_1;*L4@!E.A*!.UGR[(U=' 9!W+5@46IM?*Z@0J6*,LTTU>25[W[\E
M"RCZ(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHBYA^:
M\4D?D%P>>3ZOTK/'.^,I6$5WQ&V1^QX&VT^#[_!MV[^LC9&*J+(ZL)M*W^Z9
M.BQOZ=?QB?KGHIVGH?O_ *7.7-6ZFJ\FNA$P08-F+/(ZU+)[(I2IM34=%(:S
M'X34YFX2KUFMB)@,8'L61 FY:CF.0Z-MC.YR[2!Q[8:3>4#WZ*.@GJ;'I;_>
MV.@7:3P;B='XM\LD;_\ )D*^G-A_9\4K5SNAV>B/YF2.Q C:UN&?/DAEBO;J
MM;7LP2QRQ)\7>I'OV??FBVR]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1
M/1$]$3T1/1$]$3T1<V_Q%TL3@>/T<C)4CZU9Z%\<1.117 :6<F"%*/2)=E]'
MXWX\O?#W1@D9:'2PSU>GW>:NM3(*D)067YMYS[_FTI[]PN7A7]1MY/F\'$G5
M:_=*?.]=/Y5VB=F.B0L:>?J>_*#*^)DFCFD8;O[9O:KGC[>.).& \ON9[^+!
M9N,UGX:,#P,_52<>MMI]@"?.\KT'\*LX*UQWF,W*WU7<P=S_ !*\W9225E.+
MG[LF&DQ+*L,SGR0UG99XF:NQSW*^&6.=6Q+,L,4J%ECT1/1$]$3T1/1$]$3T
M1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1%R^\V7/7R#X2DK7-;6XIY!3#E
M@?\ &:S]78<!_7OJM=[Q21C8ZP&Y79*U_O+++\41/G\H-K^!M;PO?HG^/SO^
M/(PM!.0CQ%7K?E65JK$XW-U/G\!R)EA;;J\8CQ]Y3*+1[G/>UCFR2O+5VL1J
M4[UBW-!]*221?3Q\_I;T^GCNE]\;'K<CH-@/MLNQG@\CH_%SE=1$8E093T80
M0V)C8X$  =AH F??5B8UD<5*<+0HV:,<3&PLIS0-B:D:-3U*+;#T1/1$]$3T
M1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1%S>_$@H,QO-Q_D]^6
MG(TO&[.=#/;\34?"PC>X^<&AR>WL@4L*D-@X",XG%GF#I%]S04>; U?I$2M"
MW5>_I[]$S:0+C/G[\.LX6C?0.']#\9H,#T=^;I:#=^5^LS'+->!KE(1@K(=T
MV)S04N3,-WXJ]B.UBJN6-#>6[W4"Z<AX:G- AL!F=9;VA,GDH]Q[Z?RGA)^6
MV?F3L>IN(7;CC&!J<JY/SGF-"](5I\\Q&4Q,!>:O'4G,_P ,9\<&F+V:L<ME
M*UPG9IS7;M=UNX^&Y//&ZU-\45)19-]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/
M1$]$3T1/1$]$3T1/1%*3S+$Y7*_X1L8Q7?)GS:]7N>U&L1OM(Z3^7W5$=[>R
MM]_;[JI%2+I*:&:"!LOTG6)&Q1MDC1)Y)7K\VQQ01Q7)Y?>*.5ST97]ZU=D]
M^=WY:M+\"+F]^*C<NZOPRZ)R+-_ER'1?)4KC?&_F@2Q<E%QFCO5M:.I&F3$6
M@#T="+(\^I[/;Z$G^ADI F;R6@FLCDGA9),4CRF+^\9PN7O>N8_B8\Y <Y[?
MY!;Y_0>->.O=N+>1'0P-?N7'NCVHL5RKI /3; ^.QF!_#6\>=-<N!L+5U,UA
M!O875AX_\\1+_J],7;I6HCQ,"]XCWXF_0Y4@C:+R!M,BQS DG:USX+TJ4#56
MU0IWQ)*H1%$1](J+*#FH2JE*5R-L8^U5L4(IFD:-YJP2Q6:,;XTIK5^A;>RY
M5D]2J??OZ*JU2+I:[)_K+-"_VEAMQQQ35Y(I5_D1TM9RM>R-_P HVV(V1-F:
MU'HSW_F>15:![GM?\_97-?\ %5;[*QWNUKT5BI]_A[.1$^2J[W1?=?\ (BC>
MB)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(I6>5['(C55$^**J^R*GNJJG[
MJB_Y?]/^=M^L7:Z (D0)SL2#X>"N,:")(F_CX="H3K"M_P 4OM[?T^+57_/W
M7V3W1%_X>K8K]1\O?X5)TY'RO?T]>HP86 N[]9/8(7G0^%'CCW4.@FG9GG@(
MK]5!3;<(^Z2T6QU"U98;-?&8 / T\=DKS5)S%EPK%CR0P]K =V+T4IJSIV,9
M&;8ZS-A_I0"TDR+#,$C!OGP,YVZ25SB[3=Y7X_Z;@9_32'>A=QV/5&W(-HP0
M/T'8ME!SX(0N:&+,?5490SV/U124!B"-, _.\ZQ]7K3=&6%#:!'0&9X<RHW)
MB38$ P"!%P+[R8M:0)M7JID&&]8,G(]8&<0)R-@KUX):U_DAYF&^H=C 9?-5
M_&WC^=DX9S?+ZXGO8,WHO( STT)T7JI<Z2PV!BDWUD3S*/!9S\B.-"Z>7/:.
M>H;G-']-8FAI)!GK]+> \501 C,[D':+2=P<^0\5U!O#Z987>#%Q]<D-(CYA
MQ0022"X(NT;=:2O<I6(""3UR XK KZ1-MILJV*I58Y'.;,]'5*/?7[KB1F]Q
MT;QSP??/#1PANKX[RB]J>+\:ZZ&UM\AU[F?,MWR#,=$P@*_SHMF)6[&MP,?M
MAF9HRB.A3;,GBL-GOH971:5HV0W00[5(/<B\QF9.TX(W@*<WB)VO?RL/EF;7
M6=^(6,T_EO-_([Q.S8P!!I,H&U!WDV8CI@LKT,-6K2U-3B;E-L%$#6[2#L1K
ME8])7J#[4NSS\H/4E+F2S$C1E]AI5+-L2,R3>T0"0-KWR<=)UT\$"9(!EUMA
MX$3,F]K=%TKYUT;-]*Q6:W60NOO9K4B:1@3:?4GI3_E[L$<KJM^C<:RX.+#9
MG2C38B['$0!F:=\&2@@)#K<$=BHXTG%KFDP"3&UXB(\"1O$&(,JD$2/*?,=;
M1X6E7O\ F7)]D>KE5/=%^+?M[_T^S4]O;V]U]T]_\U_RLMXECS#<Q\NFWT5S
M2T6-YQD>EC[^TM;MSPI\FO7W2-WTVK]!D4MAT<S8('OD1%:LLGLYJ,<CG211
MQI[I*YKK[-4=XS-Q8"UH%@%2\ &W3$Y-[77PE^94^;IG-B=_@5:R0RN1\*2L
M:R&5SWS2,;^9DE=&B1(VD]$1%;+\JE3[Q'OV-E5*TCI&/^;VO<R62-5:U6_9
M%16?)%^WR=&YCU^/V]G(G[HJ^B*9]$5-O69*[D^,D<3/I.>Y\GNYC$8]JR.>
MQD;I5=]%'_ET:Y$DF]F.:[]E(J<XE8C:[Y2?SQQ0^\<C61/=),KOR<CWI%(R
MI6M*U&6;,K)61RND@AA9)$Y4(JQ1DDEKHZ5[GR(^5DBNA=#\7LD<US&->R-S
MHV.16QR*U%E8B2?[WHBT&_$%ZKV?QZX/U/O7-M[7&IA 6&<(QEC&!C].^0,]
M##Y8[>)6[E.4G.QX[2474:]"[3BH3T)K5QMF&98T*1?WT!]G/@KH+>12<2Z%
MA>4]/T&WW!7KG21.$QNOBQF2%@P6FT&!,:8-ABLE"UG+!Z>^[$ZXG"=RN>.U
MZ,-@:/T<@+VHV#;W[]^?51XW][^_2ZQ4S\3SBK>=1]4MY;K]+'$\1UWK.;NS
MXX+6ETO).%"Z17J?0@T=[1U(4"8^0F-$VPUVTS=E[5B24+DI8&K8@B?7RO/4
MCR2#Y7 Z7),"#U^OA97#T'\1#F^!RG3M6[&=/T$?(^=[S;;4>& !5_1"W.>.
M9SN&KPIXC;.0#,YHA&)U5&:8L:O4<;.:'$L=6T$FTD# C<I!\/F/Y]YQ*V+.
M]Q8!X@2[,=SI7'PBLA=UMS*[ GF19NE^6JV;8P*5*"[NDS5"YH;4%071G9?L
M554K7B2:,RUPYA%@?\/OR=U/DIQ317-_H,5H>P<G[-U?B'4R/.VPLPMS1XG1
MSW,L>RS5MW9US.VYN5QVM RV9_S"TSL4-A\UB"2S,3W?[>8WZ;A;SQROF:LK
ME<K)&H^)'-1J_![4?[>S43^5BJZ-'*JJ[X^ZK[_=;;BXN# +$3/KA5M( +B;
M VO%_F!O]U2+]J&FULDLJ1NF?]"!7L=)"VQ+]ZZV%:Z-&1/?&^#Y/G@;+--!
M6A>^U8@;ZL<17X3@Z9J\0]K0(DET&Y/C8DXVO$&P5-*DZK4 D@S $;?+QB_6
MYD +F&7\E>3&_)+H[:VLK](U.3PH# \]PO/8(]9J3J6M)I2/4AV>8RN- W[M
MHN[ 9WH@&4K7!Y.;&XIO33H=LMDV"Q/#=JN65JII\+6:\!VGNZ7=X1,DX@:3
MD&3,8C)U.55&4?B.U D$D08 BP&;WSOU@PM.LOHSNH-[ORD[3," &2/ZSFLF
MVD0O39[G?"<R:)QY6',:5[:ELW)N:E23?Z<\P=4L'9]+C<P.EI \=FQ=K9:=
M5O$4R^>L1$7 .JQ$R2;B\$; K$:2QY;)(W)$7Q$F!>9&V9)75[PQY*5R//S6
M[W06P$Z!UHO4T9(#=;]$CB\B)'.&<_PMKZ*L=!:$#+)+3FAK_J-";;::P71L
MV1U$;8]66MB9W,B]HM$?GJ5>>08TS : 1?/KX1A;C?D:OLUJPM<QK$C:R172
M,:Q'I(B(Q[G-3W<UONJ)[N:R-CE5D;&MJ5"Y:^7^*7E_5H.O5*T\.#ZO3S^:
MZ&19*L-#+]%$?4S&0UFA(.22:L%Z &* .:%;EN62D,.Y[G,8L;+</'GW(-2W
MPHDN,^.PS(B8B^\1?-4]PC<2=Y@1Z1FT>.RU>Y#I=5P#MY#+A<T2UG#>Q5-1
MO+>:R(:Q-H^:=4#3BI- <PX-BVIM'EMOF[;-/I\AFJEW0BM%B]?J\Z%;5UQ:
MDVQ6G@A\8 Z0-;B9=838 @]#@8$FP*LT*#J]0 6(.D FQF(-A,=X#(Z&Y!6Y
MOB+W?ENKU/:N?X+HN+/4HNES[3'!Q!=L[IQ&@R.&O=.D"TK4;7E1 CK-[;V3
M9@:<(R5]H:+"- T28H7QS,:.U/*.)JBB_B*;:T!F@N <8+G%\3@&6F<:3 )$
M+,5>4UZ-(5"UQ'_:26MD]T&2(U6B1N<R =_QL_YEBS,? ]C;-B#Y02NFC]X)
MGP.:LKF1*L\:L6&VQ(HT@NLL5VM5L*229$TV/8*M$@S!)!)\1US:Y^8LL4)8
M_2X&QWF9&9\8\A;$%4W99(1M05H ?BMV!-NP,FLP42Y(%:<X5?C+P*PN(NCR
M-#X6Z5259*MR!\K(Y*TRRU9IX)+E(ES>]D&,= (^2K=G,R)'DN,OCMK0^$'^
M2O0">LL7--F?Q,.J<4XP0Z-U/I^@ B:^I< QV7S8[+L+7Y-R^O5V1,CG<57D
MJ2EBMZJRUH,D*9:TXJZHN=OIM>_SMM]%<>%_$F[GT'!Y[?9GE7(U'C?"6_YB
M;P==ZA8$N/6\V6Z!FR'-<GJ#8"EE<=%?*8P;:GVFYOV1XW/7[EE]:-:ZE((!
MG'O_ ']O24;3>8Q-O0Y\!*NRC^(MTJ[0&UX\WS)L_3.N7>6\'W!4G8QF9V%D
M9XVTNX3V]5D=SHP!O*V26RL$^5B 5K3Q%KL.4T>W%?K=)<\)T$^_/V;*/X]_
M03MGP*V&\8_('J7:>M^4&<VDO.AP_B_3,!A<J"Q<UPL4@%Z[Q^XIV>4Z7T5@
M[4I:L"0-;\@ $%0^1JPW&56VQE]U:N0:L"=X]$.!!S^"01](7,+Q>W?2!7=/
M'\J=Z%T!^&U/G;^)CQ&EG!?3M9M2NX<.VW9R>"'=2P>HMC0X+G'+@^&GEJ:7
M.U=80_6R>"ANV0&</-<:8^?G_KV!LIC-I,-N+8N;;_[.%Z+QOQ_)PHQ?>-&_
M&)?FZ1%C;]H_B]?='-^")\5CDFB]O^ZGFC^,CI4+#'D)P[ ^1W-S_'^G5[UW
M"ZK])72#117]&ME:P8M5.#ZTQ"NZL1@K0&APVXK:=^NLZP?1F^I7?-#*18@V
M7AAR3>=/#]CT=O>6=V )<XT%(F+WAJA6J'N4U-B/SII@BG=KA*DU8;O-&/G%
M41E<#?BO337!EJW*^=2;1Y^^EMK+7?L_@($. . X'#$3N?YAQ"CU64)#4ZN;
MP&K%:'=O#( +CM:P)O EX1G1Z:N$G1TV1L:&.T= ,SFJASD.OQVGC?>/?K_O
MIA\O2WJ>IB!Z&1<+*P+P4YW_  MT<)O=9T7<D^]\?BYCY&__ !SJ\OC^O:DI
MR =Q+:]2(<X&FXLR%V6[R(Q$,3CZCJD=K\D>H65-PQ&%GW[]_A))Z#IO'SR)
MZK8FQQK,V\7@\';+ZFT&YV5QQ@59NZ)Q$R2)8$P'T&=?J"1)+5TM$-T (449
M699=7GD&#4L0S1T:T<3W[]^:*#AN$8+G_5>O=BRT)Z'6=RMXXGTF2P9GD F"
M>#S0W'9<K6$RS?IPJW0S846(GL#J5*X6KCJRF);[X8',(LPR/6'YQLFC]UB2
M1B1(KVR>WV55>Y5CC_NX'1Q1L:UKI/DY[?NCE-(#Y)$!LQ%[$W.\>NQ(NH==
MI:,_:8O$$F^?+Q7*7SN[R;)%X/'#"$YQR7 = _V,W5FL0$:><--LIG.=5)Q\
MM>:(KKYJ!.]L_P E8HW*O/A[@0^V/T'0<V7H_-'ZS=MG\NK,Y;P-8M=5IN:\
MTRUT:G/ #PX.,LAY%V DLU%S148>H?I_V8;S;B&?'H_$']K7:@=0@:B6%I@6
M $W)<8_:3QPU_EQ>\8^QUQG&,J#N['%\N(Y^M,92./"X^;9F,K=CKNH9U!!4
MKH 61S%56@J1$.$D':<>2+7 ET&)IW]+_3[F?',I,K<36)?7KU'TV.@/<W31
M::[0&-[FIIIM=J#7/;4#9=3>6_1=/]'#S+A]=2A5'#-IDU/AAY:8F6N<]VH3
M+7D"VC2XG2\3T._"<Y3/V/BV6Z;V>]:TJ<BU?]GO)\O9HT,[@+8GF0+*CA6N
M-9Q]68QI=,$U-6_09&<(W<V(U&($Z/-Y\!I!D=R#ZOY#6JU."I/>?W2!W6B1
MI;WL3.1( VC>?F#MWR;A>1<XK<#1IN8Y@U%[R\NDU*C=,$Z!!:"'$ZB202!"
M[UB_;Z,O\RO_ +]?=WQ5B*OTH?=6HY55R*ONKGN_FDD5\C_=[G*N<S?KT_QU
MS^ M%+7,)#C,W&+ X%LQ>_U.54O10K*VF= ZT08S&I"B=%F]"&M!CX$[4A(A
MC@8G!<HD1),;<CL#B-*Y3LSP6*=^I9K31RN22-_LU$LU6@16!AP(;UL)($&6
MSWB;A 07!DW. #!O;WY;&"O-+YO=!ZQX'^5''JO)"R:[ YG,Q=/S@WKL-W53
M7CVAJ]0Y2=R5S?![(4[;'AL\3J%ZQ35D]+I9=#I6$"I0E%3#!;^V<+R9G.^4
M\40UKN)IM^&P2\.D!IG2TM!#@8PX"-[A8>KQ_$<!S&D#4B@YSBYNBF1IM DL
M+IM_:YL=-QACB'5\SW0?KRH*L<YQLL1TO2&:217J:[#G$AJZ6/Y?0A-77@8T
MRX+ER]T'0/S5T9H26?T-7:@U_*ZK%VOAC]3^&YUV)[5TZM?72X4,;5!<" &?
M'K@"0T?W-)EQ+C@F T#Z%[-4^5=HN3CX9IFN*;6.[[SJJ -EVDO @@@$ :!8
M  DE>AGQ [[/VCF<JG:@\/TC#F&8_I(P76EK"E-PCZ%P1I,[!9=)+'E]9FYQ
M1<)2G?8L@8[4F6O6)R0"]*O=?TU[8T^U'*Z0948^JUI:\M@"0&D6B/VGH&C
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M?G;P.!Y>83.\CTZ ";&P.+V\%9VL\<2M'/\ :.<T=?L RV<P;ZMM*J/IOO\
M3_*?F/#_ !;(Q:(MM%IV25'^/.[]?!UM0'S^OSN=- <68$!H\]G+NC)ZI'R]
M_3%DGUZ]?/TO>#GK"N 4![EC3; '(RQ 9#TP@:J\LY?XZZ,7R_ <LZ)7ZAL.
M4<O[5ILVXU<=MLCU4-SO5=@UN>DSQ$=C<!SS5E2&(WQNGMM'2GW?S]1[VNEL
M'V+3N,8M&8G"V;Y!^(YW&4IS^CL<#5Z'9Z>(K57",WS?6<7S7/NJF,^[>!,D
M_H_2#Q41M,IK\)G^A'\4:RPTU>/?PW0T4+W9+<A9@10NK_!^UY3OW/*N^R2W
M88H3>EQND$DHZB$,SO,(<O9/>9*[:%W"8$M:RVL%%@5@WES!S*&9:#R69.&
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M=9L_HNR &VUR4%P^Z]8DC]X/PM0%@[  DG<3&8L0=K^H5*@:.]1<;3(U8%L
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ML.MSYFQGPP95C0YLAV3>3 M &T";8O\ Q+;/LN4N3[*F!K:70SD^D]HZCG4
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M+\5.LR )MZU49EW<XS?T.C[P:S'\@5GT2G&\S8!F,X0K<[(,92A<'(_G+-Q
MV8L6;L\.3QD8&Q3$ ^+OP(]_?*NU'%Q:XF>[,P+W/S]2?-7K1_#K\14J+ WE
MI$>R"JT&/J#>G=<%1YG&L0BL?,LJT5OJ;<IR6:J7?#>Y'FT%<TOUJH2D0REB
MMFL]"+N*VIZ;\.WQ"<D_TN7WQRR4B >JX-TWKH.0+EBK2#26!RT@??49,CS*
M]^HJZUR_+.#\\ED&9N5^963*9AXB# N=K^_X^2F?K[GS\<JFV/P^/$FK*BT.
M;' ?T:GZ4.DS75NQ9G^%<K9?=_,X/%KG]Z/=A.5W?K,@,\QQ3@//[48_*+8S
M4KLGE_TJEO>'2#:)Q;:?3PV2?7SC-Q(W!@Y_RM+O/K\0R3QVN5O&[QP$!(^L
M0Y>I3):(M3AK9/B(LP(JR95E7.4(:]+0;=XI1]X+E(6B0&4&% 3RUF.F4$ B
M>X]FNS7]8J&I4(%-AT  7<X &\"0WO" ""Z#8#]VL\\Y[2Y73<'.+7:/B8!(
M:7.:#>=V.-P0!@&.[YM0?*ME4ZYG?(#5]%WG4.R94O"5$;'OG\.=B(P:""XE
M]CJ /KH7;XX 8KDFK(,DHYP>6SS(JUD5<S9=[X*/53^FW"NX9K](,L$W=8D$
M6 <(/2""WJ#"YLW]1 >(+-0>"XSI( @&2"&@:Q'6SB8&H"5U3\:M1G?+3JU?
MF/D%K=%BNOV>F$^W\.(AJ&9L\A(]PHLOZ(@\[DSHVWOT/RC:VB<N1TNO,9$I
MF+1=<='C3V>YE?"<T[2=E_Z5+J;):&ASG$D%HUO;(!G5I EQU#2"3L8Z3R+M
M!3YA3#AASM)%G NAI))P 0=-H!,",SO#KOPI9&_KLV2Z\(DB.:\CU(B\[S*&
M+7F=$?#E:^GY?=ZAFM+3F">,O0HS&LRNPYF&Y>5.Q9#==&B=I2$5J9MCG[@Y
ME2"=HP.KAB3N"+C_ +' MM)J-J,!(\)!Z7W$@WSY8FV/"W@3Y9X=I32\N-82
MJ7%Z2OT?FU/*;W2!<GQ@7&?+ZK7\EQO+-*!@Y?U KHS9F_H>=]5ZA:$5PO2]
M39U(O.9/.<[QU CZ7:B1)PV/+)QL;R9)C:QM9:X:77M.3!D6.9/@+9^^$C>6
M\FO'MGYTKR+H$N#YB>YOL.?X$X*I&;NIYH T?CE=W+NW]LY2NKXWS"7FW_9;
MR2YX77RQ;<EN25G5(Z6YZ9O-)9"T[[BPC(W_ #:V?"Y5?EZ_(^$]0=L3B39@
M'LP.<9( W,2Z'&B.J!,/T+MN!E#',-LM'T'E>%Q3*G.7971!]WT+9]*PV]\M
MQ8^[D,?KK-GR"Z\#PH]VMDH$S&*$_+%O2#;;J<[^*18B2#Z^,SY6/2%V,\#:
M93>B-OY!Z"297=&TER&I2N4CM&6F6 Z"W:Z1-;'Z2-I*K<QFQIUO'O//E:]T
MG+O'?ES8DK?EEJ0RH(@^_3V"1=='1T'Y>JQBPQ0O<^269(41&2SS/=)-8_E^
MSG6)7.F>[]WN>KE^Z^B*>]$5OF&1RRI%+'%*U]=6K',V1T+ZS_K1W667?1GJ
MPP*Q\$B-O1NJ6IH&-E8]:[%83W_*Y/YW\+? IJ#ND-=8+1I-C='S$=8Y2#!<
M^U![F>TT$>CVN6ZEIBQ+IK-_;/2P"D?K: K*[*E:'M*A2(<W<)%RI3/D?Y\/
MXQUVC=C"^&WBSC8W1!>&\^E4:8S]X1^O"(]<F5LY"*])CZ^'9JK)[^ 1618?
M,?PJ Q\>:#9A3!5H(,+B(6$GB!T"B3[WW];]?X6RRCJ/R5CJL4C?C)(OU6_6
M5\DB.9(^1TJO=(Y['O8Y9%=[LDD:O\LCT=**GVH8FN>^-B_6CBG<QR*Y[T?*
MKIOO\E=\HY'UE62-45CYOHS/:Z6&%S*B!(P)#9MU-[FVVT0C(<0'&P<ZUAC3
M&X)@[&QZRO)KYX$K.Y_$C[L+TB(0HX /RG Y-EQJ6J\63GYAB^D204VVD<C8
MOXMWNK6Q(SY2S3V"44TCX[,\+M)[157LXEK2Z&&C3!;$_NJOG:<1@Q.+&_T5
M^E;.&_I1?\-OQ3Q58N=)DZ:5%H) ,00+ "PCQ V1Q^0!O!QR3M;,Z6/\PK9D
M2>)KI)7VGI]*9SXD9]>>:1(48V!BO5K(VM:Q/6LZ: =(;?-W.,DD_P#L0+'!
M'K$+NS7//#L:P B +0=@9G-\6((@@'*T7\J<N%<)*TG1PV(;4%ZC].=RN9[W
MW0Q-HI\G*L5<FCY*=ML:QI)$D*/^T,*1U-J:>*I:"9T"\DC]Y\?&+$_*%KO.
M^&']+JN< &N>_4(@Q\-MB3<00/=UZ=?!+4F-WX8^+FOUD]F^=TG".7%+U\C[
M+=*/LXX2^,S=:B,8RT:B^F6L1L9%&V2W]-K&1QQL;TWE[WU:--SCL";"\6&U
MICR]87QKV@^"SF/%,9@571<D7>XG>^8)(.3.Y6X4%:NC%^+/E\W(Z17N?)]1
MZ(B(Z17N=]16M^+&N?\ )4C8QB>S&,:GL,28Z^S>ZQ0! ;,X&>BF8XF1(K8V
M_%%<KE^ZN57+[>ZJKE557V1$3W7[(B(GLB(GJ%*@3N<UR^R^WLQ%_9/W]W_Z
M?Z)Z@@'/Y14@@Y59&Y6JY?9R.5?\#HW12K)&J)[>Z.<R-53V^_LWV7[>J:$&
MLYIF!$1L=O/UGZJ.(EC!IM)ON2(B+RO$B0+%-CUWL6OT<DBG=MUSH^A/NGFD
MDM?4); Q/5"$9'N1\D6<&RU<O6HR>]:F.%5AT<+*L#(&_2_87E_!4N":ZG2;
MJ+0\G74/>+&-PYQ!@ 6C9<+_ % XRH9U!VL4M+3 :0W54(LVW[M9G-Q!$"<[
MUPHY@5CV_ET<VN^+V5B*JPNB:U:[U?[_ %*WTT9"E:3YPM@BB@;$D4,;&=4I
MZS1:#^W2>[I;!B2-I B&_N$^1(/SB[BN+;Q[]!<!\2UA.1<D@G5_=)D@D$&T
MC6C6F">&*!MAF97IH\5H@NRRWT)9%MMT6)(IJ,]7J*CE=_M9095$R5?BZO<I
M7IJ-B&Q7^G!ZYWVSX+AW<OKU2P"IH<V 7 Z>\08D B76&#!7>^P7%\;5JTV%
MSOAEYU2UL$EE,%Q<6R+";&;6 ,D>Y*G6AC@B5L;6>SY%1L2JQ(_:=)7HC6N1
MK'22QI)8:Q&MDD5S9&JW[>OEBH"^L<6L-\$$7)F)B,^MY^A6#0P P!$^!_G'
MT.ZFD%T)%:LE6.1U>69U=TGR>Z"21%:LL#G.5T4S6/?'%-&K98(G.AA?'$Y6
M+6JH'LD[SN=MHL-E,14:D,<<,4#(XH8FP1Q,]VQL@:QD:0HQ%^/TDCCCC^FJ
M*Q61QL5JM8U$*5KMUWQ?X=UNTPMK^=YZULZ5;.M =(J#*M7I^<NY;4P;++3Y
MW?,2+5#&#M33<7MTZ)>"L7DMD(3<)&F5(U[*/?OZ]=TE9)Y5S3)<KQ G!X\?
M)2SX.0@^!EJY?OD;Q$Q?LF]$9/7B-NY=*'M#HR9<X<)7K-BV4)$;)"Y--:LS
M2O)?=9'BAC@8D<35:Q%5417.=[*Y?=?N]SE]O=?LGO[(GV1$3[>B*)Z(H,M>
M"9?>:)DOV;[)(GS:GQ57(J-=[M:Y%7_$B(Y?LBK[(B(1?#J==_\ C8KE]_=5
M6257/3_PR.^?RD8G](Y%<Q/Z-]$46.*.%OPB8C&^ZK\6_9$5?W]D_I^W[)]O
M1%]_%%7W]OO[?'W^_P"W[^W_ +^_HBE;$<2(CE3V<KFK[HKD5?BJN1%5%^Z(
MY??XK]E]U]T5%7T)G/2,# Q\MD%L2,[G>Q^87GP_%E\3-Y_'X;R]XYE3.R49
ME8,GV7'9FG8)'8A F2ZW+].% Z3'ECE//1W6B=]1"5C!>()3S1>J+KC1VI(R
MZYSKE;^,=\9E]-(,(N9@N<)(((_<8_$+JG8/M/PO*:9X/B7AK7\47L)P YE(
M$3'_ &:X@DD]Z ;!<P,CY2TOT6K&TDV9SVQPK)$^6*&:Q!#$RS^4GCIDUMUI
M9&NL01NKT$A9-]%2ME8_JKJ'].XACRVY]P)D3&=MS<@V^AN"[6\ .';#F/;L
M0X2+-) Q$#SZ"8(,/G7.>I>??3XN9\IJ6*^=K$J_]IW4UJO3)\MSL-T?+=N7
M)K%FY6,[:S0DN.RN+IV$(72T(L@0;1Q-?7G F5X'E+ZM5I(-C>29 !!)L3/[
MA8?E:;VN[><&S@JW#->T/<PO8UN@ZG.#F"3!(,L@2",&.];V'8'&B,3B\IC,
M\,:%SN-SXC*YP2RRMM@S/@1]<:$H):57/G2B+KU:BR3+)-_<JR>Q<E:^[8WS
MAV-I4PV0"&Q?8   >G@)^Z^6..>[B>+JU3FJXN,")<228G @]2!F #"R/61$
MC]D]_P#%_5??_=:GV_T]D^WM]OZ_U]U @S&Q(]0I=_;_ /(^Y]_13'J52I2S
M]OO_ %5OM_R]_P#^U]4R=4;:9]914RZU')$U$<YR_)$8W[J[^[F56JGO]ODC
M%1KD^Z_%4_I[^O.7%E8$&),'RD_+ @@3(W1XUB]R+B\=(MC/W7E@_$-\5=7X
MV=>W7:\^%OW_ !]Z;IC&^+ZFC6G*T>5Z[5DK1S6CM=7JQLN9[)F=!?G,BM02
MO6L_2NG;6>=-DA(0%4(=M[$=J^$X"@SAJ[X<'P0[=NBFP$%PQ+7$WD7#L@NY
MSVL[..YC-4 __D  )$D/?DC#H<UL1>) )D+2:'IE=U-OTK-6>)L$COI0W?S\
M;8V016I9;E\2/N5G15JEB&TZ47+=2K7FAF+1T8Y/DO9!VJY:.'ECFD:;'6!F
M^F"1FP!@G'2%Q\=@ZIXDN<TD.=).APO/]HU],V:+. O,;5>!OBYK?+'K^*Z$
M1#6ZOCUSL\/UY;=3,CKCN@'<X9&:3*9?&V)G6*.M%J?#U[>QT0"Q,"_AVB0R
MR+&=OW(4Y)VV[6T*M)U&@]KBZF (-I#ZDDPTD&"# @$EH, VZUV2[/'EP:W2
M;NU3)[LL:T-R+P#;( <08B?6E3]TA]E<KE^H][ODUK5:^3XO='_*B([Z*N2%
M'+[R*D:?F'/LK,]W%:;FU'.<!:?K8[&,>GR71WR"&G8"WS]_[54@7W:Y5_?Y
M+[_\51%]6VDF9V<1Z*]:&D;B?J5&]5*%!EKPS.1TK/FJ-5J(YSE:U%_=6L]_
MBU__ -1&I(GLB(Y$1/8BB,8V-J-8GLB?ZJJK_JKG*KG+_JJJO^OHB^O1$]$3
MT1/1$]$3T1?#XV/]ODGO[?M]U3_HJ>B*FVJ5:66%SX6N6'Y/B<KG>\;WM?$Y
M[/YO=LBQ/DA61/9R036(4=]*Q.R2EVH]W^TP3('7K$^@*D0#J!(<+-@D1>9Z
M?=:L=&\//$SH&BMZK=^,' -KI2;/S!?3:_D//CQ8@L=B".-Q$L7!VKQ)85F?
M+]"Z^6M^_P!6S1?-'++CN-I4J=,O:UK7"Y, R 0),S:^#:^1<K*4.;<?3::8
MXJH&D0!: !)L8M<Y$&8_=8+"N6\GN?8O?AN)XWFT&-YN%VQ?DS=/7'!.>Y8#
MN:9-HC.Y4%BH!ME\6=/:H//B6:)8*CRNEO 9,0 .Y[4P'<[HS>VW!\OYO_2N
M++6.J,#J;W 4P'O>ZGIA@(_=3(,EQ<3(@&!6[AN+XUCN)+GOT=TN<9, :R(,
M"VLG-IF1OOX-EJI7^%?^X9\W(YC4:^-)$]DD9&]KY6?3KN1:K889GPTD@_(1
M?3;4^E'T/AZPXBDUVK47 N:X0001  +06S.H')DF9()6&J$TW%K['H;&UB;V
M/SRKBJM<V-4<OR7YK[+_ *(UJ(G_ *?_ )_?U>8W2""9EQ/S 4VL1,$3<0IC
MU6BD['WD1J_M\$7V_P!5<OW_ ,_Z)_7U3!U3%HB?65)(#2;R#/I\Q["I,Z>]
MB-'>[9$6-6/5SFL5&I8>GW:J(U88_P POO\ 9)$F1)/E\&(SS\1H8 \PTD_N
M).P<>L Y-A)\@%33<YQ( F\@6W!&_2VV_P M0O('RG!\>TF9QU+%WNB$R0R?
M0ZP<.+A!=[)X]\L@H18;^KNKC+FFUY);E+(Y@R7S-75#,WNI8-)#?SM4.;Y_
MSW]0N"Y+QW"\$QY?7K2=+2 0V2&&]ID$@2'&P):-)&6I<MJ<10=4<P.8TEI+
M@() D@7FP-[6D6,N"D<9XG^$'20&9ZJ.\4O'Z]_&8X3MPI0YX^80,<EJ'XHM
M((O$PIG)U3(DU!"2B?8JGZ%31#;S9H2,,-V*15Z'RWGW&<=RRC6'$50*S=0&
MII(Z003IM TZSXYE82KP5%E0M^&P1. ?203!B^1/SMN=0!"*\==(A]:)M.K$
M/J01QI'5ITX',DBKTZ;%2K4C1S(?=*\,2O;5IMD5[*51(;I)JB:A+B3)))N>
MN>GI.RNM8VF6EH ( @P+#;:)]X BKLJP1HC6,5$1?=$^;U^Z_=R_=R_S.=[O
M>O[O>YTCU<][G++ *8AE@3/6_F9*$!QDW/JHS6M:BHU/9%7W7[JOW]D3^JK_
M $1/0 "8W,^JGH.@@>2^O4HGHB>B)Z(GHB>B)Z(GHB>B)Z(H$GP^:?)/?^7_
M #]O\_\ 5/Z^A,*)O$'SBWS4A;J59G?)T+5<YL37.^Z/<D,BS0HKVK\U;#+_
M 'L;?=48]7/:B*YRKX^(I"J !,&Q@FY!F\GV?%7J9BXR#_D>&9]+87*'S:Y
M+S^D9T2.M)5PO2OTS$]1JTII:%85II*ML!B>ASSU'P6*7Y^(A5PY8C5FB,/T
M#.4-#71+JI8DORS^M'9SC^'XGA>><N^)3?PC&BK\,N(+:=:H\.+"',%ZADN:
M ;-)<XABW;LYQE(LJ<!5#2:KW5*9-I+J;! @2(-,D"X U2 +K9/Q6[00ZEB)
M06JMHG4L!-6SFWC2O6BL')'TEE ;6K4@@@JT';0/2E*/$QUV4<MK*^KPEG\W
M:S$D\O3?TA[:4.T'*.'I5*Q=Q=!II\0UX;K=4938W4X,!#2X-) TTR=#C\-D
MM)U[M!RBKPG$.<&]UP^(PC&@O(+8G^T@7)B[3,&VZE!SG0N<KVO8LGO$YJH[
MWC^G'[*KV_W;_=WS5KX_Y'1_#W]WH]5[#3=JUG;6=-Y[L Y\Y*PQPW_Y /F)
M!Z*=]7%"E)T_G1?;[_!$_?\ \R_\O_3W_P"/JES@T256!+?(_2.G58JZONQ/
M-L=H]MHI7U@6:#6BQ":LQ+!"2."&Q'%1%TOWO&25B:*@"&L3ZA4E9CJ-5TJ0
M06-4[5\U'+^65>([H:QKG$D"8@@P  =4&V ;@N@$'U<NX1W$5VTV"22,X,$$
M@] ,G-K7L%Q]Y_D=#Y']@G&[&&%;>UEEW_<$JV'V8 G/H[$8[*\ECM5H&U[8
ML]!6CR%-T/Y?]2S8'<[:"*L:T%J[/\M]G.7U>W7;0\94J%C*+RRQ<6-ILJ.J
MZ0)D@BKI'=,:220!W=ZXEU+E/ GA7@N>]OQ63(/>:&:C@6--Q)D7&D7LNVPJ
M".M5KQQQLBB8LB001M^DR"-)7M;$Z-(XVQS-^/\ M+&I\&673,9[M:GM]B\)
MPM+@.'I<*SO?":&M,[1%KQ$S?QP+ <ZJR^J272WPWO,VOXY/KE7'57W8_P#_
M %/^C&?^_P#CZ]3,3U/^/PCS)\A'R)^?K=3/JI4IZ(GHB>B)Z(GHB>B)Z(GH
MB>B)Z(GHB^',:Y?=R>Z_M^ZI_7W_ **GJ" ;%%^?29_X?_5W_P#/II BV+CW
MZ*02,%8YZ3C,]M\OHLII!L9$#HP-L09J2/FC6S1NMDK2?1F@DCLUK-9LSYJU
MJI-!:JVG06J\\-B&&9FL=J.44>;<NXOAG46U*M;AW,$ZB=)#Q9H,3WB00)!N
MO;P?$OH5F56NA[2 TF, @P9!M<S8R+00+<7<OH]AXR]>N$CUN\ZWS>_/C>KR
M3T(9)MOQ<M<0V'ZH*JT(4<Z;,U8DW)1JQRPQLJ]LQN7K5BM\.X=\?<@J\=^F
M/;$T.*#J/"<3Q%1KPT2WX;B8 %1CW.!+3!!8]SH_\C&!S3OO$!G-^7"H[2^J
MUND2=-P X-.@AK3WS)@QO, +N#G+[;8J&W7LPV*UA?K5G58VMJI6>QGTFU5:
MY\,E16?WE26O_<OKNB_O)Y$EM3_:G*^8</S'E_#<7PU1KFUJ8?W2'"238$2T
MB((()!$&2#)YP^FYE5]-W=@PT$1'3$;RT6Q;95])9%]_O[?NO[-7[(GO_1/_
M //62!=I).1,6C;I"CN]T"]Q)OZY5'NVYHY7(ZPL<:Q.<KVQQ/DB:WZC?FR-
MS%1Z_4D@1$=[HOLOV]ODGKQZJK7/?7(=0 )DPV +Y :2 <DD^A%Y)+7!K0(/
M4];?@>4[[<GO,3M$&HV4>(=^8DR'([8<]MU',?-+HNFV(:I/%8 ?!&YLA& %
M'=HZ@@+A<TJ9V4W/'9^W4(9NY#8^7?U3[;5N*YBSLWRJL7/XEQ96#&TJ@ESZ
MC6TC+'O:YI'>TD.DM@PT+?.0<O;PU!W,.*9+73\*7.;W2R=8<UVEP,]V< $G
M]W=W+\3.)?V7<]2WJZ%?^TG:SQZ?>6&2LL_D2-D=#1'9:G<A5L4PO& VP9RG
M;K1P1%+,)C3.A80TQ26SU;]*>QU'L]R:EQ-;APWCZ]1]9]74\..ME, .9(:7
M- (DAVF7-:=$+6.<\PJ<=Q3W%Y--H%-@($AH+B!( M))O>"/(;7QTZK&HC(F
ML3W5WLU7(GR<OR<Y?9WW<]RJ][G>[GO<Y[U5SE5>L%K7$.(O O)%MK QO'E;
M "PWX4RQC8T5&)[(J^Z_=5^_LB>_W5?Z(GJH "P1?7J43T1/1$]$3T1/1$]$
M3T1/1$]$3T1/1$]$3T14N]6CL2L27W5C8W)\4>]GV>R6)Z^['-7[LD<B+[_R
MN1DC?:1D;FT$-%1E0CO-G23,#TG2<WU CY!+S_ZVMM-_Q\_1<^?-[E_U!%;M
M^>INE,<[#D6;*M38DET_RVQ*E[0,@C65J7SV)L0.UV5JW&V&OJNVV6#U'$-]
M8LU_GS]9>R3.<46\?09HXCAI?K;JU%K"\DP)!O5)#3\-I-R7.#8VGD?'EE1M
M!SNZ\]X6(#@ +DQ$AH:22Z9& )6-_%#OUS&S8CQROY[2&Z5PI?$\MV@B7.WL
M[6P]7*%]6,SIFX1/TR"W<M!GRN:#.HB):MC&5L?;L20FK16G2P7Z0]M*A;0Y
M'Q3JE2K1KOHZZ@:"0UE-HF8<X'2 '$MB2 T:6S>Y_P N:RI\>D!I?3;4,:A#
MG/<) ,' UF)EQF8,+J1'8^HY5:Y$:CG,7[HJ(OP15;[_ .'W8YRL56N>GNW[
M2.^_KZ?JN#*;'3&H@SM%B,]=L$RM0C2XB.CB/,F<3L/3HM4_*'R%_L3K!1 C
M(&M9L]N$U4N0_(?H: QAC.N"5*$VP=>/AS<><G*:@;,2L9FD=(U!0\I;4>B0
M1O7F_P"I':JCR#DM5P>P5ZM*H:3=1U3I(8XM#F]S5-Q<EI$$+-\IY8_F/$,8
MTB&$:ID0V+N$#Z$@7-\SHKXM\OL[GI]8IHIKQ_.\E)Q:/2G"M>O(_H7>C]>@
M9"D[L+H8)):F5K%:^Y9"\6%>,TFXYRS/C!P?%+&GSC^DG9?B>T?:!_:+FC-1
M9Q52KPX[Y8"/AO:X"=5B:<%SY@#6'ZWN.Y]I>-I<)R^AP% M^(&Z:C@9(IW;
M!:9$N(=J&(EQ,P#V=%LC_+J]GQ5%?(B.8J?3<BK\I'1_%?BK'3+*YDGLDDC'
M)),KIGR/=]K4J3*5-M-N V#%A.]A;USXG)YF\DN)(@S<$7R?46\3]@*FB(G[
M?^_Z?_CU<PJ4]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1%(V&HZ5/=
M/?WC3W^ZI^SW>W[+_K_T_P D]4$ N .PD7(@S$V5+B0+=?#Q6*NK\SR_6,@=
MP6OJW;>9THJ<4=JT#!P/-:&6ODVU6GNYXD*)UZL\"2Q2M_-RC[\;Y:A2E:I_
M.)^)YKR[A^-H/I5&@AS7 @AQL\03,VVWBTP5Z>'K/HO#J;M)F9@'[VZ6-C]]
M2>;>(Q;FW7\KK:_0Y-'A,A4*3# FDS=:CJ:Y0F%NYNK-_$^?2AES4%479MUX
MZM;.4R\SK,MPJ3NS25'U^:\G_3KE?*^;CC^#H?#JZR^]2O=Q=GO574S<X;<P
M1:\9BMS7B>(I"G6JZ[  EE*S1< :6 BY+A,S(F8@;\5&.1JLE5KU1SE<YJR-
M]WO1))'+#(JOK.=(YRK7=(](T5%:Y&/:UO733+Z3656SI B"1J@  F#O$0"1
M80L*YS=8<!$@23.Y/SL;6\()NM3O*+ANJ[*3YF_&'\]E[^4,EU,F= ,NGVLS
M.DSQ@81I# 0^X,G($;%ZN*EB2T;$#HG5V?G(S=:2P+=S?M=V0X?M'7H-XJG\
M2E3I!A834%R^H3!IO:X]() N "9ME.6\TK<!4-3AWFF\B-6FFZ!;9[7-,7FT
MW$&ZO#QZ\;,'PRAHG9N71E3FL)4B.KT>D)JM_0%!8Z,;2*2@!$8C(@KT Y(Q
MK9<_EL]:F&U:-<DI!:D%V7-]E^S?!]GZ#:/ 4!1: &@#43  _<'DW-[N[X:0
M"2T7L<=Q]7C*IJUGZWDV, "9))(  N3>PDBPBZV:KUH*K'1UHTBC^2+]-JN^
M#%9''$C8V*JMC8C(V)\(T:SY?)_M\WO<[<YGQBQ\\^N5CB2XDDR3<E3'HH3T
M1/1$]$3T1/1$]$3T1/1$]$3T1/1$]$3T1/1%3K<\S)HXX5<KU8KFL9])S'O5
M'_3CL?-JR1,D6-4CE8YJ*C9_?W6-%:169GM@#T\9:4#I1NC;FSQ3(&Y!URC:
MFH:K.3MHF\\3;2@^C5,T+:*TD/1L4U>R]SHTCIR5D2D@@AV8$&XO<'H?7$*D
MP20?,"XC.+8Z&^?)39PS0$4+14G?KCZ(ZK8N72UZQ7JU1U!L4C[-[Z\S52I^
M5AAM,E=)7L?=D?S1WNSXVWUFM$&.IF-_J<8VS&56+'RZ3UCJ#NO@.9'$:,!>
M"<=9KD:\-NI=H/9-6DJ6F-M5F5KT,:NO,^=B9C)_IUD<YC_]E;(UTT_F'$4*
M=SI!F9WN-L[@XR;1(D5.:29B\1?.?I?:=^DQ$G.,KVJ]:%'3I,GLUTDT;9D;
M(V9K)5DF9% UC9V_&&J[WNWFQWY:;9D&S5IJ3S"F2-+A! W&;C+O$1%B3,"T
M*11+LVN;$P1@X&1>/#)4CG]2!U-*U;#GANBJU2A0+<O +$5NO1-9<O:#F*MJ
M6C=MPP6:1D?<J7:22LLU'Q.H7&OEAE?-<I\71-BYI)+KB#;]IVB"08,QOFYJ
M%&H(,=(G<GSO,#S/VN>*>7Z:K&]T;/IM<_X4WM;&BN<U/H(JHBK(B(KV^SD1
M%23V17*J^@5&F=,28,_/,".DC.8PJ"PM-\7MC%SD9@^(^DS*S2QHY[9%2-?W
M3X*]&+[(ONCF0R?2<J>R_4G>Z+W<K4C16.]JV8)ZDE4G/R^WD/LOJ.>PYJ.;
M,QS?NU7+#(YC43[_ #6=L<4;W^ZJWW8Q(O9$^RK[JM2A3T#GN:[YJKE1ZHCE
M^'Q>GLU4<SX(B?#W543W]W>Z+[K[>WL11O1$]$3T1/1$]$3T1/1$]$3T1/1$
M]$3T1/1%C?HVLEQ@#3Z6B .:LGF\O</5\MFJ"E#>D?3CO)2"T:5-DU]]B[?6
M&.#YQ-A]UD?%*V&(FQ[T]^_\2GOW\_JN6 H%Y#>,6E[F/QV9+]+I=;P?(.ZR
MGN><MTN6BGZ+C;H#G_DJT52*S:()_;9TCAF9";SGH6Y(%KFNHYPV/(9^[.=:
MMZBI4T,(MU&9P=\8'SZVD(MU$C>X-P/G/C>!B!5]W<Z'8V K3<ZTGE-6R)?Q
M6\D"//*9O":"$=0ZG8,!+N0IZO*Z; *1'%*XPN4O9ZIU6U3OF:V696DKG!]M
M&6<#Q7$!I,.<!\,EIZF^T6$7))QD?M*]#&#?8SOOD9-R=@8(!@85\9R[Y$0=
M'%V#TW0+G/#/(>=]199JUPM*03T3(9LYDMKR1XB^+IF(/X\T&CYMMLI*<I"T
M>5S?01#3 _-5Z8^WA*G$N>[+HAI![P( !O:)N6P2  8$Q!-]K6$&0)%C=VY$
M$B09B20!;%X6OH\YY%Z^I3M';WDSGLNSR;X?H(K53#GX-I3Y9J>)CH-</5!_
M+P)JP)%=UK6IMZ+IA+\0F[8E@B^CBZN=(V;+:D1&HZBT@DNR9U$7)R&@@ S@
M$@ JX-+1(: ;S,Y_-I!G<DF";Y('Z/R4D99@W$G6:&'C3SR_*GLYB_K[2OO*
M/>V6_%MTX>EE'TK@Q_%[1,ME+$C+&*+GX?TWH-LG>2N'?6:Y=!=K@:PUW>F;
MD WO!-KP"222&D&-9:($1 FPQI@CKM<#PQ,IA-+Y=S[#*F>HV^CU]#2[/P 7
MI\B S-)G-X<V<\:<\WM$8 E#C+%J_DH>]J>AI&KNC(WX_P!&<T&:3-WJGYO,
M<-Q1AMW22TD'<EH!!EI(-@!< 08D25;=&F+ 9W-B?"Q$7P;D3"S5Y'E_)BN?
MZ[1Y='IZT=/QQ$%/&.3+"Y2X+0>4:Z[H3#87J]WZ%J@,QK:,?$J,$VK(Y_/M
MSNFZ:5E(5K>=I%@6:97<1W3:^8B9%O"QZC'B5Y'@!T=<WMGK^<++'!X>HW.A
M][T/0];OK(RMU/1 N?YG0A0X7)T,/6%@+(N7.V&YX*7,5(BEPS5JD+JV6W(:
ML;W6+KU?<F]37%Q&0(OB)G\Q;?TE4_+)WDC,7C[6^BVVI_:!K?FK_BJI[N9]
M-WW]G>SFHB-]T^7V5J(U6^WV]_?U6H4UZ(GHB>B)Z(GHB>B)Z(GHB>B)Z(GH
MB>B)Z(J-?16V/K?1=(D525OP8B_.P][95:QCW/\ H(Z&*.=B?4@DE5;J-BEA
M:^9DY%K#2\BN14Q(<EM^N<.'62'\26:7Z+U?+GQY,;F^@W,/0-UR5BB%MFIZ
M^@J5!VGE0#6'XW<1Z,=9OS*-JSQ^/B9!!_\ 6T;D:H$09S^5(F1$1XWBWV]9
M$DDF!%E8SR3R&DZ=USE&F/8#'[G%=1N83$AH-4,9I.@9P?Q#F77KVD'#3:4[
M[YPE3I9>G;JUGVZ\=3,D3D*WQB7:5?5^+UR;BS;1DV=O<[D"3O$/_:O2 8FV
M;V)Z1:>D#;&]@L>YCRYQS]_'FN@ZWB&/ G>*>.O6<;L!?6!F@R&P-=\U/1\E
M_#V TUX3E!>\S*6<+F*F;THNTTELK>MJ679F"N<!TW81Y>U^F8,-,"(&9$1,
M-TP[.Y[T@B^+B8D21C&/O,7!(,PLAP>27+*QX)C=7TOF #5Z0[U'/Y431Z$(
M+6#;>2;*GD]#5?9M.SZTM:-G?2JZO&I5)?H.IG(");V@B"PDBM.IPD%P_P"I
M BS1:3<1BX@@S)F 54 2#8F_0"QN(-P.L#8W\*J%[7A"6;P1DQO.5BM+N,CB
MM35J9CH877@+\72*4]?,6\;N+E+(2:3+FB%XF-YUL; <<,UM1EJ4>#GM5IJE
M"MI=J ) +B,[2((DZ#:8!U$ &+F"K;Y%MQ/AU&,  ^8GH!*NW,=LY=J-"S+X
MSI//=/IU;I;+P69TV?)F'0XW5?P9JWV1U<E]1(,3LG2@M39CLV[-$N/LTWUJ
MKUEJ)E.&U6@@P;B(F VUR)ZZI>2 2(:8-$$FP[L9R3(B\#-S<F#U&5>\_3\#
M1T$.,M[7(U=K=MH+'YNSK15,U:L7*!(Q0'0#72_J#2,^>$E3 N%PN:S="4"U
MR@EQ]4Q)#L7"'_QDF#+G 0=M(P8 L)B 9\2258JCO7W$B?$N.TC[7,X5G^-W
M80W>L0;WF1(XLGDV[?7Y?/U\P0KD6"Z>/,S9UK#<%>_?I##A=H_^*4&5?H15
M V@"_'\Z^12Y+)TYM(%Y\[>IV\\GJ8MD$;$86S<#D<DBI[_]Y]_=57V<D<?N
MB?)57V_R3W]75"C^B)Z(GHB>B)Z(GHB>B)Z(GHB>B)Z(GHB>B*@%/9+47P=$
MEE\3&Q/F='(D*QNL6&+'76]4D]IYH8_KHSXLLI7BCE<_Z+&L)[]_)<U-3X)E
M3F%Z+BY>KU(*6^XYYJ\CG(.PMFS.)K^9?7K75[1RO)#M:J?6YO;E00-1K&NC
MC'Q/9(Q?>-OBXHD6!T@L#1W08)+@#Z>1@38S"J%SMU.1@9G,Y-I,Y"O=WC(7
MBZ;6Z0N]%NGH>4-WR>43'@B#6+8_[)EGQ,BQ,TJ["S^0'5Z=Q=71L1-DDDGJ
M34:\<$,:R2:UQ;W'49!+271!G)$$ F&R<6$2;0 O0P]/+:!T$&Q,R+&1>+W&
M)@O@]<#8:AS0WTNJ>S%OQ-X1XL:V-,2^D>,"^$%MU9KZK*%Y]G)0 %]:/Z1=
M$-9>K36@UJB/-";]*::ZUN$J R!KL6Z3W9F''$VO:Y+9B3 +BK[;W$ SJG:3
M<";$ '$'&VXO;*>,.LQ/0\MNQW3@]UP/4>5I,P(N\\*M'F<]Y+]6R749\\LM
M3H<459^!TV7%"OU G5NCKV:M6HZU"B0&2VY:#J$&1O8LB)(L1,0+220(NTN+
M9%4^$1N#T@;YCIXGS5B9GP0;F^9-Y7)U.T6SYGCGCER?9D+^3D@,EH_'J(8.
MJZ/.$H=4UN0)[0.RI#:H3-L2#C]2R<!7*9 T2EDEDW[P@ALF)@-@@7G23L"0
M3>2-15MYU&]A>Y P2#Y"9M/0Q;&8.8>,13!;C [!FUK%ZF+U/E[IW#1^/L#_
M -79Y;]XH]MNC*UJ30DJ5:+(D(4#/MRPLFMCEC?!% GQ>_*<,]T S(U.( 9
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M(\_Q3#PX/,_401#H=GI(X%FM.ITK.WUQO9D!8.G:L6G!,P(OG; K+9Z.W:A
MYVF,%1VK7Y5;$OK;2:W88@W.? 380K;G%QD](^I^9ZF!)V656L:WW^*>WNJJ
COW5?NO[K]U7U<#0,#[JF9^R^_4HGHB>B)Z(GHB>B)Z(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g509388g24m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m01.jpg
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M0IP$X& 2_P!/]0" AY 0X!YW ' ' ' ' /@1  $1$   $1$1\  !^1$1'\
M!^1$?XX!Z#]V54)U"K#9:^%F=0Q;$VKGZS'?KKBOG?)1A)U"(^Y_4%88TDNA
M'EDTVYF1GRR30%Q74(F(&0< < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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MY$DYEY-N0,Z.(O\ HE]+?P2?X(' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M1%P@<Z2I!$! #$.8H^!_/*DTU=.Z>J:V:ZE#33::LUHT]T^C/+X X X X X
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M+Q*D-[[+Y]G4'#62[S[Q9I2V\L@@==W', ;G)(2JJIU0^)VT/]FB8PI>#$*
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M45DCE.F<HB!BF 0'GIA--7333U33NFGLTUHT^36YY0UYII\T]&GT:Y-<SSN
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MK72IZ.L=?E4"KLI.,<$<(*D-_P IO4?=%8@^2J(+%(JF8!*<A1#QS-#8AE/
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MEKC1*HUN3.@K/71;,_8%DVK0L7)G;':'.<A3FDB-#1Z1Q,FI_E*.2* !!\E
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M.4Y:MMODVTN1E639+@<CPD<+@J2BMZE26M2K/G*I*[;;?*]E]R;W+N7<< <
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MKJD100156664,!$TDDB&.HJH<P@4A$R%$YC"( 4H"(B !P#FHP2=T#L)*ZI
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M1! '*9W1! ?41)Y]3<$V=UT>_/57W=T^U^>STT.[A),B2::29"III$(F1,@
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MJ/R9#O5:Z33K#;*5$R>=SU?"G$0K5AD(Q-I"#*B#O[-HFW(D0!$4B@'J7P
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M.$E2C24(QBY27#%[:RN[\3UNKEOP#K8G,:3E.4JDIJ3E=W77I=:/WM_1GK+
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M7KU6SPETKD+:ZX^2DH.P1K.5C'J)@,1=F^03<(&'P(^AP34*"B9O!TS@8AP
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M2TULSH4G9>7SVRU#=:4HJ$U072+N7;,S%+^Z:.^]23<,Z.;V+]O]BJ:025,
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MDENG=:WV25M]K+E<[J/IU=7"=3.K](SM\BD6XRR9[C?52"53S:K FDZ?LR+
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M[^_[\]RV'Z<<PK_@;(4!50S@,LN4[4472AQ.JNW,Z4E4 4,(C_V"3XC8@
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MRDK8^H[)!(0.*9LX$YHF\:29_,($]@%=M3(E>=9 H;SZ@DE+A'K"40\G433
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MKMN+_P#MR[[W3TH=Z Y397_=.HYKHM.GJ8A9Z?HU)L36[P[V$CUB2<.HU<1
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M0+L&<O#3L2"Y&KYFN)#E X(NG"1BF*(""OL'@Q2B A_?D>7E^(9QD44:.J$
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M@FSM?3:]N=NMOOY:[79X^1]_,5UV?ID*VK^LT-CJ$[<ZQDMST>@.H#/]2LE
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MT&.N<4]:R3B*71F[E89A[#76[,BK'@Q#V2TT;VOSMUYZ<BT#@I' ' ' ' '
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M% S9_!4:L13MN8/4R"[&(:-U$1+_ ,OQ&3$@%_'J!0#P'CQP#9O ' ' ' '
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M7TD&Z4%*.'<2FV;$9E03'&[7=MKNWE?0D_P0. . . . . . . . . . . .
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MB1^P5%!\R.[CEW+<KMFN4R+ML*@+-U2BFL0AP$O /=\ < < < < < < < <
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MZ]:.K>5=3:C<Z3D2=L3@[YJ]]V:>"X7*?NS\;GH\@A(V(S"1L+QZZ8Q'S-D
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M'+(P,A6G3B9"VE_>RO\ K]NY+3@@< < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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M]"-E0B)-E)#&2(M&K\&$@#-=863T6#YD]!JY^)<6CQJY!/X7"1S@>XX X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X!'7K1U>S'JA4;G2<J
M7NJ\+>]7ONR3AKS=9V\R1;?HT@A(SZ<=)3[ERZ80::K9$K"*1/\ &F?[E^[4
M>R\C)R+P2W??RV2V\B/GU)+U'9CD687^6@Y>RQ]8WFI.W,# W>P9O+20/:=H
M,.FDSN]5$)^!,BK))NU5H_R=X@W5C%P^U>KB +GY/OMK^Q&JCVFM;A!SNQ,Z
M::L.93/.@L=$M)ZR2.DV6#;4OOQV%;( ?0K*@C99=1U)0C:9(L]$J[-V1L/R
MN562+C@7_?[JQ%PFP0SR;NM1'.X4'70_-=';V6?5<ME7O8O_  A[A=;[=)NK
M80L*DM77M^E,TFYB75=/;JBVME]EK&X;S!$7T3. GHW]N6J:OZ&Y(A.M;=CG
M8G;GM1@H5OL_4?NW9HFDF8L9F/SMN]EJY2;#$PT@JR8@[+;K'G"NEVETA&0Y
M9BYVB6?N&GW!"NE0OYWTUOTO_;RMW/<=TY.OX5>[5JI(-[)5:#TROT4^:5:2
MAZ5&O'U_ZW0\<G:0?NJM;XMO(054SAU2$DAJKA1[4[;+P@/63$GP.!*U[;7?
M._%O]_MY6S+'$:BOV"K&6-*BV"'H?8SKYIL&\FW865^!;-]+'1*1"QCIS)LA
M>.YBLIYH:5_=KIZO(2SR?<&.T8.6JKV1%-_?W_4C&WUQQ7]JZNXBK&*++6!?
MH];(RR1)ZS H,8YKHR48O&V)HE37MPN$NL9I8V[.7=:+&PD/7[%^AQE/04+8
MY6VBM+?MQ?9+O;FGMR)JW;0#=?.DG2;L2C%!:EL3HV)(KU-1Z,*G:HW1<;0R
MUPV3FP:2OZ \BW]GBK,D_&(FRN6L(^KPLVXSA9N)%*Y^3^VO[?N0S[!=K['9
MI;KQ,6*!;"Y[&4W'[O#$K@UN"/2FL/V?GK37H&RS;NFSENT)*NP9ZO%1!V%E
MS^):VN*L5^+ ?>6AG#5@2EI?NUUVC?WTTZ:[RT6&@J-EU%NS&"B5$:%0.U.P
MS<&WCVD>C>/\/.^'5O89:N2SI%%4J87-6NR4(_EG;.7!JK8GDPZBY@".8N0$
M/IY/[:?2]C2]FU^H66U]?])F,W=QM=[C%>5!KG=&N1*E&9O*43M-..9:YN)A
M2JS;VT6*\6?1X2XSKRMM\R=$LE$BI<CQ:579R$**N'\RO^77;>Z_MH7)=2H2
M+@>OV?M(J/81Z3A*?DW9(]DW8INY.5M,W(2<BX3;D(59](/G*[Q\[4]UW;I9
M5PNH=50YA%!([@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
K#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g509388g24m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m02.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ X@(9 P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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MM%-U/5>.>P*0Q3C=TW#3:61RL%V)<F[SG=1T>N%3&$2'!J=*?Q+OP"+L]R+
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MHNJ6;3^N86HZ5A#V.>M]B@DK1L$VX08%U<:ZL-F59GV??V>?BJ;@ VN;BV8
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M:AV9LZ)21^ C,2QJ2WD];$]@8C\3\;.NWVWV2&(KK0<AA(9*2X%MK'>N"3S
M! \N?E7KAT5"=$6I7.OBVG-;B9N?BZMZ^[1-N@A 3[<I6?ME]GOJNU +-])^
MS/V@JOUM\_\ 4?T+YG[0#?FOI7TGYUSYCZ.\1?EJ_P#(@>'_ &PO+_O3D_\
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M %/7;K3[VM_RK;\V'[6J?I3,?'_2@R\_"UHO9/C_ ,#_ -O'GH=M!G_(=/\
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M$9C).8_YL0L!_G&Q<3Z!Y%U#92A;38<*DC\-6DR$FUQ$PN;$T'D1O2:_S\]
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M(-6L+PP^1IM!-B;+3CY<'!L (K7,6G8QL65$D9L60^W$J?$P,Z2-Y>P.W'7
M:X.L2.+@0ZQL1>W'@O*GJYG3NI:J!D$_0]/&8INGBEB#PQY#C'$YKXW.8'M+
M+'?:YKB#8;F]>/I[GU$^CDK].G#7EZL^'?KU1.G/O_!%JURNO3U:HL>MP'E9
M(7&0Y#?SPSRQ<:"PD;>(^RN"]\?I;CD2%GW[XN17Y>'957NF'QFH,-+T;39T
MY+20;$1C-Y&8UR;;B'%=+\&&",Q'&WXA.S>@PF-LS 0"UU9*7,I[WR/1-;),
M+9MD9$>WS*]?5$[_ )KV]WQ^/?LOA4[_  5$[:CGPR\F>5QPTM8\1QO?._T:
MJ_J]4[+ZJO?PGJB^[W_#U\=^_0]=SG<::9GTWY>>UD3X^?/;W=_5/7W+^'CS
M^7?UC3EF;9VO;@>&5LK^G2Q5\>4]/'A$7MV_\70<#KVD9G/(WTR'7PYHJ?EX
M[>O?W]N_X*OHG9/BJ?#IR)S)/#GD0-1;CV7YC(H%Y/;H<X]Z(V'M^.%;L4ZH
MC(/U6'D25@Q)ADX9&5P1B2FXXY+"%,DR\204E(F*LCV9+F.6.28Y)?8?2>/5
ML%*7[C97.WGML3NL8Z1Q:#^.\M80T&]W%H/&^M;7X^=E]F\5QUM.*J2ABBZ&
MG<_HXY)ZFHAI(!+(!=D#9IV/G?JV)KR"+ C5EGD'R0XZV*JO\PXVKSFF]@YP
M1V&YM0";$*":EN)++%((+8D$V3+NYTXKFXW"&7IG*)&BSE;0O@VU+PS9R!HJ
M"OCD]RS4,JH+N\6JG,+JF)N1D@<QK!TK+;QA-R6W#,Q9:<W:?:S96KHG;=LP
M>IP'%#'$,>P*"JAI\#KY3^#IL4CJ)9B:"8D1PXBW<:R2W3Y/!;Z-,/LR66I,
M=YJ3'?;;?9?8=P=8?8=P]MIUEUM<L'&G,,L<\',5RPSPR3+'+).R]8(@@V(+
M2,K$'>!!%]>(TMEIH+V756N:]K7-<'->T.:YI!:YKA<.:X&Q!!!!!L1F"N9?
M:]W?^9.WP5%]4]?S^';QW C.]N>5S<\0>!TN.%[<+A2H&Y"\AJ5QUI;=ELK<
M\Y8#<YL!K_7M?:6=<-B6Z7^X'5RM#&<'7WWWG,\<IDQ6EB#(BYR96:?WMIV]
MH:&6OEZ*/=CC8#)/.\[L4$8_&?(YQR MDW5S@ !;X0UK:C:G#ME</%96"2HJ
MJB04V&872@R5^*US\HJ2DA:'.<YQ(,DNZ8X6'>>;EK7:B"MZ\Q=7;'T#GR.$
MZ:SI7)"\XZ]C4*A,G&KWJ.S%0Q(Y7FYIF83GC+L.B,C<X5NFQ8D6/!EN8OPW
M\8WT=N5DW4>%5%/6G#WU?34$)G,\VYT-3&U[6/+6!C71.)-X@226@[PO>VD0
M;1[=X/BNS1VK@P#W/VKQ$86S#<,%2,2P.LFIYJBE$D\DTL.(1,;"8ZZ1C&MC
MD=O1O#-QK_31>WC\%\+V5/7LG;^?\/547TZU[/SC, @\[<>%LLS;RV77._[^
M2>?3'LG?U7M\/"?K3T\_C\.E\OA"^=QG;7Z./FX%$3M^SX=U\HOA.R(GN7NO
MA>RIZ]^AN<^8X]F>9[.>AZRB?_?V[+X\]E1>WCWJOO[^/*(BKT^BP.G7;7J
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M,LQ*M)E,@)_S8Y(DIK'S-CQP2U%/$R#%8]Y\](PV95Q@F\M.";FH8,I(B;R
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MD;@1Q?;G92.?8S:*D;.^HI,)QM])BY@I*JGJ)II,+KI,2PR=AJ*BGCDJ6R"
M3W0M8G8UHRV7L:Z1KY=,P[@4#F(#X@*C504UUJ5-8K@I9Y:2Y*+N,QLR1J>2
MDRI;$>+&:Q8CM>RYKN(XM3NI/<K"Z!V'4(G$]2)IS4UM941AS(W54W1PM#(
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M'1'(%SB=6.L+ZD.')8-SH\(J@UD;_$ZXO+(((G2.BKF@.<V**-I(941!SRT
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MDLR43%O!J!<;DC]VG$($C"XDAI$ARO9W5;/TVR6.$U+%TN*.KW.I)HXF-#I
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M%X[21G'<<P;920GW,DIJK'L>A#BWQRAH9J>GH<-DW3<TU97SB2JC-FST]')
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MKF;CF>?T>+\XL>$UE\RQCY<S<P>,XU58U4B:<,A@A;T5%10#<IJ*F;DR&!@
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M2*L. !.^QUFLCL0>F<\0V((D*SC37'[:M[VP'Y1<LVJN-OE6@E8.CM!TF?\
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M(3R@>;?7S]G@'^(P_P#%D+^@Z=#%^2C_ $&^Q/':SXW4_KY?KI]G@'^(P_\
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MPR@E'*2D@>/^E&5=4OA$V^H9.EH]M=JJ63_+I\?Q2)Q[2RJ;<=1N%&,CY/\
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M"9+CESMGYNVWI[!96FG\0[-4)=/,P-QBYUIU/6M.TK6+\W6BY !E<T]3-ZT
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M&\U.MPZ8S$*QR-_Y8:EY<6:/9+,_9)S)UEBX:K;JM;457JM]656P25+X6,U
MC%'"F^5NL>@'VK)[GQC8M=?D" ^QS]5*,[$VML.$=#,*U,@EMH"K3 E"G7!Q
M063;&P6[4ZW)S%EPIN</P<8@%P4Z2P5A$OZ@/-;TY?N6"AN$PN"'V</GW>/A
M)VC0]Y48EA5:3$JU?!,[QKNI:^3E5\"X>./,,U['5$22,BD#)&7.4Q)^MRLR
M8QG/F$OF#RMZ[GGF3_!90UQTL=:N BV#]K H]2K)?<-KCA+50I1*36#6ZMJW
M[8M_M]5L,/8==#A+6U6KHNOZ]9;'5K:M8!0S;T&+C"O%R#%B9<O3^[V=I6*:
MYX:SZ+9P-\RV@/,VT(2U/+Q))0YK,2P1=<5W=E/)D+7G/V";LEENMYK>][5)
M+7.=:LE8MD *=4/.#L2:M*)?(#E?TKZ@\*FA])PU6SLR5GK.;'UF2LHIVI15
MM!B[:GU30]5U4O"M+9QN*'K"LZPHEK*59*Y/*S;")FQL;BQ6R\P#T2^=[9Z^
MF_M'9Z9MQT6W'B[#:%W>R "-]TG2M-,6 !\R-/5+&D#]APAESKL_')Q8]B;=
MV \0AY9-JT/G!X+K>3OMN)B4**=9\/XU$/6FT3[D,F%;=C>UGP*I2,JE6X;U
MYH&H=?2GQ\$G;+D==>9@:?%F)4L]9SI(H<.FGWR#,)($&(4WRMV>B_M5QU]Q
M;E:Y,ZRC0ME8RZ!K2ZSMA5^IR:C'9/SKD8U!:M7'4FW#[0N-OU^5C:[!<H09
MFM8$QQ:6_!RL$P!%'#QQ+Y>OLU6%;2XH6NQ5LP(J^P(DR"$V%=MFZUKLBMPX
MA"MW_:FP9ERN)BT6?,V[%M0VOLW&^-T^N,U^KXM#S<:/8YUH)CA9A@E_H![!
M_ <]%D-@XES;+E>S%CV=%RLNUZAO:E[,)CZ2HT++&[KH.I-=QWJ6&DW A)JD
MRH"]&:V6-F:.71HXN%KQEM1I5@&SJX0&UN0MEV?Q*SS#C>&:==1;5/\ G)-=
MY8@D;6#$3/Z/RGVN$VD=EX8_/^UEE3IPM@..Q1/8(1Y7TB9E'>]AO(E_H] L
ML2%<7[-6+/2C%:V8!> TZP6&V,U6YZY(6.(Y;+$,#UW.U09038].2'8 M5@F
M@%=DD(AN$,:MUAFYCI4MR!G")?7K 'FTY^58C5N&)&L3BAJ3MN,8M<]S1+,*
MQ$J*^Z3-NZ'V-8-BCSNQ)LR]S#5]O-S:L)<9;SD0Q5P^'S$ C6JI7H\26,GD
MO]/'GR[^7EE%=XF8UKYD"&V.XE&F7C6&Q[S7Y%7C23YF\:DLU>MM3FA+/B;:
M9JPTEG4*,-M@:;7K+B2$ ,LZ]*JA0X4+/DOZK>?N5*6G]'"M--!UB6*67;!Z
M'T;HW%R=$C0L71FCDOZ#K"[DT]GBW,.I?92SH:*L>%]7,?,.N_/N>P2_#K)\
M]O8IYZ*$Z(G1$Z(M#<Y/(>R7\<RWMF^5&L6;?>V=;R!8/7FLW&JQKRJTNTV2
MH68*6M&O;#*P,SK)5QPET_97+!62H*PRQ4.O1[%F(LT$IR\WIS&7F\O6H&"<
ME]\E;#K]NPV.RU!NP4D<UL<4QK5"$RC9SN%A#=<_958H$;5]AL)2'"VY&C5<
M,5LFTHHH[96+%IX=JDK8@[5FE%-A?+TD9YVUR[B^ARR!G9_*&S0]<D#PHEK;
M:9\J4J^PAHK7H4TYIZ(6Y-<-Z@]7:N:(P+.(,126EK;;KXU8R4^T"I!4C-/2
M8>$"D85:O%&5^K,CGE>U\^/\%<IMIY&C!HQ3UFMFQ8AZZ[NJ4H)8=:4IF ,$
MZGY2U.AZXMBX5JCAICARTZWC$SYF9+DK6#4N>Y9:E7JT-'PXK!,CPMJ;WZCE
MGUVMQX9ZK&36]]QR\K 9U]N>82IA7=,"B2/MZUK^H']1ZYKU8VQ)+;0+V )Q
MVN$&GBMB[3#TFC5B)L/7EV8A4C$6:(&P%HV#EA2R$:96^GRW](4JZEVKO"9N
M/7]5V/<V3CIZO5ED]5J-4)T.N#7\M##+@>MIH=>M64/8 JL%=@-S6J_M 9<#
M55:,&!^CS^K:[?!Y:P#26U/#AY_+GU>7MA_=ERV::LAV3F<LYBZ4TERLPBZ4
M378\E4ZI6@6M;^'T_:5FL5#(N<^\P#C7[$VW8K4=#V(Y930*LC(+U.+#!I!;
M/0Y#UBX]:S;8&X^4H^49"PL$K +7FRH^LK[LLP,CU84^*L;E]O-?V+#M$S5V
MTPD&$*H8[0=<L5C@ZXL5!&VC<VP19S !.U\X5J1,O+8_1^^W'3+GPCM@\FL]
M?76V7';<*LS@UJU131<J%56 >OY8 IK?6ETLU\:O-ET!8B];GG"1@R+^TUTU
MUAKD+.?)UA^O I\X >JI,OW\?-?Z;]:L0VS[IO9G3QIJ_;+U5E8MDUH-+-2]
M>U&M9V.1;>%MUG B.TP$@ 9%E,AVT6 S,,1$+P*T[9IL(7#9:(-U-H,3CI?S
M\^''S^M374=V[JO7'C8NX4!3:N:<L@ZK!:S&K#QLWKN#3IM7UUOVPLUWZ$\6
MNQFA[#'[I,54;@R2AW@!3J?D$'36; N)(A&>1OZ._7R6%T6):]K<AM;E3]RM
M6QM8ZN)[TF:WN1>F4+$)?EBUGC0Z#N1"9$UZ/"Y&P%HN^XJ/4KCK^)2WI82L
M3XT"001VUDK"3Z?/Q'IXKH7>V\C(\CD%*H1TW26M=U7>^Q*B.$:QK1>%?[C4
MSD)RF!CV1FN3R!H,='Q)4(G"JL\#:S[,UN4(M(N3#;>=*/)?OWY]B^+U;N40
M8]N&GU[8U_>@:MI/(BVU*WO:UUV0/7T[2]4\2+QK:OFGHVNHU4GBI%LVMMRO
M+"J%;KY^PC@#0V.;;.UDJ6D%(MQXD9\N:SS+:VT=2[+QK^R+G8+-K9).&3]Y
M-T,1'?4U8=9RC0BI15HM3&Q%BXVFME&:TRD"6>GECD&GS2YXQ.KT6436_/EU
M9W\V2A.+N+F0QK9=EP'+#:;I-CY@0VIY^M!D&LNS\?D\F=[Q3,S +4OO#>.3
M.24!VJN?0CS8-89A^@0ZIE961\]HF60TYG-;E\7+-L2U4VT$+_<*Y>VFKJ]%
MIUB $LS;SU:2JU23*A'S<?3FC*^6,C[;)L\=7JS16( P>D"MEY\NW K(N!0M
ME^B)T1.B)T1.B+7?D.>MX*'K'[/G+U5:T4V3D.V5:=<4MF]VL'4L=>; )"LX
MH9^F7_&-")[#'T<*1+-U4F['8)?0D^@MD7"H\G?/OZLUH3I6=R<H&CM>1*I6
M;C&($J5H_2S4(OJ>"&,5JPWCBMI,=6]VWJ*]4QUB(0].;5%%0%[&$V'(H039
M+(/.1(C%#&#1!5&U[]IU_P XY9?01Z5E\:W\Q3YVZ!Y-KN50RQV@.J;L4-1_
MKXP!I\KE]K&HB;549=AXQ"=>1!\CCI*NA(^1); VTLYHLW=Q8ZN-5,XV+)EZ
M"?0>L\;<M-,TN6S.4]?-;/#58EL^X_5QV0U&+O:^?"AZK3(V^Z%7)LJ.QCQH
M+SL+3!U69L,FLEJO+Y!!]@ @=GVBY6*GG "52<3++(>?UY@:]GMF_.U[EC:2
MTZ0LMLN$5XUL^Q#]J;!HE )&[M7]78M;5F4>='KEATL#FNS)!8;JBGVZUX:.
M&0)(TO8+<'%5T)+AVD.49 \_+[/4#Y2HH(7??I%2(I3^ZCAJ7-H .H4\QHJ+
M6:GL/39W4U4E[&V/L,G'U]D[1MBP3Y394QVO,7JFNC;;3Z)1\-=#4MV(NV$Y
MZ=^''OQ4)@)O*;7RNUVCC;+KX*?QBDXE@GT^W3HTW8(G0'%:NUX98Q GC_ND
MO/K<:1#MD24(@9Z\DV*6,M J'=QAFM*L(@MG?JMW)'5Z<N(F&XG=RV2LS,Y^
MR.1@.RA=MZ_,; JU;TU C5^E@:_RTUY$=C4FUIJEZ=9ZRSJO*P%9S4:3L/[9
M4X2W;2Q *(^M!]O(+<AH>O.QUY7/9ZRN8?=>08FPFQN'WCUF1'V>8^Z^F5K2
MPQ*'L> 8Y@;E%6J1L&Q1M;S$KT5=61:@8D6+&Q4^2@ JFUGRMO)V"7)P)EY+
M>FPZ^?TJ<N.9#?'SM6>V=8KO;,[EQZHM[,Q+I4:O58=/VG)F2T.U<>Y5Z35I
M UQV*0B1R@&Q.FB<% <6;'PA/R#&1$H\EO/])6K!*-O'==$J-5M!_=1V-*.<
M/[9MR!9--5BL-5#9;&_J=+OU(K<(SJ1D=9*,%&,%;%8T<PN3-0@4FGEY-VGA
M[03>-E.0]7:#?/(Y'AY?*=@MZ;,W37-^TBNT*)L+.LY&= 0B,"!49Y>E&@MW
MV[,K&SR3DT7H^YXYK5J+FI,^0+[HU;'I2Q:Z6063CE7(]G(+6\_5P[>?"V?-
M0L+RY-3 NEIVP-C[XD-_5G"39EYF1=>5 5-@V^\D=JA]RTV6+K&IHS[57%2H
MNO\ .S5R3"E%:7%?8)G"L&#-G37"&V=@-3GK<<-;^<+&: 5WW4YT@C5H&S!V
MT['GQS4?JE[3<>NZ:N [*J Q&SYEHL[6L(8^E.56O8G2"QQ-]IS0:QU^KB5$
M3'[)]06<G;QOG?._[^L>4:K.1&RM\.N59F1>^0CVNYSNI<MK; ): @A]@T2Q
M%J1O6?=ZY4ZQAI;/&6#2^ -)A; \M'N7V,B6DA':M6.!!\G5">;CQ\@Y?1S(
MLH@HQSDU1==ZV"5\1>ZC6I50HD.PW9W6\VL[ ;,P]2#'P4"P0XG&?=)GM../
MV!XPR8U@PV%LX4!0_K>M8FVJH?)E<C(:\>OA<B_+LSM=;<:6NN]9F]9%<V.<
MM]@%2*D5ESV1VN"M.UM7RH\9K[!E&\+3J0"7B-D2DJR2Z>5B[KODNSQIQ^&>
MI%;F5C*'3R'J]8OYM1WS6]G10G1$Z(G1$Z(G1$Z(G1%Y>;A-<B*7LC;N&MF+
M-4JG=-KVDO)O0RMGBDC*R">,O$X'KAF-$%:"Y"RC-6)DHVS\)F,*F"(A:V4:
M!4/MV-*2DJEJ*K*POR^D]8ST\G!60QN7E<FQ+4(@Q]HQ@:"-@Q;)(@ZO*%VZ
M3%K.X]/UERXZW$2>/<0;.,?=,2VML#5%:E[/W87V/%BAY9:DN$\,J<**.&@X
M<?7GEYO*-%9A5GW/3SIHE3;+OHO6;%N^XF$2=IJ4(MVS8K@_0X@.4R=F\>2%
M=?A0($"U (0(@FC8%LKL@C<XVS\'*O,L(DEM>KK'7UY^3S%3YN:?M>K;SOY>
MN6S;XZJG]:<:X/S56I$6Z!:T$A[GV9!W':*6/^[VS82KR$K1JFXEHLF07EQJ
MQ:)EGSK1UBJ!L 13E8::GMTR\G>XN2NE>@&R-Q<7Q 8Z3V+,F2.3VI6H1>50
MZ\,N]KU&"Y?4MH?8+C1CFOW1 ^$UKZ*EF+//4H-%F! L>S&AP\//,",BC0G3
M3AF,QV^U8R7VKR(/3:K0JS*VE6SD.SW8!L4_ TKFS%"BTYO: HM2F!3EJUQ-
MHD[/#CB;V>5%3!F)H=G4OGMAEXLUL8.,M%( XVZL_P#-)YWUM?KT5WKUMWSA
M:8]:O5ZW<#A#; 0#4$L"TN!L>6SGX/*3<E-GL;(E1-9/!@@R+I:OZ@(03\2=
MK. ]7K=9-CM33V W*=7BC+.UM+ZZ9#3///AGIQS47Z]+;SJP^I#2IW<S5?B@
M=<5G;.V96I!QG;-=9AW/E*MABBY'W4RY%B@Q[4)U%7"#^-5M8RKT&XE+\,42
MR3?OL<AU-K<2._T>3J6?5FT\JI\MNT$+'M;(0 L''D37ZQ,U=40S>PJ1<^5>
MQ=?VZ[7N!)UQ"M FV2^.F%"OUO"!9E!B:W+Y9%2M4JL1P@#9)E;3B>/4+>2Y
MOY+76":7NV_-G[<TXY?@NT)E8J]VUI>\9UUHQD-)K!VY<=>;U?O@DK/71.EA
M,#,!/BZR#&PD+[<C*G9[+!#)>B,H_!B]$/MY9>D^GTKO78YOBF7_ )(II^;N
M)^U&]@;8-0:<NHFIVOD!C^%42=2+O5+84UK\R?//;UK=%JT"&S?#P\F1(&JR
M_5)/T68\'*<LKVR\_P"-IJ.OSY\UVMCV_9FX+)L+$+5+T8U[ LQ<72)1C3!^
MN$, T0+PJL." R%CI(:VN"9=N*;9<>EM/Y0S4P&<@/O3F*-&C@RCAYN(Z^7D
M\_6%9?I^X;+M#6-B,)M:U7 7C($;#KMHTG'8U]J^:9YL\/\ ,F"HAMW5PH<>
M%PJ#7+.8!6IZS70M$JE*&[:%'A4QS.T32G+,7_?DZWKL1UVUNK_7+;RB#AM7
M)L"^;JS 7+7/&JV[=ND7451E6_6]BME5WI+V0%J5=KFH)3<?!R^5[3%6M@@M
M4;>9H%6/DSLA^O.29=M'E! SL>=L^7'RCLTYZW>?:;9?-+<,MA';IMW!UG>%
MM+6C9%,U8T4O<&NXZ8Y.U4,=L-,'ZKL(^KL$WYU9"EY,G70U@:1+Q8638<A,
M8S;(,K]GT@\_5KP6&T*Q[X@9S#>R9^Z-6BKZX,L][O5 TPEEOA'8@[C-QF'5
M$7)IKVL=C1P@T],QVA*L$4;2,(D'9--#ZW^NH3\W.K64IY:&PXY<3UZ]76NE
M=++R5O6EMG"+TQLQK=!;6YB+*T.*U5EEI]["1I,27AN0-EB:.;*PYLS8CSC#
MY(;>KU(C&9)VCQJ23P$XD@!!:X/"XXCGQ\@^F_!9\FR>2<0YJ1JREMHX'W;/
M7PNT:76=5)&K^-G([8A"[2W4K(YIN[ K?J 34Y6#@:64V'JRU"=4J]L(Q<[+
M><B0REDL,_:-->8SX'7JZ_3'HJ4Z(G1%K:<Y5ZK D[ '?9O,TC7[60I64890
M[),<-V ")?/6MBL8XPL,K# J(9N-)/&AF+X7 D6"U,=/(W4K#K;I38]^O3LO
MUKI-<O\ 2DJ&=,#"%M.U8#%&/NW&NT&X6&KDI1:+3)\$.'(AA$YP@<EC]@U&
M<-%X1L))Z.3D)7<2[P2P,BBCZ5]SN6^HQD8FX1QO$2?6&;'.V$"RH5FD'=7!
M:DT'E'K!L(?#@2<@(5D?8 AD5+;<FY6JO3ULE19/ !Y8D/*;'TV[;WMKV*DG
MEYIF&[8\9LRVPHM>>OL/ K+HUHC"+&4UCLT-IV["ZJ1>&X1S<D/L6R5RNXR&
M,L!A)TPDP40G#Q%CE!B6[/.%WI7*G4PXE7@QARW@BYMT*R0&&Z39!DRG+9;\
M6U;6Y%R:E0</JD;8K\"+@@9EA9P8I#'2[?$(.T1ART8DMW]/J[W6Q_10G1$Z
M(G1%UY<5F=$E0I".+'F1WHKZ,OOQ759D-Y-.HU)BN,R8[BX9Y>P_'>:?9R[.
M,N8.8XY(16ZO5X'4@0FLUH7""5\"/C"PXD>SC'A#Q\-K%F-&CM8^,<&V\43N
MJY9YY>UFYEFYEEDI%>>B)T1.B)T1.B)T1.B)T1.B)T1.B*-=J;/$:FK;-F,B
M#AF*^39%8,!5 P\&'784\AE++G[<>JM.K0MN,-D-H4M%F"P9A1T971K\VR'
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MC$NZ1KLZ:XS"K[+EC$YDVP\=[!J2X5)[Y64KZ1TM;];7FZ&BLBHQ*J2B38@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g509388g24m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5Z^=1@X0DE-! 0      'D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "   < E  "')R,3<W.#8U' (% $!-:6-R;W-O9G0@4&]W
M97)0;VEN=" M($]R:6=I;F%L(&EM86=E<R M(%,M-"!"=7-I;F5S<R!S96-T
M:6]N+G!P #A"24T$)0      $/0)GS7[ IY1(HI+P WO4V\X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q =>            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              .,   '
MJ          !                          $             !Z@   .,
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   .,
M     %)G:'1L;VYG   'J     9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #C     !29VAT;&]N9P
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M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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MGJ5<F YNSD?O[_<KBQNN==?T:^BRZH685@BUS9]1AW-#KOW'55M=[V?SB!(
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M.YK;/T?Z+_")Q-?5:(D@D;1%E__0]1R**LFE]%P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_\0 'P !  (" @,! 0            @)!PH%!@$"! ,+_\0 4Q   @(#  (
M @8%!@@, P8'! 4#!@$"!P ("1$2$Q05%B$7,5&6U1@90597U")QD967H='P
M(R0R5&-D@8*BL=/B"B9A)4)86<'Q,T-2976&X?_$ !T! 0 " @,! 0
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M7Z_/[5D^G?$X]8K?88U4DG2Z=6#->X1)>KW[FMDJ7)+&S];][%MVQ*CN[&#
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M@!BLVMG[[5FK=[Z^>R'KJ;T%#Z^+4?7^@)?8:LCH2^C=VZBXZ5;+)U;IM;)
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MO-ACN/4-^K.B;-.UZ ]L-SCUM\=CL)A;I2_^B2G,!'BA%C(NZ">A'K@'UO\
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M_1_S.A6VM7M!S[FL]JMK4BAU+\75"M.VBJMR@:.9$25>SW*3HTJY>0@'Y5W
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M.=PO91@)+6SOC=R?+(X.ZB-WP=F.DD!;U;9/;7Y(7Y++.F[(V]7:S\KJ]'&
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MWVWZO-:YOPBCA[<\JZ%W7UOZYQ7F5J34:S]9JD_.I[B\B93CUNIW$L1!T%N
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MOXB6R(@S?X;:V>P5RQUV/FG;)#U5B]6)-:^Z9MFWP7.B.N%<ML/K3WP9O2+
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M8AM26(YFUNMBDC?,.ML[K%#OE1Z;4TMXHKT.QU>P"?:UC4'ZW6.3&DTHQ0I
MY$<!B]DN-')7M53 <5FI9"E+60@IPI \>Q5O1=N\(L6]<[#1>)U.6W7MG*(%
MN7"I4*UP<[6Q6=^7'/*!7:PD$QL8X<EQC$D8'AUU@"7B'-VA*],M8L1(/8?'
MV'ZD6D9T/U%[MVGI/3^T=:VTI]-O?MJ\I=AD-=*W-WLK&TH&'>R*NJBK;9L'
M7E(_'MX$Q%BF=Y)0&%*Z_65Q^T$[RO\ E/IS;D-#:8USTE79Z\]JL(:VF:C
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M?;77&<^$6&^)^Q?%?8M39GW%;^HZ"EI]J+I;YJEA9Z+X+ $&$?*.$6P!#A<
MRAL R0G:;=@D90R_6+V)6NDF=.]?QF0Q4D,.2IV*,UBM%<ABM1.AD?6F+A%,
M&/ <&2%CN'B )V/)=:K<J76R/J6(;+(IGUY'PO;(QLT>W61ES26\3.(<0!.V
M^W:LV>=%=E/")X1/")X1/")X1/"*OGW$XSRUUT'B?7KYSJI6,,%JSY6]LK)
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MD%JZ+2;,CCH74NIJCJVGA%_X4^MU^FP0_8M)'1)#GR [3]_C9.Q<K7_4=?\
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M-^%I=R9%&"26Q0QAD,+"3P1,8W<[;K8^/HU\;2K4*K."O5B;%&.6YVYN>X@
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M/GCY_+]N/VX\(O;PB>$3PB>$3PBZE?KL@YK1[?T.U$[AUFCUIY;+ 5%%O/-
MGKRTEJQD@'CQF4DC @DOV<6+7:8F?,<$6NTDFNN9:"YS6M!<YQ#6M W+G$[
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M?-%C$AD*53'/G;4 7Y<3OL.[F-_B]9Y_*?:=D5Z'H[)-)ZB^O>LN=MHAN9H
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MV9%&W9L;!R:!VDDD[^H8^KCJL5.I!U4$3=FM',N=_P!4DCBW=\CSS<\\SV;
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MQNDBGB<P\#W!P:]C^KD&[2'=7PD@.)6&S^'&:Q<] .ZB1[HY(I7-+FLDB>'
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MX6ZO_818?]$9'\!\>Y_6?[MWO\/-_ I^<M/_ +:K_P <_P!RGX6ZO_818?\
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M")X1/")X14N^X<T*'V>Z0W>21Q*\\#Y.\P21MKK!HD46#N,3*/.^^==?JEQ
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MS3N7MA>KTBT\ZG7OD?3$M9KYM0W#@UJ=B#&DLXM4M;49($YE-"?3%4B_5O8
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MYZ3NG<$SFU"<QZQ>*U1=K4ZE0JJ]93Q4NN<3ZP.3UT(Q&HV1W-A@;N="!OG
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M9:^AKC:FYWM5=)J_1.37</Q>.87!S=^8[?'CD/KY5MA^GW1Z)Q5GVKUW36D
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M>AVIW7+3U*X00*V1-68_>]7HU:"FV,#H-58;QCRF8P5-AK;K),$N/MSK .Y
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MB;VRQ#VTZTZ.B8G,E=<>R.R:6223,/:E4P^@'0L0[;:9RY5J2]Z/K-)%]/\
M"8X-7WSA0) #I'W_ %[>/E4;#LY^?MVY]O=MW\_-]"V7-<YSKC.?UY^?[,_T
MY_IQ^6?\>/RS^OR5*]O"+HO2J1%T2F-JMEANF,(E4MD;R,,=A(@M-9<K[/4K
M!&O+_P"*G[HK,G4ML DYU@-P'D2;;2*;;;!%A/UUH?5Z$YZ*%<5%(JE#:$)&
MM1J%(L[BS)@K@6592>E6*O0.:Q7)Z/3KA+/5G*WGFLU@TK]HVNI4+B<1J-).
M12F\(GA$\(GA$\(GA%Q[94L>JV*1TO#;)W ):QLJ8C0F+V2T^"04X \,C20<
ML,P:64<H:>/>&>&3>*73;3;;7)%!W3TY=Z6GGR4^_([APCG]K.LZJE7VHE6>
M]PK"Z#>Z#MSHRYF6#9/:*;E5>B5\)UIJ;"T8JP9=<L#6VFNLV54\?5O]2C;G
MO]'W=_>?:H^O+/R;X8?LB' >2KY?Z>^W8C@Q=7DR!E+6N3>U'/:^!.8/5:W5
M51NR>L]SY.H-<LU:M9HM67?D[)Y]#0R^M9O"E?A9>N<E^)=WJD^NG-K-#?/6
MKC"RO>PWM'ILDL*D*^V36TF">MG%685E4IR3:FPN%.M_7;O'&-**PVY73:N9
MDE-9WXFQ%)HOU&<C7"Y"4>\5_F?&[P36)V-7HE+R@O%>4UNCURC?@;GUG7NQ
M:]1ZV<-6\,L-5]0*L26:PV76KDH7<ZBTIY!(WV[^U06@[<NSL^WU<_B4Q:S6
MD-.KZ2JU=2 BKM<5 (T296/H(N5*%@T8:]>$-'C$< P@L,4,,>N,8UTTQ_3G
M.<PI7.>$3PB>$3PB>$3PB]=_RUVS^S&<_P"3]7^OPBTV>M^H=B<>J'Q#.S47
MW>Z+3Z?1>Y>YE4K?$*IU+V!%J\ -B[!=]Z544RRI>TU9YB&%;P+:NQ74T/'2
MD[05@-I.CM&I9$K$H^SZO7X[NU;@-)"KZZF5)=4MEF]5 K2(*L[I91YTVU?$
M6"P)ME,P>VXDRS*V,;($HN^X\@OU6T&VT6=<Y*5V?PB>$3PB>$4,OB"UWM-L
M]2.IH/7O\8_I8/,YK]PXY^Z85ZX;J!>L48V\1)6JB^\L;Q2S4(>SQ%"J>D49
MJR V*6+;0E-,@.A(JVZ[ZV>S)/JE2>D=00=#<=KY'>.XKCZ]<G)UNZ3>/6RR
M]-<V"H11"D=$[-:-;-14T:%E2ZA9>O==NN:N'8*U-:7-KM 0P&'S6._.-3A9
ML+$),D!.P#G<@Z,D]G&!L-R ';;D DK9G17K=NBM1MFN\9PV3:RGE T%QA8'
M%U>Z&-!<\U)'.#V-!>Z"28,:Z0L!HR[=Z4VBW67J_6_78ZO-:C(GJ'16-07N
M!$C->^N=Q.IMBL=(:[2CJ(AMK<15WC5>P,5%"/']D<KC9M@I5<&K;>C;>:L0
MY3&SLH9O&V*PF%GCCCG;%LZO,'L:YT=F#JBP[L<V:-L;26R#X?Z!8#\IG3G1
M?B+N@=>8NWJSHJUS@\T[%NP3Z=V]B9,A'+#FL:RM8GKU;F#S+KXN1.%J*;'Y
M"?(R#RFO99%1W'/53O:KM'.4H#,LL3K=+K547=;JKL<4%XLLY"B.,MW#"$4<
MM:U>QLPVI->L:%@R2G?9SEOVN!VH<JENZ1OL-]B=N?#V;]^V_/MW[>?GYK\L
MG<'$[J^+@XCP=9MQ\&YX>/AV'%MMQ; #??8#L4HO)4+H72^FTKD-/9WF_.=$
MU?6;#0;2:CDGL&#$^?016E2J%\)+1V];FRP@J4RH0MBP,FC@&'DVSGY$6EOW
M[UB[A[0^Q7=.]=#V_ G.+O[-KZ=@IJZ3DWQK5&R3%IJ%06@U=RW"K)RCU[K
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MO<T5IZ"^B04KHB;HW,[Z7NG'8YV87&L0 56,@WZ&C1*)D'%PV@8J&2@K#_"
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MS^?EIAAAK0Q5Z\4<$$$;(8886-BBABB:&1Q11L#61QQL:UD<;&M8QC0UH#0
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M=!6'U)TE9K)V>D36F1&:JX>S:;,['09,LM20WNM$LI?!C&5WS0U9(JM"_:$
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MX6R2&."+X$#& O#K-J35>=U;<BO9Z\ZY-7@95K,#(X:]6NP#:*M7A:R*)KB
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M3KX9Q1\)C)#V4R. _H6/:"UQ)?PEP)XG<8^K/./GG.?LOZ_S_/7'_P"F<?\
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M1UUV<JY_!"/KC<KSW("Z.(B5DK7/L,+^%KHY6C>S'N9''B<T/ZQP;/GU-M5
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?3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g509388g24m05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m05.jpg
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M,9)7.D<<SGY]#1\/45#6,JHKY88G,IXC<Y)9G.?4U,DCB72SR@B,.(:&1-#
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M7.<8SG7.?_O.,_DSG_\ '*E0OZX1.$3A$X1.$3A$X1.$6O#Y99I?4ED,9@D
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M%-]Y-MM'7+T^@@<=KB,LU7)=%(DMON]3T7P2YZ_6WPT7R$UM6%:YSFN>K(&
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M:KA!+=7.FJBR6N<[Z]4P%U.QHW="T"^URP#58)T<3T=^JS6=C_*K=6K&?G#
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MZ!S:2P>X9)3[=B"%;1I$<TG$N,I-'\4BR>'AHPF:.IL%72,?,/U"@@@7]7M
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M\?&Q&'*FFNFF[C \:W^FWUTTUV4]+;777&<8QJGN+W.>=W.+CYN))]Y5X"P
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MD:Z;P0@6$-R^DF)'")=P2P2_RYZ7!\?&_FHY%/)W=?(>=CLB&W/:[LG$ T.
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M"?93#\/PB>&8Y[OA/LIA^'X1?,1J-Y\_F  \^;/FSYA3#/FS_JS_ .1^3/\
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M0@[>8 -PUP3Z,'HBP@%L(.-1,*>Q\[C<@%V+H$-<<LJ>ZC8T9"QF0V>VY<&
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MNG_V1[_"^[/^_P!+?\O8/-+BOWX?]K_BU9,&SO,?!;F/-2KZ<(G"*V?N1UK
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MCYF@QL8*2<.@[!\B8]GL! $647/4^O7V]53_ !Y)X89V!$F=T0XC'F4*CL>
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M)DXZZ>P26/:T,DHT4&@G*9 >!;CWZ+5F3 ARP^MT<3RTN-RT-/WR+M#@YN8
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MV%#2QAE/1)ZX2*BYT7/GXI 8,9!&HM=XH7DYF&T3<H#GDG(QKK7MF:UC3:Y
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M-W4K*<Q^'NM\AM;Y5&E/D^A\U>228G[&9-[1/K5"_2D<,K[ZLXR.?5!.+FF
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M5+[CV%]Z,=_I'Q:7\<?])W_,EV?A=^8?V)[4J7W'L+[T8[_2/BTOXX_Z3O\
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M%.B3]PQP@L\<;J%"A(NB*/!F,R$)354AS^4 ;7)P77D1'F,MHPM'W,:;Y)M
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M9Q9==:'QY59994FZW5555W';;J**;[;;J*;[9VWVSG;;.<YSGFS;+*&M DD
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M3ZQ+ ]^IC\3F_P =PB?6)8'OU,?B<W^.X1/K$L#WZF/Q,;_'<(O%C4_GB$<
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..G.VVV<[;9SG.<\(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g509388g24m06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[36F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    -8J^$W!CA"24T$!       <1P!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "   < E  "')R,3<W.#8U' (% $!-:6-R;W-O9G0@4&]W97)0;VEN="
M M($]R:6=I;F%L(&EM86=E<R M(%,M-"!"=7-I;F5S<R!S96-T:6]N+G!P #
MA"24T$)0      $%WUOZF9\MA3=0/.LFD"OT4X0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <E+E8         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $E+E
M8  0 ! 24N5@ !  $X0DE-!"8       X             /X   #A"24T$#0
M      !    '@X0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              2Y   &:0
M !                          $             !FD   2Y
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   2Y     %)G:'
M1L;VYG   &:0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   $N0    !29VAT;&]N9P  !FD    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     <X0DE-!
MP     *OH    !    H    '8   '@  #=0   *MX &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
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M7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
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M.6[JW5;@V1%FS4,9^;D!G[N*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 8P"&0,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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MY42001(4/<=550I"AY$1^P^"*Q<^V?(=9*_-EVHY[HQ8I86\F-'N->M7Z<N
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MPK:T-K/$/?UM!(D? 2K]N"$64I4WC1J<JZH*N3+%(M??JWWO5\BT;TQ_3 [
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M4?#Q[V6E7C:/C(UJN^?OWBQ&[5FS:I&6<.7"Z@E32102(=150Y@*0A3&,(
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M;3W\:SL;5:3ABR$J1\Y=.5D7Z";,B3@I4QXAZ<^T9MC'IG9Y.3]%<S/3C?\
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MI/0]%B+%HTKIC2E7!"SPD?4)V&GIYV_D6$C<&;Z=1L$$@Z,U*:.;/5&K14H
MHJM:TCAZ9_3X(M_'/)$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6O?U%HV9T
M'+\^P*&C["_9[MKM+J=]6K\"XE%HG*8-^%NT*65E1;+QM:%M%PB*+>4?B54R
MSCZ:-(K(*(@4H/SG].?T6M,?AU;*6<J[9RH']1;NFV(:2LT\2(:N>KN&*.'#
M.OVIFR6%2+BW6=4*8B?T%!1)X]6EQ4G'2/RN4RD]3O@9_3SW\_/I;J"L9IN)
M5)%9"+CDN^?>R3T*PL8J*<3\Y6NOV"2SF93>QKM8 2FJU'1N7P!2RRP#78^(
MM@H0S)RFHU37(2>6?CM^_P Q^U&C<YKVH=?\<J=CK"D>V[W]T+UV1O/P.8[/
M(>5PC' EK5!+MG$$>-?4YRXH-9I#Z%91+E"9-)%>/Y-^W(I(&X4]]]^FRA2O
MX76V^8=0] HMP'/MNUO0^P'85[LD\2P[/HE#Z]4"JW T74IL;'(&=6FBM8C]
M'KC]R+Y@S._>M5XA-=\[^I/4'NF9D[9R/E\!\E'UW_Q('\JWHG.M=SFT]7.Z
MTE$Q^P]G-[P?;[QI$+;9VNYA4X' J-&5N=KG]G[Q0TDSK4PTC'4=*?ICX'KN
M03LDNA*238S(@#4'RXN< 08!B!OD9.>6<_%2H](PA<WW%'LMV[I2UXH79S!C
M=DH+)J?2;%J5=ZZL2&A(0T_>ZTG$B'ZY::H2*:R-Y<0B*"4FVD(U(Z3<AG*M
M0>TN)B)  R!MUD'/G(F BNO&IJRP%AN>8]E]PT?JQB32O*[1T_RMAJ[[*7;#
M)=%EYEVI.R4K#RC=U+2%=?,4 A*.Z?.VM7CY)!L6,/\ 4"0IC6/+ID2<9]?J
M<\O+HGHLC>M'=#OEOV?7%6/V2%RE'KJ*M;C7][SB.G+1N;%NP7LU5TS2/UE6
M,7K=8M=.<08(&@VK%X]5+(S1G8&4*W)#:;2''BP'$3(&!S..>XCSYX3[*?LL
M]7;L'N&5(;WE/72A2V34:,7;Z<6PWV5A;I;++5&13Z.3*6:4,YBDX>%>(ODX
M-W:')#6 $B 3Z0ARK&@4R02"('GOW^HQ*C/EW^GU^*R8A/6"Q&TQ[*_U/+MA
MLG7WZJ'CI[L%'0L-_!$ \D@9IOW!HIQ,HVR7@*N_>%C+/8XB%=1L8[0=B4[A
MNU56+2&N(D QWV.JE9!17J3]/9K56>0QFIB[G9*>1J499DZS9O[,I*WN#E21
MJC#3AB_X*=3ZK@P-4V",P8QW@"R*<70"D$08F,(LA*]V.P*V:'*9-6-CS>?T
MR%%P64HT3;X1]9F:C3S]8BK$MWAW?SL_:;ZQ B9E6H%-]01/VCXA%+3>5BW;
MART:R+%R[9F KMJW=H+.&IC#X KA%)0RB)A'[ "A2CYX1=WW%^_W#[?;A%]]
MP?U_]?\ X?\ CPB^_P#/_#A$X1.$3A$X1:'_ %M<5E'M8RCLM!LU7*&7OW]-
MOXH%,<[6G6]=H>,F5@( B#6'L;=))RH;P5%&5.H80*4P\PVNVCKNP?[,35HG
MVK!$\0 (>T>9:21YM"Z3^%?B"EH/BJW%R\4[/4Z;M/KU"8;3?4(-O5?D M96
M#09P XF1$C59E5R0(FV\K%\"!!+_ # (&#[?CVF\" ^ \??[_< _QYRW!SN)
MCE)VD]/3D<3&5]COR 6@08!@SC?!S(@P-SO PLSZ_>FX-B?WP ( 'D!/]O\
MN\^0_P!_V_?GM,;F/CM(Y])V\_HO$MS[LD1TC_)V/Z<Y_4_>6_P*>%BCY ?P
M;R(CX\A^X>/Z^/W\>."=HS.V1!C?/D/\&,(P29QN.8GR\\<QL5ACJES0.FY
M5@   XB(F_']/OY'R'V'_A_GSQ+B21.Y CJ>0 WW&T3ZF5ZM'"WB, 0<DQ .
M22<8:))Y0">H6QOTLNJ']I'6SLI?KO'_ $C'LU"RF:4Y1VAY5-08B.D6"<\F
M43%,9I)V5\Z>LO $^9&-07*84UDS<Z1HEF;2PIMJ"'UC[:H,R \ !I!V( ^J
M^-OQ/\0MUWQ7<5;2I-MIK&6-I5:X.#W4'N=5K,(D0:Y=P%IAS6M= )6GRF-[
M#E]LL.979LK'7#.I]]3[&S6_E.5]#+BU!T0#?8[21;D2?LURB8B[9RFJ0QBC
MYYHVIVCK*^JTR/=+BZF?]KF'((],S'QR,?4/@OQ!1\2>&].OF/::HHLM[MC3
MFE>4&<%5AXCQ $M<]A=ES3(D2%GM1KN@""0?,'X)]_(?@/Q]O/\ 7[C]A_\
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M%+;*3V'5N':UZDSB\M%I*JY*M1W*4;8IURJ$,@1Q+EGT5%G*QR%@.I@.!'4
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M8-TDU$XR>;@H91ND1&0*FN7WJZ=K6B,#C<VKV4S4< :#BU@+SDFFYQ:QL_\
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M3QOTRNO6--F5SE A+)"R-[I\S+S46T;QBR9/IW*KZ-57.@(.WL]%D@HXQRE
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MN826D-=)/L*J28C97.\X37@-0K"M.8L4(JI@TCVE9>1CY!PV6!_&JHOC/4S
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MY_?]SNG??U5Z5WLGN%1RKH7)S&F/XJ6M_5CL9N&FV*[/6TY%7=W6\U)8Z_\
MJB+9LNZ:KM)28C;4T!!1LVBX9HZ@A!PY%-((17DMVRW&H4KK2_?3,0>QSW0;
M;.PF@'TV+@(-M,7"M5:O2E>4;/F39NI'G0G))126B69460UMTT5=E%R)#%(O
MU:NUEZI$'GCY2F9];)MMZ:UZ["VU"V4Z(I3I*>3) ?20[!0%D",ZW/R+J2:V
M2GLD/B11:1JZJX*NT2&(NQK78R(HD*]*3",EO+"M^G";4YQ,M7-6T8>+L$S
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MB8"_ZO!MX=G(E;D+]U%3&;)I%'[* ;QS'7%UK.GC^K>6KB" *4L=4@<RP-$
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MS7D)9\"48U1:,8U,[E^Z(<4T6")4DCKJIF]B;8OD@^TI/M#G!H+G$!K022<
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MC4AO I_3'<J3,:Z*D  <[ LM&G.45!0( \U#\C=Z6]SZ=O0O[8'B]YC75&_
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M8>7VJ)937;[58MDQ.MUW/)L%S?QZTO4RR3*K/ 5_#1R+49%9T;ZTR9SWL(
M!.#M'K/<_ HI0TCI1V2[>6>@6&F=<G/6,<"C_P"(7;/3UZM$QFT3,5(PDE"8
M@JUI;V6%WGWUT0,@K8Y),6+-\E&K,XY7_6"%.J"6D"8S$ ;S@G,Q@=(QA1WM
M^DQ\]E*5XZ ]LNU.ET?<9^DT_K?:NNK$)++JY9+4PO*>I75:9BGKN(O"U20!
M&,SQC'1SM. 7 [V7;3<@VF$X]$&)T58=5XBT\,1,B9D&/(=%*D.1]-;LUO.@
M0?8G5+-F6';1C4>1E@,%37,KIM:(\>OE%K:[T^1>LJNZF(BR1X$B(Z*B$6SF
M!247DTWBKPPH&&I+@X"(G&.?F /\8ZHK[;^E5H>CV8=XVS<X6O=H:PUCHC';
M9CE26"D9A7V:DBK-1+J#N#YV^O*%W/)*ELR<DYBR V09H1AFRC<7"D.J.)D8
M@0.?Q]8QM&^,HI,BO2:I,NC)W?5MJT>T=DY"1C7D9V"I2$1G<[1XZ)8.HQK4
MZ17&Z,Y"L*FY:OGAIJ)F FRS+M<7;I0%46PHT\;N+BG./I^YR?.3S12A"^EM
MU=;U!S"6YI=M"O,C9OXRE=NL5ND6&R.[$$:2&3<-KG5Q@G,1&HQ"9(U&!B46
MD*1J @9B=415&"YQ,DF3SV_1%,L;T2ZEL,OC\>=X?2K'1(Z=>6HK"W1YK1).
M[5(A[9&SR,]-*/)I]/2) !-[)KOCN7")2-U#BW332(D]2BGJ'RK,X"GPN?P]
M IT?1ZXD@C!5)O7(DM?B4VQO>A]#%&:F9MU$U!%0%4T@5%43*B<5#"8817VF
MFFD0B229$TTR@1--,A2$3(4 *4A"% "E*4H  %*      'CA%^O ?T#_ (<(
MOO")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M"7J$>IW9J]:ISKQU7D6J
M%JAEE(O2=;*@C(HU)^ "5>LTY!4JC-[94 $Q9*47(LUAE!!!%-5Z BCA=5UB
MEI[0Q@%6Y>):R0 P&(>_RR(;OF3A=+\ _AU>>+ZIO+ES[/1*#@*MR ?:73P<
MT+783 /'5,L9L.)T-.DH<TF+Y+N;3>I*;O5HD%C.7UBN$B\L,JY74$3'4%S)
MJ+BB B)A*BW!%(A1]I$RD#V\T>YU*]NW35KU(..!KBQ@&?\ :V ?CUE?4.C^
M#O#.@TF4M/TFSIN$3<5J3+BYJ.P0Y]:H'.XI$P#PR# &":G)81&*MQ!:%9*@
M!1\ +-$1*(>!\E$$_<40$ \"4?(??P/+9E6NTRRK4:1S;4<,?!T?'I\UFKBP
MTZYIFG<V=I7IG!IU;6@YA^#F&/@0>LJZ^NVN:AT=T,- RQE'340X*+.U4.>0
M(JTG(559%5ZVAYA1,\C7),01(=LNU6^B4733*\:*I^?;F]-UMUO5'YJFRJQV
M#7#&BNV2,EP@O&Y<"#(YRN9>-OPSHZUI[FZ'=7%C7HQ6I::^XJOTJN]K'!M-
ME%Q>RUJYX6.I-:T<1+FEHQZS<)VS'.YV*,[K76D=9Z?9VZT1:Z=:(]D_5AIA
M I EZK:(9XFX;&=,E3 !RK)*-W2 HNVYCH*D,._,>RHQM2FX/8]H<QPV+3L?
M+T.1S7R==VEQ8W->SNZ+Z%S;5'4:]&H(=3J,,$'D>H()#@002""I(KN)X]4:
ME*4*KY;GU?I$X#@)JHP]/@(ZN2X.B?&Y_4X=K'I,'_SI^$U/JD%?>0 (/DH
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M 2F*8 ,4Q1#[" @(" @(@(#Y#A%^N$7Y$Q2@83"  4!$PB/@   $1$1'[>
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MB23N(!*JEL_M=QYM")=E,_:T1E;$&CB!NU??+S=&;O)(@+HU&SR:B*:M9M+
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M=5K5JKB^I4J/)+GN<<DDG[#"F?E2\4\A_7A%Q*KH($,JNLDBD0!$RBJA$R%
M \B)CG$"@   B(B(?;A%$5Z["8'FC<SC1]JRBC-A ?*MOT"IU],2CY 0_P"M
MI5L!@$/("'@?(>0X1>$;U4N\W2;KIWZ@7%*L5/U3JUJBC.T:N7JYH-=ML_$2
MC=X!;?#A""Y;1%<?V10OS+JQ\X9B[9/'#IJ@TD07*?'U],M+BZHW=2G_ %:1
M!,1PU.$'@]H"#/"8(ZP)G*W#2_'7B#2-#OM M;D_D;QCF,<XN]M9"I)K"SJ
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MBH,3&$TIWW]5&'9B )3\.]1GJEH'4+8]4[/;/VBN>Q99=*QB5@O$%=J59[O
M6*@:"SU9C%.XB'+F5=:FBGD O+M9F.4BQC(^-7(]]IB=]].^>%,FE]<=!NNP
M7-E8<8M5DI\SZQ73W0'C>2ILE(P4IGU9Z[UF/FK:Y(LR5:.ZE#S;08^4E%@4
MC&[U [1VH!R'3X16UVHZ]WR"[0]N-#AL/L%AQ2K=P.@FUV;+*_5$$F>\5"C9
MO8X^[L*%771&,-HEC@)5:(FWM:C0>/Y1S"%; @N^213$HZ^9Z<H'>?T65OIQ
M:+0=<]47U!-!S?#KKAM>F<#ZI M%Z!G2N66BUR*;S3!/;)*D.D6LE$?7( FR
M;'EVC23D$(XKM1#X#H*&*5 ?J$X==[GV6]1:E9]CUHE+WO74CKG+YU+P6?OO
MTO4(W);W,3>UYNWT9M&EAH^SV>H)HP8P<Q-,75C2<M6) <D*0A"+(+K[,UKL
MIZ@75_7>M'7[3<3S/KYULU:B[S8KQB4]AC*3?71.E-<]Q]LRGH>"6N#^G2D'
M,SBYXY"0A8,A2BUD!.^ IR*]>^E %WZ@'7JQ&R^7GT]#Z@]K\1KUZBL]?V6.
MB-3M"%8<4B*LUHCHE\6H ];)RZ<1,3CIA'HB=ZB1VB+A4#$6#O6&Z7/0FGHQ
M8-'=?NPT!9NGC^V5_L;-73'[C4JCG=CB>N%_S]M$_P 2S4:UBY\DS.*",;*0
M"\A$J-5&ASO2*NT$3D70P/IN]_Z-OI'1UJZV.RV"M^H)K-[UEK,YHH68AH5^
M^WYXQLMZ*ZBP=MH=XX_A-5!Y->&+C_J0"^X@LP BY;GBUHR7L/=]OM?76]VW
MK+DWJIW?5KK1JGF\I8RK56W]9:-5:ML5;SF.CE3WF"J-]!ZY?N(&-DE63TSJ
M0004<-EC$(J-<,5GNP\OM>P9]UPT*N]:=V]1WH38Z?GUGS"7J;RUQF6KIL->
MVJ3S)_'-I6M56;?@P(\?3T1'?JK>&&6?("14#G)'[+U=Q<5&0S!"-B(]E%QS
M<# W81S1!BS0*<YE#@BV;$312 YS&.;V$+Y,83#_ #"(\(L.);TW^AE@T^R[
M38NI6$V75+A+J3]FO%DSV!L$Y,S*J**!Y%ZO,-7B:CDR:"11."1?]@!\>X3"
M)%DO4LGRZ@H_!1\XH=.1$ **56J$! )B4H !0$D4P:E'VE "E^W@ \!X^W"*
M_P I2D "D*4I0_!2@!0#_(   X1?KA$X11ML.347=<PO.0:7!MK'1-"K<I5[
M-#NB 8CJ-E&QVZHI&_VD';<QB.63I/PLU=HH.$3%42*(00""" 00001((.""
M#@@C!!W53'OIO94IO=3J4WMJ4WL<6/8]C@YCV.:0YKFN <UP(((!!E?S].U/
M5;2.BNYR> Z<#V1@'!WLCA^FNTCE8:AGZ"@@T!1V4OTY;M6VYT&%KB?)7'RD
M)*H)G9NRJA\U?B!X+K:)=OU*QIN=I-W4+X8V19UG.XG47P/=IDYI'  /!F!/
M[E_]'7_4U8_BOX;MO OBN_IT/Q%\.V5*@PW#VTW^)]+MF>RIZC;.<8K:A08P
M-U"BTFJ2!<AA8]Y;CF,-1'&B9!9M"@ L-5KFEU=K9VB"JK.1)4K7*-*O9'41
M)MC)/8N7BFTFE.Q$FS52<,I6(:."#_(8A[;\--5=8>)*-FXS;:JQUG5IF"US
MRUSJ)@\P\</+#H!6:_ZY/ -#Q7^"&J>(J#',U[\/KNU\2Z5=TA%S3M_;4K74
MZ37@<88^VJMKN#2 'V['_P"T+T2]FLQ[;]'Y/.*'%_P=V?I>T6X<\Q*]V.QF
MI.A0KP\&^GBM]=8-XIU&3[&&A(]TLO:ZX+5Y) W2*\BDWCHRH]VNO#%&K6%2
MWJ^P82>.D07-;/\ P(,QRX3(&X/)?DYH'X_ZKI^F&SUK36ZO=TJ?!;7K:PH/
MJEH]W\XPM>U[L0ZK3#7/ '$TD2<N?3B[A-^JF:8UTT[;T\,EFF(NJU0]OCYA
M&>P_1+'.3DC,)P*M@!!HZSZPO7<F=K#0]K:M64B)"-H^57=B1N?9J;0UC&@D
MAK6M!.Y#0&@GS@+@5U7==7-Q<O:&NN*]6NYK?[6NJO=4+6]&M+H'D %Z "F*
M<I3%$HE. &()3 8#%$/(&*(?80$!\@(?L(#RM>"_7")PB<(G"*']TWG*NMV<
M3FK;);H^G4N!(F5=\[^1=Y(/W)@2CX2"BFI%I*=GY9R9-I%0T6V=/W[I0B2"
M)A$1 B\KW<?L5V!T/99'OQ3NM"T)DM"PI]G;BCZ)>6<%KMHII+@C;RWEE6FK
M%]&U%=LD*ZCFO3<F,DNP$AG16SIJ#?F*U;3?]2HTZ8J>S=3>7@D2TR(((!^W
M4<UT+\./'8\!ZK=7[]/_ -0H7MJVUJL;5%*K3#:K:S7TRYKF$RV"'$8V,X5@
M^H_U=TFI=)7>V=KK)77=JU&ST3.L,P+/7KV1SJD/K^L#N0O5ZGG"3-SH=QAJ
M:RG%H0GTS2K5^043?-63YX1!TEA[NVM_#&C:EJ;8JW-M:5'BLYH]VH6EE-K&
MQ#9J.;)(<3Z+I>A:[KGX\_B9X)\"5!_INB:YXCL+6KI]L75'/LV5A6NZ]U4&
M:]2G9TZI: &TZ>[63)6F9$L56H1%(HMHR&A8]-(#*G(W;,F#% " 8YS>TB::
M2*7W$W@/M_7GRDXU[VY<[-:ZN*KW& 7OJ5*CR8 &9+G <XE?T&4J.D^&](IT
M..VTG0M"TVG28^H]EO96&G:?0;3:7O>YM.E1H4*8XG.( #22=RO0=Z('IX3-
M[N,+WRW.LNXNIUXKD>KE+GVAT'DNY>HF;O=NE8YP0%6R"K-56.S]!R0BWTBC
MF?*F7ZB/5Y]*_A_X/_\ AVR-Y>L;_JMZQO&#)=:4-VT-X%1T!U:-C#9P0/PZ
M_P"L;_J3_P#\S>)Z?A?PM</'X?>%;JK^3JMEC?$&K-XZ-;5W-)DVM-G]/3FO
M']CJE<M#JN/65SHJ^*TX1.$3A$X1.$3A$X1/(?UX1?/(?U#_ (\(OO")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB^"4#?8>$7P"%
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M/,L)!<42V%PM9';-9!R,=&B!4QL=5TZVU?3[K3;LO%O>4_9U#3<6O !#FEI
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MZI_Q#>O:8YP&]WB1>W2XE]Q_YQ!&PST@W#R(_P J0>/L <]468W")PB#]O\
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MRKF:7)(V]J68!K$Q!&,HDY<KG19SX-D62YQ6.@!.^JVK>BJ(?^6[]=#[A_\
M+^N^/_UEFP'\?;\^/^?R1>MWA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X10!VAZ^5'M)AE_Q&Y"LUC[C%D+&3;,"EE*M:(IPC+52VPRPA[F\M6Y]
MDPEF2I! 14;"B;RDJH4Q%H7R&W71!_:L-VUNVA.Q&*.6U?T2,2 R32TQIR"%
M8U*K H5,7M3O<8FE)-W"!3%CY/\ 48AQ['+,Y H<WIMS'+;?RQCD-MD[]?\
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MFW:M&C9,RSARY75,1)!!!(IE%E5#E(FF4QSF H"/!(&28'4HM%?8KU/-?U:
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MJ ;MW]?=DC7)$7HF;N5/IOYR+GQ?I!WSZ0I9%;^NL7@FRVEYTYQ[K'L]-O\
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M)"#)O?XFB6]4;U^18.FI#+&27*.^GK^_W62ND=<-U9=OF728*;993KSW)O\
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MW7BFZ)$:$U9JL#V*;U.W29'S1=(4EF\G"(OF4!)(*>X3@B]BUTTE2E41*F8
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M>T0^W]/]_G]^$7&HBDJ04UDR*IF#P8BI2J%$/Z"4P" _U^X?^ >"+] F0
M*4 *  4    I0#P %_\ 1#P ?8/'X#A%^"MT"G,H5%,JAP %%"D(510 _'O.
M  8WCP'CR(\(A6Z!#'.1%(AU1 5#E(4IE!#\"H8  3B']3"(\(@-T 5%8$4@
M6,7V&5!,H*&*'X*93Q[Q /'V 1X1?000!45P12!80 HJ@0ORB4/P43^/<)0_
M8!'P'V\!]@X1?I1)-4IB*$*<AP\&*<H&*8!_82F 2C^ _(#_ $_'"+&SLEU4
MS3M36*W1]2>W4M(@K*QL4E4:G;9.JP5X18&*LG6;XSBC)!9:DLY207=P+HY&
MKHZ)2K>Y(QR'(LC&K)JR:M6;5NDW:LFZ+5JW1(5-)NW03*BBBD0H !$TDB%3
M(0H 4I  H!X .$7,9),Q3$,0IB' 2G(8H&*<!\>?<40\#Y\??R'W_?A$*BD4
M *5,A2E\ 4I2@4I0*'@H  >  "A]@  #P'V#A%^3MT%#$.HDF<Z8B9,QRE,8
MAA_)B&, B4?Q]R^!^P<(OW\9!'S[0\B'@1_<0#]O/].$3XR?8/:'@H> #^GV
M /M_3[!X_P ?WX1?@C= ASJD13(JIX%10I"E.?Q^/><  Q_'[>X1\?MPBYN$
M6B'M=C-AW+U;,RIL#V*T3KL0.A]]D927R25A8'1+,V;;%7#-HR)G)F-EPCXJ
M/?"A*S163(R[Q!L1FJJDU66,!.G??^5A=3N\/:&>2ZPLYK4Y.2D8C+/5<J$[
M=F[");'UA_U@C6L/EVI.!;LS(HR9A;%D%U8HR+!W* [7%(Z9P(!%6L^USMOU
MSAO3B[!6+M7L'8&7[>X'JMAUS,="/!.<Z-.5CKJOK]1>4"OP\(P>5F292L:C
M&/EDY!X>;2=.UW0?,J4"$[W5OP51U6RRGHN=IM*[AZ%M,[V,[%5[1K5F-I?5
MEQGT)8K7AVCSQ R&'C8EE(5:(I!'2U<>1PO9!-R@*:K\Q'Q ,<G?V54ZYZ-V
ME[<Z1U9Q.2[8;#D]0O69]\;MHDME2]<K]RL3O)^T9*50&S"<<P,@E!A$13])
MHX=,F0.GL>V%FHJ7ZA94Q1Y?Y\N^?.56,"WOLWV>C.F?5*^=IM*S1M:K+W99
M7O?*2YK]9UW5R=8M1&AT*F-K.ZBW<;&STA#/ L=N<QL4#V90BA,D1%,[@_"E
M;*/2BO.HVJC]K*GJ&\SG8QSC?</6<@J6FSYHA24>4RI1U5)#QSU6$:,XQ>1B
MSNG+64<MT"%<RI'JXE**@D*3OO\ R?WTW8\;8LCL'8S,<_[.ZO3@[8>LC=.O
M-ITZ8D*[(2F;5=I5)*[2TQ1EG,&C'Q&A7XT<QI+>:?)O46Y2QQF# CU$JBA1
M/?QW_3TYK<=TEG]4S+M[VOZ:6W=+UV*H.4Y]B&K4:[ZF]B9O2ZDZU(UT8S]!
MM%FB(^+3G&Z*E5:6""._8)231C**-SF5;@W,)2H[Z5PU9LWJ.>J5+Z^PA)C<
M8#1,DKM 1LC=F]EX;K$MET2_I@U5%^FJHRK<O;W%R6EU8P"(/9A X2(F723#
MA%C-VJCNGK2M8S3NJ[:#/78GUH,'1V>%ATY-Q26&QRLA)2-XCH=O)$-74T?>
MNW4EH^KE_16THJZ(LF1^9R42?;]OYY?NIZ[TP.;TWU O3#F\NC*W6=;G=$V:
M#TMQ2FS"(L,CUG1QFSR%X-;@A2(.UZC%6%O67;%Y(%.BPG_H_P!/43=*>#%'
M?U[\RL0=,SW$\9U_TT^PG6]K@]@Z8G[.1-4I\AF#=]_TFK7K6QGN%9D;1:=,
MEU74A?**TGWKYS<ZJN*<RJ1JFX?.SH1Z:!"E>H7A$X1.$3A$X16S9KA 5%LF
MXFWH(&7,)&C1),[A\\4*'D4VK1(#*K" >!,)2^P@" G,7SRBI5IT6.J57MIL
M:)<YY#6@=22JFM<\AK6EQ)   ),G;963&;147SI-J]2F8+YU"I-W$U'&:,U%
M#B!2$%T119%$QQ$ *#@R0"(@'GR/M"TH:E87+S3H75&J_P#XM>),=)B?AZ[9
M7K4MJ](<3Z3FMYF) YY@GYJ]+C=:CGU6F[O>+'#U6H5R.<2T[8YQ^VC8>*C6
MJ?R+O'KYRHF@@B0GW QCA[A$I2>XYBE&^WV7@O.-J/?[T>] ["?VL6W#M<U2
M6^L@1D-5;YA:I3*95U5@40KUHD:<]G6;6U+5U$Q@B;"O1I-TV;>#,E#)@D/,
M_3\+>(:MN+JGI%ZZB6\;7"BZ7-WXFL_N(C.V1M*]10K%O$*;B-_EF8F<1T7H
M)Q3:<FW[/('2\6N4%>:%-(F"+F8!8IVZ)VP@BXC';42IN8J2CCA],]BGR#9Z
MR5(**[=,0 .8)['TW.8]KF/:2'-<"US2#!!!@@@X(*\B",$0>A4L<I1?A51-
M),ZJIRIIID,=0YC 4I"% 3&,8PB %*  (B(B  'Y^W"+%NV/C7J<1EJUXA&D
M4*K5.RD1%1[/D*/M,V(U4$J*D,14!%-=T4ZBAR^]J"9?YC<T\:>(M(:/]+?9
M,U.NUTU27%C+4B 6-K,:7^UZM:>#J3!:LWIEG<3[?C-!CAPB1)J-WD@XX3&)
M()Y"#*U"=^(.6R#L)UU[0V!XQ-1IJ,G.MFH3J$>9DWKB-ND6UAS"?GG9G*A$
M(H+<V>U]5VL!&[-Q-MA.<A5A$+?P%JNG"M=:9:T*]JZN/S#6W%TRLU]6FW@<
MRG-*D033X8!<XN+7 Q ):K0K ,JO<UX8'!Q8PM :YQ()'$['6(WG^W*@72<6
MB>\^TT'ILD8DI6FT%:-DV=\T.5VQJT1%5V7ALL:2QT?D03>V"_R3"48Q[@2K
M.F%?=.DB@1/Y ZBT0(^O7ZG[?OA%3<EV^*I77Z4?;+)MJQ=.N3.1SC:XF272
M;R,3<\Z3&%<I@S,?YE0M0-&<E6Q2*H$NUEF1F8K"KP6RX'$ 2>6TDD^@SZ ^
M0+/(2>0 R2=@!G), >?19@= ,PO%&ZXP\]:@+!W79K7<=TML$_C_ /6X5_IT
MTM.1<.\,'PK_ %T-6A@XMRFL BBLU41\ )!YI>I7EE<7;W&@]_LQ[,5&U> O
M+#!(;PN'!D@'!.#"W[2;&_M;)@;<,IFH35=1?2X_9\?_ )$@S !@-WP#A9_4
M:;-1+ %@EFQ; @JD5LX7!N)'\,@8?"KF*3*(I"F(#Y=)^WZE1,!]BPB'L&ZT
MK4K6D_V!H-MQ4=#*O$YY)Y"HYQG)Y- 9/( XL]9TF]JM_,-N'7)IM)-$L#>%
MH,N--K,$QUE\2)//...D64LQ:R4<X3=LGJ)'#9PD8#IJI*![BF*8/(>?'V,4
M?YBCY*8 $!#FV+3?@1ZX^$;@CG*[O"*(]MJF07G/)RF[=7*U;:!8$BLI6MVB
M,0EV$H;R"C=-!DJFHH9\BJ!5F:[/XWC5<A7#99%4A52R 7$  DG  R2BQRZZ
MU?JUUK:V. Q^E3-!8W.:;3-CFII6P3:\Q(LV#>'C#R4Y8)::ERM(Z+:MX^-;
MN7";..9)E11(@F EYZNMJ[&\;J3PV)GA.WPRG"1.",R5FZ>09$9FD#.D"L2H
M?4F=BJ0&X-_;[_F^83 G\?L_F _N]HE^X#SQ11>MLM8*L8K./L<HS ? R;"'
M548" #X,HD=0Z2RZ8>!'WHI*%, >2"8!#SC:NLZ70JFC5O[9E5KN$M-5N'="
M1[H^>>4E5!CB)#21Z*0X*P0]E8DD85ZD]:F,8AC$]Q5$52>/>@X1.!54%TQ'
MP=)4A%"C^2^/ \R#'LJ-#V.:]C@"US2"T@[$$8*I((P1!Z%5GE2)PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(L
M,NR/0#JUVPM4-?-IH,C,WFNUIS3X"Z5V[7:BVF%K3Z0"2D8>-G*78()^U9RB
MX&3DTTU@^N:'.T<BHW-\?"*J)=%.JK:+RV$99% QT1B^=:%E&;1T:XE8]K6Z
M-JL0W@] B$4FC]$KQ2SQ[5$LC)2'U4F=S\KTCPCM=98Y%=B74W D6_7]J2@,
MA;=76#J,PY!1]*JHTEB]J0T9TV235>G)*IKU81BCEF0D/*7E4?*PBH)%CW0O
M2IZ,9GJ5>V*FXS^EW6EV]_>:"92Z7I_6\[L,LE))2RU IS^R.:M3V,H67?F?
MQ4#$L8QP=4ACM/[E'V$4XYETTZXX[9JE<,ZSEG7+%1H'2*Q5Y%&4FW1XN#UN
MYI:#H#%-)](N4%2V"W()2ZJCA-55J<@(,CMVW]SPBP*[H^FTM<<HSG.NLN2]
M?;)3JAI.A:5/Y7M,MHU8_4;7HSYQ-2=NH^PT1\OH&?3R<Z_E'4DVC%314['R
M*L8Y12010*!%D#Z9O2J0Z/8%8,_GEJ42UZ'JUWV&T0N;,9-EG]2D[FHR*A4*
MA^M+*S+^'K\=',F19:8-^I2SH'4@[ %7 \(KFM'IJ]-KFKO!K)DQ9)OV2M$'
M>M4CCVJWHQCV_5PR:D3?ZRP;SB+>C7ANLBBN:U4XD),KK))G7=J>WQPBE7K3
MU P#J1#6>(P^E*U]>[S",]=K-.6&Q76[W&5:MBLV+JT76X2DW9IO]-9E^DC$
M7TFLWCVPBBT21(8X&(K%['^GWU8[56R$T#6Z%)'T. AEZVQT&B7:[9?=U:TX
M5.NI6Y.SYY/UN7F( %U%5T8F5=/&;=9595NDD=503$5*L_IL=+[9UWK/561Q
M>+9X?4+5'7F JE>G+167C6ZQ:[MVWMRUH@)J/M+ZRJO'SMX]FWLPO(OW:ZCA
MXX64\& H@;=/\?HJQUQ]/?J-U1GY:WXKDC*$NLW&'@Y"\6.?M6@70T$HH596
M!;6F^S=CFF$(LN0BR\4Q>MF3A4A%%D3G*!@*52J'Z;'23,]J/V"I6!5.$T\L
MM(V&-DDG$VY@JY8Y@RIY>R5.EO)1Q3JI8)0[AR=_,U^#CI!R=PN<[CWK*F.1
M9R\(G")PB<(G"+$&S.%9>\VE\[,*AXR1&!CP/X$&C-FBB=0&X?@@N5U#JK'#
M^8W@A3?8H &@^*JM>K=TK1KB*#*3:A8-G/>7"7 ;P&@#I)6?TFDT4G5HE[G%
MH/1H P(!.3Y3\ (IR[5)PBH@NF"B"Q1(HFH4#$.0P" E$# (#Y ?L/W$/R'W
M\#S6&TZ])S:M-[FU*9#FN$M<TCF'':,_=95T/!:YH<T@AS3,$'>9 &!M)$+2
MEZR6B6^9S_J]U_\ U1R:EV:V:79;RP%50"VIKEXPR5.AY00.47D8SD9\DBY9
MN 40=N(QB=<AQ2^WTI^%UI1U?5;*O?TVO;;V1O7TS#FFLS@93<X" 0'NXH((
M+HG *URG;#\]4HM@BFYY$C$ B!SVD#FM-Q(%V!"B!/'M   I2>"E\?8I0\![
M2@7[  !]@ / !^.?30N*8P, 8$0  .F9VV@;X"S/Y6J!($<\?O('Q6U/T1+S
M8Z)W TW&&;E=.BZMD+S37T 502QC&]TBQ0T&I8&;/_S;9[.0D\1I+*( 3ZP\
M8R57 ZB0'YPC\4;"UH:C8WUNQK'WM&J+@-$![Z!8&U"!CB<U\.,9+02228PF
MH4?95&$B"\&8  /#B=_W]5ZNN<M5@H<TV45D',?1V*IR?J:9G]A52-[3(02*
M@)_2"<! 2'E7 @W^P@86R;GP(?O@/$>J'3-/J/I$?F:W]*W',.<#Q/\ (,;[
MP)P3A7UA;?F*PXA--D.?Y]&_&.Y5+18IH))HHD3222(4B:92@4J9" !2D*4H
M> *4    /QSBAL75'&H\.+WN<YSB3+G./O.)()+B=RMK'"  &\( @!I@ # Y
M=,+4MZI=E>WR,R[I-"NOHT^RZMBD-<DT6R*[Z'PBBD8N+8C&*+HK)QTO;I=[
M$UB,E2 1Y'$</GK Z;M!)5/;O!^@LK:C^>JM<&6 :]@DCBKN)]F2X<FP7.$0
M<3N%BM6N2RE[%H$U/=<3DAL D@QO!@<I),%8O=039YZ9O8Q!C6/=7>LO9&OV
M!O=T)Z4?S[JF:UF-.?V.LS;2RSKE].?I=LJ$)+P:T*M(+M F&;):/:HK.E_E
MZV#,GGSVGZ;+6MAS./*8 [^)6*5@ZO1'>!*Y=RM,)(078/:)..TK)7S!Z\80
MV85^KN#/\1A)*IH*(5^U+,XU&-<VES:(R2>23A\Z1,J1)NV*G0^' L/]KFN:
M[>8+3,?#I*J:XL<U[?[FN:X3M((.>L1D<]ENKZB;,\[ ]>L[TF8:-XZVNF4A
M6= B&I?:E#:)295Y5+K&D3-]D44I^(>+M$OP5DX:B41*8HCSR\MS:W-:AR8\
M\)/-KH<WK/NN$YW^G3+.]%W:4:P(]]@XP !#QA\#E[X.)Y]%DM\8"  ( /V_
M B'_ (>WQRUSR(^1_=>QJ'R\IG;ES4F8[8U(.;4I[I40BIGY7L$!Q\D:2) ^
M1_'$$1\%3<I^7;9,OV*HFN4H?S>.;KHEZ;B@:-4S5H #BYNI@PTD\R.?KE:5
MKMB*%?\ ,4A%*N<CDRI$N \CN.GQ64/,XL"L/-=>N9/07318YCM8&/CT6* C
M_=I+OTCN73H"_CY5"F32]X@)BII^TH@!A <OIC&$5*CA+@0&XF/,8WDC;_'K
M2$DF-A Z=8/RSD*/C-S"42B!3%$/:)?R @(>! 0$ #P(?MS,<0/G._/YQ/[*
MXD'!; (YP!\/F>SBZ(69>OZQ'4APLL>.3MSM(Y#'$14BFD6661BS"/\ ,+4K
MM0OE/SX,BF5(?Y \<Y[XNK5-/L+QUL>![C38QVY8*K@"1C<"0!RGX+P8UIJA
MIV]8!QU.?/J%()4@*4  /:4    H 4H!X\ !0 /   ?8 #P !]O ?CG%#0>?
M>/$2<G,N),R3.2<F3]E?^0X9$P",C/KOB3C?YKOT@RD5?FZ;8PIM;%&/@D&Y
M?)4U'<:"*S9Z)0'V N"*BB"B@%]RA/8!Q'V!XZ'X+NJ[F75G5<74Z IU*7$9
M+ \D.:,;3D9@; 95G<- (<-SAP&TB0/3 ^*R,YO:MDX1.$3A$X18P[UW1ZJ]
M7IFN5WL#NN?Y/.VZ/>RU:B+=+_0R,U&1RZ;5^_CVA$EEEVK1RJDBNL! 3344
M*43>1 .$5[8=V)Q'LK5WMUPC2JSJ%4CI9:">SM6=G>,&\NV11778*J*(HF*X
M22<(G.7VB %4*/N'R( 131PBL/0=0S[*8N)F]&MT'38F=M->I,._GGR;!M(V
MVV/RQ=;K[153^564FI Y&;!L'\ZZY@(7[\(K[ 0'_O\ ^[_ZWC_+\#PB^\(G
M"*VKA<*S0*O.W2Y3+*O56LQCJ9GIR14%)A%Q;(@J.GKM0"F$B"! $QS%*80#
MS_*/"*M,'[.48LI./<)NF$BU;OF3I(?*3EH[1(X;+I"( (IK(J$4(/@/)3 /
MCA%PR\O%P$5)3DW(,XF&AV+N3E921<I,V$=',&ZCIZ^>NUS$1;-&K=)1=PNJ
M<J:21#'.8"E$0(H[QS<<C[!TQ+1,4T"LZ91EY*0B&]JJ4@24A7$C%*_!(-F[
MU,I4ES-E1 ISI"=(P"!DSG((&$BE7A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$77=NVK!JX>OG+=FS:(*N73MTLFW;-
MFZ!#*K+N%U3$21123*8ZJJABD3(43&,!0$>$6)^9=].FNS:*IDV6=D\DO6BD
M%X5*J5ZVQ[R2D!C@-^H!"^#E;3HLO8<SK]&7?? 0ACJ>"@)@(J;9?4.Z-TVZ
MR^<6SM;A5;O5?FCUR=J\WH=?C9:'GB&3(>)DV[IVE]"]3.H0JB+DR1DQ,7W>
M//CA%/=_VO(,KIS?0=)U"@T2C//H_HK?;+7"05<>_J!"J,092\@];L78O$CE
M5; W74%9,?D)Y3\F BO:O6*!ML)&62KS<38Z]--$G\1.04@TE8B48N"@=!VP
MD6*J[1VW5((&(L@LHF8/N4P\(L6WI1&T7<? #YMLCX 0_/\ =M_(?XB/_=_7
M[CS4]8MQ5OPXC_\ 9IC&^"[!]>(^>!\=ATS_ .5/7VKC\@%]%,P??P ^!_;Q
M]O\ /_T?Z>/]W[<QS[-L''H.6_\ [03'JK^3OS/PYS_*T6^J9'!(Z=U20]ON
M\,^QQ_ ^/R$IGX?O]OQ^X_OSN'X6.%M>2<<.DN;C_P"I1.>FT^15MI-/VVLW
M#2)_IU7'?_E3Y"=@3^ODL!)%I68(&J,[.P4*Y>AY:-Y:681RSG^8J?ENF[71
M.H4%#E3]Q ,43F(3W>XP /9:FK,IO#756LXC#0YP!(GD"Z=R!,<\S 6Y.MZ+
M  ]U-LC <X,)DQ,.@G<;9GU6:7I8QA8[U'H42  %7ZRZ><HE\"!BA=*%X$#%
M^QBB @("'D! 0'SSF_XCW'MSI1D&&W'3F:>>OTZ3*TWQ-1%&K:@ 9%7(!&9R
M#YCGZF%ZMC& H"8P@!2@(B(_8  /N(CSE_?<K6%CM!+&F7]@M"H@89J5<),C
M"(&]D/&'.QCR$$  /8<2+.    !,J(^1$//.;^)*WYO4W4<FG:L%,#D:CO>>
M?48!\@9V6RZ72#+?CCWJA+I.)&(&TP )Y[RKJ*D8?P!?O^YOO_E]Q$/]WV_]
MO,4VW &V-\ 3W\/W5^7Y/KB/UG/Z'X+1OO;@MB]2O3%5U5%/[,NK>35R,0.8
M10:J7NYWBPRRZ!/P51V2'C4E1\>3D;D ?/M#QO'ARB*5C5? FI<&<1_:Q@@]
M.HCJ =EKFJ.)N6B9 I](R7NGRGW?OS6#'JI5)[;^GEF;13Q6,EH_0<H=,9)N
MH9%TR(^OL) R1FZI1]Q#N(B7D&9_'^TBX4(/V,/G86'<?']_LL<M@T%&-X*%
M@X5H0J;6%B(N*;$*  4J$<R0:)%*!0 / )HE    _P 0_/(/]WUWZ>NVW/8;
M2(D, #HGISD4AY'N50A7,I'UCM)+3\0V$0_U-MH]$I]P>()  ^TB:LN[D'7M
M#P '7,/@1$1#5-=IQ>4WM@<=%I)Q,-<X3F3)SZQDK;M"JG\F]G$896< #L.)
MK78YYWQS6/\ ZG_K,UOTU5TXB>ZJ[KHKV2: >#NJ$<TK>/O72I %-J-[,,J9
M5PD;R#ID$6BY*8@E3]P#[P\;'2S=@'\Q38)RV2ZIC_QQ@<XQ\A/M>:H+(EOL
M:CW1[KL-INGD' DCD<_+*P$Z*?Z1]EFSJW+0^WMKI76R.CIID3'\]@*5H=A^
M<(U4CJ1GK-I8Q[B*=+."A^E(0S!NV^(IG3EV)0^$ALK3TU]C=4*ELU]4DEMP
M\O8T<#A&*?$"0TRX\S'/=8VKJ++ZUN&7)92) -NT,<X<;3,N?PG)CAD$#.5Z
M4<T]9#TP=59-'-5[N=?SN'***AH^9O,=6I% ZI2B*2S2P&C52*$,;V&*)0\"
M _TYL*UU7&_VK%M&O4_(T;7LON#)XE"?2.*W?:M,IN/^KR!_<C'RK@5#>1\>
M"E$0'[" "'WR=@\-94_]P_3'KOT^*O+4 ATD;@ &,GOX3\U7$I. <O1BVTY#
M.)(/<'Z>C),EGO\ (4IC@#9-8RPF*!BB</9Y(4Q3&#[@(WPJ#?B.?. /@0<>
M>.BNRQN,"3T<3G.(!@>@_@=ZO)>V7:IF#QXM4F(_M_\ @RT_K_X_[^:7XM:*
MUI6!V+Z/_P"31DC?$^9"L3(N" <B1GIPG?;S5\R5J@XB7;0;Q=4))RS!^""+
M55P"#$SD&97CDR13"BW,Z$$/E-[BE/\ [0E*(#S0:=AQ,+@T<(P9P9W(&.F=
MACFJBZ"02>*< &1\L3 D*YH(OB_5@0\>!93WCQ^/_BJ'W#\?;_CY_8?ZYWPQ
M0%*YNB!@TZ8^KCGG,_#'545R>%@)SG;;U^O3GC"R'YNBMTX1.$3A$X1:".[\
M=NTIZNO55MU[JN&6Z[ATHWL[J-[ 'L1*6G!AIV?_ %;EJ:LL)&0_6TW M"-
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M\EZ?+E(&BJI89(A@(HSAY!9(PCX %0;* D/^(@H)? ?\/OXYS\F 3T!/R6G
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MDM@DDM:?[<9STW4(A?[^T_L(30M$1*.-2=LY&R+.6C-)M&P[>%4G)0(<J8%
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M$*0I0$1$1_R 0 /R(_8 $?MS5F5J]9XITV%]1Y#6M;)<7' &/@LJXAH+B6M
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M9Q.T^2N%E&0]?1>GC&+6/375.]?*I>?E=+%3 IEW*QS'564!),I"G64-["%
MA1*4  M!-2J6M)))AK!T+B ((ZDYQG?K/JVE3I-<\!K6M!<YVT 9R2Z8$'?^
M%EYD$8K&4&%!<HE7D <2ZI3%$IB_J2YW293 /@?<")T_(B "(>/V\<Z1;T_8
MT*-+_P!.FQG3^UH!YGGYKF=U5%:XKU1M4JO>/0N)'TA03KS%S%Z Z>K$.5I/
MQ[!5DX, @B=RP2.V<M2G^P L4@)+>P1]QB'$0 0+YYG-,>R7TW&'.]YN8G80
M#USMYE4TG02)B8.8(QZ]\^2CX[CV%,8Y@(4H"8QC" %*4 \B(C]@  _(B(^.
M9G DDP-R3  ]3 ^J]RW&3MY$].I_975#PC]A5HZ[N4%B1YK:Z<*^Y,?<E#O(
MLL0C*'#R)BMS.4BF$XAX! X+")2>1#GWBVD_4+*\9; N>TTWL:#/&*+VN=&=
MX'N@;[C=>#' 5>*<3@Q\!B!'P$\LA2 18#D*8@B8I@ Q#D$IBF*/W 2F+Y]P
M"'W 0'P("'CR'YXG[:H"06N!!(((,@C$$$X/D<[*_$'/NF<\Q],B/.",$KO4
M<BLO?6R[8OR,ZY%OOKW)?YDR/9+XD6[+Y #V"N"":BRA -[DR^SW@'O#ST3P
M7:W#675Y5:YE.N&TZ7%/O!A)<X Q D@#'7JK2X<TN#6YC.#MY>7?(K(SF]*V
M3A$X1.$3A%K2[/\ 4CL;-]@X?M7TZV;/<MUUWE"F&Z%!ZY196\4"UT4E@7LT
M#.M6\#-P<O&7*GRSM^K%*?4N(R2:O564@W*0"J\(H%4]/WNKDUO8Z[UQ[B52
M4VC0,AK&4=D[3V&S)W;HO0)*JOIQ[ :E5(^J3L"K7+)6D;"_AXFNO%7T$YA&
M\8U?K'5;*+JD4I=4/3+C.J>F93>(#2W5H9Y_UAN^'3R4M!)MIBYW?1=:)KUN
MTMR[;/19QY9.?6D@) (M%"-DG")"/!*@!3D45Z1Z2;V]=$Z'U/C=Q7I^C9IK
M5MT^E;A"U<Q9"$"]6VZ/K9#-8A25]Z:<W1[W.5!VN60\F442D ('QE1*15;L
MQZ8$O8;3@FG]7I#"8*Y8;B+;KD6C]CLB1UG)K5E<>JQ=09C1S5W'3%<M58D6
MJKV/EHE;XY!-X[8R")D%/D BO+#?3FN6:ZYU*V:Y:[4K/9^O=([#5^VL*=DL
M!F=<MDOO,C7WX'K,!5UT(RM0M.1@DHIBDZ;RDI+-"(N'\@9T"BAB*V$/2M^>
MR9I)SNHM)2#I?;WM'V6G(8E8<(*6&![(TJT4US1$G82QQ8N8!O95%3S?Q+%?
M?")2,FYC 8K9%%/6WTJ-QP.]9/5B:?UD7ZZX;8S2U0DX3J_6&O9>[5I@+T*S
M1- T:07>P[9O!)NFJ3JX5J,:6F:"-;JJN6BZJZAB=[]]XV4WQ'IF2<9U3ZV]
M;1UADJZP3M=!=E'%J"K+E2LC>%VBSZN-53C!EQ/'KN$K"6&+)G=NB$5:F=BT
M,"GPD(._X4Z]/^K6H]:-6[>24Q>:;;<BW_<)C>:'%,8"5B[W4K'=&S1&XPME
MDU7[B&F(A-2,8'@5F+1HZ(470/ .)R>TBP5W+TK>S5LK_9;K[B/:&@YGU([1
M:).;%;*O/93(6;4:;=;7-Q5CNE;I]F;6:,ASTBXSL8,J]/*1JDW$G>/&<>N*
M*_N*12+I_I[=L(JY[XRZK]F<\R_'NW;:,4W:!O67R5QM]0M):/&9Y:[OC4JS
ML49&MY.WUJ*:%<1=J9OXZ,E422+05 $4.$4,=C/1UU+1ZU"81GFJX9(=9D,L
MH>4PL3NV()7O7>O[:FP*-?>VWKSH,)*P#N(L5A21"<,2P'<-HFR@$BR.9#PT
MX13;9O2A?3%DL,NRVA7Z.6['=+]S:!-5YQ*3(,>I=&1IBL'+28RZ7ZA+7@$2
MR*LT"*9&"QU"G:._(G G8\E:WJ"]*S+1G<OL<J^TZU.M/A.J[ZI5[$Z8UL^G
M9;;>N%P=3D-IL-!OI-)'0$(5])HSLI3VS=N^DH6+DHUF+ERZ2 "*(O370[$[
MEW]U3M-J%\N6IT.!ZP5?%8:_3O7"T]8J@YM*UZ<V:0@*#2+TY<VV9*P8MTY"
MVV)\<6/Z[(#&QGM;-2$ B]#_  B<(G")PB<(G")PB<(G")PB<(G")PB<(OGD
M ^PC_P _\_MPB>0_J'_'A%P+.VK84BN'+= RZ@)(E6632%94?PFD!S%%10?V
M(3R;_#A%3Y"Q5^(=,F4K.P\8\DE!2CFDA)LF3E^J'Y39(.5TU71P_<B!#F\_
M;QPBMJ?U3,JK8X6GV?0J57K98S 6 K4U9X:,G9HQC>PH1D4]>(O7HG/_ "$^
MG14]Y_)2>3 (<(K<G>P6%UB^QV6V/7\X@]'EC-R1M'E;C!,;0]4=AY:)(0SA
MZF^.JZ#_ .+)?""CC[?"4_D.$5MR';#K5%:DEB<EN.9,=77=H1R=$<VV)3L(
MR;H@*-HL[(S@!3E'!#%,A&*'(^6 Q130-[B^2*WVW=?JF[U0<4;[IGZNF!+*
M5_\ AH)DGN/8D?=\M<2DQ($.K84A*)5(1-^>3(8!(9J!P$H(V\]D5MUKO_U$
MMNDJY3!;7675L!_)1+-15*29UF8EX<%S2T/!7)ZR;U2<E8XK9P+MA%S#IPE\
M"W\AA3.!4<^OV14*G>H_T[O5J=U*$UY@W<I-+ ^C9V?AIZMTRT,ZLV<O9]Q4
M+E-QS&N6=.,9,W3U<8>1=?(S;K.VX+()F.$P8F,=45#JGJ==/K2]E&Q]!E*F
MR95^=MD38;]3K-2JS<JW6VXO)F6H\Y/QS1E9TFK,HNR-XY0[YTV\.&C5= 04
M$01DB$5%K?JG=2YEO975@G;QF"$#69"XQA]6SVQT8;U6HXR!%Y//DY1N"MK.
M=1TS(WBF)"S*PO6HECO"P#P6D$ B)V\T4D=>.]N.]C+F_P YA872\[OR$&K:
MHFHZY2'U%F+54D'"+5S9*NF[7<H2\>S7=-$Y!%)<LA'"[;"^9H%5 0%I;@B$
M62E\94R09)(6TB1_88RK(Z9E$Y!!0 \"HT60$JZ)ON(")3 0P?8X&#[<QVH7
MMA:4HOGL#*@Q3< XO (V8=Q(YXQNKBWH5ZS_ .@#((]Z>$-_^[TS ^X499[1
MJS,/7SU^V=R1(QTD>,3D72ZS<I1,<R2JK<YOA<*I^PH@*I5 (;\!YYK_ (8]
ME7J:A6%&DT-K-%%[:;6N%,@P 1D0 -B%D=3]HQE!A>\RT\8+B07".0QOM]E(
M&OKY8US6VEVC^%_[+W$.Y8VYM<$VBU;=Q#LGP+,I!L\*=!PFX X(I-P(=110
MQ"HE%3V>-XM;6YO*].VM*-2O<57<-.E2:7/<[? &T 228#0"20!*P[6EQ#6B
M2< +R@!U@Z$:UW<R_,,"9:&K@UM?BSN4 QMUSC().1,$DY!I6EG3P\K&UY4J
M;1/X47#=(J?O1;BDF8 #M#+'7M(\$ZJ_5+JYHWM)K3:!MZ][J5#W&^S/"Z <
MO;'$2!L1 "R(94IV]0U'$.@<(XM@(CG\ /F.OJ_R+'<QP>AP>9Y#3(6AT:O(
MG2BZ_!-2MFJ1E3?(X=.#B)W#U^[6$RSQ^\67=NUC&5764,/GG$7/<]SGO<Y[
MG$ESG$N<22222<DS,DYG?*QI).29/4J2Q$ #[B ?Y^/_ %\H) &=N_DBQ@LK
M"4K%O=E@XI::K<RHJ_=(1QBJR,+)JE][I1NS\@+EBZ. JJ)IF^5NL83%(<AA
M\<=\6V%+6O$3+/3319J7L6FHYU0%ETQE*H[A#F BG<4^$3[3W7-X=BMCT]_Y
M>R=5KEWLP\AONY87&!C=S"0>4@D[@KHR<K8$XQ^[AZQ,J&9-%7*KF4:*QC%L
M4A#"8RAE_#AP<GCQ\+=(QC!]A,4/N%EIWX?ZQ5K<6HOIV=LPDOX*OMJ[V@Y;
M3#/=#B)ASB /,95%[KEO:V]6LQKZQITR_@:"T2T$_KD@#<=,J+:U%3MT5:B"
M\ FY2E"/WSYZ]2;/7;@!3\)D(HH=<6K=$H)M&Z)")$ !,/E0QCCUBQLZ%I;4
M;2TILHV] 0P%P+W.$$O>=W/<1+G$'<[ KEEQ>7_B*Y95J.M:;:54/8'5 U\2
MTAH!DN$-@$0)GJL_4A R9! 2F\D+]RB E$? >? AY\A_3F86YCUGS6..EZ?,
M(3CRD0;-D@<Z7TKI_**%23/]4A_,"(JG313(!%/ +*F-Y, @4OV'EM4K.#S3
M:&C !<XQD]/3;GGER.LZGJ]=EP^PMJ3 XMX7U:S@UIXVD0V2&@0?[B3)Q *J
ME'S=N\SYW5[&JR<_5/UG[1Q%/$W*C!4P)B@Z;."!X(X15()O)?Y#%$Q#^XIA
M 992::3Z3^%['R'##@6N !!^,Y$;?/(Z#0K6%JT>T9[1M=U9CJ-3B#>+A@<0
M@8((@2(P942SE&N=5<*(NXMW.,2B(-YF'1,X!5+R80%ZS((KM5P+X^02%41,
M/W*8 'VAK%WX?JTWN?:.:^D9)8]W"YOD"2&D=#$C /5=+L/$=%[6LO&.96PW
MVC&N>VIY\(!<T]1D;0>EM42'FM!NCBMOHAQ#5F,\.I"0>'%-W+IHG2$T<S:"
M'O327$WM<.%#% J0&(0#'-]O#1[(G47LNA3)H OI-IOXP8X?>J$#A,$X:V>$
MC).ZN-<OA_IC'VCJD5SP5G5&%A:"7>[3D\1! @DAN#,+/A))-%)-%(A4TDB%
M23(4 *4A$R@4A2E   "E*    'CP'V^W-V6@JS;TG3EX@6]S*T48*G\I)K@8
M7 +% ?:HR%(0737)]O:HB)1+^X^/(<]:5.K4>!2:YSAGW>0ZD\AU\E(!)Q,^
M2QUSN@5*>N,Z*WZK+034H.8EE)/%C-"$!P!2?,D'L%<"%#Q\;A14/Q[BFYDK
MT5:5I;M?4?Q$\-0%Y,R)B/\ CD#H8Z*MP+0,F3/$"3@@G&\;=?IE99.4(])@
MJW<I-R1Q6XHJ(*$)],#?V^P4A2,'Q_'[/Y?9[?'C[ ',)5JTZ%-]6J]M.FQI
M<][B UH',DJ@ DP!)/)8_N:G4%9=LR@ADT(QVL";ILV?NTFJ0*'#W S*)S"W
M3$HC_*F)"E_[ !^W.+Z]TN^US3VV5&A6I/JAMX_\N(J.+P00Z#(#<DQC')73
M6N93=Q':8;/( F>N\CZ*=H2 B*XQ3C89DDR:)B8WL3\B910P^3K+*&$RBRR@
M_<ZJIC',/W$P\Z2UC6-#6-#6C :T  #H ,!6BQ3[&]ULSZXV2O422K>B:9I%
MDB'=E:9[D]8"U69E5&#@&CJT32:K^.8Q$-]8/T+19X](M)/@.V8(N%$U/96&
MEVPF$4,2OJL=7482IR=12U#4I6RQ3R;DZ9FF>RMENF?Q<9).(:56T>!*JV5J
M+J/EV3^-/&/E32;IRR<_0-'228J#(:XSC:9^"*IV+U3NHL,VK+R$LESTAM8*
MTQN,BKE] L=W_@2LOU'"*<EHB<2U.K4#HK,WR;J,D4PF&XL78J1P%2$W( )F
M 3 D^B*O6_U,^GM/DHYDKI+NS,G<! VJ4LE$JEENM5I]<LS0C^%EKM8:]'/8
MVL-WK%5-Z))%9-RU9G!T\;H( *G :3L)A%6K;ZC/3REW5M19K8HI205"#&0F
MH>+G)VEUL;*B@X@26R[Q$>[J]94E&SIJY;EF)-J)6[E!=8$DU4S& $R0-M_)
M%<<SWSZDU_4$L>E=LJ;:\'E&$"JW [Y>"8V&4*B:-KTI;6[-6K1D\_*Y;_21
M#^8;OEC+HD*A[U"%&(,3!CK'P17&AW+ZMN=5#$F^Z9TKJ0RIH *B2P-A?&L)
M2^XU>3< /Z>I/E#_ &H4CLTF _R_2^\!+PBN"![1]=+1I;[&Z]MN9S6IQJCI
M%[0XVW0SJR(.&)3&?-?TY)V995VQ*4QGC1(#N6H%,*Z1 *80(KGK6Y8S<K;+
MT&I:KGMFN\ "XS=2@K=!2EBB@:J%2<B^B&3Y9\V!LJ8J;CY42_"<0*K[1'QP
MBN6!T"B6F2EX:LW.K6&7KZWT\[%PD_%RLA#K^? HR;-BZ7<,5 $! 2.4TS (
M" AY >$5?9RL7(F<$CY)@_.U4^)T5F[;NA;*AY\I+@@H<45 \#Y(I[3?8?M]
MAX1=PJB9_/L.4_M$2C[3 8 , ^!*(AY#W /V$/R _;QYX1?KR _C[^/Z<(GD
M!_XB'^\.$7WA$X1.$3A$X1!^X"']>$7Y I0\> \>//X^WY\_^W\_G^H\(OUP
MB<(G")PB<(G")PB<(G")PBP6[$][Z5A=]2R.M9OIN\:RG"-+/.TC*8Z'7/3Z
MW(*KI1DG;K!8Y>$@(567,U<A"Q2CU65DR-U%T6@-P!8TAI=MW*+%N5]5!YJT
MU%9YU'R]K9]1CX%]8=?A]PE'^<ML3%K-*U]M5K<QBF,]+/;=+R+5XK'-(HBT
M8:'03F/U%5J\:@I6VF7&#B)GX?!%"2/J6]C>P^C3/7/&H.C=?-CR"*<R78&7
MNL>MJ,6PD#RB+"MQ>9M&KJ!0GXFP,EDIQU.2GTR\6R<(,%&!7QA.4*9+BTD"
M-S]>OT1116>^7:KM)K5NZVCJT+UNM/7MF_::3<<V@(64=;-:4IHS5E)T,+XV
MEFL/4(>(!BYM<8@F_DVLW(C&+/$6J!#JUMI#B<"X>[@^ISUV@?KM"*,:-V]W
M;LWH]ORC;NREFQJ PUE+P=4O.4S\?DS;LA)0EEE8^=U1*;]IVSUC4V[6-AI:
MLPSG]';3A9)VZ;F:N4$DX:QI<02.HSR@^FT GRSA/B/V\CY_N%$])[-3VYS<
M\3O#V.O-!I%*KL@RZTW!GH$MB59W2E5ZPV&*E-[9RM:?032X7)0\='M56I#K
MMFR+=&4819D)@%#&M9+@<P2!F,;=>1.^1$HHWJVPP]R93-J]3B]WQD]&E-9S
MJ9/6B7N-:):L+ATWS6%U"I-:NHS04U>:.G'2ED?K)%G0.[B7  FU=?8P,(<'
M#8R#MUQ,\^DD'K,)C].?W71@[5$053O\OZED'>[EMD_F,1?L-L4M$6:TS08"
M,,2-SMQ4I6!*Z:T:Z1TF1-Q=99RO!.C6-T65?R*I?)R2SV9#@Z!)^.-B.8_S
MC>2X"G/DN=[#2.]676_7NV]@I55O<7J32KKZ!]/2+O LH/&5E].8B\:Y4--E
MV*D5*/7K^$;IS47)6%NX>%=BX/#7,#"",[;"9(@P<^HD0"/11'R\\_JJQ)0\
M_B^0[CUL[$Y+/ZYVC&8II;AV-80R,_35;-M:T8VR.^6[7_YI"B.*JZ>,$$$5
MQ2=M1B$UXM(R#M-0T!S!3(CWCO($[]?\I]O3Y?7R7>DZG=,[Q^_=&+QF,Q=-
MD;[E3LAM'<%NE'.J&CJ.TSD79*3K%DN1E2W%A>(]K-QCINS2CW#Q"61CVI7J
M+57R4'M#"WA!,'KOB),G;??,#92N^[HVA2F1-/3ID,YD64A']E(CJ[,=Q&+^
M'-56FC/GA;TGH48V(Y2O_P#:6^B'*;GZ@8LK5*PN5#+S1F("J,EXX WA& 2!
M\?3XQSB91=U[F>D=@<GR7T\IBE)YS6S;Q9NL*O9J%F8MV@>Q]?V4K.2M@IU.
M:BC=(R?M3*".5W(R[1C'-CR+M9:0<-7B"J\&I[H :)V./Y^AP//D7.XS/5>Z
M-:Z_=*;O4H/(Z:E8M<K<9LM/G&4[(3L]U0B9.!52A\_:)(6"C15BDT62DV2Q
ME; I$NU8,"J'EFORR:LMB,B"/@?V\AUF47.M1=F[^Q6!X;I];J63UN.HNM;1
M3;G09T;G8+);NMK[^ HZ/F*2BT8/*%7I&SK)*3$#*KNEY--%2M"!5A$"G5>(
M  9$2#MZB(V(VC'Q3O[]^:_<K2MF[Z-LU'5(NHY^IDO6><[FY6IE,F\T23L%
M^J<W_#D#%W.)7:1 UQ@K+0,DW5I7S2"LB\1?,%'1%H8WB'52>' !!&W/!Q!G
M'SA1Y_SMZ3\A^JSY]/I]J^^]N:5IVR,Z+"AF?5*O:70V&5RLC9(1VMV,4^@D
M#7&<E6,<XCI=E&558L;5VJ+IN4JKIXJ^549$]T/J<8 B(^,X W[Y94K>-;Z8
MM/.V\FR<II/&R8)@BY+[VZA2")B#^#>TP&'^8!*8I@_(>>:WJ^BF_K4KJE5#
M*])O!PO'$QS02X #8&=Q!!YK(V5ZVW:^E482QQF6F")@&<\HD?R2J $S;ZLF
M'ZC&1ZS(GM*91N"* >T!]H  H"'@PA]_YD0#\B(A^>> N-4TYG]:WHOI#=U(
M-8 !')O""1R);,F,[*X]C97;B:56J*AR >)V3_[AZC!@B"%&O9G"XKM_@LSG
M"TV]JQI=PRDHV423%<&4Q#N!5;E?-2G3^L8G4 R;A(% ,)# JD(*D+S>_"/B
M0Z3?6VLT;<5FAE2E4H5#!+*@X:@8[9KQ_M?$'F(*L2#97):8J<&#&S@X \YY
M';KS6H^H8EZA_1U@<N?57'-0ID4<5!=M8JMDF7#8HG.<5G[Q*"LY/!1,/M^O
M=F*(_P OD/SU2YU;P3XN>/SUSJFGW500&OJ7!IM<3 #6,-:W(!__ (V2,$97
MLY]M7GB<^FX^I'0$XCRP,3D;3GUT8[^-^V$E:J'9J4I1]*I+$'\JS:.A?PD@
MT3>ECG*S1=0 7:.&SPY$U6BXJE$JA3(N%0*<"Z?XM\&N\-LMKRA=_G+"[>64
MW/9[.M3?P>T:'@8<US 2'  R(($A6]Q;^QX2'<37;=08G/K].>5L#L;9^ZCC
MI1YS%4]X&.4@^TRB8 /DA3!X$!\^!_;SX\>?OSD7BNSU*^TI]#2ZKJ=9U1IJ
MMIN+*E6@ >.G3<"TAQ,'!!(QM*]=/J4*5PUU<#@X2 XB0UQ$ D0?GR5FQ7T4
M2N19['/"NTP'^^,H8Q0$WDIA @@4/]D1^_\ -]O/@1'\:)H=/3M!KTKB^TK4
M&7U'B!N7/J/ +P6.<*1:QL<)(,N=DXSE9B[96NV%E"YH&DXC^F&AI,9;[P&>
MG(SF%?S=['R2"HD.15'VB1=-4/L!3%'W%4(?["02B/N\@)1 1\_81YU&PU*S
MU*F:MI5%0-@/:06O83D![7 $2,CD>1*U^XMJM \-9D!P.\%KAS]<'((VW6,E
MW88:BZ<F*\<-9(#']R=;,9P0BP>1'^[,!FA!]WV$"'* ??\ V?'CGI4%N#G#
MMSP$SZ;D9GU^"TJ_I>'FO<35-.K+B1:$N/%L?= +)&8B,G!Y+J8Z\LQK8#>)
M7G'5.]B_SFERF^(A 3,*!B^3J)$< KX I$#A[BB83 7QQ0+N. 7&G!_NDP=Q
M!(^@,?14:)4NS><-%US4L 'AQN)AHB6P"3PO+H$ F0#(B(E_1V&8KD*K=3L6
M[L4Q^!<BITY0Q \^ 3!L!EU" /V+[RF( C]O'CQSVJ"D1-3A]3@].63]0LUJ
ME/27!KM1]DUP$-<3PU0,[</O$3@2")P,K%UXO%LI1 N725N5=BL $)\8E2'[
M_8J941 ZA?/Y!9'V&+]S#]A'EG[H/]$U/@2)P#!V[!$3"U)SJ%.JW_1ZUZYY
M=@9+,;   \0&)#A$.,]%DG;XRYR]/@O *_J!&Z1YYDT4^-5=4R1?/@J?M]_Q
MG 3*(E'[F'^4# 4 Y:ZQ0O+BUI"W))!#JM-A(<_ @ B.<XF)QYKK?AJYHT"Q
MVHBFRX=19_4> 64JD>_Y R<D=,*U:C-5RI.05?0$S'R1DOIUG:RIUB^TP@)_
M[A0$O8 F !\%3,(?CR/WYBK"YL]/?-2UN*-8M+7O>2YIDB?=(; P)@;Q$!9W
M4;>]U!G#2N[6M0#@YK&AK72V8RUSB3!//?EG$_Q,Q'3;0KV-<D<H&'VB)?(&
M(<  1(H0?!B'#R'DI@ ?W_ AS:J%Q1N:8J47A[#B1N#S!&X/JM2KV]:VJ&E6
M86/'(C<=0>8\U9.A40]P29K-7A&KZ/!0$06*8[=4JHE$2G OD2B!B@(& I@\
M"(& 0'R&3L[O\L7AS2YCX#H,.$<QR]>>/@J&/+"< SUG'GC[95@EDM$HJ'EY
M$1#R-;E\&6;D:H#\9/ "8QVPI*"(@/W$Z2AOP(^>77L[&Z)X*M5E1QP'28)Z
M2"('PD],34 Q_,M.YG(R1@;<R?B><J2H69::'6EE$TU&9C*BW<)F$#BBX2]B
M@"4P 4%$Q P#_P!D1+Y 0 W,!K6D_F;>M857EK:S6N;4;N.%S7-)',$M(<)
M(D<U )HOG<C]"(QO"IZ$19('W"T38NT2C[O=\:0*" >1_)P*H _<0\ ?[?U\
M> YIUMI>M:,"VU;9W-($&2Q@=C<RYK:@ Y2_'*=E[%].H!Q%S71&"8/+;(&!
M_$F5<,%9#2:ZC)VV^F=I$,<?8/N3.!1_F_J8IB_<?'D2B _8?/CSF]*UEU]5
M?;7%#V%PQI<.%P<QX!@@'<$3L9!S!E>52GPY:9:>N"-OF,[CY+31ZA<-J.<=
MLL>T_%E:0:>U_(M'HEV0UEW)PV>MHG%(N2U&'?M;'!M)&88604)"P$+%_0*1
MLG&MG*ZZ[99BD8^PL?P$F)D=8[]/J(7B2.?/KCZ]>QLM95!I&O\ 69I6^PV=
M!2[%=NYG6;1.U6W,-=>OZ'6H&S9PNA8&Q*&^B6<PJHT&"NJ+9*NO$4/KV$:C
M-K/T7+U<A*A4<))R(CZ0)Y' /+?Y*?T^7T^ ^X5*@*3LG1>+O;W*(FI:,OO_
M %@CN[VK#J$JKGCZIW>Q."0UFBJ7%(,I3^*HIHZFXY-"F%4:.6#D4$3O#*3)
M0&6U8G SMY1R_P 1RV"+C+0M>]/6N[S@F856N[!4Y#-\PVFVW6[RY:;8ZQ/=
MAC)9_*1S&DJ-'+[0(:,LA%%H2 AEDG48BLVK8C]1\8&-J\(/NYY1]\_I"+XI
MG.G=/Z+V Z-U2G16I45"W9519'=K'*H1,E"R/;-HSB6"E@H+M->S7<]:>*O#
M1+BN Y138LVK%0R!XES\1M7!#@#,\MYY0(^&WKA%S(9QI&39AHGISQM%_C*(
M2[$0760O:J4FH=)D2Q["5A>8BX6BL.E#7B3O%<BYA%-.0C6#M@J^CV;A&31:
M-EE$7M&AD0)@SC<YZ0.8._,B$5(;4729O)(3TZX7-Y:)MBW8F9Z[0O<YRXAP
MI9M*I$RZOTEJ3-=)R6]GTX(J.6=>%8U$JME!1,9<S$Q5C1[1O!P\(F(Y\YG,
MDGRR(Q'D5$;5&^;%C..=,LGRZ6RKL UOMYI]7[6N$6,91/X\Z_*2SG4+[3M#
M9JFM$W/VS]/D$G3==J@[64E)#ZY59%J<1ESVEG# G&P( //ZQ/7ZHJ6LWD=M
MRW"<@ZEY!9\/[*P5>O-K9[+(0*%&A7L!DT+*5_;!I^M?(@.F&O<HZ&,*\9NG
MB9%I5&?D3MP8BL2'.:6@ 09.>$&>N>6\^<;@HN&?D8[1*AG!_3JSZZY'L55R
M.QZ1K-K9UJ3S:7E, :02T)I,8%GDACTM-LU@D5%BUBP1KN<30GTT)].5;&.F
MJ:7EA: ,$&#C:(D\\8Q'R0^?)=ZSZ+6$6T-9?32DKY6XN"S@9[N+8Z:C=8MS
M$==IIU%-9*QRA+ 5,\IJ[0OZW*P=@CD'LTT;,YUZ@_,!"">7EA+1@; X@#'E
MD"2BO"Y;TOE=AAS= =IO4ACM@@(EGW&O4/=+/HM=QF@VFS5QE :R66M3R93J
MVDN4UYMJH[:'1<H0[A_.R;4A8A)5,X,):!P@\68Y>1Z[;[#=.^_X4F6/M1J>
M Z77,?ZP]F;G?\LU]*M06JZK<[C_ &UQW626LEC;M8*[Q]TGUY-E%2U_COU*
M'CH&9>JQ2$@9E-)LD2% JD.8SB:UI@&9S,=#Z;[]$4QRW=KM#U[VJO=3Z5N!
M-SDMR:07\+ZSKC"%L3S )UP[DSR(6AS5VL,QLQ+5!Q+Y>A5V4%NX-,(G(99>
M-]Q!EU)O$T!P$S,F=OEGJ,(I@5]1[LW@6I,NJ]["C=C-HU>+CYG"+:6*3S",
MC4_J9-"TH:]&PIY5!E'P3..-,0CJ"1(^L"(+QY6Y5D1<A2:1#@T$9Y_?],;Y
MZ93OOOU4UPGJH3.03LAE';K/(\FS2D+'3^.1?7\TG;&FY)/90\,\@:S#6(L9
M)P5D@'OP+S))ET$.C#K_ *M^J$2072+#J9:X 9)R/G'IWL$[[[SGHLK>O_?F
MD[-H2&/W+--,P'5Y2->S55J&IL88&UXB8U,JTDO3[36I>:KLP^BD3 O*PH/4
M)9FW$7 M%&Y3K%I<TMW19Y\I1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6C_OG
MG&MXEV!J.[8Q9*2WA^TUXS?%M3:ZG"SCNGT6S,(J6B*!>DYVL*%EF2$VX4CZ
M<K#.6ZC!U+NXU8CQD==<QO1C^"?./I/F.OGZ84??!^L?4_5:]*E@<S'4"#['
MQNCRM [*6COW9>N/9C3\]:Q3M*Y52:N@4*&8Q.8VUFZ:_203N.J[NL,95O\
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MV).P-H+LY"-WBXKKI$."(^2VQ\PD""9$3F+,?;ZS^JGOLY5'ZCMS2:F20Z"
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MUK3 _N C<9GD9C',C&\J^H6*BF)3+,#%7,H42G<"J"QA+Y ?: @(@0H^//M
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M3 %SK (IM"IE54.7\";VG_E*7[^/)O'D?L'D0Y:7-W0M^%M4@N?/"R))CRV
MGKYGDKFWMZU8S2/"!N\NX0(@G(R8P8'.%%;XA+!_+"519N8P@ .@%5("@(B
M")?!&_@P?G[CX#S^?/,?4J&Y'!1M7B0(<<#;RQ ZR=]QRR[";:/S%Z'"<TP.
M(XS'_+.TY'.!LJS;[]4<-RZ2N6L3S6(K4"U,>5?NP.X)[7*GQ-H]! A#JO'+
M@RB;5NV3(<ZRA@(4/'WYG]%TS4+ZI;Z?:TW7%Y4<>!C3L!))XB1PM8!Q%Y,
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M]F'O9U[SM74&UE?(,'&B%RY6T5>W/I@4P5CI:BQ;=W50J+0?HGKN>8M5#_\
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M?^50LR2]N3^G$=R=6-:BW[RX\67LB!;#152O:WH39@SB8 R?SBSD@KWFEG6
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M.J:5=@X0XB6EN2 0,X.>:OK6\_+M=3<P5*;S)&S@<3!$3(&TCUY*S7LI<:J
M&=2,7(MT_'A-15+YA / >")A\2__   _C]_( /,-<7FIZ6TNK5K2O3:=C4:'
M&2 !PX=(^._HKYE*QNSPMIUJ3S'O<+H^,F/KGZJTMOQFI=ML1E\ZMZDA$1L\
M9NY0D(TY/K(F8BG/S,GZ *@*3E))8O\ .BJ D61.H3W$,(*%W7PGXFKV->TU
MNSI /;QL?1JR65&NEE5A<(,$ EKA!!C!V..JL=97);(>601((EKAL1,@P8\M
M_):DU^M7>;I1$*'Q_LGGDIGT4*R[>MW1Y#5M$6A?*A2F965-5F*HAY 1:RZ1
MC''^[, &  ZV->\(>*ZH&IZ#?4[ZI ?7M6U:YXB()#Z!#H ,P^D0!U *]C5H
M5XXZ3PX[ELD ]G?>3YK*GT^._-P[062Y9?I54AXZZTF,&4/9:FJ=:NS#=%^E
M&N2*)?,[1;NOJ%4U6RS5ZLU>("H9(B0$^^O^-/!MKX>H6E_87-6I:7=0TOR]
MRV*])Q9[1I#@&ES.$<+@]H<UT9,KRN;=M(->PDM<2(<""(]>68]<'*V@3;-R
M]9&2:G]J@& XD$PE!4H>?)/(>/N/[>?MY_(#SD>NV=W>V#Z-F_AJ\37<!<6B
MJUIS3+AD _*=PEC6I4*X?5;+>$M! !+"=G0?D?(JT4%?TP !["B<Q0#W*@4Q
M_/W^P^1 Q/MX\^0 O^'C]]/H7;]( ;J&@5'ED W#9?,;NR'4XP<-X1/(&9R]
M0?F\T+_AXMF'A:/,&"#S(W) /.1%W1DHQDTSE;?R^P/"B!BE*)0$!#P)0#[@
M/X']O(>/P/WW#2=9L-694_).X748%6@Y@8]@,P8&"TG (QZ'"PUU:UK9P%7(
M=L\&0[F<GKGZY4':I'Y?!';&F:VNI(R@+*H#"E*T55,4P%,90X&*CY$YR_[2
M2AA$0'P(>>9"L*(_N823MP""?TZ<YPM0UFGI% L-S:%]:L'%AH -<2")DC F
M?^)SF)RK.R*)LQ+85_$,YJ*J'A7ZA&55.<BR0I&!(A0$B)55@4$AR*)(E]@
M/D1#E-%KN(%H+:<9#B?@,Q/40(Z[B;+1:-U^<]I1IW%"Q <',KN)XFD'A D
M$\6Q:T "0[)61-QAZJ[BG<E9HEL_:QK51<ZAD .Z323#W'!!0@D6 P_L4J@
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ML)^_[JYNYTM$%T'L!&2<VPDI'_HV>G_!1L@_68U9\P.[W(THY>H4GWHNKL0
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M*MA'<="VDK%P[%%&1,*#N-.!JC3< "1N8YDR>HC_ #RE._G^@V^Z[^@ZUJ=
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ME)D6*HH50KPJP& Y@'_:-Y(K(B>J_6^!HMFS&#PW+8?/KFH9:UT^-I4$S@;
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M:3F*E+:6JV%.O#LH*W/*'?WLJT4K[Z_,&?RV)U)Q,VHG*O'TFQ^-5Q\1 J.
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M8K6<V8'6M3Z='GGZ*$00+X$/'W#_  #P/C]O(_OY^P_?]N:S[0\@.XW[YK6
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MXVD>\<8SD=(WSS6'K5/ZU7&?:5-SN>)V/B/KCS7,\<@9NY#W??X%?O\ D/\
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MPW;;F%$[^*>UR1=0$JBHVD(Q4S<Q#@)0703$2H.T!'V@LW<)E Y%">2_DIA
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G.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g509388g24m08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g24m08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2GH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *<R^$' #A"24T$!       >1P!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP!6@ #&R5'' (   (  !P"4  (<G(Q-S<X-C4< @4 0$UI8W)O<V]F="!0;W
M=E<E!O:6YT("T@3W)I9VEN86P@:6UA9V5S("T@4RTT($)U<VEN97-S('-E8W
M1I;VXN<'  .$))300E       0] F?-?L"GE$BBDO #>]3;SA"24T$.@
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M)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M   $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V
M=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M  1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%
M15;G1&(U)L=                $)L9"!5;G1&(U)L=                %
M)S;'15;G1&(U!X;$!MHI_         "G9E8W1O<D1A=&%B;V]L 0    !09U
M!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M      5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M         08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&
M]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W
M12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M     0 .T4_@ !  $ [13^  $  3A"24T$)@      #@             _@
M  .$))30/R       *  #_______\  #A"24T$#0      !    '@X0DE-!!
MD       0    >.$))30/S       )           ! #A"24TG$       "@
M !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M$ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M    $X0DE- _@      '   /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H     /____________________________\#Z   .$))300(
M     0     0   D    )      #A"24T$'@      !      X0DE-!!H
M   S4    &              2^   %+P         !
M        $             !2\   2^                      $
M                  $     $       !N=6QL     @    9B;W5N9'-/8F
MIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&
M]N9P          0G1O;6QO;F<   2^     %)G:'1L;VYG   %+P    9S;&
MEC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E24
M1L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
MQ%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
MI%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   $O@    !29VAT;&]N9P  !2\    #=7)L5$585     $
M!N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415
MA4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415
MA4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M  !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9V
MX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;V
MQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W
M5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'
M1/=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!
M$       $! #A"24T$%       !     DX0DE-! P     'QX    !    H
M   )(   '@  $1P   'P( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90
M!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,#
MP,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@
MX4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,#
MP,# P,#/_  !$( )( H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'"
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.3I8=':BL_$:-%-X@IC8559B8V9R<W=YDI.5E[*TTN;_Q  > 0$   <! 0$
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MFA7IU%F LFVIUPKUF7C3B(E L@E#2+T[,WN*8/:X*F/D!#QY#A%>[E^R9?\
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M?4R_35?>XUU<1R8V21<?68^,FHT]NB&[N:&8GFX_>S8*KJ',A]V/_1R^"D^
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MF*J:95$C)JF(LB^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$$0#\Q
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M%V*!EFL?/5^0%N<C@C*:C6+E1N<BY$S(F*<944U%,4P>2B @( ("'Y" _("
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MU\M8LFVUZ3T.U/H_5 BF3N1:HQ%/1$*Q%J2[I"PKI6=14S%&)48JK25'!T$
M >0!]_\ F/?O%;ZN4T3A$X1.$3A$X1.$3A$X1.$3\OSX1:%.U^#;-I-P[43D
MEF;DB?:S4NN'3;*[3,2#FV.\\Z^LE64WK6A*PE5/+-83.;?:XMTL2NO_ +%2
M>D7#)S>W$="JD;-2*/NTEL=2VJ]U)_/)6+:V.D9IB7IG8+7Z16&T\I9;9MCV
M*NV@Q;!0$W\*WNE2@Y:2C$Z\E&-H>D1<2::MA'#3^P:$52[1+,*#<=J5J;*Z
M3%%]/KHI6\)S;[FTEKC>H;WV,;-J!&S;26(8SN1FFF42-3<3MO6C%FU>8&>$
MA$EI)Z]03(J3NL)7L9LV99M()94E#>G;Z;5VO"T<O6C6^KV[8=CCF./U"!?4
MLZ;QNQ))6BL#,PR+M@M:[B]M'V<<<$5)471/7KU^*L74<'I4-2^D_7:=KFG?
MLQT[Z1[#W UMC5YU'*=$J%M>T8&M14C;G4SP\DQG7UX#08!2G0B9(!!FB@>?
M2>,8M@T<1!(,@Z^M^OO11<EUT/E,%T&D:-I-3S/L78^N'87M'V$[$VE.P[6O
M<:4A0:)8I2&U-A(3<99IBI.T4JJA'V\KZ(9PLK16\948ULK*%C.3![@2Z==O
MC.PZ#Z^**UJWC^WTG1NFO<$U2E-S[>]K\BV"5T[+YI2!R&#I^*5N%HDY")9<
MXM3]2-J[VGHI,':<-8WSRS6EIH-J<34A%%:F;LYA5(<20'?+PT(ZCS&W1.4>
MOT43>P9/:L![W]DJ6D[PWMO W$^?895HB3U][0)?'X6"84/9]-IU8A91:VRI
MH&4T6-E;-&0$M YRWD*FB,D!Y%-XI'.QSP7"0! D3.T3\S[RBJ]+GUK#NJ#.
M'LE^ZY^F[VJDI:X9@K 3T]A$)N^W9O6J_$3K6%=LE*S.TZE7II-R4^SA(YS6
MEM2E:"]E2-W35LM]Y$"FZIT$;<B?#D!YZ'DBG;)>U/8MIO-UZ.]<.P4VEC*$
MB_NU>[#7 $=KM]0:52#K9-*P/*K=?%)J$MS^#M%KK<@O(6PMT<4&&?24(=%V
MI]F2,ER-[3*",N^G(3L(^ \-=D]WP\5D55/4C[7TK4+ETD;,Z!V*['03J,MU
M5V&YH_U=T^-Q:2KS64?3&Q0E%0.5U?X&<>L8*/AJ1'0#.T,IB-EU$(!)L\57
M&D9(!GS$:1(GY!.4_P"?7DI[J7JT2U9>3V);;A\C/=P8:98-X')\"DD9JN:9
M2I2"/.M]8@I^]NZXE2Z7% V=P]K"WO3.8*<39Q[1>:5E&(*2FFX.RQ)\/\]"
M)13Q6O55ZXC3[))ZPPOV+:13[A#42<PNQUI>W:L^L5DAW4_7!HU=S@UM7T*"
MGH2/DI5A/U8'K!%I%RAI8T8I'.DTH%I!R\YC3KT13M1N^/5*]Y;9MB1V"MTV
MD4><)6+XXU,SG*YBB699%-RUKUPKU_;U^9@)>1;+(N8EF^9)GF&RJ;B*%XB8
M#\@008(@HIPSK:<BUREIZ-E^F46_T)4[A(+?4[1#SE>369B!7C=S*Q[M=HU=
M-#&*5TU<JI.&PF*"Z:8F !@BD!A),)5JB]C'K219."B=N\8N4'C1<@&]ON1<
M-SJ(JE 0$!,0Y@ P"'GR'"+N\(G")PB<(G")PBB_;,M@-NR+2<BLY1&"T>F6
M"H2"A2@95HG-QR[))^W\@/M=1SA5%\U4#P9-RW24*(&* A @$$$2#H0=B#N#
MX$:%1!+2'-)!!!!&A!!D$'D0=0O%9!QUOQV]VK(])8JP^@9I/.JM96:Y#)%=
MJLCB5C/Q_O*47,+98\6T[#O$_<DY8/4S$,(E, <RQ6Q=8WE1D$TGDOHNY&FY
MWW9Y%A&4@<FC2" O;W G$]'BOAZTO.T;]MMV,M,3I C/3NJ3 #4+0<P9<":U
M-VQ#G#=CHS4I%[3(BE_;%\"!?(";QX^/[Q^/Y^ #^7R/+ '8[$;Z[R=>0&GN
MZZ0MN<)@3H.9WV@?$[B3Y[*:"7Y#Z  #@@A[?U, C_?^?Z_Q_P" <G#IB 3^
M _4>BI W<G0>_P!VGHGX*,K??4C(J_VY? @8/=[@$?R'X_/\O[@^1#^7)7..
M_*.L'W>/Q &O-3AG*),S\.1WT^9\ )6#V@S<Y:).*J=/CE[#<[A,,:M3X!D4
M57DS8YIP5G%L4"%\C[/KJ LZ7'PDU9I.':QR((*'+<6%I4O[NG0IB6N)?4=R
MITVD9W.G2 .?6!'7!\4\06O#.!W>*7+V9Z--S+6D3+[F\>TMH46M&KI?!JQ(
M93:YQ,-,>E&\] 6CKTUDNGD"LV6N=;H<3-0<Z?VHI/=J@7R5V4FU%1*846]@
MNA'S9V?Y.6)E7"0G$?)C=.=0I.H&VR_R32-'+T9ER >8&QZZ[KP_;XI>6^*T
ML9;4)OJ=\W$.U))S7 K]NXDDR0]\S)V)"\S^86MZP66C)ED[A9Z$D'D)8H*1
M(9M)0<]$.56$O#2#93PHW>1SY!9JLF<//N3 X>XABF-RZ[MJMG<U*%4$.IO[
MI(T<PZL<(@$$= .8Y+W1@.-6?$6$6>+651KZ-W2:]S06EU"N"6U:%02<KJ3Q
MD(/(,=LX$YV4Z^HE01]RP>/!?:/N#X\>!^?(^/C\_P!/Y?SIAVG=&HUC_&\:
M:Z:1)63<R3WCH=M"9Z0#UU@>X2I1/?D/HB'UR>/:'_;#S^0!\_O>?\?^_D2Z
M)GW:'?X ?-0[/209)\3$'S_(*&[K>TC(J^%B^/ B >X/)O@?(!\_   ^?/SX
M#]?D?,'. (D3O]"/=(YZ:;'13,:3(YG2-=.4SMI\NHU6( U*U]A-/IF$Y^FJ
MXMVHSJ<"@L@0ZI8* \@K:K8^]OCZ,;6H('DBJNJ8B9G!&C,HF7=HIGR6"V+K
MV]:7-)H47"M5=RAID4YUU>\MTT[N:# 6B^TGB:EPSPW=%E5K<1Q"F^QP^G+<
MY?5;EK7&70Y+:DXNS ?ZAI-/WVKVM9]2H+-J+3\^K#8&==I%9@ZI!M@  ^C%
MP$:VBV1#>/ "?[=J05#  >XXF,/R(\Z3[HW,"8$Z\]5XLUYF3S/57APB<(G"
M)PB<(G")PB<(OGD//CR'D/S#S\_Y<(K5:WJE/K&^I[&W5AY;8Q '4E5VL_$N
M+%'MC#X*X>PB3L\DU0-\^U5=LFF/CX,(B "10+6^[G4:X:9*8Y6>Q6236FPR
MLLW?U%C=(=61*Z@"**6!DV/]P#.0?P*:*RDTPCW+IY%)HJG?H-RIG$I%CS!^
MK-TRFIM)DXMMVK%/E#6!*H;'<LUN57Q307-:9.I"19T32Y6,0@)]RNT8/E8,
MJ:J"=G!JH6MJRICHE5C! !@P=BB@)[ZRU8IT"CJ.Q=9M>R?K[:8U^]S37)>5
MJDPYGW1H=Y,T^-NE#B'I[!FB^BHM2,ZBM-*/FXR;Z.CYT\*NZ*!9BQP )&Y@
M>MD6/^H>JOW(Z[Y.3L3M^-8?(Y5=H)R%9J.;/[J?0\HM-K@'\ME#;0IB:E7%
M>O\ !/)$D7!7N0J<95UH1R\5D8Q"0CD#<BZF6MS$]-.8G\D4$]ANTOJ%]=\/
MKNM4SL3(]B+IN\:--4S8N?T1NRK]COU*EIZ)O'7AO48-C8529T$>M*!!6:3N
MY)VN-5GCI7\5(5RI,ZF T.#I!B??XCIY(L=G##K3%]E>D-NQW:I+5K=>J]NS
M"QOYO;[%IUCLK*2SF,GW-LL,!.6:<+ 3"LS7P1DU&\9""@[,:&.W(2/1:-/%
M/[P?#:=[^S#Q;6B3AV,\)8@V#KW<?L[,GE_3>N&O*0=S'3O9#6-+CC#V& VX
MMK^B3/\ _;&J-H.]+74;M,Z%0+"X./8+7&O1_+F;#.=OHG8??;E&ZG/0+R*I
M$[DLO7F_8FH9=99U))K_ %CH3=XM$"#FB-%I=W!URHO[&5FU0BR%5Z]^S+QF
M.//8'[+.(WUA<7=3A6QPZ_JS+S?X'FP:\[4ZS4=7L7.<3S<=(A:YQSAO\)XL
MQRRREC1?5*])IC_2N@VY9'^T"J0(VRQU69,;4;?ZE&G]4*CNN<O.O]$=K]B;
M?EFB9[?8"[W:0[!X,BE4A>PC9-BW?T2GU*;=O+>S4ND,9>=EH:M0LTPC55TT
MW7=WU<P:!((U)G7P\?U$^6J*Z>O.9SW9+;NOL-W@L='UUEH.>]R\9+ECG/GV
M7M,?W;))^EPLT:1>_M&^6M6L/Z^E*.V(UUQ!_@4:T?VBE +5!>03D<]SB).H
M$<M1SGKX\D5T=%<GAJ+I_7AW=GVE6-]O] [G]%=EOUMT&>U)&RZKCEV=%@F]
M+=VQRZEJ!4Y:J9[I$U$+1#-L@Y>)-8RT%=R#)A)KP))W,IYJ[NF$-5\RTSJ'
M39&(HJ8/H[N'Z<&L4R4J4=39=J?,IE_H^82E[19-(N$M5QNV7P%9))1K]LZ)
M:8^Z)6BL&%-_*$7@H?KZ'GS/H5GJ<O*X1IO41>2),1C?,M>[)>F?L%CB)16Q
MU:TJMIY;1NM\,R9/5"R3*K0[]\[A(&0(DL\I[DCNH2BCB.4(_3*/KU\UZ0.$
M3A$X1.$3A$X1.$3A$X1.$4%]F]<:X+U]V+8G*\*B?/,]M%EC4["\,QB)"=8Q
M3DU>AG;@GE;S.3AH^(00:E.[=.7J+9H0[A9,HD6J+JE;+IFMXS^@V/5=&?9-
MU.Z22V\=B4TJ\YAHM+<=JEE-.;T^Z-WJ$C(O@I^<S-@DZ;18V75<0#5A%JSB
M[AX=@F8@]>C*DO!MPG-TG^HV9;!@]&/9[_2;MWFFK.]<,ZDI3XNOWQ>&Q&V0
M=8A@E EM+GX.QU:1N2;N;;M()H[DRO'LDJHFQ,16K7X;IWV:E<VDX:ZWAAH7
M9OLX\[(.ZE<63C0'6AMNHD])45Q6YIK%&<U>N8W7UH)H6E/W[P(4DHM#NFBD
MK/N0;B15'2>KVA;>;<[=4KS0+?2>VO:KK\WO"&=R<>5>,ZZ]?E6=:GDHZTS1
MEP<Z,,W5CJ6=O$%*6$1CWK&N(ISA'#]2,_7YZ(H9[?YUH]VMW<>5D<^MY$-^
MTCJ'T>QBZ6T9".A8#.Y*QU^7U"50@F7WJTEE;JZOG@OY%=FU4O<D_<0+IXVK
MS5-\2">A^?F#MNK;[=6IPMIW?@])DX^*L%9PCK1Z>^3UFDP*$PK;[#O,^ZL<
MG5"N1)(1-?N"$?9'U<C(@T82/IL*\8VNP%>-5V39O'E[S]/S1=CMZM%T.V=I
M'%?KJLI3^F?IF0&#5=I<;,Z8)5NZ=AI"9KI)FKE3<@_E'#[.XB+86:?1;'E)
M=S7V58K1QD5)!-0-QRU&O1%6]^ET,3T%E'HVZ22:= _2VO+QI8\UJ[5K)Q&E
M:TE YU *6)H9-*.C"S#"B,;+1*JDZ;M@=,)F9FA19Q<>JK!/7OU_3YJT=3RZ
MET=OU!QW4<]RI*K=2/3>WS=[M5]@.WOV92UW=U[/J:NR.SF"231](05Z=OY>
M2N3IP+X\;/.HV%^X--O#H1C\0/C/Y(K(<=<J%*9SZ76 OH#0%(_(NH&Q]L[[
M#TB04Q6]59T_S2N_A;YE:JR:*FHIZG?[:\IB-&9.Q0=I.&C^V&>HUQ$CV .Q
M'F$485'KC$Q6;>F O2=)5R?9-9SOL'V,US?ZO'N=<TR;K#_*(R\N$-(97-8Q
M;K4U&K>FU>P6"911.ULU:K,74&D(:8*#:;,0XD'7KUY<D]?!46H8-K<1']!^
MS5*G(F=[C]NW>SN[[=M[E6\'FEHQAKGI[M5*D:.H<4_<9W[:71:M9Z1'0B$D
M%;?O[@G;'LZLL*:DPJ.#LQ[Q ^$E%;%5HNQ+WKJ-ZA*%59[5V"[5SFPY PP2
MC'9U2M1.,4^OR3R$L>97C09*,CY25CT,_F+8WL5D6A#:#6]+.TA8Z%;M2@I$
M5._F<.40/+3Y_#W*'A&_A\9Y?FK0?M+',;=CWJ%ZQFDD^RK7])M_7FM=9JDQ
M_K5T:#O.+0=\BX3<;)3ZPB_:7"W5QW&:W5Y-M5T;"%1J+V#EF<I(>T3ECVC3
M4S.&@$ [[$D:>9T.^BBJ#:Y.J6?5F78K0*[+YCZ9>SZ>SS6VP]H8O:97M,[)
MY97;Q#Q=RU?.VPMY&)J(S /Z4JWM<:S-,VRB1+RUQA6<?&J\CF87R1W<L08&
ML]/GOX^"@9Y;]?7Y*OP5\C&VQL\^Z^Z5:\A],_8KQ"URUW7,[#.9_G,YV&K5
M2N<LOFF3WYFO'EIM6N@HUMC?%*2[B8R;MD"%;C))M*KS2"\(IN?&P/B )Z?'
MIIYJ.P\O>5+K'L9MF>=D@Z1]?NQ-[0P74'M<-*[-,V=75K5A.@QM8O=GLV%9
MEHMZ/:2!9],KL'6;$RC[&ZL;ND-/QUQ$,D',K'IM8N8WM T: [CRUTB8_34Z
M)ZZ_3Y*7''<WMOAF^->BM.VK^M:?UEA3[32-OW"%B;;;L+AE66EO[[!V-&M(
M4^-T*<E8RC1\GF$?/!'/4Q?33B56E(>*3 L#2!>&@P(UYG0D'22>A\.?-/7K
M_*D63]1;MS@NIQ_46PKYWV)VO8F=>FNO^H35;4S>$@8H_P"V"^CK[16*G)NT
M'S:FQ--=356"J.(-Y<3NQA!%FLP=2*9U*'  Z'F=P=>739%(#OU3-]P^ZGZ\
M[?EV<:KV*TN/C)3JV?)'D[G]'U-,7ZC&[,[PVMS^Z2.>ES%LF-EGY=M(V!*;
MK:A!AXXLHFHTY!U,AP:-9$C;W_!%?:7JPW+)I*4S/L_@+%ANU@80K[ *GA5T
M7NM=WUU+S:%>>UR'E[A!4YW39VGOW;:1MRMF:A$,ZJ9>QLWKI-JLSY*:;@0"
M-3,1K,;_  0&=E>3'U:ZW0_V@K7:+#+CBNK$BHN:R[/*E88C8S[LE-6!A5&=
M>S"<@VL"W>7=C8I6+8SU;FF<.6)92#>?/(K09'CUI L<"!&IC;7?QV19)]<.
M]=9W;2)#&+7E&FX'KJ-37O\ !4O3255ZG=*0Q?LXF8GJE9J/8[37)-2NR<G%
M,['"JR#6:B!E8URJQ.R>).>0+2W0B$45>H3Z=L%VRCVND9_),:)V'J<:9C!V
M5T@<T!=X1'ZKA*F7Q)J7[I1B1P<ZD+/-BJR5><+*BDD[8N'+)6QOK&A?T31K
M-\65!H^FZ(EIY _U-V</'5;)POQ3BG">(MQ##:@(<&T[JTJEQMKNB'2:=9@(
M[PU-.JV*E-QEIW!\K#38U:-8)>FWQ-6GV:NR\E RK614,$<:3B'J[!^$=+B0
MC)VW*X;J F8QT%Q( ?5;IG$2EY_7PNNU]3[,YMTQCBTNHF:@(W#Z)BHTDR(
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MH=8L_P!!/=W^[QCBYTFP:=#VN\S<#3:^V9OH6ELR4BFN&2T?(S:*8V1\0HH
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MGE&LM4M-@;+^TPI-Y--Y6UD(=,#>T3FFI-HO[0_< XB #J5[88+9YQ]IKNJ
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MUFQ0R<X<J#9Q"0C\@6!V9N@JR?.CI%%,:S$<_P _!1 +B&M!<XD!K6@ESB3
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MG4SK*QZL9Q,TA*]V32YNVZ#<-1N=TL[.&BGDU<KN[1=3;AE"5YDQB(2)]S9
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M(?S\>/'D>3!@UG8C\NNWAI.X,Z33+SKWMC$<O(B#T(,:1L)5D6C,DB)*!]
M']X?/M\@/@1^?R'\_P OC_'SX\#*YHUB.4@]3$:GR.NN@"FS3$DD;_#3E&OA
MI/N*QTC)[0NO&F5K;,BD#PM^I#O[EL4#J(QUGAC*E-+TJS(HB'W]=L+8IV;E
M!0#BT7.WDV7T7S1!8,GA.)U,/N 22;>I#:U/4]V?OM;,![(!!&X!&Q6C\?\
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M[#F\,C5JH1LI,K(3=TJ4/&.Y!(CI([>);N3R#P@*F;-U 24$I/%8YP_](?\
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MKK'P.>[;^Q_]9];5T'69MO:1H4R:PU(57E@ODK)1@P\P87I/P5[&_=F\)/\
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M.SXTH4JCLOV^QN[1ATCM0UEPQNN^847@ 2<T 1FE:Z<IDD2 V-Y+X#Z8@/N
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M+,S8H&E'GXE<IRPS(_="W1$4!D1;(^S^P12 Q@,19"\(G")PB<(G")PB^&^
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MR;UJH)@,7RGA?&O$F$7SKEN(W%WFJ3<VM[5J5Z%=TR]I:][C3<3(%2EE>T:
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M5&G4>RG<4VNSM968"&U&M?WFAP(#M1JLSR$*0I2E*4I2E*4I2@  4I0\%*
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M?Z:EPPU-)_ETYJU/_D8?F--U%R?M(4"@!2%#_5(4! "E#X*4 \?   > #P
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M(G")PB<(G"+6)ZKN#6?5^N#+3\RBUY?9NJ]Q9=@,[AV1/>_MK&ML'\;IV=M
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M'J#4F\<U9% JSUL=#(6M2FRT8YKRPN>\.<UN8@M>&@.Z"-=8F?<J3@2^-]!
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M(TGGS^/QE;IYT?PCIA$71#)F=PF[AIDTTL>IZUJ=TFM(UO39M@W%G'OKG>+
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M+#A$X1.$3A$X1<+E!%TW7;.$B+MW"2B"Z*A"J)K(JD$BB2A# )3IJ$,8AR&
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MI.G#2.<G$%6* E(L0>T_]'ZZ"=R:KUJJ.Z*;M/LNJ6+PV"97(1^J?ALT;/X
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M(G"+X( (>!\^/Y?\_E_+\A_7XX1>=S-*Y_4QO7;KK,=(6D=0-GD=>S=KX!-
MN2]DE'NG13:,1]W[D97-"<Z546J:2:;=HW@FK1,!!,#G^%O[R;V=?\.^U[ N
M/K2WR6''F!LIWCZ;(9_'>'G4[*X+B! J5\-?AE34S4>VHZ,Q<3U[@2^[?"Z]
MFX]^SJDMDZNHU\SF^YCVO;KL"!]T!9""/]J(_H8H^/[P*'Q_LY\YX_F '9S8
M\X<-.FQ*W<G<CK/E+-/FH16MA<$[C]6=_.NG'U.[2LGU-UYV<_TFX0&N+MY/
M(Y>0-[/I"6"V2$A(!JNX43*T1T*3!(XBY.DM]4?W9GM*&&\4\9>RJ]N<MOQ#
M8TN)L"HO><HQ3"&FCB=*D'.CM+K#:M&N\,;+F8;+R<H YWQY8FI;6N(L;+J%
M0T*Q '^G6@TW&()RU&D208#^2]!I1\@ C^OG_?S[,KER^\(G"*U+S!*6BGVF
MM(N"-%;#7)V#2=*$%4C927C',>1P=,IB"H1$SD%3$ Y1.4HE P"(#RA7T:#$
M@$D@=/?"B!)@<UIO3]+JT,?1T5]+T^MP![0IE<GGG];1:Q(A @O(:0[O19+]
MF1E!D?HIMEPCC(?B?O%8HN .!/"7,'7NQ3NOM1:2UHC+,&0 -X.PGD/?NK@,
M)IY9U,D#Q!Z_!3)VVZ13?8^G]*:S'7V*JZG4[LU@>_2SQ]".Y%.Y,,<B):->
MUR.2;OFQHIY.'D@6;/W)G:+,$A(J@L)@$-=^V"A4O*A87&XH5Z30#$&M&LY8
M,$;:*OV>9E, QD=).^TST_#GM"QSM'I\]K\?V;;-+]/[MY3L'I?92]N]2UK'
MM=Q1#7:C$ZG-MD6EKT;,7;*R5B0KTQ9TVC1W+0LE^(PCB31%T<HI"@W;63\2
MLZM&C3Q&S?</M@*=*K2K=DYU)A.6G4ECPX"8D!NX@""H]E4:XNI5 W-)(.L$
M#D2#I&H'YPK@M_I@O[_U0K.*7[M3M%W[$4C96W9:D=MK2[2FKC3-_8R;F2CI
MRIT^0<N:[7<XCT';NML\LB3-8!M6'3AHBH1XH9Z-@W%Q1O:ES3LJ#+6I0-K4
MLV=UC[=VC@YP )JDAKC4@DNWTT51U"6!KJA[0$O#]3!WT$[""(TYQRF)6/IS
M=T-%[+]0^R_:[NI4-4F.J&CV6SP6>Y]C/]6>?R4#9*#8JA(OU69+%-2#S0I1
MW*1+AU-OG@0L9%12\9$0Z)Y!=P,'XOAU"SOK.RPZI0%[2R&K4N!4J!P>UP:#
MV;0*8&;0-+B0"7'82]F\OIO?4#LAF "!(CF>9YD[#0>/7NWI#S-WSGM#64MW
M3JM\UCOQ%=]L5O,13$9=EF-[JL946M4A+=5YQ\HPN\:@YKCLTHD56.1<)OD%
M$2E4:BFM%G$#65K)_P!E+J5###AEQ3-2'5J3R[.YCV@9"<PB6DB(DA0-&0_O
MB34%1IR['6!KO'4C4'96O?\ TSN_W874^K&O=G.^F=W!]U8W^A;+5<KSC EL
M^RZ:_9U\;]H'T^J>XS5EDKF_A#JQ%>?*.48: (\D3ECUP?+%-<T,6PVVM[NA
M:X=4I_:[:I0J5JE<5:HSM(#6G(P9)@NV)G<;H:51Y875 8=( : (G78\SI&@
MW66\;T6U2K]^-Q[,5G7Z.\Z^]K*34*MV,P>VYNXE;-,JT#/Y^BUE2EWYM/MF
MT/'NBRZ;N>92,$]^[;IN621BBLFX2EIXE3J8?0M'V[A7LW/=;UVU(;#ZC'.+
MV922X!ND.:)(V*G-$MJ.<' M>.\TB3H/= _7R6.5,],_OMAE#<]8NL7J.-,X
MZ@",U$4R+L^$Q]N[#8Q19IX[=&I.9:LG:HF-%&$3>+,*M.SM><2D T,@+$4U
M638Q<]3Q&SKU&W%Q9%US#2\MJD4JCV@-S/IEI&I'> @'0Z$F*!HU6"&U.YJ0
M($Q)GY\YGP"R7WGTWK99B]8=.ZS]CK?DO:WJ729+-Z)N&I,U]P-J5"L,<Q:V
MVI;TRGY-E+7=M99"-;6!682F&<I%SHK/8X2>]--+(V-U)JA].F:59^=S&RT,
M<!'=$<QII(C?JJ3Z?=!!,MYD^?CUY:^ Z\?5#T[.P^8=YYOO9V-[6L>P.BW'
MK,;!K)!QF>ES^J5E9OH;2Y1+7,X)K+2:4#2(UDW<%792KN7GY:QRTK-O)4J;
MA)DAL=![" UC<H&G7J?"5;D0=3/7?>3UWY+<ARX4$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5$L5EKU1AI&Q6J<B:W7XALH]E9
MR>DF<1$1K-(HF5=/Y*07;,VC=,H>5%G"R:9 ^3&  'P1>?3NQW%B^V5)[&(X
MEK+>0Z?=;(>,K>C63&KLG^U';#LO?VS!CE'6:@W*IR19*(S@9^QU=/2;)67[
M:4M4K*-Z5#2S6.CK8L,1(@D1/(CER/2#R(*EWVV','<]-.GNU6TK->F6;RG3
M##^J_9:I5[>HRAY'GE0M!='9DM9I.RUJMQK)_,H2$H"TBWD$I-!P>/EVKMO)
MMB$1,DZ3.4#!!3+S]]9<CSWI9_2']]ZU8$R<QN+;ATKJ6NOJ2I-35A:T*\4V
MP)0)19/+!*2THV9NVYYA5$CAX<$E[(X:M2D;IIEYIW'-%U?!" \M:VZH.>P;
M5&]X!IWT#B'P01+1.P63PDQ=;3+' G>-1MXD'WC0^'IM!J4? &_E\!Y\?I\>
M?R^/G^_XYR:G8Z0&DCI$_+8@A;1G/+7SCZ +S%;"\J'I,^M54=KD;#"YOU$]
M4.EV6O;&\GI)K TBD=D,Z\3;"\2<@^.WC(A.Q(R;<BSQPNBB9>R61RX$J:21
MT]X;:OQ[APV;Z;JM]A%1IMA +ZM$MRY"-R([IG_V;=^6$>18W[7_ ':-<=[7
MN@STY;#R)GEKN1H'J?\ IV5J?L<0Z[S=4TH65*C8HY8=WS<6[>15.+29: H6
MP&3(9=0K5^1+W%$QU71RE$/<!=MX5-\S"Z=K?V]:A5LSV%,UFEIJ6X -$B=3
MD!<TF-=.D+'8CV1N7/HO:]M3O'*9AW0^)$'QG765HK]7KN!GWJ"6+!?3ZZD[
MQ0-)D.ZVYL*=J<[E=T@+@>C]<,H5;VJX"]<0$@_+%*6,8]Q-)IN?I_B49$R#
M4X"U7/[KVZ<YMS5NJS'"CA] F@""!4N*H(+A,!Q BF)F"XQJKJU:UUK2M*3F
M]MB%P&UR"'.I6]$B&N U;F<2\]0T3&D^@C.<YJ.34&EYA08=M7Z5G]8A:A5X
M9F'L0CH2!8(1T>V*!0 3G!NW(9=4P"HNN91=4QE%#F'2GN?5>^J\ESZCBY[N
M68F2!R $PT<A 6[LRTJ;*=-H;3IL:QK3R#0!OI,[DG4DE:+_ %G8?^O+LKZ4
MO2ZSOG4?D&[]EY^Z:>BV?N8I>R-LBA8E_#U=*1:*MGC<90D[+MA%HX1>@J[:
MK-%47"*2G,OA)-"AB-VQI[6C1#*9@&,XS$P9&A@Z\AY+#8L[[1<X;9O(%&M7
MS5-3KDRB/ 9'P(YDGH%O\Z-]9NN'7:"N$)BV/4K/IPTSYL-@B8]1U;+-'/ ,
M\ASS]MEEI"RS";,#.6:"+^5<(-Q;F^BFF)C>=IP^Y-W:4:SB"\MRU"(^^S1Q
M@?W$S/,;QLM5Q&V%I>UZ+ 13#L](';LWZM )U[NK?=\-2S5QK/3/M!WSU"DW
M2[6&:R#4%.RVUX?;KA)R=0W_ *8[:5U8D;KF3&SR*\;2M=Z]V*/NU4BUZN>*
MA;;"56-IUD9*OIB$D65Z-?7YP/?R5B9$G?H/Q]_NY+?IA?8["NRU.87O"-8H
M6JUA^R8O1D*1:(:PC'A(-4WB#.:;1CQRYA9,B2I2NHR42:OFBY5$'"":R:A"
MB"-"(/0H"" 1J#J%-G"BG")PB<(G")PB<(G")PB<(G")PB<(M+WJ"UK^K+MM
MU:[!HI C :]!V_J/H#D $J2<XL1]K^*23PX![2_3E*WH=2:J+"4IWET8M"F,
MLLV2'PW^\%]G;N-O8!B&-6EN:V)^S_%['BBAV; ZJ<->YV&XS3!#2X46VMW3
MOZP:6R</IN.8L#3M_!5Z+7&647.BG?4W6QDZ9X-2D2.9+V9!OJ^(,KX8/R$
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M4TV!A@"UW@4=GE:"ZU"/SD[A4+(\SYG-#775K0:_2^F:)0FP&-46^M[P=?N
M3Q^\-86=86YN^R<+<5!2-4C05")#1/,@SIT,[* +<X9(S1F$ #;G,==/ITE
MA?(@8WGQY#^/SX\?KP -(Z^4S_GU"F#=R[D/A'/3Z;ZGS[90$/D?S$?/C\P#
M^7_/QR^HL.G+:>FD:^,\M/D5(XR2?7^)_P !=WW)-D3K+J$1103.NLJJ<J::
M2291.=150XE(F1,A1.<YQ*0I"B8Q@* CS,VS"8TD\AK,GH/A[P??(\PWST'E
M.N_+>5$TYV>Z]4W-ZUL5CV"BL,KN%G@*75- 3FT)"JV*U6N?&JUR&AIF,^\:
M/W,Q8BFB6)VRBC=9T E!;V?O<V6TM:DY"PM>T9G#8Q$['P)_6%:N>W+,D@R
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M%D;?ZABX7A$8]2>PM3>@L/UVT[*J-(H7S%S_ -.9MHI%:4!.7E9!FSY7Q1B
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M]F-FSF3[:9UV^]+7&J(DC9;)GO1_8;W&K;I>J5 .7Q8YC>])+J$(.=:/<6+
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M?J@RCEF+G,NIJ)-PT-R8HF9N+\^9RL)B=3,?VF3,^+,J2FAJ(F$#HH4Z/5\
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M$!5J^CV[A$ 43+RO(+M-9TD]-9$1MKI.T;PJ?0\QJ#T/4+-/H;L,_MW43#-
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M%^4Q$K0N @( 8I@, AY Q1 P" AY*8! ? @("!BF*(@(" @(\^AX(< 6D$$
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M4WUG]MJ $$?;Z9+6AS2[NG ]Y]MP.E3<XFK8U'6SB=S3'?I$^.1V7G]SX9/
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M<'('@!674-X^0YSWBIU6M?TZ$GLJ-%CFC6,]0N+G #0D@-'DV=UL.$L H.>
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MB<(G")PB<(G"+6+ZM5#E9CJ9(;%5(U62O752[U#LG6T&R7U';F(S]\=#3XE
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M'X;^O71:GO5L1!?K/'-Q#_K>UO64OQ\^1,:SC^0>?/CP(?[>=!]GS.QQ/"#
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M@B&LO<:O;A@!&4:->!]T?5>K<,M!;X?847:FE9VU,@F=646-.O/;XJ2Q./\
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MWR:/\2JPG^H_K\A_AXYK=!K3 ,1IKY_J//Q6:.I$GD/&) E=24;*/(R1:)
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MK^X V<\5!_\ [&AWS))T72VL/,O0P\!\+6 1_G_T%N'^P>9FS_\ 6&_]#_\
M_E4+7_4C_:XSY#ZF%K(TYFE;NW;"G,6,)=WR'7:;>R%%T1TXCJ/'MY.RJ,F-
M@K[IJRG')[4].1TPD3(P1#M(A--9.9;*B1 ;EYS58&^62)VDZ<H\/'P.]\X-
M[7+HXBE!#CW1KH>>IU !VF? Y<T.+@8*+S:"K+L'L+!3D/"M%1G7=E,F:,77
M9.F9IQ^LX>R!F#M!9D99TJ9<HH?24*0R?L+"N?\ EHZ.;U^OC//Y0J5T *0B
M8EH/F =/(:1U 51L-S7SS!96[-F)))U7*:I(-F2P"9NJN4@))"Z O[WVB1U"
MJN_ @(-TU/ A^8<Y=295Q6LQQ#0ZY,G8[ F(_JTT)T!U5M4)#!! $-T_3HH\
MS^/F,IUBLT%C.N;%1]/I5AN",<=NT;L*;8H!6(6?*5MLS(1..JLZ6<$&\203
MMV3TB9D%!,NJ)ZMZ*=:W?5RAM2B]M/-)&=KI'>)_J&7<28\]9*>A F9U\H<-
MOF/J5FSCW_O,RGC_ .^ZU>/_ .;./'^S^/-EL?\ U*U__P %/_\ *%2=N?,_
MBM+'IE=>L$['W'U!]\[&9?G.R]D'_?#L/D%O?:I5X*^35 S',YEA7LCSB$8V
M=G)I5BJDH98NPL6D6U8)2IYU5^N+A3V"2[4H]:1\M_BH5[5XEU&S;/NH77KK
MO(0EUR6K^L_ED-><J?2#:ZTK+;?:&UDM-KQ^+@I%JO&0M6BPG6S]O22D=1T0
M,NN@4I!4.BF45+/J;81AO7C>O2]W7KUFE R+L*[[Z97C3)QEM7@J-*7['=(C
M+(UUVIV)A6&4:E9ZXQ@&B<XLE*-WB42LW!P@=L9PH*A%'_J>=8L2J77^PZ[@
MO7?KT\QFM[M$=G>T?:6GV:/L7:"DS=#V./N.IS^5#(QRAK%<&BD,]CY5*2V2
M!4K\>K*P,)4))RS:0ZA%Z.:],Q]B@(.P1"XNHF=B(V9C'1BF(9S'R;)!ZR7,
M0X 8@K-ETE!*8 ,43>! ! 0X15?A$X1.$3A$X1:N_6(>J..C-UH+<"*N]ETG
M!<=29G4!/[YC?-KHT;8VY3B8@_NU,D\Z,!3%,9-L<A1 Q@\Z5[2<>9PM[/>.
M.)'F!@?"7$.*"" <]GA5U6IAI) #C48T-G^HC?97^%V_VO$K"U__ *B\MJ1\
MGU6-=TY$GR6.8&*4H%+X*4OP4"F\ 4H?  4/@   \?I\<_)NYYJ/?4>7/=4<
MZHYSC+G.>2YQ<=9))))YGF5ZZ%* ! (  G3D(C?EMNOP*I?/CR CY\#X\?[?
MX_(?K_O_ ##3,<NFX!'+S\!\5.*)@Z0(Z;CQY?">:Z'5A8K[U-ZJR,D F@^D
M6ORQ53_O>PTWN.*QH%1#P(I*G)%G^H?R7ZB7A, $$S^/M/\ NL+4-X(]K-T8
M/:\68#0 @R.PP6M5(<2(/_K+>Z-&N!.Y7#_:T2+_  AG]MG<.!ZYJS=M]=-8
M)DQT6^+GU67(TX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$6#W<CT^\$[M%HDSI"VB433\I=23O+-PQ._3V6[!GXS22:,R
MS@KC75TEU8>6*@W-(P<LWDHARLV;N#,@72*IPBB_'O2GZW9!0=_JXV/:]3O?
M9O.YC*]?WW:]1FM/W&=HLK$R4.C76%QLI'+: AX=M*.%XV)A8AE%C(%2D'[-
M\[3*J!%C=5O09ZU,F=,JFG=C.]'83'J,I731'7[;.S=ILF(.D:B9H:L1LS0H
MIG!,):"A18-"-:\\54@SHH)MW,>NW*"0$64G:7TPL*[0:! :R%\W[KUJ,/36
MF:2=\ZO:[8,7GKIF,>\6?QF?78:_[V,_78AVZ>*PH+,TY&'!Z[2CG[=!84@(
MLM.O'7S*>K./T["\5K85;.Z.S<-H>-4?/960<N7[UQ*3$U-S4FNZE)RP3TN\
M>R\Y,R3IP^DI)XY=.%3'4^"*+'1O;9KS_P#'G*_X@+=CY_Y_7\N:MBM<4[\M
MYFC2.\&)J;;;Z_/W[#ALBUVF:C_AW1OMH0-)'S -DU:%G8BP:)(RCUJYC[-9
MF$O7D6XJ"LPCV]4K\,LW=@=-,A%C/XQTL4J1EBF24*H90#*"F2A5O*;F4PTZ
ML:YKAU,SXDR"??XR5=TVN8^H\ZA[@YHZ "(Y09UY3/F%K:]6=4$>MD4X,/CZ
M?;#K(?S\>?W1M'S^0?EY\#_<'-XX#?VV*82!)G$(&^G?((/Y>?DK$.+,;M'2
M=*E D@;#+R B- /GNM.][I.8;#!QT#I]0B+?'1,BC,1'XB#E%[#2[< !*2AI
M:/<,I6(?%#]W[F-?-5C$_<.82>2\]!WV"T+R&W%%E9K'9V9I!:[^YC@0X'Q!
M&P$D+?:@M[ID5V,JAKP]F;1S7?W,>TA[#I!(=.D:;J--(@:70<6L%5HL$PKL
M,=]%/%&;(%CJ/'[JQ0PN9&1?.U'#^3D7/TR XD)!TZ>KE33*HN8J9/&*Q?#*
M5CP]BHHTFTV-M:KX;&KG$2YQ.9SG$;N<2?'98_%'4:&&7=.BUK ZD_0&<SCJ
M2YQDN<?[G$N.HF=![WX[_P!SV/\ \1M?_E!.<)7-%!K@?=H=^$WR8AJRD0?X
M)A")J^S_ /B+*'_^N'^'.><95LM]A[2[N_9ZI D1)J09UYB%G\&'\JN>M1OR
M8H^L.BRA-+A<KJS6--.NZJ^NLS*3?W1HZ,@FK]**:(H-6:B"[V2DY!0Y"!]P
M@@R:MU7"AEE#(ME,?:M:+8W=1Q[,5!18&@2ZH9<228 :T-D:@DD#<P+ZK4/:
MMI,'>#2]SCL!.TZF9(TC25QY/ITYHLGHZ;^ ;PT?2+>6EM%"*N%EI"7C8MDZ
ML:AE#E(B=FVD'A6[%1(A#+-@*HJ0IS^P+N\RV].@65"XUJ/;$::!Y)ID^;1.
MPB" =%+1JOJ]I(AK7!@UW@:^0G0?/HM&>1UYQB6Z=L.KLW[6+NI[3;-NS!D?
MVI!+8?V!FY&\P3^(((%^X85RZN+K3GWT15".<Q31LL*9%VHJ[IAMTR\L*-5K
M@2UHI/U$A],!L$;ZM[PVT,Q!"URZI&C7J,,:DN;']I/CT,@K'/8,CM'9*S=E
M.SN<Q+NS)>FW7LR/0_PLAG*EDU)CI%=UOLA68 J*2A9"8A,1J\95G#=(5#IS
M5D/$^S[D':*>3 TU VU]:SIHK<_X]:K+71-\H=)P&<[#M)=K-TM"C)W&KNXY
M0KD+4I-,T34V)AB)F$SV2M$J_BH:+9(B*[B0?HMB%%0PAR7*,PC2-8B>>OEN
M(Z>&DM3MJ3MXD[+.#HODLUA?4O"\UM?M)=XVF)S]] #>[_VP;W(O[[? 44$Q
MOJJ!;K-,%.KY\*J *A0*!O:&A7E<U[RXK G*ZH0V8T:R:8\I#9Y[[\EOMK;F
MA:4*3M'"FUS]#(<X9CH-_O0#TZF5)FYS\E&05-8QZ0.CV33*= /&1EP;IR;%
MPNZ?+Q:RYBF*1M)'CDF3L3D,D9JNLFJ4R1CD-4M'->^H9@,MZSP2T.+7!L-=
M$C5LYAX[:012NFEO9QJ7UJ3#K!>TF2R1, @02 =)&Y(5LY&JG%W+48%ZB-:G
MWKBN6HU ;*)N82OQ;^+&._$(%ZV!-F[2EI-D\-*_:M&(-WK<H':#]0'+B6\=
MFI6]0=^FT/IBJ1EJ/<UVSQ,@MF&$DYFF9D91/9-(JUV.ACSDJ&D-6L:6P#3<
M!!:X@EV@@QW>N:&%G$9N^$ ?)#?LXJ(> \>\6KT@C^O_ &4R!^?Y?X>-EP(D
MX>V>56J/BX'PYDK7<>_[0<8WHT?> T@%=G<E/IR=$-_^/L ?'_Q V_W_ )<V
M.R!-PV/[*GX#\5CK8Q5'+NG68Z+&2[9-ENE2$7,W:H1TU-0B2C>)F@4?QLPR
M:K"85V2<M$/&$@=@N8YQ6CE7*C)83&%1N8QA,.3=0:XZ@2/^F0"=O+IYC?99
M!P:XAQ:"X""3/.-H(Y#]%>D%'Q,(\HL%!1[2)AXR?A6D?&L$$VS-FV1$Y4T4
M$$BE(F4H  ^ #Y$1,(B8QA&A=LRVY@0,[1O)V^$$*WN8[.!IJW3?37W^HDJ^
M:FW:/Z5$L'[9!XR>0J;1XS=(D<-G+9=(R:R#A%0!35153,8BB9RF(<@B0Q1
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M?FI=4<)#6D:D208$3H=#J#III(TT"]4:C0P )&\'G'2/(=(T&@"8//YB ?H
M@ ^/[@$?'_=^7(-[0DD F=>Z#/OF(\OR0-G;-[AU\8UVWDJH=+6AG?J/7F1
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MP$/CY#W?[0^/'S\>/'^'YA[#=:$F=#Y]-]B.NQD]1H5G&7T  YMIW(\1M.\
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ME71K *)VR:D84P%8NRG+Y^H] Q$R')X$BA43*'+Y,02@;W>VC5J- <T.(=$
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M4JZ2THKRN!3[.3J[WS/AITY:C\4]>OFOEAL^;/:!M5S[2:5/P'J:5FX7B/\
MM&5YL,9M=.U5M-R1,1JF&4:-E4BO*?*,$ZG^R4=7820KUL923IQ-F>&>OS%B
MT4S3),2 ?,?G&^VGCH2\?7K7U*J:]WA9W--FU/N-M%MHGJ,4FS72-=P\1I=E
MK=_RN^1+]ZVQRG8EF$7/-V4O5[)&EJCZ(:1U<F([0%9MVM+*/0<+ D:QG9R3
MJ0>@V,>/K?FH;QX_YU];JNQ&BR6B9GLNW]R^PNBY#W:S>0M#1[5XG7[)GKO"
M9ZOQQ/ZN*_G^41,ZS@9]A:2)Q4ND+RNV8FC.9MTU66D4U ;IP:VGD))UDQ\X
MTW]WNVA15T4S6M)VW*-BWGM?V;UO!^R^5J2C1]2JYJL]E4'@2E5KK!_1SAE#
M*295^TJWDGV=QD5;="V1*WJ6)2!8@#%LV8H18QI8XDZ\C$$1RZ:F1Z">MO7Z
MJX,BW#?.T.:Z3O?8OM?KO6G7\Q67AC4*EW5+-:;B;6KTN#EX>UW/.7;8&-R7
MOY7(:+(DNJ$E'.X6<:UJ)09HQYS',IM<PF3.ON,:2!KI\]4]?!7#@78_MAW1
MSBZ;KIO:+2NK]PSQM$5]IFF<A5JK5,_<1&=5:T*Z'J->MM>EG=H2T)],+6]&
M,FWC&$94MU'1+ J+DKUT$&4VN#B72 8D0!RZQUTY&-?$JWU\[9]S.]E&G-A5
M[*3G61UGD=5*U$4#.ZE1W,(\LJ.:56XS&HZ@A>J[-2\M5[Z]L(RE:K#-W 1\
M?3D4C(OG4@NK()Q;3:6N,D[@$ Q($SXCU(*>M//3]?R58Z\]Y^[O?:FR^D4C
M;(#K&RS5"#S\:U 9C4KNEHNFQM4@9^SZ1:5KTC(2,;DMO<RR+K/(2K+0<LZJ
M2Y9=6S.'"R()P;3#@9=!D@;<CK//E\_ IZ^?EZZ\U=.)>H9W=[M0$E8<9M6-
M8$SREO$4*Y&G\WDM4#3]H:PK:3M4C%">XUH*ID:AGD>%;6:_BEDD4'CIT=R5
M)LV^X-I9@9,=(CGM,Z@^XHH Z>ZO<NPY^R'8O0:W$U:[:OV.M+&=BX"04EH5
M-7'*?1\,5/#R"I4UW$.K)YS*KQ95R_719K)$7.JM]14_P5_>58\S$?;[A>#Y
MCDX=X!P:W())';8EB&*XG4.42&/[*M0#C,N;E!/=:%Z?]CUIV/"U:Y((==XG
M<U! /W*-.E0:9 G[[7]1J1RUS+_>^ \B ?Q'X_S'_AY_G^7/GKFI YMQL0))
MVW <<L==/?*ZKE.X,$]29CQ, _)?/:(_D)1_C\_^@?S^?\N3"O3;_0Z#U#=O
M ?2?>HY"=W'\?Q*@[J=W&KO7[M/W@J$9D^L;AI-JF,"D@J.5QU;%:OTVL9.B
MB>?LL]=;-4JK$-'<O/J1\(S-,*S4T[*^^VCS,XURX;_H?_8!LC;?LQ<&/:P
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M<;:[\_/F??NL0K;E(:%5.9PY.1JL?]XRA#E3,<0\?)B#Y X_D C[0$0^1$1
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M[_<[:/#D>I)\QI"F.I9O 5]PE*IN59=^4IA2>+G(9),RA?:91!)+W)@<2^X
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MJU'U7$E]1SJCR3)+WDN<23K,DS/]4\H7OP-R-8W;*QK8Z91$?+XK]<D1?!$
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MNL\$NVW5&U:PU*>(.I5*%&F_,U@SU?Y^66.RMI.T @ :*E;ON72*9!#=\T$
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M/)FWZQO9]8,L/9]P19L :+/A#AJU:UOW *&#65$-;F)=#<F09B3W=0-8^?\
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M^4-:(,DD@ =8\E!YRT:Q'*FX^<-<3\@?%2%Z4'1'JG(]4>KG9&6QV(E]3ME
M7OZS^PR5BGH&/L-[<S+F5G8:ES4L]IT3.NX^469+6&,@6<J[;.%U#N"G>+^_
M]:F!4S1P/!:&O\C"L.I01!!99T&F1R.FHV!T&B^?%XXNN[MTSFN;AWF36>2[
ME][0[+(IEZ0_3Q!TX:3,;IMUSMNQM;&FXG=],L%DQK- N41)P4HYH-'>F!M$
M.6,5,R32L'>.I,E0(Z$U93BCHMSHY8N<0 22!L%;K'N]^B\SOM+&LV[M3K.@
MJYPP;.NL:-Z@JBM$Y)=8%_'2%1N5O+7V,1):S-0B,2VKI'T^\8J?L^]F 32)
M,OPED8E[C$\OARW&W)%F'TRZH:7CEMU7:NP%RI5TVW5(ZGTXZ6;Q$Q$4"E9U
MGYIIU UVNIV-R[G7KV7G;+8++8Y-^HD"SMZQC6R -(=!=>+WEY!( @0/U)U*
M+8%R1$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%3)J+1
MG(>4AG"[YJA*Q[R.6<QCQ:.D6Z3UNHW478/VQB.&3Q(J@G;.D3%5;K%(JF8I
MR ($6J\>J\!_I1AD@;!V7_9 ,/-?/H_U_P"B?B V#]M"0/U/OQE_J@U^P,(?
M;  %^K_:B/N^.%"=8\)]>>OP6?NCZ!6NN^2+VB;&=F(FGQ<)",&H+FF+/8Y)
M=9C 0,<5V^6(=_-3,@NT;JO7S@H+.%U7CI8H H?A146%[.3E/C;S);IDEARU
MK3Z0GH#>282C:\5^:B%GA8XL C/1C%@R97E*05:-%:VY*)%!>HN6,D^9E7<(
MD5!@>T<C/RS6E7:D,Z#(7VK6N2H#Z'T2LW@Z[J#@W4PYA+&E "DO5[.E%$4D
M$4$C2L6H+1V@A-*.4 (<H:SMIU41]5;;:YFW=8D)BSV&60F>F3Z?ET9*;DGZ
M4K.EO-8;%FI$CIRJ1]+%;K+(%DG(*O 1653!8"*'*,.9\A]?R3F/(_3X;K)S
M6MUM5'U"B9+1\R4T&T7RJ6NUM%%;2RJT5%LZC(P+20"4>NXV1,FFNC-@+11!
M%911\1LT,@5%RJ\:Q0^4^OJHSM'<H\+(7=W#9XA8*1EDH\A-#L!M"JT+.I2L
M(@BM;$*739'VR-M0JYE%4'RZCJ$&0<M73:#2DEDP(8HJY;%VBEGMBEX'%<ND
MMC)4J97+Y<I%E8XRM-F</;8Y6:KD37DY!LZ7L=KEX5$TFTB2ECF7T5&Z;B6;
MKKII"4)U(Z1\_P#"I]@[:KJS#.NYUG:EBGD*3 7FV1M[N$)DR]6:6=!=Q"5I
M="SH+/7=S=HM':IXD&;9@Q322/(S#0'38%2BN@Y[D#-CB#;+,QF;_*[A&7Q>
M*C5YV+KHU:6SYRP93T=:WBR,BS:M8Y\N^;2,BQ4??3.Q*$:UE3/FI1*!.VFI
M]:[_ "E1MJ_9[4Y.LT]O2*.M4M#@.R^=Y=J-.E+A&M11/*K,Y:,B&4^UA91M
M)U>^1SQM[)]LW9N63+ZQ'#$5@<LRDUZ?'T5+TYVAMI7V@K43%I:^U/'7B\/I
M]B96V&BG#:P14<WE+/!TB&?M!7N+RK-EP+)'6<U]NNY S./5=NRG1(45VC]H
M92R:+4:'DN<*:$UMN85?7TK0XM+*L1;"EV*65C3K+I/(UZY5DDD_MUV,>D01
M?*'7066CP;"LH4->GS]<O067W"BM<THA[[%;3>//FW68/U\_$R]_W>/^'QY'
MF"OGD5ZC20/NB9UVY?('<1J?'2<99.(UM@,M(F?&DWG\# ]ZX!:B'Y@ A_(
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M"J7#=&^IV='#,+L\,I4VW+\6MS4S-M.V<>Q9WZK@02,SNR\)^UD<+X%9X*W
MFW7V4UW.K_;32[1U>O4KN.3L'1!J91+B8:->0O[_ $>O4Y_^%FZX?_993/\
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>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g509388g30k30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g30k30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *6*^$%E#A"24T$!       &1P"   "   < @4 #7!R:6YT;6=R(&9I;&
M4 .$))300E       0S.@=$6]K^>CEX],GCR"LJSA"24T$.@      Y0   !
M     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G
M1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M     +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$
M]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64
ML .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G
M,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M   $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='
M9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
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M]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M 08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&
MQO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 5
ME#5  !  $!64-4  $  3A"24T$)@      #@             _@   .$))30
M0-       $    6CA"24T$&0      !    !XX0DE- _,       D
M    $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0
M!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M   0 U     0 M    !@       3A"24T#^       <   ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #00    8             !$L   4@    !@
M!G #, , !K #, ,     $                          0
M %(   !$L                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P  !$L     4F=H=&QO;F<   4@    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   1+     %)G:'
M1L;VYG   %(     -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $    !#A"24T$#      ?+P    $   "@    A@   >   /M    ?$P
M 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ A@"@ P
M$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
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MHKLJQ_^O/K6M=6;:7U![JB]I:+&1N;(C>S<'-WM7'_ +0'U6Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-C=!MK<D,C4Y46%U=H&T0E)Q>)&6L1HE)C,T1%-4LGG_Q  < 0$  P # 0$
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MN-8$B)'5VR:!+776562L8+DCDT;(C(M].*H94>*-%PUKB2VF!$H66&1@+R_
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MFY>=L$-%ZN(7]HRTN-/SL.70 4FU-E65):<CR\V1R>F<TI#:VGONIRE"D_&
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M;32J#5.BM%;'3BE2()A8&K77+#1S%<.B(LD>EN%-&Q"+8R='8B)EPWLPH:F
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MN#@4%N;9&STN[PQ"9#LIL*NXT([6+'/!LRI$J3&"DB4P7$DS)DF)$8?ER''
M-L<K\8\N\2T67K?EG2]/TY5"<YLH;CUUF;++V0FRQB*P1M%H.32MHLTR-&QF
M/$?.F)ZX3"EL1/L,K4C($G? (U=4\?\ .';>M8>G^H]8P=L:W'VL7>(=8(';
M97F&;2%'F!0PMB?33U<++<BP#Y>.F,Y/7"<3,4MZ,XZTPMH"1D.'&'PXL"&U
MAF)!C,0XK.%+5AJ-&:2RPUA3BEK5AMI"484M2EYQCY4K.<YSD#Z? '@#P!X
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MI4N8]-4, 1&Y*UK;^XL#KQ:8X;TW["?<U[MM0]%&-I3];U26FTC*?3=E6:E
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MSGORZ9OV[N2M2;+@B-*76PN3FR,G$8/.#3FAPJ1+::<2-*0[(@<VS$B!71<
M8(AC@+[-4ZNHFD=9T'3VKZ_&JFNM85$!1:16XCDA]@+6:R-CB0X],F8](FRU
ML0HK27IDV1(FS'ON2I<A^2ZZZL"D;HS^'WT1N7<^[]M:HZ>ZPY+$=4/O/=3:
MGY^O\&O:VW4H@J6L^Z7!RQ<E$=ZS.E#DD[&)_N$%(E'SBHP.)'+$HLL#/N@/
M0WR7M?3_ "+K34UQW#RW:.&D3D<Z;>TY:&&+_75&C4.SV*78)Q:%(R=)F[;%
M<N#Q6*\%(PK-/)RA\F,.(SA4D#\YN]%VB^<=W[PZ'C='=6;;VKT=SM=>=]PV
M;<UXJ-W)6D;L!%658;MDM(H\<\Q:6Y-1$+"L/%Y@ 1":2*:$.PFF&VP,J$>D
M_G(-ZP[)ZJX^S=V.Z0L]D;LTR^O$J+G:K$UO:X/;N&(T]%&14<1LGP,4=E+M
M2==_2'GV_N_FY;F-@8ET!Z+M%;;5S1=-7;]Z0Y=Z&Y;T31N<:7T9HVY0:SL&
MUZNH57:J0D;L%$(9 A%"*A62"'2=?56'7VRTL;/1/"1A(H<!MWGGTS<9Z%Y(
MW?R"0#W'=%1Z<(SK!T9?=MV19K9NV;9-6U*C68M9A<80H62KI5I!RJ/B6(TH
M,>^Z?7+G'IA I, C?SKZ$*'H#8>H3#W=W?>R],<\W09?=&<VVS>$D=JREG@C
M[SP1N="K$$/DH(%XD/L,"!$:KPI,.3/&$6YH@J6'3P)N\R>M73W+/77779%)
MNVRCVP>R"L4OL&MVJ;5WZ;6WXAF<;0W38PBKB3<=E4F>ZTO!LV;7]A",)7A>
M%+4!D_L/X*IGL=T(CF_9>U]NZPUK/MX&UW"/I\E5A!2]QZTM^6*JMDF6BK6M
MIRL-&50K Y"A18DAXT%"RUROH@X9< T_7?4;S5KCM+4_;6D3%]T;<M9:3"<]
ME-9:[DU>+J/:.K:U6D4^O MB@2]8*FR;@>N0*O A3!MA%NI<H]-G.X=FAL/R
M (5V?^'/T1%O.SI?/O7_ &QR9H_>9R>=W)S3H3;+-9U5:72N'&RHX5#=%2%A
MPQ"*Z\.=&EF+2Q&#O+!#<002(PR.!.!'JAT+&[9Y6[E@WO<C>P>1><A_,FNJ
MB4M8ZSU4[1A@?:0.(8O1BT S&P[%;_PMKFU2C2[I'Q.E#A4B7&>7B=^:!QM:
M]07+HK?G=F];9-O.S$>PFI?LG>6L+K,KKFOH@!26$N,T](.N!K2*F?,=I^*3
MEV4@1&3FV"(N3"GQHTED"$FOOX:_E:L6K6<387278N^>=-(V_-XT_P C[<VM
M"-Z)IYS,UV>EIVNPJ^/3-$ID/O\ WAPYL#DHQ(EPST@O"(E8T\#0GO>UCS@*
MZAYRW[?-:^RG4VR*SKDN.%=R^O8#!+_MYJ(;FQ@NH;LTW(;(P2[XXQ;I@T[&
MF5R1'&G&PZTW(//(1*H!%OTK^L.Y[WI_M@LVZZKT]ICF[N^",U1JHUOJ6WCJ
MJZ4EHY<#QO:5NF6T/-;E68HR9 RIEDG 9P&P6(F?_1%3AXI,AT#L9"O5]SHU
MZX8GK!M,R]7?GZ-0%T'];-%Q,/8JFF;@[?0=E;, P8P(Q9*S;<#S0=Y%>R+5
M($PF2@HE#7-BRP*T!G\-?IV7"T9'V3W9W=M//,-PK![G@?:]ATPC4=45VGRX
M,X+3*W3#=(/ X4!<@0";)S1S8UZ0/ !Q(]@4,AXBK L]G>MW4$_V/!_9H[=-
MD(W(%T^[I>-2&YE8QK)VNNP2D!1-^$JL*M.36&BSZ\.MVEN#]QMK.8.4X6E8
M&B]^>GG6^X._J-[%:/T1T-SYN@+%HH78PO4=G@B:UN"I40@(D1ZG:_N0\%F0
M5E$@A%:N EHA*!G PR K(>,49>(R -Z^RSUO:A]H6BZCH+=-TV11:M3MNU[<
M@\MJZ96()^38*W4[S3X8V8]:ZS:QR@SX^^E),EM@<S-5,B0%-36F$2&) 'R[
MZ]:>G>@^P>1>T+7=MEA]B<;PYT+7U:KTVKLTNR-SW9#KJKE&)5<B<DK1F0O#
M?Z(<"IQA*?J2K.,YR!QE2]6W/]9[?ZM[F(&[Q<[AV'IUO1VU]66URJS]2JHR
M@NO*^0B#!,:L0[$M9@5KD=$)-E[*4A/M%3"$Q4(=BIB 5RL?PRW)2)T2C2^E
M>TR7( _8&=F0>))NY\KT.S95S%S%L?AH#H+?I*\NO1ERF9+%T5%??4JZ9(/.
MD%@35]@7I]TAW88YZOHS9NVN6-R<MQG!&F-K<\%1U6.UFL*4/5%K3;"X651X
M()0Y+E7>"3@DL&J8290]*@SWX2@-):5_A]>0-67WI.^W?9G1_2,SK30\S1.\
M(O0.P1-TDVJ&5*T*Q%[[FU1*N(NS-]?M&OA-A%E5V-^+79SGP$A0VAPE,$#%
MM=_P].B*[:M$IVMUEV7T=H[ERUCKCSWS5N/9( KJBA% DAB17XTN(*J@N>:$
M 4QH\,8)COA82!3. <AJ0"?FBY8&<='>BK4>U>DK[U;SUU)U=POMS<J%-;QE
M\O[$_:(/:2Y#F'2)8J-_'1+'GRK^,3B$N*3<#OF,*/Y 8/RB).<!:)RCS/2.
M/]!T#GG7=AV);*IKZ&18A6/:MS(WR\F99DP0/EB)H^0PTC+DLL3FR&AXJ"+"
M#6G$Q!0N%%;2U@"-7/WK,TWSIU]UWV;4KOLTSL+LEEIG85:L<VJO4RMI9FHG
M)S38PRK#3D967481G];-F\?1G.,8PK^MX!'_ $]Z0N;M+^N_H#UMUW:&[R>H
M.BKN8O=MNAHG0W-DAB9IC7$>1$KLV#1(-89@-(UD&RRDE6"4C"IQ/*Y"\+B8
MB <ON[TG<J[UY/Y8Y@L%IV_6C'%P*OB.=.C*/9Q%9WU1)%>@#(2"+5B@5] -
MY15X(#)E8K "$VDJ%%DPRPQ"$Q*0!D?!WJ%TAQ#MC8O2!+:V].I^I=I FJG:
MN@^E+DW=[NQ4V5#?FN@%I@QOT^%+9" HLV40DF2N8(6 *@D( 5#@QT"$UB_A
MIN7R!K>H"F]0]DZEYJW\1.VFW<G:RVG"K^FFKV6:<R./X#N@YL8T,JI#$ K7
M*]9AYE#,@*$@$R10"-8#^ 2NVKZ0>1MQ\0\\\2W UM3 [E.,VK0F^ I\&%WK
M03*9:YL@O!L(^N,U]W!5U,))D7FMMCIJA(:>PQ"-!Q1:$!S')?J2#\XV79VP
M]D]E]E=9[0V;J UHE^V[^VV0L0VK:U,N-R'1M;JB\2!JBC,QO$YDH??.(C2W
M)<@?"@/$BCDX"17KJX U9ZU><HW-&GK=L"[4Z-=;3>4&]ERZ[-LRB=LR/S.B
MK?J]=JXO,&/^G,_B)P+Q(3];GWI#WRGZ0)V^ / '@#P!X \ > / '@#P!X \
M > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#
MP!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ >
M/ '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X
M \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '
M@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \
M> / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P
M!X \ > / '@#P!X \ > 8%;MJZOU_)A0KYLBA4F82^G(Z);KA7JW)GX6M3:<
MPF#)&$[*^I:5(3]A#GRM*DX^<XSCP#-(<V&1BQYP^7&G09;*)$29#?:E193#
MJ<*;?CR&%K9>9<3G"D.-K4A:<XRE6<9^? /I\ > / '@#P!X \ > / '@#P!
MX \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > /
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MX \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > /
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MR6)D6/*:PE]AI:0-:U7F+FNBA+;6J1SUHZFUR_0HHV]@*KJ:A5X)=1T+\O\
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M/'A+=:N9"ND:I+*2((@E!@'FW 9:=$P//QB0]"GL26XJ9+33J (SW+U6<&;
MZ0QU?;="#2NYG;;5]@DY_P"[[_#I-BV%26&HU1OUIU5!M4;6%FN5=99;_3;
M<J,X@A[&93SKTM2G\@<J,]9'$ ;J1_LD=HT='WY(M)6_9L'[IO+M48V.>$Y!
M&]EP]8/65S6<'8I83G\4A=(E29L$ESY(.3LE%+FJ GIX \ > / '@#P!X \
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M.EY&(6=8ED"<2,U..WF4G<V8_P"A2"*FTI:7K%$O):'&2BU.1\0YS;F0+,?
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MGX_L\(YKOBN1VWGLJ+M^@Y?%)'MU(WQ[[[<V.9OMMOMR1-]MTWV\MT/=YR?
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M&5$-578-NBTFMV LR#!67:!^CU*RUS4U;+E7V88T_LPM4Q$Q;B7&)BV<_<\
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MS4$CQ7T!(9!_[1><!>;X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X
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M#8K###8F%JJ'*85%%3(ZD.MV%J4/0PB,PC/@%K?@#P!X \ > / '@#P!X \
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MX \ > / '@#P!X \ > <8:_Y&+?]F3__ "KOG7+]ZE_JW_X5)5'Y;3_.J_\
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MG"^Y:Y(A%GQ7R%2AEI<<,X.D/S&DDVY;F0+SO '@#P!X \ > / '@#P!X \
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MO;C5-EQY&O-56$"2C.T>$L7/O]B;0PM\?-MQU."@:K1HLUN.2C5FK9(EL2X
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MSF?"65L6K,;'O@J+5I\*L>:FO^1BW_9D_P#\J[Y-E^]2?U;_ /"I04?EM/\
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M2/EEEE>Z26661RODDDD>JO?(]ZJY[W*KG.57.5555/=YR=9QAK_D8M_V9/\
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MY'8E8VG9N9MY6S04/5%1$3[G7Y5 J.P+%K>V6 Q96R%AL 0>9#11*?D>^^0
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M*D+']*"--W2SRJR*)J*^1[6HJI5E[(HNX]SZ)<L'/&=YU1R@S<E310>:.:M
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MM/S:J1CI:2J(M:P+5? '@#P".G4O.(GJ34\G6)#8VU-1$8UEJUWJ6S-,6O\
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MQYIF9'0TS]O\F.\MU,=,AUG":^SRXC"68X65K+[L4]&>)UML5BO%;KRPI:9
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MWKE0MIM?<_*2%O+RVRA6]M<I4ZM*%.J0VG-@QEQ26T+<5A.,YPA"U9^$ISG
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MDJ]8;6UENRE"MD:?O]0V?K\ZZ48"W6B6$7::N5?"%IH$RR/-AI,L?+=%FAI
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M$F#.CY<;;7EF2PZWE:$*RGY3C. /VTU6LWBMG*==*\$MM2LPN8$L=8L@N$;
M'@Q%A<:>),B"3,F 2'38[BV)<*9'>C2&5K;=;6A64Y 6FK5J\5H_3;G7PMLJ
M-J#D:]9ZO9!<(W7[$!,1'8!8*;#DF9(\H*)P7WX<\?-COQ9<5YUA]IQI:DY
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MPT<+AQV84*"PS$CLML-H;P!Y5FLUREUNOTVG@0U6J-3!BJS5ZO7AL,-7ZY7
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MVQ]:]"0]K_T0IUQ;V#4B;;+/<W-LC8%IK'Z;%*5&#7263[3+C3+6 .TEX \
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M\ 2"\ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ >
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M<3'''0+>/ '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ >
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MQUU:U ;E\ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X
M\ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@
..#P!X \ > / '@#P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g509388g31k31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g31k31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2".4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ('*^@P8X0DE-! 0      "$< 5H  QLE1QP"   "   < @4 #7!R:6YT
M;6=R(&9I;&4 .$))300E       0"<2=# TR":T*.P^V)B,ZT3A"24T$.@
M    Y0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L
M 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!UX           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _
M@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #00    8             !0,
M  ;[    !@!G #, ,0!K #, ,0    $                          0
M           &^P  !0,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P  !0,     4F=H=&QO;F<   ;[    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   4#
M     %)G:'1L;VYG   &^P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      6-P    $   "@    <P   >
M ->@   6&P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ <P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MK_6;&Q*:\;J<6U.N-@%MK6O9:W':QNZQF3^D9]GN97:ZJS[+]I^T5?I%H?\
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M.IMY_D^WVH:^/V*(UZ?0\7_1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1QD=;Q%L^^4K6/?5O[#Y]/:UUKT=T!Q''U'9@%MTKR[U8YR18_\ 2)(FR?\
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M4,RX[T9U<.9+'2T-OMJ:6J+/'OQ9\*0E*LY9EPI,>5'<PEV.\TZA"TXF+&)
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MB)XB>(GB)XB>(L-V+@JK7U[2"LL"F'%4VSX#7 KAC(NIE<A)V!UE)8DXS&S
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MT=7J0BL"5@"I#%GUZZ^Y/#N&&Y#']?UE"&6VFR@K+"TR5L2,O9=>PIME<?\
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M%Q(O><7$/<%V=W9V!W!MMA?CLKMI"E9I3$@.1NH0$P"0D?O$)-&[QL0N[L[
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M%CAOY8-+RCZ:1K2A[+M%CM!LU2]16<^&%U34^SK_ %[:&C--6"LBK+_-$[;
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M;.SMC%BURS7;AMH>U2ZU2H[&H*WM;=8BB$A<XR;(R=IDYDEL%@>ILD13IO\
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MAS-HL+^XKN&U[2;)!K\0ADK)I$FS'QL:?;XL5\+ 8>R^Y)5A.$Y(I8+;*UR
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M.?[>(M91KY9^5:O%-JMXW>5.,UAW).S4^UZ6N &[5K6S-"E;0([FL57(,,E
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M6V!F)1M$(RO(G+3T-$)F \^16Q\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%@>KO\
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MY1':!VG? DU59UT3JU?Z'NS\IO7:)$EN:Z,:O62#\F72<57]QH56\%B#X S
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M;LM:A\-XAT<9FYLK-C,=!5Q&6([N'K#7KRPUI!=B&(JQB]>&6"TSM9J<2AB
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M9ZD?%HJ]*Q+TG%Y7E+K.>\I2\N3&7N<!81:'C<=6J4(ZX,1QR-UI.H3$YG*
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M+%#6F.:QAI<'BW\Q(9C[]I_I!>2389M#?(K7%&JMZ0'D&8-I.5\"U#Q@VF7
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M6MT5;J+KO8,?BL'9']:"W(\NZRL5IS03%@L#RP%3V<3#6.'#&BHJQ[N98^7
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M]<?Y^(J%_'ER)L;E&H76#M*Q40U9+$-T32Q\76V#G],,U/GG0&O-#5VP2LV
M:)FLVJ\,TB3:SXIB(^.K+) 54H1NS-@,V,H1;$O$3Q$\1/$6HSN;B'?W7>XX
MX]B3HX/S:YJ"Z5=^1(/6\)N"-N.X:\VGK,/MHS !ZZFCMAP=1UG9IIK55$*[
M&K0(6:L]RM9/]XTJK9KY/S^?S^*M#P_SSL'GNB;*9VD2I,J];7VY-V@:$ZW?
M-3*/5TMZZUMK :% $+ (KQ4@B2*UG"L9*1) BL,F3Q& PS*8A-DYY%=+Q$\1
M/$7'EMR'8LEJ)(3$E.1WFXTI;&)*(TA;:DLR%1E+:3(2RYE+BF,N-X=PG+>5
MHPK[L$7G$Q\,72M?"[Q@#>@-,[&*[7V'L@^H[<:1<J;+/XZ XI)\L[MVY?FQ
MA:]MS=L2;685LR%7Q6&*S9GHEA&YL5$A7R/ H)%Z)ZP#;K-:KU;:ER9[5?!B
M0;<Z8K"Y<QL3 CP$2Y2L?V5)D)CX>?5C^V75JS_O\1=YXB>(GB*DO>O,-EZK
MT_4:?3S4478Z!NW5&YQPTE=KYK43<$ZZ/YG$:63V+K!+VP*&T?$RY[4*W52$
M2*@3#0T@T-F(9<9414]XT^.#>G.^[:!>]G[CJ.T E)KD@\1MS.+*ULJZ;4LG
M+W,'-5F&GH1* L9FCCF>>9MV$6!^S$K*;G6@4-+@H$BMR3I\BW.>(GB)XB>(
MGB)XB>(GB+6=W'<^L*SNKE$=H%&S<4DW9XC=T1K_ %[&NE;-V-70',0:17MS
M&W:G97-?:TQSF=Z:LJ[.LE2X:#]<&J;M&+-$J@0P1;,?$3Q%H3M=]^2VNW:C
M \&MQ6II'5^V@?\ .U70D4;3[B$B;XY''T4!<(JJE;%4/GM?/EFZP+#+S-M0
M]MPI4 BIVU3%SB@HYTBWV>(JF]PW>S:ZYDV-;:=G>JK*.S5DBXO-FNY&S]QD
MERK@!C20]7K<:B;-=A13$)V2,L]N:H=HETBJ2C=M%B)A<./96141XRV'W&?Z
M7J@/<M@W);]<*T0'E'S=MY^+Z=U>;9:T=RY/ [#@N6C6-)L]>W1:=^&NEQ%I
MU89(C#]?J@:(X?UE4H@ZM29A%N@\1/$7F<V9M;Y1@9?JE%<D]:S1J.AKX[1S
MU4T8@JW2JLS7NV\Z+U7K:F&]$$7KI4B>P*IR$]LC<E;L.S:1-IVPXL$U8-=-
MP;W,C$6Q[@Z[=C6C<O20_I6+L2, %/N*&C[?08]3H=8N.-]=%" P#1=G:J@'
M.QJ!.YQ#<]V@R=:/WR+#M1N6T_8(-EG6< ,(MEECBG)U?.0JP7A5^R2Q!&,
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7?IXB>(GB)XB>(GB)XB>(GB)XB>(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g509388g40n10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g40n10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2LD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *PB^$0%CA"24T$!       6QP!6@ #&R5'' (   (  !P"4  (<G(T,3
M4P-#4< @4 .DUI8W)O<V]F="!7;W)D("T@06)P<F\@+2!3+31?,C R-%\@-#
M@Y,"TU,S@V+3(U,S0@=BXQ,"YD;V, .$))300E       0X(V-P0]>OK.<ED
M!R-)+TXSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90
M!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6
MQT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M   !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&
M)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M  #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&
M]N9P      .$))30/M       0 &     !  $ 8     $  3A"24T$)@
M  #@             _@   .$))300-       $    6CA"24T$&0      !
M   !XX0DE- _,       D           $ .$))32<0       *  $
M   3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M       0 R     0!:    !@       0 U     0 M    !@       3A"24
MT#^       <   _____________________________P/H     /________
M____________________\#Z     #_____________________________ ^
M@     _____________________________P/H   X0DE-! @      !
M !   "0    D      .$))301$       0     @   D    )      #A"24
MT$'@      !      X0DE-!!H      S\    &              #?    Q@
M    4 ,0 W #  <P T     0                         !
M    #&    WP                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG    WP    !29VAT;&]N9P   ,8    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -\     4F
M=H=&QO;F<   #&     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    &.$))300,     "!F     0   (X   "@   !K  !"X   "
M!* !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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M=&<23B5P3]&/;'YU?I_P WZ+W?I+*=L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0'_P  1" #? ,8# 1$  A$! Q$!_\0 '@   00" P$
M              8'" D#!0($"@'_Q  ]$  !! (" 0($!0$' @8" P % @,$
M!@$'"!$ $B$)$Q4Q%!8B05$R%R-A<8&1\#-2&"1"H;'10Y*RP>'_Q  = 0$
M 04! 0$              0(#! 4&!P@)_\0 /A$  0($! 0$!00! P,#!0
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M:8O9FQ,QY&3(X3F("F /_%G:PHP T==S6QJ8Q_%GZDS)V'4F2H J#))6RDT
M51WJ7*2DE)"220]?0V(Y(_#H8XTPN,XBLV<KHZ=JR9+#U*%K.YG(5WT:J3)<
M-[R EHD&6]9ZO()*?LA#83))RY/6HR"-26&+->*0[8>@3@Y8P_\ CA(R)38
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M,&/1_@*PD[*724$$L6<%(4' ;13 $.*VK&TPG$</X@E+5G21,EK+$.E+>4$
MEC^T5 N28GM\"BUETU+DII^3(DR05!O54OM8^:^ZZR/7M>):FK$)A_,6IMEA
MTY1)-EFQV$MLO&+*0*/(5.(27W>[X&HF5,223ERL^H)+EM-'LYM'RA^I>"3A
M.->1*0%@N4@!\J);.P%0"0-@ -(OUPKI/:LX[ZQE6<?X_O[=_MU]O;/[>WF]
MCS>*(OCJ7XG U#I;4T22_"![4VJY/MJVVW%Q"X'6]?>L#->(-)Z9E(FVDA5"
ML2)+2ZU\^O9F(;^?#9<;T?&YZI4@978D@M30:ON13H6H\>B_IQA96(XR@S,I
M9F"@"FI.A#.0#9Z.Q#D&N?4]+J8>H2"II\; ' @CDR;.)R8[,)B#"'D9<N3+
M>F*Q'87,'BID-^427@6QEOY4-V,4F$85@X02EXR8J8225'5Z9?+\P+C72A)^
MKI^+PO!4N%RAD0A_*D%1*$KJ:.'4>3->D<MN5>H&ZU*G"59EMQVT-+BRHI0,
M8%R(;[D:2--5ZPML6($8$26GAQ00?CQS8LC&E0BC+!%A]I-^9@ITF6D@'D05
M ERX<W=J,?81J9OB/ <5/P 99*PH*#)*20X"@"P+L!SIUBP7X&MR..4+?>GI
M<Q^76M>[&#V:GQU+=4P$B['AG99L+#2M66HL)RR5DE8G(<=+<=PI92A%QO,P
MA,==[+@3_P")+2HDD9R7#WFS-ZZ7W+:O'S3^HF%EX?C4Y<I*4!4J7Y4AG(E2
MJT8$U%6>@<L (OK7Z4M_TX5A6.L9ZQ_ZL9QWGV_[<YQCV]\>V<^_?F^CSB(.
M\]QF9W&K84_$=Z0BG$]>;,DQHGRT294356R*5LJ3C#RL8S'PS'JLES#_ *L?
M+[4O"D*3G.?*OU73-F>',2N0HI5A?,L)HZ2D$B]/(38A[#GN^"(SXJ6@)?,2
MX-J.11BY<6-&KI":X#;"PY4K-I0@^K)#4DZ.NN-NMHB_B-7W"22(T]Z%$;QA
MB,.K1>';-:0X,7&(\$=11KK#;4>?'1G6?H[XI'&."_X,U95.P)6@A1)9/QEY
M6<FP.4C0)2;$ 7>.X+_'GYPD ++4H7"11@-0Q&Y)%WBPW&<9]\9[Q_.//:(Y
M^#Q"#Q"#Q"#Q"#Q"#Q"$!L+6.N]L GZGLZAU/8=5?DP9TBM7>N!;7794T;+8
M(#I;X6P0B UV5 G1X\R%(7&4]$EQV9+"DO-(6E#OOV$-_8^,O'>VVIF[6C2&
MJ#ERAN5IZ/9C-&J9"P,O4YM3=1=8,3 [\]EZL(4K%><;DI4%PXO [,;UY\0Y
M:=VVMI#![HX#:!VS'UF*EZRU5!HFI FP@53UJ_JJND*:#9V*JHR"MBJ8D<X"
M<K=R#NU3U "0A>1*UF"+).N$)K0X@T-=M[:][-U:)!(=GYG5M:G=ZW?G:':J
MG$3CI6A:8:M/:^L167JP3I:R6VTU*M6*YWG6@>J Z2BNWNU$!CQBYQ9U9K80
M239/R)3)2 -@L38ORH[,=F&#^XZNU_:#GY@TT-;6:\/#G6NNORW5:DY2*JY6
M*5($2Z< 770[H>L2:ZC#->E@!SL-4(/+",I2@5(&LQGQR<>F(MG'6/)B+=W[
M-8S -:Z^JUINMVK5*J("Y;'=$2=@6H-6@HNS7>2!')$@Y5P.P84<K9GPXO"1
MPITW)FN#H&,0X:F(^/E^(:-I^8@C\2[BC8^7NEH-*H#@:!L[7M]K&R->SK%(
MFP:S*+8BDJI9 U@)!&)YR'$E4.QVA]#$<<Y&EE6P+K[R'(["FL+'89$V3F5<
MU 9S_P"-@"68>[[&-_X;X].X%Q)&*D!3T2IBH"MB<I -ZO0)<M6L6_AY4[AA
M4M@S:*G=E1WERIHL@F))RI0\F*&54@%26K]E8T6%/#_I\A@8F28 W"ZU\G8+
M@O"C,8Q8@=?FII@75X"7@DS5#,A4T$M1B&))(<$T#7J&!# D1V'C#$>*.)2Y
M7%,1)QDK 94J<%?PO,E( F',4JLP_P"+M+#D K9CXJNAK-I[);?6MA$\GK^X
MS($380($+EED4RY%9;$$#;A(,>SE"*WLDFZQ6[=D;&0Z(O#X2V+]6;Q;9LBS
MQ/ABIT\S)09)":"WE2D.R6=)(( JQZA]EX+\=*X9*_Q\1/F@IEE*#G4**42H
M9BHU<D@EB0="DD3@^%+QAM?'?1QFP[&$9K^R]SV)N\GZV_EMPC3*XF"F#3*8
M8DH[2\7'15331IEM:HHPQ8"<.)A+2<J5L^&X4X>62?W*O>@JUVO4VU?4MQGC
M+C2>,\57-EJ*I:<N4DNYR("B!5@"&H:EWJ'-I2O[U64)SE/7??\ GCKO'M^_
M><XS]\9Z^^>\>;0$/NWN*?R[\HY!0):K?<6K8_/[16C\4;B[8^27'A2:"PJ=
ML_4UC8VAK\*TIMEZW3Q0$Z-.4EB2Y(AI5,L]?)SFA$!V>-CS+)  -3S (<Y)
M.C==Q/##$X=20 5"H!#^@)#"CF@%0+"L=9X0XPG@_$I<R8!\,L"J@REZ&UW/
M.A-;"*\OA8<=K1O$FC;VT*^;#:LUG97VZM7+$.D"I=QV]7CL6=(*SA9.' +0
M8>HC@Q+.%R8 ]9#9:&'A;(C^S9<21K>$<*3(=<U((!.4* +',3<AZ&KO>L=G
MXU\;JQ:!A<'-6I<U"?BK*U$(EE  21F\Q4&9*LS 5I^Z5OQ-J%PU%!X)[;.X
M0?&S:M@B%4U*]C!LLZ8MV1@J! **N.KZO ?);)JE-'-@R!0_,0,>HD=H-"1<
M:W7#!(<4N\25A4+1+/PT*(!8I35FH  22 '-V&E8T'A>=XD6?\G R,7C)$N<
M/C*"YJDRT'S+92E$)"B30$.7+.28<'X7G%0[QDTP>D6ZPU"WWC;EKDWHN>U^
M;FV2FQJPV,&C:&-KEC)A*]//CIH-/YI8FN"(<9DO93;D%O*)2Y4K88%$M$I.
M0) \QH!J2=&N=12IW!C5^+N)KXCCYDPA:4I(1YB5+S(0E$Q)*E%@A2%!G >S
M@-%I[>599SE6.OTYZ[ZSG&/1]OV[Z]\=]]Y]^\_OYG1R8L&VB/?)*CR=B:$W
M/1HZ%9D774^Q:FPOT]J7(L=5*!XO>58_5\MZ4E3>%85Z%9QE..\^</X]POQO
M#_$5I=)&&FJ44A@HIEG+G8C,4Y04O;*&;79<(F*1C9+9@?B) +D,"H.S'5)(
M.E2*VBI32>S$U#8^A=V1G<Q:M?!0C7%S<;6IB(V"V6FM3*9-FMM*;;RU7]BS
M:$.BDY6%H# +C<E1U,QTD/7\2?I3XUF<$\<XG@JI\Y F8H29THK+%22"E*R5
M>4)S@DC,^4);4>B<<P4K$\.$T)3G0DJS90YN38>912634L2"Q8 WW1%X<CMK
MQG"O5A7><8]./5A:L*QC'\)5C*<9_?&.\??S]#9$SXLF7,_\TA6_XCRM091&
MQ/??N8['EZ(CCE.<Y[PK./\ #_F<>00^I'0M"/GIS_WY_P#?_P"_(R_^Y7O"
M/GI5_P!W_OGRDI4]%%N9+PCY]O;+F,9_?'?_ -YQY(2=5*?D81D3]L=9]7^/
MW[]_]?\ +RH!MSUO"#*4YSWE*<Y_G.,9SY,(,XQG/><8SG'VSG&.\?Z^(0=8
M]_;'O]_;[_Y_S_KXA'W&,8^V,8[SWGK]\_S_ )^(0?\ /]_OXA'STI[]7IQZ
MOYZQW]NOO]_M[?Y>(14[S"VQORK[U55J-=F*348FJ*K; 4*;3:M: .P+0_:;
M[!M\:TL'E1+*<ATU C5;4*NZRM6O+$P[>EDS]C(0E5^.*TO%USTR)GP\V5F#
M.QH]=!6EQ^.^\'\%P'$RF9,)5B)<].=(KE2%4+:>5B]WH.7E+V.B[47D#LA<
MT>1UC? .U+-M:H/ C;\]T)%MY@@>KMKU_:(\($_. BURYU%^<V/$&)"0L"&=
M&P%+<@1_(\3Q7&X?& (,P',546LJ )\KETN/*4."78.15(^_?"OA/@_'_"9X
M=C<,E24RA+S+$L)6X4K,$.0D%1((+',/*Z2DGU^?#AY:N\P./T2?=<QV]N:]
MG+H>TXK3+$=B>=B1(\D?<(<%K^ZBB[T"DQ2[3#+>(HXBX> L*5@8XGSUK@./
M/$>'29DT_P"\ 4S 7<LM0!<_^02"P)/2@'P7^IO@V9X+\38_A\D+&#4K/AU$
MU2F8A*U2\P+D2U+9*MLH=2DJ4;#&&4L(]64I]6<K]7>,9_4O/3O7?OG"E)3W
MGO'>,8^^.O-XP%OHT>;A[J+G4N3]?GO VO*G.D?U?NK/[_OGO/[]8_\ ;O\
MUAB%$T8MUM2 (.IH2&.G]]\LC[?JZRO"5X]\=Y3CVSG]NL]]8Z^W7^/?DPJX
M()!!>A;Z=WB/W)?D71.+>DK_ +@N+J/P%*")D0P[+B6)=@L!*7$"U>L#EY0M
M#<ZPV8J%!LNJ0N.-<,1"!'#,'*G<X>-Q<O!8:;/4W^V@D)#54U!4BY(?4 NT
M=#X;X!CO$_&,'PO")4N9BIR$3)GF5\-!_<M1 4S)!*<S!1&4%X\-6[]J;;Y
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M)6S-:NE)]3AX_ 1%64&?@PH=XUVX3FY9BPVK3 @#30-<F3"AL[#JU)('YZP
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MQ:'&WD"&3#Z)]NELYP\'J$0N;9_5"7E'GGZJ^(O^W_#&,Q2)WP"J4KSH($P
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M?NE*<XSU[=L=VY@=_>,*HH>ATB-YGEYQEKLXK ,[UU%!G!G[(T7A2-@5IJ=
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M-,.;7F[LUE>(NF(C^T-=W8AOT!R9EA+!=9%[=:V!JZ5M .X,FT*.$I+Y+6Z
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MUY(:>1S"=5/$6+'KPJ;4[4)P; V*4]ZY(J&=<MD3L[6Q3B/BC](?&7$_T_\
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MILR0'$>FS_'1QG"DR5**)PEE!<N7<AP5,E=&9V00 ^5B!QB/#9D8PJ"?*2&
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MV2M3K\_$;Y#B)\AQS*W'7Y#S+,_+CF5KR_A#_>7$)5Y^)7%L><3XQGC#O_\
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M*IS?I2GU7/"%JQC&%+2[3;>A:59Z]TJ;QAM2<]X4CM*NT^WF1A/WINS%V_\
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MA&I+-B)OM5X+/M]:>,U@!;W'L9B\1-4%*4N6@I2,JE%)4$))9P02DD L[*S
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M=[,H(N6:H:6L-![Y:X<I#O\ 9^_/G1HL&4]?)QEXB<AQS#UMZ;:4OHVD36A
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MVPYG&32M+,5\I8+E81NT-Y4B[:M.0YY")<8NJ0]#!E-I1!]@DUY]?MM;EO\
M:!]!\R:#6U&KUY,%05Y+U&+/V$7E:_/M"R&NJ3N6AT(2LY:HDSB\42.2\2V<
M0C0MDP*=5;+J/B9QVTU:"$XI)BC#FWMG29*+&)=E& "O+\?.OR@UA6Y?^F?N
MFT6)<)9C%PVB9#TO:$#8-&TZ&'5NY'J@1AK$W.UAOS)66S1V&!*0A0V=<MPF
M.3FS28V;7Y!,I"5JBYO$9U8EZTP*4T[]N?MKO#?<[ #ZT=FVL0 ;1< VG*$8
M3G/><=YSGV^^<YSGKK&,==YSU[8]NO$(Y^(0>(0>(0>(0>(1%'D=Q-I/)1^
M];['=:Y^"IUXUU.<I<NNQ7;%KO9BJNY>*4759*U:$Q(1F330$ED[7, K0*>B
MY4.+QU92OQZ:=Z6A6C4J#9_:WXC3T[@GQ?J4\478U6'L9@'($/5PQ?9A6^EJ
MH-KKS,VMU.J$;7**N@*36BC*2H"HBE0P8DGV2B0&""EO^._>'RW:C]6OZZ4M
M$H:[3ZM5(#HZNUJO@(DB=/*RXH,,-$Q))4I(7*)DGHP^+&9<FD9*U2)<E;:G
MY#JO6^XXOM64(4>$(3WE*4IRI65JSA.,>I><8QE6>L>ZLXQC&59]\XQC'?7B
M$<O$(/$(/$(/_P"OMXA!XA!XA!XA!UCW]OO]_P#'_/Q"/F4IS[9QC./;[XQG
M[9[Q]_XS[X_C/OCW\0CJK^7AQ7Z$=(QTK/2,8QZL>KI2^_[K]E8QGK*\YQGW
M[QXA&=&&U)0I*4]?='Z<=X_;O'\=]8]\??&,>(1\2PRC"$H9:0EM&&FTI;0G
M"&\9QG#:,8QC"48RE.<(3TG&4XSU[8\0@Q'8QGO##.,X;RUC.&T=X:SZ>V^_
M3_T\^A':/Z<^E/>/TXZ0B(FR>"G%G9T2>-,Z;K ."8Q</S$SKQXOJIJX(OV!
M*[A%OC6MB%78OHVT2 L!^R#+DT<A%W(41<R,^I*U9-W]&Z>L2"07U=_X.M>1
M'.%3Q]XY!=!0S$:!9#MLF%F*X+22.Q0 Y(VO5 0R#J]?'#JR*%P<0Q4),OT3
M"22!/,J=/2B4W"D8CH1$27\0@\0@\0@\0@\0@\0@\0@\0@\0@\0BN_G_ &B]
M4W_PF$:;=;53V;1S9X[:PM[5<.DQ$>RT#8=ADB;16RV!\J/GY<_+ _\ "2V4
M*)PU_B4QI+3,QUO*)&NM/;G3[^]A'9LG/^B4:1LIDQK3=4X'ISD#1>-^QK@/
M$T)8>K739PO4Y#7<Y^,;V4)M1JNV5S=-$%L$!-:(G(92<XP4!_@VL6*>B/[V
M&O)M/M<@0M)'-NAAP^QB-KH^SJH2U1O+56@;O520FK$K +MF[9.OHNL3#+]<
MMQNN%*Q8_P"U&EO9(#CSI 6Z1D#2@B.2'S&&XJSM:^]P/4?;2&H#BNIH-3L=
MNCZQIC'/*C5[&P7+%J[= )G4&T*%J[;;TX/0<L:]F;.8H4VB6DEEC8;J[%4S
MT+953E9<HBK79!#4YR/8:P(FPB#$5SKWWZ<JQ+<Q9[GVLX/5O>D*^V<QM=4Q
MC>,@J&NCB./%UH%*V/F..!>F(]LJO5.T5H\-^;9D*GUQ8>Z!537NL&XTO\5&
M;"R/E(=>F(_L?;?NK6C07[G-K[79'=40O1-JDX/'LIKF'M<Z%#TO(FM"=I#H
M):L6E'U>^BYYX"V.GM22SE?AD3(]QN3$< 9D1G4>1J1SY>]ZCF/M$M0%Q4<_
MHSB-R?YK:<KFQG-93"<V><';)HNH;#*$Y!NQZ]L;80^NDZZ G@Y9^+?)4)4*
MY4R88M(.E&*E6F[1'193P?Z#;< 9?L5[K0[:P8_>NHU^5>;0_-PV8&IQ:JUQ
MYD@;M5W;..52K TCWC1EFM#4E3\UE!$@)'PA8R(]"1(,&)P\4V1)!PN9F#I\
M +*HAO;4^_7:(K[+Y\:DUI FJN$*W5RPUJB MG7NC2U4B->*=4K#8+2 !.?E
M^7=8^=A%CDG7]]>%5W4$[8U@-":[^.KP<O-/TZ!80--1Z/37UVWZ0(;8^X%J
M?R_72(';VN]YB"?B7NA]B;'@+IW*_@0S378U]MXU^LB;J$XD2;17@R,F%2 5
M7LV;.?R=K$-V,,DH.%(9"#E$N8PJ-Z:CU84KM_-(F^7H0*TJ34Z<P]J&+VXN
M,)CMXQZ,8QC.,);SG+:.E*_NVOMTVW_0WC'Z4H2E*?TXQY,1'8\0@\0@\0@\
M0@\0@\0@\0@\0@\0@\0@\0@\0@\0@\0B(G+'0-BY#P=0P*]?X5 SI[>FNMX.
M29M*=NC%A+Z\FK(B*N0BM7FC2(02<N;EXK*'RWR3F40TP)0QR.^N2B79[UI3
M;MO1QK#+6CA.1V$$Y$C(^X6(C'(3E?ISDT3EQ]?S_DUHYQ^=X^QQE#CH=V%$
MEE1!R=QDIK5B*J0.?E#C%NA0$,*EUHA67??>D1WWWK[=[8/!0U>"F\)R=L"1
MT?=N]^*N\IT96N)4A5?E<4CNH[#6:I$6QL& W,%6DAIX!]>D?)@/LPB)J".Q
M$6Z*FAT._P QCV%P6/7N!RIAN;7&C,\I-E:6V67>C:Z<>74Y^DPNH 8:!%4[
ML!M9MHW'U% >)N3<L(849GLQ6<-H9]#OO3OI#O3\?4GEJ^BVQP%OFRRG)G,'
M?@^L5CD_+T[9[0&_LIP6,UG8&HX]/"L'ZY89.P\1,5RQ5BE"QI2G$J\1>:G/
M2R(FT"&EQQT1$O\ P7[Y[7C?;2X,V'9<'EO#F[<@#5\M@NMPAN7!UW(]=(3K
MT"Q74OATO[&<=(LE1C4AY]J?(6N.2D.26\/=)SE5_J&^;O\ )OXB%UK[C+LK
M5^[MIW^F[C@P-6[MNU?VKL+4A/6[!<RWM0340-+LY_7.PI-[=C4VJ[(#TRH8
MM5)L-.ON \F$4+:\/T8G8R>&4-M6^G3ODT*+DKQLN.WKAI7:NJ-MKTSMO1LZ
MX,5VP$*:SL>G6.E[(A@H.PJ+=J0NRTJ>2&&DU6KDQ1,/<0I,"<!0B4=3[K;?
MRT#W5O7TA'YXK[?&;Q1O6E<A!P"PW;6%-UCOJ$;TV&L,*_(H!_85BIUWURS#
MN(&!JVY5=W:%P"AIIT9M 21K<H1#NU?MA8'&..FYU_JXI\OO#T]J<WL7<WM>
MA#"$U?."I6^-\FVWMLP!:.2.UM';0ELLZZQ(;IBM$1M81:W78GKN3:#D4JWJ
MFN/F9LAH>VN1)*MPAD$=);',(18(-8E1H3#$V0U*E-I5AU]AAV*TYG+BU)]$
M=Z9/<:PE&4H].9;J>TYRC#3>4LMH=]]TCO>(0>(0>(0>(0>(0>(0>(0>(0>(
#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g509388g56s02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g56s02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %OZ^6(8X0DE-! 0      &,< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(T,34P-#4< @4 .DUI8W)O<V]F="!7;W)D("T@06)P<F\@+2!3+31?
M,C R-%\@-#@Y,"TU,S@V+3(U,S0@=BXQ,"YD;V, .$))300E       0TRAB
M7B:E1@BSHB:;7PL!RCA"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
M$     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#
M;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O
M;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !"
M;" @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L
M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!80Z8
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"
M24T$)@      #@             _@   .$))300-       $    6CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #00    8              *D   )D    !@!G #4 -@!S #  ,@    $
M                         0             "9    *D
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   *D     4F=H=&QO
M;F<   )D    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   "I     %)G:'1L;VYG   "9     -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    !SA"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MVYC6Y]@K8S:2=7D^[<YSIV>W=^C]G_$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ IP)= P$1  (1 0,1 ?_$ !X   $#!0$!
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M,C7[NR]([JU-2[!9JXJ3I98+D.S-?8I1Y4Z4(OF$*/3V$I^=5@]91@.*VIK
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MU')]Q:]=Z1 L;$ V-ZOJX.U+5?:(DXGCFS9DJ%980FV-CTLCOBQC-<+W)MO
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M "3[_P!%ZMF8D4%3MMU^=2(J*6 +W;YS;P@5_A$]D_GROY_RZD+3JP)LY_Q
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M/),0U;C3]ZN,8A675A4%>V3(OM>A%6; F1H7!'(LDB3C9:4H;W![^=/GEO$
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M!TA!TA!TA!TA!TA">_-]!7%(%0&U0551(B4B7@?$!1245_(N$3[>_'OU!S:
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M@Z0@Z0@Z0@Z0@Z0@Z0@Z0A,DUC<E'A)TA1Y'!/@05?%TD]4>515^IOR:1?N
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MHU\LA1*="01<69Y.^*>$=M/]-O$^'B;C.ST]:?WS$(EAV4"Z4A^\Y#YB5*H
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M^*3"WT%I+.0NC.^@#G[;[(S7?A@LOTS#5NY6A!?(#9K<(1I40D(E<&-L-T7
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MR:)+A&A0+.MQ63G];%?:+Z)M+,PBKO+*K=$D0X]E;TN.73:H+AML."G&FQ'
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M8+B6.XAE.67D1['LDII-A"LKBF&KDG(C-V]B (\DC'I-B#STZ6OOH-36E/\
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MDK4H)2E"I3YF0G,HE01E405',4@ 9%GO#N\#VDG83#B6@2C1LRPLJ<.7=,U
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MSL!!;>$HSB@7%TX4@L$@-0!R2";7 <&EM'<O:Q)XU-2C,Z55!%%92EQF([Y
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M,3#=2X%@MJ[<T<3(Y-H^P,/XW*<YS;,I,>$CHONQ*U<RRBV<IPENMM'/.O\
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M.7P":(GL/SZ [+!2+F.'DG@@\KIN*$!!+%B[W>@K["AY6:.N[,32,0@. RP
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M*D!$N)9&LZM?A1R11AO0YCZBP2GTGB7*EF:L#++&8VV?,;FM;;]082006_N
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M" D5!)$X("5" A)"\@-/J B1/ O%40P51)%1>.K9ECFS5=C\Y_&K$T@%CO<
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M+QRJ_5P:\JO*^Y(J_P#'CI"*_3']$_\ ='_Z>D(QC@1G'OB%$D>\ ;0Q,AX
M#4T3P1?3^I55'%4%5P4$354 /%"!(,= :;$5%&$%&?%?!&T'A!\ !!;3A$1$
M3PX1/;CI",EML6@0 YX127W^ZJ1*1*OV3E255]D1/?[=(1RR_%ZU-E6S>SK-
M,@P.H?MMAZ RK!NYC7\6,RK\F;>Z6O:Z_LJV,R">JZ];87(S*!%99-ITYBM
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MH>'\,.+E"8LY7L H/;44-]O\*F/=SV+C(8KMBT%IKZ>ZJMLV4I0L\5F/J/D
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M2(:D4-O'^WVGER!X=CC?PJK812XGD')A(88FP#EQR#SC#(C*1*CHKU$S#K9
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M848@JY':<<7ZS%2+Q)/'W)51!4?911.$%?NHHBE]2KU5$1DHV*%Y)SS^O/\
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M&MB@<J<1BT<J2K;1I';%7Y),L"3J<AVEXYP?@LK/Q,X;Z:P^590I;*M=R7<
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MBBBB\$;GNBBJ(!"I<(B>2DH\<>:^7'E[]>V825+D2DRI89(2D@'=N;D7L]/
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M,[1RJ7JG9F(L[E&%"JTTY>W6[L&VUO39.I[-R987E9=X?L]Z[L(NPM$7EO\
M!QIFPX>-YW:L492(5A-?K@23 ?.;>#M=KU%!MR(UM"E*&OH#9M_OZQE2=R[(
MO<)U%4RK0,4TU7[9V]49KGV2[ZV[D&C\FMJR'C$O6IXKW"U.-8QL#^RV3(M\
MN_9SYY(&K6VJF*UW)[R,Q6E(AQ4VN1=OYL]'U/.)9K@EV%N\SM:K5M3R#Q>8
MN=G3<>Q>_N-LY=#L(O:1W1Q<1W348;L>YLZS!TWY@,3$[D($\8&?Y!45V%LU
M[-ED4F3"S6VQMN1E4%&[(7)"2[OU(I\!IX$LXN(?=B0XY\J,^C@:F)T?AU[
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M$JKSY7P_] ^S.#QJ\2I"IN>85DE-"H%P2Q<C6M2"<US&YG=L.)JE"0A:D2T
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5MZG\P@ZJM"#I"#I"#I"#I"#I"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g509388g89s10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g89s10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?B^9D@X0DE-! 0      &,< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(T,34P-#4< @4 .DUI8W)O<V]F="!7;W)D("T@06)P<F\@+2!3+31?
M,C R-%\@-#@Y,"TU,S@V+3(U,S0@=BXQ,"YD;V, .$))300E       0TRAB
M7B:E1@BSHB:;7PL!RCA"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!SH
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"
M24T$)@      #@             _@   .$))300-       $    6CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #00    8              R0   >\    !@!G #@ .0!S #$ ,     $
M                         0             'O    R0
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   R0     4F=H=&QO
M;F<   >\    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   ,D     %)G:'1L;VYG   'O     -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    !SA"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MH$M<,IH$R6FH&1^[_.)L*VRU[MV2R\- #F-9L<TN#;&[VFQ[V>QWT'L0\^X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ ]@)= P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M       '" 8)! 4" PH!"__$ %,0  $$ @(! @4! @@+!00'"04" P0& 0<
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MJ'=;,Q\]$%R!9 ]6J60'W*Q507.FVD%49\*SE0T0%+CSW'OT_6J%+%5& 6(
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M*<FTQAVSQ1KH9M4S#OVY\_N]?S%0*Q#$*2%&6(!.T%@N6]!N(7)XW$#N0#C
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MO@L#W[;JT_N:VTR]1AE>IU5!5$3<Z)V*JO9"OW*U4,$V*I-UN$2Q4\;4<6*
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MVDM\15<*?BW%5/8I[ ]Y)I1:AG4>$H2'B-#2T K<H @P4M<X;K<Y%>%$)DM
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MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*P+:--G[#U[;Z0,MEAHD^T
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MIY,D/,PKRMCIW5EC<WD_4&GW%II>H2?:>F;N1H'@U+3,*/M-N8OC\,DHR>(
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M$8(T:+FPW>L62Y[JK+E 4.< SEZVR5A:Q:A0Y>)ZKQ\_\=^_KY=NWSHONO\
M$9QF#E0>[H:>HL/YYU'76<KY34KN*\G';9M/Z25A&QG$SR[[FEUXD0&51$M?
MQ=>8DE3RGO\ SV/Z=_E5\:QVY[54S0&D]I[!T0$N=9L$W7M:O^P3&P']3WV,
M[L#=L?4E3LN-*/ZI)LKD&JZ=I&PB@Q5FJ2HSY\J#9$"%"F6W52MJV/Q_\_\
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MA1@DZ[KCP0[ 2HY0GPE)4,$W%F6-2S$]">_AETNUTR.SAC2UN)KB,R1QS?\
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MUM81)F&':WA,TY;X\J60* 22PVV?880E*%93G"L9SG[XRG[^<_?TY_'Y\_\
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M>VT''13<$3G4]O-U"T3YL[$V"ZL8\\ (F0SC$)PB0"H2ZH9'GJP/XI_K\_\
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M0.?+\Z CS&?O_+W_ *KZJ?@%]M=_=TNAR]S=DKWG8FQ_XZ=AU+-BS7:M6,Y
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M4K8<E7J3A6/QG[__ #_Z_M_/+2O+BE8G>FK@_3[,UK^0'B7=P"734I-A3)4
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M@/\ 2@=Y_P"T9L+_ *GGBI7U._!T_P"SA=X?]5.\_P#<9'XI7PAJ_.?Z\_\
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MJ;B6XVSN)UIAII$YJ:V/AQF@S<>!!2E#T#+,)ICU#Y;K&%)5%$N#'K\_?O\
M[I6,9^'V/5B>AWM9W&DQBA2&6(09FZI4^%,?@Q1,6*S(8GB)7KBH0'94ZUA:
M53E/OI)KG(Q'2P]^_6GOW_JN[F]'LRQ#(-[L[VFFQUSG)LTN3VG+EV=M>1$H
M6E(4PQ#AH#H>2^Q]2A_(S1)>*Q)C$1KSA4E+D*5-'6[KY!ZWTTQ1Q=\O6PAQ
M"T3+)%-;',JL-K9R0&B8LN%.-*2RB<W\] E3(N68<%F+'F-P$1LXB?,R'O\
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M]=>M%IY'WZ_+_'Y5]!H]"<#H*,XPI*8<5/C/LJQXPRC&/_8XPQG^C+.,-?\
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M5&2/O_0U\ZOP0NW/:VU_$]ZEZ\M'9GL!8J!;=@W1RUT<YN/892H69Q[7>P[
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MEU?5OX>]-=*W^J06NA:3JM_>:?HMM!*;FVEF!665YXA%+<&3QF9S=W)4;\Q
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M(JGL)]Q3+;BG%I:RKVTK4M24^<JSS9O+FTMP7)C%W<,J[CM$C11*65>0790
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M2VRF3-HT<HP*>6YM+7+C*F6R?H>;CI#9!,MLK8P^S,;(I>DS\9:F.O?X G]
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M2$RPKF&FP];7]GJ'3IDT+7(HX-<A2&+5EM/&GCB8@.MO:3* TB-NC9I1M8J
M#A5);>=3ZETQI_4.H/TM?2:Y8-<)+IFHW-D+=_#D1)0JZ?;QR1[TD)4%\KE
M709P.;U*5JT?J<_KC0-5(YJ,S:E])3JNX?4>+V&4FQ('ADGYZI)=JCT'-6#
M\6&:=4F889AD P0*5+S<Q2/D>F]$DM+![0Z=?Z-IYU"\N"NH;UGNR;A@H@28
M[Q#(%&21R3P50[ZU_4/6_5W\5;].H.LX[BT>V@32Q)=V,&GSW-AIDTD5M'%9
MPI&&2:/$DDA7?(K;650O-Q>L&HY&M;-OZV$G ;\_:^TG;7-(B,)89D3(8$."
MG1DQ<B8#D&+%*CR"HD9TB9=RN7)=E3'RJR1$G[.;57U)+>'QIY(-+A_E\$4J
M(J0+$[.PC91ND#&3EI#G"JJ (JJO;U[5(K^UT*UAA$*Z;IOV<D%B92\SRK(V
M;B4%@C(A(B@V[=H7 PMO_<;^_P#C$?;\_P I/V_/Y^_V_&?^&><%>;KJR=@
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M83N^IO$D6.T5>R&!,EBNS(Z8(4DV7GF:Y<X/;/!_/(^GT]"!G.:H.T@D Y!
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M Q":7'\3HXI+*83,CWY&7&V4YS(?SY>7:A[GS^?K4C<4JJO:,><)HTQ#K!%
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M3KKKG4J%L*U[%G&BMWMQN?8$UPM;&X4PM1*18B$8V]K>NDF8[,A-.&'VYT\
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M7C(G8(#?U/LL"T5O8.O=LZM8$!+[4F*0_P"_L0(0UE;2FPGPNOS.P*,/;G5
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MIK&)L.)-9'Q4X:Q!81 CSFX*2;DJ6^I[_7W^E9'-Z5'I82"#_P *+LHI#1Z
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M%-R_)G3G),PM*=D_),L1H+WZ?I59BQ+' ))8[551DG)PJ@*H]%4!0.  *FV
M:#E4N*&E!Y!++[D5[,*9'E8:DL^CW8[F6'',(?;PXWEQI6<.(2XA2DXPM.<J
ME=GQ2G%*<4K +MM;6FMF79.P;]3:1&8@2BKTFVV4/76&QL)IU^9/4\7F1&\0
MXC+#[LJ1ZO:8;9=6ZI"4*SA2L4@=D.OQ0:1,C=UZJG!PX>?82Y6)?JO('"P0
MJ1&ADS!&:T35&ABQ\N9$BS"$AUN)'DR66'G4.K2CBE=-&[9]7)JVVX?8S1LI
M;ORWM)C[6HSRG<3)P@7$RUALXO+N)1.P AL92/*7R!D7#;RJ3/BMNJ5)]8V/
MK^ZU\;:Z?=ZE::R9;G/"+!7;&'-!2C0R2[#).CB@Z9(@S6Q\MEZ-.7&?<3$D
M,NL/Y0ZVM&%*#=CZ_,-BG1-WJ1)L\'180:X%B$2T&0#J12VS8I<>8X@@(<0>
M!J02B*=AK29$J2]E)*'EYFE>LALS78G*<%;Q4QN5FQU:;Q/L(J)ERPE_E_I(
M1'S$MO"BQ3,N*D:.3G,R>J3'1%9=6\VE2E9FR^Q);P['>:?:SG.,.-+2XC.4
MYRE6,*1G*?*58RE6//E*L93GQG&<<4KV\4IQ2G%*@$QVKZTU\B6$'-]Z@$%0
M.2N#@PEL.JPB CZ$0LXDUDE"D%&Y$/ DI2K<-(?,-M_*$*V9A/>B2/D-H?09
M[GCY<UD%9CA59CAC@ DX52S' \E4%F/8*"3P,UW!GL3HFN"'+!8=N:^! 6JT
M N3AHQ:1 P2BJ6HI$"5NQ*(S93,3 <X8GP18R?[WR\N?,BQ6G%//MH4[=P0?
M0^1^?I4(*DJP*LI(92"""#@@@\@@\$'D&L1C]R>ITO*\1NR6CGEMR5PUH1M&
MF96F4V,L1I4?*/K'K][Z/4K.52UA/K6- E)R$JC0WG$L'&<<=L^6?2FUMN[!
MVY*[L';N R1GMD#DCN!S4G2MP:G@PF2,S9E!BP)$$,39ER;A7V([HVQJAIK\
M]#KI%"%0CBB$# B4G.62.9L3Y-;WS#/K5*],?<^HI:IR(NT->R5C7,-3T1KG
M7'UQ'51A$U+<A#9)2F7%PSX&4A#F$J7'-B'4^4$H>7F?W_+BE>$#=>H"AD?7
MA^SZ!+/%A[I46&8MP%PJ1',/HC29D(>F?F7)8B2'&F)JF6E?)O/,-2<-+>:P
MM2I/XI3BE?BE)3C.59QC&,9SG.?QC&/OGBE0F2[+]<@R)SA??NEQ;8QIA\DL
MCM&D04#V940Y/BO3ERCC2(C4F#6++-CN2%-H?B5X[(:4MD007'4P?2LA,[HT
M_78:R-@VGKL# :(A!#LXU<ZZ*AMEK+"^I5P6Y*G$8[""-@'?Y>#A*<Q)+0O$
MH>W(8SAS*E8M'[0=;)<-!&'V!TG+'N,.243XVU**_"7&:B6N>[(3*9.K85';
M@4*]37'DKRVB)2[;(4K#-<,KA*N#Z&I0:N52? -6MBSU]ZLOAVK"Q86C YP&
M\ >BXG,FV2R)&8#@AZ%G$QDDB1F$Y%SB0A_+.?7P002",$<$'N#Z&C*RL58%
M64E65@0RL#@@@\@@\$'D'@URV[& =FOC6S0I9"-%B3I$%)"*J8Q"GN$&84MZ
M,EW+S468\)*-19#B$M2'!A%#2UJA2<-*E<!^\4V+\G\S:JZQ]1(J$#_>-#F\
M32R)[@M8R)E<G&)!!!-IP<J&UE<A,YM</+?S"%-X4K)FW6W4X6TM+B,^,X4A
M6%)SYQYQXRG.<9^V?SC.<<4KSXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE4O[UZ$V[V"TH]6M(;:.ZLV ",MV4;'BNALT[94)H26#F-6[.@G
M*[:A\^CW$08G0I.)8 X/&&4ASI2M6L>)D5LHJC'G_P!?.H%^'G\.:I=5-?:_
M)7^"$N.X:J.LK5<,SJV&PK4XJ\3<S#M0HDA9&TS@*B$%D1$OT@%:%5RX6V%8
M+K %#"%UM;QQ0G/G_P!^OE_UQ6TK&,8QC&/MC&/&,?NQCBI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7&FS8@Z))GSY+,.%#8=E2Y<EQ
M#,>-&8;4Z^^^\YE+;3++2%..NN*2AM"5+6K"<9SQ2L6JE^HNPQ\J?1;C6[B-
MCRLCI1*JFAI^#&G_ "L.=F$],%R)<9J9B"0@3<QG',/)BS8DG+>&9+*UJ53H
M+\.?0@:XN["24V?,O2\GD-W!R]3AEDCQK(4MQXI&05K<<%(?4^>NQTFZ2GYF
M&Y;4ARND"DRH3B]=)J9]^_N'W5(8GI9HX)+5*&B"<)IJW4*[C1,$H^.K@>PZ
MWL-;LU9(#ZP.^4KRB;!*KP(\BS3ADVY/ 9)&JXLJ*O*P':4]_6H:NGPL>HUZ
M/N6$K5#D*5.F70G8F AO(IFW%+X2L),Z2M$B/$P3)2\YLY4?%R@A&92(S#%R
MF9<2!$;:9/ SP,X'IDY./3)))^9S61=V549F*H"$4DE4#'<P4=E!;XB!C+9)
MY)-9E5/AZ: I5#NFLZ[^MHU)O;HZ:< SK.X:AY+CRM7*9,M(-1"'OR26:14!
MYD>4^HUXJ*!(@S CC1BR?6E8UACOPO.LI",6;-Q;65DG@IRMF93AIE"IE?+'
MKF:'!TI5 =4Q$J46XYJ]4]MS#PNE 1%.4[(K<JR##[./S'XC%4$J<C'9AR >
M&4J>"",X)P>X.""" 1SU_#*ZTKFQR&6[WF5%@MCFLNVM<N.J+&>L+\!J4/G0
MI0TBU'79B:I\4G"F0[8\YF9>8UH(22,N:H"000<$'((X(((((/<$$<$=JDC3
M/2/3>BMK6/;-%0?9,6861A$!A$DW-%+(%7P*YQ]2%1D2'S&8U<@P(,R2^Z\/
MA2C49ASV"SC3+N<^9H26)9B2Q)))))))R22>22>23R35P^*E.*5Q9<Z$/;;=
MG2H\1MZ1&B-.274,H<E39#42'&0IS*<*?E2GV8T=K&<K>D.MLMI4XM*<J5!6
MU^L6F-UV6OV_8]/AV"RU0+:J]633KLN.2 B;N'E@+5'$S(DAA\>HT(FR(,U^
M*MIYUG+>%+RIEE2%*CQOHCUI04O)=VB*F2MDQ;-"NS4\V>G#S\2X2*Y)L<68
M,E$G1^(Q1=4#(DQFH[<9UIJ2EQI:ITQ;S/!'D2"1ZD9 /W FLQ(X1HPQ".R,
MRYX9HPX0G_\ $.^/_P C4;EOA:=(S5@GV.;IJ"B60)RRCL <=LP4 T[,DQI;
MD:+70QD>$CCV7X<14. W!Q%@M18<2(TS#@0(\68_7(K')J3[?THTM=Q]/@6%
MJW%E4EP8V*)&KG8[*8EB1UW'WIZO&2MG(FIQ8*8F0GJ^7CRWEO/TXF1J[$B,
M+7'9C6I6 #?AG]0Q'T+([7DV*NLPXPX&XW<+EER! B)'88B(6\?=4ZAOZ:TI
M+DG+SZ5O/K0ZE7LY9$DDDG)/))[D^IK)F9V9W9G=F+,S$LS,QRS,QR2Q))))
M)).3S7%D?#$Z@.C&Q;6O9K4:*FE8@(=M5H),PU:["PZ_35*AERQ"$1:#B!P^
M(J$7C$!Y-$-"R\2>Z]*6_02,X)&00<$C(/<''<?6JDDD>[PW=-Z-&^QBNY&&
M&1L$91APRG*MY@U<W6M!!ZLH%.US6\S5@Z36P]9&2"<M9 M-BAH#$!L@8(NI
M2Z1,D/8S-+D7L>]/)2)4Q[.77UYY.U85F_%*<4KKYA49"DP(,V?%BRR[SL47
M&?>0T^1DLQ),]Z/";4K"I3[4&',FN,LX6XB)%D2%)PTRXM*E5,F]#>KL^Q[!
MMS^M_9L6UW+-G9),9;;V&<N\6Y-26K0'LK(BTPHI6N'/FG'R-8ELNUU^:B*0
MR+Q-A0WV%,GU[=OE4BD>KN@BPT\$(:JI,FOV?]#_ %VM9 06ZP33KBSR[C34
M2ZTRVV"?;#V.:^0]IP>IN?C$:&31-@0H<5@><9\L8^0!SCZ9)/WGUK(LQ"@L
MQ"*50$DA5)9BJ@\*"S,Q P-S,W<DU!XSX:?3 ,<CV87IV/ LD&3/FC#\6X;
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M\[=C97-[>V^GQ6TLUU/<1VZ6R+NDDD9]OAJ$)RWD<'CD^50LJJ79@J ;BQX
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MP6E&56,?'*^QCA8U)!P*YNCK(?M>O*\<LK3K)F>Q)<G-.SA))3;B)3[+?^6
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MI>K:B;ZTZ<T^ZL]/B-G;6_V02S+E!+#&DDH\"&!0LK,% RH#%R;^<W5?/JH
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MX3Y]D '$PV_3CTX9BM)2I>,86KEN1MN(T(PRVUN>1@@2PQ2#N!W)8G]?,XY
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M:^A%]DCJO-N.6H4N16,.QG0DZ*$8M"FH;L/,\LVY&@D8SI+ ^3B5%C;*ULK
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M]*,^M;BTH3CSE:L)\YY&) ) W8!X]>#P/4DX 'F:SC4O(J#'QG8"5W8+$ $
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MBLB<^_?_ 'FK$Z$H0[5^S;[K\01L1<;4M-=? ,0E939,R0E,"9&V1D=US$F
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M&U3A0D>X%0!-)*BED1&;LW&F:MI3"WUFW%K<R*+B*,8Y@D9Q$V02"2$;('Q
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MYHKA[<6]A*P$DZJR;Y)/"(161BY+HC8KIZS:/K^S-WU\<%<J=(>N52=N-VF
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MAK"7BQ':K.)CT-I[$M\:VW )09,>"Z1BLLN1TR>W=6#M=0^%J@N[.T2U6$I
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M(]WH%M=:H)K>PMV749 4D8JC;P[/&=X!VQA4V.27(TD_0$/3'B2WW5.D7O\
M-;E[ZW6T>]NR;-XXGCGQ]CB5!*9'A5&9FW6S[F.!F>-*;A[!!-O]I#M5ZTXV
MK<!=QK^;%2(V^]=P6]3X73H^,  XL97#4TI.).QYS&)7OJ5AH<U76,0I8TNE
M_P"9V6O6FJ7UW ^C[=0T24027=K':F:ZDFC&YYQ-? IX84JI42!FW%@&R!Q?
M9-.S<HI_ET#21#[2VF7<":HRV\#M)%<O&J74:-)\1C']-SM.2.94HM8[/R]I
M]EMC[$UZB**L *FG5Z6J^P1,$Z3'":J3@(!.GA%.L!$S];>KSS400)L-=21F
MNN1BKSXZ>]#5[",Z:FGV5U;Z*EEJ\TES'?7TTRS3S")T-NPCCD>V5UC<=E;&
MT,N&R:[EZVD65AI4NG6L#ZFPO!=ZCM<ABDR&)1&YV-*BLKAFCPH)V@GXA=J*
M%V'52Q&^B],@$EL56("S"'[UM:Q;P('AZ2,$B*>NC)J\-YA;K[0YR&,BR\+D
MN-+EY3)D^[Q-([1"%B"@D>4@JA8R2##L9-OB9; R X' XXK0-=SO#]G9@8C,
M]P1L0L99!AV,A4R?%YC=CY5P1]B[!$=@5VWIT?7AXR1KN5">R3VJF.\-F&2(
M8N@<1C8I"B+)*&@=\M-9:'OQFWW?&):\(<\9JT:V;IXF)/&5A&4;.V-)$!W$
MA2/C&<$DY)'%9!HQ8R)O!E:Z5PG((C2-UW=L')?'EVS@#-6CIQJ?9*G6K"4"
MRZV2. A)>?72'GZB ED8+$R0%(8RE'B>+=>7!F8]",8D,.>$)Q]L< Y .,9'
M;T^5=2LC]*?/GQCS]\^?&//G/YSY_I_;RTJ#>POMHHP%QSPE*=R=>U+7^,X0
MG>VNLJSYQ]_Y.,>?SS%N!G.,>?/'EG@CMWI\O7C'KGC''KFM2#=U>"]@]Z"]
M6::DW,)#WLZ?V+8=EPX5BGVJ<4JU/'U_66K?U2\ZRAJPE,G9E=C0IXC$&#@=
M<<3,4,!*$'MG>:IJEX^FVD)@%M96*0R2VTJPBW1)G=I;M(XU/CJ) 2Y?+[5Y
M+L37J+V^:\L[",ZM!";6V%NUK;QR HRN3FY$06-9=NTG.1@C*[G)/$TY2M@,
M[@O8K3O7WKN2(6S9YS9>]+8LXDQ20LD4W&KS6EXI)-2,O@#X\NR?G^W%!0Y\
MI\D+V&@?@&^2"$.+5=7OC#:0:<TD\=M T"![AK(ONFED,KRQQ2.TDGB$;I"S
MJF%4D 5R7VKK?06B76NZM=-:VZPQ*T,D@MRK("(#<7J*J&*..+ &W8 "!A2,
M6U-JSM 1[)[^HXX?I/Z%-V8,MUQ1'K8><W2JP9B%BP*LUBZ/4',*0R^TWFGE
M\)KK=JB%1L*P0_DD1C")/@=#N^L/YCKAO+R-K=[U&@BBO"TEJHC.(&E^S*9!
MMV@R2*SD[B""23V==ZXZ:U33M&T_IKHA=(U/1+3[#KFJW&MW$B=1WKP6TJ:K
M/9PH? F4AU6'QVC =MRN% $F::ZR&@?8+>-0IVKXM7JELV"'FVV]%F\76,(2
M#$A+$_5A!"WDXI[(^WYLMLF,6H"-&V865?"/8D9')8P,RT/29;+4M>NDGEM)
MM3NHKB\\!YP\SB,XS.\IQ@R.VZ)(N6.  5QL.M_XD=1]<:!T9HNI:K;B#I/3
MI].CM]-A-I/"TTPEW2S1P6X)>WCM4!4,^$$BLK.[-M*.:#IJ*T,#TBLZ\KDT
M1+"N,RB5!!6.*X*&2HSLX1)BOHB2W6RT)AT>Y.019(1<R,SV7URFL8<]I'--
M"@2*:6-1@_!(ZY(R<M@\DDDL3DD]S7SV&6:WC\*&>:.,\LJRNN]AG#N0=SN"
M2VYB6))R>V*G[EME&)6Z'1-*@]<1[50]A#A>S*T_J)FP70PRD0$M+%?IE8>K
M\6#8!I 06@JLMH;L-='TR,9 &I5K$Q'7W%<@O+K_ /<W'_\ FD_+XN?S%<OV
MN[ Q]JN3GUN)3Y]_[^__ 'Z57G4M@[Z6+L#V)UN/Z\ZAT;IC^/RHG:]=OF@%
MMG3*D)UMK600!VJMAB\T)&.D0[5.G24B'8$QLH?.1*P3FM5^?;87 [-(VYV9
MVS_<[%F[=\L2?]D^N:XG=G.YV9V(&6=BQ[GS)/WYR?/SK=MC\8_9]N2L*<4J
MM?8*SU6DDM/66YF(%>K$&]V!LL7)+9:@1$$-4[%&1\R5O-N,X3(ES6(J<.MK
M0MUYM"TJPKQG!UW*R_\ R5EQC.<J1Z']/EYUDF0P*Y# C:0<%3N&&!\F4X(/
M<'FJ#=>9?8]W3][VF1 #A^M@NO\ 8D'5^J"ZP_R1J".;.2UV&X!*S7)$(^D[
M,BHQ#C@IT+)0>E>(!.4(+XDDNIHX,#65O<1-%;K/$)FMV5)U@,P+O%'&J1^+
ML)*<$%\9+$G/8UV[U-M2O)IB]Y*JHXN)II6G?; A\D9B5P%4;@3@ !> ,5Z+
M/]I8G6)G9]W":_<J8O3"0^LM.T9#U8KN8]>$SGB) W6)X5:G+<8.Q9,6>CZP
M(P\9DF\R7U"'Q+D/?]6RV)Z@U1])ENQ8+>*R7FMO*T^TA!//+&D>YX$)=DV@
M221@%@&&!K=(O;F\DL[F^A,%M)+!)/.'ECO(X2X$DK0/"621-K84R'( ;!!6
MLDU(-[#W;K67MMX5&J%0O^EJKKVL:KD2H42158C$%RLSR28(V"68)F[[,RW-
MK3C9H3/A#[AF!:$F7@5:A@/*:DDUY9W%O'<V5W!<[8QJ-L9H[>>-W7,]O!.@
MF1'&=L<A5LY.<9!W]P%N.HI/Y41+IK7XGBO+N4K</:(1,9'0P8\150KD,%R1
ME06VU<&VZ V=N6B;VI.Q]EO4P3L407H=&<U+,+0705)1.=F5VQ%4G,.OQ-@)
M9F2@5A769HX29#H3[SKDKZ2Y7]H48P>&CLC;/##L,,,#86QR,8R5SGC!KH03
M^#=1W&Q)/#F$NS)17P^_!9"& ;L2I!P21@DFH!LVO^ZG3WJ\8-:3N0'MAL'4
MNHJ94Z7J>RZYMD(QLDE3HT*OH)9L<S?DUR%928QU\J==99DI..#&6(XU19]#
M[N42&-%0G<0 "Y&"Q ')Y/)]BL9Y1/-))M">)([[ Y<)O8L5#'XB%[#=\6!R
M:Z8]J/M?:M"[.V3N[;M>B.[%UU4[]8=%M:[+PFM5G:H/:NKFO:]9T;?LPEK,
M<PQ%J5N.QZX0:M$ 4^58@PBQ%4]K/Z$@Y[@X(^7'RKC!*L""01GD$^>1\O(]
MJNAUXU_NBKR-A6G=6PF[2;O9^*0%5 *XX[2-="!L=R&P&J;LH>/(24RL92N>
M0D11N">(T*?(#0#3YEZ;:QJR^$(3G.4H2G.<YSG.$XQG.<_G.<XQ]\Y_;GBE
M4+WEO%GK4:[0;OD4ZQ7N)1=1:)*3*K4Q,ALX4C.VW:PMZ1'G$9ZALR&,;FY+
M%R4*.PT'##Y^'(DZ9#=5(V>C:8-8U6QTQK^STQ;N1D:]OW\.TAVQLX\63(VF
M0KX<>2 TK(F06!JA)Y,K;VUQ=S8)2WMHFFFD(YPD:98D $X 8GT&#56^UO=.
MY['ZF['8U!K/>.K]B62C#R%<MYU[5U<C5;+TL64(OS9T+:Y T+DMAT3X:5-"
M'IK4MQ#>8?N>IO'>@'36BZ@MSJVL],]26.GSR&\TBPU5EFU%(2RF*%KBWA@(
M+ 2'?.%9%(#-D ^HT?1)A?02:A>P]/P1AY)=1U*R:[@TUDC9A+=V;(5D6-P
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FX0VVA",)2A"$8PE*4XPE*<8QC&,8XI7(XI3BE.*4XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g509388g97s30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g97s30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1.84&AO=&]S:&]P(#,N,  X0DE-! 0
M    $WR^28@X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <Y<6@         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T#\@      "@  ________   X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             !A0  !ZH    & &<
M.0 W ', ,P P     0                         !              >J
M   !A0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !A0    !29VAT;&]N9P  !ZH    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   84     4F=H=&QO
M;F<   >J     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,      C=     0   *     @   !X   /     C! !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  @ * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN(N/V9#2["3<VWZCV%]-?OCOH&K%J-7<Z,6K'@TFHV-K$)1BVD%.)[]\6Z:
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ML#SSC'@!UQX>NY.<\V%[7N-N;N,<UR!3\X<DA<F6%EREI+G V8<UG,^FXSE
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MY\=*4AF^[$:7?:W2ZTGG#G#.NT=D19OHLMJQ*O/5CYWV,LHU972513H1#);
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M2)/-(2QWG^Z*5"H?;(8R1JGS][^_E53=NV/S^%[O>[C/Y7,TV6H(N-.U>:N
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M>*:4>&QZYJ.I\!L.>_GCE[Q5YIX\?;\=>0Y#&PQC?;E4T=32L.<C45R_A/\
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M5];>VGO;FVL[6)IKFZN(;>WB3'%)--(L<:#) '$S 9) '4U!( )8@  DDG&
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MD>3*4;.[9RDPYL@<I68SD5XL,D[$R-V=Z$%MYAXI)BL7=21Z*O:/83A.T5
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MU&^V.77//KXGTVQ5@=OG G'O$"Z+18#5V6I#Y$&S5A.825FC*\N.IKB8 KH
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MK+$^-"Q7%0$C-('<Y)H5(&(@21C?>AEC]4;HX@I!(XL8^'!/%D@ ?""222
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MT@F"(\)ZM86(^1LX[G,26-OJ;Y5(_O\ K^]-ATI1TI1TI6'?A?OX^R_?[?\
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M^<6!E=5O\MLC7C@^ERD(U?2W57N[5'C$J&>+CC9VC5D[Q>,,Z_$B\ )9QDJ
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MM/=UF%JH9D$C%3PM(PP59AE0Q 7J;WM*;*SUG4K+2+PWEHD[H]\$:(W18 L
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MU'44A-1K:8N@.+KL\!0H!56@M:;.V$]BD&6YGM6FP(U%J,,;%-1O^G7Z]/\
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M]W^].E*2WB1H!?<UWD"QM'$D>'P2+:$UJT@)\I<V&OT^9+,S]N;;/LXZ^8.
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M,H<;*I/$R\04*5!!)9NF#\C%SJ,O:.!8H(_X1_#;E&G,F)OS1FA 9(B/CB4
M*&XAOEA\(!9S6?Z*?N_K^?SUU%=17+I2CI2J2YXX(RW<%E:7):VSO*JOI-96
M:X>>@?5M*F+K@K2LD$E^KU=N,R$JNN;"*,P<:"WISG!7M!955[5UMB*I6M+N
M'X*XDJ\S\0&^V&HYU#SV;P^,T=I+4<Q<S["9!8,/-=G1MQ6AY._26FB?)$L
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MY=C^RWXD=K.T6G=G^T^D]GQH]\Y_/+J-W#>6S10C\PR&R,S/<R$1D11HA8N
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MQN-JF<7PS>WW;\L<7]T!=CW$Y+69G(#QP\?C\[\CBUC";&GT$#V7EL5<E\D
M6E7'K+,2</.;RAJ)9QX/G:LI(R&D6SZC?26[VCS*;5W61HA#$K<:XP1)&B$
M_P#(8&2!G) ->DM]<31F.5E;)V8(@89.X'"H&&VXAC!P"<XS4T[4][KJ_?:G
MCDGACG[)YK1FC[2"^Y=VF_Y#K<L5^A,;6FXW/ZC=1VITU;':5)UJ2._2.@BN
M-(LU.&0\O2!9/3K2SZ=>@',_WV\R.F,5L0Z5-:S^[IP-OL=Q7&< <Y;@^;BJ
MNPHFLXONMQGULZC66QAAH==:Y$8913*,ADB1Q_78A[>8TZJV@U3F):^X)@^F
M>G3EX;U .XW QCGTZ\N8\=\[#E2RYGM6X6Y[KL03RSVM=QD<W!67TMWBG[_F
M?FZW)M;3%5>#CAI*RLTVA'2K7<D&B6=+!51TC"_TK%',/ ;76U)1W^C=I];[
M.PZA!HUV+1-5@-O>DQ1RNR895(:16X2JNZ@KDXD( ! (\);=)GC9V9A$_'&H
M("AM_C(.?BZ9Y^8WJ%G< <.6')+=2O99W WX1_$]21]#L-SS0-14FJJJ*^V]
MU()96TD-U+I;&4F'"C1F3,CLBL]#[=+6EFU\&AYFYM+:\9VN((9'<-Q2+$BM
M\6<LI5$P1DD8 "G< 5=6NL:C820RVEW)"\,D;QA6)13$RE#P'(X0<;8 P *N
M'>]@G;GP5DW8C%<1\X;.3?U/)9:;/-<A\ED6V#MZK S3YM(0<F6-3S6%M:B@
MUF:?=5CHULY)9; XJ"&*OFI-#[*Z/H$<\5C%)P7$KS,)G,O"\@ 8@G&,E1RW
MP!N2-^][7?C#V][;7=M>:YJL4DEC96]C L-E9PHT, PBN/R[\;'.6=CN=@ !
MFI'F/AR=KO/5?G-GL>%>2N+B<M9#.FR1O).[+;K ;'.Y;3MCN)],1->1 #EV
M+ZHB*FFS5F-:5EF$;-'/#*(/CJ'9/1-3O['4KNR5[JQD#Q$2R=V2#E2\?],F
M" 0KC&?GG/L[^,_;[LSH^OZ)I.IP0V':.V_*Z@K6-HTIC"-&6MY5B0PNRL1Q
M#)V&W41C%]BW:[H.2+NI)[9>4:#.RZ2]XR'0KDOFP/-U(N-$T5T#RE7SS:47
MYH'DEQSL^V..S.K0'YRDD]^6>X]N?I8F$*LL,<,0=2K=U;6\((QPX/=I_P"4
MXSS.,[U\QFE>=.&X$4S% A:2))&(P0<,RDYWR3M@D]!4RUWPM^V/C?@;E@7-
M9+F'<Z1N4V%Y2.$YAY! ULUY'FWB4HV?KLI;Y_+$6H# 0(:-QN6LBR2!QH3W
M6JJD3]32[2+1K=K330UI;/*\S1QLS@2.078-(S298@$CBX1_Q K2T>U@T&V-
MII2-:6YFEG**Q<F6=^.1^)R6'&YXB P"Y.!7=V7P8>Q[:[?CW>_IOD_+E8(Z
M&S;29GF?D>"EU1$)X-H+'IY+>^NKY(0S@()QI,U>9LUKED]PN1KO2ER-6U86
M]Q:KJ%P+>YB$,T)=A'(JMQ E0W+F"#GB!(.Q(J[76-26.6,7DXCG [Q>]?#8
MY9PV-O#U V-5KE_AY]J5WW-<G9+1]KO)*X-,EFZBEM]-R;R]<\<&'4<4FBN-
M'1&&:N6<BVVL?)8^5TE?97A@D#.,*M:P"0@C5-K:WNU(P5&P !P/#GCR/^#6
M@)' !#=<D$>?+!Z''IN<C>K&VW9QP5V9<,PY/M3X-YMHZJ\O=%[5+P/S;SM4
M?I#1V]#:6D?().6 V=O3WDD-A4UX4ZV]%:#RQ,JZT@6P#A"I2,@@4DC))VW.
M??O%0SEL X &3_2.7,CEL,^G7IRV+\.[RYY*X_I=A?XF]X[M;.2SC(R&ECFB
MNZIM?:G5L"GLG#!>V0V ..P8C1O9]HIGRQ!HWM&$95@/TV]\_0^>:B7<S\K-
MPWIJRPP^EY#J[\FASMKF<E\[]=FK+N]KJ\VP$2N"L3'?1X9W6CVQARPO05&G
MR"USC#!U"<>7/?PY8]Y%:JR\]1G;WEL:;M,[O;NAT>;7*RA2\T=Q&=Q>AH,5
M1;V4:O!K1;L(-U?I0S&4<.</A?2ARMM:ZD#=$5FUY!]()Y;6>&Y@8I/!*DL,
M@X28Y(V#I(.(,N59002IP>0J&4.I4D $$'Y[$9QQ;CP(YU"N</A^=HN JM1Q
MW@NR[E2VL *'*S4G(>&T_*=Q:$SV9QY=LRO*F-M**6S%95#USH3U?\P;=-99
M0YNK;%?2='J/;CM9JL@GO=5N9)<)A1W*1@IC@^&.%%'#PC<*"2,G<YJ($2&W
M-HD<0@+AV4QH^#RP"REAU(^8R1M5P9#X=?9IOLI:<O7_ &::O)ZC&5,RU>$*
MY!Y1=<:9AF'H-BUM<AE]5G/-?8:"PR8T$GRCX;@.T%L!ABVSA!:$G:7M%+;7
M-E_%KQ;.\?O+FV[U>YN')!9I(VB96+$ GB'/?&2:W[._N],GM[C3IEMY[5'C
M@FCBA1X5E_\ $"-P$KD$ABK ,"<Y!J$<:=DG;5L-'>8MW:AS%ALQO&T?F\/Y
M YCKZ7 D7_%MU86:9ZNT!@HEF %H\K(',;I:I[OU-J!TL:D(0BIJ"^3O=&T^
M_MKJWEMTC6\A>&9X56*1ED&&RT87?&=QR)S73Z-^(':O0M7L]=M-5:2_L+F.
MYC>ZCANTD:&59."9)(<O&W#AAQ9 V!V)J0\F?"Q[0\I3<=\71\*<F<@+J+VP
M//Y'9L]U+)0DYPVNTHM9H!,Q.!D:Z'>/]>):>^AIA@*@JUL9;-IXL"D:^C]G
M=,T2SAL;.-FBA#<+7#=](2Q+-EVR<EB<>6W*K+ME^*G:_MUKMQK^KWL=M=SE
M2T&EPBSMD=8UC5D1'RI*J&8\9RQ8C?&)W@_A$]EU[>\7\Y"\:\G<;%)B:0V?
MAQG*F]$S=:?<45C+.-HQS;%^OBT%*FE,KC&5^BIQ'&5PBDUCG!HQ=EM-MGU"
M+46AA-Q$$6*3\O")8PJNH"S!.]X"'(=6(4J<$;D&K7M_VO&D7&A2:]J,^EW;
MA[BTN+JXG@D*G*\4,LCQ'A8!A\!^)48_$BD2O._#*[7]5<=P%+L./^3/T]8[
M4"ERD5ES'R\RM"RT_$G'D1JXA&[-C'4\NFFT19#[?ZV3%JGWK6E,"B$K0+>X
MFENX);>Z*3PS*4E1HHP'5N8. -N>WZ\JYV'4[N"6&9&B9X'$D8DMX73B!R P
M*$,NPR-L[YYU2?.'PP.SCAOC[+18?M=Y!Y./-V]-]?M:'DKE0[1I6T,5GNSY
MM**!=6,15)J696/CFVFJL\E@!6:YKJ(>2S'K:\K4BMXXK5+&/BCM8D"10ACW
M2*  JB,$ *O0 #&-O"L[W5[Z^N)KBXF'',S2.D:+'#Q,225B3AC7<DX Z\M\
MB[\K\);LMS?)&7[@<5QEL^/MS0YL@6KK,MR;N<T2!\_4VP)4#KZNT4.Q#L9!
M+NPKB9@=:-$L$LP+FNKB3!RO-()45HHYG2T>5)7M5CAX2\:E 5E9>]1-R0H;
MKMN31M5N6L7L7CMG1W5S,UO'^8!084"4#C(4;#)R 3@[U9G:+O\ 6_J[5<?6
M'#W/.*SM\-#R6%<<QZW>[L7-&RY?CG/&<;T6HW\9UP0V.Q'M]4\26^(@CGM3
MIZ^!D\E]4Y?:48 &VPQL21]3O5;UY^_?ESZUL&ZFE'2E'2E07>\98#E$"MJ^
M0LE1ZX"FMH+VJ&O (#F5UN/#.*P\-96.>//("6=6%^TYK#JFPL:HUA%<>8+,
MI4Y:U&M1J?A$1/YKX3QY7^?2@V_QM4)WW(_'O%5"NIY)VF5P.<0N(!;W7WU5
MG*GYV:(@B(7ZA;E!B^^Z 4HGVO=]31ABB7(V >>2-3SQG&_O]*]5NNRKO;_[
M1T372J:C(WVP#9%=60J19,]"D>KUU\"+,<SQZA(O[PA(V??I49]^&:ZEGOL/
M2@&6EML,Q75U<+.<<:;?50PH80M;%<E%DD3EQPPC#4\\-L1/(]L4-9+$=(YH
MTC)7*FO&L>7^*JFF9H;+DC"@TDC@&1VA6LHH 9)+4P:OK8HBI#FPRS6!Y@@(
M,,;W2F&DCB#,D(GBC>J,^_?W\.O*I,-K,R9*- +H*6<DR0N$02*T!>45/7P1
ME'#CCM(66:<(::&<N%C72#0RQRSMC8]KE5/E[]_V-5]H>X/@S)5%=?Z?E[C>
M@I;?YWZ7:6^USE<"?].R6EWIRBE%V4,,Z#8G&ZS72K&]R,S>;N[IRI75AA$*
MGOQ\JG..VN2Y"SX.LPVCI=;F+/YCZ=H,[9A7%,?\H5."6@=E7SD!DJ*<*2&1
M[4S_ &2AYH'^)(WM12I1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1T
MI1TI1TI1TI1TI1TI6/2U?RU%_P $Z4JH>:Z;EJ\R(H7"U[GLSL&:2@LYK?2-
M>\!U+1FMN3Z-8FTE\CX=9)7B9*WF02$RNSEW=VE,:+? U3^E0=M]]L[#&Y/7
MWN=Z58C%?$<^LU=P/RAV[/8/.0MC02TFIBSA8LH98L$;H64DMZ^:"9XQZ3,T
M B?-L3RV0**0 M4'PP?4<Q\R<GY9\/*I/F*CON#U%^S4Z+@VQJ+?#Z(NCGJZ
M_0,J\]O:P>D R5=+"0T2[?2Z&6TOKC2%.6XD!ERP4-:R"'1/ K'OG^WU^WC4
M[>>0<C;[9Y<C@=/ Y%>U#4]]7UN>8G2]N+L]]81!@8ZO=.M/H+BW2>9CG1-'
M^K1"QPCN2,)1"/?,?&H<B"OB>_[4P#T(SX_7IN.77'0=!49CS7Q#'7$19.^[
M:TJ(LM90)6A9W:P2%:V:GA6L),F(B,E95"7P;8Y'A$BOEJ;:TF=6J:/5Q"J8
M&,8(SYX^6V_TVP,>%=>DS/Q%*\(_ZAO>VJTLS+8ZPA6>EVS:\ .7^]$I!8PP
M:V=01W1P!QF$O)L6BO/(+FLCB!)Z]3Z_/_9VW./T%1?D; ?$-TIAKL!R_P 7
MX"A"Y-UEF%"92I8ZFVXXDN=*RAHC")\[>TD1;ZLJAG F&A#+$96P1VAA14]A
MYC?/3'W]^_4/GGKOX#Y<\^ \? T]?'D6JAP>.AW<HY&VBR]#'L)Q6PL%GT[*
MH1E],,T=K8$'EM$*?"D+6Q>VYOM-2/THDU.W3_7O].6U3'PG\$_R3I2L]*4*
MB+^41?Z_?I2L>$_@G^2=*53W-5)R]>9VD&X7T.>S.C%U^?MKDW1H_P"3L<M2
MD/MK/,,<RDOU@9K2 P,S;'1 L/KLW:W=A2EB7HU9,U4<O\>^N<_J:6(;&?$1
MANGVI/)G;R4.D5G'!0MH]3!GU]RN''K7D,CIGWKIHSAYCI7,O6QLELIF+&4$
M+  JAQSP>O7_ $.GUWP-S7M8ZH[\0+S5P[/0<&VH]S0::RS)=/77L-+FM(&%
MC*K&T+_F&#7A%7;SOV^BT9,X=Q)6&5U4@))(5\M'1*C /0GGMGH<^?7 P/TQ
M7L_2^_)=!9RNT7;4N94@GZ2(M;OUMF#?.LD!4PKT(,Y[1$6(](AVK,U9(1'C
M3OBLH%2?U]_;GO\ K7@29KXACK0<A.0.VSZ;#E+H9P,6;V@R3[$JA$;3V!#Y
M8SR/I-?I0GRS,&,'D*I[:RB>'\W%52U[?W[W^U-MMCL-OML>OGUSC;<5]*'-
M_$$ FF^K[KMTM82+8@]SEI]@UXP$AR21TXD0X->U!H:^.,4<B>0@V.24R<LF
MQGF'E%?3WC]=^NU3UY'WGV=M]OE7W(G'_P 1O36-A-A>8.*\-E@]SI#:P7Z*
MPW;6V*_5-J37599)V>NLU 7+1050><)C0.<6N+>W1SD7*2%P*@@;Y!Y8Y^./
MM],<ZV!8N+108_+0["4:?619ZFCU$X2-:'-H65X[;J41K&L8T:2R0EX[6,8Q
ML3F(QC6HB(J:DOA/SX3S_'QTI6>E*QX1?RB+_ATI1X3^"?Y)TI28[_)=ZQ.R
MY0.XVY"XBK,;?BUL''-9J*VT.M,B0#0/KS"B)0LXR(AUM>DR7\C39KX<1E:#
M5Q"R#F'.54 >.^#]1G..OCC?U'0U"VXOXBD6*M:%G)G;Y-I2I+V&MU9%1J''
MUX-B<DE?,C(Z*.JDLZ4*62"J>12%!I\G$VX'NY#7%@/?OV:C8YV.QY;$[]/0
MY\O/ VJP@A^]4[,96>4[A&MTDM&UVK%L@=*V >_=H;>5S!8*LBT@46'-_IP:
M5(;69K[*'21PD/B.IK2I>_?O_+TR=@/0=/#QYC/+QKPXZ/X@#@QHY-=VS0G(
M:<AI<=#O9HYJU4K652BCI,.@E@Q?K!%H^:0X:=SJR .$9C"YGOIU_P >_O4D
M XYD;9&V_P!0<?K^E>#+D/B)3>@5W)7;S&(V.R(D,@I-0EI,9+:5RUE>J/J?
MD8Z<:J;;_-2LA^KD335@L98[Q2[4Y]O?I_>F-\X/AS_SY]?#ZR1]/WT.H+^&
MRTW!C+B2WQOZ3FS%=I%B"KXH]&S6+J%O(8VG"R&R8\AJ4\(ILU8-I1A6#%$5
MWI;_ -M_\;?>FV.1],^F,;\_#E@]=\F.]NN#[[LSRQI+;N0Y8XWWO'5O6'.S
MV?P51'6P9D^72WM\C"9CLW4WA<T(>DK,A1O6PL0TR>#"*N6+J;,ZTM5#OR!&
M/$\SCK@\NN/VVI^%1%_*(O\ 5//2IH1$3\(B?TZ4K/2E8\)]OLGV_'V_']/\
MD_RZ5&!X"J0YTH.:[ZGR$?!NHS.4NZO=TEYJ9M/"^8*_QE7":19Y!B1T=Y**
MNF,;6UYEF-$*?75:G$5Q3#D'15".7/Y'EY^\^E+<#B_B(PZHJV.Y,[?3*&4<
M\:#/,I]*.#$V6*GC#-:C:&2R2R:X*S(]9%P6".3;O]P$\ $6N13 .Y!Y\CR^
MF<;=-M^?/G(,73=]HEUR%!M])P=9#6E7/9X4BGK[X:GHK9),E6!T3D(B?<J$
M^N U]X8^Q%O'"WMM4.AM+*K^9HJQ4<]\$?8GGOSV.Y\,[Y'6N[+5=_*W1,K-
M)VTK0R"G?*ANJ^0/J,)RR3.K'RE(WV90$<Z'Y\3VF$J!&HHY[#WNM.F_O[>_
MEYU/KD]1RR/ISZ^9\^5>2;F_B$*T.<+?]N#B8JG0P$B3YS9#UDMP6&#'GC4]
M$9MBL-98"E%&PQG#,,#L"0U8LJA&5JGAC/AX?/&WEXXZ=178S&9[^JR^ 2]W
M?;[;YJ350GW*OI]:R[_3"F-<;45'R0-;7#$+7Q1Q@SEQE/B)FF<1.3X255/,
M C/CC[[],\ACD?'>KN0>._B1Z(L0O$\Q\7XW.5MTI9E1!2!E[6_J![NIM[*M
M:9:YNZS4,]DRD-S^3)0BH6MRFL)71K+I 13J]4$@>/AS/ASYCD-\[X()YUL9
MSD=M'GZ6*_>-->,J@&74H;5:'+:H+$EC(*U416C/+]YT#51%2)6(J(OE$5(Y
M?ISY=.>_*O9\(GX1$_P3I4UGI2CI2CI2CI2CI2JLY7XCSG+U7GZ^^L--2%Y3
M0RZC-:#'WQ><T5'<%9;3XBP)KK01'/A=8X_9ZG/SO]MTPXMU.;6R@W(E;9!*
M>_W_ %%*.5\,7M5--L[$O.:(DVS.Y*.<3-IBWD"/Y7SS<QK8Q2'0J0[YNH8P
M=23)2SS%C:ZZ,ME\ITJ-^I\.6WZY]YKSY?A9]I93+Z.QRMQ9IHV5<=C(9<-;
M.QM4906$7R$X@(LM<V<RA57PANB'!"N]#34L-71V?TV!4G)Z_7)_>N9?PO.U
MXX1P)%?L/EI::\IIXHM)'#!,W3<R-YUT%J@D58P,>\M=W' XBQ#'&>RE%%IQ
MF#C"P+&P/#S^?C3?QWQ_CZ>6:F6&^'IVY\=\@9?D_-T5PW8XS4;;6YJRL+N8
M[Z=:<@"TX6D3T/@8L\18U('"LT[Y+*:)TL1]@=$T9@ZHWY>?U'UY[\_7:JRL
M_A/]J&CK*L'54>AO"@(>/H3+-M^55%7C.,^/H^+,U'<I5L&0P>7!LDS]V(]W
MR=N'86\,X[!;0L614Y(Y<_\ .?\ 7@=Z=#@?A3,]OO'-=QCCR+ G/4]E?&UK
MK29I!D US='6L #Y6LC22.L'+AK8IE:DQ48C3"W2&$$2R*;[YZ_KUR>OT%7'
MTI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1
MTI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1
MTI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI1
-TI1TI1TI1TI1TI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g509388g98s89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509388g98s89.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]Z^4(8X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-#$U
M,#0U' (% #I-:6-R;W-O9G0@5V]R9" M($%B<')O("T@4RTT7S(P,C1?(#0X
M.3 M-3,X-BTR-3,T('8N,3 N9&]C #A"24T$)0      $."-C<$/7KZSG)9
M<C22].,X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <Y]TP         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              &@   'K0    8 9P Y #@ <P X #D    !
M              $             !ZT   &@                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   &@     %)G:'1L;VYG   'K0
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !H     !29VAT;&]N9P  !ZT    #=7)L5$585     $
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M!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+'/*X:<<E6RMN^S/:&3LIK-OK0L[34%@[P&WO6"QKWBO&LD4C9[F5 _$D@&
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MOT[0VVON8X*Z"R(OC)2"]5]!E#,NTG5DE%G,.-:ICK2.:H'H("#6,(NA;DZ
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M1&^]85_\TG_\5_+_ %4Y<U:RCD,^%>%_**G]47BIJ(:1??>6_P#^JWJ=WO\
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M@24H121!S!7B2SM):^)O-]F-2O\ 4-,BDU2R&G7Q>7O+8-D +*P5UR3LXPP
MR%!QG(KL?XN]F-$[,]KKVV[,:\G:C0S#9R)J\**BK<R6Z--:R(K'@DAPI;BP
M23L,5>A%1?7I47VGM/2^_:?U3^J?E.=+7RS/X[UX>JHURI^Z)[_E_P"?XXJ"
M=B??G]O"JB](]W:GL;O7R%ZVLRX$K^F;/+U1-;/G*RKLA3M4+=7%6V"PJMGJ
M(["KDRXM%:?6'CUMB<;<3L=5T#:V6LE>/OW[^H9VSU]^OD.OCXU;MW^R[^R_
MS]?R_K_+^_%356?&:*6&^\I&316$+W>3%W.UEG;?>REA)ZEZ?(&E:;\^?Y84
MX\D4U95_&U*.MD$I/D#?;_IHE0/#P'OH-MMO&K3\5-.*4XI7A51$557TB(JJ
MJ_LB)^55?[<@D#F0, DYVV',^@ZTK"]KO*##4!E_;D/?$/*((*"$QI-I<6UB
M7"!4T=,$CD>?<7%@2-7UH;%:LY1$;5?&Q))(YC5[AQ'$ 2P+%V.$6,?WR$__
M  09)/ECF:@L!L3ORQU^W.M8GE9%Y+RB9*XZDR@^][\N-MDM->9  FC+ ZLZ
MGR=U%J:7/AV=ZX.L@^][K-YY^KN8WP7&YL K!*KUG,K6AT-?K.N:II*6T&@:
M5'J[22&"9))FME-O/&\5S>R%70$QQOPV\1)5N(Y1F#<7T_\ AKV>[!:S=:JW
M\1->NNSNDV^EW$VF7EM"T[W>KQ%3;V@A2WG9T/$QD("8 4%U)%;!H=OV&&$G
MW#I[333,8GQ)G]1@[.!7^O2K&MW?YB5(VK[5/BA^-WX;\'OWZR/-)P!FA(/#
MD[A@K9Q\R)ASNV0% \]L@<.-/TUY62'6(UC[PA'GM;I#P9."0D,[;K@GY?')
M!YUG\&NWNT>TY.^9NR^K='UA]O[AMI\X-H<U<T,MM56<+(DDADM%D'M4$2MA
MCFLJN5]?*\M%@56?!(_5T_6OYV\O_P"%WVF#3#\!B^9&:\: LYNX.[1 L#=X
M0H/'T^8D[=A_$'L5I/8P=G?Y7VNTCM5_.=)CU&\;291*NFSRNH2QN>3K,H^9
ME:.-EY,-M[T:0FS"S]V92P*5<"U1Y%6,D Y2DV$0TCPQVC&6U").Z<AL<382
MKRF&D5Z-GM:^)7%Q6U?.#]O?U_*J8>.MOC/-CHK/]E]GT&:[&SY^GU$F-^_Y
M &K,&KJNP(I8"["K&T6GKP[="1RB(5 L54-D=5,_X;FO^L14]??OWY5F<75O
M6_7'D'T8/@L+E<A%'UEWO7QIGZ2OK'LKGWO5%K]N;*+!'*E>RQ,*,B!1_P!+
M#//(Z&)GOUQ4<L>N/P-6VXJ:<4IQ2L*[$U@^'QM_IB!Y375H$C@JP9S&EW5J
M2K0Z>A 214:^ROK8@*GK(E]?./-'B145Z>_20FXECA7;O6X6;HD6"TLA_P#6
M.,,Y)V &=N=0QP"=LX(&3@<1V'XD$^6:UR9VU[>Q78&!9D*.QVY^OU>P;VH;
M2SU ]6X'-GE071$T]S3GFUE<;W)HNPRZ)8Y U;F8PZULJ_1A."Y'7-5U5=>L
MAIMI)<61DECFB#(J164,*PVW?M("R2=X6DRI!9U9#GF*OM9J.KZ=J'9;1]+L
MY;F"03W>M/#)%$D2W,49B:7O8Y 6 >->(=V>&*122>5V[_L6F=3V]7OLOJ\L
M"=6'AF3V&<BO:A "!9H#9";"F9I\_&,D#I'/CO4BBGB56D!20_-B6[34A \-
MQ)'):2Q 21,W$0KH.\SWT/\ XE0H&#\2LO#Q C&V1KY$$B7,5Q!&.(N[QEHN
M$ ECWL;R(5 !!+% >$['K@_BCC.CLYT=G,MTB;7WW5<;[]M3.RJHJT8U#KDZ
M>XC(KZ+-Y>LE1Q\YD,DCJ:)Y3&J\B0ESG3/MKS7I>U4YUF:[COYKI$5[I)7G
M5S @B50\K22?*$Y<6%(8@#.*]:7=VEQ:PW6FW*2VS,TEO-;R#A'S8)#1M\CJ
MRX !!&.E0/I/&:WK?.GHKL_$]CW.3Z^R_778;#NI ;/3.S)ZMDKJBP%!J5T+
M<U55MI8[3(6[ZP>B4*(["@3Q#(7]&57\P]MJR:W:O;ZLT6C=T[WFE-$)%N;I
M T<<YE?BDC:,3@H%8(. ?+N:^SV/:[LZW\,^TFB:IV5M-0[5W.J:=_+>USR)
M'=V%I(>\>V,:P]Y.SFTF7O2YS\1B1_E53LEYT5?)ZJ\[OLW_ (3@OCU#!1R%
MR8PS<ECDLU0&@@S0[1QX]"'.9FALK;ULMX7%GF"T]U8D,*@L)3"PR*\FL:J-
M_P#>-_MR_/'0FK/2(JQO1/W5CD3VGM/:M7U[3^?]OY\5-4#_ $X8H8>E>S8Q
MWNDA;Y8^6/P/>4\USD7O?:N7XBI#+!\JHY53VXR?X?7P(YJ-1C5*O_Q2G%*<
M4KP[]E]?A?QZ_G^?:>OPG(;D<'!P<'&<'H<==Z533(=Y=6VOFOW-TV%K@).S
M*3I;I\JRS'RS&E0CU&C[/MK!WU$@C*^68.M[#Q1I HY;R8A] %(^)$^;\N^N
M-$U6+LMIFNS6KIID^IZC!%=\<3!WX;9$+1J2R+(]O<E2P /=.H)P*P)+$UQ+
M"I/?(BNRXVX#L#N=L$$#QQXXS<M')\*.54]*GOW[_'_:O\N4.1C.1CQR,5GK
MU>Y$8]R+_LL<OM%3\>D5?Y^T_E_-%3^J>N <[ @GPS4'8'TJ@N"\GJ#2^=_<
M_C\)E]%#=9+K#",-TTJU[\^2Z@F*TLT438B7V$3B8.W*@<5TPK$?+3VSG_#$
M@LD_,VVOP3=I=1T(0SK/:V5O<F8H3 ^<_P!)7ZN!(&P #\IW(%?6M5_AQJ&F
M_P )NS?\0)M4TQ[+5M>OK.+3(W<ZE$62.)99(\[1YLW);A '&@R<U?QJ^VM5
M??M415]^O?[?S](B>_Z^D1/Z)SIZ^3#<"O/%*U@_JG0D%]/]?  Z/25=@;V.
M9&%0YA,2ECK$;U=V6IU)')M**UB;'9U[B*6PAJRPRRZ.WMX9ZG="_-P.E4Z^
M_?X_G6S85/A&@3TC?43/PGX]?Y4])^&1_E$_"_\ %L_/X^!O^RBH'UZ\ZK_E
MO^E9W?\ ]0WC-_X\\JO_ %_]5XZ_;]?I[WZ5..?F?T&WZ_6K$<4IQ2G%*<4I
MQ2M27ZIEL5KJOIGH.JE':9M-%I^RK6$NS96!D4/5.=DECKS2)(IHF?67^FJ;
M*NCE:UQIN=4<9))FK&O(=N9%C['ZL=A)>7>FZ9 7 "F6XN!=3$,<GABMK24.
MP!([P#Y<YKGNTVA7W:?3CV?TT7!O-4FAA06\YMCW2MWLW>2B.3$3(G P( ;C
M )WP;D>(N4;2]-4ETLI[R-G++H6SV![+(Z6AA%#S.%:8;&*#&66)UWG<B"22
MH<#R"AIR)8(I9I&)U5M%#;V.G6=N<P6.GVMI$0P88BB4.0P #9E+D'&PP.0K
MIGM9-/AL])E[X-I%I#IY$\QGG$D2@S=],RJ9G$I8<;*"<9-2K0=6@Y_>:?L"
M'2ZJPLM8*"%8U=H<(110"U<Y<]5$ %$!!,-]M^X'Q"N^JD7Y!DS"/GN2)\>X
M\YDAB@,<*K"6*LJ8D);&>)N+!SPCIMC;&]9I;QI;:&U,%LJP%BDJ1L)B6QQ%
MWX\'B(&?E&<=,U*']_\ U_\ 'F"M2G%*<4JOOD?UDO:?7-KEX^Q[/K!;"-PD
MNA /($@:&=+%%8C'"QV=6)81FA*0$R,Z9\8[BG$11NG:SE/K6D3ZU92V5O>7
M-I++@=[;ERZID%E"1LC'B4%>?(MO5/KFB7.OZ;<Z99WMYI\URC)\18AFE57(
M[S^FA'&60,@R<*7+<Q764/3]3)X_$=6ZKL?0:JAMJ)M3KML3=S(7>YY(!Q="
M'&>4=8I1U=Y1#EU)SZLZ%U>,><;5$UY_RBH<^E6$VFV45E/<3W4T"A'FN6)E
M8A5 X@2Q38 \)8G?).];&EZ=/I5C;6%S<W-W/;11Q27%YQ"XD9$5.*17+%2P
M4'AY DD8! %:Q?$'QGJM1,;K.XCK^*O)I*TK-Z#L2"OD>A'5+.M*"GOBA+<&
MUD)L<<"PV'Z5]0?J)V%V-Z[0L6%PEC5A[Y8J4^SO&KJ;3Z1VAONPIJ#2$MR
MQ!5E%BC76A.2FM+^C(.K]!2D5UE9R0U\4,I,H4A4F5H#:2!T-69;I*I_OG[\
M:S/QZ\>LEU ;HM3D-S;:H#>05=C/$DP+LX2;'45(,VA!;7K)$23<LK(;.0I2
M2&_5V=M,._Z>PCB'4JT?%*<4IQ2G%*<4IQ2G%*<4IQ2M;OG78LSG8OB5JX#<
MDZYJ>W2!:"MWMOI*+,?<[$ 6)2'6.:J9T&M"(6K659NBL7T )AD,A5#;P2&D
M5JHQS_#;EZ[]=S^?2MC\:HK&*BHOMC5_']D_U7BIJ!<K^/)?NO\ UZA\>U__
M +/Y"IQ4=?H>OIT_7I]:GWBIIQ2G%*A/ORU.$Z].H*B>4>\[!L*KKFG(%E6(
MX"39%-J+6_"].:LDN/S4M[M9F,<UZ YPR5%1(W*FQ9JGQ*S2?^*UCDNI2?[>
M&!"X5L[ R2&-!SSQ;CEGRV2410>*21$4#F2QVQL=]L#/4U2?"X_KS=]EXJWT
M5?0SCR0:YN2:2/%%9B)IHH]1225!;?A-#(H\(3UY25!=;,,15251$84D+V>V
M<'+;V.IZW!>W,:RLB7T4,@[T,DLY[QY0R\&)$' B,>(J>(J5RV:SM#:VMWVG
MMXI50_R>S&F1;<3&;N(Y[IE89PXG?*R(5>-N,*^2P,M=S&;3IP:F[,F&.VH'
M6#;,M+T:!7WA. M( X]QCM1&&/(I*?1UU=J,_?BBPPE:7'YX#1-KQE-M[+M-
M+27OCI5PYEMM041P3D\307,9"P=Z,=>)XRZX+";#;J,QW\E@T8NF[VV# &ZX
M&>2 ,2,W(4@NJ@[2HI!'_EP1QGD^-3Z[R#\=.O=9:Y\_#W$*6A>7L:ZV!+O:
M)Z6AT0=Y27PD"B2QV WPOE"(&,IK0-[ZZW"M*^<B";+J>C1Z3<SZ2TYFDLV$
M;7 BDMV+LBR, DGS_(7*$YPQ&=N5=8^MQSW=Q>:?/'=V5WPB2*17:VFX4165
MTD"MD.N1(A! (,;*VXPG8>7U[U'Y$]+^-?88(I]UVBL: ZZDKGH':!G$$5U,
M9,%+>P29VP2Q".&N@T'O0V11"V8!3F&SUM7R-YVDAT[6=)T*>"22XU-&-O-&
MG],!,@]\<GNR ,G8\QDXVKZ-H?\ "ZX[5=@^V';_ $NZA@L>RS0B[L+F[5+K
MBD42/\..Z(G3@<=WNKLP92H9>([$F>EB3XO:(J+[]_OZ]K[]_C^:?O\ C\_G
MG4^_>:^1 '&"=\<ZUM^-]@R/SB\P:FHNSI*&9<=8$U!&1%E@+O1Z2L%(M$[&
M2VL+J<BKEEL:=F3OX0QXJ^41^7&&!I;2)7C^_P!=_P!O3TIX?CT\?/E]_3K6
MRAW^R[_^*_Z_R_I_/BIJH7B6L2G^4RPH.C%\K-NJ_38BVZ^C61<!U=\U74-U
M_P L,G65'J5LHO57V,2LW85(C:74 -1[]*@>'D//Q_:K?<5-.*4XI7P)=\$$
MKOY)&]5]?O\ AJKZ3^7Y]*GY_KSPX)5@-R5(^^,_AYU!. 3X#/KY?6M%_BOK
M]-V!YC><!M:=B-G8U?<DM)U4!69F*K#QC  R\GJNQM:?7?3MNH@JRM#S-3*4
M?87MUH$VC<[/E0-IJYW]AVHONSZZ!V:TS1&#ZPEB6UY4O!.T4SR++ DT0D9K
M4*&>5H@L(=&AC82,@=>C;LCK>EVUKK?:&SNK#1M20R:6\]N\!OT$:$+92N.&
MX!);O)(^(0@_-PG K:7<TU9U1FJZ>39RU=UH-GE([_6W$U!!:ZJTNK>OJC(3
M)K(&4%7/KY)(*NNJX!8JD($0&JA' #2#GRW7IO@;>UD2[%DSZC8QS2 \*R++
M)PR+@\7"K+T!^7ASYUH?$_%S%9(D[B."5+6%5;@A"I\B_*1Q,Q_N9B2S').^
M1/+C(%A1JSP.56HU%25JJOMJ^G>T1$]?CW[1/ZJB?CEV;BUQ@SVV<9($T8)"
M_,<;YQL/\XWK^ZDWPC@X.Y1MMCOR\*P#K=M2LFR^V/&D6+:6L!*C3MG2,B.,
M1[HI$:]Z12M5RJ^/_*K?B]JU/YTN@3VTK:F;:5)A'J=Q$S),LP7  *GA)X/F
MYJ=\[CEFMN^$A%H7)/\ VL6"<_\ %F&-P.6 #^'2LYT3A&T-PZPD(A 2N+4V
M824R N$3Y+_J)1IJZ2&PA(CA^-\,P$L9L4C6R"O;.V-4Z2M$^_V^M:]/TO+(
MQOC(P*TLCWC56\UP577V.$SN$AHP%G$+;6 )EK"SH[\9TQ)%G+;C'F2C&V!E
M&485)3*0]4$[^F_,Y^OZ>/05:?5RQS>0W1TD+VR,7K_O9$>Q4<U5:?U B^E3
M\+Z<BHOK^:*G[IZXH>F_7]"<>53[Q4TXI3D$X]]:54_OG4D%7H&=K6PE-PM<
M+V&>)(KG0'[:U/ERG2&7.B<Z)LL-QN)3M/')!+\^NLL-32S_ "8;&"5^83&T
ML+J[92))5%K#C=@LAQ<.A&_%O'#MGY)GV)K:L81<WD,+ =V3WDKL<*D47]21
MF)&  JD$YP,[]:Y/4AV*Q L3[K44PDUN@F1Q;[ZSKJZTOL_A(G5/W 2(B89;
M.6[O9[O2/+$BG<2R^&E?)(R2!4K-,@FFCFFBAEFB4B,2I$SJ(H0RJ\D@!X5E
M<-(I?&1GGSK2A6XU.[U'4X[:>59+F1$*1/((+:-V2%2RKA$;YC%GAXD(K(]=
MV8%K*BXHNN*<CL*R/KSP(# !&38>&>86<=LMSIK BMSE@ -/*QMI64UI9720
M_.8RN<YKU9:BSC=N"_*0V[X617;,TL9)XTCC0.X9TXU!=57YMV WJTBTU&8)
MJ9C@M9 HEBD(:>>$L.-(8DXWXF4,N750.(G<;&HGC%1GX/I[(1=HU];TWLII
M;B5=SU/6,J.K[&&:W,^A;=P?46M1$3&*Z,<PG=5P$,YLDWV$QLSV_)]:EH>C
MVU[/%V8B-E8QA#%!B-)Q(45G+1(J)*IDXS\JLQ4C+9XB<&I=E]"L[B>+LE =
M-M(U1Q;VG=Q.795,C/;\ 6<%CGA=6;<'F :D(O2V\'EYTO2ZH306YQ/6?8"U
M&PQ]OH \!8!E%T9:2:#*)83T["6I6?+E)DGNF*>1FIV2#_"$@'!2WDD7:[3;
M.Z,QEDT^[X'A+K;-F1<"2$@JAPA#-Q'!*[ ,,<V-=U6UU"V[-W&GM)9WL<M[
M)J<<']-)[3"P12L_$\+E996X0S*6*[ $@7]YVE75:S-C<,S/ZF&#E$+RMC9:
MKQSLZVR9?VVL#U-;G*K1:FTCJ<#3U5#'CK<B>Z!=:&A6EG=[$X66\G$;54U(
M!"8J!U]>OOWUWS4C5/ZB'CI?VN>H@K'6QGZLW-5M4TO(6XO_ "K6_:DJF&13
M,C)#=_SHYI,1$$<T$P+X'1K):YA+]4^_?*L=_3,+)/Z#[ .+4QTYGE3Y6E?$
M>DB&.B([UVDPSIVS2S2L<X9\3D9+(LC&JUCVQN18VA]^?Y_IRH?MR_+]>=;#
M^*4XI3BE<<LF,,:8J5S&101OED?(](XV1QM5[WO>[_*QC6HJN>Y4:UJ*YRHB
M+SRQ.P52S$_*!N2<C  ZDG8>="< GP!/VWK67U+USC^U_(?N7LR^REA3;+L'
MKOJ#=Y#L2IA%I-1E<F5?]OT6(^QZ :9F@KY;W&YS-VNCHK""2LL;5]S1Z.NL
M*<:( CI]0U*]@T+3=+2Z=[*UO-0C>T+=Y;/*ZV+RL\3#NV=9'D6*0J7C!)1E
M)-:<;(;R3$3!^Y7,C#8AL[#P WYGGT&=\[\B>_MIXL=1ZO0=HWM.-1AQ!UV7
M[K;0'6@0EK:GP5M:!V'@,Y!8VPUK,V=C1;[(UEMG;:Q^?(3095JUM):<O=Z'
MK_:6U?2^PWP4?:J[C8:=::FR"U,B?U)'+2.BM&L2R,>)@0 ,EMVJ[T9]+AU&
M*;7A.^BP,9+\VIX9NX48X58YX69R@ YYY$;&LKH_)$C6]>XD_ DY[LBU[+SP
M)V6U6')FM*-E=.'7RW&SO,R8VMO:>MHX+(8Q^;D6:T)L9P,M+.':6$3VTD@[
M4=GG_EG:+26_F=F!;7TMDK-&+N$<$S+!P\31=X&,9A>8.F"I8$$V4%EI-]-<
M7]O=-::3$QGBBO6*3RQ.Q:VM8I8RW')*H"F9UB6,!I"?EWZ;I2_S%?Y+=F=;
MT DI!%9T[U1?6]W:G"QZ.YM#]EVY/;6MW4%0!7++0^R.GGL7RA##PQLKU'@B
M +K(8MJP%B\0O;:ZXKARUO/9F"2*</"<R2S22HA)_K !" 5PV.($XV=8?5)M
M)LY;JVE2T^/N3;M$1\!$CPV\44$!$K B-;9EW#-D?,Q8D&]K/7P,])Z3X6^D
M]>O2>D])Z])Z_MZ3U_3EF#D CD1D=.?D=Q]:Y7E7MR:5K]_48#I+3I.NKKJT
MRP$7\7 '0C:W_$& .TLF5-[5Y@:EL.L<YHMI%I0-I;YK0@56;CK[O25U';T0
MEK40&&6]<J,;\^F,=-SSR=O6N/W1T[Y;6DF7K_&;MUN+QM%U169P8C<;>QLK
MNUU@^HI2@[>YCT/5VZOIYJW,U<S;6ZM]39W&QEL9J$X#-N^XZ6T>_?O_ "'(
M[9/Y'D<9/KY<^M2OU2)M0_*/R#9M[O,WA4G4/CK/239C+6F5@ S4F\\HTJJJ
MU@M=CLWW%X(YI3K"_#(HJ^P2:!@V9JU&D>4J??\ OZ5;/]N*5QW%0LD2)7*L
MBI\2-1JK^/Q_1/ROY]^D]JB>W*B-151]O3(S]LYJ"3@GA8@ '(1BNYP/F *C
M)\3Y\MZY'%315]?E>02!N:5ZJ]J>_:^O2>_S_3_R]_R1?2_Z<\-(B[LP QG?
M; Z9)Y9Z9QFE?GV\C:2_\L^X?)2SQ2F/GR(N&\:^EC0-&9013;<#L$AVBT41
MXD4T\3*;41=O4.S @BE4_$9.*RD<D+1WQ[NCZE!:=N-"LI5CDT_0=&U#7M:#
MP+<)\7K*BWL+;@<@1W,6G0/-$Y(PU^H)P372=DYA9ZT+V5@EO:6DYN&:,2'A
M,;RLJJ>3Y$*J^0065<@$UNZZ2Q/^&_4/6N!^1,,N/Q>?SKHB+-;HA'U5= (]
MT]JL4/U\LCHEDD);#$Q[GK\N-D:-:DWUT;V]NKL\.;FXEG^10B#O'9\*HV4#
M. -\ <SSJIU.[-_J%Y>D@FZN))LA>$8=B0 N^ !@;G)QD[FI1YJUHTXI3BE.
M*57OR/Z QGD=UIH.N=Z9>C4EJ(0R.2EO#JQ S4=%.!9E!0SQUUPZHL!A+0$.
MY%/ 88)%(^!?;E7<TK5KG1+Z/4+<Q*\,A;CF5)$5.'AD!:3A[I6C+H_ 0P5B
M%;F19:5JMQI%VEY:K')(N!P2)Q<2D%61>'# R LF5()+9R"!CA4WCUUME.A9
M.A:ZRTM9UK/5@Y<UD^HL2#Y<],E?7VN=%M3R)R*>NTU='/2$P4DE?(-';FS4
MBUUG-$3'XO-0EU2ZGOIV1YKB1I9'CC2-6+L6# (,-D$88Y)7AW.!6/4KZ?4;
MR6\N$CCFF8LRQH%'-B PZLN>'B;)(4 U5H7QF\4,SJ9I=;WR7;14$@@Q./U/
M;=8 T6NGZS&ZD&I=%\BTK[=T!^8A$B*5TE>7J#OF3:>;0NDA:/J_[]X^@_.M
M'?\ ?;]_?AOO4SZ'Q<ZL[3O+/74F^NOOPS:;+W5O4SX[3+);8:]%NAV:!EO0
MW(AV@K[JGSP]C':12$,IZ6+-300UAI<$DTKO^GLCU+T=;7]97]P#WEMJ+:LS
MLE)?Z;-S'Q:G.5366%6%&UZ7YEV:TYMY:U=F=9G0FV9-E%&/]W)>0I[]^'UJ
MSM/=5&AK1KBALP+FI-8L@=G5ECG@%QM<YBR#%BR2CSQH]KF_'%(YOQ-<GOVB
M\4KL^*5QIS!1IA!YYXH9CYGCA1R2,8\J>,><M\,#7*CI96BC$DNCC1SVP#S3
M*B1Q/<U2OD79  .:TPL<97K"UOSY8XD<X@F(,=C5D<WXGSESPC0L;[=+/-%$
MQ%?(UJJC(]^_>#X&OO\ 4P?4-%^;']0^%Y#(?C;\QT,;HV/E:SW\3F,?-$US
MD16M=(Q%5%<WVJ:X]C:5U0,IEH<+7B(^.-Q)D\8T#9)7I'&QTTSF1M=(]S6,
M1SD^)[FM;[<J(JH) Y]<_ASKFM<CVM>U?;7(BHO]47\HO%37MQ2G%*I#Y16%
M8SMWQ3IGT^'LR[SM(D"VEU/7><VUC%0+3SD?2T=O;EQV6.-*LQA9X;>J!-:]
MU<YA<@S8HH3E1G.<=-N>-QXX.XY;??PK@]B^-OD7J=#<V^0\LM7CJ:Q/LC0*
M"//-+97"6%O<6,-1"4%H*=K1*ZOLHJ (B$>&PC!@@,>9+:U=0:(I@'FH_7'7
MQ&_U_$BLXZ9H]?0=_P#=@&RV#=M8,ZI\>E%MDHA:"6,%MWWU!&*7 *8:PPKZ
MB$DN:P5\+IW%(SZ:-(4<]3'+Z^)\-AX=/T%6TXJ:<4I_Z_[>03C'F<?>E4O\
MD-,R*YL6_7."AZ[ZX.O(2?;F('O>X3S.I^M+*)[&JYZ !_XAM-^!R*+#8"3O
M8]'Q>O%U<K9:+>W1.3.PB7.^8HN!I#CP[R2#/,$(P(.X.W8+$;N.6;'=6H-X
M^1RCM5>:1B2".'"!2/\ V ZU/?3F89F,!G09 (@2Y!'6Q@[&Q^@SKF>6S(!B
M<UJ*L-<\GZ ?XE56C"P,_P#<3UJZ? (;2 $#C=3*^PR'E^8C..@(!^V3BJNW
M#,K32+B2>22X<G'%WD\C2N"1SQQ!?#"@=*RS;5(MUD-34%1'/'M\_;U9+:B9
MPEL^"P!F$E;6%QNCD%L',E5 B&/:Z$GY4K7(K$Y9P3-;SP7"=WQP312IWJAX
M^..173O%/]R!E!<;94'<5L,@D4H>3*RG;/RL"&P/0GZUJH\+NL.U?'+QNP<W
M4+-5986 O2':3J#NE0BM)6R&7ACI+;%Z;$UWSZ>OG]*<9239W:*1'),91U\-
ML\D*SZ_MWKL.L]H+R]U""WD?%O&;W1U9 $CMXP&EM[A\W!3)#.LL;E>$+QJH
M6JZZM;K2&6*W)GA@P9HV5N\X&^8E!ARQ7..$<P/ER0%K)]GY7X,GRM\4NO;S
M-AY_4]B":U]+/?D; V=S(Q%4(O)76%.M.M[JNT1 Y8L:Z8F.V =7R0V]52%$
M!CRUEEV1.K:'JO:NSDBO+70^ZS/#-$!&LK<,W>1R,LP,:88\,;9VX22K8WH.
MT&H6\2Z;9S :;K"&6X0-PBY,7S A%#*#&2V5+\2D_P!N#6U*-52!'*B*OPJO
MI$_"I[5?7I?2_P"S_7\JO[I_+G/>HQSV^NW4]/.O8Y#KX=-NGX50WQHV]KJ_
M)GS6&EV+]%2T.OZO#S^63L #7P8:5F)*K[RMBS]??6HV (MK.L?;%4+QZPLW
MYL5L4.Z<J3Y:A].AZ>?C[Y<]JXB=K?J ?=XQ7^-W6ZU"6PPTUDS>U<;WU2F#
MP%'QP.URSP>X%G(B3Y<Y,0[G3*%.4#'6V[KY;_IC]:8SD<1Y>]P/+'O(DOQ/
M<>\OR7DM10 K.7R2NI[ .LVMQV$"&=-U1U#(6(-J+VNJ+&>(8ATD*4ZU8 66
M<UV6JQHJNF#:B@^G+I[Y5;GBIIQ2G%*B+NS7F9#"'24Q4 VGT9(F/R$LZ-DA
M'TVFD^V5MF3#\2/FK,\DL^GOOEI(\?/TEL;\/P"O5,MLH>=6?!@A!GG.<8BA
M!9P3T,F!$IQ_<ZX(YUZ0<3HN,L[<*+G!9S_:%ZELX( W.#@'&*UZ>&?7/5'1
M.K[KVE?4'UESV-HZ>2FKU)L;F^/S2U,.GSM0-0PV=J>991U&@#T]X?%4 21&
M7I8A+6B5*+#Q.F"QM]7U_4A'(-0U&[6:Y*L7DE5XA+"D<'&P"+"ZE<8"JV!M
MM7?=OOXI7_:?3.S78^[G>2W["69TRVB,, :>Y>&)[B6$Q,\\BX,:CC5,\()!
M)8UQO.+L*RNL%@M?IJFDSF KN[^NZJD&U>-?V09=:%;U4BLC*BF>1745..T<
M^L0F6Q*6XA).KOG5TQP$CM>;0NTG;^=4T54M[+3)FO>YO&C+:@EFX[V1$)52
MD)#$*9,OPN5.!FOF5WI_:[4(EMNS306=\DUK=W#3@2O_ "Z-P]S$(C/"J]\A
M"OAVEX00G"Q!%C8>SNJZ>-OW1_COJ6M;\?U&6T^*I[1SY&JBO;0::> 2)C$^
M)))5U<DOK_[N!_Y:G0?]/R1(5ET:&Y<C'%'%PMQ' .48#(X22<.2=^F:LN+M
M-'_Y8)KC& 4M)F!<<B%BE88(&=A*Q.^V#7&\)-7UEJ ^Z3NM"UE&E[HT;K<9
MM%45$0Q<H83V)#-2U8 EC$OP/CC+:5:QJR-JPFR12,DEJ^S T&,ZHNBV$5@Q
MU2X6_B0/QO<H/FD/%LJGD "0&!'@:I=,UZ+7/C>Z6X5K"_GLY%N%D61&B ++
M\X *@[ IQ*3RR3D7-U=L/0YF_O#%C02FI["T*=*6"!$T8 60J=TAUF4#6AL;
M%$]7%6)H8(Z(LIA8P[))V=;5K6K;Q=Z4S?EYX8]/_P",&[UVR+SV\WVD&T]!
MVS+O66%O!;[7*LA(U9IVMK]?3UM3=GU0P-N^Q9!#$M=8P_']S#F4W'+V>ASS
M'[8QYS_AN@,)T)W5T%08D[;35E9U7W]5"BZ+<ZB]KH0R-7UCH'RQ9TFR3+P6
MRFVI$).B&HH=):B,'BNK>R?&LKWID^ ]]2?Q]34';!\]_/ /X#GC/3J<5=D&
MWK+)Y,0!PI<H<OR2XAYXII!9O;D^40R-[G02>V/162HUR*QR*GMKD2 RDL 0
M2IPP!!P<9P?H:]O')&(S)')&)5XHS)&Z!U_^2E@ P\QFNQY->:X5D<)6@%GG
M$Q!A!CS$EESO;' *-!&Z:<B>5RHR.&&)CY))'JC6,:JN5$3D$%BJ $EV"@+S
M))Y>7D?'%-^FYZ>M:C>EZ+R% R88W>>YSVV[-[J[%.[>KK3.T#J(VER1V>SV
M0ZPSMY7_ " V06>54R7<B5C8715<>&L@5L[VR%-NRK/MY?Z#/=Z=9]FK"YL8
M+:TMK26*>7O3->J[F:YC/&YX'9OF9F_J&$N%B4)&LQ/<6FCZC<2.#=WK'2[-
MEV$9N6!F8#/S&.W1^+'1M]\U:34]9]1[OM[K$#6Y6ON:_H4.:JQ YU+/<!MV
MFBH@WF E/^A)&;%F<<'3VB-L)?HY2[X.P^-#Z%JP:,6M-V>L1IL5W)!)K?#&
ML2!PTMI8_P!ZH8P @XSEW<J3&DB;K(0;W3GO]+T:XAL76.*Y6(3GO0KQVL#-
M$CH"P8M)(2@95XBHWV;>Q>FU^9J:^PJ@B''60M>2U*:@9*3:0*HTWR4>VL<D
ME2QWI(XBRIZ\>%5:]"H4;\:<]J6N6UG'*\'_ 'US%'+*EK;KW[RRHN8U/#D8
M9QPL2PP3O5?:V<TLL+RDQ123Q(;BXV1"SX+L6_O SN &)'VJ(>@KL^;JB@A;
MUILQ(7):PNJ[2]K;@L:-+(MJPR&:G9$V\T3T_P \<1+U;&R5&,A;&C?51V>[
M6ZQVATZ/4[[LY>:?=RLRR6^((Q$R,44E2X<%E7B&0-FR1DD5=]HK"VL=9N((
M-7LKL1&,K>VRR*D@[I263NXE X"0A SDC(.VT,D=>4M=YG=,:&JZ\WN2@@ZW
M[726(.W?#UX+8%G9)H4YF>HK*QRPADL1.A1S(4KYCSK$:S-',*$$)BZZ+6=0
MN(7MIM"7$LL8_FEQ+8F\MHT21WBBS)\6896$)E"HVZ)PD*'%91965SV;U/4I
M]0LYM4L[VPM[1&BE^*:TG2=[K@F8*.$M#'Q!E.RD<0R!6Q1/?I/?[^OS_?F4
M9QOSKD:HS.?4&>?M?0C4N'F8#T%8:*SL9.M<S/LVZYVG'JQIX>T&V#].'&)E
M9X1"LR14P!S VM<8)9F)(6*"Z_3W^7E]>D<QOGGYC;Q.PQZ;_EFZDE36_ YS
M0 VO1JJR1HT37L<WY;F.:]K$>CF.AA<U47VU88O7KY;/4T(&_/S\3MC'G^]4
M0_3@*@-Z5[.)&:K()?++RR6-CA'@N3UWMM&N]B2.>^'VY'*B.<OQ(J/3TCO2
M*GW]ZV \4IQ2G'*E01WFY=)6Y_J<.9R$]JVDN?NTA=(D@O7@0WW'L,V9T*MG
M&%/HHTQ8]G$K4 T.SSSED:^6)';-H%5GNR=K504SLIF9L1#I\P.7'/Y48XVS
M7ACN!SZXP<'D "?#/GSQG:L)R1)X7E-VV)--3P4@?170+1Q1V3,/AC9L_(5D
M2/<LZC)# Z,I7LA'9ZA)KV-^%62K-ZG8#2K)G=>+XR_:5LC^X0Z<[$YWR Q+
M$C<$^=;'PX[M9Q%>\3N8>)U'PQ8 \(B*@EB<'"@D$K@56?S#[WQ4_37=-U3T
MT?;S,Y5KC0<M3YD'L*@>:==5D&DMM>*5F-ECQJNL^%D,X.F"B(F!IKA]>L+C
MQS8/G][VCGTEKWM)IPOY)-)C$&F_RQI%NFD<_P!>ZMY4!50H;NRQ. H<Y((-
M?5OX;]@5[3=J="[-:Y=Z=H=CJTTL^H7FMRK;VZ6Z0O)#;M'W]O,9)F 5.!_[
MI$+ CE+_ (\=*]?;SJC&=K[KK2H"W6[R68NGH=FZW.:;!U@M3%%G<A4%5-90
M6&8_AL!?AG=3PT:ONB;6P&!JXBH:\/K].UC4KZPM[Z6>\26]B2[EBN7XI1),
M!(XN!*"K3<1)=BN./B(V-<?VSM+71^T&L=G=/N+>XTS1M0N[&WN;23CM+Q(9
M2IN8I%>3BBE"@H>-RL>!Q$C-1%TST'B,'^HKWSO:?L/LJWN['Q]ZMKR,AJ;W
M0:>E!9=Z'0"'2#:#2?<;(MM3#@<\?4B3WA;J\S;ZIH[E$FB"K>RU'7+J][$Z
M5HLVG:=''!JU[)_,;98HKN5NY 421 J1@SL'DP>^6*'E)$Y?E>YG0"<RW1MG
M/=) QD^$22/+'NP24[S#DON&'$#C#&MH3?V3^R?O^_[<Y,<AUJ.=>>*5A.LZ
MWP>[-H+'99*@TYN6(.+SI%Y5AV;Z<BS!FK+&4#ZR&9L#CZXB8(OX4]3CO^"1
M'(UJM4K,8(8AHHX((VQ0PL;'%$QJ,9'&QJ-CC8QJ(UC&,1&,:U$1K41$3TG%
M*KYEE1/*SN_^7_L%\9E_*_\ []\JD_\ 7]^*9Z>?Z X_/V*L/[14_=%3^?\
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M*KV[%NRQK<73@LMK$6C51DR7+_+!&-]B&/>;CE&1@YKW$O>21QY"F1PBLQP
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M$%B?.23.[Y<,$,;5=)--([TV.*-B*^21RHQC&N>Y4:BJDDGD 2Q("@ DEB<
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M/I,S,E(//'4-B/;93#3F/X.STZ'3)1(\4VISR.)+NX1T_K8.70RW#1,D38(
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MJ!7HMK4WD-@1JMI:/;;T>GK=E66*0VVB.':4/IJR.U65L2+-,9;13?,&N;2
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M+* OT(C-!6%3VJ0ZXRP)+0,2#/D>E5$ 5%"A0 H4 !0-L  <@-ARJ5 154*
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M%G+$D 5S;21CCHV0 .@K8H8IV0.J!(Z4B.>H)L@3U*R+-^"75>3MM#8TNB[
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33BE.*4XI3BE.*4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?0:9C!;9Y)>\;?+2@DV4RFZ\YYGX;R3*\?DM31F-H]#G) 3W7'R(/N(,?%F
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MM:.."-.&GB TWH'V*ZW=T? !QD<M_PM02P,$%     @ JX.>6(K/DBPN!P
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MF">O6PN76IM\6.N:?K8_/&_@B7C?\TQ6?\VK3_:L/IXD[ZJR6=KD;9GKO+O
M<R#5TSMQ]+Z>'%SQC<XNDLMQFDQ&D\L#ZUWZ_5_2>I='[#]-[F"756%R9H="
M=M3:ZK+A+ZIY\I,I59D9520/\*4&]6QL\I_3F6UJ4+#_&F(1$W U3  :W=_L
M6F7ZQY,U/JM^U">O_OJ7\<WH^P/;N_+;NSJT^C\LWH.K#]/^_L-O;Y-Q\M>_
MO)R,)]\G'S[]/'U__Q_3W^X_O$^F[]\D'W^=OD\^_)2\_OQP__[MPT/RX>/;
M3_3S0S)M@+S&9" (91M@\C3[LS76$/EW5;V^2.[OD[-FJ6G]R>C[NVJU5N66
M/HV_/T^,350R@U6^)."_,O@_7Y"8,H/[*]BKSN%#\D87:J-JG<#*[]06](ET
M:GR1_ :KR[+)1MD$/1_< _\D^.!U"\M8C<J@YW-P+BVPKUS 8U>Z7N@Z33*U
M-D@\&"\0H+]F2U4N=)HH:\'+JK"E5"Z!)>$:"Y?4NHHE!H^LX)G@1,W*% H<
MD!,;;&L&JDA7;4RSA&UHO'Q5P9;<5=IV>.5E?A=N=HR[2#Z4R?OJ4:]F\+A+
M9L8E;=CQ0O@PG:WK*GE'>TT>VIG(Y4P>$GYP2\/&D\VR*HIM4FU*6,&V,VMR
M S$ F1@]HLM[$&59-4D!6T>9-16LLU8UJ$>+K#!E#NX1UP#V@!C@'Q21B,?B
MTAEH-08;D<_0_G<>">:A50VT@OXM-/D C8+%)19@?<!JIU+P&PH5]I,MTPZK
M#'XY^P.H(K*+PFVT-O:+146HP(?@KDAVQSW0:'N13&ECX 5%4.()NX]?JIQ8
MMP5U@WO!267P*/RE\M8.2P%9%!1-LPW:K6M3Y1V+2,[ =O0:[SJ':^JJ72QW
M*0#5+6!'%C<<T4)NX,7W;$7B9?%G4X(%@(VLVUD!]EZ!)=6XXUA?[^6:CWS-
M![DFZ-5F:;(E,CO7-JO-##8Y0YB1$A=1S?2?+7AH1].>!=/$Y'"5F6]93QH%
M*MQX,2-KCE&>C0&&(ML7ND0NZYCCL'"M'W79 H=:>!:P?MYHYCD^J- NP@P_
M"K;4T,6H*Z )S<"S_7/+JGP6GHO7U7IA,$310ZR+7%[J?6'M812YPUQG8'[
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M0X_R:-&\B6_:2,%[2'M2W#!H +CKF)I9A:TP'*)P8:+WG*Y^L?"DEZN_KHW
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M/'4<9ALQ02QA588380KH,\N8[X"TQ$OUO!29RUF\JG6K172R1.)"[#4'#8D
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M\'Y95;7[@1OX_V.!M_\'4$L#!!0    ( *N#GEBNTC2>V0(  !P&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)55VV[;, S]%<(=^I3&CI->UER
M)$VW +T$O6P/PQX4FXZ%RI(KR4W[]Z-D)\N )L >$HL4S^&A+-*#M=(O)D>T
M\%X(:89!;FUY&88FR;%@IJU*E+23*5TP2Z9>A:;4R%(/*D081]%96# N@]'
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MZXK0LZ2$<$C26ZM71)^WN4Q#B_0];AK1MTTV]R_:K^5W/RC;@"6^BE K]2-
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MK^M;\0B@DF4D&>?K*H-L>&3 >6-Q^\ CN(I326UU1?<?$I3+KV0 ^K-:P_E
MQ1PJP4'J>Y+5*2GLUL96@HI(_]RXE.]/!D.\EV1POTQ1 4G6'17&X@I@GJ::
M]O=#:"WOE$B4K5",! 7T;/*BU*O5_?%")E_YB^F+P:#=Z&J-!ZY$L7A@&U?!
M@1Y#EIKN[.J%4]]JY=. -$!0E)FJ@O6EN*@=,M$YNLU"%UX.N2F<QT=\JS60
MIWOG>#*N#5N11A+!M64!47:2\'.-!6?3<^$=3M)NVI7SI!J+/\Q&(3:\K?:G
M;&G-G4Z5>^@.=GQA*G)^4)V=KY9+LAF4+94%4(G6=^$0/$IDC3!Z\"0:E@0M
M%(RH@CQ4:ERHTIFH2&HP8$@I69:93CCM,B3A,4+O"UU^0Y=&K,WC=2B:Z^81
M1<@&@-2+70G=W+I=1/M3E 7D3T7G_3H9SR9T-1RAJQ%=YM<GH\ED0O^ ;%ZA
M%4Y<X2XC44J=B@ %5%M(7E#["@(T<O:Z7D!]\0D7M7@\$,\]E>4#C4$ZE"7S
M+Y4*.IZ>;^DXG8S.=RCID[PG)&0U.Z"4]VS:$-D=7<32FMS+RLD^2#B5I8W\
M6PNV@H#SIG,F4]E]\PSA1T[>CJF0-0BWX8P94:;]%5*2-E(PQ$K1\UD,X;&8
MIW?:&5CN4UMRGG8K3G,\Y>,[:>\D0#(BZF' C>9!0(VC?C6312=I?.9MUAI9
M&N5QK47I<+S6J]1<HU% ,[P7@: R!NT-E"A\ [&J6($U!R3GXE[TK,MU_>D+
M1PI#<0=WF2+SM];T;:K [%/EXWP[[,8/<\<JG2^ /'1FYQ*$4_09<>2ZP1.5
MU45$UG 0HTQ3JAC<@H'NV6PZ4>'\Z"FR-5\5![2299,!D_'DV3\:Z2MK$$8X
M(\$>]TCVC:!>4Z/HI.WRW;5 L*@P --CF66&69DP9>N^3@G9<RAGZ.QL5WK&
M^Z7 $H)<T-(02-UL_+GH>2& S8U 36[7RWM2!)FJ$SPK345?8J<&DP"]L:[1
M;6= SMF\(.TJ7T"C0-RWTLSBL;X+41.#B$T7 :6/>(A0QM'&$..8G1^D_8I.
M-:0X9?B\M*@2T] R]$_NIVR,K4[JLM7:!/51UTAG5 P5\6&$DD?(;)YN. _-
MBP;%DA;%QN)+^; B#*_UH= ]?Z&\+7RLAV33MI,H<ZQ"(#AH&>JJ=KZ@^IU.
MYVA19:%,[;+[-E"VRM.PZA]-<?Q9@:7Y(/_$Y5PNT-X'RY\-&9X\.*\R4!2$
MRZ61CGPW3\ :')<Y^+$ >+$+KJ[$^_>7XI#V!^R]@;U@@ 9Z1UN.;+SG(EAO
M:7DZ.D7M>SZ9.*:_VZNP.>T9O7OV);90=LUQ0LH*7EM3&O"P6 DX:D/</??7
M)WM_2BI#61"_0^_02'W[O?*#C/9.G=+65'\8*2X\!&OWG#JF5Q3,C4$<;"SN
M/>OS1F,Z =Z]EFAS6W V !=#WDXZ'3%! 9</LDE@F:'MZD@$K78=! 9Y*]Q2
M<3'C+2U<<%4,,$9A]6QV/IK-SH/0)M":(&'RT%=>Z!R^T=B>46$!Q&Z\S@4/
MC2*_1H@'2!I,(LT'$;^@;K_V>E.3X!7NQ<$@4V\9) *^M?\0R(S$? &,$!^4
M75'#52_PQ)9C=*?8F<D-\;<$WYB0G$TTMAO:F."\87&7[8Z=DH(@WK K5X8-
MU )@-_3WFZ(Y8=R; =#V_?M&#1V^#'CSAJ+C$#$%"HI]D4#N%X.;M18CDQ1J
MPT%BX<41V!>BY?[8;$A@BN8$F45MFD8T ;3[H3>*T)J3R+0I \%HM-)[X3'K
MC)J>LC(KA;6V15?#'SE9).<I$:@,5^<Z:%5E?!@%Z1YD\/"VLZ-U:A3K]7(U
MP/^.C+G3<)2S/V>5/@3'$SITTKO_:IAW;"?I+LWZE8(=$<!*5R[&MQ*%S)E'
M=J,<K6Q&5 T =54DX\;ZMTPLF'E1X[@PTGKBYZ]L[ /L:1.-9P9I3<2XI%H?
M>,HCL$#[N2'I^I?@!B6HX^3%/<S5@334C+8+:#O=2N=JG\EZGGD;M]UB6QLB
M_CK>GMQN'^HC 98J4*M1?PNFN'Z1GQ55FI@Z:H!JZ$+XO@&/%K8;LUWZV=<-
MS;Y&.&#G">U8"QB4^$$'#0VJ^^X<8\LI@TH@T6M&7VH5HD+[56/W0#NHU^;,
MM6TZ7C\4PX+(_*NUH3&7_Q[_P)?HZTA/'QJL,V[KC/$Z7Q_Y=I<P.XSS:%W7
M4GI78/0]_)AOFGK17G],8V[/*-@!#=&C-#%@\"OI'^W,B<JTV:SV0(Q571;3
M#-Z:XY*H1*?)&J$@54P\,@T>PJ5YQ*'JAZ>E;J=&^T<_&^D[?Q!P;=+.^.L/
M$+CCF\14U?%G@S.-F-/XA,<35SGGN*<_<]^13I\_?3)BO"3*1\7DL(D<N4!7
MG2C/.>X%:C#IM:(&L" 9("#&TKGXU@-^!O*340@!&73AYV+6K/7"\U[TZ30*
M:9#[QS&SC>;>5/XF3M 6BD=7*LDDQ7AWC#8\%R29=R%!+N<7XJ/:Q"CRP>4#
M+T3OCFYS,#" J:3,0JFB156BHADTYY:C$!^E2^4W*!%T\.O(H,L82?CS/,S:
MIO2A0.N'[%EQ'DKG%+4 3"1\J'@U98(BDDKR&ZO)$])3>3X]GAZNC@ZG1TQ-
MQT]%#JQDNH@]=U)G'%8Q>FDLR&U54'DIEC"E&QYW'<HE-0VP?.T-1+<MY;T/
MM%RB@1PPH(TMBVN(<).,_'HAS+6/1)G5CB/0J]!J6_9>QUQ?7;\5[^"%(N%4
M@Q( II16H<32!+8E90&-Z841FQRZT.QP&^G$LA'G\8N#W!D(].BS;$_+* Q(
MR2\%]YTWU_-+]#,E^AGJ*-A/+K%Z\:.4[\'X+S)=GFL! .Y"7> 1$L\DQ[&5
M>*\J[N,>H?(_UZ;VN'B#8)F6"YV1-9,A)M5O9O?,$6-219K:5J\6G"\TH3WZ
MB_=5.G30@XMW6*3G)-%$?#3G.0$P."DEW6S\_#RFQF#G%CT0WXGUBF_3U^DJ
M(&FJ>8(R&YV=/QN=GI[^CU+)TP$_PT68_@^^FCI[/AT]>?*T.:KI;MF2NW<]
M?W;*>F[M&O;!3XLA:."(+5&HF/406Z-7I MV0('VM$6&7L/>..ZF+DMZG_8W
M^M2&N3:B>N'8??#PC"[8^&EW=WV<$(R"@T('M/9\_8[ A,GBDHG^3\: 7]TH
MOV/YQ=;R;B0B]EF?PJ"&<S]$DPU<W2-W(*FIYR+PPE+>&=NA';XX\=O@-$Q\
M]S'VO]$J] GIL-PP(_#,>T5S1__"K0PSJI'P)XC&(7E\\;(Q-;VLR4N$ULB_
M%%C2VS!"G1&@.9.($0BIX$]%^_UK, L ;(YHA_9[ V7T(V8)@ZG_CU6VWJ&%
MZO*(@@]1D"N*MW 8C1')L,W;36)4P\'-8^[X9E>F?X$;-+?T*ZG&'*<ZJP,-
M1#:$2P^]-^ &F'P6L^R'TN5B&#*[EPWU?;N)^'$<WL$#=_LQ*+ _',9BZ)<R
M)YW?-?&DAGZ]1>)1Z/U/G.*W\0=B<_^[J':Y_W79!VE7-*7/U!);)^.GYP?>
M8\V'RI3\*ZD%^@:3\Y]K!=YF:0&>+PU<%C[0 ?%G<Z__"U!+ P04    " "K
M@YY8\3%(=U0,  !N)0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RE
M6EUSV[82?;^_ N/VMO(,(TMRXKIQXIG$22>9VS:>VFT?[MP'B(0DU!2A J 5
M]=??LPN0!&5)=MH76R2!Q7Z<W3T ^6IM[)U;*.7%YV59N=='"^]7+T].7+Y0
M2^F&9J4J/)D9NY0>EW9^XE96R8(G+<N3R6AT=K*4NCJZ?,7WKNWE*U/[4E?J
MV@I7+Y?2;MZJTJQ?'XV/FAN_Z/G"TXV3RU<K.5<WRO^ZNK:X.FFE%'JI*J=-
M):R:O3YZ,W[Y]CF-YP&_:;5VR6]!EDR-N:.+C\7KHQ$II$J5>Y(@\>]>7:FR
M)$%0X\\H\ZA=DB:FOQOI/[#ML&4JG;HRY>^Z\(O71^='HE S69?^%[/^H*(]
M+TA>;DK'?\4ZC)U,CD1>.V^6<3(T6.HJ_)>?HQ^2">>C/1,F<<*$]0X+L9;O
MI)>7KZQ9"TNC(8U^L*D\&\KIBH)RXRV>:LSSES?>Y'<+4Q;*NF_%.S73N?:O
M3CQ$TX"3/(IY&\1,]H@93\1/IO(+)]Y7A2KZ DZ@4ZO8I%'L[>2@Q'<J'XK3
M<28FH\GI 7FGK:&G+.]TC[SW?];:;\1_WTR=M\#"_W89&40\WRV"\N.E6\E<
MO3Y" CAE[]71Y3=?C<]&%P<4?-XJ^/R0],N;VT]7__GPZ<=W[W^Y023>__#Q
MZN/M+B4/B_GYT^U[\=TW7YU/1N,+^C>>7,2K= 5^\MU%LXZX1C(H:U4A&!$B
MSA0WRFKEQ!MQ999+9-'.IV]W/Y5B/!P]?_X,I>/96#A^]B% 39A9)SH/D\,
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M"VEWL4V[,K:KM;K!_MZ^%?KME[:.IO738H%B;%(,AB#*U:H,35U,2R)'=YO
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M8/:ME/CM%C$AW"\+H4"6HZ-__F,VF8Q>$AX?+B]OZ/OXY3$ALVF4;E#@ZXK
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MTB8?[$P"?Q!B_IH:ZB <2>KP)Q-R[+(MWCYS%Q.PI)]*\A%A4:>#/'M"GW8
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M$^C9 R+\[=D4:FQC_&Q4Y_+V6_1G-:1?!Z-YW.[''AE[.1T=OX@^%G1QUB4
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MY%EF^P5DB/ZBSZ*JZZJ@CVN(&83"%^#W9575]@MNX/[&TYO_!5!+ P04
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M;@.N;Y2RQXDST#\1Y_\"4$L#!!0    ( *N#GEC.E?&?#00  +@*   9
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MTO1LU7V-CKFO(<HJ?/2LK&EQXK=X4V&FGE^+H#TT!RV+)]_-04/[&:AFHYI
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MU"]GJL*EJF@&,P>/O0*Y!2?]^2<_\G[I8_V?Q+XC'W7DHR'U]%<IE"*5%!E
MKOI0!_U?BMJ(C:V8*7[;-/3:OZF[[>$8=QSC08X/H-0EF;<<A'(N,GL<M"#S
M>HFGBWRA4N*QZX4<%'\I9",6[4&>3_P!QJACC)[!V%\3F%*U/?:94/V(@]HO
M18R.$?TH2A)O/.EGC#O&^!F,=Y#CB3174!])?+2)SH,X&L7^*'K*<!/GX,=^
M\&A-.I3)?Z,\D2AR)G$ 15.WL81!L01I*^ ;4E%FS;_3LC9U"*VCWDH].<Y\
MD,3!!'-_P#X8W0^R)QU[,L@^Y[5=Q@*HJB7^X'6']UF&1_#!W'=;RFLP9U-V
M^6EL?<C)$?(H3,9^Y!\ '\\+PTD2)9,3>]+WGNYO[QDX_2=/U<M_\#8V,!76
M4K;$JUL.[M_V8_L;. Z2(!H= O5,#+W$2^(D/"PE[EYW4H!<VZ9-$=M@--=R
M9^T:PRO;#AW8KTW#:+N>)YFFV_Q(Y9KA-N:P0DGO(L:X9-/ -0,M*ML#+87&
MCLH^;K#I!6DFX/N5$/IQ8#[0M='IOU!+ P04    " "K@YY8$FW>G% %  !I
M(@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RUFEUSHS88A?^*AG8Z
MV9DT1I+!.+4]$SO=:2^RS<2SW8M.+Q20;1I +LCQ]M]7? 09?[PVMIR+!+!T
M>(\D<QX"@[5(W[(%YQ)]CZ,D&UH+*9?WG4[F+WC,LCNQY(GZ9";2F$FUF\X[
MV3+E+"@ZQ5&'V+;;B5F86*-!<>PY'0W$2D9API]3E*WBF*7_C7DDUD,+6Q\'
M7L+Y0N8'.J/!DLWYE,NOR^=4[75JE2",>9*%(D$IGPVM!WP_H6[>H6CQ9\C7
MV<8VRJV\"O&6[_P>#"T[KXA'W)>Y!%-_WOF$1U&NI.KXMQ*UZG/F'3>W/]0_
M%^:5F5>6\8F(OH6!7 PMST(!G[%5)%_$^C=>&7)R/5]$6?$;K:NVMH7\529%
M7'56%<1A4OYEWZN!V.B W0,=2-6!;'?H'NA JPZT,%I65MAZ9)*-!JE8HS1O
MK=3RC6)LBM[*39CDTSB5J?HT5/WD:%I.'_ICAJ;A/ EGH<\2B1Y\7ZP2&29S
M]"RBT ]YAGY&4[6(@E7$D9@AN>#(9Y&_BE@Q'^J0&L[01RP)4!!&*\D#E*AU
M&":^B#E:\A2IC5@U5:;\-W3SR"4+H^R3$OXZ?40W/WX:=*2RE!?6\:ORQV7Y
MY$#YF* GD<A%AGY- AXT!3IJ+.H!(1\#,B:@XB/W[Q#%MXC8A.XI:')Z=P*4
M0^OYH84>/:#W917SE$F1WN\;G+)O=W_?_ IPGRV9SX>6^HIG/'WGUNBG'[!K
M_[+/F"&QALUN;;,+J8\>HDCX]4+2R^86L0RQX!_U1=B>W7($2EFGD,TO6>\C
MXA'<=?J#SONFN=UVGN?VL5<W:Y3MU&4[8-DO/.#JLOJJOA*-M?W7$X]?>?KW
MOHI!Q;9S9DBL8=ZMS;L7+$W7I$U#8@V;O=IF[SI+L[>SY+#;I]2QMY8F>/HS
MS7FU.0^<PT>>")4J!V?1,SF+AL0:1ONUT3XXB]^*/%>1Q-[5HIUSE"V8.@M2
M9)-)%5DJZ6[+ -LW#*6VNSF5F#@]K]_=FLO=AL3K4H\Z[OX+#;9U3MN7&ZAR
M=V^.VJ=ZV-/RB(D-V,"@B?$.(51T<!.)3)% #@F%+V NJE-X&^79=]C9-@$6
M<N9BPT0;)::,0G-&3K(*EG*N50TH& 2#T1>1I&?$(*S:]M)B2JTY!II></>"
M*,0@^[2V:DBM:543#X:1Y^PXK'2=Y@7(P_8VJL$%G&M04PV&L>98)&*C9&-*
MK6E6LPV&X>:R6*S$-Y.BY]CYS_:47H-QL(8<#*+%Y=GIG>KS&HB#->-@&'*,
MQ&O_I,P!"SG3*-$P1& 8,A.OU4ERWH&\PK6<ZU4S$X&9:5(FZB1B688>P$R%
ME=I>FDRI-7UKA"+D@DPEAJ"GLGH-A"(:H0B,4&=G*JS;>A3H3D+W;.R1 ]A/
M-!X1&(^.12HQ"DBFU)IF-2 1&) NBU18O/50."UOY8C&) *2R<69"LNW-NJV
M-:H1B<"(9")4JU,<39K>GNRUR0$'&G\(C#^&TM([S8/7QH-&&P*C32,%QW *
M&F*3RL\U2(=JTJ'V)?__-X0FU0. :X .U:!#8= Y.P5AW=:C@'?O4SW'[A]8
MPE0##86!YE@*4J-(8TJM:7;CL16,-)>E("S>>BCHT=NWIDL--A1^;'5I",+R
MK7UV6_K43$-AIC&1@=4ICN5'U>RT_* :5RB,*V8RL#K)D9OCO:UV+'0V'MJK
M:_R\>)<A0\5S]_)Q=7VT?E_BH7A+8.OX&-]/RK<>M$SY$L832^=ADJ&(SY2D
M?==38YN6[S64.U(LBU<#7H64(BXV%YP%/,T;J,]G0LB/G?P$]=LEH_\!4$L#
M!!0    ( *N#GEAS+.W 80,  *(,   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;*V7;6^;,!#'OXK%IJF3NO(0(*%+(G5ATSII6[5HVVL'CF#5V,PV
MR?KM9P-%>:"TF9(7P8;[G^]^/ALSW7)Q+W, A?X6E,F9E2M57MNV3'(HL+SB
M)3#])..BP$IWQ=J6I0"<UJ*"VI[CA':!";/FT_K>G9A/>:4H87 GD*R* HN'
M#T#Y=F:YUN.-'V2=*W/#GD]+O(8EJ)_EG= ]N_.2D@*8))PA =G,NG&OX\C8
MUP:_"&SE3AN93%:<WYO.;3JS'!,04$B4\8#U90,+H-0XTF'\:7U:W9!&N-M^
M]/ZISEWGLL(2%IS^)JG*9];$0BEDN*+J!]]^AC:?P/A+.)7U/]JVMHZ%DDHJ
M7K1B'4%!6'/%?UL..P+7?T+@M0+OI8)1*QB]5."W K\FTZ12<XBQPO.IX%LD
MC+7V9AHUS%JMTR?,3/M2"?V4:)V:+YOI1M\SM"1K1C*28*;039+PBBG"UNB.
M4Y(0D.@=NDE38F8+4W3+FI(S<W<1@\*$RK?:Y.<R1A>OWTYMI8,S0]A)&\B'
M)A#OB4"^8':%W.@2>8[G]<@7P_(8DBLT<FOYJ$<>OUQ^,+JMB798O0ZK5_OS
MG_"WP#)''_]49(,I,"7[> QZ,,O]6I8X@9FEU[,$L0%K_N:5&SKO^^@TSH+:
MF5GJF[DSM3>[ (8L]G(<=3F.GLVQ+Z]!U:EY-<["G:B]T ]&DX/DCLU&D>?[
M87^&?I>A/YCA)TA!Z&*/H>22*%WTLA*8)8 67)1<-.6?\(VV6D,?BT'_I[+P
MCV;0"QS].V!QIC'WB 4=L6"X)BB6$O$,_<9"F(V$"U2_2B[1MZI8@3#/EI!4
M0F\D>D]98$HA1:N'1X'L%+UK9G#T4WD&Q[4UF?01/=.H>T3#CF@X2/1[EH$P
M^W#"93^3\*@LW+'G^*XSWD]C,3C0B?#B,SG;8S+NF(Q/8()T#?$$*UU'A"$%
MA5F9^I4&>OM5#WW$QD<3[X9A%#G!P;:R& SC5&)G<K9';-(1F_PW,9EC 3FG
M>J^3 ] F1V46.('C1P?(!N,X%=F9G.TABSIDT2"R&#0RH1'Q9U?@H*-3=Z7H
MV3?YD$63JKUS(#2G]Z]8K F3B$*F-<[56(M%<R)N.HJ7]1EQQ94^<=;-7']$
M@# &^GG&N7KLF&-G]UDR_P=02P,$%     @ JX.>6&&O!'ZH!   @QD  !D
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MS4,U@6H^J@6H%J):A&HQJDE*4^.JK9%7%_]?)G7:87J'%ZE9J&8WFNY=O>B
M+JIYJ"90S4>U -5"5(M0+3[^E)34@&K,M/7OX4E+>G^MX\3X63]K0[O?J&:A
MFHUJ#JJYJ.:AFD U']4"5 M1+4*U&-4DI:GYU#;$AY/WFK6A'7!4LU#-1C4'
MU5Q4\U!-H)J/:@&JA:@6H5J,:I+2U+AJ.^!#_8+@NY^0\J%9ZFUWW27C3\WZ
M;WJ[=V*A-7!4LQM->?UM?ZJ&=KM1S4,U@6H^J@6H%J):A&IQQU/RJFNU5$D-
MJR9,6]L>ZFO;!R9L5;#(IS3_^&6QR#;+,QERM3U,TLWHT%(WJEFH9J.:@VHN
MJGFH)E#-1[4 U4)4BU M1C5):6J M=WOX<U[S>C0+CBJ6:AFHYJ#:BZJ>:@F
M4,U'M0#50E2+4"U&-4EI2ER-VB[X2+^^]Z_;.9PHBG4Z^V!LOVV^?OR6%)LD
M^[$YXOI2?^K ]W3[\71.EM^G\SKH=%.^9O#=H\YA==BI'G)^U>]BWZA"-1O5
M'%1S4<U#-8%J/JH%J!:B6H1J,:I)2E.CJNV!C_0]\,-3P_UU5CJC"&U_HYJ%
M:C:J.:CFHIJ':@+5?%0+4"U$M0C58E23E*9&EME&EOE.D\$1VB%'-0O5;%1S
M4,U%-0_5!*KYJ!:@6HAJ$:K%J"8I38VKMD,^TJ]'_I=>WM/;O1,+K9&CFHUJ
M#JJYJ.:AFD U']4"5 M1+6HTS<O),3J@I#0UAMIN>'7QY(G>%_VL3BOU#AU2
MLU#-1C4'U5Q4\U!-H)J/:@&JA:@6H5J,:I+2U'QJ2^6C\7O-ZM"..:I9J&:C
MFH-J+JIYJ"90S4>U -5"5(M0+48U26EJ7+4=\Y%^%?*_-JM#:^:H9J&:W6A*
M0VYT4_^S5]U$AW51S4,UT6B#RYW[Q#R_&:MWB(\.&J!:B&H1JL4=S[C]-B8U
MH!H=;=][I.][[[4#[C:?^'V7YMM^P-%/_&YTY7.PW[SXC_:X4<U&-0?57%3S
M4$V@FH]J :J%J!:A6HQJDM+4)&I[X:,>O? O?ZT7KA^J]S$-V@M'-1O5'%1S
M4<U#-8%J/JH%J!:B6H1J,:I)2E,#K.V%C]ZK%SY">^&H9J&:C6H.JKFHYJ&:
M0#4?U0)4"U$M0K48U22E*7$U;GOAXR.]\/ILD3'?3/R,V3JOSQ.MTGR>S5[.
M("W3Y^WO"^T)I'%'!?RFXXV'7_4[U#>84,U&-0?57%3S4$V@FH]J :J%J!:A
M6HQJDM+48&I;X.,>+? ONA9XKX_4U(_:]R +U2Q4LU'-0347U3Q4$ZCFHUJ
M:B&J1:@6HYJD-#7+S#;+WJL>/D;KX:AFH9J-:@ZJN:CFH9I -1_5 E0+42U"
MM1C5)*6I<=76P\=]ZN&KS8N!U9QP._D[^F*@'N\=66@_'-5L5',:[49Y$?7<
M5&?/+CJFAVH"U7Q4"U M/.FQBM Q8U23E*9&3%O]'FNKF_UF=[^D15F%T.:
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M$:K%J"8I38TELXTE;97S_S0GW%^!LS.ET-XXJEFH9J.:@VHNJGFH)E#-1[4
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MWIRML[Z@AA,HS0.E^5"TYE50V5QX!%VO0:TM4)H+2O- :3X4K2ET96UA\_M
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MU=[7W7NN^SN/)/XCRLX==_;*\::>Y_S1F3CE)BIDV7WIJ>(M#?RXK,X=;]$
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MQKL8(%C6]T8]T:*TK7<A-#9R.USA50O2!.!^)H1^GIANWES>\1]02P,$%
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M@1+%J\M -9&L,/WTF4G5G<TP51<HX#I /5\R)G<3O4%S)8O^ 5!+ P04
M" "K@YY8A6X(>AX#   <"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6RMEEUOVC 4AO^*E4G5)FWD@Y! "Y$*[;1>5*I@'Q?3+DQR E8=.[,=H/]^
M=@(I()/V8C<0.^>\?MX3.R?C+1?/<@V@T*Z@3$Z<M5+EM>O*= T%ECU> M-W
M<BX*K/10K%Q9"L!9G510-_"\R"TP84XRKN>>1#+FE:*$P9- LBH*+%ZF0/EV
MXOC.86).5FME)MQD7.(5+$#]*)^$'KFM2D8*8))PA@3D$^?6OYZ-3'P=\)/
M5AY=(^-DR?FS&3QD$\<S0$ A548!Z[\-S(!2(Z0Q_NXUG79)DWA\?5#_6GO7
M7I98PHS37R13ZXDS=% &.:ZHFO/M-]C[&1B]E%-9_Z)M$QN/')164O%BGZP)
M"L*:?[S;U^$HP8\N) 3[A. \(;R0T-\G]&NC#5EMZPXKG(P%WR)AHK6:N:AK
M4V=K-X29I[A00M\E.D\E#RSE!:#O> <2?4$+O4NRB@+B.;K/<ZB+C%Z#T!PK
M0'-(.4L));A^%.CC'2A,J/PT=I5F,LINNE]_VJP?7%C?#] C9VHMT3W+(#L5
M<+69UE%P<#0-.A7O(.VAOO\9!5[0MP#-WI\>=.#TVP+W:[W^FP5&=T2FE,M*
M /I]NY1*Z#W\QU:R1C&T*YIS?2U+G,+$T0=7@MB DUQ]\"/OQF;W/XF=F ];
M\V&7>K)06%6*BQ>40P8"4T2:<BA=#J&WDLU](^DW#\B\A3:)UPO\L;LYMO56
MU GOH.4==/(^ J:R<7^%B_(& 5,@]-YF^L6E;+ #"\89Z3[$/R'UPG!@9XU:
MUJB3=5I)/2,ET@5=$M8<1=CIU[L$:4.-K!Q>$)[Q1EV63E#C%C7N1/UJ0!%F
M&=)TF"IB!XSM@/'@##!^-^"P!1QV L[6F*U ;TZTP;1J2HFI[G"8I=8].K2B
MQF%TAFJ-"X+XPCX=M;RC3MZ'UU-4"KXAIJ?:,$?6Y4?A>46M<>'0C\XPW:-&
M4X!8U?W7[,"*J>8-W<ZV+?ZV[FQG\U/=^IM._2K3?#<\8K$B3"(*N9;T>K$^
M/J+IQ<U \;)N9TNN='.L+]?Z\P6$"=#W<\[586 6:#^(DG]02P,$%     @
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M7Z7KE>RI4%\6>CC"]*'4Z)VD&5N:_C)K#6#J(:Y.RI*O/G,V$SFU@S\XX6A
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ML%7 :@?RN_- 3;DY402KBGG#[F <21(,@5ITUV@<([,3P\>]/MA=$D5)XD8
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M==EP?F7+9N*[I,7F\'QS\'_^&U!+ P04    " "K@YY8UOKYL7@!   #%@
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M$+2.'[2!H$W\($I1QE1!T@1K!5H3<DT*O"8$FQ2(34@V*3";$&U2H#8AVZ3
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M=;^>9U]02P$"% ,4    " "K@YY8!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *N#GECJ%OIQ[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( *N#GEB97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ JX.>6-U.!CN/!   SQ,  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( *N#GE@2ZJ/\VP8  #<@   8              " @=,,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "K@YY8E[EWT[P#  "4
M$   &               @('D$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ JX.>6.DJ"AJ7!@  6"@  !@              ("!UA<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *N#GECK'+#2
MS08  %DQ   8              " @:,>  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "K@YY86ABWX4\"  #@!   &
M@(&F)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ JX.>
M6(K/DBPN!P  &1\  !@              ("!*R@  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( *N#GE@L_7PY;AP  +-;   8
M      " @8\O  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "K@YY80Z'30T,6  !D0   &               @($S3   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ JX.>6*[2-)[9 @  ' 8  !D
M             ("!K&(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "K@YY8TGS%&X<#   O"   &0              @(&\90  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *N#GE@2&LT9* H
M !P:   9              " @7II  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ JX.>6&L6Z:I%#0  0B<  !D              ("!
MV7,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "K@YY8
M\3%(=U0,  !N)0  &0              @(%5@0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( *N#GE@92.2Z:P4  &L-   9
M      " @>"-  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ JX.>6(VR(5$2!0  K@P  !D              ("!@I,  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "K@YY8J!KJNS8%  !$#
M&0              @('+F   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( *N#GE@?_,012Q<  .])   9              " @3B>  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ JX.>6,PP[;(8
M!   +@H  !D              ("!NK4  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "K@YY8SI7QGPT$  "X"@  &0
M@($)N@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *N#
MGE@L-[HXX@(  $X&   9              " @4V^  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ JX.>6+_[^R1K%0  V#$! !D
M         ("!9L$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "K@YY8KFF#&; #  !2"P  &0              @($(UP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *N#GE@2;=Z<4 4  &DB
M   9              " @>_:  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ JX.>6',L[<!A P  H@P  !D              ("!=N
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "K@YY88:\$
M?J@$  "#&0  &0              @($.Y   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( *N#GE@*9Y43(P,  - )   9
M  " @>WH  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MJX.>6 4$4^\[%0  #G\! !D              ("!1^P  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "K@YY8Z.T0PLX&  #Z.0  &0
M            @(&Y 0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( *N#GEB]JDIS8PX  ,"K   9              " @;X( 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ JX.>6.UJHXRX @
MR <  !D              ("!6!<! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " "K@YY8!JR/@?("  ">"0  &0              @(%'
M&@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( *N#GEB%
M;@AZ'@,  !P)   9              " @7 = 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ JX.>6,9>,E3' @  :@@  !D
M     ("!Q2 ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M" "K@YY8(<[-,X$"  #E!@  &0              @('#(P$ >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *N#GEA)RN5^-@,   P,   9
M              " @7LF 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M A0#%     @ JX.>6(OXJ]M6 P  TA4   T              ( !Z"D! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "K@YY8EXJ[',     3 @  "P
M        @ %I+0$ 7W)E;',O+G)E;'-02P$"% ,4    " "K@YY8MI.>_W #
M  !\&   #P              @ %2+@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ JX.>6-;Z^;%X 0   Q8  !H              ( ![S$! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ JX.>6.N(NN65 0
M@A8  !,              ( !GS,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "P + #K"P  934!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>256</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit</Role>
      <ShortName>Consolidated Statements Of Changes In Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization And Plan Of Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations</Role>
      <ShortName>Organization And Plan Of Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Initial Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering</Role>
      <ShortName>Initial Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Private Placement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/PrivatePlacement</Role>
      <ShortName>Private Placement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Summary Of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Summary Of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary Of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atlanticcoastalacquisition.com/role/IncomeTaxes</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Organization And Plan Of Business Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails</Role>
      <ShortName>Organization And Plan Of Business Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Initial Public Offering - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails</Role>
      <ShortName>Initial Public Offering - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Private Placement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails</Role>
      <ShortName>Private Placement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d509388ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>acab-20231231.xsd</File>
    <File>acab-20231231_cal.xml</File>
    <File>acab-20231231_def.xml</File>
    <File>acab-20231231_lab.xml</File>
    <File>acab-20231231_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="d509388ds4a.htm">d509388ds4a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g509388g00n37.jpg</File>
    <File>g509388g01j05.jpg</File>
    <File>g509388g02p02.jpg</File>
    <File>g509388g03k03.jpg</File>
    <File>g509388g03p03.jpg</File>
    <File>g509388g04p03.jpg</File>
    <File>g509388g05p04.jpg</File>
    <File>g509388g09g09.jpg</File>
    <File>g509388g10g10.jpg</File>
    <File>g509388g11g11.jpg</File>
    <File>g509388g15x15.jpg</File>
    <File>g509388g16p07.jpg</File>
    <File>g509388g17p00.jpg</File>
    <File>g509388g17p01.jpg</File>
    <File>g509388g17p03.jpg</File>
    <File>g509388g24m01.jpg</File>
    <File>g509388g24m02.jpg</File>
    <File>g509388g24m04.jpg</File>
    <File>g509388g24m05.jpg</File>
    <File>g509388g24m06.jpg</File>
    <File>g509388g24m08.jpg</File>
    <File>g509388g30k30.jpg</File>
    <File>g509388g31k31.jpg</File>
    <File>g509388g40n10.jpg</File>
    <File>g509388g56s02.jpg</File>
    <File>g509388g89s10.jpg</File>
    <File>g509388g97s30.jpg</File>
    <File>g509388g98s89.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="399">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d509388ds4a.htm": {
   "nsprefix": "acab",
   "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "acab-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "acab-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "acab-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "acab-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acab-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d509388ds4a.htm"
     ]
    }
   },
   "keyStandard": 163,
   "keyCustom": 93,
   "axisStandard": 17,
   "axisCustom": 5,
   "memberStandard": 17,
   "memberCustom": 25,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.atlanticcoastalacquisition.com/20231231": 1
   },
   "contextCount": 133,
   "entityCount": 1,
   "segmentCount": 42,
   "elementCount": 402,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 399,
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.atlanticcoastalacquisition.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
     "longName": "1004 - Statement - Consolidated Statements Of Operations",
     "shortName": "Consolidated Statements Of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:OperationAndFormationCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:OperationAndFormationCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
     "longName": "1005 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit",
     "shortName": "Consolidated Statements Of Changes In Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
     "longName": "1006 - Statement - Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)",
     "shortName": "Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1007 - Statement - Consolidated Statements Of Cash Flows",
     "shortName": "Consolidated Statements Of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations",
     "longName": "1008 - Disclosure - Organization And Plan Of Business Operations",
     "shortName": "Organization And Plan Of Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1009 - Disclosure - Summary Of Significant Accounting Policies",
     "shortName": "Summary Of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering",
     "longName": "1010 - Disclosure - Initial Public Offering",
     "shortName": "Initial Public Offering",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:DisclosureOfInitialPublicOffering",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:DisclosureOfInitialPublicOffering",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.atlanticcoastalacquisition.com/role/PrivatePlacement",
     "longName": "1011 - Disclosure - Private Placement",
     "shortName": "Private Placement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:DisclosureOfPrivatePlacement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:DisclosureOfPrivatePlacement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions",
     "longName": "1012 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.atlanticcoastalacquisition.com/role/Commitments",
     "longName": "1013 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit",
     "longName": "1014 - Disclosure - Stockholders' Deficit",
     "shortName": "Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxes",
     "longName": "1015 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements",
     "longName": "1016 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SubsequentEvents",
     "longName": "1017 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1018 - Disclosure - Summary Of Significant Accounting Policies (Policies)",
     "shortName": "Summary Of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1019 - Disclosure - Summary Of Significant Accounting Policies (Tables)",
     "shortName": "Summary Of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables",
     "longName": "1020 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables",
     "longName": "1021 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
     "longName": "1022 - Disclosure - Organization And Plan Of Business Operations - Additional Information (Details)",
     "shortName": "Organization And Plan Of Business Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "acab:DisclosureOfInitialPublicOffering",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_13_2022To01_13_2022",
      "name": "acab:GrossProceedsFromInitialPublicOffer",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails",
     "longName": "1023 - Disclosure - Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details)",
     "shortName": "Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "acab:GrossProceeds",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022",
      "name": "acab:GrossProceeds",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails",
     "longName": "1024 - Disclosure - Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details)",
     "shortName": "Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1025 - Disclosure - Summary Of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary Of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
     "longName": "1026 - Disclosure - Initial Public Offering - Additional Information (Details)",
     "shortName": "Initial Public Offering - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "acab:DisclosureOfInitialPublicOffering",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:CommonStockConversionBasis",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "acab:DisclosureOfInitialPublicOffering",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
     "longName": "1027 - Disclosure - Private Placement - Additional Information (Details)",
     "shortName": "Private Placement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "acab:DisclosureOfPrivatePlacement",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "acab:DisclosureOfPrivatePlacement",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "1028 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "PAsOn12_15_2023",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:OtherLoansPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
     "longName": "1029 - Disclosure - Commitments - Additional Information (Details)",
     "shortName": "Commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:UnderwritingDiscountPerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:UnderwritingDiscountPerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails",
     "longName": "1030 - Disclosure - Stockholders' Deficit - Additional Information (Details)",
     "shortName": "Stockholders' Deficit - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "acab:NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "longName": "1031 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails",
     "longName": "1032 - Disclosure - Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details)",
     "shortName": "Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "1033 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1034 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails",
     "longName": "1035 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1036 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_11_2024To01_11_2024",
      "name": "acab:PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_11_2024To01_11_2024",
      "name": "acab:PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d509388ds4a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "acab_AbproBioCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AbproBioCoMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abpro Bio Co [Member]",
        "documentation": "Abpro Bio Co"
       }
      }
     },
     "auth_ref": []
    },
    "acab_AbproMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AbproMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abpro [Member]",
        "documentation": "Abpro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "acab_AccruedOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AccruedOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Offering Costs",
        "terseLabel": "Accrued offering costs",
        "documentation": "Accrued offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r463",
      "r523"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r360",
      "r487",
      "r488",
      "r489",
      "r506",
      "r524"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted exercise price of warrants as a percentage of newly issued price",
        "terseLabel": "Adjusted exercise price of warrants as a percentage of newly issued price",
        "documentation": "Adjusted exercise price of warrants as a percentage of newly issued price."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustedExercisePriceOfWarrantsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustedExercisePriceOfWarrantsAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Exercise Price Of Warrants [Axis]",
        "documentation": "Adjusted exercise price of warrants ."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustedExercisePriceOfWarrantsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustedExercisePriceOfWarrantsDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Exercise Price Of Warrants [Domain]",
        "documentation": "Adjusted exercise price of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustedExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustedExercisePriceOneMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Exercise Price One [Member]",
        "documentation": "Adjusted exercise price one member"
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustedExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustedExercisePriceTwoMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Exercise Price Two [Member]",
        "documentation": "Adjusted exercise price two member."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Compensation Expense for Fair value of assigned founder shares to Apeiron",
        "terseLabel": "Compensation Expense \u2013 Fair value of assigned Founder Shares to Apeiron",
        "documentation": "Adjustments to additional paid in capital compensation expense for fair value of assigned founder shares to apeiron."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdjustmentsToAdditionalPaidInCapitalExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Excise Tax",
        "terseLabel": "Excise tax",
        "documentation": "Adjustments to additional paid in capital excise tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "terseLabel": "Fair value of Public Warrants at issuance",
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Allocated value of transaction costs to Series A common stock",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Sale of 13,850,000 Private Placement Warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdvisorMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisor [Member]",
        "terseLabel": "Advisor [Member]",
        "documentation": "Advisor."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AdvisoryServiceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AdvisoryServiceFee",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory service fee",
        "terseLabel": "advisory service fee",
        "documentation": "Advisory service fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock- based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r248"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "acab_AmountToBeDepositedInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AmountToBeDepositedInTrustAccount",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount To Be Deposited In Trust Account",
        "terseLabel": "Amount to be deposited in trust account",
        "documentation": "Amount to be deposited in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_AssetHeldInTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetHeldInTrustMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-in-Trust [Member]",
        "documentation": "Asset held in trust."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r122",
      "r139",
      "r169",
      "r172",
      "r174",
      "r179",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r272",
      "r274",
      "r290",
      "r331",
      "r396",
      "r463",
      "r474",
      "r497",
      "r498",
      "r510"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r127",
      "r139",
      "r179",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r272",
      "r274",
      "r290",
      "r463",
      "r497",
      "r498",
      "r510"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Marketable securities held in Trust Account",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AssetsHeldInTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrust",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-in-Trust, Total",
        "verboseLabel": "Common stock held in trust",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "acab_AssetsHeldInTrustAccountPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AssetsHeldInTrustAccountPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held in Trust Account [Policy Text Block]",
        "terseLabel": "Cash and Marketable Securities Held in Trust Account",
        "documentation": "Assets Held in Trust Account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrustCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset, Held-in-Trust, Current",
        "terseLabel": "Cash and marketable securities held in Trust Account",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "acab_AssetsHeldInTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "AssetsHeldInTrustMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held In Trust [Member]",
        "terseLabel": "Asset Held In Trust [Member]",
        "documentation": "Assets held in trust member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldInTrustNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held-in-trust, Noncurrent",
        "terseLabel": "Cash and marketable securities held in Trust Account",
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "acab_BasicAndDilutedLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "BasicAndDilutedLossPerShareAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss Per Share [Abstract]",
        "terseLabel": "Basic and diluted net loss per common stock"
       }
      }
     },
     "auth_ref": []
    },
    "acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Weighted Average Number Of Share Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "acab_BasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "BasisAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis [Axis]",
        "documentation": "Basis."
       }
      }
     },
     "auth_ref": []
    },
    "acab_BasisDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "BasisDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis [Domain]",
        "documentation": "Basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash at bank",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r333",
      "r371",
      "r391",
      "r463",
      "r474",
      "r481"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r120",
      "r449"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodStartLabel": "Cash \u2013 Beginning",
        "periodEndLabel": "Cash \u2013 Ending",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r85",
      "r136"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Change in Cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r85"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash Equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r520"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal Deposit Insurance Corporation coverage",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassAAndClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassAAndClassBCommonStockMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A And Class B Common Stock [Member]",
        "terseLabel": "Series A and Series B common stock [Member]",
        "documentation": "Class A and Class B common stock [member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/CoverPage",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r124",
      "r125",
      "r139",
      "r159",
      "r160",
      "r162",
      "r164",
      "r167",
      "r168",
      "r179",
      "r190",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r204",
      "r205",
      "r208",
      "r211",
      "r218",
      "r290",
      "r351",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r383",
      "r405",
      "r427",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r479",
      "r484",
      "r491"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r167",
      "r204",
      "r205",
      "r206",
      "r208",
      "r211",
      "r216",
      "r218",
      "r351",
      "r352",
      "r353",
      "r354",
      "r458",
      "r479",
      "r484"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrants or rights exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Class of warrants or rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsIssuePricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsIssuePricePerUnit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrants or rights issue price per unit",
        "documentation": "Class of warrants or rights issue price per unit."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrants or rights issued during the period units",
        "documentation": "Class of warrants or rights issued during the period units."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsLockInPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsLockInPeriod",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrants or rights lock in period",
        "terseLabel": "Class of warrants or rights lock in period",
        "documentation": "Class of warrants or rights lock in period."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsRedemptionPricePerUnit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrants or rights redemption price per unit",
        "terseLabel": "Class of warrants or rights redemption price per unit",
        "documentation": "Class of warrants or rights redemption price per unit."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrants or Rights Warrants Issued During the Period Units",
        "terseLabel": "Class of warrants or rights warrants issued during the period units",
        "documentation": "Class of warrants or rights warrants issued during the period units."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrants or Rights Warrants Issued Issue Price Per Warrant.",
        "terseLabel": "Class of warrants or rights warrants issued issue price per warrant",
        "documentation": "Class of warrants or rights warrants issued issue price per warrant."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassificationOfCommonStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassificationOfCommonStockAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification Of Common Stock [Axis]",
        "documentation": "Classification of common stock [axis]."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ClassificationOfCommonStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ClassificationOfCommonStockDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification Of Common Stock [Domain]",
        "documentation": "Classification of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r71",
      "r332",
      "r382"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r184",
      "r185",
      "r446",
      "r496"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Series A common stock [Member]",
        "definitionGuidance": "Series A [Member]",
        "verboseLabel": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Series B common stock [Member]",
        "definitionGuidance": "Series B [Member]",
        "verboseLabel": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common Stock, Conversion Basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "acab_CommonStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "CommonStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuance Costs",
        "verboseLabel": "Less: Series A common stock issuance costs",
        "documentation": "Common stock issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r487",
      "r488",
      "r506",
      "r521",
      "r524"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r383"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock held",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r75",
      "r383",
      "r402",
      "r524",
      "r525"
     ]
    },
    "acab_CommonStockSharesRedeemable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "CommonStockSharesRedeemable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Redeemable",
        "terseLabel": "Common stock shares redeemable",
        "documentation": "Common stock shares redeemable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Number of shares issuable on acquisition",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r335",
      "r463"
     ]
    },
    "acab_CommonStockValueRedeemable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "CommonStockValueRedeemable",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Value Redeemable",
        "terseLabel": "Common stock value redeemable",
        "documentation": "Common stock value redeemable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r110"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r451"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "acab_ConversionOfPermanentEquityIntoTemporaryEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ConversionOfPermanentEquityIntoTemporaryEquityShares",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Permanent Equity Into Temporary Equity Shares",
        "terseLabel": "Conversion of permanent equity into temporary equity shares",
        "documentation": "Conversion of permanent equity into temporary equity shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r486",
      "r504"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r486",
      "r504"
     ]
    },
    "acab_DebtInstrumentConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DebtInstrumentConversionPricePerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Conversion Price Per Share",
        "terseLabel": "Debt instrument conversion price per share",
        "documentation": "Debt instrument conversion price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Common stock, price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r200"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face value",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r199",
      "r298",
      "r456",
      "r457"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "verboseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred underwriting fee payable",
        "verboseLabel": "Deferred underwriting commission",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r503",
      "r504"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "verboseLabel": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DeferredOfferingCostsIncludedInAccruedOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs included in accrued offering costs",
        "terseLabel": "Deferred offering costs included in accrued offering costs",
        "documentation": "Deferred offering costs included in accrued offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r503",
      "r504"
     ]
    },
    "acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Start Up And Organization Costs",
        "terseLabel": "Startup/Organization Expenses",
        "documentation": "Deferred tax assets capitalized start up and organization costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross, Total",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Total",
        "totalLabel": "Deferred tax assets, net of allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r502"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "acab_DeferredUnderwritingCommissionNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DeferredUnderwritingCommissionNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Underwriting Commission Non Current",
        "documentation": "Deferred underwriting commission non current."
       }
      }
     },
     "auth_ref": []
    },
    "acab_DeferredUnderwritingDiscountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DeferredUnderwritingDiscountPerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred underwriting discount per share",
        "terseLabel": "Deferred underwriting discount per share",
        "documentation": "Deferred underwriting discount per share."
       }
      }
     },
     "auth_ref": []
    },
    "acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Underwriting Fee Payable As Non CashInvesting and Financing Activities",
        "terseLabel": "Deferred underwriting fee payable",
        "documentation": "Deferred underwriting fee payable as non cash investing and financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r60",
      "r61",
      "r64",
      "r143"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r492",
      "r522"
     ]
    },
    "acab_DisclosureOfInitialPublicOffering": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DisclosureOfInitialPublicOffering",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Initial Public Offering",
        "terseLabel": "Initial Public Offering",
        "documentation": "Disclosure Of Initial Public Offering."
       }
      }
     },
     "auth_ref": []
    },
    "acab_DisclosureOfPrivatePlacement": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "DisclosureOfPrivatePlacement",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Private Placement",
        "terseLabel": "Private Placement",
        "documentation": "Disclosure of private placement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic and diluted income (loss) per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r159",
      "r162",
      "r163",
      "r164",
      "r165",
      "r284",
      "r285",
      "r329",
      "r341",
      "r452"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r162"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Basic and diluted income (loss) per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r159",
      "r162",
      "r163",
      "r164",
      "r165",
      "r284",
      "r285",
      "r329",
      "r341",
      "r452"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective date for Levy of Federal Excise Tax on Stock Buy Back",
        "terseLabel": "Effective date for levy of federal excise tax on stock buy back",
        "documentation": "Effective date for levy of federal excise tax on stock buy back."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax provision",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r253",
      "r267"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r505"
     ]
    },
    "acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Non Deductible Expense Business Combination",
        "terseLabel": "Business combination expenses",
        "documentation": "Effective income tax rate reconciliation non deductible expense business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "terseLabel": "Meals\u00a0&amp; entertainment",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r505"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total",
        "verboseLabel": "Fines and penalties",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r505"
     ]
    },
    "acab_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company [Policy Text Block]",
        "terseLabel": "Emerging Growth Company",
        "documentation": "Emerging growth company ."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/CoverPage",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r116",
      "r131",
      "r132",
      "r133",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r166",
      "r180",
      "r181",
      "r220",
      "r240",
      "r241",
      "r242",
      "r263",
      "r264",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r344",
      "r345",
      "r346",
      "r360",
      "r427"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "acab_ExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise Tax Payable Current",
        "terseLabel": "Excise tax payable",
        "documentation": "Excise tax payable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r66",
      "r99"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r288",
      "r311",
      "r312",
      "r313",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r227",
      "r288",
      "r311",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/FairValueMeasurementsScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r311",
      "r312",
      "r313",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12"
     ]
    },
    "acab_FederalAndStateAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "FederalAndStateAuthorityMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal And State Authority [Member]",
        "terseLabel": "Federal And State Authority [Member]",
        "documentation": "Federal and state authority."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal"
       }
      }
     },
     "auth_ref": []
    },
    "acab_FeeSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "FeeSharesMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Shares [Member]",
        "documentation": "Fee shares."
       }
      }
     },
     "auth_ref": []
    },
    "acab_FounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "FounderSharesMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares [Member]",
        "documentation": "Founder shares."
       }
      }
     },
     "auth_ref": []
    },
    "acab_FromTheCompletionOfBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "FromTheCompletionOfBusinessCombinationMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From The Completion Of Business Combination [Member]",
        "terseLabel": "From The Completion Of Business Combination [Member]",
        "documentation": "From the completion of business combination."
       }
      }
     },
     "auth_ref": []
    },
    "acab_FromTheCompletionOfInitialPublicOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "FromTheCompletionOfInitialPublicOfferMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From The Completion Of Initial Public Offer [Member]",
        "documentation": "From the completion of initial public offer ."
       }
      }
     },
     "auth_ref": []
    },
    "acab_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "GrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds",
        "verboseLabel": "Gross proceeds",
        "documentation": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "acab_GrossProceedsFromInitialPublicOffer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "GrossProceedsFromInitialPublicOffer",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds From Initial Public Offer",
        "terseLabel": "Gross proceeds from initial public offer",
        "documentation": "Gross proceeds from initial public offer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81",
      "r103",
      "r169",
      "r171",
      "r173",
      "r175",
      "r330",
      "r339",
      "r454"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r249",
      "r254",
      "r255",
      "r261",
      "r265",
      "r268",
      "r269",
      "r270",
      "r356"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Income tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r113",
      "r155",
      "r156",
      "r170",
      "r252",
      "r266",
      "r342"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r250",
      "r251",
      "r255",
      "r256",
      "r260",
      "r262",
      "r350"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net, Total",
        "terseLabel": "Income taxes paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Classification Of Series A Common Stock Subject To Possible Redemption",
        "terseLabel": "Initial classification of Series A common stock subject to possible redemption",
        "documentation": "Initial classification of Series A common stock subject to possible redemption."
       }
      }
     },
     "auth_ref": []
    },
    "acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InterestEarnedOnMarketableSecuritiesHeldInTrustAccount",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Earned on Marketable Securities Held in Trust Account",
        "negatedLabel": "Interest earned on Cash and marketable securities held in Trust Account",
        "documentation": "Interest earned on marketable securities held in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Other",
        "terseLabel": "Interest income \u2013 bank",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interse Transfer Of Shares Transferrable By Sponsor To Non Redemption Holders",
        "terseLabel": "Interse transfer of shares to be made",
        "documentation": "Interse transfer of shares transferrable by sponsor to non redemption holders."
       }
      }
     },
     "auth_ref": []
    },
    "acab_InvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InvesteeAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Axis]",
        "documentation": "Investee."
       }
      }
     },
     "auth_ref": []
    },
    "acab_InvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InvesteeDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Domain]",
        "documentation": "Investee."
       }
      }
     },
     "auth_ref": []
    },
    "acab_InvestmentIncomeExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "InvestmentIncomeExpenseNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income Expense Nonoperating",
        "terseLabel": "Interest earned on Cash and marketable securities held in Trust Account",
        "documentation": "Investment income expense nonoperating."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r139",
      "r179",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r273",
      "r274",
      "r275",
      "r290",
      "r381",
      "r453",
      "r474",
      "r497",
      "r510",
      "r511"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r102",
      "r338",
      "r463",
      "r485",
      "r493",
      "r507"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r119",
      "r139",
      "r179",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r273",
      "r274",
      "r275",
      "r290",
      "r463",
      "r497",
      "r510",
      "r511"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidation Basis of Accounting, Accrued Costs to Dispose of Assets and Liabilities",
        "terseLabel": "Expenses payable on liquidation",
        "documentation": "Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "acab_LockInPeriodOfShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "LockInPeriodOfShares",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lock in Period of Shares",
        "terseLabel": "Lock in period of shares",
        "documentation": "Lock in period of shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r43"
     ]
    },
    "acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Cash and Cash Equivalents Needed To Consummate Business Combination",
        "terseLabel": "Minimum cash and cash equivalents",
        "documentation": "Minimum cash and cash equivalents needed to consummate business combination."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r229",
      "r315",
      "r343",
      "r373",
      "r374",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r455",
      "r458",
      "r462",
      "r464",
      "r499",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "acab_MinimumNetWorthNeededToConsummateBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "MinimumNetWorthNeededToConsummateBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Net worth Needed To Consummate Business Combination",
        "terseLabel": "Minimum value of net tangible assets",
        "documentation": "Minimum net worth needed to consummate business combination."
       }
      }
     },
     "auth_ref": []
    },
    "acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum notice period to be given to the holders of warrants",
        "terseLabel": "Minimum notice period to be given to the holders of warrants",
        "documentation": "Minimum notice period to be given to the holders of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization And Plan Of Business Operations",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      },
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "presentationGuidance": "Net income (loss)",
        "definitionGuidance": "Net income",
        "verboseLabel": "Allocation of net income, as adjusted",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r87",
      "r104",
      "r117",
      "r128",
      "r129",
      "r133",
      "r139",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r161",
      "r169",
      "r171",
      "r173",
      "r175",
      "r179",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r285",
      "r290",
      "r340",
      "r404",
      "r425",
      "r426",
      "r454",
      "r473",
      "r497"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NonRedeemableCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NonRedeemableCommonStockMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Redeemable common stock [Member]",
        "terseLabel": "Nonredeemable common stock [Member]",
        "documentation": "Non Redeemable common stock [member]."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NonRedemptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NonRedemptionAgreementMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Redemption Agreement [Member]",
        "terseLabel": "Non Redemption Agreement [Member]",
        "documentation": "Non redemption agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "verboseLabel": "Debt instrument, unused borrowing capacity, amount",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r101",
      "r519"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "terseLabel": "Extension promissory note - related party",
        "verboseLabel": "Notes payable to related party classified as current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of consecutive trading days for determining the share price",
        "terseLabel": "Number of consecutive trading days for determining the share price",
        "documentation": "Number of consecutive trading days for determining the share price."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Days After Consummation Of Business Combination With in Which The Securities Shall Be Registered",
        "terseLabel": "Number of days after consummation of business combination within which the securities shall be registered",
        "documentation": "Number of days after consummation of business combination with in which these curities shall be registered."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Days After Which Business Combination With in Which Securities Registration Shall Be Effective",
        "terseLabel": "Number of days after which business combination within which securities registration shall be effective",
        "documentation": "Number of days after which business combination with in which securities registration shall be effective."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfDaysWithinWhichPublicSharesShallBeRedeemed",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Days Within Which Public Shares Shall Be Redeemed",
        "documentation": "Number of days within which public shares shall be redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfSharesNotAvailableForRedemption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfSharesNotAvailableForRedemption",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares Not Available for Redemption",
        "terseLabel": "Number of shares not available for Redemption",
        "documentation": "Number of shares not available for Redemption."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfTradingDaysForDeterminingSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfTradingDaysForDeterminingSharePrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Trading Days for Determining Share Price",
        "terseLabel": "Number of trading days for determining share price",
        "documentation": "Number of trading days for determining share price."
       }
      }
     },
     "auth_ref": []
    },
    "acab_NumberOfTradingDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "NumberOfTradingDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of trading days for determining the share price",
        "terseLabel": "Number of trading days for determining the share price",
        "documentation": "Number of trading days for determining the share price."
       }
      }
     },
     "auth_ref": []
    },
    "acab_OfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs",
        "verboseLabel": "Offering costs",
        "documentation": "Offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "acab_OfferingCostsAllocatedInShareholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OfferingCostsAllocatedInShareholdersEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Allocated In Shareholders Equity",
        "verboseLabel": "Offering costs allocated in shareholders equity",
        "documentation": "Offering costs allocated in shareholders equity."
       }
      }
     },
     "auth_ref": []
    },
    "acab_OfferingCostsAllocatedInTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OfferingCostsAllocatedInTemporaryEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Allocated In Temporary Equity",
        "verboseLabel": "Offering costs allocated in temporary equity",
        "documentation": "Offering costs allocated in temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r171",
      "r173",
      "r175",
      "r454"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "acab_OperationAndFormationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OperationAndFormationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operation and Formation Costs",
        "terseLabel": "Operation and formation costs",
        "documentation": "Operation and formation costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acab_OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfStatementOfFinanacialStatementsTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Statement Of Finanacial Statements [Table]",
        "documentation": "Organization consolidation and presentation of statement of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of statement of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "terseLabel": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Advance from related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r463"
     ]
    },
    "us-gaap_OtherLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Loans Payable",
        "terseLabel": "Other Commitment",
        "documentation": "Amount of long-term loans payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r101",
      "r519"
     ]
    },
    "acab_OtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "OtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering costs",
        "terseLabel": "Other offering costs",
        "documentation": "Other offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PaymentOfUnderwritingDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PaymentOfUnderwritingDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of underwriting discount",
        "verboseLabel": "Payment of underwriting discount",
        "documentation": "Payment of underwriting discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Redemption of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Investment of cash in Trust Account",
        "terseLabel": "Cash deposited in Trust Account",
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "acab_PenaltiesAndInterestOnTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PenaltiesAndInterestOnTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penalties And Interest On Taxes",
        "negatedLabel": "Penalties and interest on taxes",
        "documentation": "Penalties and interest on taxes."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PerShareAmountAvailableForDistribution": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PerShareAmountAvailableForDistribution",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share amount available for distribution",
        "documentation": "Per share amount available for distribution."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PerShareAmountToBeMaintainedInTheTrustAccountForDistribution",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share amount to be maintained in the trust account for distribution",
        "documentation": "Per share amount to be maintained in the trust account for distribution."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PerSharePaymentMadeToAcquireRestrictedInvestments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PerSharePaymentMadeToAcquireRestrictedInvestments",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share payment made to acquire restricted investments",
        "documentation": "Per share payment made to acquire restricted investments."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PerShareRedemptionTriggerPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PerShareRedemptionTriggerPrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "per share redemption trigger price",
        "terseLabel": "per share redemption trigger price",
        "documentation": "Per share redemption trigger price."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PerShareValueOfTheAmountToBeDepositedInTrustAccount",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share value of the amount to be deposited in trust account",
        "terseLabel": "Per share value of the amount to be deposited in trust account",
        "documentation": "Per share value of the amount to be deposited in trust account."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfAdvisoryServiceFee": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfAdvisoryServiceFee",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "percentage of advisory service fee",
        "terseLabel": "percentage of advisory service fee",
        "documentation": "percentage of advisory service fee."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfCommonStockIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfCommonStockIssuedAndOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of common stock issued and outstanding",
        "terseLabel": "Percentage of common stock issued and outstanding",
        "documentation": "Percentage of common stock issued and outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfFederalExciseTaxOnStockBuyBack": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfFederalExciseTaxOnStockBuyBack",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Federal Excise Tax on Stock Buy Back",
        "terseLabel": "Percentage of Federal excise tax on share buy back",
        "documentation": "Percentage of Federal excise tax on share buy back."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Gross Amount Payable to Sponsor Raised from Investors",
        "terseLabel": "Percentage of gross amount payable to sponsor raised from investors",
        "documentation": "Percentage of gross amount payable to sponsor raised from investors."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of net assets in the trust account for which the business combination shall be effected",
        "documentation": "Percentage of net assets in the trust account of the acquiree for which business combination shall be effected."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfSharesRedeemable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfSharesRedeemable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Shares Redeemable",
        "terseLabel": "Percentage of shares redeemable",
        "documentation": "Percentage of shares redeemable."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Shares Redeemable In Case Business Combination Is Not Consummated",
        "documentation": "Percentage of shares redeemable in case business combination is not consummated."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Shares That Can Be Transferred Without Any Restriction",
        "documentation": "Percentage of shares that can be transferred without any restriction."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PeriodAfterWhichTheWarrantsAreExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PeriodAfterWhichTheWarrantsAreExercisable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period after which the warrants are exercisable",
        "terseLabel": "Period after which the warrants are exercisable",
        "documentation": "Period after which the warrants are exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PeriodAfterWhichTheWarrantsAreExercisableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PeriodAfterWhichTheWarrantsAreExercisableAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period After Which The Warrants Are Exercisable [Axis]",
        "documentation": "Period after which the warrants are exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PeriodAfterWhichTheWarrantsAreExercisableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PeriodAfterWhichTheWarrantsAreExercisableDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period After Which The Warrants Are Exercisable [Domain]",
        "documentation": "Period after which the warrants are exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PostBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PostBusinessCombinationMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Business Combination [Member]",
        "terseLabel": "Post Business Combination [Member]",
        "documentation": "Post Business Combination [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r204"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r383"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r204"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r383",
      "r402",
      "r524",
      "r525"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r334",
      "r463"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r182",
      "r183",
      "r450"
     ]
    },
    "acab_PrivatePlacementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PrivatePlacementLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Line Items]",
        "documentation": "Private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PrivatePlacementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PrivatePlacementTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Table]",
        "documentation": "Private Placement."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PrivatePlacementWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PrivatePlacementWarrantMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant [Member]",
        "documentation": "Private placement warrant."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants [Member]",
        "documentation": "Private placement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ProceedsAllocatedToPublicWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ProceedsAllocatedToPublicWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds allocated to Public Warrants",
        "terseLabel": "Less: Proceeds allocated to Public Warrants",
        "documentation": "Proceeds allocated to Public Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible promissory note - related party",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from equity used for funding business combination as a percentage of the total",
        "terseLabel": "Proceeds from equity used for funding business combination as a percentage of the total",
        "documentation": "Proceeds from equity used for funding business combination as a percentage of the total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from sale of Private Placement Warrants",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Debt",
        "terseLabel": "Advances from related party",
        "documentation": "Amount of cash inflow from debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from extension promissory note \u2013 related party",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Cash withdrawn from Trust Account to pay franchise and income taxes",
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfTrustAssetsToPayExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Trust Assets to Pay Expenses",
        "terseLabel": "Proceeds from sale of trust assets to pay expenses",
        "documentation": "Amount of cash inflows from the sale of trust assets to pay trust expenses."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "acab_ProceedsFromTheIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ProceedsFromTheIssuanceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the Issuance of Warrants",
        "terseLabel": "Proceeds from the issuance of warrants",
        "documentation": "Proceeds from the issuance of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ProceedsFromTrustAccountInConnectionWithRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ProceedsFromTrustAccountInConnectionWithRedemption",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Trust Account in connection with redemption",
        "terseLabel": "Cash withdrawn from Trust Account in connection with redemption",
        "documentation": "Proceeds from trust account in connection with redemption."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory note ."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PublicWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PublicWarrantMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant [Member]",
        "documentation": "Public warrant."
       }
      }
     },
     "auth_ref": []
    },
    "acab_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r221",
      "r229",
      "r235",
      "r236",
      "r237",
      "r314",
      "r315",
      "r343",
      "r373",
      "r374",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r455",
      "r458",
      "r462",
      "r464",
      "r467",
      "r495",
      "r499",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r221",
      "r229",
      "r235",
      "r236",
      "r237",
      "r314",
      "r315",
      "r343",
      "r373",
      "r374",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r455",
      "r458",
      "r462",
      "r464",
      "r467",
      "r495",
      "r499",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "acab_RedeemableCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "RedeemableCommonStockMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable common stock [Member]",
        "terseLabel": "Redeemable common stock [Member]",
        "documentation": "Redeemable common stock."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ReimbursementByUnderwriters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ReimbursementByUnderwriters",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement By Underwriters",
        "documentation": "Reimbursement by underwriters."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r303",
      "r304",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r401",
      "r403",
      "r434"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r303",
      "r304",
      "r305",
      "r306",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r401",
      "r403",
      "r434"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r509"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r412"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r303",
      "r304",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r401",
      "r403",
      "r434",
      "r509"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r307",
      "r357",
      "r358",
      "r359",
      "r410",
      "r411",
      "r412",
      "r431",
      "r433"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayment of promissory note \u2013 related party",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "acab_RestrictionOnTransferOfSponsorSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "RestrictionOnTransferOfSponsorSharesMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restriction on Transfer of Sponsor Shares [Member]",
        "documentation": "Restriction on transfer of sponsor shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r95",
      "r337",
      "r347",
      "r348",
      "r355",
      "r384",
      "r463"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r180",
      "r181",
      "r240",
      "r241",
      "r242",
      "r263",
      "r264",
      "r276",
      "r278",
      "r279",
      "r281",
      "r283",
      "r344",
      "r346",
      "r360",
      "r524"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Excise Tax Payable, Current",
        "verboseLabel": "Excise tax liability",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39",
      "r159",
      "r160",
      "r162"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of the calculation of basic and diluted net income per common stock",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39",
      "r490"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r178"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r408",
      "r409",
      "r412"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r93",
      "r94",
      "r95",
      "r123",
      "r124",
      "r125",
      "r167",
      "r204",
      "r205",
      "r206",
      "r208",
      "r211",
      "r216",
      "r218",
      "r351",
      "r352",
      "r353",
      "r354",
      "r458",
      "r479",
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "acab_SharesAreSubjectToForfeiture": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "SharesAreSubjectToForfeiture",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "shares are subject to forfeiture",
        "terseLabel": "shares are subject to forfeiture",
        "documentation": "Shares are subject to forfeiture."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "definitionGuidance": "Shares issued price per share",
        "terseLabel": "Sale of stock issue price per share",
        "verboseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Balance, Shares",
        "periodEndLabel": "Balance, Share",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current",
        "terseLabel": "Common stock to be redeemed (2,768,301 shares of Series A common stock)",
        "verboseLabel": "Common stock to be redeemed",
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares",
        "terseLabel": "Common stock to be redeemed (2,768,301 shares of Series A common stock)",
        "verboseLabel": "Temporary equity shares subject to redemption",
        "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary Of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r137"
     ]
    },
    "acab_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "SponsorMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "terseLabel": "Sponsor [Member]",
        "documentation": "Sponsor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/CoverPage",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/PrivatePlacementAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r124",
      "r125",
      "r139",
      "r159",
      "r160",
      "r162",
      "r164",
      "r167",
      "r168",
      "r179",
      "r190",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r204",
      "r205",
      "r208",
      "r211",
      "r218",
      "r290",
      "r351",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r383",
      "r405",
      "r427",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r479",
      "r484",
      "r491"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/CoverPage",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r24",
      "r116",
      "r131",
      "r132",
      "r133",
      "r144",
      "r145",
      "r146",
      "r148",
      "r154",
      "r156",
      "r166",
      "r180",
      "r181",
      "r220",
      "r240",
      "r241",
      "r242",
      "r263",
      "r264",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r344",
      "r345",
      "r346",
      "r360",
      "r427"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r166",
      "r316",
      "r349",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r406",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r468"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r166",
      "r316",
      "r349",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r406",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r468"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series Class B shares to Series Class A Non-redeemable shares, Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r50",
      "r95",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock shares issued during the period for services shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficitParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during the period shares",
        "definitionGuidance": "Stock issued during the period shares new issues",
        "presentationGuidance": "Stock issued during period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r74",
      "r75",
      "r95",
      "r351",
      "r427",
      "r441"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "verboseLabel": "Forfeiture of Founder Shares, Shares",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series Class B shares to Series Class A Non-redeemable shares",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r24",
      "r95"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock shares issued during the period for services value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "acab_StockholderNonRedemptionAgreementAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "StockholderNonRedemptionAgreementAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder Non Redemption Agreement Adjustment",
        "terseLabel": "Stockholder non-redemption agreement",
        "documentation": "Stockholder non-redemption agreement adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "acab_StockholderNonRedemptionAgreementAdjustmentReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "StockholderNonRedemptionAgreementAdjustmentReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder Non Redemption Agreement Adjustment Reduction",
        "terseLabel": "Stockholder non-redemption agreement",
        "documentation": "Stockholder\u00a0non-redemption\u00a0agreement adjustment reduction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders' Deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r79",
      "r89",
      "r385",
      "r402",
      "r428",
      "r429",
      "r463",
      "r474",
      "r485",
      "r493",
      "r507",
      "r524"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' DEFICIT",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r138",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r220",
      "r282",
      "r430",
      "r432",
      "r445"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r309"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r309"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r309"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r309"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r309"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r310"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/InitialPublicOfferingAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplementary\u00a0cashflow\u00a0information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficit",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value",
        "negatedTerseLabel": "Remeasurement of Series A common stock to redemption amount",
        "verboseLabel": "Plus: Remeasurement of carrying value to redemption value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "verboseLabel": "Less:Redemptions (redeemed in December 2023, paid in January 2024)",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r46"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheets",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Series A common stock subject to possible redemption; 667,391 and 30,000,000 shares issued and outstanding at December 31, 2023 and 2022 at redemption value of $10.93 and $10.30 per share, respectively",
        "verboseLabel": "Plus: Series A common stock subject to possible redemption",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r247",
      "r336"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "acab_TemporaryEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TemporaryEquityPolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Series A Common Stock Subject to Possible Redemption",
        "documentation": "Temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Temporary equity, redemption price per share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r46"
     ]
    },
    "acab_TemporaryEquityRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TemporaryEquityRedemptionValue",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSeriesACommonStockReflectedInTheConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Redemption Value",
        "terseLabel": "Less: Redemption",
        "documentation": "Temporary equity redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "definitionGuidance": "Temporary equity, shares outstanding",
        "terseLabel": "Temporary equity shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "acab_TemporaryEquityStockRedeemedDuringThePeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TemporaryEquityStockRedeemedDuringThePeriodShares",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Stock Redeemed During The Period Shares",
        "terseLabel": "Temporary equity stock redeemed during the period shares",
        "documentation": "Temporary equity stock redeemed during the period shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Series A common stock reflected in the consolidated balance sheet",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r46"
     ]
    },
    "acab_TermOfRestrictedInvestments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TermOfRestrictedInvestments",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of restricted investments",
        "documentation": "Term of restricted investments."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ThresholdDateForConsummationOfBusinessCombinationOne": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ThresholdDateForConsummationOfBusinessCombinationOne",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold Date For Consummation Of Business Combination One",
        "terseLabel": "Threshold date for consummation of business combination one",
        "documentation": "Threshold date for consummation of business combination one."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ThresholdDateForConsummationOfBusinessCombinationThree": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ThresholdDateForConsummationOfBusinessCombinationThree",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold date for consummation of business combination three",
        "terseLabel": "Threshold date for consummation of business combination three",
        "documentation": "Threshold date for consummation of business combination three."
       }
      }
     },
     "auth_ref": []
    },
    "acab_ThresholdDateForConsummationOfBusinessCombinationTwo": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "ThresholdDateForConsummationOfBusinessCombinationTwo",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Threshold date for consummation of business combination two",
        "terseLabel": "Threshold date for consummation of business combination two",
        "documentation": "Threshold date for consummation of business combination two."
       }
      }
     },
     "auth_ref": []
    },
    "acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Limit Within Which Business Combination Shall Be Consummated From The Date Of Initial Public Offering",
        "documentation": "Time limit within which business combination shall be consummated from the date of initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r492",
      "r508"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "acab_TransactionCostsOfIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "TransactionCostsOfIssuance",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs Of Issuance",
        "documentation": "Transaction costs of issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "acab_UnderwriterFeeWaivedOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "UnderwriterFeeWaivedOff",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Fee Waived Off",
        "terseLabel": "Underwriter fee waived off",
        "documentation": "Underwriter fee waived off."
       }
      }
     },
     "auth_ref": []
    },
    "acab_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter [Member]",
        "terseLabel": "Underwriter [Member]",
        "documentation": "Underwriter."
       }
      }
     },
     "auth_ref": []
    },
    "acab_UnderwritingDiscountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "UnderwritingDiscountPerShare",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting discount per share",
        "terseLabel": "Underwriting discount per share",
        "documentation": "Underwriting discount per share."
       }
      }
     },
     "auth_ref": []
    },
    "acab_UnderwritingFeesNetOfReimbursementByUnderwriters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "UnderwritingFeesNetOfReimbursementByUnderwriters",
     "crdr": "debit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Fees Net Of Reimbursement By Underwriters",
        "documentation": "Underwriting fees net of reimbursement by underwriters."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized loss on marketable securities held in Trust Account",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r108",
      "r109",
      "r111",
      "r112"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.atlanticcoastalacquisition.com/role/IncomeTaxesScheduleOfComponentsOfTheProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "acab_VolumeWeightedAveragePriceOfShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "VolumeWeightedAveragePriceOfShares",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/StockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volume weighted average price of shares",
        "terseLabel": "Volume weighted average price of shares",
        "documentation": "Volume weighted average price of shares."
       }
      }
     },
     "auth_ref": []
    },
    "acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waiting Period after which the Share Trading Days are Considered",
        "terseLabel": "Waiting period after which the share trading days are considered",
        "documentation": "Waiting period after which the share trading days are considered."
       }
      }
     },
     "auth_ref": []
    },
    "acab_WarrantsDisclosurePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WarrantsDisclosurePolicyTextBlock",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Disclosure [Policy Text Block]",
        "terseLabel": "Warrants",
        "documentation": "Warrants disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/ConsolidatedStatementsOfOperations",
      "http://www.atlanticcoastalacquisition.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfTheCalculationOfBasicAndDilutedNetIncomePerCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r164"
     ]
    },
    "acab_WorkingCapitalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WorkingCapitalLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/OrganizationAndPlanOfBusinessOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loan",
        "verboseLabel": "Working capital",
        "documentation": "Working capital loan."
       }
      }
     },
     "auth_ref": []
    },
    "acab_WorkingCapitalLoansConvertibleIntoEquityWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WorkingCapitalLoansConvertibleIntoEquityWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loans Convertible into Equity Warrants",
        "terseLabel": "Working capital loans convertible into equity warrants",
        "documentation": "Working capital loans convertible into equity warrants."
       }
      }
     },
     "auth_ref": []
    },
    "acab_WorkingCapitalLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WorkingCapitalLoansMember",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loans [Member]",
        "documentation": "Working capital loans."
       }
      }
     },
     "auth_ref": []
    },
    "acab_WorkingCapitalLoansOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.atlanticcoastalacquisition.com/20231231",
     "localname": "WorkingCapitalLoansOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.atlanticcoastalacquisition.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loans outstanding",
        "terseLabel": "Working Capital Loans outstanding",
        "documentation": "Working capital loans outstanding."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "SubTopic": "30",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480034/205-30-25-6"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001193125-24-125209-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-125209-xbrl.zip
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M^OR,X22F,L7E1@Z= /76(3I0A9>QKYEX9?+((>NK>Y0C;+\AQF#/P)U:#IM
M=+<;TCBFPJ8-5NXP#N1]I1WM)5NP:@6L+V6GQ+_*R?>9$6FU7&.<;/Z&'/J?
M3#A'E*VC#ZNO202MRL\R5(0(XLH"Z0MK7[)+PO[+&ZWJM;C'>/(O[(LQO:=0
M$K!F0]J5J=H'TOXF&.IC'/!K1A=C!A-9<@T&UCP:15A-9]^(F+N6D@VN_OJ2
MMJ@_(Q;),_$OB/T&3 +,1QF/H7KNWW$H+U;FD+GJ/7;8>ENILRB(T=20IJZ\
M* G\(BY#Z-&]3T*;L5BL3;E&JWGA]L);%49WMG2T<+5KJ+MNJW'*AD,.6R/J
MSNSG!68ST#^4?A9SN>]!T6I_G+:#TYW-,9;' ##+?/X])F*/#&X"TIVUU,;,
MAL'^N&N!I3N#^20-V>5\[>VXSP4_@660IAP>394)A7R8Y[(\Q"I3AP-'?=^
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MM!G#5D<JZ5!VZ&HR4^^MJQ4<N7OP'?=YOR9I<AB&\IJJ],3J)24].70;@]@
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M=X%I=SCTJ'4.=J \Q= &PUM[Y=M<X6NDWYV?7V@8+W#IKD=BEQ=C>';>N]M
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M>U%($&Z8*P3\>SA'*:9(/5BV6G!<(3KR*8F6@ G"^_(.E5HG^HWG^,RV8X0
M$(+PH_R.XN=9B2:#5SP+/*/-:+&:*^%Y5,1C"4U&_="A>'B\8R:9EA"#*%P'
MR'X9)Q7QOS3PH#7LB>LAQ*@#<ZK5((.H0;=,++V,;U%]N\+G&2:_)6[-B5-
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M'G<<D*F%&(A^ZC<'YU+4ZRS'$TF5CV=1@4C6JI4OO@:S<&,V@K_\;!^K 6Z
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M5UC^=QH:N %.^[50]%'JXM11$1I;E4LH&P"-!@@!/G^^TB48;2C;CQZ(5>U
M]OM-$VJ_8L:IJ\)"5BMFG,)E:#3@ =39\."@R2Z!57#S >[P$%25"PM+'@02
MT+F1A42F<W Z:S["1?+ER ?I!])B4VA CT;V"*MZ]#WY=U.H<CXWLA( BGU
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MK!YBTA][S4'6.41?@ ;@PH8OQ"TI[Y&R?%C#*1L/D(U*]"P7TNOTU5;E&J"
MH%L;_@_+)#A88O+E74:+XCK++Q&9B+$.TV?IX#?M@D$Z]1I"VHFG5E@!^HSL
M%PKZ+O"Y 8VK,GY%H&BC&=(GT[A##G=W/T$+R &B>W:NL%[2\71_)S]8 W
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MG-^=CZPM/( M&^X?R]3<E]&BH#(I,VU]C\O93;H4_1&-*Y(+$15X@4Z2<_2
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M-]2/%*XN:C*BL@M8VHLC)CL9,#X :94,,P\PX9-BSH(\SC>[7G;SF]E?N!(
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M])3#:^O0-4L3\B.OZ9&[)@^XDP)]UL%93G%Q\MHIB-<ALCP+FD#B>QSB;A7
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M \Q%>@ABP0H-DE:=/(.FYMT6-KS#XH#3'0,;Z'0'  0\+"!KE;C\B ^/.-,
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MEO^_V567A#;9??ST7.37>7XBL?")'CANG_$=SN(T^I3$A3("'4 (:OH8(J,
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MM(#JQR F\I%Y.)*M]-WMQY6F'ZMREMPX=KRN[*&FJ=X\6Z =#@."QCH]HF"
MS2X%#5-;^5WP1C7Q,8CP-EWS+;1J5L>MQ'OE^?8 0M#V["*C>MB.G H9L0C3
MP2OW&^M@A8U@3<J[U3H/K-14_8RJDWWZ&-VIK9!5&MOLB%,97.5_$"EH2W23
M4SU:=7HEV_@?5E(?9EMZ<6*#.Z(!V):Z(E_ =G)&/D<:_JI,^];/0["G@C,!
MV6'=-B6>N;JY(/%:0X@ 7GAQDDT8R,Z])MJ=CF7Y7@D_RB2C26B@BHB?*RL3
M"IF70I:0K(4D$RO""B$A+ZJX8[5_%\4=J",B@WL<'QY/9 BIZSE[J\M/D%%5
M10#:+E SO9[O/H0ZK='9&VJW]S9S6>B^,T-!*=YJ)AHS (]O3:T2TAY^0J%F
M1:]NU0EJ=_S"F[K:CW5/P*G#+$5_&%@/=HNQE?]9]EJI2ON,EL.R\)N[.)=-
M?N"^O(3WYM/W6\*J[_ M,05C&6RI2RO)Z8R@U0@2[VW>!&BS>-9C948+[HXR
M[D !*HRN@$5A:.%@5S[ 4ST7PGYG0J&\#S0H%9Q+49 CWGC%P4KKJ/"SZ\EA
M&^$=*W60)C_3R\V):-/CY"B?.3*4V02T/EOVRR4$KSW4?V)F'B%LY\#9T 3N
M9G36+/4Z.E,>L<+IESNG@UY=^NN]]5670I>N>P80@EH-#9&Q#R?QI0)F'A49
MQ.D@0@AQ2OZ>,IA6W*IR/1.WNL I>;PM]_N(P6 <=]:0?D%LM;+T.;I3';AL
M<7;8[)P..+5=X!R)CF]1R]F!3J0+.YJT4'[/)F T;XG^Z49@,C3'!WP3'^*B
M=95>?>&FE9%+MS")L=*:DIN=6*^+F*#2&N;\))@US:HW 0OD:XA]KEN.0IH,
M7U>E:'V5E^2C$SS],,VIE97G(Q_W9]GS ['K&;X2%-IY%G@T[AD:.X4S]'?E
M6KGV_+B'SM"LE"QQ<K*Z?>3CDWDYFB4<L&Q@5KJ R$H6)+)E<PU'30\P'Z/C
M6AB4IG%9YHX:>=G>GU4;%=\U2ABMV]G44.VSJA<,U&7[J5#<+B!_A7%^BPL:
M3CB?\KG3@4+\  G[(]%YX(#28-7CB"TL\Z!PZ)AVS,;K@%H9T]0#NZ,#2V]U
MLP!YR@-(A>W]FF:_T<(WP3$N@OU-&B@3U64MH>Q'RF5?D64C5+9"M!GTIJ@[
MMR%OY<U0U0#HF.+,HV]E;$/TBO:DV42G]7E6M Z&R+^:0R'RC[_=$S;P^DLL
MFY]Z?P>PFSY'PE8\U75>Q"'1T4<<Y*>,^YG/M/V_^X"C5(<5"*4*G'<H/V):
M2T\WF%4+R.&LN;(>T(N4WJ3P.Z1=70J#VE7D;,-:UBO5#FRO#=#0]CE355K]
MS%MX&TRI!MO#*57?B/CDX4B6UVFF'#)9(ZBHI,^;8)'\[\I! SAV&LLB6!@B
M'>=.!#+?(%L%'Y::A DU'L)G')UHGJW\+1CQMQC?!@===#*.))";'"EW?\S:
MKP319IZ#GRE&M>V+IQC2V2"L^CB/5A0@-74"@J&1=S/0/ =E=MIO@\E.]6,N
M_*5Y(=G;U\_\ADY@E_@,O OW0TA[^2&7QUAA?B'@+MC98*E[E0X,2':7YF8=
M"YC\V--CCO]QHO/,"_F?+?F4(OPP]H#,C55R+01\=4O$FB+:UF,$8:EW(8]1
MKW1?4%&& 19]_,)%&00H .,Q$K#6OP5HW.. T;"YOMLHHP-)&T!8M#D38L&[
MC=<)4JF]_B +J@,9U,T+SM;[?<K?-#UJ0T"+/H"#KN-<>%""M'U7-T:\]2)@
M8=1_'R9&Y0/=MX]?@@+?[8.0;7L;,:/J 'J/7L&S>)V<-41URT4@1:]R\8JX
M3M\@&.EE:9^]G>^#/-_L6+KV5E&+W*4S(':L9#'=EUC1K +6D>8;\,L3GUEG
MK\"R'Z<^R.P'R0?@;LCJ[+K !]T:2-W%'[C:?!NOX'RFK1%KOB00";HW0$=0
M_(B=+;(</Z3\.9DJU4[[+IJZ/=1^EH;C/@!XT])Y5(UYIJ:7Y!L'UF]PGO^$
M'G 6XQRM:78OE:2Y8LDD\?N0F@DZG3TL$-Q8;5^YXT>F]:ERW#K/L*N,KM<(
MRM+ZO,D?@Z\:>+$H.Q:/"A;!3$4ZRAW[F&^(K8QBN!['G*J4Y.@*+:1W%+8I
MOP?Q:Y!E@:YXJ;DCV.F*A0S*"EQ!U8F5%>/7,*I^/@Y9!LC"YZE!$L&=N-CB
MK'OJ @HRNY.7N< &7S*J%]*NPS##5/1M2N\F']A6#:O*N([^?N+'T_8K$SMJ
M_A8MEM*:E\@U(3JF#2G$:)$_U]1\%>"81G#F9)H..?JVOGD>)^@"AVR_!E&0
MK= QB-FO_Y\@.5%=D=_^E^\6M-IS@;IA(>B"\^E*?O0^I9JD3;T\%?,0N3=N
M&_0-RW^)#K,0?%YNVBVESH8"/+JB&G,B9T@%#1<$E>4RL@9!K$2PAQ*-3;Y=
MD"5Q\I17-8'.@CP.S][X6I?M29JVFP?0@CSV'B"I<!Q>TJ!;SQ65IA;4"C%*
M?(>:;Q$P:BMTG83[4\3J^KRFY>XU3TM;PM[U8 P(1^Q# 0 "=2E/-OO;IHZ
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ML8P91FD*VS"/EMHZYC6.!!OV30R]_)I#BWMK.TBP_S#(;BPL@#_+0(Q O,V
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M,B_)I#2=5?V9BY/@IZ# D;-=64G5"+#,R4@--*/MJ%$&8C-7."*VN[].PO2
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M)!VR,+FL%Y3(D2=='2-J#B$4OD) D$:C@'56Y4QJUF0VRDMI(!LG((9T?()
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M_K'B3TM[8'W9EA1//Y]M\$"_ BANKO\.IZ2+EW%<L)"O+N>=92-2(&_OY*)
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MI1WXF<<L0?8E84<P*H$[$L\?*KK98>!/7Y=EZ/X'4@/7=J1$D.QQ",K17D"
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M*3ADV[0EQ1/:<NL!KZ^G=G#58?0S\Z8.M"WY+&^0$T(WO+Y>_T%6!UK!W_S
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M92DA[/<[S00"S#L ]!2QAN "3D^]+)DW/Y0/.0#C_ W6D?+ #B]UX$W-O 7
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M-K74'W0Q'8V@.G(R0K[!;W4X,D/R9$#:/<5U2,8QNEE82@#Y@MZ"(#6S.D"
M.</Y$4 $3K/Y/$N%;XIQ\[196(J@1P]#-ZD!R-0@ <@,P#AU1Q+F9GP;Y>5K
M?8=W^EK_BV%2MF]$B.PK=G*T%K-T&XR 6H22B[H.S#AY;Q:6<D!>D=OP9M:
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M.7+CY9JI 28OBK5?OFG6NN&*$=")[KF;E,$6GUB?'Z*"_/O_!U!+ P04
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M!V_)TSN$+XR)F><,@^4K^!-02P,$%     @ J8.>6*P)[6B> @  N 8  !$
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ML[];_VU7?/C';T,>&LSTW)"[ (*0/X:[^-HG9@X,/^#A[S>]SSM'6PSGV.%
MK>Y_WVJ(QW=Z3R.^M0N#[,H9^I[UQ(+PR>&_;^'Z=P;<OAN$)RZNWOG4-\P?
M=S[<&&O']!S//WD8V"'_1$L\./W-8 .?W_Z^]<_0,[=.>T;?X<R[97*VX+==
MXQ1F.H"G+?M>36/9P<@QGDZ8Z[E\Z_0W^_$$%\-]\:=M6=RE/^'WJVC(?=MD
MKC'$-[E]<NZ9\)T;TDZ8C02"WJA4:I7:<>5H;TO YC'LX,JN]RI_P?\0T7I>
MI?I73?R]I8":FF;RK'68TL)I/SO&W7PST-KLQ_N=_</*X?'6Z:WA!'SN"9O
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MS^3N^#T=>:$@O]/3+HQ?&W_:18VY=:SRM5YQ NN,OT61L-?PSZS;H?O>L#=
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MJ7X\/,3<%_UD]/^N\RDM!NIE@"X/3MD%B4WN+W./VI ++E@<]*3UXD,[ P%
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M-[R"7[:8=)MU^*U(KQ1UU6M48UWZ/;?(KV(_WN_L?ZQ6CT%(#1UX'P9O>$8
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M?]G9MUP+<\^!9CY)>,%[/]C#@%-U UR\5OJ*SLF!@>%X3),[V)$%C@8/R,>
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MG.85"[N4F/1P&*"[W,D:"PO7MM%LS#.KPRP2+*!7810$8&WKEZ#^-WJ:,VX
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MP:4X$&)F8:"<4K$T+T5<!Z%(K;SG;/O@@QZ<(1S[HE-]G\=F8VD[]SF\4/L
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M_2L0'ON$%(&615)K>\;WLK6X=4YK.:)Z?/QT R1!$6X0H+%(K?GU-[<J%$"
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M?B-.N0SM677D!\-2"#"I4[(GQW4PZ%T$@\ZD'+$?NJ(]!)E^BHV3P?\."",
M9.T==<@C@*ZJ,"<Q+7#.5%4>2#TL*U2M; 7D!4,$U$PN3R]7QU1@_HSUSEB'
MV Q'F8W_AQ?TPWO;R,Q)T@J92VE.,%<U5%&A4X4@[Q_?CT0@^7;1";(M%X?:
M*_/>[-BKSBJ]9-\;];Q9&V1Z<QO.3XTLV**?+U>#0HQ#GWNN5$IG$S[5H-?Y
M$%TEE=FV[H"'%FMCL 0"(S?IMCIJ2&8=>899CK^$(6 A-I%(0R9Q&O,T9$^U
MT+IY'T;)T"<$R;:VMQG/TEB5 D9B.SS+MF'J46X$KY9K5BN62N>JP$R2J;J'
M M 3/CP_\ BVPHMR*ZZ36K6),0MC "V+LXNSF[/V%ZMS<WGT/SS<#JR.BYN3
MBV/,7!&4D22DN "W_:4&'W@?9@9*Z#.9<I,K1"48&FK:YIF<68<[3^0LU*+@
M<)F-AJ -Z"DS4HU2:./94 AU2:8>-K/.RK)ZAW*;HZA>LBB;K/&A*/:IH 0^
MSM<Y&.L92;V)3EP8G>NH$P; $%%Q:&TV[#6;S#IM#/5K)Z!**]Z,S2A@2AM3
M1#)\:8ZWM<>@6V&;S@C]F:(=OR/$G_4%&'X#AXQ@& "\7]%HXN%KOOC,W*83
M67=@=X!?#<NCIE4\'D#+?7OG\- ^/#R<+'0JL)9JXJ'B,=I6WD[2WGW>0V"/
M*3><G!NH# WD&S-K=$3KBPE 4I:/:2U2XHZ&SRZO/IM6(%AA I&16\"MJJP/
MW")@"]/^F/6B9LV=JN6*"S'G[(V%70K;F.&-J).H;YK%7^EH9C"3%NRWYTOT
MNQ#]JJ $,MZ&IQ_5^P;F.LBF6]>$W>";Y\*^IA"C.4D3X +3 %^G%" 2RS&W
M6;$<^%%6X)_K7S"@^IT9):3/+DLLE)(NKBR1$.C+0I?E%,JU7PIAJBL;USC?
MVJKSK:N?;WWAREE[R:6SDZG!3$SKG!A?H"V;DO-H8!@X79!.2JIQ0BAGZQW8
MC;U]NW6X/5M[&GXNS:-XMI5HW+$.J"_>V]U:5V^W&%!O6YVOGSHW[0MR?"^^
MGG_":4T<:+_Z^NG+V5'>&R8?^.S".FW_^_)Z6BVF]I"M-GC/&K\/+C^[KB'\
MEN-%;ZT8.TYPWV4:J4K%3A'QM0C+2O9O9:8S=QQ/+Z\+^<K*6+I9#Z!+]D4Y
M38)-340:%PJ4B^@"3\7'?08B[JM[UH1.-+DTO1\Q-2Z7H6.@/:!W;0X(ACSV
M@I<8T O7.3"W/-$S=9W3M,J8$,BZ_ 1A#<S,R$2$-(V7@6VOZC7)4"BB0FSD
M9VJ67L.WDT&:Q@43B-#:"M,L37XM@K64YA/*7!/RHL@H$HLG!C?FQ(CBZ-68
M5DMQR>Q04O"'.\UI,)5;8K*5XB:2":=(VU7S3$VW5X]AKJ2:_.#"B?O.W]:1
M-,"<,PAR2,,URR =T=6C-)V3&_>EN<,&OS'A^CO?MZ?!"%8*%KY%;QB&#,@S
M<;T06+V*3<P<A. -$ OB^^?DIU [FTC6]R0OI<%GT'/A Z0)1 %+S3%D?6=>
M[5R%D9AO\N(X=2>Q3)8M1&YF5KJI6B8Y_?F!:"'LVJWV^.>" (^S C%B1QL3
MF!BYX'3L$(\*BP;8(&^4CKCPTZ@JNZG\3FD^M5:"<Z"R5CH]>5QQ.D0E .2Y
MY"J\#UZWH<H1^^G8ER*R36O#V2Q4ZC%<E'X,W,1LC:A E.28H3<"F>CQ:<[!
M_JGBN@T.6D6ZSEYUKV7>4K80\>UBAE$D1+K,)N@*NF*%Z.I<M8]R&B4[>9MP
M4OTT+KQU42W/R0IFJ9]C79U=G:@B*HS7P ZGB+M!)8VT)-WO9X9%SX41:$>/
M%"-DY?1G+-K*+U.)WI$K!9V,S%G\^M[Q[HSYRP(K-KM(5)DTNK"TGY6-ZH;@
M2ENHK'KTI6>_YW+4U492)=3^?.)O3K1]K:+*O7_JR9^6U:EL [UW'P_(S_JP
M,!N3CA"]1JFE.G'T)>]>:"[U@D$:ZR!Q62D')OA+!U,:[5ADV+X\0EA"@YG,
M:G&0Q+9"LYNG:%Y%L&#_&.6T&B!NEH4@;<*F9<@XNMI:G1=4)]/HQ\HFZ(#C
MT7.+:&V>@C /<'#I'151<P.1ZX?W'S%G46YW&@8O @C?!_#IT!MGY3(3-E]C
MJU5>>U1UZ$K/S:^4W,@.ER?IV<G5A8BPFUO!_E9C42M0^16\%:F"L_R$U[*'
M[RWDX9S?N1,24'W87.]^L)"7QY"J<+I92_;>6!Y.>3G+OR9S-_5VK'&2:*=.
M$JU!DNBYPM-ZC-S<?U6Y>?@TN<GGIR@\^3PA2[^PTTRRK43FQ</PGOVC<8@<
MC-)&8??G XNA ;AN"+]N,421(RIU,N?K6F/@?P?L7MMJ[OY<_L5^U1>XAZ1V
M2KYE1UOU+TD4 #0.O+9(_"H:<"S.93(\HEFTHE0DU)UM.'L!?A(/G)YI1<Z#
M8C =(4;#&>!XTT([C:('K*+GI+'+=/&R)I]9Y,"D)N'Y1%0=EL$.N YIN?LA
M=F>IR%B4^P[G (P<7]+!JMC]%D.1KO2M<G5)68TOM;DY4? !(Q=Q5B1M-I-)
M@".+W J/@0Q/1YDC"D2C[E_W.Y#>?]"C%0BJ;>#=8CL3KDI%)9Q$W6$Z<0H.
M% YQ17,@ZW@RB]QFT!E>BT8A]!R_E_J"U\Q13]VW2QSB/W =?+:#VF^D+9+\
M<:&P>P8IS"4;[9E=9,^(X@>>"OSZ[AV&/7+KO,?J[L)B%;^HC8$EJD7@MLDT
M$;7D8DGY-%*1=R4'-,.J8XG=@Z-2'8TZ(:Y#_D.QF!MQS,,(-C]BSEW"I1E6
MMS%)^ \=.0VPIXYQ^:X038^")OIK@Z5!RS7+[VGRO31W*/EJ_IR456O>6QAC
MEU75F*>FIEAL0947 C0?FU,5U47_5OG50K9S(ANZJ/PK6$>P/K:4#O=^SE*Q
MIG(48^@'2KG^]D-93I6MN=PWA10IO[PR__!RNKKXG_H>;_<>E"6=)V]OS<^_
M>)9F+RT[;SJK_\C+09.AP_NO'_=TJ8#X'.I.?'34(6]L;:,+&(<^O,X_MNE_
MQ;H#]; 9.7D='+@(_]F-?OG-F" P63OS]JD %FY-AEM>T_X$+=XM*="%61PM
MWH2H:K[XEEPJ%Y9V FQUCEB^&E.^/ 5._D[!Q/Y9O?&, &OE9;E[OB/RU0Q4
M8*!W\,;UGM="HV:@5Q8:9/"(B[\XDX>B"UVG]^V6(E0?)"O4Z[GN8##=&GI2
M2;49M4#R8M**4C\>]9)^_* ^+*YQ1@U,1:6HKO]]#GM-HH!4,<&S[Z#8DI)<
M/_ZV1STUC64L:6UHL+VU]YSE_/SB!)A/["^:3+O;V_;N3NNI.N>E7N^5J?XZ
M>S/?4[>W=E=E]WY>ZTU^G>UK[.W9!SL';_!H+5ZB-]=+HB^: #+0C]HP=I:R
MLG=Y K>WME] -"XY!HG&[GK:W:J@8<UM[JR);:T.YL+)L+.U\[ZE=,T(-2/4
MC)!CA-V:$6I&6"@C+,N$6ON8Y@2^R8^_W5 =IV%R_3-.2^K;]G=__M4J>Z^-
MQB88L2E:9R]JH:UQ: 9.O([!/BNGLUK46HNM7F.VF6]MC5UT6!=/D=?>O^HT
MZ3OEY)<76BH;L%9\\Q:V>HW99DZAM;-U6 NM=\#)+R^T= 9EG?CF+6SU&K/-
MW$)KOQ9:[X"37UYHZ8#0.O%-O=7+$S2[J[+)/T\2JDY8<@]YR7"3-<]:ML#=
M:V"LZEU'IEOO/555LT'-!C4;U&Q0L\%2V*#.5DXWK*IQ0M;<O&JT[(/=.O/?
M:&VUWK=(K1FA9H2:$6I&J!EADA%6WLQ:%VNJI/9+C;2E&K#'UGTUZ[JOQP;V
MJ>:+7:<ZL%]G(Q>;)-BKLY'O@I-KH?5NMGJ-V:866K70JH76>]SJ-6:;6FC5
M0JL66O56KXZ@.5B537[!NJ\WD+?LR.B4*QF=LO:92KM11Z-_:VP]"S3OO8#&
M9<RR(OIK1>F^RIH)67U%=J^&C7O"]BU"7J\HW6NI7DOU^L"7R.OE2^(ZFV[8
M^)?)T(VRF9MK;^$?;!_8N[O/@AI] [K@657-[T<7*&:I=<'Z6OC[J[)[M87_
M% M_ ?)Z1>E>2_5:JM<'OD1>OPD+?^W#^]-!%'&"^]. %%MU0>TCCT9SVV[M
M;MO-YNZC5KGJU%J+K5YCMIDS^WJX]4BV6@_FJ\L\:J'U7K=ZC=FF%EJUT*J%
MUGO<ZC5FFUIHU4*K%EKU5J^.H-E;E4VN@13+\'ZZXRBT.FXOC;SDX8V *![8
M!P<[]F[C?4]<;NV_=TR/FA$4([QW!+V:$801WOGHMYH1%"/L+8H1ZJQE=5/2
MT(G@D[,X3IVN[UI?QV%@G7QWHYX7NU8XL,3Z0OQJZW*<>&$06T[0MZ[=.(F\
M7N+VY<NO@;?^X(L-N]'8M7<.#M_UV6MLKUMQ3,T(-2/4C% S0LT(:\0(=6CK
MQ(F",$TLML(>6QNV^SJU80MGJ1T:(OGN&\E;6\\2+6] Q-:,4#-"S0@&&;:>
M18":$6I&J&-A\UMC5V=7)T;O[B.ML;VW88VU[/V]EKWSSD]<:W'!YS4E0,T&
M-1O4;%"S0<T&RV"#22LL,S$:X^_3;2:YX2_/(F/%Y8\UQ;IAU'<CN@:-KO%W
M*PY],![_L4W_RY[_"*/H1=:P*':LZ5C3L:;CZJRAIF--QU5:0TW'FHZKM(:Z
MM\ ,^3%&AQ3!7:9)G#A!WPMN'QO\VWD;P;_&]H[=/&C8VXUG>3IK[^DUMK??
M?>H%6*'1@'_VWCGZ8\T*C>V6O7^P;>_L/ZM9YPW0H68%8(6]!OS3?%:7QAN@
MPP)9X2T& UMLD/;#%+L*7LDJ?L0B5M>]J"E94[*F9$W)U5A$3<F:DC4EWP,E
MR2K] ?Z-?:'PM[YW!ZN0_Y0$QQI->&Y^:;].+,Q\K/5/NA<\ESI/Y8:?+J^/
M3ZX_'%U^^=*^ZIQ\5'^8/P*)M8CT]A^W?[WW^LGP(UCK/_]H]5S?'SM]#._]
MZ\=M_CN:ZO+WN0*A!5N<;[_S<]'*QZ"@\A@P9/GC;QN-36.OS:\6&27-4V$J
MQ2AXRH_B%9ZFOO_PH>_Y*?;T)A08O2+,8A4?]6*KZ\3P91A8<3K"[N#\!=@7
M+)_\X421$R3QEJ4YC!A*\=-[V?;F>FU[D(ZZ;H0[&_.6#EV_;W4?K&3H6IUQ
M&,1A5,H'D7?G)*YUY8/K.W(#U=)DC?TT+OE6L0=_?XI5P_#83N4SWSL;M=:+
MC9(RZ'/%4E[0\].^2]M;S66V^7T"S!(/W"BB>UNQ3%(=JTFJ)'G@BY#&+WFJ
MA/N]<\W.>G'-51@G'X["4=<+' 2:L.#/8R=X$':*)[40<1A_*SR&C##!<CE>
M\N(X939B:(L8T2L$58S%$7\>&F 7_$F405[0CZP4(2_XYJYT<L:9)IQX'O47
MU,PIS+F[\LP)JL[Q@>]Z;N!$7@@[';D#W^V!VL(M'X<)J#(/> ^WV EZA)>2
MCG&KL\8E_"S?YFMY ]NZ]Y*A%U@#[\ZUX!W=H.]$U@-P$?#.( $AAD\X\L,8
M-L,Z!N7);'87^NG(M1@T$+C* 2+!QH D]/CQPG3PIXX;>?"GMM4+1R/4U,2R
M\(<+)^X[?]L6OAX<+I:9?.+PE#'.'O[4_=X;.@'<'7YT/_1Z0_,853X!OL7K
M A3:?5CBR'6!8/ PN)WK]I%VD>M^@"? 2\*.N0FO/K;Z[L +X!= %WS0IQ1>
MWHUCRQ0)[5OX,9H0[_WX[*W[\3$/C:XOUPH_Y&N4L%0\ 6)X'*+P)UEZ"EP1
M(+UMRTGX^S0"GHV- _%38QO\7VL,W$;WMJT . Z^B%S?P2,$#_!&]*>Q-D]A
ML^#? Y?Y?/_G2F;+Z&F0DSSAZ>1L;,^@IR S6>%] 'IIZ(WAC=P85I6=#V9S
MIQO>(3'AD/H/QD4#--1]4&=P#!.4,D :)!WK)E.).H;5[\"FC%CQ;;%V[3E!
M$.(1=?N@^JQA> ]OAF)C8('RTPZ@J43OX;EPV@5#"I;J11;ES7!;AR"RY#,.
M G!$X8=R4I8&$:P"8^:#"E6W>>:&F S>0Q)'/_[6V.5W^.$'?@O^]P_P,O!)
M*6=@A5)A'?B1(1VZ+NP<2 ?_WGF(\<3" W[XYU +$NFM/*3__3ID]-C6^+LI
MFG[!7^S^]D_' E$[^->/_X#=^?&W&^(7V+<C>$MX@_B?OSBP9+B0U@M+5\\H
M>57S:W[2P=:N-W'LU691G9;EI$FH/B$&X(]^A ?^LQ!'6NQFP1/RD0G@7E0;
M?"QZ3CP$[H:3@"9=ZB>L6_$:YGW+&8%'FK!7 =]DYZ/BKG B>V$0@&S#7Z-N
MK]9@(^?!ZGL#\&:L012.Z$)^7FP<7SK6M,@X[0UY@88L@+,%UP'7\'&^"Q.T
M$\;A/2\35'B$$HQ.<,[ S:S9W,>X*,>/PXF5R8IXZ2)K!KSF7I*"O9!1+2;5
MSS<@\2GW !F0$RME(B,9@@#OAQ:*&A=U!(H*)J\(BSSE1<2,T0)!'4(N!"TQ
MVU4D1-4N;%DW\$W92H1T($N!W)8S!E)])_T GQQL-7\F3#P@ZW_]XZ#9V/\5
M?N",/7)/\"XVORIN!KU2$%KW*M1!DJ_K@F6D9&/?IOW(/V2GN=7ZF>7R -TC
M2[E'(+"]F%@"J)2I =X44@8V[@T\LNR]IA#S$=S+C%@I]&]#WG4@'9*@],5X
M4ZI)B*H;#JE8 *5'"#W]LB<T=O7]<RYCF!5VJN^K?$U["N6K6(9>?9);&O"Z
MMM6 ?[;QQ7&GMW^V-C2#S."-3?H%O!+<8V?KD/^SS_>!/\&K;E0ME54\A5F8
M$_/6%OX][Y)L/I=LEC<".>CQBV<.S G(@AY9'RB@C<-A2@UM(.)#MN$]F_C.
M^[ORJJ#0\%3'0Z(P,CL:DO&8;^P_;.7LB-+,Q,%C,Q.+]B%(8:V>$S$#C?Y_
M/T[BXB_?TYAMB157.NE[_/&Y?6,=75YT;LYNOMZ<=,!'_=^OE]=?SRWX_.;S
MB=6Y.CDZ:W^QSD].;LXN?O]_9MOWV0+W:FXJY:;VQQ7CDPFV:,,=_PIQBH"2
M9T7#28E*M,! ^)@2,!]&82/ P@!0XG-X#^[E*C^T ^()(T/GKDL/&($?!O)=
MF5,VZEPP7F*XX0:'5N[#U._KV#A?UZ/[.=:=%Y&M->*[;6(T)7(S8[&+CE_X
M_<&N>CRL#C0\.+I)BFNT_D[#*!V)FK"(D^2:?@JV5U<IW?+;@0W2C2GVI>*C
MW2C\!K?(R9/)6L@??\/(+)(I%L'"JA/HTD/[%XFN;6"RU,6E1[\52=YW0;&
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M)K&K+R%:8(A+'OB8I,)>1534#+B"/'I<E'2>HW\$5@KZ\VTB !:%E1U[9S!
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MC+)[8]P]I05PDS+-HR!?9^U6[3W7LG:QLE:$9P*WR6K>IDBS4AL298A*SDW
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MR<' WQQE/R:"6ED&[5.ABH>%A@J#/CT5)XD%B;YL6<\B0*YP 7[:/+ /=CE
M)_"5L?G.4FW+1H#"MY1,5FS4YO$3<"F&SS+[W;;PM$04&K&E5.01[P5VD506
MWG*P5H8$34O8X)XZL+TCO#X(C9:A>-/.OJ&8K(Z<S]YMC*\]86=A,1A7Y:=,
M*!E%;YJ6R\Z,,.4<^=M8<S%6G *K@P&E);RZG9V-$*'*D@^JLH1OHL+C#/D-
MS-O:M[<;Q?.3W]!EIW<O09""I>A+T?&!*CHN25B;0Y'),Y3Q; Y.4"%!K&>O
M47I:SP(@_M/EOT0>0A//H'1QTJ]BKYY9/QP6JZ(/U0)S1:R%0[AG[^[MV*WM
M@XK=U-O/90]]KR_CIS%"R[N([6]99![C_?*I@BH,<JQ@,R.H16F0=*R<?QBI
M,:U(P._>B.US+(7::1B.-!V2! =B\P/=/IUG8"4<L*8&M%.) V%X*/1%JK'J
MNBZ5 ?==0BKAD?=P%NG]Y#.:P:LQ(+D&33)<2112PDN,$7H *'[8$C!D\EO0
ME"TH+:LF*DPPAFVF7/*E[#/3$A=A\"'KGE99"<-0X.?BU@'CI8$S&'B^)[4#
M7M37I>NT8_@SRLHH7!G@@ &N5?.BZL L94A[@M<.FKMVL[D[LR9.SWR3U>!H
M-F7Q#3A--N+EL22=9+P*B3_9.+"[L#,\2"/RDQ=UECON.)D\S#N8#=2^K)'7
MTHN=F,VT.?W\V_M[!W#\&S-W964$P?X.DR23!ID,:!.#TFT-]6JK)\/]\@S0
MTITC;*?<.W'QB?M;._GT<IE@>3WE0])"V06?A9288 P2!RY_,&R#?7OG\- ^
M/#R<W.N"2:%,4Y*P)$V9>$188FL22%-NV)ZX(1F28J>7.)RE)VS+^J. ##M3
M=AB*0;%3;-@@O JD2$PRJI1\VOI2,E#?E,T1/<26?59Z,-#;\T5 %AIF*@YY
MW@1S>M] C(->N54/-&Z>/1;SR:J:2Q+F?0_#;=V4;DJ8:P54L!R?MO,V69X>
MN@:-+]!6L8DX+P-68NE;ZR*%,;UK2V+Q#21A=^HD;)V$7<_^8[@W2>XA*K*B
M_241B.W9XKI038M>WT9#)-4,=W2#]$6^=&@S[]@O6U=^'8?!A)5:Z9=OF$YY
M'ODC<Q>4B:%JO\=\G0Y<9%=J.PD,KWMSE+ # CMA<W+GT#X VW.WN?^8K;"Y
MXCQ.1*]H-=4ZL \.=NS=AK;BLI(JP_8K]YMUM-4VM-%>/E2EMC2G6(0$$U-?
MX"[>IM6R=W<:-MRG>(^$AD.#W:J@%^6W^/B[3:MA'VP?V+N[!^IWRON(^'T4
M5BUHZ3M9;,-N2!QIXNUC-[JC%"SCSJ@5WFG*@?G;LG?@I]EOJ&KO3#UF=;F5
MC 1C>]6>Y5E8YZ(K<&JL#3T$5L7H02!ZHW1D6M"*\W2[= RKB0</ZB?G7D _
M.7+B(2HB]DLD>4XK=C%RK9]]%<EL-33H#UMFD].B#EAC!^1=:V_E#MC33@;^
M\!%'PWO&V< 5OOZIN-'))I.TN$+@%31?L&#2H_!(G.3&=E*M(:JHKD,5K4&N
M@H684;F%652=#A-ISJS<MQ^2R4TTX [RS-]V_TYQ<E36!I[/(9<=78+4Q2^=
M'DTJ',!_P8KV!@@\078[S:0RUY<\CP@J\,_/('^JDT]1Q8_N#?D:.$ Q=">O
M@$2GF/RB ^\&2&Q,*Z'Y13$E?G?X@Y1 YU&7G]Y,TF&B/UBYQ- 1.+E86/W)
M#=R!1T_C[^G6YTX M%)!!;W1T[))A07. 7."P2D5!S(2@Z^ X'&MIG7G%(HQ
ML'O)F;(;];0N/0V>SS H*)RZKN^Y=ZKZ7*6J*A7>56Y\^9&$"-HJWI7_^G=@
M^RB@J$+^BV-YO'7B2XPO_[VT^9S%V'@S\>NL</[*=[*?:A9J]_^"LQL0>^DO
M/8U@WL5JENR8F@RH(;%-"TK/6A<:35Q$P0<Y+:>7UXI%B9;Z^1LXTX(7T',T
M5MU42F2WM-I?OE@7E^=G%R<G'5V%WG495*0[\I)$(A R=GXB4!"K[&$LR.(C
MA2P^5_+\\9))O_A%J"#P9OUDSLM$E<[.LZLER'UMM3$K\@;-W!M4'J4577TK
MM_J2D[ZBZ][)K;OZ^*WH\G?5\N?%[[V9(DY7]!WW<EM4(>V?;K L>_G[N>67
M*:-'U/ LQ'K_8PB.&N*=J1YYB2K/L$I 70V<NS#2B9\L_19G3"1#- 0&[IOK
MC@D5VPLX<&Y+DQ^9U.SU9KK7B7,ZRB;=JK*ME. 5,U*:XC.SA;3U "Q+5&WD
M;V9W%35;CNNE>NRT%4XKLRU6S\JG %UJ\X2,W&)STU[UD#ZM*]/NHGN\-2N=
M%>T5'?@YSM'D4M%D"A%>O80LM_[B7%X,#9AVRPO8QB5+R)E.RG.CT$ 8P-(;
MA[N_EOY'\L+ 9(<?L==Q:[2%!6 X%S(@M M*;A-"&K>;@L'U"A[)O.QT\EUU
M(<[#6,O>JWGEV'PR3!<,S)!@7#V0(XNKR:)ED'KL(V11AB+Q9G)UNW6NKL[5
MK6VN3@L$RX2]G<-22(8AN_0\'M?4'0*J[S]025R<EPV$4FL+V($"6\-T?@T7
M4K>J/*I5A?KU'4*WTB/DV(Q&1IS,/C=:NMQ[''EW^.G8=WH"P:O2/'0S+G=Q
MOX\1U?D> ]H^:C*OLI3&T\C24EC7MZ7J#GZ3!D9#&FI G"'I/Q#$ ;&IKC$F
M%+T^9:WR-6#3[2^=9S#K?L8JPT43\0K)+$Q\3;LGIL-4"?8\UI^MS1(P0*@^
M2^HDB\$W6RI[>%PW9LR&+N@ZXB3K5OR>J4NK44!KR;$TR4'S4;E>D1)N</:_
M(:NJ;@ _=-3\%B^1&I<^_6KD?',9?:?8[T8.?EGF5^-FC<UD=-- W*QYO>;U
MY6E)Y%ZN+\V7L#L9;%.>BR?Q+KL/%O<O3-2NYTHV*4.#N1IR1]U*_[#F]YK?
M%\KOR+5E%2V,D5JT$']J[I)YJ&R7TY#G81D3EXW"Z*SRPJP BF$I!&(:)#[/
M,'$5H+F</P* E?-5WK>R2I9C93G]3/M1RC1KZ[&6,&]8PH!L&$:.T[7:PY%#
M7E^(WF NP'PT]-S!9&"9@0C="$M1Y @:85P*E=[C;#YKI(:=JD"*BK%J8$0O
MEL))+#**LM\VFUNMGY6PD9(Q?1/Y6&Y2GXSZ9"S@9(#>\WK>F.KO0!4AQ*(4
MO4W7 TZL$P[J,.C2+5).JI:OE[5P34'IKKFYYN9G<K-@I>;[MT'0*@09C/%E
M];LBD=T[BB9R_6\:J-&NQAQ9;8^6)L@$$)7M(7@.55:CP<@8J':5!T?5UWUW
M!+;G \8@L*D_B%.C4QUS?SVX5"?H;NC%VO)B"H07'ICVL+G<]<-[,R!A5O53
M1H"L8(R+4L,DW:1X'9YJK^*!<LA-/!XDJJT*T7N^X_%L@ U'M2CB\%K=)_[
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M@N2'Z'(-S-',&"AJFC+MQ*?1HO"]$Z,WU.XQ""9>=^X$(#KHE<[.4&2 4VC
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MV^2O5>IV5I[ZHP-T=G5IH_3Z;R=(07E),U"+NH&:MMGWFBNC[,LP:I;\&L!
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MN-G<P/E%+CE%KRUS&[O?&[MO6N:V:IE;R]SW(W/1M)_'ROU@7836M48'L#K
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M6WN[]N'^H@JEULY ;C6V[=V];7OOX'TW2B[Z@/B>T_5\:MQZ$_&?G5W[X.#
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MO"BH?[;'*Y15"YO:"Q4^;:!PK;V#+?CX=V@._Z@WC=>J'1\_WCC5-/B76"?
M2X+=(;/()P-W>5%TJ"2N\MJNY/Q<5LS](9461/\5^('&*J 'BCT]&*P/GA8<
M]@7H&1 \^#@O,W@X9)S'+=BMP54_)K*2LFK,NN >.4M[#7O:=,5 S8*.ZM("
M;K:CM[=.+QRO'K76I]2:HC'ADDZ")CFQX'O38:*]00UX<Z\NJQR_!7H]-7GJ
M<)G?R&G'E79M5[L#^QL(HLU.'WM?MZ^[Z=2PX%_DA.VFIZB*HMI1F'DCNP:;
M!+$@G.K9ONKPL,'_0& .8KY' SR(G%,Z=/X/8U)R=GT=98_A-L70!^_#.P#+
M[39;/@!S!YO!$2^\MZV)S[85.MF<B<@<?Q]%&W?5G[77W1PTT.RM21WC@RFL
M7C376U!.\,]S?$:$!K_U\?TB;=:8"H"[\&WSFIZVQ@B3$<2R3^D*3LX*1'Z6
M;C#E,:,\%$G@[ LY'KMJ-M?MS"#\B(/PIT6%6_"E6J)W=0<O[9PS*'_J2V.0
MM&\_%IIWH] [C[<S'OP [-<# UZJIM&K4O#EO_ZO(ZEG^48_/XP%#<TV8US
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M$TF?R*,1P(2SV]$^H%CD"WC_S#+NLEP\BPUN:?35N=M78G?PC-=5H6FRV\]
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M:&5NF!+T*<)XVX/J89S^*9KO>7S.*T\>/S8PM6U!M+M60\[XG5!7)DXX:F@
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MQ#\K=> 0>OHZ)"EO/>'FR^X0C_$(,XLOV/S_[+U;D]M&EBW\/K^",3$384=
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M>3%1>?TNKQ[,,FR#P4<L"8]@53&]1P4$#>7BV"3J-#V>Z6;85Z3<&UY13.P
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MRD-]:G)<:,7[0YK:,(D'36(32V]_W5(I+H>+O#%NNWC^^M'3)\\D:A/#LP=
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M];9'S"BMBAV\9]9C B <HPE%RRYC\D*TNJGBD3@%,R?I1?3H?([4U+=8[U&
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MA,[SX= C@0GA9OK@3*'(-I,HV^-IJB$-%#L25<1J,GAY54>V"*U-"_F5$G(
MJ[;SYE9V<(Y8VOQ+#._HG(;<#"XU.OSD(%3U=#X;Z690_>7QXA.4&WCM0[,!
M8_Q%_26%:^CVX<==I/?-IA)3G8:5PZV!?]M"K(O6'>SHHOHA7-)?4XID5:=Y
M#ZJMZ]P97@9J05B/09'3?U5+$2G%_EE(*8?3!F"/2+[VXK4WU01<"_<>/9
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M 0L>9M/84O[\XXN+J!=;JP'UEJ$&#C0:"\1;(BX[,LS"&>T3-P.ZY%L/UI5
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MA23@XOYHB2+(@N+(<_ZL%6D]DMYB5O!KA>H_;D0]D.VF<-?BV(=1K.>P*O=
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MF<O]6NH-8HE.DWC,NL5:G!UX@==M%]:_M)Z)+B>B73<[U! "_0O?E T3:<2
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MBMD_AQ#05!V7\UA/G<>2+SC?')..&,_?EMT\A%W]HU=_;*H#5SJ-[8J"#]-
MAL&P0B!W=="(E[-_E/VR_"=V0ELU0)5%9:YRM^.&-_]NXVENXE61='X9KBXX
MER52JE+* UO8''1\Y2H?CI1T-%=P#/"1;&>)A1P49W,K.U>L'\]4OS5XY?U0
M-KIV?FR7RT<_=V7S?O8;!"5O]\'[ -5O#$3@+B_ %]^&I?&Z"YN3 AU3;GY2
MZ#2O49B#9M^KYV8[K.C\Z['\7CIXN!&I\N'0EPAUWY4'.1:"C1BM=5JN6'D2
MMJ<!8/=5@S41Y.,G.I82R(BJ#D&9EUU[#:&L;+&W%H9PU:S?%D)ET$D!B>!'
M57-5=VVC[])_:QW,K"$#?>8#O->K*'7K6JQ(\C(\[Z8JER+N+880#*"?0/BU
MYZ[U1!?6K2E7\HC17-[.P8#2N.ZZRK,LP!> 6<AJ3OSX:!&8L*.Z7X71J7Z^
MN**6;M=DJ@$5U8B&P^ C3[\/,Y,H':?HS+F",4EFUUO22QBVUE8.Y 1876%>
M"+^D/^/<_;-S[OX!YNZ)U@,A]7O7/YCX95@9QR)C$\P7)@K),]"-CP2Y'=<@
M18GU-(ES*\#E\E=<R\IQMD :.75!Q?&RG0IQ"$8?=+AJVRH7$4B8EW^MH2P>
M0"ES"55L^=(.NQ^W\"0J!S]CCV4)_@5ZAF:6^BG#)"8#DF=@)8#1#="B[!]@
M$E.1]ROLG7= &,(BM=0/CX"AJG/13RW,I5%8FOC<U$ U$]%B1$@<-$XC,\6(
M<9H3\',C8PFG'1:/^[T?' %%MP098/T'N93']4-;14U<")!^VTK+@/1]=& Z
M&?T1'6.X!NB9:%CXBK$ R]Y-8E)Y&;FTZ\CH<D6%&BZR[\5> B0S2H9^=!4^
M<_")-\%)K&0+T=$"1[[N@!:T(('<EM\=8X7H[R(_09"!L"Q92@1^3Z_W(5:I
M7BH3O&(=M)&HW!S@/4GIGC0%#.V%;=@4,:!$$'WLFVES7RWG (")#8JFD1E&
M71)#)OK@P =)2'F@-ZH =%;=9P%,QL'][["$^G79D3UY#:DOAV32A(!//_M^
M6FFGE?*10>=P(=(4<8.*07S<&]*W(O--\SD8,2:_P!3XR7X@[EXV)4,CC2(]
ML(>Y;:'#BCI. *'MD-PZ%'+1S=2LPG"LO2#[.MD6NP>[9C8CA%G,JS'.'0$;
MA&7AB$\'X(2>(1\[:"*7R@^)R&JPX:S?D Q!2R\.15K1L_HUO:'*<WQ5O[#!
MP:SV-1D(WP)T])EU;?-#\M/E'@[FFQM>D=Z>Z3_JC1"X0LL"Z*SIEN5MVN";
MN9;MM('@&,)H/70HL:GGNS9S^-0=U?;=<W4WOUU,$/'S_1HFM$7(6[*@TM<*
MG=?ZT,OVNKD,MZF(+^>DG2?X(Y9\UT0+N2ELU[80,S-T&0]]B<2,UL1>X&VW
M_LAL/3SS[^C),*>!2#4"1R,L4Q,;M91O(GX66RPZPT6:<2:7J\)";R>X=@BJ
MH-E%?^]$(#3G#%L?O!T!K4'9$&-C%#-LFQ4W3G+5+S,8M8NR1J/-&+TLN/ ]
MGS#_L\/:+T26VTB[+X^3-68R*K-(.&Q/*^V?:9HQZ\%J5@LZ6K%!B#.V^/_9
M+)R@+_(7O"DWJ:E)O;/$+$C:A"ZILG$YC&\N(WGR<GP\>Z/3XP6/,MEN0CLJ
M]\!N4\*JQ1<$!#S,<=]A+2U=<<QK);$8P2X(O\H<34(6!$G F/B?KJ6AVZ=/
MO,3$C<>RXVF:OUT,EC<#>,NMWD64P^1:,64ZOG[R]70F=]:W!H5VDPQ0,2AN
MUJL#*ES08A]U)=]RN?P<S"%V*[?,:5E9QA<)T2=-8C_]X#7B7-IN:?#J6SP_
M<UFC-9RRKFQ0$20GAC9K7=LN HA[1JTD27F[S, #/-]^JY12#%%B2UM&+@$;
M9>:]V:FXJ]K>>'FDA"MD7T1A(AG+)>22VUV\A$J_BABAA3"6DX_8?->VO'B$
M*A-C5'(LDN^# &9>,)0T]IGG$2I1#M_DR!TD6Z- Z+(Y!=,8$5?!>.ZQ93"S
M$DZW7M<E3-UIJP$.:?24W?ZYKLKW!&8$(CAJ'KRE<?K5K)\HM8%27]>!:Y1P
M5N(N![XQF7A:'@N,H.SJ0#51<&!#Z/>A@>BF@UF2E!0&2$<7/SD&/!+<.M Z
M0O3&2%\BPZI[. (6ZO##\=INL-EWF;=8TN*%R!K28)P:Q6><>O_JG'I_<*GW
MGXZ<]<BYH?V,EER4S$'84=RAF&QD.6@(:XO2PI1599;1F)1V7^UZ+GXCN^$M
M#0;[ZQ5I0T&(L:W*'L\WS@--EK>4#KY#5JVFI=8TW+O"HM)'@ [R&0&\S)@D
M/'TI+;6GC4O6\Q[Z&2\R=A?Q1J=:>R1> @3A I!@0K*[<#$_Y(+E<\0.$.B6
MIX9F#: V9?#KB5X0&Y[8=2/M=QTDJ(6J["![K038H+PL?&V;MX_*GSJO9%EQ
M]Q6P'BVL&B#VN'7G_[SLZUY\%SY3#C,OBZCS5]UN!@N#](Y?141?GGJTM#-T
M_#!-N=E9,(U3I 4;<93G&K8^8J:)[P3[2LN^\DH=YO"IDS?J1[5\V*:\CHL7
MEI34O,B&"R>.TIB,1VW!&_?7B/].>8Q*4$,;9IM-2<H_(I.2INI=SL3CRGR1
M*&UG)4XI-D'7[*#OR_<5/@WQ=S+9D_\:W&F/=9T8?FG JA7M1,*2@]"; XTS
M?6!F17]Z0_0.,1P=]0 C2WLRB,+'M&N$3@*83J@506'94>-(5-$BT:F#-I'(
M4])6J#@SL_\,&H'#1'8 ZDV?',R.^-ME-88K61G-P>>L* W; CG4;&4_@KK(
M M>AQ5Z(ONL&YX >M,3(O?;I(]CPM]NA48).V'J\9"1%"U[\GIUEG2&K+3;,
M&PXP7FD6\?(W7J]*20F0@>(>C\@_KV_AA,!9(M.,(0_/SB%"BT M#"G8!;JW
M(%!;GDY,!&!5A0_Q@Q@T;F<S 0(P4D._EPM6Q+W.F$J&8V(/_AS./-(T35&>
MZ#&X?BCNUN0%73%028R%*(53K&:YQB5X(MLP46%*A 2552/<=HBXI2"W2ON6
M/[4,+SRAP2Q_>H%K'L09JBN>!=A4)TQC.W9<T^\4L(6VU,>U;J\Q1?H(42OU
M%3\*5S+#,\*^$V<;V>W,TRJ(#6\> DM4DQ[OREF+&7+<DA:(HC_#"1GP[[>L
MV(!O$URZ9A^Q87'W(=O8D@-EO,?OP_)22=?#&8EPU4>L.LT\)JLR& +UL\./
M,&R#6A?1,;40L&LF 0I0"(&E+82%LW#$AT,1*+L\[9W.+M^'I C)+Y3$OM.=
MDGV(Z#>E*9@?D%5@T$[ Z]9HO*IV1\N9V@&"^R.L)DL\-SIN@'#S^A -V@O#
MX;KS*EO=*'3] B62LKR%-0'DCJF[Z7$0[LIT^+'<A@<XL0G0^G'3DU$1VI-[
M@\K;6,/:7POMG+*OK 3KX4&8"0\7L0D6R63A=52BD]!I&,I:3[AHC\;>PZIF
M.+-J?GIDON?\CMT2-%4OK+6X'#\:/(QRMA][O3E$VF(3K$J(E9 [ OFZA [C
MNM8&97K35W4O[_:&7->?V^C"^;^+%Q?//VU3RPFEZ8:\9>P0(.@ZP\JOJT+P
MY/R7H=>^H[!,I#5IZ.2O7;4B;EM\L"@9F2NT"B+X*-!@U8+FGJRUW&5.V+)_
MDM5[70+C<=6A[X+$PX>TM+:ORBVLW8O]!A'AX<'"CTJ@L0N[H*]Y+KK=8U^'
M@#-E43+H[8$D_5]&>LP29L=/CYM?AEN-2/:+[.P8YYV2L?7$/H]T84P3[3Q$
MX!4:.FA)Z=%? =K[#W\1GW&F^^MSIOO!9;K_;;RQOV!+&JSF["7;TB\I$PPI
MN<NA1+9=H:M#.I!<4[^#GYL=Y92.@E^"#_O_M<.L7Z,C!7<PJ8QJ!C1BX9@G
MND$(=S+P=]@IVEY-%:-H;_)GT7[#@IZW65YKPGV/-,\26EMK3Q5BA> Y#!WT
MI+F/(-XGYZ(W;$EAU+R7+:N,0;_M/4,_M#-\Q?I4*629>Y48[^SERQ :O<P#
MG9-?A:OC$M(61FS'(B<RW/Q7A)H^>_+L*:97I;*'?RGHEY">;0?LY*:4/.13
MH !["4KH0LY=3JPT6)(_]6"3ZV%;@,+ XP+(0:J2M1J;]@H:N2B-1/!91#LL
MZ2ZQZ!J&E-3:\!8RP=GA0*4XZFTD\8&2D^\_5_,N[)X#&>#OH^+E0W(4#-"P
MA <37?1X*\A"MXS&2_M0W"7J8,VV,8 ^;HVLNLSF1-3HFCP?*:Y1[M]ZM.22
M)((%F0'#,D@K0*X+0.KC' X3FWAN"=V;JW*WTWWS//E>U[%(8'AX%M>..;TE
M-![_PI?VK=Q1S*J2",]O^5[HMM/OA?+ 8?E JV2RJH@D",^5'-TM9EV9IY#8
M2L.]W?J;$G:E$)592<I^XMWXKNN".FLYB5)*IFV!>37XDS4 B\AVY7)VF&_G
M,^]]5>WPOZF/MF!2H*2?=+Q?$(*936K<2X\G(ZVCE"'5W*35%!$B#?P[HNO%
M5'E,*#J]WJE%"%.)U=)XHPC["WE9CO]E']!KLWP8?JGB3&+X84I]!@I?87X/
M3.!&V#G(50X=<W\]_>XOLR7TU2*!OW2BD5ZU-I"$;=L[OJ)PFE3N?N_H)L)S
M"^!T3!L)_YY)BM'V?Q->ZLV,+L_*1]\*E\M-9N,Q\%PHQ-^M;1,-H DV>*C8
M$VO=@CW9#;QYKBU;+*A2 =W':U5@/L&AV+)NA AYA6>_\2EA+KXJ'SV5)P6R
MZF%SB<OKYJ<FVXNXI<CX)DCJ*5N;(0SNJZB7WMK%V<QP_X=*?]AWE60B$E5!
MDX6N]V83=B/$E[B8I&,RK\I@#O;-YM05!\R46I6 3A1VW"+>+Z\A3CHS,3/-
MTR>/O_^*G!UH+, VBD*W2>T()C%1W:,J7*^B@V++7=MKO*7%*[C&VIP@(L(T
MHC9SL*+KS<,$J+YK9UMBNN4: @@^8P=56'NP\VTMXNN?5U63,+8T"-?3Q&GF
M-/K"CB_;![RND:BQ(H6[")#\U1?EEU\\_?*+BR^-ORNW]+_$MQ3#\9Z11_L5
M[GVR!60?PE7>L9E- T7];,8IZ"(ZQ?'SU"3'K8L9.^L/@>CBAFPB+1F8WQ;;
M1S=JHC._$A["+YRH-E> 6/II&0[M$$0K-N7+&:2<-V37RBZ8P<[C'GW?1X23
MC6!&G=\!B;9-G(=,=HJ;H.SSB#V6O0O<JEM0TA'RRE; %D=G,]8[Y5YM^-82
M6*D[[0>>L![R,QH#.F.PN$"SC<^!> 8XH'P>'U5'7AM:=1>[RH,@DN?6BXJ5
M@D@K"5RZS18D(I]]#5_>KZEU3,!?0CJ'&QL]'\Q!R^&9^ODW;>6;S[%SI/)1
MD8ITVR,=YAP;]Q?<;3\/GW'+ T%MXF!E(OMP8HBB\YG]@NN1CC=-@O_'$O2_
M:#^HG G,RC7*;7/[(J+A.&'7=NXXL9;LN))F."HXUZL% XEXKR%5HC9]TBUP
M&N4P-A-%5$'0B]?TY<+$'^*S&Y]L?'BG8=RU= DZ%\TY45$PEU5#]WD",>.G
MQ7>?<>[]+^?<^\/+O3^L?,&MPH]S!N&<03AG$,X9A',&X4]"L!WF2/FWP-8-
M@M7N]^7B?<\5..+"'Z3CPC/O&C BS-%J7Y#JM"D^%4;D!7V"=>^4H$#YR !,
M0-UUKP!>9--I@4?K$F9BMJ\6ZP9U<&,@F']([<D/?^S*^/ ,A^&PE%X*ZX 6
MAK#8(VY[QC;6X9!%<0@A*="M1HT1(%'ZMMU!]9KQNY0CV("*(S)A\*O"N5;*
ME /B0!=K]-79]Z>QTX'@1Z_2E9/?& ]5%//@F06Z*'233N^+\*6X$</A&FT>
MT5Z@CZH]=,#YJ::Y:WJJB[K.X;UTG%(:H\&DR"&L:: .\N438-/QW0T^J -
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M%B<V@F.W4=2\Y?;QXKOG/R3_DT'DDQ($W)/2]6A:N6%,9^E^/?I,Z!#C#T\
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M4H/\_ G^/Z3XC W1:AL4^.Q:A?Z$&V%ZO,ZKQ1VG+Y%$$@!-\>X8&4@X15E
ML+_@',-WQQS#X\LQ4-Q.2X7_W,ROU/D),\]E:P!7YAM%E9E=-]#3Q;?]W.FS
MAM+L6ZN&!!,!JUZ&A3U\F#$=NE'C(?O,%H&X$^'-VR_">YG(*S_]SN:5=]U
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M*QW#XS(:Y!QJ4$27FV[\$+EVJOUA3CT5VS@NI=J4C?/ \=L*N\Y?@J'\_MH
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M9:8SJMKZ&?J&FQSH4#",+B9A,VFF)-TUA6,[+FXA]J;[GMO9Y)6G2.VO,66
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MAS0+@,?/=DOHO3O3%#Q3'$L=-X70NLGK)=9!8*#R)96Q7GSWW3<2_\%K:U$
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MJ:677W+(__DQY/_H0O[OJ=< -8Q>/<,U<'M4ML8&NZASBD1)L!WO.NC7Q",
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M7%)^&7;,6:6:)\FS2TT.Z8#I9YC&1GG^I"W!Z45(Y'N50:+E)K\AAXJ!.Z
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M&BD":R]\7,^6G@=I^:?GSR3F_>I_7OY3MIVGTBF,F.@ZQ5*2;ITDM!'\5T.
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MDL.6T=H,F2 WL93WA#N,O@5'9]ML\/%4>LZH]QWCBC"MW':$?10AN;DG: 7
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M!FE">E\B0Q:@(KCL666Y\B!MK!HKZJWTZ"31D0I12'E&C22\"8\(R9<1R-)
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M;(U>_6FFJ_&L\8^E\IY^60,X9_SHM9Q9)'E0&C%F>/S(9GCHB;'EVL-ZD=-
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M>)C?7U=4904_7[G[V)O=E6O-<I^XW+M[4TA^G>?>3*"[&FSYW><[%@*[M7K
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M9E?W:LZQD@]IBT+/$SM\3Z,#Z$UN)'DA&W O;20.T _@JB?$I:;)T3H K@=
MPT==X2B&QT)&_$VPQA'[[W\=  *9]$F?>XJ+5@/+Y!N\>A2$N!J%?&B=$)AU
M.)"N*'X7!7(''T#6;,/E,@M%4 NH8$'8[1SP&*[(ND5VCKZ&)W<<$:QN!8._
M<<)XHHN22'0I(QXF_@Y0%]OY0]_.-\:.!-.D_30_&?ZU%?[5K1;_ C+C(M7]
MKU+%N-#F_BPD1QG^D"Q#M]?XLQGS!HEX1OC)H. V4/"L6B@H3!"%?;KGMHCS
MOTV#Y' 5R"Y9HT'([<3F&Q7 2+"%(\H'R=D5G;Q= 3BZ$.E\[,@,*IO$LVGC
MRXGCT'U(8AGQU9("*!+=[F14P2D/;H;E:D%NLB]!#PF?W3[C^D2K\;:EINS2
M=%FPZ0$-N?5$VHA;G%CPG8&-%=(NI/ZK3&QX/DI&(T</Q(OGUZE^SI0Z%<VY
M:YF<NS?FW!F&K!ARA;*E0J:;O>U\Z L8CU:DS;E+GSOO;.%T0WOH?3.?J8-V
MY> 93>.(1]^D7VT,9I<K6"?\[&SJ?7X0P]>2GR$;<R.9-O6^:1\+RQ99(VG'
M7]S AIT++BP_5CH.^\'Z"7KQY2M/T@<S46PX&C!AHT5OB48JEMH3.2/T[^ _
M01X.6-0'_2+-IKL*]-3!"'BL$R)>HE-F+')W,/AV<G)JM\^:5I#$40SXB'@]
MYAEXN1P^E+P\U4YX;LA'-4,1*/)2V\*NE'YV]-5SI4CX</3W:JF([T]S7FC;
M0B4?MTROAVWP *##_3YJN5RN!JZ%?P/% C]T1B+A3R>Z<Q&_.(<]Q-P=_PSH
M%W& $1Q&S@190JK/@$+B3ZP'>>*^%B)(? \_ BOF"2X)H^D XT?*.G&BB FG
M? Q:G!/%H'LB(X#_-P5?TS0FRN64=I!-,!:.I^\.**_)R+I5URT]0/+6X:*C
M@#,N@BF=999*IJNN;J0GS'#_ 0"0QX74,B%Z%8/$PY"+=IANG@/#7?54EI@,
MN)Q3]IG8CO@L'S!=&'V!9V:L[$9D1V("-WHVLN\A[R!A 1Z>)X7B7!6'GB_,
M>3N0"9T2SV2>KO/XB-[#6%]1Z?<C9\ P0":@)R,G]/$, KJ[Z9US-PJG!.UZ
M#P'_O20JW'XFJU3#4$W9UJ'K\/R3;S+_Q+; -(>E$Y\HC#8AHR4(9Q?/PM'-
M8\_,X\DA:?K4"Z&!@PE]N'P$5Q4-)\1H J#M1^[YE*BF<NL!2.1[BM753".C
M+MW)2G!]VL<T4=GJNQ0:<EV5[*@I&5/&FDW7@.Q%! ]A>WUWS*-PVL/\M,0+
M8'ETP"X0U+J:WEI7R0- <0QV90:R:25#$<\A1S;/4\I("9X$RJ^W0'A$RQ<V
MT.G>I(CDU((IM6&MB@I7#TY/?DY5%K[+CPUI19 9$7)K(J]6=,D,6EQP)O6@
M]L^RLB[_QUH6V4"KI^ZB!M1R;P4^D3<6V8F/J-M5G.UV16'^L>=,/A*N?$#<
MR.WVM<52!\3E@R0"W(\.W]"M:4KS!.,9?4!_?]=2&J8P<.5Z2QST;6T2>A&P
M>R 4OJ>KX->'\)?/J=S8;">,TL-#Z$GK PJOZ?QIO13'#:A2=U=;1B[-[ 8O
M5''5)VT=)#?3,5OSMM7E \2&VRNOA;HJ0T27?DYQJP6M'#3M9F<'_<WK#HEM
M=T0RS5?7V9G#0',GK6SKH6W=A,%,8[\6,J/5LKNK39NIB<AH=NSCD_8Z]:O*
M]Z1IF_AXV7O2%%W<'U>]/[Y>WE]\M6YNKZUOU[??>];Y]=77BZL[^.S\^ON7
MRROXR]U][_[B^\75O77]S;J^N;CMW5]>7]WE/8\[. !LV;K_[<+Z]T7OUKJ
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M/61V9W9G=E>BW6W H"-6MV&NVUX7UT6IYGD.R%G9T8)8[I;'4+Y?7\1+M+V
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MK\$^<G#=B-K4QT_,^C=S0NL"?C:POK(^&SV !=5NVE:KT6I;J@?(+$0^61U
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M,GDD9L#68-$!:-WTO+AI$0P$8(3"%M&";; -6).;*Z0DO)"YEZ*KTW]"#6M
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M-W(%1VI4?3?L)R,T'_I,5X/0$^?Z^<Y^&=95Q(N4>@SZ;])/NZ/W/<<5X1(
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MM#W".W"R-A:9=+H7(TW"$RD[5!I  )J5/+8#C?@JL'JB.Q1>,L]WV[1.?%^
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MYI,@V_F&-;V+BZ$^_(^T/*DW4$0MK[,PR1R>2E\?^=@>#!<I8$G?>+I]V''
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ME'C%0+SI,1Y+.#4W+=F^ 3.G%HE!=FB3Q>UDV6UA!8#.S-#:]:B_[>26STE
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M]? F!D%7@3ZWIO!W*09UW6$71@42=[E&M@,<JL1)?1K+@,8RH+$D?K]?*QJ
MVSMY3P*OATI71M13H/J0C#0NG7C@;,.1!73 A@G[7@2CR.)KT&K*[8#.SWR6
MABLO)6!LF,+Y.JX&PI6)N]XL\?!&*(^X'(CY'<X%*@YZ^#0!)F.Z8XJE%T/\
MONBA%=F.\&$7VNC<X&%7^.M'A X-Q;5E,3&%FT[4-6=,DV6">O6Y^X8@HM96
M?T/\<#/XI.5U#DR&"'Q[$!$^KAT!5@MB:Z%(_)6KLASEAL4R+<+F0.-PX<(-
MU<B9OFR%!BWB.G(@+H-AW<9:W"2;*@#Z'79 TKA;IB^TG9,AY[3,YC3?(^'B
MUEEYC.2=-R@"'],&/AZ8(X!"(>FT(\:V,=*96- H27RKXLSLT\D8>ZVP20IU
MU[0TT/;1;92D=!(1XXY&S2/G;<X0YHAJ309=L%1J,)]P(QQ(QG61WU4WBF)E
M+.@T_II(TRP.A9$;X#T%W$CHVI1O73/JA># \9=8I>EH]5&"!($H><YC])T(
MT%!R)]HZ:P--3F@WI(&9B4I3><9BKV?:F+D$=6>T@"MX!>/]V5)L>X0+)NV&
MC&OI?+N /+C*53[,_2+D,.(D%,(64M2P-BI'):'E4,T8G#LCHXYPS.-^)<#&
M8+CCPB#WCR,9I:#[#*3!4;,/,AQ%Z=4J-YB#E]YI]V95G//,BG.XZ*%3XXD=
M9AN =(L+,CNIFZFXY:Q /.UC#GH+RE(9*!GFG44XH!319+),-('L"K_OW%)T
M<DTJ+8XBA\ F@3VD_2-%4H(M,XQ3Q*!$=6H0001USV,-Y3;U&DF%+7<52'N"
M(9LB*Z[NWB>H/?Z1N:&'1GJ2JORPU8 A* :.WXB5;^E2_#Z&9A^/(ZL^45K9
MO![?W8S,"$BJM17$]2N?6\1ZX]DDO>Z1WMH,/L>J110L88+ @;(L,AX/JH@X
M!W'5)P41CT52-T5080[Z#TZ.7P;G0&#9;8Z<W!M:HXU^JIS: LI(.WH$T@K;
M^=IO%R$:B@*]4%8FW&H#=D*9*)64(W]W9-=<9\E_(EO^9H=!$-XR;SYT?\[<
M2A$1HZ IB9?WXRQ&,P\GGA 3;I*)"G$-&GPQX=]G5+)$]^*O!1'R*4IJ2".8
MOSA!G U@!-&U&-'2RZ5T=\K)OBBX"9]L @=VI_=I&NNI$II_Z4<R5?VN>)!.
MKHG"RU+']33;TVICWVDGTBX>GV!#JX:60L<V%3E7#<_1<UV1<[6^6>+GI]W8
MIVZ)DB^A_%[,6?#?EKUDCU&AG7*E'/&%AM6L'D^L,E@R03FAY@=;D<MQAZMC
M9W7LK(Z=^5G99W3*A,[<RRE#^5ZET^5^.9?SCLOIR6E@;A0,UU$KK>2!NXZF
M_XICR4S>GR\[SH$[_._[9,A7Y\'J/%B=!]^8I7_P7K;&X8 +2 ;==Z3X&TK3
M24RUQ"\*@23 &""UUT4(>$2JN/GXF8,[!6HXX?BCDS5B\F!]-L5'R[A@6!'%
ME5YFQWCXJ>:Y'&&):A4 +S,+L+>UR@(\NRS 7]CZ$M/"JEU&SBSS5/[6J5DI
M>45PK4GE)9=I0]GT&YWA,]:]H,0G,>']Q*@/J/'1[I%E23(V@_.6YR1\3DQ+
M_+70"&"JSGF1S0H:&*$[:S-PLI>\4N+U=A2_/$Y-L<XY66:_'S?YE+LN#OFT
MF5_$(6Q*(# X<TR5U]?BA4K1/A>6CX#*PC1'.SI077O_P"*)%UG:<&SA16PC
MB $Z6E#,H=N-/ZW)5:M$/_B!W:2^\+\D[: _0DN325;-7I*\.TYN/J#\,U''
MU4ZQ 8,?$R(E,BY28W(7[LB3TR*NX#T4WJ,3(.%%5P_L;:_LAF=F-WP#M,=V
M#=ICUX/V^/7L]Z,+V!J'1W]64 ^J6ZLA>RA^.+C)\23B*B9%#J,#3J#4Z>23
MX^<:@?$S*D#SSZ"VG*TZ-S@ ?079#4RXI?AZ>((50Z8YN2:"=1_9N)V=APJ[
MJ&0-*6-G'$AAL,V*"5GTHW#2B=[4EMA9P]'_H$$\G"HNGL!*2IDI3I: (M*4
M+04)V4\H.&58,(<P87D!,Q"5"4=CJ@5()PT7D)BJ?ASV26^ +(48(IR% KU+
M_'9R8SZM8-)-*NZ[/MJ!JR\=1C_!]C?(ADQ)94VR^; SMDJ[SARW$)2$E[:*
MOACJ$0236YI"+RKA0MI/0R;UP<L-\MYIOBGH9<\P=&-&N=M[&]P+*^-!%=<]
MD"/=>79AG)R2) -T;*ZUH)&='1!ZR1*3TH(C&;GD" '3G?NO,B[ LY:*=V^#
M9U/S]8R$8O&<_!?+Q.%<F7C4PI.7(1(\)?_%$O'^;?!$.>%G) #U&?@O7N^C
MM\%SR_D\(T%8>FI>G(0\'8?$L4\"OIAZK9J[FJW \;]:_^_<.K]M,/#S^,;K
M,-9M3S4E@&TE:<^01F+%\_!]/ \M,O"T[ XHT4LQ/#S)R'LED>E-RU+9&D-A
M6*B35[5MKH0K:]U80Z@J09,P,@42GU"B48T_M)%O4P5'62L NF?(Y 5'QG=6
MD?%G%AF'9W]W#"[D,!O%VTCR%P7<PLZ(VV+$#91<"KLMB=&Q-)0'/OB=L:7P
M)V&3TK8[*N>R!FE&\5O1*\\@\M>E,TGB8/5 ,-_N_?4;M/\S8HII/4>>.S^,
M&.:Z=9X)/\PJ"ZU9Z)9<WLO./^^N3MEG=LI^0_YYIY9_WO/RS[HU@J,3^/<1
M66*?, W=TU-RH>L>SO?;^<\?N;3H6.%/&GY_C;?)_EW+JV\[??BPF2^OI<JI
M%R 8X=/7]M=957A5W::M+!23 B\U#M8ADVR'G%:GF,8A]F/P@X[-T8R',;V7
M"N/8(HN_3KAQL%JN#R[*,L<%)BP:]^/@C-[9VMD/FZ-X@F%PST=S)$\PE-?(
MZ$66+@UG$"&6"Y>_-=S"<CK !'PNLC*<IC.6$.$/-60<Q!+F/B2.BC2AXCQD
M11=[TO3<%,$PCJH;#BFY[2><,K<"QT5Q^#5H Y&8W9.E\0%WW.,$.6JUG%G.
M!97#>7A<\@^,?]Z?JUQ*[*-2-F_+3BW#^<A?"]X1S'N)]Y;O&*SSH(=?DV.'
MT0YM9MI%M"IQ[,/IB3,IQ-?WYKW^&&5@Z!CC_YTVV5CZN47=.A\6UD^+\?]T
MG')/&G./0('EQ70<)*7MO72\QR(VV@X\ORB8I-,B2I][,)N:>,9QE%D,HHX#
M7<6V1#Q^I+.,$XD\<LE^K1FT-#5B,BN;E W&!M3BBY5KQZV)S,;0.ZG:.A[6
M/&@8I5RXB=KU:Z+O(I^=2)PP9%K$PD#)4\YC0IF16G&:8U.D%]_RUIFYNW.:
MD5VOVF0S^.\.S3\>;^]WQ^)-@OE([0%[SI[F%1J4I@>V?K^;/%LDZJX-JZ+2
M_6Y"]IM7LR_?IW7[@>+F<6*3#8PN++[YK_:R<Y&0I?WI2)CGB<4JPO:8#,QS
M)/7ET2_/V_&/2<(\9U)7A,Q/1\@<+,G%O(J//UY\W(04X15'O</?-$[^X?AW
M)_!X>O;Q^/3H"%YRQE3-S5$=GRZ(5;[L,/O>*LS^\L/LN[4P^[X79O]X=/'K
MT45P?'GYZ4_2ZW6O-N^[V*3ZC4-$IYQ#Q+F@@UO=!+=#"VL(;(N6AV14;_>>
M;VH^CA'OM9POLGT)WAQ!,[XZF% P+R/XE]F7J3&$R@K8FE!<&L>@"(-)2BW/
M>.R3+U:G7YX_# <CQ+!L+TW!W%,SFWFY.;8LA5;X%OQUDMV?0OH[EO)A+(#/
M-S,^.$^I\^W205U^K-C9YUA:'1D]J!7XV6UV)-$2T(K3J!Q&_PY.I(O_8@KZ
M?__5[OY:M!XB>0;\G\$Z,VD,UQ]^IWPB!W7NH-H_K]0Z5^0;2#A:U% R8"T7
M8*4S<G>; G,P\\E-R3B4): Y&'PHI[ CG =17V1>,2[XD#' )^Q0Y^@G*-O
M("IOA,5$8B'H@9#W8 -&%(W1$8<^#AEV6Z:$[D/^1OQU(,5_.UM_;0<N<U#*
MV&)H3DCM8];RPOW1A?\GG T"\XF+05(:7@A72Z__@E<@30M_(;ZN04U1AZQ
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M6]CIS(#A#-JA+< _IS3>+<>CN4:9Y,9RF*2"ZOO$51PE15D%PVAF>K!&23F
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MOKX7A<??P#S4IV.IR=:Y_M%SYXQ+]BW"5@WCHF[V\?N?[U0WC\'FZ$55NN5
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MP\@@U[P9:@_QYWG%UODM^AH$F<FPB!E&"-)(?]3MX(SZMFW4M+#F&V.LH4K
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M<*YGX')).E(T=PXV Z&CT*/<,\8]Q,;Y<\E$HV.N2D#;-'2Y6YQ:4>TA8],
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M0ET%09S=)D4N5=%A4.:49F&(1-TG7#A-6T6:/U*1+I5F6/8O<>7(:ZD?0?!
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M(WA95U9N.V=(25#-1'"KU>-- T81L8%TV"JB!C5"\PW]^"9*1^RG1*:FDTP
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MC&[2//M6+XLDJ6; LDS;Q'G9X>+(5-%'>DT6C=$%E*9"%\V4N](D4U(<YJ3
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MX=GI^^,KO>;BZ/+3R15=<G9^=-'#/UP^ 3:JW];I5PG@830MJ<2DO"$;E"R
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M"7K:P?QR5M 9,S<",CZ-^6WY9UCBUO9'&08&61^VW8L98(1*(\ZNX50B!X6
M.>QPLES=[4H88DP9 :CHH6%))V):AQ20>IZ:;6!KL XQ 06MPSH6A*/0@=U-
ME'-N(Q>>Z>8%H=18>_WZ#FP)GD3'<F@(4,H9=EZ"H18Z;9-]4-9W?*Q[?&8*
MK^^TP,$OVWL#/[>0P^F4N=/IEF" 99*D'M!^G3.I\UWFT5F>;=A'HX"/8P.:
MA40OU)<B01WY,W9H8!@(/YCKL]APMO5-1'(E3[DBC)*><NA]UH(GPP]7:TWM
MQSQYS%AC)F\-9R^-KZ,T=-/DQ$I#ZR$H*-IH2NW4U#V'LY)@IGV=8,+N8H1T
M$4X8CRBR3MWYM^X-]&.LHP_2OK:0 \Z X$=4W:SK, I^W@D/=K;#O?TWHK!0
M>A-!Z*BO&^.H8&LFWKF_$^YN[?E1.Q@'=IE_QP+SH\/7^WOAZ^W]D/@5N$4Y
M'XVP#;/OBK(4'XV5>4<&_O-V^.K5JW!K_Y6#I\,<G["!E2^TBKYZI1UTX]Y.
MN+6WS1=K0Y2@8M$<P$VQOF/[]>MP[]7NP_<Q+KO..]WK?'#P*GRS?7#O5=X.
M#_8.6A?Y6Q9V+]P&:7OS>CN\UW+"FNQOA7O;6Z$/8"H;CJ[9?;43[F]M+;-R
M![ AWKS9?MFP*'NKE.ASAT5!$$[P.X<*NWDH;C_87'"X8CWR0\-K9L$_HFP*
MA@F+Z?8;1TU8.X5[PSH,%5RU76**)+;(3W"5L6X%WX.)C4538V2"B12$J8T:
M+^] /<2&URX!4^TV+F#QTIR!I/*)0A7ZO'NP4=T7(^?<S]M;F_ SHCGB[T*U
M17"LUP5VZ[@=[C_O;IG!;P:7R1BLA"B+\VF9"HD[63Y@H\NWSIF*QK2YW?+;
MN^&!,&J>2]/\N6F:MVP1%3$D"AG"S]OZ)9VW,(E>LPV_SH \?Q+LX!ZAZ=[A
M;F<5SLO)8::?MU^'.UMP#FR]#O48DIG'8_\5SR!VB*C8*)@.B<0:-6?AD;#'
M5SK$Y"WR!A8;B N>"_K8H;9,>L]'4DDVP']^LT>#(U$@MR37C4 ?8XDK+:(@
MIC&C[B?K6GD;@5F>.MBM5/Y:O59RCW2+Q/]&Q$_&VN&M<WV-X#)5' :[F_M_
MU?[GIDS,\4V8>=P^BD7(3./CX#; 6,=)";(](U0A:>UK@UV89HP].@S2'*-V
M9,!0[E<)AW.Q^+F_+S5*.:/)4!=PT6K49^D.G("%[>KH'ZGE9#K5P8)2<\=;
M,T?Q@27Z)MS??>/14EGPD_KL, %5J[*G<3*!+%8N)V2>?XC[A;T43P2\]#$L
M61?FIE//MIXG(K2M)T?80"_I5L*(:UCE%?=CPOGPRAQN.%.D8A<YGRALCB;#
MJ[NDI)"P$FD/%R]KCKHCCMMV;21*"$[V'AP*J2SU@>OFH04>!1B(PO&,XU@5
MK >*B8DX1OUGP1?,:H*W9F)XBM.2=F$81YY?C+:@JF4+@,!CQCA'+EIK>X0<
MGN-[+2*AN[QXKAN_\RK<?[4'_N7!4IV_%*5!^.=XS+RT]&5?$QP-B#U:#.#3
MX3E+3Z/IJPUE5X?B31+^*Z$8%9@=6+4#&-FV!A@6]=2K_ ZES9=A63$(4R!R
M$)M#9*)R<P%^A=(W>F]H47VX(+>X_\UQHMCC/;..Y[*.FT&O!<,+#/[K7/8<
MAK+TRZ789A!CSC7R"K<;<_OJP,ZM689'(/M>AO7ON^(0NZ]A\VV'>R \:S_O
MO E?[QR X\AZPHI;QLR1PR*ZH]-9M#".8V^]9N,@J/M,FQ*Y@(E16V+T6F%2
M84]320::MO [ K8J86AQ5$Y1NA!WOA%-(];B**43KO5C!*=U6KH(^=3%@DXQ
MXMG.BX+*9-[&SG=:$X2LL=<P,;O[X<[>?DN$ ?[\*MP#IW_OU1;!F2;]*:^$
M"+R@MM/C8?P4>27UMX/QE?#UP7[C-AT)DI3;;W'C.8]@IN3!F%%[%?^C_**=
MTQ2$% FI))/:C^/,C7:@C@?%#SL0J5\9*-M ZYJXI3TQ[/%?3A4B,*@$_.=2
M],+N6K2^MKV^UENW5IYYJ*+-]0;5.I^R^AM$VRVF _5J2'QBDB9?)G9$9^-'
ML2&E7_]I\W+3K;WPVU5;!+][[\E9K@#A.'\Y'FJ@DG3/M-R52-1QS:(_B(,J
MW2'P#Q'B:JBW7)<0.+7)1T6:,-A$FQ'8:HKGA9F#1T&]]G#@$*["*;3$S ?3
M&MO:R,X9=NT0(JZ5,@4P$!F;@H/YC:AN<]+7J#Q 5!$7)I"QQM$V:=!!67-2
MZ=V9A2L/-=IDXSV4.:9VZ!.],RJTD"O8\C1FT@DR'"E23SIHJ,U\RXP@%/0.
MH=:S#E.WK&K>GW0KI@?RX@N#[O&8'>>#K%>;U9*EJG,HYX6#_1=R+R';?HU"
M5*IRX*\!!^\.# *I DGB1U!_RY^_= : /;>_>U #,T0AKLDK.CQ(:=&<:GM
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MU *@%UYT@B$84H$:H8G]5O>S$OPX-AA[!V'0Z_1VG[O\'#QV^3EO"@T[7;"
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M#Z[/8,HX',>_P'9PNQH:L)2]DQVJJ8#7@MJ&*9[.4)S/P.?H]]MNY5A$F_J
M]U-QS1BB1?4ZAL2.\8OVY-!DB9D<.5O=T3KD#\R"U_BL]I-.*N]MDLJ//ZF,
M]]DG U)9QI]])W8HO/$)-U-QG44>8U\4?J7CU')DON*+4G\]OML-G^!PM2XG
ML\:.(RHW[;R:P%44EWVU@%7Z;E \[BF=.XN'STMXPYEOYGKI)#M-^<7*R7J,
M]-IC';MR3KR3)NK/-$.H:GJ55((#$BWPNG=1R)9^V_;]^F#+<EY;%QV<J*N$
M+LXHH<=C1/,+V?_\6.*[E>J3W'0:."0RU3K3+1GH$I/@VW4 5EZ1K5[(<^\,
MXZ&K,S$!F$SC@(E<K<)0G"&OK]@X%/NY40N;->: @Z(7M59N-<! 6;@V_"\Z
MEF^9$&S8:B/O=LS(#1,YM@]-"AOH,93B$LZS5E[=^"8!_'!T$C(4U-K8]*63
M7U9=R;W.-2NY@"R]&HH"#^U/<MG&D4+&Y^ \4LE?^)M/5:?O*&V'S!@OA78?
M?CTZ/_]?CFO>;U'-A2#\"?(UW9)?QWM-Q-8D 89)VC#_L@PN)<UN$LEOW@</
MS6-S;=US@ S?-8FX8W&4^UUL'K[=W;E/P.LC_^=I?@V%KQ\8X2%,\+KV\H&F
M?H0#&,3S"VLB?=1-E3=)>XM:X:#(D0YPI1B(!Z\VRFNB]B39,Q44&+8!T3-,
ML50S9((N8Y/V,0'HF:8CL!5MBVE#-HCVYTT(\!Q.%;8$IF X!MGK36G2K$'>
MX9=;D7FT1#KQV3/CT35T^*'TD6QAO6<@A0>G,(@P^*M4,25UR &D+6DQ5;(\
M>ZFAV6C^WMB\M;OAUK9B 'H;6"657LCD2YO/K*I"JDI9SCC*^7+!%L@WM"LK
M0D8DV8YG6)9;K[2&W]3X]DB3+<$L<Q(OO7_Z40L="A/)7DI;7"%L">TGF/W:
M8BARJ7A!95 )WJ:4C"H36=(R08:[\3SK@RV;L]0P;A^XZYWISB7M66'+!E1K
MF4^Q^"_GX*<I=Y-3 RIHBI%8:<-VSP%NU.I?],P:.)QDEY;7G(LS2E]EUEFY
M"[R-03'?*4K90I.]B,8<+KJ&FUX)V?E#$QAY[T<WHSK0D3^Q\^//3:R8@B'&
M2(=%_2QZ1+?Q$?/O]9]YEY#2=9:_%M%9BB$^O+B@NE^N3AM><LOQA;1$WZJ'
M)]4K4;Z9KDGY];<HO+^[ZOK#H6\1F886F#>3_+-9[O4SDO!EF?.<'4&YD>O;
MT<U5;EDX4]UTHNY\7IK*)+I1-JX-NT0CK,!':V)4QNAEQK&]SLE71X8'W"&T
M::3D4 J5RV92<7E+[M7JP2PI4RG%Q/E\$K!,)C"UB83KT?I:A7OJY,-QB^P&
M#]DAU9RTA^1J72D"R3'\:U&W12X)!8>5+0K\/";JXN#=^T^.<,0^&U;AW>FG
M&G\9?RDVYAL,SKA)M*J4:(-=_I3I%OYMH@F1@O8RAJ+']%EC^+\]/@1O#>QH
M,G;!H()1\@WGX(H-:,7-';.Y8VYQQWR6)AG2I/1&M<L/W[*4,9MBVU<@4JB2
M., GQBF5YHJ;ZU]=J#RLER)$'^D4?%H*?-VJ?'G!&7ZBF;D7F\S<#3-SWX&^
M/;A&WWYC50<KJGP#V<3;E&O'<ATY@&W2[I,.SI,!Q-%?9<3!3Y]+<]6P<+=C
MS697P_+NT]$.JI@Q6!\@I?!VPIX-5 8;E") ?F6[O+O7](*C&'OG)4%WO]W#
M%U7-W[#&$E/CQO!L2E*,2*)(ABLUP$+=*F%GJ^XIJL4:TC#5VVPAYS 6*> *
M5.FXN_-2.$YW7VXLGXWE<[^6SWLO%A@LC/&MA=)MBKJN^."[AQY47L :Y4XF
M60^+?HOHZ++9>8W A*B* O">/7J-1]P4P,"RFB@A/_92YZ;ZAR3E!C)P[\"3
M^0MCA8W[-O%LVA+D>N)<NV2SX9YB:BP,LQ14JO2'.,UVZ3$D_'5*G?WH6WYB
M87EKR,6YA[5:6GJT._;.DHP4? 4'=GU?03L*OT&B[YRXGC3\1H[?,[E66(_F
M^\-9D/F86T.:OO%H)/"#2ZB_1B+8-2O)$'ZY%!\93'S]>SS/GN'$\7QC7AA^
MQ\$85'8F20@PO5RC@!7]/&O:P%>.#C\'YZ$,"KL>E@7/E0)_.+\\FDQC?#^U
M:N%\&?*&AN(>YL3TS9E(NP5F=JY58)G0"<9Z4M,M$/>5HUE>]H'+Z A,4&57
MVA@M&Z/EOHR6HZIRC%/)_NNO>H!H?(?$J6!-W!WGL?09CK_E_="KS[(Y8'*3
M";J'0),*VH?+.CTH4^W3B[$P<$G\JI(2<\F]3O= L#&$7T&(3JT PB"C2$/B
M@.6FSGRBR4H9B*A-2Z0\G]<?2<4H(0%4-HS2N7KGT+94P$H-J?Q 2(W"/J;D
M;J6(>D %BRX5PK*')E!59MQNU%5/C[4:_@53-@MDL$"A:3!O,@.U>#_?&$V=
M49WN)@*)JH9?U/03:Q6I"6NL0%?>,!;7#GXGM%.]<;CD6/[$=7'>^DHLYW5'
M=X6RC>:^FW[!O']E65S;C0I+D=:2W%;/ZVX_#LC5 IN*U(93%90AT^D%S' <
M#5K<1QG3.EY]4_66-'F@! Y9"^LL TS)I<AD+RV,D>H>H4EN^,9><4@_/[,^
M,(FBS1VZN4/O]PY]30:Q"@S-)C9MGE%E\@4CFF[?!,96&&(K&'=N:\U@FI&
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M/A,W,O*4S!(UE=3R[1DYB?X!R3@=+;#7LI'S?$@B91)B5:RR(>8+!K,BI=Z
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MEKJJ>NYS5*-1X[#L\A0I!:"]#2RB/"]%6J:Q2CA-%U'KMCHAY$I$>G6MP(>
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M*JZ(JB0/_BKQ161$8N@=3UD")EB9(OLHW1*$/LL)4W[Z]F2;$4*5>X5> ;Y
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M9)(9SDB:_5P9BE5%,2DH*>1/+GP((I<]!2FX% !*D.Q6V/0]75S21!A\ [.
MU9P6AHA?($QHRWI62'M#+L*]-Q]>W#=/-YJ_?$R.5?\1^63NE@=IPO"4_1>(
M4HL=VH!V9E+/F:!;<!OVZ',P)8:=JCSATS<:I][=Q*F_LCCUS;;?2V]Q@LV[
M;6'V%@P)^>6 N6.0)%(7VV@_$ZI02DN9"5O57/&K,@#)9,(_,L,MQO0@20[G
MWCGKS=*9BYX:T#+=N;A)WD"$9M?6/P@U(/"Z.#EO-1SJE,Y'3=%1GRI#-TN6
MG&4JA4I%@&K/?)B+A+,P=R/P*4H$ ZJ;Q>)FPBZ-ZYH?*,$9(873+3O7$5\
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MJ""!'M4HQVO/*YB37A5HBS<)2DH&Z5*!4J>,JY9(;N\KEV-!,,E3Y/&AH]S
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MG)PI6X ^?A39U(:@<"8%_DHQ$#4=S4_S<D;;SWW=^4PS1.;'(T_A*C*(4?9
MZQJ^A.?]4B('Z03>:=E\WY3+NLK=3QF*8*MN43;R+\$AS.&$NG_;JLHH\P$2
M4 $1D8,U * E@(-R;/>7N;8A*[#"G?0,3F;A!O]FI?- J7U7)>(?RGI!.H<
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M=M'E#I6Z\D8>.S[3PE12IA5M6E/ ?.7P/*6+UJOZ5KX2_I>TOY(AIGX$XI0
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M:7/9KW39A2K8;)BJKKQSYM/[Y\P9,BA:SGL$Q$A46_S<?H_RT8[PJMS(MA'
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M%"NY.'W+]N@GJUG(DHG:1M/KU(/L_P#J<C7#5!'Y/Y51S$U)-VV36Z&W+(4
M.V&4]NNI!R:+B&UI ^,D6I+LC"[QDO_%;H"9UEFR(_#HX1EH"K8]6N].1I9C
M5VG7.+E":JIG-JOXMP^2%)622[O51SW)M!/G5/WJ0-=M40#+P9'Y!-5BD]5
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MY6\PYY!>T&##TCJ)F..WBM-@P,ZM @E9HG*!@9Y]8>TF=2$^ (,AQW7JG3
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M)1=XLA8\I5PWEFF$N.?7BV$*G,&BJ.W1_@Q]DH]/HD[IT77WQ=A _<RE6[1
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MGS$H*Y+!IZQEW?6%UAYT42\4 &?O"VV[\N7)F;8[02'!45DOM>P;_YQV%="
MZTY$BY1:1^SXK)P66[(;125.V51*KK1>)CJ9NF@3;;Y9&%$[W1Z_6$HB34F
MGK9CV3HGH,\SOVZ:*M:JR'(9G*GX1 /-..%2##6YG80FH'<@.'X39EUK!2)B
M=Y"GM)]J\D4<8,E/LRUBU&9*)VQ,O4("7A[73$O[%-C8W1S<)RV+BJ/!D_JL
M(H,BX#)2I.ZQ^F-ES#\KC-UZ,K+N)GU&[RQ!ZPIO1C70IB PS))A<8TL!^0U
MA-7+'MNZ9'1C&L25OD\^^9BN3^Z]AN3I/F@H*'-%63-F>0?GXT-JF(N],"L_
M%BSVF FM=5E):N H[K"Z"K83(YWQD*72R1++EPVPTFK[)O,R8/\+\2:DRE(H
M?PO?H4@#&.4LJ=GP?:B4I)Y6@9,-@)S';8O2;X@5XTT)CR3C)X?H[L,>K]P6
MV6)K1-SI'AX5M$+4>31V>J.KSY3XW<,(=59-0G!=]-JG'DHYA;STHG,.6<I*
M!1%!),G7T[72H,0N&?NZ>D"TV_T)=JA>6&&-7C']I+9*&>KI9SSC$52>HF V
M&^H"HAS.'FUI;PTS?S5U+Z6I0L9]%(4)Y!+^J(Q&RIDRX8U&^0!8\RK;@'R2
M+Y:: V=*F2):+96T<:B$Y^+.!M!O_<^D;64Q/$' 6],U/SRK]K&1(%?67[<
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MCK<.I*IF3+=S\*AFC'!9D;)1LM 8Q>]"O*N0_C)J:93G);(DO.]TRKP3S]
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M&OEZVT%))ZY%G; */J%>RI3*N[#4DP\1(_'@]YC%Q4TL;*+Q!JGZN4[5Q]
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M>%2?WW2.;^)?O3=$Y.O>2Y2^/J2I(H>O&_\#M[/L:W_9EP0>,+*!LNDXS'R
MO42842_;7@GJ!(0$( FH >9L",?*;5,XHW?8<.9[.;2WG9.M=:@C[L$Y=ZY;
M'6R-G6]GUV!A4XLW0?<@5QZZ2V($3)0!!T!L)2L^+T,V^C@K>8"^-A5S9C*>
M7(<)!K2BNPA0"<@T6@R4>W$S9VJ27L/V4(U303&^?S?,6<&'7 $7X Q]Q?5M
M@4D4%[['_ !.&<HIB)XM8 JW)2LP08 FL0=\+I'+,\Q( \^(51,S*F#KQ()B
MQPLH\.4W6_C"_Z)L4#^4S227*W!7<N]F[5OM>%]0OZ@"8%66>8T-3X(9HS3^
M1@V'\!I2&50<<(%.1OJ+8G\=M\,B1)7*07Q@0FY-[4M9]G(L+^S_$]\A(H2O
M M6>A,*F$9<+U9O7$:$MS9W'<V!?$Q,L&Y:@<9(6-L,]HN]W7<A8?,%52>A.
M2%H0-G"\#LD=ET:\\$'_@Z,G<$_HV0V#,F=7%GTD$C: GV68UG_-\A=WH_&;
MU+Y)\,\T0V^*;!,>HK(#:C>%3\0QXVQ:%B#U*##MUO(%4U1G/-/M;RFXJ/PS
M9DRGW8S8K1@;?=.@9]7>DUT5Z4AA.TNQ_>"C6.2V3Y Q6 _Z.+X&X4*7."TS
MU!D>01-=I02:F-Q[L-ZF"FM&2%5]*$7P8Y /@G]Y61G#=QA70<;$=7%SN+$F
M<??);)##%!WO+/'PB=[>:^=C<[OT5?<UZD<#-8S09K)80??,)3#<R)3[T&*(
MOA[)IFH]<;CH#4O+/6W3D']@)@O99J;(B2@R ^>/.1PSCJ9B&OL:,]&9[3 Z
M42?3,B8E4F5#E7&)('L%G--)#)\*"14[ "P8_ED.1L3#D+D%6<;LKV2^@T(7
M%07RB@N3LOD/H&H6I%8"5871-" 10KH!"C?G?/-U0V(+KGFA&U4(^>Y%+=-L
MB%<M5WV6_IRDI[9*$5$2KPF_N.Y3XWDL2A>Q,CC;8QBGZ]F%GW2LCR+84?[U
M@9C"I\20SU<%HJ5,0HY0UNW[I9Q>JS91 CQXHIS0Y=K,),,S.T(>;"=44%#]
M6'<7@Q3.EJ3%LXX''+3Q@"<6#X"U+<^UTL.H1W7,12]P5!1*5+8L8!W&+(&=
M0B<@74!89:RI U>W!*-)T/8 *<996H[&&] C"5*P0V)5R?C2"UT'&?L*]1',
MEC>D>]8<I.\IP@&U=LR(8 DW9TN"'AG0*YS4AO<)X"JFMI9Q(-Z=S9B.$9NQ
M(A5PDH+1EF8Z^X+</#E+ >VIIBL#.9GFI0X(K^4/* >1<[^.K3XGOF?<P9I2
ME77#U3PL\WR]-Y$N)HDC:']6-IR;'0,*37/*VW3PCW95!%\5;D& (>$)MJ;
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M>>5D_P N90:2;W2*9WSH*RJ*_,]^]M,O.S^\^L^\;&"SQX<_OO::U+V=[BL
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M?0PW!ENNBY7Y>!]36+OGZ2)7>/@*[I%:CN&L5CME\5(F8%''RVH]:=.P1S/
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M(Z?D1G2/.^"PX5K?()"XC/8!;](U[:;!3'?.HX;^<*/8"H\&G ST0&5NLQV
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M% 5Z\*TVIDNF$6J1[FH<%89-@<3JP0S+SNM&64V ^-Y860"ZJ@$%%K&YI\N
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MB/Q@HE1153J [:.T=FC66%8U:%5STC6;?^6\T+TN3/D9T6V193RRI1N9NHX
MZ^$U.Z#G*(ZHB M/^.NKGRV# +Z05+DT\J1_*K%['4@#/R@GW-G#KS)"?B^Q
MD=)T!I&,.KV\L^BKY^UV/V[=[D_,[0YKCT'(@T(; OIJ>4E:E(/5*B.=%2@5
MWQ=FJ9%B1:;0Y(B .-AU1SJ_IA#KA")A-K.BS"$I+<?RU]Q*KHB(C+5BA(NB
M'[CDF5]!QMVI# _0FMMT&HMK6[_MM59"*A3WVGVW87&%"L<)H,J(-2C+UOAD
MHD3)8?F-*+PPBY-AH:N#UCLH*)EE' #89ZX>P F$HK?E/X68)*I(*<@DV*=3
M%/2*)/ED@NYJWL^KPV_9QUK5'*GX@78;L*]&%!KANOEZVJV_R"='3%^Z\SEN
MUJHKT7=%N2.X$5[P-;E-[":TQW&1\? @:A&F?XC?$.QIV!(%MC&SEVN_T-JW
M=5^P6[2EQ/@P1VDT]:IR@CW'H-Y$JJ!U.*Y3\<7A*%5,OZ[DG3<ZD&=B>+&Y
M%L.G"5U7Y6;13UX@PHYFKLYOU 1A%:)-Z=:0Q-R,AW;)#BBO7#*_'6M VW?2
MYY$,$B(W XX9]0BD=U&Q8B;V9I [T:05(,7*1[2>K(-9M#@I(C2: U;#D;J%
M[]-^EB+EP)@!A:_+/LLL*F964;'']:N<$86[OT#-8=.$W4#J.B!GC.;&\"^
M#6O!N6\8;!.CFS=*Y\"_F#<O^)'F8 _CNRX3&6@IHYWW?>]+"E1T$0'0^BH;
M^=[Y.%)#+)(C-/4^R9@^PW0FJO N TPX^PI/8>$L7M8'!#;E4^L&HG#G;[(T
M_0JP5KI0TL/V(^BGT!GIY@F;XLY.70-#N!M)6NG8_J7ZO1[>+IGZU?:F^C2,
M>O,_8[N49"-K_ X/!"BKPM?&D"ZF,&*M&BP595+J/;Q^AK!#,:;57I(MO&:G
M:8-DOQF:Q)I12=#3EH\.+@W+C%B<_D%*Q2?E%,_!=1','BS,\5=7XV"<!4'?
M.QM/@H&^W LSA+%VNP^"A&?3+(HE?-+56#AO$&.PCT0747"L"G2;$=O_:^?O
M'=CJ.Z--_9JEY=3W?O_]W/>,TL03AU$VG*=C ,S_#B;3UR;.7D=(3)HBIXK&
M3/J1Q4HW\,TT+3MFX<JO(.</\5"J49173.058D7=/XQ%Z\@5J5,>!=V<>%L3
M$Y"<2T6X)-8PMUD5M%H9P;1X!U 014.7.^5534JHX4'X75P-U.UC>3Y&%:=,
M-2CV*N><)U'?#%4=>3O+Z ?/^@I)+$,?'_SFOX,IV+V_4C E!A0IDUS%[J/4
M6AI0*!\'WI^T/@/,\% RE72EZUMTP*33B4U"?S#H2;J!IE-;O\;C7(GWW=6!
M=?]'>J/@YXEX()S#629$9^J#9IP(5Y]+!OA_[+UK<]O&MB;\_?P*U)ZD2JJ"
M%4N^Q^>D2I;M;.\3QQK+V9EYO[P%$J"$& 087"3S_/I9U[[@0E(2)4LV3LWL
M6"0!-+I[K5[7YW&VOH2>*+, #@>A#\38. :2,!?;W.M[]FZ46*./#.XUIJOM
MP-9Y0D?_#LZ6YZE:A]</>"F:!\W>T/QN=P81Y#TX;$[!JI 7>>Z_B(80NTMI
M%YHZRAK0&R0&;%5:9\%O])>8&9Q3Z.CV3:">43X$M9Z)W#@8H^07KAVYKM #
M<2,HK X*!IV;HJE6>9 Z^.,4%/^D*<&L]DT(]JQ,I@=MY8:B&1FL?!;:-0XU
M:TDY+#]B$7UI[0!3.Z*3@#D/>%4\A6L;NPR#N)@V]&(22L3;Y?!)B>\%3F*R
M."MR\KG53JPT#-M?K8*H'5DTP>\PBL@E$'2%NN<1!3ZK3@9S:#?KG=FU4:_-
M9"+1,UF2KUH6F>GD=>+FJXK35-I_NFEQ;TN';E)S(-()Z/R-IQO\6<F??_K?
MBKW9=YRJF^18#&A$<)87*[P+3G;I&0URI\:OVA7KA?WFSQ*QBYPY>V),##P?
MG2_V'UOCH^)B!XP&#9A:JTJP>JTL.Q=Q8J(XE!0.XC*:U?1)4)TEQNJZI\'N
MYV.P^\X%NUMZPVYUKE0B0ZFS#7'WFJT<RN%F]S;6>21_-W!MMN1RG]@S@,3!
M:3LV_>.@V(NDS41B$B\CR,IW0%)N4>,^W\Q#\=M)7'NT4T<:*DF,>*Q#5]H(
M1NX%+RQ:!4,380D%Y^F3;LGJ+4S72;*H74O)WVJ\3_K6DC>/L7""/],<S8X%
MAD<NX/.ZAB<$O_UV;+Q_\UL; 9B*_Z81(8X->3^D>64[92\XS*H"+;>A0?OS
MI\>?&#ZN>O>#AVN\ ]X%M+'QQ$R*V5==F=9+.I5>@P$%6\$D#@3"JV%L+>7L
M<7M9/:?H-E_2.>[7.[\@R@_ @(JUY^N2PAT.S5?HZE''AL?)^ZU()A+VHG^Z
M&QP_&-C;7VL^]Y\,!1F\L*"[ 1+3:!-)T[-_1U&IP\)HUW#]$GY.IY\?%+/9
MUE=PT+#+X;2'$26+JL\97J\7OLHJ/O=6L6W,6H>SSS7X%R;@,(*V!,=L"E.[
M<_3V@P3*7D<(]A"<U%%^411QL*-1LEW')\4#++>.I%/5Y)V$1BVUAX?)#65F
MTP-PZ*RMIBG._0QS]N# W$(&9V@7.Y8#.>5;V\M#.W9XDSLJ"%5,S^;&M 7"
M<FILHH:WQ.^D<">IL!H[I7)**4:XRL9_:WG%B$ 0WB]DAKN6<N'X%3;X<-)?
MVHO U"GR#?S,E7%QG% R/:=-%I5PRUDQ94RL7/<L)2+5NUU9.6>/=QXR%SS@
M79M%')E*$>>TM2G^J.TC?MV3LQU#-'EKKI^@2MV\:*C =+@(V"WL4[<"TV@X
MZR8N[67-Q0L8EJ"O,AF/_,E@:%JQD/B-^ M,6G))*[<796"[SE)X=ZJDH1,>
MMLGO288Z]'V#B<TJ^)AFB00>V1(XF4;EI."8FVL0^-=9R+=;F) /H,7-=#S5
MV? '%.*J23^ C;>)S4_Y8JZE9]-_,WAHOXS':*Y;3D3\#AZ7LQO<TW/HY!D\
MEE"-23TU_-T5CZ*_;A/FL)DF_7@3K79@;*OTG@[F_&E*.'A.W\G5M#9OY&<'
M!F7/#N&)[9=3V$)STS*91VENH#KZAHQ-MG/6[UBA2F%Y:D$71%D\*Q44&-5'
M7,*5.5_)%PBZ-F9RD08UQNY$Z4%JSYA%._3[JGJ;I]63P2A@A,<[K\7M^--#
M6X_4C9D_+.DAO'%:GG_"\8%B$Y]3F3%H(:JO53QQ+R=#H"87!1@E$95)G)9D
M)IW D49M"-R#04M(#[!XUQ%5\#Z(XK\:BL\K[R_>GH)JLX86"YSM)(=/:&AT
MO.MCNDVH/^SO'?";3KAM3:EYZ=F4-W%"3>U(2C>Z8DI!Z)1**[U3S]['B=!:
M-C=C528/W#9IH3GUYE .Z4,#.(ES)H5_^' ]]W\ H0FT@1%O#'*>]-U+:\=I
MGR,*E.EFL;\U?B"UWCT[>&+N+*5C:+2M.)KQWG T82.;'N2[3C!@TIH^7RO=
MYPCUBS%"?><BU/^AQYQ_<"5?I!4+S<(<#JVS=.&TT[BY4>K"YH(X</9B6X=A
M6H&QR]7 (W2:<HZ2+*O!V\EY7R(F.?MJC(CZW["^R$&0%@M00'/PTQH"*[%U
MQ+_2<42U9,Z]NRK)O!Q%<%NV(T';SM.*W[FF-D(D5&8XJK,TH2;(MZ\/2?Q)
M997-*>(QQX@@I5#!C@+45.<$'#B8%"=!RG7E*9;3$D*QR84*3 3&]=.:<1F<
M)ARW*4YZ7:N:*!%8GU>2HE6EUZ<I;__<W#"DZ\?B5YAWG5F6I$6_\:99:^6E
MH)ICDP*TI:V;HK2\YF'29I.A=]ZL@75.Y]S6[E8P2B!>E]%6:F_RX-M?.&/Q
MV-2 286L=NRY!?$C_.YM%IU6,&E)\-JX[A_)$ B#,U!Q&:HYW:^?X40F5*/*
M5&'#!S&'D12BQ ?2X&8L$Q;8<\9*]F+R96$3,O!+BF!H1]^L*?.T.N,( 3RT
M<BPO)SR 3\1PBS1N*<B:;!@V:^[C^F J!F=FW3HE<U"\%4._R/*PA?47F"X#
MU4=2$!,&OR*H] F= ><PS,3\0CWKUG<$OHVK!'\S90V\TR+!6O"O-]./AQ(V
MFW.04+<XS""U%>8*A2+[J((?5]P/L%P7X[*NI8/"Z&S/%<>>]QC;>^C?5IK_
M\.2)0#9F67%AL!5L,GG_( !E6Y_=3F%^:SF>7V_C4ULO^/_-7%W-U1(@E$OF
M(B1V@C.9M(JJ#KE1CYK ]3":#F-3+$%X_%-T4]V+>5'5Y%5*,5<U@.+S5<^$
M1P^OJ7-PY@@"Q,&V6[\"H38*9NDTK8E#HN0]2G883&EB7$=9"1\N*JWLDXT?
M*@T_FRTAG28^&IDE.4"H65A= 5EQ-%K8$^"6P)8L=3&IX+?2TN1TW>%0VEP#
MO6KQ5G9!?PWF<+WS!OJ0TQGROHYSK!6-DD%H(:@PZ(=ISA;2!-E$#AZ@0H08
MO!P,)495'/V-_VJ]CA=51# :"NL<"7PZ;T&\[&U1SM<GCYX_^&]3O<WN/=F(
M?<8I#IKG;$V=XRT+O8!X!;+0CP<:4"B*FL1#C2C4];'-WI"AN*E&M_O ]2@:
M9! C]2#K$)N8#L8#B:.^I4:C4E! 0P</6".H,;AUYS0?,R>;EBA6,BPGW]$)
MO_>B_Q$DB.E&],#Z,);:]]*,]H-(S(JK96%Z>#X-2O+C'W5?M;"JRB@5,K[V
MW;T[ARY:>:<L;' '</!PDPT"]T=0G"0V*4Z"/Y'"'I+^[N7>3BQZFZ9N7E#>
M8MS;/00L:2(I-BE4HE[2"PVAJ'+R]\R1XFM72;(I;/,K:MNF>,(']_8GH$]*
MR@[W BC?X(1\,LVP)F79,@,J(C^2&F_:BI6'F:(@(4X[O*8D0",3O9/M2V4>
MBC[$.AN0I?[U!?.!GJT E@5O4]9@+SB47L.:\/9KIKO$_E_.)Q*V'<,&<H\T
M#4O!M9SQ$=2;!BYL)26U+,SX$0Q\U@*T--+= 65SHV[*A!!9TBG-I+2;,BUS
M(C5-44]6)?Q7X!-',QP&V4"$K\LF2[K 1Z?YX%"(A1'C6\L$8UP@R;8?_5X7
M4C]^.(:I[UB8N@>]^&/"UF#L-8FXSCEAUA-F@3GWOQ; L4]GRAI/9)(-% G5
MRG'03_4I8!:FVGM%C)3KG/P>,]MR]0X/*(QI2_#>Q"LQV%!D;(TZF [11F3(
MIN!D$(NW9N1A5XL-WM>@!2"VN7(R&/N^S1?AF##T$)R@D,X:>FL&(,\-7#?%
MS;6%W&\AX62&DZOWS3,V&7GCF2"E!':]J^)BL?&L21AI_62(]W ]L.-6\41W
M1[J9VRB@,\S!JW!6+S34S6V<"L6VL!T%DP3,'=IZ% A1>97R  (1Q*R&@S>B
M]W!&,Y []EL=AP5HW7MKPL:@FZ6U!V%?"_R;01ZI<>JY<.1O=''2V=)#V:0.
MNE,U!\^5@=#$&C3@W,("J5OO[ FKGRBG2DLV<.P/IM2KO[?V?3$ J#$4N0@-
M%<:F5>BY09)T! HQ@N4NNE0C2*5-[E4"8,U(3=M +6?<3\3)0EVE9FQ(U4X6
MQBDE]^)T1OV+M4PAUP'K9_+DFS?Y*9*$<:C(%BIXLUQN<N!P/"D3<78GU4Y=
MFR0]K30A^2 K"JG&#/*(ZCS@AF*HHI41:HZ)RGPBNI<G=%WI9%]W0\?CK8SC
M-QG'B9*_5R^#$P2X+9?!Q[3Z'+SEY[P4&(DP^!CEGQ6QXP.]_#L%,GD=U=%M
M^RNX"TGUKCYWUZJ-#@R34,Y&,--I23<L%FEN:FJ,"6Y[AXK2'D.T[0V8+P&:
M&[3\KJW@@^S;XWX.E]1Z6$H&F<*3$6M:H]<=X$\1UA82$K@(S@BHQ-: SR-(
M["D[(@QR[?^P8J &^K062/:!IF$U3Q"2"]4*Z12*T,^CSU)]EZ"_B-L+Q"];
M*KBOIQ&K5N*NOR[9TS_>@ ;61AW:%0-?N6Z":$?8<GI8M1:GYW!C4@KI5K44
M%+=12W\9$\'6^)DCP"E$6$&I#H<-@ZECPG7@&,,;D+?"P9X;,D17F#(F4*.P
M#/J6/W<5I>>A_">\49=I[]F3'U\&_<QN/\$%OVCL^/)>B>ND/?[QD@N^3ND?
ME\4"33.4OD/8WI,B7@;',)VXK=G7*B:(S0X*KHP65*,3'*<+:EX@]]04ROP<
MR#N^6A)L;BF(@C6%<<Q37A,G\;OYO,F32TXEV.K/'K_D^608&03P>1]-+GF?
M3^_-/>2-B>8 ?KI4'&!X.Z%7D+FH3*5ZI;50TF/@3 :V+CU0'@&R".C^A&=(
M=9J@E D0EIM\>4=S5?H4]F,T$08<J: ZS8H)IH3\^BAI&&%0=$2^3>M&U(>?
M\G6+4+'KPBMJ6IOO.'QU_&#_X8'->6Q A('7'#S<#_6B6<*&#.X!:NMRYJ9.
M0)!!:;)HRSJPR12BM?T)OW^5=K_C9 ,V1K+!?>&:C RSI.B_]!76N\'+:R<E
M]DF1)I/?<B8W<@$%! .45X*#@587VF?!K1$&W2N:FZ)36ZZR<;Z*F+]Q&!5>
MMRKYCCJ5?,>V-A"TH:REEM1=KBC0*3-LEP4&EZT(#,[@A^"0E9HDP#N<$1#?
M2=' K>D&P<Y_?_P_/S]\^OS@V4-IHA,DQ[2 "P2B$D/[(8W 5*R87SFH?'3N
MIW$J%.KV1D?%7O!;'</#/IR\/OS?/^^_>/+B!3W/C)8:6C ]G$?8V/+'*=*T
M'Q5T&<U$3)J0:Z PP$"PU533IF?DG!Q$]%"+C#DR4SO9,$\.VFQG;EY'R6GC
MS<R=VY4GU.,,K_*6Z]I_%?3)6?")15-PZLS)TM)O_"/-)DKFGR-!Z+#5(HU8
MTE),,\KF6(TLUX7(-D+%\K&D'2[0F_UA_XE7-<_$+$>'OW[$X>T?[#WYT719
M(142O0;\XYF%TF3E#68W+U!M#]!5SX;__G#PY*'_\,F2\K7M0?QXYU;TV.A0
M:I6H(P0=IOJ^0ZVI8D,B3896]28/)KVF2I+/+O^"4JKGR-F! 1UNL28+_:>B
MU/84_!@4TG1IVBRD2(Q?R)SE39[^W23\"Y!@)%FKU!2Z$^:/V*3&M@'/:18(
M28V!:;;OQ7TZ\KY:WB!UY-(=--7(A,.V004]5=DL8'_?:[SYQ_MCYN@V,D<W
MJIJ\ K0]U02O?4J*+Y$-.)CS7DD5-8_0;I\G-]Z$.7K!Y0SX&ALDX#3516FQ
M\&X0^"T@OX8#%-QZ'N'9N-9'OAS.W5YP8G$!6AW=4:5A$@X4,\ZQND$&RSTW
MW%["(4*>"BD;E]'">0Q"%7;K7(L2=!J<FG?N;'0XL(/?B* \K9=F(U( $4ST
M4T.!ND%(I"XX.D6SUD\H)W3"4=7/>YL)&:*6T:$!.X_^@C/OC[V3/;F'I4WM
M:>/HB2))9TQ%WD*K7Z[@$B0_K9;D9Q'UO6<Z+W=N]2SN\I$VEYBU6S<?5&3J
MA-8TG,:M355K!SL\&C8:R?CRV!#>U)@H"%U:#<* CY-)[33T,IE46ANB*$X0
MMQHHJ\3F_]:]!6NDI-V([0Q7T.-53ZI5I3TZ[$O+CU(#M$5-6 E7"'8Y<51K
MM=A%]-Y@8E,:F1N*07O-7<Q+RHCCJ*_PNJ 038./!GXNP'=]8)G6Z'V$(DQ:
M<_GM[MSN?>.0EU';/YIR.>/7LRKYE$3SO:ZO'^4>\1FZZE*29LN_78(U@V"_
M'HP%_O'@K+AP[?@X21:MM,A B,Z)/(3H"9,96K9^)(<(5UED:4Z[IQVS<"A4
MV,3%L\X-6SA\>L*48*K%10B%E[,].3A_$_  '#H7Y]TH::,(++#)>J)\K]C#
M=[D'K75QE&0830M!<>?UGW ?^/9M20""X* XX5HI2'Z%-6",O0U3$4?!KU0:
M]CZ)Z7D?-:+X3B**K$+>%S$&3/946%&3T;X0M#XLW[!'LH.7.U^45(@*/Y!Y
MP=5D DB9#"0  E%7"<>U2Q<$BG/GY.<W.*QDHSY8]]L_%IKPA#7B+D7OL#.6
M&57E42.AH60T);D;('/M'SR@7AT5H R> 2M"A07<6V0:Z5;8!\XSM:=R"LM3
M4+H7#OY$Z<:D?YXJ":57-9VCM85BC^%%0P4I29I8DME:X6]K]L7,TWI1&%<!
M,C('^S!ET *;G/$;JH9,HCNW7S@+?F@)<:J-C04UGD#5$&=J%"!Z(+D)MK>+
M2PQZZ\Y][A8N7 "/<.E4=@C\>&@KG3!!4PRV)AG?HK)E5M:DZQV%XD6:<!CU
M03DD.RX-3X=NQ$=&1"3RC/AB>FP$KF<AHG"W^)A9[3FN)IEU5FC8WU5UF9.<
M-*SF$,)N=KB[7$H\3JLVXPF5REH>R)E0#-D2D @#A[2R=GLP8]<=V\2_"U@W
M!NULSM7S6)QTN0%-]SH)-LSIHE7F3%YO)S=%H62-*9V%0;AR;A8'*<[ &O&H
M.5U,-YL*^/IY]K9'X#%RM3A@\]CAAVWM6\PN:,S2*:R#Z_-5E1*72I#_?-?V
MY7N/.1!+DJQV];^S,]FI3NTP\QFNK7P&3R$[)?CC<QDI(P!^^3Z-8]"?;Z*J
MMM@X&BM.-0I*+KGHHZ'.!!<X%[%\[I[)8_;-L;IBQPXIZ?MH&?P.N^95$ARR
M Q=[B@%WK.L\8=T?@V8$>@1)5Z'.5(O2C$USAL&M/4WCL$BB\VSAD\2>Z&51
MY7+L"(WI"*-P7C&C3PV+LGOG5N.C]5(.Q4NQBP"3^H%*T[A#@U;!7X2\R)-N
MK,Q&^",GP(\Q.M<I8O1BA:6D.?0R;R&WG$2UK:11#NHY5HY,D/DD3@SGI'TJ
MDD*6& [#Y%>4YGV^V)U;B3?8\OO@!%-;MLT(<8=%?WXPA7O_I)"%'^*S!YT)
M*J"+3?>LZ)Z:/I;.:HY[T+F0%9;XWJAK6R<HO[QS$_;))JE15W=V:)?FW+X3
M!0"LQ\AUU!7N+[0C$P;5QOT*&RJVY*M<-4";\'XGG@[&Q-.]3SQ]3.*$2;MY
M_[OJP F,GU%RWXVEV9JC;B-*DHG3#M9CDLS%SY=.FH7?7)]76+V]MA<=]8K;
MU.W9L&\TWWMT1C4F)A[ J$>./6K*>GL?,H>]1R54")Y0X\F!082J2L4H$'\_
MN7-:S,W>_!M>=\C:<2?-6S&T@&;@@0N?KP'[<ACGSPN,R-ER:#22R+B\/X$/
MZ;:U29)JX/B3J- &P1U2^'H[SE51DXVBWLCE)GHE(W \1Y8MX=[%$R9MH7QC
M%7%9W#U;XS<#6M+2&I5@A;-=8*%-E.I[I?.GYAHAYF U2A+\U<2G9/\2'QS5
MO29H8B<4TF= J'/<JQ3E8#<'D[@SA$# B%V2_U4H,?<&RN8.SC2K-]^;Q,EV
MV-/;=@HX$8CWAR0\C,P<F89J5(?H=&K#D$,K;]D@N:=3GHRA^[04D$.+J6$C
MQ4Z F+E%%38<8ZT&47!I<[EW;I)?"2/]1MZC!8MS8XUZAU7ZPO$UD;9PJ2G&
M."!^;.N(ZL>B$KBN:<$(1(@2,"NC^=T[B;AVP.M3ZYD\#IY5M2&;Q(SK*A7+
M'9)\^L;M: D=<!3!HH(RJOLR/C/!'VE9>M&44VU)VC1*K<8$ZQ6A4A<=+6V+
M36["!GPB1OWW!5^@C7+/'+B/[]PZ2K7K.P*1X:(=QZ'?)*IBSB_-J3NW^L:%
MX/<"X;_*>-.DW#'1SO];>[1,AJYKO5DJ2^WVJ_%!#YBXWFE)+CMM@$- 1O?B
M!.0<H6NQ?B00)>YR>9_F& 1:8D SU0HE#J8/&\*^ 4R'&/Z!)49ZNT7[=G<R
M$_(VD;@+UE'D5=(R:O7;1+[M& IJZ*YL7KR-MEAICF1/RX=2-]W#234MTPDF
M)2;%>;*^4*:=RQ"\'+F=DVG J4#$? I=T4O?N=3".Q<\0K/WQ[![74?FI)BO
M;?8U?>X6CF)52=_.)0"B/FV65OLH('R'%CJ;5O'@9?"N#9%AEO>UUQG[0=]Q
MQ=!E4K1GYDZ*+V?CR;37YG6SF/^6ZA/>M:2_=.NVI=C+4E@ZELB5&9DI;>\G
M-P";GC=<6[>_WI]9]" 2=C:2K$HN&+Y*T 20\&&)11C<L/^35MPU7Z>EN*T1
M6F$.*Q*2X96$F]CT6@_$$&%SKO++L;S)E@I+<K[%TLUH>785G$[AMD%K Q$&
M$(>+LHVO998.=.53GYI%A7R@XA81LV9)62H PP5F3Z26!<X'6R"!CDS$;%A<
M:F=^3FW1--!WQQ]"!ZC&LGCWC3,B9$'$2H,5V7_QY&7O?_311,P=51Z O:G%
M%J_AI0+EZ  LJ]F1H#E*D]:* 1G4PBL.2W$B%2OYZ^?ONV@*?4ZJPKX8>WH8
MCJ@VA;#LW(L3M,K-A:.4^M+;=&%N38 5DE5*;0.2MZ%SWZF2K7L1DRYL2AP3
M79J95QV@VWP0P6^'U"EF@>'A;LR9.P@T&H@-YUE_J)S+2K" JJ9HN<3B37$<
MQU%4M@F- "&R=V$&IM."(">0?6;==+CL  YTR&J8K?68!AMB/W&+UC5!L>XW
MO-^C,5=V]^']3EI1^^</?PP^X0Z]8;2^=Y0WCMPHJZ C"7RTD5-KX954+$AG
M-%T4FW3T"MA?UG04&M#>2$/?%2'0+?8EXULKU"X_@EA3C-F"91/2;A7L)%^,
MX1)]P>Q>M.3-DULM"I8A*)M=CZA*'N !44>!Q.SI<##^ F$<K'XQ[1Y9A=)F
M0>^B;-71U:74Z=&7O3.H>.0("HL>ZKV>T!5&S/,;$3[/[\-746393J'KY?W
MFQ7@GI>YE"O??M&A%Q2?ZZ:549?(KEP'>XH]D04C]\ZB\Z)<+5^> 61AXZ*+
MB&IH$48EPN<;G@KAT!&WS#<+L.FL]*90<ZU8B=Z4+3PM$QFY1/S#9&@=\#\8
M&966I5[<"G5'P8AC;-AZKVI@I_:"#][ V#ZBUR<HYA:/(3I49J0^J/\<X2 O
M@^<JMI=944'+ZMJD-?(@K0,)9;TK\XUH/T1 V67=BF*O?-5G7ZB\XC[2DJ
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M-+,TP2(M-*'3<T6H=>T8]PRDFU$Y#)6WL=G#1YU!^V ?C !3V[]L%1V6D92
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M&& K(WQ:S9:H:J6YT%@7:B_TWN;0TA5<L$5,*.M)5%;.Z2.KS5V=-$O6I.<
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MYB\KF)*+<S.JK__0:GOV<MLUJ'"V8-ZCXD>"ZDQ2]/:42MM[4U+V]%H&')O
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MO@DA.7@4OG@RR@BX/N'#Q]NR6P<+S-U*FX-MH *\[RLLYN;_K1./XRWRY+0
MYW\E$;E!8UI=E+6W C'AAB ?C@LL*T)@PF/#20=SXW.IW@J.0Z<@[BKL/F%0
M-*6ES7*(2QU\[/@\K01FWG(/$0&UXKZYR-D(KB#$==G2K';BXY(@:X0R'[9X
M:+$(UT.0P%IX1ALA- C:8!=(/IADILJ=ON%1"2@0DR49',:_FGR3^D'";PDL
M2RG*0AG549NRL,4Y^ D9 !@R)<C2>6J C?(&A:N[0VYFUG5&%2;#G7*/TY?P
MEE*"*6-JJ 7\.:7RH2RZ,-)7-AEO;^4SE*$PU\ 7>!@8?/BJ#*N!+T60P8Q!
M+B O#(&Q%QSF2P7OZ&R.V&%XE,O@W7AUH[I%DNF ?J0,Y%D9[77IE3.HY9=8
M$0L8W[\6M!EA)RCB'$*LI%3;"G=99!'SJZ14H*C2D.2G8 +UKAP]3^Y)U67S
MALM0<2VDP+VTJ%Z5@! MNW?:"WXGT*"9 \;82TRA<*F$U#@LJWVCM<_8^AZG
M4<V1CMZ\G4,,>L8P1TO=& AB#SM#,<W@"D0Q*E%UKX7FSXO\ ;-Z:DUOFN/$
MLY+ 98C3"ME >7I(^R99QI). VN)>QG$#8'N1/AN-6QCVO0PG"(63*B/R2FN
M*S[@O0,3]4;%['"JY*:178\IZ44!I($OE,*C06SMZ6=XGRR)3[F"F:2&2:&M
M>D4HW?JL:$[Q4YQ?106"XU_.DMY7"E7;%>CST563)$]@97&"BXN</RP3,1SH
MWUCURYQVE7+:&299IA4WY-9D4@DYPZJ7Q.,MI46FU^-M5G5>T^ 8.:38!! $
MFR+'L?*%EH-%9[A<:6-LQ0![QQ+HX")O77+,?K%OWJN%/;5#)[%PVW8.9&9A
MR,!CBY?N06S64X?365%> 9"6#GV\@10K$R%S)V2P\^*SWHX9V^EQJCB%%-$]
M^V]^R3[Q#ED(9E2/.NJ<^%-].8*BVF53OV]+&IBM=<9QF2#58SZ%->#YAJ/V
M<Y*E9T5!'7S%!%LT6K/< >\:8K/8F<@8D4D>/JUF2Q0] 2\UI\U*/#.G8>2"
M+:0:GT^ J%8;R6HSOS'-DC7QA)ICGM2N >'.,LJ*/]-H0,!_F\S0PFX&+\E#
M4D(0.P;:ZA-$T5->E-ZQZ)E9)FAQL$ECX#)/>,<*Z#(C,?N?/=6AN0J_@T_N
M*"9N]72,.IE,LG=@B9QIO06)\/I:TUE[<G"H\P@QT_@=:+VD.6>6%5&M5?IJ
M-R!S8Q4<DNU4Y+R#U314NBPU4ZV1[1Q!JE3DAEV[5.X2.IAP9%ND-6')I5/<
M0#"M<Q B[G4J1:3HH7\W12TN%%JXU%50H@+5!H/64XF7G3=:E+E?J!TM:W0_
MNX2>/!R[A*[8)713Z_2/7SZX9H2U'1R#XI)F!"BS%'E;:LMPMR3!43JI=ARB
M8O<2#(:Y;]1L8S3B\E9-LLZEA',R206EL34^M"71X &9;;3?%FX#(X"+<,A$
ME[FHF3+6&C,(MEJ1H3D!WTX,1^_.MK$?;P-:)!/% .?O%^N,7*J_<2_XU"6L
MV/K$TD9'_Q1AGE=.K7)SL8&NFT "A3BOH/;@RH4)FO7;?6I/)E\6)=(<JGNM
MAMZ G:?1&O7TV?'O\_/QQ<G6<MG"^N-A8*C03H$KT SH.!)$RRUVKUW\2%:5
M5D]F50_O7EMCTLC<Z%DIKV3\?'T&&1XX=HJ$M.-\\R21PYY# BL>N1=L71\(
MS"2NDIRBWKJZ@8/*B>Y-HLI"C[N["J,['",V)[I<1UWY)O0TB[@=SU="M#]@
M(I+S""U.@GO% ?(6'(A@="P5LA5E(3=PR8T1(B-+8L*+<<[W++JX!?L+#5)/
MX6U=*R@DB?DH=FU1B6$T<*ZNC:[L/YP\V'^ND96!>;5+-V'3L64+]QB8"B:M
M%Z1Y)]!YF0&&.D+>VBERG%;1#!V"<H)8W[B7+?,#*B-8BG2A6X9?S+/R7X#G
MMW.PJ]F4S4?S9/5L[5UIYE&5:2-_G4S/<@))<_T&<8E0DT[$C4J%N9 0R+'9
M+5!R%W=N>!4\[J165.42RL@(_P;:"%4GF?&>D]CO3@B?H^/"T3EVGA:H3 =7
MKKC,/E^[<+>>P1*EAF1^[SE+%SA$!C>7M;*@+/\\^>BI3DHS2+ !]YOC<(.(
M-=DI'VT80>!9E!C=6U&VGTJ4]B.,LG.\=T<\R[>?CI23T$)6>#$NA_[3I>9L
M\@Q/3UA>'.OO<$ 9)AG&@4 G.WA;E',>-DH2#7C6E#G3?\F./T0.63)%7J<2
MJ!0#Y76RB$J#>/$O^ F>?CKT[G6&75&G#=Z.+-L(%2'<2@PO><V+B"E ),;L
M2;6=8([LI)B?&<3 2"LWRL!I7^]V^%AO(IFB&Z>Q3C-1VHNT-"@ZT7K9>?3P
M01PMC0;V7\9'IJXOBF!&UK5) YD XJJEJQQ2MNXJN;,,$L^ODD1EQCD79W).
M84-1ANM='AR"#9,A&L!CP<(GR@-*J<,0D]@?W8Q&T70$8V,K<M,7P'^+RP*/
M[;R%:J%5# K;L5)J3EK!YP&[]V1\$-S2YE!+L,_PQ9&'G8(M[N8JO=61V[2V
M3V?"PT%1+74*0[62X*DU^#TX=G#U+?7Z:7&>E#D*!*9>FOJL*-$JX+!OC2<2
M(TY,'=O 2;M&YN%H+R+0!/_<W BMVPJL9<QV$N-(B4@W\-YXM<2D)*ZF-1DN
MKE25))^%3"/)_RI,8'33.3<!7T1UER#RR@H.0HV#_82TTG4C%23@V]4.73TJ
MD#A-.,WS$_)EL9ZQF/.;Q6W1.S2'FI,():)[?F__@7O!,;NUI#@U* C.>$$7
MD,SADF7)*272G#7#4;06B[]0Q3M-RVDSQ\TYQ0>1%IA&.?ET584SL2P:X[KT
M[+K0[CFSX<#W@Y?+P=,Y943*T$_&V]WG;!EC$.$Q/V>V2S ]LBQ!ZV,X^)\[
M+\BEJ;Q"-K ;.?=)*XGL#KQI5#%S9B5!^?L=Y]P?XYQW+,[9,7%[%BY(8WC'
M+T\>OGCT_/G_?_#D'[\<__'JMW='P:>/AZ_?_?YK\/[PXW^_^71R\VXZR(C!
M2AOP2@QK#'PDA3=6]53+.;RCID[T=F 7LJ8Q]Y:CX"(JT3IA__A2M_VS_[Y-
MGE[E;G^8N[WU;+?+8RFNF;T=>^2U9K5JW*.R[\&[)H>W^;N].C9O=I_5VL&H
MUNZ_6GL*4_//-\&K/T[>_?[FY"0X^O#^U;O?#S^]^_![</CKQS=OWK_Y_5-P
M^/OKX..;WPX_O7EM/[UYS;<>@I'@T]C44@Q')MDS=5N70'-E?Y;OL["%"LXS
M"%$UJQ*I3)!O.8Q/-A?>YB?XF]RPID+%_'<#@T5W&7^/BA#3&F4"MM8$:PZ(
M@&QJHEWJ"%/'P*;(FEC>M*!8EPT[UC7X^)@  '67Y\D75A.'_)R5@\9I(/\=
MC'RPC0W7.A6OE+7$Z<Q 74^>,CA8(I696A&W""Z:%,UP'L4!SB1+%\:0SO&)
M4@\!AN%>\'_1.D2XZAR\I!(TAQ3\1)O4?H.E"1/>D#>2=]9#WUO66L@,J>0R
MEI)&=&!B-E&Y!A8IKZ2JK/NB9-R"R4V^O-3AN;\"NY?YY9M+;JN]X \.-HD_
MQGO%%)](K*!BRGNSQ2J[G9'YT63)Y%BZ2$(MJ)!/FLI46)3Z&4RZ?D@W-CR3
M7&9E=O&FQ%\&[^IK:Y+U>X?W-KHDF'%$IUV*I,5@2B7G- 6_*H],))RC-R;X
M;)U'3D]0*(X=LN@*L+K6,:Z$0HTN%H!<=)Y+]FL3,$%BT4),7+CY>U!/!PT8
MX_92Q&8&JZ65TLPQ\+X4D/>+CZQTBXZ<1K9XF4KB]6]\6T:FETI+N6E/&GRC
M5I&6RM]\)C:J7./$$@8&YC#EJOIQS#I^,@VS)8Y1BH+1\ZU085/Y?)QD,'<E
M5PCP#IFU8X/^WMG!VXJ,]MW2QK3YB, A4FDX11C9\A>U:'_@K)5?04MA- ']
MUY.6 DX^H2;M?PD^< 1(0U=8>N:D?27SBMN,RL<U/>362X(+,.5E+=/JL[/9
M=#.4D91K@*0G%39!I142;&IC$<H7*FN0C3]!Q J)/6=I<FYK4_K70\\U5WOK
M&64MC0*#_RD!^=$VB$$@*])RA[$-A(4B(=Z6X_>WNTY;$^355L5S[;;#4Y@2
MBGP8VXA]-)TV1%7"&H8B1*ZV8,3:HN>4;UWIZZ8U9]3A%"O"80'PG?-"D.N5
MW+7$\A#)YZ^9C,V$3C.*9+:D; 92*?D&9AHF-<\BW-VPE/^C3,+\OG;+\WO3
M%G).^#!@)&^D9?;HCD.%+'>#;KP7-SGW;B:3M\%!=Z.=:#U#6G<VG]1E,]5P
M\.!&6#NA6TE(?LB#U\G4 7+>WV<@9PEEDH]%^IYTYIJ9I@-+J$IAR[O[R"T$
M9H5LOY6F%OQ;S5!Y(MTK=.\+BNP\I:@[UB!A00:HH ?8:Q'S"Z MF,8II0?X
MC-GC+P8Z!C</_].$T% E=XW&]M30)B$AJF-^\G#_R6#;<""\RZ<>#+=C4A#?
M3.43SG3/1U)_H+XU\Y!LY"%H!LQO3[IU,;T4:GF@*V_C7&Y)U>U(QK&S83?R
M6?FX?4,M>[BJ>,>1[MJ+,HU,).N82-Z0!=S4)J]KZCE9"7CQ7(W43C'-EF72
M#0 *#5]#E?9.JCTLJ'10)#G ,$VH=*BG<O39P=X3O@3>(4O)Q.$./BTBTMC+
M$8_FA*/.!YWK3 !';J #1H: "/<*!Z#06\K0V,9@1.Q8PBW#P^K"5VD!#]\+
M@]_J>(^L:W(=N!Z.RD#@'9O*1+J/WQV_$:Y#;5(HM)%A&BU0"]%=-,)!#S<G
MC3(8[3A%JFP9>;H>-#R&7F!6N;!2713NE/&@!=H_#4PW+YJLY#*@E<4N@FW(
MZQIB?=,A/Q:F,APOS[KT@L-[SI*TEMW"WTK5"B8(V"^U!AY-YRYLHTWWD=-K
MW"SP-_N/PR</'X8/'SXT[3%H?VZTI_!A:^MD9!7>1&7^ &1'"V;\50C% TC@
M5_".^S\]TMJW\R)KX.CF\PJG!<0'^Y"Y%%>+D?[]Y^&Q*3]:PR!GSBV3S0+S
M&F;IA_U'>S +VIM\\-#TRL31DDMQ,-B84P*_4D#[1][/I(#CI;X![4D<G/N8
M)WL(LH_KN^I7S^%7='#A$Q<%J L_ZC5+9V2,Y>B[5V)1N5OK-6S.04:/>YH%
M>C1F@;Y?JI_10+FT@>+2F%F+Q+=!0'W+#]QVB*C;XK#F-* ZG 1#.Q>Y*JD\
MP2MK\@2EQ6*730KJ,CYT3JV^Q_685>UV4AEZ.L>Z*6X#\M2D;_*'P;S)ZI2+
MQ.$HWGGEC,"4/7_$\T)TK^T7YQ/'XG>8UR!'59 T!G\]H^(Q.V"UI\0>\)]M
M)Y,/Z>Y4HIK8'<D51XUQ,QKCX\D?P8XVFC%7#-<8\[]WAW2) QUREY4&OM[V
M-<8HCJ,X7E,<CW4C"HQ%*%FWX9C#@A+C& 5NA1U\P5PI'BDE;6 KV#8TC)Y2
M,4OHGW,;"AQ[[RPQ=-)I@C1+_V[2F/VQA:U'*=P>T^&7ZSTL-Q"[K6?X_1I!
M#I:'",R0<OHNF2^DW54S?:N9EQFL)L EQ\,]BQ@PS)U33AY/O5"LQR1+3B&X
M,J<%CFO29%DBK2_1:MI''G26L=;+I$Y(T&VBRHVE],99O?"P":,/QE;O%7$D
M:L0K,4<^?G8YYL@#P_K8\OJV<YO'Q"HY<A=>(8>Y7"1LQ5##]'(;B+AR]FR-
M^G+C*,R^K^DN/1U]49G?Z4CXSTGYTR_OI(9YG*/6''U,INDBY1B0>U;=!('B
MO0&9-O7QODL@<6XX-R62N7MS]* X&S_=S&U_^:?%=V)KQGW-$67\.]P Q\:P
M&O? FCU S9E85I[FVH#^-BVKFO-&P2<82U+?OWVA%XVZ87O[ @RS L$*QXTQ
M;@QO8WPZ2\MQ7WPO^^+#H@O<OTD,^MO9$IQ9JL;=@)Q/)W]4W\[*\MO<*NG*
M0$'N /:&($LHR%^DE9<.D@_A06ATVJM<9AB35DO7)K@:+GR(4X$5_)9@V;M;
M_^E^>](LJ.>@]37/=.=+0Z80_ ;*HEG(S?= HYBHZ+KZV4#XWK0V=LW/-_P9
M;ZJ/,N5VP'*YQF$)]:THO=[(NUECK* HL@>TCNGKU^%?;NR44CW&PCQ3:?9A
M O(MC1ZW,^16$7OA# #FTT'DVJS9AQA9%'VL4[+NISPD2=,/#._W>5$+#0%\
M"8+-#M9/IC.LF["@M3[W"_;+8<F;VYW'V(87U&C("-L"OVA1X),O:557ICC0
M G19-)ZQ'GS,UEXJ6TMBY.S.%HK7CL)"$B!HQ?J!V\0,.%*=SJE=QFCOD-LU
M-=TKS#F&GL?+K I@FNW*%2F2/?Y'CH7$/)4G-2%0#@(22EGU,!A@S\UZ\0%#
M:OTQ<[(KS#_8;]>#(\<%S@JMC)!S(3<1*D8:UYV8E]XA4#&LE [[-(/R;-$M
M]*+=UI!>CF4:H^!?3_#S0I!E83LB'9E$K'%'4GEX4]:2OE\DA 7\5U.F59Q.
M%0*P!Y$/6P[JI?V2D=VHH KY'=A$+L[22:K%$TC'8X'HNHUR5SNB[:&_XUO7
M&HP'Z<*/D-F,*J4&Y>F>UI@_'FO,QQKS4?<-Z;YUW>V3!-0>@9Z:.LJ>^C*R
MW)49S72_GUA0>@(]S0FX82'*5O2.T;5TQ1O%CIT+E9312ST@M2M'SK 0.0'O
M3)/$ R453,G.8&J01;A3SF8*#$"( @9'MTC(K!MMD%$.KRV'+:(8$RUTC.K+
M-J,;E@[7=#A/H^"B1'<\5U-^W+_C_KWF_HUBZ80A+WD3SK]6P!;;A;.,0>.F
MC3C/?8@*]"'<?U%4R&;4JL\EED*F 4=W?HIY(U'?!&U6@=_+U#R"^N#WCZKT
M#9QQKW\]^HU;H]TKV?"GGE$=NH>I1)W.#JQ"<"CSHSVNH_R-\G=-^?,V)%LN
MF2$*E&B)S?T(RNP $]AU/4TVILQAQ4C>3G^.3Z?0;M A:1$&4+I/[D6&]-V4
M]"O-&_R5OJI'%&&8Q$,CM(INQ;^EAGJ.ZL'G*;<N;,36;(E^>'^DN;;".S-*
MZDBFE7A&*NG^QZ.W*=G,9!(8Y;*@3R.*#VP^9:HF5[5F^=Y_.Y7>+L#@_GTQ
MSB]!&+>K<\O88;H%,)YO6"L5Y)B;YD?--VJ^ZUD>Q.9QRO AXBM*,FJ+(3-4
M$:R9G'/<$C3NK@815ZD P<Z2J*J#'YX@1@?\_WV4P3R!(4?Y:4K,'$Q:L1,A
ME",'SED&VP;)6CV%K%&\AH^B)_L/]G=.=W?VI=^QF*F^<ENP1'5,ZUU/^_ 4
M=S7/)7NUMI"*7I^]_4#AUF[^^8.?,R5U>7QX1*E=5("WE\AM96\-])@#TK93
M%Z?4K>M!W[CC-? HV\KEK@\4;SG;R_@_B&(,#NX,9R*MJR2;M>:B)\<[:TI:
MY#'7.QX:5SPT=M)=WMRBG]\V>1Q)ZN9C"U&4-?%,U?!Z"=JU.%!UV21BJI8(
M-Q@(P+D!?I6 )CP%=3KB@G9.,AR?1306?AM1"0Z ;A=O6U_NO3[L,$9P(=7B
MS@6$Z@J/ /_;?91M,R5+-@7SSF*YNL!$(3>6%LWI&6,]:R"@]]?!3O)EFBRZ
M;/,"CZ3$\LXJN+"N2Z4 ,I"TQ#"6@D:(:2S(1D=0:.3]K[W;\&+=DS49W%,\
M/S0![@PQI9^/,J9\52O!=+^5F6I-T+B;[_X:=3=Q&/"\AZJ4:7X47'J:18A)
MB)N<.+9+MHUF49H)&G#/3'8V/+O![9D,B:PMMZBXL$K*="%HY,:GAP.[*G(P
M*(A7./F"[T2M^"&,MR%DIC63>(7S9XPGC@;2=>.)BH,L%7!8;&Q 3X66>?#<
M<0"?E?R ]*>MPC:4I"QA]@%<'^?0/H.GD+JU9NO27G6G^ER4]2@4HU!L(4G;
MV_LK^#Q48>D&0!E"G DR_R>)O[7:JB=C;=586S6JBR%U :?.-&GQGJQ/AN?%
M6HM05$PQ)9Q*@:42K"K.AXV'W;A[KYM7&;2D)$?;R:)2XR!3<0E[1O(%@;6U
MEMHY"4$8X'<,/2?$(S'W&@YXY.I<B\^J.&P.^;:P$K%=>L+)2I[IIWL'.Q&X
M@9T/)Q( 0>.T\^749$HVLCM+C8:G*\[Y4?I&Z;M$,]*AJ8EZ+85%EM*'[="4
M.HI2C51$TC_GVJ!&!HFHRR6'LTP/*54\(;LE1F.FPA4A_0!CEG[<S]O9S\J*
M9N, -OY7]"CM4Y/\4XOHM678.Q&&/6^S.XUF?)+TX@++T7*/T]<LNE\O9ZTL
MDO<T]8S#'Q/+HYZ[D<2R3:I1P<8WE5I6 !1;C[+-U(]FTN#CS> RXB0 =0_W
MK"X'QJ$UFTQ1.DV3ZCO+;-]F&<+6M\DETMJ;4>5ZA6!7D$FA^.4+#E$#:>'=
M8Y.0M(?<K69HMS[YWW4*O?WR]V'!OOG\^:H9&Y/GHQ'X=?*$WIER-_+H<*?Y
MF$D?)>1N2$B9:*.8:8IX'CYC\E*USX/#<SAP:#L<1=792,DT;KPMJ.8WH!>+
M)2DY!Q@2$7X$^))#YNFY2XCD1ADKN%\[H#XJQ7%O?JUZ@946\%@L,&[=KU\L
MX*"8&)5)L(GDQ:G]ZGRE=Y'$SY6+"^#A-UM;\*BOMN#1JMJ"1SOQ=6H+QGSL
M*+"W4%] [9FEP=F^7J5!ZV9K:@Z^-9[[IV.=[!7K9&]LG>B[2T&:MW-WN%W_
MM*'.NX%=OF:0MUPY\,>&L:901D4Q_/,(K(BFVB"T3%J%DP2V/H#"V54QYWAV
M1:>[/;XYY&WNAURX;%.8BH5H\U Q@P2RP6[K4BJM2Z&1\8M99:C#O@2FBGT@
MD<96:[-:#/M&,?)H7J#M3U4-]1DB4/\,HSZ-\O1_;.+#FX67,&\+VD[_(W^+
M854O7_+;6,2L9@+G<!HA@ SL!!@NG"?@@!@X1OB4ZGTFE=("-[G,%$Q%ED:3
M-"-\R)>*1%<Y*%T63]< BL$/N<2C>FG#I;AJ933%SYPGV:\)V0*^Q$>=ZCL:
M^!Z>>[]6Y&604(@@L?CSBRS*X1Y)?IZ6A8+\PC/@(?!Q"MJ/&'>16QFQR>!X
MA^G*H@G2-=A?P0;!9\*T1%_LYY.R^$S_ ,W.P$9P/68]W'MYI34\9K!R,RQM
M@BO!P(W0_#Z/IDNZ0R7\IMU7Q;&6O+.0")J@PQG:O$X?8(:F65AC%2:#!FZX
M)F#1%Q15?AF<P6AQ&'C8EPT6 I\VL/&*<ND\$R]&EGDS\XI5](X^IM55&_]0
M3_ZO68"U7H-^)>B0S95I9X"7U:M<W34JUBTK5D>1&G7',)VK59[1#_URV-;7
M"%.+F@'&Q/KW$U$ '$ZG18-8GZLUR66T)-[DG %^P<BWF"TO5<F(<BXR$!RL
MO;-G!,QT43(X'<P SZ/]UEEU9PPNMEMW<()IUP<$=]W#R9P&1F5[^KNEX2:Z
MU>STO%RA\JQ*_->'5R>WH02O8/P.!1?OFNJSU%7KZGYL\7M'7:+2$]%EC44U
M"J*4T.W%W>X4<02(&UTA)EBU!XL<8$0#'WN;P]$GM4I,8"R\7HE70$)\)%$9
M5X3,MVC*!6QZ&H="CJ$(79P1!A7X^NAS<OWV)E4?%.4S\6;B3=GD,?H*4Z_X
M64-UE@G$A,*HR A%MJE09,'88G3R#7F\;I#&ZZCW%59$^WR6K]V5&F KA'#'
M35DU46Y*KM8)5G1)R(]Y$M'&$'!V?'<LU@:S@8@N0C'+0]F8H>Z7'#EGIFDY
M;>:X2:>TSV.X)BL6<RT*0U,D!M4:@U1D2\=:B$YAQ*<4U$6PS;/(0=@<K"02
M;.U@0&:P=&TG<FH*5;^' M478L%&DW$*$<UUK9-W"LF#'7,"A8ZA#*\*YS0&
M @U3R$5:);M.6QQ\;F+)?%ZEI'-65.'S0?R2$?ECE).SX@*FL.R4>FF5%T:P
M\R(W.2=;$J\4?URQ101_$1L2>*]^;;&^?;6RZL&LSR1QE\A='_KMSPP$*W?:
M\J8"TY@D=%86<_S. *<7@2GH/@5/$,F6S/$.OT.NXF*>3EV=E1(E3,1 B=+(
MT*5;"H,W#?IVH$S@2Z:1.6R0'08L#TZ,L-^JA7RADCJ=9L4$"6;HT<M AI7!
M7K*EKP1HJRX>B8?K\RT*-&QDTU7%5)QHYP4V'S,^J9"F"=@4Y;+-XICDI]&I
MX (OKW-C'-=9 7866V6AV7#P8ZP47+0T6IS [BX-A4YD)P1& P*23TESP+EE
MIM9N%ZK)@A& V\^V(?XQQT=CM!Q_GI0EV/)532S%T\\A'$N@C.%5:>V6$SC,
MY"=S6AE=&EU6_Z!3N;-*8A+EGRE])N8]K94EU #]_QEA0LWR7W/9>->?XM=R
MHXNBS.+^G6A7V'D;VF/(7U82G=@UAT,%<O;FB0"4RLUGLF"R7&)#"5L37$_[
M8R<];\TYDRXMR,!W;MY"F,:8!_Z48_;W,^/P;,PXW+&, ]S[U\/#8P=+]S)%
M'COGCF:_ 8L*LW%6E3C"(,H4["T\G%(6(E4^IJY>&*M+A'#UPL)B#Y$XGJL*
M=#KY;,65AH]"Z0"@"BSA$FXF,!P0TQR$>YHH1>%F<23\%=+TJ+Z_ 6JU]I&7
M@OE#A01$#ADP$#S;%/B$LW0!;ZE1ZZ9E^X76LJ.PAL8>Y!)X!KX8*&<,"<%G
ML"S%G/[)88BB=&Y.?V0)45"&&C+"?\*.B>E+]!]S^@BF.,'DK/DG/=,0V-5G
M:1G3SVTD3 @W,!X&J^L:']HG8+K,^_8&K/\\26K_C,'86KZT 21=_^H,EZ.)
M3\GBAEO^Q2$^^ /U$EBT) I@'\SIB"!=GPA)'W;U9-*.@FM!1= 9T0N0#/%Q
MX\A()3:]4%"1UZOO-(^6 Q:QW[Z"1HE95MSAL$40"Q]M3.JQH+X$X?]SC!<V
MRJO :24L:>16@M I.$>;8I<=A//4F_TSD'N0WYQJ6V 68YC46584<)PGL(!G
M?S<P=OBN:G+052%:1DW)83>81O03YDU<9> [H)F5@G$^2TO\=[* S\#>Y>F%
M23-_B,50);EXNF0]F5\XC;UK8<N//OS[W>L'^R]V0X4HIR6">_Y:Q'9#M@>M
MW*JP14ESD5:\MAVRPBPB+M@*S&A/E^!F/"VHJJ['_[(M3=O5X7:WTO:*)#@)
MOZFF93J1)H-\V1GEJMW6WFS\Y_#VOUV'T)<V[ANJB@P;_5O?<+OX/*'GN'X^
M9J[2BDS"DGP#6)*N\\\*C-7W.9V(O$5(%T[3!?5EB-_/ZF+C$Y/J8(:.S#L<
M!-JD26V, &T2 >K&?=KQW[YNN55!(2FU<M@$[EZ$:$W!\ET+#^W@EBKCC*(^
M,S?TO_M50D=W,CJTM6C0&/W99O3G*T=[;BJZP\^X;HAG6Q[YU_? <13FU%B.
M;O>5W.[6)$JYU-:]ZBTXU:V1CI[T=^))WT5'>MN.,QZ87VXNW,D* 75&86-3
M.  I;B55Z7#!\KYP!]3A<_UH>.!"/FQB2V<EEV^HA/'VMMB"CSQI_0_=OG]<
M/!^2+0J.WQV_,>I*^OPC<BVG92KDO$/4=OXSO3N9<E_W@3#\62/.*VR5><IE
M3?<Y9?)\3)G<O90)'86\E<'@SPW>Q>X87;M!9_K60FN;Q#JZ@3>\8G7$S9C%
MG6(Z,8SO8(GED<%XD5UTN^7EEQK>;381.:U!MD)0Q[(IFHWC*WBUV^+WF&C6
MB/<Y]M%>JH_V9+4]-] 13UN:6N)#U4AD2ID H:@T6&S8RM10TZ#F'&;Z WV+
M<5JTQ9(28TB@JXV*)Y4+>IA3KC!&&B<U&F$=;TEELS4ZS]X@W'X&&^J6EB2J
M3(8[F+&8RXS'/<+UC.+UE<6+0@=QX1MGGJX?M^?@]MQ_N'9_'GSG^Y/3#&"E
M(O!FA%PHL$(<1YXA)CE]C-,<PJ,_)QSLX?#=VO!-7N0/IE%U)E#'*=JVD\;I
M%@BHLX1. -C<(8=<%DT);@X&-"G, NX2(IK:U(%:;R/HS[C[K[O[*9-&<7'P
M#E/&VIV2^4T[/9I'V6E$26=N'\1 )G4V<RR:-ZH7A@=OEQQ\"7V5X#V*^:$A
M];-T$3+BK=.EQQW'<$T8_ 5^=XV1^+HI"8:84IA\#Q/R-+8*_(SRYJ7?O(G^
M?WJ>$I^?Y!-&>1GEY=HH6?%?306^:+6 /6M$!5-($RIFH6B':>?EOS+8P>G,
MKQ/1" H)"6=.O:-@C>IG()^J29RPO>(%M,\4^#-+DX8*6TI.X$PJD!G.$F*F
MUL>$Z#QUE)M1;JXO-\6B=E+[G,Z?)WE,V1#)P2;R!Y8E:(\WY<J+V($BT*R/
MV;'<<X]QQ%A L"J#1Q_Y",L&(2YQ"5_%K^@EAAW1Q,?M?WU.F6@7%"K&BO L
M. 5#ABHG9ICRH'T(9D\TB?(8;1R$4DY,L4&(\:+B C=O%BW8V$J^+-#"\@X4
MC-47E:UU,G%\"OJHZ$G8I\721$^,&;Q&\6K PJHE4<\1^AY\G(#22!4FWJ48
M ORA8H*)!DP6]#W9UGFV(V,P<#7J7GKED5,85\UGK$82Z"Z8YF"2A@3YH^P(
M-,Y@N:3P)]5NSQ%[J],T:I)1DUP;_=KH#;+_0L7/"46_P"$:HT=WBE .;0V!
MU!U::VW^LHJ#W"M'RB*2F]!63J\V2OVB9C),-<HGT!)XM),H4%VR<_ZJ5\??
MNG42\&^\]-0: [98P18T@.295OJO,4-KK/4=S72[P$>8)^8Q=*_$8"GEM6N*
MT.>P/TP76:=0-ODB@#E\7[D;(E'GE'5%X#-/>_+O>$QT'5;#:"-#EIQ2N7 #
M9T_&7C_':/,"=KX"C<'28EJXR5.N72N3\Q0&236#6KQ)+U=9<H 9#F;GB>P/
MX\#'T;*R86"*,.@=%$%IU)RCYKRVYB2# <PML2;@P =7P9?_23)%=#2,2644
M_@UVM$A#E8';PYFU>C](.YPV$>[[)#%%T I 2":'-!Y1#$VK.^-D D:*9@W1
M<>$NA1^>,)>&9]R@>'--BQ2;"P 7PP NHB6.O6+SJ+1P;2NLK=WUK3BC_(WR
M=VV\:BQ=HX*HD#W_D/WZI?"Z^O:X$1HQ"KA.!#N8SE5\R8^R8FR(@SF+4L&B
MQOX]M?J;@@-.Z22Y4R9LC#5Q6.4^Y1(I-5#@,$XNL 9[9@GMNG=VSV8\37%0
MW"R$;R\>0F'PQ>!2[ ,/:*]Z)SN7;&&.?XH)*0N21V7W?-=9V/]^P\?E/2WL
M?#$6=EZQL'-4K=^#:J7$-(5"BHAJT.-S;MQ =TG:ST@Y2/:9>R"+/+$&C U6
MU(5OQU0]AHQI D@-("::'*&3( Q;MLS!$[)E-FG[=:P=KVFW3-+Y!*T7;63"
MLM=<\ BM?[3>XF'E:ES519F W30W:*YQ NY'RK56IC?(>G.;Q*]&<VF4Z6N:
M2YR_:#O[ZXAFF*'7I#QL=:W:#&SQ](&CA[;&G>PSDWE9:G%\NVH1-4V!_+.N
M;;?>#NM]NFH4Q_##B@"0;WY''B&V-D^75,)X6D9SB2.Q[46Q%5,=CZY2[W/2
M&6DFR;^:6NU+=8Z:8G]PL[!&DXLE\ =D^.F'G&9R7@)^-2GRIE(_+=1R(O=R
M+2_B7]*4<EQ$0T+P8^((+8//B;.6W*/IXPNYRI0U<B0DRJXBQ@[11FK^X;9I
M_6""D6Y^Q3)*1<4V"QP)R*ZJP"K*I)WZ(CJU/;YD&Z\=&CW-S 9K7ZH17Z]?
MN441SK&THNY"CE)AC&F!.R&=,GNU;<'U.KAK/2VY<37@#HTDXR)>[M5;\D*S
MZ\%KHGVQLIE,TSDA1V,U>DD-55[+WR:WD:T0</Q+0A#ZX756WK96LW_%T :T
M,0D_H,AI;]:"=+Q1-1M6"4V%JMKT)&YPY8,S4$?F@KS('7QP&_U-L$!N2D%+
M;1!P>M9,/]W*R7#ZNCTYK+#!2%N#;,F%H)NK$,JJ6.>J^S!#+2DQ(2P2!(T.
M H#2IKQEI3,@;A"209U)YLZJ23>Z,RN$3VV7]U.9F3[=Q')>PD1XZ[]3:$@)
M6VX<'=B:F0LA 5\&9ZGR.J%)PY$K.R)\\=.R 'GW#2L!C^:O].<$TD]/A,4[
M/97CYH^]D[W@3Q;T0RJ:,>?3QP3T-;= _5[4)K&/N.GXO/T7SY^/!M1H0&TU
MWD11(B=J1/:-9Y3@=I8:*4<T!P-%/9$9$^_9E=I'2@2CHIC J\F.Q_Q1"B\4
ME0.MO+9#F&Z*RKRB=,PTS2HGTMOD!K@=]TJ0)<1EL&OYWU)"I%":-U1N2^^;
M"=PT]KRM#4[>E:?N*+:CV&XCEJ%]OFRRG!>?6\%AY.Y(,B&((2P5YPOIMD5A
MFB?U&0(]S-*LYPYE4C<E2S(>X'EB;T1P/.L,S!X=8N[JND1L:QIAYT)JAR@&
M/2(N8J:OM$*%TLNV/F5.+<3HH$1?L,VV GG/$G63RF*>BETWS:*4<*RPI*6J
M%*FI_XFK*F(Z3R13B# )\J6U:?EYV#E!> ($9#!\$Z'-4</6"[&3F5JJ$X8E
M@ T!K(%IDQ9T9ZH:%W8>#U^GLPQ]L^ :6N@>]CQ;*)/(XW%=;^_G")U .RKX
M!$_ZR-NHF/C\2*L2;B8A8/<'CKDZB\KA,\(;O+NAZ$[TX'J3X%0H6?ITCM\+
MI0?^@,^&N(!7QYXK0Y7$2S?FX$?E?FWE3E(6JAL:.JK+56A,#[.48+*XU+CU
M*76/,F:DV]%]>"'?@HL"I:_$XLPAQX[&BGS@*(:Z*HF:2YBD6!C(KPD#P:2H
M4[0A34@ZS<^+[)R]2^/88UR=G"P04XUY]X2X3>PYG9MR:-5?&[KB&+]'-#MU
MJCTTF1QM/'0+%4Q2VB?11K5<80YPFK1>@B>X,Y6A21 1[R0ADH6$Y6".XL3J
MVS3_"\Q3LG1A9=.$C&C#D*W3U'\ X=# 3C[%1065E%)*M"SRT[@8>>U'G;.-
MU@-EE:=F'.RN1Z]'^Q!(-!@>+X@8%#$W44$.;O?T[2"0+@>M9\QBE]32&0HO
M"SLX2T%T8NE9B].J*K*&_Z 85S,%DX$:G9UFH4A_T.YC4UO  =L;Y6*4B^O*
MA;A8?BN-XSR!A9A/4]C:E:1="-T'?@S*ORGYW^P+<8\.^5K5<*J(_#3QY.39
MSB'KNEZ1;=)ADLDD=CM48P-DX5 \2K*I#\+9EB<[+0(&(E4H4C7ST [J$+XH
MW/N8H30MZZ.9IP]4Q8S.T*LB*N-@1Q"VCX\./[Q2.KC \/5]8[4Y3Q^.M3EC
M;<ZH9C<(0TM46#P0TT_/W, 8I.(*1UM20QC2G$QRRX8#1=-#Y4D)&?D\)2VH
M:.YD8&?<]FB?$\PP$<3/,EI_ECA9..JOJ"H)<O<Q,5\3]7<T7D:INBFI,KO8
MZ1KB0]ZQ+S3/7/G,1M8O%L$PI S8.$RP]Z8JI4XZADZ6YGZJI!7DHRZ>P5^/
M0C$*Q=;*0+7FD^HCXQ1Q5 2AOA6(H@+-!*SV'_:I.),*-%N!YKZ;[5"PK90F
M-T4][_EEM=O)&%)15,\O!="< )<0Z@Z!VUO>B5,T4DW/P W)N%=N/'-&\;IY
M\3HO,G#YHA(N)OQ[#XH1_M^L <,+=JXT24J%H1,EA8U+CJ5ZTU3D5-K.36W!
M= .T3">?ENI'4T.GZ5!73$>NI1,)$+X,JE?B@E!.PHVI^U% ;M,H<]P$QA)+
M\G@H/"3)8&ED[CI)&G?Y*$<-D690D2<11]BTZ[K275/0$[88*BQ8Q.:(Q.TL
MJZECI5PZE=2ZY;\A]UPKY(RM-2R'6QM&N1SE\KIR>67DF0& &2:IH63L59%8
M;//S,%Y**$"Q#"2P$5\*YD5)PBLX)WEQY&4J39.Z51VV8D3FQ%956*X@5%%)
M5")#DX-*,04'CBC6:JYS\8@]$)!9X^+40+1T?V"@[?7&H4M5T+ZU>Q-S7XQ8
M3Q**TG/:&KET%,G-.L%'\@K5^IG#M^4219XV;R9U[G0NVYT$)HKNE:(8YN -
M"_HOSJ0\6:$Y9HH6 C=K)$E.\:[^78,#P)1%3 EF[O'"0A:[RH5I4#.I?E;V
M]"YTZVCT&$;%N[74\PKD+O4@VMTH>8(MDR@F/M+[AKJR74*XZB(O)N! S?\%
MCKBI9J'.!OU+_!04M+DC5MP=:N)>!I\87G,4HE&(;B;4*[+#Q@A1W%+[%///
MM&P7Z:J2$BG.B?#%#JR\9C2\ )1'!C32(8QT"-?<S<>;\!T(7Q/]R4UF%!=R
M0D!E0KP?>4W$2ERPB^9-/X+9S[:S5QKXT()+ZY1J$3_G1*: -%(YFF:8YW Z
M4L",8R)P).-JRCRMSJ0@4\*QC&I"%A4*T*Y[QQEL*B3=Q>?@SQO.B^0@3_+T
M_A&K=X 5B$NMUA+"SQD:ZCL7)3H4C!U71MEN3_&\+=: VU1,+GDL=WKI-/'*
M6SFOE&R.[\\<JUKJ:&9!36:%-),,;2>A*FVD$8;G5C.<@W,F';EDQZY_.WV]
M2^7*"N$=I'H57%DFSJ;6I+6//'<!%:3-4<V;JDX655]&.5*:6EI8IWUV%:">
M5+2:2"D[25,TG6B+2%\C XD:HC9S'DP+P]G#MM5%M+3+@9YR59MZOFFZX%_2
MEWU[V__<2A&]!?'VT&UK3)372OXJ6P)6)2[8:4P^RU]]1'1[:GRA@T(NT<[A
MKOIJ-3;I4ZDO5D,O4)R:1<&OYG(*3\3'LU_T+26K'QR*L.,Y  +2>>WP7ANO
M;/!^W&5BS,LXJ='V;8&KDMM&%<'"8,G3,X^017O- W8%T..53,CG)%GP=#CB
MQ,*)''HY=:N8+[3%=Q)5J7FC#N0TC8!U#VDJ(^FP,(&4?*V2#ZD$$UW:$Q_M
MYM.\.@NWZ,-NGQU$;QM4H<S$4/FVD+(V.-EO/&=(@"8H]K54X669L8P,.&['
MR+<(>71.E*<26))B/2EI;1>YNLP1B-*I5?<=D4<X"7IQ,_,MN#T?6((O=VIF
MG6(:S28Z,6"7U'%]M)=F MLP"?3 0HU+CF9%60P14$R6+G $;7GGS04J=7/P
M&H?EV*13":IAT$B]IP6&^V.!X?=;8#@Z%.L<BL/*GOF$_&/.-4GMTA;8B6SN
MC:ATR=J!#QX_%U@*U#.[EEJ--1H,!IN?+!,K$H)7M?3 &Y(&VS!%7.XPGB]+
M^^U/\#=9Y0U!B<VU)ST@VG=BW])L.;HV-OUV8BV_0ZP@EVBRS^C -HW@=F7<
MQ%D(I#&HY"81DZ4D-VI:+(QIQ;=S6< /!6]8#" A^B5&12KMA@L5\X/)X#/;
M4J(^G;AR'OTXG1QR;\[(QZSO-P4<&CIZ3*^_F1JG %0Z_^5JY=KHTF? 25S6
M/&V<I[D,/4:X^?$W1D]&97>S9)*14,P,AUA(-HSUR>RGMH)'2G8PDQ8Y7>=5
M^H6G9YE$I=LT^<8HK4_4&HHZM6AJ#O>+LXNH0P@W'ZF3@,Z/.@,,9T:#UIH@
M"\MNJ=%LZ9#>KX>WR6@F>BT!(JJZ81%.-6#&H"SQUVA32\&W$HV3$YYWYM)_
MW5&<1W&^KNUB97)#ZF,Y[6=@\9"#VCUM"0'K+()-BC'1!1(3%$U%81DG-QWE
M>OPW1&3@'K8#7U2]BF4#*7!]DRT0TU^6Z!TMH5OB><='C33OHZZYD[K&]Y-<
MY\@>Z%_7O4'Q(65HPE)Q Z,]35F9I5,NOB++/&?K!94>2\8)# %C8.^3A&JE
M%+19 %ZX*];$?\F>Q^?UN3\O\=8\ #=@51HH0FIT#7W?![TD3P^3UZ%^#CD]
MZ@%=S^D9\#CP0TT3#?D?GW3L/,UX0.QPE9"P"B%M1\ULL?03SBK%973A@.%2
M)-B\NT0TI?P",SDA B4ZT\3;"V.B32;@108OSF/;P3HPQIYCX_&T /MS%G'3
M!-BV6#)"K1Q%W[#,$X./WM@L'&07TLI<8UL!T[B!?803WB@546=I>0\["$Q9
M=$'KE3NC0'XC[DCAG79D,#=;XZN*($,]#U*I*0PD2ZJ,R8Y)(B41\N(5ID^+
M\<X#S0D:8>&UTLGB_*$;V1]MV/%<^;KQMR*WE5.B\Z-E.PYW&6QJ%"$JC"<,
MM8*VGU7Q<)/WE*0!^W8B(2S6RXD-3&TG)&6?TQ^7&@-'HY3>E<#10,C(&&2F
M)H?^XFHS.A6;"2P-')>I6X/32N!['LNXB\=:R.MT<B2?,79A3&D*A. V6UNK
MM"B3![*S^5UQ=VN5DI^N\,H%^$2X'ETW(2.7#9AO%K52W),^[FXIP7 +5TI'
MI-+2D[NQ4'^4J^O*E?CI!$()MA/,9\B^2U$:.@XBRP )J (%'9;*-BZBBS%P
M(/Q*<IF6G5B$W55,L5V@1G>7A]PEJ*D+%+H8)*DEJUSP$]HR2:)FW? BJKA$
MRMR8,PA-;8H KS9BCX)C%--13*]]_,%FHLX\]$@$'1P$MZI208N5;:CU4'2L
MV3K7GEW,Y6>N',NWR[;@PI]9FC1"$0!_4;5<6K/ 8[0-X9M9,CIC&#?_N/FW
MS%]L>8:Y8AE94"_%5AQTR(<EACGC,E+[.7X VZ$L+N!H8-I "F4HL 0[/H(E
MXT#);$XC?$]+$P_&TL3OMS1Q5%F; U(1+RDI*F4F%9;1?G9291+UR=(=7 &Y
M&G^WQ@H=3]YQ&U_[Y#4FXE7\(/R* 0WH!QIRO*"N*\&+(#L5@SJ8PR6#4CJT
MV]5;5QG * *C"&R33*U,\N0BU+0S.6'G2CXD35><ON$TC]OFI'U[;@^B#0DR
M',',K]3R0O/"O5AX]=[+S5)C+BWBZF'N^F?-&>&:E,M!$-^^V[4%E_I]<FXU
MX]2T9V);@)P10G<4Z5L2:4*TE:0T[OQS$Q2QO68>OI.#7FN ]SU9&2@VECN'
M+D0AW-B%[S<00J;VR8H$<\ZX*--N)YU[%Y&PN+?1>@,5H6W%G;RV3$2G>9FG
M1R"'6!=F"C"!6L$V69 ?WC"Z7;DH2F9^-9V*NXQ^EPA!;5H+OM-.4;K7$L3%
MKNV9GDK':8;74FOK[U$51W\SZ:S3(QC/TUQ*VY@*F/]6:,H I@)+B]J82:.B
M&17-2,#3)> )F-6*L%O%^A[-[E%TOG'R"&H\&ODC1L&Z]X(UL@S?;Y;AKT0Q
M?.>9A<,VZ\A(+3QJ].]"HV^+6MCH%9;S';&4"(N/6Q,3C&-PUIN4!5E)X8I;
M$F=B@E^,.WW<Z=O+JDY-1Q4=J62&$$HCZ.><F@$=*P4AA_L^7T?SR2@ 2O0I
M)2+]])DF=-?#HTELF(%AP=3XE(:G'$P7@<=S4EP9][E1>JLD-X?K6TC@3\'/
M3Y!-*^STY)FJY)!;RSG AQ?0N+C6,42+J\+_2A\,?H+!M>HLX3#%O,D8-);#
M>ZA>. 9);9=OCD*G6\?I6N?$1;?M3["11STPZH$MZ(&B-* ]A'Y,@LCERFX]
M\DS,Y"HX2S*R)#]1/;[PV'HF8$I&7U63<S)/@B0J<XXM4S]+@R70=!=JST)9
M;^6OO,!WJ^Y_/ ''G7_MG2_<([C-D5311%V7X^8:-]=U-]=.M,M IBZ.:>)5
MG4?S"$P"]!1L)-94J8%=,]$4I@-SVFFXZ""GBI7F@*?"!YRZE!LI<F^W"BAE
MBBT7PC5 ^!H'ODU!7)F^1ZPL5OL<E]J5&#-G)QFG-2IK^*8Z2Q>A<78L+I5D
M'\/@KP(.C0#[FAOJ)*FJ0@N93%S80,<JSB_&IOU$"[;8<!R$,1A6,4C<TY+A
M1V/)\%@R/&K?;;-]C#0>(Y[ K:)^8-*?@X**!>"X_A/TGBQJG4._(5N7T)^H
M./@0<YQS./((B(DAP?$6/2&4#>J76"8TD$&-.YEP:IK2()?YPH1#&09$LQW,
M#9(IV+\6'^FM)%1CFK6=^W;?,X_FB2E2YO%Q](ARRX*)R4@__RPRW,M5&+S+
MIWN*D4GOKLB<VNXNG>PO!0O]O/-8T!H4B:V6\TF1>5GO5;.OA52$GB6W,#,W
M//Q7QSI: N5"],'AI_0\@MZ1LO'^N$=--6JJZVJJN@?4A#57CU9R4-80)X5A
M'(2'FE&U?/3M2:)5V(E!P*:(3Y)X64[SN9-<7# 0BY0U^O$HOG55.'<7U@,9
M,@?!%;UH41()C$-D0[@3_%XB5SPHES>%.OL-]V0>Q(W<4D)E\+V;_#WFDLN3
M-M@HU0APISUUUS-$A?Z:FH)#RTVB< +Z$'RH3! I*<0PPSN+-?-.5+'<[H-R
MY B\'SPH5CQN<SD7F<X-J&_4,H;LA#BK0=-[I '\^3R)<4JS)?MBA&$7,A8"
MH9[/E4A&7H/ WZ+S*,WT^,+1=Q:5=E_/V=8WI+W@4)#SYG R^>>@L>7"UC-X
M9S.*'HQ_5*"C OV*F.,&0.K.08X;F'&_B'X8:]R-Z8]0XZ,4WS,I[N-=I#(-
M.2DV)N/H.[T(WPKIT20GK,!5:/RW2!V):9H?-/<9'ODT'XD=-R!V'"2"6\?J
MN!8E#0:GG'I*[:@8:<Y,7(+5\6(#5D<N'UKS5MMG<USY/(\S4?/"O=7<5P4*
M%0"XX6)P!O^4WS%_VN6()?,.I:3?-]T"F5M/*NE?<)OLDC?&*4D\2<.4DA27
M&3DE#:<DS<?MDDH.CG";C)(]$ *D68H,FT",1%17)YMLXWD0<R7WH%9<'6\2
MA%-'D9C\:N=:'.VZ9RIJ.):+_U64LA5P:YP7Y";["L'MARFN0HMI]4IGN&CK
MX]D_12_ ,E!>1X.. ,JC_?Q5[6=B*;?N,8<6';3QR/#I65H G^"B'WO\78Y)
M9/3^CK,H;T7^1#;!LBZ*O$WEX>.FH];2P]^AX!AB^<C7VX=O04'S,$X>"!,!
MF UJ(HH!9A,IJ,^[!BP.[;BHZ@>NO"MW\)13!96?#K*L(?[<=&96)]1=IH\G
M?P2'%UAV^ZUQPSX>JRFN6$UQ4^NTGIWJ?5,W8+]Y)%4D$>(PWPY7%5+!+.2)
M'F75G(<W,E>-1^\=.7J;JM59T"HOX!Z#.94C#FU39W.ZI+E9IMV2)(;=WDT4
MCZ@B+I])XF7^-GHH1[O)VW+S='PN5YT,X3]//B(5%ANV5-W.!^K4.$PV4YE\
M6:2EJ1QLA?'(C;?'\$7$23&.K[LBK4_<B8P>LF0K*[F^)+J?DO.">YWC>N@Y
MX4W%]% ULK$6&>OC1X5Q786!H0K:?'*DN9%+$-L9AT4XAM)79$1(1'B#M>8P
M1DDEN-J4B9CTAC!3S>))4E\D22[!)I!M"J.$2MDF=+<L023P8C ;A1=1#([P
M#\V/NLFHT&2BPF!2%)_90<:F,+!\@YVJF\>;-F!F4Z\RH<*DK&=&$1Q%\+HB
M:*.B/3M6 0I,QE..2&PN/,?#0L"]%!>)HSTV=#]\WO;L<9NK'K?UN*UOW!0U
M]EFOF2-V(]$F(,J%&["NJ:DKIHHLC7W[6%QN1:@4&&'L6T(\)YS[X8E\]/3Y
M3J0!([;KCHIX)"$91>"Z(D!$!XA"FU!B8%JFPG!K><(9QZ>HQ<JJBJ:<<F;@
M^-WQF^ MM^%+_!3NMR'WN9=6["8[EZV[ATJD&G,FFG-79\(,:8!U$+P7WMX2
M]":*>6%(QDP) _J 3>YFN31KAZWR. [J"\:,>Y)%RR3>M9D\Q=6H.!DECB@%
M?KQACR(ZBNAU150B#A@.5W9H$\, J8%3"6W^HO2"$ER"BI+2"JE/$@:321'W
M00X3S'R";#6XG^$FV/[( $U7:-H@T:M,8MS@/%4BWP:+3P[%M0'6*(].[:WY
M333(.I1V>.LE3OI&+-Z<',+<Z3"*ZBBJUQ)5*>^7T\ ) 42&S-LFZ!#&26K?
M"=S. +^2!&$Y*<GQ]"R)&\ZT8#3.85$'8S6=2WA/_:,F7T1I3#59><713C48
M.7VV0?+<S3 ]WT*NB[Z[X-32I,CB]4D5(^2OO=+<-XR7#V?Z!RW2O9WTBJ].
M3$%T6F/ U-:_J;8=5$OT7J$4J:@V9B9&0:5#G*TD(!8X+$]A@E[&5&0LI//$
M#1'-P!AC1+I"ZR^IAZ6"/:D0I&PI46ESGNB/0^KU,%<@ "JB?5'BQPS,NPV5
M@BZPF[_<:^=\W!US\!4F7,N3$K-!3!4W]NK1!,A;$0:,0[[0^NVJY5OYVE]'
M4$Z:\CQ%HQ:&_M&IM:5:_C^9DR65AB>;HKR]G&39'M.%&5/H^AA<,Z?C^W_L
MO6MSVT:V+OQ]?@5J:J=*JH*U)3L7.ZYWJA3;R6B?Q/:VE<F93Z= $I0P!@$.
M0$C6_/JWUZU[=:-!@KI%LOEA)A8)-OJR>MW7LUACV%0=*E4Q"5-!6$R@&L A
MD=CQD<$J P>N8\HT7C22^ZQ2CR#4@DYGA/4>J%[@!"9(S V63359[C2\\B7?
MT#]X^EW:^^B'X*-O#XY^P#&#3Y\>CDOZ?H"$?*HB7O='GALHC'5L2VA<E!9Q
MN,-A"*#(M&BFW0)R[*:4M(>YC$ @\;*:79Q]IXO>@2[*(IL30$3]%&>]E+#;
M^-7.4;&CN)M3'-!4"DVO5'Y^* P11-K*0LQ6LEKJ.,D/-1-82=1T.:L.#18=
M01*WZ'O&1BK1T<BRVT\&M]E:C=8$OJQTPN]VZ81?+SC3BS7LZIXYA=G1L?E"
MNN0%"IXF9H)>K$WE:+$"M:]<G58Q<^4WK&VYD6R/R=1W4V83"!;<T%F)0?&G
M+T6#W?#TR,?H&%]Y:[(UG\/Z_EU,X@[7]PX=9:]Z)_?./[FP(M7WXP**?SF3
MX [A 16,M@&_Y,PVJ(VC?^;MOBV562^H '':B!1H*[;G_FU^KD0,#C,D7(J6
M:O*:?!\G..T:[@8'F1$X8?I(!83SK"D+ZO!@BPR>'=)_9X8%LS$JVAUAF@C>
M8!J4&OQ/5W%2TU&:/#U\^FVR!^]@TM86V&MSQWA']P^24T@=U"F)%&TKJ)S7
MH63P@7GUPD5P8E?P,T37\/(,1W"&MH;[BBTT<X!FW.*R<W[6[K8_A-L^\I[C
MH?&0J=QN!,RB3H+V;N\,EYWA<@N&"_&(ZU@N?9YW&T9,4)=\'6OFP2E=U^7#
MPH<> X-]*'J2YI^/6#D21+?[T9 0Y"O0@[;2?]B+(3Z(^]=U0F:TNVY_JEFR
MTUQVFLL=:RYY@10JD!=.D5F/I3"J-VF(0&*EOR@O3CN8Q7#/0E[ZTN@D)=:^
M.''#]6V>8-!,;;06PRM:HKX$4#&2E&GCQ%#^AADSD.L)J=TD]T1R];6=&VZ?
M5\&0J7"A:Y&(HF3'"':,X X9 5RO:!]3Z!C6HLH/ARDP5!K<AHL9H!]25IF?
M(?@:M,<HJ-LXX$Y089"/6=/4Y\6$JE1O@PT1,@<P"YFH-SW*ZFFQ(QS!?(\J
M]<N6RSQ#U4TTA]T]W-W#NQ7('Y<YMBS\+<_Q=D !PP2J2;'4P#/$KY)L]J^Z
MHUN+HK5N5\NZXNPGLF#V4QS"W"GLY3E+?6C35J,[(Y#[K#-W^*)>*;L/9ZIP
MH)-C*96XS,C&D9Z].T&UNR"WF"1 1K+MH\S9TT23^%6<*,&BMM@-8]7#+?.>
M;R6+]60< FN;F&45,P GMYEFJ=F1*A?+4J!=6*W>,"!FNN)E!R;BL) 9$&_>
M-<B@E)]OM(ZM\#.=-JN+\/$]3GNW29CL<D"X.-#XQ=?PAYGKO"N3G] 8$&MY
M#YT6<]TF? /.1&A&>.ZE+=;7R,1^;K)N=OWY/, 4RY_S7-+HN3C@?A(MWQ %
M,&P_H'M/\K*^Y/Q&F92M6# BL&NH2_NM K2BP%PQ3L-ZI70E *V^]6OG.BO:
M"32+MRUC *R_S<M4]R2>712M%"YP@^(,.U%(>CT6:GA&*RW=@GGB^P ME;=F
M1#P26S)PG>1VWC!Q@&:(_$2NU0M6-)R_#JI26J_KAO10X,(3XMNN_*2:V6_@
M-_8+V_K&ZW? M^:1YEM]O\NW>F#P;=?@DK^@H0S$_FMV^7!2T8N637AI*3XC
MZ(&F&R[4++-+YYM><:'8Z]Q\G#6JU\)9<8'('M2Z08"XSVN(DY@?<+MR$/)F
M@U;R$7*9EO&J&BA0LPU AUYI$7GQJ7]U3='."*1F/U'HX@YT@3&O! :+UR2B
M7@^@%9/HNQ^@/#Z&WNZ2=_I R(PK'C*8&B4G$<@SNG<![OU*E3(Z_8HA!,BD
M=#V.S-,V)F?4?>L:]CN*!!!*+AH'KBM;:]/_S=B"M+LYW0^,07WL9P_?V?%=
MISB,-B?Y-5_!+KI3OA]R.XGK;UQW-[9!12IGG*#LD3K)3),?CDU6)9(*5UM:
MPDI^*NKD!'Y.HP.$+_3D\_+?AG9+\N"@8I(@_.5)!30O)-OD&*9]>O#B.V[L
M990]Q.7%QEFV["+>2@]]0.8%T/?"70.J#TV>IM]^]SQ]]NS9MF-Q59&Z+E3\
M*7JH#?^:A7S[XBC]_OL?Y&A:;O?%UW/H5R^>/\.)!;_:O/];#CBG#@;GK"XS
MUH@#@!SE]86V9HNE"C%3<[$5W6'42T/D9X?(;H33$JZ7;2(D?1^H$!/DJ%#?
MG@4RX?/J*HPXN45TS;*VG5^)<HAINC7N"TNT;4#J9IX7*TY/@M9+L]PV<UA#
M#G@6ZNN?AJCE 0I*N6\?NR4T 7^TC$S=0)^9Z2_ZB[3<S5VH@^1WZ]$8_*'_
M0F16>+G ^9M*7>*"_=!RTSRB5S5BW/I# BY7L8*RH0%2Z3( R6J.>1$E$ED'
MY+BWJL](EPP:)O1;Q=M>K*! FHL![^8F$: 18SN#O,KG!8$1I4D,&G7M+M9<
M80\U^\!-I4M#[ 5)?<D-YI7J,N-P,F4<:9'#T6%<P!M:VD>[-!$\2H>JDGEV
M0?.Q>& CPV>C/![$;29J9&[\P#TZ6MIFGQB%M,:E/5K(@;:;+("$9D"*A*G$
MM#BO'=9^PO[B>$0CH!/TI$A'%2<6;(Q#_Y8'="^2,O$X%*$ZM0_B>CY5<&_2
MQ<2=FJ_+9F=F)BW=.3=%3)]DPPJ%C,!*02^6Q=)(JI8:DYA/YSD0G;T/ZV<1
M-&S*9D8A;R'M(2,K3S"M!E<,66_KF))Y1VW#O*UWA4"$>J7,"23KG;5A?X58
M^T&D4&@ :COPK+TB5F[I]U,8V\;0&([/;8;M9\P6;SV7-#N.8ZM#P$TJ?.V)
M= 3.:L2F8G!VT8R5-5RE,Z\KPPQ&S]?&#:7Z'=W6G IZ 3COQ;9Q.S#*5@+1
M+H'.WEINH))[F1FSCK0Z:N.&'6.H<1/LAMG+V+%3BS1T^. PV>Q?7;L2;SO'
M\<UF/)D59>?0# QMK7)F5;&.$PT#/[@FV*,D2XQ@S V$L!C)XG"47E/MN#)P
MPPR'@^08#)HS0$4EH?1]^NR';],??OB6^^%MF!:<RI%Z=,,VP!/J*JZEA[M'
M>P%68[MX<;;J<AS%V^ A:M.-M%KVL)2*-OEW9U1)=&, @+0A1+CM1N6^DN,9
M:MVUX:9DV!-%Z0< ^+""U&E"_@3NABQR7.@N57.Q8\)9%96YV.;EMI-<@4I8
M \V2\VJ:/V['^0\[Q_GC=YQSQ#Z\(_?EW+PM(TVT$EI.H&TZ)=!;+7"MCX%N
MB3J@9^6UO#4AM*IV60V^0FVH*\QT1N#0LRF!T*V;+:OOJ115?,N-H,[KSFO5
MS%8,8RT-=Y( 'C@KC&8@F#D6W(%U$F]/_0Y7MJD5GI"MPHKWMYI;V;^VLP5R
M: !A!H=*FBC 6^6L5EYM,6A[?5K!ANU6MO>H\L+AZKQ.5\XX6C;2T+[U%!"T
M>-:>B^><%#68?H"O=I8&FC#CVN]M80L&N=^Q<?<]U5)DG.IF/Y;Z$@H\QYT2
MVIU 6\U..-Q1?LGF_92&8D;?%L0P?A'JQ*Y1XN2*R(ET70I' >'&#L'J&UW%
M:-]<)D7;F!'\&+OZ*%<@*Z<=0P9G1C&IFVZ!+Z*D/&OL \E%V\F-4B%NY71I
M YSW90']6<U!>*"S"C\9DK+RUKOS<]*O*:E^ QL.XS^W:3.C&V>#,4Q;%YOM
M+9=1#%RE^U"S!Z6T9]#W94HHXMC*7]/E/FX+N@;?>5D2YED+*)/X3\_Z]UM[
M$U8X'TF971K:-"= L..),9_-YQ5\E,_.<"@C@9:VQLS+33?J<K>8Y-;#($I^
MY'*[[#4N@M0 _P5W:3:44+BXNVK3I)R4$(DGZCJSZ06J=;3P->'-FVZXQ\.!
MQG-EIAMN-#'<:.9;-KS*@>-7E\YMH=XHN,7 S6B_?Z7]]ATTFBF*@QN](V%O
M;W,5EW3=7>!E9+_OF"- 21L5)SG#RE0^8JS[H6DMZTL6)8:7U4V57T4F*^UT
M780Q.KV>AC"P'<A[7 _ROG,*_+J4E(F$U.]K_:<;X(-LXS[L[V'E]H&9WP\I
M:$:;MC$B^JMAZ4]^7THH]-[-MO>]G) U!AAJ<'A7Z:)N7%T)J^OLZI3EU3>T
MQFU5%]DJER&@.P!R)_*!5>!4Q(\J?#P-S"&[)TJY54.YF,@&YZ!M4F-32X?'
M^BUOSJC@&4H=&LD/CSBK]SZK.-'J,B^-X#?OQ/A$!485:8C]6)M=UMZ5R_0A
M2P]NN+EB)70Y-]H>0J8ZCKAIG?F_.XY]@-S.9VWR7T=/#PX/0;>G'V,F-WF@
M)12/'[=&:@-#H;\HXZ*:F0^DU!^.=0JLW._A@Q^P.2(?6?%<%I_R?8IF 0+L
MI:$5HW<_/91M:S(4:HA2P,8W/GA>0';#WK/(@]SSD?JK<-<5Z0J_D8#K*G]R
M;@1J8W.#<:KS8@ZO._I.WJ=@$[SC0NW\/^K0\5![#X)FX+SR:SI#2ZEMBRK<
MO[MBQF;  FDP]>T\.--SD+WA&3CAW!:&R1CK3JMI'# S)&RT_:(LV @JFIED
MD8!!8<BJ*PEYFF/5Z^8^6%XE%]>VHY$YPZ=%X_L(-O6P0-,I:XWIHL/=C0K)
M&D[Y$$')?ZY):WM@B6<80CQY_RX% OV?K.H,>V(XM&>(A_;4"1_.*NAW9>1:
MA1YTO,VO\;/4S-7$+7":I!8\@QNU1J+$S2KS1^L<)53[0XZ5GH@A>PL("4PP
M90(9^N0)B1I/;!_JD*[0:6)O^F,.-CS?!1L>6+#!C*W5@] !DR43T=JG&[I#
M"@2[2RDX2-[6*V !UH8,;<8C7P=!U<,J(GT=),;"6YO\QY7U3HV+3_YZF@J^
MTFHJ^)?65*ZKF#P]3(94D8TJQ;/#)_Q;T2@V*"E&RX@J&6,/'2SIIRH_/*XX
M^ K#>@6A:#T4$YK2P+&16A,H"]LJ 4Z+]6AIG+A'5D\)' &SECQ::+N:M?GL
M 2H&'W0DYP-EA#PBY2 FW[W@%">YQ(7]VL7;6(Z=D,V_ 7TCP^PX<,99GPC,
MA=L)]:U.3QUP_D(52&'LMI9 0&9)MZ1NVF"V\16\K!MT5(D67M89L!4"%$G1
M+Z)SMA?0X;Y;)K:)T2PW&SYKJ2LCK%UUSM"K:*/I7 N=1N6>@.[VW&?2YG&I
M :#\MU%1#GDQLU!S3Y"AJPW[ *5+WQY]-_BZ('M*[R/.0);$Q[PLSLZN)MGT
MD]0.1RG$>8GM[H0!3H S*2U#&HI,Q'/W[L-?N/XR<Q$J)XQB!E@\C$N+'#QK
MY&J,_0<H-)0QBDY&[.1D(\;*1[&&'H!HA4&Z&E1P$QG*U5W3U8R&S9D 5\]0
MRIH< U_.I.MM/V;FF1Q\NPJJI+$76"E^9$9HC)+1XTX->K'3UA^8MMZ3^Y&#
M2XJ96>/G[PY?/'O^_/\]_>&O?_OM^/3-AY/C7Y/?#SX>)#^_>?WF@_GCY.VK
M=[^]24Z/_V_RZMW;CR?PZ>F)^=>=<["-_:C.5>\EB"9.NQ8%XT# PVO?F)57
M;8'*F_HA*+50+V\;*:^RS\R^L(EP?L$2:9BM>P%88&4(,D#\$'E+N;(*A%$T
MZTO):N"W64P"@ OB,"0R3  EFA=3.IQY#G[?,B4>D@)WA+]&PVK!(&(-0."$
M.Z.QP\), S-L_MWE%;>1'F29\+.&ZRR]$+PO/T%;.-BL/MZ1TOL;IQ\P9=/F
M07D;+/S4+/=59+D?;!&:+6!YWTW,FOPSOH>"8$?D$#P+"%9TFX6W1B80.=S>
MD8*FI53-B-?>,WQ00S#T3Z:\:'6&?N./0_V>D6PS:S!M Q3"8+YJE4A*,#TH
M;S;O7S/'@A54,,RM5@PY\)3D,[0WDOS3?S?N.&H$$"B!"6!*FL-#(O5"NZ1[
MFXTSX[)MS46V. !TG("M:IY 4R,("2'Z$.0L-7YO.XV/,NE6.&?QP# ?RTHN
M^H384%$5BVX!2R#MY[=\9BYQ0XL"\X.IK<HA%_\BYRH!Q4,PZ%#,,>JZ&M@'
M.- KF[&1\6)@KY7#J&48-@ N$!T5?Z><2:NK)>T:S07[K:Y;\*Y#WPX*;2LH
M- <65$A\EI'5W3=MWEP40-]H:IO+NX/@V]'=32'XFOI3WCR9Y5EI),2.H'8$
M=4."<N#"W-8!O/Z2A@L8180[3"Z9%15"[\AN1W8W)+LF/^O(.%3:XA0]:#M!
MN2.PVR P $M'-X@FL15 %N[H:T=?-Z6O_/,R6S4%IL"!UE\W"V.IEG5U]@22
MD"$@@;BZUFWT>X6V)J+;[0AP1X W)<"BP@02:!#?Y)"0[Q<[;'3WKK+/QHR@
M^D:;4DI0KCORW)'G3<F3@A<M!#*P(BR;KCJL\^.B0B.(,?9;7NTGWWU#:)4$
M?>$E;W(U#[E!=V2Y(\L;<\VVHTJMG;&QHZK;HBIVQR'N4Y-A[,;K'K91&&]\
MP,SXDUG $_AOOK+Q4A+;BWQU7L\P2DT"?*#><B@NM[L!NQMP2^(>(G98;QZ-
M5F84D/2ZB$#:TVQ6YK;=IM8.,(D[3<[S&=0.Z1Q'T7,!*^"L"=,,L$2BGS"\
M(_0=H=^C7HNXOE2M:=,:=R2X(\$;DB FJUA@*]7>"'OS[ ,R=YLG\ZZ:$F!W
M@DUYJNF5M+U&=Q0,,JNAT\Z.)'<D>5.N:*0Z@R?KPI>L;9^LSINZ.SNW21 8
M971('.VH_"L+9M2#:[9-[G=)%CMJOB5J1K0;PQHI43&'DEO!$($LGQV%[2CL
MQORR;<&\$?+:!<%W9'8'9)8),J)MN0KNJ*DY@;SAQ@;8"N&L*FSQ;@6=1'($
M9CIKZK:U.;PMEDQBH8+(7/YJDH,IQ /]!_M-89,?E^FODB*EN&E'WCOROB%Y
MA[6V8IO;NA,/'7U'<#N"NV4OIU_&_Y+JK'9$MB.RFQ#9J,R-_#/4H$D 2&S?
MP4;IC[."^(?#707Q ZL@_NO?3N:(S4E@.;XO)UD!SBSC=R;*)S3.QT/MOZ*1
MH]3Y+",CX&L%6-Z^6)KEZ'E@;?Y97L$(V")HF5>HKF(IK5%-.YNOQS_CIN3@
MT[=-R\)1$?J4*\]FN>KZTYK=GN6"6"[S*O.+O#S OMG8\ <ZFWD.M U!M&IF
M'X<UVHZ#]O?M.37CY;)B5U'L%1)G$^@@+. 4896KX(5SR:-XE^\#GZ)7:#E!
MR <^I5?UC#L993,H2R38A ML:U 9>3P5@-E_=3-R%,[R*78[;ADR$7M8 @QX
MW4#Q)NXG0I1C1ZX\:[L&>G1A@CK]S&\[)]W@',:LAK-BG$,S7%L L#K80I"A
MU]09A33-:@H&=J&'6P$@MKBU9CPZ$%M4[D"VUC=,P"I*[@8=*SEUL!<$A=LO
M;+4EK$;Z-U""BV#'E$8 =I\J+(?KOW59N9F2PX."L;U;;;X%&ES9CM#NFIO/
M]Z@NM$W.BCEAR7"&-WY]#S#L6.U]GM$&M>#79DAOBW72YODG #=N.D3XL#@E
M)Q\^PL3YI$?48D>/BL:!0S8G1CBTMF9:G2']@&8&B,T>4Y**XVXID#T @- U
MJX/D-R,:H1XHI4J?9&H.8 )0MU JS7E36' [[U:=^;X$V)*2C[-Q-R8-[R;M
M1DM!4O,J=2?MSO6P_8GQ3LU[IQ:+5D'L('OW:/<@^?OXRFFXMUUSYB,P$*M4
M;#(*6Q[T-@\)F)JWVY0;58+=%JM.VB68E2.&(UVPWD7-F@(!61V6C;2$1]"8
MX!:*'U'W57^ (&*X4W^W  GW@1GV<]#"(R 9!QLN^2@JNBH9*8L\ RG0"SX-
M$Q<T1Y8VC@5W/]ZD_^QJT'>&XG;>79".M@@ 2 Y!*:9&3_U/7E%_%RI"V=6@
M["CP;N(+*BZ:[-G /UN'H.H!#1#HBGMR/V&X4^HI(:U"/"G7(]?4"3ZI0Y8^
MJZ\+ G\CX[OL%I,BVU'WCKIOSE]S2V\BL76_$D*4(2+V8F6CW!W0+[:9E=PM
M#[OK&=5XFK]$LVI'O#OBO1EKQE)GQ'RUC;O8T!.8Z!Z/106"D=GRSWDSA:9;
MRZ9 D*NV6P*@#:5?7S"[UG:>[KG6M62? P"]U':)@NV]D4,JHFKK=,;".7SV
M&1>_6YW7#8J6.N$L'<)Q[B8 ;+7RW3W>;+"/DVQ$L4(K/DLNS)[-",&,NSEQ
M9W$GD:Q+2!FXC!SH^3MCZQITR-^AC^*$M@V[HC,\5A(8-5A:-P HUCJ4-HVU
M2ZD"%OD.,6)IEYV?0BSR-?XIMZTM;[G%(6;RV-@<R94'?DP^,A;8;Z[KI ?"
MAP\^?:DQ^PCNEHU/6W1 =*+<R,%Z1W%T=&4XG_+E><Y^+&\HZ:?5$MD@JK$D
M5(PZ(HXYTOX1/3\[?&H[])CK8M%L-[]VD[M=-^#T*=Z=.TUHY/EY/@ YGU-V
M"L*,U%F=ZOOU,9RQ[A_$YRG'R;[J_BY8[R9MQ]5M;4:33W-J(^ T773)&<5T
MT@7]YH>=LCCO>]K/UVIRO'T'LG]_,.EF<0K"E@:P9^[*:-HO#0?+R?6-ZZT!
M;+'J! -===_5I;Z,UNBFJ!#%O>W'] [P*DIGWW @'E\U_#7,]#RAT!^%#BPP
MMUL?^5<;#]TS?@%= "E""1NH*=DSE&&]VYYEY-/+?E+TJ-<*\J*UY5-.\I7H
M%<901H.9_ZM<SC/FQ51;FBK1J#LDR$LL/JYR(\O08JM%) SV<34J-(R%GG.2
MP?U%P(4T>G NRX!L-2.9.?Z1V589(Y>#)]G";!%[&\#N/R_+#)4*U$3F';Q%
M![0>:8#\:!<@?W@!<A<$QCI<8:6N7ZUKU^DHM#67JH4NFZFOKAEI\2EON64%
M5?>B_$+(68YDV!*TRRJ/<<P4$4^Q2_!ZWHO*8I,'A6QNW&)U8-B9GAW$DOI/
M8U-NW5J<6^[@.-2/"X+>^E,SNH30)7W/.3<90%\J2 K=I$[/YIP:AUJ^(RYX
M,AXJCR&AON5M4A"2D3V)O,+UA\FFF%@+T[<&$\9H;*-<FBFUKW:"@UT'&Z-4
M].LI_AK0A*><QQNJYM[+S;>(1\V-0K +!IKGV.O#J,K<^6B=Y$#2)-7'F#)P
M"[.S/CR'EK$"U>'3)+>%C9)3N+?%PE@= *E4ZC9,JYY4QH;NT>U:H,FKNZQQ
MYC/G!$P@9MFV)'R?'WYCLSF\)1H;^0Y7QFI(1/EH<JM0*$QZ';K%TUTO:N=)
M7N#*G=7O(*C77O]KK8RZ<K#!Z-G86[]VW#L$2]K;WM:8\,59P:Z+R\Q,FJ+?
MML<(*&OP,2DVF'KC.G];$'W$E.:4GY53W3'O(<JK2 AP@Y\V.CEK<O2WE(0"
MGM:Z+;J?IC!C-%_=TF6,PA;186/Z)018S0TS:AD\V4U'ZI<^PPJUS0-KQ00S
MP$5P)0/.(O9Z^F;[MX9. $G\X@R >3;E=C >'#M8<)>Y9%Y@D@<(&I" 4Y:%
MPM9;:)#-V24$OW^1PY?M(BN#^>.[X[-%1D(_,<R%?&JJ&9IZW]0<+UIB.M0#
MP481.4#<UAF'CD%GT&3S>58TK5,3 "D[%WCW-:=O+='3?K[%2BGW3J*B>A-1
MEJ)-*'#C:L@MP9E3+EB5UUV+1AT;ZHYF-'H\-\#5/P)Q/#4'EO=;PS$[L_#^
MO+\0*Y-L<JK7IG)62">D3NC(?"@[1;F&]KDK._<T#E\7JF=!)B"N#*1G/QE0
M$E:B73XR3U+=-3,ZF1N*JO(A;1FZ 3AE>24M]<(+'EKE UX9X=BZHXL5PK?B
MY&*?S#5=,H%'Z]@Z+GJ7 HB(Y1?U[%ID9(' TC#I,,)+A4U8\;J&[\..S&:N
MKB;&'&W72_=2\X8"V^3(?-BK5C<8G&!7/)RXRIK<^A4L15W/] 'SY6YSHK9+
M@7IR8[?G?35>[$GQ045T8\.2MN\L"TW>P+]F"PMMXY:SC-(&2HJY8K'A KD]
M-F>U2;/<;F0*)8JKRYPY!3\*",&8@A!1VC80&U:5Q9O-N+6U9B1S8:7%6W3N
M?4^B0Y"-+W98&Y*L<>[@.J^;-?,TLA(L/LQYAM8QW,E6^D4;DQ%[YG1&ZID_
M4S,XJR<#00UNCAASS,4GL%74"-2'MFM1I\(7=U7%X1[%"D'[CVY"T4J,QH4$
M_!&VVCML1X.3L0)H5!:TE4"2"NT!N< :6;.6$"R).5(@-K[!'-T3.#H9/%B2
MLH-Q>0-T9AWZJ?.R3(UB@R*%*+'RHP*^B7<IG@K=L.?<**#KWD49U/)+R.6>
M0<T$Q5N;!*LD( *M8FZPC49K_C6ZBE;7(D]&M$(>=SI@\R@KTY^JT5M!+Z=I
M@=(Z(U5V4I18*#-7O5C;ED+M:H^P%5'&;:_O6L'Z1;A.JODA%'QK5N/O818:
MW.-YKG5$^"_#_E\4-W/!?D580!3.F["]PC'(^$37"93E:P\9,''>CJ'Y@@>O
M)<<H] 8]2'[Q^'MK]J6<<F^$-C>F(WF-0LZ*S;XF)7<RUVZ"1QK*>+H+93RX
M4,9?CHD<?#I#UK7B3Y#W9PLG*\5#+3(4OUPVA6$(4F<'G\RRJP.?Q8)/ ?ZM
MNL3A>]<HD]%"-\^N-3=%@C$@Y2^)X4''7^X?9UO'K;@3Y2,S#[3)^/BM 6V:
MIZ0W>]9ZP&J52TGY'$?EZMBXR0I;7F<%]Y3VO*\$G(=Q)"A$6C!;-EI6A>5,
M7#HX+R"VD+DZ*^LN&)Q&8_XHEF5^#])>4PA*,E#V*>E4UH<I$1L6&-GQ)E]U
M3:5U&_2K66<!MN<T(Z-.MN*6L* H)7O2@I$27OZ3-_7^-7P*4:(BF\NY&WBY
M$:?0&44;V0RTW*G,'80=&4D6'6>X(O=N$J2V\!VQGT"TUTUO&9-%Q9W17_/%
M:IVVUE,(I<EJ9I/^M;LXN+:2>R4B8M9_P<SYL87;D-[4L]6T._ @^0/4) G.
MP,DOB>SWK/\VC;3_3-44U 'V&YG.@VHR[PEVK;NI*Z5^/Y6[!.]QY>+#5AJE
M!2SR51K;'SR &]LUH5^>*502O6;NS2Y/4EUP9;^@T*6X\B+[++UB$PH"8+2-
M_(9QL[,-_ U_GI=AV5#>K$_=*!G8&I>0]+#3P3O$V%S7TCO?"3,14H*DW3AN
MI<K"FZD@&Q(G2B#X*=KK9+!:?\<F.L/2Y<"K[E?W1/P36]UC9^-3FVAF$WRQ
M/!L25MVXX=AFW**-^2A;/J#>NA)]0]XZP@.!/1+S;&;S"/2I,<0:]R<N2.D8
M/+X_7_<\J:"+%9WVAQRCAACNFB4_9=-/W1*9JQ#2/:F:5G: /\I-K['3\RC9
M]9!F2C*WFQV;,9UUD&^DAA%QGD@OT0"J@A!\!XB\6!8Y)-CP!EVJ#?+FPA@=
M5URYW@_#S+.B1/I@"4&"U/P"7@HEG)">0&N71%K(S@4QXKY!1RY.3:!,*%]I
M EX8<W>)[C@B"3%FDMJKP!<UZ2]F#Z@ %T'#\ L%"0%? ,_/FNRRN@<<ALA^
M,[9UYA+/B'&2.D@LA-@Q1K-=(4)DN60:6CT6,I%$S3(7O*MFO/N&G,SN6?TV
MJKT.F0!ED;%OT"H%5L]I4& Y<@<SR6P!I$49A9M2 )C"S3$^P$+_C5SZ;8 *
M<K^@ (AY(@4HBCE?U1U<3O@/",41&A9K3.%R?/R 4 <8,EN,_M-:N ^%3' [
ML[@IBL$.Q&!7IW@7=8JC-#I!,K"="LV5]> /]A1FD$W.HZ:<#(C0L@-B75].
M+0:1U-&N:1/5[7-_5UF^(_H_"S=!6#%6 -P#AL*N$GU'[+<'HX#M\: 66Y.Q
MIS6/X*VW;DN .U!!0DJVME1H1%%VC)W?DM,O(D- 3SIZ_@Q"7*TM?N<GY6I#
MI@9<M<"_/&B1HB-']%)*G]7S2O&[(!QV!74,&LN,$"?$@34"@PZY"(7+X5<X
MX,#T'G/H^=DN]/S@0L^00C,]SYIL:B9>_"<;7X4?=?6,4#.'K:<UM?A?/D2"
MF(^]T&L#%FU=^>G ,7X2GJ* '81I9%O 5*2W%%^+!;Q2FQ :P\554^9U7Y.P
MXEGFUP  V/;]8R.$=XW1 +M\1TN\#A["V&V)Y.A;%)&L56$AB6EQ3CN' B;Y
M-.O:/ PA:>^CD2*&H43B+2Z312I[P+J-7*_^S;H3[D<NJLC4J3H6-K>7U!=F
M>6B+6X]D. ==<HL_/>\:-)(VXU#?2[3DNC3YF)+^O628VR:IZU8*7)??!@*,
M[U;H\ D$&", *ZI,,&?$XF%S#HE-E2T@K;.J6')3=2D(.UU+1L&EG:MT9TAO
MW>X(R0W*G55=,]-;/G.5B^8CB+O31<66]$#)DZXUPJ-M)01X?<UE #X.PH0I
M:R_BA W[-!3@AE(ECB+<(@!J9E= G(#W  M?%YR+-R\@[7Y":0Y%M2)DEYLM
M:G_G[-K=T9O?42P!+_S(>Q9'/H3$0U;B5E<V04>Y>T6K'-<@=T4X\@7D5G>-
M.'FP]H9B?%A+"[!9Z'OB1*"<$"XX]U&Z3'A>J480,N!YU&%OPCLP^+XF\0(Y
M"#,73&2Z1%R,,6C^G*T#&1? \:0-H64?6% A?=CAY#_EC'!R[<5D+567IA;5
MIM\'/B4'($:FOOMFK9?/.T7%92.G^$2?XA+RK:QC+S@]5#]NJJP-%,AM.!9!
M-1GL(S&\$U&,O>W/-U(!>/\>YM\IF<AOB8D+L\D?W//DLFB-CGM&C80\GQ&<
M>M,:E;4K2[.L95U EB(6,@RG8RIT!/?B(59""6V934^ZMG:08^H$OD:BK92$
M0[5YXQ=V$S-#923K6-LH7HJI6P GX6^JGUK$/'T"U'QND^3-.,*VBP65UR(
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MVWNX(70-/YZ^>_5__O[N5T._'SEZFGPX^>7OIQ^OPX#P_44%R=(_?OO-UF%
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M8JE-R=<^R:'B;,E)*'?M&PZ2-Y^G^1+!LJV^# =K!FH1%J',"74D.GA_=>G
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MUT!4X53*WGS\,,Z%@#(>A-M%?P;7+&F4#Z6MZCB Z]#I/%NHIJHZ/.@F#"S
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MR_$&,2$:!@RZZEEE1M(IULU2<F.* X- QTQL? &;V58AVNALB,T67K)WI7;
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M'^E3NGY/GQZ*FYK+F?PB_+2'Q2F9=BX+AO/ZSK.6BUL$\VZ6+X *B)G7&:3
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MM*TQEFD;[7&(D^L_Q)06<N)$*-N$&I[Y51*O>E<F#NO\,L[(_4W"P"L"X>2
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MD> X/*HR9K;8+.X_U4L_XV(.V[L(=[)K^A-"Q:')2[3<N8R4Q8[5]73-QAH
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MI,,PHX])@PR@;.])B?S=NMU]KU#<++^&X5#TVF+C5TE'->9H'@S;/U!VJ]0
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M?>%628Z?PE/!34*59DD*"@?5O$A9<,J0$S\@N($L'[-+_FCGDG]P+OF_S&I
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MD!TZ^*F: C7:^;NKXE5B;$-I7?2"8F,V*O>##!7X(4LXS<0-\9]A82&\:93
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MCZTJO<:48B^_#:,X4"$\1Y^MW[0'Q6A71G>4\CIJ-DG?"P>,TT50/^^JZQD
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M7UNO8[5GY7KQYTUIN_.B,99YWQ@>:1M"];J%15'!-ENR0^B$P;>T11"K..M
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M+5%17CR?IZ$=+*\%DN[8JA:*5"!:/75(RU;^-=(:3_3$<4R;.;/%LM'7 F'
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MM[4$]MC)/R?U'CQR$Q;&55<HK\)G)XJ:VJDGY$9=3L@6E^)NCC[XI,"$L4K
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MWE IF@'FDV:QF0;/[0L:1Q]N,;/1OG\VOEB4YGJ!;KGL_4(?E)9-I'JD)9W
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M>;B\<U#8; 22$QC:T:-N)69+66,UD3%4N>C<C*#!9QXB^HDAO(L?CKRQPS+
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MI>\.$61"BI%4\_0(@4.^WQ&<\IP(SG[%;_3HS- ))F/K^2,PFVN#$>;\_/@
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M!26#V:!G&7.V8IOP67J^]XOSNIEV\Y:SL3Y;A$&E][W!JXF4EKOPQ^(9;8#
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M+[IOB=;DV%:46WL# ]UC$V?9I8O!7"46"W;NP,8=5O0TH; TB!;?]OQ[RQ7
M]U%C-MF$>'Z;282E0>P>!*/2>F?Q( *DJ@.2,699*K<ELE4PI1;>W"J45$+
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M;];)7++H/]7)J4FIX/"9\ B=R8I5#<6KLVWFXGL4>Y]IU#JN.[']Q*#(IUB
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ME.I_T#A:]EAQZLNGEB=A&O3DC/N:FUL3F6\<,\?N_-^V-P.^<#!NDW?[NV2
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MDD66+"KP)R=\&/K6D\OF1TR98Z'HQ'J&=RQW\. $-B7/.MKUZ1M2]TODV?>
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MHY-RR:R7=M #M#"3]F9^A9F4%^J3%,$/U"[S9E:NS-HND1$21:$6&E*:CAR
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ML ??#7$P8M()?-_SZ<1S7./,'EM/>$C"R%^L9^:."A@AB!=Q;."I*L8VGJR
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ME/K%-L/D$M:[##ODQ8[8'T<?=C?8P<@$A23\4>6!CHD7;+Q)IO(Y*YO4X/W
M-\#W9IXOWE70Q2D(MXZ3@=Y@*XR&%)./%MWF0N<Y2?VT!UYF:3*WC3"OA,?\
MY>#B3/>\#RAO,GM(62XY/EDL@$9A2YKI_).8WF56A.GR :S/XBZ>&"%L!O5\
M@H48S\:<ORSRZ5<$QG.J$T;LD4S]Y-7@3@QGF![U#Z7Z4R$^PQ1\F= UB>SA
MJS='7I%5JH#W OT.<"W(<;_/IAQA-&XQ/R01N0KO_X!P-[TU$:UIGB4)?MA"
MH-H?+68C<(%BA>P$#Q>1NNPMY(+>1,Z#"C+(J(,GT&"B"_Z  ?BX-_D_%Q0&
MUGJKC^"!</'Z="C -;M'IP[CT#*8Y5MW!W3HQ&(E/-N.AFELB,8199-)ED]1
MB.:\A!C/82\1#S#^TKB<H-G=KYM-I-)H X,.1$QY(1TIQ(A&EJ8RJ"/O#VNX
M.D *$IS(NH4)+@O[UXM#BC=SBGP7/";R,F5:BI40RCXJ2!08>/G#G: !5ES%
M0HAOSL!X&%'2'-O$F.YL,"U]M?8^Q]%05(*K19:(!",[M.\F.L #]FRI?AVB
MX*>).@FTC;XM8T0\UKG 95[>8)7N@K^F-1>1-!HPE(!(EG@23;7KOB!%=BW&
M6*J4SUFC&>*H]MC)S0)^SHX:4TCV0H;!))GQ]:O7LN9";1,.1(4VR<5]S#"_
M7*"AQ.MJ2R-RXF'<#T0#KO,@@_'<LKFVJX(?2AS2S&+-"\B.7_:\^@)2Y:"6
MPK=M#?)?UI$8OE*ZPW\0T;B(G6(LBK^AW05*])8(!J4!AFNAC-2F?*B\[,$H
M_1.S:9]A#&)XG9UK@*7GOM\Z'N'L&.$FG/#M5"5::N-)'F<4@X8_23RP!JMM
M H<PBJ6U1659>+5E2)F_?V<J\V=A\,%ZP'HGD%_^&QR4472?Y>HQOR%Y,2I=
M&/AA5>VF+0-0L4GTH .8:IS#3/"#N'9#8<+PU3>BSM3EB;IP,0<Q@64**_=%
MB*5SB*^B4X.'M2]3I3@&S&>2SCQ' @JBVB.#ZD*7<N+*VA?YTI\V^59U!5'J
M1JN#PAD@65KV!96#,:IM#<I[7!FK#@?Q7M9]!@9WHXLDK]Z?&P0J4?DGI=</
ML\&,DKC&"H$/&4%L$>>]&(6P60_B'FM2ZRYFFI>%F0.Y*,D$Y74=F2!1(&,@
MNYE&<>I_^9+R(.=M[F4I]&S__'N6.@80?,?W.76+'L13%H;R;O$CO$WZ]EBX
MHW1>VIW4P&N:^6O;\(TE^[22D.7YZAUNRC/XB@BO?"8LI1O)ZZ1KDH\^"-6'
MC*U\91%;GK/":QZQ:.(:N,:1JE8>!L,98X-RJ]:O;LBVLN(5;)+=_I 3_6A#
MA0&BPCUF':7W*$ZVP)R+<WE!4\':R+9AYT9YX31N(\Q_*OG!RMZA<SPR/)DD
M2O0Q1(\GR5:N==@3E##MTI A>@-F_A)W2_,EA3ZCUO=*)RZG#UG0EU?DTHTK
M. L5>?8:<3VWO&M\T+ @&CS>))8OI!O9GC1N)P8Z^ *'0Z'.Z,-=-JX^CK78
M@ZF45)C]0.13#MR9<@0D/IFHT@/[S,C#9&.%.CUUT*U[0=\)&B;4.ZR%"=D/
MJP--Z""V77,-^>&\),L_36"JM4G9.J7 !"QR2K"]6U ,MW+]6H88^41=PS:=
M1^E;0:!I#JS]"5\%/G<_G2LPTK+VW)KB,H@P/5H<EW%4!(.N$(;$1S]FS[00
MZ;2DK[=RV"L9"SO6O30ZQ=+*]B7A7 X[T2YY]U',@8,X]WA&'E\'GBO=)7CJ
M7?5+7AW[\&/?I=G6UPJ#G9O**"WP1<,PRX,LJ<Q1%"=%*<GM59/Z=KX2DRFC
M8202]I FOC/857$W>7\P/A9.MPK[KJ8A=^)=/K_#>#17T!^\# :4>YC&8PO$
M6S8MC LL^2&R!WMW:[:DKC"\+I*C[V /Z<TR_)%5=?.57HLA^0NDCO0YCA<%
M7)#&M?3E,#:N>$XQ,%++&-FT&K^H.N:2W>)*J74Y-TNI$]\KGP;K4L1;E_P2
MHK8@JR*KA$)A[]7!@O<^$F^Y.'$WR<6>#)]).?)RWBB&#T1:4H['7BC+G*@+
M!S9&=KTVI,\/06L+#0E]P/=?0#$OH)@F4,SI0E#,.E =O:40!8?UJ(Z-07'<
M&2X%QO&,?YG9'CU_4,[14A,Z?@'E; "4<[S4'IQL 91C!_:1"JNA)@2^\2/R
MF/U)U2V$_*B'?5A6$Y8ZP]>\@[]?CJH<%*#N6E)G>FI*QO"Y.]M@.CHXL#TU
M751"#UI@VY85:BVL]Q)[H/XY4S,8*KQ2"#!&1BL/#+8V'R0S6-6O\(0]=:)W
M@,DL3BIK-C,D#P1'P\<]^!!S'&@V"2UC+Z(*=[#K,?58R&@K#'UNVD3=S!@:
MH$,!C[A1'7,0-WHO_KYW%P_!OON5_Z..R$GUPZ O'/I9;>=159'!_H>665;V
MVBE:M.X:H D^BU\@!T;T$*%&!<D:@]!@MB@6IX,I=GH8=EX5'-34*ZB:CJ?,
MBTJ8U&S24".O\M,?C;_]-BKBXG(DAT+L_=15DNINK[-WL*X@K/  Y0W[Z?!C
M'-W$B8_>?^.)OJ.##GEGM57'>OWE,H%4%%G"15;B.ZC[0F#1-0A$/#3U7O"-
M-T(EX-)ZS(F"^EM>-YU^I4U@VV MX&.SN/"%NLN>6.06<-G%093%PJ?8H1D(
MC)6,9CFY?#I:@D5)5AU905%DD))=KK$&C;*$2AGIBF+RALPD0YN7DDY)*?54
MCC'DX.;'7(5I3Z^4EM2/WV18\X UXW%.G)Q%*#?NGJDM=7F2&4F<<CYA@.JV
M)F%OGPV.&VG.6,R2<G2'@$>HF0=)%(^9 12F'N,P](AE,HU3>;KJ6Q:JX-K!
M^UJA$K*&S5L*A*!$D;X-)#O&;\8$/>F 50-CC=?>5F*FEVG0!TV=R/#[J<T@
MJJ!MI$?Q!Y]45:E!2R$3ZW>XDPJ%]$$P9XDDD5="F4N,GV-KQ!ND(!/&'I15
M.'<)XJHY1M4OG/,2Z1Q8\%X-; ?KU4A-NR2E^LV$3E!FJM)2DA:'X5%FDEAJ
M+6?/H<@(96B63)N2 25\$@64.3Y7X;JZDNQ1KL5X^%?G5%J,YN^/IWM;#U75
MT4'WU9ON<7AT?!CV#DZK-X6A0_2=,3]%X@,>[ERN$9DLN.C?8Y0A4*,; X2M
M<75K(62K<0L>'?0(1';H@=P@B(Q6V<69-@<-?IXV!DNZJ2=+N:FG]:U;-@/8
M;5+*4BN%WI.$,6(</"9-K,L=M51_(N(<%L=")_^&B=G@XQ03,'5D</)LO@U^
M+V$D[L',2Z<1C)+8_[#EC1@V\OW10ZA"+T=P_F"^&H!^D4ZSLH9<30N^;<<:
M*A?1?O@K\50/OT3Y=&Z16A5OY_9O-JE##U^].0D/S\["L[-J1_<JH^S;@.?-
MV<F2;F60!EW<4:$3_51Q#B9[MJ!NP=XJ[LQ*7WZNMKFSH=OI>>[+T7+[4KK&
M2OOB!E/4,IMN#"F5V.=#2E'JA$MD93YSE?D<N)G/V,Y\VO"(_>#/DJ&[:,RJ
MJGFN/*$A^S!DY>@)J<%+O512%"9$HX!4^J4/V2P9&CB0 954*=!-$"NJR6BQ
MVZ6^:O MS1X2,;Q57VB]W'QM"=).64*;'D0'T<KZU:'5V0_ZA3'^*LMB.3/X
M@+9^E!%MF$,D(*F,(FZ'-:DQ>/C$7AK/>LVFSJ:/ZJH6$K<A/.L=A<=G'C-I
MX6FU0A&X?XOTI.E=O?)Z_\A7%H*&:A:Y_J;:L9 MRIS9M5=^ZV"A2BP3###7
MTSR4CB+*A.KWXOZJW%L$68PWTG%!A=Q4_%=$3,<\2ZE #KX5 T\8SLGGLK6=
M8G37V@2,RQ3K:Q*'A&XQXJ+Y.+P3-],+(L)!"?X $^W3VWU1R\Y?G4,^"G^H
M<>/';?'^F*6WR!2%/[^>3[Q%B6N)<9ZN<V('SVAB9U@>7-./=7FX3:A,".DE
MV*8,8I^-;R!C:4X Y?'BM1(-HMF/Z\S:&PJN_PYZZ"*ES("]/6^C!*VOJSNX
MJ#]F3(Q#*OC)-[1SL)DUZEAKU/G1UZBS5J&7#5PH&44P_YHXL4NX&".:;,B%
M&10Y'-HED"I,6B$/(JOO/HH33]K49_WN!W_HJKN%EG*Y'-0ZH6Y)@*S>4DF0
M7$Q8J*P29SKN@:JI(:^PKK!733K)(H/Y-N^@!6WE.5F<\RJ%^(@<K(W.6O?-
M)_UD3/(8=X#BCF7'N705+F^%/_:XK:_"]:C3W>@J'?PDJ]2KJP->13L]_@"L
M_H*)'3XVT><+UD?8U&Q:U7 ^,*Y/6X66ZBCJ=(>IZ9A$\;!D=7!Q+GGR%AI
MT=E5(0&9J9Z'O1P)5/<A*$6$B$?T=X=F IZY!>V8[JOP^592=5ZG)$35#J:9
MRKM+O5G-\I8TJNNQ\#4E^2LIP<G7QE!&'Z9UM B<M>*5]J;G<&-*/I/\S;8R
MG'4>V[-9-__RU"<LM[5PI6_W]9<,:UJ;8D6V3O^[D<E4M4,]=WY<\SCEC)3I
M51<%U Q!BSJW!GWUJ &N?2'D#U8 RJ*7?+QVS_UT[_])38%5RP14*BUN5V[Z
MR'!HZ>:8"M>$=U71*%5Z>@JP@#<IEF<& ]!VL+$YROP$Q!Z+11@'@1LB<0[$
M[CT :4P9]*#,2L,A'0;,WFR5(!HB*,9I\"CMZ@B.>Z* [*\1KWVZ5!;OK!7@
M]Z7,X&]59O!A[ZRNFF"MV/0E&3 /?O#: IC 4O/]$2@_E^/\[+R0?FX"N-%9
MCO6SLPW:SZJ==/1<4'0U<#=XTZ<H']PY/SYT8'0RY%68B)<;X4+ *=H56$<O
MQWDC4C&*RY7?.D+FJRC$YQ! R6!@K*9NHD;BH/MU]E:\4P$Y&9J43EPYKMG]
MJW-DRBSDWS<2=#Q4;80]*.F<"K#;],#Y%Y*:7HZN[\3&INH/9?16FO31JS<'
M^P>'5=8 $@F""]MP;HX&: HE">RK*:.6AZ1254+T6LRTH1N.UH!K9<#SO7+0
MWA&@V7[9.)H;"H,H9>NU3-$46I%1$\IUWHKF><05.,D\N$& O\2;%O%W.LP%
MC@83^@:=BORW]!%>*1D1-N4;C(70%?/N67TL*-5M,WS%Y_XZ^P0?C<#EM?"2
M5V!0)>118,^<XC-!]U6)N;\>H4;ZUI1T[F#[M_#D^#3L^;C'E)I9D.A7[;%Y
MM8;Q4$HEQB%92I#+P10$6!7.[C?4R"\A6S0GWCD\BYB6OJ8T^$(\!U'B!9&@
MQ7:;R2:[6+GD$#*JP'P4J,"\(@=J"X[EAEL8:EUJ ]<<":6>=OO''KBP!K-J
M-8'R'BL($FN-)?J0<H=05I]457.=?8GF[V5]RM/=&J<@R6?A2?<T/#OSW!S<
M!0=%:IA'#Q8LR;V*48!5 -30V=CWK&3XE-(B[W/_H]Q)#->N*'B=90,[:2)@
M"0U"JEJU+U]"K_"%UZ:_XEI@V8_?N[/FO:,V+-BP*!=C4LKXXAI=9)E=5@4+
M8_T0"\CP.Q>A)QF*U>G8$D/F0D*<)Z6965!-\[MB]8O=DEAG,I(^NDICT8:N
M+>2SX7[61Z);7Y.DSWBIXG$S2X)[:O=';=I+N7^:P&@1-7RP@P%5(L4[WFVH
MQ8S=A-$*Q"URDK7SE%RBDG^4OBA4#"2<8%)[)+M>#2VJ$[()%]63DF6K6__8
M&7SJQJ?4K3S9/BJM4N),([8MX0B1:@XN05U J+-KYK[DM@@J\\[,LZ8ZT(P,
M#70'\JH&+UEAHN;NE)R&5[TOVS7X9 W?5T/XD.7OK $\'37S49>[>WI\M]VG
M1R)>6$@2N):G0C*N*LFME4D7X$'($GVL<9]C):$.;''$J.5,9K,P>$3P:%FL
MB4X,_"K.T>+(IW.2(_#>[T$<4-!0$V!R@UB2D FQ0+;1<DUU&"BB<$TO*>GX
M=21#4@YB J/L_2%Q^8R,$PI*R2KPC)J>&LK)R.1!8$2S@2@!<)I;/U(?C&"G
ML_L(V)I'^-&?_Z0#)[YV(PN.1&.Q]SJ/1*<>I; 8,E4F-*<02%="]$FMR9B/
MW([*\PV%^SK[9>=7;3/#VZAN.!/2NIHQ1%J]W=&7TJPFK1FZ%<^R53H^I4O>
M3;/$&V%9Z;(2'EL?4E\4Z;HDLHI?$EC@O8;US/.*0=1TW![N, @A!C,.>]#U
MS-RP")!*N=&CN:BIN4!$W7O4$:SR($BR#.Y38'VY05N4(GEK0ETM?$TE'%O_
M7JQ[&Z<6][=CU"R@0%'TM5A/@[S,B>%;""VJ">O'UMI8-*6&G;17RT[J/FY2
MT)_ X\_8.*W@9R@X+/=<[GA<6,U1;W"Z I/% T%*74W(D1WW/M RR)2H^-/8
MN@^DYI>"9427U/V,E#*\>(^%DN7%TWN'Q$\=.U; ;+OPR[3YX@R*+%#D-N<M
ME;2-WN/L8Q" (X.KCIS),L;.)BV\&59T2.60\L)2; 18JR0/@2]N;==46KUF
M910HTC0>P2C.Q[MAT[4F+$IO<@=B47O5D?6K/A@J"3#WFD7'IQ<=A(,+5^:L
M!&#/T>4(C<Y2O MJ:[_%Z5!Z-\23F<:BP:9HVP73Q/P3;)'B)BYJH0O*!#7]
MQ@(6-_6O%LX,?D^6$'<%\L.G,#P\\H4*#12*B%KUMR7%.?SW3"*C>2ICBOO)
MF)SVR++9%#P1>5L0NY'4&-/Y?G/^W4GNG=8DDAY5,5Q)<LD$(>4'6\ /\.^(
M;:$R[Z6Y^OROBZ<1G)#JX[]A9!-3D[!\J3?[WK!^Q^NPN/O34F:LYT,V$5W8
M@CC7>53<;9V4ITML"X?A4<\3.Y7M?:R.>E'Z3?=MEKF!ARS_QMV/)KA+Q,@]
MB&494+TU^R=_[)P_]3&+MMYYY C>^N8H[)T=AF?=:C7NMMJO_X!(ES]TO^YV
M#5@\I&MH:!2*+(D=*%2E]=8ZM53#BQ.N<551*=#D9LFT;TJ*NQ64&P.I3(>D
MPN'> S%&T:! &=SZ0S =;@71-Z?--RTQC]&UC'=;#D9 PHQ48"C,B%NJ8-B
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M<^5M#/4XRH*R4-ZM.]\2>-OYI)Q+5(!X)ME#03V)DR)[W(!?:-3;Q!R78V#
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MF6#(5X6W2\QD%1?>GYS0NVS0\P:>^"5+$#A;H._]-LFJ&8G.7P<=P]RGET#
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M1?I81$)HICG?_AP=(Z+Q0E+CR-8&.JID68S^BQV!,/^914F))FJ9J-=%.L"
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M%G(V%:N\$R.1@\X]Y\*;]9)P]7HOG [S!DX'M?C!)?+CHK]!@*=:VH:ZI=P
M->1XDN"%[>\C(VNSUUV1]=S?U[\ZEY;(X<%>YV#OZNQLK\,_B=*A9[NNWI\C
MT]5H%)@VEL';64)]<W5SP*O^6]T6D#DLCOI6?TUXXKTB\H:%5Z*BVQYKV2&P
M(),.%%/5N)#8).!CDSP;"3"QJ)1.-A(TG91&@KN1S4@:IW=@O=[ROKMU3I)O
M)U(53XF"^C++3TSM4R3L5XVK,D*J^=,XX1MB"96D$O1&Y!3298WX4_E"'/47
MV>A&06G5=ZOZ#ZS"$O""H:'ADI_F?K;H0NCZK-8#MD'-U5<2U0.I3WZ@Q'Y
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M(ED;D:SGK[.>%_\G#ET'ABGV^N-2@:X/!.<3P69,W-ME,A_>='9;(35QXV=
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ME&]&9:YL2^&5L[5EOX0!]=5X.&SSI-L ^J\7GM7MPHQW >\<A'"#65100=*
M<E#_6+!L-$1>MR_X&45I4%JI?G&9VLIZHXP$V$+C8-\W5W3C\1OW@\8$F$7F
M8T)Q2$C14@"69C;YB[6&+ FQ/R*?E+^YS+^BVF-AL:ZXPZ-7;]XC,!PGQV4
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MR6>+R+(D>$DI,5. X#LO83(E&A:9VCIEP[8+&^L5 PBWRK6?M^))M(O/JG7
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M37*UTO+4)]0@O>E05G@W[!2%D<?9O;#/J+XR-9N&ND&H7IR0%O67@N\6:':
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M)DS^7>DK97@%?0)\P5B(*5,=)1C?<^O8G-=]XB?MNL=H@E<A9G^X$$_G7+$
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MLQ/>9]ABY^SD.*1+DOFU;)U"WWE34(M+61@#-BL.[A:1=2F^*$HD[:0N]DG
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M<EF23(2L$*=C2,%!Z^VR_'=X+,V%6#4*7-/J'@F=6N/DCWJ]M?A,@(-;5KC
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MH;PX>?U%AP!?=Z9743%9K5555JLZ-FA1&G5KY^':8N:T8;&8EF_O6O-:$#X
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M.WF<'>+)5!SR S^.C+'_G$LQOL!3.*79@AF_XZ4]DI;=*JG&#J"/P!Z_((R
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M?/953>6GU\S\->AAEY,RFF:SU2IL9ON;R%LDLV;+TK%EO6YV6Z\K7E2NY5G
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M/!CH3/3MLOI,W=E*2/5>:P$Q"RA;U"VZ;-'#F!F6;?N3J>6]P--@^2(8@Q7
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M@3)>F!F!B)HEX67B>)X9;%4*$T 9Y/(SG,G0RI!;L=8#K]>C-.H47Y+:Q!(
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MOL0(Q"R0A:+=1,["K4T3G/V3*LF%9R)@/&&"' F\-XXZ!&%U2@=*S6FX!6G
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MS\_2YC@5>4^HSB#EIR1$<^DH^F[RAZ4-AT8X_C!BT_!7X]1YQT<H7/<OF4B
MT_"=0,\)W=_#+;GW+&KRF2KY]$BZ7SX@I0E>HO0)QM9M-L-KG\2ELK%H_I72
MN[#V(%#ZG\IG)_R69;=32M%]ER$I]D0-1^3%6_ RN>+*3;Z'[:91W6!B+6 %
MSG %C(D_9&X27D';4O&N 4,/> 6 .7^-0YH.KS8US\#\=N)>EZNL\_R:PZUX
M']%VA*X,05.Y\F)B_2@-%$EB4DS#]T0!@_3+3"T&7J1@;=9-XF#RQYGL=/%
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M5/4;X6^$I44HA!,RIKXCPA#P4R"(:3BC]#H^)5#<X9P)$#PFI61&PLI-WH'
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MAN;Y(4O2ZGGA0;7&<8!>*GN,F?B+XWU \$9..D59H&@@VVK:+H\+$:/@:?W
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M&1_*1H\J#[^5Z(PTXXDPT^EW8<&;,0(^37E>'JI\.#M\E4N[!W#:_QT:?>M
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M);S+55B_G& W*M5%-) EREI-N%8KX&>-RIK!TU1-A7(G,*M#G%R$E2!%<LZ
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MRUZN)8XLE-K0VA(.20 EYB7#1R92Q<]86\A16"6I5)C_T"Y7EF-CT^.)@%1
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M0YJ'?W<C<MMGKFF//=!5U'2*-*(GG6,^7%2_*\7AFK#K;(W,>@A";P@Z+]<
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MH(7Q*2Q)O"Z.#H\FC18A95"+IRD'E@Z+G?%Q,ETY8$Y5AQ3U4IEP+HG+@^B
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M\IGUACHMB%C*Y )#G38%TWHY46 OM_GE:$M[_23>7)G#YNKVINW3"2JJ(@H
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MZBI\C50_A,<]3VT$AF46#.0&0]>Q!BQRQ6CP%Q_BKW^!]NE;(^908=6(X_]
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M=[FCXFG3[>$&B)&JTY2,U9.GC)PU@/W#LQ[J$;K,"6L%,/A(>@-UMK!:??N
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M*%6^G4R*\= A&8^9C]XMLGRFKLYD,DGS"I@5A\R/F$A.0 P3IPH_A3(H4GN
MD&["PSN4 C*O*=DV!3SX=P?FO$,4M@+TTCZXHE:$OD:2@YDU30: N=[C,<R
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M$Z6DRTW V'W4,\E1U:\P;0[/U)DV?H(2ZDSS"%B.,Q8U4/@]]X+I!$!7$:]
MY8S;C49_UVW;E8-IL['Q,%(3!;F3U.@W[O.0>42,V'#B^FX4APQ+CU6$'FTC
M%\]N]'N[3G.V$9UN]^NO1%<.T:-6A6B6_=_A+OA0J@"G_=^AT<@.)!/D-HA!
M EKD5:B('%0]'<)NU4THU\8CY.SZYO5=(T-5RC5_ %O<!2FJ$H Z@"V6'8ER
M2&$19U2$NKB O(U1$B&GTO1L.@V#[^Z$Q=Q[M-ZT[&:[BV\F/D91W/FPO 6Q
M$R'WF.R=G?CW5,W TKMKJP+XU*H;*]SSM+=88 U$E(8</P"DMEA:8?]85=B?
M4F$[7$ZCUA>5\6O6,W?6:/>6[\L)L)%CP:;FZD]O=F--M;&5 U#ZJ\K:"^-/
M^AL)/YE3)"1)DBZW=6-$GKFC5[EKGXX[[97BL'+Q:ZC<S&Z"3W)*WH"/@A"5
M/.^!/489#1NG(IAR>=;K/YY:BA*W<+F:&MCH .ZK?]ZA8+4H\JA5:_;QY=Q"
M:]U>P5KEU[J+TR(?)ZR26>.0CWX]^@?<B-3-ZR>>=YI3*>LD--Y2E!)@^SD,
M!=]'O_S$<A"T?ED!G_)GKXJ8USHN()/^.!+F="^A6+8(=\I1;OKJ:-T8JF=%
M3(FSVW#(E%K1BOZ0)1WLT2R@ 9#@MSU_>:-96TL >GKU\\A1MHUC18O&>C&J
MVQ<J_L-"T=9C(27<H.B6HR-SK0J>?VB+Y+J=CB$^%PU(1*N:IX_)2,@B<%@$
M_V(BYA2D/.1,ENN/\ "%!#L(DAB$20E.$.^F2>B,&4B_N8XO@9[1N40\-4'&
M)34GZ3\WQKC;7A1C7,0HUXPQWL(0)E;TT,,-31.0G3Z^XCX(^/?%=QXZ;B0^
M? M=QS2[V+]#SAI-X"=4ET/FQ GSZ/-G=U3:H1O']1X'[S7KC5ZJ%E3$3[V%
MN+-NPZ[73XPK>M.!U^W:R6:ZK!]6&&2WUFR+:<D#8)SY^QPDMO\[W 57?A7@
MM/\[-)A@,,&$=&Q:B/\:9*;H!XQR<*,HP2"#T.+2-C"TADF(5F@L@_&8):PO
ML$=3,@_FIZK&ZCD] >,:7)AFP.,'SGWK"R8CB@$:+1R@5:<!KIPX2(=NU.4O
ML*JT=[H3^%2B@XSJLDC'AR2";441ECP9N#[]9EN)[^%WZ7[6B(IHO#PLHK&9
MN CC4JZ:2[EE7,H5=2E?^DXPX=8M^\Y?QZU\L.SCE@CQ!&@R^3F!#+L"]C]9
M;[T@BMY9(A;)FH;!O1LAJ8:/^.N ^WSDQM8H#";OU%LQG1C#V"7CU*Q:Y:2F
MJ9Q4"7>'J9QD*B<93]L64<]43MKMPS.5DXR[<WU1]R,(J!% M"*>SLHY[-XV
M&G:O=Q"]-RL(^[[=;V[&7;HF[$WEI9VD9I] *0= 5H28;<-/;EK9/B,HPSYI
M=4U(P3X[U_9_A\:1;##!U%@Z*&GG<Q!%RA-QJ;D:*B+^5%"? %VNOAE.;W2Y
M=6'?M?O]S=2VVH@N=XB26"5*UQS %G=!%JL$H Y@BR:L;Z/FG31<;VFT'A4W
MH@YAS'^TAB".^T$LFUU93$4A:/$96B0'B^!AC.= 2Y+UX,;C<>!1OKJ(XQ#Q
MA#Z-,80_:"I1I:AFK;K"9GZ%:1NN)]86C*PWK59=K[VT>*%L.O5<'/..@>P>
MTX1OFG:]7K?@('D4!SXLG#UBHP1< 7?OX6F,7+'.N>?%L"-_I:#"0T3%^1 A
M0H-</) )_ZE\^$_?A/]4PXUOPG],^(^)(#'A/^;P3/C/P9B0)3YMIPR:$,6,
MK;AXSO_SCWZST83-]1LG[34MN=5SJA\8>$WTSD[ZLS[Q(?9-JPA)VD(@RGX1
MG;T#H)&$]ICXW,0L/N#^C(;T5!J 1J+92:)R\/'(AJR\M/]K:S.Y)R8RN:+1
MFON_PUV(AJD"G/9_AT:9.A"Y1W1_5:$LBZ,BC&!D!*.J"T9&R:JL#^LC'W&,
MPC-DQ)"12@+0"#E[+.08=Y4A/E4&H!%G=I*L&$>4(2K5!:"1:/:8]!AWE2$^
M50:@\5Q5R9J__SLTGBN#":_HN3+"3?D^J:$T&1NGE!%_=@V 1ORI$DO8_QT:
M\<=@@@G<.4 AJ?*RT8'E,QX\>$T4=(D,IA)ET@Y@B[L@3E4"4 >PQ;*J FHU
M>5Y4/&PSW5WGY#!YD+)>RKH%OIZYHU>1JCX==SJ+FW(NP%>2#6<WP2<Y&5G4
M=P89V7M@CU%V\N.4<>7:W"K\;>%R-2FZT6G9EOKG';*C167C6K5F'U_.+;36
M[16L57ZMUZ>QJ$ -K))9XY"/?CWZ1QPX(%=2#;E@9)W#LU@Q[Y>?V&I(DC]0
M5;:MUG$!0^9;R\H%AF(MH@!=3ARGKY8@R6:P<#=J&)Y1W4G?<3TWUV]:5J4D
MF;9W&EE\-.).[-YSO2AER&*.]2?QA=]K-S68A<4 W/#1&HG N+FG8?AFXT?2
M*=9LNFVY$=;E' 6>%SQ$IHYBY>HH]EJ+ZBCV7EY'L6OJ*,X.,SN8J:-HZBAN
M&_5,*;[JUU$TQV8J*!J+^2:%Z*\\MCRM$0](N\9(7CSG;O3?V3^H5ZSSCHF4
MJCA)NTDU>5+LE3JO]/B*D+<MA/>\1B_B'[=(NPX&I,;Y5Z7HDOW?X3-=?P<$
MH?W?H=$(#T1\N@4Y"5M#)=BAB\6I_)0Y2 Y;BGK;M-N=_GYK@=L :\ONM+>B
M7!LU;R?I%!4:R$5WVI;/8W33*I(UX#X?N3'Y85']<T(^=..J1(%NXY+UFUNQ
MI.PWY6K8C49OKRB7D<.V3]]D?28KY!%GH3,F*C;D]]P+IM3S5%"S R9FS9.M
MW+K])F:MUGZ1,D.DRB12WSBL#7L(6T-W-.(A]YW*9-ELX?:T-Y[GL=?$IK$[
M-7"-1+1]8G,^9OX=JGS6/?,2$?/+,*26 =4Y7**#AA-#=]8BT_;)R>Z0'D-4
M7J%HG/7@QN-QX&$P7(6"H/:N",A>TQ63Y[OG3M#]WZ%Q]1L<, K5LV6?UD[)
M/I=9AB/_/N5^5!4MJG)1R/LB%%4.L$9DVG-FLO\[-"*3P8&R"J(\KZY#KFS
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M9_JK<?K.>F#(E1E*BS7K]U20AD?LK*@ACC0$X=<+IL24J9S'T$7AE(X](51
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M+^U*K/3#M^LKZ\O%]6\7U];-[Q_DZJJP,CC0*BR# (10N;H6F%^!17T\N[T
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M]R=_$A]5@A^3BO$H(\.J4E#!:KH_2$72N[H*8^-WPJQ,T<0I>O8#J7&:3/*
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M!W_R*1DWVM6C8R9+DK%]?$3.H<&W8DGQ+ D32_LIQ7C:81B\KM=2$2;%2?;
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M/[;#NT<0,*GW*/[0B+MB;4DPG*ED@S9_.XBPT+(.2"/.9<(PQ'@0IUG33B#
MT5V[]BB,?";F[ J3UK9FUXSGA\9U')/G^O!X2C(,6?L>36>-4IB@EFO2=,(Q
MBPZY2N>/ S-;<>+]]( 3;Q#(UXT#K:A[R(X;7H".)J+, 6PW,%$Y?SXK<9=P
MO&129%EQ;U)BF&['-!H^713236HZ)%)L&,?^-U!)G^;VWY+0)W]XE"1Y +,(
MFQS6,U%:#]I6!,.([B+0 /AP#:OVO4S("I2]:R^&6KE:,T2=PB*;!/=E"MX4
M:8>*1 PE*2YFG+^+R*5-0CL7_LLG+@.)5<BKO'_8S5?":'N2A69I/:<R)7=
MW9:(C?2P%9FF?XHDK)FY_!*#\=*WK=.G/U([+*DF1^6O:]A6N\FG<3(;B&EL
MNG9=<G4@UYF),Y.VEHI=ZI]F")%M#$3VJZG?X.(S=.-J0-^F"_1=08<NU90=
M6?:UPNK"O"QV@EJI3NN&  A+[]:7^+&(#WA $7<WQ7>U@YRS(YUBX25H.#S
M*,*-+V<HHP)\$NM+4/(%[ Q2?; 24P($FK[5HR(J8_P\!B-[3.D-ITD['91R
M2E#Z=)DU3E)41Q_U[-CX&>U7T_SN;H13;5H^UOT0:5*-R^+>B5:LX_ZC+7^5
MHV.)RR;'^27?<8%31F%YW#:2N]$Q2$'C&FC,]M/-P_E6[8P9O;3:8K4_93([
M-KT5)QGQ-9R$1T='^+^E*N%SIZXG;HPJS\ KX[0:(7?/0*IA:"[,TI(YD00?
M<$NUK2NW7*>-[T0G+H^;<?(M ZAEE"+42W4D_N(0S)YY[[M6C!?#MX;##$V\
M=-34?8%4UC?'SX^".)I7_:>#G7$)I$K9P1CSS%F6Q!NO&19KQP= ,_0G/^%-
MV]OJ%A1MW( R-VZ*DVZEA6G;TP/@NU5,6 [MJX@.V\Z2<I$+Z>\]"Y>RQO@^
M28V83Z.DPNPRT\I6Y)"0Q0U71/%=6HF?TTTBN?_V_1YC99NCB)6+>%3.;3=X
MCEH!)YB=(KOC5 S(%NSN)#<KW3\17<]MHU]XXW=X7@3X2J@<([(DZ_D!71_L
MG3V79;I%IK>V!4QH0[-4*P8$1KC(,%YCPX6!4=P3!"=''XH2<^LM#?/60!<T
M;LEPYKJX23B@B!AIV J5) %7NJMWZ+*N5IG"I*^VIS*6D?YL015=VRHAX[.!
ME8T04VDCJ*%GO/8;8(OG0()IQI3H?:D':.;V8R[,F+<-]S%\>-'1OZZ5-7AD
M-7F4I].BJ;[HR17Q**G&9'4MM<VILY-=ZFSS4F=?SQ;R[""2=<+]M@!57]/P
M>=@6^]J63P=2QA;/ZJ4GJ[_@%JMP!S[^]72P5X_TZ,Z#MV%:990D-$7F04B^
MYM;Y=C/3V3BR61)WN[3>_$LX"=_N#7_DNLK-WHF4%A>+U+9.@9,OYI@)@^9^
M.WQW&$R2F$I)L(@1ZW6C3Z;BSBF ;.DS$P;'1F]JEL%,4K[9+SC4@EW,3<N6
MD6):#JDYA%6G3Y];,SKF>-Q[!/@C<2KX+$T6\<IA\J_);FCA:+4HE]'*;SF9
MM][A?LXP85Z\D>[!'D70H7GX*%&Q617N7_,N>0_SC^]<]P11-PZ)]^N;W\/@
M/<K>JS?7ET;Z&-OAI#QDJF9E,J7PGF[':5,W('JXG/1Y;PG4Q 0);XJ"=>)=
ME#5,*.67U##R<9RDHDZJ9@*>7YKD8_(FY9@%W:V[??Q1V?WCT-TLLH-XR[#K
MBLHD2V[ [9S#(==@E9'>A5)0D885JQ\6+-/)V;<ADPC2^#__XI*O@<E^_?[J
MXO5E<+5(C+X5U\7%Y?7[\ZM?@Y>7KZY^O4)6B0[AV%<6[B[U67O.3EI\>L>'
MQX?!RV1"19D@>-]^.YX+.T&G"BR4-+ )^1 (RK 7""X+ ^<]1 :C!'ZUZ&6>
M#KR+Z_#@NWS6NZU((@(;.L,X3(L. E^K"CLH- J1@%5.5!D&S\:?$,R<K50L
M4L7DF/X+I[,LFAN_$)Z,/ H#E:0BT'XH"\PAII7^(R/\!@%:4K1S8SI]*,8C
M5] 8)1/- SD,W@MN30\+N=1[.=:@!=;A<TAJ:.BJ;(O[A*)4_ U>-:8SBL*!
M])FCFJ>V5ICJP8H,]:9$Y'0&[V\3 3'QY!"8Y3Z';V_3&5YZ5W!>/!DW9<IZ
M=#3G%X]X"+0 ]ZE6FEG GO_F,(WZ\GA9ZTMXAGY+(FYD>ER498)& LL]PB"V
M1ZZQR!?/M L\H,['=9^$RQD%4PL+]=:B+ZF2HGN+8.]M,SH,7A\&Q\?'A$HX
M_O'X[/D^)\G%+I?\X#^2*(/-0S^EWKUQ,^;3&YN'H.V=\C_QOK#6)T?'1[WW
M?W*R;Q>W'+#:W%2F:ZQB .BF0"%"=J]M63Q3A>@A/?I55+<@M!<E0F7,*=5N
M:-XIQ\U%MHQWZ;9,4M=]&Y3P@:);'[+MUEZUOFG#-/W,71?%Z7__<"13&%R"
M/UG,N6RT/>Y5LO5.S;E@K^TWL<P;&MC8GICQ,26!S33#L01(*"#+.. $QBBQ
MGZP-R&;K=VNDKTX/+N!X:&9*EM K?NW]Z3C "?O+KT!#@24;R,U "Q,0%W$A
MXSKTW<_?_BOX">NL0>A1:Z+*; 5(6B#[D5Q=R+_'_H@#.MTX#HF</<R#(S\*
M ^=J NJ"\3('/4I6".6HN-"Z<FJMMV7Y#-Q8P1H7477;OX"68D6O]18QHFIN
MO&328#@$99K+Z\3M]WG6][08.^9VX#9/:)2^O>,LFG-<BC#21>G5)8\2_MC?
M:-N< CK=I8"^10JHO=_62PD93;Z@,!T,MNX&I+]_('(\F+Y9UE0&'3Q:L)^\
MR@##U^41H;C&'W@7'ET!12;O,8=@&!U<$A#$#3)I B*7B1(,ME=:ATK&DN*3
M<ZPZF-A;HC9D+5L5<%?V:RSKPK)WGZ9Y4RG8VZCNW_)9E I9QN6G69*#9[8E
MZO0GH70;-,#B!(Z_8J8(W!R'=$.<0W*ZP#P7,3D.8!$E#1R %(Q/IQJ_1X*I
M.Y[H&?LK%1L5%79!9A<C2R?) 3B3"<@'15IC< PC"CS;T'L.]\OL$RF46S;8
M08 8':;3)B\.P#\!Q7"#WN_LMKZ-LJG\DY(*L.GHNI1J($CEHS9'5A#ZOF78
ML*XV%^VKA^0BOS"/81B#T%%>1NRU99(1O(SFO=(1(8(R--5,B+P)WF'_7_@X
M(-L[YPMR";=2 J@<(XO9*,H_4LT"#NM_BO)C:/ZBJ&P!F\B<KS="<>48H#BK
MRD:X)?-Y<7Y]^6[0F_<,$S HBSRZ2\'\",Y3\/ZNDRQ-))UX">)83+'=,L=6
MYKY[O]1E.3Y^>G!\^G3?Y0;ENE%0;H(%NTLL'O>F29ER;-:,LK3"LA(_MB9%
M)I0RFTLI*<HY<M U]2TCN)P,VM7UN^#7@@WEI:,].3HY.C@Y<0>[VF^>/MD/
M]5=>"2N1HVF1&;\ID2.X'TV3:0'"%C?3;NK/? -2^)(@5_C=VVB.\2A*VKR!
M>;J12 >(^&M"Y8E*>)-S3&/I2UR\^>?5RX/C%_H.+],JJLB_98[D\^8&C%-I
M[T(,HD?[DJ40HJ X+G'[XE,)X_U'D^1RX*W]]#V_P-;."<XKL:^5=- 3B*ZB
M-X?'D)=4,0-=&63%&$0"_E@)1(Z_U:?CDC&WG/M8]8"<*F1:2DKZ<JY<%H$@
MY\/"N>]G"_'"1)N-<A9?$84A%;YF6CV+,<8QYYO*A-_;'4VMR3N-/YO9,6Z)
MZH2N[X&!G2)+9;$Q&3XK4WD?<B^1,S8,_G%X?1@<GYYNBQ)DSBZQO3$&_I8=
MI<5*D0A2FC%(+[KEYAX2!<;91SN>.6_1J$!]%7KGQ:A P\TH-5.VSD_'_ZJA
M:A,%#$Z%3=1DM'\INMX;&K%DM'9MUZGJ% 75#8R!5#:2HB<+&ULXD#)&6$W1
MC.J0"M[\C;%T?U7% 6S%+%%4)-TJ P,,?!.RRL5YW:?LA;<Q5O)K7:N^?]+@
M4Z; ))R/SEMH#J-)0IE7L:7MNIG'<W(+[JS'$/]Z;DRS:]$.C*%R*[[V9(>A
M*B,I,@E[%*0;<#@RJ1C6+ =9]T5II$1AOU1$A&MG:M@TSC#XUB;KX09P5I6&
MA6G_3=KE1=R;E0M,Z Q!#F4.2O@:MFO>"'8"IOSXQ?.G;DYB:]Z8I<XEW=7*
MPN6JS3-L03EQ<1GA9T1&7%W"J41!,!AEM8>[=2@12*S@I;.12 +5K:XL"YGC
MW/#>-Y12"+*G6BJBVT0J8BS>Q ]9W1'].#W LH2WD?"][E)[.VH.2+>E&0!3
M7.W;Y"/H44.*;DY+.8W'2N:OZ'X-(5 Z%K43*U$)(;AY2C*AD(Q@PF:AF; >
M=8CQ#&SCK/=Q3O_4TD::(YVG0<W126<R#M$P1E5AR ?]3!C_DI@C'"X3D Y0
M$EHR;"8L+_)>6NDA!)V<,4N!<7P=_<FU%Q93!<?EHIW@<M6Y$S*-YE)WJ9^\
MF1GSF5++)4P&CG:,%2V)Z_UUN,_:-Z8Z0E-5Z);)$Q]:EWD3[O>WHO2B2'$R
MJNT56Z:3C"./2I<R&HBTPC5).FTP1#MU,Y-F88@AN?=.G3JXU^#BY=70Y5LV
MBXM;< V<=;T]JQ;=J:4Q_88XOT2@PP1XR$TC3K9M$IT:IP'!HPLJ+A8#KY(
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M*L_$YC/(PP$SKP^>2N34WJ'1*P#8N]3;\[=@P8%=E-/^A1T:PX:=9$41(\L
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M%]9U1W.OU-?+I+$,Q05-+3SI-AVE-=L5+/>9)"(GB.$RT%#1M8;R6\SS;4[
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M.WPR+8'YL,DM*2HEQIQPO5,2P+D )(SHZ13:!H=Q<J)5#Q,IH^R6>9$5)4K
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MBC +Q?AC2\.G5=7(I,,3JQK^P"5=6PS!(\-X8"*.8I$GSO.+Z;3(^?$AOD(
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M=5FTJ!D[*6HV_,@19HAO1H.$69-_A?S@DD>"R(<L6WUA^;BJF@R^D=!/Y>H
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M\U^5F'3]&]YW!]-9AXUTUJM]*;R@(^O25B)YO8>&# "N?X:$XF_B..W &99
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M5GBQWTZ"N7WIW=E:A1=_3ZV"![%W5ASC6,%^9,-?'G:9W0C(L74)0^8T/ /
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MEF.<N5ZSU#\<X:TNL\6R*OQ<K5/']",N]HB=YM:_1!;*AKKO!&\0WI0']I6
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M7AA?GK-)OM]>NQ(X O/ U+N/&L9C6Y"(,MO-ZJ=O7.+;W)X:\@[%%DBTX[^
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M,B'%[?/R'@"*H(3D:8@H05@(21+C0MKP#J@16PBU^^ =2L&84.Y<=>,#S<C
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M8BV%'KZE5NH.:':@_5KBF;@>1M*X(8FD_5N*8B316$B\!L-_&74J @AD)I/
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M@[C^KV-&L,?J,V$Q Z.APIC'!*(-=AMXY.7&_H<IS*0?1%B59!-?M.-U!#X
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M-AMC 8Z9XL8(I.W^6>H>O'N!U6BOVI"/C NHI*1%E??2<MH()2508,/@.NV
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MN2G;;"<K4V$>R?9SQ!<87IY<[0:#P'R A+?BP+!_HD%$A%RW1/8ZA([%/9#
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MW?INN_FX)A5.*M<NG8Y;.GBG*U:OLN!,::41)HK)"$>4ZS:R=H!#]#:ANO.
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MN;/R!>U+NS%68S4V:L8J'W2KRA&[2[/4=7%!5P7D&./V;B<:/847\BTXOR[
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M*+1(>]WH4P2'9,?[Z]P88O. <<$=($UU</8 V<) [+/=/; AD Y.+N]%2IY
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M='ATV2N-^35F'^]E$$%H@N H0WZBL>3<2)S$8%!IT(SG7OJLT!-O?W?VM3@
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M9N(MMC1PI0CO"O$@YUMX!'@9LM($##;_GL/>DF5H)=:02AW,%^65_E7F*_B
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M'&A:UWX^<B\ /6P\%2I1FJ/1+C;$58Z9Z5**F_=6J2K<589U!?L-K4=+&+
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M&@]@Q:38V<5/5JR*?E*.TNCV)]K89[B1E=$N=N? 2:^#.!HS9'X+JV9GT8=
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M7^W^=O!)/ OJ3",))$'8?C[ICDVECRH:*GZ3X"QJ!PJLE&Q$.=9N-<'4O[\
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M@Q'L^L3RY *E?LYIA6%4]B:X=F$PB(<8KF;%$T_0J<"4<&G+*]"1F6#SUD#
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M[$DFD@C(<CW36%@:?Q^1]9U3^4F:$!$!<BR,N=CV6RQU.8X2:=4&"UR&V0)
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MFO;\\']\'/)&25 !TY:V<S)=%%B[O=15L+)KU58-]4(-]5X&"[L-!IMB=^0
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MQSTJK^MRWQ]++SXA4^D.WN/'X7$Z)>G(=9&?&E8=.T1NN#;/_V"!"8E^%4)
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MDP5&[=Y*_*CR33=!0T:$^886=EGZ=25*9D%5JWF*]"^\#<V"U1>FV^)A2CS
M=^W565WB !I&( #QM32"@,+'8V68]SQ@76J-(M6#^E+01RW3_#=$C'4PYN!B
MH2^6X(>MW&@O)C2B2 #6Y+1@J 4EK9\>T(QN'#<4I]UCHWIPFV[=$"R<ZJ7M
MPZ=M59$"C?TM@QNC#!..V&X3[Q8/U-6Q&"W+"TN39,H,L[HIWV[I2@CCYU;Y
M"T;!1\O-<8&$D9&@E36$>&JR/>A/"CO$^#K))R6X34C1-[X2X]Q%V:Z:&F/W
MA6I$3-50ML)%<T#P#UO,8F)$6*@'9ZE''-FXSD*FVS+;AVZ>)20"+:BE;3>H
M<*]H\*\;@JC+JK!NG'*S%<1%>>UJ.;1QQ)J")@.=]@/]< [$.60NA?'2;)@Q
MK.A> U(^0_6JB&M26#]-V<K7+3OI.@L+MUILW;#M=AVE$SK9[/<F)=/>L H
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M@TF2"!12ADTHF5KL](O7]:X4UQAS7'QZJ:OIFEPBU\@*O5Y:-"/)!F>+K1*
M,!;7%5A"IGM(6R<KUH_ <1N/I-I34,%=UK!P*^UF:<<!"R]-#LW\4!6V0*LF
M;>&(@YF%W].5,:Z/[0\=(,]Y*I4BTF\L3^2]N[G"6L&87!GKN7S)Z"?B2RWI
M$2%9C A8 6,814E?F]!MK,P+68YK3I@M+%6^%"((8!0PXR:PF]9<+'<X(+C;
MX#J)VL]NRSPM\"$\@HTPM#[Y=7'-C7>?2;9,TC,'%C\35D\7[9_U7PF(N^7V
MR,;>1 8I1KO,A3E$/ [98?<.Z$$W/ /3[K%I ]*R:2FADWN(;L# P)Y[QYDJ
M*NT0&^(D\"LT^M :S#C"1F.*G*-))[WI+O"B&1-#9T&G'_$<2+#1N:R?*GP=
MAA1<)X7LD>^<&'2V("?<")X3;VXW!O61.2P.-AC))]@!I])--&YL-^;HI"NR
MI$P-9.U@@KB('.8W2!09UDMU*BM7YK2L3I HK^#S&NG:I38&/0U88T=8R09#
MS$?U9=  %RL EKD_B2N'!GRRON/&K3HO]'A:]^V\6O>_)WDQ&9I/([M;ZF=^
M?%(W>V+Q5C5J8W0^)HR04\\:&\$XC6MT'W%=J&B<#LQAYL9AMIR,(A7KR9=J
MA+G+A#B=-J(V!E,S_PKM!>NU'H?M[R$^X+Q[&2"3=O 0#:OIJ'PR-JZY!;?D
M$N^:!2*9"E#I\(<)!1'_00?&R***%%$)8H*E4;=4Q';];CB/PC ]XF'3QJIP
ME^/54F7,:\5M,'.LC*R&J9C5;@)$H\<&UBRO4FE:ZM=ZGJ0M,F;R;IPBH#VL
MBU)'16F.P"R]3=V%M%K8))YD$UX>&8@=XP3^F+HAL:8Z6LX9]8OHAJF>XPP+
MJ&MAB33&L@!K_>J0FBO"VV6"XW++P=.2$7+SG:LS713P&72NEP63H<!-I;^E
MD>6;[R367U @\CKV#HQ[1N1\U,S2A2ZO>[K:\%]1%M:NHF =I;=J/"I6E/*Y
MN#3$4<^TZ_NMLW/N4WB'M>]7DJY.M)CRXJ-T4D2I<]]P6F7E\JW+XC8>E9W@
M*ZF]",QJS&N-Y:S0] SN%OTC=E$.$QO9GDN!\K95E>ABNS&WX/<PPVIC#Q]B
M1VIZJUW-N#LU1MKLR&D=\WII89NUX9%^X&MA3OQB!LMB:SV7 -DRY[_FCK<>
MN&U'[,S>JQ5<GB8A,V-4?QR;^]V\-G?'R4^A.+(>=\<@X]1B8)UVF\D"Q@IR
M BX^AWC"FCU5-Z<6LJ94<$\UH1[\()(DSAS7F/A[=(84^1?=3R&.HAK $"\Q
MBX4TQT3W9![V6>8%TPM^U-^,B$&/DX/]FNI14\YYA>9P4;B!?]H9-[\_K*6C
M<5^-M><Y[_R.(0%8V@XGWT0EA5 D<._<0J?#0=/0!EZ 4ZF.<B+I= B/W$--
M&4\7S(VRU-]CF_ILF*%;"M6\"950;%,0U18_S*@P>>HYEW>;G,LFY]*BB?9V
MYU5% J!P1IEH\Z5/]1HE+7]D?Q%_.;4D42/T_X^]MVV.VUC21+_OK^B8O7.#
MN@%S1$FVCZV])X*FJ',X*XM>B;;GQ,;&#70WFH3=!'B ;E*<7W\K7RNK4$"C
M*4IJ#3DO89'L+A3J)2LK\\GG,2=6?!E15W@XK8.T48)7*J7H'L5'Y+A!MU:O
M17BA[(^LA[%WM$X(4K><I6&%PK-N]<H@C&T@NN'<422N242[X=LC.<<BB+ZG
M*JXAX.IKQ^\66X)[_;E 9\XI1>Y1QG25PR/Y'"B::<!B\*G%;4-4F%MLE0H.
MSEUS^ :0#T2B,HY!QAE&9ZZG35,4J*'7DC,#'-J29$-6, *0^PI[;$NYO*D2
M=5E7YT254]8?7^G[]9B&@[&FX=]AGB:GR/J \&&8(?WRR2!SOUN;L/H#'G3>
MI7H^"SX8=S+LL)M:P8^\W[UC*S0J>"4E:F>.X@5$TW]@G]T)XU8F7,SH'UQ:
M?PE+7G[%KBSLP*98W8:B11E[-XDN^6W7@MB)IW=!^F](?@)#!M],);B&'Z7A
MRNS"])!$YQ]QBC()<Q4>2'0]P9<B-?)BSF@H]X$K=<)+=XUNUH)^HR)OWG;<
MH4N\J>%.X1X&O;\A#A5(6(+43SWQB)X52C_ED'.)K^!> L<:)X]F),6 'R=[
MN5"R+,BX ^H58T$9I=D@>EEBYFNY?#G9F_J/>R_4?">*=^F5I-4NF=8 $CW;
MT"#$>O6:XSH$Z$+7S=89RI7P*<&J*V?K92YU+!FYH@N.3X!WCM^G)*Q1=?$,
M3(:/781]X6M@D6]EXM60'CE7&-_QZ +,;$,%]6[:H* E.K[PBW\[>I.%!]FS
M@^_=8*J7;Y8)E?C9>CZM5*AO6/1)<W"X@V:X9)$#O@1;6P!SF=+(1/&G!H?P
M&QK !/Y9:$AF0QS-!P?^-.AM'!8M]^$!F?1G8TWZFY+X_M];E\16T,0U*@A_
M:.C&>^ENJ%DO_6J!?DUO@"(G]&8!@B#<B=@?3.-?\M+>$(GFBER.Y=5%/G5_
MF&' 8PY;$):K6+1883!(K3.*I2,-V!3GKG<L\Z/'4ZH-%F/'E]%U65_YBIWB
M0VZKA2),0;<ZSCDC;A6IQ==W5G.)S((DEN[<M5OPN=S[(3^1P414A3NTFC\S
M;Q"2Y/V6L!^U:*@U!:?C>Y7&K*AQ"._HVDTPK&*I637+38H;@,9$)@",U&9=
M_#T&4T(<?0H1DZ1 MJZ]UGF1! W$B^$C^#+Y=5XNZ1J*!,FI,4O&6* 5'798
MLL45*;Q56*CMR7#L^,(Y9AY(!GU#_22E"M,K:G@U69TR!?78P%,;WZL>D'5\
M/CHL2T?W[ZQ-\[./$^'7W:6$#W<?!8>@74*IN]6K[6KBM:-]5+8W^<V)X'0Y
MG\WNH";W%OT!'!Y[EI!F8=^P!TNU:^73!R_V)Z?->5Z5_[FC3'*^=OIPM>DH
MQ/S2B,IEID_/_8<#RD-_D8:[2DM "]9A!-H')/'35H+?VH]'(0#XW)LBGSMC
M.R^N"APN[52"13YX0/\7S0/SW@3##"([551$;3RZ44Y#(F$90NZX2FB&<2?I
MRG[H_?!;57@?<=_&U,J403NNXX=NF\!U=F4<)@L0I4 ,[T,S&<&SV[AT<6?K
M8S=66:=J+U,1,CR1J1(=RSGP!N.K.>1J ,"P-=WH^H!HC*>5\FYWHS6*1:#[
M53OO(E]YH:P*-%W!:5.!+=./N*QD8%>:A,]8=D.*SR'5,<71B.)02:U-3[*@
M&PR3%K;!O)+%!<V3D@:!'S6C_,=Z?BY%;I27Y2YF5!\S8HS\!8UH&LQD! Z?
MJIZFU=P E3=UOLP%82XP #C/?4#".GL=^1$_*^;U,0WE7-553E%H#FQTT1T4
M<5D4DI:L6\629Z:/B,*F>[QS0H6>-H"9)GPVD>1,T'[3H\LFQC=,2.Y*P US
MI2RDBDC1EM0(D]3DRNJBY?159ZN>/7W,5NT>]]H57)96&4)HFW*FF\*]27,;
M741-IA=O&&$V5VI=0QV@:*_Y_/ERZ?I,1X)$PX2EBFKRIK=^9V("(C#0BFAR
M?H9L>BC%-HFFJQJJ\:%[4WP:5=<K,) 1E<JU0.D%JB*@+Y!'H&4T]E8UZK%4
M4D30/"*LU\Q_8%*P^B!%@."#73UP@OW)KQ1)YG.!@@ZHQ:KWX*&";IFZ]"&6
M]1^] ;MKI/PG$<'X^L+G_0*F=5D"?!L]'S7O0T[/LQ?W8)=BMR9IJ-Z=G1R]
M.9Z<_/:)551']>;5R;OCH[/3=^\?SE7]V]&U@A2X@Y5_5A#++%$Y!=%,<P2G
MA+*&O%8R;SVT.D/HP'VSPVR&,]A!G )JZTCY:5/3)PL-&V)]#KFA,? 6GNAQ
M/X:QP8<B+*KH5B!BAHB^K<E>NX,6S3Y<E;R'V,=MTS%N',Z@4R)?::R3O56W
MV"I5/M60Z_T17GX]"_^[L0O_%TBEAC%[=:/QAK%8.',^O+9)BQN77-V8"O\1
ME$(6L\&KYCX@M0]HID>70Q\)D-8,O\8BS356;Y@ZZ;;(!?7"&Y9P_@5I%QJL
M=060#,25ETA&,9^73 KJC0DM#,_S,RN;V?H2PAXS2;LF(/\DEPU[&?L&2 V!
M!,\+*/G,V<08);>3+/CI!%=R\)N33%/JU\7R=K\O$%$&6!7 @;;P3(L8Z/&&
M\J6S=7.,-Q$'4*AF6(2,>KBWX/=>VH0T6EI.<Y? T<)@3J+G&18UBUA_W T7
M!#CB9PSL2^P:'X7\ OQI.Y"=&1/UM6C AXHY"#X#-:#Z0(/(T;=NJ;YO]&MS
M"B7UWF/?;O3KW<?[K2[*YC._WOCW^]@7I&SG>L9%N!M><[#V9_AIO,O@.9%%
MD1,,"PN\:F!K! ,I!!9T[?.?)!]'=W3P/0-'5!F&!A!HF0NNW3-!:!RJMJ6(
M.H:9U&GSZG&4$NA\MX";%^0*BQQD@QJVQES1 @#!ZWR)V+MY04J:F@-/.,\:
MSY)W[B7?;"^ M;H*%CE*DE4S:!>NJ_R-!^0&C*[/_DV(7_7LYUM_PN_BZ1KR
MM#(..MZ#^Y!%Q+0<X4FL [?4UDMB, "X9G<!@@%I ^W#3!:DAQ?BC8>]7!**
MA<I9%H$-R6^C!_)JV[BF<;T& +W$RQB, >)JE5$W1$F9<6D&^VJNG,NE.,_6
MMOH_(8Z W>E4O5FW'L>02%X0*0X=+QFB*" V#F6^W8+>X;PDI>C<BT/XYY+#
M\?(H24ZO4GGH;'OR,%[U&8TO,&7 ;U,KM5N#)G7MOD1N9>IT;&:*_. T_Z;G
MI A,^::-YE< #LC $AA1VK?K2S/)?.V'T!0";WI3F:%XP6Y8=HA\IZ<,KD#B
M*-%O2<=Z"92+&7E 6(\&?^/DGFM-7#4)@E.G#+%NY/3X 3%TD_#KKSNU<_"8
MVMF]U [M\5N4NY/-#2?I;+;&$QQV"'F(N!]E82H[BW<T33([C"=:A]/MJHD\
MLNSU Q)LF,1P+S$HYZQBZ"]5(*U>@[H%@0=+1\ #]"1'5QV_\\,5%!6K48*
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M@ ZQK(+> *$(+VN(Q"^-T5,BO)K)JYJ 816:=DOXZL*Y*M9/R-UJ=V?J-Y<
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MA+"TEG7T,7K=K&GX ;CJ!JL(HV/H]>#H<]&&M:PE,9L*V-[YN'"P@MB:8(W
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M39A<Q3=2W?FRGMWF<_BK/B(7=PU,=?(9B<!4-^=!(_1G45PA'(? QU@^_2<
MI?&:X$XU.H)FLWKM*]QC<H@)P'^1 )-/2V!CX3BY/5E)B ,XO[4N$YI;:-\&
M1,I+3EDHR4L.'P/^P+SMU(*/6"'[0X/3N8HYEV"8(3NJJI^MW0D]OY5C>;$&
MA#GAT69K0,0G\Q^#??JOM?D&PF'=-^\/AVDV[2/"8;Z-L>&P[H:+G 5CV8,G
M>/H8CJPG\H(^WD%W]B73,P2?-G\;>R+T#>Z8\Z%WF^AIX0>Q)]WI/VKZ'G[6
M_.&_U%K?M8/F?/N#QB?&H^J\T2&U[L+K"ZDE]B-^#IOQ9T4](J3V<(\W+KC]
M,L?8%E'#>+(?M_Q7A3UZ?C"Z4(@PS@S .!2RH3%,5-UJ4 %,4PZ?)K!NS(%G
MD]K,"-)!7S)CF3-@$'919A $D0OWQX1"(P]H0I_=0374AY@MG*%?-93+6>\H
M$]JS1>/<IO^=T><\%.2PY9WP-(4JO(FX-B8O5[/+L";B$$7Q&?> FXN:+8W7
MX,":7D,PNT0&:Z* :8T2X8HX^Q#B3%4(Q ($#TMU,!3*U&ISWWRB'-0_38X8
M(8-'KV\&5;%YC*ON/IPBU!YBAA7(H/A9KGR/:'R30RMLJ%=-\<=Z;NJH2>/1
M.,;=LY&HNBEFZ3Q$P$!K@0P]C #[[(H_F*TZFGE7E#_[=JE!$:&M]1@IV;6J
M#8 #;U2\T+'*[LK%K&*U5F)7"!#@9R764+4 (;[=KJTPX.W;'Q /F\J1@6G5
MLC8 3:0#\!M?92>%UP6!CXH*(]FK0?=M:-$^>_&Y4=PGNP#C/OZ/XZ-?STY.
MWTY.7T^.3M_]<OKN\.QX<O+V_=F[7W\^?GOV?G+X]M7DM].SD[=_@\^\=Y]_
M=W)V<OQ^<OK[V^-7DY_^,3G[^[%^%YIZ,*9A-)4O+WWRRHY4'>,$&6,O.^GC
M/D) M_E*=^.!4CAWU!( 0>@\*$]6.'M!81OO.&,F"_]=-[?6-9.=YEEDNX=O
M1BKQT'TDFYH6[JQ9B%WXNM,UWSVF:W8O71-&&&Z-EDRINP5O(?4,_YVQ"XH>
M<&>!!M2NYF?G8^67WE_RJLO2' Z<>R01\*([U XV;[E/FJ*'*01Y3;L,^ER@
M4'@KT?".!="T>G?3DNY.>#!V@MJ?V^H"]'MV4<S^Y'*))E^ ;6KR&YJ'O/JS
M]89E7ES5;<FU&L!"AT$.@6"Y8[M,!H8HQRU\,1Q!&BXF8.W!:5"\:*\3F]+5
MGBBXK:E4\/,/KL3]/.4+%.#G*[IC# :H6 ,6'45W]Y[=&L%NPR1>U?[?>$>'
M[PJO>,CD?)NB+X8H7\D%/78>U WD.P2T6ITK>3-NKJME,3\O\"R3J6](+!+O
M("5L2#1W HU70J!&?Y5?PE)X0/>0;\<Z&R10Q=@>B1^>WA@ZM",;1325'*U2
ML[)/'L0?I<A'O^M^BZW6)-HGK=O5@""555LL%YE,'CL:( U+V2)<+LQW;X3_
MX&8S)^M(.-KZ WPAE*-B70X?6R!/99Y%T02SD613CQ<M2)='4VD7M\M'P&AB
M@2T+\&C)AXB]';O-[,1UYOW?#]_!S<3=4\Y.C_[GPS$.HYFD7DOF([R2>,F?
M\";B-E:3+B(T8O">I\.M_YEI*O,B@U.(,IB_S5E#Q'I'_=3>O?MH/^BZLIKY
M;I-)2[EK$@JS,C::'!J96\F1IX2IT>%\&Z701C;MZFKI_@RG'-94'B,O!H$-
M?<?[!W=D#\N.IYC6BZ&CWC[ .%*^+!.]YL1JN"_#U\D")4T?#F 06THDS7W.
MR[612I7SLP(86 *.E?&@W IIGZ^QE64F9^M%>3GI#CB7'S:$Y5R8^_BZ(6<8
MOV!&7JK^1!H;"@HK4J8R*9>,XO:+0I,L1-+D7J#)&V07ACPQ3R,BQ,&'TE;-
M%4/SR<PWA3>,:#5XCW &5,HB[$4YOE$]8LI)HOLS39>PB]HUG-KE2EZ>?N,W
M5)MK5![KHQ= &7Q3-%OU@&.6PI:-SWA +N3W8T^)-T >DSP4#B>5>Q$[>Y#W
MMS;8VU.:P;(*Z96'OLO^'"X3_GK"J01^SG-CMG#E+EV7,[":RX(N\7,0MG.7
MF7GF+\R7^9_*IXIA]'E^+1=/MS86<&$)'<?9,G>;1>@Z0Z-.)IJV0?_C";5D
M^V\49! \#73;%5$$H'!489/O, R:.=HT^&1=P1YY@MW^G@VWQ.81&P."NH/O
M7P)CWCE2GO&IA#D(#!'FYPW)%8D2;'?:Y'P53(<A.1 ]';H&(G*_,^D3L-KN
MXCFMJWD"R('706[40GY;Z1&(:9WG$$2B90@32]/.%H<$BODC\>-C%=QX.6RY
M)G>.L^ O;IFRY=S!:G+/3Z"=I$P05I&8D[C?X?-V"><9@2YH%R *01@EWOE2
M\+$2X7JP8!I%(N+CNJF*6V(B\%=+3[^/S\[;8HPC9\R36^$< L'-3A@H(#NH
MYLYU&MZP%!B9+,L_NQ[*[DVHIP>(C:/Q,RCJ% 9C+?H2PT!@=R[5]0XY4(+Z
M'<&K&-X59P/:=L.RP; 42:12OE/\BW&K;NBI-S9.&?25HR)L*4GV7?E8C!+7
MU\Y$]OUC!N9S9& ^Y<'QP[Z[?'T #^D=6>-7Z"_NG,7Q1\A)Q0A-//SC#4OZ
M+C:I&NQ,>V?VF@[DMR 6HRO1$EHACEZ3#OIE(>+"<,[TQ/1)!>>#,^Y\WLWQ
MU" HD_F5P1"Q%^DO.XRE$ I6$VE9T.31;WU;4!4+4GW#;&-$3I;L1Z@5%@0[
M,L$YH3E$6<+OGKK?-1/F,W"_.'CJVKIMY<YH;VWD1 H5XPFH-<1=5T*IH2"$
M_<X"G3.:=10NVWK.>V=<_0Y9;$N6-E!Z -5PNB6A>YH]F17XM4Y>!_U&3*#^
MUR37D-W+PPA1H"()$./?=Q= &2<]X.)CE@?V/H8-%LZM8$OMIJD#1LZ7B0MM
MR,0M<<;,N7<W4":?B3E0*S"X]>#B%2\83 A0GXIY1 ZZ0Y9O>O^6CS&;[MR]
ME=D@=1 8XVINTKX0>"FG&M1U<UJO[%<(F"B7S=X'>AE9_QT44*4+F806G.4X
M)]EV-\,BK5Y\H-_K$M-4%-[SO=:(QR^3%@@KJ6XRS"RX=4W*U5_(2@_:8L24
MN@<&]A;-ZQ5"[D0OG-YWR*9N:3DE64N9>![IK0QB,""I.GMX_38>KJ98DA0H
M!Y0>3HSOQ=/Q<%6(BA8JR<ESMC]\,8O2!K 2SBL1578[;>GF\)KQQGR+I:MS
MXQ\77+H9C>%C5G2G,D9&K(J(TLCIP6)"^,W,5*>P<S&MUU741UB*$&E:D2<O
M1HI#037E.:"/[4HC3-@?SF.9<#WDKT.;P>\9Z=IIB MOM")PI(\.%<840Y0/
M20T)8\4KM\AO7)]V+1&\$YG@T[._'[\+T*JO'RQ.]<7H\J$@*4R:U1Y#$D!%
M( K; OQTZH8"\UB6!U9 =H,%;-G$Z))3 "4(:.W-@!F>,@CAG?,[;DU!=$]4
M^L4G+>\?B)%.1E*2VU2Z,>)$J4,-]F3#5<H.$$O4EY=H,:2,A;THD\23"Y%^
MFLI!Y=-$*>>&T]SD?-ZOCFDL\ W36=" A"E19]J$J=6@&?W+1SOJA*Y4GP*6
MH5F%QJ;':_#6^!UN0N 0FUE>8;=*0)Y6QR9C3JV&Q=3=NR BK9L]S>B<6S7K
M%LH>I(YF0F8">F7U+<F;N7OG)5,:9Y$7)FM%25]1\J/IUQQ6N+[J:ON^\+K&
M[)0NN&!%=CMGL)B8S>93=E:#SXLZ]&[KY^1"\G5OVWYEW8GULP)I-H@DM'DY
M-YB/T%R,6, ](-6/W_^06BCR)K&%X1NII'TXJDF( (( C/_AL0!J$U ><9M!
M'@02Z*T=7L58+ 9S8W_+</*S4= "&PC::M_4J9?N4$H7RQ+/FFS[W8"D>^Z/
M&+N2*0]#9S'VAU/;5*;!3R9'&.O?3?H9YX_ZKR"($1/@WVQMCXZ+G%29^T<Y
MQ9;R=:<8_O*88MBQ(H^M[A,G_[$+MXE7)[^=O#I^^^KAR)V\&%VA_JIP]V>?
M[7PEMW7]OO[&%*[D5^#O#: S(TH-I0KP1#O; 2P]WE,U(J';@\44UFV#RAU.
M[8@.(AS[H9#QOGE7?LR5\S>0?C)O+PA)@$G]E<I:10A;.S#W/PH/* XVNFQ;
MIFSRKD 92_W>3^1Q],2X,SI5]=Y90-0&Y<S6^EDJ<DIXC/EU7BZUPD4#7'R3
M6U^22WDY5*O4H>L0X$G90)4"1$*+H%(4JH+^%%X=1)TU],(,MH9_MB1Y7JRP
M?L>MZ,)=\A@,!CTM4&H#Y:M-5([_V!1NL3=,,''I?'GQYYGK Y=].@Y #5@G
MFF/%FVJUZ*4 /K>>(6J,07/L8J;##OV"Q3B;E_4<X&O@+[H5 DJCEK$!1RP4
MJ5%>B=+=3_.65+V',5Z?/2ZW$\?HZY/W1X=O)O\X/GSW< S1Z"+QUVZS.M/_
M#W=U"H+P"_K]+5RIAG!MFO0>4]6T6XMS)T+&)V]?'?_\]N3UR=&7" ]O MJ\
M^'8?A1L 6POGO;I;&D$XU7+^8R[CI* LQ7$/4>IL][+3HZ6G0FYMJZ6E-&<I
M)3U!(Q-Q@FU"B496 4MF/]I.XK]T1(6>U;T@$.)L/)]$IG,2\RFCE3 %UC8\
MDB&(Z2O6$139_^HO";$ZONN+-80Z-G0]2,,IJUZ #2=/BL60/!4%$[57K*FA
MD$Y/#3_9JZEX5')F3]QWRE4I$3];\\W,4'OE$]I"R9$K6\G*+6^#S@I2F,KV
M,]>,M,.NN/0(COPQ,;ZD+^):W=2]./\75K%1+M49_-#;LW<7["_1MUU3_"M1
M%49AZS%+'?ZV5UYOZ'5J*.D9[E+3\@3OS9_LGD4:+5TV8&:W03>'-JH(&N7Q
M)YE*E"1&O3C8U-6HR>H5J8PX*+4W >E?!^HEV>UXPM4)05A:$,'GS;C'J>V%
M(9YY$A//;"9G4(#2[JV;T1)2QQ] )K/8M$H84B2#:2+"8'%J4BY!6WC+/ZTN
M\.91A;M./L/M^ \Y*U$0HTA-XIW+ C,",PG!$#&#-W69SK^[;)7+S-UTH#@J
M=__*YX#_@2H[3*!B; .,37G.-4)3$3@4,XC%5GA^8)43AK7Q6IHX%U*$=1F_
M-'\/+F9XV11BOW^N(<>0NGSW/(1N[1V6@PR'S]WSVHOR*IO\@7JTUY08R"B_
MY)<QNI)730EL;8JMPK>%80(+C30HQC6WH^O^?7FU<N?0HEXNZQMX'7D//.T6
MP$0 2Z/@%014K6LA/>LY4\<7"L<G+VU??]!U/1B:/Y;>05/$9A\3VK*")7R2
M[G6?'W!!<XNSP>P0-'5?=S[BA\=\Q([E(US;=]\V>T21OY*2'38?LF U-(3F
MR1ES;[JITLMXK5*G6& H#Q3 R>0F.*JD-33IGK5GZJSZPAGMJV5>/>DM>..4
MXZT7P(O*E<A/6U&M[!ZQI^:+%:$:H!3TF=L[&R(D&VX4Y@D23*'_8/,'+Y]D
MS#L04&YUA@G1?5<H%K[D$E#PA<7P(,F$(O#6RU5YZ4Z^)<?_V9' "2#SC)RI
M$,^?%S,B)L8HJP)0L2H9H+%\#6*8(Q4X )HB'*Q[&BOJ6S['WN4V2A4.&1GC
M:(RHPZL M(E<%^R_L9 4\X^Q?9:[@/MN%(/0DPZ0B9\_F_ V8I'&D]79OO,:
MM\HZIN4UDVPO1.Y S\^;_.K">:5\C<'3N/N^R),ECEBXH1*Y?=J. Y3YX@0/
M.$-!.C[M%B5Y[4-F8[@VZDOZ^SB64SP16_5I'#W(LT47![1V\+KN.+D5>G_R
M=' H]8:._H 2V0JWK8]=H/,+VQ"#-$PAY9-CVGL8!JZ+<0W^<UTWZ\N,[JW!
MHPQ9+5L7_ZQ0>C[1K?#S_%"&</A"IOCQ\GQRF@#+AJ_3:4TVI>^0LVOT0\;A
M'A5QI:I\X,9KBR6)*0B1;WWE9HO2/^P9+S P]&=5WRC7MYB[;Y@?@>X+AN"7
MNQ)/*DZ>,R1UA>L!H/Q%WO 40Q$&* E4YU#!HTM;X%$SCD-,<\".,=\Q=IVS
M*IVOS,LY!Y6697%=J"43J'5]!2FCN;S4E%#<_8F@W;M!CE8A/08M0W*L-0#Z
M._L)\)9$(,YDT.B.80U7Q?X"H] E3,@2/E158P(2<KG'/#+90/Q[3QAUX-2(
M)7]HZN3Y$++DIR.QCV5?Y\DD]A>*@;)NA]M L19B[FD'I\7JIBBZ82[)_24\
M/N95ER,]'@4(LL@@.+M::7 X\;XPSLE[C2FBP!E$_SKAZ1@(&-1E8&$-)B"Q
M=T*:5Z^I" 'N[@6.S1]K=_=T;@+MT(6WK#@.6.= 8]7_;B68OJHLYDR87R_9
MRJ-9B*QH5<=W6F+WP2>)A6!&RA^XYJA>=&ZUL5(5(FY7*R5-);@KMII7OC:C
M\-M #[,2NP#+'RJXDF^0K&01K 9JFU!7T!N"[KIUUB(T7#"TT!$"7":"U;W#
MG/7G[H*:FKRDS#<<HPOL@XVGT8N:R+N,BDC<7A;T!_22\H80")0B9Q]#) 4L
ML'F+^*^4SD6N3\3\(MW22DEB:,'?0W)\</0PG#'&D_JDKLP]NVE/J!Z.-]IV
MJT&70MZF5@,>O-&QZQP20&A@>='NG;X$)(Y8=7 !\/S(JP6SV?<J<DE6-[.P
M8E3<8XPU$E\?[@68,*KTW'>G-"DOT"R72U,=$2P[O9ACL#X%Y.YWS.J&<C6F
MVNZ)$@9QJ#;TL8(0(CBKA0FG=:Q!QZHO(K/9"OQ'\C]E,UM?MBLR_-."ARQ]
M/*)]$=MB+(*8&6MEMDY39%C^G^-TKO-E- R)J]8GF(A!@TJ#/?C6YF )+#>.
MEZYE @<ANT_1KMTE2*>OUY //Q8M*=D#9_NF**&VZH^L(IT.'IN  !MP=LA7
M[ OAPL&-1P:9L>FZF1<5GY77NE'[EM+&H(2RNN.PI_N0C8U3^'FI[Y\W_<MI
MN =_=M?_5?&-^\VL^-%=[=R]'Z(EU3?'7)+K[@+2K!O"=^AM!]@)=L"]C J7
M;+"9%4\7Z^W"#+^O^@WJ86EMF7(G;DEE6RBX7W"P;$8,<%Z%*%SUJ_4*4RJB
M&#8"_YIYAGTAB<K\Y3TB97%>K)Q6[MW]#<>N(^<0U."ET D\"TCMZ.64)P\7
M.D02?>J";BW!-S7;)!]RH[4LU..GW=+E#_3J5C,W#9:!+"++ZH>$Y $C:0 0
MR?1&EYED=*U9:#ZNZ4+9?U',-/.U7B[!&=@(K[$J0NE4]E>=^7G^]#'S\[G)
MKKZ<>OC[=7-=7J. ZCU96T)DK_4&8 $!X#$$15U]67361M9]Y;>XSV$3<>Y8
M!FRE77!]:PKO_E,FBLTTH-+!G&"!M02.S/6+T5%TVFM!XZZ=S*,5?4^J=MV
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M&$>#Q_W!^ M=Y<$1F_P.F^ZHOKQ<5X;*Z]=*JF3$4[PH$)9B= =3)VAFW*\
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M(;R-/96$O!J:-9]'@'$/M,L)=]&!VZ:\I!T)V^_T%?HLR&TC+KGUT2?<(W!
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M]US3\Z*_IN>)9YO98+@>Z]P_,S+IWKV*J7H5AST'57RZ951DC4>X[E4U!"S
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MPGP@+(3OC06%_O5SC^YT#_N6'Q9[Z\%\!Q<9]^^-3DE3?".?%Z/3:U.D[++
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MA%U?%GR7\'C^^RA "8L $LLST+JTAP[E3>Z*1DXC\ D+Q-F]*OTA#S^@0'.
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M.Q_9@,MC2S@(5JX#D@DD;M-6@M_:CT<Q&?C<FR*?.V,[+ZX*'"[M5(+*/7A
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M_.MB>;O?=\LN V0,8!!;>*;%)_1XC_G2F=0Y!E.('B;4RRM"LC7<6_![K]5
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M3=U(L3.,_LL/&S:<+*IU,"1#BPHM&5BFP9FEI\&!H- ?V BZ0"78)U7O34?
MBE)IP0QKH02[:NRQPWI!GA89IMRK&@Z/V03.RFZTR-K?]T]>Q1G+0?&1%?/A
MD*EJ*<?'KR- +GTE\?)S$;JFV(XF.(<BJY.S4DLI."]:R2!!&X&Z5\/5]UGE
M%O-XV7EUJ@=K3@6#5*@%9'XXM%)87';1@H ;<FY__/ZC8S[PTYHKC$_4A;S=
M7:6,AW* G4+H=LMN'4G7/('Z]"VSR7/#\-K+@4NQ.);DIM-\0_?P.ZT"\[;C
M;*E[D]0MN@*>'$0AR9K.\K>!T,S@C^3K4T?NNAK+J4P2&.82 7DS&PY4JVX%
M;^G\>/XZA:#% 9B5%;;H&/O<'KAYE^N03=8H:_+R?Z^#;GE^^3^7YQ>?SE].
MFX?]UK6RYP%8GR9R=*YL7?V\_L2JRO"G*/WGI!Z6P!#<5O/Y\MF#)IE1=TK#
M:<^M%+"%.):E2&!$=0-#(>#V5]VQUBJOF8+T(90W/QMS5)8"I+EN[E)*'[4W
M9O6[\(*\2*T+2-61>=<!-7/3S[UC^=/@(>XPC]562( ^#VKJ4^CO<@5/7=76
MG1]&NGQ#NX=$KR\FK&!,YA7B5( #5! _3#$%'_V(@5.SAB4O7Q4B"F7PI+Q@
MR23&'S/NQ!SD5)P"%!V RB^)-3C3@%H,4%==RZ<E?TP#(/942MTGH-DI[4Y0
M!XCLZZU"'L!6J<33NJ@0B1>%J4C%@#)P) %)%(YZ([2Y;2>=YB098BH0:@]
M(=AOSZX=IQUSFW/H"O<0K!4_XV;#\_-E'EV.KH48?7]Y<W;ZP?O7Q>GURV%$
MK<M5W\-E!=;_+U"D'1?VB#^?H8(]+T=(AXS;E.RL%W&NA0/Q\M/YQ<=/E^\O
MSY["6;@H367_8(?PT3%/$>6]5K>T/?E9%Q9?2(TBN^C8JW=*+9[6+[;;NN6.
M"V%K]Q#2 %5U'<149B>7<-M#:,B#W,$W;,Y<4MY %E&N9K62^'TYEBV2"/^T
M"9"L4X $QA9J42Z9L'0U^PB 1CH2^AA-?3QE_#73XEM.QVQ/2Z,"/1$+:,F)
M*FJ .B?QF55;Z<IC4 H$H#J67@(Z7]% 8GM;"9>JJA#@-CP3YJ%RR-D5Y@(:
MM!5N,T^KW;DP4T'&:.9,5J7!,DA !X91XXAMI&:$.E@;%URM<@BC+II>.9SI
MULQQ:!@DL*M^V\8DS9>1O>[8/553@\9>Y3:\!_^V%=XMF'7=5O([P,K,Y("W
MAMOK)R):]]":(_>62=UUA4;@#"K[S_T2J5,J-2[#2QVW.JS&;HDE.$<]&P</
MKI*YIH+UY0/76B%EV3D.=KF,6Q*I'UF8)-ME3)+%4! ZWVK]Z*9UZYR+;]BO
M,5A$)9(AI3;3<M@BQTFX8P/QPIG\EH_)%(S=6Z>^(^.8+P&7"!B_).$NDE%
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MI,-&AO,J"W12N(MYE]NPNF9:[O?EI1(.-T4TY=>K][.$P[P@6DYE-'4IS82
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M$D[7WGVN5-+;56%@)(T+!*ZG?A!_(^?@8MKYZ /I,.T<;6CGNVBG^VQII]M
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M)!F&HQF''/4KV5/E9WICEEO7O;_TQJN(I]G_"6QW"%^-9J65*.^E7M&&N:^
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M@8XF?*("/3\1*ER#&PS$: (!<20(#9X;O-H49+*>A0;&*QJ2VK@);3&C(Q3
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M)\(K(,PMP"?!QR\A+$SW?3#(8,,_I: @6PD#)97O\N S:8;OAGEZ>O)X"O)
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M!;NZV9ZL_0[]-41G#4'BY/D?/*? ,D)2O+\#_S5!M+4EU%W<8$ 7Q*-?&3B
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M5^/TD8OR$Q\HF46 Z(S0H('"(N$!5=[[:7-/T#LSEB4?UG>[^$2/2O9Q'-;
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M&_:\C $#6V;5G]$($HN;ZG>\<*:ZXO<;*HG3IC^2\K<_#C;5H>[0&>YR7)W
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MC1@<S_+HH:[YV,KKMV_CKY#5&2QZ#*B\&W8,(+CXWI)WS31K7'IY_3W1]C'
MQ<K"W[C,)QWVHBUY.J/[U@<2X"2O@UHNWF-_!Z_TRQ^YI2&4)3[!2L$=19?B
M4^J8ZJ-KR/%H6S^I\%F4R<DK^A)S:I"9YR,]\%Z[J/$L 05;O5!2P8A.75Q1
MX9(!-L-CS[O>K[7Y09+";-&M&>N,14=,Z\N5"8)6/7=(#N9M"E\(^4L=Z1)_
M4)&T&O\<5B_QM:T]8TIXV];QJWY@TNQ>UZ?9]VFRF?ZL$9_I\KQK:V:;#E0Q
MO1+V"Z:U^OTY] Q+-^(^MIWQD+_Z^":?Q'[""#Z1/VSB:->V)8F<_6L7 I\N
MF]#^C0"#.TL=HYA^3F?]OK>@\$'1<_D!,Z7H+UZ+,9_"MKVR%#BR.J18:=:U
MH:A2ZE/#5_;'TXZ,KN7[[\8E>_U8PW ,L-VH(:SW2:9A.EJN.[7DWC% @(DZ
M/^RN_3% #*$L0ZG)%?QDWMZ&<EPI]<-A<W]-3O@ZXLJC(9D*P1\*$9)$KGZS
M<,JPDU'@C9!\Z@SQ%;3,BB9GKSQ1VF<MJWON)B;[@6&#$_='29IY1;AK1."N
M*3L&.).SW\.,VP'"G3- Z7\QPG^'H1@2#]U.,JBXF^$'A%N8]E50.(P\%TV:
MD!&?ZM7!IZ]2NMF$_E6:0T"=\L$WQ">LP(Y=_I?X#-H.F#P*GORPD/.(^^("
MOOM:!MS"]>7'5TX\)3N@0B.>>S![D,GZ,KQE_'-%3:%?SI>$!D0@_&1Z^ QA
M+4YWEB82,L5SORZ];*\ZXEG?0.,(E^8M?1J>"6=SZBCB@WGK+V=RL/W)9FYF
M<#?3_)H1'LMMG9^_AU-WKN5]#'1IZBQ@PW ]= =4FFQ^^IFN97QFP15O:MF(
M8(O54]LO%1&QPJ6?)J.)C/-DL4&+FL1^22S_]#M2$-5/@_-;,L$7_3)3]LX\
M"\?=/P;TJ*Q*N:E^;4/0D^H8;!&SK2 CXN,HNV+K>._K4&!6>HPJ%WS)*0=E
M]KV2J.V0Y8;XH4>(O(&PV#:^V,I%DQ6G>,FWU4^[A(]892R\[50L-M,0L\1
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M'@/@63']/2O8#RX?W&CP./H G-,]ZWJR SHTHJ>6*=#+CG^^5RO:]M,UJ<<
M+,KZKYEGU1YY#(AZ86]8/*Y/=C -5Z>FI3RU<D$%J_<8D$JA6WFFSP?YE?G<
MYE%CV/J]L%\3E&+AEZ[H[&\[<S.+9_=[ OX]A=D/K#0_KN=\-_HJ"AL"3=,8
M]+V:58\!J,:R40.0XOC0<$=\(D_8F^[42JO..R0U"U_5WO@/(3(#SZIV#M0,
M4I:-]-*J:6*W;0$CLJ,Q->U%L#XB!ZFK*TX:6>]N(X(?DF1:\^6KT9(UNG!V
MD]T(R[!O07^V: *KU<F-ZH5FWN\E0Y]RF AO, R^52?[3CHO! -N5Y-?EI9M
MI-,]BP#-]N_)N 9W969*7/G/E%=F[?^<6O(A?21I]GM_/NUG9UF&:(CP/B)1
MD>MWDO.]TZ>5-?A%;6;0ZV>?*/$G>^"7W?-&YR1G:_WS3Y365#\2$-VE^MZ5
M))JUK7EW;]*]-<O ,,Y$=(SKM.NVCK2S*M@^UK](= DZM.MYWN3ZLX+RO6YN
M\WUO&9!-> ]^=<L4V,5\Y<[WUO;WM#=ZTZV[%E6Q]O9LTUG^\BHP0RCB9PI&
MN=\;QA^?"48PL#IE,/RE*_,7LR\.T\RO:9:@(/9M1 S\9S3@09#4Q*<\Z^(S
M/ LI^+;' ,LO7O ]IQFQ^?,9?HJ[-R+UHPV3(+:M.\-U-WEBMUCWOEN3!=\*
MSIB0^E=#6BXN//V>7J;^V @6GW42"GZH@IKC=T^WF4I :2;A+UWTU];&>"2V
M9WB3'EY.WT,H=PPXI!/NU?K9NV:XFP]H@5(0RF9:3W+??*;*E5@HN-KF"O\-
MS;=KJ:(UN#I!.$@9$<$+$?GE7J6&A"859JL<I 758R.<IK4R>TWRJ D$2&W$
MFJ\&J-ZWBB>^P2=F*;M33,(N\$HDP"$YC*EP*>8#=\R5NRDO+_E;FC.(F"8^
M)<07\:U[7X@Q_\I?_*"[Y<9=)SW4<=ERLB9'B(E5758IY:>-MYUE7TB*P0]R
M[0P(DOD^W;3@U%BI8*W\M&7G5!7 R#)?_ 3UYGZ<OK$<S?U/R0U-0#_LN!$=
MS>1CP(T\TM%9=9-;$]5VBK%^.T4;!&7/.$@SD?=30]^985EWHUS+?ULNX(%'
MK;WBI<7L",/=J;S:F78MQ-'R8:HH&&4)I8M%Y\++;)ZW$^$/A]W]GIL!'$8I
M!G'WZLK>IN]?B,>QT[S[0DZ VON9HV7<AY45RI40RB+W70]L,*IQ,:>)PE3%
M_'Q>:X"+^3!_3Z.*?-&[Q<9M7YPZ0"$]:0DU"B$HFV/4><1@,_:#\%MIDYF)
M)VQ][C&5+4;$-V 6'9<"PST-Z=*NJS)]P"S5&GN$^I(0-5;K>1S)*XK71,K,
MS^(%7LH)4ET7&V.PQN,A%T7W-JY_\Q&+FNB##V@[(O\5+#5?.?$.E<*%E-4<
M06SCU6LT1&%[UTH]I\@D=-E]A4.A!-0W\&0P!H$;VPNW'/5!=QI5M8\B\JGN
M89"6!(CHU3I]+A*<;#73TL%>R)HBD[2TJG3<T=EK>^>W>[&0V[ZD_I:75VC:
M#-2!_1CPI'T@BR%RO1QL_\!#'>*BL4B[&<44"-1=&T[!!&MH$BR3RTH&AVTM
M&&S %,@J5BZVPX8/$M2-OZ9;5,Z/& 10W":4;F#&7W^N=@R8X/(>GGTJD"5E
M1?Y,]@4P9F>A>NE6M=J+=MB[K!O+:"3-Z,RZWW+I-\+J@JN0=M^5!.S/=2(3
M91VE>7GY8=!<Q!K,XB!=3 ?.77*[V9U7*ZO7;G<T*&+E-MFJ.Q-?C';TX5$?
MNLGAK:KDF@L<Y)G\ 9^>W$K1V(6 YT-I& L2KQ*K%_99L[E_\HD-7638]X+;
M@AU&MY_3>1% F/5QF+"6B^A)+SY^8.FL:^@M4^8DPHG]GI=<A@^6'[_\G/OD
MG35CO5$B9ZY^233Q9)753&"&+,@T<.;;>CK<EJ^KLEJ^<W"/]68OBXO ]SE%
MGNLK $GFKOF2-ALRKN7-KZ]%W:VI&5&67-?VWL_8OM?>W*(6/GH_=-4_/.O>
M]$Z.'%ZW_RV-"OI]AA?R=6U6&LL2F-89I\NW]_=:A+R:Z0O2/J092+O>((NX
M&OF*:Y $'PNRUJT6=LC029^BN;.V7? DC%95MG,6[M2W)O6[[5O48OY,0[I4
MN(HIN@EQ0@,TTX@,J?A*P3\T[BN\7%8>%O:,=?<MRX##U>@W-PD=[7/EAQ6_
M9"9!YFYP9#MRQD?6%VB>6OJ@=U<YQN(88/+90?TN[YUK?KL4\'ZG__KKQN++
M+6K1;RRQW/LJC,6\V\@B"U-&OEZ:_B[8=3=?V5!.6)4.JEOAX]]^9@/\!HTI
MWE#SNIMV#( Z\!X#Y,-O#_<_S-<'KLVRV#$+PCG"4I8:_2V[(!E[W>_)::5#
M9V)XBZ'S$CG4*-K^3S[#;V2RV\N//D_Q8(M\\?72D)T*+ &O15'5]6@&28N!
MX<9\715M?EM:;_%D!N7!\LPKH<3>9W/YD7[)V-QO\"%8++(>&H6-'7<<#SQF
M*2\(9UC2(K48MRU(95-4/C.;BLMD+/17&O)^9TVY5.W.M&Y=>G&RRESK;:GN
M.(M,Y<C3VO+BB/?D>"ECW@?%OE9U+*5M[; 1G.QE-F01/%:K;M+2&0FEW<WX
M:G'V+]TQ,6VX'Z3=J>!Y@?7M,6TA+VZK;Q$[/N&P^F%WWI$BL? GHTJ"JSU2
M@,U$.9E54HU:%#)I=MF1<ET9+Z].Y*R1A_"8OW+:VW4)"U\.N*@T)/[.FKN%
M%-.DO)\A8IPM6D<C=)??I@E\V!#& 0X7N@.@O(AK4!TI,!,CVJB8[1#ZE"=6
M\QA '-&[X;WI**<#SROL9GZ;0OR13RV4UX3NX&>V?5ZX)<7>^G"+6_ ;3T(O
M!O&C5)>WR'*Z6.!]'F-Y"HS'7$'#S,.97WN2L=%1:-'\7=I<EUST,TAR7)1]
M[O'[:6H=1>19% :T[VIP=EQ*1!3WX1>.F3WEF$./D^2@V6#SG:/&T?*O%PI<
M."!C2&_>&VN8V_?00-GG,Q+!'R>307(?>>"@@3GGY8=RX$%>_!5:81N2OKB.
M"IXSM_OLS!@6T*%"+[,U!JH1?G"B?WW*HX^RWYQW9FX/\<GXX@]18#<O3A&W
MUW3NWU.;^7:7(9AU2^[&J$6C= /+X5<._'WE&-Y##RA2 70H!EZ;;P6/&NN6
MP/2K]0WM-;WV3^5ROW"I7!>*7'[V)ABERNSUN]+W9+([TXT?!#HD5)!%1. 1
M:YEJY](E'";5B<J3;,:C:YY]D_" G02OVT$PL$*%"X;_OGXRPP$O[O9R5-B
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MWYQ6UU*5-L"/8(&CS@<J@!BN><94\U*H55I$A[Q.5#L_NAA.K@&UKCIB"G2
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MPCA=A<I.\1-V-"B%FDEZ=79AM(TZY1Y5RI*U#)H,2HXCAC>CCT;&9\&=G(W
MBFS*7WSZ8 L)NU0#\E8K80G-+>Q11A)R[F@;!WX<Y:$KO0?TNV]MRJ/P%?$
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MGH#0V$/6%\+C9YN9%6<1S[WWI*.4)J2G6OH9%.TVT5=ZJC8=W8V,@_C66<*
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MC\F9+;AI@F*\:;I D+7QG2G);R2HO=OX3Q*S:KP/K>XC(0;>LWA5P'W>23R
M<DZD;]AYHE\K_]+D;-X[XYOQJQ[@'W%;1[L8]\(=(1ZZS9Z4_SY+GP#5<US)
M3T ;<*6YZ+^H,WSDP>Y /=5Y<H\*LR976S*L%T9$GRO\L+']0((Z[9)U0^=9
MD3H3)&0L>Q2OBO_SKG$'<N?XE\_@7US/0=]22IDB3U@U>X\*Z7]1#_@$D,)^
M_7TEN/MG16K5+WP\2//A$Z"7MPUY/;%"A$IW<70G$X&S&YXH0YO27<.U/+0#
M5W.Z0>=)J)>M5=1D(!$6&<E+WI78%E6M$#Y_ATM3=7DX-4[P6P](L)["8!C!
MFUG!7?U%=FB.>TH(C0P*5YV5EI0VI#A3#D:<5(]SB@'2EC8EJB0# 40>]I-O
M;BOO[&_4>1Q<"0GQ(J$*>(6P@VC QL<_:E[9.B(N0GA^*B**@A3.F@B."-7V
MQB..#%?_AN/&.A^)#/6'P%'""^+"*[%CMFXCFV&1D(P7C:(N"S"$,DV7PRW<
M DN9>LY:+5N>2U*M7 /JPBX,! (5TM@4,67A,5^GT9R.[/3HXGRX+$AD(0L#
M -QD-//3<N7D*Z\A2/??[Q^5!*CS"S^PA[/D+5/V9F*J+?/1Q]%GV ?F#Q.4
M!9E_8YJ.RE/*0X/A=A];#02.&Y'MGKN&_YH.ONF>'8A7>2RV*P8^2FPF-MR_
MWE_UF!IA6OP5,L0NA!%V#KG5\ZM!G?97PZC\NOI$I.]_<Q[S6+>TTUR_X/9"
M***NNG5U!H%)=WI_.@?WB#/'R?3FU;;]U[OS<>#2I=G]-BCN*U[K]B2_7^5#
MP"X*;]0MMX^/4,$7V5J5,$&\.<;:R_6CGJW_:'H1&ZZ-V7 ^(E9M\J\I&R9T
M"J""\'G4C4"9"U"M59FY8RN2V6ZQ#Q9 (U*I>NKX?S9_@B.JO$+Y;OI8N[0=
MZK$74!\H:;5&=%OU1;7L7PQ3D=;+I0M^MM\RCEP+TG\4]73#\@1L$#L?D7:*
M+KVVR9['9]7DR<#<,@Q5JT.\B@AZ27HP%<D-/%ZZCOF?7_*4B*X@67^AQU_Z
MXQOW/A#MC_3@6U.W8"1Z!Q61W?,;;>%\H2Z_KCN*JNQL_=CURX30 @=:4__:
MS#@LC_TG((%_7?4I NOR:V7RTX"R]!T[(]'4IK% AG^^<6[M#5N10KY(C<W7
M5^-7EU')?]K<_H=6C]W'UV=)Y7MV3J5?YKF[KWX^'F.S-5$ZJ^M'365Q#UZ2
M_S?;;Y\ ^M.J\H,=SMN@#](NP?(37:GJ=Z\V#XDOJ5UM3C&/K4+_ ,M4JCZ*
M##<>O@W4T*WWZ&KND_!V6T&EZ-YJ^JM]B'8)U:[J2H&W*^W#*@(4@2G //7_
M93[F'^-_]QKWMJ0LV7O'=D7BEW]U^024^V$=Q]7X62MM_!X0=I-B^4#S'ZF1
MG.V_Z9[) <8PTUPB K';Z4I#4=\:-^H5>E4[A> <XB+_=&520 /T,U$G<)AE
M>\1+"'%HDZH\;?)AL[+AL,U.^5^MTIG!/Y#O3'=-5>(S\A#58]C5$!5%282+
MQ"5W?&1?^;NQFYIKAF=Y1"M.9F3J_QSFHSI:%]J\.F57L4,/6'IP57%W&J%!
MH4-QFIF=9$G-I_ ;H[K0D1X+7;T0@674+CJ@#VO>VL4,1]7DI)0&IPTU-+0,
M"V&],/?V'GGL]/56]=:6"@HS,W.!30I:!='PE)$P_F'_VI&@"%I4["33W=TQ
MY@PW>?HD?>H4APGFI/'Y<4@ P ZFX"__0N,EG_YIEDK],J%.<NEINY,H:VJI
MK8\Q+VURB2U0A7L$BXA,;G@HRT')P=!!DOLY(WG2*LM,:4B<3F^29WJ7(I>1
MJR7;GW?UT X'_@*SNVMN3"/Z"-RDA2A/4ZF\0?X"RM-N(?E^'/A07;.TF\XD
M#6S!\ZB\XJ'6JN8-Y5^8<>WRSX(E)EL2EWG-Z1_5V#T;U.XK9H=A#I1(G<BY
M/$;=4%DY2'T@?:?1@O$!Z/)T;/O6XF:A[AROYY2%?X\[3O<^2A Q?19HL@6&
M$1M/IR$W)$1"!P-/ISLI190O"C#E#1L>7&MB3"+%)20A6=<ZB/?LQS7!+Z"%
M-%;#)7R?E8H_)+/%B.F5(AA/T,S@N@?48(&?Z(BZ>:V^PR9Z+C2_T]0L\"H-
M*>\D# ].HA/NYC72SN..?2QX2TG+M(WNL15$AHRA:>R$%]%T>? L=F9/T9%?
M(1\F$E1!BP@M^L5?,U6*LG"H8CQ?)#>4I6@6!)S'/YKZ[)-8SY_. J&+&"N/
M*G\$&R%5K$,IL\RQ;Y?B3'?9>%NC=7M1.]/7U)PQ*C1[Q0@=@\/N<L_5B$:Y
MT:O-^)O%;A6X,*0%@J<D$K.[OQMB2L:H44 8*T:8HM];"FM7^P;ZM<A%*8IX
M!7KR- #4X9 +?3U'!3\(].C"F%;+&G[[I 2YKZA!K2E:OFP:RM;)037Q0!"9
M]GHSJGJ/!NFQZ( R%Z-]YN-Q$)-0$)<EB'I9;&<\2CE1/ :9QU'W[+64SX)4
M]'L9/!3*M^S^;97+F"@B K177DEP&7KT.DZ^+LICGZ'$K(!5$&-,ZZ#!9-.J
M]C5^&3==$-+%:K)7F$_3$I'7B3%0'T%,E[;7*9C3T1+PP]D4E'/5NWO][2,8
M&29!ZI"B#>3\A5M$+2BS2?(#X%-WAG-^L2?KP+:XJT_DIT"QJX!LH\Z^%_=$
M'=>_41G+(2K^J!'.-?#R71\#16(6PI_B%T8;QPB):P&/ML^:_R7YOI1M0*V2
MQ\Y[^OOTUZY_LU7!)6=%%O$\J(5.RQ_RRR? B!.%A6FA5&_]7XO%ZRVP9/.A
M2#B>)$9>@(L[AMN]N"&IWGD"==3Y*G,[W4^.3!\O:UODB<A2 8''@[M%CYW-
M,NY(!ZB/()"R$WR-4V=JO=;AL#QM_H[<\K46PR^UJ?^ZC%_D@K!\&;/0L+Y[
MQ[)#O<D)0$G\>L.WG5"IEH#F(PV;)M,TI@&%VK]$WBD(5<R 4F8,Y;H=H5^M
M<Q!=[(I-5"B!@[Y!!=+O^[$5R8+:%CC]5*M<5H:@OAI*0[^IK?1<F?8 [V?1
M09RZ)B\#@WG(_A!'YP,#S:\*<Q2Q04)_V+>72)@"HPIC>-:KZ:(&DN#:@A2X
M.VF-SZF#X$-GF:@)M)Y&/2JH5E!;8<Q#/)E=B',\[1&MW,V'K?V5TV&+6+0T
M7L <B%K2M5J<@ XXZVZ;9*NZ9'%DIWY<8*(HU:_1%H<<(']B'E.7]+<)G"5=
M,Z2%,B$N$\5-"*7J.E&+3O10X5%S@V80<^ZO0:%'_P*I!DE'>-=Y;JQ9W>L<
MT]>F3M!6K!8M0WL0C0VF3KJ2Y:MH*#;&_@3@E5!SSK#8__C#W[/OB>/[E194
M5)QBTH?Z &\HA)%=3C$:XG='L)R,0>24OA#-T ;)50#9L7(6J9563J]67U%J
M%N'-@3S )BU3W%,<"@KW?JQS(OFA;0:VYS=(TV6.?J@Y3[G,@!/A)'FGJT$P
MP)H0BMO0I,?*2JG4V!67%=:IT:;HJ)WF23<,UEU!^<@KF%@%V:;(%%Q%<$(V
M1<,"Y\XFOVNT6PA8.H@\$F\VM':=XV7X7#4EZJO1X.2NNTR;8(*G/S![B!KV
M+6CT: 27<Q@P<Z/!$>NE0PK\P);K2T5/UPF4WQU=OM^,X;CW(OQ2?Z1"+EG&
M,"Z;4/*ACW[[:;?"C$=-C@CEVNMMU:E&0HSIBWF6/>!<,9C*EG9IFZ_,4(IX
MW_V>MZGRTI>;BX,/K:' S]M*34-Q,N^9GY6\W>KFZRZC:E!ZN7<#79UQ\T7C
M&AB*OA">UAF<==WML^L^(CBG>-B>-HX:TY%1CHV,ABXO(&'N,^L$E1$QISX#
MC6V-3=G[X<""YX>>/EI@K@TR,C(AJ63=%G/I?;*\?LCC@*3$,+]DFJ3JPL!D
MKLY0<,M87MCM=&0GQ6=QT,:!TN:_PI'@'Z+*G65:;1)GKM"?LZ'5'^5*ET6<
M[AA!6E-.KXVA<D(G1AZ30I:N[/*5# ^<E8V\FM8@F5\P. QTX4=YU"9:$2[_
M%@F"B9H^9,:G46<RD# L9^^R_UT<N=.YB4+0\7"#3I$6AN>J"X'EHS,2"PE\
ML)S':X9QN^Q1!YE@\>GL9*9L,3(GH-6TH?"@>HU[$*,=V4>,WE;/#6H5@CO^
M$(P/,2004["2=+[7Z_X,T.6/ (>+%*0A)(C5U3HNO;H2=3^^%FI$@Q@+N8"<
M@ALY*;T26DVT7,>L-=X3 .VS$ZR6EG1^L,PA:D<-.E[I@T9ZF+T?W[D1BZBA
MBU6I[R^'LYQG*6_M8PW&)V2N!J:$\UR6_O0)-K51DLB'O?NNCUUE4'2:R]GB
M!GU.CIJ !<6$2EWM2F!7WW&^J?,4^GI5A6V?-WA/S2A$55=4^ 66X.W%Y7!R
M8+U&[PCE;]T Y[C;OLC==JM]^WI-S$"2TQ:1GQNX3YP@.5-\E2^P/X5B6COM
MQ^%<X*]?OUMJR&5QE/L(GRH9=7XB&4NVW]9<VML^S"#.R;PR.8]5Y$9!!J;#
M))+ER=7Z'NC0QQ[Z*KR5D//413HM6BM)28/D2Q]@4P'77O!_W+2EI&'BXDVQ
MG>A/'#F13E<X4-;L"*Z&VDK](E'?#AR[:;A&^>L+@>[0.#KA%]W1*+:.NP+N
MO<<!U0,BWMC&ZKXD7P5#I(P& ]UP8C(.@7HT#!L\YQM<_6L-BQ6@VXLM3#S>
M,66,2">%^."SW93.#0:F20L*$PP$735DL<KSO7,I1!0Y& -*$W6,BAE[KA0)
M!8,L,1FW#0B0>VVE824S0'I+Q5%MZ[UF E++#4'*!.3HA;HW?J:P=)9@+60<
MQ+(K,.KB6>E5_DLG7M=52ATQ OOL'/DP6(]62JS+8\5+<FDX:0)[KF'";\39
M;@NM\0QL:&D-$9?BHA"I\O8JH=5]TVWL@)G='MW%1VCDLP,&2]-42Q/86F.K
MN-I3Y%HJVU'5*H.I&*8].4,M?V0@MU?L,%)R)%068R)N'&&[(BMKSQ(=WVLT
MD4")CT(Q2+:)ME@1Y R-M6>%)@BN$;DUOSF$2M!^ M04MAPAM9K=.KH.[<\G
M*Y<GD(R4M=!'(^%@FL4Q$+E;E+^_,N3>3'<9U]JO)TCO D74T=7E3!69>4@\
M0<>YD$M5(1YUHY;)<\Q'5>/>55P"1T.JT C  D5)>4WRJKM-$3< "E.XW1-S
MVE:F87*V6*H8 >K>&3&Y^ECFKT ]V=JX.^2RX1_L/% -8<Q..5BQS(I+>#'I
M:@BU.%L8@E8 *GV#XJE:BC[2P< )@^V5= X\;A=Y$(N8$PGL3DJ890=[SLL$
MPV-!H,E$]Q!6TJ90*RU5!SFOVJ*$>!.3,32\^^77$KH%<F(!;V=PF48B0,4F
M.UC4=%%+/5K=1.@ZY[7?G>PK\H G<VX8NF_K>L+1NPU&HE-<YU5FH7'VBL)R
M(VG0>5\[>*V!*[Y^#2!7#J]M= )2P(0':CN<H^:\^BI\Z](YNRK'/'-JI'@)
M_.F[M<=1R/K,]<')N?UJ(>5]<VS:7"7-F3;E*[8YDF(=GFVD@L$<P!GT(\%)
MR4W6T :%Z]'S%X$_.,UMC.2C$;G=1=.R_]9@BGBULE$-Y!?BJC(DS1?;&I'C
M_'V!(=XK[:]!T .B.ND)B_;FC ;J(NU!]<!R$%(A4W+1TTRQP@'.H:P1P\/1
M"LO4]&0\]NQR(*+@+ Z%@[IP6?OO04F1A_L)Z';GFAV4%KYZ$YL15SL!"F7(
MW%V^$D[2@7QM^PFD^+W-JHT]_1;D2(OI%.@4G9B4UE/REED E<(APZ[G;E;6
MAT7@I:<<.(@P@E:+:'Y4$5TONE?X=A)*<5&6(T/Q1[F<GZ*9>S&$29@W4U>3
M9(JT%,'BD98@8['$?6>YR$+GH+W?FLZS^DE-]GPDE*;?>@)KI5G:=$W@FI[^
MH(+.#L1"GF8J2ZK 7H=:\I)]49?3>T'00)#$7H6Z-"-F85YT>G'@+2#A:MDT
MET9@2*%NDKV-$?=J]%LUA".09@XJF$]PMH.<$2)C^C7V]A.0*H#<G^E4[4J
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M?B7C):5II#;T3&VLPD[!$'"E>2>G8-/FN";()-#NK%Q/8]*)38091JF^K 1
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M#/4@S"B+^?L?AL2.1(I)JE0#IL2&[.SU=:'>!OXI ((_XUG'/\TWLY,V6%^
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MZ2QL/!'D\\W@R. E(RK&42JBR\2E21.'#58:+J*9I-5$5AD77XPJ3)8'05.
M68Q&3^%5OFGN#?'ZX['2\5M'H7=WPI)%;O*WG@M3!RR8NA0K=MD<\DB/E#L3
M8S6J5;LS AVJTT?*4X-WW+;@VVTOK#@#R8Y ([NLGWUB<V &<7_H]G.%DX$A
MTD&P%#@*4+ ,$HPM%KOGL5C<79L#[0[.2Y$%9N.)ONCQ\7.%>ZO7-"ZS)U+W
MHTO8JT-T*7*&>S1&>M*9+(;G,[$CSM&A5>N2DU]#=N?]538_+5K@"(MYK[;#
M=@1AIL#3^3505!89TRAULX4XE@)*=4.*J2DD9B[NG+":-B.-.X\?B'"%XGW!
M<#[*QE(:GK#[PP"MK9[?RO/TEMQ\;-9F)LIFK&S5*$UO>+PTZLG01^V""6K0
M0$*]O+_JXGJBN,(_W8KAZ(*23]/@U17,$.D*,S^C)&KCJU2M-OY8E:='4OR)
M/DU(>58':=T78_1+(,)B 2=;J2(1WYCC3,QDA/0K8-JS197370UQ 8/UD+=2
M-*A[K_5_9F?4QNO;62 #]!C6A6-++#>AF66%W%'38QAE?K=0?WU<R24PQS U
MU5=C$70?-U@L.QQQG'& 165:UUWCJ6 W93#_V-$P%BM8Z5A8:1G-Q=7,&6E9
MV>A90),Z_9.356FT2L/90DW)QKYNP R:3IWA67D4?3*%D:[T5.;>)@A\(>'L
M$YQU!D<K/5T1GF6WVJ-Q%*^'HAJP.,ROP@]'1B &^1:K:.<;>GR_*I('FN=/
M<M8B$GD'9T3#,<=H6L166'M:>UVTC +"&EN]V5KHXK%2C2@ZY1D4/!3[FEKJ
M<"06K8WI[&V<"M@2[6,?@D@KQT_&N(O1RD5QQ3-\GQ)+9D?R%<H_Y:JR[%AD
MXES^ R!2#WKT&=C>L,?8Y[K6>UKTTZ38U;I'TC6L+(Y'6E\ZXI-C2(\,P3[V
MBL*SQ7%DX,#;RD67O^!=J)Q+,> U*[XT#]EOHWEY;$A2]LPVN\+T*K>>%:8R
M?]/_+%HX&=G2B.: CW_^XT<"W5%Q#\XHOB6_ F37&TU'?"$W.*^Q?3V")^*+
MDH(UUUQT) -- 0Q'OH$NFN7/=014,%/1K CO.#HB+G(5B3N3C=$E=5K;UTM[
M1SQ,*I@8=P*%*(IN!^%@D;DRWC\BA][P]!< HSOQ?P#GN&UO(Y31P8XHHS&,
M.&78TLJ?,:R.-/4+YK92@S5YH3_AS>9M[4:_^ (R%5LYLP.H)V!1>?(@W!--
MS> LY$D)9+L@<1!0+TY<<Z6Y@^U0A'6C#DY.'H)D^E?J%'T8&..$OMHM*#KK
M(Y%<?D.2B",E>?P1(>HVW5'6BD]QSG[_'4FB ,V5O6W2Q#=)I5@(8TOQ96(Z
M'ZN3COE<N'"3BDXTW>!(ZD7I\,SO1MAB8QH*[FE&#_4D@N_EM/N2,0<#;NKO
M@2+^7#)T.G]:A'8?SDOPJ)+\?2\W(AN59N8$&+WU[B%AKI]747G/FV$5C*F.
MIEMW!$V]%[RS%97SAL((%79>NBYZ8AT=OA'D6]*JDIVXTJXGHBI84IA$0Z'\
M/LH81#60EB25@,7+S-+8;WW>KA1I/+ER3R?F'YS)SB)MSN!X)R7/DB8(>_[.
MAN)?C(Y3>$ F5CY%#O\@BM%%1F9^04/E^;%4=!T5)CM4QZJS<'ZV966SYS8:
MK]:BF8KF5.-29/AIV"2.V*PTQ5G9,%VRQU'.1XM;4>[>5;MU(<A#B/@GO7.R
MA'-4X.X0%QTE+2T$<2U+[T^1L!JSAS?3MX6+FE]O)<;:Z<1M$I*R< <-GK1_
MXF"GC0_BG;M]8I0<=,:OI-ID4%$CH)T&W?;"Y+WRZ1"Z?_TMSG;>:W&![(#-
M+FL58L8M;MK6IA04L-FF*[3L$Z5_XL#J)F)*1?U@!%!U=AT:7M;Q=V(-T;L<
M.5)KYX6-3QQ%7UP.1E4,/I:)&_T=#"F IY%E=82_;.I&7LZ@ M/%ZU6H.,)B
M;''!+,'P7L1"+I21\=M$3M$4M2-#?SQ1>FGL3QM,1&BN3 ^ZMC)1A5O$%!(%
M)8"JSGH2W0UW>?\2B+6>=#KPDGO65:*XRDZH.8[R:@$/.2O%>RY]IKP"9+9<
MX[+48ZA )G?LW)X%:35)4&OFU)Y @O4E$W4E@]K.+'=?2^QI/J6I;XS(H/,$
MQ&:>*IA)/L7DLQ0[@XL\1<\(9C +UE[0Y+U>W"%M(RCS]!-'Z/KC, /L]]9;
M_SP;ISN<.E?#\>AFRI+;P3_"YUB%C<]^AA'> 5.!V((1$RE"#I'G,C/32@A3
M>DHH>(26;5!)=%FTZ9ZIA,$:; Q(; /IZEZEQ'9JW@2ED11A6JR9VA++:::Y
MSD>B."/'7KZ(<0F_PR1]R'0D-;"WS(^>IOTVK6ZTHZ;)?%:+ED+F!S8^Q]A^
M9V,AYC7W)S3R,BN=1(_7[+*C^"XJAE.B+7W1NA)A*Y_K6)@Y"=N,E J;,I5Y
M7KH4)JD R.L,04K,8,+3T+O7U*#[A#2..H]-(31GS\4N%'0G<U1D*LWOX+''
MJ?$N>YHZ]!#Y0S7>W$TQC:\'U=E6K[SUFEM$S('2*T\J1"=*_K9[_FZ'D]G;
M\#[BR!T/!(J67=#EH]N@2K;"! (0; CELRUHXLKFK9&R* 4@QG%I)4&KYP>$
MJ^?79D=X_1D_MFQMPUW"U[US/1,<>'@,+N76[(BERQC"24'>6>:Z^O$-M8=<
M(FYY9FUW]=I=9MJ/>4JF^"QZB%D8&UZ.BFWHBZ5_<?BFKR);V:9C++AAH<W4
MP119X.I4->^U-I%4%JW%BH9.#1OON)AU@I768C1[XN!/J80K5/-1?+5@B+VU
M7RON_G*K>ND&0RNOW9(\"$V]"KZ(H;5/"SP[RJL48;=&;>40/HY*XH25OQ3Q
M_8WOP'?W:(S-:/)OL;3H<"T62HE(\_NR08?*3>T^5^+&ABU3/.TC!*^B"*S5
M>5A#Z=0@43F1>$EVQ,FU-\32[KSGZ/CHVO-PN6,09V60A]F@5SL5$]6\F+4D
MGE;=(2W-?!QU>>]7J==V#6"]8*0TP&<AQ!5Q1P:R4V)KG;1: J/T].QM=VO]
MJB;/T;2%JQ*I$M2K$[6$! Q<J42!_P#2$<<B5;M?9^9.1]#L263;D4X\"(G4
MX*(;&D5&KA!)":OT>+6F5VV -J"<S_1;91NE>:6:WL<-K/=BW[XPF.S%\6N=
M8.S^M>E8Y^)/86/)'/7="K$M+4#C7J<;3E@JF,>IY05ODIP<0M(=..M<6E=K
M5S,764*)B;7,C\D82Y09Z)WQ4>066QQIS#";?L] 3*-CR\D,^[)9OM0RU>6*
M:PH@ZR9#N!/F:8OYBQ5,9IU[E/D13=Q-C+HS.,K"3Q60=V'H*<,OX67@I. !
MN#6<\M#3)R!5'1JRPF7)WPK=3?/!R^+4-3U@;MSU2+ ))@/%:@4X$7%Z8>_3
MCC8;J +""G+#D#?'K9 S<T-5"]KNG*<FF,Z TQVBRF9.YMJ:U*9C\S !%VHD
MP@*&*<!R6[!FD]C5<H>%.=AE+;_D3:#U;B65A])A<2R_RMLR):AU6-CL8V)M
M,GNB I1'I%PTU>%?CPV3X5:@5U1QI6%C4Z),JE$%TO#P>-%1P@LAE>@2:(BF
M4J 1)GN_+0**R:CJ*7?6]707/(IRP2IZD3OX^"P<T+"GEFL>,E4&HLKKI<DR
MGP!5;%U1K6G*$!XIHA8/\3A<J#[?C#KR)+\ $RD2NG$#VK@2A_JY\@JC.H:A
M(U@S1*V_B8FY8T:-?S$:E0TT3^TD!48=QX9P<TS( ./MQEN[&]19J,\>;C_/
MFL]K /9>KBUJ(1I53])'+D5K$BXL$L#[!Y%-.X5]3G,) 8I&X!^?B:E5GBHH
M"7,%]7M7>0US95S1N6O]X#BZR%J>Z+8(>+ZDDAU3H(1"(\\78=W&\K3$A)7K
MANG^[^M6QCT23X[/(KQU=8M=]O,]&D$NAZN"]25=7BDU](GC5D,#JWY>Y%$F
M9ED*F2KPH:7F4^&"RFQD*6P4J8I1=#G'\[1,BQJ[U!EKC.:G$,T\C2#\U\G&
M5R*X2>0><!.#%TJR7J.L-V%$]@TZ_VQS'0405N!@^AJ21<184E&)?CH;)UDU
MJ9G>@)G; 9;U.BN38$Y@P</_!D@[]T\K/$(NT46N94DC_S$=+B.?'=_>+BJ
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MG_8+R5T[C,>TVF-:*7&6&=F86W%B3:MX\&13QM(J[EJI93YJ]9T7_E0%:[$
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M%K*X%=?J^U$TT48C-D#LCS/54]82IZ6$27-JY[O+# 9A;/ALUTNHQ2N'L:N
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M' [1A/*1+"EPZD+HP)R/ 4T6(C?@+Z+@Z/KZ.T*!OTOBHV*.2H*OBE$GK[U
M-3'70V2+<X/1P%(<X^0"ASBU]\N3-'.U6C 7-01&ZB*%\L*RJ627?#"+MV^^
MOT!@]ZWE>AFFDE/!^.314S%@5+VDC?X$=FU6;E"V HK)3Z0,%CEP,;Y"_#>K
M]D\ZJ87>R83XP+8D=L@TR=FTY_"+G>E/]5V,UZ]$?%<XB.,/*E6!XF1]?8.B
M%47O3B>0N7<[S6U/M3ULL6+ER!2 HJ7<-%8FH#1,G>8J"0HS,P@E.XJ& @^
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M'KK R-CI%10FUFAR:G2@.]*-.'L;95)I3@XCXDH&S,,*?93RI@IGV4)()*(
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M%+YI>SY6@5OE4@K<"CN,ZH^]:DY:WW"&70(3Z)#A5T7*BU(-^L%.M1%0%5F
M)<UX\"EJJK4!B[Y#>=^=1E,=;VZ<3<HHE.5%094KU1-X!8EUYN4*\C3F3*".
MZ0SE?/7M*XW'%*@;U"+2V7=:"@@@)=@19:W4D6ODV\Q1E49UG.5YWK;,; (!
M3CB.P1D1:)1JV%2"7X145U<E@77D!O9@W$1)4K3*W#HEQW8JNSWKQZUX;XB,
M72H.]"K* G75 46)Z;]/T8OLIU?7 ^NKY*2%?,>IRL4>>\0S&H[J".6[7$ZM
MP-@PWN!?,Y1?QGJC&ZDW#!4;G6*$KCK6]KZ7\];7Q"M!DU*TSIZFK2 2YJ7K
M0ODQ9WHJHD!J([K\<Z2 ;C*H<Y!2AN=.%G4B@5CR4O"];5SJ&H$W,<E0-A'%
M$1ZJK^H,4R1:@-S3$&4PJ'>B%ZAE*09T#EQQB;H6.T#1C=5-G//A&7%%&R>(
MW($R#>^'JG36P".@URME*LK[T?*I&\->MU98I"I1%:QIP!=TW,'24E]>G"5[
M=>N#K^;/BM*]F4"]ZIV"[)6A50"5NE$1&<IR&E;TU&V?*TY7B (J*';?D*VY
MU1:"25WYI0)4L+C>*<5QN 3TF 9[O/KI904)3-"?7ZLLZKU X*!F+!O4K,P>
M8!G( M:=ZZ!4);\7UD(I-:I1LRQ7=#>H126 (>K%QD%"*CNL3S;NGM/E.6'K
MW]7=.:+!2.>10OZN81 UHM*7 ::4WV"@\0WV <'>A#YONJ7%V.ZI$&HX.\HA
M6H5*C?QHL0*^K=41K6W,>C M[][ ,U>0ZX"K,GL<NA5+*K)5$+HMT?3T[JRD
MZZ]?U=6]E4Y6A4;F4Y9V9W#TBR'?OEG< I3>&7#6*-VY;4)=]QOQRJ(J+D2F
M\BA+%B.:5K+3'=?HW<AMI/6U0;Z=>_F*YIE!=50BH6E['GPJ\.T^N6\:A7T2
M'#NE\EW!BWM406BDI=.#@(QR&2HX0P"_$>,@X2KRTX8'U#@IXJW//C!%HJ==
MRZ79:*0AHR66_>%Z5O2>03X#GB+NW&CM1TN4XBT5*.Z,MENQ*$!,@!FD2])\
M*=5 [#QQ:.G%^USW'")5!Q1K%K<[5ODW2#+2W$9R'AG20T &]3?.JY!%''BH
M<E0H@J]*7"F_ AUY8E?X0<4?_?1[6QAB_(/>Q[UC/#3:;,)UW6Y1>O@-RXXX
MZXT!H_7ULK^R)!GG+D-J^;3IPODNX<FEEYBOUY\^+\L)7>3NRK;W7'X"/*N0
M2"LY=60@-)ZRQM ''B5(2N=ZD$/&HD]1L AJ=Q(+YLI6T)VE, #G6?  GT4S
MO@E6"E:,R;BJ=;VI$7B-U74V8 W W)<PF(SJ-J2&4ZR )!/HP0!&&]0MEJ4Z
MXJFQ-"@! N@""IY#<83XCGK7> TL Z\=! N!ZFW7J@MDF<4V5E-RBF]J+2]8
M<1G2]\QI7=4!IZ0)^*$6C95ZV-?8:/[3NZJRT2M'%,JPJ%]*!??:U1"P]%L&
M+A"]?KJU5&YZP<(#>R4*D@U 5:;E4,\\V^0C< I:?FH.^=]>Y1F7JGK<;DF1
MR%P"U,@X0D;N!5.=,N@ KG>GI&<YSG" CA2AWDE#3?RH*,$KL*(:%@'%1EQ+
MDLI4GK"2G_O=V@V=-\V-O40A:#PW.W B"7%C88$CFL3PFC2<MK@/XB6*FMH=
MA@(#1N,O<D]K8Q,CFH.F)4[IH9EAV4*!>#P6%B_%$T^!I$A&@G$Q,31M)EDF
MGP]'EQ9SB3:-I6R)C@RX4\\_@,>82Z/X#P>%//)B2#PGT72]"^SC#T;66J<;
M"GZ32:)HNB:YU+C:1A8&EZTQ="P,/1<'7.IO#S84FL,;3='P< :RU;AXN+K4
MZS\9T[1M&Q]#TF>70MY>^7V;Z?TP4$+ (3BPX2-YC4!/^^ ;4$ '66.CX\U+
M^%M5AZ'3M%)11_TJ"Y/J)6/$GH!T\#?87TM8$+]CNMT)=3^XRN0LJH1#WR^S
M@/\ N@H(6SBRX.5O[OZ#*5/1@->:D%-;ZKL"FG:*M+_JO W.Z\0] .G9_F7T
MM<4/1W6Z5/\ F:<& NH(A[Y?9PRV@H'AO^RRX.<IU]OY]&\*UQ?CS4AKK?5A
MW>/:+O1O"IWM:?8!T[=.A?2P+?['=;KS/B:N7*+N6[WR^SB'^Z#@?P^RRX(^
M=X H,Q\PAB?'FI#76VJ_[]HM_P#]TN&]AM#[ >G@IT,Z6_[NZW<Y_N-@;A]^
M8!M+[.%/Z8*!_P K+@?S^-)#4*SZL#KS4B-K?5?#Q[1O_6 5:%NMXHZ!=/*?
M85TL3_N[KCB3^XR4S5>IHOOE]G"WO@H(6_*TX.^_]$%:4"U-U ?'FI%_??5?
M]^T7L_56<$W=4=X'H#T[_J5TL3_N]K@+F#]QN4("[E+- -IC9Q ?ZX.!_P K
M+@]?]$%=^>=\#KO49'[[:L_O^B]GZJWJM2(.@/3S^I?2RJ_P=UNE+_<G!6)N
M"M0[2^SC26T' ^WY67!#?D\%QSO6L] UYJ1_UVU77^G:*>/\;3JX9T] >GEN
MAG2S_=W7"?\ ^-5LZIGE/?+[. 6V@X(2L/WV7!^<'0(A, P^/-1H^MM5BX^[
MM%;C^J]85+WB?8!T\%.AG2TV_@[K=3P^XS<L:A8>^7V<,]H*!^Z<67!'A_?!
MYZ<;#3KS4E/C?5CU^[M%''^-^OA4!T!Z>.O0OI90UZ.ZW/\ ]&_ M>'OE]G
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ME15KQ;*25RO49JH(>A'J,X=>_A?JGIB\>Z<:=J9Q$N#8UKDV?$;U0-"LO/D
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ML6X7'I88/V\HQ!=EW#OW(H0?19%K*;JV$W96QWRMM8T$<9Y<+#E.U\DXFDR
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M]9.I-1I*+_8X',+5)B]):=.39K ;*@2 G 2('3>O 38Z,9>P!P-ATLN%G&_
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M8RSRQ39"> /+V"1%7,_7+#-F;>()E)&3,)10@?AW;TC'G_]:^!]02P,$%
M  @ J8.>6(R<4Y]8/@  9HP  !$   !G-3 Y,S@X9S Q:C U+FIP9^V\!514
M[=<V?NB4#D%B2 &IH;N[&RFI&1H&9H8R$ 3I+DF#$A!0ND44:4&0#I5N$! 4
M#/X#YO,\/K_UOM_[KF]]_[78ASES[KWO:U_[WG><,^>PSM'8T5N 1$-%705
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M%-51]]FE[PI&A"ND33VB^0DIX@Z'0?25<%Q@GQ1M77;L>HNI"3H^?:0>8R<
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M,^]_9DZI-&4F^7*[W7P79\[0W-RYO)573MU5YC'%>_M]W4'*N53<YD!@4FE
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MG.Y\T7#=5/126F0"*\L2FQ)AP^:LI13RS1OQ7MP*2W* XUR+S9<+13>$RRG
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MR-FYGJ==K.]*1!I%<D;(/_5+9IC4J;7SW&*]I;#=&K82L3RB6.0=6B#?;_S
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M0*& /GK^^U.>+/N#AE<#$: =#>B>2795]V2D?F@I-\SD8EFY"IVHF?7D4I7
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M/A)5H(W?.GQ.X*BDH"U?]OGO86BN-34D((V2\UF,= C)^TK<0.5FX?.Y+O.
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MI9%T;(\4>%A&($ YGW@[5)GO1B'V^A-)K9+S7AJX=+J)^LB0.[7C9^Z_$"
M*98ILF@'>=>:N X^F4AL;':=D[_J\M#AZV9]']/#W.C+@68U!]4'^.(H5X/>
M_GE#GP!\1FF7*2>KE8OCI.N:0NRQYZ?Z@X1$W[M\3 +Y&!H]PW"9._Q\D"S1
M=0\T4O&YG^+=^>FTF$"S<S/<"JQRF68&OTFC<^@TBNC?:ZHMCZS:D1FY\/F
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M7]P@OI[2C^5A""#6=\!)HFS6SD?Y/O-8^PBJ(XZ.D"/^G=,Y,=,=WL\'L'=
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M;7Q&%;D[1 J;YLNB]VQ0O*@00%Q''23?)[71/)FW+TRM,TY4OS<[KSB<M'<
MPAV-A0[0*)A0E!L_DV/D.VC\:M+ R(#E9JJVM9TJ)DT;W<KJA9>AV 7%"RN>
M'QOAJJ!RDI-.ZDT2RG)&C-D!J3M^A*Z"#HTQ  *:=W;V4J#\;&RN!ALE@6FV
M+?0N(I\>:O/O/EN<KD-;\/N6#=V_YXVTZHGE+#8"^/Z&G>)F3]67O.GB0*FL
M6I+53I.NS.1:5#.U[\,*/QA29,51#-#+VOZF$EMID,5Z=D\!?6 I=Z,8$#*;
MMY2._C2L(=AJ-AS#)"BCE&,>91Y7%9O[A5VC,AMS)=N?2@16!\Y8%HS;QTH@
M\NTO/?U6Y!SJ5ZS^O8HW((\<1)GH+^79<+1H)\L3*O3')*I^)1*C882'&4"<
MC<),5205A:OM%O?%69N'8U#18_69/&J719C,;KBFC)1,:HZ$2W8QO<7 H2\[
M-R [U%JY%_]^P%.W#0>?]FIK5'T6GJV]9(K7Y-ZK_'AU[J=,:D"UO#H,.][?
MU+>.MAT*0*% G^9%#L-#$[$5'H/EU3A/^1O.KXODDC<J:=O,FOF,;R'4J3#&
M4CZJ*DBBPK-)K 2.(WIGQ7Z:8=8,R+9V;K_N]J&:W2":9T9>S&]E&9F138.:
MH":B&[2T_R!B1F,$FT](V_MV'6(AD#Y@$S/9X='+UP@>,V;*<R5FH\A9UH$<
MJ3Y>;MA[%(80KJ&;J"-W@_.GS'>.-_2%21SQ/K7?$S;ZRZZB_!W0^ONJD:C<
M@Q]J5-W*I3W0<1>%$+C)0?-%DMR81:3\V!#K-*'$>8\( V[KP-W!PJ1#F._C
M+@+3T8VA$C-*/_8/TAM+%:E0I&]RP#Z@A91'#AL4ZT WFQN\SE&RU9V<%'X6
M=J%)A"W+W#8M1CO.6;+W4(192&(GSE1:!0U&WQAL^-JK<C<RL=;"7_/5TKVF
M&E?@E7.6+&UUG8B!H[YM8$<B#-*$EY9UZ\#M"P*&LR]V51BLJ&([QHH-S+\H
M3C7N#U6G((]GJ"/L2*-STFYW__74$SVH=1-H^VZ(9E6[3F7!LI'+RDGVL#-L
MF?-@@E[1L[T%!3  ?@':OY_%]U:=B<;5#Z_M)*<CQ;Y-V<<+C5K6T?Z69Y,4
MGIHP<6TKHZO?9=+$([?(LQPSF"89:,HY_$*UQJWK5&4WG!) )WKKUL]I;5TJ
MW\GQP -5D8BA;"-UX>!=5X6STZEQ4($9ZA1S[DTB#WO5V $>YQN;])Q5A_U-
MT%4D(91= MJB<9\&TLM10&+1*UXJ7H[EZ!72M&@(RVNEHLN!\6-F3F'2]&@B
M-N8!.RQZ'-30:>PU2XE);Y&D?+[;E%V!HUA[E36MI ;ZSVC4Z^2?A4BKJQO<
M G33TV_L.-I&!5?3Q:Y/QGSW:Q36#?\TE-*;(EV'E]$I;2M.*!%<)]=O/DCO
MU1>@U'E,F0"W+_&NHH8>2&=>DDVO[=X!V?'.6NYD4HL]D?R4BZ)*QV.:_Z]@
MN/\?Q53-]:6XTJGJ);820ODV:[--MCNX5COMXRA6>.IAA AJHU;V0Y'KQD.]
MTT;9E9@TNX:,-C)DXU1^LGD&F<5MM^;62#6S1@2WU8,MSXT8NZ#^TSMLA9H"
M7>4L6OEO8SIKJ$[V&A*BD4PD#:RNS+V<^1'CCM1A_L?YGJ[)<^GK\]F7R]!W
M0"B<R3?=RU5) KG+>0-^[!Y#8'=);>S)?\S$5UJ^Y%1VJ')XR8QA[LR9=J\(
M$VF-7U)Q\!9/@ %7($>8B3%*6+3R0LYIP\S4)G^!JDZG45BWRH#$K7%V*]E"
M!X)D-;D2&<-F@<!D."I'R1II%!5M8/^0E",2T3@PNQ.CX^?ELKWCL?/]:EJ\
M.5=\9O2S<V[RJZDMVH=_3B;"SR,VO9C_:Q6M[&ZA+.,?AK#5/U.1=P#[2KQL
MT^K76Q?I9:&$IL"KK,#65[Q.VKMW@$]<T^N0\'U <&A2B:Q81A"3"E+..^#,
MQ/A?K#C_L[A_ZD?ZD1;;>>Q@@\BE4V.J &.UV>#RRLR3]AV@T%.592O)<*I3
MJ\FX>@U'6E,55WZ*S2%1T7/>G=GGT3>UP[!_%>==R1!?R^Q/Q3=7^2YKSFQ;
MM;49B-E6G1VAW?4!_-E2GV\K##^V58%4IO?J&=9=XUDL/\3NJ)V<:GF8]\U6
M#XR#S#'V%R**.7?(YX%KQ,17M;#M:O#K(=:DY2^Y)B_?I[E\<8$>^VDQE7[Q
M>+%>&BBAZYD*!^O7#T.Y1'FX<X8WSZ8A8/P:P 0D5^JZ"U2RNK/+38'2_&W_
MQ\P@6\:';IF^64QOD0V=\E+MAC^$I$^><E:VVU<M)XZOQH/ZCXYKO?,GQ5)*
M/B_&VFUC<B^.OVP)[\M'<["?7&P#EA<75<0)E$\P?$4EXNF9:W\MGA<BY1*>
M!;0CV.-PU-/5 ,A*IA!N0PY1%[=1=5T/=-(6(/M,'A,SC#>F19B,(X%V;S*$
M6F.!\JKXIR?99!QY.0CF1H;?OPKM*A[81Q4@#-"E2_" I4A!1.0I?BJNR*D
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MLZU-<(IOTE\2W=Z[?P_[:I#X?L#C,X<)YDOL&(:G'+R"VU7HMU4& O\\C'?
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M%E_:SPG^,'K^&$C[@7KQZV+7#-$BZQ3WRB+?1LDAWIJH:PJOK!OZ!IEF ?F
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M TBIFSYU=(;0V)T/QQ'4P1>.0B:MI!VX@4XZY5,CSL+JR"WCEK35<D.>,N9
MT30+.A3/AF^ACA?XALM'*I#EB.;"S2@$(T4>=_D'J2_^?4Z8N (A9$&L/D>Q
M+,E@U>1H+E=4@>4N\[J]5A/9#LT4)P22$G%IX*.J VGPA4H">]',*P\TV/35
MUW3K_V#K+8/:8+MV[;34H 6*.Y12W-T)4MR*NWN! L4ME.)%4MP)E.+N[JXI
M4-P)[@X!DGS<]_/L/>_^YLU,)OEW99(L.:ZUUKE>#[68[$$>'0#K1$>>6NW
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M<S?Y2P(%O1QI=XK] KVV+HZ,7I](8Z7$/_/P[W&%H0"'?Z:\!J:1':]7MU"
M&R"=6*D_$#+<<FN, L 'Z@XB*M9XDCKNYB_O"EL14*OG#JF?+9 _(U0@VS%=
MH8(QB<TB+$R,OXXH+[34RGOV@R/F%NI*/XD;TSNXB(OF\;2L=/,._DCD@39<
M9UW"P#L89@.)) R2) HNLNMB#E"]-#P>QU<S19$V"V')LG%A-M)@^4'6UCT!
M<2[,!2. ]?,-^0]9]W14!*038;U\QH=>HGNQ;[1_=+W(.<:DJQO^GLIT<&:(
M_6''XPBVGL)H$L_\<>)7M2UNR(>UZ7:Y&!<&:R5LSM>X.(?(*]7PK&&BA#)E
MLR7.'=_3K^1':-_[>_W>'WQV"__90[Z=5$U(7:6'BU[(0WWHOB:7;^E=($=8
M1)NSBA;*\)4WXJW&4XKR1DL[22QW*ZW)F$_<%M0O;1S)\)[C.ZP#M!DO99_A
M\FF+:;SWF7P1_#9772MI@S6)&A=,P<:),RKER1!]PA\"><K3ZKQ;,Z6A[*>0
MI%2M?6"X4YE<VYW\_7JY>8TD(.(DUOM[_LZK,XG@.RF+5V:Y:4;Z3Q3,86I)
M !V C(2'_/K9+?95^@UE,0J0?C9F.W7"<IF\9U<.'M%*%^X[-^$-W-Y85)5-
MIT4!@&*S^MW?19MSTP3Q';X/U#N8E8XD)ZU Z#]$TLQ).S%=M>\G;7#NRG!G
M%-D-) ^0+_./R\G;+A6EIR8E<99:<V%3X9+S2WO]=.)ZZX(5_B#>W+EC_AQ=
M );RR9K&@),"/=9X4#L(@E]_]L8N!J:C\3H_&+8]W^H'+*-VR$S;+^G$[&7[
MJPS+6U<R9#0^3?J0OVHT#)/K)LC(6:+6O>(K-3/6Z^<&L\#(S_;(EZ*N0_8^
MZ#%&V.7S==?.[<9-4/?;OW\M1A-)OHU+>CK+TQ1#W4DNN<7XPOQY QU--8L8
METNY:83VBA.QM#X3!V^VT&GQL7TOU:GDDDF=! J080ZLV+P#E?M-K>/K2!TY
MH "CY]"MR478]YO3DLT7<7[C5#.F;.S7O$!W/=9$\[HX_7IB(:UTOD]5XUWU
M[=KVXS/1.EE16EU3I*%)54%QEGR-X2I^\S&)<!@;_& Z4]!,44%),C7,7DQD
MLX$^Q>U5G&-P)TU/%,6SCV;^OE/Z4D.C/SF>V)6!A7,GX[C_V&0O8J?56D9%
MN3+C*E=22Q$&9]Q385:E[,9\&)*R"!IT$CU^]N>Y)^5;$R98):ZSB]1?FV-#
MBV?GC%SJG!IME_RMVT^MBK[&$[&9Z5G@$A94KB81991 15H$V#94DOLW-]X%
M+LW#7L<T6KQPF6SX*/D8&2E=;)^V$;/D= ();LWLSLA-@Y:&8NBC6OJ)#?,)
MQGEJ4LR-\LX7>)IKYX2TMQ\-36MB(Q'WF<IO([9QS5KWWWET_E\<5%MV]S,6
M+*DM2[M,(8Y8AFENW,]L>D9<-G+^%NVQY=7G\,#?2-E)/]-QR@"K0_V$9:$$
M?XWT.:+&]"7.]NL[OX R2/0PI5-Q,0<O!=3-(@IDPO2(U79+>6I.GTF;BW#K
MI5,XYETOKZO<(XH=G7]PJ[6$S1I%TWSEU)J;H*67X.3S^),D+G$:%!A&03?R
MPOT[.M[[-8FJ61K< OV^9E S7$* WH@5#?>"CBQZ+5+[^QG#7EFD$)RFOJ?(
MURHMY6D;?@C='9,A+B=ZQ)LHP_=Q9=*@B+<1%FNRSZA=Q.7HZ<C?=A;ASDCR
MD;]?7"BI]@%7^<P,^$_;R"44ROKMOMJ)GCGD97A!)_'CF#+>V.,/C^K(ADX&
M7):#'K=_:)PH]$/C;W;T]Q45+\EA8GBD%0+GXUQH7CM0*G*;^_5#;'86&!1*
M:?SX /DY[=W<3^D=7#\)=7^]=4>UVB<\#1D6^F=F\PP"NX %?'7<O4$[>O2Q
M$2;KU.O\.Y>@S#T3JA)8'I]LSP52-0SC5:'H^TQ2Q,'H6::5.@_4)#>?-LT'
M<D39:,5A%R^FVC"J\1-,@U-\40W3#3,-F#[LE1\I\T4?-H/:1A5,1[5TGK4X
M&!RS)X6^B-+_T.X2>!Z5NT8VQ9(;N8:AS8RFO*VIH?9KL7%$$>.CN\V6])Q*
M"\'213"]ICI=?MHW]*+WD;*(\7D4X&T6.PI@@DR?@G?T$\V"<\^_-BP3!7QQ
M5D0!S*.]=@9YU1/VH4^;O6(1QDLH0"050D?^L+P52WK="_BT)6Q%0.!Y0XFN
MJ5AF_],3"]TJ1P;C'%S#R_E1<V\E)8/VCB_"8H_!NAI_D\YOZA"1)K)$]Q'F
MIB@)&9CGYHVTOSG PJ:OH9(;HWH1\I6BDRMBU-$\K(7T;]_/Q?J00C:EGFZ-
M=-ZW'Z//OKQKZCIY1IK>NB'>.47[JE45;_\,O\;;Y[RB,9IH(LI/(^->G?A<
MF_-FN-\UPX*X6PLB O<7[-;R/G5\R!IYPUEOTWQA+2QT=B]RT7,V4I0::TWF
M"RO9)ZW/Z.?X>P$RC881:VO]O&BM@JBW3A]#80+C."$V#.<:)*JYLU'W)FW=
ME8=^(RU6T(! \,6? P4K__P6YL RY^U+4I=(-2SZ_565EOP6CQ^?R.]*_KZ4
MJ-I:G_T5X/PW(-WFPL#MA/*MXYA[_0/BG+1L/HLE'KI965,D!CA@#JH.*.=^
M_'80'CH#T!$4 .*Z>WZ+5"W9V[[HOBWT]C,$SE.6[:7UQD:;]SXS?=^1>Q[>
M&65?HN.H; E4!E'4'P#GHX^*+^ =+>(H@ P(O/[0[GT+2[I.]:;]G<E'FZ=Z
M*]?N?EP5!M/#^)P6K"QC>"C7<US$VZM1S8Y_TB52 7=500$*TJ%)ALS>S,CS
M>$3* 02S77S\<&O&W2?8YV#?<"C Y.#^,1BE3;4C,NWEI3%5T^IZ9UG&W'6L
MR;3BW.R/=6X(3VR6H5LB=I#)<YOCLG/V-K^J3-]ST0+"PQ\WY/<[PR3/3QK#
MCE=+[@=JKDT"MD9[.D^B65OM3]%5H,'270X5IYZW"#H:C.Z:TWS\#LJT!P2O
M08OZPR)R_!MV:OO%A=0]+BD*L%W1?J_J!V^Z,;3?-/&][BB^APZU'QTA"E;O
M34Q*3EKAD!EHS,K2S5))Q9))%>4D8KQ\=>R7'Z-6X!KKZ6GJ/G@3O1H$/6NI
M!%9,P_V::#AGWA[,AMY[_BTQ*/']E@DTGI/H.]HQ=\=3<C3Z=3*:Z3T]:"!9
M]9I]<5"@R,41JC/8Q F?AS8DDW&Y'JO:L)B]ZN?<J152LY3,J#65]8BP190:
M6>M%;]6'QK>/IOK/R[R.2<![&X3&91$D?28I3U<\&1_]E5SF?'Y07&E,G9R$
MC8],EO+.*&)HXZ4.KC(LD^-]Y-R*@7/FN$?(:_9ZH^]+T>S5/I]5&!>92ROK
M1!T5S8>C?F<Y.J 1;M-W7=DLOUB_VK"F\!2T%QN8 8M&6G;'A3G)6O^8(Y0@
M%73@&9MOEKO7M@XUG"&B=;/-C0P7X?]#:&3;V?0U-=I[,GJK)C8P*_'$Y?<H
ML4W[=^'U0*Q@]6S-%0$-*\@ME'GBS\$&PELV_ZB$X*#?7U V\9+27U>;$IRP
M!3RJ+!4;=\FP$' O1=RY5*#-[8V&Y]G3?L8PM=<C[DX)PZ#PFS4KW"SV.,M+
MYK!7\6L7%L-[C;!&3OET[T2$[.#,F]1WX^9SM;9%P7TF?Z]?"8=L*.II:R84
MZU1P&T+31-NMRNRZ/+CWR,\9E,D%?YLSB ,B@]\H+[S 3 :4TFOTR;T\+_K[
M*GM6'Y9E0THV9XR' G1-,,EZW AI1O$G7#U\%160(;O<*G%T*6U(V&!1LF"Q
M(K&8"M7OT;6?VV#8K(^M+/U"A.G&-M#? =Y(F_F]DA!EO][Q$D.HCK?L ,K&
M[C9OS)_1"0Y4W+D;,/LYPA95^ =-YB?BK0IP5K#0]0P1#(-[^P/7RR"/61HH
M('?D%F[TG\N>^"M!=YDITJ]%HJV9MU&=G#):G9NN(Y.%JM ;%,!W9(0J>>^>
M^]&*L&R<'O^LHZ7[6:W5^-D#>*F+,[9$+I2/R!1YH_X0<!Y] 5\R6+]\=,8U
M:<H]+Y/K&_8WVTLPK=+1^G!-2CR* P0>$I\<K8;.S.O>!H0EK:[!?3ROS@=Z
M#A^?$/XC(#'TX=SF9D+D8 <9#U=TFKTWGQ@,J)?.>1%&HYQXR4X7B*28[!A>
MV(&@  Z2*$!/)NZ<TLC!R6DUPG30[3)DNQ(*B_SP%_99#D\M;'A=\P#M#<?1
M[I$1Y(:N8V/BD1K)ET,WA<**_-]]D2KT29Z*^]_V>OU7-B;H7]F871^=\P 3
M,>P6L;*]/XU1*$#?O81?L__MH(A.@*.0-P)K7HQJY$$DVC]H\5BCU%UX9EGO
M>C,_^0OP^9<AY#J9/3S<\VBS2 V<3_4#+ '_M]OH#OAU7),%0JK7(2>/,"==
M?WO3D!D5D$V@1:$Q/17EOJ.-YU0!HB9T4RKWM83,4/P,TLQ.Z Y7'FC3.BAW
M4&-#)ZY@R6LLIB!B=&%CGD>@ &4&K_,(<]\M7F?0.-F^J;+LM$NNO?3YL/3
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M#V%\FU/D'9FP3<C1VG$83_:F>J[PJ/J5-N^Z1T>0QW/E '+5C*%Q;9QGKT\
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M:99R^O&DK_9(5JH+E[&Y?ZO(DR_^+2D+,FG\+\M4M-KT!Y(CH#]>3MTM3J$
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M_/@O8G]A/J.T[!) HB=:_@SM-SHC1=/Y;-RR!/T642\=L>"."]@_J[>13-T
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MATI[9O .V(=.!_1'-$3KT/T7B.0#P\O,<B%NG_EYV4#<N&+HZJW.84)G<P^
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M836_J[$JL58@8;#XJX4C?B-GA",>7TM$2)?25K<]U_)P?\2XZ-*]! 8C[W-
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M+:%K5;TS$SI/J;#*SZAO!M!O#%>*W!LB31GW=DWNCP&M:Z["+58?$7%%/V7
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MA:R0#K141U;H(C7S,RNZRCEQM,YX.2C**,JFC5':5;:)#PEIUD2B2F8J%0E
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M*KS!?+H?&/?2C-^= Q[S08@>%1_L<JEB6@KC.%'J%7J-<E[Y73YJGK\SR'7
M+@QZ4/$J"S(B!9PDU6,;TGK>*YWS&:\>D6;P>??<66:'MBBCLL3!THP@_.)?
M&!T<Y-8C&+?RUZ _\=I(15B0N_Q;Q[AN^NG!%#M:3L7?0U"$H/>UR_I;@,,Z
M1!#@\2I[+$;8994G!%L%\[6:+6?,J=P43\M.-:1Y?%A9\8*/8)M+E,ELJO&]
M7A &$)R$],[!EJW9B5A"_OY\C!?X^_,*A2]&0B5=K_NIC_YKFRZ*$KY>.RG*
M0P2% GZ'![C:O&'+04A]0"U6<=_4$7)3[0U8Q0-@RGAT5.E4'/1;7^17TCRH
M[,:ID)*-3\QRO>9%D_[)5R1Z.4\;JDE/I)H:7V;+H)]!]>$BS^^F3"=0AO%Q
MU\6)+N>4$= TGF3IO[\P#9;8T:4T?_/L7?/S$G;*:%0K[:<I/+ "'LXNN<*Y
M4!78V@.XT';!I,O?V201QARSRIYET(>!_J:@:TC7[=1%WP3,P0"VC+:B^F*\
M_D6^+<AS9Y^4*T#WE\E,(%-Q.XD_IS'J+L8T6H%M8Y0$'Q_)XL\#(K<CHI*4
M-.TKKS'(W1N+)R^^MW*G4]&5BBF7'O%-)3<Q7;\D*+$\>_QHNH(D6\AF?6U0
M!?]2C_?"D?_=H.?TVX0EWJJ1N19Q)9B49QS1#XU>DCY2CIOY N&UUAD_^=]M
M3R9-9$.E'@QU^CFJ ]W:)CM3/IHQ(B3/NT6)%P[46J%58K:#;8H&*C3FJ_E9
MB:M#FW-O H?A8!.3,:%MXOPE5SWV>(J'K(&_ 17K5JZ.*BNAAYMM&F801!?@
MQY6N5M.RW3@O4&#.VEY/!5O(:6>>DGM7K"R0::-CIOB"DH'1>R8PE\E[X.^^
MR6+#0[S)131-TF\;QK;S'C.W3_4)M*HM1NZQ'D&"AGXO[0G>^O>ZN4P\<*K6
MF.)%]@'OT-Z.'C(0,?%J?_S,LSB6,5/>!ICN6SUC%2/>LTSS;Y5XB6^LGEL@
MY S-[<L[A-4]32LN9N0<LL6M@RMVYL5D/2?B55-HUP_@ALGD'EXK04I29H',
MT6X9=:@@H@PZ>Q'>E9LDS[FS@5H%?\YY*?'@3^4[XK.+NL*F5N1D51+/TT*X
M1*EX.0W+]!0:P];X]<\;!>4<IR4@^2DAR/6F\/ 4"_FL7".\D3-=27/IMB4P
M9W!58@H '< O(&$BV&6G67XJ',>Q&*?F6#DY1(E-UVI004PGRT_V-C62/M_'
M;B1IR2*%@DGC&)3PM;(M1GR4"!Y7"'JNXO9O4K<#W_X/K^H4LU_KY%/;4JF>
MC)#CQ)&3O,%V.NI+^/+Y31*Z)$L($"^:B[*/RZQE]@T9,<@^DED0224'#(9(
M1<ST"]W5R7[W%*0_QG8\G5W!OP2*;+19PL/]F.%=B J!QSJU+L1LS2KC?%^.
MPIIC/;*0"$S'(YD0=/C9.>XH_/IZHO\.^<4'456F?0]U^7*_E4CKMKG=\^[4
MY\PG1IZJ!"[HT&\%[Y%/9&A46: (LIC2E*%0BR,1\%1LJ*KP1I[.@YM2F(EQ
M;G]CCHRQ)P/J =8DXQ535#A@(F2<V1X-!PU15M7>2+KFU_*]J4!22O9\<B[M
M,3J-4*-\>R394F:L*RY?XON<O=8MSKQ"O0&,>Z]DWG+YH;$D;MR$82 ^S=+]
M_4PEJ@;T)>>W_C9?9\.O=:CZ<[9/6PJ-MX$N=K\%M2BNU1@RJ ?^P0+RCR!7
MZ+)%E@O?8.-JE^4Q;58EUU<Q)>@ME*?;T0D+JTXO5YAQY&<0'M!&Q\\^M<Q]
M^"ZY8!N"M.9Y^K'3]OY4#W+VW;YN,Z*\)CQSP@#4L,Z&_MO7O/)FK.M,3B%^
MLR1_3WR&<<%!M\V\BWP_NX1 C/2 K%*FS&5OUCY/RP00>*3CN77LG?T>;\Z2
MB[L!4\8Z+68I$33M\1<641,I>E,B#*>EJ'3^8F:Q*!5J'!N-N$WM'A &4)5'
M+4QF* C>(0\K^!$$W*QDN\-# -@PB2+=%+!,UEZF&XPGYYL_U\;Y(DLQ(,UI
M*;RC._-%%MNB<7//7I)1FYK9%FOXEUH,FAYJBGND&+9691Z5$V0[SE65#/AJ
M3@)V!#99KL?]YNE\:#DV9O@Z-TC<,WZU\IK=F7)J95%/L]1C^,?&UTA2( /\
MV':\&V6'2I)RBB4O(O["Q"$EN[)4[GPV&RB\RY9;"6IOK2*#>%FJ*N/4'0H\
M67$DY]0P)A4U7!^@_YXQ;$6O>4(EG"@QF27X]/-L<5=+>CRWIHXZ4[CAKN1>
M,GP_KV7+ZE^XC#8]32^&2B\VXO+%R4EL:C(/="N?'.9!Z5*LT!(T3FI]BRVV
M;BY;?0?.;#+:BNS]EL5&^$#=JE"5\Q]ZY/&N4%&$)P[.% 1&WLO)%+X6_9WA
MAKWC;W/@CXN<:A/C\#7)_I2V'<,)HS-3#E._P_)9"J8,;)/+V;$Q9;>?I^TX
M^]C@(!X^A:8AB0[Y"-7XJVP8#_QB>CV;V8!D* ACER31<"XY^:%0@4#[\!W$
MQ-)^U.EMBE;+GS%E0%UR=^[EL?92@7:2LDD.9U*&$V9A/0C3AOX)$>QG;[19
M_KMU)CO*C=6<TU#IE16ST4CMT:7@[?T20-P+-*E4V56.V8L[#G.U3(^6/Y%>
M9EUK&-=HMLW3>OZ&Y)CA;H:'X<1HPF>88FR.3W[4OY1;K<N;.D?DER-2435^
M%YQZ^BQ5>R994=P\ 2@'NMNN5QKRH@H](P6Y]0![[K'8;1?6_$&4L!]:Q-AJ
M@/G$HCG+[(?&46(5!>_:)(9OIV//(!1X5*WXG.K8EG9:G-H%U(2\)O]@+6T^
M63M?;+V-=WD@;C\@6V6<J&(49]!U&O#C&U:72Z=%VV>XH,@UT9;[J8,R5U._
M K49$<\='>D^6&NSX8M0\WUX:AWJ,XM:?M<I;F:]'.Q<4SA2;,L (M[Q@NKU
M]+%)ZU'M@1=,]Y(FY!$P5S[+]AQ^F07_:34#A>V+2L(RMR\,#%^=7@?PR".:
M89J?$^R:^.$/^(M>&1V] "FK!)60Y7%'29[[X,B9KX2!(4N>3TH/2JFDK=DW
M^^E/(H6Z5PM#OP$9Q<P5 >>4UAX8XCN&6N/$MGAFBDFKNM3.:3=,N>>X_>&J
M:*<3T&VF&T7"WLF"G<6N6N'=#[B"HT>7^*O.39]QMI")T67K <Q%IX28Y*5C
M7DL<LHD^3,42$\P57%TEB^ QZL]E[QGF!XYE^/>C!L96>]^A986:Z'PS5CI?
M%:S^4%%;[Y3'6FO?G4[>?P8/!(+)[R3D@@+,GUG)#O8I:PM2K281X)7H!%\_
MLX<_[-S5/#RH5X=;IAF-K.Q0*=#TYJS-'4>B6]!-\9PY@HZL5*&XHD$!3@?I
M/Y+UHN:<Z-+I?!!@S=2":XYNB<DR'S#EV6LGWDWO9A(%7WJ[8M2? L9WYETL
M7W3  *6E!#,/O)2NCA&H9B^5@X1EAVIG*S7WE(Y;9W4K>P! 7DV_Q%</<TFT
M)<&"'&LI6_K,*WJP>G'SU6SV3[ZH!XGH@N*1+^_+DW*,Z%?'R*O\QR2&H0TK
M0<FA/V$&W<<\W\RQ$IISRTQHWT)PZF)]BBKXO]#32:@3DDMK"E?^KA$3!=-D
M"60?"".,1KUULQ_^CL._=)J<3 2_09ID_O?ZUGC=47*[VO/F8.6D]ZFUM12/
M%4 I+J!4JWJV/M[YN4.8A#0EN2*KI>Z761=LK9H_]T'"O1^.*E;&N/;>QDM/
M4W&<OC<EN?W1;]6BT(5\ZAD5FRHFU.O9F0EV4.@3C=BV+TI_G^)AWSP!5D,$
M)!"9_O4&[JU&(@E()NA"ODJZ1SGI%-D;1U29M3*(NQE6CL8S)V2PBZZXM3J*
MQW%,I(Y0K L(CVIJ>[;-NO_O+8BDQC_*067 4S]E#,A?F_MO[[I+G<G]Q30"
MGL='&VS*?4;G=]0@D%NAHI.(R PR ?&E0"4;*ENHPN/$;J*OAN=$F7;QV__&
M_(QJ1,H6VX"]*Y+(481=M?FH([;\-SKS+A*Y$^KU62+*=D$#62UXB#E5:O_>
M90S6WZ#BX:AF(=/G\G^B0-NH[Z8B?SXBKWZ 2\-V6*:"$V]?VKEG&F@"'V4@
M(-TG6<KI&?DB #8S>4SJQJT.XLV?OX@BIU^)3^"T%J]6K*CSC,UQDEI-SQWT
MF@!SXRF]#[T?5M6""L643__V&NX9W#AK]9O2YQEIG'TR^4+="9)\Z_@V56_)
MB]K-SI= U,;WRY]Q9682CI"?K20";E#14;\DJ?<O>JA(!L,4S"^)2Z7\-D_;
M(>C50NZZ5Q^#J_CN#Q8[R!G66V@(AEGR.0%99NA?TYF@+\!,2G'A;DX70NT8
M *:QIQ.5BKXH<4:M"\KFZX';)#]<%VG,15W-?6H#'E, 7:)P-2D0-Q,]IY>9
MWS0Z;G*GH:<YL_/RTR%?A$0C!6QB)8^W_9'-7TK#'[L<UWJ<6LSY?Z(OPR3R
MN] '#G A>_]X(AV[X,^[>)/6!6/X>MGP-3 )ITMQR&]2Z6Q)-%4U_\ZTFF[X
MZ07?N9FNU.?0\:[X<;2<7V?@'(,F13J?8]!JQ#K$1IJD0U:WHI_JC)*F<+:F
M]O2\VE#H(**L;30!-X1.CS[QZ5Z&UVM24E*L$JLZ[';/OE4XWF9R&PXP5^JF
M139QTUIH39( <M.EN.?0)4(U/:*1I?CMQG-.MJ,B36/^ \]:LY9?"-7#.F.S
M\?&0L&=OF/W*S9#R& )?1MO7;<2!4BY2=5Z2+L))&EV;\\'-SZ@B&9PSGY_O
M!:.NM9TAJ^#CZ[@@1NY2M]JN4C,X^P-/<8VUS73YU#Z-DVHQQ1C]%7<Z1PH0
MS55L.TJIX W/5-ZWKILSE]7>L2I)OHV4PRD6'5G_7LC?COD'RP;VT?+XZS'Z
M"Y4YJ*NFVD+@"@\+#.IG!,7MR;CT43?'X8S'3?/&%:HN4]A56*^6&W'QHO0U
MPG=?O0LI6E^%.CNT',^4 !]:H[CIWP2 -365OJW;J>3/3F!^$$_<L*I]2L^>
M=>A7#!/%;;,Q%-8L\[=JDE334O#%Z([VA\5YVSU8O.TH07"0V"8N&4=T=;#>
MN!R\6_>9QGP2M]3U ;US.!&UK..QZ+"!F4L'Q#K<.-/-1V9;&O)F'7N7_H/E
MI5#]A4HCPT[=@8IN3B6>NDJ$0<"TR$$^R&JRFEAT5E,;!$]VG.91]BEV/)[$
M;]0>RVKM+=)#P+9ZEX8(1MHNHL4\YLYJ7CXE*2=)NY/A*S<@1 VAZR'>_+_N
M\%57A8/H7.J==8;]B J,7'O)PO:W_09?:MP3FZP(M78'I8?>3/JEE\D_.J$(
MS-.7>>I:PC#5VD](>8SC J$U/X>ILE#9/KGL5"+O YDYM%@(>+N_7*F]OFV:
M;W2'A@'1M(%TP'(MFIU>SL]*1!932J3,H%U? ;PG1)$6PA,ML$7.,_,T![+C
MJ]K7,9.IITO;'V&T\@_?W<^^DVOG!M(4,@#_P:K? D:L-T6C<MH!?=38P!H'
M7$G/-1-^+IH09M-PA&5GX$. >NN"G>0BI61K6WERYC?-J"GH/UBC&+7-T'^P
M$*$YKUV'(RE=LTJ]OH9GO6 W-:AOI\RMT;+:AO8=&(%.#7+Q#@_UZE;LN" :
MI5H<>GS:;57DSLQ1YTT9RROS ^V]K 88DLXGQ+WB]M=78TF^X(2*5T96;6NB
M=,<,'''%X'B[@LZW&K[U?N38Y[LX^7^OU'0VK4^Y5[YS+U<';8=XHA%3*Y0W
MJP;22TLG-_PZ"C?0A 0VHNI U%,!L@I#G8-.KB]2)9;.PC>B(TZ>F(6^<;N2
MC.=-$X]=QO/(HU7&]]N^]0&.UDU8M9^(31KBF6VA2/51(GRZA.0A&DZ#6W(&
M_%]D>^5$ZHDT<F[NN9;*!C$OZ29D^,Q@_P/S\@'/2/M(V/%Z,"?7_3#YP5&3
M+^G6 7\&)N,)>,^5SJD>4 UC8*(SM S2J3=B N72_9<NB,\4OX$#_CC?P8*.
M^NEM%L0V73TF"G\O7"C9'.O3U=!C1.PP,OPHYMPF;)3GT&\:1??)U!3.82O<
M'VTHX$OU.[$="1AQ_#[UW>88_.'G4075(\T&<WP+YB=8\3)->&3,"@_77\1M
M)/%AWQU; G-4&(&RAM"ICKQU6$XI;&U\U^\FIPMA&M=-$"[*W@YO\-KROIG!
MA\V)&ECA<DV\O'89%(#PX$(/)HFS=:GO]S6%'#0=KM!)':WX'T+\VH]RJF-W
M9";Q/P?83%8^;%9;E9^=V[>?(% T#:LN_V!!7Q(4OO(*G'0@CZL4+\H>>2J*
MTIKS#@8E_BS)IR:)+:VN5=PF8H68[]_L'6[E&#4V/WHCF/T@\A2QUKA$J#[5
MO-!N):@9QN7VR:]Y7E(+@0R,XP3^L,Q"+[M3KKK2)Q%*KMD(3ORM'[M^:K_N
MCEPE%JUIF\M0Q&L6N.%PH9K'8F%WO"=?VS*:TW]/1F21(@Z\*M"%+DSK3#5M
MTHY+>_*:QRUM9S6E*Y:O_ /+M&_;_9(5M29,K@!D[/QW#=E=\3X4LWK<MU[9
M8$&J$1?<'(/.3QULF3F/4"C8P31\#>:$G!$LKXF3NF8OV5-7(GT>.<HN0L#D
M=" HPEPEOB5:[>PEDPW/WM'KV\W&+!S16S5!O61R!+46-#I*)GPV_\%J:,8.
MR+T!5H5$Q394WD;T%5FU:U2>:66D!>9RMNP299.+?(W_O"_1U*";ZZR1T#UR
M]>VW%XPWBL<,L15/[J7:N^C&7=2S68;G4L8ILNY.:*PQ=C/'[,%#<TX'<:P*
M7+W95QU<.:;Y=4T 9-39I:^GH=FR2)TS9M@[&IT?A"H\*A3^_1,F4%JDTX"9
M:=$R8<)'CQMU/BG_/)1H+Q*?&K-85A[',%D:P6=4'(BDZBP+\9*_3I7=1=2K
M:4EM;5\0@_O?-P."!-I*@B58>P-+PBQ-M#I;CC;YU(]FGNIS6-2QB_>JGT-!
M9*C7CBCNAAJ>IQU??.8(<NQ2 Z-$;;@?=J6NZS>_S+,YK3*DBI= #? X0A0Q
M*^OG4_RB\9WM8Q[*."=HC-T"P64T<:I01"P^Q])F'K=)[-3?<[*OH@2QS+H9
M&H_0/@F7+!SKVZFNQ&9QEG*W_B[!R67N,>56'2 EW.@-_]>V'7_=I&DVR,S0
M<:;H\KY=QU&YD>4-N9&2B]SS7390MI#+4)F83F2WRZA*QR0BQ6!'M6&$5]S]
MI3.%CLJA>WA*E=.9M*$2^D7[B>V0^PCN_CBD1L1B;'3B(<5VTZWIN_Z)C7UY
M_9GAC9I0MT8SMW*"=J05)9F\Q<&6<YQS=@8# Z,K!2>[G& U_H@YF#Z73064
MX)MOWZU6%8:[$6H:66869!)P,5SO\$65Y0B&615Q\6BVM\/1#-R !V?8_M(P
MH/%G)\$/4R\HPO>,3PGK_6*OL8 /&V^&,+N<>VV$N9(W:K!%DO-_]29S1<9D
MKH;'->A27$(#G=+K,UR36_N-<OB<"F.OVL4#LXUL!/ "ZK&T'"ACC+_9#9M<
MJHPF1.-(&_QP2*&3)"0:81(/H+%*(:&2GJN&LX^!F>%KJ:,:*KKB,9(Q.[P3
MTFITC9M]*S3KAY<K2\:@Y]Y+QYPGG_<;70R%OIM&\>&TY9Y;9WC.%(3@2[YY
ME9[8;:6:R9[VU@^G#B*_KZ:HUW\W;F=C?0*O6!ZK.>NI-_/ZU:9V\_6,$YT[
M'>"Q9-SJT83;K75WH[)V"%2;RC>1?70A 4^E.V\2BG<<B7![5GA_-[H_":_"
M9!"MO4+T/(HS13]I/*-KIXFA\X@[4W5,P.$5<^T;^Q@A9 1P>[IW,"?#9W4N
MO 2 U=*SQ]A,8BYNUTTM16S,NII'W(4T$UXXG9["(,Z25B)582NA?Q&U:]3D
M)#.\&OR"E9+,X6Z9>EFMPVD^XCM=N7'&//G.Z_I =*A_#8,5 (R\F&K ;K.I
MHR1@I@;Z$1W[Q%L*X&M!<($W!5PSR8U*>3+^&OA/GWNG-,CK@"6R"<%<.C[@
M[?._7] ]WLUYC^ :V,_-K.!FY12V3X[VD.$GY1O9RV_/?1K.-.)EC_CJN(Q2
MVO7H)>GY&3,H9#ESB]^OCO#%/W-8V[P-TP#-F%0IGM2M)@&>>#$+>57:*EAQ
M-73B'[F_Y^8\3PJ#A;80[OTLX(##)U;:';;W#3P=1XG(K%571+YSFIU;-\75
M8U-:-BL/_?@\J4(ERO(BB]?P6UKJAD:*D#6R:CX;OM>V#LP054U\%1KN+;][
MG>,$1O]WR8)9\_O>:Z533CJ#FF*H6N_;'"-8)F2+H_0)PWS]9ANKRT1!D\ 2
MQS#$XOO/T[_<:%_=& ??ZK0799X<S]EP5[/6RDF-[V,'.E.O4'*3/='4BDS;
MX3@L'S09TK<&MV6+.^K;L0#<)$UF2#YD/=N#[.$<\MK+\*FGY?-5F&5JP 8W
M4;;8T_";W_%&_(O<.L2J.+N'+Y.;$(U15?J<.LGY>ZJX1$)\93FBGM/\0 $>
M,@?1SK+P(T;G.$8C1%6US (7-?$M8P_L G%N&.Y;=V9AN6BL@2XLN@A!]1.V
MEU.N?=^8/D!*W!04QJ33/[5?=H6+<F)&J[!96ON$%FVRL4_Q@Z^3IU.WPV>\
M=7MO/D'OM%:ELO$K(8P+/SGG8?>?T)N%]?H)2X$C9SF[_C\08_55G]9N[<2$
MGK*XO#F=9I_\3)29T*J^8,O:*QI"6[EF\]T8T]30??:@2*%K8CD]BW]?K,Q1
M_@(&H7JFH<5"7K HE8<8<\D3B(DKS(BLM,A^<YL[%\BE:E*)#%]'S6/ZA1X<
M;2PVQVFFA;*4T9O6/0M/9<UL)M,K1+6RUL)?M<0O< #0-U:]:7VAJK[S;XB]
MB7Z:.GS6S>WPDS]\>%RK@/=(BT4.$<Y/N'%TKB8RDFQZXN%2'PK$/!.M:95[
M^GCH?TEG:HK)^-:M:.S3]@"=M&5<S,.O('672YZ ETEI'<N$?G>XP].^>6Y"
MS!S0\AH0Z\JBVH'];+QAY:XG@=EI8=#M)D&Z8[[08W-7U/'PDDVW+P]_8$=S
M.:SGF<UTOYNV0=*0!5ESY9FD^Q(P;U-M(+"_5UA["?DD5]T\AIR:C^++?-N
M*2AHEWZ)3+Z47)"O5$VZ8CR%0$Z$;=)%P)0\;BV-N4IT5+?V6 4DF5W^?'(E
MNY;N3S%[6@D$\YEE]7@V-_NU8\OR5T<EU XT,!'?L]KKJPT7W;G=EMVT]LBB
M,H,7#J\Q)IY]'M^+PVN(@WK"]OH-%2?FE=*K9 _9<?\NFH;'OH4^E G_.9'M
MH)]U?BL(?;O'O0'M<;GQB!7]+7G7)9 J8]^3$*,#\L%Z]LW@Z40HV<DX05:[
MJ=SCZ500?*7Z1(M^,Z^E)HM1#P)C>;.D[ %GU,GXLJ_MPE[;Q]XD/!RH%%>[
MS)J-^-PDO$8\528SP389LD_N?P(/2G/ZH#7UJ1P867CM<7/?W"X8P'Q!:V4)
MNR3P=5LP=WRQ@KSF@FH5 2/-6X%M]N>PV;AVT=4!< M&?6+_B84J*]_ I/\M
M^T *<^7IO5!5TB\+8T]3[.?,[-];2<>)5M>=R^B$Z-2AR.FAN&>?@$@>@U_D
MB85#QU?/A42=M6\SK7W'R=7T3M^?-B, A/6&-:<>"WLY3HUI"NH]()KC'\<Y
M1>K.;VF]^_5H\#8LVVV%0-C ]#.<-W LPS >/QKVIR,')Q8O.\/O<^./JU\%
M;, RGOY4''M7Y2Y8Y?(UPO7H+X[^9B%I*"ZZBK95 A]%0J)@W'7B)U9)BU,'
MS&)QB_NFF6,N^P-#)8#K/? /EL?'P8]M.RRA\I(L66P(AXG4]39.C1 W^SA+
M90!FL>_T*G<=]'RD.'"2.J9:V@@!<:1?Q*\/:V>>$^FZA90VGPC&VGU1Y>]]
M9T#R%&VGC_1>&97R'W6PKO_)J,;]Q+S:',&H9UQ?,=DS'10(G/ )SRS.4RGT
M_#")#_'05]^6S-B!6/TQX>X5TG4*<"R$Z 3G!E/W)UI+*'0V27A,T*R/81!U
MTG$ G\Q=<T'K68/UNW$MP/ZWHN^#ZZ47Q(N0#BX^T]%UTZZ TQB9T0EI4VL'
MRNP3]C81N@_XCF-CI7H?IO5=I;W$>;Q[CU6:ZJ7=:VDR>5[5/C3#F_>;)8H4
M8Z(=O)!@T%Y#4 -Q3E3H;$N/AOV@GP>EES1P"*^HS1%I%KVPNJ#M)9CME-!,
M;/WLRB"XYF&O/3REM"RTB,%5R\.&PR+C'4)"O^";%KV8FUK85M4,V+; O>!J
M^M-0?A:[L<D/:8&?!7.(T29I'K%JW2 <=5^V"">KZ!@ ZMEHEH_'WWV+H+B:
M]4L[-YL:0/\6BF;K#*,^NHJ0>]YU"+=Q-4WF9W%6&H(BNAS&\^&V^2(.2)@&
M#M\J%4_ Y4?VK/-9XL=?7_@EEA@4(Y$]HK"MCDA6FW>2127]9"PAM8S)IC=N
MO%Z2*S0<K31TEW5\MK;/4J)IY#4,?=8%I0YS!)VLPOXGP1QEC.6SEOO,AT[W
MLV=(N6QX2<MP!N^?UX4ICG:&7F0URJ$X,TWSE>;F*7RS^J6CLSI3)K,F/%<F
M9=9R5-9[TM-4KB?OU**/"V$L\]V-LC5(%)_!=#8"WH\3GDOD(.Z3E:*$%-2,
M=603O%LT=><2,4LV+]7,9^#U4U65_/.R#!#%Z]PGA>C$K&J"(R8Y#6N>4]D1
M>_5:-!=V;5Z8/A<8Y/U,-6/C0B['7-QC-U:HI_.&8[\!/W)?>Q%@W\(UXP0N
M_3<?.KY_%W&*=LY%-0D@B/OK/8M>-Z5_/O&8S[(F6J&9'<\GEZ:UXA3-P>AR
MCMM1O[1Z5W[.J=MD?;S^(3HG07D^MH1)/NBW]]%=Q7&CJ<=O*F"L%G-^-G_J
M./W;!D 3(Z\#!ZE,8);EBS,Q>?#T[#5@M+V,35%>AM*IAK]]OYYOMED6EN'&
M,A/4P=TN3*OEX:$XP(;"_!D2=LOV2*XO^Q>W.N5:%CBT<#,-76[]%F;BF!Q;
MWNI +&X6XBA3@^Z8'50@6>%W?-">IP:#WZ%CWA]B9*"Z1GKKD@9Z\Q7DA"/O
M) %5_FQZ)U;$\N<!YR_LQJ!H]O$6@&#RUF<T;%.I#9:3^F1E3+5S1B%B$9Y]
M<F9V:05!GGP;0S3LLD9AX0<8LHV3V(OLI-(_9UG@I(.^_+9B/O^X)^BH&+=\
M5S\A,I(#*%FYP)OP6TQA1FHP0I@;6CU49P=&D2L]S$F^2A(99 0;C98K"JM7
M,S"+TWK8$F3RDX))S.9(;?10?9"G1<N2P3:1OATB"&3@)W&"Q&S72A3\_ <+
MTO%00D*RUX>A0+?-=^!F@KMOY.RU +"%#5ADM[1Z^X VAK'JF1=5;_?;29@;
M7GT6#CIZ6)!*(H_K!;[(KVK%.>IRMN<@?!#= @7:*&9/9J8]II9.RS>'7\;4
M_R YY$AFP?_GD<PB_B 2OQ5E0E"%$>ZM0G^A#_KAF/",T#V3F_#V"3M8AGXW
M^BV=;ZQ^+ ZX9;=;4B"$N)W+%V4\96NEYZ.6X9,$#9-:8KZ&PP_[^TWN<O2.
MFG! = A^T])M )T+BK09LEM2>][#TMV[G$GB.O<PS^XTY<332]$?!.:<5=&<
M:(\?HYKT'33B/:_M2&WX8H)75QB5*Y1F M1SL3-?G<\X=WKH"P;U<KOS&FO,
M H+)=E+C$XVV=-A:RM,2X^Q54T>=#/E;-_MBYA&DYC\%?YI[#:- ]@VIEG-?
MSF[1Q"QZJII]*'Z]-;;A<?KS"2B0=;ZPO@E"@V]4,^%<?[WG(KH[4=P$=6O\
M!VM46[]D4\H@O+_9$C>U7K^LA1WTIOU&L*+(J<OZ@IPIS!FC84KQC.%9^\\O
MQ%E"X4DMMN/FI1$I#K\GM9^[R=*2*-#(^4'#W,)D>QJ2'M# ?KWFG1H&<O-&
M)!X_+ZA*E8R(SG?.&?BSG"X-/_B78:%1^T%<Y:0S_>)6^>OG:BHEAQ=UT&7-
M0D*;=S<4L@VN]IAS;7<TKH.%'G56&\GDZP!B"AL@K])R:;F0B58?W:?GU'Z#
M@:<W.["OGL2NY&;29=Z5'T/+-E]B5FOR((T4[WWX/$=AVA8/DBDOL.93KU_I
M&YY_LU</K:(X"*XW]DJ@P2SIUH$"ON4L-"!="6OG.9V5Z$LK>",[)!4\]#UZ
MO69@NT'\ >G&J5E.JM3IW#\UB [F)A@4BJN-G/N+N?+/=G0[,99^&*AX3E<F
MGXA"9Z>^VUUTX&9DM:3M",9T",7*8RS[.VAU*-6H4:7Q6ICB4G(V]+,L:-ZW
M*Y!K/$_PRG7CXIE$T&25=BQ)_J]9\RJHON+]76V]XOQC6*R_I4?SSTTA'G$1
M50'3426/B^5GFTW7>_F]0LG3B6J-*U?Q>R.??@^;<.^S&M!SDXOW/!OW$)O6
M+][OSM3H+,,OF!!+WI.^GHB@GXA(WCM;Q&]%SZLW:K'\* SWI#:WCE)-5I3M
MX\9W>T4C)K++E2A'%4:^YA?">_6B0-8R(^] ,W"RU'+#U"13 /R_)7B:)^T2
MIFV;U-B%_V!Y>=P'S546>J"HZ[<:*Z!8+U_.*N;("X]9^/I=6RQ"$Y^#7K4<
M"N\)2>X:0<C#?!U-) [4!7A2<&N7>"4.V<;M^U2);2$FF,KTL2#&R2*RN&<D
M0NP,H-?UZO$DLL9I*J _^-V/YWFAT[=R :>ZE!47$I4*CNCW#::5?;0EILX2
MX-^S"G&4>2GO.Q/.<(S/[[?*[5?UZYHRNSW,\3(Z!<;'6RT[=F(DR*([5R_T
MWZ(&^\V]K>]YH*Z=\(59]+Y$TQ3U2R^K5^%>C1SF@(V<RK=63G"='4,DQ;<M
MV&3/"]9.#@IST73EMS32018N;^AQN* ##^3:\\M]@:71M4T[[?\&8(R,43I+
MSV;3#$O3?.Y7D4Y1]@[)D'H1^V^1FOBC/%;@47*KF4-M*Q&Z_R#'W>>E$[\*
M^%MH-2T? ,3;X1]?U_'?)TA.8'MUTZK95)P7WHZL%:[\\<,ASH#S23#QC.NN
MW_C<E!?AJ\6D^. 1(,I ?Z2NN2W[;3?#%))N0D<1S+X(R[=3JP0I3,3PF:$V
M.>%S!MBU@4+-*@.W58Z .6DXZZI?SUSGD30!1%;Y:8R+=<QPTLS^M'&#,:+H
MAN=HF^2W6>AT@FP^_JQFR7C+J>ISO!QKE_IL3$N,3E(%\9H?ZZ8^8JVO3W3;
MA3AAA<_A3/)J&JA<1)APHI)&POCPU6R@\*1F;D/A\SIU>('C6;'AO96;1^6D
MU.8BM8R=U%BHZYQ-/ 0[=CBR3JJH1+RX2/@6/FXD/*)41_GW$/<Y/6AUG);E
M0YCB]N"<#=4>B_F$_'69@"-+R'^YIV87918G91[\RU+]+_<K_O[X3\MVL&""
M.KG:?,*XV)5^PO??V%Z0;T_>>TVT)_W+E?Z7*Q/[:N&#^@E4+^C.=?6^+;)9
M@%&^BB.,#"941P.3/';R)U6/,YHZ3O!5-&$=%>5\27%@/[E23]JUB]AK$E0U
M>.BWV7V&G(&F60-[J0%''O-F66(V'A60K$STQD?2.5]_? GJ!I^'@,*U6=X2
MD&;_NCL/:O*)0Q]G0WC[%7T8Y;]5=Z!G''%>LJE@7]'+ H4:,IVG!7J+66V-
M.ZRN)(:]]3YU9(\$'KJM4\0DU,)@+QTSGC2KKGCGK S[./MP!+^;IN]T,$K?
M#K]O':?^!:C_"74WH3>L-.6GDC4!4E0F0%>C"2"F;Y1 >HI[*F//4W#,U^HM
M-\/'WJ:.FEMN!)I/ *J=DC+DP%N\O47N'JDM;M/9C(=IF_!@R\+% 'J1=1Z%
M>OMTWZYU;7VE-9-&JB<,'V[X;5E+CBC/G[_DOE\7>6."39_&'>2GUB_;OC-+
M^NY\]G'2!P,E.>>+[!1ZV9-*46)J1<,',AKVC?@[AB$W%97V$%%?<^5%P["E
MN^T\U%A[@0EP7;()1ZGM\X:P3H2OJ5K/>UP.I=/&K0,4935Q):9AAU$AU9K\
M*DG'TP=!=9T QF/T>LVN,C-BX:RHX4$BG:-X350]::"VJ'>(>LCJF7G2@5FU
M7=2ORCQ+;QH<Q4ST*C2UWKUZ;8UP\1J^LPIC^0Q<?CML8$4?L*SW#@W7C+:*
MI;KM%64/RZPE+-4/C-@I># Y#'S5E!SXT5 ,FN'-^[Y(=-FSCU%2U4#VFK#%
M)GE*$91!W3!G;H+^U9&1^P!-)::0Y](*!8QUH ^@SR.1-G<SI2M&KIG_DVSK
MO\T!\H!WTK1\I:HO8O2Q>8,YE?X]$C??;NXD)-S5GDIF9Y"_*+^NSTM8J*Q-
M;KE@>#RR,6%:Q4%@BM_=NV'Z>+GA-9[W]3WEFPL3JYQRPI4*-RYT -VCG^W(
MANRVBVQSEYM2BP;]O$E384MS2'^;4$91>U&;_BJ1<2F>)^-^0H_:JN659-?G
M+PWZW(/R,*%TO-SVSPVC#8;<:H0$\LYV;B*8]"%ROQ>.6^AG%,8MY5V#VK;-
M>M0C@M3KI1/4RSU;U\\,Q,P&;_EPWQZIZ>OM_W*VU?QT=Z;,[X&KG@EP#\N;
M_Y50JB<8A),@M%9-\IM!!'^)LSJ8O78K"OF=N>,L?6&*@9-LGP'PJ=,#=6SL
MW*FRX9Q,V&D&VTS"0/@5]PQ6^^$K$G'V2O(TS_E;S"5Z%=F+S!\ 3TX3U+Y2
M^T$M:HE^TU3;/C<G_5Z5^"'G'36.\/=L'?UT0-^?$::QX-_Y!L733AI:LQ%H
MIY-7,^F=+T+&ZY+R_B@_;%)S2989'U\+!A24OVE!S*U_^FN;&9J<A]T9,%8K
M<6 GGQ)CK+7XG+EG868],%/BS+3=24<K0[26E=+3(_S^ZL'8]W![#O[*J$=$
MKS<0TV0D]Q301]A^ZH$86DN'9<^&<&$N8T$UJQ(]=5TZYF<D5@'Y4@Z$O%!L
M"X*!]?0='#XW58>,QPDV=6KQ&]?U/!=Q-'3OO[Q@_]<BWYKLN//OX9<CW>0H
MW>37D9S'_V5;??\^&O8/EC^Z9,_@N 2LKN]1$0E%LWG(U&*EHL0D?AO-NOT6
MM.3;3KC1%IKQP7F::H YK+'SW/.UF.9&,M,YJ" 'C7A(=YKK+^0& \;/5ZN^
M+%V=^-;$<H7K^OEQ>$71#+G8::0%--,0:I'0MA6R6O(S+)SWU%/S"%JJ54PV
MU[3<LPW\5.;_XQPY_.V!YVR$1I+1J_<L'Y1@4 %+AMYM_)3,S;<?-"H.60WA
M4@1:@1=+34K)#?[!2B@+!!E-K_#(;JG7=@:FN2-KX[F">;PZ'9:MBB?AK%O#
M2WGSG[D-_2P!R7Q.+P^6MYJ1 IV$\U55(K#C<VF& '=.8]+1(TA=]3%;UBTL
MC*8B#.=&VS?&&Z2>!UJGQI&RI3I@J&TA0?D+MN6FR#P77&[(?6+P1'9-Q(!+
MD<>W<SIT1OBA[V^95HG5.V<S\:V.?I!'J%93:S-P CII0 18CMV@(R%</OCL
M4SXW*.H)ZYC)7!:4*@YMCY6&H[4V-+6.I <.!MXOPRRQO_#A3ID$<W4QK04D
M!69/PQO%"Z&%\ ^EEU\?J#A^]CN'L$F,[DB4V:OH901P:%+-K75(I8UEOZ.H
M%&LD;;D_Z2=("[IAQ,S:7+LO0$]37H1MR F5X*\4P2_@\W!KXK6%1=F? KH?
MQ4PL&T1$QM4: 58\9VTG6/3YK2\$90WI2Z]YW0,IJC4&_B?BK$<.Z$P:.-MB
M2&JM:\P.?]U\!R_?-E5!\[MC"'T>7 BMY[:B'_H9JAA6K;*[5CPM6>RFJM"I
M>#Q,%B;)%M1*R;NU$^S#'V3^2)<MW8I:S?I]NO.(*1_'!&B!4$GSLT 3#S'/
MRE0)1G\O>Q>!=^^?FKSE#^SY6ZO =9D!E/T[@$MD-H;:+PSC-'L[(F39*^.S
MR?QPQERIHHG1A4CN82+FNC%U<,O BF4WS$VTT7J*LM%Q2>';:8E9[GKF[A-E
M-3K&UD"'LUP\G$.[R8,Q*)6HD)/CX#NO9G@^ZW;H]Z7F]S6/AI! ?2-D@T '
MT\*P>=5D[S9[FA%^_K60]1H:HCQF)C3)!WXS/"V1$B1P:604N<J:&EU 8,ED
M5$V[?_'"._ ]@)_:N\<D:D?[O<=\FW$#[>E%>ZOG4(?_WND^R>&B+_.[6!F?
MH9AX\FN*XL(%!SFR@%5-8X.]F?1IZJ<!:4V,KK"'%:YX!T]&ED7D_<C%%O)C
M!%)0P-/&R<K^23)O(<TR1@_30@4K5BL"RH)?;#8:?DJT08@WG!E24ZQL,'TB
MJZA4N-YNGRNZX*,U"Y[,%4D^XEL0^9<\SBXJFM__2R,=%U_K_<?(\4@W(<,S
M^+\FQHU(.MXEH$_O7EJPBO72*"B//5(W4E(X10:AIPJ\S- B+$P)F:5,)ZKC
M7E:^^RVG!48_X@W+!H9I7_6D0=>+QDU'GP:!%*1LEJ*:R)R-WY_?=!%T #<G
MC(KP)+!G@FK+;]D"BI<?2Q"+N\L0/CDOC<8I#14.=$T<VW?ATZR5Q3/%?1OM
M5;Y/O*QO$1@.1S"%I)R.Z"R^'E,XJ&V=OTCF'ZQ7(/GL0:<\UXS<SIJ%C)RI
M[(=F08]I:OM?U4&AJ,^G]X<Q?Q.*>@+^P7*\#%FAG5IE/$_*@HE^Z-+XW0B0
M\/L4PQI%RQ]#C1*F$;B"(;ATR!+<1:B-1"%9X:>5>7'(>$-@]V^YYC#3C4P9
M80J^:#/4ZC3';7C&I[>C&D@X%-.\K\D&.:4]YZ.HP@,W43;L=)!S[.AVI[$N
MY^H'N@\\:C0;C0 %/9_T4AVZ3,5@O>$PYDB)N\1^-4Y+?+)$'XDM:\+NB62P
M=P.3Q]2C2.N).I.AP9/XW6;G4D !&_2&Y=+FRN9\&Q2V"_OL:2;[8 O);KQX
MU/8NG XAT[>]OPXK)JB&=Y2> UIN9H/F!F/ZODH<6-N[5 S[5K9ICGD/_%VQ
M>1;0"!F5S4'>EY917'"TDKXR=T5,3M\EQ<I..JG@"N;T!Z]_+2S#CF59N'3/
M&>9TT@NVUAS8'XMYXR)@OK_-YXVH3OM_00__IQ!!*TA,.^E,,ATEZ].!Q''X
M;E$LKALEY^X',IV;,9:$@AAC'14S3<*H[&M97[%8C.4+[BW.RDQH_%M)C&6S
M&GHJFU1-CW_.=,DEL@YOH25;!!;FP#>7PD4F%=^T+-Z6E0G$)JQG)>D6O.3-
M$?3N_&[;[#!CR9[S@1VR<! <N!SF/MAS UNLCAO^ZN=$LA8E'[T:9E-:,R%B
M7_%AJP\W%ISB%FM[.K+/>UH25:?GDZ5F)^^Q81-!U.8]N%9[V(L4?S0!,&I7
MXGM*L]6;^N2\9O>E$+.Y HP^T]$/TE293.P_XFE=ICC,X17TTBH1O$-4[X,O
M03,AX=&-<&J603<I+07/FK5/.)VF4U-DH1W6^?6&>(54>NSK.01V)ZGMO/7D
M&Z##J^TB#^6^G"@^EY-:5<F(@WBUS?"#CA<]Q3603=/&-UW$LOPNJ4^L6ESP
M@(S>P!03=O6_JY.D.+J_U/0=C=*&4D1VQ!Q0).(%1HG_XO0;_G4MHYAJ?"V#
MF)?/_\O-K>6[GUTM/?%_>[K_70Z20WS C__-+O;WK%,I,,U5#K<&OC5&1;*H
M71/=]@35LS T-OGD+*9M2Q/8CF,1LR>XP 6!7.DN$@Q+-%"ZM^KF9O,%D/]^
M0W6*A25A+3QS$QQ@R*8RZH#U]<O7L[VQ1/H.^++&A%\UO[26;T[/;N[U[$Q)
MR'@7[!6G;=$<C"W/<0#-;'^+F)V72>8E$=_UBV>T]/]A9!KKS/<?6N^?2@ZX
M,^SCA[U\YUTD>>E*SC J:[O,9V9*RN"6T*#Q:+M@H)=*LPZ)$B9)<>M83LX0
MNP*U;7%O IW)L5\S3(P\&TXD2D(%JYFR<-P/=MR&/;.&/MJBB_BB3.2>R(YL
MK5H"*GY^CI*DV&LE='UWTS!D\>9,B>JDQ1=_2*RR8M0@*Y/3Z=%_L\U6S.7A
M)NA4;> ^>BDE?)5-K79H[&DOPU(W89O%6U5)E@:) B=.FF)",P-M%$A%@DNX
MH-M?P(D7@&K!?#=_J56<7^?>)5).KOL_=I/_,^?_VUK#:F^ =.4Y5LR:W;
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M(=%R;*K1E8-6PKLE'K]R,W[L;X('S$86P0"<? L_+MEXUPLKF6PC(8&;X1M
M-N4KN_Q&<:P0-)A6#A5JAS@MW/36)ZJJFLSD1J/D<Q]Y&]E1@'^P:%^0$AYX
M>&WP,Z>32_96NFFCB\AB&H26*>H*I]N 1-!8LT^V*3BY8S5_(+$DNF!;E8YD
M/U-+94Y^"H[ZI5=WL _*@=W>I"13=XWU"*PB'[R*5<:X'5W6H-Z )^:M: D?
M=C$D >!IY6D0[R=;-N*: 2.F7/;,A*,^ DZ,ELH?]NN\7>@RZ#VC*B#L:=_)
M_9X?:-ZF[I4SWWE<#WGS2@TH7;DFTFO;@P)_\YU5JJQI6 :_]EJ0DA;7"V+%
MV27ZQ;XZL&/.)<\)OMZX\FF&X(.M8XA^=Q)B#F'U-# ;%YH=Q&@\XA&RSL#E
M_.@F99>;_,#W0IO-.\4I\^%R!RXEYJS^[_WU.7%-BNC>+'^#N.LOS%/?0CX^
MHD&NT$"H@.#*1B657I]G&+'N^O3A9_6.#XO/F(2M=5HV+G#XLU?2O?P-747R
M+\:=P.'NVU1ZL=[M>3-_H6<@P-FYK^KK#DB;9FR/\7 OI*%*E'NVE>_6JMJE
MWZ;?Z G%9'=6AY&6^5/50,_ZZ7R@ZGMF]DG8BW\S:=PE&Y"^J9<;SZE!'=KJ
MM6Z<:^DUCQR-/M7JN*S4/J/'DR3F:V*>6>RGH[_R/+[>^@U*-,^D[[Y$I>]Q
M6I4UVAR==@946K_ V*[%MFQ_5J1N3(C'F%GJIA/2F'N307+RS-8D>J")=@(M
MCE,YMJUOZ7YP"$[D9NR_".*L0;&/^NZ:+.$&B3 ;Z#TV'X5T^^8UD9N/1WQ/
MYT>1V7W+[O<J24N:W%B4(Y"7K_8R\O7^/9.7F_"1.PR3D%PAH&T<W!K\X3LS
MS.9KSVAKN:>5Z+K0H6@'B>XK%\3G0K%F/UTS83*!VQX#V<I;,O+1C#(! MT_
MD%9/UBHW[[0L"NU]\\C7-+:EMOS,"91(710 996GYS:_V?E_E&JNX4PX"AB7
M)-TF]] 0DCNAD44A5"ZYS"4+DUR:K8[+IH9R*?<(R:V5^VT8QH9A3&.2A R;
MK2BEC76=9-3YG^<YW\YYSO-_GO/I_?I^?'_O^^H)+A6.?2EESRC%2'UT&JMG
M[I_E"9H+_&5"I)+D]S"YSY%=#<Z%6L':-TS<[#^NG)8'M$$Q==C/O2!L1  3
M%9K)NSZW)F*!LLI-VGP>>+518U46LO-NSU=;XE?Y\_E:MN(]$:3=?E%ZK1GG
MX-&2Q'R#GF//WE4Q#-8TFLI)KTY"V\B[4@N52"!\Z[W$DM9&:GLHK:4*H?AZ
M/=SD\UO8+\OKN>)CNLR3+\ 'WG:I#4TJJT^:O3D$J//:_"-2C2:%DKP)M9=(
MVMB\8'FP>S(':D@H?4*>E\<HQN5[]#F;;(@^5AQPL6]G?H9P.S$[UL?.)CLG
MSN6-7E#OV*25]J&:9_DG-.P0**BO.]IR)O$4,2S#0FQ!:X^$H4D,RB CF#Y0
MH'+YI'ZS"P7X8<&VO3#XE/K/OQ%?O"0S\/YQIB1^@BPK 5;S"@3$-284EG1?
M]"0"!J*AV:?DV+$A#:2]1^\U"@J1%R#32(LF6'#_HS*/7L(/6*9DK%$U^_?:
M[T&>0@2 VT-3#;MVA$6 ^&T*<6!\&RJZ-ES9!!C@%K'FU J!NTF+9E;79R3S
M.^;+OQ]<D;<W_^SQ\*4R+.LL<D+"=9YQ(C809Q4TXY><%E\E**Y]G-&*^B,"
M)WE9SS<TK2,)"*96A$)WT7'OGJ?AFQ\F]6*2]2K\5QHL"UQ<4T$11TQWG%)?
M$$I2R:0TYW75JSE&]0CPD1SV!AK]SGVWO@V70UD8WKPSVVC=19ENH2:G)&!C
MY-D(A: \ORO&U <.':]"=,W.P0/)YH+M]'ZI>!-A6GO<;O<USLMFKN[1#X*E
M6$8.8[7/W*?_?'L28].GA6D4QO7-H758BEQ5)HX1+G8-&5_+6W)\%ED]XBK1
MTV6=2F\:J;:"LJP2@BGGB&!?.=,V?\:J]]9,_K"3S48;'&PC.NNC$93X'J24
MXR-32=$?\*KUB'YJUB7\=>NR>D5"PJ+DTD43ZJ!5K^4#.-6H/F&+-\K.A'8*
ME6'#%+90H;%%CHVZ6LNU*U_D827Q43'%QPGPTB]J87,7Z&6MCFKU&N[Y.M'$
M+6-PAZLX'EN-L*0$<E:> )I_5.!L1-OJS$['CC"9F&5=,6T\8Y3P_69A0 E"
MVI#'=^WS!YV-+$YA%0*[#T@Y[/UX5S7>Y<#:8:$!".NET3L6(_)*BL%A(FX/
M^['R&%:U^A^>818)(-B\PWL7+9%H&F^)9E':6OLFQ7.'!$+;ERI!Y-=SV;$W
M-WCKQ+5&9 4?&S69=(Y?=L)^TI3.90:FATXP7@C6Z=IC '59)V!))M(9RV4?
MO/Q+$0 I<\<^-"ZK#]'T;>G\4OEYQ=+HFL#YC"7.C1LQ80_6F6U,K5"@&(*K
M?,O88-\@"Z]]6GD1<)]]JRH$^&M#S_:FUTT!SI*8:^:0/&FEH*(K>:'"+.KW
MOJAU-F"L\@P<^ \,RK1.@'LD:+E.;AV4H:WTT&)V,4ASG+;YH<L"\R"V4E*(
M.K?,V$V@(5KAFI4<W?H^WJ#2L/+FW^("A0?Q$A%N&EY9A^BI.,9Q31L@P.8A
M/1%R,CSWC*9EQ#[A;.7XO2,K4TH^@\/8OS![0J*;LZ)P;W>$91\^CCX^$>Z1
MQ==3*2M[K9+I/QJ4Y<N^P7A^&/J,[5'FO"<I -GYJ(.UZR$AL41DZ9!+* "(
M2+$X*YMG;Z"S>.2-_>&%8^;6;=/R(:NJ@$<]CR$.W]:\/Z]:6)6T4Y&ZR]Q(
M@F'7=CS_:?7ERFS-<1"N[EP2'GXK8S\L/+MD-/:H% )#N5>7;K9]*4(WYIZN
MSC:4]:0*G=;DG["@W-4OO'T%,R_!D]^.:R/KVQ;)\ST*8]W7F;,[5E>('P,=
MQ1="Z$'BQ^B+.@1 C1KZHGNOG:$"A_3S3&S@9G3 *J!T+6"2=13SZRSQM',&
M<C;.R/5T@YMCR TT7-+\#NN*29-TZ2WNT/'#,NFV%;J.W2$U4N%]1Q<OOE$J
MP$:U*Y34:@M5 _WBH==!,E=66_PC9(5AJ/J1U$^VE6+%S2!<(HRQU!;B.RRK
MQ/&3D7,93SMM!)8[ZYY^)R4W8U<[N5N9,JN3S>3_!H(E&YY:-&,I\\KMR!&$
M#(717+4V6>XONM17?V*2L21S#GNG)2VKQ<MXA!CO=/>\-3]X.K=):,W5VH:N
MM^3&^<^".:PO"VRV=X6#R$MZK\!DO(;[56OB7..8-Q4S_[Q:7%7SM8^GF.T>
M'0E(AUV 8E8NO/C7L''.!5TU9O]>+-:H$W_Q2H],-+=EF!M0.X,^I,,>6-A4
M(> -,"I)7C6^Z@'A?JN08N7G3UXD'FIU^]8YHKF_P-D<6._2)7R9%Q*7,K3[
MF26/U66>X=YHOA;H]!7 FX"?6.MW#$>?,"$%3EI6CCL]Q0;)X"IWTF8^H(LG
M!^CZ1$[WR''$J26W]&,>6Z.2%O:?!#NI=CW^)IQ9:QK/SH]>2&Z/56&XD6CH
MMY?]'Z+[&6 9V#R?G<#L:0S:.X:/K_#2#6HG.WJ?^B;&8A88%'Z _!A!Z\@&
M[EO<PVG8V>Q(MCTCYW:0D[@^C0>;1AD1E--:EU_X&1D/^PZMZJ9B\R[3^\+P
M*OD[C[-F,.@^<3OWPP_?#RQGE"-0I-E5FGS!K*S5X+M=G>N,4CS.Q6-Q:DLU
M&>4'FILB.M5,>]A1?$C\MM[I).CX@\II#DZZN\VMM&%S)=XN# X9T3*[!)!+
M,_,4\V$OADPV4V:1N9VQH U&\^3Z+KQW!-!ALF&[E\5N(K!V3VDI'K'Z98K6
M/Z3.-:.;+-O2]O;M-'66R-5^?VO*7<537RU3'"&Y/U *.A*#@UY@L$'?;2LW
MBJ:$2/_^[OG[*?XM0Z\60X+2_?C=,U*#[^ V9#&)GZH%0?.IZA?[?(&AVA6,
MV-TO0=W5T"&O#1@ZLZBAUPR>4P?-)@D\NX%D#MBXS)%U#'#@-*KPS=0G&=N*
M*S)9)\5(K==X%@?>VR/WY.KJY9Z_+FU5(6O^FB-MK7E_E5N(C[*I?JKGS4N+
M_W$?=S5OS8':[T!A@O<UW5#K9#^Z7^LBFM)B9B6Y3'V[ZV4=;V!1Y9J>VC^$
MFH>3=NBI?UD#RJ*'.)2]KK7VG>E'$>4HH_.Y7T$,.3FGXWZA5=,UD!N;TO8O
MJ#"3$W,_FY/#Q]'DHL>9L/(@?;S4;Q?;@\DZS= ORWQ:(&64^=H-4^?VR01;
M-,^B()3JKRLWX_SXI9T#.@YJX">-B*1'@Y:4MIJP415:'3*BS 7FA'P6!9L#
MX/;\E:\CP8M'.7X3/IMDQPHW03!K G+M-I6[M7;!_"I(O&1NDS/407I)FQ-L
M%>I:N/<A^\PTWWHGMAOVY'RTOQV][&LX,.5"LEK0SZI#[O,DO_J16EZ-&((U
MD>6KFG7DR.S,%B4@IBN*(T^T0&6WJMDM[D_4/"\ZN?P\T?K@8%NP XI8E9L\
MY2Y7:4#XG_OZ?Q6CD8/Q$HKY]<9!5,B\H7-Q?5Y);DD4>X.LZWK)UF2K*#H[
M9(0MZ*$8]7O?M!?^7V62\SO%X<C'M_[U,SGM$+D>=C<P6:0B>>J;."#QI#30
M\W.EF,67*2'WCPCB^V@.ZV;DS)UOCP-D>[?A$Q*4._]V2Y_;V/_B@7V],?.(
M0>VE(JNN%Y57:X,W^]@-TOG9UM^=,3.KT$BX4T -QOCIJ5]YM_]C'K3_,_]/
M4$L#!!0    ( *F#GEAC/Y,IL44   Z4   1    9S4P.3,X.&<P,VLP,RYJ
M<&?LO 58E%_7+SPT M)=TDAW=S-(=RK,," Y, R-BG1WI])2TB$JW:@T2(BT
M="B((O !QM]_/._[G.]YOW.N\UTLKKEGK[7V6K^UUUY[WS%ZGTV>O0?@JB@"
M%0$(" B A/,_P-D6R9+F72@<ZG(7ZD3#Q\D-$)8%JB$C \Z)I.>E><@ERWC!
M G !?Z%+G>AE<_F''N&2PW2"V3C"-5SA3J[P<Q;E0J;I M<!0:'VESV CG (
MQ-'5X6?[XEO.'G;!XUS:ZMAX7/20M8%?V/SA$P)3MW" Z"H8ZOX"^VZ@"8-"
MK70@<%<G#9 M^%R,!= $P #0\S\K  U !P !P &N *=+$PRG7[U_NI&UASO^
MB @+Y&IC#[=QO'1YSE^[["VG9G3K^XC%+OHC<OQIQ/B_C5C#"6X#=72YR.#E
MN)S@CC\'<3Y($.P7HVWMHO:'!N8H]P?C"/^#4079N_QBU*WA;K\8!0=[^5_,
M>1[_<"T+MK/^D8CO 0*TE63ESK^0+MN6-#264%>0-/3]K\E4@CG^329K__=^
MLC!+73U'N"*]MCW\]V*0M;>D^2>YMHL]_%*NZ6$O;?A+C.$& <.A,'D+N,6O
MJM"TUG3Y6147[1_?<I=)@%C!_\F][GG9_I-<!VS_7:X) TL;_1+C@F%0)X.[
MD//)/9\O&T?KGQG#OE!HG\<D"X7#H0[V4$?K'R98/S47(?PFO_Y3KFUC??=W
M!>9/Q7ELO\07E8.T]3T&0,+ P/FT(/S\OJPJIDL=]A\CD/+]L<*N7[(72Y+Z
MDB?[,X_T\9*_]M,.X=**^?MJQ?@Y_=]1D XNV\H +BNK<XW]^1'UA]%WR>/4
MM%\2WLNC\?GQIT3@\LCQA^32Y]%E^WPEG?TC(7VX4/_/ZRYS@?XCHY=ECBC]
M_?-#)_]+A_@W'?6O''[GR2]:2#*_1O:=-,\_ Y<R:P W@ ]@=WG\M:3^1+_+
M!G[8_LL./^F/#03@Z&IO_SU4 "H(ZNIHZ?*7]0N&\_P,^:+H?RLXP%\J$R#[
M1P5?AJ']1X%>#L?%W@8,<=&W5[U88@A_PD&YU)TW\,\_:)<,4/XWWVC6,*BK
MTY]$J%"8C;7-K]U30>?"2.-2=LY?MW"%0Y4@CA"8!1QB>1F]I]//S1_C>^<+
MR84&Z&!-\[]A_$BN,/L_G4(ND_]GB9J+]9]/,Z@6]G!="^L_R;#!D',[B <<
MZ**LJZ;Z<R-#_RG^4^=K=Z$P+QE[&^N?F<+Y/GCEG^*+[%I"K"Q<+W>R:VX0
M&/P?NNO_%/^Y.R;(6@YJ#X7]EER\[P:R2K\4%V&H0QTOOJ_!H4[GIRL7R.^)
MP[ _3^3?I%B@RRWQ;W),V,7&]Q?QY6JZ^=WN_(,HM0OX0XYWV43XOD,A$UYR
M%Q.*?,E?] =<?_0C8:GG'_'SYOF$V0V>RP, I "$L\FS+0"6C"44!+DCIP9
M/-L&8%]R $O?"[NS:4    L='?T:.M:U:UAXF!B8>$0X6%@X1*0$!$0$!*1X
M6)?TX^N?">$Z)N9U[.NXV-BXA-C8V(07!VS"[R9X_XZ#LQ8 'OIY\*E("'0
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MK^(4O7SH>!X71))?G.N?Q'\.5$U-%.CH K=PO'C>+'DNX+2QL12UXK< BUB
M!#@$A,""'/S"_"(<(I;"?!P@7GXK;B$1 4N0D.!E['\V_YMK>2C8]6+1G>N^
M;U"64/"Y^S_"LN3G$;82Y!/B$++DX>. "/-;< B+0$ <@OP\5KP\W +\/'R0
MGT"_.?L;T/?'WA;VO_6Y&(OE.9@@KQ4OKX6%( >/L!"$@]^"GY=#V.)\++Q@
M 1%^$4%>,+\E_T^(?W#S-RAE&Y?SVO.4_%/M7VYL.A#G/TM_*NQM+C<Z)PN8
MR^4S=PFZGXN/[F\&%S:7VX&H!?ABBY0$7]:II3C7GZ3_VLSF[]/Y[Z7@;^;_
M&L/]+L3QOUI?O_7ZUTY<H%9P=PL81,;Z/-/_[;K_)YN_)9OK>[;_OY@%J./%
M#P/_"_-PCF-Q?C*&P%PDK6!0!YKO:]C)T9H&#J6Q<'*RMP%;7+C@<G.T_+%+
M_EH7/T%^\_&_<:PN%F[_6;UQ@RU %CQ@"PYN/H@%AX 5/YC#@I<?Q&$E)"1R
M?L5A9<$- OW']28BRB/R?[C>_O -OFOA: VQE.3Z:?A3\'_3M/'S"HCP<H.%
M., @$#^')2\_'X?(^3QR\',+G&\>_! K/AZ^_X%I^^/D=S5M_R,[RW^SF5SL
M-[]?0/R?W%HL(3";_Y4J_2W*7WFB^;]MT/_QPOSW+L>N%N9?I'^^'OMYC??W
MZ[>?%ZO?:U/QHKK^O<D6O[S9^D^VTK^8_Y-WR_^WE[1_,_\G[]#_],+Y7[KY
M>^9_2_#OVHO;R8LK[W.SR^4LR2/.]3?97_L;7DR)O>NE3D20^YRX>"Z./TQ_
M5__5U.B_-C7Z+TS_4.DYVL E>7^8_$7\F]7%/>_W>R\=)PLP1%)00(!/0)SK
MK^*_6FC:>$#L#>5MSE/I<A$'+S?_#Z._:O[1TN@/O3#W[X9&?S/\OE)^>R3S
M_7D/UX\'/I(8YY/W\VG3/ZW7_WFZ KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y
M KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"
MN0*Y KD"N0*Y KD"N0*Y KD"N0*Y OD?!L'XX_T-$$=+"3IW.BG)LVF ' #A
M/Z0+)_^I#X3OKT/4! P@(>#]?!UB!^ & (" C/3;JPX!@(NW'**@8B(@(2.>
M=Y##/9< +M\VB(*,<O$27(0?[T($X%W#)R DHN61(:;;Q2#1>MA*;^$<R_NX
M<FB>E(R!1<009.V>4M,P?NZ$\MP](B+2[^]>/><NO9QKE<_C.0= 0D9#1L%
M1KN$P ,@(>/37KQ2$97 PAF-CO=A[.-=0NW*(7I96%PK.A&?#LC%KZIZGIBA
M;8]?#AR?T[[PY[<2-G>K: TGP/-MO*BCLRT3UE[AZ#2-?DRCLGGZHL*T_!#]
MV0LKLJ*,4#P;EL9DU<4I(KT$-60$:Q3>;2+@,T8MB YM%0((T0\XB<!P7(+L
MRQ #F(D'>+_26TV3JKW3A979T2D6W/C\,V.9 TH[_Z=;O$]=(IQ+JDYE12.
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M8\X[@K1;&[A)#7@521 <QJ?O9>.D3)NJ;8")PEDY%^BT7Z6\^_(@^LT7MS.
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M:>?8YUF'\_4,<&?SY)ZD3Z+=/9FU!O&7=[I8;#NW;QE8#]I#Y$/*'Y%)+M
M',^OJ1]_^AH-OM>AU#S=;$3#FRBE")="E%G&9:-7%J56ZC+?&&<V$Q=@P,A2
MYU_+F>V ^:[N4VK?/+T_YX3[!7#2%((SLDD['CD:H\'#1\ DT26X6Y)PE!4O
MGON NK+\F=ZD.)]KS!"W.]$$]HOVK\B#-:IB7R*4Q1"($B()4I0&F/C#7#IN
MNNTG$L;12K%((\F^#\HL3!ZD4+5C4FIP-.'%>?CM?N'<SA.R]6=5N5R6[S=W
M6#V=/AI/.XI""#C:/Z:$&9#@M[K?HZ=Z_L1V4&:FD ;.)A'-E?ID,O<6^ZM
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M94[*Z*;=E5(7A26LS&CR"?42MZ+N\RX;H>AR)8X4CWS*>&[.R!U2;, QIJ9
MX4N*U5D]R".>Y81S^Y-YDG!FE-C;"!U(?0=W]/WAEA2[!Y:=57$R0GJ.%N4F
MFGP*Z5$%N&E?Z+^H&':Y0<,/<88?8-:? 7A:/1++R2(:KG>S3WJ_Z1*6:"H.
MZ86BKLQ15(8W.?N)@2HFH48[.0*]3Y)ZO&?5FV"^II1R;W-(![B%0U%DZ0X0
MV3EF$+! !5LY06(&(9X!/:(*ECB3:RE(O4=)2 1ME4>O*<+EH 1^'6;MM\W
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M6V85TXI01N?VU]UK9Q'<80-F[/]_$P!02P,$%     @ J8.>6$2)#S@$?0$
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MQ]Q,5R%?PBMI*A.ZRG4 2+FL>P#X^+J@<O(S0>,[#^7Q2%120ICHR)QP,<&
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MPHRPM%<WO#\S>0^ST1 X.M!"C,E(C=.SRL_,#*6_::)UU:?W=H=95E_ZK*]
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M.\RRGS3\W.@ L&/87-"3E$*5N[S]Q=0'%0E[_KX;%+01, 7Q?C0P6!MWYEJ
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M@RXW(SVK R^[(#T]85J^_6MN>Y+ M9OJ"]9"HNS3W;4V9A\QX;"9I8T;#PX
MLOR Q_7.EPF:M1J7N$A9>+D::[K9XB)H7E-[4)=_[0ADH-)(_/313-VUO93E
M;EZ_90:C?<9:S)NHF3"(2&'MIJ!Y@U/JUSL'@!REHJ&<&H+K+0-4\?DG4-DY
MY,HVN)?$%)K9Q0N<VSH5G:YMS]16K$C4\^5%\_-F-QD;AT>#@F;XVDK<7E&*
MWJA7<N&:V'1?6 J:*6:IW$;9[*"2.]LM,K ;@.+B,RZLM1::.X)7J*NX5",
M<1R7F!^44;.[KW #'Z8?;A^*AT=+G94+RL6PALTVC:/[Z-6EI2:9%9E!F[/B
M$X-X0MS:HK3<A>M1@SP;$IH&ZBO2U<FK'AJAB[N?B^>*!Q>;TX%KX.(S=0O3
MFDX(B0Q>\.T F>>]0E$N(QBAP?B9R5 DN)@5N^5B&5[JJ@X$N4L;;NYJO2B7
M?G&ZH']AJ4AC%L'+J6EMP:18$D K_EIR&R=_,06)2#R<57VQNZ'.E:[#G1IV
M1.[.#2\N[:!"OD[JB_-GUZ:J<O.\[;@[;SL=)CSCJ>_(,B>]I75'NF8RU,,L
M?,USOB.%8:GY *!F4WV&T'%X<MVF7$KU66V-SAWVO5E[=U^25R(S^3X>^&/#
MAC<C^]7.!\$W4\9Y%X<UI+Z8N)<E@*_,"C'/]&=.!@ A/0'JI1;!G)<ZG_DS
MR=*O-AH_KZ9\S!BA4%<IRD@\$T7+UKEND2Q9?5NCY-IC=WD7QG, L:3P$I6H
M"X("4_73X[S\KY- X!8K'I7V1_$QBUTRT]@]L590>BY]DX=')1\7OP>'@-.J
M=(W!B<!%QGGX)C!ZD&/+;^52G"%3D?/=L9?>/&GM2E7&9I^NOTGX6,Q5,QVY
MCY"R?J'_*6?I*JSK9C4P>5M%I;8R%C1^NWP."$\S,1XMY9;^HDR^"@UM>C=:
MV>0.RF]>[D0= #)!GOI"ZVXZTI6KJ\V>-DAKQ^'A$".VP 2 Y,N!@?%:3H9Y
M3B5PD&8<4@"R&$Y].\::[]4D[2O&9PU#[HIK>O-R9^//CX^\SGK"F:*[X6>M
MUF="*M?RU(A<^95V6FZ'6=-MTRUG;_'V)JNW$?9IG6]1"0E7M-G%.@WN+X@W
M0]QX<L)8BPJ\IY/3)6OMP5R%[;&A7H6CKVNXA"/>+ZYQ DD91#/S?)IS!P2N
M3#3 R]#C3DWG)3*U %92%_ GUFQXWR5^[".1?.)C4F+#+FIRV:I!6=E ,*>M
MNMDS2SF[H^/E-GP^I;"(NM(5U&&IXA!RXY/NV6KA^_V9D L-S3?KN<1$650-
MXN]7.5K;&(8 1SV:T9SF.+%+L5TW,L]Q:W#D0]7\2<Y6/6POXJU:VQERL8).
M$UM=I;YA*FSY)4<K/))+V$4J-#1F,JS>;LGD_JLP.)*;XQ8S%:S+(3SQ7/G\
MC">%Z'N:1TV!&"W3H(NPCPD[/!S-[7JR&N?E+5_Z.768Q3$[[J[!M)-A/DVO
MM*+I2!S!8Y$"Z$K@$PVH/T3XWDO*C^R#DX[VN^_=8R.3O.>#&AL2PMF"19WY
M.\*:=="SI"VEQN4$[@ >X,T8XGLK=*X*N5OBTX)H5SN ?QO;(X:TAE)!BZ9
M.7\?\P=B[<RMD3>$7^XS,"RP-Q&+![];(2JX'4>;\4F*\&M^=NL=I80%KT:I
MVOJ3+K>H'P^^RV=H"Z)UB1-YK&UB6#9AY1B3GD]&]F#J#6][?6CFB40I$IHO
M#]J#U>-<167BPO'76).0V2Q2=H.#8[7)#Q<\Q[A UO#1<&$J<5,%$P.[,A#%
M/&\71"<8* *E&;L'4I,7,&N3N7X^Z@7[K/;LJ;M!K=PGB+H_/&.9[I;H8N5H
MF'U4^Z7:I;SZYM*=20-KI/YMF[=+*QL9[I)[[L!$MWW#U2[.)%711;HX6GM1
MYJIH=N')I))UIGVR1(1&]>3>1?B=,;<#0''"Y8(SE)[Y*72.R1-?MK^X-M.H
MMD]\45@)1C&ZG R>J38?#>;X("#7T3(D.7O.0;%*J7YX::"+J7#P[FFSV=;9
MWDX]BP$20W^AH--MM:;J9-%6NBDL):+3] 'O8J8+MQAOB!<6L@NO3'EX$(YN
MJV^-B!G+EKZJFW/"WA3>>5U]IIPE#GN[8\]2DX+"_\HZ]L5P9<<QZ*,/$G5K
M/&Y:2V\U^2-)S!O6S[NXJR]'F)[G1C P%8&"!JU>LFFK<9CQ\ET4FW(83U2R
MFS@K-44]U6 Y+\AJL& "*[TD/?26=CS#BE^ XF,)<9F-&S]=8JE,=MM E?T*
M1<.G^]#@)T43F/['&?$W5VT=F\U08O9E87=I7P^49JNJ:2="U?0=@URVP&&J
M@8O-5UO:-2V(Q^U>IQ&#? #)U4C6!/,>65+D+=Y^KJ)H7,I&D1K;HM= KBL?
M!GI%"_DU$$R? R6IP]1,H6(?YF/;V1U[@UJ8@!?]1;(^4L<4^O#9 !WAI3[\
M@TW;T;SUO+N-VQZB]\-TF20?(EVV[,W"D[M\L=NB:O%-F[WYA>4==^Q$D]SE
M[Z51P+AE/A'TJ%4T*N0%OK6]K63C-MGAG>]V'78-LG87^LILM.>X[NQI)EE]
M ' O%M]T=AE3DFS&JW49Y77JA </3C*J!N*A4N<F(Q%[>D.?FVURQ_M3I/>_
M%BQFWD&E^ \F'P FKU;X"G$J+>W@9,B7=2Y5%SQ<WZ)M<N$:;Q(*6M:(7,L]
M@]T15E^VDXGN='<_ 'B*=XV]I5'QS:+;;, Y(?$2+X^<:D8FZ_5@2UP[G\?.
MUJK-,G;3-IZR?[AIP^XGD^X!1Q>:"V:6FVYQ=CI G%DX$XM!3/<YA,M]/7%%
M752P:U#UL@$$O&RU;K-7L=R<+B-E,[U3$3G?B6FI6^"X;>V_X[J5@=V<+/\_
MI+UU4%Q?LS8Z"4F0! ]N"1 ([A[<W=W=W3W!W5V#0V!P']R=X,X $YS!&1P^
M\O[..=][;]U3=>K<JOFG]UYK=??3S^K5O6O7GL<7G_UX>%@\ZZX?/*&7)?;E
MN%=NSX"J<(KK.#,/"S+:X0DZ.T3#W/=RC>EK' >\TG.HK]7&E^#;OF93A7%5
MV^V(C-,U*-,:6AMND6UO9J/6_ZE/9]R.\V+9-Q/^(&&/4M_V&:;MRAO#GFPL
MY(A(8<_5)UHHLB/G:?$I^)OUUMJC5=GIK#GN:8EKXC.@\9(8' N+FVM/&^P%
M/U6<GDH>-4W+I=R);8N%.AZO+52Y8VU?^Y^Y/Q!7Z5>!.H]?JI;RM,E@:*6G
MNW7E)G,J4>/:44U.0:5TE'E39^?&\94/43O8';20,_;2C#G%8S<V36ITJIYC
MV%K*\>:"6D=CS[W.*\'Z57.P^Y>*DP]E?6+B>*'JT^(H[8U,WR$F1\BYU_VC
MEFO,\&Y=T^:]/HD9KV].FWDGJ*EI86TE9H*"==U=,BTKK&&+N0U/7C?61*XC
MO:'AK7,..+"N:2'+[;'J[I[O@S_)IV@SYG><ATO<N4*F243NN_-OKK7;7W+$
MJM?]_47,24-LT]HUKR84.NEO]S6,2ZL+'+[IUW:)'>C$*%H73ISX<^%FQ*LN
MM^74W7SAA;]U?&V/JX\=$_,&KEG'S)B%4:$*FTR<L/ZZZ;Y5^\8SM.S%HY,!
M7MWVYJL'W4YL/P9U\_ZEF.VQQ:PM%&V(!SCK)-%A$N0^<Q0\:,>K,<'3L6!^
M^E*A$;7?3*X\H6APQ=D/R!ND,QEQNN=M0JIBG@&OG&/6UX]@,#=C?ONZA_03
MZ.3@TM)*S),PNB,FN4.N1CWRM P!Q1:%TW%4P]IK'N6-&\>8R4C<)UK(YHVW
M-]/!#8_'@I"Y)U^<RS3Y;@5-5R8:7U:)8[Q%APF#\IW? 6KQ")&PZ,$]6\C<
M.SHR@X/*_ KLH(!DZCQX]WG8!DLCO"_NMV_E%=?&%IP)5R*N(J8;&/1,2^S3
M66A;DF0"]0#N<*;23_$+]Y6IV12DY-86DSS;63N@:Y22^K0[R]^(I!2+TOA^
MLJP:OGS^I4AK;/NUK6GP#8:D;V=<HW,;<;F'[%U$H.B2W&LTR-4??"5W$"49
M1X["N+)"'F7T^5:;J/!-^VZXB!8FG!J,R^\B*]-7W)'7W2Y(I%=SZP976<HO
MI(\\+WEKFD2T]=DJ-T?4.A:P1Y/UPD5\HNZ):O$@C<XK^")?C54-/YKT7G/_
M1N?JGM637+5A#@.8@^ENM=Y,_I)KXNL_7>(54%^>G6H_@;4-V+T/G%X<F3.J
M6(,UJ^L237GU/ /$%M4M^LD7NM3Z2$^,OUWE-UZ)S/;6D>F.2-8(5.+%2&&D
M_7A]$<?$,C#/O4=9H:GT:7FIK[L1*M)_T5X@.==14 F D2B #@U4=[G%&KQ6
M[^4@NN27EH[$.4B3GM]L1':-Y"S#IPA3^%PLWT<SA9A6EWR<3<GTI1%R_)15
M0D\0TL1;[#3TNEA?+'_@ ;70?<6&8WXC#QQ';\KC_"Y&U/O\MOT @?:]J1G?
MSPJ-0"M%55ZK>G[A;!)VZIGDI@))/+4HJX AJ8\DXDOFORP<[2S2P[@#\<=_
M.J1SC/C2@MJ];K[9)Z2@KRTK$%5;DY^P(N_JEJ(LJ.*[IIP @=YH^P8TZRP,
M]QG#M@3-;%$>/V1U-I?M,'^&5)'W6&/M,QYN'9G:.A9I3EB@.X.TS[AC1>)_
M;K7\Z R;I"V9 >SF6(WM/ZG%K*7<94D]BLOW-J-25M55A^7\CJ<\+-7Z+J_(
MXR2Z@R=U(VMK]%:?3UZ98 89U#2TT,N,U*#)A0&NIZ$HD4Y2 #"*@EA9+"!M
MCBTRL2JGG1JK/KK6]O(KE%(*(> 2>29AH*8.39L1B&)4@-^:S:)0VZ4_(Q<H
M8%7PZI>:1+V2D+TH@DS#>(90=$#>F'K\?D^@,#;"GY0_!N9QZ>^V6!IV.(J.
MW?7,Z7E--367>$F;3(FH:;1\-ZE9JG-_,I&I8B(![8&2LP+=13.P?4DM&L.P
M=JCAFY6TXLI^5W?%U[Q<:*O# ZD88[A7AE.4PEP:IH8D V>?WB02LAUVN@('
ML/S;CA]))V;%NJT^8>V[[6,3X*<QGTXWT# CF;MJ1T6W!+Y>STOJLQ+D97TT
M*T')DB]]!_\CH:@]6FXM2@I:9-CSQO  )YTWLRIKVZ2Y;;</;[**)WRTNF)*
MMWL&XS O4.2]5-JFK4'KU8@GG2IA<@#3:0=JMK#(KXTO:0U&DK\Q2%TM7H.Y
M1*F#0LINA^-\HDH.WJG=OO\4F8Z325P35R]>L9?;9TJP]<3:,HI5U1JY@-61
M'6*-0][R^B&;?Q:H1Y<@9^?4 Z"I,1.39MN:8SKHMQL]/HB.%-6K][P181+J
MR"U;11C&PZ[_LZB CK>.T-8_!@Z/%/\8&8Z7!>0=\.4J;]Z9W__*QT!6#UV1
M5XW0;AC_%<7>[3CCYLWVMIO,*V@_T]BZ.?472S9/.[9@F[+EBC!*"U])H]1[
MAH\V<)E6^U2_KDJX]_YP$*&(W7GD4,%WXVO[$Q_^J;.UKXPFJ;<JFZ'X/5>V
MQQ[W^U<]%7[,$.QW'G+L)E*['8YD?,M6PD7?U0HOS3+2PK:2X9&W4.$R+1PD
M/^6VYMPFSB12;QEAU7FD2]P=+?-DA:=_X (TWW9V &?P=C%\AJ47_17=R$[$
MPFR@<."L\>Q.$*]B+"L7KKDZ4OT;S_U$+*+:TVBA;./>'@2!6-8L(5I9%![Z
M3_W7 <YMB(T*G$0F-$EG^':'Z6#CGIF4=G?WQU78+A0R=P@].AKTMW?W>ZEK
M;S-72@4V9,_#$U^2,6'B%'K7\*B_OM\IYMS*_5I[=G8GBO<3\3- W=S/CT3/
M.8<E9C%]@ZZH+A.9&4!1S1G53F[?D8J6-FGG77?JYN9F7@?:O 'Q//$]K?KP
M9A4*-,^;B8!E+VSG/^U3L>"=K=E.>83'D06X&6]!3XYO>'AXZL"'T./)P8/!
M<M W23!V1QV%:&UD]%+6\<>FRI=*]&EO4F6"I^[^J>U!=[T#'-E$ F_?F_72
M0,,Y+L6!?0I\B(P%1-Z<#3P#Q".ES.OX2<J;FG!/!EBNO9U77@HP=3-O$!_*
MF^BE/DPC<14$[ G1716B&LQ.Z16:01,X=AUSXHZ'!Z*6%TN>/KA?NT%>3G50
MYP9<<D@U ["!O8U C\%6C]\]K/-]I2.L+E;?W+P_RLV8!+5JX^;^;.5@@/.;
MX(BY)[-<NG7K ,N73WJW7LYWQATN-+GZ@Z>/5?I^_(%S*TM9L*=G (5V/20Y
MUL_QDQ?6B#OFK$%@<0K7H&HJ[LG)O6[ZI'OWRM]ZIL+M[FSI]#Q3.^J'KS%7
M8TO:T$2X9?/(*EN';Q<:2I8&%'KE=<^R<LV',AG(.5E^<W_OW!TV286^4'&
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M)%BWPUCYB<Z5/L_"Z'YE37%MJUQQ)Z%&E7QN/"E1%,0[]0<3D%&FHF>F5K?
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M\E(P]_PLZ >@?S>6,/9WQ>Y@5_34?>*_T_+OJV&I"N;7(!X>?O^H%VI^ND.
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M+?_0YX48/OR/!G[S7'_WY0 K9#F1PL#=?C*V3N*_0)6_%[B^N_GK>>T2>2[
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M;5SV:JG;_[7&7T(]9ZNM;;#X>C)%O_15T6J!TJ^[&XKA:J,!_/;*$B*LUL,
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MH?^IJ;WR(QAQBFH*^/$@DZ=XABXQXGB7BZ7(%/9+WMS,&#)D3BQ/S(#0,7)
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M6.#?M3^Y<#<C@[C^PJQL,%8S)&&60#A=($TV3HLW&GJ #ML[^FZ7G*&(57N
MJ3J]P.//5>DUIM:+(:LA:(X,(&,_%C"81G*4LHA3:[!4T'Y')%7O)73!K07<
MP>CNA?[Z]GDEBB[@EV?RZKSJSA0GW2"R_6!O@0N(TP;P;VUXGJR@F)M@-3O
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M!IC^%BO/\*RVD/ K,@QZ?/!B)I H'(4#4Q6N#!GD$*IB1RS,W!ILKLV,NT<
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MFPC/GNA<T\Z5 ^=E;T/RC\F14482X%U/Z1'MSWXET:/@]23*<9[U+HUA";=
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MS?"^S59V1.#Z]4>)Y.=6)\WW<DH%QH'8$!1MV_BI)9F:5IDFPN:2P1IT&"O
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MN:U9VD<FOV@!IT^B.R.PTCJ,W(N/$1,X(<&7^5V6@Z9K7#V*C)Z%;@=F!72
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M8 5Y:>.6$JRV+QNM/=0+&.9QG/NQ"6NIY:<+&T)XZ;L!\FC> S^_8-T][@H
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MF^9=5B9ZU/KJ-ZL2H@)!]N,Z+VR$1*%9?!GP>7H/K>FXG(.7/KU[\26<CA@
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M6F'F:7\'=9$NCF]*UL/G<@=P\7':$&L5$TX1_C]&[66/RC\IHEB^84OPGP/
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M\V!AFG1:+CWC:]K^\U%4_\B'-"F5Y</$>)3,YRFF*#X\PB5#7KF^LO*=)4*
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MOLUY+X,1-8M\8\F2K$5R2-:<XGB42HA7[Q!^6D+J,4716C\SOO_;FC.3JVQ
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M^#*G[>/\TK[DBZ-:A+_*U)44!?-\G,;K;P31L951G,M\[K]*DJ2;66HXJNG
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M_2T-UF$*]IJ1<BSCH/6F/EQC(DCMS+O@W"7%VP]M[P!NU $!'1N]''JZYXZ
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M:A8=-QWZ]AW<(ZJC\33.1I=.NNZ!3[ XN.[!KG <W?0@%02$!7/$D=0EU;B
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M\<<:M2=;+C87.^WEM26TH=O<^BAIW"O&.YMN&KDEU^NZ"+7Y[A%(7U=7D)
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MU<O]CT1\#Q!@JJVF?G B.+H&<W*"D1@7%>1SP _21B'^(5.#_;.<&@IL;H%
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M(XH_$O;PX*-\</D< $"K'(!M DX!\+Y-?EL'4*J"D2X0)W5# /ZW#0#U$0<
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M8B*IHQ#.B-$2'D3@PT5')'[U#OUA!$],A]Y*\+@LHJ[%JILQN/I*ON,E/@R
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M$I4"NKFXR@#=Q"6E@7*NDI) ,7$9"1FPC(N,G)CL49O_U?P?KC60KIC#V>-
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MW$V2R5MRG1E/*N&UY$;9/>S9F:T51GT(ZE+?)0MN$KH8PGMC[SWX1GQFTWJ
MC#S$H%R%VPOK[ V?I5:_W)V3EZC86VX+:WXYI&J^-;S5,3^<-3OVJ-K [*0Q
MXXH[B7\6Q<<"%]@2*2GCGO%"LY;.F#ME/<D;CME[>OD)Z*$$LH;R@HXX(]10
M^%01U\B=<A\GAT@"VD<VA+%3-Q]-<L1?Z*74:=-XK5W1H3+X)1'U,1:=4^G
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M5F?&)"B:?9=9R'LX++^5L/<!\^3\ARA7N><,W(\</JX1CXU\I2"2'O^P.S.
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MV9RZ*=RSX\98-[SM@")PG/^L*// "=[ !#85&H&R?'9KFV5)D+QNK#ONG&L
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MB,A^)8T6-;AQ.H7;T2BCYWTP*Y562O8&Y8! ]@[EX(P^(R,4RLC( 84E$(E
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M'8*.WY8S4HR9XP&L $'9#G)9;+,C!'-1O85PDFU.74/M9!M)+Q_]1VUM#5]
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MSSR1"9]CXBW),; _8+MF<<.=U<7VD@\=@2L+K^CWUKEWT&-N2GGA3''%UM
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MZ0%<?:15-+WY-[=@#HRGQT+5V7.:)+*/O]V009]EOKXPVVP1_5\P=+EPT<E
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M*,9964U);#L-8$XFJS>HXF+O^N2#% @)K+58 P:X>66JUS Q71_:)=Y_IZ#
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M1IKK6!Z_9+T7+_M-)0G>@(=\A__#S:#/K_KH)\LQT8&\UK=/S7^0)O+_T(]
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ME,&?$B1<_<\*'/UG11\,0_VH&#JAO7]4--UA&C\J1W'\T[2:@YO3'X'XYB#
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M4!3""^D U?0^\H3S]Z9,H/_0Y]^;.FK^6T,>WY]\_T, OXN_Q5[I3PL*1W$
MJB.A(#14X^BC=#2C)(5$Q83$1,W$1(&BLD ).0%1*:"$J(+(7UK^S@8":89
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MI/FTR+@NVEG6]K:-K.XA8&_SZ*+]\1!00KM4?6"8J5K"[RZ"L8BB=0^AJA*
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M.5QS^/JE2J_Y,E7]5P26HEKE"BG&F MI1),!U.W$MHBB>7N8O'+533[_%X<
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MN^S" :*1D^)AL.1H+; O,[-=RPDT<2KX)"TTZ#;D=,%JMT4>9!RO;AK6VE=
MW*)AP)G']2&4!27 $NE$/KYM_3&42\G$RAIWGE/8+K?>YAGC1GC!JP=EU-<'
M9S]GZLTYN>4CMEW96[??3@5+1QMZ4;6(]][-<G[_.<SMJ];.P1:OB^Y4#)=1
M#-W@;57Z!![-2<\0A=H) YWJQ,L-DI'0QS+N+-<5+16J(-LX]VP. 3R^ING
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M%6:Q^^)F XSG]DM]S*3XZU;5 VH*$W1?'M8VF_1FW"><OL,?(D1F\HBCD0#
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M^YU3I^Y__^\[MVNJ9JI&JJ9G5J^G>W4_G:S>) ;6K$E<DDQP6"?FE,-*GC/
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MFW+-+Q62\;#T]/SKT?TUD'\-9_M+9BKQ2N;Z>F9F[OKZO])Y_KYO9J>!+5Y
M^S)<(SCOI/GF1%*_O@JO*KZT,MJS;(O&N#+-^::_U52[WWH#ZG_<$&["0W>Z
MX&WR_5!BSFID&?2]^7</)5X"-=0K%I(.5'@#Q.V N)K7^Y+9FM\W"]K#BN73
MV8#9.1YE!W;Z)/_$P\0.@2IXRE0?GE/6[VGKH7@=5@$3%"U"[/\^$/G/SM:W
M,*[*AP#]#]$:FP$UZ_2Q=FCW@\%X/ES=+1:B KL))M7S9>'W*'_)D7YDJO#N
M]B=E%^BM+,1C4 -*+[5MVY;VXD%ZIKN31TY*[ [/O$.\(AN6N#G@^WF08L0>
M$J;T3@%!Z01!.CWX6)OG';52XHB#YY]/IE]+'?1@^5X68R)DFH'WOO^R7]4%
MXR-8CR#N2)J[JJ_6SF[CZ! U0-,<XK*+K<[:<ZN!+<9E$%+9-UW^P)PZ'M5)
M6HN>(Y&-*8IV %Z_ KH[*1.C0]D-%C(]5TW&N7Q)!YUXY(+LV&+",2K:"J2R
M_%X[C=O_ZW(@&%G?8DA$[=Z#-!8<UA#',=9A$,_'G%? "Q@C+IWHNX)0U3R&
MU^W677D+9@MVHA0-#8ZV^6T(K4<'/UV<6IF)+5Z2JI!&<-C(LDD5.L1R+&*8
M[ QU24!;WJ,'72LM;-RGV:$22KXZ,B]Z6*'XNHF@5[.(W2I6E1S/SEI;R".D
M_;II2D@'FCEGQ/Y8\!_:-HHU ''<U4.$:[A>\-S#_KSL*1S@U6_!>#]<XAOM
M 2R">\W#MD#M^C8;+$RX--%3OJ_,OB\D)Z1,SQ6DD-A\U.H38C)#DLEBRT)^
M2X\1G/AD1+>LN3W&#GN[Y=I+KMJXZ?OI>2\?/[WXNO0GAN]/X:5;*%R1,^G/
ME:L$"@<CC*ONAHNX<,*JZ4?;SG$QZ;^HOF(-*TK)]X!HD:AJ!UQ\JF)'MM7P
M,=.]M5C> (K4\7#N@Y=98,GGX_'CBFYJK7UA4<L.&4EY82Z#6U>'>(;W)16C
M!^*&!0=U5?TAYA('3\ON#VB_Q7IRIDNX)CW<)7<G1@7\>$L3P\2%4*0*:,?5
MBGQY&H1)Z@2J"DL['LT-]=%G'N2-/]@]''*X..$0_.C%X"WVT2%P@<KDPL-9
MAU[^2AS],[3*]3Z400RHKM%>R-0JY1=ZSW0N[*O?W;#'6D6QPQ/J:QSOEF.'
M%4T]UG\2,7>"47.P&)<62+ "PPU"Z2 /;-K@7C-F=URS9KJVZI]1B8-OO#6Z
M4EMJFI=(.7M -6\]?]R4\7.[M=CQOCY"<Y??2H$MF7:SI/Z- .C%]@-AU=*&
M1)[ GO!YZ9C=RRO&<R>(..;*MN--O,,:?P"=_*EI:6/$HA[I,B=^IZOCIT%X
MJ%/V$&_L0IEF &A%& ]&6<YU@<LJ1IV2.%H1  X&EQFM%*Z.D^_WLO7O#C/>
MSG'!UQLED6P=9J'N)C%-+&Q:=@=?-^WOY.(<1N;9%:@6$GU(5I,QE>+$Y%YE
MO./#ERA?Y;2E*K5G*J;O2W';5H\RI7"$J4JB:[[>72[EM45(BAR1O5X^!^_=
MYV9DZ&-Z7"Y1LN8>UN1]-_A@EW0>8IR72$/3T&\T^H308A#8E!<'#J9EF,7H
MCI0C<MS5(4&)EOQDP!A ZB//X8N9\@._C!6Q6CW\,P8L5CUG3=R/NCRHDA%0
M: 0K>@AQ9'5HQ3J)<KETT*-BY@VPNGGBN/E'MG!>P(%&Q>@/J887IH,7M!VS
MR=N=)&(NVQ5A=F@U9!"QZ]6^Z2[5_:ZF+8NF=(6_)+)V^ T0^!2BZ6LQI;"S
M(-7P^/ -=>B/0<MGN\$I6QUD(U.KQE_(10MJ*]<HW9CVR<9*8B#%YY*:QNAG
M:0,#< )B,DJ-S"1N7$*,A?$L^C@18K2E(? .=IN)R8WIY>=O;!^& *;J/GG4
M1*8PUOQ#S8*?\YTQET.!D*-&6E+IWXH&5)#V!CH>C(N36(Q-WNE",;T)\Q)G
MO,L9P3[+TY[%:.>J5LP?S;++-<FXIE'5U<<R1)3LQ*5P[)7 WQ]X:)).2V9+
MWPL72U!TQB%-3]AE/+6SCU3%T%1;S#<=[%AE)M^#N2!Z?L!LT=H$AT76I(?-
M4\6\_BTSL[.\DC\IB1[K&X_33Q HOV;ZA@)HI>)UU!VV];H!*VY[2ZE'!H?2
MPA1:1HG'O[Q<_>FT7]!5 "S0EKS@ H,/&$2(3Y]+*>SG.Y] M:V0%[:T%+KC
M+9E<'IU&*G[N-(MLAP?SZ%!P:AI;G 5^\FO9S0 E<</,Y#F'42BND27'FK'M
M7=>.5O RCKJEC:WNN&T#]:EMSD42O4E-)80GK@TR+N>+:0>X0;&_;JLI)Q0U
M6SVMNEDQ<9G/E#!L)MN^Z?+QO;9S;-93,Y#2B<\X@TJE172-3:GGCW&F6)+J
M\1%<SN?)V, 4[N856% \6A657L9W(:9?9X!0ZIEHZM4#]00QP4"0O\<4M+ST
MV<H"Q\#@WJ /6MYV3-N0?=&8@B:ABW?2BS>()-I+9 R%C_;AF5S?7!A='XE<
MBUS+7=^K6@HN1M>L09. (>O%$H7"?_+K<CB_:$_$;$472!1(;N^V.:F\^C^=
M]H+\-)+P,MC1*AUSW3\I*L1\ UHA,BIT" &RK?ST]7ZVQT64UMB1(V:_1Z:@
MN#@.C?Q[8QS6D:FXX;($I6PR3./\*I6.FQ='5T^%4%)DV.TT2HZRB[K+D=0W
M@*NA5OFHT 'K7"[-6N\G+!\A;0GR>OB<CRT_!N,X?_-::[/I=:=7%]TW8%P0
MEVLL3F<[W@);+_YIX%1#C2$4(..-E-6 $S60=H#2;CS$4,Z$Z3<FN2HWI80X
M@I4<2-5U08!%<,B[^\Y<G"!.6^+;4Y)[4C:7I13@C_Z>$.?'M2J]F8/SW[^T
M:O6K#>C+<VX3%J*W%=04:%5XLRHX5N[P;:'JS:[W_&.DBH$-NF6WOTA8=!=8
M+2XI@O*%D#V'9=4@0(6ODFK>F83>6=D_.F*0!/7STTF+[+L/-Y?;T;>D9:2.
MC[C^"(@:C Q7 A%EJNEMH#A]Z0VVN 3?,C_D5G5<,"0,-BI27ZRM0<Y9Q#&O
MNE]$.CG_S'@S!/([#W=R)-?1H"BTI]8U>/](,JE/W<5?[CJQY9#6Y7GMA$Q5
M-]D5"EAT5?CS>WZ[,J>:>=!A+P-=I' +]F[0C:U@&C3T7'?F=^W-&4/SSGL'
M,]<\C.A?BZMLV@*X3K*>I)&$[(6(<T3 O^8N54)0"7%R^W/3BDBXLA)"H RP
M%#U]@WR?57DT)C>J3E$34!KV5S2^7/"L18C0J36*#!<RA!WD/@I/,6ASY2U@
M0^;(_ 6F(!$]!JC,_E9HE#O:<D]I\S%-,0-Y\*Q,D1++;H/^@TY[Y$_*NRS5
MP-KGXS= S.T':ZRY6 '=C@-^M9T96<4O#X&B2U*QZCMZV"F'MI1/3SQ47=I*
M*#E!&5\_]W#&-,95%:%?)/5R_00N_!C'K#G\V,WYBJOJ%K.JP;C?G6C]6F2F
MQHX7QNUOAYMG+%HECO/K]:KCDXVZ,ZPMW'EO+!4V)?K7[TTMDT7/2+PO6YZ[
M>H WP$BW[LK68?0^R\+SSYQIJ B]JK!S$:6C';V*>N%:(,97Q2VDO>U1;=;W
MT32T#37:%3K&9JXEB@4PV=HG%EG\$>>&O!K/;P!5)B_773 $_WWT%PJ'R/4@
MHLW=^R(^5*6I*K.<!HRU!GJ"X!I,4PFSF7Y<I9]*TE:6(\J$5,A4W%[+K%?5
MQL4BI5)H:;55JLJ;%_>O([77.PTG7?R?@CQRW(2B26-UX/G:@/Q&":TL0I]O
M#=DP1<A1L5HBZ;1SP*TW"FNT'F=KBD6Q:YGAB!G#,84OS$&>(VOH6O=]GKXW
MPS9KN++,48<]&-+SG?;$'S3$S)K@LV::5?JP<\9#CS:RF%V(N%5^1$+>QT:B
M1HLBPGV563>92ZJW5!Z'@;HPN=LS]:V^-/I]L[_ZF4O7H4/BOO_:,FZ8)\L0
MP?) 6,VN77+9Q)E2I0&[[YNM=_4&H,C8:*UGO_YD@S.%-HH$DBH:9'TX2+U]
M PPT6)FR<1-Q[^SD%Q$ML-4>*ZA05TL>F4G5(R\/L<PFP8A863X+&B*D(K2)
MT5;V-T:<QCA^2%2(OD@9<%:("SK4W9\@_VR52?)2?J,=&+EYC<+MR[8K9&EO
MUXS()D,6DO/!:-RFOFQCA4'LZZ2YQ';IR 69/6I 3KH;4:D4*/"]X\ ;8"M1
M03+X7#8$L<_*1Y,WI=)7CE/5[9S*?0J*GKE@J8:%S45/(:GE_H<H>MZC-5:&
ML#&Z_&'LNR>W9-3.?[>6E3GY:Z:N9\<"OMOGT'6,&;TZTLGC3V_$O"]4":TY
M;C<C-?!P4/(I<<7U6=$/H DNAL6 GB\9W(Q4"QECP'ED3?1+PUFZ&'M_S_.5
MH>!QCKU<<!#%=)C$'L=ZKL<#G_+*\KN#^4).\<90D5#.=Z;)4VF^:P.R9ZV-
MD_;%N1V>O_#8MYS/P@W6_2L[Y!KIPCA_H\$*XDI@GFRUF#UP_>?;!X.CL'"M
MR(J85Q%+]301AR]YPK<$$L+5BXIM25NHB>'M7=+]V[V;X]*]U-HK=Z81T!3M
M?8\73>@F9+(]C-0IP_"4'0GY]2HM'YG4QSE"+CNQ$Q&?,(4W+5#)\]MFF_!U
MN(!7A-05]CYR9VW;46V;S=_MGR07KB&N)0/WX3D#]R6\OX?Z_YU$,#R']^1C
MD9D)L5S)!G/X</ACG7#\2[@G)E<RLV<RNQ3&3P;5_W--C#=&S$U)EG1YZ?EL
MRM(P1C?)@6\2A5:?5PRCTZJ_P;MDP2-[V^6]%L9C<Y$8U[E>RY79GREA(.)Z
M7)7)L4XG'=S:?&&%Z"7'?RT+U.R FARO'EF]@QAU0'_MCOFS@V+G)$VN(,?3
M(HLP1>R(^E[2K( ,:)CTIB9S8%Y'  ')U-".'P-Z>HE=_$\HYIYJ-T\]4^+=
M$L:YY<&1E"\^^V<IPF!9F[;#"7X1,O8]K5(4F)C$.%Y$VE:KZ-K#3&JD!"^Q
MOG'&,XL4+7\(\**:Q.6@W98/Y]MJBB*?Q4#!,]<J-F[^XI>*4 ]R,$XYNT5&
MBQR\.(5H0!'UY KD#QU8 3@#HT=S5YB692LUFJ?B+A5<S=OZM-U"P5[E[G6<
MF4U2N]60?+.UM](,FI72KR-'>0,\&4?<XD4[I5\2LBN"HDVC'M9QCNR^8U%\
M%^;\JN[6;=%;VBP(V6YI'YS\^@;XSH\TH42.GH#KS1$D5!OZG21L,*LY^BLL
M_,?7G8C?G&\ "V0Y=/J&Z..%5<;,1,<NJ6U^W#@[7ACJYJ!>2*9DI3:R%$WK
M3-WWF1/Q600CF<'AP?;\43%$D,)V%1E55>RJ2,!9(6)I7KE-;43)7:(#?U=0
MH0UL\12=CVY9^5*6B$)QK\]06X3H8FJR#,-I) )!HO%V,_<E<2[_"@UEPYXY
MQ&7'GF>)H2IWI%L\18C(N3/TYSJ'.IZ=?2O&U2)(M3T"S=&R_4.;[7MW$^ I
M_^@D49@*93-&1[+JY[AUSCNK!@&;6B>I^B84&C'^KS^US]Y9"[R[^52%LQHY
MKU33+:_B$]NG;55^IK.#S#H,OP4A-/MMPC+X)Q[=SFL!0:H?J!H!(YQ>49@@
MUT>I-VFB4KE/@DC%(MHO)9,FKD*(@U]N\YX*C[D=2)=F?B%3@Z,!SM604KQ9
MCH[4O:X3GH,A32LKKW0HI]<HK4;$K+'#4\ *HN:O*GQJ"+AC1E)+C^4RX%Q<
M (=AR2 >%6;,72SI_XI.)R@X;+&(I&O^?C.H@@VA02A/F9V*77)&\\!JI4J5
M<D].5AB"MZ,0*!QO=FA8Q:(\T= 4@U4?@A;GK2;:YZ-+R61?\"=,3-NT98JK
M^RKYA9R58@]A1@]O= 6ZY-E#W@ *8"^-AU9MHV5EHYX+W3O*(UCNE8W,"<-&
M(!&UB*+X+K<[4PN]CI-_A-UFN#RN_]TYK)ZB9K=I1_8%<;L]:9L#@_O<-F=9
MW&DP,QZBZK$=X[, ]AN@M:ZL@ UZ07&76FTB3_+<B%/3RH/&5"]\;&4W4I&6
M*L2,S7,E;W[\)9W>^,>/%@LB$%%QQ!SWL8C7M()Y1H\2'M\T%"S9;UXI3QN=
MNFS=U5HK0<=-P"B-TT[TJ#,4\F,<"9G8^E?:1/TW5=F5+-FJ!-Q?> 0J-!BT
MRRT\D3OE+$=O #-C,E_<6]ANJTERG?#W!)V?<)FBB:Z^ >N1S>)D_/O'4\/9
MS6B7[S;98/.E*^ %77[&<L4H];+I@R)Q0H?Q?D)O#.K:DH8IP]M]LF=G\T=?
MUH+F4J]N9^[#B%JG'O4T4C/FT'893&@7QS0(F@O>Q_7$U"O,9>,+0.G(D\3X
M:AR7?DCJ3_6.25UR=.S'U*56E%ZF<KCUY:DV2B'WQEF#N#+#Q5VZ7"4H:RCO
MFZ^Y8\;+/8HSICVI@9MY^7KB_Y_%L*AR80W.,^2BEYWF]V>FD,/&6G\-(KFJ
M9:BP,RGL3XK8LN/;O 9UG)EULQ^"5F19P]U$<]Y)ILT1CLF1C<HN+/W;.M^T
MV>KJ:MJ3?;]OJK2W&_']^*2T.3@R:R%)1X+>2#5,R8 BU2(];TC1ZAB_DRI&
M,6&E)Z^69/,]IUU9G,'RG^*J=2L;Q.'1"^KR#:DPD/[5L*:U+M6KD\J0=M]M
MYA=?F5VC+<C^/"(%+(H]%>&KPP;WSYQOY&^ 8"]0B/8X#@5\M<R  6<4'TEZ
M, M.VCMDVI@1N#8,'SX@SL RA6D^50.J-"Z:'!S%**I7^'/A4?+B";=3VC-U
MI=X1Q'T4IXQO0A]*DR9!TZ#D7UR,&;4749]Z,["@]9&.-@09[N8/FI_H\T_Y
ME-AZY+N31*8/;99?UW;PS;/PASBVF=<68*7D& NT!*/2*U'UT4/5[ F;D)82
M,3PX_=MXH?"%.* ;\2NQ2/+8^SY^=LJX\AW_WWE<0\_^LHV.LI?%JL=A^N)V
M','>E5/=/47PS1=MLY558WJ8E6<J+!1[)L.4[!DK<"Q);@CGIY(9;@V[._0%
MDS\MOJQT82Y':X_^87T<D])VQF:H,K6OS,-+_9#82XZ:*;TK5DW=6Q7)97N(
M7?#SEPQH&C4))365C7JE2AH1A[-MO"I6C]< LJO:NLGE6O3TO03M*;344!5)
M>/IG6:XF:\GQG8[BV+3:2C'"E^S!;+JB)102ZT+@S::67?4!H8F%YZ8IXWJN
MG0%*D)T&Z]>^%4V"KX8T-4ZSC,@=J.A6BBF6^SP1P8QN\6\ P%[A.)>^R.4;
M8+AZ74-%I6NTHJL5N!5505\@7:0JFIKJ1R"%%$GS[EL>-E(<"A=6,$4.*(:>
M4Z5@WNA])!6$K<&YUZX)M=0YYG@:?TA0ZEJX_#A:3PQAE2O6V[R,U#N)3"U?
M?,>5^#W:E-J4$?RL)&=<D:$5'55.JU6HYI2:LDC@$]<3NIL'KM!/S>VM==UY
M?S$KOGCV-6LX;FR;3UG,2"[9AX4A_364B')B,2DJG//K54P)$OXW<_;)4ZLG
M.>BN>VZQ; )U;N7["\06+)5J<ED(FBY>E/JG[RCA'!]EBE-X,YI5=I.-RYYC
M&A4\VIK47JU-A+J[(\#::Y9\R  @'5I\:-3@SBDAX@?"V"A3)'@QT%R?XL<(
M%+:/14,_;-/:2M>SN0^;I03-).?^ A<2X/E_0SVIMES%@Z6:=5NZ_#$2ID0W
M!0H_IMI5ZU#%_A /BFKR^+I?VJ$C44C<>H2!B_%Q"$8BZK<R!-)\WC&GEY!I
MG$^DAD7M N X-0%B_2%Q"OL,A0^H)&F\1MV?;6J'IJ:DQUW'.,PXX^#PH#&/
MV9KN5/O.#U5]PU%]ES07]PXK96S0[>PKU>19.P5E=./K4;6,Y<58\2;)G"[9
M:\#6-@[4C^RTK;RR+3X2E/X<\>[]("YU//\2KYK81"IH^A.6AU!1#N'=6*,Q
M&ORXR^@-79_>)5]N3IX<]SG7R1"54+!];F'L -]GYZ"AW0MBWB+$7QQ&K31I
MW_77EU%<,'B2K$B]Z!<BE :+["._QP0+JXTB64V%#^I)]!;2T3!@^#6<(^1R
M7QAP!9(EH*O=?2+TOPLLDLIKG7*)5N^*E6%7+( @% A%2Q_YEGRQT<+3CM(A
MBM+#S.:0LQR('[/9A8*QOJT'=8X$!=,NF\7 UNX<P2+V S(5R=$G+2=B)IFJ
MU#!S[BS^7A5^,0!WOA59%(P#;QH#1W^G._F_%$Z#6PWU0HZ/P$]XG 0R3NSP
MX'*D@#%:?2*BK0%L.0.8$<5WH)OR\&)"VZU*RBRP9S@+-FBOWP)*W:"'[HU:
M0#M5G76KZ&%H,!V(AG4Q0F(_ T&N,:MP$M\5,D=A%OZI*\^=6#3NW"/U'7G?
MA;Z5IE!J,AR6F$DG45K-LR&!?8EY@@UXY[U-'_WH_D@K=/DLG> O+QZL1TPB
MS2OMA8/E#U0&LMIF45KCC:X/6I=BM6 H?"\:(4& CX6(+A=B9'_4A/F2NTXV
M<JZ3*$,(WJ,IMCL'YS?%#M*Y/SR%GCC([PA89 8E2]7A"PZ7[;#M2(&\W,)R
M@CI$T?@'4L;8N6CK>7O+7$HKB%R3);#5 V+ABYDDC'M!^6DZU<$(5'6[C+.[
M=#^3"&3H1MU]!? DJ<!2L%ZK8WERH^>+JT96_7FFE*)8#MRS5*3R7^1W]Z'%
M&N(,_O]!S2U-N[O;/PL_R;BD61SHQT?T81H@YY*_FM#[1(@J$S?.B:3V)-3F
MO@&^R+*F<8"]#I.F/9XH5Q2;)KX#E,T)[%\ZQ#T8VT5PKWY_&J>-]"M.D2E"
M^0.6PWM*9FS[$KH(6[+Y'2WGCCC?ZE"<A3*8Y8H/QD?%X76/E53+XJ?8SOM^
M4F("A#"/.+7?O4[?LULVW=<8O<95+L887\?R%=KH5P7[N,^T'H?&6C75E2U2
MQBJK8HYE3!46Z[L]9#"B$=3&FM$]/HY;YC'<BV4^LZD-240?_MZ,T>$K6F]O
M6&:><+\YM:#N=U3;+1D=FSB%FM9+"?$;<)/L(.?DK'SA';?<BZP6%V!M.P ,
MW]HG E,=8\Y)D-8G _&@O)L(O)QGFI+5&!7^@:LN6<PZPX6Q:4.L/Z[8'LT4
M[!\V&6I=JMX ^,E@^^=^47EBK273G T^%P[NU]B,X"91ZONBI,Z>31OB=+ZJ
M%P_#]:6+CYRHV(K/EP(8@FI[5J1]IL/$G\F,L#C4.DE.9S&%EV_:LO_O%N8*
M1NRI-B?2%..3*&H>,BJNH3Y7C)ZEWM+9&8$*J[CF? 1]IBE\7@^25%\:/+17
M%_U;Y":"(5C>N#0$J*))(Z<C%.G(LMV!X5GSKU9&-R.7&E31$R]W5@6-7!,O
M94X3;/2-Y2T?HH9@<A(1: =+7-G=^PD_!N3$>9-6?\[1&7!.=(<O*CU3)KO<
MPA[_KPJL-,?N41I@R !H3"G;U4@O=<.PH-@M7MCA3F5J$B..BR_L:FLT\3.K
M=O:E'L\,CD),G$?6&.VK(B8P_W_KV]0TV<RA^<[@L_GI&^"C/,0TXV%;J3ZG
MR9E1^*P%/EO+>_A^)CD3GRVB4^\-(&_I6[L36&ACGV-4RRI8[5%L;=.#L=K.
MAOE)XG.QC.7NE/)*FT9AFO+D8/8^N+YQZO6X"2"[82,5(98[N>/H(_W14<T)
MX]<F^TJ77<'!@^T7W2@\7 4&<%BXK<W5>>-0,1$_3]= UU7V&\ _G3K$"CFS
MTZ740\4]:T_Q;LKU]JZU+,H.;V9,-[:P-:_>4<16"$*KS&9\(?&E>7US97ZO
M)C:^_<>@$JO5-F-I4VQ]4[FC##J;UM"-,W8.J5>4H+Z8['Y8MB7>V7*4;S7C
MQ(2FW-WZNH.1$I.!#4.P)U5M5JQP4-:+H,6*T]?<U@R@"A=^&^V9^9K(^-"0
M-M=ZE726R12!">KR)CS?]/ZS:_PP;&:W(Q&;-L+E#PT^XZ]CAQ-3<'3)6#E]
M7KT#8JVLSOLO\ALK4'M/H>3FR#A""2M<P\QIW<9O"?AA.WR[Y'0^0:9D3@ '
M>U(2Y8'-;)XR;C".W^(;8-O\K,U^[V.X-2]\+$&K>8X2>5M$ZTQM-4GMWO@'
MEV^T/"(T<A;L1[6KL#%M&AO <B%75USDS/S5S'<FS8**6&@_T+CX'4Y!R/B)
M"<K6 R ]JP#3,U@UUZL0\K7^7MO^9S-J)%R0^,_%H*\[MIS$ \L$=/!3A#P*
MT@LS-,<?FFQ5L?)$J81ZCU(%_[>N7MW95@0[?%"0W5\H%,TWQ!9?=S=\/WWW
M!LA_>'H#; X8,A;JE[!C4)<@GJ1Z2WYB-=C!ABP^SMG,I'(D@Q?Q3SKC;5Y<
M%?'_WCQ]UGJRX"Q:99C!>TY87#$[>96$S&W[FHC;>(&N<>#_(NU".B*O8_.L
MR:H/.T=6VZ])?CXR7VBY_&)(_U'V3HDK"AV+BM$83E4TR#6SSX5VB^B *E7+
M_DZEBK$9N  CC'M,62>[NT'HK/.EUM?&V-6BEWT/9\)LEM9M=7$W(Z)<D9S2
M<#BEF<GR$P8OI0]?XZQ0LCDD-Q$IZ -LHY'?@2K3 +I:^TMSGFQ(MO.7D4NW
M?O2[:[&%?MO.0M^5G.=Z0366PAT"93E.G8L%G?U%Y_>U!)__W%T29PY?AF\
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M2SR*#89DR,7!GIXP+TP];7&*4&]Z="O7LFAZKPZ@ZJ5GVA3ZO!"ZGM3'RX>
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MHY"<J)?@P<5YJXI>+Z=BWZ6S$KQ7O5[ZEP[?F#9R)4OI0<&__)YE6DXL8+M
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MFKY'A1Z4/W .?AX*-Z".AWX$52]A^U4QVK#/M!FE.H7%,28-X;SJC][:)P$
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M9_P^8RS-(;,\B1G>J2<HIHT(@JLS@0@==EH H.EQRFP _*'<%/<+4.M%?>(
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MWRLJ_EKY=JP'^^M292GA+2#YRM'6>E[1.F5>Q"H*US-K<P*=(43G1Y00A+=
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M8%EC3@VA(,H^F+:07=O?ID2+.=,1H&YC6/'%J,34KTH]W'0GW<E:NT[5'6U
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M:GMB=)NZ.V:4F!C/$Z>;;"IE[+^1:(^_+V24SLXC/YL]EDO7P]UIM\LK&C!
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MN.#&8V!<<NFAW_%:7I[:"C08\=&-'LO(Y4\I9/ 5KLT=Z:1 N6!IX48O23]
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M8*8*3)+0(7:G4R!CH 0B,8HY%Z!*I*6P0:",^T!KU)%4%(.4@U)P!!U$[*J
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M8@G,ZNGMR+\V1D>M8V]%291C,I9\/X)-1<[,T5/;%%NU'DJI/V9^@LQTS4R
M/H,S2F"IC O]1#Z.PR6UUR@25G5,EZ"LM?<6IA P)<[$S/<=Q(F+&C(/?_\
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M6"8974W0ZL<5"2F+G6[TX/O*O"^<D\F($UC9IW,62[U26T86&XL3!(IE3J\
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M>).)0LPX[E1_;_"TW4V8HT;;3?)U;W=C["LI?=2Q/..!^Q^=\BB51V.Z<]5
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MA(@X>$^IZ!4%"95FMF2D5"DP+EVV_?@O>P/=RGP9TEG*S/;O4Z;1W'+)5UK
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MDK:9//^0*H;Q:A^]TD8(4ZHI3R"^/@Z=I3/I-ER(XDQQD7Z"#))"!1]-*ON
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M3:I<O4*T)#X[<(IW$4H;FNFS9Q!WV]9M:5:I[@\[>V)ATQ L3K)MNK&5"T0
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MZSK(=9MG"=._=Q0>-RC]WN )X8)(\F"KS[1E\9ZNK%#$X;BTD37],7++W'2
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MO&"=&(CT=@8SR#3@D6*QG&/*;:@2=?V*BS&(#25^KBRH]F[G=>$N>KPOQLH
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MR#+"9!P!@LV'GY;1/;3/D4HJ/0)QP8>[T_X:U7)X7I5*97C%,%Q4,@!DL]D
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MEJHP#1@82DX;5(K65A>C"%E7] *,,6%I( >,@@ $+E5Y&^X2@W(BRU*Z$!J
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MI(1J5F"Q1<V*ON'+JKGMOX:Y< 3(I8QR>PU@;Z.7&F6HA4 +4%2JA,&<AN*
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MJ#'G* 1=R:C7@O@M8)6 7;6HR>!VBNEZB$^"I,'9&*$HP@DNAX50/XMYD R
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M\>PFQIB!N=7=%V2H:H[V/=0G,#YI7#+S!N^\>6^?N+#;9Z<<[YG2 ":7/_O
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MX?%.&_.!I"ME4>&R8VSG)9'&CGZ!NVQ9#ME35DPISJ;W-K.J<*4=!@C]\J+
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MOD0KJ$(KHTW=\RPR.P!7@CMF[!MS@1H4!I2C53TVSSL=:"8/A$YCTGYF=Q^
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M?I1)L_.7K9+//9!A0;:KM:5Z3+[0R4N]Y8+BU3@VTK/90,=&EVA^%5"]9?+
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M>(KCH@;?!+ F8]30'>#6B(Z>7)Z66JD[H^4TQO2;EY] FS\Y&G61^QW::(C
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M>K?,B:.X=TI3F\TMEKZ%>G\>GUPC@#%:SLP6F<XJ($#Q!KT0=-@"A98^5\'
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MR$LNY&^Z\4//IR4%8F>WSOK),(VL9,&"]]-*UF@$'/_)?I:S'+E?R&B]]X[
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M<IQP;@T#_))3QTT0"#$OP\2-DKPR@3]2S'T+?5M7ZL8_RV5+W+3/NU9J^A?
ME?>^8X)>;6JT'\6) @[7IW,%&HPW?Z37^MR/.8S4'!A%$VVED+7SM&?AX+%@
MY9*NM28>!2V2V<ABT#M1/JHHGW=3T;T=%^=WX5QZP$8;/W?M:W@D[N)WM$MY
M0@HSF<K __JQ Z]('*@Y-SD6Q$4IJK[1+O"VMK-^"VF>PEET>%BF=J,Q,#1U
MRCRKX)PA1\UFX8)8:M8NK2J3#7Z,W_WFX<9MX6*MR<,HX.0*1*?U/PKCB[^
MTRS5:227+<S,QZ8N=I]9\_/+5A(DDYP--\@T0[3 CM*!]C7?3XH&,;T&&!:$
M60/**N"DD<&>SACHE"S52LS4-79*_CGF+\!R4#>IH6/1=V+K7!F_(C:WC!)W
MA/'$TQ;:HCRDLM.N&ZVK1ZV@#M? 17AD[X9!8R;Y[Q?--:_!T[RK&(8)UJ-&
M]QLK/]='?A,Z*F88'Y$8CQ4883$<1!&@"Y0AEF19V2$&(43F8)U)D_@UQX@O
MA?\;DI%"J,OF\"LKG/E\A0+(R3\"0(_V)V.:6*K2B  '0$/W4"3JVD?DC\@
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MP7+%,'8&5.[16S@>&3?N\6S;V)ITW%] V+;_IHOU)N[RWGC5U0BB,4TQSOW
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ME@S+I\,K_JI<WL1* % R4$.L_P>I9$B-2QGCR#8<L1S1P]PQT]9_D8S^#E"
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M='9^E*&C,U-L;VMC)RWV]N#@UC2 GY,6C8JQ<'BF2$';E%H.G#]"&@_(_P*
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M[5KD6J"9^#+RUEME?M!0"E-PKR+IH2&^3%&4+MP8ZRM<6,B1#O1N/R#NWK/
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MS#&LP1,*9F-$%LQH^$,$B[Q5=-LX1-<<UN)'!*T6X'@R:24XZ0@L,NTBZ;3
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MK /;8O92Q:9D][8!4XVRG68%$3#;R;TZ=3GU3*E:@^R:'G@QOK_Q@(G8)+[
M_15#I<2X76H7[WD[3K+ U@7(KYA WU([67AN9FWG8?8V:"WR$U)2I"IB2/L"
MDBJ(!9)@%AD;P9>G[=I#1+ZEX74)K@W[F-J"@^/C8( GI_UM81=C/R/;XZ?L
M]#-[(<_E6=^6P].BK+\SL*9-D??[%?/]^W_9S:MZR=[KN%\^'_+] K@>&EFP
MH+*,5TFBZ69Y,H<D+:44Y0A\85UFSW1+),&.3S>JKY-%X^@W0KHXEZOEC4"Q
M,\<C,4*/("SZ^97=98+/-E3A>LLX"S!?-HM]0)YO3B'<?:PS]UUO.F)U=NA.
MY(@B;_3T2:&\QO#$]GI>H@K_-$=7E7,1S88-KW:&T9$T6*9S1>Z<P  W06Z:
M7F^,SM/-2">OU'9Q@F]>GR/EQF]%4NE%HXLD?'JUR;?(>@E#\S[UHMWK!%="
M?(A7STZB[#4W[ZJ;"U/*H%Z!%9%,IC@A/D@@9?@K)0S<82%:*T>FZEX,1"!0
M5)BQ^]F8_731YQ2FH3Z,/GX1<\ ?$Z2#M9HJ-&R::!TZ$2*CHZIU10.?@&[*
M/M^K]4C@%S&L36GGO!@ZI/5<3'H_ZLEOJX=)U<G>P$].*>\,WOWL,S;*F:DI
M*-WJV<M9KJLJG\F(R8T [SV6-'?WI6O9QQ^T7!>AEVF-T5Z1,E&4& &3M_ 3
M/?3.BD0ON#;.CDQZ0T74Y7,U%(VP D4Z^@4^5% \##O#@$C>J-3:(TBZ(L)V
M=A/A\=-'LBIBU\?W"3V@YL&5Y04990;H+/](Y5OM^4"-0>>CM<Z))\&3LZ46
M?1[E*ERH<#=*+_Q ,B>V*%S&\49/RI(38JB53^N2"QX^#YUZF.7D\2$"ULI'
M0?RW&L5F\-/JD9D["8.X?9SZ(D1V,9*SG(W%TBN4HS!3Q5BAR\\[P?0LJ,%(
M&FH[(TT6<WQ ]4XG&]=;_ +;3(BN7'X\4+V-)E VQ_@BH9"Y)V,P+0MD^_W4
M]LOH5AF;]'XW6?L8.@;E='I7 NZQ+K_69>@$RE=B941EFI;";]09[N.Y)QZ,
MY<[)LSRBZAIC>&P1KO9%M*5//.CR,$;D</U.US[[0O$2Y$>RT5*?"$Q.UE8U
M4R?XMC^[#'H\7*SI"Y-@+GP3VW.8'7,G#_PXY;4_LD+_HK\T^"E,EH9KQD1-
M1Z%HD/-^"R3/'&=_06J KHVC<5>"93M;3\D6Y#X0')$V)M.R+;18^;$\^4I(
MFS5MM:Z9C@J4CKQIJ.P^_H2T26%-C5DW<UAR8K4#*^@@Z>.FNFJS?$0+G&4@
ME_OX"S!LG] 40@6:C-@?4)T>>#&9=3@/0-_6B20RKI.?EF&BN@KW+1'JL#F1
MV=%/-F/3U\.VW#^<H)FQ/+:-V"/7VVKKS>;G&MIC'SI2D]G0.3M'B1I: ZSE
M 5KOJZ7+XX"Q_*9GY5V2959S?/U+H7L_<)B4T%]L*X75/:GLF_7DDU5.-D(H
MI@GF?""D]_."!.M$" _H26$.HBL4PDH,5C#C$QOU+E,DK=K/Y/&;W?6H =VG
MGYA^CM#W'@ON[O:W_^W0K3\]0OGX*F!DRJR,E-6J\-CS;?E'Q(CA_0I5C&X*
M$&4L1Z6'BJCNDL2>56$!GMGE+ L9HN[MY<F2)[+J\)/?C/NV5X6OMOG"14I.
MV,^0A110-@YVX0$S>V; H,O$B8R=BMF"^LK'CWI#2&T'R+;*X>FUZC)+*E(K
MPUYRZ46T !NX&R.WG=(I1K^\4I,K?>\PS2NXAB<F/7D':-)38]M7O:JOZU3Z
ML@2M+/EF:SMU$KHQILYC>OL<;<0[0!(RK*L0BIC&4G*Q5<K:@A'=Y04A5&9>
MQ[E? -J(H6"'*B=X=IY5EB-*(5FS@%&Z%K8X<+R;-L'1F%%WMK&2^5@2V"3I
M#KE:A0:W8WTA[W%BV2'W*),2J$[^B4:W(6*U-RUY3 5A#+0VR"<W<#T263U0
M1YN8P;P$2T/MJDUZN-"T8(1BG,;9#FFLM'R0+-DO\^5"=5.8*8Q"M6^D2L9W
MQTLW)<R6GK"J;XD5'.>DIM(0;%F <O$4JJ\]&2!Q %FRR6<:QS%D[,RGU*I#
M!O>Y8/A">]O:7N5'51^PW!?A+DP;6UEZLZ,*N^M\&X-)T\P 3A''CN@1@_<9
M>IP88V:DPABI'+PFT3SE#1A:IJ2X,*XXJ3TRNA,':!=%%U'6@G#.98V=?QC5
M<>.HJ]O;NPRF,[!3:T!Y]IN0EA/DL)R+.9'?-DKMG9OQEZM2Q91)CH=*&[ 0
M6?-.[;!#[R/$F3?(G(4C#U'R53^Q%U6<94PE3YT"ZY0!#2\CC!F$'YKA*Y@^
M6PGR])/#DW/X)^]41C>9N6^X;M#?(8+:"LW HVC8USJ>1=\.KW+R]@<YRC(&
MZ;WLABJ6TER3*2<IL--X0%9P5$Z#?/3DBM<S>X6^ML"CM(+&:B;+V1$U -X^
MQ&81\FAF]L<6<<S0_Z:5GT]RY70LYO?U"-6<%Y%I?'[V,71=']A,M0]P>,))
M/>6(HN:M*4SCX6TD)Z=]7VF-ET(NYTD8&?<)BX7L+6X0"X)9<?$/0T,/[\,T
M<()#6"R][?6FCX+/'4PA]LYRUEPC*-.?(6=%\+&<25R04V_ PWZGPV[ X3Q&
MWUVZD,LDDCMLGC5I'5]7G/M!DRQV:MV^>A2H+7<5+)BR5^=FV[5W6%+2!!SL
M<$^@LU$+D76%4.2FK0>G6BT@U?-=E8$I1![\THM@?=@D\SYJ4D'>&2I'67TW
M^>F$ZE="$Z<<=I.+/A2Z3)G/1._H1'!?'"("U%$>PQ$9C7!/2V5@FP6&2L<<
MOWQHG#:@.^QCN4M]=V+5U]"Q\*C6?XA(%^@C@-#=L,J(N_9SFW DT$5W7K%!
MEF%7M_R<#[ +MFY5*V:B8#KG^*H8,JP'7GBS'^?B*$TQP-;$IHI5M#G)RZK;
M@IB9J>P2"& %8J>.UA]WQJG2>62.$(-'X[78>?! T:W>[?G[]DFA<\7 57.8
MXB0&1QZ5\ ;Y*[%D%*3@;#:76+X!1=I+!9VQS*CO#C>N;ULK;:R7N"7L([-K
MJ*%<WG0A2W$0EU <&_CT"SH:*V9)QQ3<?&Y7O$M'[M!DNHEY:]H)/ D"H3)3
MIR(O90Z.68J20^VL@\^@9&TG-UC5YA*+Z$$PM"[A _L-&00]X@TX#R/F0_\C
MJ[]<S]7UUU&U]@JU.C<RNIGU ;'4=YS6LF3:@[:=:6P<'-DWPO49K.E.[PHR
M["[<(':G>G+W$&,)] T&_<$$18(*_)BC5Q&RRJ(]I0DM610.D'621(E-RC$2
M2OJ-1*EP;Q!L1S+"!Q;<]/!)ZKJNS&H7&V?JT#UDIHA(\15H!(.+%_N;8RIR
M2G'L='+CCU>W(%%8;&6CF\WX5Q _*%KF'^M$B#VB!BMK])/Q.D(CD.JR0YN$
M(+^") E\FV$PU=>C:9LI0\EL1>.^#!C+QESOU16QQFZEN[\6P3?_A+>EV_-F
M;"" ,7S-C2B<WR+7$)DYH0EOIC;_8/K8A^C86(K'>G2K>O *G]OEC<I% ,:N
MP0AZJ<\LZ;-HK-)R$I["M2LZ>O]"_T#_#X6KH6_;K_W#KT1G/MKN2/2R'-E9
M&K"XYU8L^1%?%4\,9;MOGG=TEK3:K4^M=^J/;2YX^=:,/8LTU]]=ZE/D].C)
M_P*XZW?GI8F$W=\+G?:[?$>,Z+X86[SE>/?M96.HTR/6_Y43S\]EKY=0PQ>2
MU:6':K2I+6;J7X!V%H/I<9*^'][$=SM\S[#]FP]FIT]X0=_]'4PV.J1$OK1D
MOIQU^G]D]4<]/]L7]OH>\?S],>[&),KWYJ!XW^_G3=OU@X/[7%>&T.+,#<?*
M#W^;;KO3ZWN_J>W#DZ]_J%?Q3_7DO1A^^ T'PW\]M?K(''7[9V><UQ7AR^L=
MAQ]U=S^1_A!<^Y^'[2?YVWQY:!_L=L3?<.A_@1#L7YQA9N+T 6$62W\PKW$J
MYC0\, DTV2F6+'L_&1@T 7X;8GEC!GQ_ TB6929P'B":F.8X2!E>O3TJG5%*
M<Y5\/]YHDBEOH:2Y]3F1X%U L;M^[?F<_759-%3_V4E!E2YIF_'*_?L5M8>X
MIH'VI!]WN/;?#B_^4\J682*N*-WI$[\ =D$!;%M_?J'U_UO%]*=/.-'HH;&U
MTC2OXRNX=5DLJO.4TWS,3DQ8,R9)AAVU%G&CA[14&/5:>Z 'G\/<+#(+)V(8
M*R^J%1&GN9H9-)2-J9T/!<0=.#:6<S6SG_-UZ)LJ@D-U9Z7>JY3/25$RDTQI
M8A8]U2M+28/$+]"9)+DMO8IJJ&K@T;DF8I%9\LBVO\M/RI+)S[H?[%? $6NG
M5[(@FQ",UI98KR[K/5\9UT//DV#I%[JYR?466=\@SKB5AURH&Z5FP$U7ODE(
MQ2>7*T^A7%5"ML9./@H)LI<BULYG8AU0]#D]1+W/L&% "UP)D+1-2U?8BAS/
MO+_#4[J'%B7;-'B*!?6.D-$UF@<V<JBEUS3483-54='O+JVM@AC%0V0&"TC3
M!3K^^ZKS&B)H^'4]S3; 1#[4H/%#M)3L@*!QB/,)SE&P8JZ)DF4FTL!RE;*H
M;/&LEHN>AD?D*#T@X.ZN7&F,35&#;RG"B/Z.5FNYDFL[(W.[4D^1=Z7:QT:"
M4/[-V=([4E$^^9),YL/1^_'LS3.HZ2@!P_ZY*Y@@+?L@MFK<3M4DNVKENCO!
M]>?M'*VK(E>+B4H$6<(,8\)2'07)^4(>>F#_P/H@EJ8;1Z>&<C-]'YUFD<>
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M<\O%WNGJ;3?0W!0RC-##W4L8HM35GJL/)ZIV[(V[E<S)%AFC4X#G!P,NS\B
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M+(M^M>WTU Q?9U-^)9 #4#]2)(V$*\LYOQ09! >US5O=" BY3#J0DKF:#IA
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MI: 7%-F T2_V]2IG&=TRW0P&D*Y,UJ 8G,PR0:^&AAF+ [I1O1)54;KO#E+
M%\*R"%WUTE Q2D6]XKZ2Z!2,=DBKZU[P:WX>B(IYDU.R\5@^656=;-.AK(AG
M@'J5BG,,, @.C%<-$@$Z&33 L319=7M>_=KH$&1'2CLU+='J5>I5,DI1%L=H
M$A@(*V:R;6C 9IQHG.'7N!B#A^TL%[$AVS0R52T3HZA,-T6WS$$B0+Q$X$-R
M'8VC\FW'I<J#(7<\763#=B$-R/5:NJYVNDP)XYIZJ"%U8KR;BE=XK5H,PVDZ
M C*&'_.QN%W7"Z6ZC^VD@7;%0;PHZFLC!! :Y)1@'8YN>CE8]Y$2 (YA-QK,
MEEI>=B>%8CL>X54DV.EZV3T*>R$DC63"-: '=@&XA0*F9#K^@:?H#A"->Y>[
M"<RM>WX0^5)#HRF&$9W0:W8AP[L.Y>4I0A8I,D"@K58Q9>;[-5P+JRA3&)1F
M7M2IE^L,048!B@[#J!1+9&M%,):,$R51CW*D$U \TVCC4:]@^A<F.=#AYN]*
M!;G4 S6FST%YLRRJ =#K?E,HE_HEBL1"\2Q/9=,IF81QPVCI(&>F@U)IL++$
M"%S9TUQ9",6J ;\78_M0IB,WHXU6W$+D3!K-JY@1ZS$A?R "&G@K:A1\NH\4
MXSVQJ7OU2CGF0YVB3\&= 8+U ]5TV</^I8Y6QV0C2(E^*YEIM>2TK^6VT8R.
M-EN5)$Z2>CJ:PLT, S=(J,>6 CXU+FBAD.%K);I,C0E60H.(78-%/&>6Z8I6
M*M<]S8XMU79LWHOL87\@WI6E3INE8EZU&(2J;"NI8:TV4_9U05'!-1_H=WI5
M09%-CA/RW"# &B39+< $A0/QA$W3+D/:D7HOPS,(#OE!R2QI3([V4&>@+:9J
M0<J;I1Z9UPNV9&"UGALBG5J%\1M=U0X5!X^0:"F.RI4TG]/C $]*1K\G^IUP
M(DFW6Z4Z4S,0&],S<99W63N4C25358FM-M,I+9OF/=LMF1N[U_H4\*^2W(93
MNR#G";V0Q5TC0N9@.:"U635#U22:;])))H5;XPS9$MRJ9V4[&_6I$!B)MN-*
M.V?J NYO>:F@KF9Z'51NDXI/<VM:SQ_5["C/>+D!]H)-1^&8&F'D-2O;0[/B
M8-VF;)*!'IG-I6U:"I(IC 22B)F24VD7A""]R>2\R2]XM7LVWE4;#NK4ZE1%
MT[(<W&HWV_$4I+*A:H?+=AFI-W ]3HZB^6X*UU)]SP5KL$UE.0C1#:&?[=I-
MM-)OUEBJ$.Z4&[*4Q2I2VXW:LB]?S+$&Y6:"?D8 >GJBJ!%)<;"89ID!H29G
MB2S5[^@NBE7Z:!+F\D4#*Y55IA''/8C,%'H>1 W!&M2.2F W[1EYU322KINK
M1MB\4&YG"FA:I :+&%B+:M>B?D#6#(5!?'1:[L%RIZIG(HU2.=&C1)U"I:;<
MR?I"E6R_Y5F.SRC0:0.E'%%CY'PS7/3);--N"<X@+Y-@3$JXW:*9RF.)&.H9
M,*/U815*TSY/#[5>"W![N@<Z;2VL ]T8F JZ3-[:")UN=!IGN+D;&YT,4J1"
M:%ZR$W[%KG7@AMHJ!&2AIA3]& )B%1%OIS7/'B&4;@Z6G<-<6@CW==FN!72:
M*GKAGL^;BJ3D\W2J%&9H&4SSC80'+)H8D.FS@;S2(\PPVP]4;7\G*_8;8@I2
M6G;%WR*A@:=0L*)H+::BR"F]5.,#1C/CH^H*$:Q):(% ^IR)9?,X&A'2I!:L
M8.6&2B? N!/IX92D*"Z=MEN<%N@!>';@*2B(YT5/1SD_&*HJ<:CE>%$_D\KH
MM-KL9* ,1=/)EDOY4:*)D?Y4A-.<7M-7SG>XA FJ/"2:!<.?+( !EAT\7U:J
M+LYV8E$IT_4ZXG2KH10:HW%<@!FQ&43'M.@K99*RGPQI_9ZD.#8I-WDAU6H[
M(8@$8:;*QF*1%DK#7TGTW_RDDT99+A2]U)WNU)0 #N74)-7O#G)*+^!O-6.D
M6.L64GV8](>\6C$-],Q(SP6<3@2(YH/-L9="F#I:KL.&#[;JD4@'\(U=C18V
MO3I8U.TF.E@9\ )!V66BX68(A1VR+"J95-9EU [KA6[0Y_-ER%JI4/+Y *68
MCAMY(,0@H8IGEPCDI6$HF?68AP>>XJEIH_Y$)-3K#<+ C+#Y7K(@X!'GS+B3
MAU2EV&AJNMF+**U*VDBU!@M!<C45@^,YIAI#4321;-->.D-3&I4GHB@SMDHY
MODR)?[W]#TZ#X/"U?E+F3, 1- C(5;P>@C'(@V*M+;;_)JZW13'1+,010#]5
M +X0,ZA3OB6WKQ,S0+#?8DC?4H<HDO&#MM!2P3+MQ16=*!32'"L[0BG0IG/)
M7)_,V+5"JBQT54(*Y4,:T90,D^<RH:JMXN64-@@.[5+#Q>DZ$T'86"<32\3Q
M5-#TP>U"K)Z,)%"Z!#33E(?PZSX-0-P27??U6BB3#\%V.,%U"WR9B=2++%P,
M4:6!IWCE2QS38+9J-J(5(U3'\PT(+_;-0KV$X50 UL 2[64LO)@F/1<&*Y&6
MQ8^];X*%&< !//Y!W2@ 57+L_8?!$H&_'=<]1!T-U\+>+3J2 %I>4*;L>E9I
ME&4;%5@Y4B^C=EX34V*6L8LBX:\P";P'Q6(QV(,&&B G2I*.Y".#IV8X7D*4
M(B?7<TRA E<S:A'(R)C+,+ )R1&!\]"<U5 Z6B9B^&4UWO2PI,[WV*",&U%#
M=M$>ENIF BY#6(-H\S^R$$KT,#9=;P+!?MG#Z&"R5Y%9;/"PM0KTVHY=!3L^
M4"9J>-F;ZYI$]95&@G5 SJ_:IH1GD8"?1D1![T &8-MN'"08FM"!$,U%?&VS
MB91 S=&#ZF!A/!]O1EI@5HJG4OV$FR\57"K7*U(Q1F-]N%X!]:9-!ZQ"+P2R
M ;_"@0HHU#HAU(.V?*+D4E31R7 IQRCG:H-5$8MMJQX/-$7'&G$M #%LQL?:
M &'TRC9H] I56 MELBS44IM4,>&7*CY,K2:EHIOV@XS0"!DE,,OI):T>H@?K
MV%S%1OV=E(<=R3*/DTJ$RD$EHZVU&HF>:]4:O"[Y$]$.Z19R_J(0#YAF"U:R
M/E9@:A[6MX(FUZ/BKL)6_<2@7JY"A,T7<D DF(,,(I:%C *3]P7"!F'5>RJ8
M(K2*Z;"*:@496X.D8CE9*Y%=HM9V>\ERK"RA=H#ALKX 6!<&#VA8/AS3P;[>
M:81K.@@*A @1,M<-P$C8J[W\;9K3_":339FRR(;R,3H3(H%@B : &@F6@(XV
MYOW@-XZ'7SU1A5ZEFV]@,;#5R?8(%TKH0L_H%CI>B!Z4%7V4S0)*6D_I85-'
M]1H;5XH2TA#%'.US8<IP$2W$4D6DBYH26JG7?$6GG[;]%F;GG&R=1/(<7=?3
M5% /*(.RPK!X/!>L!ATD &>H'AXM2#'3<RN&+/7*/L$BU S'U4W$K'K)6:X%
M"BZ!260F"J-=,=;RG#Q%^B&H6G<8<F#8JH\!^I(85,JT+4A4H).T63X M_AV
M&V'S5)@MR&F&T:HTVX3*+7\$U]1>,R3"7L93S8[<]U5K#H*5DQ371 :@W6GC
M/@6KDEP3$^16(=*KIMH,1]-9,-4+&DBJBT=0N@VKELF1^9YBJ+1 :R00\-<\
MN!#9! $,ENZ_,5PH\"*;)2,=KR2O&6&_CPMA7,AG]-%**!6-AE*9 22&*UP#
M99EB"<JX3!5H&E[B#CNB7H=;6-UGL'@'Z()> $#*#NWXR'8!8+(>6@AR*K!)
M,XWR#4 [!3<[=J%58A$R"!%=/VU7,<>2(+D= (1ZGVS%C:Q7WA*EL40? ;-
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MGV[8*$*),IZHIL)IS6@@22#7@KN>7,1/L6&E+3<Y;/!('>I4Y&JFQ@4X!BM
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M.RX_=P:W^L SW_X..DTG_GKZ<]M.G'-K^_4I1Y[RYSUOF'STKW9_V_?JLXW
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M9UHA(-#I)U#WNP@7'= Z+)EF R5ZMI1]/!!7PQ'9#I01J[J!5V2%"HT%I?Q
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MA;D7Z911\07X!"CM)2X92 9 !U;AKQ-,<!@NQ&R&.%2G)+U]JZ+J.^\'A(B
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M\S*H[6D099R&H0?@G[6!"!)WND\YR=0Z5]\#8!SO_Z63#[V3*S#PPJFUOBH
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M^3^;WRT;5R_UN*H:"RU-2S6PV&I:,[FV?%6L,;M(Z>0FF]9#H_#45P%E4V.
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MYE'2[70ZI2JBJO(/X?0/XU%>/O1 ,5Y10E>?2XB-6THAV*&#P"A9C-CK!65
MG?TF MO).\FY&VN?OM(7+#T,UA,4<<G^U+510K!PS\'KLV1'AFZG(]!2(*SX
M8.V+W/(K(43&XRF\7G.$4&VG\:R974:2!G^1[LO>,F];MXPI(1_;D,:CR_7*
M&TI-%KWV*Z\2QSA1E5%7K$1^@D,-=C<)GJ'5KA+8VVQ[L=JPC+7REL2>!F"Q
M&Y>EKVS"?",J_*^NQV)?_.VXZK75>0V4Y,SU@.DAV1A.0U[$R;S#_;\PSOPW
MW'F3F(H;>I8YB1PR ))-U =Y;TV>84Y[3+DY5C87\P4J?[WLO%B44[+(OW J
M,*Z$A?<L P*9KN P%U0=Y2U.^,X"ZC!5Z!;GT)_LZ&_[U2VT%?V<VH*57Q(Q
MQPX-/^FW/:'CL#"*J)8_IH+S%UKYV^J5U-M7]Z0:CA7*!_!/F91K3BU264@8
MW#4V'E@I"WO#KI_SL!E9M MPDSUV>,WS.*J7!5'9W!__/93WN[7TVL&!MM9=
MG68@ "52HW=?D>I(?QZN.\]CY!SA_NQ\%%%PW*BM/&7AVZ:%OH:-=>G8IE*-
MQD54S3THE"VN@+-R4ZV7W'Q6GC,%UVTOKX;;W#E(2LJD<&S/MG-4TA8VBOZE
M9<FF""R.Z&VA@LUDRMD6$M8PDK.X8MXB!3C(N84&$P_N8)TBN@P&^65D[G$8
MK.:_U_?>'GBGD>I:8T&8O)&/(7H!7F%UXR=DI,:?<TC^T1[BJ5V6PL(A\HBK
M6"69.#6"(KF2GC%R]PEH%,6,8/;@PPSQ# M[L5 2+IAMZ*35H?<+TP8TO%.H
MT@9X11\1?IMV-TJ'Q/UX7>@UP?;8=2NSX,F@MW2<K1-(<]G[BT,1F[803.N
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M%O,]F6/L*\6EU^3.H@HBO,HU(2CV<'=G@='/TH>:AM2[]]+:TAGA_HC<WP4
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M^#*JWG<.573J;+_=.'Z+HU ^K=91[N%5=5-P\VSN_\4</AKO:M]=AW=*)CY
MW;S];?/Y9#\0>HOS2-?JR0*^P,ONZ\^S[E EYF95N!CW2I.H2'D5GG1@C!W\
MA]KV3>3:^(@9*,>R-<1#W;#470;5=#*-)$03Y7/:?'5L<[LV-DB'O;]$Q@$4
ML=2')KRCHQ84Q64>\.GI*'[?%/A5*(@Q\+W&(4N2"H([-*$;< BR6.@HA87H
M?&SQ[9LJ[\ EX^#UWX]0F4I#__QK!O[/3%TFM]G>4^H6AY"T^0COBBS8>U$<
MX_47OY=_!7=?K)=.SOP*; \JO;X7^&!^UFL(.OMO;DC_C^&+B/U)#91NG][^
M%N?-7(N79SKOC.!?70[PKX#^>?(U<N;1E:+A+<XOP;U_F%I2_?WA?_M__W7Y
M,BI<]\RE/9&!>%39/H&-D"PNR5<BK8PK5/6/B7<"^?<?_4#L/'>$40[F)R@4
M)QH^ODPAANNW/Y!1)G:U8@XIAL59]W<S-(]\4A$4LH)M-FX;W.)0Y%9;"&ZG
MY18]FDJ0M#R$D_H\I&)?/2P\ 541X3FMK-9UOKNT-W+R2#T@@#1W3I8(;)JD
M)8L+SJSH_ZA;1R9GQ;_4K%=R?TVB3%C'3O\-IHRU=USF2;7]$P#R2ZP6@'R%
M=87=WR:4YD'L2A=N8M^:=!U^V;Z>ZH'AM,A)<3X=.U3;TZD\.NB\K%N.)Y'6
M*Q/H?LIW8)N3#B",Z*:V+CZ0Q97GBX?.B=@(JE:V)Z$:+_7'YX04BR?\M8;8
M:XG;<7\PJ:D/<1,H2K=S%5<EVSRR4J*PJU(?V"1C@?5LKJA.+;J!>.1A,3>0
MD/WA@GM&K^/'1KYJ__CO4(VJB?+\NMMT/-U;KJC%Q-4RVK9/+69,RJ75H.R(
MM#Y;LSUI^O9-]1QS1Z@3O)*_IT?34]8P)':D2'^[)L\S.X.,HIR_)T*9F3>U
MSZ.S2?RJHKB3;W:ZL'TY?=9EK1L/-LRU*AI:G$G_XD3-YQNDU*/>J-BC2QV?
M[5-+TVH( T%>;A*R_<8NV/I=:H3AG,LG.3+A!;%?7T&L,8T<G U"MSCQ3B<6
M:&B:>;^IV##OVCG:T8;HX=JVZL,24]6B\45F5)'_I?G*,[1B4PUG;1";D8:#
M+O//AB"=-G9!P,4N'TQ"C39 )5IF\UBU-$/"5U["[WQ7/_C^@4I1?)*#9)JE
M+L&RFZL=<Q8]\2=!6?<I%W<:39KB\.15/6O]R8A<L,!6K2>,*%LP$]'XS$FR
M8BMGQ<T42SI]O'I:O>"SNS7^XN7_CD+^?Y_QC_@O]LEW:X\"%;O.ER/9P64&
MXMEVDX3 3)TJECO#M3T#V3S#C<KEE=_4O RGNRA#.Y/0[-%#-@?!I.,YS$+1
MJX]TISC$"\KZRVWJD>LODCG/OG=_ \Y(I0)UK#R2\]'/D(6G]=3D4$':QA="
MX\ #.Q!JW<>1MT 9W^G32ZDXD90O7PO4/XU0\NTVP0]GMZ_"%EPNE_>"1P+?
MW.)\>\.W[F_S^YRL??&T;QX__^;C+<Z+#[;HBZ&6 ^Z0KMV$5CK-ZWLW]#@8
MQ''&YR53HJ@Y[B\2V1>/KJ3OY"EO2C[J;F*A:S)][*]PA'_VY9Y:PE@ ?HR?
MFJ1?TXN+J#6Z_<</T[B+K^@8SE(#SOWHC^E^22Z\P!,Q-3@SU[[ MI>T?E)]
MR^61A\?@F"J;$_/HP3=;W$-<&#VLHM@*7$"K8[I*$ 3J-C0KN$8QP[<K,9.D
MUNE(5P"L+RS/[^KUW'^H(PFY?:'K@S.9#<GO@>TO*:%-%7M^_\T2H'4+*PT9
MH4Y;8I&OQ7ZG^F4+Q^I%?]XNO/M^*T-=+%5'R4@XL-9,*<,5(KDVEJ3E]9GJ
M4X:2#46LOW!*;;1$^KE?\0UW7=?AW)L6'[5ZKI^?X2^M>>YMCKQV>9#,;RUN
MIGO"::"6CZCJ"*::/A;E4;:P%^36M20NL+> ^^1.//,>6.$[&-QK,(A:.$XS
M=_FK8X4: @\/EFE9XS'P+H2UK1/1*G3O;B26V>S;3413792]JCFU<S54)4L^
M(ZD0&A;!VJ@F+N;")IH"J^KQYO\3_^8ZW):9):]UKQZ^H?6@F73=KGA.0U5^
MF>T1>5D^;^=0_PYM!R<@7:_PK#H=, K7URS@,X*]3W$'D,OG+LT(8.ZL?<#!
M6>/TL'?6&(]HZ6E\6E.5*\@+T"\3L7J^\^"E_IK=P];GO#)Z2& 9JJ6]O8"?
M[_H%O7ZI^5X:V\H[FKU_9 %?S/O<^RK@%B=A\> 6YV^'#> %@!$)A/NO-O+K
M>7P0EA7>ZK%<*$K"_36F36!3(%KG,C5[N#3/)-6T:!QH2^,BZ>_!U_Z>^?6U
MUTBJ'>X?KK""&+4 @?6O/__J6J)_:RZL.;F9]/E')_?U1U\T"Y;20FWFNS3:
M1,QKPN0G.<E(-R7S<RK6MC^$EL/I\,V]WK70V4>8 H)893B$&TM9Z^*(<CL=
MXZ_8G 7;<@8EP=8^*O;.PLB$>"RL2Q*$O#QM5P*8N6P7Z4H9<@[A*DWVV/[@
M+)RY&%59)H;/NIX_ W"(@4)_EGQCU!N8>9'O[V?"9%1O)/7T135/L2N4?N9;
M,J@8-3#9@Q$K_#+E3_8.XF%*Y/7U1XV(PBHQ=_#G57/5(E;MBKIO(^G<)&O)
M@XT;[XI>B\?N)HP%AX+E[%'8<U?Z =M(QU\(@YY-[?CLAV5,Y?;I7(,>C1,U
M#L8V]4(;96/ T.R<!J6SH1SZ@^-!'2OG\4&Q$&7J]H-2 F'TME!&OJ-3= 9,
MVIU<^N0C=,JNLU#V_VCFNJ+A4+BUDR)=H@5!'*)$C^@M'"$,@PC!&"711AO"
MZ/4D>B_#A&%(M%%'KZ-$B6Y$'8QRE#'&&+U$BS_KOMV'^W#NN@_W<:_U[;4?
M]OKV6M]N^7LU86(3GCFW6LWDV-HZ@1]V@6Y=<MA+&B,X%3H>B(N.12BI-M=?
MI(TB_)CSSJB,?GH"U#$M'3?A.7KU":C1PN1[X8HRZU.[4^.2ZQ"E\V*&6,W-
MAU+)M.HZYF@!RKT9?AY:"@]?BCTL:U^ZV6,A<)))O;PM9_WD.%1<WVP/:>./
MSE60\7+\RZD(>!O8*U4TKO43AC'_8M +OM[Y+:4.%,!VW<R[!G]O:0=&$!"4
M&@WGWG0&:DWO2@BX>J;C/!M7EC*0P28LQ3R;G,S+]X?/\[P"!M&**^EN;>$&
M)D6>[B[1%D=#KWH*2]=D' =XG<:89=^5+<,SKE6F*VR6.+S>^3G#XP.UB#H+
M[K\EA1@FPI7Y1EZ8/'<N(+?ZITB-^2N0"AKO1 U__!%O:-9S0 9P-'<FZHK9
MLZJ_NBI>O&2F6J)]TCD<S>]JP)=N5C2?J&H>SR%S_S'$ITL*.+FGCI:)CK,4
MQHRS?:\?K$ H. =.;L@3.-$>?2>%L7\WPZCNSKK4^P\47FW79CM'E^W=SJ!$
ME;%./,MD**C0KGE"IVTPXOFZ%/IU+'H7V8-HRRS>,T%])7##/S/84VPWYU?;
MC7"GU("*,.(^Y*C!4?U)4%.(M J,- T+/[7C>T,R+B[CCR$U&$E<\T])UO.>
M"BG/C\>TI/!!ZIC6VD;ORCCFU2;3W^(:Z'(GHJ>](>/2PTLXSP42(RM![O#P
M&",VN]&CQ>+D%1],U:X?57H) U*D#Y12L'!E4Q_>X(QN0QVO]3.H:'KWI_8T
ME<<'IQ9:0PEU*0W,>4 _8%+O,A&<,G R*2'U6;X1GXJ;M;&L/]&M2WKK)0!X
MVG"NNK@ _>66[Y<8;0=8!G"0TCA.W?A"P(*K)0C"JWT93]NZ7%:H[4=]%R-7
MOIKO;)R\4S"SR=>\II'87"=X<QSPPS+8M_"W5&U@(N/T10^)&N(+0Q3R9Y7C
M2==!MZ=1.@Y/(=S@9V=?300M ZO>8U^Z93[NCM;BN6X\CM5(L.%4KEJKUFY"
M=&NUVV*2T9&--F4NQYZ#C\>169+DU@!#ML^L<"R[518)'/*U0D^IY10!<R*/
MF$Q6T/YS&O/VCTIKHY;Z*'<E,EY[F,(:!%,T:J,V^8#,)(;QGZ5\3:=M)%-L
M,?I^PEO]?V["&?KCAET1) 0T!8#)]I<L)6#.[B3%D!UT46+Y8L5A-EWPO#.G
MW"SU#4'E=_A'F?M+NST"T]>VF H)E< 4M6P49%3 %SX $''<GW]4X*+7(U=\
MS.*AOO2YIF6$::EYL%V7?[QYCQ(>0<*.H <V:E-OO.P3[,]E%TZ-V6#]-%OR
MA]#';;!<W;3[NDAAE3D&H)SI9OW< 8B3:XIQM6;5J2Z CA2*QW%K+\]]+$(
M=23;Q/S(6<>^SH.%K@-_(-KS<L+55B]I?(ZE0X:L3*_L9<L2PBL?J/Z[<GV=
ML>*2YE8D**3RDB;RDN;<:Y>/MF)]Z7?V6!JN'%U]VG-5SX0Y%I5_>"=AJ6IV
MH_+MK#$L!JWYN<ZCJ;JOVYZE!IF78\[1\"I>Y WGHW<N[UT&GI[I. -N$1Z-
M.3?]FH"X4@7*VXY*GB_>"19^3;CI"L60Z.]18OIFS1[L6EI=W# ?>#)Y)4,D
MP;BM"B <.BO"(/D.IY>"]LAZ$C,W(2OD.)J6WAFL$]O#4(.DNGN1LL&'N]N[
M%./'TH,<ES3W Z+:7PGS\VL\4^#4E.C.3$*NF4.1T48K7%X*6'Z^M+-7=$XS
MMA:)%Q)@M<AXPR<S=!P?HLVZ-VY!FX87UGX>6J>1&&#7#:Z1M'$MI6\T_CE'
MB?MF_XA[:@MGO!4ZN$H_>/OIT4^G @]F8:(3"E0..HKUS"A-0BM[_HT/ZA^L
MEB$6T[HV;[>7M9GU-T2,Q%!BUA60'6<\)EHNTU^)6D3XM6>T@WO'8_$.J;CJ
M_98F:F8.L&HH'YG:6IRD+/\(Q703<:"OYVR%'/T2\ 86L2*S396DM"]B[9EI
M=I96;_=T?)JIW%A6BP$8#=G!D-&,\5B//FZCLPEJPOO'2-[BTNAK%[AVS)/G
MJ8S]@HD?U@,=<Y\V^5'%^&N(MI9"SL(WG"B84\N+!DJ#5$?(WKS@N%8N+]@
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MIW>D38L(*Z)U6U0 2._UL.;=B*P0D5 7NVE6E+KANACP5H_)+O70V=($A56
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M11R^8)\PB\Q@BQ/U!AF[/7:/[_CU74":+"4FS!;)%X/E2]I:KSNO/FI KC
MS6W8?<ENNB?\_+B;J;R&PWJ[7D:12O+C[IA.M;U)W --N180QG"<?L+%@.Q)
M7S=L3"A)ZJ93C=_3.KBHOLJ7N)JUC&I*4\@ET-_=;L7)MLJ>C-)Y+(:O-C?4
M&>IA)J44"3R_1&K\: <U+.I .O:?G;"W#?5;E E3J:=](7Y>(8&?&U1MU96>
ME0B^B=K#5X#>S#CJ"6R.@;^+C(%@V:8HWNY,7S^O2.N%N]X>#M=I1V77M59+
M.FUKI34FQJ'66\5#[?)>[1QSN$4#YU#F+7]-M)P;^_YFT$7'X WI$T[KQ[,
M=B7&JN7=@_3T,0C "W])4QJ]A.$7Z0CX"9DS$3T4J<Q"U\ZEO*!,<BR-?NC_
M'C5HHX5QJF<&#!87"Z.5IHICD\E6G;EB@\Z@J[..SI+!)2BFH859WBH-5SI[
M'/V+P'5XC)YY8V'6OEQ^0Y?<SMG0OAO==V,5Z:-%E7XT\#JD6,%)?[1*MCQ/
MH(\MUU4N=7)\FE%JX%D3S+6ZIY9AH[4&%*!F(C-FM3+XL)[O@YI'HO]3G5@1
M')P%-W=(=&]($8'O0T-'6M)FMMQ='8C>=Y#XO&.TL.\E#<<4XQ6N H^93R"I
MA\]=#@]';^E%=KT>$GD(&7_ T)]GX<ZE(Y72#D#]>.34XY[A+NF>-3<W(G9!
M"HXO,DQ;-HOY6K+AJ5W=Q/P>W$'ICO7&*[A4B0@]P[/KE2I Y'$9KPWM(R'F
M)'F\XLEO4ZD#-:;ZFRGW0C15;H?W_]K><KRD61P-LB%>TB0B0G;Z_I>[<<Z)
M^<98CTL:X"M%B,/Y)UUM0,FUP-U)MNCJ)@"O5[XUMT2RJ5$=I0R:+$1J6)>Z
MON?CU%/.P_:@PM?Z7>4CDMD3^0CV)[APY! ,!PEV%Z_M_27F<IM:2)4;=QFH
MK1<.N,*[DUX0[V%J.RO+9V.9?A%DQY$QC.JW?NE%L/I>W$0P7X%Z]V"=ZY_I
MB(P-6:9EG)/B@U]77=(H_OGKQQ_[V=(G:KWGFZ%GJC=POGCB':[]ZOM4&B[Y
M%:M4D1!<GTHM3>#_,WQ<N67"E_7IYB94JSN>>17Z.-O/'3Z8 :XW#9[!Y<M*
M?IVW-+>R-&$G:T_U#"1W+$TZAG-#U8K??Z=O3)DO#&2N20+9(^Q0@=ZHCW>3
M\"H0XP%<97[I29[CYGCCL>Q8I-[\4K7@^.WA6Q:,G\W@!+.!2J:7<UK<>Y+W
M/WRL&@  !*%^SJZBS8 Q LF](?\7R\Z_O5;\XY=NL/1B&/_^)<W)RX9+&K+0
MC=^B<.54(-[)A5/UOV.Y?K1?TO"W[T1\:[_H#[FD44N6'[FSW?G;]>+$+T3\
M8(F9]#_&";F<^0]02P,$%     @ J8.>6/N'GFOID0  Y,$  !$   !G-3 Y
M,S@X9S$U>#$U+FIP9^R\>=CC5/DW/L,F," P@&PJ#\-.F$G2-&DR#(/=TB5M
MFC9K"R))D[9ITF9/%U9!E'UG$ %%!6019$>&[2L*R"K[*B"R**NR*@CRYGDZ
MPPPS \KK]_>[WC_L=3V]^B3G_IQS[G,OG_NT)Q\__O$?9FU:) ODK-FSUYH]
MFCV:->OCY\33.KYO+P3!OK= 5BU%6]"T>N!0MD%X 03.6K3/T):;AN9/*5I;
M[^\][R\WW#)O2E?WGB>B9:ALI[6.GA^[&CNFN>;8:!+JO'T6;[AHN'#8LWN:
M+T\->V;?6SC<>]X,^,+H\_1E<-[43!/?V'M><OK&E%1FIM*6JTUA"Z#Y30B*
M326(!3 61V%BSZD8%(- " =CZ'PXL1"-+X2@J66O>8LWC-X7N6IK82U#+NLN
M^F_O><OF-1@,%@R0!9;;!F&"($ H!L9B\Z,6\[U1WY>'\_O>CA.0Y3@9S6NZ
MNNWK5G]J^G]9L0)_[WGS-IQ:Z37IR%ZIHT\I,+H1*1 !UR04S7O-0LNU_AE"
MN4*O_?F";5#OM3]+O%S^?.%>;XV2GE_3/F.2RR4];F1K8$WSK,!M:E'S'=<,
ME W]+P*4#;6^OT8HM?D)CAVXYLSBJDU0,[5>).)%6/!G:8%C_H4.?=!>LPH]
M/Z/W_IWQ1\VTOA=9C_<9>B#[_Y8>2.LSIC]M"__*$-8DIYMFX/FN[%ONFL57
M:C QQ,4K4!9%)KV0<2TU:&KNXHG3,I''F;KBRNYH"DXL@*!%X*=:K20=C7EA
MVM6FH3G+,I<!%%9T.!5#%T!3NXEZ7[4&WNZ+P%4EU@2F9:*_Q5%XB,^'D/DQ
M@HLA"Y'X0@0#('0A JT$,FFY"D;94O76Z-_!6*GEJAA1.%-E7_ZW4%9NNPH.
MUPEZ2E_636_QIY9N)B0E3?_35Y??,/69$&7+KJ=-&\W>\Y9[S[S5!);U-!U&
M%@YTU>\LAN.3@:UTZ?.$.IK>[OB+8RBV0FK9M<\3:UEN3_87%YEL;H7<LHN?
M)Z?WY+:V&"2Z8#R9K+)&HUAK)U/)=C;))E.%9#(#)JI)C\]U0C5'C.4<,2AD
MRD$YF8Q7#9-. E!RYI5*1NVG7]GD+CL.DWLEJ]/"T:N:3(% /)DQ2$.)%<UD
MCIL(M$ E68ANMJO95)+/IMH\F6H;N52U7DP/VKE4NUW*)"TJ/;"H&<!,*EG.
M) ?3?]5,,LYDDW@EDRIS9*K*98<#)3?TFODAWOKD;Y#-IP9-.I.$ZE$/]5R'
MKY$U:^;>#."G&G_!/Q"/)EIM1Y-.EY.#;&TRY62AEJR6:]'4LDEY9O;YY/3L
MJMGDBE>53 X*N4@M^732B*87W6L7,JNV6Z;#9#J:;:279B%=M4K1[73402;9
MKJ:C:Y%&(J!^.5JL<BT:"EFH%895(9O+QK)ZLY[ERW:NDQJ*PZK.I&8 >3_?
M*0\;.IZNC=IAUJR.:YSA4*,ZPJ1IOMHWL,J8[JA\(\]EH*!0*%KE8KK3;G2*
MD>H<%A)\6J!2[B@.,MD90+C"00U))$U9A(>J9!)B(]:QY9[O*2(:UI$:K/;5
MN";9B58>!EI()=NIRWF]T*/T^(CN6D#:0%G!M+5ZKS$#Z"C]8DSKHU37IL2>
MC>FVXP2>*V.A58OT&TV_D$E5(W.IUK/IR""4:9UULIE4.LN6^2S)U^A.H=T8
MMAO9T0R@I>0'9#E?B[-TFA2*>C/,CHN96J;=D5E^).KU1"F=0AB6UHK9]E#E
MC4%[9LK%;H/,Z:JADCR".Y7Q8-2V9P A@!EWBJSAESD>96JF6A<%6Y%(6)/@
MFMGHJ98LVJZ2@P,E]J^F/P,(9,RB*)JHWNC90;/?P%J&4S%L6>X[5,]QL)'O
M.D (RLGD(#-M$=EI$\O@28*/.PE2JCL&@: ^)*91;3P#V#$T,(P3=JDRK+F]
M6B;.:KVT)XV-1DUWC!*8+"-2'\!CO:JL9#7#!&G,& !JJ#0A!BS@=2=&D_A@
MW,X1^& &D+5:,0,"D+8?'S$9 BB-JJU:H2PH>3/#Y9"@U.5+9I>P1A*!#A5T
M:%.&!*;C3HPI,F8V,9(9F>L#<EP7F^ ,8(O*5\#6<"@@0+I5[(-)LDY70*Q6
M8/!DKTM*K7@![RD0E.?:'"+"G110+X@!Y;?B93PL@<TA)_HM0!2QP%5F &,@
MPI7RNBL!.44O@5I>)&J^B=@YR%"AT$LK045C^Z-F'HGZM %5D=2BFXE<9<#6
MBDJ.0WM"1G6& "_'G1E 'QQ*A) 'T#ZGA!R91()T.U!:BM,2_&YI("&F4!8X
M?1RZ%.!#@4+%NX$K<XDL7G(+W5;1+*:&@C@48E0PG &,/MF<@_2HW#@0( !J
MMWA5,J2>V4E6TTX6RAI0EV=S#$C58291J"?J3H?$ \QTZBA03T"CFA\"NDOV
M.SXY T@RWJB2]N!A M>=/%"M.WVUWQ!54[$5D<^JOE)+U 8#RY,IIB$DDY\,
M9_6WB6'3&L 3I7[0"Q,23)=A>CS20$_,\MUH@0J!V*UQ8#)MUCJZDZOXF&_9
M-MKIL@HWA.  %CJY=J(E6E0 26%A!M!N5!+-E.X6"F@!K<-&M\[DXID"9I"L
M35:K-3A2D:H[K(PZ*J XI9J:I[I"R61X,Y#RQ1*+. *AFJ#<Z$W"EUC,$+9C
M@&FW[G35/,0.H!Y<)AV7M#/C0.D)01/".V2F2!=4I![Q,RK='@KY^L1-$B3O
MXI!,I- 6'B(3U_/&-;_LFUE(%S&%+A6AKB[50;* IKM(A?*D/EB&BF@5&H_)
M8M(T&CZK0PG!9;E^!?;B0<Y/Z&6MEVWT!6,&D,G'57"0ED@^9H#E[DC--P:(
M@AB.RZATO5:-H@+H%@.(@S-*+T:48-B()SJLR?F<$_D3@W8!+N0@V @;Q<F4
MX18\M/$R[:KLF*7EP%,'G4Y7EVMYO3$<"W JAQ8LVW)TFL%Q352K<%5NR)+"
MJ!7(:V;H5,7(C@<"(=1+D^ 0!8JZ7<4[N01OZXX67ZX<*9O4.TBT)#H\3H)F
MI9$ H#Q8\4;T"$Z/2%FLU1,('50@21,9B_%= )H!S F-VECJCIT*3>%.@L<C
M%S(D V-@-QTE :K7$E%.:W9C_ABGG3:>]-*6W!J3W<@5&2\R '?96SU$9P!Q
MW)7[:*\#A5Q"P\FNC0M$7I/-2I^T1[Z7*28]BJV-JSX ILN(DS93$,.1(DT#
M4KZ'#16>AQ)\O!1% B$Q611)825>SQJ 5XL6AY!95Z[6:IU&6B=9G6!E/8R9
M?,;-Z8!,5W!83CEM=JB,4VXE'",=+Q1[@&T9HL[&)F9CMT2FENT7!H,L8&-,
MK$OTVHC02*$JKF-(0R9LT4-PV('P%M;HPQ25# 2Q)302FI!MHX7TJ.8FA48O
M;O2UW@P@D71L+(,6\;$XQ$-,<3*Q*M0:#9LCB>ZK Z8 PTTPL*V"8.AR,=NQ
MS &+BC6@EI?MH= '5O)E?P:P[ 2VT,X)G9I9B1<8/EMW!G(7M,9@*HKP#&0#
MNB:!<DAD,!!K=3FL#UI@:3AP^HC1"?%DG_=+;04@/%>=!%@J+@UZ'DCD30DK
M%GH#JM^;].>)!A['.D74#_P4!')UUV&XKM*RJ5K"JB+4$"F@FI]2<G0H=+LI
MH !,LI[M\E2N$%D@"3$X1*3@/*?$P,!2G $+A:C/=+N&7X+",L:-JL,TR26[
M(W:4+AD018V'_;@8F4\9P4%-,"=V&)3XT.6[56[LR[5J49%*2"W(.I(..*6<
M8E3:O&F6U2H]]G5'C$FH@=5*+CG.T,TA:&&\K 5=AB3+.#$L3OAAL0#F(3A3
MD=.5,)8:DBS"D4+?"/%1Y+=NMXY 5@>V$V.^)!2,=I#U8X ME1U*'P=NU2\1
M4E>L&=E^2?.3Y4D*J"E@LJ@#DN*,PQ#B5,W7JC%UJ(GU7CLH6$JG3A9+ W94
MS.>;A9P]*G-]DN_C@U8O;& "6F$!U$)Z)$'[[@Q@ O/\L#F*>4USU&Z0/:.;
M8K,534JRK,/%7-TM*N/Q$*U[1%UB2WJBH4"CH9C@.WTM5Y'CR7*9]P<.G2*+
M17X&L"FH X[GL2[)4R%J:AS2[1MZ8*.&GVC'%)]L2(8EHYERIZW'JS[F653.
MJ>%Z*H2BY3 B6ZU)JDLVAZ6"-P$<1?%&KK#I:C(!YDG*80NMAKDB-0IMT"F!
M>HN@0%R+#!^P !L8<Y&_=T9 "PZ),8Y3METJM$JQ25X>(=D@UI'#@LN."-)7
M4*?6Z>$%5]?U4.9<(K#2GO$)>&\\,M$VC(BN"CJ!:2LQ<ZAPF.I:FLQ,*'%"
M*/0%U()J]9@ \M8(1$9N+=2K$")498!E:-4OY/V6D^W*BDO ;F "+D,Y2%I"
M@Y;8#LAL!FA#,M*(5Y:Q+Z<F1FFG1:)E/";Z"!D-2DE+4AZF4#B=@#!6%$K5
MHBIZJHTUU5%!,M""&72;XPQ>*RGI@'(4K=JB)6!B-CR.ZG$OA"+ZY&4&#C2*
M068X;"BQ4CS*2!G"M/HD)\CE9+I).1%)D#2GR]$IST;C29J&6P)=#6+=!M;+
M\),INX-N5N 10\*P/N6G/'7L\Y0E]@UEW&'LH!?%'P53R90E]A"R4Q_'/&-,
M-T=1](/9"BOD]*Z(1/(-0>8FGC*P.T(* =$FT(0@AO=S4(SC^CK<&WB*A@>E
MGJB*G9Z7:)3485:O>L6L(1;XNF?S,$,&/<K"$A&SB(<Y?"Q-XF%,:= UR.43
M0)XO\@;<XMT\%#E4(>?W%;<H(RG!2F(DP#0X*#6@=!XW,%<!N )!RB./X$(2
MIHC0;"1BDYSBI3)$/2PF>CDYA[;;9D^,W$5H==($J-NPT!!0Q?,%3TUY)49P
M0XQP^"QEJU+=!?!FI@D74LRX@F*1.XY6T#DFLJR>#(G4 ,)+I<C"!DG#JT>Z
M23(^DK6<#,;351%7S5PB,\UI):^%TRTK#Q<9-MY*P +8TL(1,9DR-HXL+X$A
MB5B(1]@NDTHUJVQ5RLKC*NOPIF[PY2XUL(0&QV>S:I0N<:_B 1+3\0T#EJHU
MHH>D2HAOA9W<A#E$7-K.5A,4A^E$:ASC*7MH:R[6<'R?J$- G(WKJ7@XI'.U
M(<S6,C6CJ<+U9#?4G?*J'''YE%=<\[0^/AY+N"OVS5Z1KO8$W0"L@"VED0*=
M0UD7;%5\)A$48-<;%^&AD,-*5KG2ZXEQT]2(2?'(8C;1A'-1H<,V99/G,W*E
M2/4[N6! C*(0UEN68B+>+)E=UL4PDAAJ$$S7AA*OU+J9)I^O20W5%O*3XK&8
M' $QRFIFQAT;0( NABHEJ,C E80MA54F12%@P8K*&Z8BF@/#=0QZ;"4R"46"
M2L5T. X,@H4C@L &D?YG .N8:<>L*N#7)9Y&TIKA9?51*8RB.)N-8F3M$^X2
MO>G5),M5,TTCHC\XV,^/QAD*2F.=?!.A$K0<6U;X)/KY<<<?EHK@(')T!FO@
M R1BTKVNKUB:"3O-=EOLXZ/!4//+".#$NX!&N2V<&DDHJM5=@N!SL)*F6PX\
M ZAG$@-J3%,9L$07XH0G<!A%4;EB(>(KE6*29.DD*53I=C+EI?1/J-Y*C#@,
M*<0,@%Z9F'B*K;IT,P]VXS+)" @2,^QQ'HD[5BM>A>!JRR'&#AEHB(T0,2%)
M6&A1ZN;!9,0BP4S,<OT\JL,4K84Y4P?C,X CT?6!2A1?""@4K5*?BQOX$&L+
M@=NQ;&J(J3Q5*#;4D,ABN#74HW10S3D@GN1'$6$9)'6B B:*94&./D\8;)0J
MDJ$0$1R)Z8(V)Q*MR-!),N0BREEW(*:8-QO=4:"D%*(#P*VPJ/D$ 4%1M5DI
ME#3$CYL=/VYT="E1;LX RATA/TI:92$JZ=25EW2U-S8A1)UIB5H(U(<@8%7B
M$0EIKMQJLBC_"H-(^#D0C12'M1.1'0W77)BQ@1M,5MDO:2P:3&=AN="T&ZB8
M+EBXV-"3T9KRW;&-*G6A&_3,*M@P]$[?J(*8:W4I!,KG3!7LED:1RA) +ZJP
MW?X,(.CTNVP #DVT!29ID&L1!7@,PMS0CN+4" \C+P#MB ?:N: %.!I-)<"<
M9()@,D_0X"#UJ<8S@"&X''\9]"#9B!@FL1PZ24>%@9#$NJ@'L2P.^9#1:]05
MNV\6?*4?%VB_;') E :*_<G>U\#IAO@TQ"#3@A"0I9L@P>/DLH'@220:"-25
M&%!@EL\13):B,0S2AHR"F!V'W D /@&<1DEF5Y&(* >XTAR3J6F%+(?&DRL4
M@B>!2"' -/0@/=DBB"1T@L8'6-'AW4%,2)!TL]8UBXH0'U,54]3EKL/TR@*7
M(<6R7&H,,;#9BG=@LL8HN5H(Y>40YWF>RCK^9-]F"(P@#TATPBA6.U2+% 0#
M6&.]OFKYWG(K'5EUB, 38IVL44-CDRH SFE9/&M2:397;66[K9(+T;6(_M9:
M-BBV( ;H!G(K;@(!:+6PX0!4 1=KP5UL/,!:B5$K!/*<B>>CA-  V,F&9 HM
M0<F,#705#C0&/<J&/]?65RKNN&KD.=2@T@?SZ CH$Y,DQ;M$C$QK&AO=-#-T
M,E)N3)5;>"\[*'(N*?60OC0>NKT>H,0C"H9D1D24/\M  R+H/%&5[7*]T!G7
MFQ$GFRP*(RKMFJ=B78447* 9EBM=0&8J?")6@S,CT 8LD4*R8Z112\B4//0K
M==]M6EA RC4[GZ<K <Q%Q3LDX4-ZLJE+ L,>U*@3)"<R4!8&"3G#Y50TK.H&
M&6("P\DU4W!&J38'%2(.S'KA. >/$M/[GUTH5Y1@&6AQ?K8M$\QD'UMF\W"7
M+E4$/Y8ML[92&110KX5&RUVA:1P9<5C>I0DM)L$B *70N%KS+)01.;A0$((4
MQMML.7"';&%D6)F)ZT%#H> 78&5<:@"\Q3 5'QL7FS'([P"&$E8M5T8(4NA%
M!7"9=C#'B*MBO30RC"8=SSA1%G,8M(,-+<)W)G0.:T#%@H*-/!/.P;XKXUF,
M&_2JM7+'D'-Y".4;';XI2JU&5W< ',< ):$1E7YFA"JLW"%M%*Z@78EG"U!W
MLDO<M0IMU'=\:L#5FQJMZC"C4TZ'!AK$D*Y+%1>+E \G:G3%<UL\S06-4A=J
MP-U 496PJPQTBN<J9A!7VY ^ ZC*Z:CN):M 2V4#I2LAOE_L5$PY4R0D&>B%
M0KL,V6V]+^JC6B=;+54J"E.@U/8P-A2Z'HC:6IT6NE% R. 3TMX;<;8[D@4G
MU8$SV+@Q=@A+Z96K""NZ<&V #+ULIC#"Y9Q=$#B)"QFF5TPX:,3*F_[0-6(.
M)[=(.R'I(%^? <SZBEC11%YB8TT>L?MPRH,X?U1!!M%28&"/<<VQ*BMVT <D
MR(![>,4NJC%XJ %=4AG)4BF3+S"BF.9'Q<E&$!:GREF<:@L,*9@1'9+J:@L/
MY9;+E[EJ#<'3G$Z.TB.R@T?4I(YS/E]W>AKE36=+JAT5[I&'(4J3RB;PR595
M%%BIG)P"8V-WQI=3E%IW!A@ 4MRHY!3AGB30%1W.$7# LFP<3F-=W0RLD.]F
M(ZL=DQ6>'1;:T;IS[B1)#84&.'+&7$:5LE[/Q?I%!1G'C)X=*[$#K:/2C>I@
M4--<-LNF+1^.8C6&ZYP4ERF29RP&;7%]/H$!L(R%Y+(]6 AIRK:,<9A7$KM>
M,0V'S6PJ9Z9RXR;#I_%V6G!U1QEI596JZ+&*.4 $6/%M$R*(R--K-$DT.GW5
MSC7,&<#2,,Q6:Q7,%*MM1\X%E 76F)+0L>E.,];66$(&3".(RB7%LJ"(HU%)
M-RQDQ0J32#LAR:?;R62&Y+LZ2"4F\="$8#]OPAQO$\ELV?=3EF= =3]NV59,
MCU.CFEV)=X40J9N&TJZFZ4'$,3A (CM,Q#DU6[:=G".1A&(W:&T&$.$&FD\J
MPZ"8RN<BKFH1""DVC!*-1 RJ)455DN1$K%\MEB )3MB]/FT7O'Z@Y-B4:#1L
M-&=TU ;? ^OU[,2PR50^4<I$P47$P5*FBH9BQT\$N$>7PY*<'L-YUA7B'07A
M23_J#S+0X8AU 2S9K4<AA@TB9D(B+2-3<UV.G@%4(-16]$I)*HT8OHATY3*=
M8=)&>MC+.60U2]NY0<:)$3*<BYAXN66:=<!L>C%/-@!;JEA5S%,%U>6C\IF?
M!(>"#S5(P 4Z0Z*H,=EA5B,C+:'@* &A:"ZHT[709?AN*W2:FC6@4Q@4%9EI
M$7<Z4D<C+:3;)06-]@DPK4]20&A+!E<CRJ'/A%91T5D,(DIQS:6P ,)[-EMC
MD:R'QN&2&2?CN$9U;=:D*+N/:E %@O*U$E-+T&BQ)(^6A2^>&Y-<0<CC0YZB
MP$+D5[D9OW(R(*1&[J7Z XL+1US$>:R&%;'AW,HN-<.T;80>DHJ(3_+RD-+*
M/$47"ZV40') <BB@L 7VW+'KD!VTQL:"!$LE\+'H)QS#(PB9;J:I;*XB(QVV
M@O0\T!M*2<D89WOFQ&RB@J5O@Z@NI0>Y(9SA[-)X'*TZAZDE.V8V<]EN#&<Y
MG\[!$!'H-:!+YX9HZ(GQ1)\4?!--R  ^&'*Q$-8GU6C-IK-&1'J(O)W,!RVW
MK,8*(M>V&B O=JI.+@X#8-JA?6:<@T8BZ!-,2#.A2H>VBQ#YJ&QE!ZV@T?/%
M(-Z=K#)>AJ!63J336:J,#)5<+\73%HAZFNC7/342KW3"4H=F92";Y9ML2*7L
M0=&L6UUOF %36"MM,[3<5DV!G9058'G,*>PP+.D Y/**B'EN#_*+:EFNI!)&
MV/*<V+A0:-B%F#""Z;Z3X;/"4%"CG$.:J6:8:<J<4Y;%2#&52:TGY7,QC1J:
M05#L=H-,OH+6\4:VT4T7DU8]:]0=/:1ZGMQM8D/4A/I\,5,JV0+ .)Y)BKZM
M5HO-JHNG75 U)[5>%T& _'0Y..(^J;@&+CBR(F(9V0T10]*="EADP-7#\$Q;
M"X$=$VE(I(5.MDS-80[GLFH;BYAR2$K]OMD:N6B_AP< 7XPK3HE5Z[@GFD.;
MAVBP$9EYLRU!":7GN$S#K^IPIC"H=]IP4ZA-@H/5,HNR9-IRR#3%P,+"*'23
MB28BNF)9C<KBK!G3(U/R22U9&HI4N89+*9ZJ!(0@B!A82DJD Y555,'4\60/
MUO9+1(E3&,Q5*"FH-7NU0JT,DKE"W,^/$*>E1PRI- 0XE4["72ZB-KX:H45U
MC@CX1:($$4H%\8L)KCLL3RHIK]A'4VT_YP $%_%05P$-1!:C<-(;PZP8:\-Y
M#H: 8:?;38/\J&[5;92L1_K-%D/'J#68#I9OM4A)Y@"^.@'D@V1I-/)!-V?)
M4I3N(83K-*+96$Z3:Y)Z%@IPGR)'PT(% #F25QP)E6+"&'4"7^MT(+WA8F).
MPZ+D.*%S(M@7XG5(=Q4I[P[H;(Z-^(V;I/'J]&Z1BC*>&P?J(1UX$I^)81(,
MYI68'-&W,DYV%3N#A<-DUL%#A^0F.BP@4>3TW!4[+:M'FFJU5=3:696!E)6X
M<GWU\GYBV*O=&/0BSQ-3,!@'*PP$6B.?"096#= E0VLC23S VJUJFZAU+ &*
M03R4,3S3RV&ETH1P2NUL)5%(#EQ<RA8;S+]3 3A)N"_1%4A'1#'1[+$\7A+A
M;KXR"5\:Y^<S.1JI \B8CDK:*FAEHOJ$ XP@W8IW@1"TNY@_RF=@A@-<4-!4
MC0'P5J+;A]!6GO-UERH%8[\4BQF3 *N,TA74;W2&9KLG- I(OCWRTFFF'U7+
M+DKAOI/T5 =G,XERLXGC<E)+6]U.E3'*BH  F58IXD9A+ZH,BU%E./E90H]V
M$F JG*D\QU%Y:"!1'<GE8!5L(S.5)SI3>?:BRM.IQZ+*,P=,5YZM\G31^>G&
MD_#U"?X$.IE4IBO/9=!1Y<D/?3[C,"93*R3&+,16&D(OB!27QH*6SHO0&&(2
M8Z"1;%*3X+"&T:7DJ Q79BI\?-PBBG14M$>P44%+SU3X0&.ZPE\QAFF J,(?
MT\OX86H5B40T1XQ5H@K?[DY#)Z?G2"R'3M+")^I+,LNGAR>G&T^BC<NU2KV.
MK)3A84/D>0&*QT,UVT1C$B#8$LIFM2@T<?DU6C(?P!(XO?&")WOEUD2'$:]-
M=$FQ O:*0+T9FLE8@>.@D''U<=DV@XQ"C0=XA0[3-9+!S&$T1G78US-5,%L6
M>*8<HEW,MDBDE-?DR1?6NCBNLN-8<XSHG:!<-OB&$9AB$?;C&A\'M292B":9
MCZ("AU)@V65!6D (WH]JP:"08"OQH,ZX%$,5)68X(>UD/DKM!2A%-N2D4" I
M/*#<3^\7K=E;)-F-3 J1:7"<8T XA>26?4<OH2ZNB_D>&V<U&0@2N:KH$1U*
MX0=9-N9#?-GCTAK5+(V(<BO;)\.(^)E=- M86%>3?-<-[$)I5():#@I,  ./
MI3ILL6[G_5Y?J#NXP8^R37^4X6%!@:(*@TY#78F$Y9&F<OD,QJO6N  5ZI:A
MC(6XYD!=-U>IR=5VSYX CNBFL&I,8$'!UZ $V\GZHS'3E%)4#+:378X;&:J6
M95.]@A@.:<+4T!QE\=.U6<%A2MH$D&=8%VLR,*)1 <@!3N2;O(]UP62Y2U?
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M](]?.6[+QPY .5>]Z_@7-Z,VN/_FW5YY$EWW=19YWK[CJB=_],3#.XP[_+F
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M[A"'F6N7U)Z2BX8/D-%^XR^1OBM];7$X+_AS=IO2U<$_MHD!2&/G+%U=!;5
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M?(EJ\DN(Z541W/GH=-K!O51.,NGMI\IQ+PRGF$7X^Q5;PI.4XMP#\'(.K[=
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MF"*2/2U,VWNER@\F6A HL!\48_A#)!LQL(D0L'B!MJD U1J=&^<AMB[HJ1-
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M9SJ1SJ]5,1^^!K^E^3/_7U!+ P04    " "I@YY8QSLBTW$J   D=@  $0
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M<GI6U/7K!2$?-*AP2[KN!NQ]M-(/$TX/O4L6=3>DTG\GDZ,DTX\,L>41T]L
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M@>.Y!59!BZT")A90Q])XY397F1,175FV$=S)!=%<A?[ED1LO_@]02P,$%
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M+KD.^%-/<G:*]GV&PB0_2YTV*.99^C0_@-;D1X5%H[9DU.EK !KUJ5X:0 U
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M,*>ED#F0!P3A!YL!+7\2_>+L'T3?W\4R@_Z2Y[0L%B@R'A ?/S^?&1\GGY
M'R>O$+\%IQ"?.8@3Q&-N)FP&YN,U-P/^I/B-FW]0*:*&! SN_M_KVV?7*D<S
M..+L13!QQI]3(>,_ *>8L\E9Q Q\>I630)BY0"S$N/^B^W>0S3\;\[]6 ?^
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M\<@Y.RTTL6UR4:CYH?.=C#9A4Z*1>;^8CRUO!B',:^[12!C$\L.LRT$KQI*
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MV"24^8OC+Z:W]V,,9@1$ZBW=,085*Y/"!IV#+JL4E"J'3P_="G44$%H-C&J
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M%/WN&G+BV]W@L)^'O*@U#1A4[R+LE$R;1)I%DW\+[>30%,G]U/') )C1VU5
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MX2M@]2!$#8M4LF3014EOO-><#BFQV8J>41O3LEX@-$7H:I,PJJ$I['[UL)L
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ML<)F<K6E<0HOIR?R(1R;BQ]0%ZXQM^!<SS(B-^;X4HCON:,'QFUD]'D2Z?J
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M',9<T;!2-(%?WZRL"8<H'YGM^)DC#>M1HDF- 5M,(7!I_H@1KX5^'*P<!M9
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MX'M?A?NYF/_VHVR&V$.I+%.3IMAKRF'!S7R7+'[_M-RDB/?H"V^Z@CC(P^"
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MRDS93OT #0M)ILZYVEFPRAX!RVT'_Y;75]0>(Q<LO; 0)E)HN=;)_KB. ]G
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M]A/]'1EMI(J=A]C6N7M[2XT2O*$PZMTYN9.+R)6919*-F,+4'T,&&\I$N^I
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MX+O@MDDFU)OHO;A!\=A&%?D$B*#_N;9D_@G<11 :^I_I7,=7W_;L!]X+QP\
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MLBH,29[SW69T]5[_+3G_\_K<GXN5':A>O4Y4+4F1'1ZM3@IYRPR[K+"F@7P
MF*<>O+R3@%)EGG<$>TM",^O"\M&<<Y80U0D/W/I.%:$Q"O+9_;9VL<_,\F^Q
MLW/1PPV+V'.1HZO'?!F:82]%)52]B'@EH?MM&,J;S@$S_!<=\Y MG_J?4QHW
M$"T[C%\Q085=M6;C*U<&UO:S\AE+?)"T^#ONE 1CS@F1?XX@@825Y#IKRV%C
MNRV_.*OPV-Z":R6ZO*,D?W4WPK:X[\KK[$U.)_)<(Z&GF9/(\Z_J!"(H +Q(
MJ8R5JV597H!Z/]AV'A[<.RE.;2&LIT&?+*&069_0-QF,Q$@+/6>O0 !.C>^
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MT&QL@^K_)=O_ [%!+_ZA72<^"27=9Q^ L*]&FQ^ ?44Q[TPQ@W>U=^'5QP^
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M5":!\YFD(&-FN_8NG7!%)J+2N7$C!:LM1[?C2-[MW65GRR!ZZL_&2.BVSP=
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M45>3]$0UV3+K8,LL-*\_'FLLS16_O6;!^QG7R\+Y&SS4:=&\_=C+SW<+BO$
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M=Z-!S.-M R"\_ZB;UEOZW^?XEOZT+?D74$L#!!0    ( *F#GEAFZZYSFU8
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MQ"Q.?/I^TA/!0$<]J79F)0:@,0JBD\CK88 ]MC&#$G*Q2)FJ.T'/7K\GTU?
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M(-#Z/AOI%*C$]%X(:EP!X3Z7I9ZS&*MT[JB*S(RK4FFZDSLC'X?PJ"'U@%%
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M1VE()'H.%"&FI_S*CKX@9+Z-.FC*S;/9I@RH2"\_**0T4E(EK%Z%R'IV<Z^
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MY\_($9-BQ1])W/)MH/\0E>HG ?]Z*\OBG>UU,[X.V?3ZE<7##VBF@\2W.:,
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M*1R F1NW#RY;WI_(37#;*VGF%*,2SG  :=H#Z97I*/U334"6,O<PHE.L"[#
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M=I<MX(+VM<!>"\M6"?"J@B+LBI680RD%1Q"%-C';J""VNY9<-_^ ="A'D 9
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MW;/T*O\VNXV&[[7QQ1-AB7O01J933HLR2%W.5?<M8PLR-XV_H*30RLCT?3-
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M<)_$P# 8V-8&;&?^0P7KI^3"A5_XUW_R52W-+7X58/X4P'W[@WW1<Y#6O_L
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M(B#A(IQ/P@-%/V]"$(9[B8)P23_2B 1 0$1&045#Q[B&B?!W(0( $>FG$ >
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MV4R 7/_#9OO;S>&JV>!-! 3;73R-\]]H.CB.,7S=#+_G"YE!P+:4QO;V-I9
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M0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y
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MTUO^5&C! \K 7HZO_6*X0&5W9.D&%-9KF=]#/+7P)L'6Z=6P8"D2:&!*;]=
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M>%,B?-GUMSZ^7#BNMA(NCBM%RN/W?1E.>(<F;)/3=[-QW>[Y7J:RDRKFL[F
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M.?ND39U(KS74@JE]'+*6I>4@Z[ 9\-*A'87)=/, ,W%8SV*'V$.T![&<RY,
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M^W?4])?S="/JI8:%PBKV#S0P,0!=.,+(CX-_S@IC]5'QRVBT=MR\+-P\9*_
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M0_78S/TK'3'&VZP&S3*WK1--X^>PJ*,KI2_$M,N7SO/8"[[%#!4H*A/IG!K
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MA1+-(39$8=\Y 7>NNM3/+>W9^)(^H=$F1=/.#,\%KG[X#V5D'"-[LB?Q,H/
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MBKUB#HA6I?IZN;?9B+>7FY]%*].(GLZB*,T:/8(9H$5T4$%9M(BC:#F=I]&
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MI&&YU[']##A"Y@$E%:V"RH@M>S[%$QF&Y]BB-@VP/ _WRT-7Z-&QZI>,$6;
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MH9$0 0EINPVKU"DW^EY/0$8>P6J0Z$&NF1 &-%V+_:D;%RBO1TU,QO''<1*
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M<CW8-2-80QQ)8^!J@_4P&)3G 4VOD95@1$WU5"L;E6 YAC/SORA"#S::]'Q
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M:C)QH+KG=#">S0#I MJ <B.<"'N!;<Y:V-++N.<SO<1V&DRN-B$%B$Q19'6
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M<CJUE9#K#&W(=D;_0X[V9X!:6[0OO]\\IT!Y]K;_DI>45P6?6:OWFQ5>[^O
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MK/>K^![)058S>BU6-=[.96R.A0&_=;H9>DBU9GW4I8?9/]^2RK=+'2NY3-&
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M#7UD*<GY\AH0"EIG%;9="X7>"]=+2^W?*#ERU\E[;U4YD:=.N@L_][==K12
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M)GOX&#WJ\\\5Z+T;D$FUSX"-A@C$3*:/2$!)(1;W9K]:,4N?.JTY&4QGX1G
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M8[*A!]Q9%4 \X$/!'MZY\>ZRR1J$D_XLHUT:2%B">?4CZV&8,?'1UM!:D:;
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MLMQW@>@R5T2<,*5P[(Q^<C@@8F00 N!O(6SN'T$DQ@JQ+US>'8+69Z6*\1\
MW)+,BF$V=5Z=B,JP'/.GWH$<Y2R%QT<BG)V*(G: &#*E.E+IIHD/@0YO7*'V
MLB?*8-SS@N\-B"%S]>1S+>7:7DT*Y/)N+^[@%++&9WB(3!^)]#LHZJV'%,K_
M^6ZU9NRURWL-W"1TK=E@ $:MP2#%BM'W_BQ:L[P<+)W\K8R?88)>3@BK++BX
M9#(Q9DAR;S"6*I18[@LY8OY2M]?($,;T;U/*E:(A'O9"#U3"'R921(VV2>J.
MZY0?@+$L>8PB\D#3%#Z$W/\1$GSLFL1!*(VJ@1&.37R 0:^@$9'$'DL)^/=\
MB4NH7H8.^S.+!)F%HT=+AWRM6D+<?$F[S*,TD(&C"1U+5IB>_>C<[BHP@X2H
M=4 MD&$/CE* '75I'W;,+-+OM2?/\>2LM!RCN\!(L/-NL7IELCSL$$6X3"N;
MNT'AP!,:^'K5W))<E4#Q63U%260/369(:Q!).PU#"@*K)NQ'0#(S,U';,VMU
M]\XR#O6S_U O0-&]EH=33E#$6R,]SO+;/5ZU43\G/U%4Q'7IZA-.@&2 %K1O
MI#?;I;R:3@G#FW! \1W(GBQCLOEA>;G2$UCT2H&DMI&9@8XM!%U::1EL_Q)!
MYD6M%N0>6W$<$38+C+8'@UH/5CVG+/9+%EF5:HD(  I';4%BJ-#:,QA8D=Y0
M4#!>&/]:_U!ZXE998?Q%V4LGR<K0>WZ2XSRQG6C"UQX/&P_%2 JN(?Y+O%QQ
MM^VVWD&F]L-VP:'OO'5%U,YPHOTT4(H=^^[/E3Z.9XTV)RY[9V@G3Y-67WR8
M/]=5SM!SQ(OT-4B)-^H9O%(>P#O\D4.4FE'.5A/'T: 7 R!+  )@0DH;'U[?
M8W_DEWKJ<3DN?KD46,CUU4E-7SW3D??Q)TI);,W\)J_BX&:V\]=BO62KV/J.
M:^TE-PKLEK_E_P&H[).B.U_X>ZK<-G'O6]91MS/-[V[,6\7=[F!I;2)6],@2
MJ\JQO:L(5Z\U63Z='?O=.53:2D6#E=JT!H%^0 RE5W?5UR:@W6G_;G&DR:M<
M;WGDK\L5.DAN2(Y7?I;N]X+R+ROF!2 )M[H^%0DWHFDD(I(2Q=M/ZOO_^)8&
M'[.DA$*68H94[4@(;\1)^^M.;RD.7[%XQH*:"JY_ EH^!H5ISJS5'F[5ZE/
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MT3HB&5.Q_4M&N3%^!"ST=+87AGUW]#VA(  H_5(]7_V&N?9G#2_CA+$*&=-
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MA5SXTY^L[O0=@B75Q?.U&W_ILJU<PC;(D%@S!54JE(MN#=F[P LOI2TYX.E
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MR6M1/ADYWZX,+/YJ.*.*:<#,>&1WT]ZHPN/O:4!KO;)N*;'H5J0+R<PS]IB
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MVA>Z/;IRPMH%'56R:Z< A]&:Q\N 5B64$,[J5OS?).BWDRGU9U@<[_00-TL
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M2=0F$[<E$B9XS@WN6L'[3I;6_=:]G,0$Q)ZGS^_*VX*TYO5-Z,^2VOW"IGW
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MK5"/NO0?)\180,WQXSQ<R:NSE34)PS;-?%[L#'I6KA_:E@78*49"/D;J2\8
MWTPOORP;./3M9^]\_4;](8A7S]82^[I.7_7M.<E&M^&A$-^H;. 6AQ%]6JMB
M64J!@L?>#HYOJ9-97KEGJ1M1!;.,(/7M_<6+U[)4;=>Y3_F+>(5CC'Q9$X_?
MG:Q5!"K]HN]!6RQ25%NX8^J1G,;J7$N'IQ1D\92\]$V1J?5&(76PM-W]G0U\
M6VUAPL$O7TIHA$]XQ"&?2M,F!?[CP(/A.'HQU.^MC\_O,8$O)&[$/9K6='FT
M5#KV.(HGT5#\-*T=%\2W=>L.K89U![/'T:G#\^AK_99=0/T>Q]B,:>R/Y 1S
M1MQ5.=5D2)_&\B(0\3_)CZ)@(17H )Q10,M]WC43IRPYV&M)"W3P#V)^,5OQ
MTIZ&#)HN5I_]5$SXO[A]**SFI'Y^$H([AQ?"=]V.<EB_S!,;DNEAIKF&V)\'
M\/=VKM?UO>J?>WH_4@9Q&7D&9J.M]=?.KIS@M0L/*[O-_<(LXGE1&OLDEF4/
M6XL?"WVLTCIC7UE@=^-J)+0B6*U!8G=UE>L;5$7QX;+&X%OH+=AZO-;WD-..
M]F+EVG1,OK5&FZY62X5:@?PP/]\KE8A4RIVN\K*=.W9R%JOW':QG4T7$IW:!
M B^X=TDUH!7#!WKI:,>E]#B>"(Z!B5/;#WZX"R'_-WI15+?0Z$_&#+^UHI$+
M&\A[+-?/6/JEIPK5U^ ;J YG(F.X5>AA0_CSDJ(CTYMA:\831=\E>](^U^YU
M^="4Z! ON]BPT!L8W.A[!@4UX7D^;DK+-_\DG110=5\[L!*X)'1R]O8DT.6!
M(P.G3GM--JM=A=G[Q:T/>EK9,&Q_%XUHG'!E^-S5H0V77#LH" I:S17=:M6F
MZNBXW*K%< :TZ?AW&O5B+=%\L*F5ATL8->X:!1</>=ZW4+M9+N#[Y$QY*M?=
MVBX;_IZ,Z"_NJ7[CM79S2M@M$BOTLHZCYF*17[',R==4:%X;%E#WP^9R6XJ\
M56?5H,7+8;VYOZY0*SIYUO_U,L,#$6/F5G\<^C[ LO$E+0[OB*U 5].V+L/E
MC"[]8-^^;,-NBCOP[:+Y:\D%O[&<T'0LHY51:+D^4W0'#?"\[W)K ABS9J]\
M@?*O&C*YJ]^*KZ-._/(F2V=M#.EF51+)SR3/6JFV28$296&/0+-@[VL&KC#1
MJ >LY>W"$^D BK*\=K>/T9JUKGQ?"JVQ\EH1<&3W0V5+)BAVS?\"0JLF([5P
M!(.S/PKU!"('*Y"[N'VL9.;]&I98S,B:@G.:^3K7TJS:1 U6^49%+Z3D!D!!
MP?KZ%P#[=G\G3%;/9%$SRY(G,P(F89?."J+Y0A[S[F/47T!55%3BRY^WS?M^
M!0@[2BT@.0XE,4:E9NUGY+@%W\@DHY*$W*JOY#149HGC&R-O-:_,$CL1!T(?
M 2P?ZMD]T;:-?!L6:BB!;)4==Q-T\MQS'B*EPJG^@WGW+ ,.0NX<Y6'Z"A<.
MF]>P1E5FHN%.\C?SN([],K,<,=8@[6S=$3Z]7<T65YN+BXQVV-;,F.WF5DWO
ME,/RN/QG=J'[A3Y>W_82,*6[! 3W=SO<CV3QSV,!%,(*D\MR=T10X4[E]]'A
M>\8HGAA[-KH8,/PB'^,$KF7Y>J96P#1-I]SLJ@.\3#^WVWIY\FU6=%^J*>T[
M1_["O[H&O$%6FKN.DT+-?9UN@<C]TK:#&L.:I]3V]/P]9*;T*J-FO]2[J.F/
M"<88$7>G1YB>\2V=C=90H$NOLO,ZV=VT&_NZLB.&_)M:.0VCWW5-WQS,2"HR
M3Z:]:7,2^N; I+HKR0(W?G7)I&*!]ZY*FI&AQKOJCM/^^,(6123+>8O@[>$"
MR/2[]V"W;HAV?4-[^NL0V[E#J.99O5J9TKRO2=4 ;MESU7PRW*_7N/-MCS&Y
M9G=HQHD^OY-J6=&KG,VY<*1*18-=4G;0E\2&%?O$5!N@W6<V_[C!-Z!VOM8>
MJ*K36%^A)KW@V7S7LGFW>Z2^)Y-P^![GJ8 )*[[,AQF:;MR?C(+=E^#W(Y94
MS(YE[(W1$^JXFUFE!?-G0-+MHYRYLQG<X(_B$$DUQ&9%XTOPVKJ!7D#[NO'D
M5J$:.OPF?U]8Q*Z'_5JP;?K[Z?U)V-(WW69'@1B+-KVT,(L9:RD"DP5BPWW*
MUQIR/))0%/J2EJH<-O-PQWZZJ7WE3ZG=^MLR7>R=K)P+?JG+_W+DFZZ^LE/B
M87FY>B9:.#^&5$_N_%\ P%6N/8@F&NLEK-\Y1/Y*7'HC#!N+'A.Y/] P9OH,
MD6Y[-V>=-K&*LV 5A_G/4S9MG&T92YE (1V7Q$_FX$\_*/=>O+&L1E^<?9^5
MIOFR!GFN+,^K^9K@-T?[&M85,6Q%B8DT%OA<"::4- PXE!(%".;]0+YIVXR5
M223)5L^QCZLEDG\!EC%RB>;545G(.T4L9,/8 *P3',K+HV#=(X S6LIPKIW@
MIJ\7)#5 L=7.#12P +N%Z_-%EZL_(-5K-, O%E;E<LUAL.>Q\!P3[AS8-U12
M&1=#OM^O/Z3#E1#>\47^7A[]K=FR!)]C=9LS:&X)@)_<\DY+YSAZKA%B+;43
MO2N7#T@-D/+@F##Q).TF.? 3#9LNZ@Z%7L!*0.88YB[672M07U@*5-URN-]
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M%^<4K.BJ<]J&N\$Z'%I8H#$183,H-8$4U9B>*=*6L);"%QN^13QAA4* HTV
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M930(9JGM8"-&WD$JK>AHN./=3OW#%FUG^IG50Q5FP[3LA.%8"CFB<W3X4;E
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MZ @-\FP3XR)R(\_&@^,2VN_3V'/<I*"J<3"@7\>CCA7'+(^/7<]=KRN-OJ6
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M<J]#X'<GPW/[?_@=<)NS;&#9>5?O3S6<#Q SL6A^P-O:1P7GO>]3]V]4YW?
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M\:5^$RXD$;EL_F)[W3LOA[J:T^'BN,\_]+:>0 Y%$5](92#'ZH0A9P9>ZJ^
MX.4N0I-LUOF2%8XT[R]<^D5VS,JQPQL=^1Y5,&1,W)B_QKU0RL)GX67#NGMF
M5(%RT?Q^D*Z-]HKSRI*7)7%VUC1E)V!T45FC7A&Y)VO2")(L[]N!@VE]1BDM
M<>J=R]/(S<ZFA/=H!0'EL_4TEGG5(?^:MF6L#4V*]IMW/E7'Q7H.4X#%S&8D
MP/8?KRJV_\&T0\^WPJ" *K2C#L;>?//_Z?(3VC\!4$L#!!0    ( *F#GECC
M6BHE7%P! *&* 0 1    9S4P.3,X.&<R-&TP,BYJ<&?LO >T[%9U-_Z>#;9Q
M8A*' "&F/#]3(]N21F6D9_- HU&9T13-J,Y@BJ219E1&71II,#VD40TV$!Q3
M8PC$)IABFQ(@! @M 5.,,1U"QR% XH1@PJ=[YQE<*5_R7^O[K\6\>^^[5]KG
MM_?99Y]=SI'.3Z[[R1</_':?[;$'#AX\[F!]L#YPX"=?TLY8Y7E\! 3#[&QC
M$9GVV5:T!BLC!N&S(?# N8^H8L/R[?R0:2_=\.&'O_NV=QX^Y"X>?EC#AM P
MINV5RV]36]J.9&OK6^3B\"..GGQN=:1:QVL[-PY5ZR#,CE0//[P/?J3Y?>\R
M>/C0/DGN/_PPM7?CD#X4#]%1:A_"SD;.LB 8/H3C9\,HAN/PF8=:$-P"H>8+
M/PM&CV#XD5;[T+'/X:,G-S_/31?.D6F7/<:N^>OAAX_U:[/9G+U!SH[2)0B3
M)+D'TVJ=U5"<E=5A;E1GA=D9.Y";<;IV9J5NG+M1>&CO;\.,BOSAAP^??.@6
MGQVCA?53/G&1!OM<%A9H!_;:#O.LT2$,_A1\#W]A'7&B=&WD1XTX#ES+V.,"
MQE&6[WB>"_Z,XM;-K-0V\B@]>BLI]N65[.365V^^$;A'TQ1NMPD<.Q<\=N'6
MS<';M]^7X/;,]D3(W3RP[T  *LCO3( ]/1T)C'#Y\,/560O;,8H@/WQTZ%II
ME$5.?DB,-G8J1FZ8'SKKT#AU&QLS@D/NVEC:67-%.@L]U"DR-[2S[%!F6WO:
M.CN.\^KG]>?6XNSWYU:2[ZAN,<K_MZ/?&/!/A_\.I\^=-.)ZZ^7/;[@$W?7R
MUI;3M#M"[PV+W6V^C[:@%GH6!)\%D3($'T'(9E8 $'8$@<X%;T-Y1QA1*D=1
M<'0W]7I!4&1YNG?U$"WAAQZJN>$BVF0/NP74L0:WP1I&"]>I?QEY;D%Y6XS&
M'2R,W/BE4&Y)>QL<>56LS=!P@^Q7M-"]_V(CS6RYCNV''Y[:652DEGWX=@V.
M<=H;O2,;=Y&OCK8P?%^P6USZ>8U6MKM<Y4=AB/A9JV/7?EZS8^Z@+S+<S]K=
MSD?<OMW^+#H*DAZ(4M1$\N?]Z9+J4$N&DJA.CZ*Z8'M"90JW*A<<N34X<M/K
M#HLA1:$3/QA1 $3M?SI40[_W8:@'GU%1YU"3O<;-9T)U0 "ENC[KFZU^0''R
MKH$#FE2ON;F<,!U*83I+A>TL?:XSF?7IS9+K+)>#+A4)]"82]@&['6K8I39[
MWY,NA8H,18R[G:',=B8R4VU,KLHLOB*<GWYO&+ZSL49="IHU'&;<2IFRTVC_
MWC[@K8A_Q6^0:#HZ65)FTUUJPTQW7:9Z4VHRG#9=8RACO_<\M=>["4/][#-A
MJ4V/:]3"TY3?=*^YM^QU;TMW3(<4W?2VT8O5HR?1H+E--PRZU')"-]<:C31
MX; 9K.&TT3_;F_:JB<IP3(MQK1FC#&-NU:FT:N**G7U )>=7PVKN$O2T7I9,
M,-E.93\1ZADBTB-E$OKX>#M:+90Y+W>AHM?K1\,^O5K.5_U&=8D$J?E(%3II
MC8(BLP\(CV5HKFML8&APM= #4INW5K&QSC-3P\H9,H47X0*U];CM\##@(&-F
M-3-XM[<67+0>>1% ^YBD!K$]6\_W 1,S[+?L$!.\6-#6,>[&25)DJ8&7T;31
M;]/]7K<S:<QE,F/HQB#,/9VMF&Z'9J2APK#*=+3J+>?5<L[4^X"1R6_8(3]%
MI1'-JGW7*IEMOSOM+E>&I-2:.VL/Z XB2B.[SRRKA>)OEOM=[GMSEG,7_H)5
M$"(9;S?U,MX'A !QN^I+?CZ4%4R<!HN9IL:FSL*V#D^#^7H1&5J<FAQ<F*U?
MU/U]0* ;]#4MP-SY.BZL<(X[?C+V8\,($V&=)'B=IPE0@D9C:-T]BV#V3*Q+
M4*2")H2[SL -A:JNOUP:J+$/*! &50ZAQ$Y-%_;)*2CW30>O.7)44H/59(6:
M.H$KJXPI.@MI:LQ6_GIH9;-UV1T(P:86U<U8&1HY%<B$N@_HQ)4Z5%UP9$C
MNNSYQ8P4RWGDD)VU/Y$VTU$RA%!_DF"1FB]])9N)TQ78=P,+]C RE$ W0_-I
MUL;Q9=[>!Z0YPR:LS: 61K8>S<.BP_9E/^M) ]108T*EDM23P"WE:Q*IX[")
M1RA49],"T_.IB&]!2I@(TPR3(:]2=H.".O,6Q4I#5?(U!\LLI1@-08FQ%J4A
MC09SW!M[DHPX414/E]889+59!G4ZZ*IJ3=#(+K19P,94/P&R'KP/R 2+;8VZ
MN1-O^JJEVBRX)F,=:\LXF1!(4"\J3!X593N>F_/&'"D&1<>.@I@!V&4'([!6
M<E$<I1B;]\K1/F ;+DI %(0)CV]Y4^$[YLIU<H#"ETH':=&KL! RFR F>#R*
M@R1?YBV416BS&M"3S7:-\ -XW%VA6]3)9\D^X :11P-P9 9<WA8M'F];&AG;
MP[D/6AH""Y4?% K*3C@F&\&,S;>ML&?.U(F#\^ PAJ"HDHP51S",OT[&^X!S
MS#?AU6BNH(/^0A]:6V ]"%VASRW %;]!$\3$Y\!\VX(1NC^2!^5PR<#5.%O8
M"M3WT905MA$KKVG%1\.=A$N]B.1^WB>(C;&UIELQL8KUP&(,V^1P*@)A708&
MTF@A"MB*5 ?I'-! (4J42L*W4$E00YI<*W@]2(0QMO,VG$"Z0()DF1YI:JTQ
M>2CTM!6RTL9#,#<SA"VB2AT,6A X8O"YLZFZ"KCIC#BD<"!G[.,TPC1FLTER
M%=\'M!LNFKM2W?$$X%;T*E/G;6P@;Z=\-['T=8]HNP)!CJ&"FBAACK:-#KN>
M3N0-V4SLM9PA@WRI#L4A9*>2O0^HD9H'S8*%;F\+%H*7JN)B0YEF8 >=$HMQ
MT1+*,)47++BA+1\B2%MOA@HU\4V9K@7#D#BM);52EIPS:+X/N"6#$EFP8VPT
M'J,).\#U:K)!B,T,'&Y'IA,M3!AN-.)6=..[4-QUID!4BDJJL89$X+ .S.7<
M352-#YSM/F#:[UKZ.$)(B%V742EE45I@FCJ;)K*="I!;)ZS2DA7&,!6VL355
MVNIIEVBA[5!I.]-UT9WKHV!@:+ZWW<449!6,0$=*K1[D$44SK5RW,R:;H54@
M=1KRVRV;^'Y;TV)):LEX.C*5@C;MMJ$110DY%.&D]MI7K(XWRV8[?ZCAW2CM
MLBJ<1GQ8DFS9388PUD]@;V8$77;1(LEA+UVC?%0;SJ!2(W9>##-W5'NLIL M
M%$UB70M!JA\@^X#C6.[/920(1SBY@;<+61+(2!H (U($THKP (R-TG1,1?V4
M4#6D4M>EGY*B@YJYET+F!,_:V]*:E+V^%.X<+.K/F:XW7V9SI=O:".%:*"JU
M]7_U8Q_PSDD&"QE6-L/9S&DC9.Z.@VDN(S43*Q@WZ-J89)(]I"OE/#EW8)::
M^]WU+NIUF247V""#T34F=OA"V^+Q@%K:!FZ,:'RZ6EM+%N/H7JDGVR$E.EQ=
M-E1T3%JE2(*U0W (:9F"38O6+EER],$6=(@0[.2@OJ/NEFF @24@@\L6F'IS
M?>DA'02N"1 !*?IF"(*QT3%0Z"'0&/T^Z<X.;TF_Z>RQI'X&3<-M )MRBW0%
MJQ.I&N03:F$#(J-R0S[:@"HX;B5;26R,<>BKQ3[@:"5PLS%2:L4&Y(>VII"\
M@8XZ%(U13*R"+J^#0!HN0,+#1,#(5E7=1@100$LL<WS>05T8;.)*L4# 6MP'
M]$$LJ5!L@8.!I1,ML>Z6C7MNB$;ZN UB_)[$(TWD!Z5.I"ZXKH#)HF&S[8"P
MU6X<RSX%/".L@MPEG'4Q $P>ZR! SQGRH+HM0&#::)3JJEXC#7P+859PDV'B
M>\)LJ$9>@EJGO!<@*:!6SG8&]G8>N[G9"-1D GL";>@]K-L+--!!2DPPI)&V
M%N^P3\"L8;#+OAHRL-<,Z&W9@54W;1CM=0STG7[#^%C';NZ30,X(P$!F'A21
M4A$6TBYI7\DC0554T !Z<UT<3V&3$.>ML8UY7&EQ(PFPQ?'07UDXYB1R2\+6
M2A>C1D%G*[=K#&V+&\J9\J"TFH/>;E"V*Q!V%A,0ES 0, C>D]M; @)]BP?B
M#0A%BX;P-C0.%R(AE@+3C8.'W08L+L?(&C/8?<#<AIL"8J(6V*IPR'#%:8ZM
M\%/<LM!)8Y<"UW2;<YIV"8"O0"C8-G^/[&X5DQA@./6X"RJH@ROC1B6[#!:P
M&J_23AJI=7%/3R@P$DMQJQ/>$H3'/! T*I_?BFBK>R@$$.!H'XYB?T:T#_@S
M2H(B;@]'8^(8"5E>K=(<D.*$@K?##>"S;I<<B_OJ@<=+" .7*S">[ .2&CAH
M!A];J 6:LW#;';24)&B*^9*=T^Q(#8#!?"N;KL"WVA@0PCIC<_H(*W,]4V9H
MV'<!WZH0NUW/Y9V$F5;T-5$I*I ?U'BKUZ(;FXJ5?&X*;7:+CVHBA,=(OF;2
MV!J-ZV(&,/) DCW:'JZ27E7/EJE.L_YR-#+,G3]L)UM9-V62TS/6;/'3M3\D
MM955-1$*#Z'Y9+7@4$&($-8U"$OI.NLZI+8+-YD"9FKJ T_N0="LIE&FWOG#
MR61;M=)@/* 4WU\5;,0+V;1"J#8XGZT\ 7 5?.O@<;(74.)BC:]$OMOC"VPV
M[PTF"20O"]])ZT1S0F97^& #;12M+0'#U&KF^TD.D!7F T6E+6# ;3ORQK3Q
M E,"K;$K>8I-F6F?RN;>2O EV)\"-K)9$G ?F>OL8.=@!YR?R:XD3#K^0J)3
M8:HPS&)B=4=-IN5[<11 -;?JJ8:WF6]B'N%[\['L&XKN=RFK"A=-K'#+M:R.
MIIJTL\.\'_5\"!?Z<]V04DYJZ2Y<6>S$D*:3$.W/!*L)Z4-AR=54=V5X?:&F
M11GP$F?83?DD,CKI,$_[5MKS=Z.LKFC%-NJ5";-9%+-];RUI[J!OU@2-;+ID
M4R6MNL(HLSBE*@$3<;;.&(C$EF,%Z3J7#-]G?#ZN<:4:UJU=TNZ)W2:==I6@
MB/><J0=[ \CH^WRB)%ROIZR'!MGF1^LAGN).,,-]$'(&B2<* 3YSDO5:(Y;K
M7%L9Z&H:[&9*XB*+EB 'L!CWN:W3X;NRS\9EMJ'6XW0>Q[ RK1-PA9"(WR/P
M>=]"AHLB"9*,6*&3:B#[;6A@J<E$@'9E19A"R+BE4N.Y,*%;M5_.>_8"HX)2
MD'.^&0%C().QZSN5W6.G;526>MR40V-FQLF9NG#3SD+UYXT_U&9P;Q=3YDZD
M$%. VG;#[: 8]A**K-EZ,&NS*HT7VDJQ0YH@4F?N>D+'[<!BE2TC 1A+'@?V
MDQJS>;_;(S<IV:?W ?7<DD"M3!=;HVYETG3$:6MR+ VM=2<%\$5=RJ@[E99(
M+PXB*EF:",B/-G-9Y%$_6O=0 XD\JW%SS+H4=^4MMN):WJ2:QL:@2>@T5&/#
M9@272],"^@I<%Y,^TD8&F]IC:!;9M!TN!=H+=MZIN2'BYY6U%N919<F![N7H
M/B :D@RM.W /[L_7WMJE'1-G5':X[2WIJN;1)OI8!!B$@]ZTY[F!2E'$&%2Z
M-KKU=-AR1XD\AF'-ISFTY^^2]JEJM^P>3P)>9\*IW2).FO1T84#U6A,=$ZA:
MW$!3&<O&>D6?)V8MK!LMR K""#_S0P,M85*-YF;0;W*]G83<2M)$%,G1VH#H
MMIWW9300>4^?Z?1HVL(<SR$GN(5T G](K$%Z;DW2VA]M*;L-C!N[9;J;I5[[
M8Q</%ON \3!'.%0SX+"K$<1LWM08O=DPZO<!%G?S!:YR,Z+:^$I;[ RJF<0D
MO<RK>S@!NN*('&\=! J!S(&QW#U6@/.^SV4(',[P?%Y:K;8L(<+(; VB6>2F
M&;Z6!O!\WIO6ZYA3O4Z"4.MP@RH,I!1PRS#P8C1H*O!1$>43H-S5*7!%M>L-
M4U63.C'7$Z(?<[2]W%:9H8CB"FX*15<>-,ZG)606L6GI89.;Z. D;W<-+=72
M6+-HU=%$(>3Z.^?@^MUV*LEX55&)*/>! <TQ2]L5<[.%E'DWGX,#".KE[?7(
M21AT-?3I'IN,%:FD-A1-V&+?X$VJ[F1F?U=6I./8H,Q2&8#*@)/P+#*UUK)<
MDQJUF=9 TAZ8VXBHIZXVBA73AR=A;U0WOV3TI XEK*TY\F!L0^Q T^AC!;BE
M=IVB-6%%MS/CS8)VPN5\10/S)J![*T0$-B V'OC#$"K46&QO'"_:#(9SI)G)
M$SLQ=,,(3)=#=31"M)T.D36EE-WA&I>J8+GI"O8:V;8VKCH<KH<RRP/;[:P]
MPNQQZ"EI,44UH-A(U&8RY8211G9 ;3[1_1C'FHD/[,J*Y3I&ZDV3/G6#)3KN
MM<TEL<+,)C]L 5(QZHW(!(AD:A.D J'CA4\X2>0OL[95250G0-S!6&6=EKOP
MRN5NZB74'& KN=]J!3"85&F#-1HO>,C>0NLMFQHKE]Y*LBSQP6 @8 GD>PK?
M]U!P"C45AM94&$R/7L;&JC_J["KZ16[Y?BO1R#IV.X@Q6X_0#=L.5WQ?!A!Z
M+'/SGM^%(E TR007:"3O=GA;RL6%;J767,<8.U/F=3;IF]#.8Z,]A*'(#MS'
MRU'/[4'=0B;! .G-T[Y)JYJC#0)'66P[9E%+&=Z9.)*J2U-$L+09Z[@(TM\@
MSG2UL?I M"LKO!@804Y,P-@PV^K,W%,D1B-5>@CIC#)+M_X82V$TK)0YDQ=#
M'W%0D$?IP6;8ZN !6$%F"GJC/ECUL-5N_1 +$&Z 3]N^Z&M52XCU!&+" ;P:
M-H$DK@@JZNDHV>HG0K_H]L36,A^6%1_K#6P?+O)J#0S<B%O5!. <R[%5,%R0
ME%8":7_0)]45M<K-(27,P)R>I:I!>1Y!9QS229KRID>H9KAV"E.D&6\S;:VZ
M!1@Z6:=L[ D1\IW'GG&T4@]K& UZ*.J3XY$Z=]O\2BW=&6B,+"9N">9PW$1\
MS< 4JG&9))&.,3S@YAHF=0JRGYMNX]S<:<S)N[@<![[N^_YBLNEVJP[5$\W!
MK"&55_.<YZQ"6"T4LQE+!Z=].#<=E50R5#-AWBUY-3:4P0CPX$$N.VUY5_@P
M5ADT-3.@ \!BX5869S#V0AZ##H"S(1HN.&,1;6Q(AD--0D*MCWB"&3!31W8'
M:HP;/@/%I8[!*[]N[]8/K0H8F.0@2BO/'57!9IVTEX('JGP+'&_C"4NIT^DT
MH\9+;E8M,HH2NKA5]K;\0HKL+1<XU#H"&]^F;X%.M@_8\<HFS5A98C>&8\.U
MZ:D\L&6KUV_B55;&JUZ,]0*LL.5^;X(G"C*!*[J62GD6BP,++J5M.4\E8NWE
M9K*SPS)<%8T*A$I#AL$F2[=2Y6KRDK6&*@9C'35VE^9PLQDBL\2'06PQ(E-E
M08H+*9_'G&\:=G\>+$T/+\5CF4-@325:AI5T.P%GC3KFN3MK9]9B-"[*D8'K
MK"$;#IU78Q\NY_IH.Y=J?Y,.1Q/?S?45'[&0W84YS H%=Q<"3+IJ%3X"%76Y
M$&##E$T#-AQI4*-A$<_[M(CP:3+7>E9;$@AL[L@ 5"JA5W'"1!CT[75G'2!K
MFL5RKMC%Y8G:^,>XW=O,P.5P-31'P-KO^)W!%FR\J+>7#R4J,'-(M"\"0Z6I
MH^F9TY]@^3@"0@RT=&.OOEET=1&8P<<*GTAH54&3QI=)"&H@DBE0/;"R]7*U
M]LCQO-,+)O: +G!_& .S7M+U#)JR#;D&M,YPIJYA@6@2%U_3!&Y7^&Q&U7P<
M]&5FOC%,JU0PI8V)'K%>XC9@Q8JX($F]<5S=>LNLDPT>BK:L+V"*4_EF9"F8
M4U(YY#N-LT.+Y4Z'O->*>Q"*KGJ^[R%-#=N$H7:F9!QL]]%<+E3+7$_7?#TC
M5D!GVUV/ZK9)FTNF[VLP;2S-S30EU>X0&: [P-54B^54FPQ+="[R:KL8)0X3
M62Q(IV!3%\\FUI"+MG6#VE^N.BH2#@<@-<A\"U)GR["%T[F5#2,O $)R5U:X
MDPJ+U_$21NJAG,,4,QD[ZV(];8_M%F-FE3V? 4W4W$X+?A9A_;[I24F8B&6R
M)"9B(?NNI42064PX<.SM5HDCDER,VUC+P";M4<KJLTCJ[(70<NH051NDQ(7(
MS2> !XY 9!MO0:\'HC,'6$]D1RX;NK!5@IP@@FYOYV"]/CDEV]EB "ZF8.*U
M_0K"-\5H M.M;#"WU6HAQ5U&).(6[98(QDPSB-L.?*:WGF*4!F0#4)ZU$X\"
MPMYNB:"U%&# -M$J)^ *DUE!APQ0==G)>+SMK$#&ZUE]RY^CN1-Y2F-SC@YV
M!Z#.KP2'6R$%..4BIXV#Z-S!=V&4Z.M51+9+:)KP % "G X4(JT2AFBW2<98
M@64S.+T]\CNEY&^FW.4VX"H 4V\3.)QW&X:W1FABQLV4O(=D.FP2!2DML'Z;
M[:A>#:3^;@NIHY!V/Z'$(!AF'7Q<;<ADPD'E.M !RAF%S53;@$30C(+1%#K#
M JM+3-HXVS(3\=!!.T2K833H@K6Z G<K[6E%<+I5$O%,Q) 63TH,+!*9,PI(
M$_!(S:;+WA"76EA?A8S1BI"'8P_FR[8YF[K^V--]N$5/4C=%>5).=[NW^ZTC
MN,;R]3HHL.EHV)9:*-"?^2N62NEP4]%EX^1G(=LCV56:,2:IBW63.2RP7F,V
MFRZ6@QM:XT'_&""XU9=[0K:<.E@V47'FP&-PGPR;-=WQTRY(#6$4Z X*'5 R
MGFBWNT",[!32='9#!7MTZY+?[ Q[48.W1LKVD  I$YL,3/?V].;<3FT9#_8;
MH?90]@ VU+[&=G;8=+Z1'# ;+@TN)C1C<#MY!KD&"N%6=!(.B.UPO.RI5;\S
M ;8.KV"Z*-4!9&;B;E6$XWA"0PH17XLB((/8*JDH*!M2BS5;F8J(U!0F TJ]
MV(;=O)3 +9@%0)R"@<)CKD-J(1BC>0DD19>(=QZ[73:B:.0 ;&;!'BT""I&X
M94 \;[K,-+Q 5><;XMO2T5O0;SPN <-=H;5>3B<C?)<?5J[1PEA@T"^05$&;
M/*S"26(]$GVJE[8G*"#GLE2O:6L-R0MK6"P8"V@[!2 ((*9V@%D(JC&(VP,3
M3-*=A&*]E@L JT7,A$H";/>=9-$H.5F"0QE,() 4V<8L.JKE[ @=S+A3NF-+
MI@VQB.E]Q&G,.S=TP"']$NYQ.N&"8AMQ$0DW<*G?FR^C8C!)MT9OXJ^SP,FZ
M%8[-AF,I09UJ:XWM$MIY[+#R>A.SQ.4M:O-[ZQZ&-VA&O)\2&T4:LPL!C98J
MM=79K*EG3,COUQVH-5GC3:]FB\R0F$E'],>XCA_;-=,Q&PQ&IJV;KJ@NIFL6
M22*=A%S75SHSQ0@7+22N6X VM[N2V\D(9+*(%UDX'M-4PK<"G%_/\-%$ K,Y
MLYO+L34=AYV^+14Q']?,BD^Z9%#T(QL0TM6BM6+F##1GXIBQ)T#/,]QV&TT*
M;[WR,6"-E[C)\JC/NQL\,1;=76[CIA$6S3E?&T]UHU\P23*14FN"L,FB6\VX
M<&FI"W*V)*V)'95I(*$NU@TK;=E'2:/KBV6E;N5-BH?"=/?@!#Y)!XJ'3J5<
M(T:9JK3'0&:VAG5K4;%6E533<+68L]UN$@M^VRUE5FWK;.$*;2E*QILI-Z"H
MK$*32'3E73HW5-7A7KX16(B:&IN1N)#['2IH9DO:8?C>:JJN>QPV&JIZ75?5
MM!P(J.=ZG3DR6PK)4NWWQ4F7U: %SRJ[/:DA)=$3HYT8C#.9-ORCIG;TU3D[
MD 3=4QAUWI'2)H9;J[)17KFW=Y/* Z[/NH.EE-%UK%ANXG?<#MKU=POCH,C>
M:JLG[??17DN=]]GI&JA3A@K190$[1 SSVUZE.FXZ67#S0%UJ$VA&M9>^B@ >
MJT78+-XM$6#3<>:"6V$R1<DFUQH,>)8CLM0="T,V7+A4DG04WR>IH6K.X:FT
M980(]]?+2C4RHCO@ZEI0UV"A=5@^V945)NKPZ%0W<S=UDLI.<7'DJ"@!RLE8
MY_*Q.LZ%QD[V9"_YMJ$3V4C0>&^46!0YTN9]9EY8C)3WZY%B[ R["^&0;!<;
MOE+ZDVQIUMUY?['E3,5F+%\M^/E,\71XT@N4.I@R\"1MO UG4U2OQ=I2,C.F
M?8Q9%6G<MNU=CIU#?CXHFF"D]2''SXNE'R@0-8\B=<Y0"B0V*AX: :"+^""?
M#5R.H'+ :4RH%]@B'"@#0>9"=JS#UHK;[050XT$W&JH*V@-KU(<E01@-L'D$
MATMO36^R'C;'5@QDTMYP*V6,IT5SO:N8[6F2)%-C@0VR:;)MR?BJWXF'.[.!
M<T=7>UYE$W2+9#L322K8_HR/!,LA?"&2B+RL@=(/!L@XWM3C1$84,%I&X_DD
M!(@I;D>90$R5E>%M=DNFJNQ(J-C; C-4S9K@T<;QP!L5\]ZT3R4:M R[@YZ[
M%#B!:\; 7=1C0"@E@M9G2;4EJOZ(\X@07R[FS K:K3GX3I(R#,:XJC9QRDE-
MITNJR57'0M8ITD%C0%X@0'8LS)=BVEMV*!69])"^2ZE8W^K4DTE7#V 3=5>L
M-MKMC6+,WCKZR!,7+30S<3CT;8/KE]JL6JNLZD:*I4Y+5W:2!#1951G0)69*
MN OI-" ;8P%>2$N/CSR?&0B[W&9J,!:US::EEE,<G;1:2W PIL?M685D'8,<
MY%2GVYOBBQDHHRM-F91:["$ZRJ83J*/*C1\4>\0XKK3!8+$K;R>V!I<#'.L,
MYU/5-X:9-P;;%9Z5U  66VNQ):G*>NT0C5>@MP6Z2L2HP-8:ADTFF<TD6956
M*KGM0RT*V95FT5:=JUR<()AEF&F"EX:C868!^9V0%MQ(FM'A<)JX,"8X642Q
MHC* *A4?8"8!&3JVRN=I*&_[FZ5/<CM_.%?1(8<* !Y:YGA< !W!G"7M)M5.
M-FUBTT;JRJ2W'HP-/*B=C&U!T!#=5R)BZ#%MWB.7#MMBK9ZZ@B1PM\P2)WZ"
M-]4A82:-!4=%0'("&AI^WE(72U8<Y% ,Q5EN*:,M+@+ZL ACD24M-Y/'^<H:
M>UK=-X<].!BHZ&XQ#1X5K,B# C@?24FZ'0!ZL(;L:%KI?HK/.4WK >YR)7OU
ME-QPO:A3H7!D-X4ADZQRJ0GV&L1B?8'$*Q@@=WM2.FP/S2#6+3]:S7D^AM&B
MSKJ00JHM=3I.:B<@%_;,+( 2ZT.PL%4*.$,B?VQ&46)IZ+ 2UC':?'G.#K"5
M>*S2G8>-"1=5 3=Y4]N@M^G 'KL3B<4)S8&#1LO >#(%&;%5;)!*5>T!D:>J
M[RW:T&#4Y04/7L[RSJ[+W"#61LP8',^$7,X6L+B!Z53(^P39I#4#/R?IK&JR
M;\%10Y3J:UC!RQZPG0B@HB3E9,D%ZF!LT1E;M#UBMQT\BWL&/HTA8C9T!&T\
M\&O69VUA9,6%[RD U)FH&&6BJCX2@7D_'\1>5(2C7AIE;$+%W25H^-C:$B9+
M=K>R1+-];%&(E9 %T%A4]*QNI5I0FHA;]CDVW]"K)@#%57_ K91N*F/=>*GR
MH)HZ7D7VQR)1,DJKR8]*5O5VWF;DMX7M9IJIEI1(4<OB(A.#$<!N8N1RR??H
MD3$V2J(']$@CK"IUDZ,=R--SH!XC,JL/.G0P9HRT:K1 [?93<,]L;]T$W#/E
MH%P+LJ9 ZWG.Y9%9*D*,*^S&F/I65?>!_MB%19W5!&.1Z%BLI[T*:BPBM48%
M!,U5=P=H10[BI$$Q8KL]8QG.VLY\D[A!  XK4BSQ5A"82!_MQX0DI(*[0CK^
M:&ZP34T6+%923CM-N ]-K<2"C;0+4H376D 9-)E&NNNIO?G8%#BQ$R&6'53I
M-$_6;AB[*ZW)?A4/@3:Y*8T%26/;XZU/LRL>+]LPM]!ZV'#9V2V,CQ9 .)LE
M2:WKV'+=SB%9-GLM*,@U/#3;LT(+A)4C,TA+E%0)K'+97CDN.Y>6& 9NA[K?
M(WM0:SK)9XF[VBWJSA##H[90AW&3.#*XW" -(7*)IOIFRUZ0I[R,F8;L]4=]
MH0M@8CRUF[MS:LO40&1 8WA<")& -/4<?*S6&R)#>ZU9)M19+1>B9$BQ ):*
M@?;=GCK-.#,9%RB=BA:]'^WSH3N<: KCQ8J*HTE3@$CK)$K"BJ+PW9[46LAM
MKUNAP+ID2#423#?$\\:(9CTZ5JI$'5>Z*RQ*O,OJ'$V1,WADYY,Q  C%J*0V
M$63X#-P3O*0)7KM:KS\0MKYK"Q(]0F-5D*:9&VB-9Y@Q2F\L%,LL'2-+B:;I
ML4#W6<]SIZS*3EE4:)*>24=M4423$(I3%[.*G83$"AIU]%0G]W+@3)5,Q1F-
M@CDN=Q*WDK8MHLWT0AZ:"X)7CP@&C!G.GT9=*8[=A&H*C&K$P+S2EF5%VNT%
M".T"F&CCB4#'6D^FQI0TW4X(7[1FAAIP'?V8^_[9CU6[!:PRU \";0K;TIBA
MN1&F85+![ P[F#4%\3(G9'X^+1:-B*E6CL=K0TRHQJ$)BW#8*VA"LF!-]&L_
MG\ \[[E)QP6'98WTD!@JF'#.^N[2%MU=E]U"2EAAO<(L>:*V&[DFA;C5B+3:
M;C854 [GN#N"O9[N<VY'=RR&5M=(>UHX="HEQ=I9C^)6BN2YB8N[E!A1<=]W
M8UM>C>E67:1LX_IUTU_IA!T,#347MV,B8P?SN"M29A$O):V72,N!,.\6$T;U
M>V, J9$JUMH\L7LRS1%@O-_*D= 8M[SU.@S(ONOVJ6A1:^R4](GE&.4+(1=B
MC<="H^_H<&YJ9&D!P4*J-GUKO)QTL(G=F]/.3H>=KN<BF[;*E]-8F\W8A9ON
MKT(NR383D.R<G7<'(XY(BA[26/0PB;O2TF)G0"0(LM*&<+Y):APB[4/3Q0YP
M#>$:9X\E6K/[<8F84P<?.][,%VN::#)T:8GS:-[DP?D:''7KLDOE=5MV5+[E
M%6/!TLQ(H3 "F(R1EK-;X6S:Y(B#K0&]/1[6B*+"9A5;Y7R;#^C:ZBM4GY6)
M 9TJ .NAY(@P5(G',EOQ\$77\FN*G>(#D_75#8_LDJ6PU?A_!0' )MQ@99.D
M"(CK^T7/C)O$WBQ[32HYL=)D*%51R<7SHBET%IXG)0;8&,9"VMLLE-!<2MS)
M=/>(T7*^Y=0^YA0U3DZK7M?D6_N#9A+;4;=8#')RZGJ!06O&F-9MD6Q!62?4
MRLJ$XPV_]Q#4&!@)]6!*:ODNC&H94[;ED-3\.>S-891=<=@DK\8DK;;2I<K-
M$K](]AX?R8<YXP9YVP#)&8>'2@>-8+J<!DSBYX33-6?AKDY1G;RC]M52W%)
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M?G\>I]UV7&X[+MO*\UEK2'BZM<IBC&$[1M :]54&F@^RIM3O@8'86PB!ZHV
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MG%/)1\]_OQ]^TV@(-!_DX_=QJ%"RE1U4.HUQE'X'[_U1K)'S@><.[QZK0%M
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MAFPP2XF0I8E;LL/&AF70(DM'2!I*)'G9*& =N;K)-H!S6U$QW?)'%#/\.GV
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M #3/,6M)!!$4<MLR"-]JA3ZIK^L Z51JX$J%1K(Z,(KU:K@V('!A1<-M&HT
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M)7:O5&8LR)+=V<8M#&LG!\AJ</MI!IQK%R?%Y?QBYHB.?3;PZ.UR,B,[Z_
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M1C"L*&( NLA,,4M,(TO2?O-8[<<A\&QM;?<\YMMA3OI".:@MY_7M^_Z,6MW
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M7SPW//,->*4[*TD,)/!8B%!:TD^>>B47.-:XVTA'U[W[Q!QN5QUN=<96+H:
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M%6%QQ$"",LNNRJ2H-#.G*KE@64R25I!GGL[RE21R:HP\&JZ:@WN<#T![G?A
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M.E'?BUNCG66=K,ZJ>H%]QT"% PTNQUG8\]74UMZ>QW3\J<1?)UBXXZJ+5_E
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M>KR#2*4-R463M5NOQ$[>F!W2")K,+J:ZEX75JP?$41,X6+Y'#D@UQHDSE)Z
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M,W-0#HCYA,LC&<%!J;OU%SX)5[MNR1JL(8V/J/.>+S*K&I#OVL9WOOSQE]%
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MF6X(G;EDM%5+\XX>KI,&_AMS;Q44!_!^"^(.P8)#<'<9'!+<G0$&=QL\0"!
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M[2_[\T&+PZ2Q+3M41UB'K]W2F\'ZL-Z1)F5+,XI2.^5$VM=R&BC<A6;7\.L
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M/=YD.&ZH9A&+M!R#'WRN4V8ESP)+7.'6HAT$<)*-ZJU!1&!T.ZS"P5#,7EG
MV[WS)$5G19&^>0G[M ?GL0?C>Y$9GI56T7NQ\$K-T>A,VPDM>\"$\%?GQ5?R
MP%X*6H66GW'4,^*MSI?)(.['G6G9R[NW2[B._23(R,[9,=L5$E_7)G?Z9#K&
MI26A=5((B<JB8#RVPY+BV:?&,GEQ*5A634[,<(J%KE6?I7O5^]9KX%T5W#MQ
MB58(^LW</"^11S%AQ<RQ9GM()9/4BC8-8%H@V=I\-(-,E1@^B-EN,F"AS@A(
MI<G0197(0'GG'CFT'W<\/B%7^,OL&ERL/B)91].:LR[Q)F#>&K_=U;_(*+WA
MS]K$19S"!=\R),6UIYDGK)3,,#LRO"H+&=RZS&'4L($S.C<=-)$V9<8K<I\L
M=B2RXW]Z=CM>7B7%_%X96B-I4C^0V8P=6CBS*/9DA@?4C]$[SZ03MT%CNT'
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M%*B0GJJ96[W!M9W_*E1MY>X@M=S1W:7LLH+BO_D'5.YZ!I@O)6Y>^2%9X-A
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M-K#,#\G\:-\9V?6GG";",%SQQJAL+,9:)R=<4UEVDSVWK:HR;H([NQ2K'W-
MY:=5FO!I$-QN03G'=[Y>JU8=;[FUW57]8?=@8,5\_;4YCED*;CC8>9H+M38$
M0@LYW.3?Q7M:>>D-0YB^E8@+0S*?7N-%,O=C&G(NL=F;SLA&G2%$P^U^A#2^
ME_?.KIH-GUFJLVJ^0(TI$F>34&WR\:-1T,E?INNZ1)S)WO 6VJ<.LB(U)K'P
M.2.;1R[$8D8+RNG4^AG%]R3FO9W;*[7T6^"C3:*E]T-?"VL2%$)C- GO0':#
MNL[@,"*\:XH*UG3UYC()(BLHD=]1VQZ?FP$Q K_*;#VDU3Q[6_P%2/G?>#H[
M(77H_S+H3 84C#R*0STQ/^MY>JM-SV&14WUD2^UK@A5CK!BM1V0F **-I)&4
MF;8V+7(4YO)%"0[;FNFB$/UIR;G[4H=K_5 _X<WDVV\9A$-NGAJ23N.>-"\)
M8F&DH8[VP4]X=V<;-^-)(ZR-I,C/.GN:P;=8_E]2V2/;WD\.4F:C4]0R42KH
MH1;(F.RF '#U;_"+P+;5I&_J=F/MMZY':HG+5X.>7IS(9:1]IN2=L1X(<(QW
M$*4S)]$M:MP0YU>$C6,F2?;!/9]][Y%VQ")8NSJG)^>=9]+5:K%10[K\'$?1
M<8(O<UU.7@:C\JQ,WJBA"M8W,6YX2HA-P\Q0M;E*.\8R1>5O1Z,BP$CDG"8.
MZ;<57S>D)42%Y3&1=QA=1--4.Q!&C7QG%G09P;YW_3AC_:-*E64LGR0^M>BY
MXRLV(@B.4?HZ!$!UN'+T)%PY*&/Q5RY377O+.C?<K&F5,>X1ULA:9#TSW\B3
MHM,\:&K F&(*F?/BR'O5*J(4W/@*$LO3!X\5%M//?BK?0#:IW!3U,J?M^I\J
M@6EQ[[?LM^&!:C9LR#MK/SDK[92FZX;D2G%8X3I)8Y S)YA<?A /B?CU:,+J
M62?*!&$\EB@YLF@Q;UTQ$2L:!K!#="D%#)W_Q8DO@TTI$6=5C:&89SH OX&L
MV*T@(I6!]_K1A4+D;,,9+D-VL2HS40M:4I,C5!4-5P<ZLWG.+[EZU*@VO/7&
M!LTO)M<;@I1YZ"N$14: ZP;JF.QD*3OKX5:*BD[= >5/MG4RAA%B1'GKM8LT
M&;(QGJX1+4DNB>FGMT<7CK3W"U0K[E5L5="7(^LFGGJKBQ(G:V]<(IJ9/6UZ
MZMP*^3,[=OSJ3U%30HPF,00(ZT+_/K$#DF%Z0)T@,8=V3=#O[ET$ S[_L[5E
MOZF-7VD_5Z^?U2ZT=N0L7GA.;RTP2(^G=YN/ ,L77RO)>R4.) <-8EC$>#TF
M@Q5_$I7MY%E]M4V^/!*[#)Z6Q$JF:7(07IR>G,PO=I+_[[Q1D0Q^QC%696N=
MY#XZFCK2:C=$],$HF5RT2V)W_4X/)"F3QZ*^)E!#XWJ!/E_>)Z<O"SJ]&#ER
M:L/I8?#QA093NRU_>W3L:Z#3J3 'RJL8MIH^.;Y>!9'RP%?0,V5AY>M9TWY,
M" ,U2+4J8T"'M.:L82&W4>@YJ5-PAS?(VSJ[6)-JP&=IW. L?UEGS276E"0S
M8Z)ME?_ECBOP6X)4R\+Q3_I/]O9 &'6I,W%*JZ?"Y@:KBSX5A6?.#MSI7?^D
MJ#@ZP>-">V_B 4'4A.JR#!)$6G-!M]J$97$/3]_U(#'+?QI66$)?-ANTO'3.
MF8GD[TB--?]A1?,Y6FMU*BD^BUS*PFGD63)4_N;YW&)H,%E5 D;.H5N%-@N:
M%%R^@6@^>F 'NC=W8'SKK4D%-J[!QM,^QA<,V-< =./)/7#: 7$*]G[DT;-M
MV$8WAS.M+X@V8]3HV9\IF15>FU=F#,"*;B2?OG\-:M+D DY3Y4V1&NA%0FKL
M7Z1? TV+$LH6)8I>*]FT-K)OER3RC> GJ*D,800KIXG?2Y1O$(!3J1C)M'["
MPF..C0>HT_OS>:WJP-#@<!T1FF*ESU_'[8D$@=BX(;DY_>]0*>(@[7]:0XL*
MHA@+:LL,Y5YSE:M*-D63CT^M F4W/V?R=_E<=YS0[W^O,RE1NW(8@,5/Y[DN
M?U";3#[LD;\-5FYHTWHO<R(G(6[PM(W,RYUO\_%VE03K*)8D,+(M1=%04H>3
M2_H1O]!+QW"OVL7[X]&E%>CY'9D#N*J07*VR=(6_N?+;7:KFE B4OY-_N3;G
M/,1M4/)-,D8@^EP5/7Z/MH*.=K[\-%_"2\QQ]$F7, =/4+Q<646\YQ:7(8\Y
MS"OE=K"U]O[5M55PH/?NXI&H,(_*5MBNE*Z]0>>O-!VHL)H*!4W/>0'*_G#D
MC0!M*W=A1<SZM?EAB\>2;1,!<?YT<7,N;AOF$O(X+,&..3B'_^IYQ-FL*Q1S
M#@JH=]:N3MZ]>0&Q\6:N>FRT2?]@\&XVN-FRH4\>_L9CP)K0+HY%=H<<5*XA
M"P+<"0I%+BQ#:/!AH3X8/,4/5G"+_7\MQ7O#F4:<EBS:($UA-RHK<8B-5(O]
M5VX;@ 3F/))GY^S:OJ-2]TBN2KG>X8B3^I6YEG;U;Z<54=$>7TABK>Z_S\A=
MXGVWM=&K,C[@/GT $@3(T$4^B+F3UI)B9/:(<$C/XK"(OTUOGS;?U0/0?1:1
MYE[&VKA>^,[W5WZL/!3$?RCWQW5EY)&RE\+(D1=CGGD^I-!6)A^^M^.)7#:1
M>L)NXOWC!UE-^\"BJDW.;E.%MTP(!1OT)W-%86<X$<%^ZY1LNC'&5)\!DG4S
M/$91G.8$B-;6:&H"E6+1R:D!AVR8!WFYQ$Y62Z&8O<8,[=.<N :+54=HSO2S
MEO;(<D>7PFF3]=,-\^.WGJS5^/@P,63T1$]U.KV"Y8CD\L,,H/#Q#9EB"/[4
M.Y\(XM7(UNHY,AYWOI:MC'QIDKH?$(.Q;(L )PUWK(DCY4BU;RF;PN]NM(2O
M<X.S3/S+G26W'4B<;L__^*S;Q!*#K>H89<+FFT_;=M,&#: :,'>VP[%9")K+
M2[<U9GW)H*X&*;\%%"9E37-M BWI(MHO7O('*IKK86$A/AUZ]_9BWRI);7]B
MN3^+%A^=5D3KSAN\0N-04,!MW+8&LS=(11SGFBK$=[!%3 Z/ @5NX!P&)8K0
MZ=-X[&J'(&G(\:2AW@>G1WK6QN'@L/X/O@T%KV$^Q/DETJ#84RMW:[;YE?[P
MX+-6$A"Y-6-(Q@ G2F&\?.16FYG!  S\"(]H?L8^@\D7*TKYT:PI0Z3>&=4&
MYK$L^K6/UK-#O!+H-Y-3Z$B4JDXZ4Y#N(A'_B0Q,.^-UI"%;TVOR[(8IZ/O'
M;SC'.C(JB$,]A2%EY[6-\R-H_7[VWHT$U_3$Y<I&5 ,-QC6C^7!=OE7IP==5
MKJ,G8A9(%-7MAG-A?J2\WK%DY)3M468A6F_AR;<^;WE:1W>N!G)8\5[KSG5<
M>Q#=OD+9G 35^7I>'E7J+"$U7:@V95.Z<<4WS]<^_\UJDOPI55WVTF'1'JIK
M7IGTDP"R9E?H^H'S3'.I+0L Q2=*:Q-8F:BM2%MT4*7F\=RML-3]&]12F]42
M.[R=I6FI+9SS^W?<A&OM]SI[5;G2]L+BMSU690OQ."];VV4C'W,)JZ5"<FL3
MG+5._1,L-@GAA4".' @"&9<Z;3"W?>"EPI$"1OS;;:I=FPEG(%_S=4I_25]1
MW(<6+9A1=G_B1[NO9LQ\)VD#+01+()EI4 NO>:/U>IIKDNG==6<]28]"SD":
M<0ZS?=9;NS;99PA!<'%:=W_.YTF2/G^&FNQ(<:70WS>+HT+7RAH\IXWVIQXP
M$&K7JS>4.+[=1W?Y+\0,7^;T'H)$)&$YS&3,IT-3(Z7#UI4ZV06VY2ZKXZI>
ME]+[>18AS#7+T\*J9BK6/8N1:S/$C^>;#$2@HF?E<^CX'GR_/**?"!'9-Y5>
MGZ4*(]-I:X&L,YPVB^TK5;511!8_9Z'OYTG:H# 19+OFZH<S8C.$E"OC#T]5
M;A4.4QZ]<+9,+5CZH(J_R!6=R72839(>)@2]]Y+=GJ%.)7B<VN'$3S7TEP#<
MRO]+F,CXFT2R<,BND.R7Z[&U[>FD5$,"C$2](]27) M5 DXKRPQ;/3WH=NMS
M]59P^M*Q !,GU?>SB3%"6NA88V0\/99R^HROIH9%EWZ(!;%(T\^#W6YEOS \
M9G%PG+ A9#+[3#8:0[A#UJQ][7^B-/WU7.)<(>('OE.GA<I(@\H3X^!!7PG*
MPWUN9)X!)1//E>.CUN^:B02U9SK2I":DW3]\?[<Q+8YIX<0S]-4F"+7>\SYM
M^Q]KU/\_CX+NI1QHP'VX]:M_XSU]6\%7DSJ[]9U-4EIX.R:D^N/*UY91FDF:
M,ZTG25@Q=?73Q,02)4KJ!7G^X)KV^^6Y_!UX9C4?///!4@  V,]SFEQ'=]4_
MR.Y^"#H?R*#^QWL<4-W,S.P<OFT23JM,O$ _[9@,4VH95XH]2W!2OS-MY86&
M1>PK 'B=3HLSJ+\NT/I-LOQ']?W&J5G\QBG%)FD,46E\Q1F4_Q$%0(AA(N(?
MKP(\LA5[=<F O=J>?^+NU28EB^B6U.?OIO$AOL( O/]<46.2%@STTP"#UL>!
ME""6/)86< OPQLY5J.6\. ^+YKH!&B8F)];6UB;_1XH73,($!%[&:1@1P7$+
M=-SAHT\_@1^VDQ^DF'D('[(OXU7W'RQJ/C#LG^Y^I_DQ./W6B'"!-D%?\IO\
M6Z ,/(3G1?"RSR8/0_6+6U'!?^/I)FULEESX!VKP!&I<7H? E.=;$MK.8!'S
MK27S76=_#KLVNGP\#U\-PFP'OY\_/-B^ SS\SX>A%9]DR?!#TZ!I;R>Y-#3^
M+, J;C2>GE1O&&2@\JA)J!4[;VW\9\7&)8"V2D=_@" N0]QWNHUQ6%.VSQ,[
MAEU,Y8_3>]WB?Y)HB*F %*_   #>("#0%K7;6U]?_[ "!$W?&",6:.E9_,_.
M(!^#S5 *%2^A64M<%T=UYV97)>>)\#2![OH*@9WZ_VOAR8T"@\G_@-7Z$IA
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M$-;_D;!W9W^R9Z=?  #?CV?R5,!U -+IX.DJ $?4%&(",A27!R"?K@'P+CB
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MU$U-<5F$AP)()&YKI!/)H/G6 $N'"LW 4 ^>]:V#HQ/EB3TH=@'OOF%7YMO
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MU[N9HS8"(D?A#W2/K,4F%0^,>E=2@$8Z*?$M];C$2<SOG;:USO'T7J3@DX[
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M.F-BS.I_-/2>R'B^W<T/[Y-CD)\ITR\STAN:D*KFFTSE=Y35VN$175AP"F'
M$NR2;Q@OZ['J*E<&NRR'V&AX30;<3J=(EB8RGM/#O3N9OU1Y+=$,Q;!Z$/,#
MYRQ=)VV5@W#JDY%HVBD>@NS13SX=^;9%/&TZS[0+4;%O?O(K\G>-(;V/=4+N
M$?.P1M!I=7,TR;Y(T8LEM9_:3YF0.40ENY T/CY'@V_/9AG.WQ?UO)]):FR]
M(NF0O[#&9*L4Z*=JWE:;",:YSQ ]Q/BT__:CS",CN7N#D+(XN8@724[W^_T
M#.$O60&HW%%UK,88>,]][VTNOP)3WJZAM)>\4=)09IE<MOP*>'TCR>W_W#+X
M'V+O'8R[Q4_?* QIKE_N5TGO<<A*TIG>%L3TKZV4+=%IZJ6#EH[QFH'U,B3@
M'SWZ1[>H!XBN]SWX/(3-P+H3ZBNZ_\/IHQ.M]B?F+Y2W0H[$&P0@LJO?0F*T
M?>R==F8/H^8?Z8E)+36@[@F47[,,RC.]_G&8.& IUS*#S<H#-I!5J+["-=7D
M$Q_<^.K"H=\<9Q<INBI*\U-647(8+FLD_*DQ*CE3,G7PG1 ;H"_FK1YG4(A;
M;E84N&C$_'H#;)*$8*=ZB%EFU?N^\M!^=,_*->E'^FE7BYJH^J+%7-!-&?G1
MB8^N,NAE#<M_Z=Q@-U*:](5I%.-SL!C=(@PR?_+SJ[1[1T)K@=@[5_@+*M_[
MYUS/3&,)ISM2M]@%9]4,\/G.K&9KH'?V1^3$N)1]'4B7NZ--,PSEC+9!IDR-
M'Q>\!CF[.3!6\7>>*D#E?M"Z4W/CWAP63^>X2-;U#P6Q6/:)48MWW@33<XXL
M-"='+V\=V&25 WEK9 ^_T7Q+B24P>A-,%X#4Z.><$FNS$W#/V$]OG3&ON0K1
MS3O=HU\\X;;;4 ;.<ACA;>"(PZQ2M]$0,* P_8QLG?IT\WIE5'<CG_,403+M
MTW>?262D[EDFM.=)"A)"KD79^&]/V,!>[4ON_3%*+/Y^5Z\!@%+)+PM--E.X
MGJ,TOV 5Q=$J?A/\F3%FBM)8VEM^]JW/3/<]8(\E[80^5[N=) F3^XK+IEX2
M8F10\PWCS@E7R[J^>\-:266";+YL-C\VZK"]:CD>3N@RF XD2Z.JV3]6R$CJ
MN?"VQ,24S^,5Z@VC-<%)&;3$PH\>>'5715$=//"%&ET:;^)!("ONTQM>FGA^
MVC)2*Z'81R?V_:G$@XR?[F97/24FO5_AAU'Z$BUN1:&TL"%TWC(2ZT8>.U>H
MZ"KU:\DJV6N'_[%9\,'0]PGI9'%N:5A"=E]9Y7&KIQNVIY*2TA&#+6]6"MWL
M@\H[;9U T]>6K$M?\YCY_8A1=S]87SN(1&;,!'>A8=^]M<,\YOL"O6Y*_#I,
MRZ7(FY>4Z+,WWU, !H34MK92FS,KO&D9)]]NL)2^WKXO8]BXDO.UV%R_.5$"
M.-[+D>QF'8JTYB<,HO&YPA=IM )3V:L8A'O@C!'-"1>ZK6B6!8('6T]W/!)N
MX#HO<[7HW!/+="B-$2*<B\12]B*N\F?>P69Z03.F(-^=URKNUWO@#PON.<P'
MXY/"Q_;OMZ&04: LUYE8PUI1GW*M15$P1F=Z:,:R;>CTDS;LGGAM0P[N6F2]
M>7(WV)[X9M*A?3<?XZX(BZWK;E)Z6%,C]+'7_0"3Q. .!4$#10PP)=N!M34!
M?X4__-E O%>?,P_FM)"#_W@IB"(7IE&">+C M9%Q3[[]S=,W7Q@>+<GVF[CQ
M\>BMTF^&QBRE%C???_L4.I6;BMR:7.Z"%9^/HT$=E%<C:!U%IN5H'=34N2N4
MZ.#-Z2$@X/S4F:7M<S+'+<]F4]8#JY#.%I.LX889BR'C@'J!WA0W,"+9^.1S
MCB+1M--HP)T8'PJBD,>'6;Y.DCUEQ(<IK??ZUX)<X7302,DLWL+A&S%%"&(=
MS@>?ZWV"IQ_9T):^M*#]+%Z3^(*(I9/2*2E6:WK$;WQP\.#&7.XK<.Q>94TF
M4 ?[[3SO5[ .$K/]#( VN]!E:R0733:GU:PO-3Y;IX*@3'L^5]#?][JQS],J
M;5!06P#O(';L'E<FZFN2Z($./\,\_8Y16P&PI%,U-):'U";!1V%*3>;.47NM
MF*$I<>$'W>$^BO7L!V7#'ZP,V_L85#$3^[E&UG94T) ;(C3*')++J^/Z^E*G
M9D'R(C*[=*4,4_[MA2H5$+Q<@1G@!#9=6%>]#N]G"'C&IYTY;-+_F+GW9K#!
MJX7 K_9M5K@(*1O1'N:4Y\0!/;WOJTWN[^.<Z(P2:M:9,*C'7AFB<!IF&ZV,
MJ79L22??/YIZ[QL*B:H?_<;MC(^/D0H_B>Y(&TOV[^[1U+F]P+<@%&N;B*&@
M.U*F>M*!EM=>S&J2J[Q O_YIFP3U_9PX70KC\)'179G5:)$7.^4F80N0NL5W
MTTLCMQ/05B>9F7 %']@ZH/(25(OP8F^U:EA2)K]JTFR8G9#O7U%Z?JM&P;R]
M25LPN(XF;-V7I8>M4Y"7+2O0!)O622 ]<JLD'6N2A'-EM$W18J;R;I 6Q6#G
MN\7>:":L+9=G"4P%R &#B8FVM&)U.=H?480B*!^)1>>@KC$&FS@!ZX:EJQ)U
M'%WE5FS=GDR&?1)B!:THIA>N14Z Q_A\V\IQO=_=,<;ZAK#AS_ZPEYQXTUY"
M+5YYF:QHBR&ZN&!.48NI7B@IE,L?636^8$+AD$-O=N=.1,\ \_2.0GB+08HC
M?F0ZL:[CLLF:G-3LBBXPME<CC=L,X^&G_6R-ES[6:A[LM%HB+>)2VPE=Q5*<
MB/:XX#OJ[)-Y^3.Y]O7!OHR@DK%^E4KBEA</Q%?4HRPIB*;@!/)]VOOL2(X3
MF! ?8X/%;OVO)Y7\794!L\NH)H.=WL1:;K*!MPB8O;Z5\@[ZHJWUYKWAHD(R
MJ4EX2$%2N"<+U$%+OK)$5>/3S'$;?=ZL@Z0M\OF;T0!%RW5PZ5XP):;0TZB;
M$FYW-1;O(A_,!O [?].-SXY*('!4,V30,VI2FV*V2W),"V7G*>W6B"5;KOQ:
M&*05.U_1DID32\ 1%\X1-W2P+YDM4C\_]<QV:GUNQ[R_%>_J=B4):FL6_",0
MITAO&^-6 U1'2!&U0:EF7#^5UCPKAH3Y:Q^8,6@M@/ZFUJ2]Z@#YD2XN#P[<
MXOI$>$%[#M\H"^@Z%I/UNO]H'&, WM)MQYJA@. 'NGU%BC;N#PV#6_EMFT;Z
MACM:EK;MGY8,*WH49*>#U>:T^A7OW*]\<PJ0UZ50(*-QUYE!"Y?+T$R1DOI\
MQ&TARDQGE7I47U,IGW#$W5H.=]@TX(_@\LYYU!I6R6!5G2^$)LVM4<+KFL*^
MS)BMFG&=?'+8H']9'J+TL/7)QV(&(O47].@A7HL]LI+IV\62$1"#S\L5==PB
MO.54*F06D]:2LN/*83!N_J4IAEAI@'6.BL=HV+CN[*?RMS(#0MQP0S$J[6Z#
M],[K2UH&KUB=>\214"-L6J!7U<*S;HQE\.7.PK3>"^L(:# HFO4 8[&0T@Z
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M[;M:GWKWH'B$W)QTW:MJO<Y86MJ!&5.T8>][^+(&-T1><@O5H-I[E;8+>.@
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MA8N6O-.-_+[,0 54\N/(EI)R< ::L;HXQ3I*GVZ19Z(JL7K+LY7SHX3P\%_
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MN/(N)HSCK63FYH3T/U>RI3%_;=\GV_BY/"/Q4<.8D),LJGCR@"]G&MJ:N;!
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MRX7P_PAK/HJ-D[%*+[$K_N1\*_M']R>-(X:(_:.X@Q5Q=DC3_38B!R+F]1R
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M TFA1D]_*"W.936&]V$[EEJI885K@OXO0!((KM"=,420,!K!_VTH[DR+J_$
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M'K.7^]!>7=.:N+ZPMZ!E)+H-V$-(P#(US7B(%HLUIHJ5#$_D]!,:^/N&:8M
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M,\^=^0=F?EZUGJZN55U=;W>MMPAL-Q8J&VP(PYJ7N3NF$(=(*4RNQ'<X][3
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MLQ0K2Y+IDNL#DL^%-</%)X( CR,^FF".*$(XGOQ^*8,K5G)/K5WR@F0;YDN
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M:GX QOKHC=>(O%WGUL0-X]=NQD\)60R<!^<LL16Q1@HT;-,B!36C;84TQWD
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M%<\5J5,J;:GATFI2#.H5XQ(,RK&2\@I([NPP.AMW]G@3]=>5'Q'ZE+@4X3V
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M8);46$GRX4B$TH$.JKZ1'FPS'9A 4CH]#] =-B+\HL;,?JS6T) !)5JEFJB
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MF=^H++O)2(QAU>:+A%+C0Y'!=:X"#XP"*3E[.&:_+#ON\H9;I"L*1D9$ ]B
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M;CU3+TT)!R,9HLTEPV>?2G):)LF3^V*M<U>IL)=C(UVG(B%1GXVL:RK-[DJ
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M>/\XX'EJ5CK*NI"QF53LV(J4/IJ7AHH7C@^3AY9:-LQF5\N^WE8R^+AKR&I
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MX$&!=,NYU#:GVH9\L**0*C#:.@U3R"SR.H:+!?_K:38Z'2BOI@+W0[#*-A#
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MO7VRTZ:R.2#J41*KQ,E<>Q<1<5"F./)EA8-M;(!V^YPX%5#'I$3_@H6;AZC
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M@60*=MSA_29;]82,,Q:XDI8!@YKERUFO.<2Z#*N-))ILR2&>PA)6S,QR E&
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MFB:%;19@Q\<R@:=K@,-:6,Q9U+#JNNS(Z4E&3VIB$=XO [5%* ^5SJSP1L4
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MMXMO'2O.'NYPO=:ZP")U%D5%U60"BC0!X9S/ EDKSCNZI*R=20"X,=!<2 B
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MW2.O%>"_D([_]P\)BQ5OY_YR[PTZ.<^TD\@5E!EO+Y2I\WI4I\OZ>7E&%0Z
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M(>$4=2-SP6.X"8UEMF=.+H7H2D+J<$D$J>4V2 Z-/CY*-,2 '5M8.:7Y^*5
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M]=,TU4Z*.8F6,478Y*S4NI)175;0MCA>34FH4SX=>*SN)NL@TQ[%$A!;<<;
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MJ]_XSL&G5.>AN%W&.'W%2;MIR]JF"FO<"U<6E9N!5V<@ZI#KX+9Q("N-?&/
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MRM0B9^MX%-BECJ:N:5-(B+*D&0ITUO=L?=T4_A.JH:2S7[G@@\Q(_8'PB4Q
M=(BV!JO%()]3\"R/*'S=_.C9'F7_%[ZI8OI.>4ZM:\+&H<1:/4'6.E(-]1B)
M38EJP2,L(';*)D5D;_7M]GT'E\*!<5^@@+XUE5T35.2A\$(NQ?8OY>F-K@6W
M;;%?\^=Z&6=&B(Z@6;@7VAWS?N359?,06HB1[8%:N@#)WWQOSHN;MC9?2?</
M_?\@YL#R_M,K,F=GPW[$5\-;FWZ(A5="\,Y$=IK?/QR*V>_>TZ3,5/HR?GP3
M>EB3S#H=CJ*B<2!&J6K_ZQVC/RK5GVMJNILN1C-9&W[(4*<'(+AHW86QPUP^
M1=G/[DRSRQ ;U],W:%!XIAB(33TE%FE)<0.]^%)G+>DN-7/+\3#A6-*!+3_Z
M@B6U,05MH6[9[ B-@:%FB)';,X;,W$@(_[$F.J7*QXJB5N,UPW-PY$.PIDU.
M63(Z7M+,NLC1C3856RR".6[_."&RQ]DQD^+,M'Q<46*,66@JE 9,WZJ;="B[
M]=?) >ZT,US\MC[Z EZ5<6Y=)+8))[26R I2$@#F&]1CIP<S*3&S)@0]8+EG
MS@[- F<;#:7<Z[AI>+%"F^?J"0\A7E;$C=(>T9U'!I2$713#MD7(DY;T;%HX
M^&WB^ONCN_=TU/_%X>']GP?C/UPL L:OZU'E.O\-Y$T"IO/V]O^"3)QKY.J2
M;DI&:SU'[>CG5>')%S!Q(6S[L4N7C%*P5\QA2AQ[NDH*08E0<X?7<*M?&2=A
M1HSXE=QB=7$T>CR=<D^N9PPPU3/:M3K\!:%& UG<_MW4EH;LKNQ41352ML!^
M\&.",Y37PLRWPP]A>^.VP+8'=GVFHIH%5M RU9\^O:W4TL+L&$MT=J>F0B=&
MC(R4<L0TR?-ZS:!5P?#=W;0#[^O#EBHXO(^BW# ^VC=)C" V;6A#*(D5ZQ_+
MF2RP$J6_\;</ *5;RMF2N_.,C%@/$/C6 A*?#I7K0W8&(#D3M9,4=)-1?%N?
M*H-1DF>/$<"*U XOHK1P4T_ZNN5Y]VE='KRO9B!U7OM\UC[?.>^SUWN-BZS>
M61Z\C!4A#)?0BX\;X\F_= QS3H![P%;!FV,TOIZ_ TE 5U+ @:VG!/O_NQ<7
M44!OD KGL3(9BP?[L\VL;\2J(S%-5/C36 HU1.P8MGT(W"ZX6\8< N&'\[D?
MU)U\SR$";A3'0PKF%U3W^0+//V+,NM,]/ST#T4:!7)_*Q]P%HC@]'V3GJ9T;
M;&+ZG/]+X-;7UM:Y6Y)8G+ALP$)H@B5^^9%!%_LHBY* <^2^N,(/@Q.IU)\Q
M:J/K:XS^JL3%/#P=2Q+A"'I$E:.-(VF(W8%NHD-&H&CW--9&5U>P+!DNURW]
MJ"-4E31*-FOTZ/G>/F=K&NF<<X3%.!@E1?30=,5TWKXE%#;.+L++$%TMBINT
MATDJW',@FN0/%FG\['0M.NJHR8B)GYC500W:3"9?=5R3%/I9>;FGC744LHE8
MLSA$T%C_W':%\5?*1JY+!/^/XLIAS_MP3_N*:+K"$=/1)@3BF]1@[HE0$^<U
M-?41D6CC1#YMQW36!X5G;#_-;.CA+?>$\\Z&P)5_@BM&77!@^P_E)WQ$8!]B
M:-QF"Q\Z)OP<BQ7*D3JM.%[$(*TE\Y[32,//3!$7%OXIM2$CB8373U*MP^]N
M8'X(Q3T<*B=HS%N389FD_2?_VDV.YLTTOJ_AY]3309Z\KF:I29N^B1VW&Q^M
M/KPH-#:;J58>5%:0A ,6&[GC_E<'0Q8C1WSS^#+,YXZ2: YQU%\0/F>N_>D/
M;2_4_L]?G#C EYK7..D)LMGH:4TK_36=9&,ZE+DB'X:\A!:>@Q?\R#C;>3AW
MR_J$5F):[4\S3*[X6S(_7$NM\OF=?0#G/H"Q8:T7DS#B%;JXSRM6>XR24QN'
MPYC6."DEG]2D,Q7(5EJF!,_>W ;G4A:M!3>I&V$[5:!U!ET,"YZ#FIE&([>Y
MM,0P,]GAP4N9ZU> ;_4/58!_TCW@=_KYY2?F:VCDF9/P1*I]^V#$P# @EEX0
M;,M"=YJF_G$G";/#$W>1&>V<EB<>(YLZ/"R!S>;+@020$[-\B0;#8+_X"/\
MJW9-:/DECK>:I+&L-3\EH]08.K:+&BL*+ZW3/N/NY\LQKRA EVOJ O,=0I77
M&-ALEEY:^B:%IGXJ@^+0XM4CG<3@\7'^1)=;LJ.0J\GZ%IK6"G*"1>'-3-]:
MI")NZ<RJ-5,)DYZ6[=4TBO=*\B@?,@L JL<Z"_;7*PDIW11%JI!%=!(8B(0V
M;=AQ/U^>#[1(R!E_Y3]YB#"\<MLZF=1:N)N9F5)-_O&5/P''%Z>'<@'#0F B
MQ%@\C/RC)AE0O)J@2;/F]#O)K$ 4S#HHH#1[M",M-?&VV^;^3&%@;,'FJ@*L
MYWX1QXDE;"(I6FP&IQ9.NJ\1#XE9\X8$A$#;= 6SY2+%&6D.VO>HLE%F8B7R
MGB(V>3<R&*'@?,*1LXQBVN_U%7C&O6$ ;E4,*+M>_=F>I>6.Z+Q7"D/U6U"Y
M-4'Z&"14^F3E]R$A%MGMY'G=:!2.TL44P=(A]*@<'>N#0!YS%OGCN4M+L59>
MW!WS@J'=>5E[1W('ZY[2= R[R-H@'Q@%>:W3;V5>!)T]KI=1=[Q0MP]"Y:3@
M3"EZUC72!).ND;W-45@0^XM( -#0HQTA.:9:T0\2G;FCK.M#7PCNH/TV0:EZ
MU>90BN2^*AV]!2134F>ZJNXZ';9:O)=[: ROW9?%/DQ;B$4?JYNIF&82.^*'
M""75Y"A $OX/3O&$ZKF?P_G'?7?Z./-W<V:B9.I''RU*EGRFB)A(<J9*J+&*
M5:]>;C95J8-G<*E(\9481C1_FKC91"O>H7O:-#+;D]PFZ.:O2$]1K01F\(6K
M;^_M0Z^4_MT74[M!X[YD,!_J_X>XMXR*LWOR13L0++B[-QK<78)+0W!WA\;=
M"1;<W=V#!@\0W!NGL>#N'CSG?6?^=^[,.C/WS)PUL^Z'YT/W4[W[5[MJ5^U:
M5;MVV^:1J0!03W>/GZ1KVY60"Z^; H_SJ*CP2W#T"#A"S/,"U8XTAIS,S$PQ
M$C\&04!;A\E?Z\[UZ0^@>4O,,:Y1'TO^.+OFF M5JP4%H^I(MKO6\ZMX<(QT
M2_0R:B%J-C]@F!C7D-"'5[N ZYJ!G7AL=YL]?7!5">XK36Q<L9+6G;<_.MS.
M2.>OV4>8)/_==[(*^5JA\XDC*W5J'S\RX)L!$.A3SXS3;*JI6'9L^H-D]BW<
M'1S%.7]^0/-CQ2S[.H&(IY\F^FX\;WV!][M#7I8F3W$4F1%&>'>CE:+,4DGA
MEQ.VKR-CT=B:UI; SAG[88=S$'MR:I "S[L.Y@^"DL_LHWA>%*%E#&>S *6.
MH_+J*3OWFR-W$N564O[LH#&8(=D1K3GMB+ZV>JIFOVEU[PE37_K6+;9/6WN8
MO8K ,VA]Z?0S?ZFU(7M9:10VX\ A N@N3_H#*25"/K6=40%T"= CI51I.'5+
M1HQ,#O,M-'L6MS2<X3;2I2!^J;"(L^@F@L2!E29["BDEDWT!<D-H82G" ZJ)
M&9HI68=?Z"X8Z <]Z)<-_SIOF%MS?--JQ[[^>B<"OZ4=,HUV>*EL$5D(A_=&
MF&$X6P!7J/X:;#NV2'?Z<Q4%(POZG1)_DNC84'U/=1S#B[2S4'6?/4D[.WN]
M7RW )]JH-O_CD6]^22<[07=I$\;TTFEJB:$HH/)4>Q?RB?N29^YAK^5M0@QI
MY&<1DUZ[(<NFA<^7+QRH.8YGYLI/1<6#/]#.:,:8GXZFE+IP1R__+JS!HP<;
M05 N?H\IO]C_1NSA_/B^__!NBU>$U;(C&<%.3A%M^7)K<-GVP;S]9#%;",N@
M>@NXLM6'M/=S&YR'YI/&"[ZK#A^KBGLU_W0YA#9$"SON@6:F<JR-X+H?\)'=
M@^F@F#0K"4O8=HF;RX3H'!.*&M00W8=?233:RCSM:F=(#1M?49WP#<@QT-D]
M1!H\/AH0QCXB\+$""[$7AZ8VHT"9H$GW-SZAHZ=5<SDA$F3'\C=OO<-+KWOJ
M^/?7$VL$H]X*O#^ O:XW?$-*XP 9%R(')&5Y1@;J>%V1?,G2WW*C98D1O[+G
M:RC,Z0FQ!LW0)B<_MO\!V+)M)2=\X%;&U5=81H4A .V,UL2WH+HYC_N52!.[
M+'\':C^Q@'4-WQ*[SIFHA!%21^A .O[G_&VY:"LZ*@'C'ZX])6T9GJO\_,BT
M?'$-LV#H@;2!/L0UFPQI@BNM>.^[.UAYIY$J0](29%LU?B<VY)G7U]_XPFC/
M"BUK,JU%QT/Q5Y"S<]K8K.@XS=#=0W4D0AP +!RK+.VZG,0)BH(TL35*:0OK
MO&NW#?, I)862GV%)#+Y=F;AQ;&$^1]FE:PZ2T5O,PEVACAU&1MHWZ+R=%@:
M)&-:J;Z.0VJ8JSL?$4DL:;\W$AJ<D(69KXH)DN,UUGI+587L>A$I%,.#!S/)
M8!4R-@DF9M+Q+7S/3PQ7=/UAB- O+T:(+[Z=NZ^*EU./)T;&TXK<>6Q13Y[(
M?L$&[:-#Z#]BC\+E\*56SQCV) R@46CV2HN-A"J1+]^Q\EGC8\$H*0Q,!,=V
M.E+URQ&VLR]4N6:G\R&_\_MF@U*1!*%LH>A@.1MX9XK\?9H+7H$4(:ZU>>47
MW&1LG!WQ&@9W@\;^_M%!TGUX<A*2=]E0M8 M/I_@AVA*BM. 6-D^:?TT''6<
MP>[DLL+]/F;>YC8"=J_[4O&1$SGV;5>JH"VLA)%(%-HYVJH$6-)U3B[^ :GB
M:*)M-%5=G8P$L$10/0N"F@K8=//0&SD!+-?R<F;67#=2HWA?^54!JWJ+\"2)
M:7E)W%R%$NLK,Y#G7>J^RO4OCW+SZW;,-%>X' 2"![A;Z<6O\?*,$3SM6/R=
MGM11MC.%O]N=/9=SUVWGLE:X+*ADPH/TVMR\09-WBT_+>AY&6Y<GWP8AKZA#
M.5U5/]O]/^=0_1)]IM[8\E_^ P@L[=D[);-Q-NI!?S:ZLAW]MP%8A6=^3:QO
M\KSO00T$A8;<&2Q.&H;HW6=;,\%58[>HRF?SB9ZR%H*/UZ>-PUD4N[JSB$^2
M7*)WH-$Z!S8(-MS7WFN^%MAU?X^Q*21+N\Z8SLNIX!/_I-L<RKE'_V6A4"A=
M^YJ]*<%]1Q=/7'EBL-GPTWE#_OK R&[]^:CCDA]CCC&?$4X3/L<:<J8$OQBT
M-K_=AA5#7=T90X^#83SV<\WWW$TO(,IDO,JOB.ZKV;.NB.9:)M 9RA^ TW#I
MM_8&ZCR'/.*X'VD3(J#UXNJ9O%05 XL DYQPF7?Q.-Z</()'C>POVS9 3MYT
M8Z5S-?&^7AG21&$,U/'P29(.-/Z0=!!1NX8ZU^*\PL8DL*7>F5!\XZ.8=4\D
M 'M;OF-HS]KA_B^7Y:??6/5W?(#J_]@;$[ /^0.(A>I39?XC/S(8F(9<!-_Y
M.I^CQ=;2<)UF8&8NQ3)VS,D<\"*DZN4 G%X*7IA/F&XMC@@GY(Z24_XJ6_R)
MVL/40IPEC9ZY42'1+E6.KSR;LRYUDLD9@#4M2_D30YR9@AC#@87)0UUVK>\7
M(L^N_=A+G?\B"E-%>2KRV"<8S^EGY=$PA)-!Y)JD&AL)Y;T.WP^LLTM=/LEL
M"..20/$%HK"QEQ2#SM[$*Z<?7*;QS;G1!ID$23V2O-QE:3F1RZI'P*;Q%6[.
M].-W\(],H#4#U]);I\5E="]FIC$NP/I]\UW7W;WV@^&)@VY'%YRJION"&EY_
MC+0=/9-T5]S6XE/%":#0^>JJ@<"E+.NH[)Q-R"ZP;,. "VHAS-P,U;<B&*H\
M9W7-\W2-CL^.I%O7V&0"' +N&: ,JCE43M'[&[_R[ZW>2*C"H>39(^3GYD8/
MQ&28BO]HJ6N:/B:\>/YSW/PVW]8G)V..U]/H=Q*R/X#]F)BM\6.[*0/00[01
M3LN:[VM1.%*]'ZIG")2-2$S91/*S$)\ VH,(1V^#3^3EA"< )1F[3_'4'9B)
M_)'^&(#5)QE6$UA$-CR@WP]4D_O5U=C(=E'HB[D3A]I?P5?==#Z#<KO&,$05
M[M409<+K_V5'VW7M6/[GDX><$&_@\G[4MT2E%=LJ1F<A].*\RIGMX,JC<L_.
MSE7Y8\AI\^<>H\..H!)'*HKG\%E<[*A/6_%9&/C:&FS<).;!UKE.@\ /Y'?F
MPT7+6H[S5$7?8&"T@@NV('3;X("X3N("/B7\KR)HYRG#][9>#)4YT&$)<7E]
MP_>E07+,C0#]ZVL]')G# *HSP<:\L4Z!H4LTN&T\YW@\9V9ASQ5GR[]T#G/
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MU;[]KG+,];K0FU4^''^-3+ES_+MSXX)?^EVNY^\N-;^389_UI$!IHU/%\NI
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M(\&-APHZNXG6<=JE5/>H-'4GGU!ITWP(I5,+6J]7N"L^V]LQ+; *IDZW%_4
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M0WT007FN*JQZ>;MDG*PFXWIGK8@8VR5P8X<<65LJI_:>^[($>8H_TVE5/+M
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M1^/04%'9/;OZ[S7K,Z)_VMNB?G-'X>I?I  F<JZTU0GV%?48CW:+&/6G96%
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M70A11HK(Q3G#F46EUA8H=L@KLS4]>F%V'^$*BI*2/*]S _LI"BG>DM &E+^
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M[K]6>W/6ZFXTZ7<U;_DO4M%?BC,"O;"C_O1%Q36YU?H[6K!\5?P*I'R\_@N
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M&P-%SA)A)IN':V2" K23:9GUM^O^E7!(L?F^/3/.(AFOVAF-\$UL?,1%7>
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M'[_O/30L;'WTJ3\?[47@L:SPC1J[6>X-'-64T8-$S%NIM:W)73GE8@M.2FC
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MLVZ!SC#DZJ<5V#$%+]0$Y"#'!6&(BF:H?**UXT'%7R:IP$DX ;-33%<9DYE
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MO<))1%E9K-:Z)*::ZVW7B4,7N.GU//.\:7EJU>*O(-7'_&?Y?P!02P,$%
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MLT_%S&TJ-:S%;&[JMA\@GW@_'[&FN(MYTH<4B6E$Q$9Q3M\'2>?WDU"29]/
M,MBPF'%H]BQ[D!X:&1N9XI?K5^I7Z]?B]R9R,'VJ;+%YO6]_YOS\K!]H)Y3>
MI]78Y>H'V,YF@<6+EC*R[,7)@.*T'%44:/'W]X_R;XF*:L4NSZC 4=YL:=E2
M>0"!J$ @#[!;+JCU^^UO"+N_O+Q_=@"8G8,3G9V=$X-=8-=+E5:<_X:!OA,
M#ML?Q1@=8,<% 938V!!LBM-^V-FE[$04#W:XP5;&OJ0_SCOL #9(5-G8T3\J
MHQS[GSNQ 1#['YT5L)8H-CM(%*3L:.ROS/Z:'1MFG%T<API;G8 0AX..& ]D
M(D=*A@_F$--@)J3BE*%GP6=WUJ$1P:0@Y.54L6&BYS"7XY:6U&?DE3#QH3&D
M-6*Z)2_$:RC"9>IU6U9/3E]!4>FVGKZ!H9&&A:65M<U=6SM[!S-7-W</3R_O
M>_=]?/V<8.Z 8-Z*7OKD:*RF?.$"!QX.2)* D B7DEV-G@3G-LP#00(6"@0.
M:58B>@9J;H@F+Z<2KK()S %V9S-]%FHY[ML0=TD--4MI0[8?+EC_K0>F+C]=
M\#O- %HNAPW!1MC$TM#?&"5/?.:ADLV9-WPP_>Y^##DSB_&K<+,&AP*U8BC;
MYG7A\V62E?,<S:,#];<MNV3!Q,<4]1MWSYW\[6=K#UXU]V@P'DV/6J>&0%4H
M^\HV$<.CZXB/*%+UIK[L\4ZLC$5N(@?&C;HKC;[KF8(B4&'A3VC?-=" ?ZV7
M/O3YU2C/3)6W;[R[FW[R^?SYP%G Y+G-T;;.RGI]/6WYQ&X^-_H^I/DNUB96
MCU*-][,MO\S3]$W,(<Y==]: R&(?TL\(-,4>CM_L*Y>D#WS#IX^^F+F+;"(^
M$Y$L&XF-]$RV@V9W1&!^G?O6/.Q]V]&[8T:'OM?.X);!/;TG1Q4$@ZLE;^ W
MM/9S83X;A.NYSPNG5YZF^R08G&QL(C!&*I:M<9_*(-!QKF,5U."8?1 B*;Z6
MVFS=:9(;X7M0^W%?MUGFLV_DYC7NU  YAMM%_.D*E><OQA+O;#S=?69V9]%]
M_&:]I8]]TVJ#+%21V5ZJ^/E8593$38%7KS\?/?.AV$2?7RY9.30R![@ Y.@<
M/TWA4/,\Z8**H,0#,+1#MW]P>OXD[+Y-;SUA97+GH_U;W WG#/W9X8E/XOK4
M")<,6XP;:E%"-A-PZ_P,O^9%1WPY($IV6MU]6"?P>-E\720]^GCU/?8QD<%K
M=]H@RK/P=PY8)G=3/,X.<FM';/2]1^B^YDUQS@\C,*[D[:6-T 0O^5CE)UNY
MN5?WW3L;NG^K^MGZ;H&=ZVFZQV??GMWFN7.Y7;S1C1*3>MK.A9C)U'W'C[P&
MZP1)+JE'-]/._391_52;EWR8F._I3,JYU!.>.CYOUJ]\!G[1$$I6%Q0S&JDT
M7-&4_>RDD:EL$VU&[5O#2,J-B%<:K:<FAW$#6)C7J$D.A"*Q*LYEH'Z-NT+G
M3V-2XQ+LSK4;6(#$3Y!^M-"E]\@;FX#8^5/><[7=T$<S^I#S=1Z66L#GJRMW
M!L+7(^&RH+/KD1Z[>K[][7F9<M0QJC%RU''GIYAE)7O70H]BI]QX>!Y4Q-L;
MNU"@N-0<A4\U]1AH^&5Y[!CE-@[LCC#NL*\#5;PN#]T;$I.7'>_>=='QR)\9
MG(AO@-7%DQH7W:6$.OA!T,-\4"&?$$8.E(BL0H<M];UY>6KK.R_6_(JIM*Y7
MD7)*7%_N,^G?%# /GM$&\R);V[&Z-"=U3.P*!R T&/+9KW[4G)W L>B5(/E6
M#Y?>&/JWKX-7=$57=$57=$57=$57=$57=$57=$57=$57=$57=$57=$57=$57
M=$7_M^A\3HS(RM75D9^-S=Z%U<3<P13*:N9@Q^9IXL@&865G P1%/!U-S.Y"
M74&F4$MK>R'P1F,S&&1M+@36XE9@5W"4@%I9RWH[0]6\%=7-O.^:\9F#1831
M!3WY/>T<[:"N)B!/.UM[%WY/(?"E<7[8\P6;#0RZ%'&]*P06N^@ :2LH@R0<
MG*$@;E9.%C-V" 3$P\,*X>+FX8$P@SC8(1QL[+!_/"P0+GYN'GX.7M ?!!9&
MAUT%G<TM^%4EI?^ @[6$P'^,R\/#@]6#D]7!V9(-PL?'=V&&@X,%)L'BXF7O
M:N+)8N]"]=W(#SN24!<S9VM'5VL'>]!%V\34P<U5" Q&!_U"WX',S7[B.+HY
MVUZBF)NQ06VA=E![5Q=8#"%L/XU?V#<WX[=P<+8S<16VMC.QA+)!'5TL!-G^
MP?U=U,P9:N+JX"S\&_*ECVI0I]^Y/SILK86=G2&\O+=XN 79_F#\KL[V9_U+
M#_X,=N&"J[6K+?0O'!"S=?T[!RYBPV]K8F\I!/9D,8=:F+C9NH*%%:S-G!U<
M'"Q<0<H.'E!G90=K>U<0"TC)V1I65R:VH,MXN, X:BQ<('$W%VM[J(L+R 5J
M=I$'5D='5\]_-9[?W;D<SV^>?Y?Z);/_VXS#BO9GRO]RROR6;I@TO\1%7*&2
ML(\P!SL'%PL[A(6=3YV=G1\"JV-.)G9N?DYV0;9_DOPK&P[.Z@X.ML+?Y\L_
M?KM20HT'1*]E;6_NX.'"\(NA/\3_R9*"@[FUA==?>,,-X>?^S9M?)/_9!FP&
MFYNXFORWK/PJ^Y].AN,O\_RW9, Z8,G@_#T9,":_LK.#N9L9U%E8#%:-IB:N
M($EK%U=K6UNH,PC"S@K[^364ORG\'R@D!85_74IV=FQ_I>GB*N7N^J\U7=2]
M'*%LJE 7!S=G,ZB4.VPQHOIK4ZK0OPGA7YN"B5/]<X4K*/!+.IBY7:QX<I+"
M;F[6YORFO.86MZ F4!8.4\@M%BY><Q,6/A[8DLO-R6MAP</+!3&!F%[6Q^^Z
M?[(K9^_B:F)O!H7UP1BLUC#3$N)BW.P<')S<XF)24E(0B!B/U"TQ<3X>B!2?
M^"T.3K$?9G]1_9-965C2'9R]_F?KZF5"'4V<7: 7$1$"_P@)^$\*%SJ72>(W
MN5R]A,T<[-VASJY0<T&VW_A_KPC#,8%ME%!G%V$+9P<[D(FCHZVUF<F%UD59
M@EP=?F.YVYO_D3K''^O"#ZA?+/UI8'^YH/Y'1NQBXOX_&*WUG],L*2G%SBTF
M>8N;[^_2_"?5O[?O806U__-"!8'\6*A^D?I[(Q=[EX>),U3,$E:L_]4J_%<J
M?V_:S JV6T+-A=E^*/Y@_+^4,0FQ_VIB_ML9^\?6<I6Q__2J\A=+R,4J\^LQ
M]?_F@F(.=;;^GQ3H+U[^C!/H_[5!__MS\K_<+*_FY._<?WXQ^KL#PQ\GB1^O
M+__. >@O;/SY@/6]_*4O"OB_5T^"EV>[_^U"_4^J?V79_'\UY#_I_I5IAW\K
MJG]KX\]Y_26L__F7DQ]5_3>O*#^Z__S6^+.+7\+!UL$9]B(&%>829/LK]K]T
M^CM755):&!TVX!]?R?S5#/K/TQ7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(
M%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5
MR!7(%<@5R!7(%<@5R!7(%<@5R!7(?Q@$_1]_Y !J;RX$]@"+")]/ 1( W+])
M%T;^71MPYRT #BI<&#P) AP. (\#AX #=]X.4 !P !PB JS_Y]]R0$%"1D5#
M0$2'@\> "6AC7_SOE?!P" CP"(C(2,B(1'"P!R1D%  5!PT7#Y\20B!&"%8A
MHC)Q0J?F>!"]24PCGEE!PJG:.K!%R\4C8>I>-<=]BU]26LW,V3.ANI;/PL,K
M+J<&9ID<A@F'!/<K-!S\A64$5#1T6+\4#G"!BHB C(0 NR/!O(3YC8!(B03!
M%5/91#9QP@,_B,YL1<&O&)BCXM@B$%=%Y315<R;D<@FHI)8PBR'*:CN?!*Y]
M5\,!1("#K38ZU!2PXQ.#CXN]I[(;,?A(WD3C'P30PB.L;Z4%3QGU) P0E;\T
ML#!#K *_\4)M?YHAL^@>_>13ZZADB_'A2S3" *>/,V,+)AM^5MY4)!_)<R7U
MCIJ5^M9WQCQ>.8/+"2TF$0C[=+A"S8,Q]HNZH@?47#V,$94[<.[TI>%[>^Q0
MX(P-> NMWC:([W7Q#)7QY@V[I_$%<2_!Y]V-3C>CNRF=\J.HTH_#GSPI%#2@
MJ\2%&,M81KF/( &+!I0BD6$RCX2+F"Q8" JWMQ3HBK'+(_(, VVIK*VE(>]I
MJ:\9.6EWY*R[1IS./3GIL!TFT);8^++5QJC?&21>QL0>N#=8@%[MSAP;^_GM
M.-AL)/"QLB1>0H+"5)723=*,N)9G8U"YBO8L)&7)6U*29>NW3BO3CL6+;'36
M(QX18UZG<7U8KY7+.# [C/C^T9<=!J1LTH?.0?4F!F_]2'R7-F^ "Y6K/BRK
M/SZC>E<6=XK>O'.SKG>P.&K?,\HQZE %+NJQYU8^\]-SH":J$(7MP;8R.8YR
MF5XI4^(;J=?6_--WQ1*?*8=(='PHW6L8#LL*)4859X=R4O?V9-^85XW+IW6"
MA '*..0X1FM*K;6/-=OG35E0$75(I72J<TCI<%.\U CDO\GA%5_K?E< Y%O2
M:>,@MBC2[?M'HA8G"$A+T-F:2$0,NRP?>&D'YLVO7BOE7M:T)N8>_-:?:(8<
M&!JCN* I<;R8EC&^'B<K)IY/C<T>+9=V'R5]<Z>-/EG&NQW,VNMB;>#'$=Z?
M%B*6>O/T:^G@Y.>N<\ \7RLQ3E%'C6R?@10U<GU1^ 0<0YT[/_>4/SXQ&DI
MV(%7=X^&>@69F917/@MZ@\_]DV24&"Z^4)>&!KIX4#3.,58 $Y'PQ/9-\[+>
M1!N^KV':N8]>/AWXRKVFM=+C'XS.YB<9Y;-;"!=*@UOR!9O=\V3SB?K Q\GI
M&T?3,T?LQ<7 +,%9;,?Z5@52&0?+(X&=(H@9@6=)E&"SIF#O-6K4(;^BN!9T
M?* %3*WA("6\_%5H>NWK2I:#:KGJJ"Z%/<^)[\MJ7[A4MT*N0N8P,^]C+18=
M/_=/VPS\ZC=$U(Z7P30$B))-GE)U7W%N2<[A!2K^'[EY/?^\<0ZXZJRNG .[
M=TJ,SEI#Y@BTAGNA<FM.GY]&$ZAP,![X(*%+8:I23!F)MFYC9R&)/,"J;>Y&
M2:]%36MD8DRW$B) 3RZD13_8)BXDX,8451$9) N.FU4#;C3=]V)X&;00J%W]
M8O> ZVO?D2R9L$X]DXA F.:10H)1R80+PXJ5[E(\)0G[-$\]D2.U1,W=-V+M
M37&:^F:*Y:"5^>M-ID]SL7$]9@H#7J3?^5H;69IH?$1C!+4J<C41;K 4BJC9
MLT!>L(Q\5ZHUQP?*BGEF&E9PL_ZA\<I:O='@63&.@4LT@<_GJ$ &@8UFJ5M[
M?<*91Y;>PQZ)Q&N(5(6:0&U>\#Z?O'553O;;0)_]P@8,T"I![++]NVXB1 -:
M)X;WSCFG;32\K[\PR#8:Q@@GWM3?(U\5$UB?>?NLJ<\=HR;AWNFKT\<[9I4W
MKTTW38[Q&CPH[$]FC[>81B-^7)%1R)@118*'C@J6'+!5?1I*T$U3.HZE(S*(
MN3ON<:_JLPZ;THL[\DT8##;Q3KQ\ZIDK7NTY@ZYF"JR9B3I58/^@(5Z\<Z"(
MD?411Q0!+G[JP4S6N&6FUG,B=893J14ZE^?YE,[K]SN52#S5[E;(]\GIZ.4Y
ME-T*M3:PB2V@H5)Y4#J24O,@R%A:2B'9#K4!+"4I$ZAW8^_>%[>>@NEG'\L_
M[.2A5S2IOZ +6\4-1CDH'QKU(CYZ@9;3U7*L$2S8MXI*L:DQ]=SD& A"K189
M\]N]UR!1YDH:PI8MH: C8%)E'DTJWV=/P\(3<ET<3^UE6TT5SXMVH5,[Q! *
M.,;3.DI"U7C><-*4HD+T>HX.\-A,D<^&5G>5@[R?/&:+DKM$7;V&'SAVZ![U
M5*G&-^3)9HLI#9H<IA%ZKUN>$X]FDDE9<ACP*YF.&E8%D1*BM%L^JW&8:P\Y
MU:@Z?^PI:G3(]<@5R4]4K#ZB[5"*'%*.ZB[]PF$G093D&^<SBGR,'Y>R92B
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MH5: >6M<?!X.5 >_7]M(T,]]3#VP1T5=;7E01,B;NHIEK:IFMW&/!JJ-QJ/
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MDS:#?4A3[$Y5(ZD2WU!4\]WYIWQ8,R"J(O 95W7RE]*7^B3(ST.MQ:+1!W\
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M4GDBMD$2 W%]VSDU?"CW"8)^7B[NU^TZY#NT)Z<H$:E9=I'_^%&9 !AE> >
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MF9F\HBX[4*D>LV9^):[U&4>QKEHBCIBQTFI>IM1^WW:?6M28;J0R;D\&T-<
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M[;2@8\8Q2T@]_\B"4L+0;B,;UQY3;#L.^#=@9^.W^L@#-^4&FKDUTG)'3=#
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MW:_ED6*?IU.XS:6)^.W)9J37R!,861!#B#Z*;G#N2"N[FB$F'OE:C.2HDBP
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MN C&UV;@  :8E&B<1BG:=T  UM]!GX(S:BJ/_P R-3LI>E8YQWY'DP7[=[?
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M%4>)7%,+B^$;#@HMOK1_>;8=>A1U%I821_!_#3L4& :@EY/ !I31*P  ZD&
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M -/8H"::%'@]@HHO.^)_EK)=3_DQL+?0MPLGV(*(>9@%R5@EDZ9_Y'G;N5F
MC&>N8DX,-S4]"1_L$3P%8MG$#WQ_(J+"HLN15U%V1>TO$Z:6(=6G'R^_2OWA
M0P3'"HM "W2PH$;==GPHD]3X LG>3_\JJ8#%3;X#$$04 %#J;2;1(V1Q"^"[
MI>APG7QM^L5_ -[S%A\!#UA+E-4E6GK6UQH-&42.Q)?DF^0"[9\[!_U89(<W
M .EQXV%WI#1UY2CMR?O72P9;'8+H5&Z)_R9C8HFY<.5PG=:E(7W7IL,&(Y?B
M8F&7T7U$F\!J;7AB1F6)X_:)5Z[0+;>>,1TT+-O*33P(,( I2R)$)7'72R3
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M[S%;/A=:[_RU/JW@E#KLCA$:\JUYL\6_19VF)H?KLW90%Z0 [%2;#$.YO#T
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M(;D*AS=UOF7*(0SRT8>B1M_R-<-O>QTMYZMJO@Q-\-X)IIP%T4=-^3I%C2T
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M7G?#AK6=LZY5/V=,7@0_2BAOZ^_Z4CB7O4)Y-&L4[Z7OCE7?,.6Z9C*GYZ*
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M=A2N.D%N,>-VH)QN=A%8#*1TR-:Q6:<Z&^_#S2]31E&S"Q>D\.AO'Q\F%6/
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M=\[=!T5\T4I.F[8;Z .UV&<K?K0V5?V,VQ'PXW/9[E=(A3H(ZEA4;P>E!Y!
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M%J^&29^RMBN<TMM/NI]-<EQ E.&D.9R#5DOKBCY-6_TZ7H0(FH(P7-A2F2/
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M+,<BB7_,#ZQ*&G+2\+Z_.WWWJ;9H-,[;D"DN>GC4*-TXF7O8>"A>8AZL+R_
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M[K]F>_[0A/L'T%HLOR0@"D[X].B74)YC]4<&G53$O_27Y+@40NE^F,'':8&
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MJ2UO<]]#0Z$@XJ'%-3A;8N^;/+I/0VU^[&&?KI   [J>U)H_F$WI4+"$ZL,
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M3=!O9RGJO*K;5\"7GN.<''.29*!T.OIS^BR?N+I\B!K/[6J+7,*PT:G([U3
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M% !(9W3*3"=ITS(14JY=J#3][(6>[H.G/FK[30:36@/;"$<F%0S# 9@$N"1
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MJEL$!P(I?A7'.EDZ1"YN)7=/G+]'9!>WW[&]EW=Y$XTLCX*X/;35ED_V9,"
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M?]B2;;/-[-N'4<N)!%^BC#BISN)>693Z("B/DG0;"7'4I_3-FT@02+)9D&V
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M1J7:EJN4QAPUAVN_D:UBPYV>JIKNZJ.<(Z_SHYNU'$X6?DZ%4UU89MDU5@4
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M3\'9#E.>T440SUX46N>2 S6]MU6GP6?49;QM3_>X;SH3;\)KO,WD$> 9;B_
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MC*QABIM%0C/F;&*H;0OPA=4,>;CBXMSL9;<ZS+*)61S9 GX^+FC+7MOM"V/
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M T9Z__O[I%1!3:>1@CA1B'&C+[-D.K=3LD(@?W +88*<H55&BN2S/!Q.]P-
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M#Q/:#9CZIZ^DJJ/J@&PY"XIM$O)KF;P8=0>F:^Q1-I[(YI0XN^4#N%KHT@Z
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MKB\Y2EP7'N3QKQK\'8E##F7DY_F7GDDR51 IBNL?H-*G3"1.!S18GM(&EN#
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M1F55(/QYGWI$E'3"\,I.62DYO"7[$OJI;4(2EQT:M_4YG5)>M+W<R9YR7>P
MM)JK$F%I$@$<X)YD'X:72&HS9CA._,Z;F<[^T1.6A8X5'RW8X0-Q?0.>E;/<
M!4@3 !Z-$&[.Q@A4]ND_#C(QS4,P\K1+9#U>%*14*XU0[IC[)MML.6GBSGC%
M$,3$O@JEGMK*&.8;&J>1TH_3I:OJ[XEB3*6'*7\L,_B%>_?\_19 =NV\ @=
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MF_>1!C6:&+AWYVN-)"]U+:KG4!)@'RW0+>8)LG3EYUF%YG8"):_8?AQD(B+
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M'\[]LKNJJW=7U]ZU?L^SNJMZW=R9T0N,TG H]W#V]A>0FTP90W^&OQ>]!]^
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MKR9]9K8 CT]3!?] RDGLB*M2=;J,=3V7YKF"L(PWT"!#= D[3Y-UZ-*ZJ*>
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M%(7N?!/NIJ5M+^L*7D"K$&?UJR);62S>3S,VSG[2)>AFZNH6%(>/\=3!$"U
M)K-WP"X?^&]AD=O0NN ]\0U-KHP5?I:[D:5VYU5+OF*//*L ;(ERLL+9S!R\
MU"V:M/D" ;#U6V,<&-R/3T^\B=5EK.4>ZSJ%.D,F+1U?2TX0F?DF =.\Z<G<
M7PYEEE3FYJH'2644'&41%2JHC#$F\X09/F?8;9U5UJG9VLK=OG],HFP&+97
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M!:H?9>!J^+R;/&"6"=5+%UIXAG&I=E5YMYB)DVO69(NHE2DH"LU)Z-#CF>Q
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MB7J](?C+3V#?#N0A]D#D\X'*0_8% #[\%0F>XT_^/_<*,/#>0K\!3Q'NF-^
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M+ZR9W"BX!(UJ\W)N'LV;TR7^APAL[IL2=P(-6KSN2I&W;Y3P86,<%14&5C+
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MMDG$J>KZ*/ZCNH81Q,3>P<4M,BHFKK2\?P&.0GJ.C_:K%\ /&/0K&/!^=6P
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M9#0)RQRE&\TGQ. "7S]Y-,"Z]C1*Q'NWSI'*@K'!N4SR3DJM72)=_!)H%*H
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MY>? ;A=%F102I2?$Z'7%78T/3']$C]7)D)=#81Z>S=.-@D"*;4'FN)NZHN!
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M?/#9%SM# 1(1"G=I5%HOB%$]BGUIS+\J9I8K@QSN YN=@D)*;304N6.8AN!
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M@#GO/PS38ZTM[O?TAS%SKH'> >/Q3Q1F<'FN*).&L,D>)[&K5;KF::906Y]
M@RAW;_1C"Z_H/:T[Y15<8DK%I,FO0$>4AI&T<U3,ZT\AURA7<Y:0M6&#6J7L
M?!=^I\.75ISR-^M< 6;I5'KMCQFNS[K59YT3T_US- VK^6%FI<[MJ[B]"(7&
M3P(<AE$G3 ZK[5\4JQ8K-WO:6_21>(Y'CB5UNBV:3$9 H<W P*5)RE?APJP!
M?RZ>%1_<XI#H:6?I->[NAL;-WTUS-\OF!"$;/0Z=]@4/MU8+=)O-:H^67'/E
M5O_F^LR7ZF4;*MA/8U8LY?Z]IIQ[+LUXN?1Z_T/JC%],>C7AA-YT\/VEDK^_
M"5MT*?+Y4R XM,)TV^N:X.C:Q+'?PI_B5(V*IRX)""%]V\N]V311X_9:V[RF
M$/E!#U=1T#TB.U8XH95D(X*5"/0C+5"@T.T,&2EL+; @\5TK-::T\EU9]W?D
MSWH#%DZ]Q35PU62E]?%#9,4IJ1;C#K<)59OU"S/F#-#M=*QK<A>+2SVYP1=V
MI=\ECX^TGV=*S%"^EQW*^8M*^['\Y-L"*]TLR*)&TUT6DJ8E*&=;H84R^K,@
MJXXA5SIGJ^3=] Z]PYNT&8XSU;,2]K*8@S?/ LD-UL)(S/\?JLN%YJ]0_NX-
M76UC PR4?KZ2;C6S-VCL$22/?;O,KZUE%0W^76A\)2[F<A_YWLV@V_\ Q9WW
M_HQ4LU2IEJ?&@B<7NB=;O'H#I+C56CQ+T_"BB=7BO,IQ:6VGJ373$N^5.=Y$
M$0GPAA<53*XR(UM-UP(L/PK;DM;OGM'2A#O1WQR/I_WQ&/#S+T*).#;:7-NO
MG5_GMP=5UI];"M9PZ,0W;)-%#WFD!,389+SUX DC&#5.[60]\^A694W:'[\X
M2:ME'1HRAH91587F94Z5[\#:HRG)G)[$KIH)4":DVD+8YE2>I3IJ>I;&AWG#
M%%-6G8DKR^$NY@9WYR^)T^(5NES*ZY]2/)F-:-CJ$*1;'M.;^CVSW->%B-NZ
MAJGS-\Z^/@=6@K#>,".(6Q [6G,N&UN";VHIJ0+2(Z=NJFB_U01C+-BAEM47
MO'DXCJ,X_1=0M@G=',U,G8'N*X3-2WR?.[%#>E"\.3;%.U,?M<Y>9-$-=[RK
M4W/TA#44XCZ0K,'U[YB?AW"K$NNF##ZKLI4\/$2TH=9/EVH&$(%A[]32D^,:
MC;V36H-#]F_R-'$^X*R?2$X^U5%#=&&*:83"3^&$MRI+OWY%*!/)Y.-<),)^
MF"2:.*SU!(7,+%PIK9ZBYOPEG5VI3="UXP:/SLC<%Q%&"$OWZ1P6BRXPI;Q3
MEUI>IX'ONP-JF>E=QE6SJCGW(+5 X5NCN+D1);57B_BCW,J]A,9W2']^Z=<9
MP2)(YCS_=_.(RXN*9.$Z.(B-L *D]O%(%\<TCT*HK R7;R!F9$*QMAS9;>,_
MX.3DHN=,1EO;J&/U_$4GKS5 JBM;Q6N1.E!OQK>\=E/U>FM;- 1N;2,9<NO(
M'1AH-5-3URPI'JXF%,KP.AC\STI]'_FC3\K]JGK5ND-H?;"$_._'^YG]N%\^
M*YS$E7[(@*]]7V>)DW]U?6NZG7YZIYIB0-)K!)&= O1']3FZU>=QNG&@ I]
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M$$LAV)2@LXDQW%8"S\/NSKG%UBPK/EBZ_)OS J Q(/\#^Q-5'567@LZHI:*
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MD;.4^)X7F5J#>4,; ([EBL3@>: ^=X\A5[VGD?E2&Q^>Z;K4*^EH*8(ZHT4
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MZ#0XJS!PS8QAJ?/MUJF[AH*%<30STO+VB?&Q]3KG-X<-P*,H#=-D#JV9FC8
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MF0;@56O$F-&AQ%Z31P&/GE?E\.MT.GVEJA0*]JIY<H($G+]*Y.E]'SP]F!7
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M#'\SH SFZ%6-E*;)UITD"VV\<^ZE&0KT;)54]M7>L:Q6MF#O+!/'"79*<;6
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M?$.TFR.#J93Y1%7FG Z"B4Q*1:TM,ZKCG"!V-AK$)>?V)RY]Q=]!1$@^S3T
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M!-)NTG/ZC7Z1HEMSG\O3O4AW8,';^U<">4;%R[?\&Z>&T@S-]?!:TXD3=;7
MHG"[\.=I#DO-X*>HX"FXYX+(2R4_TK%/1FJ@7LM1<*TJ:!6TX.#^PUD?49&#
M;;EY]M*N7Z'&IJ&4L.SE\$D^.75#%TUD(JX9<%3@S[)]]/_R44I&-3TZ+L_B
M@--&(*[5H1D9<'B4PQ<TNF2Y)\.'1DI7C8(S ?6NI3QZ1YY9\ 56+6)@M9?
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MD9QY(KJVM9514'T%Q]<L :(>8&3*9>VB9;/@;<0_J/R!'+9RUV0]<"!A#=)
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M9/\Z]#2M$+@:\*/-Z(MRLE1SX1DA*;S.A_]E^.'G]]EU=8X(%>(UQ:9=P72
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M-XF5I:3 ^0L5'F6'T<JZ; YHIN&2\'F+O-42_7%.G&M&2Q7^UUL!<C:S@J_
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MHPL$><SL_ $:# DF5&KA+UK?TVG[U8:W34BW!D>#3[DC(D"".T\24WC R]"
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M];\X><N@.(.N6W20X.[N$B2XN[N[NPV#!K<$@D-PU^#N[A#<G0$&)S@,;H%
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MU_@$U"]S#[Z?PZV5GB"(6'N9N$9(&-ZDD3V_#'(B?466:";!D$H'UBE/HK^
M!V[TU_69J*Y]A$T1']9/9YN*',)*/\9+!%WS"W=,&A .M.#[WS%? >+L5S>_
M$9__>-S=&R-*H3T_<*G  =#],'E/)*X%OP6.-A\@__X#V]_+;HEJ!WZ=::_0
MT.4GB4.M>UBET?FN$3YT4EM6GNS8*!YP\A=@0!)76QVF1D/O0U(X(($&SWX*
M]XB[A_DL_^BP2ZV58>LU'#?\W'8>./?.'Z3[J.Y.1?G*M3V,<+%&I3)QYT-A
MEK/-T,^E_*F;14Z=6C;OID'\3/ (DP:3JQU_SN*3X/\XF6;P8N>JN-:\4:=;
M(DEK7^"0EA7C-=FUM_2HH H^7O]$SD[0W-&N8F/,\) 2GB@T;<;KF:7&(.NY
M#)N+5"N<8=Z$CHB>?&[;EPFVQ\DHXITN<7 <GVZS.?L^R=DC[/B[9%V1+Y\&
M6:[%99FLE#GG#I]*<"M+FNR(9F1VZD7?D[:#+R9HKC'O:_S"Q3VS,NM1*5OM
M+_6:>FSE>/\SV5QD9)6N50WO+<1ZLHX//TI.]^(K0C:)2E1*J7'/Y^Z$WB6U
MN-45,=5%O@JM? Z\JVN\%KS<>*5\LP>OS'MEM3TF%:ID#VGAFQFP)S=IAF)R
M6/JK_S0;?5OOH?L+N$QDTH*5($4R=._TNB*[*+-EBH?>.VR\>[#M$Y]7W<=F
M,2#(R773@,T0]-BL\"]L+EA[1'(8YJQ+"P_6QEM,V3^SQ2 ($,7"MES)B"N_
MY<BVG1NY&I!N>((VCFZ]7ZVA("]71K&W:H*%VCQQ(JA@CD=%+$(<I/Q"(IQ9
M$0]0(":CB%-V.?8P6FQ\_[CFO_$=_!6V$MSUV[GJF)?'AKZT[R<*U._7RQ^I
MS]RN!V5F"5M<+B$F"@HBON7=D[',KB$A.$@D"C3^"M&KLJ+\C[K E6.E8F9,
M(5?06$=Z--EJ:H^47_7)2>1X;E%*6ZT^550P$4H3/0=,[ $\&JP'WH %S#^[
MIA(Y:#W-YL<']DF6ZQ6CG<CI^_HBGV-Y;07!#UU66A%YE1[B4"I=@K?/<L*(
M\8&\^UY"WSYW2\%D81>M4=CS>O5#-"8;NAPA=ME53.PTF_$?PME"R"I>%2T6
MG2VR9ZAH8X_/>",E3-;M 1%*%)_&4FK2K=$'V=CS<O\"F+<EO/3137B2%,NX
M3SENMGX@&6&2!L@,"FCEU$*.]HE^6O*XO;!C*V1-:=U6>WBCP<,ECN@G=( 3
MCCY][[MO5E/F3F]<NS\U5G<F26N-"*W$W);6:MY L^^=,@J2BU@_+=Z8/WH[
M&S FR. I31_"@^JSE\1T>ZM"7):O7Y7TYEJ=J==UX,5D>@^<CH48) $A@C(2
M6"J_DY_B!>)?2=O&JLV%H7JZ<<9*:.F&\];1<U)Y'8(?A&H8\K1VS])( B[=
M82Q:7")Z\TET:R.(_=,N2S]1:RP 7<?^ DR8^15D89 =6F6VQ0YCCN /+ Y2
MV#>F?O8FI#A9TYWT\9"^&J7K8Q9JX,Q[: <"-<.2R6AGR1"&L;S3SN/Q]X75
MF'Y";Y0-0+G"PMU6 8^KSI331=>?N\2K<HHH!E>19^!P>8$RWV7_$/4_3L,<
MP-W>_9%__OT.<_/N.Y:4X_=C:JK@YBZME8.(T0J1NT!\B?LRK_]#\YS42W5A
MN;>]JB:](J7]"A60$S43#5E8+53'Y4Q11R80[T!.;7,O,[> ^L&XZD>/2E:,
M6ESPHA<K6[#W ^I9]#;%B>M? (M<SY,9_V/C5Z77N!NQ\2/G-&$0(KGX<GMY
M=D&B2OIRU5%^>(E$>)^9'2'_?STF/^Y>E2N#(F-4 X<E1F-MQ0N./ZN%B-.[
M/$Y@XUJ'J4H'^S&1?YF8*E-W"_E@59;U-7 7[MN^D%IUA Z5NJU>FCSHC>OH
MWQ(YZ&Y-C=>V'H3%> J5BIO>^D8O%R(5H-*&;J/G?9:RNS",/##$I:!RIF29
MX+5MY5VQS.#7X*_]M_\(T_C7RV-QE^.DES-:]U77G_Z'0P/#!#\$0['XL.1%
MK>NR7,Y.^49J_>LE(^FKM>8/-[3OA,J7<9+-)G]S5[#;X%$A9^N#ON-XB=LE
M<< Z%1&QT7RMJ?[,E#KD]./KYTG51/!35;_:+]+*?,-<>!X/NL]IY>X_<#?<
M\M'=H\"3KY$SJ*A6%INF(F3?Z"@F,[/3\AE92$D[2^U3^I7YTE0><:RI%P]9
M\E(=1PS)$=XL1,)F2#\WB^DJ(J=Z"@&W4;"G=0*[IJMN'RSC<BNERWY^8YYH
M<& EW+[D>#6.02]XL>#+D0:*-D*T0P"M8]K[9,HF7MY=]8Q[(N[#OF*?S D+
M U]6ZEFRGQZ?X/L@UQW)QEJIP=-%Q(KW36(I<$:#1%QYKF;0=*69;&FV->!<
MTXR=8.?F)_U4 PH90]J)77&'YBDI.B6V8Q,3--T/=@BLN1:Y1K/R\B*J,M+R
MPPW5.;#*D4")3%L[)_A,?'@?RG$[0<4H[ZEE$=*Q-7Z"1;Q3\0O?9N+L/F)#
M*'LP]5RK7T++ FE':]8:FFB<T=O6$0P1\$$3LZI#OI=6)_IUS'2QHB)4!Y<J
M(.Q,P&2B)$L)@3/^<VHI1Q0B)[AER^QV.Q/!4:]D'N':C$$DFX[HYDAO/6%[
M<<@-S>BQ.A0(L<Q8B7=8F2G4;@;FNU88#:S#=QQBG9C-=.TI>.0\/&'/[20.
M!ZA.-+\,'<R*_<(^$#7BC!T.VY91O7"+"<.^%0O\$GAV/I B]+#ZZZ"JDX V
M???W$ED.0V5;^7%CG9/:&AC2GY[HLC72Y*(V9J%1SV ^/D%D4U9FLU.A2Y$;
ME;>0[*1CG$2G33,2I[UX7/AJ]BGYX9?: $W-VA'>NY0V8QGZE$*47/:[)O^I
M@H U)YQ[;$,W=^K!#M9A:OH7"9;0$!0-V!"%6A7"1<RE^AI]?0@%^2J?)R@L
M36E*+HA-E=:B(6A$;WO FM6=P=)QGI$619&!@>#(4TXV< U>;6;*Z^O7,,,$
MHP'.LWAJ0O ),YV4@*?8%V)KLL.;?%5)A"_8""&\IFLS0HE?:2E*)&=_6B;Z
MGDZ.Y^[H>N0&_:$9B+TJ$B\C*,"CW-ANY&_*89NSNLV&3?#*FX_5XZXP)!8T
MR$[UAWJ"S[^K>)SZG+4H3L;FX:VH-NH@U!K1A!  'WY4=;"K<\LTOG?,I\QR
MI]K3.T6#%QJ,:DI8I]<*@/(_HDW*6;EIGZ2VL/$09(QI+]Y_X@6/PF';L/_W
MKY%GUV#*2\HG-^^//=!! SACJ(^7#X?^9='F.=:;7U'G4\ "B:L)J'+UZ&?A
MI#6#C=Y:C7_EBB!2UO<B>DE-00A,Z%[_E?BOXMA7]=U9V$(34A?,O<C]5<^#
M1$XUABXZ>T"Z76G$7IM+>?- I[=W1+K XP\[L%0ZL4^@O/_E<1,P2C2MV5H:
M-W6EXBV^SFX>ANL@-53!81T92+_D3(XWLIGRA)*)E.+MI*&Y5)HFV .CK8@7
M7SA-NUOZ,>KYYD#,80],*%#[ED[H$*!<(W<)&05G MV]9@[]O>])2.:/!;);
MC>",Z/(02CWM=?"RS^(YP+RS[B?S:/G9R#MJ7:PU]WF5G<$G?:).J2YZ=Z])
M=>3Q/ZZU0F:?_#MF@#5116'4*!U-P8U2HR4-J64$WXUQ(0 )P)N#FSZF\74&
MXG4[*J2=OA_C^A+]FY93I#1'C]CV-,XN@KUP(YM'?^5P]V?]]'H7<A\_+\^K
M7G=WH^8R.T<=C]9D+T!(/WWCMM/DRO^8,/[W1+@G,UZ)D1T.EWC(B28=F'K(
M@:RB#?B#K**)$X7TSX+_8"+U'"(6JUZ_I<T3C^[0>M25=>>(#J(HP7AN JDI
M+4R!Q$X0F.H23')#5\"S6=DVY+D^G(A?,TINM.HW(1O)WKE%N@_AZ&.%QQU"
MA@9GX@HLZJ9,YVZP<#:L#QV1*<T8Y"N692Z[?"0KN5KH25\S<72RJ9?29$V'
ML28P0MN#XBR\==:'-[PPSCHGSR6R9D6LT:[EH3F^I6=6'=G4V^V'LV+SL)%M
M:HY@4'R)BU;-@4UI"2O&=%8?]/XNG++*ZE5T(-N6FFNOL("W%AWDB0X (,R3
M\)!Z+GA4I3'K5;RTFKVT.@ITE2K%>YR)'BEZ;.^;'),KTB5[L="'#CQ3WKQ?
M7;U_+8BD*3$R?1 ]M\EEQA0.3Y-C[6GUIVYQ>=..E1DS.OPA_]66,L!AA>:W
MV5)V6>6J;P7>E*)6/XZ#I=""^S":'GLDZJL5":"CE+W@UZK4$6X')IS"O#B3
MD,K5^YS :#VR-:N7?<<>X:PMFM+W3)!BC+X3#@FSL4ADUY<WBH64'#H'(<6'
M9K,VG3NG.@'PU%$*'80@@VAZL N#P%]#\(B2+8J(>-72D.AVZ;.CKV2JM9<N
MY_ 1M;SLD-O9ZJI5-"ASTI72P1WQMS.0>F89XS?M1\22O-6*Y_[8ZW?" ?.8
MQY8J<%>)<;B6]=I5V^:RS4+%FF=7*(FL42LI%1= ,'=S>["K>+7K+T#?3>6)
M,-CX:K0:A_%'CI!%]J.R9U5Y<LN:"9XX/7V92?=G*:1,39>/_$^9V##'JB"C
MT=;OQ 8#) ME<0XA[<%WPGGZ49=L+*:;^ET=?M5F^]7G>A50DY=6,K,GW.G.
MX7SCBR:6%&:F?W#2R-\MZF"]0=&UP\7=(<<W>MH=0! DU"BA"%.H%\_EI4@O
M QA#8$Q4H2T=EWBJQ7B1Q$GHE, JUTMAT:Y4*DC7L<Z\F6,)01#"YL*D@<'2
MW0J'CI(& :.,^NEGTF9(JS!/M6(AC^-)5$EI@S(MB9XLX^3^J^RY2NMG$)8/
MI^#-,RDIG"<XEDO%9?@2\0XZ7..Y$-WL$L9M.3$5M&TE4;M9"+E,.E4"=_?0
M)>O5ASKY979?/#+$E\+9R?$S[^F%EL'''4SW+[@)U[_'LMS5PDG]V;XP3,8#
MOU#JQ<*=MS7025L(WN>UROT$,G*8?7_C%FKF1"=06[G@=#%V@,##&-JV"NJ$
M5=OZF425W6#K-I4^\729Q\A]!H?WP%Y8:T;5!]-]HH3=>"2,;,=L<Q9%MW\Z
M[\.H%U^DRS_G^Q>YESTY8R*F[B-K,\I%)M-":WWQA$Z*,=YWM?K\ED:[(5J%
MI+ 0#S3<]D9,*BKQQ#^87,K*!DL0E1]U_MMV[XA-R,MK.L85^MB/&V3G**$O
M@1.AI\TY-9M;75:]WL#.:4J7T^+A]X: '$'%*5M=EY(ZD-GB*H]@'=91(A)M
M)M6)O*F(KA+ON=%*N8>K7BG*O1DDM7K1KUPK3R[+.DNSA*"#O!6WGLG(;.J-
MX?+XXMW2-F6Q*@=1"Z3EY/41U.Q'@ *YQ&!)R!E?<GC\^#R@A6'9>;ADRT+O
M'&8H,%%146I434IQ<]SPG!.(LPB^W]9,'S)-3KA?JMB7K!AS05"%4ZNE&XH*
M%F+@A J3CPG8]HA^@>@R"[72>D3S=*;508%H]R=ZI;4B;PUE3WJ@2 >F-@/R
MK+E[)XUK (6(+P 3YC=B\,VO/X*9)EM!_[&Y$K8K9)@/.PH4(!HNE4S*-NO"
M7SY@C574R<*A;JOE\*-G!([MP7N"V^E'QP=]U+(L^4T+F- "6,5@F&1O6%[&
M"?YUAQ]5.M$QE&9-:\8?\Y1C7YZ@>5"/J#Q](82(M\.7VT/KW(+"9:,5FW2.
M+'.H3-].!8TKC7CZ7P!$/]X42KE1WM+'ZOQE<?$NVM7);57-\@_CAT\_&RZ:
M FJ]:N/X(X)IQ9HNAE^4(R]&R4,M'T,:CHPY5SS@<EJK>1W51J6K!'LM8#A1
M-BZK)UI>%LKUF:>8TX;4[)%CM<,_(,46M#H3* 3V8<U@N.&$II(;39YBPAS@
M213_!D0YF3<A(K9__PMPN++UU34*JJTMQVJ.8H?'67 >\F2QEA=!M,6HME7,
M>P9ZA"KB,D?B;0<E1-X(U0J:G=O/6R8C!"0< 'A_O ZJ@ KGPT^JQ<MECEN4
M=%&0NYPM@;Q"ATK433+,P$)BDRA[C!&\)<9O##*09H5P:@"*!B:  B#XXFKF
M>:O_]7]4T/+_FF)X5]I,<E J:P/66V+4C%5<3A&4C=C;#&):J"FZL!&F!^5L
M-^2.O7>57(O6N?-L 9&<"O34P\A+PP-W1O</,BL;)F_,W3XE7L>2,<V-/M%S
M=8,W.>O$*MQ:=3Y.QF;DPP94Y (*,85J(L_D0_HRIN579!@QT;]1".4JVCIX
MQ%?Q6$B$U.]D^4G\/:Y&<\'*",ZQ-]_I,PO=ALBCU_AQ6 7-'^%\%,QL?.Z[
M+][*M,?K,3P)_IU,>(3PL#7Z&W2$UGN"FAUN1+I:51X:.U49R$39=%A\\Z 0
M#@..URNMH4*T3=!$KV-!)IHYTUX@:#A3]J[..&K3]*B2GZ^]U5&_T'2)'0C:
M_J4Z/([/9!L@%]Q9;#[O0_D^)38<5.S62H9T[8(YU.I@N7RZ&R@Y^!R4CA^[
M5Z#%L ZM!RE^'_YHYQND;/RXJ5%+]T0AJWD1NFB_XBO\/70:\:LKHB8TC@)P
M)_\'[]O@CW8M@YJMG#B,J)FI\/2XM'C#(1E7O*&Z0P-"EXW^[Z;3I,LC&26^
MH&@G@>P!,\/<-&#B5+<\<:6SSC<)8<)%7_C%:H (+!(HQ.$Y%CJT]I7P%67_
MI8=[>'ED)FW.V6MH4])9%=HPY@;6&6?1PDAQ]9'F9MHQ6/:HVM!UHUYQ6"XU
M*KO<Y'>YZ9HQI4I)G]741$1?58DIZD+%TM;%U](HHXFNR/HNBRLH4_XQ6@46
MEGHFVCTMDAQTHF_B7P[L-?V<G3P#)<SB/Z_\Q'=MFZM;/6>6+9'J:+ZBR*4/
MO-@BFRPDF@ZN&D3"ORNW<9BN4( X6?I9DPP^V?N!I)4W/=G< 7;N<%HVU=E/
M&3XJ[>4>'F9[Z:GAJ'9Z52]Q[47(;J4RHL/:%G2YM2'T=JZ,>A/_.S!C4=N_
M?/,J;_1/@[-<.*5W]RE4EAW_^/+)+1[DFQ!N,$<#\B?%6Q .,$'S3*1Z*[8?
M>0U3VX&B'%^OLA,+)"V?=DX'9*X*93'DQ$JRLF'M+WK3.2ALF2ST=!7*[6^'
MSSCJL*U!?'2 RP%,F]J@YM:T3"1GN=:WHTA8N%:2FCEJ%*G44B8EK?]R (!6
MJ@A> >"?P>S^<W"[ $&A-J/?#\0/<'-!XHTE=2GN1]UG&3YJU09E\A1O#%JK
MYY^=PP>GA#];:,RWG"U9X^C]LM7\H!4;#Y_3KCI=$P9BY!-(I[</6]?O[Z^!
M$( OII_R3!07:JSI")<#"FNL53KR)7#:\E%V^^@>PX>?U1&OTTF-\<?<JQ.:
M(<9:6*.\M>SU7AXZ3Y\NH ZM#Y<NS%B3.IG'."IP>^W^*]X46V9;9V]5W0(K
MG]0(#1T<JW]TJ'^<)6:E098XQB-$[8B,L5F@Q>]J=DWZ:I\CJ':KIVFK^R)S
M9XX3(#G:.!6YU%JOCS:4^5SN"M)</EN&I5[%S]KQB#^,^U2N<HHQE?LV_$CZ
M2A+ \6@886ARPX8;Z;Y#NE(PMB\PRFLO]X36U.%A<I:^1D'H.=GV>/]QSH;M
MO*D6^M.ZJJL40?=55%QM9V$N*RGB-/\2;*?0N!Y$V+QZ,DE,EP_G8%0#YT_A
M(>AL351<BC++W#:[Q23V3%ID0\0=>&8PH!.F>[/MR]R[M8JZ^T2X8FZT7]L<
M7:V3H5/QTZ@:*'CESA;0S=!@YT[7@NY7G]3?BH$[Y$O8W@\TD$=>6[?,I(_@
M5XKKHXS4LB4E54Z)-!3'+G262\2KT+*C>2U[Q(- /$W(5>- 1H"M-NUUL][+
M^AKWS+;U=,=%7D0 >'Y(K%</6K>KQ]D;ALQWG<Q.X)@U]QI=5XGR+1(.*P9Y
MDAZ]U$WP-U-W.-Y_N!T=$U; ]C?3+.SG.;;?]?-*=SQRCW3QXO:DCSW'U-J<
MI<\RUBI0&5LN]MZ"YC\F%A6H,ZP=4V_2B?SJ;\$D;U\O;TQPV+2'H/@0R:-9
MH0]MT;XO#QMP]+#!O Z;;QMWT9'SPRI-67C+8XW4?/I:5CJ$KLKXV_.H5OU=
MCC)SR8N0$4HM4?"!6OI-"P\>4(KY+15N; " &(P) %# #7C<=FNN,(NN4)@\
M]63T7J[,!42SN8M,N#/X".>MEM#7 ARH9- EXF@W"XW1*!]2-C!B;7ZH7Q(+
M;)3["--0??U LF/^L0E,]$!&?<%IPL>68CVKC?.1'I;-AH J)CI1\/[NR<PM
M\D;<D<Q]%+\R13G\62V>TN6)8Z!O7_A/0>.P[?0&*S,T 9>Z-6>\S@]*<,5
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MBW-J.JV[+HC6".>_I1=[OH0X)^ O@$)*7O-&]FD<\X!*1$$8*^@D-^9_IM_
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MC T<*WW9W4"42'2W.O1P+6NC\P AUPX/"832+?<-4QU!10SV>LUK]?N(. !
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MYK'^J^A"B0G[:##ZLNSWBXJR_,HU;26K<8^Q5;DM+K^C.Q6D=0.GQE-IKU'
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M^WM+^>?P!?"7=/]=9"3K:5Z$_Y(@[?9VV1,NAO"Z\:Q6"96"C#3Y1]9$X2\
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MV,_L"N'J>%7>%5':'RHM%X%R$%U]S02W*!\5T=J?ZDQ!+5ZRDX/AZ<%NL>Z
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M=+$PL;AHK+!\Z0+71I\Q>5JXMFB/2?X%Z:<MZF^IU(\<?+&45_IV \KXJ(/
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M:W6A>W*N!QP][J5N1[%@_^^*L4E)-NO9KWZS)<2I<:/I,(YV*-W4FSRG<<7
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M!N]>K;](0?"+V\D:\WZ%2]%6.)0S_Z0T3=76-^(K,3@PHW"-W ['Q\KT2EP
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M%&]IWC^#QM>& MWJNX<,GR7\B.5LY0^.OUJ0K:MJ7."Q;FZJJQ]>N,9H@8"
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M(\=?HGQW3F6%$(.,/=2I.&;2*7IN=<BL=K9U=S9WEKI>:);WR?:.JQ3KQNT
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M)8M_65DV':_F]#&J<Y+B.1>4*F^U;XV"Q1K[PF9=XI>?3Y45AC["HSZV:&?
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M&XK&@A>]4P<0_2$1^(CX6/;(U_$QZXE_E)]!:V2>;B^1)JJ%S,3L'HSRR(>
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M3_-#\2N5F,92R.IZ">6"BL9.3GL"'5!)95K3TN;$Z'?-(%3[QJM\]65F:*I
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M#*0$$'(>3N,N,2B/-S. IMWD@JJH>J$)^Z *BT6WJ-;&.'8:TN',G<0.6<F
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ML;HD4>!NR@0].YP4[RD3)0%"]G?7$YE93/V?0SH6%B52/5ZE&AU<@+MM+8P
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MZ^;+T^[769#T_<U;^$[ P-,G(#P/4[#O;>#9\_GI;>0UY .FGV7E_R,ZLC?
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M<[8D8/_SX+,5O;WQH&>]H  N0++\H/B$P05_4#@[L9U<-9[$@ZT12%I<HGE
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M$LR\)S[UF]M?R]%'M)]6A- WV &ORO'6OHT#<LD83=>7IR^1OFZ0(%;BMQR
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MM ;D4#"*[:U_' D],$U'>+<6Q%]%M&DS/FSK!QO4CGDA\#4PT=#)V91)]8[
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M:[I&SGUR/;HM<W0%D HOIG(H;S3A2U4;9&[;?_%<_!_@@P89$!X. ,"'AP<
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M@_QR16[F#QOU)H97&/X4]MMHY0JXRD\'[3K!.SO_,I7)2Z\YK-]I6A(Y;!]
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M%]TM7\T1T;!/;Q,U1T>"X>HYX,,/B/&<VB>[,8V2:FLV2=@3U4\$[1)T:RB
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M94X\#.YFYLZZ)RK4#4<?H%PJEJV]%-IU.4//\"KN19N\I;&M-+/'J@TB^3F
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M,)W0N-$ F(475P#@5]Y^I]]X&G_H_J/ 3_JM+6(NZ[0U BXZ+0!@Q7R@LZ3
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M0.*H =Z"<)FYQLKJKTP=>/0N,T4+TF$I$98J9RHH=VX9?WM?H^QZ;QGJ/&+
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M"6CFO4QFL&=#PWUG_XQ[!LW.OAY]P;A%<UE4\,.0#,>>JA*3.E<?/4V)B9E
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MI_KM;0_07FWA\3J_:V&4?'JWL&GP>4-,\[QJ(BGC0PWGW9-V_^X@0Q?0X='
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M:GXX 3:'68LEN-.*@)1%[4O>%?OU8[\"Q%V]\94-SVS9C<DT/X&JRDRIW(@
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M&9B7@2$KMR:ZMK6A*C+@4D-Q%/+8%:E,J[9$L/Z]E?O' HO'@$=H[R\)PQ!
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M^9>CSQJZ U*X$5:5Z@8OQM,ZNY2>Q6JGL;TOO3FU]2L9<)I9=0H:R/J?/3L
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M,M&:<\-+'+;EZTCIV1:G%\3VH:^C+53-+M"-2.@TT0A3K4:?G<UK M$L*OB
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M>0A=UN'-)8_150G"#Y^G5\A!S!"3%Q2FQV^K@O?[W\M%Y++Y_$.>A"MLUW^
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M*SM$THPI()V&IU\X]Q\5T\0.W0:)6^@J@I?%">76X:G]7I] $UM9FG,%5X2
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MDAKV94CR&>,L;D@RW(I6^>S]*SB<.-:K"[WH.NN=8,>5.B)RH\=4^ANJ5R/
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M+Q&:@AH?535'1_LX"\+8^Y[&GJ9ON'0B>TF^<W.*BS SH3?56WT?S%_#NL+
M\69*8"N9J%2T[QM^*KO*-?EL)R=GK&N/^/*TFXL->[QQD9-\O8>@!8V<EZIJ
M#8</6ZZQJUE+J6'[1[Z#M@'5]!$#L":;EGG1E^<0R[#S7C!CEIE+=N)O@0_#
M#PH^23GHG<JYU3%9OT$=" *&A5C9GD:K^L1_W;XY<O^D2OIQ-3 !=_-!ZN4?
M9"%[J+QNXCF+;(_FI00,#AT(?:QG+[]B+V*JGS*B".0VTL^R%<XL&X"[3W]F
MRRSTQ@)R58R4Y]8T*/3H)!KU2)6GO,6"7-?-:39CP&6D:5=Q?Z%7D@'O;*7D
M8ET,85T*JC?SKYA@D.4[U)A[N\?JN[.QSR9PA].G[YOU]K:?0B7W#N=QJ:_L
MRAV.1?",#SA!IIE7I7VA#+UEN4_&QTZH5RS;MB+W4CQ)HSDH(=E4"_F=EN(^
M%\_(@G2V<)N"-D6X"(L\.+QW()-Y>]P1\Z;!32X0[9:U%L^(,$XAZ7=@-N>(
MD8.R1QNBS;*HZO[N V.B1B@C: .0:?(6)?)(;S#_<6Y*#AD3M 'B+V+A#"J6
M<ZH2^F2_[]9GBXR^0@@-Y,V.7^' G6W;D[V=^IVY[*KNZ__FD\0M^3@;II?J
M9F/ZDIYSY!NRK8JA@K[;VH;+^Y12FRN'XH8]M=T"-15$9P/K-NZ?SI7U[[.+
M$// <]8#QEA#X+KZX[03@)YC67>63$Q7DAIAX2>0/[J+YVQD)V[?W*H\'&W/
MTDYS72S=+N<2.QD*</E3J#@U<Z8(7XP%H9V8BHYT[17^,61HJ XZ]5,K:Z=I
MNOFF?9LQTSM?A7XX6C7/::O!]W.]6$&$6JZ?7/7[6%Q:E]>$OVVO.)P^O#>
M]%G[\7:_BV_^,"1CT?C8:E!C7>#IK1FF?YV69N;Z@9S\9J4"?<X9R6OXHR&G
M@5"W)B>?CF#RI/M:=$]@MAG;!XHYQY77,P7DFS9LP9@B/."_!MR)NG(+AVRI
M:;S1CYJ:U=8DA%N@C+; _*J@.QP;DX($44TW_$E5>#P+X8> )2'.R$Y.PXH
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MA$X1W;H;>HY/,F"9)4F(Y-XO4. GRQSR9OUYFY^/5:GSC;L[]$[_C"SC6+_
MN6GU%=6@$^N6D6'!4B:!0<*"7[PH%-7O"'@#*-Z6J2<AX.*-2'0;'$MAE;ZJ
MI=WG9&]Y^:=2C1[[7(H57+=0YF"BITQF+@0OZ:3MT&C,W$D,7=QW.[5.2)_1
M31!1[?@P\@O8)2;D0L>X<>ZSXBD\DNI%/XV\SJ"YO\QUPMD"38 ,<L ?,SJ8
MLV(!\.2+O'B-]@X?\]%E\C.5O,NP@Q&ZD 6]?J'RW<WEBKN#E.F4F;C6BTU
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MB7L<@[\8:*?#DH;$/[R[(_;F?UP3'Z7'1C5"7?/_R"<^+OFD/1C,D]S5_\5
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M-R,2]F5\@.5M*O''R<0,:JB/C0I^"^S+R]% G;@?!,MJH(9/2'B9*:"7JPG
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M]WN>Z[V^[[I8>LX^>ZV]UF_MM=?>^QSG>$['3C\"KBK)*\H#4%!04=Q0W "
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MVQGE+<.?=G3-G?VB,RM:1Q9VA13N6KCXQV15MHTN[A$ 4%&1WJ*?^W3Y$H;
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MKA(,Y\9%D==G;&X&NO,F"!L)AO.?#^CNJ=ZADX$[0.@$N7@X03P\O'1"(EQ
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MY.<5XC3GYX=P(H'-.(5 _*8\( A$B$<0] /H%V-_ _K^\H$I])<V9WT!(\'
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M@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
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M8@;"TA29ZQ5KGI7Z5I7MJ1N/UE].'SMM#N$@X--!ZI!5:0,+!Y^30BX.GO%
M5-2>>=%M.7S,&U14= C:XC)FN_CP!> +)7LU3QUOML-W7GP'<(.MZ^))G_/G
MZD5;MP82LM)V=O-KAT0$,:2GP< <-1S[N@<O;^5"2=VXU*T$'Y&X^S9R$"6
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MV!UH![>,?L-0K'4#K.=RG;ZY:2NME)K@=J^Y(IDI=%;"(J5>S-TD7'A13\P
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M JW&^",#1"'7#NA%&.@4<#N<I>,4@&8[*70_!INSJJ+2$BW9X&G8(BT5JN5
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MQZ.*T@SL\F([UL6<<++-LL!+S3$F>L&S^\XA#@^>'2M5>104VT_#4 ,C(QX
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M%!3VS_-=D=+8/%1JEF,6&12.*_%V"BQUL@FE]&J58],Y<&MQ[S]N%,'HKO!
MIWITES'SWUPJVJ;QW$I<'LTZ"Z\)[0' -^0>[282 KJXK1F9A9Q?'F@T[$JZ
M68!B0Y9^16,.-:J\L1-V%1 JP^T]@6DN'>*108J)JTG2*$QAN8%X@BJQO*_R
MPRF&/0J1DD39&(QZ/JROAU3B1?#?C9OY$PPC4S!X-QX85$ 25!XB*+-\K[78
M=3@Q6YIAF 6S[NO[(F1VP/1V 3L0&<0/!%K)Y>1*X\I4WT&YAHYL4XU=14'%
MQ8;N61HE/W:?O16Z&=N9G,]7V'-<#6:._%^1)$WD+'Q]@4J&]6I[/&RQITOE
MA6,PAPCE\R$\T^WA)C'3$LTA#O8[K%%J1(HP61[\U&7I%OYA2+5%]%<FKR&R
MS88I>2D8EV5SJ*)6T*UAO=NMZ&]3)3:/8V1B4%:5G*O60C./+[9E"8/"F//F
M4 33'[OLL9%!?P4T]&&/X<.;/T^$7G1>,LZZR%J5P6-I3:;SOC-RQS7<Y"4C
M"G3W1[).Z9W6Q_V/T7)X&H)@#'W%3"!7J76Z Q@@X*28-U_U5J*)]^=MZ(^?
MBW9^[Q_8JVX::D#N]Q+GEQ(7Q37Q5.@+2$FP&.5D!D" J[=J 3Y.2&%@FN."
MA#M8IY?5B#,DB8W_O\6&PK[WSSW_H]Q [%6Z:5+JMR.<I/]S>7SQMY">640.
MO_B:Z^G-+&I'8&;;[HY^PH$(Q?BI@JD_^]CBIUT.I!]0,UFL]M-RQ'YV8DH5
M?\D NV@/ =3(L^!,5ZWGC'9OX.K=0D8!S8IO%X:T.$_'+*';JV2ATOQ<3,KT
M?4E"A)C R)+[5S5F%3<Y*OW @JGNE@')'J]1J!YOPH#DHE]$EW!?@Q$9:C (
MP26)(?B&: ?/P=;D4.7)N\#G5_O37B:$,*YO00J*E?T.7R&#YO##;A-EYO/$
MVHDQJ-G\SGQ!J6:V5L%B^6%E(YE=A8)0.J&<1=QLXF-44H\T\ZT7#;\,8*<I
M2.4?"HCF#6)/"+%T3;34G-%*O92D?W@RR*F6P2B]1F-<H,CW39,I?D".BE%0
M9*;7LX^BB*&^5VIFX42>\Y4Q2A6NV=UI?:>49"Q5^O#=LR.F8QN,C9.+6\ 8
MD=R;:ST <P3_0R&"W-.Z3N,+DBF31>K&=P'((9FLT,)>&!B:9V[:YL=*Y+_Q
MVPZ\T@EQ,=*A9=+*J #M@7[AVIL?Z;%-3\HJ.CAI[ZHRXZ@1OT'9@>#V_*R8
M$S\@AJS&$59= Z#B'1,,#AU7V5@)^NFS!@P*? L,YL4M-QT6*4.&5>)VV(.!
MH6<5UQR5%'GHR7F3T:8C*A\S!$49"""B9/[_1>JD))GU)(^?AOM8T_Q+\=MU
M^B.Z"DQPJ0QYY4L2?>V9@3EJVQUF3@5B5<V#F:%I9$V%[.LO9)(E)I"W.BS7
M(@C5JP4G6C*W2MH[B:.S-@H]8RMSNVX.*7(FH4WOL3U!0L\*'I$IL']"-[.J
M#S5WH4=C&M]5@^XYG549L:8DQ1F06(U*=?-7=#GNV9#F YZ&L?5[;G/$SG6+
MP ?Z3&,_MKWL8IF\+$EBQ"P?N5- WOVZJ!MK6L7<.YV*N>/_UJ>^SQ=_0]^W
MS[W4&W 9&<V8C[7KKM%0.AL['@#O,3-,!X\I<V8(RNL6%J&JVD"\^!>?S.8]
M^+N,NXJKFG=!9+\7]DTWJE+J+0#24L8B*04Q:MQ6S?J5@]+0DF]^Z3WEB)?3
M?GU\6RX&2)PA=(^!M=!)&#HR2"H5:T$?5$934F6^4,4<BVH7B([ NF=_7<]D
MQU6PC_W$B=H:4)S,;5/SB525TPI@Q+XJ6BBTT)1X6YD_"\WYAV(=_ ?*]4EP
MJ76D&OFI_1]*:I8KU5,I8"^F,:8C8]8XU@ :-2KZ+@%>Z3):6[>CO/^&9=@0
MU2Z]8,K9J4?%$.]GJ5_):<0X9B?Q&Q;0(4FRQ&?&KV)(9O?>/\+2?]RWQJ!]
MXHV,7CIMDHR>;.[)TZYNCB:&LI=:Q?8)VQ"?]^68//]0NAU;%<P'_Z&TTP#^
MH838?KM^+'YV^N\E9AX(;RK]A[)XPZEI8SW\=_L?BG^$FI\"_VGVW"(@=1A(
M1U"&.Q9F[ CDY$?VA_E<C$Y0-)?O2'KPE?7F>9>K#[J8G"+3+Y=G3QQR*!C%
MSZB&K0G8G=*5)B(ID%,&!!X%Z[*J>6:_63U@"Z8_2KQ8@XI$HJV"5W!\C^:B
M\E06VSUMZZUY2DL)A^?S9?$A!!^O]QP8ILXU'@2+JWO1Y9:).=%KF*XLUH+U
M1@/JWGN%<K5[K'9C#''_,6O3/S[14(SKF[_JB$Z8#HN:M.T&JFUOPQ4K9(IX
MRBPQK$,ZXHTFEG-" G<W"19\!PUFHF7+/]<,E.LR,@+)(2GK)<D)N_B_$2E4
M\%OXF</?:1V1(LD6AD'=>$C $\Q,^BVZ%55.5B' P;D (I80B)8\<.&UO]>,
MF9+ :U+!"ZN(_T9:L,TQ]7Z:8NH_9_>:>PQ(VB;4YN%R[+Y[JDX=*WALO*^Y
M9F_9#S=\YK^=WBAX!M\.S[U?.TXCA/QO97D2^T[?'GAW[;GY">W(BGFB5KX0
MV[F[AXRWAYO]H@]F[:O$#%,Q2^;X#UC$>NCR!W6Z9J,?#(^O?L06^K:O,ERK
M38;JA6^7MX".N=4O:VR8S3@>(_OAMF?:?_?/DVKP7<<$?DX.+%C-17QXZ6OI
M>';&4O&\Y<!.-7)\Z2%#3:*<>+ARJ[[Y-GW/<&]PJ6?,\ _E=G+IYR]DQ[<K
M$^6 Q*G_+^6IH=V/5 N61?*&=4*K3M.?N4'R0?#$;AFN[&HPJV_%<$W^2V#N
MC/X0HH+IJG$V"%;+N7'G4# J/.TM)SC"XNN\L]M#7)P-SATN[#U*-GMO( O6
M-IQ\Z:NG[C;G,&\I\BS_-GK^SPWS_\^&E8ZV4Z%;7QK;+Q=3L+:5:M=*<[2#
MAAQ2NBO1:@T,%6+2@K0780:X$O[A'\P1/[=W(U$T#_8M;8=A!4AATE']1>>:
MP?=YD=I]CXIX=F7X[VU@HVC@X)B&]U@Z$#_O/:Z]6<?:F7[<YP"M\HU8.I>_
M$<.>(7^^$SZFGO$.R6_\!._)7$\UOYC]_<]GPK\]_T-Y^7QY:P30US99"SD(
ME(PI=)*I1MWJ-A\2&)ERG3YMAX5V0LBD+'-2,>HZ!63;;MAY^CT$J'&@8IX:
M>J3\+=V?)"!33%C/,%)0N]#!6UU.F :) <60XAWU<__>.4[1Q-G^W$9>VU__
M^"97"Z>RSX+^K)E>.W4LYM->]#)J'P_KWH*<UP\;9K(S,8O4J)*6 Q )TU&2
M9AK:HU\2:I?5Q[\EDA+8RI<R$V.)Z64Q[BI$/N4>)!+D#9/H)AO#+'[%E;([
M:J;'[I:Z[XO'3YT%&>][ID?_(/FL+$@0K4#XKFM6*D?N=.C[!>)04HIN<LQX
M"]$7:LQNWVRMYH(>/^"<JLH3&,^A^0JX3UKUM:CTQU(&=,@%V&JNN@OA*V(
MI;OI\%QL!W-J+3:7JYG>KZYHE+!8P+>I2PTY?>Q$:8B&^LQ(QL;C"/',?/6^
M&LNM8(H+!R8[- 3P#M-3C7TXBW&N!4%>"RVBN5-%[)Z9R]0(-J");<?VX$XV
M2BX?$V-UOK&P2_']>Y*-O5K!22+4V&%N5$M-J(^T[,P4S\/=*&/MS1Z;I#Y
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MX<\VY4>,PYL'IY1/&?!$%K:(G9E%RSG@9ZA_'-<@J1FX)GM.Y,V\6$A)1<F
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M*]#_I$]S<B6G(="HR WVHW">#_^[J#\O:#E]H=EE#85\JV;8,7$+,\L<2K%
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M"C1-ABE/BY^T+I>]1ICD]O;,KVFQ3L$"P*Z"/D"E1_AH0F]5EL="['*(Z:I
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MYP=/)_,R\22O-LWXO$>:]R*_F6091#DZOO7XMBH9J^G<:JV3DMDR"(\BA6%
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MPXF&];KWR%YA@U*"-VPT76="8"R[3VMBV;8IP97#4E4>Y6PKU937NW>!B7T
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MKO>]0>-.I<QK)940!^<?2DT)08Z<FGF!IF\7/,-^JXSO!R>K=$B()==*XBL
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M;(=1PG$)\KC5P\/\[(81BF2]G+^8QRA.T"6,]ALM:&>)V+^SDY<[:[,%*N$
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MN$QA,"(G9WNEP]:&R$2'YNU^YN>HTZ,.T%TJD0DH-S*1%TUH/2LXS& Y%]Z
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MHLQDXP5^W;NJH(<<G9*P.D9.BDX';_7$Z%2G'\Y:K+HARY7?P(2F*WHDJ4$
M5C#FJ!QF-WD92]%B>BRU''H5ADQ<*'<?1/?T??]Y@RP3&[@/O2,X.S+F8M"^
M;R0M.Q/BC.-NZ41D]WLY!?Y._+Q!>IQ^DMABE^GA?$-[8LE]>3T3X@YQMX39
MU:^9'<:6/!FM/OSDG7H!Q+@\7;X _GJXC2"4OP*:?]Y]FK_W G"[GWT!9-P,
MO0!"7P!3OYY_:4D]_G)XRHY] 7B-/+T <C8)%G1? &OZE"^ %)N:)TK),K$%
MQD1M3DL#S8^(4]EO(W&E5^@@GO/)< .H"KWBD\HT'C\-D^;K AIY*\?X0.)D
M7#)/G(%O$>#0=_ZC--MN6<&9CCT(SP8[Y>0\I!_5*]+>,M Z'BW6X!=BT=9+
MBT)$58=5\7CA"0LX %[LB[5-Y[7Q]$T(^0TUS'*;>K6!&P*YTJFHXGA09'VP
MZQB;J"I)=T-Q*M%UXA6+;ETY3P(U%?#*3E=:?%1T3C;CF70ZD#]C[F<^D3\Y
M.?GG=/"_>M'=TO)L<GUY8<I(8R$<@(Q* 256H=*+:VRCJJ,QB1$[EF1+ NV*
M622U-]+)]JIW,#(,NORS5=VG7N=G]O+/#)TLG25#'4PI0C]-2S9WB$^F3Y?<
M( YE.=/J_<GX1DY.9/--T='_OO(Y\O*34K%O]][5U.+SU.U=Y%CJ$)L*9;FG
M]Y^C;CF)O<@3H2]3@]*GP7,9)=8:'UB#-2J95U2,9Y.>C-26KBQ&YJN6^V?
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M0 TJ5LE9W'9[!2OOK!V<DEQC:*I8;WQ6ZR1K?_Z'J+ZVL0DSC"J=L; 70'8
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M>/Z+C%%Z4P/(UYMF>DB:]H76[?OE<\'QC3I;LY6_8BUQ5H5#NRV9ZR7DK%\
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MYC.\62SDQ$\_II?0UX33\V7I#JC4X%'1>6+R N;L?KCF=)3[%%JA.GU(',3
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M>XM3V$H@/?M\0TC=7NV*R^@<WJ1(PYCD<YQ9$6.>=6;1_F6(NW71(FA,$)/
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M?#2;+%,A]HUY:S4EK@5,NN 9/P)2Z7.\LM*:9#Y45K-(5*I$X.=Q<ZXN)DO
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M"7[7#"[W?1T:Q"?-J-4 ]9$* /C*J",=+K12#<#?$#A9L=>Y0IS&?SOMCN'
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M6HI;]C\2^-.1+(5GW7!]"< GE$T:^SD\((;0GHU:6></@"0I;G[V.4<@H_=
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M8D#Q].<NRT'525"XVV.+!=3%ZVS59X9_ -*L&5ESAUB(GV3Z]8VL(,O:1[H
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ML;.KLK,_PFZ]I+;O+_]"V&_+RMXNO@,LOH<375Q\+P:[P*Y7)FTX_P4'0]\
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M$1D.!14'@$N.AH?/?HN 0DR5@Y#2U/%1S!ZGVFTJ\1?E[R1B*]K>P\Q)X.
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MEU%ZLV*6MR1$]X]CR9$8B^NE5&Z3?)NXU1+&88K\I,D:SMG0TB8O$]GYGJW
M$*A1KBSYY(,WM*EBYWW2LP827&EU+2\9)Y8->%RB=%77,<A7G<(WMD[SB68&
MMK* V!6I:;DW:99PJ<,Y62?3CZ:+9F[HI/)IZ#VB3FZ[ #@6IJ>]H5(7(YI[
M\0IHBWI:P;N$\#X&5R%Z&RLQ- !+YG7K)Y';.&1I5C>U<8<_\'"JJ20<.-49
M?*HP2+\;%U7O*E@_JHSA/S#=&)C'*CW<_7[=[!5_Q9**4:\8\[J]#.5IIJ38
M2CRYOH*;;?(")>^><_BT5JXG0Y^;HF8'/#&*)=0D6J&2A.";$Q64:P^]3WVX
M/:S3^B5SGPV&0FH* E:WK>ZSA_LB9^#6#+7H+ $JWD\T)1,8BL3]@T@<)SZH
M=^K@V!F_]'V1)Z.WYIC%4TGM!>>+&KS#ZIQL+*O'$&VYIQ [T>BT-%A>A-18
M$&KM73-YY\M3J^2A)>.7U7EYKVFX[DPJR=1NI+G()7_('K&V=EC42G1#"NY3
MS7K0'',JEE_G1JD^L,FJ:-?=[-N5O=(5_D:6ZK$:P$S6486H>P4]H1<0A >R
M/1$0X'17M4TAX[N/TKBI0/^.8YMRX#E:T?;#M!=#=([)=9V3BFWH9H\&X0^M
M/XHP;FE#RS/XR>Z2! $<'[,[L1I['Y]NO;)YZMP[AR3DR]8J\%KO"=%R"E5Q
MI"KEIR^GQBP?@F4%K/S@^6C.4]_;3MOE\IE'^B_!V1*ZR\!FWB28Q_E\)-.0
M571#<3@P5<1HDM"]MV?RT'=7)S*A6K'M 'G^9"ZS&C1'*1%;$9J6;Z\>9.F)
M6N"V-L:! 8BJ6MPL5/MJDU?M>I_,!)P5,JV]];%\-AG\!O5%C6XL;M;(>TW#
M^NEC!QK= ,*:XH&S)OWT0:$ 5NN#F8G/),GLYQ+&"IK9&M.* WJ;Y/I';BSQ
M69,U3RGV&X&DPQ/$+XH1;,T!ID@]LC@UW,R;0P^JGE5.2$X<-J_Q:5=,5M-_
MVD<F3=]UJQW*F:/(.75:M\FV/.V,R_W&QP/Q\V9A/B*Y_TSO *BPK6A1>P.K
MP29L?EP1G:4(QV$<;.U/]0Q.*4O5X8L8=FGU5R?H/KP:F*A$<[NUW-7I]B>B
MN5W]\41/>*Y;'NI?X>HUU&K,LS>M\#Z'?;N+V2,U0M-497<J&,!1"R&&]Z[/
MB)!SZRG#Z*RT]3)XF;ELWJT[(Y16GP-JKR018:% 9=SLOID2=.LX;L&W[^RV
M3A-1Z6&V-]/XJMF#91)0:<L"W]#GU+57:]\$!IV?-T^>@F8Z);W_\K>-O!_H
M![UZU5.7>;4X4T&O&$F6[YQZ[X>O%9V=??[VY8F9ADYAMT-=/RNZ$DXJ?<)8
M^ L^:;749?HA*R4]&UXE[_*$=ZF@*MHL2L1R?XM.'\3W>^9M\5%/:6[5Q:QT
M1B\\T.[SX1PH3E3='-1<=T17?C#HN<NWCQIUBA#.CV+RC-=M((_[6Y]FO&4K
M(HOB6&#H*SY$%FEYU,7"25Y'Z$M8=Z!2>(36S= ?_3'D3LR0S(F+ <<]EAUX
MGRKOW:.2?6RW-?@OGC>,;>$3=;3TW$H]$/U3]#C<GO;!,WTN5'W3<L]F&W<<
MY4,"I6<F@X3YDL%*7*J=I]_$XGU_L"RZY?NC\7JG]M&7<!;44\^L=3X=8=PM
MKZ?$%"'DPP4C/:5[%(/8$#(B8YV<F@&O )#][-IP+#"CU%<]TA-CL1-?7*D<
M4PI\_G;%P?-IQ43-X8$':V>NB/SX]#QI5IY5V;K!XTU4Q78E6[Z7YM+E<R]#
M6U1>B./U[F/Q,0->,%"A.!U[X8DBO_ OR]83&FJ_EUN7%/P4Z!*/%C1P <A=
ME?WRY'QI);5>X:LGY^WW!5^)7P\@@5E8(.'5-\4-M]Q[(RK2<U\:*G&6:IH5
M)9)RFEIC'Q>.E?F;6P<9/&*S34Z;K@CI?!\&S:7UG,,C)D3J5LDOR7@JH);3
MWZ]HV'5[>L)RXZ'R8K7"^Y6'U!> &'K$ C-IS=@N.211W SL'$ 36B85#E2O
M[_U['N@8/'2 O-*%;,>]DO%PN*% J0S%]9[J<C[Y/MTG:2<$:;@SIGNS4I6R
MN26M@--;)N]M;Z''X68U*#$?,5?6Q(3@90>05^0!B%(;D.W\/CGXV'6;FB^6
M,S[E60K(&N-$#R%Z3%J4@894@'F7BP%_KWJ>+N#9%^["4?K-S$/=6[X[ LXO
M&X[:XG$TO]XM>>9=D*)E)<!]LMTQ9FMCAOY,@$V1%WRT2FMI+H>F^2[]7+/X
MC7/+J%JUDV@8G&ROI7AR@-_-L</3:"3 $^C$^XV'$ZU*QD<#"\IXF</B1+2U
MLY/Z"%836]_BO55KPAN1#V;57X[HV&@9266:V*H-:.0YU& Z3GE)#Q%  [W@
M&5@YS6S?,3,P](H2LHS[9@@D,,%QA<UR(@C<"1?')BCJ%07GLE-%WTD*$YHC
MWY2%D]34VOG 2O$5XR&F#G/_SE94?).O<G:]87-[]2A>8W90;@B<?<LV_WAC
M'7Q=7Y!]V428H40(N6W,LT<W,$S6WX/U$F@(R:.6G&*"5<35HE-K,A\_J:>B
M?LW36'E#YIT@2IOSTP#Y6WXT^0R,?(::>J$2"92]ENTK,:O.F$<MD]FN8FG
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M0=O;7#:IN7<R!NY:$NN#$X#N-U8_[Q*NK6*UN$LWNC7>,_&^#VF\A[D/W)\
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M&HZ/[2?J8C(\F(I2R(9C?)_L9X'FFFE-12%# *_?YO+=AOL>ISQ[5_0#P1<
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MIBQ],K0_:"#@\P:.A[.([:!CK2;!IE.\LIBV;EV5*66O1DPI\>MUW/7#S:V
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MYEID\3%6RZ;AK:^XC+?X$HT >.2.!JX2? =2?U1]Q9#G+#.G!TX]4,2KOP/
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MC4^^5DPCO.#V5GCU7*%C!(%47VV9.!MJFAP1?!YO)6PB8%XFC]$;!V0S,?-
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M"2!( 9:ZIZN0U3$;>CU%+=Y- $8S(TBESKBIKO'9W^/7J34(FC:-8*U;=IT
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MZ!2 J3(FEA#>*]BIR-#',W>?0G:><DL6NOG8SNW1^5R1*6O8R:N8<[OK>>-
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M>?]J^E.[.SU=V^XPGVJQTH=MIQ!JMT@TFTOC.:TIV:+<D;)][QBAN@Q7A6Y
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MR,YU<O]-@Y_TYR(!<'2%G0TVU#,X,-S5T1+YMSD*<>']X?+9P/YE4 '^-OH
M,G^.TG,WM'\.PN_A(&&V$"A2'W;S;!JA_ 4'X[SNM$!TNF&>,\IRO]C&M$;
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MN'FY>+@!$E(>3A80>Z@+'1AJ;>MX'?3I92.(SM;R.LA 4(U'S4D6:F.KY(6
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M U\UX8IB9Q7,?%@VTE'@P%BNTWV/IR!.:?GX,.C AG=A6GJ?Z4MM2TSE2>S
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ML#=? X/%S?G+4DD(5Z'01Z43A6X2\![1R^,K-06U$&:3&-=[!V.#E37[-<X
M'P[M3Z]KJ0:+[:X\\%F:/OHBM#[Q 5D <_)6)TCI/VR$.G]T;5_JRM9\D]OQ
M*7>IZ7WW2E<+68>=,*FZV]IE^D;KQ?3R&)[@3Y9<EY[0<1M5<G]^J:/E,ZL0
M[Z:GJ$_Z',4*HV7GMLR^,I5(ZTE#%,*YW"?_L;'#.D_7FMDGVO$K9",=O!W.
MA7#5NPGVWD.4G67=G D?E5"[!ZV39VHQU,4CLPS)K7037@ZZ 1\AA =2<Z;R
M40DJ-^^SKN'#NFREU92?SLL7X^_S7G4;6# .H.VKI+#R*4,4WAU/O;:HT>]X
MW;W<=5&:\_,SQI9IN)%$T1S;P!C*\@BN5NDC:"S$[4-S02.J@OBM"91WMLE3
MK; I3-XW6RA%NT_M]/W([)'D'Q*K[F%B=SNZ+$Y'!HU;>G+PWT$^*WI7\H;3
MNMY.P:W]YELJS_31ZJHLGSA^!I<AD438E-S39^%B<BX5HA]+4XOL1,:V%SJZ
M[=^WUGPTVV#[>&ET^5GKHV;#U[R21S%O5NH:;ZLVC ]%FC9WVE8-8I175C'8
MJZ&*&4K!NL:C;L)\Z#%JNFGP%"$6Q&")M8=!U_(?,C'TI'SJ.C';<P96Q1>&
M5$5@O'L^5R\X&X C$E+#2I?A_ZEPY3*Z4H8Y\&0*NJ_![2BR>2SAE2JG8/T_
M=%-YI0]<S2I!O13EL@ 45?<X(/T<HH=^WR!&AD2;:.Y!=(3YP^QJ[F1V$')A
MWM\NM-G+;\0O*0.Y2^245Y>W&1(2:,CNQ.#98]+6H:Q,C:[+<W*XB0ZE#B'5
MU7P@EE?1$+O]^ L]><.M43_4&OOIG+"E%Q(9S%P@+W_95QQ^03,>>11L/@SS
M]?1D. G5Y-U#"4.:7VZP8+203>C+5SI71<X"M'D-<%\!L6BCF[?'@T5EN$5U
M1Z@L^[.OONJY]06(;D ]4ZK-Q,BHIV_,.G4K!=W:!%JL$?2Z C3NY0<M0_4T
M!6$XT#!W?% 8<WD4QJJ@SIIYEYN14-.!=J&=*H(]$G<0&#W@48:.+SHWKWZ5
M'<N,<8:X407(C7HYN09MGX3[<AEH-]#(+8._"?^%'WCDJ.IQDE]8,7H=K@IU
M<5[@"B*/%?HF+);>%>^Z>?OEPRB"'.7G]K,TNC<4VI0F]8!RZ!HY5QW:N)]Z
M/S*XCI29?J2WH&^QL]1SNW?G<Z\+8FEJ5#QIK^4@/S;(IC(6*3'PF6._NRI(
MW--IFL"2XWZ0PAB ;B*I]UF&[19C,'<H5L#G[<^RAQ-4L-K%_DG4L)4G#,KK
M*]F2M$JV)T^<E5]!@91ZH&U4O:4<P.5T220S\*'@D_"-);9%J]Q9I?SYG/Q]
M]S;<^ .IJR -Z/Z*Q94EE=X7<_-'^455<PIF<5AYS#9*CY]4<6^R[8*\QNF*
M-[[P'Q][KPX=VMQ8X+@<'/".\N1.OMV<W?-9K#SS>B87W\"97)P3=M#PE2M5
M6"'R^-KY:E57KS(IE^\H*K;2"#(HTBIB&8Q3?YE3J\#"5[ 8< AJ&K48C#[:
MF6N[J1UH*6"[/9WF^9X8IE>E/(32>BD9EF)S!8/8P9A0UO79EYVLXWKZ7>&P
M1[DL^+$4C@*18D6$_N(M34\*CC5 DG[3N)<^5G$%^',SNG_ 2MIRQLI=B?:1
M5]LYUKO^65ZIHPT([--;:(8%J@63!UC>QR8)7UD^30F<G#8ODK[=Q)6P-YWI
M4@3Z*#E)+7DJ\?:N&;H.B6L"IL3-&(WU/J"-;3*J(*:)N;#6!P/=B*88H(@B
M^AB?C-P6'Q\+?J5^YT %D(1AB%VK Z,Y=H4P(\-CNT$E, ]]5D0=F] G.O#&
MT)K"L]W=0. *Q8- )3MXW(-D)>:4O1 :W6W+-.D]_$PY+0W-KB]'#%S$F:!G
M.1'3X8X^:F%.(*7L69F\0A&<F:OWRN=]<=B:V1 A88\_WB -H]YA:CG8ODIO
M)I?X^G*L(F&(,GG\?-V8L]*K5_(WR*.V+L<?K0W>>U$*\];:T945)HY&GXZD
M4?=-)]73T))\;LZWJ<$ ,F>4D?#*$/_X\>6K\.YP1Y1G#X1F&33X<E8=Q1QJ
M<+A3."RI"0^K[!Q"_.E)JC5!-Q2.1#)4,E4>Y.91/-O $IG;2+71-K9XI:NG
M/Q))R\.."S:E;VQY_BX[#>I-Y/RUU%-:^BH)O9PZH;+4('MQ"M91=BPV:T9.
M[IW=0$6'9Z-FR>,4LK6^UEK>[L2Y]LX%@39(DS'2O&[>%$^DM=Z<YP S?\R'
M#PN[FL\-1^($$YV9%!4X.>FCXU4I8&*[XBU+CV;VHB+T9"]1!=,D%2I82=AT
ME=(\'(TB8PM5B&AZ@L K\4-]:ZD ?"_/@ OR9PVT>F0>BQF1:$1_0UZH?Y67
M5N*>7I\K1OF,*%E, RFQO[K(,A9.<8PYMGK%; Z;R' 4<T:C-?KGIC;%CW);
M\M+[VV;$@:!>[0HEF6(@"B*0 /""=>3N%52QK"=%.#E$VSET=0+XNX$>NI$<
MD2D2,IP":K@V]Z?SE-#F9QE"N.D!#(YHS=-QWG1>5F'V5 [5U0J!)NPQDA)3
M@EJ*K<JD\[R8"<]W6Q]*>P1OQ%#?D-;1 )+:R,M%B!X]\M5QH"=];FP_G;5<
M<SO#+-^OMT8%!P?W]3TLIXS,G/="CZTL0R2*=; J%A1S0K\^W('.9BB,WDF7
M.I(QP&Y6'%M0#I8+[I4JB?-5([HJZ9UI:I3TN2P'CME2A5_%F1)"%U H1M?H
M3AJO(%\<;.!#:A/5B3V@*(]54=']Q*-JNBJ$$21%T"L0EO7@7KZY$G;5-T!<
MQLUG'*^)BKE\=S)!"<^OBC+'/OH&4.)WUKQ/BJ)68HLN3Z)X#T8>L'48Q:1N
MONM'2<+084OE0TCK,R1-I?#AYF-=9YTVPDF@MY%'*'&PWF"DQEB;L=R,9MC$
M<^@'>/"\0.'+5?:J&2(1NQR%(.ZXF5G+QRO#]ZJD5"_U3&72JXNC43P<)I P
MIB5NU01ZZNF9 _?E]4X/KGIZVGI,>KJ@WS]5!3Z(.HEE9ZF6 G_N7]_(/?H&
M8#SY!I!?&4F*D=:IFO!U!;&SW<:=:$#"L4B_ J_''6TWIF^OR/3GH\*6/M]@
MVKMZER6[W:-3?@%X5W<I[Q/)JW]@R"=.DE$98,L3Q\MMF]/J^7:&-73F'R'7
MCW<#P8Q?;P*E 7J^SP49M33F<]@9T[OTM*2D^D^G>E+&4'H(*#<:AXT=9_,2
MY,WA]F,S">2^W%=OT-,KKZVLLB+1U.\6*"C=_&#*BZ9[F?LR4-<)6*YG!M3S
M6,IDX!+H":'?NK')Z.Y/M+-@)( AIW7LL7!7<&E77L,W.F+R^\\)*G9RWC]E
M#V./Q6'+>[+=Z*L']-B77\9ZGI@P(/4<B*&%'F,0(*\QJ^Z[W%/-U@>\^^]^
ME/#_<4&PO!2:KAER7PM?2V1;7>>UO(26%DG]D2RC/(KYISNNX:+:3MD""\^Y
M=9+NR1KI5657WM3C%)T(K^Y1U:M>G1L$/0[QP\X/GS61>']XE?WQ1Y7 VW5?
MFI0:8WU>9.E^YF(L8W[2EZR7LL;^X9FYN6<J)Z+M'J/+ <97K.&.=.#2I]FT
M;P SJ9:OK:L\FB@56J3_Z.)QYA0&P([6W/)2E*//4/K"-X!4MI*<ZJ>K;HO'
M4NJT#@&Z-U)YQULH.AR*UE;6BU9*(AP7=2),EH0&!*;G3W ^>Y8Z=,SQ2%#6
MX<S@@BT#( ?5$1+&GW9:"F2)/H5#["?X*]R>CJUR+?)V&;TU:FHM*Q1I'29>
MZNS:'DUSVR_F:GKC\I;:]=AMC4 >&H5&\'J)KI61_+$G*DWQSN%^J-WGAN:#
M_C1E6'D#)R3"3+8#X:UCI]>,9&PN287UCA.T2])'6277A1T>+C!%YB^^KZ<?
MXS!*(B9CT.B(XKNMX#F5$V^6+I6JF11YM=_TJSZ5 \.4@[J\<ZS%'5FJMS;9
M'1NR-K82=\6+6UDN%2<@9=,L-9VZ8&6!3D\?371?9[Q-%@@,J';E4)Z/MJ-!
M<1M,/%K/*F6G(BNEBO2%+PY[/=O"[,#46S4>/XYB?"WD:.X_MB811SA0TW^0
M'P$F3=0GQ;ACV=DP])34JBF9DAP=<2V6<0[ZG!7N=.>H?^GA%D"GK2IWF[KG
MUD>ARZ6L5;0,D4LU!<-NP[Z0J _0*_5=!DK#51EU19$.!E:C>2S9M##LTLBG
MW),H0*^0@ X=-$4?;J"PQ5=Z(W?#17%R8"=O=[J H)"S_VIA>#QDF.GY.Z:P
MA1-^FN;B32/;@YAN"H2"[)<G$-(M,G%'G'?ED=0)V+VZP9OY!F8QG$>#[V2/
M[\@4J!_OM:[@!35+DE;&L;;O<_H6E RJ3U<%E,IR5[=/+Y+R/NIH^:"4L._1
MU5L=:<^EPR/#P16W<<_K-G(G4QI_:[)P/RC+?)8WS&RQOEYG1H3+&AZ^#INR
MFS&L&_&8'RPLP8TT#;DU.6I@W(Q);27>PI14QB0RES4F<)7<#EVF#T7[\XOZ
M.B6W&FYX1:D/P?@GA_U]']J%3P8WY=KWWNGNKF8M[S] BX>EZ7780H5DPRUV
MN>>''#7LQY\VD#H_9KT]6]PF-BI$.Q]6Z>6]'7*T]77K"?]AN)UGS0:+IVF
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M6KDP4U;/OE]N&S$VN17-=SYW B3$94^Y,RF3O\:J&U/>-S@CH]+-]U>/?'!
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M'ERXZJ['O[';.;(EJ<!:T!/<YRZ!GYR7SS9S[+B1N8(&:#-R!=135B'5%4$
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M2%P=?ZPJN/;!5)%YOW P434E"Z(DV.[U.9;Y';@1)';@>_Q,AW)7R91UZHE
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MO29;9QE]"2[*;Y:Y;($=75'(DE.26D$O1 -V%"02*V9WJX#/%R:A*E A 2
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MH-9&H-MD*^) 1."YXD:LJVV2^N30D"NM-#Y>LTA@I@7BABJH2;:-5'QYW?\
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M*G\5C(.T3XN$I+Y."4!/55!%%=4E1!14!/1\'-$R7+H"PH=:!FO3I_F/,L6
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M5>.4L)OR(BGWEO-CU<% :=;1]]1<8\75=;OR0:N[@NQV:O\ FM2;QJ>)8U@
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M;IJ^VDP8KU:4/X6PD3G1C%H,9A4DDY5%]MQRK5GZ/R$=QV>XP9"T"8I*6%=
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MS_S3"IHDJM0RG+A0%>]ET02/3P]^HSBNE( GL]I7&(UY $X.^5K],:@B]%\
MI01*DNR?VG!\@I2@T5VA;"=/T6$.^GQC;]H<=.$C&6=:9Z/1OUVVO\4 G$9R
M*9<63!?#AD<&MB;6PAA@\*'3^6^XPQ&[I!P2E#N*X[E_ORMO\0B4^TVJ,>R^
M.>$]3$$+GE3[!F3-RR>V)?66:R8+Y"YB'8VZE%A_<'T2OS_%Q>E/(;C^$)7Z
MOA?9*!T]YET5_PO N[G#QV>37>G'V#2R=?33E@!$S?_1^?8%@/:<;:$TH)CT
M@(?>C/U$UC-IH%6^GO@X_:WC)U$EZ3C65NDUOI]T]$CB4V>DUH;R'>)JX30"
M$/B%SR@0]VJS#E7(MGFZY5N=@F0<36\X6\48&PF6\;J?\@A;EK^11B1+:C$K
M;?O7]22'L,]"993-IMOT/ 2A$/5Z'Y\;=[#X_R%?_X' _I\&7<?JU/WJG[>F
M%#=J<B0IM<&Q!"4*3Z*G]Z9[XUX@4NZ2 J43C"CP[_)94)]25W:5^^>=LU5N
MI_8393T39V:ME7DL_7$19?J>I38)@F0[.]]I]N8Z_^+6Y6M[=:*1RQ6/62M%
M:PZP.%M=@]?*!+4*H-?3964U>:-]>4A]4W!)=6MZ*1O<^<[TUP37-K*_?+T6
MS>HWCY&D;7?O$VVM6BN#L5F\YK-OG+B@H'(_TO3U6/-WB@-A*3-'>9Q+PU_!
M@D8BD]7!AN9Q'K29+NY7A(Y.,ECH "V6F<;R'Z^63)OH(043#1QQQ(>+Q'JI
M;DTEIQMT&^".I#V]9O>-&!NXQH'18E/KIX5U^<W%E4^8,\LC-D5[M[4[8^'7
M&?KW;W63)V+&S'1/7C<=DM-;^O&3_#Q3^FF]*"@XFTBNA,C5MB*[%M:?:'@2
MM@M9>=?<X,U$/7'*,QEL5-C>\6HD3]2GULF.JX(:,6XTRI#E+5]A9ZTD[H/&
ML*'=PR^"E?.YMXM6?,H+@VC9GK,F_,PCJ?)5]<DM*L[7!I[S0WL&]ZM$FTF1
MX G&BJ",@UM]$^1/QDZD47/);;2;ZYF-=S O15H[VD9.Y;^6^UZM7//=.>2>
MJ^2!^G]*>0)$GC($*1=? +;C4_4&2R;=3_F#MQX^%ZS,KURI173[\M\PVQ8N
M=J\'1,C%S<)F0E?XU83ZGJ@A;)= ?[<F]D*OQ?:^ <%ME&)7Z.J]F^=Z3R,'
MO86CG^CGZO-E_5EME,@3C@H7_65[^^[P#I%O3+O)-;"33LNP)8/J:_L#H227
M#D]3%B^-BA> $>>2K$G,S0,N[Z:MPXZ^C_#=G-'9D=A&VD.'[K*E =VP.[S[
M;)GP@0*0G63EGJ88CF12/T25VN45]6A.6EI3'J_.54IO+0T"L0XDT5U])$0J
MYSBR>OC;^_BW/RO&#V.V]?40'%F+D($0?'FI(05!A3FC#4$(MQ5"-4:""6'&
MVF9TYD7@%!!\O_56??KRS\/5 I9R&F,@3;H<1;U4R(4LZ)*F" ;7F"+2BM/Z
M"Q?O2M&J=)M.84)H8"MK),IF)%=]^N@D@X\D&*HXF_$QQ0+H!V8]N'G^D39/
M+3,2?"G%>^%Z'K$#YFZ_B7P79<HXH7/S2GV&Z\0EU>,BSS:*@L=V#++@\4$T
M@USHRMRTL*&5L8#B#\I:'$W#/K%4Y#IDV-U""'/'#(Q?8"$02Y"E>4!4L.>D
MJU706CE,ZQSY?7#=L5N+R<A3WNF=N@_C&J!2#?U3R*!F4C*C6H&1+1<28Z\N
M)J$E@$+>J-?SD#N$G54SM/Y5L=0ZW@!]\-"Y_J9Y9D*>/2==ZI#PA[=ZIPK5
M2F;UP]YH.:"4I4Z'41^JZF8O\/"8K3T#IV_ZIX:<6%]>::T;%E[;5,/XG/W?
MSW//61?\!9#(AC<*+X $%6+-HA0.(0 ?$CM?7=XOD,)/YKU:,4<I-A8"S#'?
MBF+#A2 W/!Q);^BNS5[VI9$V"MXM>F6+-T32IL6A:;_U+8A#04-Q+$C>E0G[
M/OV<CE4^FFG<MX80(OQJ/T>BK^\%,*^#E9*$$3> :2>)J9^*0AN&&O@*7P'I
M1W_))$W2X*T.88&E(IHD(NR'[!V*EJ;#+B#!D\1=Y//[%;E"Q"AQ#6/F@(KY
M"@=9ZT+".$R3U#GJ&Z]DP]==!L@0Y.=;86IQ;B)I=9/37R=65JWW!Y%:!\5:
M,/Q0?'R? 5C2QNMYQEM<W;G=5CDN:07#)N30C?8V[&^3]YL,H20;7Y@NHX#Y
M$8W2"OYYB6SE^ 58=!<C2?XHVR;J"W?>D/D)6*-ZHE1A.%=OPHZQ_R%_'B?6
M:!6P=1GO!6!&?DA26'-1^J/P!4!H7),OJX@:+LAO.S2$[OB>YNW=+*](->N_
MRW%H]KUT_ZF/[[3I*5;GJC\SF%'&?;9IS5%Q@B6#W7J3S *HTL!YEQ^%X!PL
M.QU(K!Z,NU*3^[+RI?#(..7/Y^GPF7'? ?=#@3<M<\LEJR,^0?'R:Q):7"UM
ME<P .[15<B_SE?ED#ND_M".F.AK&2NV05\"%2>EH-R,K-$,O4#RM@L391)6;
MR$Q!24M<7D_2F\/',U(OXP])2L,N)W%;'J]7QV]NI<JNBR9[WGHPCCLZ6KOG
MR-?9(!RUX\9UBTXF*@RU5>X\;A+"A;0FN#<;UV(P/[5$Y]*\XY*1B\"IWIN8
M>+P?R&RG"*EF]B"(V'"D6HBSRJ@!#13>9D,V7=.GLM-4$U2O2.M-FW='<:+=
M;#):X2L@78Z1_'[ZSRQDP<@G0 ^?-UORWSWU?Y._@K7MZ_J;O^(^)WB_^]?_
MLO<*>X^A?+WY8:F)<<#9\\R@P7<(73G)MF RGC266'2*#U*EV&VV:>#48H1&
MDX;ODW<5,1?51-[$["/JJ7LLMU\:YKB^=G9;J=S=Q_*#Q[ZPXUZW6;#:&-<M
M4VGXL/KD9'C8$*OMCR9U:<Z@#X"6L#D">LB1[B3"?8>9D-9>9KAF@J-[$R#Y
MVZ,IW?O5PZ#88E@[3Q9)LU%/G)6H.ON:#P'W.3O%J+-O!5?GUY@M/KVRMXO0
M:N<U#D>94@/C28X)O$&]$!93>6?<M+&K&^,;U99X$9I=E(>J\:R1*]7\K#F^
MA]#5Y'G/<[(VYG\T/1.CV:_QMC]4.-PG(,"@<66XS/[WP^DJNM0/C9_8&=&V
MB@J:9?D$W&K#ZXV?B0D1"BIB$R6E54Y&+1(>;^K*2@:/FQYOP>W#.]4=0><4
MW@X<<HL%VF-#34N[S*F[?&Y$6H5VNL_Q P_JDW5>!AOE^.*DYQKBK;7ZE+UV
MQ8K 1"9C0RDY5"S)*%GCZQ\WZ.VI5R*KP8PAUKLW'5&"9]([X5E[/X;)"NMT
MG4&R.'D2F$(,EVK^1>H6[P*J"%9>):L[(J+,F?\MZJV:B3_/K=G\Y75W;!]R
MM;(U<3XYJF=KYJ"*J"87<JC?*]^/(0L$R3-J S.1F>832"I=.5@_#&0-7A,_
M?XIZ1B1.NC1@&69Z7E]Y.N]I]D9,< PZ?8\9=#?GHRK67OE0(BN5[) /0:)U
M\&-@('Q:CF &L@X- \M<2X_R5IKM9+%T,WVB9G-$0G8Z&=>WT_V5@MM>B^MX
M["'/-C4V1DS.VZ)M#RI[5M'O6J\)OL(2'@-!;BB=IG123FH-43H!M@Z4<^.B
M6!,".3)\7&<4;ILG*.ZPI<U>CH2?E: CAK&W&S;IP1;7;PAXT?OEL[0SI1R0
M)#V/[4YL5*?>X1+X?[JEL2[G#1C"P(A;T^(Q8FVDQP5LA'I5:RLE?@<#A?8]
ML1?X7W>RQ)$V[T0DE"&Q%.#OF3GC%[%B:5O24J!SZXM+=E!Q:_-HAH0#@@&N
MWDU?XU8;#,SQ/[Y=.$<IM78]>X"JAWVH-YVFB-&,/2J]6T>K3&\2X,=N=;'4
M4ZL/7;?JXDF4'(@3V8O^W:LF,.%>T6Q(T]"*$I$MH:^H9A$9BOZ1\@T@(YS8
M!:G1ZKV0Q;I9OT9*4MG,N4TA2GK'8G#=1.?>N]&KSJ:SA-S0$=Y7\H;Y?;5"
MHPW]B?5C,^Y,HNJO04+[ZW%#P]L*HY695]2*K07;O8%BCSBK.?.W23>OFO@^
MMF)&Z^#*L3#I8NG,:6(/":N.6:2ZYYGQ.^EOMQIRH_163H_=,#'203;2B5WT
M@@2QG3QJ5$2ABV2OFY=^H6NJ^,\=>O&OMY\0&#,M\*A&XZ1?!UY9!X%5B,%(
M[UBZ/Y=(_,6J4 UF7J,I><0%]7E24[SB3X1%VKXVBI165!2I(VF8ET]S/E7I
M5,?+: MH9-4CU15V83FK6VF#3#DM(Y'D:&#D>!Z=YOJ+MSUYWAZ=+95_?G_#
M:5Q7''6?_G_G-/YC8.-_8A";Q$U^T=Y$Y8$9"]]"X;+JM P[D 22Y3"HUGGT
M+*BF6EQ6MVHL"&Z$-#R1Z,ZA>]'C=A['CIA[7_(]B(VVA@6UJJR ):H +Y8I
MN+)8OC$)KG_0<#;ROFC,-'6__<H>VP3#Y'KJ&+LQ@IN_C[2@T.R8S9OSAL;U
MZKNW=(_@7S^SB.^LP2HM*Y6A\W?^-8/JY(N%799KNS\MZ@^P-4!O<]W-"C4C
M!Q+7 G\([2@<,%8=7PT#9L..9V[_;A)&<W[?JPJ!;,B:):$<\_\4"*3A>O\]
MQKRV6@X>1%;[5I$>C"G_-G( 50]Y%XQ[E/;-DK=;72V)?D+$>[CDC4/SQ.F@
MW9(]J#E0'!.32K5!T" &?56$4W!"-:DZR72;J:7T[^/@HX@7E<W?6/T]SKYC
MWA@3]%S>]AZ.J1"ZA"C8(T&-6JL2^76*]ZF;[FM>7-D:)!>]<0'F=/2A&G@3
M&K!B;9A&PG?+>F5U^.(8J[[4O.DG+0/6H_2B)*\..1( QJ 3W0>B@/!>9\O:
MPP9A\I&AW/(CK'YF&6Y?A@>_!!Z&X&#/.GP#:10#"P?#5VE)F+JE1KGK$9_H
MCH$&9GP\WV>^2,HP@/=RQX0(U?S[6;* I;6E]1^SZ4CNI0FLVG^P!((1>)=%
M4>#\_AHVA+5TY&G.,_L(3>Y!9$16N2TF?@K/[![[QOS ;]U-=@7T4O<.0]^2
M[M^_G(\Z4AL/ZZ+-<U*T@+G7C<(<^DJ^D+\P1SKY"Y2+_6PH+JV#QN",)^1N
MX :WL:NIS^PY%YA8KDE8FZJ$7U]]&>FBJ2JG0]\E>0T6>4T3WCN)\K.N+%\S
M!)V8%;Q?BZ&K'(O12MF-*NERDD:&^#+H;Q+U6J&6*26/E]%K6Z=OEAE' 3H(
M8&"04O^D*H$O?X)K_3%Q)CJ]W/-#!7AD3@%*)O7NDA%LV=.\\!'3>KG*D :H
MAS^^2-GM5L$YP,,I)T'(>$(E'E#"[LP.&3NMK.*NIY$=3NP?EBF27NN-V%,-
MS'C[^[$B"K@-BA3[L^_+7'(K4SL26B44&?U5T!2J&;58CYR<' Q@^,X# '6A
MT:@.MB:7YR>&EB2#MY$-5%7Y">?3G5WLWX$FRTOV5KA$M3S4!9K(W!;QOG[%
MUVP[07DNU$0=6( *P)V%))1SO ZTNG:S,%"&/K"I<>.ROL^C[V(5_CKZ-+FS
M7N=>]6=^YV(\L;:1B#&"-O@3<I6:?@:Q>P1WVJVX';)RO$W,T[I_N5@VAQ9G
MF"A;B2F42)K3XKJAIJLZAC9FT!9WLF2A+WS-86E)#N9L>/>KB>;X 6FP5&WP
MXS6FDCY,E\WZ5]:DC J +_"T H;\:WU;U"XZ.7D\'<2#A(!R$->UVQYD0?.S
MJ><]%FXZL7P0V3YQFB/-5=GL;,43#@Y<.TW(YOB4:09Q.8R:T/WNV'M.ANB6
MM0]4#!^W]E(.?03NZ5>I,88LU.[WQU3V*]J+L\J5PN!F>7H5T-DEH<_6'_^N
M*+U3H=,#/B]"Z>V\-&\Z;F:S>Q1#+49'5[=58KZLPV3AN!IKA#8JD&1? _K?
M4H1@^('( V[X3HEI+6_1-T9E)4TVY0S1I4R7YHNC*VT2_N3 H8W TC01U[99
M06*)P9X,A.OC4_MX<D'E.6"\!)M"/E+7#'W@W.P%H&,6\6\D(49^>SC10KWE
MY(Y?Y0LYHO&]4E29 ]N]1?>F!(2M&]5T.A*?#6_>GA,:=/A73;GR[-AL9*B!
M[;*Z+0P6HKD7*_&;F[,-J">X00_AAF/B")G@J\&)KL[PCUPM?Z\5L2WN7@L-
MR;HQBALRV=%!S.AM?L=B*2K=&IBV,+/52O_<7@-4J_IB:@V,-=R(WP?DYEJ7
MYB_]@I[3R8ZW>WWC$?C[AF'2H4>-[U<_F2Q5M>\8J=^/T6L8O0 _'M/,+VZH
MU-".-^3Q[E&^%*K[<XS.;KN' YYJD/' Z:L>2*X(^S!2(+Q;8$9W?(F< PX[
M+BN@/S Y2I;P]1R/6_#U8&A=MS059538;UTS6RMS]'KEV'TIB!J' F'IR\=S
M?0A75-"*V"I[<'E\RK\RHGID]9RS_/ 7E>-;KJZXJ<&#C4WL^@?"Y3:I3Q83
M^=4)R"6K9X'70R4[DBF.DXJQB@GDRF,"-T[S&$1*9JSJIK,C3BW15!F<1A K
MAO8A"R"OA?A/A>0!#KD$'HRQ9L:DJF&'.X8Z;)4<^3@MVMW:O6H\MNL'FEPQ
M:J;N@$R:W/%';Z7/!C&_^TR;XM;#"P@D.8O<39C1%B*/?\>@)FBO,SI LN0*
MDJ)*!FR9[A9_A_6!D"X(=T!PJ#!\+T43IN8_-EZ#>0O9(0B%J'V):O_/[H\G
M D&A_A/?M:;^_(F@)?;C]+P 0(4@M\\5\Z!T/#><IBH\?"0&.9126HV$0JD+
MWML+_&V07U**[&/7G8F_SM7>%K[UUZ_(T/>D;(%)IA6K\PZJH48<?>=V%V7#
MS]FD?BNMIL>G;%<<N32'5V0)>@:*&JLHRN8>/G2(DU%Y5HW,2+3RN":19Y_*
M[B;"<I'YL.&":,S)VXDF?%'.?IV8#%=5)2IZ%O%M?@">[7Z(83-JK; G);B.
M75J! S:X&L<N)_(]V$[N+>7V>$?"N=QQ.3[I!-O'8U0[,*,:3N2\+ON;+/B;
M>)$17CNPV:=F ZC-3P5Z.+IY8'TA)&HN>-37>>3=/ ;)KM"Z' U 2:6\1Y%6
M">VRK/@%X.3Q]MP*B2G0Z;C5<7@[CHK/BBR/2U];@1]-DC5QW%4:P*&:U<GO
M6>PXMG$GHE1D>61F*<,DHRUL;/#Q.HL/Y8&'3C^;*+"HIH[/OJ@GRK3)]H<*
M^.\=T?LJO;$&YF#WEAMVCFXZ"?M)D5'?<LSQE#_U68%X@(_;F?Y+T&A7IH^;
MP*3K7C;%<398 4K@=JO?.M;Y]NMTZ_,EGBY3!A>?N]>6HFC+A=3:4%,RW7@=
M,F"V>P]IZ5OJ>'6B$579N;AH06L^RLH/2EY%SOX1I_+'\<#3^:^\<^&*@V E
MO+9H-%LVH(*!E6:<65%'JFW37O2NH2M!K.95Y5=3V_'DP+AS\[3;P%,@414U
MXZGM:%Z$:F042\%ON:-V%@0M7OG'B!PE)3'GPVY#+Y^;LW1%S?U_?LXT$3\1
M::.MC:1AKE=>I/"KK%Q1>/6:0!=[)3L6;404,Y E(B+7 J(&(JALC?CS/P*<
M_PWR9)M9L-<EQ'T'6^C&PYOZ!@.1@AB@&F[^I6T[LN'9'W4FT:# ?3D=F[9_
M DRT,5W;JW7'A\+1[OS7^]/4 SUL$1RB2&G[9NTJ[, 8V<#ZK66FCL(DZ>L?
MLY5-YT>CI#5?UD4L:2G)6[?6#DZW4QL5OL<'D!S(2".554+\-]P%']N65XLG
M1^S%9;HY&V)[#7XBAP2T-%">XS!@FUN("Z8QS@K6'=I1><3O_+'?2[Q)596D
M,W)#+R4/B^EQO5KSXMUYO"=P+L,8;M?\#3[3F!>)]K<54R@6F-++L:JQX^P+
M[5WW*HX-R>Z!&1G\.J5@WEJY<9"]QD[##N')/BJK9SE*M^%L<"?1<?S@1DK<
MQPXD#<5.[,O (FV"35#BBE-=;TXKKUE6SP[89;XZDYZ4Y>[YVL;G>B9_X^"
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M_:&\]6-.3AX\?*DG):JU&\]VK>::3J2%F!-/:1^KFO&GHO;:/Z6@:_RZ!.&
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MO@Q_-Y=?@MZ[)#I2UAYHX;7V!J,%N*[H**3U,GX]^0RPTLB\:0- ,]@R=-(
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M>]ZL;X-*Z1O< YUDO[8I&579"G9OKDJ<[GY8,WYX6X2F_M!7G'CGNM6G,+9
M_&]2**%^)3*2XQK'[JBA933\Z(>Y0P+B.<A?!IXZ$R08W+Q=RJ@X>%4<_"$9
M)Q?_H:J90D( +4EHV/7>ZBZ:9YV4[VTF!/!/&W9/F@+XM#@(.JXS*!H%:KPR
MXC9]Y<0 \WHMLR4C^G(XPM,0DC(UNDZ%3!/<4L$=7H@WG9M'4J^?4K.I$>#>
MQV,=5&E10'<J(F)AF%6)*8S+5Q^*/!@"C"A@;TCVH*PLOR,=L: 2H9?1V+X@
M-/6RSIY818Z(;.$^:K]03!%L1Y>2._WY.G1EQ_/IY)#1-6(TY!3D8T'?!V-Y
M5.TE5A-F=/Z6EBH)T1YS98FG(CH;6#2%ED/9+36FYOBOA:ILS@"F/?5L."7W
M"I"P *&I(U9"#RSH)V5#LZS<75=JO@R(X>M0Z#U-L_PJ\T5X?D/)XOFZ<<<^
M!=!$R^G@YB$*;V+9LJYZ4CH))^11BM1UBC4V#1JN*ZUDC([6#Z,ZK[,RD+^S
MDJU?3 ^*NNV6\.4ETP.)N,^#,%0T9C=&)M;!2MZ$.XV1&.T<5(H2$N"ORDR+
M@6ES](I[=/>F]$KSW5U8-WC"V:JVYN/S!NZ".HD$-RTRRSIF%#S0GCD^> !+
MDGNB?DW 8!I;'[>,N5.32E"PS36DDM7DK:;_&8"R'2/K4<$4RO:I[W@IW1+7
MZ%'B\6 \ZWY93SCLQ9JQ 4:N9(TP; Z%23[-.G^"K^^8:X,\&?DE?C^RQ$O7
M2JDB([]\RH6R/KO4AZU?CDX./GXPR[@^GRJ\(-90#*Y9G1V[)0@6SZAT"A9>
M <G 2E[QC)0).-3JXY480W?E>AFPPX$IC(D0ZX9*A9O6Q"OK!*9L2)I%AJ;P
MP_M[R$^T&TURME*A>;-"/BS!?AXO7"S4AR&UR14>1$WH^&KJ!#0IPI*2AC>\
M*3@KK8)2,(7-VO)N"5#*S3ZV'8O14*(&79'2$$@':/#+B KUQ#UB6U+ 1A%0
M:I716;\;=/J9P(@HCJ.W6@"5P2C"P[FSNS!$19Y.RF\^N6%^7QW5I5]O5*#;
M8*O&3U05/N2O*G]5M.8NYV-K-L.;O;GWJS68[*'Y1C2QL+<9L?0QWP)/.T#^
MBCE=[UV64;.5T&7[E(K>>S'#2@HPXM(),!E+0G>?G_H]%IFD&-O<HL28F^,]
MGHRKTN\:D+:L/#5X*/>5]^,*_1.(7+EF>:M\)6;YZ_ZAN, 2O@BC+&'<32,#
M=+8E^Y&0"HZ5=@_L>C66[-;4GI!/,O.@*3UE ?80 ?K$H-2^=B2D$)%[>;["
M[6-A$[JV0I1E.:(5V3)=^BZ.(;Z':?"E^Q;/I^=GN8VL/\YE:$3;/C MFF/K
M478,ZU8L".%$*0\+1UY"]=M==5S=T,<J0+['*N[52^QB_/"*)XM.1U#,C:\-
M (]AF P=OT!0@MDKTUZ7$Z99_/D9FY<KB80PI,/,6S%"Y"]M<5>T!$J:51O,
M[0CQ!-B@MYL3@78^3+*T=PHQ]//*]4]M:U)O:[428S7O$1W9HQA+]6N3;>B@
M$G^0C^)C6>63</$[^B:54[];QJISMQC(1-'.<24"&5TO+IU6$8:O%RB+0EMZ
ML%RP?US%73._K<YB *LG>S-S%U1,.&54";T^J\;047?-D0@FD31%)76?Y@P
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M "WG7=7+S]3ZRVO'B(N;1U;EE(=Q"NDPBZ&L*=B.?X(CK(2]+$T-<S/%H7K
MYZ[IC=$0]COO$Z#:*:PJ,O9R,%%EII"F[/(N'(:",K&UJ"A7Q#*I=C12^VZ3
MN4P#!Y!;YL4BSZMSRQWW)2T*[=Z[D"S")3'!#9]ML[:JK!02AOC->7][G3!Q
MU[QIO;@U;/X(#+W'0UCW&>4_4T03BV80,872P<7S8*#$P^@>J%2/TS-9=R >
M[Y9U?].+.6::J%#D]"YP]1G@>3ZXYOVC7<P.NQ*5@)YV1R?Q^#RCLA?Q"\R%
MQ'S30:1(GG'=%F3M7QX.@OC>\G9&MFW@M6<JY<9-9[K;S(;C]1J[,2Z]3/_(
M1YO^COR>WD[G]4Z.'<NH,X!!P$HGA['R; "18$I]VZ,<H7X7C!EA"14*)#YZ
M<CJ;<GE\T<RZ#(?46SX&JJ-FCQCO!(9:D.HW2YF]BGQ_+,3+%!(S]!@4%,LO
MP[P&L(UWP7IYA.R'M&F<72Q>+-Y5LIY_"U^;)/VJ%:4RZP0=,6KT LI;1<CU
MI839+&+GR9L8;:_$PU@D(1N&02F0_O!YU8HG&Q,?(Q0-3C]7LN0]Y&0RPQ=A
M)\>8O2,[$SXZZ &:$7J.<)GMVS#@3AB_UVKERY=B%,S1+]X!2,(DH.V@H#"N
M1&C?XT*G;E?+9I8]QZ@7ZWZF.;6TS1ICDZ3:#3[7GW@:[FUDF%(/34TK4+ \
MDT>F(Z-]%9<ZJ&!*%$D!@1L[LK+"X8H5ZB]<OZQ]3/A,:[1W?(3=*J->P%S(
MS:]!Y1O(JRUSB$R-'NN6L9A [>]#Y_#U9G^RKE_P".6W<GP)^>1[$Q25HT\R
MZ!DCN":E<D 9SU4&<Z]40E"'3P6_BDMU/UR\?H0'#C?RJ;OO5^1[?'+T"N!Y
M1]:%'PDUZ3!PMAX5?5;USDU#;'^N3KW]ZQM7O%D?FH2YTQ+=#8]X-?H*^_5C
M3%Z=*5&G.C'2MPJLJC*"^K=:JTWD'[)S]3L06Y=J@@M>+89&\98X#DA]V6Z,
M*'K)-\X;F<82"YW#ZYC13VY='#HVFA'&?4"] U.(0U*@3B/P[8M5?]^\:N*:
M?8TXF"U\)68AJWE/">6;S"=\Q;?!,BP:BV(6'0_"Z3>M>36=9=](#K'4.;IG
MA$S:D?HY.ZO;</I*  ?CLS13Y[5.D_:D9IB9^P%W<:,%E=9#_3E2KK";1QV^
M4$QR0+ZG@EUHBM2=11<PO+ESN(OH>_^V<>R*=KEF23^8.P,,?\L*F._D6.VV
MCQE=:DRL+)Y=>VK.OP'"G$IVQ:86-]5TV!J2>:WRY,IT_KI)@5/?],%@8YU'
M>E=&_!V['#C7#>Q2H0..,T!7L:O"]?<\8P<'NR6-5_BR>"PU-:0ICY7N/R"<
M[7ZB?JCY0"YQ7<=U38HOT=\MBRY];?ODVS>O$L>%_\#+_^>- YG)/O$J6-]>
M*>:--6W^F\TK:OWWV@>:M,5*[W9'A%6D/X&JW5S5'1;-RX-RHV#)Z3U*[],K
M.?C;4Q##TBE3>ZF"JW?9I"&V4G>\=]*_#;_O_A+0?4\/*E])*F+_6KY'12U"
MB"N8M1FMNF+,.(K;HG RJ<[$M6LTL=<DROB^='A6W[RJI@@=SKZ1/99.[IOK
M&HC-3,2F*GSW*H?SFW[_5:K^Y+936EAZ^<BRV)?E\T3PI2\//Q#=#9'"I((5
M .INX[A<C0LV[;%-?6P[8-OCG=4XMF94WY!G44M!N_'T'BF!*",AN1-51/*C
MWE[ACBBEM)1B^U7=H.NZF$[$V)HO<DN[)5^ S<G?)=;@1!@]#KX&G2'4"IL7
M,.,@L^Z6/C2D1L:2B#,+)3'M0BP8<6]D.M.8 (K]U8 ;Z&+',6^\"X29*G;+
MV%U57%5BA%DF;PKU$6N_S;;@IL)DX5KAVN-+5DL*MK N$+E;O=9<J\?'M21>
M-6H8KE?R/"J'W)#9=7M'K*MG5F-F")-\BR_]8.V#^4<.GEJN7:],NND2<%/7
MX#>V<$Y"+^_7C0++3@L[0"?A]'=*7Y?+HD7S+K9-E7+;QAN%CK[[*9.P H.N
M^1:]@OF/0E_EDY>).=KUK/ASZ[4)QZ4$CHZ10KON?KVKDM3SX4&7?5>.DJFI
MD:"DP=K-QG7,4D][81&7&3.SPPC,3'!T @3\0C$*BT @*)0[\//'3.$DH42K
MA10:XPFY](=FR '$<U\IA]0VCC]Q=,J%R:GB9C0^'@NTKM=CMEW);B%-"94R
M@K1I]\<>V0U7[<Z02/F30P?$F#AK$[G$Z0^B[BC!/Q;?%^R>=5Y$VH3T1W5P
MI[_-%B PD"COD.WT2!*TRXL=)!)4*UYL).0,;21_B$R-OP$3CMEC6=Z.LCW8
M3:>.6J;C::YWB#UX]#SX6+MH:2->?'*F<D+T_2OMQ=#^I2!9LZ\]!N#I+1P2
M+1<REPC$Y*/1D7 M#N-)N]5=X=VJG!/\R \4SX<-_/@EY:;4">=Z74:'3XW-
M%/6@=35$"F/I%9P*]XB$/)EC"9\_JI/K0Q&+7FEGW(@"?;U%P88*D *VD#(J
M;'"FD45E.Z765C>K>6RMEIM!?310?>:')*"AMTNP$D.?6=W1*I'")CSHL5'(
M=@D>DEDC"]YH=R,VW7U>FF!ODK&:O&LZ+YDQL+_I:D^?^483V?"^3\_CH/JG
M-ZAP&]JMPJZ J3JBF0%/W0VQ7X91!8JR>^,*]&Q)XXX>;W>@N,YPM#^0?Z56
M!(H<J7)X.O\"E%#]21E=KWI9.&) O;?B%24,]PYGD$K/BK#0C"(J;C5^V$84
MO)B]SF>XBOOU\KAY@D68;%K-FQU](EBF&P;'IZYQOBT!D&@#[V(\!FYC\K':
MM;&WK [] ^557^P"GAHY42;B+#=,7<6=?&R=IF5O"ZZ*K%GC](@R12HSKTHS
M9C#+(OYBV<L]7W9[ELW,PVADFQ!":M,DK#,^8&N<7L,1;]GL6D1:ZBW>6Z(Q
M+.+Y=';SBH E<[ \.F,MI(=\E_<KW^[J0%%R$DL*WAQZ.R,1-8H56W>RD15Y
M+HU.Y6HSDU*2E,3[4]AKO"7HM=)OG,90F0A9H<4U#:P HK<OHKBR1Y<-(X8I
MQ:7 )UMW*GK+8](87H!5>KZTP"&^SU=-3>]-=!1-OA2?%.H8$2A/\WB"/*!V
MQYB7'9.QZ%4#,>AE[+O\(7"^-BL'>> N9_/7NAPY?'NC=/]3,^OT*7>B6?17
M1W.HI9ID,U*H1UIMF'%U#CN<P?XQ\4AFK#J85S'I[7MUEJ^X&F,X>I!X@L)D
MCAP,RXV^RJINFC\R*,$<JR4DI3*Y)4#0*L:AW%-E8XDW5J4C@]9QS[@HK1*5
M?L 4MS56X6T5P6-EUMZZ9=38/,BF-+Q .DNT^VM]GO\.8D:QW8Y:/MA1.:HD
M('=J.&RX5SI9?#6X8V4SRZ"WJ6=\7@5[1F=J$/^^NW\W?JO%.BJT^K9[9-Q4
M[.02\*#3 $[M.*:PIL:=73X5P;X6*#T\W/*HW)G)4OFU7@')__Y6@F,W9KLA
MZ>N<BUMK9)>P"<"Z>]^E2&6 BL9]B9 F:D;K\VC^ZP?"C.GMI>+])4J*NJL2
MR<-O&_ *]=/T'3CP<UY3CE\?''SF,5574%>LY&NM5$K@GD*TWYPA]5:!*-0B
M$ARK?+C&&!H[PT$(T Y')AF$D[K?;:&88/]X/L>ZJBP-^.(^2[3=7>N2^L:W
M1CX4D)CNO?.@;JW+_VOG$,8;#)<;L1(]R\RVU,M",F@/B0,U!#ZTKKWR^^IV
M0.-CYQRI:>H9"OL(]'DU5'S*4*GY$10\BUY$OU'+?YLA/.F#SROM)%T!'/24
MO7RF5MUKK6B]-JKXLO9=">&2&-KPH8(QHIG6I]4436.;>Y@F%-*Y%?-7C>IZ
MN2?P:84-=:9?*V)AD+Y1EW(,:GZI^E3A ;-NO[,SGY+-O9O1RY[72*A[0I47
M"U]K^G0=;^Z04M2R;"E-S=LZ/*E3G+4MU!,#(%LZ1UL6R=/XU5^ET(S)40C2
M,R:I#H_E3-^SY5*VY53ROJY[[^-'#Q^\X.D,D2)XAOZ;-HYH=:*M(=;1<G-Y
MU8(^LI7^?D)F(E)3E%@LY$IS#A/U!<BH$ XIOVC0UB9;G6G$PT"6NP.12PS#
MN"FZ9P BQ\;W!\YX'IXV^]DU@M;HX:.--*E/46\()3[LH(!MQ+YJ#7H:A*_T
M8;#&PD8M+%]2J&?,1A._((%98H"C;_K#O#'0S5M:R_Z +-7B"=NLC\V68M#B
M>/7 M1/UAOO+GWJO]2X!5'I*T/&7M\2G9-YO4MUZ_^&Y8^'B5 U47EG W?RN
M=I542-$2!5F7(7]][,.41PS$Z&0]J)OF#]SL+<4+2)X^<K/OZ_I<\"VR-K8J
MAGA/M--OO;(@:%@ON40E9LQ98I;6QDPBV[0(AMOSF;'^LY&?.GAZHQ3;@.U)
M,>_U59$\%U#PY\>1L_KUK@NBH)0E#89HE%Q3E5PB'G90M]M;T3;M;=8;RI]>
M>U#87W?&U@];>KB4.)(NB4IBIIQ:IQ/ZXK7-JPY[8N;FD[XV*AM!T>@F=OFB
MH3LKG-4OGI#K%G^IG9W,K!D<\.BA^&P<,WX3M3%]&1N#>3G6?[?3EEJ= VJ&
MC*[,? W@V2MU,EE1;FI8-*'Q)6HZJ??@6EJL1JA'=&*'^72ZD;ZW08/B7*B(
M>:B-X]/XC4@B-G&8T9TKD5=G8,!"[Z=5TY/R7^7&02V6;Z?'!B@AE0'K]CQE
MI5R+'*[4P9V,)V95G*O""O-WY2GKD'H]M#=O?Z-V?$1#(V+9CC*8)UM\*[NZ
MXIDXEHE05F!@H?5089<I5TA0>M>7F%4H^$#5?^446K=M[OF-6\C''>X@U1S"
M.>"F;'UK4BG>;%>.]H@(G;JZCHJ?;O_5'*]6Q(9HY(QFV7A"7FDUC=0J55KB
M.L66<\X$"X&%NNV^**Q6V9E32P)=C__1;69.BCD/$GIQN^KBDXB<6M#89A(+
M42<+(E?QRLP#2WI)JI%$Z#C4O%6,U&5?Z[C1((WJSKRF,=<[8TH6"M\5@XGH
MYSVM)O(,8F0>;BC:WC0P[=\-ZWO 3K4IU=_>J]J=([T</USX@D,5=Z0/*;K_
MZ0U^8+R$\/Q+ZYMRL!>?ZTMOSC?.FO5#F12VR49!=8EL077LM4R9C",]BF]C
M<Y<QUFVE/#C*+5*X2B>IH3@Z)-6';6-9*@D'W0O8IRD[)P';W6OW#.IT']<Z
M%63EO7Z^;V@+[<I8>*AO@Y<J2MV:%/$%^.0%H4OZ#:SD+1N0YT#=L=*@'%75
M.UNT1?( _OS!M4 BME8F C[1N9[7Z=0AK6> P\4U<GJ;.G&Y9[=*$N.69W+,
MGJ$2QK&?YK\B7^B(D2-(PE6S$>._'PEX306F7BP5$LT3P^HNO^.JTAGG62CA
ME6A\G\!86&O'*-VDA?KQ0714*!N>C6 ;<EI"RJ<EI?:!E10B8'5_LON+)]ZJ
M$7V%^$S*:C#,=VY$2MHOA&,#7HJB*=/>)KJ57'#XVE]>=&T!F%IP@^>Y_M."
M"<4)-R1C:+F,VOMKIC%9O$X<#WJL!-Y33I.\]X &,S*-T-F5/K=W0"\->>]+
M/O-@@%;O#FWG1.X^I<]Z79)/5%(YOZE";5)\;_/Z31Z:9\,5[:A#CV-++&2[
M#N.4'-[=DR;<]XJ[58?'I.)6<P5PJ)Q"G?!23Z=;,M1A<KO0D_;]YK>:A030
M="HGBH$QFLTBV6>R)O02[AOYRUWDO#5R:,:%ZBHIKKP/<8KGA%N9KS,O4G/+
M,LT&Z\H+5TX2;(2Z%].F?$@A77W^8:[QZ;:3$$5?"-Y>9V#D&: 4*88K5RT.
MW:@>&.@'KLWS=<P;S.X</>7QM(6W+A0*&6TE%&UP@^#@FDI3^TR&?%5J!MN8
M=R4O>TP$Z#A'3YV?S,5]6]A+J"1K*&3!L)"\G:RAJTO!K8A"U)9\GS!-C.FF
M8UX/*?L'0TH3C$D-?B9,:$E+%H_$Y.28V4?2JLPN_()(\0 MHRG=D8*1TNSZ
M9KL*Z+NP50&&:FP#,6SF0*7''$_9H@?S\[Y*A>?N]=/<RG_<M(ZXK2 N>!XV
MNW4\RB5&KEBG+9S%TKEAF)8(8C3.5202J':D:^/PQ>QR20=*9R%N/:G7S@#2
MAUZ+=TZ.OM'J[SK[GP'8<YJ6-@=]"Q^J#,:^:4JIF*N>,2W/562AEYG4#7J'
MM:J7/1J<0EV0IK7!$E3&0/3F@/1ZNJ^VA8'$(\.]NWX45F2Y4&[N5-6[=7IU
M 6A!<69;_(DL,I@PP&&C+>KR)ETKS^+@PD[QT_)C_SGS9Z^D'WV(=W!V=W=R
MEI!)D,<,NP%NJ/7H37,3]2 ,[:7HM%DZX2"9,G9,^T+*7!ULL-ZI%NT4]A6V
MI9X&?"[.#I"QCQ=%;=,-]]/JL,D2IVR^R8UKHZS$RR(\:V1PH#I.K#M64H.Y
M'"_45!NV G0-EQ7'0JZ5^XS42@]PT01:2G[D3DW+>5YL^<%[:['YD>SXMN!4
M8]W+>V[V-UJ7BKSBO7SW;=OX;RAJ=+$$%<TI;3?-@2$2NM=F*0QD XR?]?7V
M)/&H1F8;>LABBT/XZ26$*,(TE*R&S+X%[JY7VC _1<D!Q+_>">W9<!R8#*BX
MD:D2Z9YHQ%:FB('=JXK#.;N1/X03$YM=LU_^G!\4 =+-O";EZ#!#].:&N3RL
M%Z=\##\>VGO7;X1 [^#+&O7)+BGGWL(S9)$1*GVHD/)$L1!98UFT20Y7USTD
M&Z>7Y#9NU@I&Y/)\]Y6N7$-"SZ]OQ[K5)\7HY%>'6<:IG.GZ>;BE+?/TFY#M
M-PVVEEUI#KI5OW+@JF18TQG =FK+5VJ[X/5^T_#*B7_YK?(C"TE+?Q/#NCGG
MX2PH;4! GE0 K;24M.?<<7T>[YS7<#H#^? #6I>'RU(21SMKW<O#"\>'>9+Y
M9X#CZH #XE/ID5.Q,T",5Q[O+%^6J!Q?5G<Z&T)A?JT[:R[K<$=E%[$VGF^)
MNUL6$Q8T.]Y,@'M%'K98F]@$2+4XG.H+C(,RU<H? S\?3>GU H5%!RU)?#IQ
M0UWBQYM 9F:P$[&!P4HE83DUA_:@!6GN.[TT)VO[>RC-\N1BJ#M=F.1BY&SL
MGOC+@)!X?!ER:5EJ R'31N]*+ ?_AHW3,,9>V\+8DO 0?K$BC29'![,YW;6;
M<EK'T90&+H)-N<NP)/RF:TO,!H')+-B=MN'"+YC3;SVD_=ITLFFB;/M<FE!Q
MWI0(E,8YZQ[3% _),RS/RPM"4>8GENUK]) @#!:T:ZB8_TBFFKE>TB"CM088
MLJCM-3+I?*JULN133B>]L]!2_LAI09SG^?FS8AM\/=JML,SL]J,U[2GCOB-U
ME2V.WFYHFN8'%BLJBHYA[I-4<Z\XI$0%5<O.J>1XO<^99X!AX+'GD?Y.B<=:
MC=X@4NY^9NL($K=[&NJ\KTG+!C$5TJFF7]36R_G*/1:-_NAKWPI9^]Y1EF7D
M0AA#2&T*V076^D) ,J'8X#I]#H?IKP&[9X K!]^O@O]KV]TU#R9M'+Q:3M32
M3]WA(^\YMT;2^/G(WQ?SDZ$&NV5YUS&P?.9<HE;FB%H,*\AV&[B!CYT["-7^
M=+H>*X-Z!N@!P:Y0<*S,)4I0TTEU$!-_W-PM%,E?F^S: [^6+*/\LKJ=FL]8
M>AAJ%/AF8#1Q,E(%73E"T1HWW:396C2;_[80YC,7LR2^(Y?QN8]ZQ9'G#Z#(
MZTSDQX*(*C*N8XK&:;U)$[V[1A3&5-'GIV*A>^ ZL=;]))]<92%V/;:?JW3B
M"3:[*F=<-_:V/8VV##TX(_A!1$;1X_1G=6V/B=QF4U":?:D!_$9'UU#B-6.I
M4T=+>>I-I1N_>#._GUQX1;FN_O64'!R<BC[ W>]Y3/WBQ=WPP+>8!U?55<I[
M\/T^O<1$OVH1Y0(!3J;AQ'-9N7]K+X5#;?-K<*#(752>$]R039[\<>Z\VN=5
M%;49./V,W2B;B8ONGQ+S]8B4=I)SX%+79S\8M!GE-662R>*0+X6M7P=&SULH
MV)>A1,PPO(ZY]]0\52DK%ATW<:PY$DK#I%\OPC]L/*DY72M4.]11E-3XA&2:
MF.,9"P.@17M67;&Z-<J]R\CL,Y?52> ^=<;G3^^$ZQL2.9X\E76&?5(6+A^G
MD>>?GNTX,)D8?)']QFCD;M+^M=J1JAF%C:4WK!P55BWUUZEAR1MQFR5[@P[[
ML[Z1Y:O!2UZ+5<%;'Y*4LVON7=/N?/[\[H,.:WU%3;\<P0^WC)_))LQ(\'G4
M=\$ZFSB9:9.I)[1U(@2CP*NTU^)"5H2(_&DS^)P9!5VB>=Y\N:T&XD^*>^OC
MF#^E\LCXH3ESUXE^0X.VPP()]F 6-I _GIDJ;%$@BM9%EF8K[QO#WJ,=0OBA
M3]FN9A)M4O@1?N!S]6+CFMH'#G$XOHY3WKGQZ^N< 3J+#XGXI)$7QX?'FQN2
M1ZG8GDTJ[ZRN"L_-7JM[R:]V4X?B!BJ\P]LI@5[Q!2C],_]GF;N'_CFOY'L]
M!)7R=0D;"G#D0[=0C\>+27PR&UV+9UMIY_DGO>;1HR$N.9J1]Z%QI$S1GQ\'
M=I3!>"4,4O)>?ZA:YU<O$GY"F^/A;!6ZR"><2:-"94G0SQ;S1$?D#2' PY]?
MW6+(9$[WGO[5/(\:>:[Y2%_WZ>OCT>XEY6^OPP_6GA! KDBI"Q@K8JO&W+X+
MO%>A%!'I'I?3AB&&330?I<+G_K;*3"??_*I#Z>OA[3DTM?=I!/:-+D3)S"1W
M=;3&2^S461)K4@AIW*M?+*2SK)+EONC[^F2<P6A(-,](ZKIEBH[N _8AO@<+
MZ<MT,6I!;Q+E;[#4YDH[ESH4W>EF-J'CW66GI7\CER%U)Q"+*R87BP>/.[ZL
MXA40;ZY6O0>H0?[DE916H+"N5=547\0'2\ZD_9%U92O)KW&#;TU0'[B7"*@8
M U/WY:Z$I8LKB%YAK&QGOWVP24!2;T\KNJPTDOZ,>Q]="SM; 'G GZ8(76/+
MBTT(8A&.I[_9"?%@'[+<STEE:7NW48Y='C2^%P$JW;52<A"T<M OH]*VS=OO
MU!\]4A:^DIXHVJJOP02LZ?[0.>+HSON1R]3(L3$N@V7#W.B&USUNF5IL;> ]
M5NNLK_[4#=R+PF-G@++^)V*/BH5N6,2=F+STX7ZCC!;:^;E*38B8B"2R;)8^
MCL+).+C$B@2YB/WUY+&CGK.MR?[-D9%:$4CBO5A.60*24&*4C)*>&RP3PD6E
M8=2,C"N<NSWW"1X?Y>5T1:(%&Z!(L[;7[Z$?9HA/J1DQJ3J*;=F$DC-_?+[<
MBO]2)48K"TM9JU6$#!RMRB>)M?WVD6K-&-.S,,&:^M0E 6;7P3- 5CNW;")-
MW$PVNE8N0P_[_1VG5O&XJ:@/,1V>9)-2?6\I)_M?:,^C&>B7!'W1H\303V#4
MI=.@IZ65K[\YARPI!DD)[7F +\%F*:<@N#'@)/3!790+/E4U6IIPD\BT73*T
M/,C=XQEJXKOQW"M5]B.M2ON*C4S;&=VT'F^VM3)WM>ZM>]&.4BR3:;5%Y:.=
M"-Z(U^^)Q"%,_/00F019(,&4<DVC<8*DW.,CND=V=7JQ78_I+?J49YU/-70_
M*24 #H9MUV73D]H)HK+%T34][KCJ("YX!\ ]F1T>_.%Z1;( 6EZW* )-#.I
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MIS'_8S(/H[%^'9$2JK*5%:8(J  &X7YJH@ AV6&R*G:H+[F'D3A;@0#JQ4#
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M .?E->::6FN,DHR+5_6"C@VV-[^368B^@OA=X/1"S&$O(4%Q#TR%.W%7F<+
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M*QL"F9TAQ!7$3X!HO[AV+A8)ZSC%2EA[QG!;:!A-N$VL36X07@E=?A:)^;=
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M,)&Q5;A1_!S0+(48B#]Q*5[H:T'A>P_;ET0%OYK'+K8A"'MS+"<)5$2U7/1
MBVTJPS>_FY-A'_D:7%Q<516SSSX!AH6&Y>LF<2$=]EWTFBL*9I8X*QL!/[0J
MU:I!0%ROD3[.BQB4$RP;> ^W\TGD*30OLJD&#SARA)G:%7.[U9U3%XERNSZ3
M'$WZ+(N&5E3=X;7^^ GL3;) 231G-B.H*(H4?0&I.D(KM>[.EF@]1D&;[[K:
M7>!9!U@-];B2,+)M8:/GKZ)YU7H=>8AV/1@U.PKS0[4"!1I-$/!;R&(H:X:_
M!-$2&9&R:<SUY-?PW57WXZ@%74-)4J'#$H@\NADX"_N]N*+K?9S,$;V2^1 +
ME$A83UX\ZKBA88C*KF^/.VH58O2L6^RC9SK@_,[YSRC('3KL\+4N"DP1.PQL
M-:Q3?PT]<(<Y=F#!_^5#8,.G(>CZ.D<X/F3<QIW+S8X>]9#V5=D?A]#M++2(
M=03[HK>?VF?'JBZZ9VH'GS^)T(?NS[X:7)P/)[V!IO:$UXJ49$U:"QC)N+-B
M*#ZU70\??FK!I(#9M(+G[B)>*"!/P:?.T,;/S4A[ <NI%7FU5>,W;(/"G _V
M.OMM43R.L=NMN$+11?L9&IVL!0-4\U1L%I54*"=',^PT!Z^)BFW:?KN)M0"A
MV9()<9N'P^O[S+7>B&&?YG9/RNIP7BS-,#J%='YEUEJIL&SYBX[\MP;XV/P3
M8*.T! ;-SUAY1X[;M^[VVY<7?WW55H(T[Y0PL^N"OD^ T,O'SBPC_62T)K6W
M[>]WP:GEOD0BRJU^R@75%!/Y-( IN.@&'6U!.CQM2KETW))MC(K><6Q*O>N\
M>3\_U4+V5Y_?0TUIA%:683/"<MMT#'M7I_3BW.#8QM?Q<@1,4$N4N*$I,KJE
M0P2J3B(AYHK\F,.3C'W2]]T$MU3/I/75$[&R25N$Q<YX4*E.;Y9'ZX*-2G,;
MBO=I\#9Q, ^B0GL37!X_B7/M[^]\#M3%3IU[,O;GY,U)S8L*BD"OBA$0N%YO
MK(HBAK\Z6%+#91M@7X\[0 (?TY:F.=?2FJ'/H/;8 WW.U-0-G9)OO/338,3,
M,$3>@\#+^'0E+JD^ [/<[.;M.?1"8PP+G:M=8W0%YD /QNA;N2-HN=-EFY <
M]+,=SZ/>=/Y^[9XOK;,3SYGN1K9QQ G'BY)T\5)30\8 >4^&:+24XVK7H"=!
M54AWRZ"UR:DL)SZMJ<GG[ S_PD'30DY!8C=2 K.*GNE1)PEV3"?Q4K/W7*M9
MP?"V3&ZQ"T9"DHZ"D9%/@ ^YT>91A4'^S[RR]+(E'0=D2?36[/A,'!G*HE6J
M>V22I4SF6;Z<5N.RD>:OW05WN4E&)EQ'O)>9=?#:Q:&4_' ^&3C.J6$46>S8
M XY",XDSA[Z+4,:I.8:62<?8@%>ZQ$>\":VS*JQ5B]:9B($*X2MKO@BGLUW.
M3W4$2_G2[_[)I"0QM0II/.\%&LEO:]HV[1>[<O9G\HWANA9HB<.:NM'+>!/)
MZ_JJRWTJ=C:$Y2DV/[S,KRF2);?(6: DM8V-D?L!?-?37EZ4-AY6\$D5&A)0
MZN8'O]&'74^'WZZ##/;XB*L%-5RU.N^83-]:*5HH^>B:;B;,YB(TR)D.;NK+
M/U:>%GL+8"=8T[QO<DUD+U8(51L*ODT3LS?Q62E+;*GGL+P0(NCK%!8WZ30K
M 4[X])8MY>IG%A-8W_U5VA7B(/>2.XI_B_HVC\'3LR0&-X2KPB?CH$HYBT#Z
MB;QV5R5+@\*F7"6OI;LY7'Z2UZJS;,9"(%9]9>.!)!KEW'17ZW1^2'^Y(&0;
MDB&N  >M>]]P,BT NY4)) \\%JHKBY*7OF0?EF^:*B%2&T80R7M2Q.XJKD$+
MZS78(WV#0R .J+/_R-JKOWM^?':QL^G+U_V7?40>-3,Y!(_UFMK:'WS0KK;B
MBC"BH8*_4$14DA&BUML/U0WSHYZQX'E=SZ(!6=;#"(^/F-E,QQ/3)@/26=-R
M ]ZAGX$=* &D8)EGS3-)_=)&7ZE8JAB741NC6+_2.5G!0U/URTV/"X>)$A;<
MF99[(XWOC&2? +LOJX(G]ME_WN/6T!\,?M1HFUO4AU42#/[QPCI9F EEIFK
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M<$(Q4PFKRH)J-(GBW,&D5[KN+L)?8[N,3+-)] [Q5_*1" N$$9CWW=;FGX9
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M/S92+[M(W=I EQKUY;>WK+J#T.@R(P7V6]E8+F&3)=E,9 9K7C2[8"_>,L'
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M0\10TC2EL\7%5 73B57YDY3D78*6'0HG($+@7UDF:-%#QR3$AAK8#L!V=.C
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MQH&T'M!I3]4U5B+I.6%F?X&K(]DP3+6 ;NN19$VLNY/+H-L@59'8%.IA](4
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M=06ZACPR0QB.+2UN7Y]W0=ZF8^#XL>YO8VK8VH>/=N'\FV?0=6"O56@G%N
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MVV!"WTW)P\0-:]WJ-QZ;&4  9&@C%1^M.C+U!]&='4Q:(AUP:3A59;W&;[[
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M6_O@TRZ45M_KCUEX2K4<$VBA;&LI&K0.FT_-5DFV@8IS3CZ8(0E_K9;Q9?N
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MV:4"KO'$[J")8;X/7U,2QQEPQB8&&)(+<FF^E2_:L_'W_8O7LOM_;* 9]8Z
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M;=<""7O&?D=2F-DB)+[Z=AC].^HZ,X_9]\O:&/E+T+',"84_QPM)$7T0;/>
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M3!OH1S<1R<1S<^#M1SG;C(\$]RTQ?$K%PMZZ8Y-UO0L.F=&1,%DT)N"OYN$
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M7=];HD]X6#%L6A_,"[=SM+O'. UE01LNN!@WY7,%:[)0-)/;I6,@&#\@0Z>
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MFSD6Z==;8^Y]21-?(B0C)0K!UQL6&X;7#?'?"T'Y_IKA<!5J?Z5L$A0I@#^
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M_RI3N]6R2790IU43K[*_/\-L& VW@P;9E\A1]4 "DK!^EN%-$:=3;!7Q.?5
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M[N*87I)@!PW46(@HP1A)CO+USEC;NQZSK3CI,X&<TBQ_,^GO"C^\MM(-)S8
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MZ&HP&\=+NJJKS3U8Y.W'W\GHSF"@(P0J:>)H\C,J5,U583^BXN+]CZ?$I1/
M9HZ_4Z\!GQZ_HZL#;;[35:' >[H_R3?A$\%>VP(,'USX>%G:F?_P&-9%@QJ\
M3_<ACHX06QN(G?D?(I@_6BZZ\ O]Q@^ZFJ6YQ:\-&#\:X'W[2;Z(',35[WU
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MOR\(-S P;F#=N(F%=?,6%A;6K8LOK%O?17#^'07G'P XJ/#.OT5$H 9<PT%
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MH:)SM<]\8OJ 1)@YPI!R2[?X'O\&KF)A %*Q;+.BQ"B2G6.>-%.ZZ.E9^&*
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M%VEB(?<23^#.&^$^42A(0_M(+Z-14FE5\5G&Y M-3?WH<'S\!YJWI370LP
M!L(/Y+P"W>< MAJ^.:_=V'/ Z;N#\D/[?7@^F%6>?',FXN9]Y#1\#M V.0>,
M>NA0K*C(P'=DV9EUS\]>G:V59@OVR&M@)LBUO6KEC3,6N-TU,OY)QPJ $QW
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MCC^J.:LTXU7GGCMA6G%5J(8NN9+\Z>=P;9?IBE!>PV99*=6;()/W60T/S.6
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MYF0[""VA65V//^O)F:-/*;GFS$AKWG^^^KABAJ8SSM_\H8!6XUJ;A9,9X3F
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M,J+'MW;0$*:W,'?EB1:LQ^\B[S=^QX<N7&/);LK\!;6Z Z +TM?+N&Y%Z)E
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M>:I8;WXHT1)V?=7?&D_<R98JAEX[P# \A6WV_:M7,LI<-_UO%* $E)P#HEZ
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M.=D(;P;I1&[]DMK(Y3TI?=(RXD<V!(+,O,$-=W987T0SHZX^EM5\&O!_ 'E
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M6QL>]6M7UM[:>]N;:SM8FFN;JXAM[>),<4DTTBQQH,D <3,!DD =34$@ EB
M "22<8 !).?( FDE[7N>BN7^WKA5.WVI9I*EG'F7H+7DC6@W.>Q5#<4-*'1W
M5<'5&#5NIVUS4VPI I(%/!5Y]91"PS-M5'1-@??=H])ET?6M0MM8'Y6Y%PY%
MHK123.DS&6-N)&>-4>,JP+'BX7!X#N*\89EE5)(SQQ.20PSN.(@XWVQR\"02
M*AFR[0JBW[O^'N:;+=ZHOGFHX;Y7EJ-VY0F4-<_/:'CZJJJ4? Q0QTCLE&!R
MEN:XFMF(ET)H5VXDO6RZ$"JT-?MVW:>\M^RVH=G(X+<:+=:G92S0,C/<'CBF
MXG6[+=Z)G>TM6#-E(S'PJ@C>2-X-NINH[DDB1(7C.#L<G8X.VVQY;'D.5-A4
M\KVU*2N1Y,I1L[MG*3#FR!RE9C.17BPR3L3(W9WH06WF'BDF*Q=U)'HJ]H]A
M.$[14 #M)-R5Y 4MI[K3HVO5MXI': -W<Z.%)$<BXP8S_2LZ_ Q(&%8A1[0\
M3.D<C<'>.JAPO&<,5&0HYC?.1CA&_*O:+YQPU!FZ2YUEE'0GZ&J2WJLRQ);O
M2G!+!$0^2MH:"&QN+:,,>:.>QGK*\F"NA]R8R2*"*29-:PDFNK%+R:V>Q C#
MW*SMPQVK'FLDTG"@(&-L_P!6V,[5[O$5N6M8V[Z17,:A5PTC*W"0J[D@'J,[
M$'%)37[7N5VGQ >)KD;"U.0[<3>W[DR!B:V0./D@UZZC#S6=VM95VUBE.AEZ
MSC6&FJ+2)A4>>FT9=NT"W6"L#["./LI'V-NI3>W,W:235;3\O'"K&R:U>,E0
MSLO"P,0FD>13D.(E&4XV/E/W\<PMQ#$8U'\VX!8RQS [P@@<!0 8)()RQWY8
MV?)Y\)Y_G_/]_P#+KEAR&X/F.1I6>II6K'XH3IB<WP93!DZ$RRM.3K9HF0I^
M.A^0!-7!#QWKFGBG-7%ZFRH)FCS_ "4-Y1$,T%35V=[<4F3Y#/JH<O.]^_9]
M*>).VP_7IY[[\O7:MI<?A6-]/X\?_3_Z)_+I2EZXU\?V]]RW_>.(/_ DO_/^
M*]1U^0_?W_JE,1U-*.E*.E*PY?"*J(J^/W)^5Z@[ GG@<O'R^=*7WB!K"N3.
MY\]S7*^'ES*TD;W^55!P.!N'['V6._\ VV%W9CT9X1&NE>Y$3W%\V-[@VFDJ
M1@"SF<>!$E_=?%@8QD1JISO\%8*,,YZY^Q (^Y/EMZU/>8+!*KBCDJS5Z,^G
MX+7F(]?PU1L_8RHY?*HGAJL\_=43[?=4_/5+?/W=G<R8SP0R-@>2&K;1(C-K
M&EQ 9[S4+-,>(-Q&"/IFH[VYUZU? _$=>J(U1L!F8U1OX1?I8[O"?9$^R.]/
ME$^_CSU2=CU"]FM'P,!K1' (P<,S%?L0?/.>M67;%@_:KM P8.#JMYA@<AAW
MS8(/4'F/6KHZZ6N:I8>Z;0U-!A<Y]2%M9T*Y>X']IU5G;W12,07FWC\N9)8:
M*MLY8%E@CEB&]Z)GS93HPA5F,('@EJ-8N8H+9#*'P]S:J.&,R<[J$ $#&.+(
MQX'G5UV>G[G4I2HE+-I6M ]T&)(_A-X0&*\@3C //.%YTR-?)','!-"QT<<S
M&RL8^.2*1K7HCFM?%*UDD3T14]4;V-<Q?+7-145.K5&#J&')AD;@\]^A/IY5
M2YS@[[@'?8[[G((!!SSSU\:[O65*6GNAXMS'*_'%AF]1R2=Q=7&.C%)T0N@6
MF&>(04.\FM/'*L@::QALF0J"Z&SB*1L9,[!6Q33>I:;6M"D[0V4FG12W,$LA
MPKVW>.V%8.P:-".\4JI#*WP@$[C?%+KW9N7M3I\VE0W.H6KW"\!ETXR&X"<2
MLX"*2K!E4JW$C80L1CG1!Q?@B.WM,)JN0++0<?LJ*L[5[JTV$[$T.>HY:^WN
M2+?3$61$8.;OP*N<?0?3[ &OAHC;.$&:NB<D\6[86)TVUAL6DFF>V1(9)+@L
M9F>.-(R7#DE6/""5V SD 9K>L;!]*M(=/DFN9Y+1%A>6\+&YD=!PLTW&S$.[
M L1D8)V 4BE]I.V_M:R6F<E_S>7?F5A%5FC<MKN6: 6-YAF<T=,)GM")5OH[
M:WEOZNVO"SJ.\))BTSVDSV )\#"&+N5N;^7CR^GT./VQFK!Y%X+X2+,MB;+E
MTOCV[L%*@/LX]7C$NGV%3GL!>H::1MZF^(/N:07C;#[6<RS:67*+5,DNOG,R
M<6 2V/G4;[8Y=<\^OB?3;%6!V^<"<>\0+HM%@-79:D/D0;-6$YA)6:,KRXZF
MN)@"N@#<]3UK[8F[A,>78W=L;=%V*M&?":R%B,>J<],?Y_;RQY9IE^E*.E*.
ME*.E*.E*.E*.E*.E*.E*1+O@JY;>'MXK7[S98-EOW#8FFJ;3%4;;8N+36 EL
MVE)NR)=OD!P<W V(YMBI@.Q#FEG%C)R]A!ZVM4\??T\_7:GG'3Q!"BN]7B)B
M>KQX]7AJ??PGV3S^?'[OQ^[I4#D/04I?&C'-[Q^YUR#Q1QNXC[7_ $3QQ0,>
M0B6O<*Q[IW,TUQ-+(V1BQQR3TF2=[4:1QUEG#&S0VJF?W\>F/+Y<^>W,TW72
MIHZ4KKERRP#32P0_,3,C>Z*#W&Q>](C55D:2/_89ZW>&^M_[#//J<J-15ZQ9
MN$9\P.1/,@$X'/ .:4I?'FS-[@MU2Z$C.FYS.<4QV!A-78'UMA,[DVZB,IZ\
M::6JG(%1^;P99MN1 LLL4W]HF?G8K#:B9D=A<0-80.G>B6:[X.%@A0"U7#-P
MJ<D\<GPD]1&P.V16 ;C)V/#YCF5)!^I^PY;TW2,;X3RB>4^_G]Z+_7JN51P[
MC<[G//G]1Z5G76.!$LA9PCAX2A"H91R1B(F30SCSL6.:"6*1',DBEC<K)&.1
M6O8JM<BHJ]25!*-R9&5D/52I!!'F" 0>A -*J2WX+X_EIJ>LRM*+QX9F/F/T
M==X &LSECDW&$M,.BJ(A0EK)*JR):DMQG[*O/SUV]K/J]6;[<2Q[!O+EI6>9
MFNA*2)1.S2=X-\%V8EB0#@,&##ED8S6/ H&P ^I_?^U))H.8R,KWT=N/$'*G
M%9>FWVAXSY=CRW,&/R$<^3CKBR<K:0'6<UC/-;8RPK(\9?55W6@G:$&O?KLR
M0RX6+6% U736NAO==CM>UVSOX(+6QO-/6;3;J8)>?T3HR0K&>[F!,Z]R2$=A
M#,.'^47?S:=4GBA97XIE8AE&47A(V+'QSL<;D#-;/VJJM3RB)^?Q_!%5$_V>
M//\ /KDE& !X<O3.Q/F1N?.O:D%IZU2OB%:@F/=[N,VJX6J;(O%MIE@P!E!8
M61-2"DUQ-N;",^Z!N8S+,>(/!4<]9'-*U]U/%<%Q6T_/Y>/^JC]R?W)Y?O\
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M4*H   1J$15  "@*   !CI@<CXUZE_\ ^T/Q;_\ )WG+_9M.WO\ '^?W_/\
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M#UC8++8Y.JI<_82E U(38E-_';;WS]<>'G3X-:C&M8W[-8U&M3\_9J(B??\
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MJWP<&D@U_<WR-'W]\4\$8T5+CBN[R5R1M[ 9:^2$#2 !:,R2%Y,M/.:Q]/\
M3Z6(P0.Y&;[US%$1%#,(5 7276L:G%VHT_28;%Y-+N+::6ZOAGAAG0-W:$CD
M,JH(SOW@/($-]BTCL+V5G_!OM)VRU/5Q9]K+'5[*#1]+<N)+FRG,*%A'WB@]
M[F<J[1[=QD!N,&MD,C5?&YOX5S53\_CS_/\ X]=77Q4[@^_?W]*5?MXX+U/%
MVEY4UNOLJB>WY"TC+@B#+W^K*H;0SVGI8ZPG,VS0,[EKJ^F=$^>IS]460%'
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MJE)L+=A($=B2]XR_]9BKQ(96HQ81((_1$VL=8'=WT]9WL68M9M)$%D:U8_\
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MSAZG,>50Q(W9(M63'DZ;?["C='XL%=+],>&MHBYC?<IIF7@%G801O &GA9
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MP.F4F^ML>MN*/.HF2O@-)9EF]>598S93:N]N8$=4EB<_67$C<.):48AL1KF
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MZ!Y&RH,0P;EJ5Z..+-ML2,01 '($@/'%(L 7DC3TR:O]T>?GNJL5]*%>R*"
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M=_A_+>EZOHWDU(:XPMQ<0!!Y=X0K#+]7I0WY%T'[O2I$\3]K];QB$6Z(R+I
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MRR>@;>62]06AAPKI_'%3?SY\"G#^K"H45'1DC"L(KC3"(B049!1T5%1T) 0
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M/Y08KJA?:^RB(?#N#/"F@DU'K;PFYT,JO.NUX1F DV5)4AI$M[RO)G/3%OB
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MAE"/#^ :O/^@/_08-?BMU.*N"I(":[KKIX)]B4S"XL XWNB5UI/4E)?/NAN
M\"+L_)O3L45Z(RE9=?=X A)1@_5I Y.C5>J6=U(F7^2$&U_#Y*<XI5QTG!.U
MJJ6SJ$YX^@JYI(NEW)J"? Z/Q:0 [(PJYM2Q8 G6JKIESAOB&YOAL$]S,#G?
M:%V3FK#9L J/ OHDS[/D[5[]2@ZZ>3)-BBZ,XNS<YJ$PO91 ^Q7J]8G!.F36
M$\_#C."5N.(5  YU:6!7S?$[+?5;_\X%S&^HK_IV!K@&M6,]NJ]TU_"Q;LMD
MJ,WQ26=%!^#QP--IRB/:YB=>> ^Z/W<DE2B2@M"@KL,$;+)^HAW:+]KO9DQR
MRA9?OP*9RVK2U&MF"*:I."X%O4I!'^C&ZM*RGSUX'SRI: RD-I""KY546&CZ
M=N3/X2F%>:=*F#]."U(=B>:HU3&TC\XJKJO$.:GDR#O,? S7(XEY:/ZP;$AW
M<<(;^ @4K<I$-VS*)U^QP&!9@IK*W(FZKK+#HK:D/MZZ.^!]4 JAL=E/\?+,
M=PG/$WDEX_ @/Z=6)A>3A_Q%W4N!O,V"P[K1(4)#*SIG(D)>:09&EY>2B7Z'
M;CND-S9T_AH(7135PSC/C2<#BR6S^,,W''A$C M*#Z1XD0L_)NI68>B)KI12
MN!#TJMJVH=;O6Y.@5:Z0[MQ(K:V"=J*.A>1,-<-,3T[L%P;-<S&BQ2MAAEJ/
MPMVV'#B]N\7>0G/L%:B(?: ,6>VUT^2PT+),BZL!1= GA:PMW-4/\ +#',Q[
M*P+7IIKZLJ>:_.T6\R5UBBFZ*+,&OW@<L T&@SZ_MX<_9;HOZL<DGJA>MI/0
MJC<\DABGK5J,Y6K)1S#+:-2]8 <J<S.);5 [\3OQ[:W_]+5Y94L\.C%G%+1,
M;9_<$&RXI.YIK:_*2GOCSCSTM6$$=8C.:\W^2*&V$&$N#9S8;F*33^JW#*U)
MLG^Y\D(G4QW@:5%C3B74"1)/L.O$OHFPY-[/L.6OBAFFMC<DD"*]]5(H3DZ@
M[$JQ*OB6<F+4GI!9UN2C:X%=T\F;OGCB.R<'D=4Y8?D[8AO3\WK'2KH-+X[5
MXY<Q*#,B)LBS1D3I'C^^4ZX;*I$;9/CP1095J(T&%L5;\(>:).2;(,2,,_WL
MP*>W,94_:452DR;ZM<:C9VJF3<3<E2TS@C4K R2D0;,JV<M4[X>T(LG38GU7
M<!TBU_=Q2:4<RGI#D&V>Z6N)/^ U':AO;S**[&#$,[OK*1FIDG)]5E#/XZNN
M,SCS@X[Y-^?0X<H:=C>V1X=D7S(K':2\E<GY=H%J! OS@!!4A_S"%\BCSYN7
M[H5UF#_)S;_>>NLO%TN6.\8S:I1!\=3W*2,V#HO57Q=*A!9K;7FK4HOA?D_0
M4H*%*.E3L&DK:+I$?.B^OJ)X_Q)UG2U H MYD?T+DJ;@N,]"HW/D(L.[NSEF
MS/9F]S^:+ZN5G))6#S<FL:G5K3%D9&>4]:G(]"M$E\4^T-(3V\<.L,VG\]I.
M<,<(\O#1,3"QYF>D/JXZ7!M:T",W9Q&Y?:].!G/GPT!D_\"^ZL2[RG%BW?Y
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M'!V)=?U1>^**P?L)N-(:/=AEF;R4E6 )M(Z%.SQ"[W<.[YUI9=THL)W9Z]D
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M3&7#U7XWMD@(#TT" SIHE<V-.-Q9'1[K8I#F XO(-55.C=[?O2UN!WR@;$>
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M4CJAEC.Q @AI>5("CJ94JUNX<A$C($7A*[#,N5HC.RI7_#%;O%VNH8WOSL-
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MX)LZ[(?:\1 'W3HUH'B 97Z>G9EQPZ5A51@"I93M601,\ML/>?>5#@7$[4?
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M'H[] U!+ 0(4 Q0    ( *F#GE@8.AZ'21,  &;,   1              "
M 0    !A8V%B+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( *F#GE@+XG[M0 H
M +2"   5              "  7@3  !A8V%B+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " "I@YY8C?#\;E1!  #X^0, %0              @ 'K'0
M86-A8BTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ J8.>6.^[&(5H70
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M.&1E>#(S,BYH=&U02P$"% ,4    " "I@YY8Q:VDEWL+"@!G\U  #P
M        @ %,# $ 9#4P.3,X.&1S-&$N:'1M4$L! A0#%     @ J8.>6&4C
M=55Z* $ A7X! !$              ( !]!<+ &<U,#DS.#AG,#!N,S<N:G!G
M4$L! A0#%     @ J8.>6(R<4Y]8/@  9HP  !$              ( !G4 ,
M &<U,#DS.#AG,#%J,#4N:G!G4$L! A0#%     @ J8.>6#1U98#L40$ ,*8!
M !$              ( !)'\, &<U,#DS.#AG,#)P,#(N:G!G4$L! A0#%
M  @ J8.>6&,_DRFQ10  #I0  !$              ( !/]$- &<U,#DS.#AG
M,#-K,#,N:G!G4$L! A0#%     @ J8.>6$2)#S@$?0$ H>$! !$
M     ( !'Q<. &<U,#DS.#AG,#-P,#,N:G!G4$L! A0#%     @ J8.>6%'@
M=G(>QP  UAD! !$              ( !4I0/ &<U,#DS.#AG,#1P,#,N:G!G
M4$L! A0#%     @ J8.>6&Q&1=*2/ $ \Y,! !$              ( !GUL0
M &<U,#DS.#AG,#5P,#0N:G!G4$L! A0#%     @ J8.>6!W%9#SQH@  ;<D
M !$              ( !8)@1 &<U,#DS.#AG,#EG,#DN:G!G4$L! A0#%
M  @ J8.>6-(IQ*:,TP  2 <! !$              ( !@#L2 &<U,#DS.#AG
M,3!G,3 N:G!G4$L! A0#%     @ J8.>6/GGT\=NTP  O T! !$
M     ( !.P\3 &<U,#DS.#AG,3%G,3$N:G!G4$L! A0#%     @ J8.>6/N'
MGFOID0  Y,$  !$              ( !V.(3 &<U,#DS.#AG,35X,34N:G!G
M4$L! A0#%     @ J8.>6,<[(M-Q*@  )'8  !$              ( !\'04
M &<U,#DS.#AG,39P,#<N:G!G4$L! A0#%     @ J8.>6%; >2"3B0  F]X
M !$              ( !D)\4 &<U,#DS.#AG,3=P,# N:G!G4$L! A0#%
M  @ J8.>6&;KKG.;5@  +Z8  !$              ( !4BD5 &<U,#DS.#AG
M,3=P,#$N:G!G4$L! A0#%     @ J8.>6*NWLC3(@   FM,  !$
M     ( !'( 5 &<U,#DS.#AG,3=P,#,N:G!G4$L! A0#%     @ J8.>6/A9
MF.@B"P$ ;S,! !$              ( !$P$6 &<U,#DS.#AG,C1M,#$N:G!G
M4$L! A0#%     @ J8.>6.-:*B5<7 $ H8H! !$              ( !9 P7
M &<U,#DS.#AG,C1M,#(N:G!G4$L! A0#%     @ J8.>6%-.CU40.P$ E9<!
M !$              ( ![V@8 &<U,#DS.#AG,C1M,#0N:G!G4$L! A0#%
M  @ J8.>6%">P!>/+P$ J6,! !$              ( !+J09 &<U,#DS.#AG
M,C1M,#4N:G!G4$L! A0#%     @ J8.>6'L#E.2^#P( ['0" !$
M     ( ![-,: &<U,#DS.#AG,C1M,#8N:G!G4$L! A0#%     @ J8.>6 DV
MWBH;10( _*8" !$              ( !V>,< &<U,#DS.#AG,C1M,#@N:G!G
M4$L! A0#%     @ J8.>6"U@2,R3\   >$D! !$              ( !(RD?
M &<U,#DS.#AG,S!K,S N:G!G4$L! A0#%     @ J8.>6"\*4B:N1@$ HY\!
M !$              ( !Y1D@ &<U,#DS.#AG,S%K,S$N:G!G4$L! A0#%
M  @ J8.>6*9[O<O*K@  DP4! !$              ( !PF A &<U,#DS.#AG
M-#!N,3 N:G!G4$L! A0#%     @ J8.>6'93^A_(*0$ YW<! !$
M     ( !NP\B &<U,#DS.#AG-39S,#(N:G!G4$L! A0#%     @ J8.>6#&K
MI&6280$ )+4! !$              ( !LCDC &<U,#DS.#AG.#ES,3 N:G!G
M4$L! A0#%     @ J8.>6%YMZT;;S0  (!D! !$              ( !<YLD
M &<U,#DS.#AG.3=S,S N:G!G4$L! A0#%     @ J8.>6.'K1][ISP  G!L!
M !$              ( !?6DE &<U,#DS.#AG.3AS.#DN:G!G4$L%!@     D
- "0 Z@@  )4Y)@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>d509388ds4a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acab="http://www.atlanticcoastalacquisition.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acab-20231231.xsd" xlink:type="simple"/>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_07_2022To01_07_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="PAsOn01_13_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="PAsOn01_19_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="P01_19_2022To01_19_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-01-19</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="PAsOn08_16_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2022-08-16</instant>
        </period>
    </context>
    <context id="P08_16_2022To08_16_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="P12_15_2023To12_15_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="PAsOn12_15_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="P01_11_2024To01_11_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:BasisAxis">acab:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:WorkingCapitalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">acab:FederalAndStateAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acab:AssetsHeldInTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acab:AssetsHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">acab:FederalAndStateAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:WorkingCapitalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acab:ClassAAndClassBCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfInitialPublicOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfInitialPublicOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="acab:PeriodAfterWhichTheWarrantsAreExercisableAxis">acab:FromTheCompletionOfBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdjustedExercisePriceOneMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:AdjustedExercisePriceOfWarrantsAxis">acab:AdjustedExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdjustedExercisePriceTwoMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:AdjustedExercisePriceOfWarrantsAxis">acab:AdjustedExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:BasisAxis">acab:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:RedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acab:ClassAAndClassBCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:ClassificationOfCommonStockAxis">acab:NonRedeemableCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acab:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="PAsOn01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="PAsOn01_13_2022_MinimumMembersrtRangeAxis_PostBusinessCombinationMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">acab:PostBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-04-18</endDate>
        </period>
    </context>
    <context id="P04_18_2023To04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-04-18</endDate>
        </period>
    </context>
    <context id="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-04-18</endDate>
        </period>
    </context>
    <context id="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-18</instant>
        </period>
    </context>
    <context id="PAsOn04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-18</instant>
        </period>
    </context>
    <context id="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-18</instant>
        </period>
    </context>
    <context id="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-14</instant>
        </period>
    </context>
    <context id="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-14</instant>
        </period>
    </context>
    <context id="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-14</instant>
        </period>
    </context>
    <context id="PAsOn10_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-14</instant>
        </period>
    </context>
    <context id="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-14</instant>
        </period>
    </context>
    <context id="P11_14_2023To11_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="P10_25_2021To10_25_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_DirectorMembersrtTitleOfIndividualAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="PAsOn10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FounderSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-25</instant>
        </period>
    </context>
    <context id="PAsOn10_25_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">acab:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-25</instant>
        </period>
    </context>
    <context id="PAsOn12_01_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acab:FeeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acab:NonRedemptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-04</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acab:NonRedemptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="P10_14_2023To10_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetHeldInTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-14</startDate>
            <endDate>2023-10-14</endDate>
        </period>
    </context>
    <context id="PAsOn11_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="PAsOn11_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="PAsOn11_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-13</instant>
        </period>
    </context>
    <context id="PAsOn12_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="PAsOn12_08_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-08</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2023_AbproBioCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:AbproBioCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_11_2023_AbproMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:AbproMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="PAsOn12_12_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acab:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-21</startDate>
            <endDate>2024-01-21</endDate>
        </period>
    </context>
    <context id="PAsOn01_11_2024_AdvisorMemberACABInvesteeAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="acab:InvesteeAxis">acab:AdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-11</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="P01_01_2023To12_31_2023" id="hidden113139180">S-4/A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2023To12_31_2023" id="ixv-46169">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To12_31_2023" id="ixv-46170">0001893219</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden113139203">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To12_31_2023" id="hidden113139209">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityRegistrantName contextRef="P01_01_2023To12_31_2023" id="ixv-47229">Atlantic Coastal Acquisition Corp. II</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To12_31_2023" id="ixv-47230">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2023To12_31_2023" id="ixv-47231">6770</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To12_31_2023" id="ixv-47232">87-1013956</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To12_31_2023" id="ixv-47233">6 St Johns Lane, Floor 5</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To12_31_2023" id="ixv-47234">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To12_31_2023" id="ixv-47235">10013</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To12_31_2023" id="ixv-47236">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To12_31_2023" id="ixv-47237">890-7200</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47238">Shahraab Ahmad</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47239">6 St Johns Lane, Floor 5</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47240">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47241">10013</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47242">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47243">890-7200</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2023To12_31_2023" id="ixv-47244">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To12_31_2023" id="ixv-47245">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To12_31_2023" id="ixv-47246">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2023To12_31_2023" id="ixv-47247">false</dei:EntityExTransitionPeriod>
    <acab:NumberOfDaysWithinWhichPublicSharesShallBeRedeemed contextRef="P01_01_2023To12_31_2023" id="hidden113139487">P10D</acab:NumberOfDaysWithinWhichPublicSharesShallBeRedeemed>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47253"
      unitRef="Unit_USD">264538</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47254"
      unitRef="Unit_USD">392446</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47255"
      unitRef="Unit_USD">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47256"
      unitRef="Unit_USD">377780</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47257"
      unitRef="Unit_USD">29728990</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47258"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47259"
      unitRef="Unit_USD">29993528</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47260"
      unitRef="Unit_USD">770226</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47261"
      unitRef="Unit_USD">7372451</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47262"
      unitRef="Unit_USD">309790455</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47263"
      unitRef="Unit_USD">37365979</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47264"
      unitRef="Unit_USD">310560681</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47265"
      unitRef="Unit_USD">469268</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47266"
      unitRef="Unit_USD">1243172</us-gaap:AccruedLiabilitiesCurrent>
    <acab:ExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47267"
      unitRef="Unit_USD">3062004</acab:ExciseTaxPayableCurrent>
    <acab:ExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47268"
      unitRef="Unit_USD">0</acab:ExciseTaxPayableCurrent>
    <acab:AccruedOfferingCosts
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47269"
      unitRef="Unit_USD">5000</acab:AccruedOfferingCosts>
    <acab:AccruedOfferingCosts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47270"
      unitRef="Unit_USD">75000</acab:AccruedOfferingCosts>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47271"
      unitRef="Unit_USD">308194</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47272"
      unitRef="Unit_USD">823991</us-gaap:TaxesPayableCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47273"
      unitRef="Unit_shares">2768301</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47274"
      unitRef="Unit_shares">2768301</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47275"
      unitRef="Unit_USD">29728990</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47276"
      unitRef="Unit_USD">0</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47277"
      unitRef="Unit_USD">160000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47278"
      unitRef="Unit_USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47279"
      unitRef="Unit_USD">1655000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47280"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47281"
      unitRef="Unit_USD">35388456</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47282"
      unitRef="Unit_USD">2142163</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47283"
      unitRef="Unit_USD">10500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47284"
      unitRef="Unit_USD">10500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47285"
      unitRef="Unit_USD">45888457</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47286"
      unitRef="Unit_USD">12642163</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-47287"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      id="ixv-47288"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47289"
      unitRef="Unit_shares">667391</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47290"
      unitRef="Unit_shares">667391</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47291"
      unitRef="Unit_shares">30000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47292"
      unitRef="Unit_shares">30000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47293"
      unitRef="Unit_USD_per_Share">10.93</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47294"
      unitRef="Unit_USD_per_Share">10.3</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47295"
      unitRef="Unit_USD">7292641</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47296"
      unitRef="Unit_USD">309097930</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47297"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47298"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47299"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47300"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47301"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47302"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47303"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47304"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47305"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47306"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47307"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47308"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47309"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47310"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47311"
      unitRef="Unit_shares">7499999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47312"
      unitRef="Unit_shares">7499999</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47313"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47314"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47315"
      unitRef="Unit_shares">667391</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47316"
      unitRef="Unit_shares">30000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47317"
      unitRef="Unit_USD">749</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47318"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47319"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47320"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47321"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47322"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47323"
      unitRef="Unit_shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47324"
      unitRef="Unit_shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47325"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47326"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47327"
      unitRef="Unit_USD">1</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47328"
      unitRef="Unit_USD">750</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47329"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47330"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47331"
      unitRef="Unit_USD">-15815868</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47332"
      unitRef="Unit_USD">-11180162</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47333"
      unitRef="Unit_USD">-15815118</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47334"
      unitRef="Unit_USD">-11179412</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47335"
      unitRef="Unit_USD">37365979</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47336"
      unitRef="Unit_USD">310560681</us-gaap:LiabilitiesAndStockholdersEquity>
    <acab:OperationAndFormationCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47337"
      unitRef="Unit_USD">1666056</acab:OperationAndFormationCosts>
    <acab:OperationAndFormationCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47338"
      unitRef="Unit_USD">2050410</acab:OperationAndFormationCosts>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47339"
      unitRef="Unit_USD">-1666056</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47340"
      unitRef="Unit_USD">-2050410</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47341"
      unitRef="Unit_USD">52304</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47342"
      unitRef="Unit_USD">1848</us-gaap:InterestIncomeOther>
    <acab:InvestmentIncomeExpenseNonoperating
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47343"
      unitRef="Unit_USD">5754715</acab:InvestmentIncomeExpenseNonoperating>
    <acab:InvestmentIncomeExpenseNonoperating
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47344"
      unitRef="Unit_USD">4121971</acab:InvestmentIncomeExpenseNonoperating>
    <acab:PenaltiesAndInterestOnTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47345"
      unitRef="Unit_USD">142041</acab:PenaltiesAndInterestOnTaxes>
    <acab:PenaltiesAndInterestOnTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47346"
      unitRef="Unit_USD">0</acab:PenaltiesAndInterestOnTaxes>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47347"
      unitRef="Unit_USD">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47348"
      unitRef="Unit_USD">-362500</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47349"
      unitRef="Unit_USD">5664978</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47350"
      unitRef="Unit_USD">3761319</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47351"
      unitRef="Unit_USD">3998922</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47352"
      unitRef="Unit_USD">1710909</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47353"
      unitRef="Unit_USD">1177463</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47354"
      unitRef="Unit_USD">823991</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47355"
      unitRef="Unit_USD">2821459</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47356"
      unitRef="Unit_USD">886918</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47357"
      unitRef="Unit_shares">11257894</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47358"
      unitRef="Unit_shares">11257894</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47359"
      unitRef="Unit_shares">28438356</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47360"
      unitRef="Unit_shares">28438356</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47361"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47362"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47363"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47364"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47365"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47366"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47367"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022_ClassAAndClassBCommonStockMemberusgaapStatementClassOfStockAxis_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47368"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47369"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47370"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47371"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47372"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47373"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47374"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47375"
      unitRef="Unit_shares">7503750</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47376"
      unitRef="Unit_USD">750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47377"
      unitRef="Unit_USD">24250</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47378"
      unitRef="Unit_USD">-1793</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-47379"
      unitRef="Unit_USD">23207</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-47380"
      unitRef="Unit_shares">13850000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47381"
      unitRef="Unit_USD">13850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47382"
      unitRef="Unit_USD">13850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47383"
      unitRef="Unit_shares">-3750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47384"
      unitRef="Unit_USD">362500</acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron>
    <acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47385"
      unitRef="Unit_USD">362500</acab:AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47386"
      unitRef="Unit_USD">8100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47387"
      unitRef="Unit_USD">8100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47388"
      unitRef="Unit_USD">505049</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47389"
      unitRef="Unit_USD">505049</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47390"
      unitRef="Unit_USD">21831701</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47391"
      unitRef="Unit_USD">12065287</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47392"
      unitRef="Unit_USD">33896988</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47393"
      unitRef="Unit_USD">886918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47394"
      unitRef="Unit_USD">886918</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47395"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47396"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47397"
      unitRef="Unit_shares">7500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47398"
      unitRef="Unit_USD">750</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47399"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47400"
      unitRef="Unit_USD">-11180162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47401"
      unitRef="Unit_USD">-11179412</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47402"
      unitRef="Unit_USD">4395161</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47403"
      unitRef="Unit_USD">4395161</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <acab:StockholderNonRedemptionAgreementAdjustment
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47404"
      unitRef="Unit_USD">1378126</acab:StockholderNonRedemptionAgreementAdjustment>
    <acab:StockholderNonRedemptionAgreementAdjustment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47405"
      unitRef="Unit_USD">1378126</acab:StockholderNonRedemptionAgreementAdjustment>
    <acab:StockholderNonRedemptionAgreementAdjustmentReduction
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47406"
      unitRef="Unit_USD">-1378126</acab:StockholderNonRedemptionAgreementAdjustmentReduction>
    <acab:StockholderNonRedemptionAgreementAdjustmentReduction
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47407"
      unitRef="Unit_USD">-1378126</acab:StockholderNonRedemptionAgreementAdjustmentReduction>
    <acab:AdjustmentsToAdditionalPaidInCapitalExciseTax
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47408"
      unitRef="Unit_USD">-3062004</acab:AdjustmentsToAdditionalPaidInCapitalExciseTax>
    <acab:AdjustmentsToAdditionalPaidInCapitalExciseTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47409"
      unitRef="Unit_USD">-3062004</acab:AdjustmentsToAdditionalPaidInCapitalExciseTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47410"
      unitRef="Unit_shares">7499999</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47411"
      unitRef="Unit_USD">749</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47412"
      unitRef="Unit_shares">-7499999</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47413"
      unitRef="Unit_USD">-749</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47414"
      unitRef="Unit_USD">2821459</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47415"
      unitRef="Unit_USD">2821459</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47416"
      unitRef="Unit_shares">7499999</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47417"
      unitRef="Unit_USD">749</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47418"
      unitRef="Unit_shares">1</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47419"
      unitRef="Unit_USD">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47420"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47421"
      unitRef="Unit_USD">-15815868</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47422"
      unitRef="Unit_USD">-15815118</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47423"
      unitRef="Unit_USD">2821459</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47424"
      unitRef="Unit_USD">886918</us-gaap:NetIncomeLoss>
    <acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47425"
      unitRef="Unit_USD">5754715</acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount>
    <acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47426"
      unitRef="Unit_USD">4121971</acab:InterestEarnedOnMarketableSecuritiesHeldInTrustAccount>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47427"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47428"
      unitRef="Unit_USD">362500</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47429"
      unitRef="Unit_USD">-377780</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47430"
      unitRef="Unit_USD">377780</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47431"
      unitRef="Unit_USD">-773904</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47432"
      unitRef="Unit_USD">1241379</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47433"
      unitRef="Unit_USD">-515797</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47434"
      unitRef="Unit_USD">823991</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47435"
      unitRef="Unit_USD">-3845177</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47436"
      unitRef="Unit_USD">-1184963</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47437"
      unitRef="Unit_USD">160000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47438"
      unitRef="Unit_USD">306000000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47439"
      unitRef="Unit_USD">2132269</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47440"
      unitRef="Unit_USD">331516</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <acab:ProceedsFromTrustAccountInConnectionWithRedemption
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47441"
      unitRef="Unit_USD">276471460</acab:ProceedsFromTrustAccountInConnectionWithRedemption>
    <acab:ProceedsFromTrustAccountInConnectionWithRedemption
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47442"
      unitRef="Unit_USD">0</acab:ProceedsFromTrustAccountInConnectionWithRedemption>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47443"
      unitRef="Unit_USD">278443729</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47444"
      unitRef="Unit_USD">-305668484</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47445"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47446"
      unitRef="Unit_USD">294240000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47447"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47448"
      unitRef="Unit_USD">13850000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47449"
      unitRef="Unit_USD">160000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47450"
      unitRef="Unit_USD">49262</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47451"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47452"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47453"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47454"
      unitRef="Unit_USD">149539</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47455"
      unitRef="Unit_USD">1655000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47456"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47457"
      unitRef="Unit_USD">70000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47458"
      unitRef="Unit_USD">743830</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47459"
      unitRef="Unit_USD">276471460</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47460"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47461"
      unitRef="Unit_USD">-274726460</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47462"
      unitRef="Unit_USD">307245893</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47463"
      unitRef="Unit_USD">-127908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47464"
      unitRef="Unit_USD">392446</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47465"
      unitRef="Unit_USD">392446</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="0"
      id="ixv-47466"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47467"
      unitRef="Unit_USD">264538</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47468"
      unitRef="Unit_USD">392446</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47469"
      unitRef="Unit_USD">1799627</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47470"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxesPaidNet>
    <acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47471"
      unitRef="Unit_USD">0</acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts>
    <acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47472"
      unitRef="Unit_USD">717219</acab:DeferredOfferingCostsIncludedInAccruedOfferingCosts>
    <acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47473"
      unitRef="Unit_USD">0</acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption>
    <acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47474"
      unitRef="Unit_USD">309097930</acab:InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption>
    <acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47475"
      unitRef="Unit_USD">0</acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities>
    <acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47476"
      unitRef="Unit_USD">10500000</acab:DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities>
    <us-gaap:NatureOfOperations contextRef="P01_01_2023To12_31_2023" id="ixv-26883">&lt;div id="fin509388_6" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;NOTE&#160;1&#160;&#x2014;&#160;ORGANIZATION AND PLAN OF BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Atlantic Coastal Acquisition Corp. II (the &#x201c;Company&#x201d;) is a blank check company incorporated in Delaware on May&#160;20, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the &#x201c;Business Combination&#x201d;). On November 30, 2023 the Company formed Abpro Merger Sub Corp. (&#x201c;Merger Sub&#x201d;), a wholly owned subsidiary of the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had not yet commenced any operations. All activity for the period May&#160;20, 2021 (inception) through December&#160;31, 2023 relates to the Company&#x2019;s formation, the initial public offering (the &#x201c;Initial Public Offering&#x201d;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;13, 2022. On January&#160;19, 2022, the Company consummated the Initial Public Offering of 30,000,000 units (the &#x201c;Units&#x201d; and, with respect to the shares of Series A common stock included in the Units being offered, the &#x201c;Public Shares&#x201d;), which includes the partial exercise by the underwriters of its over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000, which is described in Note 3. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 13,850,000 warrants (each, a &#x201c;Private Placement Warrant&#x201d; and, collectively, the &#x201c;Private Placement Warrants&#x201d;) at a price of $1.00 per Private Placement Warrant in a private placement to Atlantic Coastal Acquisition Management II LLC (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $13,850,000, which is described in Note 4. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Transaction costs amounted to $17,204,107, consisting of $5,760,000 of underwriting fees (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Following the closing of the Initial Public Offering on January&#160;19, 2022, an amount of $306,000,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), to be invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earlier of: (i)&#160;the consummation of a Business Combination or (ii)&#160;the distribution of the funds in the Trust Account to the Company&#x2019;s stockholders, as described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;While the Company&#x2019;s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Placement Warrants, which are placed in the Trust Account are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least &lt;/div&gt;&lt;/div&gt;80% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;The Company will provide its holders of the outstanding Public Shares (the &#x201c;public stockholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#x201c;Amended and Restated Certificate of Incorporation&#x201d;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Company&#x2019;s shares prior to the Initial Public Offering (the &#x201c;Initial Stockholders&#x201d;) have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Initial Stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination prior to September 19, 2024 and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s Initial Business Combination or to redeem&lt;/div&gt; &lt;div style="-sec-ix-redline:true;display:inline;"&gt;100&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;% of its Public Shares if the Company does not complete a Business Combination or (ii)&#160;with respect to any other provision relating to stockholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;pre-initial&lt;/div&gt; business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company had 15 months from the closing of the Initial Public Offering to complete a Business Combination (the &#x201c;Combination Period&#x201d;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;div style="-sec-ix-hidden:hidden113139487;display:inline;"&gt;ten&lt;/div&gt;&lt;/div&gt; business days thereafter, redeem the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders&#x2019; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining stockholders and the Company&#x2019;s board of directors, dissolve and liquidate, subject in each case to the Company&#x2019;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;18, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from April&#160;19, 2023 to October&#160;19, 2023, subject to additional Extension(s) up to December&#160;19, 2023 upon election by the Sponsor. The extension was approved and a result 26,564,308 shares of the Company&#x2019;s Series A common stock were redeemed at approximately $10.41 per share. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;On April&#160;18, 2023, the Sponsor, the Company&#x2019;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#x201c;Series B Holders&#x201d;) voluntarily converted 7,499,999 shares of Series B Common Stock of the Company they held as of such date into 7,499,999 shares of Series A common stock of the Company (the &#x201c;Conversion&#x201d;) in accordance with the amended and restated certificate of incorporation, as amended. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from the Company&#x2019;s trust account. As a result of the Conversion and the results of the Meeting described above, the Company has an aggregate of 10,935,691 shares of Series A common stock outstanding and 1 share of Series B Common Stock (held by the Sponsor) outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On October&#160;14, 2023 and November&#160;14, 2023, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-interest&lt;/div&gt; bearing, unsecured promissory notes in the aggregate principal amount of $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;80,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;, respectively, (the &#x201c;Notes&#x201d;) to the Sponsor. The $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;80,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; was deposited into the Company&#x2019;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;$&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;10.20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;p&lt;/div&gt;&lt;/div&gt;er share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October&#160;19, 2023 to November&#160;19, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November&#160;19, 2023 to December&#160;19, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro Corporation, a Delaware corporation, entered into a business combination agreement (the &#x201c;Business Combination Agreement&#x201d;). Please see the Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;8-K&lt;/div&gt; filed on December&#160;12, 2023 for more information on the terms of the Business Combination Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Merger.&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;On December&#160;15, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from December&#160;19, 2023 to March&#160;19, 2024, subject to deposits into the trust account maintained for the benefit of the Company&#x2019;s public stockholders the lesser of (a) $30,000 or (b) $0.045 for each Public Share that is not redeemed in connection with the Meeting. If the Company has not consummated a Business Combination by the Extended Date, the Company may, without another stockholder vote, elect to extend the Extended Date on a monthly basis up to six times by an additional one month each time thereafter, until September&#160;19, 2024. The extension was approved and a result 2,768,301 public shares of Series A common stock exercised and did not reverse, their right to redeem their public shares in connection with the vote upon the Charter Amendment Proposal. As a result of the foregoing, those holders will receive a payment of approximately $10.68 per share redeemed. This resulted in $29,728,990 being withdrawn from the trust account and paid to redeeming stockholders. The payment to the redeeming stockholders was processed in January 2024, as such $29,728,990 has been removed form Series A common stock subject to redemption and recorded as common stock to be redeemed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;10.20&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;display:inline;"&gt;indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There is no assurance that the Company&#x2019;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At December&#160;31, 2023, the Company had $264,538 in its operating bank accounts and a working capital deficit of $5,394,929. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. The Company will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#x2019;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40&lt;/div&gt; &#x201c;Presentation of Financial Statements&#x2014;Going Concern,&#x201d; the Company has until April 19, 2024, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before April 19, 2024, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company&#x2019;s plan is to complete a business combination on or prior to April 19, 2024, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after April 19, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, close of the Initial Public Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The impact of current conflicts around the globe, including Russia&#x2019;s invasion of Ukraine and the Israel-Hamas war, and related sanctions, on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#x2019;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inflation Reduction Act of 2022 &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;16, 2022, the Inflation Reduction Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded&#160;U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;Any redemption or other repurchase that occurs after December&#160;31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i)&#160;the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii)&#160;the structure of a Business Combination, (iii)&#160;the nature and amount of any &#x201c;PIPE&#x201d; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv)&#160;the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and impact the Company&#x2019;s ability to complete a Business Combination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;18, 2023 and December&#160;13, 2023, the Company&#x2019;s stockholders redeemed&#160;26,564,308&#160;Series&#160;Class A shares for a total of $276,471,460 and redeemed&#160;2,768,301&#160;Series&#160;Class A shares for a total of $29,728,990, respectively. The Company evaluated the classification and accounting of the stock redemption under ASC 450, &#x201c;Contingencies&#x201d;. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of December&#160;31, 2023 and determined that a contingent liability should be calculated and recorded. As of December&#160;31, 2023, the Company recorded $3,062,004&#160;of excise tax liability calculated as 1% of shares redeemed. &lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-47477"
      unitRef="Unit_shares">30000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_13_2022To01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-47478"
      unitRef="Unit_shares">3900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_13_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47479"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <acab:GrossProceedsFromInitialPublicOffer
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47480"
      unitRef="Unit_USD">300000000</acab:GrossProceedsFromInitialPublicOffer>
    <acab:ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits
      contextRef="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47481"
      unitRef="Unit_shares">13850000</acab:ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits>
    <acab:ClassOfWarrantsOrRightsIssuePricePerUnit
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47482"
      unitRef="Unit_USD_per_Share">1</acab:ClassOfWarrantsOrRightsIssuePricePerUnit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_13_2022To01_13_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47483"
      unitRef="Unit_USD">13850000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <acab:TransactionCostsOfIssuance
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47484"
      unitRef="Unit_USD">17204107</acab:TransactionCostsOfIssuance>
    <acab:UnderwritingFeesNetOfReimbursementByUnderwriters
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47485"
      unitRef="Unit_USD">5760000</acab:UnderwritingFeesNetOfReimbursementByUnderwriters>
    <acab:ReimbursementByUnderwriters
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47486"
      unitRef="Unit_USD">240000</acab:ReimbursementByUnderwriters>
    <acab:DeferredUnderwritingCommissionNonCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47487"
      unitRef="Unit_USD">10500000</acab:DeferredUnderwritingCommissionNonCurrent>
    <acab:OtherOfferingCosts
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47488"
      unitRef="Unit_USD">944107</acab:OtherOfferingCosts>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P01_13_2022To01_13_2022"
      decimals="0"
      id="ixv-47489"
      unitRef="Unit_USD">306000000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <acab:PerSharePaymentMadeToAcquireRestrictedInvestments
      contextRef="PAsOn01_13_2022"
      decimals="4"
      id="ixv-47490"
      unitRef="Unit_pure">0.102</acab:PerSharePaymentMadeToAcquireRestrictedInvestments>
    <acab:TermOfRestrictedInvestments contextRef="P01_13_2022To01_13_2022" id="ixv-47491">P185D</acab:TermOfRestrictedInvestments>
    <acab:PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected
      contextRef="PAsOn01_13_2022"
      decimals="2"
      id="ixv-47493"
      unitRef="Unit_pure">0.80</acab:PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn01_13_2022_MinimumMembersrtRangeAxis_PostBusinessCombinationMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-47494"
      unitRef="Unit_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn01_13_2022"
      decimals="2"
      id="ixv-47495"
      unitRef="Unit_USD_per_Share">10.2</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <acab:MinimumNetWorthNeededToConsummateBusinessCombination
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47496"
      unitRef="Unit_USD">5000001</acab:MinimumNetWorthNeededToConsummateBusinessCombination>
    <acab:PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47497"
      unitRef="Unit_pure">0.15</acab:PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction>
    <acab:PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47498"
      unitRef="Unit_pure">1</acab:PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated>
    <acab:TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering contextRef="P01_01_2023To12_31_2023" id="ixv-47500">P15M</acab:TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47501"
      unitRef="Unit_USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <acab:TemporaryEquityStockRedeemedDuringThePeriodShares
      contextRef="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47502"
      unitRef="Unit_shares">26564308</acab:TemporaryEquityStockRedeemedDuringThePeriodShares>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47503"
      unitRef="Unit_USD_per_Share">10.41</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <acab:ConversionOfPermanentEquityIntoTemporaryEquityShares
      contextRef="P04_18_2023To04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47504"
      unitRef="Unit_shares">7499999</acab:ConversionOfPermanentEquityIntoTemporaryEquityShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P04_18_2023To04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47505"
      unitRef="Unit_shares">7499999</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-47506"
      unitRef="Unit_shares">10935691</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn04_18_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47507"
      unitRef="Unit_shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-47508"
      unitRef="Unit_USD">80000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_14_2023_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-47509"
      unitRef="Unit_USD">80000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P10_14_2023To10_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-47510"
      unitRef="Unit_USD">80000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="P11_14_2023To11_14_2023_AssetHeldInTrustMemberusgaapBalanceSheetLocationAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-47511"
      unitRef="Unit_USD">80000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn11_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-47512"
      unitRef="Unit_USD_per_Share">10.2</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_UnsecuredDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-47513"
      unitRef="Unit_USD_per_Share">10.2</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <acab:AmountToBeDepositedInTrustAccount
      contextRef="P12_15_2023To12_15_2023"
      decimals="0"
      id="ixv-47514"
      unitRef="Unit_USD">30000</acab:AmountToBeDepositedInTrustAccount>
    <acab:PerShareValueOfTheAmountToBeDepositedInTrustAccount
      contextRef="P12_15_2023To12_15_2023"
      decimals="3"
      id="ixv-47515"
      unitRef="Unit_USD_per_Share">0.045</acab:PerShareValueOfTheAmountToBeDepositedInTrustAccount>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="PAsOn12_15_2023"
      decimals="0"
      id="ixv-47516"
      unitRef="Unit_shares">2768301</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:SharePrice
      contextRef="PAsOn12_15_2023"
      decimals="2"
      id="ixv-47517"
      unitRef="Unit_USD_per_Share">10.68</us-gaap:SharePrice>
    <us-gaap:ProceedsFromSaleOfTrustAssetsToPayExpenses
      contextRef="P12_15_2023To12_15_2023"
      decimals="0"
      id="ixv-47518"
      unitRef="Unit_USD">29728990</us-gaap:ProceedsFromSaleOfTrustAssetsToPayExpenses>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47519"
      unitRef="Unit_USD">29728990</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <acab:PerShareAmountAvailableForDistribution
      contextRef="PAsOn01_13_2022"
      decimals="2"
      id="ixv-47520"
      unitRef="Unit_USD_per_Share">10</acab:PerShareAmountAvailableForDistribution>
    <acab:PerShareAmountToBeMaintainedInTheTrustAccountForDistribution
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47521"
      unitRef="Unit_USD_per_Share">10.2</acab:PerShareAmountToBeMaintainedInTheTrustAccountForDistribution>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47522"
      unitRef="Unit_USD">264538</us-gaap:Cash>
    <acab:WorkingCapitalLoan
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47523"
      unitRef="Unit_USD">5394929</acab:WorkingCapitalLoan>
    <acab:PercentageOfFederalExciseTaxOnStockBuyBack
      contextRef="PAsOn08_16_2022"
      decimals="2"
      id="ixv-47524"
      unitRef="Unit_pure">0.01</acab:PercentageOfFederalExciseTaxOnStockBuyBack>
    <acab:EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack contextRef="P08_16_2022To08_16_2022" id="ixv-47525">2023-01-01</acab:EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack>
    <acab:CommonStockSharesRedeemable
      contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47527"
      unitRef="Unit_shares">26564308</acab:CommonStockSharesRedeemable>
    <acab:CommonStockValueRedeemable
      contextRef="PAsOn04_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47528"
      unitRef="Unit_USD">276471460</acab:CommonStockValueRedeemable>
    <acab:CommonStockSharesRedeemable
      contextRef="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47529"
      unitRef="Unit_shares">2768301</acab:CommonStockSharesRedeemable>
    <acab:CommonStockValueRedeemable
      contextRef="PAsOn12_13_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47530"
      unitRef="Unit_USD">29728990</acab:CommonStockValueRedeemable>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47531"
      unitRef="Unit_USD">3062004</us-gaap:SalesAndExciseTaxPayableCurrent>
    <acab:PercentageOfSharesRedeemable
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47532"
      unitRef="Unit_pure">0.01</acab:PercentageOfSharesRedeemable>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27084">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 2&#x2009;&#x2014;&#x2009;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the accounting and disclosure rules and regulations of the SEC. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2023 and 2022. The Company had $264,538 and $392,446 in cash at December&#160;31, 2023 and 2022, respectively. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Cash and Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;At December&#160;31, 2023 and 2022, all of the Company&#x2019;s investments held in the Trust Account are invested in cash and money market funds invested primarily in United States Treasuries and are classified as trading securities, respectively. Trading securities are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Common Stock Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#x2019; equity. The Company&#x2019;s Series A common stock feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2023 and 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheet. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross proceeds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;300,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,100,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A common stock issuance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,699,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,896,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;309,097,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemption&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276,471,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemptions (redeemed in December 2023, paid in January 2024)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29,728,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,395,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,292,641&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A&#x2014;&#x201c;Expenses of Offering&#x201d;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder&#x2019;s equity. As of January&#160;19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders&#x2019; equity. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there were no deferred offering costs recorded in the accompanying consolidated balance sheets respectively. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes.&#x201d; ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of December&#160;31, 2023 and 2022, the Company&#x2019;s deferred tax asset had a full valuation allowance recorded against it&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;tax&lt;/div&gt; benefits will materially change over the next twelve months. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income per common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of December&#160;31, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income per common stock for the periods presented.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 36%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Redeemable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nonredeemable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;A&#160;and&#160;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Allocation of net income, as adjusted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,693,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,128,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;701,826&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;185,092&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted weighted average shares &lt;br/&gt; outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;11,257,894&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;28,438,356&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying consolidated balance sheet, primarily due to their short-term nature. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-cash&lt;/div&gt; settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#x201c;Derivatives and Hedging&#x201d;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#x2019; equity. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company adopted ASC Topic 718, &#x201c;Compensation&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;Stock Compensation,&#x201d; guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU 2023-09 will become effective for Annual periods beginning after December 15, 2024. The Company is still reviewing the impact of ASU 2023-09.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued Accounting Standards Updated (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(Subtopic470-20)and&lt;/div&gt; Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity(Subtopic&#160;815-40):Accounting&lt;/div&gt; for Convertible Instruments and Contracts in an Entity&#x2019;s Own &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&#x201d;(&#x201c;ASU&#160;2020-06&#x201d;),which&lt;/div&gt; simplifies accounting for convertible instruments by removing major separation models required under current GAAP. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; would have on our financial position, results of operations or cash flows. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&#x2013;Financial&lt;/div&gt; Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&#x201d;).&#160;This&lt;/div&gt; update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; on January&#160;1, 2023. The adoption of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU2016-13&lt;/div&gt; did not have a material impact on its financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27087"> &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the accounting and disclosure rules and regulations of the SEC. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <acab:EmergingGrowthCompanyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27093"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;</acab:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-27118"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27127"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27133"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2023 and 2022. The Company had $264,538 and $392,446 in cash at December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47533"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47534"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47535"
      unitRef="Unit_USD">264538</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47536"
      unitRef="Unit_USD">392446</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <acab:AssetsHeldInTrustAccountPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27139"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Cash and Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;At December&#160;31, 2023 and 2022, all of the Company&#x2019;s investments held in the Trust Account are invested in cash and money market funds invested primarily in United States Treasuries and are classified as trading securities, respectively. Trading securities are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</acab:AssetsHeldInTrustAccountPolicyTextBlock>
    <acab:TemporaryEquityPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27151"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Common Stock Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#x2019; equity. The Company&#x2019;s Series A common stock feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2023 and 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#x2019; deficit section of the Company&#x2019;s consolidated balance sheet. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross proceeds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;300,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,100,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A common stock issuance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,699,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,896,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;309,097,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemption&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276,471,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemptions (redeemed in December 2023, paid in January 2024)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29,728,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,395,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,292,641&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </acab:TemporaryEquityPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27182"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross proceeds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#160;300,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Proceeds allocated to Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,100,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A common stock issuance costs&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,699,058&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,896,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;309,097,930&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemption&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(276,471,460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Redemptions (redeemed in December 2023, paid in January 2024)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29,728,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,395,161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series A common stock subject to possible redemption, December&#160;31, 2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,292,641&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <acab:GrossProceeds
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47537"
      unitRef="Unit_USD">300000000</acab:GrossProceeds>
    <acab:ProceedsAllocatedToPublicWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47538"
      unitRef="Unit_USD">-8100000</acab:ProceedsAllocatedToPublicWarrants>
    <acab:CommonStockIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47539"
      unitRef="Unit_USD">-16699058</acab:CommonStockIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47540"
      unitRef="Unit_USD">33896988</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47541"
      unitRef="Unit_USD">309097930</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <acab:TemporaryEquityRedemptionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47542"
      unitRef="Unit_USD">-276471460</acab:TemporaryEquityRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47543"
      unitRef="Unit_USD">-29728990</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47544"
      unitRef="Unit_USD">4395161</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47545"
      unitRef="Unit_USD">7292641</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27331"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;340-10-S99-1&#160;and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A&#x2014;&#x201c;Expenses of Offering&#x201d;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder&#x2019;s equity. As of January&#160;19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders&#x2019; equity. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there were no deferred offering costs recorded in the accompanying consolidated balance sheets respectively. &lt;/div&gt; </us-gaap:DeferredChargesPolicyTextBlock>
    <acab:OfferingCosts
      contextRef="PAsOn01_19_2022"
      decimals="0"
      id="ixv-47546"
      unitRef="Unit_USD">17204107</acab:OfferingCosts>
    <acab:OfferingCostsAllocatedInTemporaryEquity
      contextRef="P01_19_2022To01_19_2022"
      decimals="0"
      id="ixv-47547"
      unitRef="Unit_USD">16699058</acab:OfferingCostsAllocatedInTemporaryEquity>
    <acab:OfferingCostsAllocatedInShareholdersEquity
      contextRef="P01_19_2022To01_19_2022"
      decimals="0"
      id="ixv-47548"
      unitRef="Unit_USD">505049</acab:OfferingCostsAllocatedInShareholdersEquity>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47549"
      unitRef="Unit_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47550"
      unitRef="Unit_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-27341"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47551"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27347"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes.&#x201d; ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of December&#160;31, 2023 and 2022, the Company&#x2019;s deferred tax asset had a full valuation allowance recorded against it&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt; &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;The Company has identified the United States as its only &#x201c;major&#x201d; tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;tax&lt;/div&gt; benefits will materially change over the next twelve months. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27386"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income per common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of December&#160;31, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income per common stock for the periods presented.&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 36%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Redeemable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nonredeemable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;A&#160;and&#160;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Allocation of net income, as adjusted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,693,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,128,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;701,826&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;185,092&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted weighted average shares &lt;br/&gt; outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;11,257,894&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;28,438,356&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47553"
      unitRef="Unit_shares">28850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27416"> &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 36%;"&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;For the Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Redeemable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nonredeemable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Series&#160;A&#160;and&#160;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Series&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Allocation of net income, as adjusted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,693,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1,128,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;701,826&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;185,092&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted weighted average shares &lt;br/&gt; outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;11,257,894&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;28,438,356&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;7,500,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 36%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Basic and diluted net income per common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;0.02&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47555"
      unitRef="Unit_USD">1693350</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47556"
      unitRef="Unit_USD">1128109</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47557"
      unitRef="Unit_USD">701826</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47558"
      unitRef="Unit_USD">185092</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47559"
      unitRef="Unit_shares">11257894</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47560"
      unitRef="Unit_shares">11257894</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47561"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="0"
      id="ixv-47562"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47563"
      unitRef="Unit_shares">28438356</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47564"
      unitRef="Unit_shares">28438356</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47565"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-47566"
      unitRef="Unit_shares">7500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="2"
      id="ixv-47567"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023_RedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="2"
      id="ixv-47568"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="2"
      id="ixv-47569"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023_NonRedeemableCommonStockMemberACABClassificationOfCommonStockAxis"
      decimals="2"
      id="ixv-47570"
      unitRef="Unit_USD_per_Share">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47571"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47572"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47573"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47574"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-27646"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying consolidated balance sheet, primarily due to their short-term nature. &lt;/div&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27652"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, &#x201c;Derivatives and Hedging.&#x201d; For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-cash&lt;/div&gt; settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815. &lt;/div&gt; </us-gaap:DerivativesPolicyTextBlock>
    <acab:WarrantsDisclosurePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-47575">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#x201c;Derivatives and Hedging&#x201d;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#x2019; equity. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</acab:WarrantsDisclosurePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-27675"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company adopted ASC Topic 718, &#x201c;Compensation&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;Stock Compensation,&#x201d; guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27713"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU 2023-09 will become effective for Annual periods beginning after December 15, 2024. The Company is still reviewing the impact of ASU 2023-09.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued Accounting Standards Updated (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(Subtopic470-20)and&lt;/div&gt; Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity(Subtopic&#160;815-40):Accounting&lt;/div&gt; for Convertible Instruments and Contracts in an Entity&#x2019;s Own &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&#x201d;(&#x201c;ASU&#160;2020-06&#x201d;),which&lt;/div&gt; simplifies accounting for convertible instruments by removing major separation models required under current GAAP. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; would have on our financial position, results of operations or cash flows. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&#x2013;Financial&lt;/div&gt; Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&#x201d;).&#160;This&lt;/div&gt; update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; on January&#160;1, 2023. The adoption of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU2016-13&lt;/div&gt; did not have a material impact on its financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <acab:DisclosureOfInitialPublicOffering contextRef="P01_01_2023To12_31_2023" id="ixv-27737">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;3&#x2009;&#x2014;&#x2009;INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Initial Public Offering, the Company sold 30,000,000 Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company&#x2019;s Series A common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-half&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each Public Warrant entitles the holder to purchase one share of Series A common stock at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;</acab:DisclosureOfInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-47576"
      unitRef="Unit_shares">30000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-47577"
      unitRef="Unit_shares">3900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47578"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-27745">Each Unit consists of one share of the Company&#x2019;s Series A common stock and one-half of one redeemable warrant (&#x201c;Public Warrant&#x201d;).</us-gaap:CommonStockConversionBasis>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47579"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47580"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acab:DisclosureOfPrivatePlacement contextRef="P01_01_2023To12_31_2023" id="ixv-27756">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;4&#x2009;&#x2014;&#x2009;PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $13,850,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one Series A common stock at a price of $11.50 per share, subject to adjustments (see Note 7). A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. &lt;/div&gt;</acab:DisclosureOfPrivatePlacement>
    <acab:ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47581"
      unitRef="Unit_shares">13850000</acab:ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits>
    <acab:ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.
      contextRef="PAsOn12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-47582"
      unitRef="Unit_USD_per_Share">1</acab:ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.>
    <acab:ProceedsFromTheIssuanceOfWarrants
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47583"
      unitRef="Unit_USD">13850000</acab:ProceedsFromTheIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47584"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementWarrantMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47585"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27764">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;5&#x2009;&#x2014;&#x2009;RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;25, 2021, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 7,187,500 shares of Series B common stock (the &#x201c;Founder Shares&#x201d;). On January&#160;13, 2022, the Company effectuated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;1.044-for-1&#160;stock&lt;/div&gt;&lt;/div&gt; split, resulting in an aggregate of 7,503,750 Founder Shares outstanding (see Note 7). Due to the underwriters&#x2019; election to partially exercise their overallotment option, 3,750 shares were forfeited. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sponsor, founders, executive officers and directors have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until one year after the completion of a Business Combination that results in all of the Company&#x2019;s stockholders having the right to exchange their Series A common stock for cash, securities, or other property&#160;(except with respect to permitted transferees). Notwithstanding the foregoing, (x)&#160;if the last reported sale price of the Series A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;any&#160;30-trading&#160;day&lt;/div&gt; period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#x2019;s stockholders having the right to exchange their shares of common stock for cash, securities or other property, then such securities will be released from these restrictions. Any permitted transferees would be subject to the same restrictions and other agreements of the founders with respect to any Founder Shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;25, 2021, the Sponsor transferred 250,000 Founder Shares to five director nominees (50,000 shares to each director nominee) for no consideration, to serve in his or her capacity as an independent director of the Company. The Company assigned the number of shares of Series B common stock of the Company, par value $0.0001 per share. The transfer of the Founders Shares to five director nominees is&#160;within the scope of FASB ASC Topic 718, &#x201c;Compensation-Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and expensed when earned. Shares granted to these directors are forfeited if their status as director is terminated for any reason prior to the date of the initial Business Combination&#160;and, as such, there has been no stock-based compensation expense recognized in the accompanying financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;1, 2021, the Company and Apeiron Investment Group Ltd. (&#x201c;Apeiron&#x201d;) entered into an Agreement to which Apeiron will serve as an advisor to the Company in connection with identifying one or more businesses with which the Company may effectuate its Initial Business Combination. As consideration for Apeiron&#x2019;s willingness to provide the service set forth in the Agreement, the Sponsor shall pay or transfer to Apeiron (or its designee) on behalf of the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;non-refundable&lt;/div&gt; fee in the form of 50,000 shares of the Company&#x2019;s Series B common stock (&#x201c;Fee Shares&#x201d;). The transfer of the Founder Shares to Apeiron is not directly related to or in connection with the Initial Public Offering and not within the scope of offering costs as defined in Note 2. The transfer of the Fee Shares is in the scope of FASB ASC Topic 718, &#x201c;Compensation-Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 50,000 Fee Shares granted to Apeiron was $362,500 or $7.25&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;per share. The Founders Shares were granted subject to a performance condition (i.e., the closing date of the Initial &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;Public Offering). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2022, the Company recognized $&lt;/div&gt;&lt;/div&gt;362,500&#160;in the operations as stock-based compensation expense as the Company determined that the performance condition has been met at the date of issuance/closing of the Initial Public Offering. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note &#x2014; Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;25, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#x201c;Promissory Note&#x201d;), pursuant to which the Company may borrow up to an aggregate principal amount of $250,000. The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-interest&lt;/div&gt; bearing and is payable on the earlier of April&#160;30, 2022, or the consummation of the Initial Public Offering. As of December&#160;31, 2023 and 2022, the Company has no outstanding balance under the Promissory Note, respectively. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsor has committed to advance the Company up to $1,750,000 to fund the expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Initial Business Combination. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If the Company consummated an Initial Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The final terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Prior to the completion of the Initial Business Combination, the Company does not expect to seek loans from parties other than the Sponsor or its affiliates as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. There are no Working Capital Loans outstanding as of December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Extension Promissory Notes &#x2014; Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;14, 2023 and November&#160;14, 2023, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-interest&lt;/div&gt; bearing, unsecured promissory notes in the principal amount of $80,000, respectively, (the &#x201c;Extension Promissory Notes&#x201d;) to the Sponsor. The $80,000 was deposited into the Company&#x2019;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to $10.20 per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. As of December&#160;31, 2023, the Company owed $160,000 due under the Extension Promissory Notes with no further borrowings available. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On December&#160;18, 2023, the Company amended the Extension Promissory Notes to remove the Sponsor&#x2019;s right to convert the note into Series A common stock at a price equal to &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;$&lt;/div&gt;10.20&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt; per share.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advance from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;8, 2023, December&#160;11, 2023, and December&#160;12, 2023, the Sponsor advanced the Company $10,000, $1,630,000, and $15,000, respectively, to fund tax obligations. As of December&#160;31, 2023, the Sponsor advanced the Company $1,655,000 and is reflected in the consolidated balance sheets.&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47586"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47587"
      unitRef="Unit_shares">7187500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P10_25_2021To10_25_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="3"
      id="ixv-47588"
      unitRef="Unit_pure">1.044</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47589"
      unitRef="Unit_shares">7503750</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-47590"
      unitRef="Unit_shares">3750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <acab:LockInPeriodOfShares
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-47591">P1Y</acab:LockInPeriodOfShares>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-47592"
      unitRef="Unit_USD_per_Share">12</us-gaap:SharePrice>
    <acab:NumberOfTradingDaysForDeterminingSharePrice
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-47593">P20D</acab:NumberOfTradingDaysForDeterminingSharePrice>
    <acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-47594">P30D</acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <acab:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_RestrictionOnTransferOfSponsorSharesMemberACABBasisAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-47595">P150D</acab:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47596"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P10_25_2021To10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_DirectorMembersrtTitleOfIndividualAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47597"
      unitRef="Unit_shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="PAsOn10_25_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47598"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47599"
      unitRef="Unit_shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47600"
      unitRef="Unit_shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47601"
      unitRef="Unit_USD">362500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_01_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-47602"
      unitRef="Unit_USD_per_Share">7.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P12_01_2021To12_01_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FeeSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-47604"
      unitRef="Unit_USD">362500</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_25_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47605"
      unitRef="Unit_USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2023_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47606"
      unitRef="Unit_USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47607"
      unitRef="Unit_USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherCommitment
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-47608"
      unitRef="Unit_USD">1750000</us-gaap:OtherCommitment>
    <acab:WorkingCapitalLoansConvertibleIntoEquityWarrants
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-47609"
      unitRef="Unit_USD">1500000</acab:WorkingCapitalLoansConvertibleIntoEquityWarrants>
    <acab:DebtInstrumentConversionPricePerShare
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      id="ixv-47610"
      unitRef="Unit_USD_per_Share">1</acab:DebtInstrumentConversionPricePerShare>
    <acab:WorkingCapitalLoansOutstanding
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-47611"
      unitRef="Unit_USD">0</acab:WorkingCapitalLoansOutstanding>
    <acab:WorkingCapitalLoansOutstanding
      contextRef="PAsOn12_31_2022_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-47612"
      unitRef="Unit_USD">0</acab:WorkingCapitalLoansOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn11_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47613"
      unitRef="Unit_USD">80000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47614"
      unitRef="Unit_USD">80000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47615"
      unitRef="Unit_USD">80000</us-gaap:AssetsHeldInTrust>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_14_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-47616"
      unitRef="Unit_USD_per_Share">10.2</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:NotesPayable
      contextRef="PAsOn10_14_2023_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47617"
      unitRef="Unit_USD">160000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn12_18_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_LoansPayableMemberusgaapLongtermDebtTypeAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-47618"
      unitRef="Unit_USD_per_Share">10.2</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:OtherLoansPayable
      contextRef="PAsOn12_08_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47619"
      unitRef="Unit_USD">10000</us-gaap:OtherLoansPayable>
    <us-gaap:OtherLoansPayable
      contextRef="PAsOn12_11_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47620"
      unitRef="Unit_USD">1630000</us-gaap:OtherLoansPayable>
    <us-gaap:OtherLoansPayable
      contextRef="PAsOn12_12_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47621"
      unitRef="Unit_USD">15000</us-gaap:OtherLoansPayable>
    <us-gaap:OtherLoansPayable
      contextRef="PAsOn12_31_2023_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47622"
      unitRef="Unit_USD">1655000</us-gaap:OtherLoansPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27853"> &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;NOTE 6&#x2009;&#x2014;&#x2009;COMMITMENTS&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="background: none;font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to a registration rights agreement entered into on January&#160;13, 2022, the holders of the Founder Shares, Private Placement Warrants, and any Private Placement Warrants that may be issued upon conversion of the Working Capital Loans (and any Series A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and conversion of Founder Shares) will be entitled to registration rights. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;lock-up&lt;/div&gt; period. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#x2019;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advisors &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;7, 2022, the Company and Farvahar Capital (&#x201c;Farvahar&#x201d;) entered into an agreement under which Farvahar served as an advisor to the Company in connection with the Initial Public Offering. Farvahar was engaged to represent the Company&#x2019;s interests only and is independent of the underwriters. The underwriters reimbursed the Company for the fees payable to Farvahar in respect of the provision of such advisory services. The Company agreed to pay Farvahar a fee of 0.08% of the gross proceeds of the Initial Public Offering, including any exercise of the underwriters&#x2019; over-allotment option with respect to the Initial Public Offering or $240,000 in the aggregate. Farvahar did not act as an underwriter in connection with the Initial Public Offering; it did not identify or solicit potential investors in the Initial Public Offering. As of December&#160;31, 2022, the Company received the reimbursement from the underwriters and paid Farvahar.&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;"&gt;Capital Market Advisor &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On April&#160;11, 2023, the Company entered into a services agreement with an advisor. The Advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will be paid a fee for their services. All consideration is to be paid simultaneously with the closing of the business combination. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Redemption&lt;/div&gt; Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On or about April&#160;4, 2023, the Company and Atlantic Coastal Acquisition Management II LLC (the &#x201c;Sponsor&#x201d;), entered into agreements &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;Non-Redemption&lt;/div&gt; Agreements&#x201d;) with several unaffiliated third parties in exchange for them agreeing not to redeem an aggregate of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3,300,900shares(&#x201c;Non-Redeemed&lt;/div&gt; Shares&#x201d;) of the Company&#x2019;s Series A common stock sold in its initial public offering (the &#x201c;Public Shares&#x201d;) at the special meeting called by the Company (the &#x201c;Meeting&#x201d;) to approve an extension of time for the Company to consummate an initial business&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;combination (the &#x201c;Charter Amendment Proposal&#x201d;) from April 19, 2023 to October 19, 2023 (an &#x201c;Extension&#x201d;), subject to additional Extension(s) up to December 19, 2023 upon election by the Sponsor. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of 825,225 shares of the Company held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Redeemed&lt;/div&gt; Shares through the Meeting.&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation (&#x201c;Merger Sub&#x201d;), and Abpro Corporation, a Delaware corporation &#x201c;Abpro&#x201d;), entered into a business combination agreement (the &#x201c;Business Combination Agreement&#x201d;). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Pursuant to the Business Combination Agreement, on the Closing Date (as defined in the Business Combination Agreement), Merger Sub, a newly formed, wholly-owned direct subsidiary of the Company, will be merged with and into the Abpro (the &#x201c;Business Combination,&#x201d; together with the other transactions related thereto, the &#x201c;Proposed Transactions&#x201d;), with the Abpro surviving the Business Combination as a wholly-owned direct subsidiary of the Company (the &#x201c;Surviving Company&#x201d;). In connection with the consummation of the Business Combination, the Company will change its corporate name to &#x201c;Abpro Holdings, Inc.&#x201d; The respective boards of directors of the Company and Abpro have duly approved the Business Combination Agreement and the transactions contemplated thereby. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immediately prior to the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;), Abpro will cause (i)&#160;all outstanding Abpro convertible notes to be converted into shares of Company Common Stock, (ii)&#160;all outstanding Abpro warrants to acquire equity securities of the Company to be converted into a number of shares of shares of Company Common Stock and (iii)&#160;the Abpro Preferred Shares (including those shares resulting from the convertible notes conversion and warrant conversion) that are issued and outstanding immediately prior to the Effective Time to be converted into shares of Abpro Common Stock. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conditions to closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;The obligations of the Company and Abpro to consummate the Business Combination are subject to certain closing conditions, including, but not limited to, (i)&#160;the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;the absence of any law or governmental order or other legal restraint or prohibition preventing the consummation of the Business Combination, (iii)&#160;the Registration Statement being declared effective under the Securities Act, (iv)&#160;the ACAB New Common Shares to be issued in connection with the Business Combination having been approved for listing on Nasdaq, (v)&#160;the approval of certain of&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;the Company Proposals by the Company&#x2019;s stockholders, (vi)&#160;obtaining the Abpro written consent approving the Business Combination; (vii)&#160;the Company having at least $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;5,000,001&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; of net tangible assets (as determined in accordance with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Rule&#160;3a51-1(g)(1)&#160;of&lt;/div&gt; the Securities Exchange Act of 1934, as amended) remaining after the Closing; and (viii)&#160;the Company arranging for binding commitments of at least $&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;8.7&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;&#160;million in available closing cash consisting of funds in the Trust Account (after reduction for payments made in connection with redemptions by the Company stockholders) plus any funds available pursuant to a PIPE&#160;Financing, forward purchase agreement, equity line of credit, convertible note financing and other sources of financing, less any Unpaid SPAC Expenses, as described in the Business Combination Agreement, subject to the Abpro&#x2019;s waiver of such amount.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Letter Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#x201c;Sponsor&#x201d;) entered into an agreement with the Company, the Abpro and Abpro Bio Co., Ltd (the &#x201c;Sponsor Letter Agreement&#x201d;), whereby Sponsor agrees to (i)&#160;retain 2.95&#160;million shares of the Company&#x2019;s Series A Common Stock held by it, (ii)&#160;divide 2,458,333 shares of the Company&#x2019;s Series A Common Stock held by it &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;among the Sponsor, who will be entitled to 491,667 of the shares, Abpro, who will be entitled to 983,333 of the shares, and Abpro Bio Co., Ltd, who will be entitled to 983,333 of the shares, for such party to use to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;obtain&#160;non-redemption&#160;commitments&lt;/div&gt; from the Company&#x2019;s stockholders or other capital for ACAB or the Surviving Company (with any shares unused for such purpose to be retained by such party) and (ii)&#160;forfeit the remainder of any the Company&#x2019;s Series A Common Stock and the Company&#x2019;s Series B Common Stock held by it.&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, the Company, Abpro and the Sponsor entered into the Sponsor Support Agreement pursuant to which the Sponsor agreed to, among other things, vote all of its shares of the Company&#x2019;s Series A Common Shares and the Company&#x2019;s Series B Common Shares held by it, whether now owned or hereafter acquired, (i)&#160;in favor of the approval and adoption of the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (ii)&#160;against any proposal, action or agreement that would impede, interfere with, delay, postpone or discourage any provision of the Sponsor Support Agreement, the Business Combination Agreement or the transactions contemplated thereby (including the Business Combination). In addition, in the Sponsor Support Agreement, the Sponsor agrees to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of the Company&#x2019;s Series B Common Stock held by the Sponsor convert into shares of the Company&#x2019;s Series A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <acab:UnderwritingDiscountPerShare
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-47623"
      unitRef="Unit_USD_per_Share">0.2</acab:UnderwritingDiscountPerShare>
    <acab:PaymentOfUnderwritingDiscount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47624"
      unitRef="Unit_USD">6000000</acab:PaymentOfUnderwritingDiscount>
    <acab:DeferredUnderwritingDiscountPerShare
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-47625"
      unitRef="Unit_USD_per_Share">0.35</acab:DeferredUnderwritingDiscountPerShare>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47626"
      unitRef="Unit_USD">10500000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <acab:PercentageOfAdvisoryServiceFee
      contextRef="P01_07_2022To01_07_2022"
      decimals="2"
      id="ixv-47627"
      unitRef="Unit_USD_per_Share">0.08</acab:PercentageOfAdvisoryServiceFee>
    <acab:AdvisoryServiceFee
      contextRef="P01_07_2022To01_07_2022"
      decimals="0"
      id="ixv-47628"
      unitRef="Unit_USD">240000</acab:AdvisoryServiceFee>
    <acab:NumberOfSharesNotAvailableForRedemption
      contextRef="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-47629"
      unitRef="Unit_shares">3300900</acab:NumberOfSharesNotAvailableForRedemption>
    <acab:ThresholdDateForConsummationOfBusinessCombinationOne
      contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-47632">2023-04-19</acab:ThresholdDateForConsummationOfBusinessCombinationOne>
    <acab:ThresholdDateForConsummationOfBusinessCombinationTwo
      contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-47633">2023-10-19</acab:ThresholdDateForConsummationOfBusinessCombinationTwo>
    <acab:ThresholdDateForConsummationOfBusinessCombinationThree
      contextRef="P04_04_2023To04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-47634">2023-12-19</acab:ThresholdDateForConsummationOfBusinessCombinationThree>
    <acab:InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders
      contextRef="PAsOn04_04_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_NonRedemptionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-47635"
      unitRef="Unit_shares">825225</acab:InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders>
    <acab:MinimumNetWorthNeededToConsummateBusinessCombination
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47636"
      unitRef="Unit_USD">5000001</acab:MinimumNetWorthNeededToConsummateBusinessCombination>
    <acab:MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-47637"
      unitRef="Unit_USD">8700000</acab:MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47638"
      unitRef="Unit_shares">2.95</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-47639"
      unitRef="Unit_shares">2458333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_11_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47642"
      unitRef="Unit_shares">491667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_11_2023_AbproBioCoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47643"
      unitRef="Unit_shares">983333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_11_2023_AbproMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47644"
      unitRef="Unit_shares">983333</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-27980">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;7&#x2009;&#x2014;&#x2009;STOCKHOLDERS&#x2019; DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;The Company is authorized to issue 1,000,000 shares of $0.0001 par value preferred stock. At December&#160;31, 2023 and 2022, there were no shares of preferred stock issued or outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A Common Stock &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;The Company is authorized to issue up to 100,000,000 shares of Series A, $0.0001 par value common stock. Holders of the Company&#x2019;s common stock are entitled to one vote for each share. At December&#160;31, 2023 and 2022, there were 7,499,999 and no shares of Series A common stock issued and outstanding, excluding 667,391 and 30,000,000 shares subject to possible redemption, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series B Common Stock &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;The Company is authorized to issue up to 10,000,000 shares of Series B, $0.0001 par value common stock. Holders of the Company&#x2019;s common stock are entitled to one vote for each share. At December&#160;31, 2022, there were 7,500,000 shares of Series B common stock issued and outstanding, of which an aggregate of up to 978,500 shares were subject to forfeiture to the extent that the underwriters&#x2019; over-allotment option was not exercised in full or in part so that the Initial Stockholders will own 20% of the Company&#x2019;s issued and outstanding common stock after the Initial Public Offering (assuming Initial Stockholders do not purchase any Public Shares in the Initial Public Offering). On January&#160;13, 2022, the Company effectuated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;1.044-for-1&#160;stock&lt;/div&gt;&lt;/div&gt; split, resulting in an aggregate of 7,503,750 Founder Shares outstanding. Due to the underwriters&#x2019; election to partially exercise their overallotment option, 3,750 shares were forfeited, 1 and 7,500,000 Series B common stock are issued and outstanding at December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Holders of Series A common stock and Series B common stock will vote together as a single class on all other matters submitted to a vote of stockholders, except as required by law. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The shares of Series B common stock will automatically convert into shares of Series A common stock concurrently or immediately following the consummation of an Initial Business Combination, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, subject to adjustment as provided herein. In the case that additional shares of Series A common stock, or equity-linked securities, are issued or deemed issued in connection with the Initial Business Combination, the number of shares of Series A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, 20% of the total number of shares of Series A common stock outstanding after such conversion (after &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;giving effect to any redemption of shares of Series A common stock by Public Stockholders), including the total number of shares of Series A common stock, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the Initial Business Combination, excluding any shares of Series A common stock or equity-linked securities exercisable for or convertible into shares of Series A common stock issued, or to be issued, to any seller in the Initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers, or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; As of December&#160;31, 2023 and 2022, there are 15,000,000 outstanding Public Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that there is an effective registration statement under the Securities Act covering the Series A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the public warrant agreement) and such shares are registered, qualified, or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company will not be obligated to deliver any Series A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Series A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Series A common stock upon exercise of a warrant unless Series A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Series A common stock issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If any such registration statement has not been declared effective by the 60th business day following the closing of a Business Combination, holders of the warrants will have the right, during the period beginning on the 61st business day after the closing of a Business Combination and ending upon such registration statement being declared effective by the SEC, and during any other period when the Company fails to have maintained an effective registration statement covering the issuance of the shares of Series A common stock issuable upon exercise of the warrants, to exercise such warrants on a &#x201c;cashless basis.&#x201d; Notwithstanding the above, if the shares of Series A common stock are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Once the warrants become exercisable, the Company may redeem the Public Warrants: &lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in whole and not in part; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;upon not less than 30&#160;days&#x2019; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;if, and only if, the reported last sale price of the Series&#160;A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;a&#160;30-trading&#160;day&lt;/div&gt; period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. The exercise price and number of shares of Series A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Series A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. &lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;In addition, if (x)&#160;the Company issues additional shares of Series A common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share of Series A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors, and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#x2019;s Series A common stock during the 20 trading day period starting on the trading day after the day on which the Company completes a Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there are 13,850,000 Private Placement Warrants, The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants (including the Series A common stock issuable upon the exercise of the Private Placement Warrants) are not transferable, assignable or salable until 30 days after the completion of an Initial Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-redeemable&lt;/div&gt; so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47645"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47646"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47647"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47648"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47649"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47650"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47651"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47652"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47653"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47654"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47655"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47656"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      id="ixv-47657">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47658"
      unitRef="Unit_shares">7499999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47659"
      unitRef="Unit_shares">7499999</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47660"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47661"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47662"
      unitRef="Unit_shares">667391</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47663"
      unitRef="Unit_shares">30000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47664"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47665"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47666"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47667"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="P01_01_2023To12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      id="ixv-47668">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47669"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47670"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesIssued>
    <acab:SharesAreSubjectToForfeiture
      contextRef="P01_01_2023To12_31_2023_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-47671"
      unitRef="Unit_shares">978500</acab:SharesAreSubjectToForfeiture>
    <acab:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-47672"
      unitRef="Unit_pure">0.20</acab:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P01_13_2022To01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="3"
      id="ixv-47673"
      unitRef="Unit_pure">1.044</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn01_13_2022_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47674"
      unitRef="Unit_shares">7503750</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_13_2022To01_13_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-47675"
      unitRef="Unit_shares">3750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47676"
      unitRef="Unit_shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47677"
      unitRef="Unit_shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47678"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47679"
      unitRef="Unit_shares">7500000</us-gaap:CommonStockSharesIssued>
    <acab:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="PAsOn12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-47680"
      unitRef="Unit_pure">0.20</acab:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:CommonStockConversionBasis
      contextRef="P01_01_2023To12_31_2023_FounderSharesMemberusgaapStatementEquityComponentsAxis"
      id="ixv-47683">one-for-one</us-gaap:CommonStockConversionBasis>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47684"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47685"
      unitRef="Unit_shares">15000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <acab:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47686">P30D</acab:PeriodAfterWhichTheWarrantsAreExercisable>
    <acab:PeriodAfterWhichTheWarrantsAreExercisable
      contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47687">P12M</acab:PeriodAfterWhichTheWarrantsAreExercisable>
    <acab:NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered contextRef="P01_01_2023To12_31_2023" id="ixv-47688">P20D</acab:NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered>
    <acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective contextRef="P01_01_2023To12_31_2023" id="ixv-47689">P60D</acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective>
    <acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective
      contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfInitialPublicOfferMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis"
      id="ixv-47690">P60D</acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective>
    <acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective
      contextRef="P01_01_2023To12_31_2023_FromTheCompletionOfBusinessCombinationMemberACABPeriodAfterWhichTheWarrantsAreExercisableAxis"
      id="ixv-47691">P61D</acab:NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective>
    <acab:ClassOfWarrantsOrRightsRedemptionPricePerUnit
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47692"
      unitRef="Unit_USD_per_Share">0.01</acab:ClassOfWarrantsOrRightsRedemptionPricePerUnit>
    <acab:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47694">P30D</acab:MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47695"
      unitRef="Unit_USD_per_Share">18</us-gaap:SharePrice>
    <acab:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47696">P20D</acab:NumberOfTradingDaysForDeterminingTheSharePrice>
    <acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47697">P30D</acab:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47698"
      unitRef="Unit_USD_per_Share">9.2</us-gaap:SharesIssuedPricePerShare>
    <acab:ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47699"
      unitRef="Unit_pure">0.60</acab:ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal>
    <acab:NumberOfTradingDaysForDeterminingTheSharePrice
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47700">P20D</acab:NumberOfTradingDaysForDeterminingTheSharePrice>
    <acab:VolumeWeightedAveragePriceOfShares
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47701"
      unitRef="Unit_USD_per_Share">9.2</acab:VolumeWeightedAveragePriceOfShares>
    <acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice
      contextRef="P01_01_2023To12_31_2023_AdjustedExercisePriceOneMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47702"
      unitRef="Unit_pure">1.15</acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice>
    <acab:PerShareRedemptionTriggerPrice
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47703"
      unitRef="Unit_USD_per_Share">18</acab:PerShareRedemptionTriggerPrice>
    <acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice
      contextRef="P01_01_2023To12_31_2023_AdjustedExercisePriceTwoMemberACABAdjustedExercisePriceOfWarrantsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-47704"
      unitRef="Unit_pure">1.80</acab:AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47705"
      unitRef="Unit_shares">13850000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-47706"
      unitRef="Unit_shares">13850000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <acab:ClassOfWarrantsOrRightsLockInPeriod
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-47707">P30D</acab:ClassOfWarrantsOrRightsLockInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28125">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;8&#x2009;&#x2014;&#x2009;INCOME TAXES&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s net deferred tax assets are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Startup/Organization Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The income tax provision for the year ended December&#160;31, 2023 and 2022 consists of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(298,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;298,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the Company did not have any U.S. federal and state net operating loss carryovers available to offset future taxable income. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December&#160;31, 2023 and 2022, the change in the valuation allowance was $298,330 and $388,575, respectively. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Meals&#160;&amp;amp; entertainment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business combination expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fines and penalties&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28131"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s net deferred tax assets are as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Startup/Organization Expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47708"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47709"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47710"
      unitRef="Unit_USD">686905</acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts>
    <acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47711"
      unitRef="Unit_USD">388575</acab:DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47712"
      unitRef="Unit_USD">686905</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47713"
      unitRef="Unit_USD">388575</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47714"
      unitRef="Unit_USD">686905</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47715"
      unitRef="Unit_USD">388575</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-47716"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-47717"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28277"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The income tax provision for the year ended December&#160;31, 2023 and 2022 consists of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(298,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;298,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388,575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,177,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;823,991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47718"
      unitRef="Unit_USD">1177463</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47719"
      unitRef="Unit_USD">823991</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47720"
      unitRef="Unit_USD">-298330</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47721"
      unitRef="Unit_USD">-388575</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47722"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47723"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47724"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47725"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47726"
      unitRef="Unit_USD">-298330</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47727"
      unitRef="Unit_USD">-388575</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47728"
      unitRef="Unit_USD">1177463</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47729"
      unitRef="Unit_USD">823991</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis"
      decimals="0"
      id="ixv-47730"
      unitRef="Unit_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_FederalAndStateAuthorityMemberusgaapIncomeTaxAuthorityAxis"
      decimals="0"
      id="ixv-47731"
      unitRef="Unit_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47732"
      unitRef="Unit_USD">-298330</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47733"
      unitRef="Unit_USD">-388575</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28437"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Meals&#160;&amp;amp; entertainment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business combination expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fines and penalties&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax provision&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 65%;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47734"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47735"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47736"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47737"
      unitRef="Unit_pure">0.0445</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47738"
      unitRef="Unit_pure">0.0024</acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination>
    <acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47739"
      unitRef="Unit_pure">0</acab:EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47740"
      unitRef="Unit_pure">0.0075</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47741"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47742"
      unitRef="Unit_pure">0.0746</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47743"
      unitRef="Unit_pure">0.2271</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-47744"
      unitRef="Unit_pure">0.2945</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-47745"
      unitRef="Unit_pure">0.4816</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28588">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;NOTE&#160;9&#x2009;&#x2014;&#x2009;FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company follows the guidance in ASC 820 for its financial assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at each reporting period, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at least annually. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 91%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis at December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;309,790,455&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28642">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis at December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 71%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 71%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;1&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;309,790,455&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="ixv-47748"
      unitRef="Unit_USD">1</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_AssetsHeldInTrustMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      id="ixv-47749"
      unitRef="Unit_USD">309790455</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-28731"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;NOTE 10&#x2009;&#x2014;&#x2009;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;On January&#160;11, 2024, the Company entered into an amended services agreement with and advisor, that &lt;div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"&gt;was origin&lt;/div&gt;ally entered into on&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;"&gt;April 11 2023&lt;/div&gt;. The advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will receive &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;200,000&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt; shares of Series a common stock in the post-closing Company and &lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;4&lt;/div&gt;&lt;div style="-sec-ix-redline:true;display:inline;"&gt;% of the gross proceeds raised from investors and received by the Company or the target prior to the business combination or simultaneously. All consideration is to be paid simultaneously with the closing of the business combination.&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January&#160;18, 2024, the Sponsor, the Company, Abpro and Abpro Bio entered into an amendment to the Sponsor Letter Agreement (the &#x201c;Amended Sponsor Letter Agreement&#x201d;), which amended the amount of shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;each party thereunder is entitled to, consistent with the description previously disclosed on December&#160;11, 2023 and as contemplated in the Business Combination Agreement, dated as of December&#160;11, 2023, by and among the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro. For the avoidance of doubt, the Amended Sponsor Letter Agreement supersedes and replaces the Sponsor Letter Agreement in its entirety. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;21, 2024, the Company received a partial waiver from an underwriter from the initial public offering that was entitled to a portion of the deferred underwriter fee. Subject to the closing of the businesses combination between the Company and Abpro, the underwriter waived $4,290,000 of the underwriter fee in exchange for 600,000 of common stock in the post-merger Company. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;22, 2024, the Company issued a press release announcing that it filed a Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-4&lt;/div&gt; with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January&#160;19, 2024 in connection with the previously announced proposed business combination with Abpro (the &#x201c;Business Combination&#x201d;). &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn01_11_2024_AdvisorMemberACABInvesteeAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-47750"
      unitRef="Unit_shares">200000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <acab:PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors
      contextRef="P01_11_2024To01_11_2024"
      decimals="2"
      id="ixv-47751"
      unitRef="Unit_pure">0.04</acab:PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors>
    <acab:UnderwriterFeeWaivedOff
      contextRef="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-47753"
      unitRef="Unit_USD">4290000</acab:UnderwriterFeeWaivedOff>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_21_2024To01_21_2024_UnderwriterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-47754"
      unitRef="Unit_shares">600000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763349726144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Atlantic Coastal Acquisition Corp. II<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001893219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6 St Johns Lane, Floor 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-1013956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">890-7200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">6770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6 St Johns Lane, Floor 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">890-7200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Shahraab Ahmad<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763349330496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 264,538<span></span>
</td>
<td class="nump">$ 392,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">377,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Cash and marketable securities held in Trust Account</a></td>
<td class="nump">29,728,990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">29,993,528<span></span>
</td>
<td class="nump">770,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and marketable securities held in Trust Account</a></td>
<td class="nump">7,372,451<span></span>
</td>
<td class="nump">309,790,455<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">37,365,979<span></span>
</td>
<td class="nump">310,560,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">469,268<span></span>
</td>
<td class="nump">1,243,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ExciseTaxPayableCurrent', window );">Excise tax payable</a></td>
<td class="nump">3,062,004<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AccruedOfferingCosts', window );">Accrued offering costs</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">308,194<span></span>
</td>
<td class="nump">823,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Common stock to be redeemed (2,768,301 shares of Series A common stock)</a></td>
<td class="nump">29,728,990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">35,388,456<span></span>
</td>
<td class="nump">2,142,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">45,888,457<span></span>
</td>
<td class="nump">12,642,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A common stock subject to possible redemption; 667,391 and 30,000,000 shares issued and outstanding at December 31, 2023 and 2022 at redemption value of $10.93 and $10.30 per share, respectively</a></td>
<td class="nump">7,292,641<span></span>
</td>
<td class="nump">309,097,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 1,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,815,868)<span></span>
</td>
<td class="num">(11,180,162)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Deficit</a></td>
<td class="num">(15,815,118)<span></span>
</td>
<td class="num">(11,179,412)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
<td class="nump">37,365,979<span></span>
</td>
<td class="nump">310,560,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Extension promissory note - related party</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Advance from related parties</a></td>
<td class="nump">1,655,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Series A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Common stock to be redeemed (2,768,301 shares of Series A common stock)</a></td>
<td class="nump">29,728,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Series B common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excise tax payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763349600048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Series A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Common stock to be redeemed (2,768,301 shares of Series A common stock)</a></td>
<td class="nump">2,768,301<span></span>
</td>
<td class="nump">2,768,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">667,391<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">667,391<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary equity, redemption price per share</a></td>
<td class="nump">$ 10.93<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Series B common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763341920800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OperationAndFormationCosts', window );">Operation and formation costs</a></td>
<td class="nump">$ 1,666,056<span></span>
</td>
<td class="nump">$ 2,050,410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,666,056)<span></span>
</td>
<td class="num">(2,050,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income &#8211; bank</a></td>
<td class="nump">52,304<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_InvestmentIncomeExpenseNonoperating', window );">Interest earned on Cash and marketable securities held in Trust Account</a></td>
<td class="nump">5,754,715<span></span>
</td>
<td class="nump">4,121,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PenaltiesAndInterestOnTaxes', window );">Penalties and interest on taxes</a></td>
<td class="num">(142,041)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities held in Trust Account</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(362,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">5,664,978<span></span>
</td>
<td class="nump">3,761,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">3,998,922<span></span>
</td>
<td class="nump">1,710,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1,177,463)<span></span>
</td>
<td class="num">(823,991)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">2,821,459<span></span>
</td>
<td class="nump">$ 886,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember', window );">Redeemable common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,693,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">11,257,894<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">11,257,894<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember', window );">Nonredeemable common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,128,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Series A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Series B common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acab_ClassAAndClassBCommonStockMember', window );">Series A and Series B common stock [Member] | Nonredeemable common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_InvestmentIncomeExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income expense nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_InvestmentIncomeExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OperationAndFormationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operation and formation costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OperationAndFormationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PenaltiesAndInterestOnTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Penalties and interest on taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PenaltiesAndInterestOnTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acab_ClassAAndClassBCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acab_ClassAAndClassBCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763349253808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements Of Changes In Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A [Member]</div></th>
<th class="th"><div>Series B [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Series A [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Series B [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,503,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 23,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="num">$ (1,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Sale of 13,850,000 Private Placement Warrants</a></td>
<td class="nump">13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeiture of Founder Shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron', window );">Compensation Expense &#8211; Fair value of assigned Founder Shares to Apeiron</a></td>
<td class="nump">362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Fair value of Public Warrants at issuance</a></td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Allocated value of transaction costs to Series A common stock</a></td>
<td class="num">(505,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(505,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Remeasurement of Series A common stock to redemption amount</a></td>
<td class="num">(33,896,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,831,701)<span></span>
</td>
<td class="num">(12,065,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">886,918<span></span>
</td>
<td class="nump">$ 701,826<span></span>
</td>
<td class="nump">$ 185,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,918<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Share at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="num">(11,179,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,180,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Remeasurement of Series A common stock to redemption amount</a></td>
<td class="num">(4,395,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,395,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_StockholderNonRedemptionAgreementAdjustment', window );">Stockholder non-redemption agreement</a></td>
<td class="nump">1,378,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,378,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_StockholderNonRedemptionAgreementAdjustmentReduction', window );">Stockholder non-redemption agreement</a></td>
<td class="num">(1,378,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,378,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax', window );">Excise tax</a></td>
<td class="num">(3,062,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,062,004)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series Class B shares to Series Class A Non-redeemable shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="num">(7,499,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series Class B shares to Series Class A Non-redeemable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="num">$ (749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">2,821,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,821,459<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Share at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">$ (15,815,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (15,815,868)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital compensation expense for fair value of assigned founder shares to apeiron.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdjustmentsToAdditionalPaidInCapitalCompensationExpenseForFairValueOfAssignedFounderSharesToApeiron</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdjustmentsToAdditionalPaidInCapitalExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital excise tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdjustmentsToAdditionalPaidInCapitalExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_StockholderNonRedemptionAgreementAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholder non-redemption agreement adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_StockholderNonRedemptionAgreementAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_StockholderNonRedemptionAgreementAdjustmentReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholder&#160;non-redemption&#160;agreement adjustment reduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_StockholderNonRedemptionAgreementAdjustmentReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343236240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Changes In Stockholders' Deficit (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares</a></td>
<td class="nump">13,850,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763345506800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,821,459<span></span>
</td>
<td class="nump">$ 886,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount', window );">Interest earned on Cash and marketable securities held in Trust Account</a></td>
<td class="num">(5,754,715)<span></span>
</td>
<td class="num">(4,121,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">362,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">377,780<span></span>
</td>
<td class="num">(377,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(773,904)<span></span>
</td>
<td class="nump">1,241,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(515,797)<span></span>
</td>
<td class="nump">823,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,845,177)<span></span>
</td>
<td class="num">(1,184,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Investment of cash in Trust Account</a></td>
<td class="num">(160,000)<span></span>
</td>
<td class="num">(306,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Cash withdrawn from Trust Account to pay franchise and income taxes</a></td>
<td class="nump">2,132,269<span></span>
</td>
<td class="nump">331,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ProceedsFromTrustAccountInConnectionWithRedemption', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="nump">276,471,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">278,443,729<span></span>
</td>
<td class="num">(305,668,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of Units, net of underwriting discounts paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">294,240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from extension promissory note &#8211; related party</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">49,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible promissory note - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(149,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Advances from related party</a></td>
<td class="nump">1,655,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(70,000)<span></span>
</td>
<td class="num">(743,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Redemption of common stock</a></td>
<td class="num">(276,471,460)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(274,726,460)<span></span>
</td>
<td class="nump">307,245,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash</a></td>
<td class="num">(127,908)<span></span>
</td>
<td class="nump">392,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; Beginning</a></td>
<td class="nump">392,446<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; Ending</a></td>
<td class="nump">264,538<span></span>
</td>
<td class="nump">392,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplementary&#160;cashflow&#160;information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">1,799,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts', window );">Deferred offering costs included in accrued offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">717,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption', window );">Initial classification of Series A common stock subject to possible redemption</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">309,097,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities', window );">Deferred underwriting fee payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accrued offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DeferredOfferingCostsIncludedInAccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee payable as non cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DeferredUnderwritingFeePayableAsNonCashinvestingAndFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial classification of Series A common stock subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_InitialClassificationOfSeriesACommonStockSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest earned on marketable securities held in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_InterestEarnedOnMarketableSecuritiesHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ProceedsFromTrustAccountInConnectionWithRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from trust account in connection with redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ProceedsFromTrustAccountInConnectionWithRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343360912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization And Plan Of Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization And Plan Of Business Operations</a></td>
<td class="text"><div id="fin509388_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTE&#160;1&#160;&#8212;&#160;ORGANIZATION AND PLAN OF BUSINESS OPERATIONS </div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Atlantic Coastal Acquisition Corp. II (the &#8220;Company&#8221;) is a blank check company incorporated in Delaware on May&#160;20, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). On November 30, 2023 the Company formed Abpro Merger Sub Corp. (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of the Company. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had not yet commenced any operations. All activity for the period May&#160;20, 2021 (inception) through December&#160;31, 2023 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;13, 2022. On January&#160;19, 2022, the Company consummated the Initial Public Offering of 30,000,000 units (the &#8220;Units&#8221; and, with respect to the shares of Series A common stock included in the Units being offered, the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of its over-allotment option in the amount of 3,900,000 Units at $10.00 per Unit, generating gross proceeds of $300,000,000, which is described in Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 13,850,000 warrants (each, a &#8220;Private Placement Warrant&#8221; and, collectively, the &#8220;Private Placement Warrants&#8221;) at a price of $1.00 per Private Placement Warrant in a private placement to Atlantic Coastal Acquisition Management II LLC (the &#8220;Sponsor&#8221;), generating gross proceeds of $13,850,000, which is described in Note 4. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs amounted to $17,204,107, consisting of $5,760,000 of underwriting fees (net of $240,000 reimbursed by the underwriters), $10,500,000 of deferred underwriting fees, and $944,107 of other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the Initial Public Offering on January&#160;19, 2022, an amount of $306,000,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), to be invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earlier of: (i)&#160;the consummation of a Business Combination or (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s stockholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">While the Company&#8217;s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Placement Warrants, which are placed in the Trust Account are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least </div></div>80% of the net assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. <br/></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">The Company will provide its holders of the outstanding Public Shares (the &#8220;public stockholders&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the &#8220;Amended and Restated Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the holders of the Company&#8217;s shares prior to the Initial Public Offering (the &#8220;Initial Stockholders&#8221;) have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or do not vote at all. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Initial Stockholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination prior to September 19, 2024 and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation (i) to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s Initial Business Combination or to redeem</div> <div style="-sec-ix-redline:true;display:inline;">100</div><div style="-sec-ix-redline:true;display:inline;">% of its Public Shares if the Company does not complete a Business Combination or (ii)&#160;with respect to any other provision relating to stockholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">pre-initial</div> business combination activity, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company had 15 months from the closing of the Initial Public Offering to complete a Business Combination (the &#8220;Combination Period&#8221;). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than<div style="letter-spacing: 0px; top: 0px;display:inline;"> <div style="-sec-ix-hidden:hidden113139487;display:inline;">ten</div></div> business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders&#8217; rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining stockholders and the Company&#8217;s board of directors, dissolve and liquidate, subject in each case to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from April&#160;19, 2023 to October&#160;19, 2023, subject to additional Extension(s) up to December&#160;19, 2023 upon election by the Sponsor. The extension was approved and a result 26,564,308 shares of the Company&#8217;s Series A common stock were redeemed at approximately $10.41 per share. <br/></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">On April&#160;18, 2023, the Sponsor, the Company&#8217;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#8220;Series B Holders&#8221;) voluntarily converted 7,499,999 shares of Series B Common Stock of the Company they held as of such date into 7,499,999 shares of Series A common stock of the Company (the &#8220;Conversion&#8221;) in accordance with the amended and restated certificate of incorporation, as amended. With respect to shares of Series A common stock that they received as result of the Conversion, the Series B Holders (i)&#160;agreed that they would not vote such stock until after the closing of a business combination and (ii)&#160;acknowledged that such stock would not be entitled to any distribution from the Company&#8217;s trust account. As a result of the Conversion and the results of the Meeting described above, the Company has an aggregate of 10,935,691 shares of Series A common stock outstanding and 1 share of Series B Common Stock (held by the Sponsor) outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">On October&#160;14, 2023 and November&#160;14, 2023, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing, unsecured promissory notes in the aggregate principal amount of $</div><div style="-sec-ix-redline:true;display:inline;">80,000</div><div style="-sec-ix-redline:true;display:inline;">, respectively, (the &#8220;Notes&#8221;) to the Sponsor. The $</div><div style="-sec-ix-redline:true;display:inline;">80,000</div><div style="-sec-ix-redline:true;display:inline;"> was deposited into the Company&#8217;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>$</div><div style="-sec-ix-redline:true;display:inline;">10.20</div><div style="-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">p</div></div>er share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from October&#160;19, 2023 to November&#160;19, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;14, 2023, by resolution of the board of directors of the Company, the Company extended the expiration date of the Business Combination Period from November&#160;19, 2023 to December&#160;19, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro Corporation, a Delaware corporation, entered into a business combination agreement (the &#8220;Business Combination Agreement&#8221;). Please see the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> filed on December&#160;12, 2023 for more information on the terms of the Business Combination Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Merger.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On December&#160;15, 2023, the company held the Meeting to approve an extension of time for the Company to consummate an initial business combination from December&#160;19, 2023 to March&#160;19, 2024, subject to deposits into the trust account maintained for the benefit of the Company&#8217;s public stockholders the lesser of (a) $30,000 or (b) $0.045 for each Public Share that is not redeemed in connection with the Meeting. If the Company has not consummated a Business Combination by the Extended Date, the Company may, without another stockholder vote, elect to extend the Extended Date on a monthly basis up to six times by an additional one month each time thereafter, until September&#160;19, 2024. The extension was approved and a result 2,768,301 public shares of Series A common stock exercised and did not reverse, their right to redeem their public shares in connection with the vote upon the Charter Amendment Proposal. As a result of the foregoing, those holders will receive a payment of approximately $10.68 per share redeemed. This resulted in $29,728,990 being withdrawn from the trust account and paid to redeeming stockholders. The payment to the redeeming stockholders was processed in January 2024, as such $29,728,990 has been removed form Series A common stock subject to redemption and recorded as common stock to be redeemed. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Stockholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $</div><div style="-sec-ix-redline:true;display:inline;">10.20</div><div style="-sec-ix-redline:true;display:inline;"> per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay our taxes. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;display:inline;">indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There is no assurance that the Company&#8217;s plans to consummate the Business Combination will be successful or successful within the Combination Period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2023, the Company had $264,538 in its operating bank accounts and a working capital deficit of $5,394,929. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. The Company will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">In connection with the Company&#8217;s assessment of going concern considerations in accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40</div> &#8220;Presentation of Financial Statements&#8212;Going Concern,&#8221; the Company has until April 19, 2024, 2023, to consummate a Business Combination. If a Business Combination is not consummated by this date there will be a mandatory liquidation and subsequent dissolution of the Company. Although the Company intends to consummate a Business Combination on or before April 19, 2024, it is uncertain that the Company will be able to consummate a Business Combination by this time. Management has determined that the liquidity condition, coupled with the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company&#8217;s plan is to complete a business combination on or prior to April 19, 2024, however it is uncertain that the Company will be able to consummate a Business Combination by this time. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after April 19, 2024. </div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, close of the Initial Public Offering, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of current conflicts around the globe, including Russia&#8217;s invasion of Ukraine and the Israel-Hamas war, and related sanctions, on the world economy is not determinable as of the date of these financial statements, and the specific impact on the Company&#8217;s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. <br/></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Inflation Reduction Act of 2022 </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded&#160;U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">Any redemption or other repurchase that occurs after December&#160;31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i)&#160;the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii)&#160;the structure of a Business Combination, (iii)&#160;the nature and amount of any &#8220;PIPE&#8221; or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv)&#160;the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and impact the Company&#8217;s ability to complete a Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;18, 2023 and December&#160;13, 2023, the Company&#8217;s stockholders redeemed&#160;26,564,308&#160;Series&#160;Class A shares for a total of $276,471,460 and redeemed&#160;2,768,301&#160;Series&#160;Class A shares for a total of $29,728,990, respectively. The Company evaluated the classification and accounting of the stock redemption under ASC 450, &#8220;Contingencies&#8221;. ASC 450 states that when a loss contingency exists the likelihood that the future events will confirm the loss or impairment of an asset or the incurrence of a liability can range from probable to remote. A contingent liability must be reviewed at each reporting period to determine appropriate treatment. The Company evaluated the current status and probability of completing a Business Combination as of December&#160;31, 2023 and determined that a contingent liability should be calculated and recorded. As of December&#160;31, 2023, the Company recorded $3,062,004&#160;of excise tax liability calculated as 1% of shares redeemed. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343303872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 2&#8201;&#8212;&#8201;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the SEC. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2023 and 2022. The Company had $264,538 and $392,446 in cash at December&#160;31, 2023 and 2022, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Cash and Marketable Securities Held in Trust Account </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">At December&#160;31, 2023 and 2022, all of the Company&#8217;s investments held in the Trust Account are invested in cash and money market funds invested primarily in United States Treasuries and are classified as trading securities, respectively. Trading securities are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Common Stock Subject to Possible Redemption </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#8217; equity. The Company&#8217;s Series A common stock feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2023 and 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheet. <br/></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and accumulated deficit. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;300,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds allocated to Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A common stock issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,699,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,896,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">309,097,930</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(276,471,460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemptions (redeemed in December 2023, paid in January 2024)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29,728,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,395,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7,292,641</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A&#8212;&#8220;Expenses of Offering&#8221;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder&#8217;s equity. As of January&#160;19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders&#8217; equity. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were no deferred offering costs recorded in the accompanying consolidated balance sheets respectively. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes.&#8221; ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of December&#160;31, 2023 and 2022, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it<div style="letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized <div style="letter-spacing: 0px; top: 0px;display:inline;">tax</div> benefits will materially change over the next twelve months. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Income per Common Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of December&#160;31, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income per common stock for the periods presented.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 36%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Redeemable</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nonredeemable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;and&#160;Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Basic and diluted net income per common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Allocation of net income, as adjusted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,693,350</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,128,109</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">701,826</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">185,092</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted weighted average shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">11,257,894</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">28,438,356</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted net income per common stock</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheet, primarily due to their short-term nature. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div> settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#8217; equity. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company adopted ASC Topic 718, &#8220;Compensation<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div></div></div>Stock Compensation,&#8221; guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the statements of operations. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU 2023-09 will become effective for Annual periods beginning after December 15, 2024. The Company is still reviewing the impact of ASU 2023-09.</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued Accounting Standards Updated (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(Subtopic470-20)and</div> Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity(Subtopic&#160;815-40):Accounting</div> for Convertible Instruments and Contracts in an Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity&#8221;(&#8220;ASU&#160;2020-06&#8221;),which</div> simplifies accounting for convertible instruments by removing major separation models required under current GAAP. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> would have on our financial position, results of operations or cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8211;Financial</div> Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8221;).&#160;This</div> update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> on January&#160;1, 2023. The adoption of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU2016-13</div> did not have a material impact on its financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343224160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DisclosureOfInitialPublicOffering', window );">Initial Public Offering</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;3&#8201;&#8212;&#8201;INITIAL PUBLIC OFFERING </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Initial Public Offering, the Company sold 30,000,000 Units, which include the partial exercise by the underwriters of their over-allotment option in the amount of 3,900,000 units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of the Company&#8217;s Series A common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each Public Warrant entitles the holder to purchase one share of Series A common stock at an exercise price of $11.50 per whole share (see Note 7). </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DisclosureOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Initial Public Offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DisclosureOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343128592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DisclosureOfPrivatePlacement', window );">Private Placement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;4&#8201;&#8212;&#8201;PRIVATE PLACEMENT </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 13,850,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $13,850,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one Series A common stock at a price of $11.50 per share, subject to adjustments (see Note 7). A portion of the proceeds from the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DisclosureOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DisclosureOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343351776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;5&#8201;&#8212;&#8201;RELATED PARTY TRANSACTIONS </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor paid $25,000 to cover certain offering costs of the Company in consideration for 7,187,500 shares of Series B common stock (the &#8220;Founder Shares&#8221;). On January&#160;13, 2022, the Company effectuated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;1.044-for-1&#160;stock</div></div> split, resulting in an aggregate of 7,503,750 Founder Shares outstanding (see Note 7). Due to the underwriters&#8217; election to partially exercise their overallotment option, 3,750 shares were forfeited. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor, founders, executive officers and directors have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of the Founder Shares until one year after the completion of a Business Combination that results in all of the Company&#8217;s stockholders having the right to exchange their Series A common stock for cash, securities, or other property&#160;(except with respect to permitted transferees). Notwithstanding the foregoing, (x)&#160;if the last reported sale price of the Series A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of common stock for cash, securities or other property, then such securities will be released from these restrictions. Any permitted transferees would be subject to the same restrictions and other agreements of the founders with respect to any Founder Shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor transferred 250,000 Founder Shares to five director nominees (50,000 shares to each director nominee) for no consideration, to serve in his or her capacity as an independent director of the Company. The Company assigned the number of shares of Series B common stock of the Company, par value $0.0001 per share. The transfer of the Founders Shares to five director nominees is&#160;within the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and expensed when earned. Shares granted to these directors are forfeited if their status as director is terminated for any reason prior to the date of the initial Business Combination&#160;and, as such, there has been no stock-based compensation expense recognized in the accompanying financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;1, 2021, the Company and Apeiron Investment Group Ltd. (&#8220;Apeiron&#8221;) entered into an Agreement to which Apeiron will serve as an advisor to the Company in connection with identifying one or more businesses with which the Company may effectuate its Initial Business Combination. As consideration for Apeiron&#8217;s willingness to provide the service set forth in the Agreement, the Sponsor shall pay or transfer to Apeiron (or its designee) on behalf of the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;non-refundable</div> fee in the form of 50,000 shares of the Company&#8217;s Series B common stock (&#8220;Fee Shares&#8221;). The transfer of the Founder Shares to Apeiron is not directly related to or in connection with the Initial Public Offering and not within the scope of offering costs as defined in Note 2. The transfer of the Fee Shares is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 50,000 Fee Shares granted to Apeiron was $362,500 or $7.25<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;per share. The Founders Shares were granted subject to a performance condition (i.e., the closing date of the Initial </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">Public Offering). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2022, the Company recognized $</div></div>362,500&#160;in the operations as stock-based compensation expense as the Company determined that the performance condition has been met at the date of issuance/closing of the Initial Public Offering. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;25, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#8220;Promissory Note&#8221;), pursuant to which the Company may borrow up to an aggregate principal amount of $250,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing and is payable on the earlier of April&#160;30, 2022, or the consummation of the Initial Public Offering. As of December&#160;31, 2023 and 2022, the Company has no outstanding balance under the Promissory Note, respectively. <br/></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with a Business Combination, the Sponsor has committed to advance the Company up to $1,750,000 to fund the expenses relating to investigating and selecting a target business and other working capital requirements after the Initial Public Offering and prior to the Initial Business Combination. In addition, our Sponsor, or certain of our officers and directors or their affiliates may, but are not obligated to, loan us additional funds as may be required. If the Company consummated an Initial Business Combination, the Company would repay the Working Capital Loans. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The final terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. Up to $1,500,000 of such Working Capital Loans may be convertible into additional warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. Prior to the completion of the Initial Business Combination, the Company does not expect to seek loans from parties other than the Sponsor or its affiliates as the Company does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in the Trust Account. There are no Working Capital Loans outstanding as of December&#160;31, 2023 and 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Extension Promissory Notes &#8212; Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2023 and November&#160;14, 2023, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-interest</div> bearing, unsecured promissory notes in the principal amount of $80,000, respectively, (the &#8220;Extension Promissory Notes&#8221;) to the Sponsor. The $80,000 was deposited into the Company&#8217;s trust account in order to extend the amount of time that the Company has available to complete a business combination. Upon the closing of a business combination by the Company, the Sponsor may elect to either receive repayment under the Notes or to convert all or a portion of the amount loaned under the Notes into Series A common stock of the Company at a price equal to $10.20 per share. In the event that the Company does not complete a business combination, the amounts loaned under the Notes will be repaid to the Sponsor only from funds held outside the Trust Account or will be forfeited, eliminated, or otherwise forgiven. As of December&#160;31, 2023, the Company owed $160,000 due under the Extension Promissory Notes with no further borrowings available. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">On December&#160;18, 2023, the Company amended the Extension Promissory Notes to remove the Sponsor&#8217;s right to convert the note into Series A common stock at a price equal to </div></div></div><div style="-sec-ix-redline:true;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$</div>10.20</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"> per share.</div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advance from Related Party </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, December&#160;11, 2023, and December&#160;12, 2023, the Sponsor advanced the Company $10,000, $1,630,000, and $15,000, respectively, to fund tax obligations. As of December&#160;31, 2023, the Sponsor advanced the Company $1,655,000 and is reflected in the consolidated balance sheets.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343312960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">&#160;</div></div></div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a registration rights agreement entered into on January&#160;13, 2022, the holders of the Founder Shares, Private Placement Warrants, and any Private Placement Warrants that may be issued upon conversion of the Working Capital Loans (and any Series A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and conversion of Founder Shares) will be entitled to registration rights. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lock-up</div> period. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $6,000,000 in the aggregate, paid on the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,500,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. <br/></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advisors </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2022, the Company and Farvahar Capital (&#8220;Farvahar&#8221;) entered into an agreement under which Farvahar served as an advisor to the Company in connection with the Initial Public Offering. Farvahar was engaged to represent the Company&#8217;s interests only and is independent of the underwriters. The underwriters reimbursed the Company for the fees payable to Farvahar in respect of the provision of such advisory services. The Company agreed to pay Farvahar a fee of 0.08% of the gross proceeds of the Initial Public Offering, including any exercise of the underwriters&#8217; over-allotment option with respect to the Initial Public Offering or $240,000 in the aggregate. Farvahar did not act as an underwriter in connection with the Initial Public Offering; it did not identify or solicit potential investors in the Initial Public Offering. As of December&#160;31, 2022, the Company received the reimbursement from the underwriters and paid Farvahar.<br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Capital Market Advisor </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">On April&#160;11, 2023, the Company entered into a services agreement with an advisor. The Advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will be paid a fee for their services. All consideration is to be paid simultaneously with the closing of the business combination. </div></div></div></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Redemption</div> Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about April&#160;4, 2023, the Company and Atlantic Coastal Acquisition Management II LLC (the &#8220;Sponsor&#8221;), entered into agreements <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;Non-Redemption</div> Agreements&#8221;) with several unaffiliated third parties in exchange for them agreeing not to redeem an aggregate of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3,300,900shares(&#8220;Non-Redeemed</div> Shares&#8221;) of the Company&#8217;s Series A common stock sold in its initial public offering (the &#8220;Public Shares&#8221;) at the special meeting called by the Company (the &#8220;Meeting&#8221;) to approve an extension of time for the Company to consummate an initial business<div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">combination (the &#8220;Charter Amendment Proposal&#8221;) from April 19, 2023 to October 19, 2023 (an &#8220;Extension&#8221;), subject to additional Extension(s) up to December 19, 2023 upon election by the Sponsor. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to such investors an aggregate of 825,225 shares of the Company held by the Sponsor immediately following consummation of an initial business combination if they continued to hold such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Redeemed</div> Shares through the Meeting.</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;), and Abpro Corporation, a Delaware corporation &#8220;Abpro&#8221;), entered into a business combination agreement (the &#8220;Business Combination Agreement&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">Pursuant to the Business Combination Agreement, on the Closing Date (as defined in the Business Combination Agreement), Merger Sub, a newly formed, wholly-owned direct subsidiary of the Company, will be merged with and into the Abpro (the &#8220;Business Combination,&#8221; together with the other transactions related thereto, the &#8220;Proposed Transactions&#8221;), with the Abpro surviving the Business Combination as a wholly-owned direct subsidiary of the Company (the &#8220;Surviving Company&#8221;). In connection with the consummation of the Business Combination, the Company will change its corporate name to &#8220;Abpro Holdings, Inc.&#8221; The respective boards of directors of the Company and Abpro have duly approved the Business Combination Agreement and the transactions contemplated thereby. </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Business Combination (the &#8220;Effective Time&#8221;), Abpro will cause (i)&#160;all outstanding Abpro convertible notes to be converted into shares of Company Common Stock, (ii)&#160;all outstanding Abpro warrants to acquire equity securities of the Company to be converted into a number of shares of shares of Company Common Stock and (iii)&#160;the Abpro Preferred Shares (including those shares resulting from the convertible notes conversion and warrant conversion) that are issued and outstanding immediately prior to the Effective Time to be converted into shares of Abpro Common Stock. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conditions to closing </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">The obligations of the Company and Abpro to consummate the Business Combination are subject to certain closing conditions, including, but not limited to, (i)&#160;the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (ii)&#160;the absence of any law or governmental order or other legal restraint or prohibition preventing the consummation of the Business Combination, (iii)&#160;the Registration Statement being declared effective under the Securities Act, (iv)&#160;the ACAB New Common Shares to be issued in connection with the Business Combination having been approved for listing on Nasdaq, (v)&#160;the approval of certain of<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div>the Company Proposals by the Company&#8217;s stockholders, (vi)&#160;obtaining the Abpro written consent approving the Business Combination; (vii)&#160;the Company having at least $</div><div style="-sec-ix-redline:true;display:inline;">5,000,001</div><div style="-sec-ix-redline:true;display:inline;"> of net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Securities Exchange Act of 1934, as amended) remaining after the Closing; and (viii)&#160;the Company arranging for binding commitments of at least $</div><div style="-sec-ix-redline:true;display:inline;">8.7</div><div style="-sec-ix-redline:true;display:inline;">&#160;million in available closing cash consisting of funds in the Trust Account (after reduction for payments made in connection with redemptions by the Company stockholders) plus any funds available pursuant to a PIPE&#160;Financing, forward purchase agreement, equity line of credit, convertible note financing and other sources of financing, less any Unpaid SPAC Expenses, as described in the Business Combination Agreement, subject to the Abpro&#8217;s waiver of such amount.</div><br/></div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Letter Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;Sponsor&#8221;) entered into an agreement with the Company, the Abpro and Abpro Bio Co., Ltd (the &#8220;Sponsor Letter Agreement&#8221;), whereby Sponsor agrees to (i)&#160;retain 2.95&#160;million shares of the Company&#8217;s Series A Common Stock held by it, (ii)&#160;divide 2,458,333 shares of the Company&#8217;s Series A Common Stock held by it <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">among the Sponsor, who will be entitled to 491,667 of the shares, Abpro, who will be entitled to 983,333 of the shares, and Abpro Bio Co., Ltd, who will be entitled to 983,333 of the shares, for such party to use to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">obtain&#160;non-redemption&#160;commitments</div> from the Company&#8217;s stockholders or other capital for ACAB or the Surviving Company (with any shares unused for such purpose to be retained by such party) and (ii)&#160;forfeit the remainder of any the Company&#8217;s Series A Common Stock and the Company&#8217;s Series B Common Stock held by it.<br/></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company, Abpro and the Sponsor entered into the Sponsor Support Agreement pursuant to which the Sponsor agreed to, among other things, vote all of its shares of the Company&#8217;s Series A Common Shares and the Company&#8217;s Series B Common Shares held by it, whether now owned or hereafter acquired, (i)&#160;in favor of the approval and adoption of the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (ii)&#160;against any proposal, action or agreement that would impede, interfere with, delay, postpone or discourage any provision of the Sponsor Support Agreement, the Business Combination Agreement or the transactions contemplated thereby (including the Business Combination). In addition, in the Sponsor Support Agreement, the Sponsor agrees to waive, and not to assert or perfect, among other things, any rights to adjustment or other anti-dilution protections with respect to the rate at which the shares of the Company&#8217;s Series B Common Stock held by the Sponsor convert into shares of the Company&#8217;s Series A Common Stock in connection with the transactions contemplated by the Business Combination Agreement. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343370544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;7&#8201;&#8212;&#8201;STOCKHOLDERS&#8217; DEFICIT </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock &#8212;</div></div></div></div>The Company is authorized to issue 1,000,000 shares of $0.0001 par value preferred stock. At December&#160;31, 2023 and 2022, there were no shares of preferred stock issued or outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Common Stock &#8212;</div></div></div></div>The Company is authorized to issue up to 100,000,000 shares of Series A, $0.0001 par value common stock. Holders of the Company&#8217;s common stock are entitled to one vote for each share. At December&#160;31, 2023 and 2022, there were 7,499,999 and no shares of Series A common stock issued and outstanding, excluding 667,391 and 30,000,000 shares subject to possible redemption, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B Common Stock &#8212;</div></div></div></div>The Company is authorized to issue up to 10,000,000 shares of Series B, $0.0001 par value common stock. Holders of the Company&#8217;s common stock are entitled to one vote for each share. At December&#160;31, 2022, there were 7,500,000 shares of Series B common stock issued and outstanding, of which an aggregate of up to 978,500 shares were subject to forfeiture to the extent that the underwriters&#8217; over-allotment option was not exercised in full or in part so that the Initial Stockholders will own 20% of the Company&#8217;s issued and outstanding common stock after the Initial Public Offering (assuming Initial Stockholders do not purchase any Public Shares in the Initial Public Offering). On January&#160;13, 2022, the Company effectuated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;1.044-for-1&#160;stock</div></div> split, resulting in an aggregate of 7,503,750 Founder Shares outstanding. Due to the underwriters&#8217; election to partially exercise their overallotment option, 3,750 shares were forfeited, 1 and 7,500,000 Series B common stock are issued and outstanding at December&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A common stock and Series B common stock will vote together as a single class on all other matters submitted to a vote of stockholders, except as required by law. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Series B common stock will automatically convert into shares of Series A common stock concurrently or immediately following the consummation of an Initial Business Combination, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-for-one</div></div> basis, subject to adjustment as provided herein. In the case that additional shares of Series A common stock, or equity-linked securities, are issued or deemed issued in connection with the Initial Business Combination, the number of shares of Series A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, 20% of the total number of shares of Series A common stock outstanding after such conversion (after <div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">giving effect to any redemption of shares of Series A common stock by Public Stockholders), including the total number of shares of Series A common stock, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the Initial Business Combination, excluding any shares of Series A common stock or equity-linked securities exercisable for or convertible into shares of Series A common stock issued, or to be issued, to any seller in the Initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers, or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-for-one</div></div> basis. <br/></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants &#8212;</div></div></div></div> As of December&#160;31, 2023 and 2022, there are 15,000,000 outstanding Public Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the consummation of a Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that there is an effective registration statement under the Securities Act covering the Series A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the public warrant agreement) and such shares are registered, qualified, or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not be obligated to deliver any Series A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Series A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of Series A common stock upon exercise of a warrant unless Series A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance, under the Securities Act, of the Series A common stock issuable upon exercise of the warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If any such registration statement has not been declared effective by the 60th business day following the closing of a Business Combination, holders of the warrants will have the right, during the period beginning on the 61st business day after the closing of a Business Combination and ending upon such registration statement being declared effective by the SEC, and during any other period when the Company fails to have maintained an effective registration statement covering the issuance of the shares of Series A common stock issuable upon exercise of the warrants, to exercise such warrants on a &#8220;cashless basis.&#8221; Notwithstanding the above, if the shares of Series A common stock are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may redeem the Public Warrants: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $0.01 per warrant; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon not less than 30&#160;days&#8217; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the reported last sale price of the Series&#160;A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">a&#160;30-trading&#160;day</div> period commencing once the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. </div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><br/></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of Series A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Series A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. <br/></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">In addition, if (x)&#160;the Company issues additional shares of Series A common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share of Series A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#8217;s Series A common stock during the 20 trading day period starting on the trading day after the day on which the Company completes a Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there are 13,850,000 Private Placement Warrants, The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants (including the Series A common stock issuable upon the exercise of the Private Placement Warrants) are not transferable, assignable or salable until 30 days after the completion of an Initial Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-redeemable</div> so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343349904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;8&#8201;&#8212;&#8201;INCOME TAXES&#160;</div></div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Startup/Organization Expenses</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2023 and 2022 consists of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 7%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(298,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">298,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company did not have any U.S. federal and state net operating loss carryovers available to offset future taxable income. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December&#160;31, 2023 and 2022, the change in the valuation allowance was $298,330 and $388,575, respectively. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 12%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meals&#160;&amp; entertainment</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business combination expenses</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fines and penalties</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29.45</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  The Company files income tax returns in the U.S. federal jurisdiction in various state and local jurisdictions and is subject to examination by the various taxing authorities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343365280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;">NOTE&#160;9&#8201;&#8212;&#8201;FAIR VALUE MEASUREMENTS </div></div></div></div></div><div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the guidance in ASC 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 7%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 91%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3:</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 71%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">309,790,455</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343273168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTE 10&#8201;&#8212;&#8201;SUBSEQUENT EVENTS </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;display:inline;">On January&#160;11, 2024, the Company entered into an amended services agreement with and advisor, that <div style="letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">was origin</div>ally entered into on<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">April 11 2023</div>. The advisor will provide advisory services as it pertains to a business combination. Upon the closing of a business combination the advisor will receive </div><div style="-sec-ix-redline:true;display:inline;">200,000</div><div style="-sec-ix-redline:true;display:inline;"> shares of Series a common stock in the post-closing Company and </div><div style="-sec-ix-redline:true;display:inline;">4</div><div style="-sec-ix-redline:true;display:inline;">% of the gross proceeds raised from investors and received by the Company or the target prior to the business combination or simultaneously. All consideration is to be paid simultaneously with the closing of the business combination.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;18, 2024, the Sponsor, the Company, Abpro and Abpro Bio entered into an amendment to the Sponsor Letter Agreement (the &#8220;Amended Sponsor Letter Agreement&#8221;), which amended the amount of shares </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">each party thereunder is entitled to, consistent with the description previously disclosed on December&#160;11, 2023 and as contemplated in the Business Combination Agreement, dated as of December&#160;11, 2023, by and among the Company, Abpro Merger Sub Corp., a Delaware corporation, and Abpro. For the avoidance of doubt, the Amended Sponsor Letter Agreement supersedes and replaces the Sponsor Letter Agreement in its entirety. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;21, 2024, the Company received a partial waiver from an underwriter from the initial public offering that was entitled to a portion of the deferred underwriter fee. Subject to the closing of the businesses combination between the Company and Abpro, the underwriter waived $4,290,000 of the underwriter fee in exchange for 600,000 of common stock in the post-merger Company. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;22, 2024, the Company issued a press release announcing that it filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-4</div> with the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&#160;19, 2024 in connection with the previously announced proposed business combination with Abpro (the &#8220;Business Combination&#8221;). </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763341999296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the accounting and disclosure rules and regulations of the SEC. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2023 and 2022. The Company had $264,538 and $392,446 in cash at December&#160;31, 2023 and 2022, respectively. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AssetsHeldInTrustAccountPolicyTextBlock', window );">Cash and Marketable Securities Held in Trust Account</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Cash and Marketable Securities Held in Trust Account </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">At December&#160;31, 2023 and 2022, all of the Company&#8217;s investments held in the Trust Account are invested in cash and money market funds invested primarily in United States Treasuries and are classified as trading securities, respectively. Trading securities are presented on the consolidated balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">To mitigate the risk of us being deemed to have been operating as an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act), the Company instructed the Trustee in December 29, 2023 to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in cash (which may include demand deposit accounts) until the earlier of consummation of our Business Combination or liquidation. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TemporaryEquityPolicyTextBlock', window );">Series A Common Stock Subject to Possible Redemption</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series A Common Stock Subject to Possible Redemption </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its Series A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Series A Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, common stock is classified as a component of stockholders&#8217; equity. The Company&#8217;s Series A common stock feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2023 and 2022, Series A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders&#8217; deficit section of the Company&#8217;s consolidated balance sheet. <br/></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Series A common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Series A common Stock are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and accumulated deficit. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;300,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds allocated to Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A common stock issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,699,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,896,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">309,097,930</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(276,471,460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemptions (redeemed in December 2023, paid in January 2024)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29,728,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,395,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7,292,641</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;340-10-S99-1&#160;and</div></div></div> SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A&#8212;&#8220;Expenses of Offering&#8221;. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs are allocated based on the relative value of the Public and Private Warrants to the proceeds received from the Public Shares sold in the Initial Public Offering. Offering costs allocated to the Public Shares are charged to temporary equity and offering costs allocated to the Public and Private Warrants are charged to stockholder&#8217;s equity. As of January&#160;19, 2022, offering costs in the aggregate of $17,204,107, of which an aggregate of $16,699,058 have been charged to temporary equity and an aggregate of $505,049 have been charged to stockholders&#8217; equity. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were no deferred offering costs recorded in the accompanying consolidated balance sheets respectively. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes.&#8221; ASC 740, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carryforwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of December&#160;31, 2023 and 2022, the Company&#8217;s deferred tax asset had a full valuation allowance recorded against it<div style="letter-spacing: 0px; top: 0px;display:inline;">.</div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">The Company has identified the United States as its only &#8220;major&#8221; tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company&#8217;s management does not expect that the total amount of unrecognized <div style="letter-spacing: 0px; top: 0px;display:inline;">tax</div> benefits will materially change over the next twelve months. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income per Common Share</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Income per Common Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income per common stock is computed by dividing net income by the weighted average number of common stock outstanding for the period. Accretion associated with the redeemable shares of Series A common stock is excluded from earnings per share as the redemption value approximates fair value. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of diluted income per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 28,850,000 Series A common stock in the aggregate. As of December&#160;31, 2023 and 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net loss per common stock is the same as basic net income per common stock for the periods presented.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;">The following table reflects the calculation of basic and diluted net income per common stock (in dollars, except per share amounts): </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 36%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Redeemable</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nonredeemable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;and&#160;Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Basic and diluted net income per common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Allocation of net income, as adjusted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,693,350</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,128,109</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">701,826</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">185,092</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted weighted average shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">11,257,894</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">28,438,356</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted net income per common stock</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying consolidated balance sheet, primarily due to their short-term nature. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated its financial statements to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, &#8220;Derivatives and Hedging.&#8221; For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at fair value on the grant date and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative assets and liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-cash</div> settlement or conversion of the instruments could be required within 12 months of the balance sheet date. The Company accounted for the warrants issued in connection with the Initial Public Offering and the private placement as equity under the guidance at FASB ASC Topic 815. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_WarrantsDisclosurePolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, &#8220;Derivatives and Hedging&#8221;. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period date while the warrants are outstanding. Based on our assessment of the guidance, our warrants meet the criteria for equity classification and are recorded within stockholders&#8217; equity. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">The Company adopted ASC Topic 718, &#8220;Compensation<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div></div></div>Stock Compensation,&#8221; guidance to account for its share-based compensation. It defines a fair value-based method of accounting for an employee share option or </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">similar equity instrument. The Company recognizes all forms of share-based payments, including share option grants, warrants and restricted share grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments, excluding restricted shares, are valued using a Black-Scholes option pricing model. Grants of share-based payment awards issued to nonemployees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service. Share-based compensation expenses are included in costs and operating expenses depending on the nature of the services provided in the statements of operations. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;), which will require the Company to disclose specified additional information in its income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 will also require the Company to disaggregate its income taxes paid disclosure by federal, state and foreign taxes, with further disaggregation required for significant individual jurisdictions. ASU 2023-09 will become effective for Annual periods beginning after December 15, 2024. The Company is still reviewing the impact of ASU 2023-09.</div></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued Accounting Standards Updated (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(Subtopic470-20)and</div> Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity(Subtopic&#160;815-40):Accounting</div> for Convertible Instruments and Contracts in an Entity&#8217;s Own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Equity&#8221;(&#8220;ASU&#160;2020-06&#8221;),which</div> simplifies accounting for convertible instruments by removing major separation models required under current GAAP. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2020-06</div> would have on our financial position, results of operations or cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8211;Financial</div> Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13&#8221;).&#160;This</div> update requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Since June 2016, the FASB issued clarifying updates to the new standard including changing the effective date for smaller reporting companies. The guidance is effective for fiscal years beginning after December&#160;15, 2022, and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> on January&#160;1, 2023. The adoption of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU2016-13</div> did not have a material impact on its financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AssetsHeldInTrustAccountPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets Held in Trust Account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AssetsHeldInTrustAccountPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_WarrantsDisclosurePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_WarrantsDisclosurePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343403648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Series A common stock reflected in the consolidated balance sheet</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, the Series A common stock reflected in the consolidated balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross proceeds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;300,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds allocated to Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A common stock issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,699,058</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,896,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2022</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">309,097,930</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemption</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(276,471,460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redemptions (redeemed in December 2023, paid in January 2024)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29,728,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Remeasurement of carrying value to redemption value</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,395,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Series A common stock subject to possible redemption, December&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7,292,641</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of the calculation of basic and diluted net income per common stock</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;">
<tr>
<td style="width: 36%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">For the Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Redeemable</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nonredeemable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A&#160;and&#160;Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Series&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-style:italic;display:inline;">Basic and diluted net income per common stock</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Allocation of net income, as adjusted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,693,350</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1,128,109</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">701,826</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">185,092</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted weighted average shares <br/> outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">11,257,894</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">28,438,356</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">7,500,000</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 36%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Basic and diluted net income per common stock</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.15</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">0.02</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343065856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 8%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Startup/Organization Expenses</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2023 and 2022 consists of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 7%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(298,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">298,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,177,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">823,991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom; width: 12%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meals&#160;&amp; entertainment</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business combination expenses</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.24</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fines and penalties</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 65%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax provision</div></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29.45</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48.16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 65%;"></td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763343257296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;-sec-ix-redline:true;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2023, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 71%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 7%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 71%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-redline:true;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">1</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="-sec-ix-redline:true;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-redline:true;display:inline;">309,790,455</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763337367936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization And Plan Of Business Operations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Nov. 14, 2023</div></th>
<th class="th"><div>Oct. 14, 2023</div></th>
<th class="th"><div>Apr. 18, 2023</div></th>
<th class="th"><div>Aug. 16, 2022</div></th>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 13, 2023</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_GrossProceedsFromInitialPublicOffer', window );">Gross proceeds from initial public offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TransactionCostsOfIssuance', window );">Transaction Costs Of Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,204,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_UnderwritingFeesNetOfReimbursementByUnderwriters', window );">Underwriting Fees Net Of Reimbursement By Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ReimbursementByUnderwriters', window );">Reimbursement By Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DeferredUnderwritingCommissionNonCurrent', window );">Deferred Underwriting Commission Non Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Cash deposited in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,000,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">306,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PerSharePaymentMadeToAcquireRestrictedInvestments', window );">Per share payment made to acquire restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TermOfRestrictedInvestments', window );">Term of restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">185 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected', window );">Percentage of net assets in the trust account for which the business combination shall be effected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary Equity, Redemption Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_MinimumNetWorthNeededToConsummateBusinessCombination', window );">Minimum Net worth Needed To Consummate Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction', window );">Percentage Of Shares That Can Be Transferred Without Any Restriction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated', window );">Percentage Of Shares Redeemable In Case Business Combination Is Not Consummated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering', window );">Time Limit Within Which Business Combination Shall Be Consummated From The Date Of Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities', window );">Expenses payable on liquidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed', window );">Number Of Days Within Which Public Shares Shall Be Redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PerShareAmountAvailableForDistribution', window );">Per share amount available for distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution', window );">Per share amount to be maintained in the trust account for distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_WorkingCapitalLoan', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfFederalExciseTaxOnStockBuyBack', window );">Percentage of Federal excise tax on share buy back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack', window );">Effective date for levy of federal excise tax on stock buy back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,062,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfSharesRedeemable', window );">Percentage of shares redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AmountToBeDepositedInTrustAccount', window );">Amount to be deposited in trust account</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount', window );">Per share value of the amount to be deposited in trust account</a></td>
<td class="nump">$ 0.045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Temporary equity shares subject to redemption</a></td>
<td class="nump">2,768,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses', window );">Proceeds from sale of trust assets to pay expenses</a></td>
<td class="nump">$ 29,728,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Common stock to be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,728,990<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Asset, Held-in-Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Cash deposited in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Post Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits', window );">Class of warrants or rights issued during the period units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsIssuePricePerUnit', window );">Class of warrants or rights issue price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary Equity, Redemption Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.93<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TemporaryEquityStockRedeemedDuringThePeriodShares', window );">Temporary equity stock redeemed during the period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,564,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,391<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_CommonStockSharesRedeemable', window );">Common stock shares redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,564,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_CommonStockValueRedeemable', window );">Common stock value redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,471,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,728,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Temporary equity shares subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,768,301<span></span>
</td>
<td class="nump">2,768,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Common stock to be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,728,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,935,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Statement Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares', window );">Conversion of permanent equity into temporary equity shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AmountToBeDepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be deposited in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AmountToBeDepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsIssuePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issue price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsIssuePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issued during the period units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsIssuedDuringThePeriodUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_CommonStockSharesRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_CommonStockSharesRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_CommonStockValueRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock value redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_CommonStockValueRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ConversionOfPermanentEquityIntoTemporaryEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of permanent equity into temporary equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ConversionOfPermanentEquityIntoTemporaryEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DeferredUnderwritingCommissionNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting commission non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DeferredUnderwritingCommissionNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective date for levy of federal excise tax on stock buy back.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_EffectiveDateForLevyOfFederalExciseTaxOnStockBuyBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_GrossProceedsFromInitialPublicOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from initial public offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_GrossProceedsFromInitialPublicOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_MinimumNetWorthNeededToConsummateBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum net worth needed to consummate business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_MinimumNetWorthNeededToConsummateBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days within which public shares shall be redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfDaysWithinWhichPublicSharesShallBeRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of statement of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OrganizationConsolidationAndPresentationOfStatementOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PerShareAmountAvailableForDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount available for distribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PerShareAmountAvailableForDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount to be maintained in the trust account for distribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PerShareAmountToBeMaintainedInTheTrustAccountForDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PerSharePaymentMadeToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share payment made to acquire restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PerSharePaymentMadeToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share value of the amount to be deposited in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PerShareValueOfTheAmountToBeDepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfFederalExciseTaxOnStockBuyBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Federal excise tax on share buy back.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfFederalExciseTaxOnStockBuyBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net assets in the trust account of the acquiree for which business combination shall be effected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfNetAssetsInTheTrustAccountForWhichTheBusinessCombinationShallBeEffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfSharesRedeemable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfSharesRedeemable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares redeemable in case business combination is not consummated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfSharesRedeemableInCaseBusinessCombinationIsNotConsummated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares that can be transferred without any restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfSharesThatCanBeTransferredWithoutAnyRestriction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ReimbursementByUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement by underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ReimbursementByUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TemporaryEquityStockRedeemedDuringThePeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock redeemed during the period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TemporaryEquityStockRedeemedDuringThePeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TermOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TermOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time limit within which business combination shall be consummated from the date of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TimeLimitWithinWhichBusinessCombinationShallBeConsummatedFromTheDateOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TransactionCostsOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TransactionCostsOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_UnderwritingFeesNetOfReimbursementByUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting fees net of reimbursement by underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_UnderwritingFeesNetOfReimbursementByUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_WorkingCapitalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_WorkingCapitalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -SubTopic 30<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480034/205-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflows from the sale of trust assets to pay trust expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTrustAssetsToPayExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetHeldInTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetHeldInTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=acab_PostBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=acab_PostBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763354634272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Schedule of Series A common stock reflected in the consolidated balance sheet (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ProceedsAllocatedToPublicWarrants', window );">Less: Proceeds allocated to Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_CommonStockIssuanceCosts', window );">Less: Series A common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,699,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_TemporaryEquityRedemptionValue', window );">Less: Redemption</a></td>
<td class="num">$ (276,471,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Less:Redemptions (redeemed in December 2023, paid in January 2024)</a></td>
<td class="num">(29,728,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Plus: Remeasurement of carrying value to redemption value</a></td>
<td class="nump">4,395,161<span></span>
</td>
<td class="nump">33,896,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Plus: Series A common stock subject to possible redemption</a></td>
<td class="nump">$ 7,292,641<span></span>
</td>
<td class="nump">$ 309,097,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_CommonStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_CommonStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ProceedsAllocatedToPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds allocated to Public Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ProceedsAllocatedToPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_TemporaryEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_TemporaryEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763443916192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Schedule of the calculation of basic and diluted net income per common stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net income, as adjusted</a></td>
<td class="nump">$ 2,821,459<span></span>
</td>
<td class="nump">$ 886,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember', window );">Redeemable common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net income, as adjusted</a></td>
<td class="nump">$ 1,693,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">11,257,894<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">11,257,894<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember', window );">Nonredeemable common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net income, as adjusted</a></td>
<td class="nump">$ 1,128,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net income, as adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,438,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net income, as adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted income (loss) per share, basic</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted income (loss) per share, diluted</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_BasicAndDilutedWeightedAverageNumberOfShareOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassificationOfCommonStockAxis=acab_RedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassificationOfCommonStockAxis=acab_NonRedeemableCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763351975840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,538<span></span>
</td>
<td class="nump">392,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal Deposit Insurance Corporation coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OfferingCosts', window );">Offering costs</a></td>
<td class="nump">$ 17,204,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OfferingCostsAllocatedInTemporaryEquity', window );">Offering costs allocated in temporary equity</a></td>
<td class="nump">16,699,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_OfferingCostsAllocatedInShareholdersEquity', window );">Offering costs allocated in shareholders equity</a></td>
<td class="nump">$ 505,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OfferingCostsAllocatedInShareholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs allocated in shareholders equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OfferingCostsAllocatedInShareholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_OfferingCostsAllocatedInTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs allocated in temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_OfferingCostsAllocatedInTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763444162560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantMember', window );">Public Warrant [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common Stock, Conversion Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each Unit consists of one share of the Company&#8217;s Series A common stock and one-half of one redeemable warrant (&#8220;Public Warrant&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants or rights exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763444118592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement - Additional Information (Details) - Private Placement Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PrivatePlacementLineItems', window );"><strong>Private Placement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrants or rights exercise price per share | $ / shares</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PrivatePlacementLineItems', window );"><strong>Private Placement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits', window );">Class of warrants or rights warrants issued during the period units | shares</a></td>
<td class="nump">13,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.', window );">Class of warrants or rights warrants issued issue price per warrant | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ProceedsFromTheIssuanceOfWarrants', window );">Proceeds from the issuance of warrants | $</a></td>
<td class="nump">$ 13,850,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights warrants issued during the period units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsWarrantsIssuedDuringThePeriodUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights warrants issued issue price per warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsWarrantsIssuedIssuePricePerWarrant.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PrivatePlacementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PrivatePlacementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ProceedsFromTheIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ProceedsFromTheIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763349948560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 1,630,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member] | Loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Common stock held in trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Debt instrument, unused borrowing capacity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member] | Working Capital Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants', window );">Working capital loans convertible into equity warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DebtInstrumentConversionPricePerShare', window );">Debt instrument conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_WorkingCapitalLoansOutstanding', window );">Working Capital Loans outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember', window );">Sponsor [Member] | Promissory Note [Member] | Loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to related party classified as current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to related party classified as current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited | shares</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues | shares</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sponsor [Member] | Loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sponsor [Member] | Restriction on Transfer of Sponsor Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_LockInPeriodOfShares', window );">Lock in period of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfTradingDaysForDeterminingSharePrice', window );">Number of trading days for determining share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered', window );">Waiting period after which the share trading days are considered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember', window );">Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">1.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">7,503,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember', window );">Founder Shares [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember', window );">Founder Shares [Member] | Common Class B [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember', window );">Founder Shares [Member] | Common Class B [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock shares issued during the period for services shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FeeSharesMember', window );">Fee Shares [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock shares issued during the period for services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock shares issued during the period for services shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock- based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FeeSharesMember', window );">Fee Shares [Member] | Common Class B [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock shares issued during the period for services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DebtInstrumentConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DebtInstrumentConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_LockInPeriodOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock in period of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_LockInPeriodOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfTradingDaysForDeterminingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for determining share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfTradingDaysForDeterminingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiting period after which the share trading days are considered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_WorkingCapitalLoansConvertibleIntoEquityWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital loans convertible into equity warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_WorkingCapitalLoansConvertibleIntoEquityWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_WorkingCapitalLoansOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital loans outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_WorkingCapitalLoansOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=acab_WorkingCapitalLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=acab_WorkingCapitalLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=acab_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=acab_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_BasisAxis=acab_RestrictionOnTransferOfSponsorSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_BasisAxis=acab_RestrictionOnTransferOfSponsorSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acab_FeeSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acab_FeeSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763345373664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_UnderwritingDiscountPerShare', window );">Underwriting discount per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PaymentOfUnderwritingDiscount', window );">Payment of underwriting discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DeferredUnderwritingDiscountPerShare', window );">Deferred underwriting discount per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred underwriting commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfAdvisoryServiceFee', window );">percentage of advisory service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AdvisoryServiceFee', window );">advisory service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_MinimumNetWorthNeededToConsummateBusinessCombination', window );">Minimum value of net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination', window );">Minimum cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="nump">491,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,458,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Abpro Bio Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Abpro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=acab_NonRedemptionAgreementMember', window );">Non Redemption Agreement [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfSharesNotAvailableForRedemption', window );">Number of shares not available for Redemption</a></td>
<td class="nump">3,300,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ThresholdDateForConsummationOfBusinessCombinationOne', window );">Threshold date for consummation of business combination one</a></td>
<td class="text">Apr. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ThresholdDateForConsummationOfBusinessCombinationTwo', window );">Threshold date for consummation of business combination two</a></td>
<td class="text">Oct. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ThresholdDateForConsummationOfBusinessCombinationThree', window );">Threshold date for consummation of business combination three</a></td>
<td class="text">Dec. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders', window );">Interse transfer of shares to be made</a></td>
<td class="nump">825,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdvisoryServiceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advisory service fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdvisoryServiceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DeferredUnderwritingDiscountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting discount per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DeferredUnderwritingDiscountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interse transfer of shares transferrable by sponsor to non redemption holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_InterseTransferOfSharesTransferrableBySponsorToNonRedemptionHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash and cash equivalents needed to consummate business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_MinimumCashAndCashEquivalentsNeededToConsummateBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_MinimumNetWorthNeededToConsummateBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum net worth needed to consummate business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_MinimumNetWorthNeededToConsummateBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfSharesNotAvailableForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares not available for Redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfSharesNotAvailableForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PaymentOfUnderwritingDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of underwriting discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PaymentOfUnderwritingDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfAdvisoryServiceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>percentage of advisory service fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfAdvisoryServiceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ThresholdDateForConsummationOfBusinessCombinationOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold date for consummation of business combination one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ThresholdDateForConsummationOfBusinessCombinationOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ThresholdDateForConsummationOfBusinessCombinationThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold date for consummation of business combination three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ThresholdDateForConsummationOfBusinessCombinationThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ThresholdDateForConsummationOfBusinessCombinationTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold date for consummation of business combination two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ThresholdDateForConsummationOfBusinessCombinationTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_UnderwritingDiscountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discount per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_UnderwritingDiscountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_AbproBioCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_AbproBioCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_AbproMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_AbproMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=acab_NonRedemptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=acab_NonRedemptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763345994416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered', window );">Number of days after consummation of business combination within which the securities shall be registered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective', window );">Number of days after which business combination within which securities registration shall be effective</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfBusinessCombinationMember', window );">From The Completion Of Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective', window );">Number of days after which business combination within which securities registration shall be effective</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfInitialPublicOfferMember', window );">From The Completion Of Initial Public Offer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective', window );">Number of days after which business combination within which securities registration shall be effective</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrants or rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit', window );">Class of warrants or rights redemption price per unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants', window );">Minimum notice period to be given to the holders of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantsMember', window );">Public Warrants [Member] | From The Completion Of Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PeriodAfterWhichTheWarrantsAreExercisable', window );">Period after which the warrants are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantsMember', window );">Public Warrants [Member] | From The Completion Of Initial Public Offer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PeriodAfterWhichTheWarrantsAreExercisable', window );">Period after which the warrants are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrants or rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ClassOfWarrantsOrRightsLockInPeriod', window );">Class of warrants or rights lock in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember', window );">Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,503,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">1.044<span></span>
</td>
<td class="nump">1.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common Stock, Conversion Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_SharesAreSubjectToForfeiture', window );">shares are subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfTradingDaysForDeterminingTheSharePrice', window );">Number of trading days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal', window );">Proceeds from equity used for funding business combination as a percentage of the total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_VolumeWeightedAveragePriceOfShares', window );">Volume weighted average price of shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PerShareRedemptionTriggerPrice', window );">per share redemption trigger price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Public Warrants [Member] | Adjusted Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice', window );">Adjusted exercise price of warrants as a percentage of newly issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Public Warrants [Member] | Adjusted Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice', window );">Adjusted exercise price of warrants as a percentage of newly issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted exercise price of warrants as a percentage of newly issued price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsLockInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights lock in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsLockInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights redemption price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ClassOfWarrantsOrRightsRedemptionPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum notice period to be given to the holders of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_MinimumNoticePeriodToBeGivenToTheHoldersOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after consummation of business combination with in which these curities shall be registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfDaysAfterConsummationOfBusinessCombinationWithInWhichTheSecuritiesShallBeRegistered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after which business combination with in which securities registration shall be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfDaysAfterWhichBusinessCombinationWithInWhichSecuritiesRegistrationShallBeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_NumberOfTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_NumberOfTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PerShareRedemptionTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share redemption trigger price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PerShareRedemptionTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfCommonStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfCommonStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PeriodAfterWhichTheWarrantsAreExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after which the warrants are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PeriodAfterWhichTheWarrantsAreExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from equity used for funding business combination as a percentage of the total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_SharesAreSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares are subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_SharesAreSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_VolumeWeightedAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_VolumeWeightedAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfInitialPublicOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PeriodAfterWhichTheWarrantsAreExercisableAxis=acab_FromTheCompletionOfInitialPublicOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acab_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acab_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdjustedExercisePriceOfWarrantsAxis=acab_AdjustedExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdjustedExercisePriceOfWarrantsAxis=acab_AdjustedExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_AdjustedExercisePriceOfWarrantsAxis=acab_AdjustedExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_AdjustedExercisePriceOfWarrantsAxis=acab_AdjustedExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763354755168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts', window );">Startup/Organization Expenses</a></td>
<td class="nump">686,905<span></span>
</td>
<td class="nump">388,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">686,905<span></span>
</td>
<td class="nump">388,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(686,905)<span></span>
</td>
<td class="num">(388,575)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start up and organization costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763342149568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of the Provision For Income Taxes  (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 1,177,463<span></span>
</td>
<td class="nump">$ 823,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(298,330)<span></span>
</td>
<td class="num">(388,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">298,330<span></span>
</td>
<td class="nump">388,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 1,177,463<span></span>
</td>
<td class="nump">$ 823,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763444124160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation  (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals&#160;&amp; entertainment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination', window );">Business combination expenses</a></td>
<td class="nump">0.24%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Fines and penalties</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">7.46%<span></span>
</td>
<td class="nump">22.71%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">29.45%<span></span>
</td>
<td class="nump">48.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non deductible expense business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763444193744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 298,330<span></span>
</td>
<td class="nump">$ 388,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=acab_FederalAndStateAuthorityMember', window );">Federal And State Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carry forwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=acab_FederalAndStateAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=acab_FederalAndStateAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763568356192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) - Asset Held In Trust [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 309,790,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=acab_AssetsHeldInTrustMember', window );">Level [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=acab_AssetsHeldInTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=acab_AssetsHeldInTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139763346808416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors', window );">Percentage of gross amount payable to sponsor raised from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_UnderwriterMember', window );">Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acab_UnderwriterFeeWaivedOff', window );">Underwriter fee waived off</a></td>
<td class="nump">$ 4,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock shares issued during the period for services shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Class A [Member] | Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Number of shares issuable on acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross amount payable to sponsor raised from investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_PercentageOfGrossAmountPayableToSponsorRaisedFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_UnderwriterFeeWaivedOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriter fee waived off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_UnderwriterFeeWaivedOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acab_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acab_InvesteeAxis=acab_AdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acab_InvesteeAxis=acab_AdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
